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Abstracts
ESOPHAGUS
1
Exclusion of the Meal Period Does Not Improve the Diagnostic
Accuracy of 48-Hour Ambulatory Catheter-Free Esophageal pH
Testing
Stephanie L. Hansel, MD, John K. DiBaise, MD∗, Isaac Malagon, BS,
Marie Haywood, BSN, Jeannie Stoa, BSN, Virender K. Sharma, MD, H.
Jae Kim, MD, Michael D. Crowell, PhD. Gastroenterology, Mayo Clinic
Arizona, Scottsdale, AZ.
Purpose: On the basis of results from small studies using conventional am-
bulatory catheter-based esophageal pH testing, it has been suggested that
exclusion of the meal periods from the analysis is important to ensure op-
timal diagnostic accuracy. Our aim was to evaluate the results of 48-hour
ambulatory catheter-free pH testing depending upon whether the meal period
was included or not and determine whether this affected the test’s diagnostic
accuracy.
Methods: 48-hour ambulatory catheter-free esophageal pH tests were ana-
lyzed both with the meal period included and excluded in consecutive pa-
tients. The patients were divided into two groups based upon whether they
were studied on or off PPI therapy. pH parameters evaluated included the
total% acid exposure time (AET), total # episodes and Demeester score for
day 1, day 2 and the total duration of study. The paired t-test was used to
compare pH parameters with meals to without meals. Agreement of final
results was also evaluated using the following definitions of an abnormal
study: total AET > 5.3%, supine AET > 6.3% or upright AET > 6.7%. A
P-value < 0.05 was considered statistically significant.
Results: 103 patients were studied (56 on PPI, 47 off PPI; 60 female; mean
age 60 ± 17 yrs). The most common indications for testing were GERD and
unexplained chest pain. There were no significant differences in total AET
or Demeester score whether meals were included or not. In contrast, there
was a difference in total # episodes with significantly more occurring when
meals were included. Nevertheless, there was excellent agreement in terms
of final diagnosis for total (95–100%), supine (100%) and upright (96–98%)
AET. Identical findings were found for both groups studied (i.e., on PPI and
off PPI) and when day 1, day 2 or the full 48 hours were evaluated.
Conclusion: Exclusion of the meal period does not improve the diagnostic
accuracy of 48-hour ambulatory catheter-free esophageal pH testing.
2
Ethnic Variation in Lower Esophageal Sphincter Pressure and Length
Kenneth J. Vega, MD, M. Mazen Jamal, MD∗. Division of
Gastroenterology, University of Florida/Jacksonville, Jacksonville, FL and
Division of Gastroenterology, Veterans Affairs Medical Center, Long
Beach, CA.
Purpose: Esophageal manometry (EM) is the gold standard examination for
diagnosis of esophageal motor disorders. Normal values for EM in ethnic
groups residing in the United States are only available for Hispanic Amer-
icans in the literature. The aim of this study was to obtain values of EM in
healthy adult African American (AA) volunteers and compare these to those
obtained in healthy non-Hispanic white (nHw) volunteers to determine if
ethnic variation exists in normal esophageal motor function.
Methods: Healthy AA and nHw were recruited from the Jacksonville
metropolitan area. Ethnicity was self-reported. Exclusion criteria were symp-
toms suggestive of esophageal disease, medication use or concurrent illness
that could affect EM. All underwent EM using a solid-state system with
wet swallows (Polygram Net, Medtronic Inc., Minneapolis, MN). Resting
lower esophageal sphincter pressure and lower esophageal sphincter length
were measured at end-expiration while percent peristaltic contractions, dis-
tal esophageal contraction velocity, amplitude and duration were measured
after 5 cc H20 swallows.
Results: Fifty-six AA and 48 nHw were enrolled. All subjects completed
EM without difficulty. Volunteer age ranged from 18 to 57 years old and was
not different between groups. Males comprised 48% of both groups. Resting
lower esophageal sphincter pressure, lower esophageal sphincter length and
distal esophageal contraction duration were significantly higher in AA than
nHw (P < 0.05, table). There were no differences seen in percent peristaltic
contractions, distal esophageal contraction amplitude, and distal esophageal
contraction velocity.
Conclusion: Significant ethnic differences exist in EM findings. These dif-
ferences underscore the need for race specific reference values for EM studies
to allow for the accurate diagnosis of esophageal motility disorders in AA
patients.
Esophageal manometry parameters in healthy African Americans (N = 56)
and non-Hispanic whites (N = 48)
Esophageal AA nHw P
manometry parameter (mean ± SD) (mean ± SD) value
Resting LES pressure (mmHg) 32.3 ± 13.9 27.1 ± 9.6 0.03
LES length (cm) 3.66 ± 0.85 3.32 ± 0.83 0.04
% peristaltic contraction 95.1 ± 4.9 94.1 ± 5.9 NS
Distal esophageal contraction
amplitude (mm Hg)
97.2 ± 43.8 85.7 ± 31.2 NS
Distal esophageal contraction
velocity (cm/sec)
3.59 ± 2.5 4.73 ± 3.49 NS
Distal esophageal contraction
duration (sec)
4.45 ± 1.75 3.82 ± 1.26 0.04
3
Nocturnal Gastric Acidity and Nocturnal Esophageal Acidity Are
Lower with Immediate-Release Omeprazole Than with Lansoprazole
or Esomeprazole in GERD Patients Treated with a Proton Pump
Inhibitor
Jerry D. Gardner, MD∗. Santarus Clinical Research Group. Science for
Organizations, Inc., Mill Valley, CA and Santarus, Inc., San Diego, CA.
Purpose: Nocturnal esophageal acidity is particularly important in the patho-
physiology of GERD and proton pump inhibitors (PPIs) reduce nocturnal
esophageal acidity by reducing nocturnal gastric acidity. Often, comparing
mean or median values for gastric or esophageal acidity with one PPI to
corresponding values with another PPI may obscure important differences
between effects of the two agents on acidity. Our aim was to use Bayesian
analyses to compare the relative abilities of immediate-release omeprazole
(IR-OME), lansoprazole (LAN), and esomeprazole (ESO) to decrease noc-
turnal gastric and nocturnal esophageal acidity in GERD patients.
Methods: Gastric and esophageal pH were measured for 24 hours in 49
GERD patients on the 7th day of dosing with 40 mg IR-OME, 30 mg LAN
or 40 mg ESO in a 3-way crossover study with at least a 10-day washout
period between each treatment. Dosing occurred at 10 PM and the nocturnal
period was from 10 PM until 6 AM the next morning. Nocturnal acidity was
calculated both as integrated acidity (mmol.hr/L) and as time pH < 4 (%).
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We used Bayes’ rule, which provides a useful method for combining new
information with a prior probability, to calculate the posterior probability
that nocturnal gastric or esophageal acidity with IR-OME was lower than
that with ESO or LAN. For these calculations we used a flat prior probability
that considered all values from 0 to 1.00 to be equally probable.
Results: The table below shows that with integrated acidity, the posterior
probability that nocturnal gastric and esophageal acidity are lower with IR-
OME than with ESO or LAN is at least 0.96. With time pH < 4, the posterior
probabilities that IR-OME < LAN were the same as those with integrated
acidity. On the other hand, with time pH < 4, the posterior probabilities that
IR-OME < ESO were the lower than those with integrated acidity.
Conclusion: Thus, in GERD patients treated with a PPI, there is a high
probability that during the nocturnal period, both gastric and esophageal
acidity will be lower with IR-OME than with ESO or LAN.
Posterior Probabilities of Lower Nocturnal Acidity with IR-OME
IR-OME < LAN IR-OME < ESO
Gastric Esoph. Gastric Esoph.
Measure Acidity Acidity Acidity Acidity
Integrat. Acidity 1.00 0.98 1.00 0.96
Time pH < 4 1.00 0.98 0.61 0.80
4
Ineffective Esophageal Motility (IEM) and Prolonged Nocturnal
Gastroesophageal Acid Reflux
Monjur Ahmed, MD∗, Girma Meshesha, MD, Frezgi Kebreab, MD, Fikadu
Gebreyes, MD. Internal Medicine, Marshall University, Huntington, WV.
Purpose: To find out whether prolonged (>5 minutes) nocturnal gastroe-
sophageal acid reflux is more prevalent in patients with IEM
Methods: We conducted a retrospective database review of esophageal
manometry and 24 hour pH studies of patients with esophageal and/or GERD
symptoms evaluated at our University Medical Center. We analyzed database
from June 2003 to May 2006 and among 400 records reviewed 187 met the
study criteria and considered eligible for this analysis. Prolonged nocturnal
gastroesophageal acid reflux was defined as a distal esophageal pH < 4 for
more than 5 minutes recorded on the ambulatory pH monitor between the
hours of 10 pm and 6 am. IEM was defined as low (<30 mm Hg) amplitude
or non-transmitted contractions in ≥30% of 10 wet swallows in the distal
esophagus.
All patients irrespective of age over 18 years, sex and any racial background
that had esophageal manometry and 24 hour esophageal pH study were
included in the study. A comparison was made between groups with IEM
and normal manometry with respect to the prevalence of prolonged distal
esophageal acid exposure between the hours of 10 pm and 6 am.
Results: We found that 163 patients had normal esophageal manometry and
out of them 84 patients (51.53%) had prolonged nocturnal distal esophageal
acid reflux. On other hand, 24 patients had ineffective esophageal motil-
ity and out of them 16 patients (66.66%) had prolonged nocturnal distal
esophageal acid reflux. Although the frequency of prolonged nocturnal dis-
tal esophageal acid reflux appeared higher in patients with IEM as compared
to patients with normal esophageal motility, this difference did not reach sta-
tistical significance (P = 0.16).
Conclusion: This study clearly shows that prolonged nocturnal gastroe-
sophageal acid reflux can be present in patients with normal esophageal
motility as well as in patients with ineffective esophageal motility. Our study
did not show any significant difference in the prevalence of prolonged noc-
turnal gastroesophageal acid reflux in patients with and without ineffective
esophageal motility. By analyzing the data from this cohort of patients, we
can conclude that IEM does not play a very significant role in causing pro-
longed nocturnal gastroesophageal acid reflux. There may be other factors
which could be responsible for prolonged nocturnal GERD.
5
Photodynamic Therapy Decreases DNA Content Abnormalities in
Residual Non-Dysplastic Barrett’s Esophagus
Weitian Liu, MD∗, Jason L. Hornick, MD, Robert D. Odze, MD, Mari
Mino-Kenudson, MD, Gregory Y. Lauwers, MD, Raj K. Goyal, MD.
Gastroenterology, Hepaptology and Endoscopy; Pathology, Brigham and
Women’s Hospital, Harvard Medical School (HMS), Boston, MA;
Pathology, Massachusetts General Hospital, HMS, Boston, MA and
Medicine, Veterans Affairs Medical Center, HMS, West Roxbury, MA.
Purpose: Photodynamic therapy (PDT) has been used for the treatment of
Barrett’s esophagus (BE) with high grade dysplasia (HGD) or early adeno-
carcinoma (AC). After PDT, some patients still have residual surface BE
(SBE) and/or buried BE (BBE) underlying neosquamous epithelium. The
neoplastic potential of residual SBE and BBE post-PDT is unknown.
Methods: 52 BE patients with HGD or early AC were treated with PDT. Pre-
PDT and post-PDT biopsies were performed. 22 matched pre- and post-PDT
non-dysplastic BE samples were retrieved from 11 patients for high fidelity
DNA histogram analysis. DNA content changes were compared between
pre-PDT SBE, post-PDT SBE and BBE samples. DNA index > 1.1 was
considered aneuploid.
Results: Of the 11 pre-PDT SBE samples, 3 were diploid and 8 were aneu-
ploid (Table 1). In the 3 patients with pre-PDT SBE diploidy, the post-PDT
residual SBE and BBE samples were also diploid. Interestingly, in the 8 pa-
tients with pre-PDT SBE aneuploidy, all the post-PDT BBE and 5 post-PDT
SBE samples were diploid; 2 post-PDT SBE samples remained aneuploid,
and 1 was not analyzed because of insufficient tissue.
Conclusion: Compared to pre-PDT BE, post-PDT BE shows significantly
less frequent DNA content abnormalities, suggesting that PDT may have
a preferential destructive effect on aneuploid cells. This indicates that the
post-PDT residual BE, both surface and buried, may have a lower neoplastic
potential than pre-PDT BE.
DNA content changes in non-dysplastic Barrett’s esophagus
before and after photodynamic therapy
Case Pre-PDT SBE DI Post-PDT SBE DI Post-PDT BBE DI
Case 1 1.08 1.06 1.06
Case 2 1.08 1.03 0.98
Case 3 1.03 NP 1.02
Case 4 1.20 1.00 1.05
Case 5 1.27 1.07 1.08
Case 6 1.26 0.93 1.02
Case 7 1.27 NP 1.09
Case 8 1.20 1.06 0.99
Case 9 1.11 1.22 1.08
Case 10 1.25 1.14 0.98
Case 11 1.36 0.98 0.99
Mean ± SD 1.19 ± 0.10 1.05 ± 0.09 1.05 ± 0.04
PDT = photodynamic therapy SBE = surface Barrett’s esophagus BBE = buried
Barrett’s esophagus DI = DNA index NP = not performed
6
The Basic Factor in the Genesis of GERD
Daccak Munzer, FACG∗. Emeritus Professor of Medicine, Houston, TX.
Purpose: One of the main aims of surgical treatment of gastroesophageal
reflux disease (GERD) is a gastropexy restoring the acute angle of His (AH).
Most studies attribute GERD to some incompetence of the cardia, deficient
esophageal clearing, delayed gastric emptying and transient relaxation of the
lower esophageal sphincter (LES).
In the fifties and the sixties, primary importance was attributed to whether
AH was acute, preventing the reflux, or obtuse, facilitating and predisposing
to this recurrent regurgitation.
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Several studies have noted the interaction of multiple factors: gastric acid
secretion, hormonal effects, and abnormality in the motility of the cardioe-
sophageal junction (CEJ).
The anatomic aspect of the AH has been bypassed and, in multiple studies,
ignored.
While endoscopy may expose the reflux without delimiting the complete
aspect of the AH, it is more accurate to add an x-ray study of the upper G.I.
tract in order to set the anatomic shape of the CEJ and mainly the AH, which
is very variable from person to person.
As we become immersed in the controlling effect of H2 blockers and PPI, we
have to debate the correction of an abnormal AH to cure completely some
chronic cases of GERD. The anatomic aspect of the AH is a major factor in
the competence of the LES, in the motility of the lower esophagus, and in
esophageal slearing. It is prominent in the pathogenesis of GERD, and has to
be evaluated by X-ray and endoscopy in the management of gastroesophageal
reflux.
Is there any explanation of this complete disregard of the importance of AH
in the pathology and treatment of GERD? at every gastroenterology meeting,
whether national or international, the pharmaceutical industry sponsors large
symposia on the subject, to evaluate only the effect of their various proposed
drugs in the treatment of GERD, insisting on a long maintenance therapy,
which could go on forever?
7
Double Aortic Arch and Nasogastric Tubes: A Fatal Combination
Julia Massaad, MD, Kelly Crawford, MD∗. Division of Digestive
Diseases, Emory University, Atlanta, GA.
Purpose: A 38 year old patient was transferred to our hospital for the man-
agement of tricuspid valve endocarditis. She had a history of intravenous
drug use and had been treated for 2 weeks with intravenous antibiotics but
eventually required valvular replacement. On post operative day 11, she de-
veloped a massive upper gastrointestinal bleed. An urgent endoscopy showed
a large esophageal ulcer with a probable visible vessel at 22 cm from the
gums. Endoscopic therapy with epinephrine injections was performed. Two
hours later, she bled again, now more severely with secondary shock. Given
the location of the esophageal ulcer and the degree of bleeding, a clinical
diagnosis of aortoesophageal fistula was made and the patient was taken to
the operating room where an aortic endograft was done with control of the
bleeding. On review of her records, it was noted that the patient had a double
aortic arch completely encasing her trachea and esophagus on a previous CT
of her chest. The patient had an NG tube for more than 5 days post op for
feeding and medication administration.
Discussion: Double aortic arch is a complete vascular ring that encircles
both the trachea and the esophagus. The most common presenting symp-
toms, usually in the pediatric population, are respiratory and gastrointesti-
nal. The incidence of aortoesophageal fistula development in adult patients
with double aortic arch and prolonged NG intubation has been reported in
the literature, and the pathogenesis of this life threatening complication is
probably related to the continuous and pulsatile pressure between the aorta
and the esophagus. In this anomaly, the trachea and the esophagus are tightly
constricted within a double aortic arch and any inserted tubes can produce
pressure necrosis and a resultant fistula. Aortoesophageal fistula is a life
threatening complication and its diagnosis can often be delayed in the adult
patient without any history of thoracic aortic aneurysms or esophageal ma-
lignancy. All imaging modalities to diagnose this entity can be unsuccessful
and the best chance for patient survival is a clinical diagnosis made with
confidence. We present this case to alert the clinician to another potential
and life threatening complication of prolonged nasogastric intubation in this
specific patient population.
In conclusion, aortoesophageal fistula is a highly fatal but potentially avoid-
able complication in patients with vascular rings and the risks of prolonged
nasogastric intubation in this patient population definitely outweighs the
benefits.
8
Prevalence of Esophageal Dysmotility in a Cohort of Patients with
Biopsy Proven Eosinophilic Esophagitis. A Prospective Study
John T. Bassett, MD, Joseph L. Perry, MD, Eric M. Osgard, MD, Corinne
L. Maydonovitch, Leslie H. Sobin, MD, Roy H. Wong, MD∗.
Gastroenterology, National Naval Medical Center, Bethesda, MD;
Gastroenterology, Walter Reed Army Medical Center, Washington, DC and
Hepatic and Gastrointestinal Pathology, Armed Forces Institute of
Pathology, Washington, DC.
Purpose: Eosinophilic esophigitis (EE) is increasingly being diagnosed in
adults presenting with dysphagia, food impactions and chest pain. EE is best
characterized by a dense eosinophilic infiltration of the esophageal epithelial
cells. Studies to date provide conflicting data on the association of EE and
esophageal dysmotility.
In this study, we intend to evaluate the prevalence of esophageal dysmotility
in a cohort of patients with biopsy proven eosinophilic esophagitis (EE) at
Walter Reed Army Medical Center. We would hypothesize that esophageal
dysmotility is an under recognized feature of EE which may contribute to
dysphagia and food impactions.
Methods: This study is a prospective evaluation of consecutively identified
patients who were diagnosed with EE from 1 March 2005 to present. We
intend to enroll up to 32 patients in this study. Those enrolled have had the
esophageal biopsies obtained within one year of their inclusion in the study.
These patients had not taken swallowed steroids or leukotriene inhibitors for
a 6 week period prior to inclusion in the study. All patients were asked to
complete a symptom survey that inquired about difficulty swallowing, heart-
burn, belching, chest pain, regurgitation and waking at night with symptoms.
The patients then had esophageal manometry performed to determine the
prevalence of esophageal dysmotility.
Results: To date, 21 patients (16/21 76% male, Mean {SD} age 43 ± 9 years)
have completed the study. In the survey, 18/21 (86%) reported dysphagia,
15/21 (71%) reported heartburn, 8/21 (38%) reported belching, 11/21 (52%)
reported chest pain, 14/21 (67%) reported regurgitation, 9/21 (42%) re-
ported waking at night with symptoms. All patients were found to have a
normal lower esophageal sphincter pressure (12 ± 5 mm/Hg). Of the 21 pa-
tients, 3 (14.2%), (95% CI 3.1%, 36.3%) were diagnosed with a non-specific
esophageal motor disorder compared to a prevalence of 10% in a population
of patients with GERD, P = 0.351 using the binomial test.
Conclusion: This is preliminary data, but, suggests that the prevalence of a
non-specific esophageal motor disorder in EE patients is similar to that in
patients with GERD.
9
Rabeprazole Sodium 20 mg BID Improves Symptoms in Patients with
Chronic Persistent Asthma
Frank K. Friedenberg, MD∗, Kellie Simmons, MSN, Amiya Palit, MD.
Gastroenterology, Temple University School of Medicine, Phila, PA.
Purpose: Prior studies have demonstrated a potential benefit of PPI’s for
the treatment of chronic persistent asthma (CPA) in patients with underly-
ing GERD. Mechanisms may include reduced microaspiration or inhibition
of vagally-mediated airway bronchoconstriction. Our purpose was to de-
termine whether rabeprazole sodium delayed-release tablets (Aciphex) at
double dose was efficacious in improving objective and subjective measures
of pulmonary function in patients with CPA.
Methods: Patients with concomitant GERD and CPA were treated for 3
months with Aciphex 20 mg BID after a 2 week titration off their usual
PPI or H2RA. At baseline, 1 month, and 3 months patients completed the
validated Quality of Life in Reflux and Dyspepsia (QOLRAD) and Asthma
Quality of Life Questionnaire (AQLQ) surveys. Patients underwent peak
flow measurement at baseline and at the conclusion of the study.
Results: We recruited 39 females, 9 males. Mean age 48.2 ± 1.6. Over-
all 26 (54.2%) patients were on inhaled corticosteroids, 10 (20.8%) were
on a leukotriene receptor antagonist, and 42 (87.5%) were on a short or
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long-acting β-agonist. None were on oral steroids. All 48 patients com-
pleted the 3 month study and remained compliant with Aciphex therapy.
AQLQ scores improved at month 1 by 40.7 points (P < 0.001) and continued
to improve at month 3 (43.1 points from baseline, P < 0.001). Likewise peak
flow values improved significantly from baseline (285 ml) to the assessment
at month 3 (323 ml; P = 0.008). GERD symptoms were reduced to nearly
half during the study period as well (QOLRAD baseline = 89.9 to month 3 =
47.3; P < 0.001). Improvements in AQLQ, QOLRAD, and peak flow dur-
ing Aciphex treatment remained significant even after adjustment for age,
BMI, gender, and asthma treatment regimen. There was good correlation be-
tween improvement in the AQLQ and QOLRAD (r = 0.71; P < 0.001). No
patient required hospitalization, oral steroids, or additional medical therapy
for CPA during the study period.
Conclusion: Our data supports the published literature that potent acid sup-
pression in patients with CPA can improve respiratory symptoms. Objective
improvement in FEV1 as measured by peak flow correlated with subjective
assessment of improvement. Improvement was independent of patient char-
acteristics such as age, gender, and BMI. Improvement was similar in patients
on or off inhaled steroids, β-agonists, or leukotriene receptor antagonists.
Our study should be replicated in a larger group using a double-blinded
therapeutic trial design.
10
A Case of Severe Heartburn
Krysia L. Zancosky, DO, Sean Connelly, DO, Peter J. Molloy, MD∗.
Gastroenterology, The Western Pennsylvania Hospital, Pittsburgh, PA.
Purpose: A 64 yo white male with a history of recurrent paroxysmal atrial
fibrillation was admitted to the hospital for elective surgery. He had failed
multiple conventional therapies including anti-arrhythmic agents and two
previous ablations, but continued to be symptomatic. He was deemed a
candidate for minimally invasive pulmonary vein ablation with left atrial
appendage ligation, or the mini-MAZE procedure.
He underwent the mini-MAZE procedure and tolerated the procedure well.
His post-operative course was complicated by weakness, inability to am-
bulate and recurrent atrial arrhythmias requiring continued anticoagulation.
By POD day #5, he began to complain of anorexia, nausea and abdominal
discomfort. A preliminary work-up included normal liver and pancreatic
enzymes, abdominal ultrasound and CT scan. Despite this, his WBC count
continued to rise to approximately 18,000. On POD Day #10, the patient
developed four episodes of melena. His anticoagulation was discontinued
and GI was consulted.
Upon questioning, the patient described dysphagia, epigastric fullness and
anorexia. His history included a duodenal ulcer at age 15. Physical exam
revealed a well-appearing male with a normal abdominal exam. He was
noted to be tachycardic with a heartrate of 104. The patient was placed on an
esomeprazole infusion and the decision was made to proceed with an EGD
to evaluate upper GI bleeding.
EGD revealed what appeared to be a full thickness burn and necrosis at
25–30 cm from the incisors with formation of a pseudodiverticulum. The
findings were suspicious for a contained perforation, likely related to the
radiofrequency ablation 11 days prior. An emergent CT scan was obtained
which revealed a small mediastinal space tract that appeared to connect to
an esophageal defect. There was no evidence of free air in the mediastinum
to suggest an ongoing leak.
The patient was taken emergently to surgery and findings included the
above mentioned anterior full-thickness perforation of the esophagus that
extended for approximately 2 cms. The patient underwent flexible esoph-
agogastroscopy, placement of esophageal drainage mesogastric tube, ex-
ploratory laparotomy, feeding jejunostomy and Stamm gastostomy place-
ment. The esophageal perforation was followed with periodic EGDs and
gastrograffin swallow studies. He began tolerating a soft diet and was even-
tually discharged to a rehabilitation facility 50 days after the initial mini-
MAZE procedure.
In conclusion, there needs to be a high index of suspicion for esophageal
perforation after the mini-MAZE procedure.
11
Proton Pump Inhibitor and Nonsteroidal Anti-Inflammatory Use and
the Development of Neoplasia in Barrett’s Esophagus
John Kuczcynski, MD, Hashem El-Serag, MD, Stephanie Davis, PharmD,
Adam Wachter, Daniel J. Stein, MD, Richard E. Sampliner, MD∗.
Southern Arizona VA HealthCare System and Arizona Health Sciences
Center, Tucson, AZ and Michael E DeBakey VA Medical Center and Baylor
College of Medicine, Houston, TX.
Purpose: The role of chemoprevention in Barrett’s esophagus (BE) is un-
clear. Evidence suggests a protective role for proton pump inhibitors (PPIs),
non-steroidal anti-inflammatories (NSAIDs), and possibly statins. However,
human data are limited.
Methods: This is a retrospective study of a well characterized large cohort of
patients with documented BE diagnosed between 1985 and 2005. Prescrip-
tion information was collected from pharmacy records before and after BE
diagnosis. Patients were followed until the development of dysplasia, ade-
nocarcinoma, death, or 12/2005. Cox regression analyses were performed to
examine the association between NSAID, PPI, or statin prescription and the
risk of developing dysplasia or cancer.
Results: We examined 408 patients with BE with a mean age of 61 at the
time of BE diagnosis; Caucasian 91.2%, men 94.4%. The mean duration of
follow-up was 6.6 years (SD 4.9). During 2690 patient-year follow-up, 125
developed dysplasia (20 high grade) yielding an incidence of 4.65 per 100
PY and 29 patients developed adenocarcinoma (1.08 per 100 PY). Approxi-
mately 38.4% were prescribed NSAIDs for a mean duration of 12.9 months,
66.4% were prescribed a PPI for a mean duration of 31.5 months, and 26.2%
were prescribed a statin for a mean duration of 10.5 months.
In unadjusted analyses, only patients with BE segment > 3 cm, and more
recent time of BE diagnosis were associated with increased risk of dysplasia
or cancer, whereas PPI prescription was associated with reduction in that
risk. This persisted in multivariable analysis (Table), and were exaggerated
in analysis limited to those developing dysplasia or cancer after the first year
of diagnosis; for example, PPI use (0.23, 95% CI: 0.10–0.61). No consis-
tent associations were observed for NSAID or statin use where neither any
prescription nor prescriptions > 12 months was associated with the risk of
dysplasia or cancer.
Conclusion: PPI use seems to reduce the risk of neoplastic changes in pa-
tients with BE. NSAID or statin use is not associated with the risk of neo-
plasia.
Multivariable COX Ph model predicting the risk of dysplasia
Hazard Ratio 95% CI
Non-Caucasian 0.51 0.24–1.10
BE length > 3 cm 1.53 1.01–2.29
PPI prescription 0.64 0.43–0.94
12
Measurement of Lower Esophageal Sphincter (LES) Characteristics
during Esophageal Manometry Does Not Differ with Severity of
Ineffective Esophageal Motility
Vishal Jain, MD, Neeraj Sharma, MD, Marcelo Vela, MD, Donald Castell,
MD∗. Department of Gastroenterology and Hepatology, Medical
University of South Carolina, Charleston, SC.
Purpose: Manometric assessment of Lower Esophageal Sphincter (LES)
includes Resting Pressure and LES relaxation characteristics (Residual
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Pressure) with liquid and viscous swallows. LES pressures are not tradi-
tionally used to establish the severity of IEM.
Aim: To determine whether LES pressures vary with severity of IEM
Methods: Retrospective review of 180 MII-EM studies done in patients
diagnosed with IEM by “Old” (presence of ≥30% liquid swallows with con-
traction amplitude <30 mm hg in the distal esophagus) or “New” (presence
of ≥50% of ineffective liquid swallows) criteria for IEM. IEM classified
as mild (normal bolus transit for both liquid and viscous), moderate (bolus
transit only for liquid or viscous), or severe (abnormal bolus transit for both
liquid and viscous).
Means of LES resting pressure, LES liquid residual pressure and LES viscous
residual pressure were calculated and compared among Mild, Moderate and
Severe groups by ANOVA.
Results: Mean LES resting pressure was higher only for mild versus mod-
erate IEM by the “New” IEM criteria. All other comparisons showed no
difference in LES resting pressure. Additionally, there was no difference in
LES residual pressures in both “Old” and “New” criteria.
Conclusion: Our findings suggest that LES characteristics are overall very
similar across IEM of different severity, independent of the criteria used.
“Old” IEM Criteria
“Old” Mean LES Mean LES Liquid Mean LES Viscous
IEM Resting Pressure Residual Pressure Residual Pressure
Mild 21.8 4.7 4.4
Moderate 21.5 4.8 5.4
Severe 26.4 4.9 5.1
“New” IEM
“New” Mean LES Mean LES Liquid Mean LESViscuos
IEM Resting Pressure Residual Pressure Residual Pressure
Mild 19.2∗ 3.0 4.5
Moderate 26.0∗ 3.6 4.1
Severe 20.5 2.6 3.2
∗P < 0.05
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Eosinophilic Esophagitis: A Common Cause of Food Impaction and
Dysphagia in Young Men
Brett J. Partridge, MD, Alissa M. Quin, MD, Andrew A. White, MD, Walter
J. Coyle, MD∗. Gastroenterology, Naval Medical Center San Diego, San
Diego, CA; Division of Gastroenterology and Hepatology, Scripps Clinic,
La Jolla, CA and Allergy and Immunology, Naval Medical Center San
Diego, San Diego, CA.
Purpose: Eosinophilic Esophagitis (EE) is an increasingly recognized con-
dition in adults characterized by esophageal mucosal eosinophilia in the set-
ting of dysphagia or food impaction. We undertook a retrospective review
of all cases seen in our Gastroenterology Clinic to evaluate for demographic
information including gender predeliction, presenting symptoms including
dysphagia score, associated conditions, endoscopic and histologic appear-
ance and response to treatment.
Methods: A retrospective review of medical records from January 2003 to
August 2006 was completed. Data was analyzed by calculating means with
standard deviations for continuous variables and percentages for categori-
cal variables. Dysphagia scores were assessed based on presenting history
and reassessed based on further progress notes when available. Statistical
calculations were completed with the aid of SAS software.
Results: Twenty-five patients were identified. Age at presentation was 26.1 ±
6.4 years. Age at symptom onset was 23.8 ± 7.8 years. 94% of patients
were male. 96% of patients presented with solid dysphagia or food bolus
impaction. 92% of patients had either concentric rings or linear furrows
reported on initial endoscopy. Biopsy revealed 47 ± 40 eos/hpf (range 26–
200). 22% of patients also were asthmatic and 55% of patients had a history of
asthma, atopy and/or a positive allergy skin test. Patients were treated with a
variety of modalities including dilation, PPI’s, food avoidance and swallowed
fluticasone. Patients had significantly less dysphagia after treatment (median
score 2.4 prior to treatment and 0.7 after treatment, P <0.01) and there was no
trend favoring a specific treatment. There were no perforations or significant
complications from dilation.
Conclusion: EE is a recently recognized disease of increasing frequency.
Early recognition and treatment of EE could prevent food impaction and the
risk of mucosal tears with treatment. One should suspect EE in younger men
with solid dysphagia and any history of allergic disease. EE appears respon-
sive to a variety of therapies. Dilation appeared safe in our series in contrast
to prior series that showed substantial perforation rates. Potential areas for
further study include prospective trials of specific treatment modalities and
symptom recurrence after intervention.
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GERD, Helicobacter Pylori and MGUS – Is There a Relationship?
Maninder Pabla, MD, Jaswinder Singh, MD∗, Ashok Malani, MD, Vijay
Patel, MD, Chao Haung, MD, Suman Kambhampati, MD, Peter Van
Veldhuizen, MD. Hematology and Oncology, KU Medical Center, Kansas
City, KS and Internal Medicine, Heartland Regional Medical Center, Saint
Joseph, MO.
Purpose: Monoclonal Gammopathy of unknown significance is character-
ized by low levels of monoclonal protein (M protein) in the serum or urine
that is produced by a single clone of plasma cells. There has been no liter-
ature confirming the etiology of this condition. Recently, MGUS has been
found to be associated with chronic infections (Hep B, C and HIV) and
autoimmune diseases. While making an attempt to recognize additional as-
sociated factors, we searched for other chronic inflammatory conditions
(example GERD) and other subtle chronic infections (example H. Pylori).
There is no literature available on the incidence of GERD in MGUS. More-
over, there has been conflicting reports on the prevalence of H. pylori and
MGUS.
Methods: We identified 394 patients with MGUS at veterans affairs medical
center, Kansas City diagnosed over last 20 years. Charts on these patients
were reviewed for clinical diagnosis of GERD, endoscopic findings, patho-
logical biopsies, H. Pylori staining on histology, SPEP/IFE, immunoglobulin
levels and bone marrow biopsies.
The control group consisted of randomly selected patients (N = 400) from
out patient primary care clinic at the same institution.
Results: 41% (162/394) of patients with MGUS were noted to have moderate
to severe symptoms of GERD as compared to 25%(102/400) in the control
group. 60% (97/162) of MGUS patients with GERD underwent endoscopies
as compared to 41% (42/102) of patients in the control group. Histology was
positively stained for H. Pylori in 27.8% patients (27/97) in MGUS and
14%(6/42) of control group. We found no correlation between H pylori
positivity and type or level of monoclonal protein in MGUS. In addition,
we observed no change in immunoglobulin levels following treatment and
eradication of h pylori in MGUS patients
Conclusion: At our institution, patients with MGUS have higher preva-
lence of GERD. Our findings need to be confirmed and verified in further
prospective studies. No correlation was seen between H. pylori infection and
MGUS.
Patient Characteristics
Pt characteristics MGUS(394) General Pop (400)
Median Age 74 65
GERD 162 102
Endoscopies 97 42
H. Pylori 27 6
BMI 28 28.17
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Prevalence of GERD
GERD MGUS (N = 394) Control (N = 400)
Present 162 102
Absent 232 298
P value < 0.001
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TAK-390MR vs. Lansoprazole (LAN) for Maintenance of Drug
Concentration above a Threshold Which Corresponds to
Higher%-Time pH > 4
J. Wu, PhD∗, M. Vakily, PhD, G. Witt, MS, D. Mulford, PhD. TAP
Pharmaceutical Products Inc, Lake Forest, IL.
Purpose: TAK-390MR is a proton pump inhibitor employing modified re-
lease (MR) technology designed to provide prolonged plasma concentration
of TAK-390 following once daily oral dosing. To better characterize the rela-
tionship between drug exposure and%-time intragastric pH > 4, a threshold
plasma TAK-390 concentration was identified using modeling. The ability
of the MR formulation to keep drug concentration above this threshold was
evaluated and compared to that of LAN’s delayed-release dosage form.
Methods: Post-hoc analysis and modeling was conducted using data from
3 open-label, multiple-dose, single-center, crossover phase 1 studies to de-
termine a threshold plasma concentration and a model that maximizes the
relationship between the%-time that intragastric pH > 4 and the%-time that
plasma concentrations are above a threshold value over a 24 h postdose in-
terval. LAN (30 mg), TAK-390 (20, 30, 60, 90, or 120 mg), or TAK-390MR
(60, 90, or 120 mg) plasma concentrations were measured within 24 h after
5 days of daily dosing. Nine TAK-390 concentration levels (15, 30, 60, 125,
250, 500, 1000, 2000, and 3000 ng/mL) were evaluated as possible thresh-
olds; the %-time that plasma concentrations were above each threshold over
24 h postdose was determined. Four models were used to characterize the
relationship between the %-time that plasma concentrations were above a
threshold and the %-time pH > 4 during 24 h postdose; AIC was used to iden-
tify the best fitted model and threshold plasma concentration. The %-time
plasma concentrations were above this threshold for LAN and TAK-390MR
were assessed.
Results: Data from 92 subjects were analyzed. Based on this analysis,
125 ng/mL was derived as the threshold. For LAN (30 mg), the mean %-time
that plasma concentrations were >125 ng/mL was 17%, compared to 34–
50% for TAK-390MR regimens (30–120 mg). Based on the best fitted model,
the mean%-time above the 125 ng/mL threshold for LAN corresponds to an
estimated%-time of pH > 4 of 50% compared to 65–70% for TAK-390MR
regimens.
Conclusion: Based on TAK-390 and LAN data, the plasma concentration
of 125 ng/mL was identified as the threshold that maximizes the relationship
between the%-time plasma concentration above this level and the%-time
intragastric pH > 4 over 24 h postdose. In this analysis, TAK-390MR main-
tains plasma drug concentrations above this threshold approximately 2–3
times longer than LAN. This difference appears to provide greater%-time
pH > 4.
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Endoscopic Full-Thickness Plication for the Treatment of GERD: Five
Year Multi-Center Results
Douglas Pleskow, MD∗, Richard Rothstein, MD, Richard Kozarek, MD,
Gregory Haber, MD, Christopher Gostout, MD, Simon Lo, MD, Robert
Hawes, MD, Anthony Lembo, MD. Beth Israel Deaconess Medical Center,
Boston, MA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Virginia
Mason Medical Center, Seattle, WA; Lenox Hill Hospital, New York, NY;
Mayo Clinic, Rochester, MN; Cedars Sinai Medical Center, Los Angeles,
CA and Medical University of Southern Carolina, Charleston, SC.
Purpose: We previously reported the Plicator (NDO Surgical, Inc., Mans-
field, MA) procedure, which is an endoscopic procedure that delivers a full-
thickness plication, to be effective at reducing GERD symptoms and med-
ication use for up to 3-years post-plication with no long-term procedural
adverse events. The purpose of this study was to assess the long-term safety
and treatment durability of the Plicator up to 5-years post-plication.
Methods: Subjects with chronic heartburn who had originally participated
in the open-label study and received a single plication in the gastric cardia
approximately 1 cm below the gastroesophageal junction were eligible. Sub-
jects were evaluated at baseline for GERD symptoms and medication use.
Long-term subject follow-up was completed to evaluate safety and long-term
treatment durability.
Results: Twenty-eight subjects completed the long-term follow-up (mean
follow-up interval: 5 years (58 months), range: 50–65 months). All
procedure-related adverse events occurred acutely, as previously reported,
and no new adverse events were observed during extended follow-up. At
5-years post-procedure, 62% of baseline PPI-dependent patients remained
off daily PPI therapy. Treatment effect remained stable from the 3 to 5-year
follow-up interval, with 16/28 patients off daily PPI at 3-years compared
to 15/24 patients at 5-years. Median GERD-HRQL scores remained signif-
icantly improved at 5-years versus baseline off-meds scores (10 vs. 19, P <
0.001). In addition, the proportion of patients achieving ≥ 50% improvement
in GERD-HRQL score was consistent from 3-years (55%) to 5-years (50%).
Conclusion: Endoscopic full-thickness plication can effectively reduce
GERD symptoms and medication use for at least 5-years post-procedure.
Treatment effect is stable for 5-years and there are no long-term procedural
adverse effects.
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What Is the Truth? Sleep Disturbance as Assessed by Investigators or
a Validated Instrument (ReQuestTM) in Patients with GERD
Gerald Holtmann, MD, Richard Hunt, MD, Peter Katelaris, MD, Peter
Berghoefer, PhD, Hubert Doerfler, MD, Jan Tack, MD∗.
Gastroenterology, Royal Adelaide Hospital, Adelaide, SA, Australia;
Gastroenterology, McMaster University, Hamilton, ON, Canada;
Gastroenterology, University of Sydney, Concord Hospital, Sydney,
Australia; Gastroenterology, ALTANA Pharma AG, Konstanz, Germany
and Gastroenterology, University of Leuven, Leuven, Belgium.
Purpose: Sleep disturbance in GERD patients impairs quality of life and
reduces work productivity. Over- and under-reporting of symptoms before,
during and after therapeutic intervention is a well-known phenomenon in
daily clinical practice. We systematically assessed sleep disturbance in a
GERD trial utilizing assessment by the investigator and ReQuestTM, a vali-
dated sensitive tool for the evaluation of GERD symptoms.
Methods: In this open, multinational, multicenter trial 633 GERD patients
were treated with pantoprazole 40 mg daily for 28 days. For the assessment
of GERD symptoms patients completed ReQuestTM daily, while the inves-
tigator assessment was performed at day 0, 14 and 28. The proportion of
patients troubled by sleep disturbance on all of the 7 consecutive days prior
to day 0, 14 and 28 was compared between patient self-assessment with
ReQuestTM and investigator assessment and 95% confidence intervals were
calculated.
Results: The comparison of point estimates and confidence intervals for the
proportion of patients (PP; nequals; 538) yielded a statistically significant
difference at baseline, during and after therapy between the two modes of
assessment.
Conclusion: There is a discrepancy between investigator and patient symp-
tom assessment regarding the proportion of GERD patients with sleep distur-
bance. The reduction of these numbers over time is similar comparing the two
assessment modes. The significantly lower proportion of patients assessed as
suffering from sleep disturbance according to investigator assessment may
be due to underestimation of symptoms by the investigator. Thus, inves-
tigator assessment alone may not be the optimal means to evaluate sleep
disturbance (and other symptoms) in GERD patients, as underestimation
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of symptoms may lead to inappropriate therapeutic decisions. These data
may also suggest that prolonged PPI treatment might be required to properly
improve GERD related sleep disturbance.
Proportion of Patients Suffering from Sleep Disturbance (%; CI 95%)
ReQuestTM assessment Investigator assessment
Day 0 84.9% 53.9%
[80.7, 88.5] [49.6, 58.2]
Day 14 69.6% 40.2%
[65.4, 73.5] [36.0, 44.5]
Day 28 56.9% 29.0%
[52.3, 61.5] [25.2, 33.1]
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Pantoprazole Is Significantly More Effective in Relieving GERD
Symptoms Than Esomeprazole
Gyo¨rgy Rumi, MD, Luciana Camacho Lobato, MD, Bernd Rosenstock,
PhD, Hartmut Heinze, MD∗. Internal Medicine, Kaposi Mo´r
Oktato´ko´rha´z, Kaposva´r, Hungary; Gastroenterology, Hosp. Sao Paulo da
Univ. Federal de S.P., Sao Paulo-SP, Brazil; Clinical Operations, ALTANA
Pharma AG, Konstanz, Germany and Clinical Development, ALTANA
Pharma AG, Konstanz, Germany.
Purpose: Symptom relief is known to be the most important treatment out-
come for GERD patients, as symptoms impair the health related quality of
life substantially.
Methods: Results from a randomised, double blind, multicenter study con-
ducted in Brazil, Germany, Hungary, and Italy are presented. In patients with
GERD Grade II/III Savary-Miller (verified by initial endoscopy) the effect
of pantoprazole 40 mg once daily (qd) (PANTO) and esomeprazole 40 mg
qd (ESO) on GERD symptoms was compared after 28 days of treatment.
The investigator documented the intensity of GERD-associated symptoms
(heartburn, acid regurgitation, dysphagia, epigastric pain/discomfort, flat-
ulence, retrosternal tightness, fullness, nausea/vomiting, lower abdominal
pain, sleeping disturbance, burping/belching, and coughing) described as
none (0), mild (1), moderate (2), or severe (3). Freedom from symptoms was
defined as the absence of all symptoms for at least 3 days before the visit.
Symptom relief was compared between the treatment groups by using the
one-sided Median Two-Sample Test.
Results: In the per-protocol population 290 patients were included. At base-
line, the mean sum scores of GERD-associated symptoms were comparable
between the two treatment groups (PANTO: 11.17; ESO: 11.60; P > 0.05).
After 4 weeks of treatment the mean sum scores decreased significantly to
1.35 in the PANTO and 1.68 in the ESO group (P < 0.05), implying symptom
relief rates of 56.3% and 46.6%, respectively.
Conclusion: After 28 days of treatment more patients were without GERD
symptoms with PANTO and their symptom load was significantly more
reduced compared to ESO.
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Black Esophagus Associated with Malignancy and Use of
FOLFOX/Avastin
Olivia C. Forys, MD, Dawn D. Ferguson, MD∗. Internal Medicine, Mayo
Clinic, Rochester, MN and Gastroenterology, Mayo Clinic, Rochester, MN.
Purpose: Black esophagus is an endoscopic diagnosis characterized by
necrotic tissue in the esophagus. It is a rare diagnosis, with less than 100
cases reported in the literature over the past 50 years. Black esophagus has
been associated with severe illness and infection, but its association with
malignancy or specific chemotherapeutic agents has not been reported. We
describe cases of black esophagus at our institution over the past three years,
with special attention paid to the presence of malignancy.
Methods: We performed a retrospective chart review on all patients that
had the endoscopic diagnosis of “black esophagus” or “necrotic esopha-
gus” between 2004 and 2007. We evaluated patients’ age, gender, indication
for endoscopy, presence of malignancy, pathologic reports, treatment with
chemotherapeutic agents and 6 month mortality. We present continuous data
as means and categorical data as percentages.
Results: Six patients with black esophagus were identified. Half of these
patients were female and the mean age was 65 years. The most common
indication for endoscopy was hematemesis (83%). Five of our six patients had
malignancy: colon (2), small bowel (1), pancreas (1), breast (1), prostate (1).
One patient had both colon and prostate cancer. Three patients had received
chemotherapy, and two of these (66%) had received FOLFOX (Oxaliplatin,
fluorouracil, and leucovorin). The 6 month mortality of patients in our series
was 33%.
Conclusion: In this small case series, malignancy was highly prevalent
among our patients with black esophagus. Of the patients that had recently
received a chemotherapeutic agent, the majority had been treated with FOL-
FOX/avastin. Oxaliplatin and fluorouracil are both known to cause mucositis
and fluorouracil can cause esophagitis. The association with the administra-
tion of FOLFOX/avastin and the development of black esophagus in this
case series should foster consideration of this important outcome in patients
receiving this chemotherapeutic regimen.[figure1]
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Clinical Efficacy and Problems of a Simple Questionnaire (F-Scale) for
the Diagnosis of GERD in the Elderly
Toshiyasu Watanabe, Yoshihisa Urita∗, Tadashi Maeda, Kaoru Domon,
Susumu Ishihara, Asuka Nakayama, Makie Nanami, Tomohiro Arita,
Tatsuhiro Yamamoto, Takamasa Ishii, Akiro Kugahara, Hirohito Kato,
Kazuo Hike, Noriko Hara, Yoshiko Honda, Yoko Nagai, Shuji Watanabe,
Kazushige Nakanishi, Nagato Shimada, Motonobu Sugimoto, Kazumasa
Miki. Division of Gastroenterology and Hepatology, Toho University,
Tokyo, Japan; Department of General Medicine and Emergency Care,
Toho University, Tokyo, Japan and Department of Hematology, Toho
University, Tokyo, Japan.
Purpose: Gastro-esophageal reflux disease (GERD) is a common disease
in Western countries. Recently, the prevalence of GERD is increasing in a
Japanese population with a high prevalence of atrophic gastritis. Although
it is difficult to diagnose accurately GERD by non-invasive tests, a simple
questionnaire (F-scale) to score GERD symptoms is now produced in Japan,
which has a good correlation with endoscopic findings. However, it may
be difficult for elderly people to understand the questions and to fill out a
questionnaire correctly in a short time. The aim of this study was to evaluate
the efficacy of F-scale for the diagnosis of GERD symptoms in the elderly.
Methods: 1686 consecutive patients (797 men and 889 women with a mean
age of 43 years) who first attended the Outpatient Department of General
Medicine and Emergency Care of Toho University were enrolled in the
present study. They were asked to respond the F-scale questionnaire re-
gardless of their chief complaints. This questionnaire was devised from 12
questions, which were scored to indicate the frequency of symptoms, as fol-
lows: never = 0; occasionally = 1; sometimes = 2; ofteN = 3; and always =
4. If the patient has a score of more than 7 point, GERD is considered as
positive.
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Results: A total of 647 patients with GERD were identified. The positive rate
of the questionnaire was 277 of 797 men (35%) and 361 of 889 women (41%).
Unexpectedly, the prevalence of GERD was highest in the 20–29-aged group
(45%), followed by the 30–39-aged group (40%), and the 40–49-aged group
(39%). The group aged with 70–79 had the lowest prevalence (26%) and had
the largest proportion of patients with a point of zero.
Conclusion: The prevalence of GERD symptoms in general practice was
much higher than reported previously. Furthermore, the prevalence of GERD
was highest in the group aged with 20 to 29 and decreased with age. The
lower prevalence in aged persons may reflect the difficulties in filling out
F-scale. GERD symptoms are possibly underestimated in the elderly.
21
Long Term Follow up of Patients Treated with Stretta
Robert P. Yatto, MD∗, Geneva Russell, CGRN, Deborah Hargis, CGRN,
Nancie Gunter, CGRN. Endoscopy Department, Cumberland Medical
Center, Crossville, TN.
Purpose: Assess long term durability of Stretta procedure for GERD based
on intent to cure criteria.
Methods: Telephone and in person interviews were done on 56 of 61 patients
who underwent Stretta procedure for GERD from 53 to 60 months previously.
The only parameter used to judge long term effectiveness was the use of PPIs,
as our intent was to resolve GERD symptoms. Quality of life assessments
were not evaluated.
Results: Of the 56 patients (92%) available for follow up only 9 (16%) were
not using PPI. None of these patients have had post Stretta complaints re-
quiring further evalutions of the esophagus or stomach. Of the 47 patients
using PPI, 39 (83%) had 3, 6 and/or 12 month follow up questionnaires that
indicated improvement in GERD symptoms, but later needed to resume PPI
use. Time to resumption of PPI use in the nonresponders ranged from 0 to
23 months (median 14.6 months). Five patients (10%) developed symptoms
of gastroparesis confirmed by nuclear imaging studies. Six patients (13%)
required esophageal dilations for dysphagia. One patient in this group had a
fundoplication after Stretta. No predictors of a favorable result could be iden-
tified based on pre Stretta evaluations with endoscopy, esophageal motility
testing or 24 hr pH testing, but the highest DeMeester score in the favorable
outcome group was 47.4.
Conclusion: The Stretta procedure does not provide durable long term relief
for GERD. If the intent of use of the Stretta procedure is to cure GERD
symptoms and avoid use of PPIs, only a small percentage of patients can be
expected to benefit. A substantial percent of nonresponders require further
treatment for dysphagia and gastroparesis
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Presentation and Prognosis of Esophageal Adenocarcinoma in Patients
below Age 50
Nikroo Hashemi, MD, Sidney Cohen, MD, Terry Hyslop, PhD, Anthony J.
DiMarino, MD, David E. Loren, MD∗. Gastroenterology and Hepatology,
Thomas Jefferson University Hospital, Philadelphia, PA and Biostatistics,
Thomas Jefferson University Hospital, Philadelphia, PA.
Purpose: Esophageal adenocarcinoma (EAC) has one of the fastest growing
incidence rates of all cancers in the United States. Although the majority
of patients are diagnosed at an advanced age, EAC is now increasingly
recognized in younger patients in whom the clinicopathologic features have
been poorly described.
The aims of this study are to compare clinical presentation between early
(i.e. ≤ 50 years) and later onset EAC, and to evaluate factors associated with
survival.
Methods: Records of patients with EAC diagnosed 1994–2004 were ret-
rospectively reviewed. Data were collected on demographics, social his-
tory, family history of cancer, clinical presentation, diagnosis during Bar-
rett’s surveillance, endoscopic and histologic findings, treatment, and sur-
vival. Chi square analysis was performed for group comparisons. Sur-
vival was assessed with Kaplan-Meier analysis and the log-rank test. Cox
models were used for multivariable analysis in a stepwise backwards
manner.
Results: 31 of 242 (12.8%) of EAC patients were ≤50 years at diagnosis.
There was no difference between the two groups in sex distribution, smoking
history, family history of cancer, or GERD. Patients ≤50 years were more
likely to present with dysphagia (80% vs. 60%, P < 0.002) and have dyspha-
gia for >6 months (25% vs. 7%, P < 0.0001). Patients ≤ 50 years were more
likely to have lymphatic spread at diagnosis (48% vs 31%, P = 0.015). There
was no difference in the T or M stage at presentation. Median survival was
16.3 months (13.2–21.4) for younger patients and 22.3 months (16.2–28.4)
for older patients (P = NS). Factors associated with shortened survival were
dysphagia at presentation, advanced histologic grade, lymphatic spread and
esophagectomy. By multivariable analysis shortened survival was associated
with histologic grade (P = 0.03) and lymphatic spread (P = 0.01). In 16
patients EAC was detected during Barrett’s surveillance, all of whom were
older than age 50. There was no survival difference whether or not EAC was
diagnosed in a surveillance program.
Conclusion: 1) Patients under age 50 comprise a significant minority of
newly diagnosed EAC. 2) Diagnosis is delayed in younger patients presenting
with dysphagia, thereby contributing to adverse outcomes and advanced
stage at time of diagnosis. Early endoscopy should be considered in the
evaluation of GERD and dysphagia, particularly for patients younger than
50 years.
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Prevalence and Impact of Co-Morbid Psychological Distress on
Response to PPI Therapy in Patients with GERD
William D. Chey, MD∗, Borko Nojkov, MD, Joel R. Rubenstein, MD, Susan
A. Adlis, MS, Michael J. Shaw, MD. Division of Gastroenterology,
University of Michigan Health System, Ann Arbor, MI and Park Nicollet
Institute, Minneapolis, MN.
Purpose: Co-morbid psychological distress (PD) has been reported in a
substantial proportion of GERD patients (pts). However, little is known about
the impact of PD on response to proton pump inhibitor (PPI) therapy.
Aims: Determine the prevalence of co-morbid psychological distress and its
impact on response to PPI therapy in GERD pts.
Methods: Pts undergoing EGD for heartburn >2×/week were recruited. Pts
who had taken a PPI within 2 weeks of EGD were excluded. Participants
completed validated questionnaires (DHSI, RDQ, QoLRAD, BSI) and were
treated with rabeprazole 20 mg/d × 8 wks after which follow-up surveys
were completed. Pts were categorized as suffering from nonerosive disease
(NERD) or erosive disease (EE) at EGD. Psychological distress was defined
as a composite BSI score > 63.
Results: 101 pts (67 NERD, 34 EE, female = 54%, mean age = 48 yrs)
completed the treatment period and both sets of surveys. 42% of GERD
pts had co-morbid PD. There was no difference in the prevalence of PD
in NERD vs. EE. Overall, pts reported significant improvements in GERD
symptoms and disease specific QoL after rabeprazole (P < 0.001). Before
PPI therapy, co-morbid PD was associated with greater GERD symptoms
and significantly worse disease specific QoL. Following PPI therapy, pts with
and without PD experienced similar magnitudes of improvement in GERD
symptoms and QoL. However, pts with co-morbid PD had significantly more
residual GERD symptoms and worse disease specific QoL after PPI than did
those without PD (see table).
Conclusion: Over 40% of GERD pts had co-morbid PD. GERD outcomes
improved with PPI therapy regardless of the presence or absence of PD.
However, pts with PD had more severe baseline GERD symptoms and worse
QoL than those without PD. Further, pts with PD were left with more residual
symptoms and reduced QoL after PPI therapy. These observations highlight
the importance of identifying psychological distress when approaching the
treatment of GERD and identify an important subgroup of GERD pts who
might mistakenly be labeled as PPI nonresponders.
Abstracts S127
Supported by a grant from Eisai Inc and Ortho-McNeil Janssen
Effect of PD on RDQ and QoLRAD
BSI > 63 (N = 42) BSI < 63 (N = 59) P value
RDQ-Before 16.1 13 0.077
After PPI 9.8∗ 4.9∗ 0.007
QoLRAD-Before 3.5 4.5 <0.001
After PPI 4.6∗ 5.4∗ 0.006
∗Significant improvements after PPI, P < 0.001
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Yo-Yo Lipoma in My Esophagus
Daniald M. Rodrigues, MD, Rakish Parikh, MD, Satish Maryala, MD,
Joseph L. Kinzie, MD∗. Internal Medicine, Wayne State University, Detroit,
MI and Division of Gastroenterology, Wayne State University, Detroit, MI.
Purpose: Esophageal lipomas are exceedingly rare with only a handful of
documented case reports to date. We report a case of a large esophageal
lipoma inducing symptoms of gastroesophageal reflux disease (GERD). We
herein advocate the utility of esophogastrodeudonoscopy (EGD) and endo-
scopic ultrasound (EUS) in diagnosing gastric lipomas and aiding in subse-
quent removal without the need of invasive surgery.
Case Report: A 62-year-old female with a three-year history of GERD
presents with recurrent heartburn. The patient tried a three-month period of
a proton pump inhibitor that was also refractory to symptoms.
The patient was evaluated with an EGD that demonstrated a 2 cm × 2 cm
submucosal pedunculated mass extending from a narrow stalk at the distal
esophagus (Fig. 1). On endoscopy, the mass was observed slipping in and
out of the GE junction like a ‘yo-yo’ (Fig. 2). An endoscopic ultrasound was
then performed demonstrating no vasculature and findings consistent with a
lipoma (Fig. 3).
The 2×2 cm mass was then removed using a hot snare and extracted with
a roth basket after passing it in the stomach. The esophagus was left intact
without complication (Fig. 4). The pathology demonstrated the tissue to be
consistent with a lipoma (Fig. 5). The patient tolerated the procedure well
with resolution of her GERD and was discharged home the same day.
Discussion: Lipomas can be diagnosed based upon physical appearance,
but have low sensitivity. Cushion sign or pillow sign has demonstrated 40%
sensitivity and 98.8% specificity. EUS offers a more definitive method for
diagnosis of lipomas and according to Hwang et al., can be diagnosed by
EUS characteristics alone without need for histopathology. EUS can also
assist and aid in mapping the grounds of a tumor, and ruling out possible
vasculature invasion of tumors.
Previous case reports and series have used open surgery and laparoscopic
means to remove esophageal tumors. However Wehrmann et al. states in their
case series that esophageal masses less that 4 cm in size can be safely removed
using both EUS and EGD. Our case further corroborates the utility of EUS
and EGD in removing esophageal lipomas. It also provides a safer and less
invasive alternative then either open or laparoscopic surgery. Furthermore, to
the authors’ knowledge, this is the first described case of a lipoma inducing
GERD with complete resolution of symptoms following lipoma removal
utilizing EUS and EGD.
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Endoscopic Full-Thickness Plication for the Treatment of GERD: 6
Month Data of the German Multi-Center Serial Implant Trial
Karel Caca, MD, Ingolf Schiefke, MD, Karl-Herrmann Fuchs, MD, Daniel
von Renteln, MD, Susanne Radczynski, MD, Michael Philipper, MD,
Wolfram Breithaupt, MD, Horst Neuhaus, MD∗. Department of
Gastroenterology, Klinikum Ludwigsburg, Germany; Department of
Gastroenterology, University of Leipzig, Germany; Department of Surgery,
Markus-Krankenhaus Frankfurt, Germany and Department of Internal
Medicine, EVK Duesseldorf, Germany.
Purpose: In a recently published prospective randomized, sham-controlled
trial, the PlicatorTM (NDO Surgical, Inc.) proved effective at controlling
reflux symptoms and reducing medication use and esophageal acid exposure.
In several cases the narrowing of the GE-junction remains incomplete with
a single Plicator implant. Therefore, we evaluated the safety and efficacy of
placing serial Plicator implants within 1 cm of the anterior GE-junction for
the treatment of GERD in the multi-center setting.
Methods: 41 subjects with chronic heartburn requiring daily PPI-therapy
were treated at four sites. Subjects received multiple full-thickness plica-
tions serially placed in the gastric cardia <1 cm below the GE-junction.
At baseline and 6-months post-plication, subjects completed the GERD-
HRQL-assessment, GERD medication-use diary, GERD related symptom
VAS, 24-hour esophageal pH monitoring, control gastroscopy and manom-
etry.
Results: 41 subjects underwent endoscopic full-thickness plication with se-
rial implants (2–3). 40 subjects completed the 6-month follow-up assess-
ment. All procedure-related adverse events occurred acutely (abdominal pain
42%; radiating shoulder pain 20%; chest pain 17%; sore throat 15%). No
new adverse events were observed during the follow-up. At 6 months post-
procedure, 65% (26/40) of baseline PPI dependent patients remained off
daily PPI therapy. Median GERD-HRQL scores were improved at 6-months
versus baseline off-med scores (6 vs. 25, P < 0.001) and versus baseline
on-med scores (6 vs. 11, P = 0.02). Median VAS scores were improved at
6-months versus baseline off-med (16 vs. 84, P < 0.001) Median esophageal
acid exposure improved (9 vs. 11, P = 0.02) with normalization of pH noted
in 31% of subjects. Median LES resting pressure also improved at 6-months
(10 vs. 6, P = 0.017). Mean esophagitis grade improved by 48% (P = 0.005)
at 6-months compared to the mean baseline esophagitis grade.
Conclusion: The results of the multi-centre study are similar to six month
pilot study results in demonstrating the safety and efficacy of the serial im-
plant technique in reducing esophagitis, PPI use, GERD symptoms, GERD
medication use, and esophageal acid exposure.
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Endoscopic Full-Thickness Plication with Two Serially Placed
Implants Improves Esophagitis, GERD Symptoms and Reduces PPI
Use and Esophageal Acid Exposure
Daniel von Renteln, MD, Ulrike Brey, MD, Bettina Riecken, MD, Karel
Caca, MD∗. Department of Gastroenterology, Klinikum Ludwigsburg,
Ludwigsburg, Germany.
Purpose: Recently, several endoluminal procedures for the treatment of
GERD have been introduced. However, most of these techniques have been
abandoned due to either lack of long-term efficacy or serious side effects. In a
recently published prospective randomized, sham-controlled trial, the Plica-
torTM (NDO Surgical, Inc.) proved effective at controlling reflux symptoms
and reducing medication use and esophageal acid exposure.
Methods: In all studies to date, a single Plicator implant was placed to form
a full thickness plication of the anterior gastric cardia. However, in several
cases the narrowing of the GE-junction remained incomplete with this tech-
nique. Therefore, we evaluated the safety and effectiveness of placing two
Plicator implants within 1 cm of the anterior GE-junction for the treatment
of GERD.
Results: 37 patients underwent endoscopic full-thickness plication using
two serially placed Plicator implants. At 6 months post-treatment, the pro-
portion of patients achieving >50% improvement in GERD-HRQL score
was 68%. Complete PPI cessation was achieved in 59% of patients. In
pH studies conducted at 6-months (N = 29), median percent time pH <
4 decreased 36%, with 28% of patients experiencing pH normalization.
Erosive Reflux Disease (ERD) was diagnosed in 21 patients before endo-
scopic full-thickness plication. 16 patients had NERD before endoscopic
full-thickness plication. Six months after endoscopic full-thickness plica-
tion the number of subjects with ERD was 15 and the number of subjects
without esophagitis was 22. There were no serious adverse events observed.
Minor adverse events included abdominal pain (73%), sore throat (54%),
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and chest pain (57%). All adverse events resolved spontaneously without
intervention.
Conclusion: In this study, endoscopic full-thickness plication using two
serially placed Plicator implants was both safe and effective in reducing
esophagitis, GERD symptoms, GERD medication use, and esophageal acid
exposure. When compared to previous studies using a Plicator single implant
technique, the Plicator multiple-implant technique demonstrates a similar
safety profile and superior efficacy.
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Are There Differences in Sensitivity Thresholds to Balloon Distention
in the Upper and Lower Esophagus?
Muhammad Hasan, MD, Sheila Rodriguez-Stanley, PhD, Susan Riley, RN,
Sattar Zubaidi, Philip B. Miner, Jr., MD∗. Gastroenterology, The
University of Oklahoma Health Sciences Center, Oklahoma City, OK and
The Oklahoma Foundation for Digestive Research, Oklahoma City, OK.
Purpose: The proximal and distal esophagus are different with respect to
muscule type, structure, innervation, and gradient of calcium channels and
nitric oxide concentration. Our aims were: 1) To verify that an improved
method of measuring the placement of the balloon catheter does not alter
balloon sensitivity parameters, 2) To assess symptoms provoked by barostat
balloon distention of the upper and lower esophagus and 3) To compare
sensitivity thresholds to balloon distention in the upper vs lower esophagus
in normal subjects.
Methods: Subjects were randomized to 2 esophageal barostat sessions, per-
formed within a 7-d period. After manometry (using traditional or new mea-
suring technique), subjects underwent Barostat balloon distentions at 5 ml
increments at 5 cm above the LES, and 3 cm below the UES. 1st sensation,
1st discomfort, and max pain (request to terminate) were determined, with
symptoms also collected. Means were generated and a paired 2-tailed T-test
was performed (P = 0.05).
Results: Data were analyzed from 21 subjects (13 f, 8 m; mean age 27.6 yrs).
There were no differences in balloon sensitivity thresholds between sessions
(traditional vs new measuring technique) (P > 0.05). 1st sensation and 1st
discomfort were significantly lower in the proximal vs distal esophagus (P <
0.05). Max pain was not different between esophageal regions (traditional
method: 33.6 ml distal vs 25.7 proximal, P = 0.18; new method: 33.6 ml
distal vs 28.6 ml proximal; P = 0.44). Distal esophageal balloon distention
produced chest discomfort in 20/21 subjects, chest tightness in 11/21, and
fullness in 9/21 subjects. In the upper esophagus, chest discomfort was most
common (18/21), with chest tightness (14/21) and chest pain (11/21) also
produced. Cough was produced in 5/21 subjects in the upper and lower
esophagus; burning was produced in 8/21 subjects in the lower and 9/21
subjects in the upper esophagus.
Conclusion: Sensitivity thresholds are repeatable and were lower in the prox-
imal vs distal esophagus. Balloon distention produced numerous symptoms,
although unfamiliar, in this normal group, the most prominent of which was
chest discomfort. Cough and burning were also produced by esophageal
balloon distention in the upper and lower esophagus in this normal
group, suggesting neurologic reflex pathways are independent of pathologic
reflex.
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High Cortisol Levels Are Correlated to Low Esophageal Pain
Threshold to Balloon Distention in Patients with NERD and
Functional Heartburn
Sheila Rodriguez-Stanley, PhD, Maggie Wolff, Tisha Adams, Philip B.
Miner, Jr.∗. The Oklahoma Foundation for Digestive Research, Oklahoma
City, OK.
Purpose: The relationship between serum cortisol and visceral pain varies
dramatically in published studies. In patients with functional GI disorders
(FGID), symptoms are often absent during the night when cortisol is low.
However, patients with FGID and low awakening cortisol reported the great-
est pain (Ehlert 2005). Rectal balloon distention in patients with IBS vs
chronic constipation (CC) vs controls (C) indicated IBS patients had the
lowest sensory thresholds than CC and C (Walter et al., 2006). Our aims
were: 1) To describe the relationship between serum Cortisol and maxi-
mum tolerable pain to balloon distention of the esophagus in patients with
functional heartburn (FxHB), 2) To compare cortisol, ACTH, and balloon
sensitivity parameters in functional heartburn vs NERD.
Methods: 26 patients underwent esophageal balloon distention with MTD
(volume and corresponding mean and maximum pressure). 14 patients fit
criteria for FxHB and were assessed on 4 occasions (N = 56). 12 patients
fit criteria for NERD and were assessed once (N = 12). Blood samples for
serum cortisol and ACTH were collected within 90 min prior to balloon
distention. Regression analysis was performed between maximum tolerable
pain (ml of balloon volume and corresponding mean and maximum mmHg
pressure at MTD) and serum Cortisol levels (ug/dl), and between Cortisol
and ACTH levels (pg/ml). Parameters were compared via t-test (P = 0.05
level of significance).
Results: There were no differences between FxHB and NERD in mean
Cortisol (11.6 vs 9.8 mg/dl), mean ACTH (17.5 vs 16.4 pg/ml), or mean
sensitivity parameters (22.7 vs 19.2 ml balloon volume; 29.3 vs 28 mmHg
mean pressure; 48.9 vs 41.5 mmHg max pressure; all P > 0.05). Therefore
all patients were grouped together (N = 68 observations). MTD volume
approached significance related to cortisol levels (P = 0.07); however, mean
pressure at MTD was significantly and inversely related to serum cortisol
level (r = 0.50; P = 0.000122). Maximum balloon pressure at MTD was
also significantly and inversely related to cortisol level (r = 0.31; P = 0.01).
As expected, Cortisol and ACTH were significantly related (r = 0.60. P =
1.8 × 10−6).
Conclusion: Overall, higher cortisol levels were significantly related to lower
pain threshold to esophageal balloon distention. The significant positive
relationship between ACTH and Cortisol indicate that patients had an intact
HPA axis. These data imply that adrenal function may play a role in functional
GI disease.
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The Prevalence of Barrett’s Esophagus in Patient with or without
GERD Symptoms
Xinqing Fan, MD, Ned Snyder, MD∗. Gastroenterology and Hepatology,
University of Texas Medical Branch, Galveston, TX.
Purpose: The incidence of adenocarcinoma of the esophagus is rising rapidly
in US, presumable because of the prevalence of intestinal metaplasia of the
esophagus (Barrett’s esophagus). Millions of Americans have chronic GERD
symptoms, and it is still controversial whether to screen these patients with
endoscopy in order to identify Barrett’s esophagus.
Methods: We searched the PENTAX EndoPRO database for the Endoscopy
Unit at the University of Texas Medical Branch. We divided the patients
into 2 groups: 1) Patients screened because of chronic GERD symptoms.
2) Patients undergoing upper endoscopy for other reasons. Patients with
known Barrett’s esophagus were also noted. Patients were determined to
have Barrett’s esophagus if salmon colored mucosa typical of specialized
columnar epithelium was described above the gastroesophageal junction.
The length of the Barrett’s esophagus in this study was reported from 2 cm
to 12 cm.
Results: There were a total of 5019 EGD’s in 4500 patients in our data base
from August 2005 to May 2007. 410 patients underwent upperendoscopy
because of GERD symptoms that were not responding to PPI therapy. 153
patients were male and 257 patients were female. 27 patients were found have
Barrett’s esophagus (6.5%). Among the 27 patients with Barrett’s esophagus,
17 patients were male and 10 patients were female. No significant age dif-
ference in this group was found between patients with and without Barrett’s
esophagus (51.9 ± 11 vs. 53.9 ± 13).
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The total number of patients with EGD performed for other reasons was
4090. 43 patients underwent surveillance for known Barrett’s esophagus.
80 patients (1.98%) were found incidentally to have Barrett’s esophagus
while undergoing endoscopy for another reason, among the patients in
whom’ Barrett’s esophagus was found incidentally. The asymptomatic pa-
tients with Barrett’s esophagus (age 58 ± 13) are significantly older than the
patients with Barrett’s esophagus and GERD symptoms (age 51.9 ± 11),
P < 0.01.
Conclusion: 1. More cases of Barrett’s esophagus were found incidentally,
than were found in patients being specifically screened for chronic GERD
symptoms. It is low yield to screen patients with chronic GERD symptoms.
The asymptomatic patients with Barrett’s may account for the high incidence
of adenocarcinoma.
2. Although female patients have a high prevalence of GERD symptoms
and perhaps seek more medical attention, there is higher yield of Barrett’s
esophagus in male patients with chronic GERD symptoms.
30
Low Grade Esophageal Eosinophilia in Adults: An Unrecognized Part
of the Spectrum of Eosinophilic Esophagitis?
Karthik Ravi, MD, Jeffrey A. Alexander, MD∗, David A. Neumann, MD,
Nicholas J. Talley, MD, Thomas C. Smyrk, MD, Ganapathy A. Prasad, MD,
Yvonne Romero, MD, Amindra S. Arora, MD. Internal Medicine, Mayo
Clinic, Rochester, MN; Gastroenterology and Hepatology, Mayo Clinic,
Rochester, MN and Pathology, Mayo Clinic, Rochester, MN.
Purpose: Eosinophilic Esophagitis (EE) has traditionally been defined by the
presence of greater than 20 eosinophils (eos) per high powered field (HPF)
on esophageal biopsy. The clinical significance of 20 eos/HPF or fewer is
unknown. We hypothesized that EE is a spectrum and lower eosinophil counts
reflect similar disease.
Methods: 121 adult patients without a previous diagnosis of EE with
esophageal biopsies containing 1 to 20 eos/HPF were identified by retro-
spective review of a database of patients with esophageal eosinophils on
biopsy at a tertiary care center between 2002 and 2006. Phone interviews
were conducted to ascertain long term symptom control.
Results: Patients with 1–5, 6–12, and 13–20 eos/HPF on esophageal biopsy
had similar clinical presentations and endoscopic findings (table). There
was no statistical difference among sex, race, and age in patients with 13 to
20 eos/HPF compared to those with 1 to 12 eos/HPF. Over 1/3 of patients
that had repeat endoscopy were diagnosed with EE (>20 eos/HPF). Phone
interviews conducted with 16 patients (5 with 1–12 eos/HPF) who received
swallowed topical corticosteroids found symptomatic improvement in all 16
patients following six weeks of treatment.
Conclusion: Patients with a clinical presentation consistent with EE and
indeterminate esophageal eosinophils on biopsy should be treated for EE.
The number of eosinophils per HPF on biopsy appears to be less relevant than
the clinical presentation. Moreover, the current diagnostic value of greater
than 20 eos/HPF should be reevaluated.
Clinical Features of Patients with 1–20 EOS per HPF
Findings
Suggestive >20 EOS per
# EOS Food Reflux or Allergy Peripheral of EE on HPF on F/U
per HPF Dysphagia Impaction Heart-Burn History£ Eosinophilia Y= Endoscopy§ Endoscopy
1 TO 5 82.4% 17.6% 52.9% 23.5% 36.4% 41.2% 33.3%
EOS/HPF (14/17) (3/17) (9/17) (4/17) (4/11) (7/17) (2/6)
6 TO 12 70.0% 27.5% 55.0% 17.5% 47.6% 40.0% 28.6%
EOS/HPF (28/40) (11/40) (22/40) (7/40) (10/21) (16/40) (2/7)
13 TO 20 81.3% 40.6% 48.4% 31.3% 28.6% 40.6% 44.4%
EOS/HPF (52/64) (26/64) (31/64) (20/64) (12/42) (26/64) (4/9)
£ Asthma or allergic rhinitis. Y= ≥0.3×109/L peripheral eos. § Ringed esophagus, furrows, non distal stricture, or whitish exudates
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Prevalence of Gastroesophageal Reflux Disease in Patients with
Non-Cardiac Chest Pain Presenting to the Emergency Department
Stephanie E. Thompson, MD, Julia J. Liu, MD∗, John R. Saltzman, Ling
Hua, Richard Zane. Division of Gastroenterology, University of Alberta
Hospital, Edmonton, AB, Canada and Division of Gastroenterology,
Emergency, and Cardiology, Brigham and Women’s Hospital, Boston, MA.
Purpose: This study prospectively evaluated the prevalence of Gastroe-
sophageal reflux disease (GERD) in Non-Cardiac Chest Pain (NCCP) pa-
tients in the ED
Methods: Patients were deemed to have NCCP after evaluation by an emer-
gency physician. Exclusion criteria were: recent history of ischemic events
(< 6 months); proton pump inhibitors use, pregnancy; active psychiatric
or unstable medical conditions. Study patients underwent upper endoscopy
with placement of the wireless Bravo pH capsule (Medtronic Inc., Shoreview,
MN) within two weeks of the initial ED visit. Esophageal, gastric or duo-
denal lesions were noted. The intraesophageal pH readings were recorded
for 48 hours. An abnormal pH study was defined as the total% time pH <
4 of over 4 percent on at least one of the two days of study. The prevalence
of esophageal acid exposure abnormalities and their corresponding 95%
confidence intervals were calculated.
Results: We screened 138 consecutive patients with NCCP in four months,
56 patients met exclusion criteria, 82 were eligible and 31 patients consented
and participated. There were 19 (61%) females and 12 (39%) males, 9 (29%)
Caucasians, 10 (32%) Hispanics, 10 (32%) African Americans and 2 (6%)
Asians. The average age was 47 (range 31 to 63) years. Endoscopic findings
in the 16 patients were: 3 (19%) had erosive esophagitis, and 3 (19%) had
non-erosive esophagitis. Three pH studies were excluded due to premature
capsule release, and 28 studies were analyzed. Abnormal esophageal acid
exposure were seen in 16 patients (57.1%, CI: 37.0%∼77.3%) on one of the
two days of monitoring. On day one, 7 out of 12 males (58%) and 6 out of
19 (32%) females had abnormal esophageal acid exposures; on day two, 6
males (50%) and 7 females (37%) were had abnormal studies. Women had
both supine and upright reflux: 6 out of 6 (100%) on day one and 5 out of 7
(71%) on day two had both supine and upright reflux. In contrast, men had
less supine reflux: 3 out of 7 (43%) day one and 4 out of 6 (67%) on day two
had supine reflux, 6 out of 6 (100%) on day one and 6 out of 7 (86%) on day
two had upright reflux.
Conclusion: We found a 57% prevalence of GERD in NCCP patients pre-
senting to the ED with more women than men with NCCP seen in the ED.
Potential gender differences in esophageal acid exposures warrant further
investigation.
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Barrett’s Esophagus under Antisecretory Therapy: The Higher the
Severity of Dysplasia, the Higher the Likelihood of Regression
Adewale B. Ajumobi, MD∗, Khaled Bahjri, MD, Sharma Rajiv, MD,
Ronald A. Griffin, MD. Internal Medicine, Loma Linda University, Loma
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Linda, CA; Public Health, Loma Linda University, Loma Linda, CA and
Gastroenterology, Jerry L. Pettis VA Medical Center, Loma Linda, CA.
Purpose: Barrett’s esophagus (BE) is a pre-malignant condition. Surveil-
lance endoscopy is recommended to detect either high grade dysplasia
(HGD) or esophageal adenocarcinoma (EAC) at an early, curable stage.
At the moment, treatment of BE is mostly limited to antisecretory therapy.
The purpose of this study is to evaluate the history of BE under antisecretory
therapy and to determine which pathologic grade at index diagnosis is most
likely to regress.
Methods: All patients with BE diagnosed or surveyed from 1995 to 2005
at a single medical center were included in the study. All patients with
EAC within 6 months of first endoscopy or patients with single endoscopic
biopsy results were excluded. The first pathologic report on file was taken as
the index pathologic grade. Subsequent pathologic grade was classified as
metaplasia (M), low grade dysplasia (LGD), or high grade dysplasia (HGD).
All patients were on antisecretory therapy (H2 blocker, proton pump inhibitor
or both).
Results: A total of 165 patients met study criteria. Most patients were males
(160/165, 97%) and white (148/165, 90%). More than half (91/165, 55%)
were obese at index diagnosis. Median surveillance length was 50 months.
Almost a third (54/165, 32.7%) were between the age of 50 and 59. Ini-
tial pathologic grades were as follows: M (97/165, 58.8%), LGD (62/165,
37.6%), and HGD (6/165, 3.6%). Overall, 53.3% had no change in pathologic
grade, 35.2% regressed to a lower pathologic grade, and 11.5% progressed to
a higher grade. None progressed to EAC; 3.6% (6/165) progressed to HGD
and 11.5% (19/165) regressed to normal mucosa. After adjusting for age,
BMI, and pathologic grades, those aged 65 and above were 1.5 times (OR
1.5, P-value 0.38) more likely to progress. Those with LGD and HGD were
39 times (OR 38.93, P-value 0.000) and 57 times (OR 57.0, P-value 0.001)
more likely to regress respectively.
Conclusion: The course of BE may be altered by antisecretory therapy.
There were more normalization of BE than progression to HGD or EAC with
surveillance under antisecretory therapy. Regression appears to be inversely
related to pathologic grade i.e. the higher the index pathologic grade, the
higher the likelihood of regression while on antisecretory therapy. Prospec-
tive studies are needed to validate these findings.
33
Esophageal pH Monitoring with BravoTM Capsule in Patients with
Suspected Gastroesophageal Reflux Disease
Soley Seren, MD, Ulas D. Bayraktar, MD, Murray N. Ehrinpreis, MD∗.
Medicine, Harper University Hospital, Detroit, MI; Gastroenterology,
Harper University Hospital, Detroit, MI and Medicine, Interfaith Medical
Center, Brooklyn, NY.
Purpose: Traditional catheter-based 24-hour esophageal pH monitoring is
limited by patient discomfort and a tendency for patients to alter their diet.
A catheter-free pH monitoring system (BravoTM) has been developed as
a more tolerable method which may also be more sensitive because of its
ability to record data over a 48-hour period. Our aim was to evaluate the
safety, performance, tolerability of the BravoTM monitoring system, and the
significance of extending pH monitoring to 48 hours.
Methods: The records of 112 patients with presumed or definite gastroe-
sophageal reflux disease (GERD) undergoing BravoTM pH monitoring were
reviewed. BravoTM capsule was placed 6 cm above the endoscopically iden-
tified squamo-columnar junction. All patients were instructed to carry the
receiver for a 48-hour study period. pH data, patient diaries and charts were
reviewed and analyzed.
Results: Of 112 patients (73 female), five had the test twice and two had it
three times. Of 121 available studies, 107 (88%) were included in the analysis
after excluding one case in whom the capsule could not be passed through
esophagus, one case with failure of capsule attachment to the esophagus, one
case in whom data could not be retrieved from the receiver, four cases with
less than 43 hours of recording, four cases with evidence of dislodgement,
and three cases with transmission artifacts. Chest pain was the most common
complaint during the study period, reported in 57% of studies. Only one
patient reported severe chest pain that necessitated a CT of the chest which
was normal. Of 107 studies, DeMeester score was above 14.72 in 56 (52%)
and mean AET (the percentage of time the distal esophageal pH is less than
4) was above 4.5% and 5.3% in 54 (50%) and 47 (44%), respectively. Of
94 studies in which AET was available for each day separately, AET was
≥ 4.5% in 41 and 39 studies on day 1 and day 2, respectively. Twenty-nine
studies were positive on both days; 12 were positive only on day 1 and 10
were positive only on day 2. Thus, a 48-hour study increased the sensitivity
by 11% compared to 24-hour study.
Conclusion: Forty-eight-hour esophageal pH monitoring with BravoTM cap-
sule is a safe, effective, and tolerable method that may also have a better
sensitivity in GERD detection than the conventional 24-hour monitoring
system.
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Characteristics of Patients with Reflux Esophagitis, Non-Erosive
Reflux Disease and Functional Heartburn
Soley Seren, MD, Ulas D. Bayraktar, MD, Murray N. Ehrinpreis, MD∗.
Medicine, Harper University Hospital, Detroit, MI; Medicine, Interfaith
Medical Center, Brooklyn, NY and Gastroenterology, Harper University
Hospital, Detroit, MI.
Purpose: Patients with non-erosive reflux disease (NERD) account for up
to 70% of the gastroesophageal reflux disease (GERD) population and rep-
resent a heterogenous group. Our aim was to compare the demographics and
clinical characteristics of patients with reflux esophagitis (RE), NERD, and
functional heartburn (FH).
Methods: We reviewed the medical records of 81 consecutive patients
with frequent heartburn and regurgitation on whom BravoTM capsule 48-h
esophageal pH monitoring was performed after capsule placement under en-
doscopic guidance. Patients were instructed to stop taking acid-suppressive
therapy at least 7 days before the pH study. An abnormal study was defined
as either a DeMeester score ≥ 14.72 or a mean acid exposure time (the per-
centage of time pH less than 4) ≥ 4.5%. Patients with esophageal mucosal
injury observed during capsule placement or during a prior endoscopy com-
prised the RE group. The remaining patients were divided into two groups
according to pH monitoring study results: NERD (those with an abnormal
pH study) and functional heartburn (FH) (those with a normal pH study).
Chi-square and t-test were used to compare categorical and continuous data
between groups.
Results: Of 81 patients, 28 (35%) were in the RE group, 27 (51%) com-
prised the NERD group and 26 (49%) met our criteria for the FH group.
No statistically significant difference was found between the three groups
in distribution with respect to age, prevalence of hiatal hernia, and present-
ing symptoms, except that patients with RE had more respiratory symptoms
(cough, hoarseness, shortness of breath) compared to patients with NERD
or FH (See Table), and patients with FH were more likely to be female.
Interestingly, only 16 of 28 RE patients had an abnormal pH study.
Conclusion: Patients with RE experience more respiratory symptoms com-
pared to patients with NERD or FH. As only 57% of RE patients had an
abnormal pH study, factors other than acid exposure may contribute to the
development of esophagitis. FH is more common in women than men.
n (%) RE (N = 28) NERD (N = 27) FH (N = 26)
Mean age 48 ± 14 48 ± 14 45 ± 12
Female 15 (54) 16 (59) 23 (89)∗
Respiratory symptoms 8 (29)∗ 2 (7) 2 (8)
Chest pain 14 (50) 17 (63) 17 (65)
Dysphagia or weight loss 8 (29) 4 (15) 4 (15)
Hiatal hernia 10 (36) 12 (44) 9 (35)
∗P < 0.05
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Utility of Catheter-Free Ambulatory pH Testing on PPI Therapy
Lydell C. Horine, MD, Sami R. Achem, MD, Ernest P. Bouras, MD, Mark E.
Stark, MD, Dawn D. Ferguson, MD, Kenneth R. DeVault, MD∗. Medicine,
Mayo Clinic, Jacksonville, FL and Medicine, Mayo Clinic, Rochester, MN.
Purpose: To determine the utility of performing ambulatory pH testing on
proton pump inhibitor (PPI) therapy using a catheter-free system (BRAVO).
Methods: All patients referred to our laboratory over a 24-month period for
an ambulatory 48-hour pH test and who were on a PPI at least once daily were
included. Patients were referred by a combination of gastroenterologists,
other subspecialists or primary care providers. The pH capsule was placed
during endoscopy, six centimeters above the squamo-columnar junction.
Patients were excluded if incomplete data were available or if the patient
inadvertently discontinued their PPI before or during the study. Percent acid
exposure for each day and for the total study was the primary endpoint. We
evaluated both the standard normal cutoff value for percent time pH < 4.0
(5.5%) and a commonly accepted normal value for BID PPI (1.6%). The
percentages of patients with abnormal acid exposure on day 1, day 2 and for
the total 2-day study period were calculated.
Results: 122 of 259 consecutive pH studies (47%) were performed on PPI
therapy. 12 patients were excluded from analysis (2 due to probe dislodge-
ment early in the study, 5 due to discontinuation of PPI during the study and
5 because time recorded on one of the two days was less than 12 hours). Of
the 110 remaining studies, 71 (65%) were on BID PPI and 39 (35%) on QD.
The percentages of patients with excessive acid reflux are presented in the
tables.
Conclusion: Catheter-free esophageal pH testing in patients on PPI therapy
provides complete data in the majority of patients. In this group of patients,
15.5% of studies on BID PPI show ongoing acid reflux (over 48 hours) using
the common cutoff of 5.5% and 35.2% using the alternative cutoff of 1.6%.
If abnormal reflux on either day is considered pathologic those percentages
increase to 23.9 and 43.7% respectively. There was a paradoxical finding of
fewer patients with a positive study on QD PPI possibly related to referral
bias. Testing using this method provides useful information on the presence
of ongoing acid reflux in patients on PPI therapy.
5.5% pH Cutoff (% abnormal)
Day 1 Day 2 Either Day Total Study
BID PPI 14.1% 12.7% 23.9% 15.5%
QD PPI 7.7% 7.7% 10.0% 7.7%
1.6% pH Cutoff (% abnormal)
Day 1 Day 2 Either Day Total Study
BID PPI 36.6% 29.6% 43.7% 35.2%
QD PPI 23.1% 15.4% 25.0% 20.5%
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Are Patients with Barrett’s Esophagus Likely To Develop Cancer or
High Grade Dysplasia If They Miss Their Surveillance Endoscopy?
Adewale B. Ajumobi, MD∗, Khaled Bahjri, MD, Ronald A. Griffin, MD.
Internal Medicine, Loma Linda University, Loma Linda, CA; Public
Health, Loma Linda University, Loma Linda, CA and Gastroenterology,
Jerry L. Pettis VA Medical Center, Loma Linda, CA.
Purpose: Surveillance endoscopy is recommended for patients with Barrett’s
esophagus (BE). The frequency of surveillance is based on the severity
of dysplasia. Nobody knows what happens to patients if they missed their
surveillance endoscopy. The purpose of this study is to evaluate the effect
of missed surveillance endoscopy on the pathologic grade of BE and to
determine those likely to miss surveillance endoscopy.
Methods: Patients diagnosed or surveyed for BE between 1995 and 2005
at a single center were evaluated. Patients were included in the study if
they had more than 2 endoscopic biopsies, and have missed their surveil-
lance endoscopies by 6 continuous months or more. Patients diagnosed with
esophageal adenocarcinoma (EAC) within 6 months of first endoscopy were
excluded. All patients were on antisecretory therapy (H2 blocker, proton
pump inhibitor or both).
A sub-analysis of those who missed their surveillance endoscopy by twice
the current recommended intervals i.e. 6 years for metaplasia (M), 2 yrs for
low grade dysplasia (LGD), and 6 months for high grade dysplasia (HGD)
was also done.
Results: Fourty-four patients missed their surveillance endoscopy by at least
6 months. The distribution of the pathologic grades was as follows: M (11/44,
25%), LGD (32/44, 72.7%), and HGD (1/44, 2.3%). Of these, 50% regressed
to a lower pathologic grade, 40.9% had no change, and 9.1% progressed to
a higher pathologic grade. Four patients regressed to normal mucosa, 1
progressed to HGD and none progressed to EAC.
More than half of these patients (23/44, 52.3%) missed their surveillance
endoscopies by twice the current recommended intervals. The initial patho-
logic grades were as follows: M (3/23, 13%), LGD (19/23, 82.6%), and HGD
(1/23, 4.3%). Of these, 60.9% regressed, 34.8% did not change, and 4.3%
progressed. None progressed to EAC or HGD but 3 regressed to normal
mucosa. After adjusting for age and body mass index (BMI), patients with
LGD are nearly seven times more likely to miss their endoscopy (OR 6.56,
P-value 0.03).
Conclusion: Patients with BE on antisecretory therapy may have longer
surveillance intervals without an increased risk for progression when com-
pared to current guidelines. Patients with LGD are most likely to miss their
surveillance endoscopies. This may be due to the nomenclature used in cat-
egorizing LGD. More studies are needed to validate these findings.
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Comparison of Serum Pepsinogens between Patients with and without
Reflux Esophagitis
Yoshihisa Urita, Toshiyasu Watanabe, Tadashi Maeda, Kaoru Domon,
Susumu Ishihara, Tomohiro Arita, Asuka Nakayama, Makie Nanami,
Tatsuhiro Yamamoto, Akiro Kugahara, Takamasa Ishii, Hirohito Kato,
Kazuo Hike, Noriko Hara, Yoshiko Honda, Shuji Watanabe, Kazushige
Nakanishi, Nagato Shimada, Motonobu Sugimoto∗, Kazumasa Miki.
Department of General Medicine and Emergency Care, Toho University,
Tokyo, Japan; Division of Gastroenterology and Hepatology, Toho
University, Tokyo, Japan and Department of Hematology, Toho University,
Tokyo, Japan.
Purpose: Reflux esophagitis (RE) has been considered as one of compli-
cations of peptic ulcers before H. pylori was discovered. Recently, peptic
ulcers are reported to have a close association with H. pylori in spite of the
fact that the prevalence of H. pylori infection is low in RE patients. Serum
pepsinogen (PG) is a known marker of gastric mucosal status, including mu-
cosal atrophy. The aim of this study is to evaluate the diagnostic potential of
serum PGs in predicting the presence of RE in patients with and without H.
pylori infection.
Methods: A total of 121 patients with RE in whom H. pylori infection was
diagnosed by 13C-urea breath test (UBT) were recruited. The mean age was
58 years (33–85 years) and 64 were women. All patients underwent and a
change of the delta 13C value over baseline of more than 2.5 per mil was
considered positive. Serum PG concentrations were assayed using PG1 and
PG2 Riabead Kits. Age-, gender-, and H. pylori status- matched controls
without RE were selected.
Results: Among 121 patients with RE, 78 had H. pylori infection. In H.
pylori-negative patients, a serum PG1 level was significantly higher in those
with RE than without RE (54 ± 20 vs 40 ± 12 ng/mL, P < 0.01). There was
no significant difference in a serum PG1 level between H. pylori-positive
patients with and without RE (67 ± 48 vs 60 ± 29 ng/mL). Significant
differences in a serum PG2 level were not found between patoents with and
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without RE regardless of H. pylori status. Among H. pylori-positive patients,
a PG1/PG2 ratio was significantly higher in RE patients (3.5 ± 1.5 vs 2.8 ±
1.3, P < 0.01). The same tendency was also found in H. pylori-negative
patients, but the difference did not reach statistical significance (5.9 ± 1.6
vs 5.2 ± 1.4, P = 0.06).
Conclusion: High serum PG1 levels and PG1/PG2 ratios were more com-
monly detected in GERD patients in spite of H. pylori status.
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GERD Treatment with Lansoprazole May Improve Sleep Disorders
Yoshihisa Urita, Toshiyasu Watanabe, Tadashi Maeda, Kaoru Domon,
Susumu Ishihara, Tomohiro Arita, Asuka Nakayama, Makie Nanami,
Tatsuhiro Yamamoto, Akiro Kugahara, Takamasa Ishii, Hirohito Kato,
Kazuo Hike, Noriko Hara, Yoshiko Honda, Shuji Watanabe, Kazushige
Nakanishi, Nagato Shimada, Motonobu Sugimoto∗, Kazumasa Miki.
Department of General Medicine and Emergency Care, Toho University,
Tokyo, Japan; Division of Gastroenterology and Hepatology, Toho
University, Tokyo, Japan and Department of Hematology, Toho University,
Tokyo, Japan.
Purpose: A link between gastroesophageal reflux diseases (GERD) and
sleep disorders in some patients with nocturnal heartburn episodes has been
suggested; however, the prevalence of sleep disorders in GERD patients
remains unclear. It is also unknown whether PPI therapy for GERD improves
sleep disorders. The aim of this study is to investigate the effects of long-term
lansoprazole therapy on the symptoms of sleep disorders.
Methods: A total of 154 patients who had reflux esophagitis and received
PPI therapy (Lansoprazole 15 mg once daily) for more than 24 months were
recruited. The mean age was 69 years (39–77 years) and 117 were women.
The presence of sleep disorders was defined if the patient required sleeping
drugs in at least 4 days a week for more than 3 months. Blood samples were
taken in all patients for detecting serum IgG antibody to Helicobacter pylori
(HM-CAP).
Results: Of 154 patients, 28 had sleep disorders. Zopiclone was prescribed
in 5 patients, Quazepam in 3, Triazolam in 8, Zolpidem tartrate in 6, Bro-
tizolam in 5, and Estazolam in one. Medications for sleep disorders were
stopped in 6 (22%) patients after lansoprazole therapy. The mean duration to
stopping the medication was 5.8 months after the beginning of PPI therapy.
Of 28 patients receiving sleeping drugs, 18 were H. pylori positive and 2 of
them succeeded in leaving off the medication for sleep disorders. Of 10 H.
pylori-negative patients, the medication for sleep disorders became useless
in four. All patients treated with Triazolam or Estazolam required continu-
ous medication after lansoprazole therapy. Relief from the medication was
accomplished in one of 5 patients treated with Zopiclone, in one of three
with Quazepam, in two of six with Zolpidem tartrate, and in two of five with
Brotizolam.
Conclusion: Relief from the medication for sleep disorders was succeeded in
22% of GERD patients after lansoprazole therapy. Improvement in symptoms
of sleep disorders likely resulted from a reduction in GER.
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Trends of Heller Myotomy Hospitalizations for Achalasia in the United
States, 1993–2004
Yize Wang, MD, PhD, Joel E. Richter, MD, MACG∗. Gastrointestinal
Section, Department of Medicine, Temple University School of Medicine,
Philadelphia, PA.
Purpose: Achalasia is a rare chronic disorder of esophageal motor function.
Since its introduction in 1993, there has been increasing use of laparoscopic
surgical (Heller) myotomy for achalasia, which typically involves a shorter
hospital stay. We examined the trends of Heller myotomy hospitalizations in
the United States during 1993–2004.
Methods: The publicly available Healthcare Cost and Utilization Project
Nationwide Inpatient Sample is a representative sample of 5 to 8 million
hospitalizations per year in the United States and provides national esti-
mates of hospitalizations by diagnosis or procedure. It was used to study the
time trend of Heller myotomy hospitalizations, i.e., those with ICD-9-CM
procedure code 42.7 (esophagomyotomy) as the primary procedure and the
time trend of achalasia hospitalizations, i.e., those with ICD-9-CM diagnosis
code 530.0 as the primary diagnosis. The ICD-9-CM procedure code 42.7
does not distinguish between open and laparoscopic Heller myotomy.
Results: The national estimate of Heller myotomy hospitalizations increased
from 728 in 1993 to 2,329 in 2004 (+220%). This compared to smaller per-
cent increases in achalasia hospitalizations (2,642 in 1993 and 4,157 in 2004;
+57%) and in all hospitalizations in the United States (34,314,213 in 1993
and 38,661,786 in 2004; +13%). Notably, the increase in Heller myotomy
hospitalizations (N = 1,601) roughly equals to the increase in achalasia hos-
pitalizations (N = 1,515). The median length of stay for Heller myotomy
hospitalizations decreased from 7 days in 1993 to 2 days in 2004, while the
median length of stay for achalasia hospitalizations remained stable (3 days)
during this period. In 2004, the mean age of Heller myotomy patients was
50 years and 52 percent were male; 79 percent of Heller myotomy proce-
dures were performed in teaching hospitals and 83 percent were performed
in large hospitals.
Conclusion: The number of Heller myotomy hospitalizations has been in-
creasing in the United States during 1993–2004. This, along with the de-
creasing length of stay and the concentration in teaching/large hospitals,
likely reflects the widespread use of laparoscopic surgery to treat achalasia.
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Comparison of Esophageal Motility Parameters as Measured by the
New High Resolution Manometry (HRM) vs Traditional Manometry
(TM)
Muhammad Hasan, MD, Sheila Rodriguez-Stanley, PhD, Susan Riley, RN,
Sattar Zubaidi, Philip B. Miner, Jr., MD∗. Gastroenterology, The
University of Oklahoma Health Sciences Center, Oklahoma City, OK and
The Oklahoma Foundation for Digestive Research, Oklahoma City, OK.
Purpose: The 36-channel Sierra esophageal motility catheter simultane-
ously measures pressure from the UES through the body and the LES. This
HRM provides an intuitive advance over the standard 4-channel Konigsberg
catheter (TM). Before conclusions can be drawn regarding the efficacy of
HRM, comparative manometry data needs to be acquired and analyzed to
assure that current standards can be applied to this technical advance. The
aims of this study were to compare LES measurement from the nares, LES
residual pressure (relaxation), LES pressure, distal amplitude, velocity and
duration as measured by HRM and TM in a control population.
Methods: Normal subjects were randomized to HRM or TM in a crossover
design (7-d period between sessions, 48 h apart). Subjects were intubated via
the nares. The station pull-through was performed with Konigsberg probe.
The HRM probe was placed into the esophagus and LES without moving the
probe. 10 water swallows were performed and measurements were recorded.
Physiologic data was compared using paired T-tests (P = 0.05).
Results: Data were analyzed from 21 normal subjects (13 females, 8 males;
mean age 27.6 years). Measurement of the distance of the LES from the nares
was significantly different for the HRM vs TM probes (43.3 vs 41.7 cm; P =
5.95 × 10−5). Residual LES pressure, a reflection of LES relaxation with
water swallows, was significantly different as measure by the catheters (15.8
vs 1.8 mmHg; P = 1.17 × 10−6; HRM vs TM). Distal contractile pressure
with water swallows was also significantly different between HRM vs TM
(110.8 vs 94.0 mmHg; P = 0.02). LES pressure (36.6 vs 32.1 mmHg; P =
0.08), Velocity (4.8 vs 3.8 cm/sec; P > 0.05) and Duration (3.7 vs 3.7 sec;
P > 0.05) were not affected by the type of motility catheter.
Conclusion: HRM identifies the LES an average of 1.6 cm closer to the
LES than with the TM method. Measurement differences would influence
the placement of other probes for testing (ie: esophageal pH sensor, balloon
distention), and may correlate to altered motility results. LES relaxation as
well as distal contractile amplitude were also affected by catheter type. New
normal values, as well as “pathologic” values need to be established using the
HRM system in order to diagnose esophageal motility disorders accurately.
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Is There Improvement over Years in the Diagnostic Accuracy of
Endoscopic Ultrasound in Evaluating Celiac Axis Lymph Nodes
Metastasis in Esophageal Cancers? A Meta-Analysis & Systematic
Review
Srinivas R. Puli, MD, Jyotsna Batapati Krishna Reddy, MBBS, Matthew L.
Bechtold, MD, Christoper Bartalos, MD, Ajitinder Grewal, MD, Jack D.
Bragg, MD, Jamal A. Ibdah, MD, Mainor R. Antillon, MD∗. Department
of Gastroenterology and Hepatology, University of Missouri-Columbia,
Columbia, MO.
Purpose: To evaluate if technology over years affected the diagnostic accu-
racy of Endoscopic Ultrasound (EUS) in evaluating celiac axis lymph node
(CLN) metastasis in esophageal cancers. This analysis was done by group-
ing EUS studies into three time periods to standardize the change in EUS
technology and also to standardize the change in EUS criteria for lymph
node involvement. These time periods were 1989 to 1995, 1996 to 1999, and
2000 to 2006.
Methods: Study Selection Criteria: Only EUS studies confirmed by
surgery or appropriate prolonged follow-up were selected.
Data collection & extraction: Articles were searched in Medline, Pubmed,
Ovid journals, CINAH, Medline nonindexed citations, and Cochrane control
trial registry.
Statistical Method: Meta-analysis for the accuracy of EUS was found by
calculating pooled estimates of sensitivity, specificity, likelihood ratios, and
diagnostic odds ratio. Pooling of likelihood ratios and diagnostic odds ratios
was conducted by the fixed and random effects models. The heterogeneity
of was tested using Cochran’s Q test based upon inverse variance weights.
Results: Initial search identified 3980 reference articles, of these, 362 rele-
vant articles were selected and reviewed. Data was extracted from 23 studies
(N = 1966) which met the inclusion criteria. There were 8 studies for the
time period 1989 to 1995. During the time period of 1996 to 1999, there
were 10 studies that met the inclusion criteria. Five studies met the inclusion
criteria for the time period between 2000 to 2006. All the pooled estimates
during the three time periods are given in table 1. The P for chi-squared
heterogeneity for all the pooled accuracy estimates was >0.05.
Conclusion: EUS-FNA is highly specific in diagnosing celiac axis lymph
nodes metastasis in esophageal cancers. Over years, the specificity remained
very high, while the sensitivity did not improve.[figure1]
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Accuracy of Endoscopic Ultrasound over Time in T-Staging of
Esophageal Cancers: A Meta-Analysis and Systematic Review
Srinivas R. Puli, MD, Jyotsna Batapati Krishna Reddy, MBBS, Matthew L.
Bechtold, MD, Mainor R. Antillon, MD, Jamal A. Ibdah, MD∗.
Department of Gastroenterology and Hepatology, University of
Missouri-Columbia, Columbia, MO.
Purpose: Prognosis and modality of treatment in patients with Esophageal
cancers (ECA) depends on the T stage of the rumor. The published data
on effect of changes in Endoscopic Ultrasound’s (EUS) technology over
accuracy of T staging in ECA patients has been varied.
Aim: To evaluate the affect of the change in EUS technology over the past
two decades on its diagnostic accuracy in T-staging of ECA cancers.
Methods: Study Selection Criteria: Only EUS studies confirmed by
surgery were selected. EUS criteria used for T staging were: T1- the tu-
mor invades the lamina propria or submucosa, T2- the tumor invades, T3-
the tumor invades the periesophageal tissues, and T4- the tumor invades
adjacent structures.
Data collection & extraction: Articles were searched in Medline, Pubmed,
Ovid journals, and Cochrane control trial registry.
Statistical Method: Meta-analysis for the accuracy of EUS was analyzed
by calculating pooled estimates of sensitivity, specificity, likelihood ratios,
and diagnostic odds ratio. EUS studies were grouped into three time periods
to standardize the change in EUS technology and also to standardize the
change in EUS criteria for tumor staging. These time periods were 1986 to
1994, 1995 to 1999, and 2000 to 2006. Pooling was conducted by both the
fixed and random effects models.
Results: Initial search identified 3,730 articles, of these, 389 relevant articles
were selected and reviewed. 43 studies (N = 2558) which met the inclusion
criteria were included in this analysis. Pooled accuracy data for T staging
over last two decades is shown in table 1. All the pooled estimates calculated
by fixed and random effect models were similar. The P for chi-squared
heterogeneity for all the pooled accuracy estimates was >0.10.
Conclusion: EUS has excellent sensitivity and specificity in accurately di-
agnosing T stage in a patient with ECA. Over the last two decades, the speci-
ficity of EUS in diagnosing T stage remained high (∼98%). The sensitivity
of EUS for T staging slightly improved for T1 and T4 during the past two
decades. EUS should be strongly considered for T staging of ECA.[figure1]
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Comparison of Sensed Acid Reflux Event Characteristics among the
Different GERD Groups
Ron Schey, MD, Tomas Navarro-Rodriguez, MD, Michael Shapiro, MD,
Christopher Wendel, MS, Ronnie Fass, MD∗. The Neuroenteric Clinical
Research Group, Southern Arizona VA Health Care System and University
of Arizona, Southern Arizona VA Health Care System, Tucson, AZ.
Purpose: Proximal migration, nadir of pH and duration of acid reflux have
been shown to increase the likelihood of experiencing a sensed reflux event
(SRE). Thus far, no studies compare SRE characteristics among different
GERD groups.
The aim of our study was to compare characteristics of SRE among the
different GERD groups.
Methods: Patients with typical heartburn symptoms at least 3 times a week
for the last 3 months were recruited. Upper endoscopy and pH testing were
used to classify the three groups: Erosive esophagitis (EE), Nonerosive re-
flux disease (NERD) and Functional heartburn (FH). Patients underwent
esophageal pH testing using a multiple-sensor pH probe (6,11,16 cm >
LES). All reflux events with pH < 4 at sensor 6 cm > LES that corre-
lated with symptoms were considered as SRE. Their characteristics were
compared among GERD groups.
Results: A total of 22 patients had EE, 15 NERD, and 13 FH (M/F – 20/2,
12/3, 5/8, mean age–51.5 ± 3.7, 50.1 ± 4.2, 50.3 ± 3.8, respectively). During
the pH test, 97 SREs were detected at pH sensor 6 cm > LES. The proximal
extent of SREs was significantly higher in the FH group compared to NERD
and EE (16 cm vs 14.26 ± 0.67 cm, 16 cm vs 12.73 ± 0.53 cm, respectively,
P < 0.03). The pH nadir of SREs was significantly higher in the FH group
compared to NERD and EE (2.32 ± 1.16 vs 1.31 ± 0.18, and 2.32 ± 1.16
vs 1.16 ± 0.12 respectively, P < 0.01). The duration and reduction in pH
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and number of preceding reflux events 1 hour before an SRE was similar
among the groups. The number of preceding acid reflux events 2, 3, and 4
hours prior to an SRE was significantly lower in the FH group compared to
NERD and EE, 2 hours (5.57 ± 4.1 vs 15.64 ± 9.2, 5.57 ± 4.1 vs 14.42 ±
9.8 respectively, P < 0.05), 3 hours (8.80 ± 4 vs 25.60 ± 12.5, 8.80 ± 4 vs
21.19 ± 12.4 respectively, P < 0.01), and 4 hours (11.60 ± 4.4 vs 31.30 ±
15.9, 11.60 ± 4.4 vs 26.64 ± 15.7, respectively, P < 0.01).
Conclusion: Patients with FH demonstrated the highest proximal extent
of SREs but a higher pH nadir and fewer reflux episodes prior to an SRE
compared to NERD and EE. The study suggests that proximal extent of an
acid reflux event is the most important physiological factor for symptom
generation
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Is There a Difference in the Prevalence of Helicobacter pylori Infection
between Short-Segment and Long-Segment Barrett’s Esophagus?
Changcheng Wang, MD, Yuhong Yuan, PhD, Richard H. Hunt, MD, FRCP,
FRCPC∗. Division of Gastroenterology, McMaster University Health
Science Centre, Hamilton, ON, Canada.
Purpose: Recent studies suggest that the length of Barrett’s esophagus (BE)
is a risk factor for neoplastic progression. Patients with long-segment Bar-
rett’s esophagus (LSBE) are at higher risk for development of dysplasia and
adenocarcinoma of the esophagus when compared with short-segment Bar-
rett’s esophagus (SSBE), which suggests that different pathophysiological
mechanisms may be involved in SSBE and LSBE. To date, the role of H.
pylori infection in the development of BE is still unclear. We aimed to inves-
tigate by meta-analysis if any difference exists in the prevalence of H. pylori
infection between SSBE and LSBE.
Methods: Observational studies comparing the prevalence of H. pylori in-
fection or cagA+ H. pylori strains in patients with SSBE (length <3 cm)
and LSBE (length ≥ 3 cm) conducted in adult populations and published in
all languages were identified through MEDLINE, EMBASE and Cochrane
database searches until week 21, 2007. H. pylori infection required confir-
mation by histology and/or serology and/or RUT and/or culture. Primary
outcome was the prevalence of H. pylori infection in SSBE and LSBE. Sec-
ondary outcome was the prevalence of cagA+ H. pylori strains in SSBE and
LSBE. Studies were excluded if lacking raw data for outcome of interest
or were duplicate publications. Summary effect size was calculated as odds
ratios (OR) and 95% confidence intervals (CI) by the random-effects model
using Review Manager 4.2.8.
Results: Of 458 citations, 13 studies met inclusion criteria. 825 patients
with SSBE and 470 with LSBE were included for analysis. The prevalence
of H. pylori infection was significantly higher in SSBE than in LSBE [39.6%
(327/825) and 29.6% (139/470) respectively, OR = 1.49, 95% CI 1.02–2.18,
P = 0.04], and homogeneity was seen between studies (P = 0.14). The results
from 4 studies in H. pylori positive patients showed no difference in cagA+
H. pylori strains between SSBE and LSBE [36.7% (18/49) and 37.8% (14/37)
respectively, OR = 0.51, 95% CI 0.08–3.04, P = 0.46], with homogeneity
(P = 0.14).
Conclusion: The prevalence of H. pylori infection in LSBE is significantly
lower than in SSBE, which suggests that H. pylori infection plays a different
role, if any, in these two subtypes of BE and does not “protect” in patients
with SSBE. Current evidence does not confirm a role for cagA+ in subtypes
of BE although the sample size was small. Large prospective studies are
needed to confirm these results in the future.
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Omeprazole Induces a Transepithelial Leak in Gastric Mucosa
James M. Mullin, PhD∗, Mary C. Valenzano, Marysue Whitby, Deborah
Lurie, PhD, Vishal Jain, MD, Owen Tully, MD, Paul Allegretti, DO, Daniel
Lazowick, DO, J. David Schmidt, MD, James J. Thornton, MD, Giancarlo
Mercogliano, MD. Lankenau Institute for Medical Research, Wynnewood,
PA; Mathematics, St. Joseph’s University, Philadelphia, PA; Medicine,
Lankenau Hospital, Wynnewood, PA and Gastroenterology, Lankenau
Hospital, Wynnewood, PA.
Purpose: Having observed a paracellular leak to oral sucrose in esophagitis
patients, we tested if PPI therapy would decrease (paracellular) sucrose leak
by allowing for mucosal healing.
Methods: 23 study subjects presenting to their primary care physician with
symptoms of GERD were placed on an 8 week course of esomeprazole
(40 mg daily). Subjects were PPI and H-2 blocker naive. All subjects re-
ported symptom alleviation by 4 weeks. Before beginning esomeprazole
therapy and at the end of therapy, subjects consumed at bedtime a solution
of the disacharide, sucrose (100 gms in 200 cc tap water), and collected an
overnight urine specimen. Sucrose, as a disacharide, can enter the blood-
stream only by leaking paracellularly out of the upper GI lumen. Once in
the blood, sucrose is filtered quantitatively into urine. Sucrose concentra-
tion in urine was measured by enzymatic/spectrophotometric means. The
sucrose concentration × the total urine volume yields the total amount of
sucrose in the urine, which equals the the amount of sucrose which leaked
paracellularly from the upper GI lumen.
Results: We observed that 17 of 23 patients exhibited a marked increase in
sucrose leak by 8 weeks of omeprazole therapy (667% increase). Similar su-
crose leak is observed after only 8 days of esomeprazole therapy. Considering
all 23 patients, the Wilcoxon Signed Rank Test indicated a significant in-
crease in sucrose leak (P = 0.007). In rat gastric mucosa, 200 µM omeprazole
induces an immediate paracellular leak to D-mannitol, with a simultaneous
decrease in transepithelial electrical resistance. Both phenomena indicate
that omeprazole is likely producing a tight junction leak in gastric mucosa.
Conclusion: PPI therapy may be associated with a paracellular leak in the
acid secreting region of the stomach. Future studies will examine the char-
acteristics of this leak and the mechanism by which omeprazole induces the
leak.
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High Prevalence of Eosinophilic Esophagitis in Inflammatory Bowel
Disease
Souheil Gebara, MD∗, Robert M. Truding, MD, Saleha Khanum, MD,
Sandra L. Hodges, RN, Chung-Ho Chang, MD, Neal S. Goldstein, MD.
Pediatrics, William Beaumont Hospital, Royal Oak, MI and Anatomic
Pathology, William Beaumont Hospital, Royal Oak, MI.
Purpose: Eosinophilic esophagitis has been reported in association with
asthma and celiac disease but not with inflammatory bowel disease (IBD). We
noted in our practice a frequent association between IBD (Crohn’s disease or
ulcerative colitis) and eosinophilic gastrointestinal diseases (EG) especially
eosinophilic esophagitis (EE).
Methods: Retrospective chart review of our outpatient pediatric gastroen-
terology practice. We looked at the pathology reports of our active patients
with IBD and selected the ones with EG. Two pathologists confirmed the
histological diagnosis of both IBD and EG. We reviewed the indications for
the biopsies, age at diagnosis, gender, type of IBD, sequence of the diagnoses
and medication history.
Results: We have 3800 active patients, out of these 357 had IBD and 151
had EE. We found 18 IBD patients who also had EG including 14 with EE.
Thus the prevalence of EG in our IBD population is 5.0% and EE 3.9%.
All EG patients were diagnosed simultaneously or after the diagnosis of the
IBD. There was no relationship between EE and age, gender, type of IBD
and medication history.
Conclusion: EE has been reported to have a prevalence of 1–4 per 10,000
children in the USA and thus the relative risk of EE in our IBD population
ranges from 97 to 390 compared with the general population. In pediatric
patients with IBD, we found a high prevalence of EE. A larger study should
be helpful in confirming this observation and may improve our understanding
of the pathophysiology of both diseases.
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Inter-Observer Agreement between Multi-Channel Intraluminal
Impedance-pH (MII-pH) Software Analysis and an Experienced
MII-pH Test Reviewer
Dawn D. Ferguson, MD, MHS, Kenneth R. DeVault, MD∗. Internal
Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic,
Rochester, MN and Internal Medicine, Division of Gastroenterology and
Hepatology, Mayo Clinic, Jacksonville, FL.
Purpose: Over the past decade, new technologies have emerged to evaluate
gastroesophageal reflux disease (GERD). One such technique is the 24-hour
MII-pH study. This test was designed to detect both acid and non-acid reflux
(NAR). A significant drawback of this technique is that reviewing impedance
tracings that were collected over a 24-hour period can be cumbersome and
time consuming. In an attempt to make this task easier, one of the man-
ufactures of this device has created a software tool to identify impedance
detected reflux episodes based on a number of published parameters. To the
best of our knowledge, the utility of an experienced reviewer hand-editing
MII-pH tracings after the software analysis has never been evaluated.
Methods: We randomly selected 20 MII-pH studies performed at our in-
stitution on patients that were taking a proton-pump inhibitor twice daily.
We ran the proprietary software analysis tool (SleuthTM, Sandhill Scien-
tific, Inc., Highlands Ranch, CO) on all of these studies using the same pre-
programmed parameters. An experienced reviewer of MII-pH studies (DDF)
reviewed all the tracings. The reviewer had the ability to add or delete reflux
episodes that had been detected by the software tool. We separately recorded
the computer and reviewer’s analysis in regards to the total number NAR
episodes. We determined whether the study was considered positive or neg-
ative based on published criteria of NAR. We used Cohen’s kappa coefficient
to evaluate the inter-observer agreement between the software analysis and
the reviewer’s over-read.
Results: The MII-pH software reported significant NAR in 10 of 20 patients.
The reviewer diagnosed significant NAR in 9 of 20 patients. The kappa
coefficient for NAR between the software analysis and the reviewer’s over-
read was 0.9. The one study for which there was a discrepancy between the
software and the reviewer had a difference of 11 impedance detected reflux
episodes with the software marking more reflux episodes than the reviewer.
Conclusion: We demonstrate excellent inter-observer agreement between
the software analysis of impedance detected NAR and a hand-edit of that
analysis by an experienced reviewer. This finding may lend support to the no-
tion that using software analysis alone is likely adequate to identify clinically
significant NAR when using the 24-hour MII-pH system.
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Rebamipide Improves Salivary Gland Function and Saliva Transit to
the Distal Esophagus
Yoshihisa Urita, Toshiyasu Watanabe, Tadashi Maeda, Kaoru Domon,
Susumu Ishihara, Tomohiro Arita, Asuka Nakayama, Makie Nanami,
Tatsuhiro Yamamoto, Akiro Kugahara, Takamasa Ishii, Hirohito Kato,
Kazuo Hike, Noriko Hara, Yoshiko Honda, Shuji Watanabe, Kazushige
Nakanishi, Nagato Shimada, Motonobu Sugimoto∗, Kazumasa Miki.
Department of General Medicine and Emergency Care, Toho University,
Tokyo, Japan; Division of Gastroenterology and Hepatology, Toho
University, Tokyo, Japan and Department of Hematology, Toho University,
Tokyo, Japan.
Purpose: The major abnormalities associated with the development of
GERD are related to incompetence of the antireflux barrier and impair-
ment of esophageal luminal clearance after reflux. Although saliva plays an
important role in esophageal acid clearance, facilitation of acid clearance
has only been addressed via work on various medications which have been
shown to have prokinetic effects on the esophagus. This study therefore
aimed to investigate the efficacy of a gastro-protective agent, rebamipide, on
the function of salivary glands.
Methods: Ten healthy volunteers underwent salivary gland scintigraphy
twice with one-week interval. The subject is asked to take a rebamipide
tablet at a dose of 100 mg 90 minutes before the beginning of the second
scintigraphy. Following intravenous injection of 99mTc-pertechnetate, an-
terior sequential imaging was performed every minute for 40 minutes. At
20 minutes after injection of radionuclide, a lemon candy was administrated
intraorally to stimulate salivary secretion. Regions of Interests (ROI) were
selected on the individual submandibular and parotid glands, oral cavity, and
the pharynx and the upper esophagus. Time activity curves were drawn for
each of these. Washout ratio was examined as a functional parameter. For
the evaluation of saliva transit, time activity curves obtained from the ROI
of pharynx and upper esophagus were analyzed.
Results: The mean washout ratio was 57.8% in the parotid gland and 43.8%
in the submandibular gland. If the washout ratios of less than 50% and 36%
are defined as functional disorders of parotid and submandibular glands,
respectively. After administration of rebamipide, the increased washout ratio
(more than 10 points) was found in 5/10 subjects (50%) in submandibular
glands and in 1/10 (10%) in parotid glands. Saliva transit from the oral cavity
to the esophagus was also improved after administration of rebamipide in
60% of subjects.
Conclusion: We concluded that rebamipide might be one of therapeutic
options for low salivary excretion, especially for submandibular glands.
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Proximal Black Esophagus: A Case Report
David A. Neumann, II, MD, Dawn D. Ferguson, MD∗, Todd H. Baron, MD.
Department of Internal Medicine, Mayo Clinic, Rochester, MN and
Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester,
MN.
Purpose: Necrotic esophagus (also known as “black esophagus”) is a rare
clinical entity with fewer than 100 cases reported in the literature. Endoscop-
ically, the esophageal mucosa is dark or black with a macerated appearance.
Pathologic review shows mucosal and submucosal necrosis. The majority
of published cases of black esophagus describe the lesion in only the distal
esophagus or encompassing the entire length of the esophagus. To the best
or our knowledge, there have been no reported cases of black esophagus
confined to the proximal esophagus.
Our patient is a 79 yo male who presented initially to another hospital with
chest pain associated with lightheadedness, diaphoresis and dyspnea. He was
found to be bradycardic and received a dose of atropine. An ECG showed
changes consistent with an inferior myocardial infarction. The patient was
given aspirin, heparin, a beta-blocker and two doses of reteplase and was
transferred to our facility. Four hours after the onset of chest pain the patient
had a coronary catheterization at our institution. That study revealed an 80%
obstructing circumflex lesion and a 100% proximal right coronary occlusion.
PTCA was performed and a drug-eluting stent was deployed into the distal
circumflex artery. Clopidogrel was initiated. Several hours later, the patient
experienced a single episode of hematemesis. An urgent EGD was performed
and showed black macerated esophageal mucosa with adherent clot in the
proximal esophagus. The abnormal tissue was circumferential and was 5
cm in length. The patient was started on twice daily PPI therapy and his
other medications were continued. He was later discharged without further
complication.
The rarity of black esophagus is likely due to the extensive arterial blood sup-
ply of the esophagus. It has been hypothesized that low-flow states may lead
to transient esophageal ischemia with free radical formation and subsequent
tissue injury upon reperfusion. In this patient, the isolation of black esoph-
agus to the proximal esophagus may have been due to thromboembolism or
hypotension associated with his acute coronary event.
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5-ALA Photodynamic Therapy Eliminates Resistant Barrett’s Cells
Kenneth K. Wang, MD∗, Ganapathy Prasad, MD, Michel WongKeeSong,
MD, Navtej S. Buttar, MD, Wiste Westra, MD, Rami Badreddine, MD,
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Marlys Anderson, Lori Lutzke, Kelly Dungan, Lynn Borkenhagen.
Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Purpose: Photodynamic therapy (PDT) with sodium porfimer has been
shown to decrease both high grade dysplasia and cancer formation in Bar-
retts esophagus. However, we have previously shown that sodium porfimer
mediated PDT is not as effective in patients who are p16 deficient which
is important in cell cycle regulation. p16 was associated with a substantial
risk of treatment failure defined as persistence of high-grade dysplasia or
advancement to cancer. Recently, 5-amino levulinic acid (ALA) has become
available for use in the United States. It is important to determine if ALA
mediated PDT has advantages over sodium porfimer mediated PDT other
than shorter duration of cutaneous phototoxicity and decreased stricture for-
mation. Our aim was to determine if ALA mediated PDT cell killing was
independent of p16 status.
Methods: A Barretts epithelial cell line immortalized with H-Tert (human
telomerase) was provided to us (RF Souza, Texas Southwester) which has
been described as having normal cell functions other than an absence of p16
expression. We used an adenovirus-mediated p16 to infect and re-introduce
p16 expression to this cell line. We then compared the effect of PDT with
ALA in cells with and with p16. After the cells were estabished in culture,
ALA was provided in concentrations of 0, 2.5, 5, 10, 25, 50, 100, and 250
ug/ml and incubated for 6 hours prior to photoradiation with a broadband
xenon light source for a total of 20 J/square cm. Cells were then observed
for 4 days after which cell death was assessed with propidium iodide.
Results: 5-ALA mediated cell death was similar in both p16+ and p16-
Barretts epithelial cells (P > 0.05). There was no significant difference in
cell death at any concentration of ALA. Control cells had less than 5% cell
death while those that were treated with 50 ug/ml of 5-ALA had about 20%
cell death. Treatment with either 100 or 250 ug/ml of 5-ALA produced 90%
cell death. The LD50 for 5-ALA was 68 ug/ml.
Conclusion: 5-ALA mediated PDT appears to kill Barretts cells resistant to
sodium porfimer mediated PDT. 5-ALA may be able to eliminate Barretts
epithelium in those 20% of patients with high grade dysplasia who have
failed sodium porfimer.
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Gastroesophageal Reflux during Sleep: Does REM Sleep Provide a
Protective Effect?
Sriharsha Damera, MD∗, Suanne Goodrich, PhD, Paula Fernstrom, BS,
Goran Hasselgren, MD, William C. Orr, PhD. Lynn Health Science
Institute, Oklahoma City, OK; AstraZeneca, Molndal, Sweden and
University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Purpose: The purpose of this study was to assess the prevalence of reflux
events over each third of the sleeping interval and to assess whether reflux
events may be affected by sleep stages.
Methods: Twenty-four individuals with self-reported sleep disturbance and
40 controls without symptoms of sleep disorders or heartburn were stud-
ied for two nights via polysomnographic evaluations that included distal
esophageal pH recordings. Two PSG recordings were separated by at least
two weeks for each participant. For this study we analyzed a subset of par-
ticipants who had at least one reflux event (N = 15). Out of 15 subjects 6
were unrefreshed sleepers with slef-reported sleep disturbance and 9 were
controls with no sleep disturbance.
Results: A total of 40 reflux events were noted in sleep, out of which 20
events are noted in the first 3rd of the sleeping interval, 16 events noted in the
second 3rd of the sleeping interval and 4 events noted in the final 3rd of the
sleeping interval. The total number of events in the first 3rd of the sleeping
interval were significantly higher than final 3rd of the sleeping interval (P <
.05). There was no significant difference in the number of reflux events in
the first and second parts of the sleeping interval. We also analyzed the data
to determine if there was any impact of sleep stage on reflux events. We
calculated the percent of sleep stages in each third of the night. The amount
of deep sleep in the 1st third of the sleeping interval is significantly more
than the second third (P = .002) and final third of the sleeping interval.
(P < .001). The amount of REM sleep in final third of the sleeping interval
is significantly greater than in the 1st third of the sleeping interval. (P <
.001) and 2nd third of sleeping interval (P = .035). Reflux events persisted
into the 2nd third of the sleeping interval when the percent of both REM
and deep sleep is very low and stage 2 is dominant. The arousal index didn’t
significantly differ between the 1st and 3rd part of the sleeping interval. (P =
.728)
Conclusion: 1) GER is more common in the first third of the sleeping interval
compared to the third portion of the sleeping interval.
2) Reflux events may be affected by the stage of sleep with REM sleep
possibly providing a protective effect against GER.
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The Impact of Recent Developments in the Management of GERD: A
Retrospective Cohort Study
Suhail B. Salem, MDCM, Yael Kushner, MDCM, Victoria Marcus, MDCM,
FRCPC, Serge Mayrand, MDCM, FRCPC, CSPQ, Alan N. Barkun,
MDCM, MSc, FRCP FACP∗. McGill University, Montreal, QC, Canada.
Purpose: Recent developments may alter the approach to patients present-
ing with gastro-esophageal reflux (GERD)-like symptomatology. A recently
proposed revised histological definition of Barrett’s esophagus (Vakil et al.
2006) includes all types of esophageal columnar metaplasia, with or without
intestinal type metaplasia. Also, adult eosinophilic esophagitis may be more
prevalent than previously recognized in patients with GERD-like symptoma-
tology. The aim of this study was to quantify the impact of these contempo-
rary realizations on a general Gastroenterology multi-physician practice.
Methods: All patients having a gastroscopy for an indication of GERD-type
symptoms over a 1-year period ending November 2006 were considered.
Patients were excluded if they had had a previous gastroscopy. Medical
charts and endoscopic reports were retrospectively reviewed, while prospec-
tive audits of all available endoscopic images (grading of esophagitis and
endoscopically suspected esophageal metaplasia (ESEM)) and esophageal
biopsies were performed using standardized preset criteria.
Results: A total of 353 patients fulfilled the study criteria. Typical symptoms
of heartburn and regurgitation were found in 87.7% of patients and 23.2%
of patients respectively. In addition, atypical chest pain was found in 4.2%
of patients, dysphagia in 9.4% of patients, nocturnal symptoms in 11.3% of
patients, sleep disturbance in 2.9% of patients, asthma in 1.3% of patients,
cough in 2.6% of patients, and hoarseness in 5.5% of patients. 26% of
patients were found to have erosive esophagitis at endoscopy, and 11.6% had
ESEM. Histological evaluation was available for 65 patients (18.4%). 13.8%
of these patients met traditional criteria for Barrett’s, exhibiting intestinal-
type metaplasia. In contrast, 73.8% of these patients fulfilled the proposed
new consensus definition of Barrett’s. Five patients (7.6%) met study criteria
for eosinophilic esophagitis (>20 eosinophils/hpf), 4 of whom had not been
recognized on the initial pathology report.
Conclusion: GERD is an evolving clinical entity. Amongst patients present-
ing with typical GERD symptoms, the prevalence of Barrett’s esophagus,
using a revised definition, may increase markedly (over 5 fold increase in
this study). In addition, awareness of an overlap with eosinophilic esophagi-
tis may lead to an increase in the prevalence of this diagnosis. Prospective
studies of the management implications of these findings are warranted.
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Predictors of Erosive Esophagitis in Patients with Symptoms of
Gastroesophageal Reflux Disease (GERD)
Roy C. Orlando, MD, FACG, John T. Monyak, PhD, Debra G. Silberg, MD,
FACG∗. Tulane University Health Sciences Center, New Orleans, LA and
AstraZeneca LP, Wilmington, DE.
Purpose: To evaluate variables and build a model for prediction of erosive
esophagitis (EE) in adults with frequent heartburn (HB).
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Methods: A post-hoc analysis was conducted on data from a multicenter,
open-label study (D9612L00083) in which patients aged 18–70 y who had
a history of HB (≥2 d/wk for the past week and on average for the past 3
months) underwent endoscopy and symptom assessment at baseline followed
by treatment with esomeprazole 40 mg once daily for 4 weeks. For the
post-hoc analysis, the following potential predictors of EE at baseline were
considered: age; sex; race; body mass index (BMI); Helicobacter pylori
status; duration of GERD; history of EE; baseline frequency and severity of
HB, acid regurgitation, dysphagia, and epigastric pain; and patient-reported
time to HB relief with antacids and H2-receptor antagonists. Each variable
was tested separately in a univariate logistic regression model (α-level, 0.05)
with the presence of EE as the dependent variable. From the 4 candidate
models generated by stepwise logistic regression and backward elimination,
a multivariate model was selected using Akaike’s information criterion. The
final model was internally validated using “leave one out” cross-validation.
Results: Of 399 patients who had baseline endoscopy, 205 (51.4%) had EE.
Full data for modelling were available for 180 patients with and 178 without
EE. In the univariate models, older age, male sex, higher BMI, greater HB
frequency and severity, greater acid regurgitation severity, white race, longer
history of GERD, previous history of EE, and faster time to HB relief with
antacid use were significantly predictive of EE (P < 0.05). The multivariate
model selected included the variables of age, sex, HB frequency, race, EE
history, and time to relief of HB with antacid use. The c-index of the model
using cross-validation was moderate at 0.76. At a sensitivity of 80%, the
model provides specificity of 53%, a positive predictive value of 63%, and
a negative predictive value of 72%. The model included a novel predictor
in time to HB relief with antacid use. Patients whose HB symptoms were
relieved within 0–15 minutes of antacid use had 5 times the odds of having
EE versus those who had no relief with antacid use.
Conclusion: Modelling of this type can help predict which types of patients
presenting with GERD symptoms have EE and may aid physicians in diag-
nostic decisions and the selection of appropriate pharmacological therapy.
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Predictors of Heartburn (HB) Resolution in Patients with
Gastroesophageal Reflux Disease (GERD) Symptoms
Roy C. Orlando, MD, FACG, John T. Monyak, PhD, Debra G. Silberg, MD,
FACG∗. Tulane University Health Sciences Center, New Orleans, LA and
AstraZeneca LP, Wilmington, DE.
Purpose: To evaluate variables and build a model to predict HB resolution
in patients with GERD symptoms treated with esomeprazole 40 mg once
daily.
Methods: A post-hoc analysis was conducted on data from a 4-wk, multicen-
ter, open-label study (D9612L00083) in adults with frequent HB (≥2 d/wk
for past 7 d and on average for past 3 mo) with or without erosive esophagi-
tis (EE). HB severity was rated from 1 (mild) to 4 (severe) at baseline and
post-treatment. HB was considered resolved if the patient indicated ‘none’
on the final symptom questionnaire. Potential predictors of HB resolution
were evaluated: age; sex; race; body mass index; Helicobacter pylori status;
time with GERD; history of EE; baseline frequency and severity of HB,
acid regurgitation, dysphagia, and epigastric pain; and patient-reported time
to HB relief with antacids/H2RAs. Each variable was tested separately in
a univariate logistic regression model (α-level, 0.05). A multivariate model
was selected using Akaike’s information criterion from among 4 candidate
models generated by stepwise logistic regression and backward elimination.
The final model was internally validated by “leave one out” cross-validation.
Results: The analysis included data from 179 patients with and 177 patients
without EE. In the univariate models, male sex, white race, less severe and no
dysphagia, less frequent and less severe epigastric pain, and faster relief of
HB with antacid use were predictive of HB resolution (P < 0.05); H pylori+
status was not significant (P = 0.053). The multivariate model included the
variables: baseline severity of HB and epigastric pain, time to HB relief with
antacids, H pylori status, and race. Greater HB severity and lesser severity of
epigastric pain at baseline, faster HB relief with antacids, H pylori+ status,
and white race were associated with HB resolution. The c-index of the model
using cross-validation was low at 0.57. At a sensitivity of 80%, the model
provides specificity of 36%, a positive predictive value of 64%, and a negative
predictive value of 56%. The model included a novel predictor in time to
HB relief with antacids. Patients whose HB symptoms were relived within
15 minutes of antacid use had 2.9 times greater odds of HB resolution with
esomeprazole than those who had no relief with antacids.
Conclusion: This model identified some variables that may predict a re-
sponse to treatment, but the low discriminative ability underscores the diffi-
culty in such predictions.
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Current Trends in Clinical Utility of Esophageal Motility Studies
Vaibhav Mehendiratta, MD, Anthony J. DiMarino, MD, Sidney Cohen,
MD∗. Department of Medicine, Thomas Jefferson University Hospital,
Philadelphia, PA and Department of Gatroenterology and Hepatology,
Thomas Jefferson University Hospital, Philadelphia, PA.
Purpose: To evaluate the utility of esophageal motility studies in clinical
practice.
Methods: Clinical and manometric data from 200 consecutive subjects re-
ferred for esophageal motility study from our gastroenterology practice start-
ing January 2001 though December 2005 were reviewed in this study. Each
subject underwent manometric evaluation using water perfused manometry.
Motility study was considered to be of 1) high clinical utility if specific clin-
ical entity was identified on manometry resulting in appropriate therapeutic
intervention, 2) low clinical utility if specific clinical entity was identified
on manometry without a change in therapy and 3) limited clinical utility if
motility study was normal.
Results: The 200 subjects underwent 206 esophageal motility studies dur-
ing the study period. Mean age was 42 years (range: 18–87) with 130(65%)
being females. Major referral indications included (A) dysphagia (65 of
206, 32%),(B) intractable gastroesophageal reflux (27%), (C) non-cardiac
chest pain (NCCP) not relieved by therapeutic trial of PPIs and/or normal
pH study (19%), (D) dysphagia associated with NCCP (13%) and (E) pre-
operative evaluation for fundoplication (9%). Major manometric findings
were ineffective motility disorder; IMD (62 of 206 studies, 30%), diffuse
esophageal spasm; DES (23%), achalasia (12%), hyperkinetic motility dis-
order (7%), DES with ineffective motility (4%), scleroderma esophagus
(4%) and nutcracker esophagus (2%).
In 96(47%) of 206 instances, manometric evaluation was of high clinical util-
ity resulting in appropriate therapeutic intervention. This was significantly
more common in subjects with NCCP and/or dysphagia (P < 0.05). Mano-
metric findings of DES and achalasia were associated with high clinical
utility (P < 0.05). Manometric evaluation was of low and limited clinical
utility in 40% and 13% instances respectively. Motility study was of low
clinical utility in subjects presenting with intractable reflux and findings
suggestive of IMD (P < 0.05).
Conclusion: A) Esophageal motility studies have emerging clinical utility
in management of patients with non-cardiac chest pain and absence of reflux
allowing a positive diagnosis; B) Manometric studies continue to be of high
utility in management of patients with dysphagia as a primary complaint;
C) Ineffective motility disorder, a new manometric disorder has a high asso-
ciation with gastroesophageal reflux disease but low clinical utility except
when planning antireflux surgery.
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Multichannel Intraluminal Impedance (MII) Can Make a Diagnosis of
Achalasia; A Comparison of MII in Achalasia Versus Normals
Harish V. Iyer, MD, Girish Anand, MD, Matthew Gideon, Philip O. Katz,
MD∗. Department of Internal Medicine, Albert Einstein Medical Center,
Philadelphia, PA and Department of Gastroenterology, Albert Einstein
Medical Center, Philadelphia, PA.
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Purpose: Achalasia is the most thoroughly studied of the esophageal motil-
ity disorders. Manometric criteria include an aperistalsis esophageal body
(always required), elevated lower sphincter pressure, high residual pressure
and elevated esophageal pressures relative to gastric. The latter three are not
required to make the diagnosis. Using these criteria alone some patients are
difficult to classify. Multichannel Intraluminal impedance (MII) is combined
with traditional manometry (MII-EM) to characterize diseases in terms of
pressure and/or transit abnormalities and anecdotally appears to have a char-
acteristic pattern in achalasia. The aims of our study were to describe the MII
characteristics of achalasia and compare to patients with normal esophageal
manometry.
Methods: A retrospective review of all patients with MII-EM testing done
at our esophageal lab from 7/03–12/06 identified patients with achalasia and
those with a normal manometry. Baseline and post swallow impedance for 10
liquid and 10 viscous swallows in both groups were measured. Descriptive
statistics were used for describing frequencies and T test for the differences
between the means. Exclusion criteria included incomplete records and pre-
vious treatment for those in the achalasia group.
Results: 74 eligible patients with achalasia and 172 normal were identified.
Achalasia patients had no normal bolus transit. The baseline impedance
(expressed in Ohms () as means ± SE) in the achalasia and normal group
was 1114 ± 99 v/s 2130 ± 73 respectively (P < 0.01). This changed to
483 ± 40 v/s 1853 ± 63 after 10 liquid swallows and 450 ± 99 v/s 2012 ±
55 after 10 viscous swallows respectively (pre post swallow, P < 0.01 for
achalasia, P = ns for normals).
Conclusion: Patients with achalasia have no normal bolus movement with
MII, low baseline impedance that progressively decreases after multiple
swallows in contrast to normal who have stable impedance even after multiple
swallows. This MII triad is diagnostic of achalasia. These MII findings are
likely due to a dilated fluid filled esophagus at baseline and the inability to
effectively clear a bolus in achalasia. MII allows confirmation of manometric
diagnosis in difficult cases. Further study is required to determine if MII can
make the diagnosis of achalasia independent of manometry.
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The Evaluation of Definitive Radiation Therapy for Patients with Stage
II-III Squamous Cell Carcinoma of the Esophagus
Tetsuo Nonaka, MD, PhD∗, Hideyuki Sakurai, MD, PhD, Hitoshi Ishikawa,
MD, PhD, Mariko Shioya, MD, Masumi Murata, MD, Katsuyuki Shirai,
MD, Koichi Harashima, MD, PhD, Takeshi Ebara, MD, PhD, Takashi
Nakano, MD, PhD, Hiroyuki Kato, MD, PhD, Hiroyuki Kuwano, MD, PhD.
Radiation Oncology, Gunma University, Graduate School of Medicine,
Maebashi, Gunma, Japan and General Surgical Science (Surgery I),
Gunma University, Graduate School of Medicine, Maebashi, Gunma,
Japan.
Purpose: The aim of this study is to evaluate the outcome of the patients
with stage II-III esophageal cancer treated with radiation therapy.
Methods: Between 1999 and 2006, 87 patients with squamous cell
esophageal carcinoma were treated with radiation therapy (RT) or concur-
rent chemoradiotherapy (CRT) at Gunma University Hospital. Seventy-four
patients were men and 14 patients were women, and the median age was
71 years (range: 48–93 years). According to TNM staging system (UICC,
2002), 29 patients were stage II (IIA: 23, IIB: 6), and 58 patients were stage
III. Radiation therapy consisted of 40–46 Gy with anteroposterior opposing
field including the primary tumor and positive regional lymphnodes with op-
timal margins with conventional fraction followed by external beam boost
up to 50–70 Gy (median: 64 Gy). Chemotherapy was administered concur-
rently with radiation therapy to 50 patients, and the 30 patients received
the regimen contained cisplatin or nedaplatin (CRT-PT) and the 20 patients
received the regimen consisting of docetaxel (CRT-DOC).
Results: At the end of this study, there were 27 survivors with a median
follow-up period of 20 months (range: 6–85 months). The 2- and 3-year
disease specific survival rates (DSS) were 44% and 29% for all 87 patients,
71% and 44% for stage II, and 31% and 22% for stage III. The difference
of DSS between the patients with stage II and stage III was statistically
significant (P = 0.0016). The CR rate and the 2- and 3-year DSS for the
CRT group were 34%, 44%, 29%, respectively, and these results were better
than those for the RT group of 24%, 43%, 19%, respectively, however, these
differences observed were not statistically significant. The outcomes of the
patients with CRT-DOC regimen resulted in almost the same as those of
CRT-PT regimen group.
Conclusion: Our results revealed that definitive radiation therapy for squa-
mous cell carcinoma of the esophagus is effective. Further investigations of
the protocol of radiation therapy technique or chemotherapy are needed to
clarify the impact of CRT on prognosis of the patients with this disease.
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EGFR, p-Erk and p-AKT Expression in Barrett’s Esophagus (BE): A
Prospective Pilot Study
Abha Rani, MD, Milind M. Javle, MD∗, Charles M. LeVea, MD, PhD,
Jihnhee Yu, PhD, Michael Brattain, PhD, Jennifer D. Black, PhD, Michael
Sitrin, MD. Department of Gastroenterology, State University of New York
at Buffalo, Buffalo, NY and Roswell Park Cancer Institute, Buffalo, NY.
Purpose: BE is a recognised precursor of esophageal adenocarcinoma (EA).
However, the rate of progression of BE to adenocarcinoma is very low (0.5%
per year). Identification of biomarkers that predict progression to dysplasia
and adenocarcinoma is important. Epidermal growth factor receptor (EGFR)
is activated in EA, which in turn cross activates the proliferative Erk and the
antiapoptotic Akt pathways. Prospective data regarding the expression of
these biomarkers in BE are scanty. We explored the expression of EGFR,
p-Akt, and p-Erk in a prospective pilot study in patients with BE and BE
with dysplasia.
Methods: 21 patients with BE, and 9 patients with BE with dysplasia were
prospectively enrolled. Esophageal mucosal samples were obtained endo-
scopically in all cases. Uniform tissue processing and fixation techniques
were applied. Immuno-histochemical staining for EGFR, p-Akt, and p-Erk
was performed using validated techniques. Informed consent was obtained
from all participating patients.
Results: EGFR expression was seen in all but one BE cases; 13 (61%) had
strong positive expression. 18 BE cases (90%) showed positive expression of
either p-Akt or p-Erk. There were total 9 cases of BE with either low grade (7)
or high grade (2) dysplasia .8 out of these 9 cases showed positive expression
of p-Akt while p-Erk was expressed in all. Strong positive expression of p-
Akt and p-Erk was noted in 4 and 3 cases of BE with dysplasia, respectively.
Significant correlation was observed between p-Akt and p-Erk expression
in the whole study cohort [Kendall’s tau = 0.3591, (P = 0.0403)]. Due to
the small sample size, no statistical correlation could be inferred between
expression of EGFR, p-Akt, p-Erk and the presence of low or high grade
dysplasia.
Conclusion: Association between p-Akt and p-Erk can lead to a survival and
growth advantage for the affected premalignant cells. Whether this associa-
tion leads to an aggressive course in BE or if this represents a pre-dysplastic
change is unknown at this time. A larger study in BE patients with the above
biomarkers is warranted.
Histology EGFR + (+++) p-Akt + (+++) p-Erk + (+++)
BE (21) 20 (13) 18 (8) 20 (3)
Dysplasia (9) 9 (7) 8 (4) 9 (3)
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Objective Documentation of the Link between Gastroesophageal
Reflux Disease and Obesity
Shahin Ayazi, MD, Peter F. Crookes, MD, Christian G. Peyre, MD, Jeffrey
A. Hagen, MD, Jessica M. Leers, MD, Andrew L. Tang, MD, Nuttha
Ungnapatanin, MD, Steven R. DeMeester, MD, John C. Lipham, MD, Tom
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R. DeMeester, MD∗. Surgery, University of Southern California, Los
Angeles, Ca.
Purpose: Obesity and gastroesophageal reflux disease (GERD) are impor-
tant health epidemics. Previous studies have demonstrated that increasing
body mass index (BMI) is associated with GERD symptoms, however, lit-
tle is known about its relationship with objectively proven GERD. The aim
of this study is to investigate the relationship between BMI and 24-hour
esophageal pH.
Methods: A cross-sectional analysis of 1798 patients (49% male, mean
age 51.3+/-14) referred for assessment of GERD symptoms between 1998
and 2006. Patients with previous foregut surgery and abnormal gastric pH
were excluded. Esophageal manometry was performed to assess the lower
esophageal sphincter (LES). Nasoesophageal 24-hour pH testing was done
5 cm above the upper border of the LES off medication. Patients were cat-
egorized by BMI [weight in kg/(height in m)2] according to World Health
Organization classification (underweight < 18.5, normal 18.5–24.9, over-
weight 25–29.9, obese ≥ 30) for comparison of degree of acid exposure. A
subgroup of patients with a competent LES (total length ≥ 2.7 cm, abdom-
inal length ≥1.4 cm and resting pressure ≥5.1 mmHg) were also analyzed
to eliminate the confounding effect of a defective valve. Kruskal-Wallis,
Mann-Whitney, Chi-square and Spearman tests were used to assess statisti-
cal significance.
Results: The mean BMI was 27.8 (SD = 5.5). Compared to patients with
a normal BMI, overweight patients have significantly more acid exposure
(Figure) and a higher prevalence of a defective LES (P < 0.0001), with
a further increase among obese patients. Increasing BMI correlated with
increasing composite score (r = 0.3). To eliminate the confounding factor
of a defective valve, the same analysis was performed limited to the group
of patients with a competent LES. Similar associations between increasing
BMI and degree of acid exposure and prevalence of defective LES were
seen.
Conclusion: Increasing body mass index is associated with more severe
objective indicators of GERD. This effect is independent of the presence of
a defective valve.[figure1]
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Derivation and Validation of a Short Reflux Symptom Questionnaire
(ReQuest in PracticeTM ) in Patients with GERD
Greg Rubin, MD, Peter Uebel, MD, Amela Brimo-Hayek, MD, Karl-Heinz
Hey, MD, Hubert Doerfler, MD, Robert C. Heading, MD∗. Primary Care,
University of Sunderland, United Kingdom; Private Practice,
Ludwigshafen, Germany; Private Practice, Dortmund, Germany; Private
Practice, Paderborn, Germany; Gastroenterology, ALTANA Pharma,
Konstanz, Germany and Gastroenterology, Royal Infirmary, Glasgow,
United Kingdom.
Purpose: ReQuest in PracticeTM (RiPTM ), a shortened form of the fully
validated ReQuestTM questionnaire, was designed to allow patients’ self-
assessment of GERD symptoms in day-to-day clinical practice.
Methods: Data from previous studies showing a high correlation of symptom
frequency x intensity with resultant distress was used to devise an abbreviated
questionnaire, RiPTM . Visual analogue scales were used to assess 5 symptom
dimensions plus the patients’ general well-being. Acid complaints, upper
abdominal/stomach complaints, lower abdominal/digestive complaints, and
nausea form the subscale RiPTM -GI; general well-being and sleep distur-
bance form the subscale RiPTM -WS.
120 patients with GERD were studied to determine the construct validity, in-
ternal consistency and the intra-class correlation coefficient (ICC) of RiPTM .
Half the patients completed RiPTM followed by ReQuestTM . The other half
completed the same questionnaires in reverse order to avoid a sequence bias.
Before and after endoscopy all patients completed the health-related quality
of life questionnaire GERDyzerTM .
A high Spearman correlation coefficient (SCC) of >0.75 of ReQuestTM
and RiPTM would establish the applicability of all validation parameters of
the former (Cronbach’s alpha: 0.9; ICC: 0.86; test-retest reliability: 0.85;
responsiveness index: 165.3) to the latter. Consequently, construct validity
was assessed by correlating RiPTM with ReQuestTM and with GERDyzerTM .
In addition, Cronbach’s alpha and ICC were calculated directly for RiPTM
and its subscales.
Results: The SCC of ReQuest in PracticeTM and ReQuestTM was 0.9, indi-
cating that the two are parallel forms. Internal consistency was high (Cron-
bach’s alpha: 0.9) establishing the suitability of RiPTM to assess and mon-
itor individual patients. Psychometric evaluation revealed an ICC of 0.99.
The RiPTM -WS subscale correlated well with the different dimensions of
GERDyzerTM (SCC: 0.65) and with the GERDyzerTM total score (SCC:
0.80).
Conclusion: ReQuest in PracticeTM is a valid and reliable instrument for
symptom assessment in GERD. It may be used by individual patients in
day-to-day clinical practice and thus can potentially assist the physician in
monitoring response to treatment.
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Effect of Obesity on Symptom Resolution in Patients with
Gastroesophageal Reflux Disease (GERD)
Prateek Sharma, MD, FACG, Nimish Vakil, MD, FACG, John T. Monyak,
PhD, Debra G. Silberg, MD, FACG∗. University of Kansas Medical
Center, Kansas City, MO; University of Wisconsin Medical Center,
Milwaukee, WI and AstraZenca LP, Wilmington, DE.
Purpose: To determine if body mass index (BMI) affects heartburn (HB)
resolution in GERD patients, as obesity is reported to be associated with
higher esophageal acid exposure and may impact treatment outcomes in
GERD patients.
Methods: Data from 2 randomized, double-blind studies of similar design
comparing esomeprazole 20 or 40 mg once daily with placebo (SH-QBE-
0053 and -54) were pooled and analyzed. Patients were aged 18 to 75 y,
had a history of HB for ≥6 months with symptoms on ≥4 of the last 7
d before study entry, and were negative for erosive esophagitis confirmed
by endoscopy within 10 d of study entry. Patients returned daily HB diary
cards at weeks 2 and 4. HB resolution was defined as recordings of none
for HB symptoms for each of the last 7 d of the study on a scale of none,
mild, moderate, severe. A Mantel-Haenszel χ2 test (MHT) was conducted to
test for an association of BMI category with baseline HB severity. Logistic
regression models (LRMs) were fit with HB resolution as the dependent
variable and BMI as a continuous independent variable. The LRMs adjusted
for treatment, study, baseline HB severity, age, sex, race, H pylori result, and
presence of hiatal hernia.
Results: In total, 704 patients with nonerosive reflux disease (NERD) were
analyzed. There was no apparent relationship between baseline HB severity
and BMI (MHT P = .2755) (Table). The LRMs showed no significant effect
of BMI on HB resolution (P = .9853). The odds ratio estimate was 1.000
(95% CI, 0.972–1.030). No significant interactions with BMI and other vari-
ables were found.
Conclusion: In NERD patients, obesity had no apparent effect on base-
line HB severity or on resolution of HB symptoms with PPI therapy. This
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finding suggests that PPI dosing adjustments based on BMI may not be
needed.
HB resolution rates by BMI
HB Resolution Rate (%)
Baseline Severity BMI N Placebo N PPI
None <25 13 7.7 16 31.3
25 to <35 27 7.4 58 36.2
≥35 11 9.1 11 45.5
Mild <25 17 5.9 61 32.8
25 to <35 52 19.2 97 30.9
≥35 8 12.5 23 39.1
Moderate <25 28 17.9 49 34.7
25 to <35 45 15.6 83 44.6
≥35 11 18.2 24 20.8
Severe <25 8 0.0 11 72.7
25 to <35 12 8.3 29 34.5
≥35 6 0.0 4 25.0
∗Day before treatment or first day of treatment
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Intragastric Acid Control in Patients Who Have Barrett’s Esophagus:
Comparison of Once- and Twice-Daily Regimens of Esomeprazole and
Lansoprazole
Stuart J. Spechler, MD, FACG, Peter N. Barker, PhD, Debra G. Silberg,
MD, FACG∗. University of Texas Southwestern Medical Center, Dallas, TX
and AstraZeneca LP, Wilmington, DE.
Purpose: To compare the efficacy of oral doses of once-daily (QD) and
twice-daily (BID) esomeprazole and lansoprazole for the control of intra-
gastric pH in patients who have Barrett’s esophagus (BE).
Methods: In this multicenter, randomized, open-label, crossover study, the
steady-state 24-hour intragastric pH profile was evaluated in adult patients
who were negative for H pylori infection and had histologically confirmed BE
within 2 years of study entry. Patients were randomly assigned to crossover
these 2 treatment arms: oral esomeprazole 40 mg QD followed by BID dosing
or oral lansoprazole 30 mg QD followed by BID dosing. Study drug was taken
30 minutes before breakfast for QD dosing or 30 minutes before breakfast
and dinner for BID dosing. On or after days 14 (QD) and 9 (BID) patients
underwent a catheter-based 24-hour pH study. There was no washout period
between doses; however, sufficient days preceded each 24-hour monitoring
period to ensure washout of the previous drug and to reach steady-state levels
of the next drug. The percentage of time that intragastric pH was >4 and
the least-squares mean (LSM ± SEM) were calculated for each treatment
from a mixed model ANOVA. Patients had to complete both comparative
treatment sequences and have valid pH data to be included in the primary
analysis population (per-protocol).
Results: Of 113 patients randomized, 46 (mean age, 58 years; men, 67%)
provided evaluable pH data for the primary end point (QD comparison). The
LSM overall time that pH was >4 was 16.0 hours for esomeprazole QD and
12.1 hours for lansoprazole QD (P < .0001 vs esomeprazole) (see Table).
LSM (SEM)% time pH >4 for QD and BID dosing of
esomeprazole and lansoprazole in BE patients
Treatment % Time pH >4 pH >4 for ≥12 h: n (%)
Eso 40 QD 66.9 (2.6) 40 (87)
Lanso 30 QD 50.6 (2.6)∗ 24 (52)
N = 46
Eso 40 BID 81.2 (2.2) 40 (98)
Lanso 30 BID 64.3 (2.2)∗ 33 (80)
N = 41
Eso, esomeprazole; Lanso, lansoprazole. ∗p < 0.0001 (eso vs. lanso)
Conclusion: In BE patients, oral esomeprazole 40 mg QD provides greater
control of intragastric acid at steady state than oral lansoprazole 30 mg QD.
Esomeprazole 40 mg BID provided greater acid control versus lansoprazole
30 mg BID.
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Tissue Ingrowth in a Fully Covered Self-Expandable Metallic Stent
Sathya Jaganmohan, MD, Zwischenberger Joseph, MD, Gottumukkala S.
Raju, MD, FACG∗. Gastroenterology & Surgery, UTMB, Galveston, TX.
Purpose: Esophageal stents are being increasingly used in the management
of esophageal leaks. Tissue ingrowth after insertion of a partially covered
self-expanding metal stents (P-CSEMS) interferes with stent removal. This
could be avoided by the use of fully covered self-expanding metal stents
(F-CSEMS).
Despite the full covering, there is a potential risk of tissue ingrowth as ob-
served in two patients at our center. Our objective is to present the cases with
a description of the endoscopic removal of F-CSEMS with tissue ingrowth.
Case 1: A 57-year old male presented with spontaneous perforation of the
distal esophagus. Emergent surgical repair failed and the esophageal leak
recurred. EGD revealed a 1.5 cm perforation. A F-CSEMS -Alimaxx-E
(22 mm × 120 mm, Alveolus, Inc, Charlotte, NC) was inserted. Contrast
esophagography on day 6 revealed absence of free drainage of contrast into
the stomach suggesting obstruction. EGD showed extensive tissue ingrowth
through the upper 2/3 of the stent and a flap valve effect from the cardia. Stent
Removal: The stent was loosened from the ingrowth at multiple locations
with an Aligator forceps and was removed in one piece. A Polyflex stent
(Boston Scientific Inc, Natick, MA) was inserted (total time: 1.5 hours); 7
weeks later, the stent was removed and the fistula healed.
Case 2: A 29 year old female developed esophageal leak after myotomy and
epiphrenic diverticulectomy for achalasia. Due to migration of a Polyflex
stent, repeat thoracotomy and surgical closure reinforced with diaphramatic
muscle was undertaken, without success. Insertion of a F-CSEMS (Alimaxx-
E stent) closed the leak. EGD two weeks later revealed severe tissue ingrowth
in the distal third of the stent.
Stent Removal: When the spine of the stent was pulled with an Alligator
forceps, the free portion of the stent fractured leaving the portion with in-
growth in-situ. An overtube was used and the stent removed in a piece-meal
fashion (total time: 3 hours). The fistula healed successfully.
Conclusions: Tissue ingrowth is a potential complication even in F-CSEMS.
Tissue ingrowth could pose a technical challenge at endoscopic removal of
these stents. One should be prepared to manage this complication.[figure1]
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Insulin-Like Growth Factor-1 Pathway Activation in Barrett’s
Esophagus
Kayode Olowe, MD, Dawn Dawson, MD, Joseph Willis, MD, Larry Miller,
MD, Jason Taylor, MD, Jennifer Kimble, MD, Amitabh Chak, MD∗.
Division of Gastroenterology, University Hospitals-Case Medical
Center/Case Western Reserve University, Cleveland, OH and Pathology,
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University Hospitals-Case Medical Center/Case Western Reserve
University, Cleveland, OH.
Purpose: Barrett’s esophagus (BE) is associated with obesity independent
of GERD. We hypothesized that increased insulin levels associated with
obesity and insulin resistance might lead to cell proliferation via the insulin-
like growth factor -1 (IGF-1) cell signaling pathway.
Methods: Fasting serum insulin levels and glucose levels were measured in
14 BE subjects. Immunohistochemistry (IHC) was performed on paraffin-
embedded tissue from 14 BE cases using antibodies to phosphorylated-AKT
and phosphorylated-mTOR, cell signaling molecules known to be phospho-
rylated intermediates in the insulin – IGF signaling pathway.
Results: IHC with Ki-67, a cellular proliferation marker, correlated strongly
with phosphorylated-AKT as well as phosphorylated-mTOR immunostain-
ing intensity in BE. Strong immunostaining for phos-AKT and phos-mTOR
was present in 8 specimens. Immunostaining was generally weak in the other
6 specimens. All 3 of the BE subjects with insulin resistance, as calculated
by the homeostasis model (HOMA-IR > 3.8), showed strong immunos-
taining of phos-AKT and phos-MTOR. Six subjects with HOMA-IR > 3
also showed strong immunostaining. Only 2 subjects with HOMA-IR < 3
showed strong immunostaining whereas the other 6 with low HOMA-IR
showed weak immunostaining. The non-BE columnar epithelium as well as
the squamous epithelium showed negligible immunostaining.
Conclusion: These preliminary results support our hypothesis that insulin
and IGF-1 may act as growth factors for Barrett’s epithelium through phos-
phorylated AKT and m-TOR intermediates.
65
Does Combined Multichannel Intraluminal Esophageal Impedance
and Manometry Predict Postoperative Dysphagia after Laparoscopic
Nissen Fundoplication?
Martin I. Montenovo, MD, Roger Tatum, MD, Edgar Figueredo, MD,
Valeria Martin, MD, Hao Vu, MS, Elina Quiroga, MD, Brant K.
Oelschlager, MD∗. Surgery, University of Washington, Seattle, WA.
Purpose: The purpose of this study was to identify if the addition of multi-
channel intraluminal esophageal impedance (MII) to manometry may detect
those patients most at risk of developing postoperative dysphagia.
Methods: Between March 2003 and April 2006, 69 patients who agreed to
participate in this study were prospectively enrolled. All patients completed
a pre-operative symptom questionnaire, MII/manometry, and 24-hour pH
monitoring. Symptom questionnaires were administered post-operatively at
a median of 18 months (range: 6–46 months), and we defined dysphagia
(both preoperative and postoperative) as occurring more often than once a
month with a symptom severity score (SSI – scale = 0–10) ≥ 4. LNF was
performed in all cases.
Results: Thirty patients (43%) reported pre-operative dysphagia. There was
no significant difference in pH monitoring, lower esophageal sphincter (LES)
pressure/relaxation, peristalsis, liquid or viscous bolus transit, or bolus transit
time between patients with and without pre-op dysphagia. In those patients
reporting preoperative dysphagia, the severity of dysphagia improved sig-
Post-operative No post-operative
Pre-operative dysphagia dysphagia
findings (N = 12) (N = 57) P-value
LESP (mmHg) 20.4 ± 12.4 13.7 ± 10.7 .354
% peristalsis 80 ± 32 88 ± 18 .685
% LBT 78 ± 30 79 ± 24 1.000
Liquid BTT (sec) 6.4 ± 1.4 7.0 ± 1.4 .838
% VBT 66 ± 33 64 ± 29 .526
Viscous BTT (sec) 7.4 ± 2 7.8 ± 2 .561
% time pH < 4 13.2 ± 9.4 11.3 ± 11.9 .602
DeMeester score 52.3 ± 38.4 40 ± 40.1 .358
Pre-op dysphagia (n) 9/12 (75%) 21/57 (37%) <.001
nificantly from 6.8 ± 2 to 2.6 ± 3.4 (P < .001) after LNF. Twelve (17%)
patients reported dysphagia postoperatively. Patients with post-op dyspha-
gia had similar LES pressure and relaxation, peristalsis, and esophageal
clearance to those without dysphagia. The only predictor of post-operative
dysphagia was the presence of pre-operative dysphagia (Table).
Conclusion: Neither MII nor manometry are effective in predicting dyspha-
gia before or after laparoscopic Nissen fundoplication. The presence of dys-
phagia preoperatively is the only predictor of dysphagia after the operation.
66
Esophageal Capsule Endoscopy for Evaluation of Gastroesophageal
Reflux Disease
Disaya Chavalitdhamrong, MD∗, Oren Goltzer. Capsule Endoscopy
Services Study Group, Los Angeles, CA.
Purpose: Esophagogastroduodenoscopy (EGD) is commonly used to eval-
uate suspected or established gastroesophageal reflux disease (GERD).
Esophageal capsule endoscopy (ECE) may offer an alternative approach
to visualize esophageal lesions commonly associated with GERD. The ob-
jective of this study was to report the ECE findings and complication rate in
a large series of patients with GERD-like symptoms.
Methods: From April 2005-June 2007, a total of 312 ECE were performed in
patients with GERD symptoms. ECE findings deemed consistent with reflux
esophagitis (hyperemia, erosions, ulceration, strictures, Barrett’s esophagus)
were graded using the modified 1–5 scale Savary-Miller classification. The
esophagogastric junction (GEJ) was carefully examined for the hiatal her-
nias, Schatzki’s rings, and strictures.
Results: Eight (2.6%) of 312 ECE cases remained in the esophagus for the
entire imaging time (≥ 20 minutes). In one case (0.3%), no esophageal im-
ages were recorded due to rapid esophageal transit. The mean esophageal
transit time was 138.0 ± 232.2 seconds (excluding 8 cases in which the
ECE did not leave the esophagus). Reflux esophagitis was diagnosed in 194
patients (62.2%): Savary-Miller classification – Grade 1 (N = 121), Grade 2
(N = 62), Grade 3 (N = 8), Grade 4 (N = 1) and Grade 5 (N = 2). One hun-
dred forty-four patients (46.2%) had hiatal hernia. Eight cases (2.6%) had
Schatzki’s ring. We identified seven cases (2.2%) with suspected Barrett’s
esophagus, six (1.9%) with irregular Z line, and one (0.3%) with small islands
of pinkish mucosa. Incidental gastric mucosal findings included: gastric ero-
sions (N = 37), redness/submucosal hemorrhage (N = 5), gastric ulceration
(N = 4), gastric nodularity/polyps (N = 2). No esophageal strictures, ECE
impaction, or other complications occurred in this case series.
Conclusion: From these data, ECE was a safe and easy non-invasive tech-
nique to evaluate the esophageal mucosa in patients with GERD symptoms.
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PillCam ESO for Evaluating the Esophagus in the Workplace: Making
It Even Easier To Swallow
Daniel S. Mishkin, MD, CM∗, Joan Pemberton, RN, James E. Scharback,
MD, Sandra L. Marwill, MD, MPH. Gastroenterology, Boston University,
Boston, MA and Internal Medicine, Gillette Medical Department, South
Boston, MA.
Purpose: Increasing use of over-the-counter acid suppression medications,
fear of the procedures, requiring an escort, and concerns about loss of pro-
ductivity in the workplace are barriers to undergoing thorough evaluation
for chronic or intractable reflux symptoms. Capsule endoscopy, specifically
PillCam ESO and the Rapid Access real-time viewer, were welcomed into
a workplace and performed on 10 non-sedated employees during their work
day, saving time and maintaining worker productivity.
This pilot study was performed at a large self insured Boston based com-
pany with about 4000 employees. Employees have access to an internal
medicine, primary care practice on site. Two physicians screened patient/
employees over a couple of months to identify patients with persistent reflux
symptoms. Patients were excluded if they had a history of other unexplained
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gastrointestinal symptoms, previous bowel surgery, obstructive symptoms,
an implantable electromedical device or pregnancy. A single gastroenterol-
ogist with experience with capsule endoscopy performed the procedures on
site. Ten patients were identified, ages 36 to 65, where there was 5 males and
5 females. All patients were full time working employees.
On two separate occasions, a total of 10 PillCam ESO studies were per-
formed. Results included eight patients with normal mucosa. Two patients
underwent a subsequent EGD. One patient had gross findings suggestive of
Barrett’s esophagus, later proven by biopsy. A second patient had gross evi-
dence suggesting reflux esophagitis, but an incomplete visualization of the
Z-line limited the study. The first 5 patients were interviewed, ingested the
capsule, and received their results by consultation with the gastroenterolo-
gist in a total of a 3 hour session. The next 5 patients were evaluated using
the real-time viewer. For this latter group of 5 patients, the entire process
was shortened to less than 40 minutes from ingestion to consultation and
reporting.
PillCam studies performed at the workplace at a large self-insured company
safeguarded worker productivity and provided state-of-the-art medical care
for patients with chronic reflux symptoms. Future PillCam studies, not just
to evaluate the esophagus, could be started at the work site with capsule
ingestion and being more convenient for the patient.
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Are There Any Motility Disturbances in Eosinophilic Esophagitis?
Savio Reddymasu, MD, Mojtaba Olyaee, MD, Paul Hyman, MD, Daniel
Buckles, MD, Scott Grisolano, MD, Richard McCallum, MD∗. Medicine,
Kansas University Medical Center, Kansas City, KS and Pediatrics,
Kansas University Medical Center, Kansas City, KS.
Purpose: To identify manometric patterns of the esophagus in a series of
patients with eosinophilic esophagitis (EE) in an effort to explain any motility
contributions to their dysphagia.
Methods: 10 patients (9 males) with EE (>20 eosinophils/hpf on the prox-
imal esophageal biopsy) underwent manometric evaluation of the esoph-
agus using the water perfused catheter system. The criteria for a normal
esophageal manometry (EM) exam were: a) Lower esophageal sphincter
(LES) pressure of 15–35 mmHg, and b) >/ = 80% of contractions being
peristaltic after wet swallows, with a normal range of contraction amplitude
between 50–150 mmHg. Demographic data and clinical history for each of
these patients was also obtained.
Results: Mean age of the patients was 32 years (Range: 14–51). Intermit-
tent non-progressive dysphagia was the main presenting complaint, while
one also had an acute food impaction. One patient had food allergies,
6 patients had other allergic manifestations of either allergic rhinitis, or
bronchial asthma. Six patients were on proton pump inhibitors (PPI) for
gastro esophageal reflux disease (GERD) symptoms. On EM – two patients
had low amplitude (<30 mmHg), non-peristaltic contractions; one in the
mid-esophageal segment, while the other was more diffuse with 30% of
the contractions being non-peristaltic after wet swallows. Four patients had
decreased LES pressure (<15 mmHg) and they were receiving PPI’s. One pa-
tient had 20% of contractions reaching “nutcracker” criteria (>200 mmHg).
The remaining 3 patients had a normal manometric evaluation.
Conclusion: 1) Although EE is not associated with a specific manometric
pattern to explain the dysphagia, 20% of patients did have a major motor
disturbance in the smooth muscle function. 2) EE can co-exist with GERD,
but PPI therapy alone does not improve the dysphagia. 3) There should be
a high index of suspicion for EE when dysphagia is not being explained by
esophageal manometry, endoscopy, or imaging studies.
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A New Surgical Approach to Gastroesophageal Reflux Disease: Nissen
Fundoplication with Highly Selective Vagotomy
Savio Reddymasu, MD, Niazy Selim, MD, Michael Moncure, MD, Jeffrey
Piehler, MD, Daniel Buckles, MD, Richard McCallum, MD∗. Medicine,
Kansas University Medical Center, Kansas City, KS and Surgery, Kansas
University Medical Center, Kansas City, KS.
Purpose: A standard Nissen fundoplication does not address gastric acid
secretion; hence an accompanying highly selective vagotomy (HSV), which
will reduce gastric acid secretion by 60%, could help sustain long-term symp-
tom response. To assess this we measured the rate of proton-pump inhibitor
(PPI) use postoperatively in a cohort of patients with gastroesophageal re-
flux disease (GERD) who underwent Nissen fundoplication with HSV in
comparison to a group who did not undergo HSV during the procedure.
Methods: 14 patients (8 females) underwent a Nissen fundoplication with
HSV, and 19 without HSV for refractory GERD symptoms, particularly
nocturnal regurgitation. PPI use pre-operatively and during the postoperative
follow up was recorded. Esophageal manometry, esophageal pH monitoring,
and gastric emptying scintigraphy (GES) were performed preoperatively
Results: Mean age of patients in both the groups was similar at 47 years.
The mean lower esophageal sphincter pressure was 8 mmHg (95% CI: 6–
10 mmHg) in the HSV and was not significantly different (P-0.44) than the
non-HSV group (Mean 10 mmHg; 95% CI: 9–11 mmHg). The mean% of
retained food after 4 hours on GES was also similar (P-0.44) in both groups-
8% (95% CI: 2–14%) in the HSV group and 12% (95% CI: 5–19) in the
non-HSV group. All patients in both groups were on a PPI (Usually double
dose therapy) prior to the surgery. Median duration of follow up was 63
months (Range: 6–88 months). 1/14 (7%) patients in the HSV group and
9/19 (47%) in the non-HSV group either remained on a PPI post-operatively
or were re-started, generally within the first 6 months after surgery. The odds
ratio of being on a PPI in the HSV group after surgery as opposed to the
non-HSV group was 0.08 (95% CI- 0.009–0.8). None of the patients in the
HSV group had symptoms suggestive of gastroparesis postoperatively
Conclusion: 1) Adding a HSV to the standard Nissen fundoplication proce-
dure significantly reduced the use of PPI’s during long term post-operative
follow up and was not associated with any adverse events. 2) This new sur-
gical approach for refractory GERD warrants further objective studies to
confirm these important observations.
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GERD – Maintenance Therapy with PPI v/s “Pre-Emptive Use of PPI”
Tushar C. Chauhan, MD∗. Private Practice, Community Gastroenterology
Center, Voorhees, NJ.
Purpose: GERD is one of the common indication to see a gastroenterologist.
Due to it’s prevalence, the economic impact of management of GERD is huge
when the endoscopy, initial induction therapy followed by tapering dose and
then maintenance therapy.
The idea of this presentation is to check if we can generate consensus about
“Pre-emptive us of PPI” to reduce recurrence compared to maintenance
therapy. When the patient can recall the event or meal that caused first re-
currence of GERD while they were off, were advised “Pre-emptive use of
PPI”-meaning taking PPI 30 to 60 minute before the precipitating event.
During my search, no study has been published that evaluated this way of
treatment.
Methods: During four years, 40 patients with endoscopically proven GERD
were followed in office. Due to severity and duration of symptoms, they all
had Endoscopic evaluation with biopsy. Those who had Barrett’s esopha-
gus were excluded to begin with. The others were followed over period of
four years with long-term maintenance with PPI v/s “Pre-emptive use of
PPI”. Those patients who had economic reason, or denial by insurance or
safety concern over the long-term use of conventional maintenance therapy
were assigned to “Pre-emptive us of PPI” group.
Results: Many patients, who had recurrence of GERD, were able to predict
the event like heavy meal over weekend or social gathering or drinking
alcohol. When they are given “Pre-emptive Therapy with PPI before the
event, the incidence of recurrence of GERD was much reduced compared
to no use at all. Not only that it was comparable to the group of patient who
had chronic maintenance therapy with PPI.
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Conclusion: “Pre-emptive use of PPI” reduces number of recurrence of
GERD in patients who had predictable culprit event. Not only that it was
comparable to chronic long-term maintenance therapy, but also the cost is
probably one forth to one fifth. (As most of the patient needed it once or
twice a week compared to seven days week).
The strategy of “Pre-emptive use of PPI” can cause significant cost contain-
ment and saving and it worth exploring at larger scale.
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Changes in Quality of Life over Time in Patients Registered on the
Mayo Clinic Esophageal Adenocarcinoma and Barrett’s Esophagus
Registry
Pamela J. Atherton, MS∗, Brian F. Kabat, BS, Robert C. Miller, MD,
Yvonne Romero, MD, Mary Fredericksen, Jeff A. Sloan, PhD. Mayo Clinic
Cancer Center Statistics, Mayo Clinic, Rochester, MN; Radiology, Mayo
Clinic, Rochester, MN and Digestive Diseases and Cancer Clinics, Mayo
Clinic, Rochester, MN.
Purpose: To explore the change in patient quality of life (QOL) over time in
patients with esophageal adenocarcinoma (EA) or Barrett’s esophagus (BE).
Methods: Members of the Mayo Clinic EABE Registry completing two
QOL assessments (baseline and 1 year (range 11–16 mos)) were selected
to evaluate whether QOL changes occurred over time. Completed was the
Linear Analogue Self Assessment (LASA) containing 12 questions relating
to QOL (overall, social, spiritual, physical, mental, emotional, social support,
financial, pain, fatigue and legal issues). Each LASA question has a value
from 0 (worst) to 10 (best). The change from baseline was calculated for each
question. Further, the change in each score was dichotomously categorized
as being a positive (increase in QOL) or negative (decrease in QOL) change.
Basic summary statistics were computed for baseline characteristics and
QOL scores. Student’s t-tests were used to determine significance in changes
from baseline, Kruskal-Wallis tests were performed for the difference in
continuous data between groups and Fischer-Exact tests were performed for
differences in categorical data between groups.
Results: Data from 372 patients was analyzed. Median age was 66 (range
30–93). 81% were male, 10% received treatment for EA prior to QOL as-
sessment, 8% received treatment between assessments, and 82% received no
treatment. Change in scores showed that the group had significant decreases
in pain frequency (<0.001) and social support (<0.001) and a marginally
significant decrease in pain severity (P = 0.06). Patients treated between
assessments had a higher change in financial well-being score than the other
two groups (mean 1.5 vs −0.1 vs −0.1, P-0.001) and a higher change in
legal well-being (mean 0.9 vs −0.1 vs −0.1, P = 0.04). Treated patients
reported higher pain severity (P = 0.048). There were no differences in the
change from baseline scores between gender or age groups. The categorical
change resulted in a difference in financial well-being (P = 0.03) and social
support (P = 0.03). Differences in physical well-being were marginal (P =
0.06).
Conclusion: Treated patients had less financial concerns and legal concerns
but did experience higher pain severity. The significant change from baseline
of social support was not evident upon subgroup analyses.
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Decreased GLIPR1 Expression in Esophageal Adenocarcinoma
Keith Brown, MD, Timothy C. Thompson, PhD, Chengzhen Ren, PhD,
Mahdis Rahmani, MS, Mamoun Younes, MD∗. Pathology, Baylor College
of Medicine, Houston, TX and Scott Department of Urology, Baylor
College of Medicine, Houston, TX.
Purpose: To determine whether GLIPR1 may be altered in esophageal ade-
nocarcinoma (ACA).
Methods: Sections from esohagectomy specimens including 13 with Bar-
rett’s metaplasia negative for dysplasia (BMND) and 22 adenocarcinomas
(ACA) were stained for the GLIPR1 protein using the immunohistochem-
istry (IHC). The percentage of positive cells was scored on a scale of 0–5
with 0 completely negative; 1, 1–10%; 2, 11–25%; 3, 26–50%; 4, 51–75%;
and 5, >75% of the cells positive. The intensity of staining was scored as
0, completely negative; 1, weak; 2, moderate; and 3, strong intensity. Paired
frozen samples of 4 normal and ACA were assayed for GLIPR1 promoter
hypermethylation using the bisulfite method.
Results: Staining was both nuclear and cytoplasmic, and was completely
abolished by preincubating the antibody with the immunizing peptide. The
immunostaining score (IC) score for the BMND cases ranged from 6–15,
whereas the score for ACA ranged from 0–10 with 4 of the ACA cases
completely negative and 14 having very low IC scores (0–2). The mean IC
score for the ACA, 3.3, was significantly lower than that for BMND, 11,
(P < 0.0001, unpaired t-test). In a smaller subset of the cases in which
both BMND and ACA were from the same esophagectomy specimens, the
mean IC score for ACA (4.5) and BMND (10.9) were also significantly
different (P = 0.0105, paired t-test). The methylation status of the gene did
not correlate with the levels of protein, as determined by IHC, in paired
samples of normal and tumor tissues.
Conclusion: We conclude that the majority of esophageal adenocarcinomas
have significant reduction of GLIPR1 protein expression suggesting that
GLIPR1 plays a significant role in malignant transformation in Barrett’s
esophagus.
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ADHERE Study: Application of Dx-pH Catheters in the Evaluation of
Patients without Gastroesophageal REflux Disease (GERD)
George Sun, MD, Sean Casey, MD, Eric Hill, MD, Farnoosh Farrokhi,
MD, Michael Vaezi, MD∗. Digestive Disease Center, Vanderbilt University
Medical Center, Nashville, TN.
Purpose: The Restech Dx-pH probe is a new ambulatory pH monitoring
device which uses a sensitive sensor to capture liquid and aerosolized acid.
Its design allows for convenient placement in the oropharynx above the upper
esophageal sphincter (UES) without the need for manometry or endoscopy.
Currently, no normative data for this device exists nor has its application
been validated for use in patients with GERD or extraesophageal symptoms.
Our aim was to provide data for Dx-pH probes in the oropharyngeal and
distal esophageal sites in normal subjects.
Methods: Normal subjects underwent prolonged ambulatory Dx-pH testing
in the oropharynx and distal esophagus. The distal probe was placed 5 cm
above the manometrically measured LES, and the proximal probe was placed
visually into the oropharynx at the level of the uvula at a known distance
from the UES. The following reflux parameters were measured using the
Mann-Whitney non-parametric procedure: median% time below pH 4, 5,
and 6, as well as, mean number of events per 24 hours below each of the
above pH cutoffs.
Results: A total of 31 normal subjects (11 M/ 20 F); mean age 33.2 yrs (range
21–56) comprised the study population. The median (95th percentile) total%
time below pH 4, 5, and 6 in the distal esophagus was 1.0 (5.3), 2.9 (12.6), and
10.4 (46.1), respectively (Table 1). For the oropharyngeal proximal probe,
the median (95th percentile)% time below pH 4, 5, and 6 was 0.0 (0.0),
0.0 (2.4), and 1.0 (22.5), respectively. Finally, for the proximal probe, the
median (95th percentile) number of events below pH 4, 5, and 6 was 0.0
(0.6), 0.0 (8.4), and 4.1 (197.5), respectively, over a 24 hour period in this
normal population.
Table 1. Median Dx-pH probe measurements: oropharynx vs. esophagus
Oropharynx Esophagus
Parameters (25–75%) (25–75%)
% Time pH < 4 0.0 (0.0–0.0) 1.0 (0.4–3.5)
# of events/24 hrs < pH 4 0.0 (0.0–0.0)
% Time pH < 5 0.0 (0.0–0.0) 2.9 (1.3–6.6)
# of events/24 hrs < pH 5 0.0 (0.0–0.0)
% Time pH < 6 1.0 (0.0–11.2) 10.4 (5.2–20.4)
# of events/24 hrs < pH 6 4.1 (0.0–56.9)
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Conclusion: The normative values for the new Dx-pH catheter probe com-
pares favorably to the accepted gold standard pH monitoring device. Future
studies can focus on comparative evaluations between patients with and
without GERD using the Dx-pH catheter probe.
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Coexistence of Barrett’s Esophagus and Eosinophilic Esophagitis
Cristina Almansa, MD, Herbert Wolfsen, MD, Kenneth Devault, MD, Sami
R. Achem, MD∗. Gastroenterology, Mayo Clinic, Jacksonville, FL.
Purpose: The interaction between gastroesophageal reflux (GERD) and
eosinophilic esophagitis (EoE) is complex. There is a high prevalence of
GERD symptoms in patients with EoE. Patients with GERD have increased
eosinophils in the esophageal epithelium. EoE may cause exudates and stric-
tures but it is unclear whether complications such as Barrett’s esophagus
occur in EoE. Purpose: 1. Determine the prevalence of Barrett Esophagus
(BE) in patients with Eosinophilic esophagitis (EoE). 2. Compare the demo-
graphic, clinical and endoscopic features of patients with EoE to those with
EoE and BE.
Methods: Retrospective review of our series of consecutive patients with
EoE (N = 71) evaluated in the last year. EoE was diagnosed if >20 E/HPF
were identified. BE was diagnosed when “salmon- like” epithelium was seen
in the tubular esophagus and biopsy confirmed intestinal metaplasia.
Results: Barrett’s esophagus was found in 14% (10/71) patients with EoE.
Six had long segment BE (≥3 cm) and 4 a short segment BE. Demographics,
clinical and endoscopic features are summarized below:
Conclusion: BE coexists in 14% of patients with EoE. Endoscopists should
be aware of the potential occurrence of these two common disorders on
the same patient. Esophageal symptoms of GERD and dysphagia overlap
in these patients. Subjects with BE and EoE are more likely to have GERD
symptoms and hiatus hernia while those with EoE without BE are more
likely to have dysphagia and rings. A susbtantive proportion of patients with
BE and EoE has peripheral eosinophilia and allergies. Further studies are
needed to determine the potential interactions between these two common
entities.
Demographics and Symptoms
N Mean White Food
Disorder Cases Age (range) Males race GERD Dysphagia impaction
EoE + BE 10 58 (18–88) 9 (90%) 9 (90%) 9 (90%) 6 (60%) 2 (20%)
EoE – BE 61 51 (19–71) 40 (66%) 31 (51%) 31 (51%) 49 (80%) 20 (33%)
Endoscopic Findings, History of Allergies and Eosinophilia
Hiatus White Distal Periph
Disorder Hernia Rings Furrows lesions Ring Eosinophilia Allergies
EoE + BE 9 (90%) 4 (40%) 4 (40%) 2 (20%) 4 (40%) 7 (70%) 6 (60%)
N = 10
EoE – BE 22 (36%) 37 (61%) 15 (25%) 13 (21%) 19 (31%) 17 (35%) 31 (51%)
N = 61
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Adenocarcinoma of Esophagus and Cardioesophageal Junction (CEJ):
10 Year Experience
Edward S. Friedman, MD, Anu K. Mathew, MD, Camron Kiafar, DO,
Richard Gerkin, MD, Kathleen M. Rogers, CTR, Francisco C. Ramirez,
MD∗. Gastroenterology, Carl T. Hayden VA Medical Center, Phoenix, AZ
and Medicine, Banner Health Good Samaritan Hospital, Phoenix, AZ.
Purpose: Adenocarcinoma (AdenoCA) of the esophagus and CEJ has been
on the rise in the Western population. To determine the outcomes, and pre-
dictors of survival in patients diagnosed with esophageal and CEJ AdenoCA.
Methods: The endoscopic database of patients undergoing EGD were ret-
rospectively reviewed and analyzed for patients diagnosed with esophageal
and CEJ AdenoCA. Treatment modalities (none, Chemo/XRT, surgery, and
stent placement), their complications, and survival rates for each cancer
stage were obtained. Setting: VA medical center. Study period:1997–2006.
Statistics: Survival analysis with Kaplan Meier curves, Cox regression, and
Chi square.
Results: There were 78 patients with esophageal AdenoCA and/or CEJ. The
average prevalence per year was 0.49%. Only 4 patients had EGDs prior to
diagnosis of AdenoCA with an incidence rate of 0.36%. The majority of
patients were diagnosed as de novo AdenoCA. The mean age at diagnosis
or stage did not vary over time.
From 1997 to 1999, up to 47.7% of patients were surgically treated; thereafter
this decreased to 19% while Chemo/XRT increased to 45%.
Early stage detection of esophageal and CEJ adenocarcinoma did not im-
prove over time. Staging, chemo/xrt, and year of diagnosis were all inde-
pendent predictors of improved survival. For every year since diagnosis was
made, the survival rate was 13.1% better. Chemo/XRT vs all other treatment
options had a 50% better survival. The survival curves for each stage are
shown in the Figure.
The complication rate for esophageal stents was significantly lower (16.6%)
than surgery 60.7% (peri-opertively 47.7%, anastomotic stricture 13%) (P <
0.005). All other comparisons among treatment options were not significant.
Tumor recurrence after surgery was seen in one-third of patients (7/23).
Conclusion: 1) There was nochange in the incidence or early detection of
AdenoCA over time. 2) Most presentations are de novo and have advanced
disease. 3) There has been a shift in treatment modalities over the study
period. 4) Survival was dependent on staging and treatment modality cho-
sen.[figure1]
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Clinical Utility of the Bravo Capsule
Brian E. Lacy, PhD, MD∗, Andrew C. Dukowicz, MD, Lisa Paquette, RN,
Douglas J. Robertson, MD, MPH, Julia Weiss, MS, Maurice L. Kelley, Jr.,
MD. Gastroenterology, Dartmouth-Hitchcock Medical Center, Lebanon,
NH; Gastroenterology, WRJ VA Medical Center, White River Junction, VT
and Community and Family Medicine, Dartmouth Medical School,
Hanover, NH.
Purpose: The Bravo capsule is widely used to evaluate patients (Pts) with
acid reflux symptoms. A preliminary study (Dukowicz et al. Am J Gastroen-
terol 2006; 101(9) Suppl:S48) appears to show it to be clinically useful. Our
aim was to prospectively evaluate the clinical utility of the Bravo capsule in
a large series of Pts by determining whether it changes diagnosis, provides
new information, or alters management.
Methods: Prior to Bravo capsule deployment, referring physicians com-
pleted a questionnaire requesting: indications for the test; symptoms; prior
testing; and medication use. Demographic information was obtained from
the Pt. Patients were studied either on or off acid-suppressing medications.
Two weeks after the referring physician received the results of the test a
follow-up questionnaire was sent asking whether the Bravo capsule pro-
vided new information, and whether test results changed the Pt’s diagnosis
or management.
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Results: During a 14 month period, 598 Bravo capsule studies were per-
formed; 550 were available for inclusion. 308 fully completed question-
naires were returned (56%) and are the basis for this analysis. The mean age
(±SD) at time of Bravo placement was 48 (±16 years), 65% were women,
and nearly all (97%) were Caucasian. The average age of symptom onset was
40 years (±15), and average duration of symptoms was 72 months. The most
common primary symptom was acid reflux (heartburn/regurgitation; 65%),
followed by chest pain (8%), chronic cough (7%), dysphagia (6%), & ENT
symptoms (4%). 92% of Pts had undergone prior testing, including EGD,
barium swallow, and/or chest x-rays. 22% had undergone a previous pH
test (either pH catheter or Bravo), and 65% of these studies were abnormal.
Bravo capsule results provided new information in 72% of Pts, changed the
diagnosis in 22%, and altered management in 58%. Management changes
included: referral to surgery (26%), stopping a prior medication (15%), in-
creasing the dose of a prior medication (15%), starting a new medication
(11%) and other (33%).
Conclusion: This prospective study confirms and extends our preliminary
results showing that the Bravo capsule is a clinically useful test. Future
studies should be performed to define which Pt population will benefit most
from Bravo capsule testing, and whether changes in management lead to
improved patient outcomes.
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Dx-pH Monitoring: How Does It Compare to the Standard pH Probe?
Farnoosh Farrokhi, MD, Eric M. Hill, MD, George Sun, MD, Sean P.
Casey, MD, Milton O. Ochieng, Gregory D. Ayers, BS, Michael F. Vaezi,
MD, FACG∗. Gastroenterology, Vanderbilt University Medical Center,
Nashville, TN.
Purpose: Physiologic assessment of esophageal acid exposure is often per-
formed utilizing ambulatory pH monitoring. Recently ambulatory Restech
Dx- H probe is designed to record pH changes in the oropharynx in pa-
tients with suspected extraesophageal reflux symptoms. However, there are
no validations of this instrument against the current standards in clinical
practice. Thus, we aimed to compare the internal consistency of the new
distal esophageal Dx-pH probe with the standard of care Sandhill pH probe.
Methods: Patients diagnosed with GERD (esophagitis at endoscopy or prior
abnormal pH findings off acid suppressive therapy) underwent simultaneous
ambulatory esophageal pH monitoring. The Dx-pH and Sandhill pH probes
were positioned at 5 cm above the manometrically measured LES in each pa-
tient. Based on the inherent property of the devices, Dx-pH monitor recorded
esophageal acid exposure every 0.5 seconds compared to a 5 second inter-
val for the Sandhill probes. Outcomes assessed included episodes below pH
6, pH 5, and pH 4 and% time below pH 4, 5, and 6. The # times that pH
fell below the cutoff was manually and electronically measured. The values
were compared using the Wilcoxon signed rank test on the differences in the
paired data.
Results: A total of 11 patients (5 male and 6 female) with mean (range) age
of 40.9 (21–59) constituted the study population. 72.7% and 45.4% of the
patients were complaining of daily heartburn and regurgitation, respectively.
No statistically significant (P < 0.05) differences were found between the
Dx-pH and Sandhill devices for the number of times pH < 4, pH < 5, or
pH < 6. The Dx-pH probe spent consistently more time at pH < 4 (P =
0.131), pH < 5 (P = 0.049), and pH < 6 (P = 0.01) than the Sandhill probe
(Table 1.).
Dx-pH catheter vs Sanhill probe performance at different pH cut offs.
Outcomes Restech (25%–75%) Sandhill (25%–75%) P Value
# Events pH < 4 37 (20–53) 34 (17–60) 0.31
% Times pH < 4 8.0 (1–15) 6.0 (1–10) 0.13
# Events pH < 5 40 (18–55) 46 (31–62) 0.09
% Times pH < 5 14.0 (2–29) 13.0 (1–24) 0.04
# Events pH < 6 36 (9–62) 41 (15–47) 0.32
% Times pH < 6 43.0 (12–56) 23.0 (6–43) 0.01
Conclusion: Dx-probe identifies reflux events in the distal esophagus sim-
ilar to current standard pH catheter but it has less variability. The clinical
potential of this diagnostic device will need to be tested in patients with
extraesophageal GERD.
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The Effect and Timing of Food on the Pharmacokinetics and
Pharmacodynamics of TAK-390MR (Modified Release): Evidence for
Dosing Flexibility
R.D. Lee, PhD∗, M. Vakily, PhD, J. Wu, PhD, S. Atkinson, PhD. TAP
Pharmaceutical Products Inc, Lake Forest, IL.
Purpose: TAK-390MR is a proton pump inhibitor that employs a modified
release technology designed to provide prolonged plasma concentrations of
TAK-390 following once daily oral dosing. This study evaluated the effect
and timing of food on the pharmacokinetics (PK) and pharmacodynamics
(PD) of TAK-390 after a single 90 mg dose of TAK-390MR.
Methods: Phase 1, open-label, single-dose, randomized, 4-way crossover
study. Forty-eight healthy subjects (18–55 years) received a single oral dose
of TAK-390MR 90 mg in the fasted state (A) and 3 fed states (30 minutes
after the start of a high-fat breakfast [B], 5 and 30 minutes before a high-fat
breakfast [C, D]). Serial blood samples were obtained for up to 24 hours
postdose. To adjust for the effect of food on pH, baseline as well as postdose
24-h intragastric pH monitoring was performed for each regimen. Plasma
concentrations of TAK-390 were determined using a validated LC-MS/MS
assay; PK parameters were estimated using noncompartmental methods. PD
parameters were calculated as the mean pH and% time pH > 4 over 24-h.
The effect of food and the timing of food on TAK-390 PK and PD were
assessed and pairwise comparisons were conducted between the fasting and
fed regimens. The 90% confidence intervals (CI) for relative bioavailability
between 2 regimens were computed and a conclusion of no difference was
made if the 90% CI for the ratios of TAK-390 Cmax and AUCs from 2
regimens were within 0.80 and 1.25. Changes in PD parameters from baseline
to postdose were also assessed and pairwise comparisons between the fed
regimens to the fasting regimen were also performed, with a test deemed
statistically significant if the P-value was ≤0.05.
Results: Forty-six subjects completed all regimens. TAK-390MR given un-
der 3 fed conditions resulted in a modest and statistically significant increase
in Cmax and AUCs (9–31%) relative to fasting. No statistically significant
difference for mean intragastric pH was observed among the dosing regi-
mens in change from baseline over the total 24-h postdose interval. Although
a statistically significant greater change from baseline was seen in% time pH
> 4 for both regimens A and D compared to regimen B, the small differences
are not likely to be relevant.
Conclusion: Although TAK-390MR administered under various fed condi-
tions compared to the fasted state had a statistically significant effect on the
PK of TAK-390, the intragastric pH results indicate that TAK-390MR can
be administered without regard to food.
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Eosinophilic Esophagitis/Ringed Esophagus: The Diagnostic
Conundrum
Fatima Gangotena, MD, Scott Mackenzie, MD, Mae Go, MD, Kristen
Thomas, BS, John Fang, MD, Kathryn Peterson, MD∗. Gastroenterology,
University of Utah, Salt Lake City, UT and Gastroenterology, VAMC, Salt
Lake City, UT.
Purpose: Eosinophilic esophagitis (EoE) is defined classically as >20 eos/
HPF on esophageal biopsies. Common characteristics in EoE are dysphagia
with associated rings/furrows seen on endoscopy. To date, no one has deter-
mined whether all rings seen on EGD represent EoE histologically or whether
all EoE patients have the classical endoscopic findings of rings/furrows. This
study was designed to correlate endoscopic findings and histology in EoE.
S146 Abstracts
Methods: A retrospective analysis of all EGD’s performed at the Univer-
sity for dysphagia in 2006 was performed. Per routine protocol, all cases
were biopsied and evaluated for eosinophils. Patients with endoscopic find-
ings of ringed/furrowed esophagus were identified. Cases were evaluated for
evidence of EoE based on histologic criteria of >20 eos/HPF.
All cases of histologically defined EoE were identified and grouped by their
endoscopic findings as ringed/furrowed, normal, esophagitis, schatzki ring,
or stricture.
Results: Ringed esophagus was identified endoscopically in 28 patients
(75% male, ave age 41 y).19/28 (67.9%) met histologic criteria for EoE
(graph). In the remaining patients, distal eosinophil counts averaged 2.5/HPF
while proximal eos averaged 8.2/HPF. 32 patients met histologic criteria for
EoE (62.5% male, ave age 42 y). 19/32 (59%) presented with endoscopic
“rings or furrows.” 13/32 (41%) had other endoscopic findings (graph).
Conclusion: EoE may present as a variety of phenotypes. Strictly ad-
hering to histologic criteria for the diagnosis may result in an under-
diagnosis as eosinophilic infiltration is patchy and likley sporadic. Gas-
troenterologists should have a high index of suspicion for EoE in any
young patient who presents with dysphagia as endoscopy may not por-
tray classical rings/furrows. Routine biopsies in this population are war-
ranted.[figure1][figure2]
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An Unusual Case of Esophageal Varices and Esophageal Dysmotility
in a Healthy Young Female
Alex P. Kim, DO, Eugene M. Bozymski, MD∗. Division of Gastroenterology
& Hepatology, University of North Carolina Chapel Hill, Chapel Hill, NC.
Purpose: Downhill esophageal varices are a rare, but recognized entity usu-
ally due to complications from superior vena cava syndrome. We present a
case of a 29-year-old healthy female who was referred to our open access
endoscopy unit for the chief complaint of chronic intermittent dysphagia.
She also complained of odynophagia.
Her past medical and family history were unremarkable and her physical
exam normal.
Endoscopy was indicative of a hypertonic lower esophageal sphincter.
Blanching of the mucosa and formation of varices were evident during
LES contraction. [figure1] Upon relaxation of the LES, the blanching of
the mucosa and the varices were no longer evident. Subsequent evaluation
excluded primary liver disease and portal hypertension as possible etiologies.
Esophageal manometry showed a hypertensive LES (60 mmHg) with long
duration (10–12 secs), high amplitude contractions reaching 302 mmHg in
the distal esophagus. However, many of the swallows were peristaltic thereby
excluding achalasia.
With a paucity of MEDLINE citing, this presentation may be one of the first
reported cases of downhill varices in a healthy individual without a previously
well-known anatomical etiology and the result of esophageal dysmotility.
The hypertensive LES could very well impede blood flow from the azygous,
hemiazygous, short gastrics, the left gastric, and the left inferior phrenic
veins and their collaterals leading to the transient formation of varices.
One could also speculate that the patient’s odynophagia was the result of
decreased blood flow and transient ischemia as evidenced by the pronounced
blanching of the mucosa over the area of the LES and distal esophagus during
LES contraction. [figure2] Following relaxation the mucosa overlying the
LES and lower esophagus regained their normal pink appearance and the
varices decompressed.
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Use of Pillcam ESOTM Endoscopy for Early Detection of Esophageal
Injury after Radiofrequency Ablation Therapy for Atrial Fibrilation
Milan Dodig, MD∗, Andrea Natale, MD, Madhusudhan R. Sanaka, MD,
Alan Siu, Janice Santisi, RN, Stacy Poe, RN. Department of
Gastroenterology and Hepatology, Cleveland Clinic Foundation,
Cleveland, OH and Heart and Vascular Institute, Cleveland Clinic
Foundation, Cleveland, OH.
Purpose: Atrial-Esophageal fistulas are an increasingly recognized compli-
cation of radiofrequency ablation (RFA) therapy for of atrial fibrillation. This
potentially fatal complication is often undiagnosed until late in its develop-
ment. The purpose of this study is to evaluate utility of esophageal capsule
endoscopy in early identification of RFA related esophageal injury, therefore
recognizing patients with need for more intense post-ablation follow-up and
treatment.
Methods: A retrospective chart review of patients that received esophageal
capsule endoscopy post RFA therapy was completed. All patients had been
examined using Pillcam ESOTM and the Given Imaging SystemTM in the
manufacturer recommended fashion. The video was reviewed by a board
certified gastroenterologist. The first esophageal image, Z-line, first gas-
tric image and any pathology were identified and marked by thumbnailed
still images. After review of the entire video, each thumbnail image was
re-examined and the final results were recorded. Medical records were sub-
sequently reviewed for patient’s demographics, and immediate postablation
symptoms.
Results: A total of 32 patients (72% male, mean age 60 years old) were
reviewed for this study. 15 patients (47%) had symptoms after ablation:
chest discomfort or pain (9/32, 28%), nausea (6/32, 18%), abdominal pain
(1/32, 3%) and fever (1/32; 3%). Three patients had moderate difficulties
swallowing the capsule (3/32; 9%), all patients completed the capsule exam.
We identified positive findings in 7 patients (7/32; 22%). 4 of these patients
did not have any symptoms post ablation. 3 patients with positive findings
had symptoms, one each with chest pain, abdominal pain and nausea. In 4
of the patients the lesion was described as linear erosion with clean base in
distal esophagus, just above or at Z line (4/32; 12.5%). In 3 of the patients
the lesion was described as mid esophageal ulceration (3/32; 9%) with or
without trace of blood.
Conclusion: Our preliminary data suggest that capsule endoscopy can be a
useful tool for early diagnosis of esophageal injury after RFA. More detailed
studies are planed to delineate best timing for capsule endoscopy, array of
lesion appearances, best strategy to exclude pre-existing lesions and post-
capsule endoscopy treatment protocols for patients with positive findings.
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Atypical GERD Symptoms on PPI Therapy Are More Likely in an
Older Female Patient Group
Neeraj Sharma, MD, Amit Agrawal, MD, Marcelo Vela, MD, Donald O.
Castell, MD∗. Department of Gastroenterology and Hepatology, Medical
University of South Carolina, Charleston, SC.
Purpose: Initiating PPI therapy on patients who present with symptoms of
GERD has become the diagnostic and therapeutic standard of care. Many
patients, however, present with ongoing symptoms, which range from the
typical symptoms of heartburn, regurgitation, and chest pain to atypical
symptoms such as cough, throat clearing, and hoarseness. Demographic
characteristics of patients presenting with typical or atypical symptoms have
not been identified.
Aim: To determine if gender and age differences are present in patients on
PPI therapy who present with typical versus atypical symptoms.
Methods: A retrospective analysis of 200 consecutive patients who have
undergone MII-pH from January 2005 to October 2006 was performed.
All patients had residual symptoms despite twice daily PPI therapy, and
were studied on treatment. Questionnaires asking patients to identify the
most bothersome symptom were reviewed, as was the age and gender of
each patient. Typical symptoms included heartburn, regurgitation, and chest
pain. Atypical symptoms included cough, hoarseness, throat clearing, nau-
sea, wheezing, globus, belching, indigestion, and shortness of breath.
Results: The tables below summarize our review.
Table 1. Gender analysis
# Males # Females
Typical symptoms 42 57
Atypical symptoms 28 73
P < 0.05 by chi-square
Table 2. Age analysis
# patients Mean age
Typical symptoms 99 53
Atypical symptoms 101 57
P < 0.05 by t-test
Conclusion: Patients presenting with atypical GERD symptoms on PPI ther-
apy are more likely to be female and older than those with persisting typical
symptoms.
83
An Unusual Case of Esophageal Histoplasmosis
Kanan Sharma, MD, Pallavi K. Rao, MD, Lisa Stone, MD∗. Department
of Gastroenterology, Wright State University, Dayton, OH.
Purpose: A 44 year-old African American female with HIV, CD4 count of
8, non-compliant on HAART, presented with dysphagia and odynophagia of
two months duration. She also had weight loss of 50 lbs over same period.
About six months ago, she was treated for PCP, oral candidiasis and menin-
gitis. At presentation, her vitals were stable. She appeared cachectic without
any evidence of oral thrush. The laboratory values revealed WBC count of
5400, hemoglobin of 8.3 and albumin of 2.8. Her chest x-ray did not show
any abnormalities. She was empirically started on diflucan and acyclovir
for possible candida esophagitis and herpes esophagitis, respectively. EGD
showed diffuse deep ulcers with irregular borders with friable mucosa and
nodularity involving the entire length of esophagus. Esophageal biopsies
were positive for histoplasma capsulatum on Gomori’s methenamine-silver
and periodic acid-Schiff stains. Her blood, urine and sputum cultures were
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negative. A urine and serum histoplasma antigen test was negative. She was
subsequently started on itraconazole with improvement of dysphagia.
Discussion: Histoplasma capsulatum, a dimorphic fungus, is frequently en-
countered to cause opportunistic infections in immunocompromized hosts.
In AIDS patients with disseminated histoplasmosis, symptomatic gastroin-
testinal tract involvement has been reported in 3–12% of cases. The most
commonly reported sites of infection are colon followed by small bowel.
Esophageal involvement with histoplasmosis is very rare, almost always oc-
curring either due to mediastinal adenitis or mediastinal fibrosis. Our patient
presented with dysphagia leading to the diagnosis of esophageal histoplas-
mosis without signs of pulmonary or systemic histoplasmosis. The diagnosis
of histoplasmosis requires a high index of suspicion, more so in patients liv-
ing in endemic areas.[figure1][figure2]
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Adenosine – A Key Neuromediator in the Pathogenesis of Functional
Chest Pain
Ashok Attaluri, MD, Jose Remes-Troche, MD, Satish Rao, MD∗.
Gastroenterology, Univ of Iowa, Iowa City, IA.
Purpose: Adenosine lowers sensory thresholds and decreases distensibility
of the esophagus suggesting that it may play a role in the pathogenesis of
esophageal hypersensitivity (Neurogastro Mot 2006; 18: A713). However, it
is not known whether the adenosine induced alterations in esophageal sen-
sorimotor function of healthy humans are akin to those observed in patients
with functional (non-cardiac) chest pain (FCP). Our aim was to compare the
sensory and biomechanical properties of esophagus in patients with FCP
with those of healthy controls during adenosine infusion.
Methods: In a randomized, double-blind, placebo-controlled study, 14
healthy subjects (M/F = 4/10), received either adenosine or placebo infusion,
IV at 100 µg/kg/min. During infusion, subjects underwent stepwise graded
balloon distensions of the esophagus (EBDT) using impedance planimetry.
Sensory responses and biomechanical properties were assessed. One hour
before infusion, impedance planimetry was performed to assess baseline
sensori-motor properties. EBDT was also performed in 14 matched patients
with FCP (Rome II). Data were analyzed for 7 controls who received adeno-
sine with 14 FCP patients using ANOVA and paired t test.
Results: (Table, mean ± SEM). When compared to controls at baseline,
FCP patients had lower thresholds for sensory perception (P < 0.05), larger
(P < 0.05) Cross Sectional Area (CSA) and decreased (P < 0.05) esophageal
wall strain. Also, in controls, during adenosine infusion, sensory thresholds
decreased significantly (P < 0.05). The CSA and reactivity of the esoph-
agus increased, whereas wall strain decreased (P < 0.05), when compared
to baseline. Sensorimotor properties were similar between controls (after
adenosine infusion) and FCP (P > 0.05).
Conclusion: In healthy controls, the adenosine-induced changes in
esophageal sensorimotor function, notably hypersensitivity and decreased
distensibility, were identical to those observed in native patients with FCP.
Thus, adenosine may be a key mediator in esophageal hyperalgesia and
sensorimotor dysfunction of patients with functional chest pain.
Controls
Sensory &
biomechanical properties Baseline Adenosine FCP
Threshold- first 33 ±7∗ 12.5 ± 6 14.4 ± 5
perception (cm H2O)
Threshold-discomfort 55.5 ± 5∗ 31 ± 11 38.4 ± 6
(cm H2O)
Threshold-pain (cm H2O) 68.5 ± 8∗ 52.5 ± 9 51.2 ± 8
CSA at 40 cm H2O (mm2) 440 ± 54∗ 520.7 ± 179 558 ± 144
Reactivity at 40 cm H2O 145 ± 86 249.2 ± 152 171 ± 86
Strain at 40 cm H2O 1.3 ± 0.1∗ 0.8 ± 0.3 0.9 ± 0.1
∗P < 0.05 compared to FCP patients and Adenosine
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A PPI Is a PPI! Similar Results for Continuous Reflux on Therapy
Amit Agrawal, MD, Neeraj Sharma, MD, Donald O. Castell, MD∗.
Department of Gastroenterology and Hepatology, Medical University of
South Carolina, Charleston, SC.
Purpose: 24 hour multichannel intraluminal impedance and pH (MII-pH)
esophageal monitoring allows detection of both acid (pH < 4) and non-acid
(pH > 4) gastroesophageal reflux (GER) episodes. Many GERD patients
experience symptoms despite PPI therapy. It was recently proposed that
revision of the upper limit of normal for reflux episodes on PPI therapy to 48
should be used to identify patients with abnormal number of reflux episodes
while on 24 hours acid suppression therapy (Tutuian et al. Gastroenterology
2006; 130:S1184).
Aim: To compare the total number of reflux episodes (both acid and non-
acid) in patients treated with bid doses of different PPIs.
Methods: 167 consecutive MII-pH studies (109 females; mean age 43 years;
range 7.5 months – 85 years) on bid PPI therapy were analyzed. The total
number of reflux episodes (both acid and non-acid) during treatment with es-
omeprazole, omeprazole, lansoprazole, rabeprazole, and pantoprazole were
recorded.
Results: The table below summarizes the results.
Mean # of # patients
# patients GER episodes/24 hr with abnormal
PPI (%) (non-acid/acid) GER (%)
Esomeprazole 75 (45%) 35 (27/8) 24 (32%)
Omeprazole 13 (8%) 35 (30/5) 4 (31%)
Lansoprazole 45 (27%) 37 (28/10) 14 (31%)
Rabeprazole 18 (11%) 34 (29/5) 4 (22%)
Pantoprazole 16 (9%) 34 (27/8) 4 (50%)
There was no difference (P > 0.05) in the number of GER episodes when
comparing different PPI therapy. Using the revised criterion for abnormal
reflux episodes/24 hours on PPI bid of 48, there was no difference (P >
0.05) in the number of patients with abnormal GER on different PPI therapy.
There was a difference (P < 0.05) in the number of non-acid and acid reflux
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episodes on PPI therapy, with continuing reflux 3–4 times more likely to be
non-acid in type.
Conclusion: Continuing GER occurs despite PPI therapy, although it is
predominantly non-acid in type. Total number of reflux episodes are similar
in patients on different PPI therapies.
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A Novel Partial 5HT3 Agonist DDP733 after a Standard Refluxogenic
Meal Reduces Reflux Events: A Randomized, Double-Blind,
Placebo-Controlled Pharmacodynamic Study
Rok Seon Choung, MD, Dawn D. Ferguson, MD, Joseph A. Murray, MD,
Patricia P. Kammerer, Ross A. Dierkhising, MS, Alan R. Zinsmeister, PhD,
Suhail Nurbhai, MRCP, Steven B. Landau, MD, Nicholas J. Talley, MD,
PhD∗. Division of Gastroenterology and Hepatology; Division of
Biostatistics, Mayo Clinic College of Medicine, Rochester, MN and
Dynogen Pharmaceuticals, Inc., Waltham, MA.
Purpose: Transient lower esophageal sphincter (LES) relaxations are the
major cause of gastro-esophageal reflux. DDP733, a selective partial agonist
at 5HT3 receptors, increases LES in experimental animal models. However,
its effect on gastroesophageal reflux or LESP in humans is unknown.
Aims: To evaluate the effect of DDP733 on reflux episodes in healthy volun-
teers receiving a refluxogenic meal, and to assess the safety and tolerability
of DDP 733.
Methods: A randomized, double-blind, placebo-controlled crossover study
evaluated the pharmacodynamic effects of DDP733. Subjects were random-
ized on a 1:2:1 basis to one of three dose levels of DDP733 (0.5 mg, 0.8 mg,
1.4 mg), and randomized to the order of administration of placebo or active
drug. Healthy subjects underwent manometry, and intraesophageal multi-
channel intraluminal impedance and pH after a standard refluxogenic meal.
For evaluating the safety and tolerability of DDP733, each subject took drug
or placebo (three times daily) for one week. A pooled analysis of variance,
of the within subject deltas (placebo-drug) over all three dose groups with
dose specific tests (α = 0.017) for no change were examined.
Results: DDP733 0.5 mg significantly reduced the rate of reflux episodes
after refluxogenic meal from 10.4 (±2.2) on placebo to 6.3 (±1.2) on drug
over a 2 hour period. However, DDP733 0.8 mg and 1.4 mg had no signif-
icant effect on reducing the number of reflux episodes (table). Significant
differences in LESP and the proportion of time pH was <4 (placebo-drug)
after a reflexogenic meal were not detected. No serious adverse events on
DDP733 were reported.
Conclusion: In healthy subjects, the partial 5HT3 agonist DDP733 at a dose
of 0.5 mg significantly reduces the rate of reflux events, but did not result in
a significant change in LES pressure at one hour post dosing.
Reflux events, post treatment mean LESP, and proportion
time that time pH < 4 on drug or placebo (Mean ± SEM)
DDP733 0.5 mg DDP733 0.8 mg DDP733 1.4 mg
Drug Placebo Drug Placebo Drug Placebo
(N = 7) (N = 7) (N = 14) (N = 14) (N = 6) (N = 5)
Reflux 6.3 ± 1.2 10.4 ± 2.2 8.9 ± 1.1 6.9 ± 1.1 9.3 ± 2.1 12.0 ± 1.3
events (n) P = 0.013 P = 0.069 P = 0.340
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Esophageal Histology in Patients with Gastroesophageal Reflux
Disease (GERD) and Symptom Resolution after 4 Weeks of
Esomeprazole Treatment
Wilfred M. Weinstein, MD, John T. Monyak, PhD, Debra G. Silberg, MD,
FACG∗. David Geffen School of Medicine at UCLA, Los Angeles, CA and
AstraZeneca LP, Wilmington, DE.
Purpose: To estimate the prevalence of histological findings related to acid
exposure in patients with symptoms of GERD, with or without erosive
esophagitis (EE), and to associate heartburn (HB) resolution after 4 weeks
of esomeprazole treatment with baseline histology.
Methods: This was an exploratory analysis of histology data from a mul-
ticenter, open-label study (D9612L00083) in adults (aged 18–70 y) with
HB ≥2 d/wk for the past week and on average during the past 3 months.
During a baseline endoscopic examination of the esophagus, 3 biopsy sam-
ples each were taken from 1 cm (distal) and 3 cm (proximal) above the
gastroesophageal junction. A 1:1 subset of patients with and without EE
was admitted into a treatment phase and received esomeprazole 40 mg daily
for 4 weeks. Biopsy specimens were processed in a central laboratory and
evaluated by a single observer (W.M.W.). The histological diagnosis was
classified as none, mild, moderate/severe, or eosinophilic esophagitis based
on basal cell thickness), papillary height), neutrophil counts), and eosinophil
counts. GERD symptoms were assessed at baseline and week 4, with symp-
tom resolution defined as patients recording none on a scale of none, mild,
moderate, or severe. χ2 and Cochran-Armitage tests were performed to test
for, respectively, differences and trends in proportions.
Results: Of 399 patients who underwent endoscopy, 356 were part of the
intention-to-treat (ITT) treatment group. Among assessable patients without
eosinophilic esophagitis, significantly more EE patients had baseline his-
tological findings related to acid exposure than non-EE patients (proximal,
86% vs 72%, respectively; P = .001; distal, 93% vs 84%, respectively; P =
.013). There was a shift toward greater histological severity in EE versus
non-EE patients. In the ITT population, there was a trend toward greater HB
resolution rates, with more severe diagnoses in the proximal (P = .027) but
not the distal (P = .48) esophagus.
Conclusion: More EE than non-EE patients had histological findings at
baseline that were consistent with acid exposure, with a shift toward greater
severity in EE vs non-EE patients. After 4 weeks of esomeprazole treatment,
patients who had more severe baseline histological changes in the proximal
region of the esophagus tended to have greater HB resolution.
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Barrett’s Esophagus and Helicobacter pylori Infection
Xiangwen Meng, PhD, Marc Scheer, MD, Tat-Kin Tsang, MD∗. Medicine,
Evanston Northwestern Healthcare, Evanson, IL and Medicine,
Northwestern University, Feinberg School of Medicine, Evanson, IL.
Purpose: Barrett’s esophagus (BE) is generally accepted as a complication
of chronic and severe GERD. The relationship between H. pylori (HP) and
BE is controversial. Some reports indicated that HP eradication may increase
the symptom of GERD, which may lead to increase a risk of developing BE.
This study is to show whether there is an increased occurrence of HP in BE
by using a multiplex PCR technique.
Methods: This study was performed in 28 patients with BE and 104 patients
with dyspepsia undergoing endoscopy in Evanston Northwestern Health-
care. The specimens were collected from both distal esophagus and cor-
pus/antrum. H . pylori infection was detected by one-step multiplex PCR
method.
Results: Of the 28 patients with BE, 86%(24/28) were detected with
HP infection; 75%(21/28) at the distal esophagus and 61%(17/28) at the
corpus/antrum. Of the 104 patients with dyspepsia, HP infection was
found in the 53.85% (56/104); 32.69%(34/104) at the distal esophagus and
44.23%(46/104) at the corpus/antrum.
Conclusion: In our study, the prevalence of HP infection in BE is 75%(21/28)
at the distal esophagus, in the Barrett’s segment with columnar epithelium,
which is significantly higher than 32.7%(34/104) at the distal esophagus with
squamous epithelium, in cohorts of patients with dyspepsia (P < 0.0001). It
is different from some previous reports which indicated that HP organisms do
not colonize the specialized intestinal metaplasia characteristic of Barrett’s
esophagus, because of the high sensitivity and specificity of the multiplex
PCR. If indeed HP is commonly found in BE, HP might have played a
significant role in the pathogenesis of BE in patients with reflux esophagitis.
Some researchers believe that when the infection induces corpus-
predominant gastritis, there may be concomitant reduced gastric acid
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secretion and eradication of the bacteria in this subgroup of patients may
enhance gastric acid secretion and provoke reflux symptoms. It is assumed
that the increase in reflux symptom leads to increase in number of esophageal
cancer. The increase in the occurrence of HP in Barrett’s segment may serve
as a co-carcinogen, with reflux symptom, leading to dysplasia and/or carci-
noma.
H. pylori Infection Distribution
Detected By MPCR
Clinical Number
Status of Cases E G E or G E and G E only G only
Barrett 28 21 17 24 14 7 3
Dyspepsia 104 34 46 56 22 24 10
Total 132 55 63 80 36 31 13
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PPI Efficacy in Overweight/Obese Patients with Erosive GERD:
Rabeprazole (RAB) 20 mg vs Omeprazole (OME) 20 mg
Brian C. Jacobson, MD∗, Byron DeLemos, MD, Yijun Sun, PhD, Jim
Xiang, PhD, John LoCoco, MBA, Honglan Li, PhD, Stefania Casalini.
Boston University Medical Center, Boston, MA; Ortho-McNeil Janssen
Scientific Affairs, LLC, Raritan, NJ; Eisai Inc., Woodcliff Lake, NJ and
Janssen-Cilag, Cologno Monzese, Italy.
Purpose: Obesity is increasing worldwide and elevated BMI is associated
with erosive esophagitis (EE). Limited data exist on the efficacy of PPIs
among overweight/obese patients. This analysis assessed the efficacy of RAB
vs OME in normal weight (<25 kg/m2) and overweight/obese (≥25 kg/m2)
subjects.
Methods: Post hoc analysis by BMI of a multicenter, double-blind, parallel
group, randomized trial of RAB 20 mg or OME 20 mg once daily for 4 to
8 weeks (Pace Dig Liver Dis. 2005). Patients (N = 560) had endoscopic
evidence of Savary–Miller grade I–III EE, moderate to very severe reflux
symptoms, and heartburn for ≥3 days during each of the 2 wks before enroll-
ment. Patients recorded daily symptom severity. Endoscopy was performed
at Wk 4 and Wk 8 if not healed at Wk 4. Treatment efficacy by BMI was
analyzed using log-rank and Cochran-Mantel-Haenszel tests.
Results: Percentage of EE healing (primary endpoint) did not differ between
treatment groups within each BMI category or by BMI category within treat-
ment groups. In the overweight/obese group, statistically significant differ-
ences favoring RAB were seen in time to 1st day of satisfactory heartburn
relief;% complete heartburn relief in each of the first 3 and 7 days of treat-
ment; and% satisfactory heartburn relief in the first 3 days (all P < .05).
Numerical trends favoring RAB in both BMI groups were also observed in
other secondary endpoints analyzed.
Conclusion: EE healing did not differ with RAB 20 mg and OME 20 mg in
either BMI group. In overweight/obese patients, RAB may be more effective
than OME in heartburn relief in the first week. Sponsored by Eisai Inc;
Ortho-McNeil Janssen Scientific Affairs, LLC; Janssen-Cilag.
BMI < 25 kg/m2 BMI ≥25 dg/m2
RAB OME RAB OME
PP Population 90 79 143 158
(1◦ Endpoint) (n)
EE healing, 88.9/96.7 89.9/97.5 92.3/98.6 89.9/97.5
4 wks/8 wks (%)
ITT Population 93 80 152 163
(2◦ Endpoint) (n)∗
Time (days) to 1st day 3.1 5.0 2.6† 3.8
of satisfactory
heartburn
relief – mean
% satisfactory heartburn relief
First 3 days 52.7 48.8 59.2† 46.6
First 7 days 46.2 40.0 53.3 42.3
% complete heartburn relief
First 3 days 35.5† 21.3 38.2‡ 23.9
First 7 days 31.2† 17.5 32.9‡ 19.6
∗Patients with value for listed variable (N = 542 ITT patients). †P < .05 vs OME.
‡P < .01 vs OME.
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Use of Narrow Band Imaging (NBI) To Detect Esophagitis in Non
Erosive Reflux Disease (NERD)
Daniel A. Ringold, MD, Sanjay Sikka, MD, Bhaskar Banerjee, MD∗.
Division of Gastroenterology, Washington University School of Medicine,
Saint Louis, MO.
Purpose: Most patients with reflux symptoms do not have signs of mucosal
injury on routine endoscopy. In patients with non erosive reflux disease
(NERD) chromoendoscopy with Lugol’s iodine and confocal laser endomi-
croscopy have been reported to identify lesions with histologic evidence of
esophagitis. However, both procedures are time consuming and require the
use of contrast agents. Narrow band imaging (NBI) is known to display
macroscopic lesions such as ulcers with high contrast and clarity. We report
our findings in an initial group of patients with persistent reflux symptoms
and a normal esophagus on white light (WL) endoscopy to see if erosive
lesions could be detected with high contrast NBI endoscopy.
Methods: The Olympus GIF-H180 gastroscope was used in five patients; 3
male, 2 female, with a mean age of 49 (range 22–63) who underwent upper
endoscopy for persistent reflux symptoms (heartburn at least 3 times per
week for more than 3 months). On finding no evidence of esophagitis on WL
endoscopy in all 5 patients, the NBI mode was switched on and the esophagus
re-examined. Any discrete lesions were photographed and biopsies taken
with cold forceps for histology. If no lesions were seen, biopsies were taken
from the distal esophagus.
Results: In asymptomatic individuals, NBI displays the normal esophagus
with an even blue color. On switching to narrow band imaging (NBI) mucosal
breaks or erosions were seen in 4 out of 5 patients (80%). These consisted
of: 1) discrete, depressed erosions of up to 1 mm in diameter, surrounded
by an even, bluish appearing normal squamous mucosa; 2) larger, flat, de-
pressed, magenta colored patches of up to 10 mm in diameter, with visible
raised margins. Targeted biopsies from these lesions showed microscopic
evidence of reflux esophagitis in all 4 patients (100%). Biopsies from the
distal esophagus of the patient without mucosal lesions were normal.
Conclusion: These early findings suggest that high contrast imaging meth-
ods such as NBI may be useful in unmasking subtle erosive changes in the
esophagus of patients with reflux symptoms that are not readily visible on
routine white light endoscopy. High contrast imaging with NBI is a rapid
and easy technique that does not require complex instrumentation or dyes. If
these initial findings are verified by future studies, this may become a useful
technique for identifying erosive lesions and targeting biopsies in patients
with presumed NERD.
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Cervical Inlet Patch in Twins: Is It All in the Genes?
Shailaja Jamma, MD, Krishnarao Tangella, MD, Davendra P. Ramkumar,
MD∗. Internal Medicine, University of Illinois at Urbana Champaign, IL;
Pathology, UIUC, IL and Gastroenterology, UIUC, IL.
Purpose: Cervical inlet patch (IP) is a distinct region of heterotopic gas-
tric mucosa occurring in the proximal one-third of the esophagus. The
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pathogenesis of IP has not yet been finally determined. It is considered to
be congenital by some, acquired by some, and considered to be congenital
with superimposed acquired component by others. We report the cases of
identical twins with identified IP; this lends support to the theory that IP is
a congenital rather than an acquired entity.
Case Report: Two 41 year old identical male twins presented with retroster-
nal discomfort a little over one year apart. These symptoms were present
in both individuals for several years. Esophagogastroduodenoscopy (EGD)
revealed a single inlet patch in one twin and dual inlet patches in the other. In
both individuals, IP was seen in the upper esophageal sphincter. There was
no evidence of Barrett’s esophagus in either. Biopsy revealed oxyntocardiac
mucosa with mild chronic inflammation. There was no evidence of intesti-
nal metaplasia. Immunohistochemical stain was negative for Helicobacter
pylori. Both of them had alleviation of symptoms with treatment using a
proton pump inhibitor.
Discussion: IP occurs with a prevalence of 0.1% to 10% in patients undergo-
ing EGD. It has been shown to be associated with symptoms like heartburn
and dysphagia along with complications such as esophagitis, perforation,
and adenocarcinoma. It can also cause supraesophageal symptoms such as
cough and hoarseness. However, the origin of inlet patch has been a source
of debate. Chatelain et al. have demonstrated that IP shares some common
features with Barrett’s esophagus, and as such they may have a common
pathogenesis, related to reflux disease. Autopsy studies have reported an
incidence of 4.5% in infants and 11.8% in children, thus suggesting it is
congenital. According to a ‘mixed theory’, there could be a loss of squa-
mous epithelium due to regurgitation or trauma and subsequent surfacing
of congenitally present ectopic gastric mucosa. This occurrence of IP in
identical twins supports the latter two theories of formation.
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Risk of Barrett’s Esophagus in Patients Who Undergo Bariatric
Surgery: A Retrospective Analysis
Kishore Maganty, MD, Meenalochani Narayanan, MD, Raymond L.
Farrell, MD, Stuart A. Torgerson, MD∗. Department of Medicine/Division
of Gastroenterology, Southern Illinois University-School of Medicine,
Springfield, IL.
Purpose: Obesity and gastroesophageal reflux disease (GERD) are associ-
ated with Barrett’s esophagus (BE) and increased risk of esophageal ade-
nocarcinoma. We evaluate the risk of BE in patients who undergo gastric
bypass surgery. Long standing GERD in obese individuals may induce or
protect from BE formation due to alkaline reflux or gastroparesis or some
unidentifiable factors. The true risk of Barrett’s in patients who are obese and
undergo Bariatric surgery is not well known. The objective of the study is
to evaluate the risk of Barrett’s esophagus in patients who undergo Bariatric
surgery.
Methods: Tertiary care center, inpatient. Study Design: Retrospective chart
review study. Inclusion criteria: All adult patients who underwent bariatric
malabsorptive gastric reduction surgery (Roux-en-Y) and esophagogastro-
duodenoscopy (EGD) for any reason after the surgery were included. Pri-
mary end point: Patients with endoscopic and histological evidence of BE.
Results: We reviewed the charts of 120 patients undergoing gastric bypass
surgery between June 2001 and March 2007. Mean age of the study popula-
tion was 47.1 years with majority of the patients represented by Caucasians
(89.2%) and females (86.5%). Thirteen patients among the 120 patients were
excluded (8 – insufficient documentation, 4 – EGD prior to surgery, 1 – BE
diagnosed on EGD prior to surgery). The most common indications for EGD
were nausea and vomiting and abdominal pain. 20 patients of the remaining
107 patients met study criteria (underwent EGD after the surgery). The time
between bypass surgery and EGD ranged from 1 to 52 months, with a mean
of 17.7 months. BE was not detected in our study group. However, one out
of these 20 patients had esophageal adenocarcinoma diagnosed at 15 month
follow-up EGD. This patient did not have EGD prior to surgery raising the
question of an incidental finding. The most common EGD findings in this
population were normal (13) and marginal ulcer (4).
Conclusion: Based on our limited retrospective study, the risk of Barrett’s
esophagus appears to be very low in post-bariatric surgery patients. Further
long-tem prospective trials should be performed to evaluate the true risk in
this subset of population.
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Value of a Novel Multi-Factorial Scoring System as a Diagnostic Aid in
the Prospective Evaluation of Patients with Reflux-Like Dyspepsia
Andrew K. Roorda, MD, Samuel N. Marcus, MD, PhD, George
Triadafilopoulos, MD∗. Internal Medicine, St. Mary’s Medical Center, San
Francisco, CA; Gastroenterology, El Camino Hospital, Mountain View, CA
and Gastroenterology, Stanford University, Stanford, CA.
Purpose: Reflux-like dyspepsia (RLD), where predominant epigastric pain
is associated with heartburn and/or regurgitation, is quite prevalent and has
variable response to proton pump inhibition (PPI) therapy. Since symp-
tom frequency and severity vary, there is frequent overlap among gastroe-
sophageal reflux disease (GERD), non-erosive reflux disease (NERD) and
RLD. We assessed the potential of an algorithm and a multi-factorial scoring
system in discriminating patients presenting with RLD from those with true
GERD or NERD.
Methods: We prospectively evaluated an outpatient, community-based, co-
hort presenting with RLD using the following algorithm: After an initial
symptom evaluation (epigastric pain, heartburn, regurgitation, dysphagia),
endoscopy and distal esophageal biopsies were performed to evaluate the
structure of the esophagus, stomach and duodenum, followed by esophageal
motility and 24-hr ambulatory pH monitoring to assess esophageal function
and pathologic acid exposure.
Results: 110 patients (35 men, 75 women) were evaluated. Endoscopy
showed erosive or complicated GERD in 33 patients (30%) and it was normal
in 77 patients (70%). Of this latter group, 62 (56%) had abnormal pH and
motility studies and were classified as patients with NERD. The remaining
15 (14%) had normal functional studies and were classified as patients with
RLD. A disease severity score was then applied (Table). The scoring sys-
tem effectively distinguished patients with GERD (mean score 8.69, range
5–15), NERD (mean score 6.22, range 3–10) and RLD (mean score 3.27,
range 2–4). A score higher than 4 excludes RLD; a score higher than 10
excludes NERD.
Conclusion: An algorithmic evaluation and scoring of patients presenting
with RLD effectively distinguishes patients with NERD and GERD from
those with functional RLD, facilitates long-term management and defines
the need for continuous PPI therapy.
Components of disease severity score.
Variable 0 points 1 point 2 points 3 points
Epigastric pain absent present
Heartburn absent present
Acid regurgitation absent present
Dysphagia absent present
Endoscopy Normal Esophagitis/ Stricture Barrett’s
ulcer esophagus
Hiatal hernia absent ≤2 cm >2 cm
Esophageal Negative Inflammation Barrett’s
biopsy esophagus
DeMeester score ≤15 16–25 26–50 ≥51
LESP (mmHg) >10 ≤ 10
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Clinical Utility of Impedance in Evaluation of Noncardiac Chest Pain
Mary Kovalak, MD, Kristen Thomas, BS, Mae Go, MD, Fatima
Gangotena, MD, John Fang, MD, Kathryn Peterson, MD∗. Division of
Gastroenterology, University of Utah, Salt Lake City, UT and Division of
Gastroenterology, VA Medical Center, Salt Lake City, UT.
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Purpose: Noncardiac chest pain (NCCP) is a common clinical dilemma. The
significance of acid and nonacid reflux in patients with noncardiac chest pain
is not fully understood, especially in patients with chest pain refractory to
PPI therapy.
Aim: To evaluate characteristics of acid and nonacid reflux in a cohort of
patients with noncardiac chest pain referred for 24 hour impedance testing.
Methods: A retrospective chart review was performed on all 24 hour
impedance studies performed at the University of Utah between Decem-
ber 2005 and March 2007. Patient characteristics included age, gender and
proton pump inhibitor (PPI) use. Impedance data included acid and non-acid
reflux events and symptom associated probabilities (SAP).
Results: 24 impedance studies were evaluated. Patient age ranged from 23
to 75 years old. 16 of the 24 patients (67%) experienced abnormal reflux.
13 of these (81%) had nonacid reflux and only 1 had a positive SAP for
noncardiac chest pain. 22 of the 24 patients included in this analysis were on
a PPI. 16 patients (67%) were women. 11 women experienced poor control
of reflux on impedance, 9 of whom had increased amounts of nonacid reflux.
Conclusion: The role of acid and nonacid reflux in NCCP is poorly under-
stood. This is the first data set available on the utility of impedance in NCCP.
Our data shows that while 92% of the patients were on a PPI, 16 of 24 ex-
perienced poor control of reflux symptoms. Of patients with poor control of
reflux symptoms, 81% experienced nonacid reflux on impedance. The SAP
for patients with both good control and poor control of reflux symptoms
does not correlate with the symptom of noncardiac chest pain.
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Endoscopic Full-Thickness Plication for the Treatment of GERD: 12
Month Follow-Up in the Sham-Controlled Trial
Richard I. Rothstein, MD∗, Charles Filipi, MD, Karol Caca, MD, Ronald
Pruitt, MD, Klaus Mergener, MD, Alfonso Torquati, MD, Gregory Haber,
MD, Kenneth Chang, MD, David Wong, MD, Jacques Deviere, MD,
Douglas Pleskow, MD, Charles Lightdale, MD, Alain Ades, MD, Richard
Kozarek, MD, William Richards, MD, Anthony Lembo, MD. Dartmouth
Medical School, Lebanon, NH; Creighton University Medical Center,
Omaha, NE; Klinikum Ludwigsburg University Heidelburg, Ludwigsburg,
Germany; Saint Thomas Hospital, Nashville, TN; Digestive Health
Specialists, Tacoma, WA; Vanderbilt University Medical Center, Nashville,
TN; Lenox Hill Hospital, New York, NY; University of California Irvine,
Orange, CA; Tri Valley Gastroenterology, San Ramon, CA; Erasme
Hospital, Brussels, Belgium; Beth Israel Deaconess Medical Center,
Boston, MA; Columbia University Medical Center, New York, NY; Seacoast
Gastroenterology, Exeter, NH and Virginia Mason Medical Center, Seattle,
WA.
Purpose: To evaluate the safety and efficacy of the NDO Plicator endo-
scopic procedure for the treatment of symptomatic GERD in a cohort of
patients followed out to 12 months from their original participation in a
sham-controlled study.
Methods: Patients with chronic heartburn and pathologic reflux requiring
daily proton pump inhibitor (PPI) therapy were enrolled. Excluded from
treatment were patients with esophageal dysmotility, esophagitis grade III
or IV (Savary-Miller), Barrett’s epithelium, and hiatus hernia >2 cm. All
patients received a single, endoscopically placed full-thickness plication in
the anterior gastric cardia. The primary study endpoint was ≥50% improve-
ment in GERD health-related quality of life (HRQL) score. Secondary end
points included VAS, SF-36, GERD medication use, and esophageal acid
exposure.
Results: A total of 148 patients were treated at 14 study sites. No re-
treatments were performed. Twelve-months post-plication, 59/96 patients
(62%) had improved their GERD-HRQL score by at least 50%. Median
percent change in GERD-HRQL score (62%), VAS score (46%), heartburn
score (67%) and regurgitation score (50%) were all significantly improved
compared to off meds baseline values. The need for daily PPI therapy was
either eliminated or reduced by at least half in 63% of patients at 12-months
post-treatment. There were no new or late onset adverse events.
Conclusion: At 12-months post-procedure, the cohort originally treated with
full-thickness plication with the Plicator and the cross-over group treated af-
ter sham showed the endoscopic treatment to be safe and effective in reducing
GERD symptoms and medication use.
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Cryotherapy Ablation for Barrett’s Esophagus (BE) with High-Grade
Dysplasia (HGD) and Intramucosal Carcinoma (IMCA), and Early
Esophageal Cancer (EEC)
Bruce D. Greenwald, MD∗. Division of Gastroenterology and Hepatology,
University of Maryland School of Medicine, Baltimore, MD.
Purpose: Endoscopic ablation of HGD/IMCA and EEC is appropriate in
selected patients with reasonable life expectancy. The purpose of this study
is to assess the safety and efficacy of endoscopy cryotherapy ablation for the
elimination of BE with HGD/ IMCA and EEC.
Methods: This is a single center pilot treatment study of HGD/IMCA and
EEC (stage T1/T2 N0 and failed or not amenable to systemic therapy or
surgery) using low pressure non-contact liquid nitrogen spray every 4–6
weeks. All patients were assessed with endoscopy/biopsy, endoscopic ul-
trasound, CT, and PET if cancer was present. For HGD/IMCA: complete
response (CR) = absence of BE and dysplasia after 8 treatments; partial re-
sponse (PR) = BE present with low-grade dysplasia (LGD) or no dysplasia.
For EEC: CR = elimination of cancer by biopsy; PR = decrease or stable
size of tumor after 8 treatments.
Results: 21 patients enrolled (median age 65 years, range 53–93).
For HGD/IMCA, 5/16 patients completed treatment with elimination of
HGD/IMCA in all 5, persistent BE or LGD in 2, 8 still under treatment.
For EEC, 2/5 completed treatment with complete elimination of cancer in 1,
stable disease in 1.
Removed
Treatment from
Group N Complete CR PR Failed Active study
HGD/IMCA 16 5 3 2 1 8 2
EEC 5 2 1 1 0 2 1
Total 21 7 4 3 1 10 3
No serious adverse events related to treatment occurred. All adverse events
were expected and related to treatment. They include chest pain (28%),
dysphagia (22%), sore throat (14%), odynophagia (12%), abdominal pain
(10%), nausea/vomiting (6%), fever (3%). Patients were removed from the
study due to non-compliance (1), severe co-morbid illness (1), or inappro-
priate enrollment of patient with N1 disease (1).
Conclusion: Endoscopic cryotherapy ablation with low pressure liquid ni-
trogen spray is effective in BE with HGD/IMCA and EEC.
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Gender-Related Difference in Composition of Secretion from
Esophageal Submucosal Mucous Glands, in Response to Stimulation
of Serotonergic Pathway, in Patients with Gastroesophageal Reflux
Disease
Marek Majewski, MD, Jaworski Tomasz, MD, Sarosiek Irene, MD,
Sostarich Sandra, Roeser Katherine, Edlavitch Stanley, PhD, McCallum W.
Richard, MD, Wallner Grzegorz, MD, PhD, Sarosiek Jerzy, MD, PhD∗. GI
Research Laboratory, Motility Center, KUMC, Kansas City, KS;
Epidemiology, UMSOM, Kansas City, MO and Surgery, Medical
University, Lublin, Poland.
Purpose: Protective potential of saliva and esophageal secretion in gastroe-
sophageal reflux disease (GERD) patients is well established (Sarosiek J.
et al., J P Gastroenterol 18: 20J–20Q, 1994). Stimulation of serotonin re-
ceptor 5HT-4 with tegaserod augments salivary and esophageal components
of pre-epithelial defense in GERD (Majewski et al., CG&H, 5:430–8, 2007).
The impact of gender on esophageal secretion in GERD patients during stim-
ulation of 5HT-4 receptor remains to be addressed.
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Aim: To measure the rate of secretion of esophageal protective factors in
females (F) and males (M) with chronic heartburn symptoms after 7 days of
tegaserod (6 mg BID) or placebo administration.
Methods: The study was conducted in 38 GERD patients (26 F & 12 M;
mean age of 41) in a double-blind, placebo-controlled, cross-over design.
Esophageal secretion was collected during the sophageal mucosal expo-
sure to baseline NaCl, HCl/pepsin and final NaCl, using the esophageal
perfusion catheter. Esophageal volume and its content of bicarbonates, non-
bicarbonates, mucin, EGF, TGFα and PGE2 were measured using standard
methodology.
Results: In females after tegaserod, TGFα secretion during the esophageal
mucosal exposure to HCl/pepsin solution increased from 15.0 ± 2.47 to
22.1 ± 2.71 pg/min (46.9%, P < 0.04). In contrast, in males, TGFα decreased
by 51.5%, P < 0.03. The rate of esophageal EGF secretion in females during
administration of tegaserod increased by 145% (P < 0.01) whereas in males
increased by 50% (P > 0.10). The rate of esophageal PGE2 secretion during
administration tegaserod increased by 81% (P = 0.076) in females only.
Males responded by an evident increase of non-bicarbonates (by 69%) during
administration of tegaserod, from 5.29 ± 0.56 to 8.95 ± 1.89 µEq/min (P =
0.08) and increase of bicarbonates by 143% but not females.
Conclusion: 1. A significant enhancement of esophageal protective factors
after tegaserod in both genders indicates that secretion of esophageal glands
in GERD patients is mediated by serotonergic pathway. 2. The gender-related
differences in the serotonergic secretory profiles suggest that 5HT-4 receptors
in esophageal glands are influenced by sex hormones.
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Barrett’s Esophagus Surveillance in a VA Population: A 2-Year
Retrospective Analysis
Lyssa N. Chacko, MD, Amit Goyal, MD∗. Division of Gastroenterology
and Hepatology, University of Colorado at Denver and Health Sciences
Center, Denver, CO.
Purpose: Barrett’s esophagus (BE) has been established as the premalig-
nant precursor to esophageal adenocarnicoma. The aim of this study was to
determine the current practice and pattern of surveillance in patients diag-
nosed with BE in a VA population and to compare them to the current ACG
guidelines.
Methods: The Denver VA endoscopic database was searched for all patients
with a finding of “Barrett’s esophagus” on EGD between October 2003 and
October 2005. The VA medical record of all identified patients was then
reviewed to determine demographic data, EGD findings, pathology results
and PPI use.
Results: 262 patients (7 F, 255 M; mean age 60 years) had suspected BE
including 191 (73%) with biopsy-confirmed BE. Mean length of BE was
3.6 cm (3.4 cm for BE without dysplasia, 4.3 cm for BE with dysplasia).
Sixty-four patients had a new diagnosis of BE without dysplasia during the
study period of which 9 were excluded due to transfer of care or death. Of
the remaining 55 patients, 25 (45%) underwent a repeat EGD with biopsy
within a mean time of 15.8 months. Forty-two patients (76%) did not have a
repeat EGD with biopsy within 12 + 1 months. The recommendation of the
endoscopist regarding timing of follow-up examination ranged from 6 weeks
to 5 years in this population. Twenty-five patients (10%) had a new diagnosis
of indefinite or low-grade dysplasia during the study period. Four patients
were excluded due to transfer of care or death, and 2 additional patients
were excluded due to refusal of repeat EGD. Of the remaining 19 patients,
16 (84%) underwent repeat EGD with biopsy within a mean time of 5.1
months. Two patients (11%) did not have a repeat EGD with biopsy within
12 + 1 months. Endoscopist recommendations regarding timing of follow-up
examination ranged from 2 weeks to 1 year in this population. One patient had
a new diagnosis of high-grade dysplasia on initial EGD with adenocarcinoma
found on esophagectomy. Nine patients were diagnosed with esophageal
adenocarcinoma on initial EGD. 87% of patients with biopsy-confirmed BE
were on PPI therapy.
Conclusion: 1) The majority of patients (76%) with BE without dsyplasia
did not undergo a repeat EGD within 1 year of diagnosis whereas the majority
of patients with dysplasia did receive appropriate follow-up. 2) Recommen-
dations regarding appropriate surveillance of BE at our institution are vari-
able among endoscopists. 3) Education regarding practice guidelines may
enhance appropriate surveillance of patients with BE.
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Associated Risk Factors for GERD in Native Americans
Adam Randolph, MD, Lila Ammouri, MD, Richard Gerkin, MD, Francisco
Ramirez, MD, Michele Young, MD∗. Gastroenterology and Hepatology,
Carl T. Hayden VA Medical Center, Phoenix, AZ and Medicine, Banner
Good Samaritan Medical Center, Phoenix, AZ.
Purpose: It is estimated that 30–40% of the US adult population experience
reflux monthly and 7–10% report daily reflux. Native Americans (NA) have
increased rates of diabetes and obesity which may predispose to reflux. The
aim of this investigation is to examine the rates of reflux symptoms and
associated risk factors in NAs.
Methods: Identical surveys were self-administered to 504 NAs presenting
to a primary care clinic at an Indian Health Services facility and 399 non-NA
veterans presenting to a primary care clinic at a VA medical center between
October 2006 and May 2007. Subjects were queried about the presence and
frequency of reflux symptoms. They were also asked demographic and health
information including; age, sex and race; height and weight; presence of
diabetes, smoking, coronary artery disease, alcohol intake, use of NSAIDS,
and consumption of fast food. Chi square analyses were used for proportional
data and student t tests were used for means.
Results: One hundred eighty-one of 504 (35.9%) in the NA group had reflux
symptoms on at least a monthly basis compared with 137 of 399 in the veteran
group (34.3%). Group comparisons of demographic data are shown in table
one. Results of Chi square analyses for reflux risk factors are shown in table
2. Multiple logistic regression was performed to identify variables that were
risk factors for the presence of reflux symptoms. Of evaluated risk factors,
CAD (OR 2.01), NSAID use (OR 1.87), smoking (OR 1.79) and fast food
consumption (OR 1.96) were identified as independent risk factors for the
presence of reflux symptoms. Further, when race was considered, being NA
was an independent risk factor for the presence of reflux symptoms (OR
2.37).
Conclusion: Being Native American appears to be an independent risk fac-
tor for the presence of reflux symptoms with an OR of 2.37. Other identified
risk factors included CAD, NSAID use, smoking, and fast food consump-
tion. Obesity and diabetes were not found to be associated with GERD
in NAs.
Table 1. Demographic information
Native Americans Veterans
Mean Age∗ (P < 0.01) 46.8 59.0
Percent Men∗∗ (P < 0.01) 34.5 94.2
BMI∗ (P < 0.01) 33.3 27.9
∗ T-test, ∗∗ Chi square
Table 2. Reflux Risk Factors
Native Americans Veterans
CAD (P = 0.01) 8.4 16.0
ETOH use (P < 0.01) 19.2 38.6
NSAID use (P = 0.04) 48.5 38.6
Smoking (P < 0.01) 12.7 43.4
Fast Food (P < 0.01) 77.8 59.6
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Esophageal Impedance Detection of Cycling, a Specific Finding
in GERD
Ryan D. Madanick, MD, Nicole L. Cheng, PA-C, Sheila Crawford, RN,
Douglas Morgan, MD, Nicholas J. Shaheen, MD∗. Center for Esophageal
Diseases and Swallowing, Division of GI/Hepatology, UNC School of
Medicine, Chapel Hill, NC and GI Motility Laboratory, UNC Hospitals,
Chapel Hill, NC.
Purpose: Cycling is a manometric finding specific for GERD, in which
repetitive bursts of reflux events are followed by clearance swallows. 24-hr
esophageal pH-multichannel intraluminal impedance (MII) can detect this
phenomenon in patients with reflux diatheses.
Methods: The MII characteristics of cycling identified in 3 patients are
described.
Results: During routine interpretation of pH-MII studies in our lab, we found
3 patients (all females; 2 with prior bariatric surgery) with post-prandial cy-
cling. All had positive pH-MII studies for nonacid GERD. Their tracings
revealed a total of 9 distinct cycling episodes (CycEps) (range 1–5/pt), last-
ing between 12 and 99 mins (mean 41 min). 7 of 9 CycEps were completely
nonacid. The other 2 were predominantly nonacid with very brief acid expo-
sure. At low resolution (30+ min/screen), CycEps had low distal impedance
(200–500 ohms) with brief impedance “spikes” that did not reach gas re-
flux values (Fig. 1). At high resolution, the first GER event in a CycEp
was identified by retrograde decreases in impedance to less than 50% of
baseline (800–4000 ohms) within the 2 distal channels. Temporary bolus
clearance (BC) within a CycEp was identified by sharp antegrade increases
in impedance. Subsequent GER events within a CycEp were identified by
sharp retrograde decreases in impedance. Because GER events often oc-
curred within seconds of BC, standard MII criteria for BC and GER were
not always fulfilled, as impedance between BC and the subsequent GER
event did not have time to stabilize (Fig. 2).
Conclusion: Cycling can be found on pH-MII studies more frequently than
previously recognized, and is a specific marker of persistent GERD. Ac-
curate identification of a CycEp requires manual review of pH-MII trac-
ings.[figure1][figure2]
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Cost-Effectiveness of MII-pH Testing in Persistent Reflux-Related
Cough Despite Acid Suppressive Therapy
Deepika Laxmi Koya, MD, MSCR, Marcelo A. Vela Aquino, MD, MSCR,
Donald O. Castell, MD, Kit N. Simpson, DrPH∗. Internal Medicine,
Medical University of South Carolina, Charleston, SC and Health
Administration and Policy, Medical University of South Carolina,
Charleston, SC.
Purpose: GERD is a common cause of chronic cough. An empiric trial of
high-dose proton pump inhibitor (PPI) is emerging as a diagnostic and thera-
peutic approach for suspected reflux-related chronic cough. In patients with
persistent cough despite adequate acid suppression, symptoms may be due
to non-acid reflux or may not be related to reflux. Combined multi-channel
intraluminal impedance and pH (MII-pH) detects nonacid reflux and its
temporal association with cough. A recent study showed that fundoplication
successfully treats non-acid reflux associated cough diagnosed by MII-pH.
Cost-effectiveness of this test to aid management of reflux-related persistent
cough on PPI therapy has not been studied.
Methods: A decision tree was used to compare MII-pH testing to no testing.
Cost-utility analysis was performed over a 3 yr time horizon. The published
algorithm for management of patients with reflux-related cough refractory to
acid suppression defined the care process. The analysis models a hypothetical
population of 100 patients with reflux-related cough on acid suppression. We
assumed two scenarios: MII-pH testing versus no testing. Costs and quality-
adjusted life-years (QALYs) for the two scenarios were examined. Outcome
probabilities for the testing arm were derived from published literature (test
positive 26%, probability of surgery in test positive arm is 53%). We assumed
that cough persisted in all patients in the no testing arm and those patients in
the testing arm who did not have fundoplication. The expected costs for this
group include PPI use and frequent physician visits. Utilities for persistent
cough and no cough health states were obtained from the published literature.
Estimated costs of surgery and office visits were obtained from a variety of
resources. Drug costs represented the average wholesale price. The primary
outcome measured was incremental cost-effectiveness ratio (ICER).
Results: MII-pH testing produced an ICER of $915 per QALY saved com-
pared with no testing, over a 3 yr time horizon. The results are sensitive to the
probability of surgery in test positive arm. If we assume that all the patients
who are test positive would undergo surgery, the ICER would be $ 208,671.
Conclusion: MII-pH testing to evaluate persistent reflux-related cough re-
fractory to acid suppression cost effectively identifies patients who would
benefit from fundoplication.
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Utility of Endoscopic Ultrasound Prior to Esophagectomy for High
Grade Dysplasia in Barrett’s Esophagus
G.A. Prasad, MD, K.K. Wang, MD∗, R.J. Badreddine, MD, N.S. Buttar,
MD, L.M. Wongkeesong, MD, K.T. Dunagan, L.S. Lutzke, L.S.
Borkenhagen. Barrett’s Esophagus Unit, Gastroenterology and
Hepatology, Mayo Clinic College of Medicine, Rochester, MN.
Purpose: Esophagectomy is currently recommended as a treatment for HGD.
Occult and coexistent cancer (described in up to 50% of patients with HGD
undergoing esophagectomy) is a major rationale for esophagectomy. Endo-
scopic ultrasound is advocated as a method of detecting occult cancers in
HGD. We aimed to assess the utility of EUS in detecting cancer in patients
undergoing esophagectomy.
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Methods: We performed a retrospective cohort study of all patients who
underwent esophagectomy for HGD at Mayo Clinic, Rochester, from 1994–
2005. All patients underwent preoperative endoscopy with biopsies. Patients
with carcinoma on preoperative biopsies were excluded. Histology was con-
firmed by 2 gastrointestinal pathologists. Endoscopic ultrasound (EUS) was
performed using radial and linear echoendoscopes by experienced endosono-
graphers. Endoscopic mucosal resection (EMR) was performed using stan-
dard techniques. Esophagectomy was performed by experienced thoracic
surgeons by the transthoracic or the transhiatal route. Demographic, clinical
and pathology data was extracted by review of medical records. Standard
statistical tests were used to compare continuous and categorical variables.
Results: 70 patients underwent esophagectomy (mean age 60 years
[SD10.5]; 67[94%] males) for HGD. The median BE length was 7.5 cm
(IQR 5–10.5). 47 patients (67%) underwent EUS and 11 (15%) underwent
EMR preoperatively. EMR was done to target visible lesions. Adenocarci-
noma was detected on surgical pathology in 9 patients (12.8%). 4 patients had
intramucosal carcinoma and 5 had submucosal cancer. None of the patients
had metastatic lymphadenopathy. EUS had been performed in 7 of 9 pa-
tients preoperatively without detection of occult carcinoma. The prevalence
of occult carcinoma in patients who underwent EUS (15%) was statisti-
cally similar to the prevalence of occult carcinoma in patients who did not
have preoperative EUS (9%) [chi square test 0.44, P = 0.50]. There was no
esophageal cancer related mortality in this cohort after a mean follow up of
61 months (SD 5.8).
Conclusion: Preoperative EUS appears of low utility in the detection of
occult carcinoma in patients undergoing esophagectomy for HGD in BE.
This is probably due to the early stage of most occult cancers detected at
esophagectomy.
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Refractory ENT/GERD Symptoms – is Upper Esophageal Sphincter
(UES) or Esophageal Body the Culprit?
Girish Anand, MD, Matthew R. Gideon, Philip O. Katz, MD∗.
Gastroenterology, Albert Einstein Medical Center, Philadelphia, PA.
Purpose: Patients with ENT symptoms suspected due to GERD refractory
to antireflux therapy present a diagnostic challenge. Significant proportions
of these patients have reflux controlled on medication but with little or no
symptom relief. Little attention has been paid to potential motility abnor-
malities – particularly in the UES – in this group.
Aim: To review esophageal function studies in patients with ENT symptoms
referred for evaluation of refractory GERD.
Methods: Retrospective review of esophageal function studies between
07/2003–11/2006. All patients referred by a single ENT specialist were
included and esophageal function studies reviewed for presence or absence
of abnormalities in the lower esophageal sphincter (LES), esophageal body,
and UES. Bolus transit was assessed by simultaneous impedance performed
with manometry.
Results: Ninety-four of 117 patients referred by this single specialist had
esophageal function studies available for review. Symptoms included voice
change (45%), chronic cough or throat clearing (30%), heartburn (20%) as
well as a variety of other ENT symptoms. Hypertensive UES seen in 29/94
(31%). High residual pressure in 20/94 (21%). UES relaxation duration
abnormal in 19 of 94 (20%). Ten of 94 (9%) had hypertensive UES and
elevated residual pressure. Overall, 53% had some abnormality in the UES.
Ineffective esophageal body motility was seen in 16/94 (17%), otherwise
no esophageal body abnormality was consistently seen. Normal viscous
and liquid transit was found in 65/94 patients (69%). 29/94 patients had an
abnormal transit and in half of these it was limited to either one or the other.
LES abnormalities were likewise infrequent in this population.
UES abnormalities are a common finding in ENT patients with symptoms
suspected due to GERD refractory to high-dose antisecretory therapy. Motil-
ity abnormalities are seen rarely though abnormal bolus transit is seen in a
potentially important number of patients.
Conclusion: Further studies need to be done to determine if these associa-
tions are clinically important.
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Factors Predictive of a Poor Outcome in Patients with Esophageal
Atresia
Julie Castilloux, MD∗, Angela Noble, MD, Chanel Belanger, Christophe
Faure, MD. Pediatric Gastroenterology, Hopital Ste-Justine, Montreal,
QC, Canada.
Purpose: Despite a major improvement in the survival rate of patients with
esophageal atresia and tracheoesophageal fistula (EA-TEF), the morbidity
associated with this condition remains high. Given this, the aim of our study
was to identify early predictive factors of serious complications during the
1st year of life (short term) and after 1 year of age (long term) in these
patients.
Methods: We retrospectively reviewed the charts of all EA-TEF children
born between January 1990 and May 2005. Included cases had been followed
at Hopital Sainte-Justine for a minimum of one year. Variables analyzed in-
cluded different patient characteristics, details of the surgery and early post-
operative period. A complicated evolution was defined as the occurrence of
at least one of severe gastroesophageal reflux, esophageal stricture needing
dilatation, recurrent fistula needing surgery, need for gavage feeding for ≥
3 months, esophageal foreign body impaction needing endoscopic removal,
severe tracheomalacia, chronic respiratory disease and death.
Results: 152 EA-TEF patients fulfilled our inclusion criteria. 47% were fe-
male. Mean gestational age was 36.8 weeks (24–42 wks) and mean birth
weight was 2515 g (555–4334 g). 47% had a complicated evolution before
one year of age and 45% after one year. Multiple logistic regression demon-
strated in the first year of life, 4 groups of significant variables (P ≤ 0.05)
associated with a complex evolution: Surgery associated issues (long gap,
2 step surgery, Foker, initial gastrostomy, anastomotic leak))[OR 5.4; 95%
CI 1.7–17], Post-op respiratory complications (pneumothorax, intubation
≥ 5 days p-op, chylothorax) [OR 4.4; 95% CI 1.6–12], Post-op feeding
difficulties (Inability to feed orally, need for gavage feeding or gastrostomy)
[OR 2.6; 95% CI 1.1–6.1], “other” malformation not related to VACTERL
[OR 2.2; 95% CI 1.0–5.0]. After one year of age, only the surgery associ-
ated issues [OR 2.8; 95% CI 1.4–5.9] and a complicated evolution in the
first year of life were predictive of a continued complicated evolution [OR
3.6; 95% CI 1.4–9.2].
Conclusion: In children with EA-TEF, we found a number of variables
predictive of a high risk of morbidity during the first year of life. Using these
variables to identify EA-TEF children at higher risk of complications will
allow us to modify their medical management and hopefully reduce their
long term morbidity.
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Eotaxin-3 Immunofluorescence in Adults with Dysphagia: Is There
More to Eosinophilic Esophagitis Than Meets the Microscopic Eye?
Edward J. Frech, Scott K. Kuwada, Mae F. Go, Kristen L. Thomas, Frederic
C. Clayton, Phillip Gray, Gerald J. Gleich, John C. Fang, Kathryn A.
Peterson∗. GI, UUMC, Salt Lake City, UT; Pathology, UUMC, Salt Lake
City, UT; GI, VAMC, Salt Lake City, UT and Dermatology, UUMC, Salt
Lake City, UT.
Purpose: Eosinophilic esophagitis (EoE) is an increasingly recognized
chronic, inflammatory disorder characterized by dysphagia and eosinophilic
infiltration of the esophageal mucosa. While the pathogenesis remains poorly
understood, recruitment of eosinophils is believed to occur in response to
allergens and epithelially-derived eotaxin-3. The current diagnosis relies
on histologic (>20 eos/hpf) and endoscopic (rings and furrows) findings.
Recent studies have shown that H&E staining significantly underestimates
both the number of eosinophils and degree of eosinophil degranulation when
compared to more sensitive immunohistochemical staining.
Aims: To further define the histologic criteria for diagnosing EoE using
eotaxin-3 immunofluorescence in adults presenting with dysphagia.
Methods: A total of 51 patients presenting with dysphagia were subdivided
based on H&E staining: EoE, GERD, and normal histology. Immunohisto-
chemical staining for eotaxin-3 was performed on all esophageal biopsies.
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Immunofluorescence (IF) was assessed by a pathologist who was blinded to
the clinical diagnosis and scored on a 0 to 4 scale (0 = no staining to 4 =
greatest staining).
Results: Of the 51 patients, 29 had a histologic diagnosis of EoE, 13 had
GERD, and 9 were normal. The distribution of IF scores are shown in Table
1. The median eotaxin-3 IF score was greater in patients with EoE compared
to those with GERD (P = 0.008) or normal histology (P = 0.006). There
was no difference in eotaxin-3 IF scores between patients with GERD vs.
normal histology (P = NS).
Conclusion: Eotaxin-3 immunofluorescence scores were significantly
greater in patients with a histologic diagnosis of EoE compared to non-
EoE patients. This finding supports eotaxin-3 as an important marker and
pathogenic factor for EoE. Esophageal biopsies with eotaxin-3 IF may im-
prove the diagnosis of EoE in patients who present with esophageal symp-
toms. Patients with refractory GERD and higher eotaxin-3 IF scores may
warrant a trial of inhaled corticosteroids.[figure1]
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What Is the Incidence of Acidic and Nonacidic Gastroesophageal
Reflux (GER) in Lung Transplant Recipients (LTR)?
Anne F. Peery, MD, Ryan D. Madanick, MD, Joseph A. Galanko, PhD,
Peadar Noone, MD, Thomas Egan, MD, Isabel Neuringer, MD, Nicholas J.
Shaheen, MD∗. University of North Carolina, Chapel Hill, NC.
Purpose: Bronchiolitis obliterans syndrome (BOS) is the most significant
cause of mortality in LTR. GER may be a contributing factor in BOS.
We evaluated our LTR population to determine the prevalence of acid and
nonacid GER and to determine if there is an association between GER, bron-
chiolitis obliterans syndrome (BOS), and the known BOS risk factor of acute
rejection.
Methods: Given concerns that GER may cause airway damage after trans-
plant, all living recipients who underwent lung transplant at our institution
have been offered pH analysis. These studies were performed off medi-
cation and with either standard pHmetry (Sandhill Scientific, Highlands
Ranch, CO), or more recently, with impedance technology (Sandhill Scien-
tific, Highlands Ranch, CO). Studies were performed using standard tech-
niques. Each patient’s medical record was then reviewed to collect demo-
graphic data, confirmed episodes of acute rejection, and pulmonary function
data. Patients with prior antireflux surgery were excluded from data analysis.
The data were analyzed using SAS software (Cary, NC).
Results: To date, 40 patients have had pH studies, and 37 met study criteria.
Median age = 41 yrs, 49% were male, and 70% (N = 26) had a primary
diagnosis of cystic fibrosis (CF). Nineteen of the 37 (51%) had an abnormal
pH study (% time with pH < 4 of > 4.2%). Acid exposure in the CF subgroup
was significantly increased compared to the rest of the study population.
Among CF patients, 16 of the 26 (62%) had an abnormal pH study. There
was no significant association between acid reflux and acute rejection or
BOS (N = 37). However, the CF subgroup (N = 26) showed that elevated
acid exposures were significantly associated with a history of acute rejection
(P = 0.0315). The association between BOS and GER in the CF subgroup
also trended toward significance (P = 0.192). Fifteen of the 37 patients
completed an impedance study. The median total reflux was 40 events and
2/15 patients had significantly abnormal total reflux (≥73 events). One of
these 2 patients had normal acid exposures.
Conclusion: GER is highly prevalent among recipients of lung transplant. In
CF patients, there was an association between GER and acute rejection. GER
may be injurious to the transplanted lung secondary to reduced pulmonary
mucociliary clearance, a diminished cough reflex, and immunosuppressive
therapy, thus predisposing to chronic graft rejection.
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The Effect of Tegaserod on Gastric Accommodation and Gastric
Emptying in Patients with Functional Dyspepsia and Comparison with
Domperidone
Mohamed N.A. Al-Aghbar, PhD∗. Internal Medicine, Basel Medical
Centre, Abu Dhabi, United Arab Emirates.
Purpose: To investigate The effect of Tegaserod on Gastric Accommoda-
tion and on Gastric Emptying in patients with Functional Dyspepsia and
comparison wirh Domperidone.
Methods: 20 patients with functional dyspepsia and 11 normal controls
were studied. Using ultrasound, Gastric Accommodation was determined
by: Fasting water load, Fasting gastric volume, Post drinking gastric volume,
Post drinking gastric volume change and The ratio of post drinking gastric
volume to fasting gastric volume. Gastric Emptying rate was determined
by the formula: post drinking gastric volume˙post drinking gastric volume
after 25 minutes/post drinking gastric volume × 100. Then these patients
were allocated in two groups:Group I included 10 patients put on Tegaserod
6 mg twice daily for six weeks. And group II included 10 patients put on
Domperidone 10 mg twice daily for the same period then the previous
parameters were re- measured.
Results: 1. Post drinking gastric volume change and the ratio of post drink-
ing gastric volume to fasting gastric volume were significantly reduced in
patients with functional dyspepsia compared to normal controls: 802 ± 322
and 585 ± 242 (P < 0.05) and 32.9 ± 16.8 and 19.7 ± 7.2 (P < 0.01)
respectively. 2. Gastric emptying rate was significantly reduced in these pa-
tients compared to normal controls: 68 ± 13.8% and 44.9 ± 16.5% (P <
0.01) 3. Group I. Tegaserod had significant improvement on the ratio of post
drinking gastric volume to fasting gastric volume: 18.7 ± 7.3 and 24.62 ±
7.88) P = 0.02. Post drinking gastric volume change was not signicantly
increased: 598.7 ± 222 and 635.6 ± 141.8) P = NS. The gastric emptying
rate was signicantly increased in this Tegaserod treated group: 43.2 ± 16.7
and 54.2 ± 5.89 P = 0.02. 4. Group II. Domperidone had significant ef-
fect on the Post drinking gastric volume change: 573 ± 272 and 743.5 ±
71.35 P = 0.02. The ratio of post drinking gastric volume to fasting gastric
volume was not significantly increased: 20.5 ± 6.7 and 27.1 ± 11.4 P =
NS. The gastric emptying rate was also not significantly changed: 46.7 ± 17
and 54.5 ± 8.89 P = NS. 5. The improvement in symptoms was reported in
7/10 in the Tegaserod treated group and in 5/10 in the Domperidone treated
group.
Conclusion: Tegaserod was associated with a significant improvement
in Gastric Accommodation as well as in Gastric Emptying. Domperi-
done treatment was associated with a significant improvement of Gastric
Accommodation but not in Gastric Emptying rate. The improvement of
symptoms was more in favour of Tegaserod.
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Eosinophilic Gastritis: A Case Report
Sumit Sharma, MD, Preeti Agrawal, MD, Jack Garon, MD, Arun Verma,
MD∗. Department of Medicine and Department of Pathology, Mt. Sinai
Hospital, Sinai Health System, Chicago, IL.
Abstracts S157
Purpose: Eosinophilic gastritis is a rare disorder of unknown etiology and
should be suspected in patients when they have unremitting gastric discom-
fort and routine examination and diagnostics are not able to give a reasonable
explanation. It is characterized by patchy/diffuse infiltration of eosinophils
in the abdominal wall with peripheral eosinophilia.
Methods: A 31 year old Hispanic female with no significant past medical
history was referred to the GI service with complaints of chronic vomit-
ing since three years. Vomiting was usually before eating accompanied by
mild tenderness in the RUQ. Patient had an EGD done at Mexico in the
past, which showed hiatal hernia and esophagitis. There was no history of
diarrhea, tenesmus or weight loss. Two days prior to this, patient had abdom-
inal pain with nausea and vomiting for which lansoprazole was prescribed
by her primary care physician. The vomiting persisted and abdominal ex-
amination showed a soft, mildly tender abdomen with no rebound/signs of
peritonitis. Labs showed WBC count of 15,000 with 45% neutrophils, 27%
lymphocytes, 5% monocytes and 23% eosinophils. The GI service did an
EGD with multiple biopsies to rule out eosinophilic gastroenteritis. The
EGD showed moderate sized hiatal hernia, a polyp in the gastric antrum
and erythematous mucosa with some nodularity. The GE junction was also
irregular with some evidence of nodularity. Biopsy revealed gastric mucosa
with marked eosinophilic infiltrates involving the squamous mucosa (Fig.
1: Striking eosinophilic infiltrates, mostly in lamina propria). After ruling
out infectious, malignant and other autoimmune causes the patient was di-
agnosed with Eosinophilic gastritis. She was treated with a low dose of
prednisone for a period of four weeks and showed an excellent clinical and
biochemical response.
Results: We illustrate a case of Eosinophilic gastritis that presented in a way
where the diagnosis could have been easily missed. Biopsy in these cases
should be taken from both the normal and abnormal appearing mucosa since
normal mucosa can harbor diagnostic microscopic appearance.[figure1]
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Risk Factors Involved in Patients with Bleeding Peptic Ulcers – A
Community Based Study
Sesha S. Uppalapati, MD∗, James D. Boylan, MD, Jill Stoltzfus, PhD.
Internal Medicine, St. Luke’s Hospital, Bethlehem, PA and
Gastroenterology, St. Luke’s Hospital, Bethlehem, PA.
Purpose: The aim of our study was to 1. Identify the specific risk factors
involved in patients with peptic ulcer disease (PUD) and to determine if they
predict bleeding in these patients. 2. Determine the frequency of association
between non-steroidal anti-inflammatory drug (NSAID) use and Helicobac-
ter pylori (H. pylori) infection in patients with PUD. 3. Determine if both
rapid urease test and biopsy are necessary to test for H. pylori infection in
patients with PUD.
Methods: We conducted a community-based retrospective case control
study. Data analysis occurred using a chi-square test of general associa-
tion and logistic regression analysis. A total of 230 patients were included
in the study between Jan 2004–June 2005 (128 PUD patients with evidence
of bleeding served as cases, with a control group of 102 non-bleeding ulcer
patients). H. pylori infection was assessed by using either rapid urease test
or biopsy obtained from the gastric antrum, or both (in 81.7% of patients).
Results: There were no statistically significant differences between the
bleeding ulcer and control patient groups with respect to gender, age or
location of ulcer. However, there was a significantly higher rate of NSAID
use in the bleeding ulcer patient group (68.8% vs. 47.6%, P < 0.001; unad-
justed odds ratio (OR) = 2.42; 95% CI = 1.42–4.51). The rate of H. pylori
infection was lower in patients with bleeding ulcers (26.6% vs. 39.8%, P <
0.05; unadjusted OR = 0.58; 95% CI = 0.31–0.95). There was no inter-
action between NSAID use and H. pylori infection in predicting bleeding
ulcer risk (P = .08). Sensitivity and specificity for urease test in detecting
H. pylori was 75% and 99.7%, respectively, with a high positive predictive
value of 93.8%. For patients with bleeding ulcers, the sensitivity of urease
test was 53.8% versus 80.9% in controls, while specificity was 100% in the
case group.
Conclusion: NSAID’s are associated with an increased risk of bleeding in
PUD patients, although the rate of H. pylori infection was lower in patients
with bleeding ulcers. Our study showed no significant association between
these variables. In patients with a positive urease test, biopsy is not needed
to confirm H. pylori infection which is cost-effective and treatment should
be initiated for H. pylori. However, due to a high false negative rate, patients
with negative urease test results should have biopsy done to confirm evidence
of H. pylori infection.
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One-Day Triple Therapy, Including Immediate-Release Omeprazole,
for Eradication of Helicobacter pylori Infection
Matthew D. Gaeta, MD, Todd Kilgore, MD, Jeffrey O. Phillips, PharmD,
Jack Bragg, DO, John B. Marshall, MD∗. Department of Internal
Medicine, University of Missouri Hospital and Clinics, Columbia, MO.
Purpose: Regimens to treat H. pylori (HP) are cumbersome for patients to
take, expensive & frequently associated with undesirable side effects, all
of which can negatively affect compliance & eradication rate. To achieve
>80% eradication rate requires administration of 3–4 different meds, given
for 7–14 days. A recent study found that a 1-day treatment (Tx) regimen
of 4 drugs (lansoprazole, bismuth, metronidazole & amoxicillin) gave an
eradication rate of 95% (Arch Intern Med 2003;163:2079). Effective 1-
day Tx regimens, if confirmed to be effective, would simplify Tx and have
great potential to improve patient compliance. An immediate release form of
omeprazole (omeprazole/Na bicarbonate; Zegerid) has recently come onto
the market. We hypothesized that this agent, which is immediately released,
rapidly absorbed into the bloodstream & achieves prompt gastric pH buffer-
ing, might hold a clinical benefit over other PPIs when used in 1-day HP Tx
regimens.
Methods: We conducted a prospective single-arm open-label pilot trial look-
ing at the efficacy of a 1-day regimen of immediate-release omeprazole, in
combination with amoxicillin & clarithromycin, to eradicate HP. Patients
were eligible for the study if they had HP infection documented by gastric
Bxs taken at EGD for dyspepsia. Exclusion criteria included previous Tx of
HP, antibiotic Tx in the previous 6 wks, age <18 yrs, pregnancy, allergy to
study meds, previous gastric surgery, hepatic insufficiency, IBD, & inability
to give informed consent. Of 14 patients with Bx-documented HP infection,
6 met entry criteria and agreed to participate. They received 1-day of ther-
apy with immediate-release omeprazole 40 mg, amoxicillin 1000 mg and
clarithromycin 500 mg, with each given for a total of 3 doses (at 0 hrs, 4 hrs
& 12 hrs). Patients did not receive any other PPIs during the subsequent
study period. Four wks after their Tx, patients underwent urea breath testing
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to evaluate for HP eradication. Persistent HP infection was treated with a
14-day triple drug regimen.
Results: We found that our 1-day Tx regimen failed to eradicate HP in all
6 patients.
Conclusion: This pilot study showed that our 1-day triple drug regimen,
which included immediate-release omeprazole, was not effective in the Tx
of HP infection. Adding a fourth drug to the regimen could improve effi-
cacy. Further studies of 1-day HP regimens are needed before they can be
recommended for routine clinical practice.
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Report Card To Grade Helicobacter pylori Therapies
David Y. Grahama, MD∗, Hong Lu, MD, Yoshio Yamaoka, MD. Medicine,
Micheal E. DeBakey VAMC, Houston, TX; Medicine, Baylor College of
Medicine, Houston, TX and Digestive Disease, Shanghai Institute of
Digestive Disease, Shangahi, China.
Purpose: H. pylori causes a serious bacterial infectious disease and the ex-
pectations of therapy should reflect this fact. Increasing antibiotic resistance,
especially to clarithromycin, has significantly undermined the effectiveness
of legacy triple therapy consisting of a proton pump inhibitor, clarithromycin
and amoxicillin.
Methods: We reviewed current cure rates regarding their ability to achieve an
80% intention-to-treat cure rates, the accepted threshold separating accept-
able from unacceptable treatment results. Studies were graded into effective-
ness categories using prespecified criteria to objectively compare regimens
using a Therapy Report Card similar to that used to grade the performance
of school children. The intention to treat cure rate categories are: F or un-
acceptable (<80%), D or poor (80–84%), C or fair (85–89%), B or good
(90–95%), and A or excellent (95–100%). The category of “excellent” was
based on the cure rates expected with other prevalent bacterial infectious
diseases.
Results: In the US and Europe recent (100 or greater subjects) large trials
(total more than 2000 subjects) show that the triple therapy of a PPI +
clarithromycin + amoxicillin has cure rates of F or less than 80% irrespective
of duration. Sequential therapy scores as B.
Conclusion: Therapies that score “excellent” (grade = A) should be prefer-
entially prescribed. B or “good” therapies can be used if “excellent” result are
not obtainable. In most regions legacy triple therapy should be abandoned
for unacceptable cure rates. Different quadruple therapies and sequential
therapy are reasonable alternatives for initial therapy.
112
Two Cases Involving Gastric Ulceration and Bleeding from Recent
Placement of Gastrostomy Tubes with T-Fasteners
Rajesh Dhirmalani, DO, Dengda Tang, MD, Zamir Brelvi, MD∗.
Gastroenterology, UMDNJ, Newark, NJ.
Purpose: The purpose of this case series is to elucidate an unforeseen com-
plication related to (T-tacks) in the assistance of RIG and PIG.
Results: Both cases involved a 68 and an 82 yr CVA patients with recent
placement of Gastrostomy tubes. T-tacks were used in both cases for gas-
tropexy to aid in the introduction of the gastrostomy tubes. In both cases
the patients returned to the ER with upper Gi bleeding 1–2 weeks post-
gastrostomy placement. Both patients were resuscitated in the emergency
department.
The 68 yr patient was endoscoped under conscious sedation. Endoscopic
exam of the esophagus and duodenum was normal. The gastrostomy site
was identified and the gastric bumper was noted to be in good position.
Along side of the bumper were the retained T-tacks. One of the T-tacks was
abutting into the gastric wall where an actively bleeding gastric ulcer was
identified. The area was injected with epinephrine 1:10,000 mixture and
bicaped with good hemostats is. The t-tacks were then removed with a snare
on a second sitting. The patient went home but did return with continued
bleeding from the previous ulcer site. The patient was re-treated with Epi
and bicap and hemostasis was maintained.
The 82 yr patient presented to the ER 3 weeks after the above patient with
similar scenario. Endoscopy was performed that day and the gastrostomy
site was identified. No erosions or ulcerations were identified in the antrum.
Upon inspection of the gastrostomy site was the presence of two T-tacks
with one buried into the gastric wall. There was surrounding edema and
ulceration at the site. In this case the T-tacks were attached to the external
bumper via suture material. The sutures were released from the bumper.
Grasping forceps were then used to endoscopically remove the T-tacks from
the gastric wall.[figure1][figure2]
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Optimizing the Detection of Fundic Gland Polyp Dysplasia in Subjects
with Famililal Adenomatous Polyposis
Laura K. Bianchi, MD, Ana E. Bennett, MD, Rocio Lopez, MS, Hennie
Hasson, RN, Carol A. Burke, MD∗. Gastroenterology, Cleveland Clinic,
Cleveland, OH; Anatomic Pathology, Cleveland Clinic, Cleveland, OH and
Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.
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Purpose: Dysplasia in fundic gland polyps (FGPs) is common in familial
adenomatous polyposis (FAP) and gastric cancer is reported arising from
FGPs in FAP. Optimal biopsy protocols are elucidated for dysplasia detection
in IBD and Barrett’s, but have not been investigated for dysplasia detection
in FGPs in FAP. Our aim was to determine the most effective biopsy strategy
for the detection of dysplasia in FAP FGPs.
Methods: A systematic protocol was utilized to biopsy FGPs from consecu-
tive pts with FGPs undergoing routine endoscopic surveillance for FAP. FGP
number (1–20, 21–30, >30) and size (1–4 mm, 5–10 mm, >10 mm) was
recorded. The stomach involved with FGPs was visually divided into equal
segments: proximal, middle, distal. Equal numbers of FGPs were biopsied
from each segment. If 1–20 FGPs, 9 biopsies obtained. If 21–30 FGPs, 15
biopsies obtained. If > 30 FGPs, 21 biopsies obtained. Directed biopsies
were obtained from large (>1 cm) and irregular appearing FGPs. One gas-
trointestinal pathologist blinded to the endoscopic findings interpreted all
histology.
Results: 66 subjects (48% female) with a mean age of 43.6 yrs. 8% reported
a family history of gastric cancer. Dysplasia was detected in 41% (2 subjects
with high grade dysplasia (HGD), 25 subjects with low grade dysplasia
(LGD)). 12% (3/25) had LGD in all three sets of polyps biopsied; 32%
(8/25) had LGD in FGPs biopsied from the proximal segment; 52% (13/25)
had LGD in FGPs from the middle segment, and 48% (12/25) with LGD in
FGPs from the distal segment. Biopsies from proximal and middle segments
missed 36% of subjects with LGD; biopsies from middle and distal segments
missed 20% of LGD. 8% (2/25) of subjects with LGD were detected on
directed biopsies alone. 100% (2/2) of subjects with HGD were detected in
directed biopsies of large or irregular FGPs. 89% of subjects with dysplasia
were detected by either directed biopsies of large or irregular FGPs or random
biopsies from the distal 2/3 of the stomach.
Conclusion: LGD was not uniformly distributed among FGPs. HGD was
detected only in directed biopsies. The yield for dysplasia detection was
greatest when directed biopsies of large (>1 cm) and irregular FGPs were
combined with random biopsies obtained from FGPs in the distal 2/3 of
involved mucosa.
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Fundic Gland Polyp Dysplasia Is Common in Familial Adenomatous
Polyposis
Laura K. Bianchi, MD, Ana E. Bennett, MD, Rocio Lopez, MS, Hennie
Hasson, RN, Carol A. Burke, MD∗. Gastroenterology, Cleveland Clinic,
Cleveland, OH; Anatomic Pathology, Cleveland Clinic, Cleveland, OH and
Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.
Purpose: Fundic gland polyps (FGPs), common in Familial Adenomatous
Polyposis (FAP), have been considered non-neoplastic, but gastric cancer is
reported arising from them. This implies a dysplasia-carcinoma sequence,
but the prevalence of FGP dysplasia has not been well studied. We sought to
prospectively determine the prevalence of FGPs and FGP dysplasia in FAP
via a systematic biopsy protocol and to identify endoscopic or demographic
features associated with FGPs or FGP dysplasia.
Methods: Demographic and medical information (age, gender, race, family
history of gastric cancer, exposure to tobacco, NSAIDs, or acid suppressive
medications-PPI/H2RA) were obtained from consecutive FAP patients un-
dergoing routine surveillance EGD. Endoscopic findings were recorded: FGP
number (1–20, 21–30, >30), size (1–4 mm, 5–10 mm, >10 mm), duodenal
polyposis stage, presence of H pylori. The stomach involved with FGPs was
visually divided into equal segments: proximal, middle, and distal. Equal
numbers of FGPs were biopsied from each segment. Directed biopsies were
obtained from large (>1 cm) and irregular appearing FGPs. One gastroin-
testinal pathologist who was blinded to the endoscopic findings interpreted
all histology.
Results: 75 subjects (52% male) with a mean age 44 yrs were included.
88% (66/75) of subjects had FGPs. H. pylori was detected in 33.3% of sub-
jects without and 1.5% of subjects with FGPs (P = 0.005). 38% (25/66) of
subjects had LGD and 3% (2/66) had HGD. After adjusting for stage of duo-
denal polyposis, presence of antral gastritis, size of largest FGP and tobacco
exposure, multivariable logistic regression analysis found PPI/H2RA use
had a protective effect against FGP dysplasia (OR 0.15, 95% CI 0.02–0.95).
Subjects with > 30 FGPs were 9.4 times more likely to have dysplasia than
subjects with < 20 FGPs (OR 9.44, 95% CI 0.96, 92.55). For every increase
in stage of duodenal polyposis the odds of having dysplasia nearly doubled
(OR 1.91, 95% CI 0.87, 4.19).
Conclusion: The majority of FAP patients have FGPs and FGP dysplasia is
common in FAP. There is a negative association between FGPs and presence
of H pylori. FGP dysplasia is associated with increased number of FGPs and
increased stage of duodenal polyposis. Use of acid suppressive medications
has a protective effect against dysplasia in FGPs.
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Effects of Cobiprostone on Indomethacin- and Stress-Induced Gastric
Ulcers in Rats
Hiroyoshi Osama, Sachiko Kuno, PhD, Birgit Roerig, PhD, Ryuji Ueno,
MD∗. Sucampo Pharma Ltd., Osaka, Japan and Sucampo
Pharmaceuticals, Inc., Bethesda, MD.
Purpose: This study was done to evaluate the ability of cobiprostone, a mem-
ber of the prostone family of compounds which selectively activate type-2
chloride channels, to protect against indomethacin- and stress-induced gas-
tric ulcer formation in Wistar rats. Another prostone compound, lubipro-
stone, accelerates recovery of tight junction potential in acutely injured
porcine ileal mucosa.
Methods: In the indomethacin-induced ulcer model, fasted animals were
orally given 1 of 4 dose levels of cobiprostone, or vehicle. Ten minutes after
dosing, all rats received an oral dose of 20 mg/kg indomethacin. Six hours
after indomethacin dosing, all animals were euthanized and the stomachs
were removed and fixed. The maximum length of the longest axis of each
individual ulcer was measured, and the ulcer index was calculated as the sum
of the lengths of all ulcers per stomach. The effect of cobiprostone on the
formation of stress-induced gastric ulcers was also investigated, utilizing a
rat water-immersion model. Fasted animals received orally 1 of 3 doses of
cobiprostone, 1 of 2 doses of lansoprazole, or a single dose of vehicle. Ten
minutes after dosing, all animals were placed into a stress cage and vertically
immersed in 23◦C water up to the height of the xiphoid process. Five hours
after the immersion, all animals were then euthanized and the stomachs
removed and fixed. The ulcer index was calculated as stated above.
Results: The results from the indomethacin model indicate that 0.3, 1, 3,
and 10 mcg/kg cobiprostone dose-dependently inhibited the generation of
indomethacin-induced gastric ulcers by 2, 59, 65, and 77% vs vehicle, re-
spectively; this inhibition was statistically significant at 1, 3 and 10 mcg/kg
vs. vehicle (P < 0.01). The stress study shows that 10, 30, and 100 mcg/kg
cobiprostone dose-dependently inhibited the generation of stress-induced
ulcers by 21, 36, and 85% vs vehicle, respectively. This inhibition was sta-
tistically significant at 100 mcg/kg vs vehicle (P < 0.01). Lansoprazole,
at concentrations of 1,000 and 10,000 mcg/kg, also dose-dependently and
statistically significantly inhibited the generation of stress-induced ulcers by
37 and 95% vs vehicle, respectively (P < 0.01).
Conclusion: The results of these studies indicate that cobiprostone can
protect the stomach against the development of indomethacin- and stress-
induced gastric ulcers. Furthermore, the cytoprotective effect against stress-
induced gastric ulcers is at least 30-fold more potent than that of lansoprazole.
This research was fully funded by Sucampo Pharmaceuticals, Inc.
116
A Retrospective Study on the Role of Helicobacter pylori in Positive
Fecal Occult Blood Tests in Hispanic Veterans
Manuel Salcedo, MD, Doris H. Toro, MD∗, Javier Pou, MD, Carol L.
Torres, MD. Gastroenterology, VA Caribbean Healthcare System, San
Juan, Puerto Rico.
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Purpose: Fecal occult blood testing (FOBT) is the less expensive and more
widely used method for screening for colorectal cancer, nevertheless upper
gastrointestinal tract lesions can cause a positive FOBT, leading clinicians to
evaluate the upper GI tract when a colonic cause is not identified. In Puerto
Rico the prevalence of H. pylori infection in adults can exceed 80%. We
hypothesized that a significant proportion of upper endoscopy findings in
patients with positive FOBT could be a result of H. pylori infection.
Methods: The study consists of a retrospective analysis of the records of
asymptomatic patients screened for colorectal cancer during years 2000–
2005 that had undergone upper endoscopy as part of the evaluation of at
least one stool positive for FOBT. CLOtest was used to assess the presence
of H. pylori in all patients. Positive endoscopy findings were defined as:
erosive gastritis, duodenal or gastric ulcers, and duodenitis.
Results: Study group consisted of 273 Hispanic patients (97%) male, with a
mean age of 67 years old. Most common endoscopic findings were: erosive
gastritis in 115/273 (42%) patients, gastric ulcers in 26/273 (10%), duo-
denal ulcers in 19/273 (7%) and gastric cancer in 3/273(1%). 117 patients
(42.8%) had a positive CLOtest. Among the patients with a positive CLOtest,
the probability of upper endoscopy findings was higher [775.2% (88/117)]
when compared to those with non-significant or negative findings [24.8%
(29/117)]. (P = 0.001). 137(50%) patients of the initial study group were
using either aspirin and/or NSAID’s. When these patients were excluded,
35.3% (48/136) had a positive CLOtest, of which 37/48(77.1%) had positive
endoscopic findings and 11/48 (22.9%) had none. Again this difference was
statistically significant (P value of 0.001).
Conclusion: Patients with a positive FOBT and documented H. pylori in-
fection are more likely to have significant findings on upper endoscopy. This
study suggests that H. pylori infection might be a significant cause of positive
FOBT in patients with negative colonoscopy. Prospective studies should be
conducted to determine the role of H. pylori infection and upper endoscopic
examination in patients with positive FOBT.
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Okadaella gastrococcus-like Immunoreactivity in Gastric Mucosal
Lesions
Takayuki Okada, MD, Kazutoshi Hori, MD, Kazuhiko Nakajima, MD,
Hiroto Miwa, MD, FACG∗. Medicine, Okada Medical Clinic, Brisbane,
QLD, Australia and Gastroenterology, Hyogo College of Medicine,
Hishinomiya, Hyogo, Japan.
Purpose: Our previous reports on the nature of an intracellular gram-
negative coccoid bacteria Okadaella gastrococcus (Og) and its association
with various gastric mucosal lesions (GML) have been based on the findings
from histochemistry, electron microscopy and culture. At present, transmis-
sion electron microscopy is the gold standard to visualize intracellular Og.
The aim of this study was to examine if intracellular Og could be visualized
in various GML by a newly developed Og immunohistochemistry.
Methods: The gastric biopsy specimens obtained at the time of esophago-
gastro-duodenoscopy were used (total 8 patients; Helicobacter pylori (Hp)
positive cases 2 and Hp negative cases 6). A rabbit polyclonal antibody
against Og was raised by a standard method by Japan Biotest laboratory.
Immunohistochemical detection of Og was performed on formalin-fixed,
paraffin-embedded sections using an avidin biotin peroxidase complex tech-
nique. Polyclonal anti-Hp antibody (Dako) was used to visualize Hp.
Results: The heavily stained Og-like immunoreactivities (OGLIR) were
detected in the mucous and the epithelial cells of gastric mucosa of active
chronic gastritis, chronic gastritis, gastric erosions, and gastric ulcers includ-
ing Hp-positive and Hp-negative cases. Positive OGLIR were also seen in
the specimens with atrophy, intestinal metaplasia, dysplasia and malignancy
including gastric MALT lymphoma.
Conclusion: The present novel Og immunohistochemistry could visualize
intracellular and extracellular Og-like organism in various GML. Further
studies are warranted to examine if those Og immunoreactive organisms are
identical to the cultured Og utilizing the method such as immuno-electron
microscopy or in situ hybridization.
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Unusual Case of Gastric Diverticulum
Alan Brijbassie, MD, Oswaldo Bisbal, MD∗. Gastroenterology Division,
Salem VA Medical Center, Salem, VA.
Purpose: Diverticular disease is usually present in the large intestine; gastric
diverticulosis on the other hand is very rare. We now present the case of what
was believed to be an adrenal adenoma, however endoscopically proven to
be a gastric diverticulum.
A 60 year old Caucasian male presented with a three month history of
left sided abdominal pain and gastroesophageal reflux. CT of the abdomen
revealed a left sided adrenal region mass exhibiting air fluid level (white
arrow on CT). Upper endoscopy was performed, revealed a 2 cm diverticulum
in the gastric fundus.
Gastric diverticular disease is a uncommon disease with endoscopic detec-
tion rates ranging between 0.01–0.11%. The majority (up to 75%) form near
the gastroesophageal junction, usually on the lesser curvature or posterior
gastric wall. Gastric cardia diverticuli may simulate a left adrenal mass;
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those of the posterior wall can herniate through an area of dorsal mesentery
and fuse with the left posterior body wall. If the latter form occurs during
organogenesis, they can indent Gerota’s fascia and disect between the left
adrenal gland and kidney. Size ranges from 1–3 cm, however larger sizes
have been reported. The majority remains asymptomatic however perfora-
tion, bleeding, aggravation of esophageal reflux and cancer formation have
been reported. Though uncommon, gastric diverticular disease can be a sig-
nificant cause of morbidity if complications occurs and should be part of the
differential diagnosis when investigating upper gastrointestinal symptoms.
Methods: Bibliography 1. Schweiger F, Noonan J: An unusual case of
Gastric Diverticulosis: American Journal of Gastroenterology 1817–1819,
1991 2. Thomschke D, Gockel I, Lorenz D: Gastrointestinal: Gastric Di-
verticula: Journal of Gastroenterology and Hepatology 227–228, 2004 [fig-
ure1][figure2]
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Effect of Prokinetics (PK) on Gastric Emptying (GE) and Symptoms
in Placebo-Controlled Trials of Gastroparesis: A Systematic Analysis
Preet Bagi, MD, Michael D. Crowell, PhD, Nicholas J. Talley, MD, Michael
P. Jones, MD∗. Division of Gastroenterology, Northwestern University,
Chicago, IL; Division of Gastroenterology, Mayo Clinic, Rochester, MN
and Division of Gastroenterology, Mayo Clinic, Scottsdale, AZ.
Purpose: PK are typically given to pts with sxs attributed to abnormal GE.
However, the relationship between sxs and GE is poor and most studies have
methodological limitations. To better understand PK efficacy in the treatment
of pts with abnormal GE, we conducted a systematic literature review.
Methods: MEDLINE, MeSH and Cochrane databases were searched for
RCTs in adults published prior to 5/07. Primary search terms were “gastro-
paresis,” “prokinetic,” as well as specific PKs. Included trials were ≥2 wks,
placebo-controlled (PLA) and used validated GE methods. Studies without
raw data were excluded. Changes in sxs and GE rates were calculated for
PK and PLA as the difference between BL and treatment scores.
Results: 14/92 identified studies met inclusion criteria. 7/14 included BL
and post-treatment sx and GE assessment: cisapride(4); levosulpiride(2) and
motilin against KC 11458(1). 7/14 met inclusion criteria but did not measure
GE after treatment: cisapride(1); metoclopramide(4) and motilin agonist
ABT-229(2). The trials included 685 pts with 185/685 in studies reporting
BL and post-treatment sxs and GE. Median (95% CI) percent change in
sxs from BL for PLA was 27%(18–38%). Median net therapeutic gain of
PK over PLA for sx scores from BL was 20%(−0.04–34%). Median net
therapeutic gain for indiv PK classes was 12% for cisapride/levosulpiride,
32% for metoclopramide and 2% for motilin agonists (Fig.). PLA was assoc
with a 7%(3–13%) improvement in GE rate and net therapeutic gain of PK
over PLA for improvement in GE rates was 14%(4–18%). The correlation
(rs) of net therapeutic change in sx scores with net therapeutic change in GE
rate was 0.36(P = 0.44).
Conclusion: There are limited data to support the concept that improving
GE improves attributed sxs. The greatest sx relief occurs with agents that
also exert central antiemetic effects. Pure PK such as motilin agonists offer
little beyond PLA for sx improvement. The clinical utility of GE studies
requires critical reappraisal.[figure1]
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Expression of MUC5AC and TFF1 in Intestinal Metaplasia Subtypes
Byung Wook Kim, MD, Lee-So Maeng, MD, Kyoung-Mee Kim, MD, In-Sik
Chung, MD∗. Internal Medicine, The Catholic University of Korea, Seoul,
Republic of Korea and Pathology, The Catholic University of Korea, Seoul,
Republic of Korea.
Purpose: Several studies have shown that type III intestinal metaplasia (IM)
is associated with an increased risk of malignant transformation. In other
studies, alterations of the expression pattern of mucins and trefoil peptide
have been described in carcinomas as well as in their precursor lesions. The
aim of this study was to evaluate the expression of MUC5AC and TFF1 in
different subtypes of IM.
Methods: Endoscopic gastric biopsies at antrum and body were obtained
from 70 patients with functional dyspepsia and endoscopic IM. Alcian blue
(pH2.5)/periodic acid-Schiff and the high iron diamine technique were used
to classify the subtypes of IM. Immunoreactivity for MUC5AC and TFF1
was observed in different types of IM.
Results: IM was detected in 136 samples. Type I was detected in 47 samples,
type II in 40 samples, and type III in 49 samples. MUC5AC and TFF1 are
highly expressed in incomplete IM (Fig.).
Conclusion: Type II and type III IM seems to be more common in Koreans
than in Westerns. This may be associated with high incidence of gastric
cancer in Koreans. MUC5AC and TFF1 expression may not be coexpressed
in any of the different types of IM.[figure1]
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Clinical Presentation and Endoscopic Management of Dieulafoy’s
Lesions in an Urban Community Hospital
SriKrishna Nagri, Sury Anand, Yashpal Arya∗. Gastroenterology,
Brooklyn Hospital Center, Brooklyn, NY and Gastroenterology, Wyckoff
Heights Medical Center, Brooklyn, NY.
Purpose: Dieulafoy’s lesion consists of a small sub-mucosal artery that
protrudes through a tiny mucosal defect and is an uncommon but important
cause of major gastrointestinal bleeding. The aim of this retrospective study
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was to identify rates of occurrence, common clinical and endoscopic features
and to review the outcome of endoscopic management of Dieulafoy’s lesions
in the upper GI tract in an urban community hospital setting.
Methods: Endoscopic data from EGDs done at Wyckoff Heights Medical
Center, Brooklyn, NY between 2000 and 2006 were reviewed to identify
patients with Dieulafoy’s lesions. Demographic data, medical history, exam-
ination findings, lab data, endoscopic findings and details of therapy for these
15 patients treated for Dieulafoy’s lesions were reviewed retrospectively.
Results: Dieulafoy’s lesions were documented to be the cause of bleeding in
approximately 1% of patients presenting with gastrointestinal bleeding while
they were detected in only 2 patients when the indication was other than
active GI bleeding. When we analyzed EGDs performed in patients above
age 65 presenting with gastrointestinal bleeding, prevalence approached 10
percent. The most common location of the lesion was the body of stomach
(seven), followed by the cardia (four) and the esophagus (two). One patient
had this lesion in the fundus and one patient in the duodenal apex. All the
patients were initially treated endoscopically with epinephrine injection, in
eight cases heater probe was applied following epinephrine and endoscopic
clips were applied in two cases. All but one of the patients did well in near and
intermediate term follow-up (Average follow-up period of 18 months). One
patient died of multi-organ failure during the same hospital stay. Average
length hospital stay was 7 days.
Conclusion: Community hospital gastroenterologists and endoscopists
should be aware that Dieulafoy’s lesions are a not so uncommon cause of up-
per GI bleeding among elderly patients. It accounted for 10% of acute upper
GI bleeding in elderly in our study. Early accurate diagnosis through emer-
gent endoscopy and endoscopic therapy, especially in patients with multiple
co-morbid conditions, is very effective and life saving.
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Contained Duodenal Perforation Manifesting as a Cystic Mass Can Be
Managed Non-Surgically
Purna C. Kashyap, MD, Sahil Mittal, MD, Rami Hawari, MD∗. Internal
Medicine, University of Texas Medical Branch, Galveston, TX.
Purpose: Perforation of duodenal ulcer presents as an acute abdomen, with
diffuse peritonitis. We report a rare case of contained duodenal perforation
that was managed nonsurgically.
Case report: A 48 year old female with chronic back pain on rofecoxib
and ibuprofen presented with epigastric pain radiating to the right abdomen
for 2 weeks, emesis and low grade fever. She had a 20 pack year history of
cigarette smoking and drank 2 beers a day. Examination revealed a hemody-
namically stable, febrile patient with epigastric tenderness but no guarding.
There was no ascites and the bowel sounds were normal.
Work-up: Blood work was unremarkable except for leucocytosis. There was
no pneumoperitoneum on X-ray. CT scan showed 7.3 × 6.5 × 4.6 cm cystic
mass adjacent to the pancreas. EGD showed purulent discharge from an ulcer
bed in the anterior wall of the duodenal bulb and extrinsic compression of
the duodenum. Antral biopsies showed no evidence of H. pylori.
Management: She was kept nil by mouth and started on nasogastric suc-
tioning; treated with intravenous proton pump inhibitor and broad spectrum
antibiotics; and was closely followed by surgeons. She recovered without
complications in 1 week.
Conclusion: This case highlights the following points: Consider perforated
duodenal ulcer whenever there is inflammatory cystic mass in relation to the
head of pancreas. Endoscopy confirms diagnosis in such cases. Although
most patients with perforated duodenal ulcer require surgical closure, pa-
tients with a contained perforation could be managed successfully without
surgery.[figure1][figure2]
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Case Report: Zantac 300 mg BID Controls Gastric Acid Secretion vs
Nexium 75 mg BID in a Patient with Gastric Bypass and Clinically
Significant Vomiting
Sheila Rodriguez-Stanley, PhD, Susan Riley, RN, Philip B. Miner, Jr., MD∗.
The Oklahoma Foundation for Digestive Research, Oklahoma City, OK.
Purpose: This is a 48-year-old female who has had a Roux-en-y gastric
bypass, with an anastomotic ulcer causing pain and vomiting, which pre-
cludes adequate nutrition. She is on TPN with a venting PEG tube surgically
placed. The patient has had a recent onset of epigastric pain and vomiting.
Our aims were: 1) To assess 24-h baseline gastric acidity in the stomach, 2)
To compare Zantac 300 mg BID and Nexium 40 mg BID regarding control
of gastric acidity, and 3) To assess symptom improvement on both regimens.
Methods: Patient was scheduled for three 24-h gastric pH-monitoring ses-
sions at least 10 days apart: baseline, after 5 days of Nexium 40 mg BID,
and during 1st day dosing with Zantac 300 mg BID. The dual pH probe was
advanced into the stomach across the PEG tube at 20 cm so that both sensors
were placed in the stomach. During each pH monitoring, patient consumed
her usual small meals throughout the day and underwent her usual 16-h TPN
feedings from 1800 to 1000 the next morning.
Results: Patient had 3 episodes of vomiting while off acid suppressive med-
ication. Acid was present throughout the 24-h, with mean pH of 1.5 and 2.0
(sensors 1, 2). The gastric pH was above 4 for 0 and 6% of the time (sensors
1, 2). Although only 1 episode of vomiting was reported, Nexium did not
alter mean gastric pH (1.1 and 1.8; sensors 1, 2), with 0 and 10.3% of the
time pH > 4 (sensors 1, 2). After BID dosing with Zantac 300 mg, 2 episodes
of vomiting occurred, and mean 24-h gastric pH was increased to 2.6 and
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2.8. Gastric pH > 4 for 61.7 and 69.7% of the time. During TPN infusion,
gastric pH > 4 for 0 and 8% of the 16 hour period during baseline, 0 and
14% on PPI, with an increase to 24 and 4% of the time on Zantac. While off
TPN, gastric pH was > 4 for 0 and 2% of the time on no acid suppression,
0 and 3% of the time on PPI and increased to 68 and 83% on Zantac.
Conclusion: Although TPN increases gastric acid production and decreases
gastric pH as evidenced by baseline 24-h gastric acidity, BID dosing with
Zantac 300 mg, and not Nexium 40 mg BID, improves gastric acidity in
this patient. This suggests that 1) surgical alteration of the stomach so that
food bypasses the stomach dampens the meal-related acid secretion that is
necessary for maximal PPI effect; 2) H2RA’s which do not depend on food-
induced burst acid secretion are more effective in this patient; and 3) pain is
likely due to secondary ischemic anastomotic stricture and not acid induced.
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Fasting Gastric Leptin Levels Are Elevated in Diabetics Independent
of BMI
Benjamin Young, MD, Jatin Roper, MD, Michelle Mourad, MD, Asalia Z.
Olivares de Perez, MS, Guillermo I. Perez-Perez, DSc, Zhiheng Pei, MD,
PhD, Martin J. Blaser, MD, Fritz Francois, MD, MSc∗. Medicine, NYU
School of Medicine, New York, NY; Medicine, University of California San
Francisco, San Francisco, CA and Medicine, Beth Israel Deaconess
Medical Center, Boston, MA.
Purpose: Leptin produced by adipocytes is involved in the regulation of
weight as well as energy expenditure. Leptin is also produced by the gastric
epithelium and may play a role in metabolism. The association of gastric
leptin with diabetes has not been evaluated in humans. Our aim was to
evaluate both plasma and gastric leptin levels in diabetics compared to non-
diabetics.
Methods: Patients referred for upper endoscopy were prospectively enrolled
after a 12-hour overnight fast. Patients with documented Hemoglobin A1C
levels >5 were classified as diabetic (DB+), while all other non diabetics
(DB-) served as controls. A detailed medical history, height, and weight were
obtained, and BMI was calculated. Serum was collected, and biopsies were
obtained from the antrum, and fundus. Leptin levels in plasma and gastric
biopsy samples were determined by specific ELISA, and gastric concentra-
tions were normalized according to biopsy protein (pg/mg protein). To avoid
confounding due to H. pylori’s known effect on gastric leptin, H. pylori+
individuals were excluded from further analysis.
Results: Among the 278 enrolled individuals 169 (60%) tested H. pylori+
and were excluded. Among the 101 H. pylori negative individuals; 20 were
diabetic (DB+) with mean age of 66 ± 10 years and 81 were non-diabetic
(DB-) with mean age of 63 ± 12 years. The mean BMI was significantly
higher in the DB+ group compared to the DB- group (31 ± 5 vs. 28 ± 5,
P = 0.003). Although it was correlated with BMI (r = 0.59, P < 0.001),
plasma leptin levels did not differ significantly between the DB+ and DB-
groups. Antral leptin also correlated with BMI (r = 0.23, P = 0.024) but
levels were significantly higher in the DB+ compared to the DB- group
(median 127 pg/mg IQR (50–173) vs. 105 pg/mg (68–244); P = 0.006). The
positive association remained significant in a multivariate logistic regression
analysis controlling for age, sex, ethnicity, and BMI (P = 0.029).
Conclusion: Plasma leptin is correlated with BMI but does not distinguish
diabetics from non-diabetics. In contrast, antral leptin is elevated in diabetics
independent of BMI. Further evaluation of the role of gastric leptin and its
receptor in regulating the energy expenditure of diabetics is warranted.
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Gastric Lymphoma: The Vanishing Act
Krishna S. Kasturi, MD, Rajasekhara R. Mummadi, MD∗, Qing Zhao, MD,
PhD, Wendell Tang, MD, Shu-Yuan Xiao, MD. Internal Medicine,
University of Texas Medical Branch, Galveston, TX and Pathology,
University of Texas Medical Branch, Galveston, TX.
Purpose: Spontaneous regression (SR) is a well-known phenomenon of
various cancers, especially low-grade malignancies, and is referred to the
disappearance of cancer cells without specific anti-cancer therapy. Diffuse
large B cell lymphoma (DLBL) is an aggressive malignant neoplasm that
can be fatal if left untreated. We report a case of SR of a gastric DLBL which
is considered to be an extremely rare occurrence.
Case Presentation: A 40 year-old man, with a history of HIV, EBV, and
CMV infections presented with abdominal pain, nausea and vomiting. En-
doscopic examination (EGD) revealed a deep ulcer in the anterior wall near
the antrum of the stomach, and an adjacent 5-mm satellite nodule. The pa-
tient’s ulcer had perforated through the bowel wall and adhesions with the
liver capsule were noted. Biopsy of the gastric ulcer and nodule showed dif-
fuse infiltrate of immature large lymphocytes, positive for CD20, BCL6 and
lambda light chains, and negative for CD3 and kappa that were diagnostic
for DLBL. Bone marrow biopsy was negative and a nuclear scan showed
uptake only at the gastric ulcer region. One month after the EGD biopsy,
a subtotal gastrectomy was performed and the entire gastrectomy specimen
and all possible lymph nodes were submitted for histopathological analysis.
Immunohistochemistry stains for Helicobacter pylori/EBV/CMV antigens
were all negative in both biopsy and gastrectomy specimens. Intriguingly, no
residual lymphoma was identified anywhere in the gastrectomy specimens.
PCR DNA profiling confirmed that the EGD biopsy and the gastrectomy
specimens were from the same patient. During the 1 month period between
the biopsy and gastrectomy, the patient had only received daily Omeprazole,
11 days of antidepressive drugs, and 3 days of Acyclovir for a herpes skin
infection.
Discussion: SR of gastric DLBL is considered to be extremely rare and
prior such reported cases involved use of either eradication therapy for H.
pylori or histamine-2 receptor antagonists. None of these were used in our
patient. Various humoral and immune-regulatory mechanisms, including
the induction of an immune response secondary to trauma resulting from
biopsies have been proposed to explain the concept of SR of cancers, but the
topic is widely speculative even today.
Conclusion: Further elucidation of the process of SR might offer the pos-
sibility of finding a cure even for aggressive cancers with currently fatal
outcomes.
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Cobiprostone Is a Type-2 Chloride Channel Activator That Protects
Against NSAID-Induced Cellular Damage
John Cuppoletti, PhD∗, Katrin Mende, PhD, Danuta H. Malinowska, PhD,
Ryuji Ueno, MD. University of Cincinnati, Cincinnati, OH and Sucampo
Pharmaceuticals, Inc., Bethesda, MD.
Purpose: Cobiprostone is being clinically tested as a protectant against non-
steroidal anti-inflammatory drug (NSAID)-induced ulcers, and the present
study is to determine the cellular and molecular basis of protection by co-
biprostone against NSAID-induced cellular damage.
Methods: T84 cells were grown to confluence on solid supports. The effects
of cobiprostone on indomethacin-induced changes in intracellular Ca2+ lev-
els ([Ca2+]i) using Indo-1/AM (a dye that measures [Ca2+]I), and the effects
of cobiprostone on mitochondrial membrane potential using JC-1 (a dye that
monitors mitochondrial membrane potential), were tested. The effects of co-
biprostone on indomethacin-induced cytochrome c release, cyclic AMP, and
cell death and regrowth were also investigated.
Results: Five hundred (500) µM indomethacin caused an immediate in-
crease in [Ca2+]i, which became irreversible (calcium deregulation) af-
ter approximately 30 minutes. One hundred (100) nM cobiprostone was
shown to protect against indomethacin-induced increases in [Ca2+]i, and
caused a reversal of indomethacin-induced calcium deregulation. How-
ever, cobiprostone did not prevent or reverse the increase in ([Ca2+]i
caused by indomethacin in the presence of different Cl− channel block-
ers, including diphenylamine-2-carboxylate (DPC), niflumic acid or 4,4’-
diisothiocyanatostilbene-2,2’-disulfonic acid (DIDS), suggesting that the
protective effects of cobiprostone are due to activation of Cl− channels.
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Cobiprostone has only a small effect on cAMP levels in T84 cells, precluding
a role of cAMP in the protective action of cobiprostone. Indomethacin caused
depolarization of the mitochondrial membrane potential. Cobiprostone pro-
tected against indomethacin-induced depolarization of mitochondrial mem-
brane potential and reversed the loss of mitochondrial membrane potential.
Cobiprostone was also shown to protect against cytochrome c relocation
from mitochondria into the cytoplasm, which is associated with apoptosis.
Finally, in a novel long-term assay using T84 cell cultures, cobiprostone
reduced indomethacin-induced cell death and promoted cell regrowth.
Conclusion: Activation of Cl− channels may underlie the protective effects
of cobiprostone in protection against NSAID-induced damage. The results
further indicate that cobiprostone has the potential to be of benefit against
NSAID-induced cell death.
This research was funded entirely by Sucampo Pharmaceuticals, Inc.,
Bethesda, MD.
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Is There Improvement over Years in the Diagnostic Accuracy of
Endoscopic Ultrasound in Evaluating T-Staging of Gastric Cancers? A
Meta-Analysis and Systematic Review
Srinivas R. Puli, MD, Jyotsna Batapati Krishna Reddy, MBBS, Matthew L.
Bechtold, MD, Mainor R. Antillon, MD, Jamal A. Ibdah, MD∗.
Department of Gastroenterology and Hepatology, University of
Missouri-Columbia, Columbia, MO.
Purpose: Prognosis and modality of treatment in patients with gastric can-
cers depends on the tumor T-staging, particularly with the emerging of novel
endoscopic therapeutic modalities such as endoscopic submucosal dissec-
tion. The published data on the effect of changes in Endoscopic Ultrasound’s
(EUS) technology over time on the accuracy of T-staging in patients with
gastric cancers have been varied.
Aim: To evaluate the affect of EUS technology over accuracy in T staging
of gastric cancers.
Methods: Study Selection Criteria: Only EUS studies confirmed by
surgery were selected. EUS criteria used for T staging were: T1- the tu-
mor invades the lamina propria or submucosa, T2- the tumor invades but
does not extend beyond the muscularis propria, T3- the tumor invades the
perigastric tissues, and T4- the tumor invades adjacent structures.
Data collection & extraction: Articles were searched in Medline, Pubmed,
Ovid journals, and Cochrane control trial registry. Two reviewers indepen-
dently searched and extracted data.
Statistical Method: Meta-analysis for the accuracy of EUS was analyzed by
calculating pooled estimates of sensitivity, specificity, likelihood ratios, and
diagnostic odds ratio. Pooling was conducted by both the fixed and random
effects models.
Results: Initial search identified 1,620 articles, of these, 360 relevant articles
were selected and reviewed. 20 studies (N = 1750) which met the inclusion
criteria were included in this analysis. Pooled accuracy data for T staging
over last two decades is shown in table 1. All the pooled estimates calculated
by fixed and random effect models were similar. The P for chi-squared
heterogeneity for all the pooled accuracy estimates was >0.10.
Conclusion: EUS has excellent sensitivity and specificity in accurately diag-
nosing the T-stage in a patient with gastric cancer. Over the last two decades, a
significant improvement were noted in the specificity and sensitivity of EUS
in diagnosing the early (T1) stage of the tumor. EUS should be strongly
considered for T staging of gastric cancers.[figure1]
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Endoscopic Ultrasound’s Diagnostic Accuracy in Detecting Distal
Metastasis of Gastric Cancers: A Meta-Analysis and Systematic
Review
Srinivas R. Puli, MD, Jyotsna Batapati Krishna Reddy, MBBS, Matthew L.
Bechtold, MD, Mainor R. Antillon, MD, Jamal A. Ibdah, MD∗.
Department of Gastroenterology and Hepatology, University of
Missouri-Columbia, Columbia, MO.
Purpose: Distal metastasis in patients with gastric cancer predicts prognosis
and guides therapy. The published data on accuracy of endoscopic ultrasound
(EUS) for diagnosing distal metastasis (M1) in patients with gastric cancers
has been inconsistent.
Aim: To evaluate the accuracy of EUS in diagnosing distal metastasis of
gastric cancers.
Methods: Study Selection Criteria: Distal metastasis was defined as metas-
tasis to peritoneum, liver, cervical lymph nodes, celiac axis lymph nodes, or
abdominal lymph nodes.
Data collection & extraction: Articles were searched in Medline, Pubmed,
Ovid journals, and Cochrane control trial registry. Two reviewers indepen-
dently searched and extracted data.
Statistical Method: Meta-analysis for the accuracy of EUS was analyzed
by calculating pooled estimates of sensitivity, specificity, likelihood ratios,
and diagnostic odds ratios. Pooling was conducted by both fixed and random
effects models. The heterogeneity of studies was tested using Cochran’s Q
test based upon inverse variance weights.
Results: Initial search identified 3630 reference articles, in which, 346 rele-
vant articles were selected and reviewed. Four studies met the inclusion cri-
teria and data for EUS accuracy to diagnose distant metastasis was extracted
from those studies. The pooled sensitivity to diagnose distal metastasis was
73.2% (95% CI: 63.2–81.7). EUS specificity was 88.6% (84.8–91.7). The
positive likelihood ratio to diagnose distal metastasis was 17.2 (2.8–106.3)
and the negative likelihood ration was 0.4 (95% CI: 0.2–0.7). The diagnostic
odds ratio of EUS to correctly diagnose distal metastasis was 60.9 (95% CI:
8.2–463.7). The SROC curve showed an AUC of 0.98 with a standard error
(SE) of 0.005. This curve showed a Q value of 0.94 with a SE of 0.0. All the
pooled estimates, calculated by fixed and random effect models, were simi-
lar. The P for chi-squared heterogeneity for all the pooled accuracy estimates
was >0.10.
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Conclusion: For distant metastasis, though the number of studies with data
was smaller, the pooled specificity is high but the sensitivity is not as high.
Though EUS is not designed to detect all areas of distal metastasis, im-
provements in technology or diagnostic criteria are needed to enhance the
sensitivity.
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Incidence of Endoscopic Gastric and Duodenal Ulcers (GDUs) in
Randomized Placebo-Controlled NSAIDs Trials: A Meta-Analysis
Yuhong Yuan, MD, Changcheng Wang, MD, Richard H. Hunt, MD, FRCP,
FRCPC∗. Gastroenterology, McMaster University Health Science Centre,
Hamilton, ON, Canada and 2nd Affiliated Hospital of Sun Yet-Sen
University, Guangzhou, China.
Purpose: GI safety of NSAIDs is often evaluated by comparison with
placebo in clinical trials. The incidence of GDUs in placebo arms may re-
flect background noise and influence interpretation of the relative safety
of NSAIDs. We investigated the incidence of GDUs in placebo-controlled
NSAIDs trials over three decades.
Methods: Randomized placebo-controlled trials of NSAIDs from 1975 to
2006 were systematically reviewed. Trials required endoscopy before and
after treatment.
Results: Thirty-six studies met inclusion criteria with treatment duration of
6.5 days to 24 weeks. 3.43% (98/2861) GDUs were reported in placebo arms
overall [1.04% in healthy volunteers (HV) vs. 3.93% in OA/RA patients,
P = 0.002]. GDU rate in placebo arms was 0 (0/83), 4.20% (35/833), and
3.24% (63/1945) in studies from 1975–1989, 1990–1999 and 2000–2006,
respectively (P > 0.05). In univariate analysis, pooled ulcer rate on placebo
was significantly higher in studies with mean age ≥60 yr (4.14% vs 2.59%);
treatment duration ≥4 weeks (3.85% vs 0.95%); OA/RA patients vs HV
(3.93% vs 1.04%); patients with previous GI events (4.12% vs 0.83%);
subjects with <10 mucosal erosions at baseline vs normal mucosa (3.85%
vs 1.13%) (P < 0.05). No significant difference was seen with cotherapy
with vs. without low-dose aspirin/corticosteroids (3.79% vs 2.64%). 11.85%
(N = 8125) GDUs were reported in all NSAIDs (nsNSAIDs + coxibs +
CINOD) treated subjects (68 arms) from 1990 to 2006, and GU rate was
3-fold higher than DU (8.48% vs 2.84%). GDU rate in all NSAIDs users
declined after 2000 (13.26% vs 11.33%); the decrease of GDUs in nsNSAIDs
users was significant (20.08% vs 15.82%); no significant change was seen
with coxibs. Overall, the incidence of GDUs in nsNSAIDs arms (17.06%)
was significantly higher than in coxib (5.00%) or placebo arms (3.43%);
GDU rate in coxib arms was significantly higher than in placebo (5.00% vs
3.43%) (P < 0.05).
Conclusion: Endoscopic GDU rate in placebo arms has not changed over
the last 3 decades. Treatment duration, previous GI events, age and baseline
mucosal damage are associated with increased GDUs. GU was predomi-
nant in NSAIDs-associated ulcers. nsNSAIDs are associated with a higher
GDU rate than placebo or coxibs, regardless of risk factors. The GDU rate
significantly decreased after 2000, which may be due to increasing coxib
use for high risk patients, and also because high risk patients are no longer
randomized to clinical trials.
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Syndrome Dyspepsia in the Population of Jakarta Indonesia
Marcellus Simadibrata, MD, PhD, Murdani Abdullah, MD, Ari Fahrial
Syam, MD, Ahmad Fauzi, MD, Dadang Makmun, MD, Chudahman
Manan, MD, Aziz Rani, MD∗, Eko Rahajeng, MD. Division of
Gastroenterology Department of Internal Medicine, University of
Indonesia, Jakarta, Indonesia; Division of Gastroenterology Department
of Internal Medicine, Universityf of Indonesia, Jakarta, Indonesia and
Ministry of Health Republic of Indonesia, Jakarta, Indonesia.
Purpose: One third of patients who go to the medical practitioners, and
half of the patients who go to the gastroenterologist have this syndrome
dyspepsia.
The purpose of this study is to know the epidemilogy of syndrome dyspepsia
in the population of Jakarta indonesia and other factors related to syndrome
dyspepsia.
Methods: This epidemiological study was done with interview method to
1645 patients that represent all of the Jakarta’s population. The selection of
patients using the cluster random sampling in which every area represented
by one area and the patient was interviewed randomly. Syndrome dyspepsia
was defined if there are symptoms of epigastric pain and epigastric discom-
fort lasting for more than 1 month. Analysis was done by stata program
after corrected with the certain factor. Interview was done on every selected
patient after being given informed consent by the person who were in charge
to do the interview and by signing the consenting form.
Results: The proportion of syndrome dyspepsia was 58.1%. The most fre-
quent patient in syndrome dyspepsia was female 59.1%, mean of age 44.05
yo ± 10.72 years. The frequent symptom were nausea 30.1%, epigastric
pain 28.7% etc. In the dyspeptic patients, 25.85% patients has a smoking
habit, 2.58% patients consumed alcohol. There was a trend to get syndrome
dyspepsia in patients who have anxiety, depression, who consumed NSAID
(P = 0.000).
Conclusion: The proportion of syndrome dyspepsia in Jakarta population
was 58.1%. Syndrome dyspepsia was more frequent in female, who has
anxiety, depression and who consumed NSAID.
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A Cost Analysis of GERD and Dyspepsia in Iran
Mohammadreza Rezailashkajani, MD, Delnaz Roshandel, MD, Sepideh
Shafaee, MD, Mohammad Reza Zali, MD, FACG∗. Health Informatics,
Research Center for Gastroenterology and Liver Disease, Tehran, Islamic
Republic of Iran.
Purpose: Gastroesophageal reflux disease and dyspepsia are both highly
prevalent conditions and cause considerable health care utilizations and
costs. The main goal of this study was to evaluate the health care utilizations
and costs of these two gastrointestinal diseases in Iran.
Methods: A consecutive sample of 501 patients who referred for upper
endoscopy to a private outpatient gastroenterology clinic in central Tehran
was investigated if they have gastroesophageal reflux disease (having heart-
burn or regurgitation on a weekly basis for at least the past 3 months with
symptom onset at least 12 months prior to the study) or dyspepsia (based
on Rome II criteria) from May 2005 to January 2006. Then a questionnaire
were filled for GERD and dyspepsia patients to determine the frequency of
health resource utilization (physician visit, hospitalization, laboratory tests,
imaging studies, and drugs) and productivity loss (days off work or with low
functionality) due to related symptoms in the past 12 months. Societal per-
spective was used and cost per person per year was estimated in purchasing
power parity dollars (PPP$).
Results: The cost of disease per person per year for patients who had only
GERD, only Dyspepsia, and both GERD and dyspepsia were about 271.40,
286.90, and 408.10 PPP$ respectively. There was no statistically significant
difference in the cost of disease per person per year among patients having
only GERD, only dyspepsia, and both GERD and dyspepsia. The direct
cost of disease included 63.50%, 61.38%, and 46.98% of total cost among
patient who had only GERD, only dyspepsia, and both GERD and dyspepsia
respectively while cost of chemical drugs and imaging tests were the largest
parts of it. There was also no statistically significant difference in cost of
disease between GERD patients having esophagitis or not.
Conclusion: GERD and dyspepsia are associated with a considerable health
economic burden to society considering their high prevalence in the popula-
tion. As medication is the dominant cost factor, more investigation to find the
best treatment strategy seems extremely necessary for decreasing the costs.
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Survival in Gastric Cancer Patients: Univariate and Multivariate
Analysis
S166 Abstracts
Bijan Moghimi Dehkordi, MSc of Epidemiology∗, Azadeh Safaee, MSc of
Epidemiology, Babak Noori Nayer, MD, Mohammad Reza Zali, MD,
FACG. Cancer, Research Center of Gastroenterology and Liver Diseases,
Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic
of Iran.
Purpose: The aim of this study was to analysis the survival of patients
diagnosed with gastric cancer and the factors which modify prognosis.
Methods: Retrospective cohort study was performed on total patients diag-
nosed with gastric cancer registered in the Taleghani hospital cancer registry
(Tehran, Iran) between 21 December 2001 and 21 December 2006. Infor-
mation about demographic and clinical variables were gathered from the
cancer registry forms and patients were followed up by telephone contact.
The Kaplan-Meier statistical method was employed to determine the prob-
ability of survival and log-rank test to compared those. Cox regression was
used to determine prognosis factors. P < 0.05 was considered as statistically
significant. All calculations was carried out by SPSS (version13.0) statistical
software.
Results: Of 746 patients, 38.6% were dead. The mean and median survival
time was 42.45 and 22.8 months, respectively and five-year survival rate was
25.3%. With univariate analysis, Age at Diagnosis, type of treatment, type
of first treatment, pathologic stage, tumor size, histology type, pathologic
primary tumor and pathologic distant metastasis were significant prognostic
factors related to overall survival time. Tumor size greater than 35 mm (HR =
2.12) and have a metastasis (HR = 2.04) were found to be the statistically
significant poor prognostic factors related to survival in multivariate analysis.
Conclusion: According to results, early detection of cancer in lower ages and
in primary grades of tumor, is important to increase patient’s life expectancy.
133
Assessment of Reasons for Non-Adherence to Nonvariceal Upper
Gastrointestinal Bleeding (NVUGIB) Guidelines
Sean M. Hayes, PsyD, Ian A. Hawes, BSP, Martin Dawes, MD, Alan
Barkun, MD∗. Performance and Education Research Division, AXDEV
Group Inc, Canada; Medical Affairs, AstraZeneca Canada Inc, Canada;
Department of Family Medicine, McGill University, Canada and Division
of Gastroenterology, McGill University, Canada.
Purpose: Nonvariceal upper gastrointestinal bleeding (NVUGIB) causes
substantial morbidity and mortality. Guidelines for the management of pa-
tients with NVUGIB exist, but are inconsistently applied by healthcare
providers, resulting potentially in sub-optimal care and patient outcomes.
A needs assessment was carried out to assess healthcare providers’ barriers
to the implementation of these guidelines in Canada.
Methods: Semi-structured key informant interviews were conducted by tele-
phone with a sample of 22 selectively sampled healthcare professionals ac-
tively practicing with NVUGIB patients, including emergency room physi-
cians [ER], intensivists [ICU], gastroenterologists [GI], nurses, and hospital
administrators. Participants were chosen from a representative sample of six
community or academic-based hospitals across Canada that had taken part
in a national Canadian Audit on the management of NVUGIB. The inter-
view questions addressed themes related to specific prioritized NVUGIB
guidelines.
Results: Participants reported substantive gaps in the implementation of
NVUGIB guidelines including (a) substantive lack of knowledge of the
specifics of the NVUGIB guidelines (ER, ICU, and nurses), (b) limited belief
in the value of guidelines (ER, ICU), (c) limited belief in the value of avail-
able tools to support implementation of specific guidelines (GI), (d) lack of
knowledge of the roles and responsibilities, as well as limited effective col-
laboration among respective healthcare professionals in the care of patients
with NVUGIB (ER, ICU, GI) (for example, lack of agreement amongst ER,
ICU and GI on a definition of “urgent endoscopy”), (f) variability of knowl-
edge and skills of healthcare professionals (for example, nurses’ knowledge
and skills in endoscopic procedures), and (g) perceived overuse of IV PPI
treatment with limited concern regarding cost or side effect implications (all
participants).
Conclusion: Knowledge, attitude, skill, behavioural, and contextual gaps
were found to impact healthcare professionals’ adherence to NVUGIB guide-
lines. In response to these findings a tailored multi-faceted educational and
behavioural intervention is being designed, and will be assessed in a national
cluster randomized clinical trial.
Research supported by AstraZeneca Canada Inc.
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Dyspeptic Symptoms in an Aspirin (ASA)-Using Population: Celecoxib
Versus Naproxen Plus Lansoprazole
Jay L. Goldstein, MD, Barbara J. Hunt, MS, Justin R. Boike, BS, Byron
Cryer, MD∗. Department of Medicine, University of Illinois at Chicago,
Chicago, IL; R&D, TAP Pharmaceutical Products Inc., Lake Forest, IL and
Department of Medicine, University of Texas Southwest Medical Center,
Dallas, TX.
Purpose: To evaluate new or existing dyspepsia-like symptoms in patients
taking ASA with either celecoxib or naproxen plus lansoprazole.
Methods: In a 12-wk prospective, randomized, double-blind trial, prevalence
of endoscopic ulcers was evaluated in 1045 subjects taking daily ≤325 mg
ASA and 200 mg celecoxib QD (CEL) or 500 mg naproxen BID with 30 mg
lansoprazole QD (NAP/LAN). At baseline and after 4, 8 and 12 wks of
treatment, dyspepsia symptoms were assessed using both a 4-point scale [0
(none) to 3 (severe)] and Severity of Dyspepsia Questionnaire (SODA).
Results: As previously reported, endoscopically confirmed prevalence
of gastroduodenal ulcers was 9.9% CEL (42/426) and 8.9% NAP/LAN
(38/428). Baseline mean combined dyspepsia scores (sum of severities for
abdominal pain, nausea, vomiting, and heartburn) were similar (CEL 1.8,
NAP/LAN 1.7), and the mean increase from baseline was greater in CEL
versus NAP/LAN at wks 4 (+0.7 vs +0.3, P = 0.012), 8 (+0.7 vs +0.5,
P = NS) and 12 (+0.8 vs +0.5, P = 0.043). Among those with dyspepsia
at baseline (212 NAP/LAN, 220 CEL), more subjects reported symptom
resolution with NAP/LAN versus CEL at wks 4, 8, and 12 (31 vs. 18%; 33
vs. 15%; and 32 vs. 19%, respectively; P ≤ 0.003). Among those without
dyspepsia at baseline, similar proportions developed new-onset dyspepsia
(36–42% CEL, 36–38% NAP/LAN). More subjects treated with NAP/LAN
reported improvement in heartburn and belching compared to those treated
with CEL at wks 4, 8, and 12 (P < 0.05). In the 299 subjects who completed
SODA, mean baseline scores were similar between the NAP/LAN and CEL
treatment groups (16.3 vs 15.8 pain intensity, 13.9 vs 14.0 nonpain symp-
toms, 14.1 vs 13.6 satisfaction, respectively). A greater mean improvement
from baseline in the nonpain symptoms scales was observed at wks 4 and
8 in NAP/LAN versus CEL (−0.5 vs. +0.4 at wk 4; −0.7 vs. +0.4 at wk
8; P ≤ 0.025 for each). There were no other significant differences between
NAP/LAN and CEL groups in SODA scores. There was no significant dif-
ference in the proportions of subjects who discontinued the study due to GI
symptoms (CEL 1.2% vs NAP/LAN 1.3%).
Conclusion: While the incidence of new-onset dyspepsia symptoms in both
groups of ASA-users was similar, subjects with baseline dyspeptic symptoms
improved to a greater extent with NAP/LAN than with CEL.
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Novel Biopsy Technique for Diagnosis of Gastric Subepithelial Lesions
Shashin Shah, MD∗, Mark J. Sterling, MD. Division of Gastroenterology
and Hepatology, UMDNJ-New Jersey Medical School, Newark, NJ.
Purpose: Adequate diagnosis of the etiology of gastric subepithelial lesions
seen on upper endoscopy is challenging secondary to current techniques
used to obtain a representative biopsy specimen. Traditional tunnel biopsy
has a reported yield of 17% compared to EUS-FNA which has a yield of
80%. In this study we describe a series of patients in which an alteration of
the traditional tunnel biopsy technique yields improved rates of diagnosis
of the etiology of gastric subepithelial lesions.
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Methods: Seven consecutive patients with gastric subepithelial lesions seen
on routine endoscopy were referred for evaluation. On initial endoscopic
ultrasound, none of the subepithelial lesions were cystic or contained blood
vessels as confirmed by Doppler ultrasound.
Subsequently, endoscopy was performed on each of the seven subepithelial
lesions. Using Cook forceps, five to seven biopsies were taken from the
same area of the mucosa in the standard tunnel fashion. Following this, an
altered technique was used in which closed biopsy forceps were placed in
the previously biopsied area and while applying pressure, the forceps were
opened and closed such that the mucosa could be further separated and
dissected. After doing this five to seven times, the closed forceps were able
to penetrate the mucosal surface and move safely into the lesion. Multiple
biopsies were then taken directly from the subepithelial tissue.
Results: A diagnosis of the etiology of the gastric subepithelial lesion was
obtained in six of the seven cases (86%). The diagnoses included lipoma (2
cases), leiomyoma (2 cases), GIST (1 case), and a pancreatic rest (1 case).
In the remaining case, spindle cells were obtained but a leiomyoma or GIST
could not be definitively diagnosed. No acute complications including bleed-
ing, perforation or infection were observed in any of the seven patients.
Conclusion: An altered technique using standard biopsy forceps to dissect
the epithelial mucosal surface followed by direct biopsy of the submucosal
tissue yielded an etiology in 86% of the cases studied. In larger case series
to date an etiology using standard tunnel biopsy technique was found in only
17% of cases. This technique offers an advantage to EUS-FNA, which yields
similar rates of diagnosis of etiology of subepithelial lesions, in that histology
can be obtained. Larger case series with a randomized prospective trial would
be required to validate the results obtained using this technique in our series
as compared to traditional tunnel biopsy and EUS-FNA techniques.
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Can Polaprezinc Be Attributed To Reduce the Risk of Gastric
Carcinogenesis in Helicobacter pylori-Positive Young People?
Toshifumi Mitani, Dr, Daisuke Shirasaka, Dr∗, Hideyuki Miyachi, Dr,
Toshio Tanaka, Dr, Naohisa Yahagi, Dr. Department of Gastroenterology,
Toranomon Hospital, Tokyo, Japan and Department of Gastroenterology,
Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
Purpose: Polaprezinc, an insoluble zinc complex of L-carnosine, was de-
veloped for gastric ulcer treatment and reported to inhibit the development
of Helicobacter pylori (H. pylori) induced gastritis. Metallothionein (MT),
which is inducible by dietary zinc (Zn), has been proven to sequester reactive
oxygen species and reduce tissue damage. Furthermore, our previous study
reported high MT expression in gastric mucosa attenuated H. pylori-induced
gastritis and reduced the risk of gastric carcinogenesis.
This study investigates the effect of polaprezinc on H. pylori-induced gastritis
and evaluates the relationship with gastric MT levels in young people.
Methods: Fifteen H. pylori-positive subjects (HP+, 26.3 ± 3.8 years) and 15
negative subjects (HP−, 25.6 ± 2.4 years) were entered in this study. RT-PCR
of MTIIa was performed in antral biopsy samples. Severity of gastritis was
evaluated according to the updated Sydney System. The same assessment
was repeated after polaprezinc 150 mg b.d. (Zn 33.9 mg included) was
received for 4 weeks. Serum Zn was examined in all patients before and
after polaprezinc medication.
Results: Good compliance was obtained without complications in both
groups. Serum Zn was significantly high in both subjects after polaprez-
inc medication but within the normal range. MT expression was higher in
HP− than HP+ and had a negative correlation with severity of gastritis be-
fore medication. Four weeks after polaprezinc medication, MT expression in
HP+ was significantly recovered but HP− had no significance. The severity
of gastritis in HP+ was relatively restored but not significant.
Conclusion: Four weeks after polaprezinc medication, MT expression in H.
pylori-positive gastric mucosa is recovered and H. pylori-induced gastritis is
relatively restored. Polaprezinc may be attributed to reduce the risk of gastric
carcinogenesis through the reinforcement of MT expression in young people.
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A Patient with Gastric Hodgkin’s Lymphoma
Kaleem M. Rizvon, MD, Omer K. Masood, MD, Nausheer Khan-Bitni,
MD, Paul J. Mustacchia, MD∗. Gastroenterology, Nassau University
Medical Center, East Meadow, NY.
Purpose: A 58-year-old black male presented to the hospital with constant
abdominal pain. The pain was upper abdominal in location without any
radiation, achy in character associated with a 30 lb. weight loss over the
prior six months. The patient denied nausea, vomiting, changes in bowel
habits, melena or hematochezia. Past medical history was significant for
history of Stage III B Hodgkin’s Lymphoma diagnosed more than 18 years
ago at which time, the patient was treated partially with chemotherapy. He
had subsequently refused further treatment.
Physical Examination was significant for a large fixed, non-tender abdom-
inal mass measuring 15 × 10 cm filling the entire abdomen. Rectal ex-
amination was negative for blood or melena. Lab evaluation revealed mi-
crocytic, hypochromic anemia later characterized to be iron deficient with
normal liver tests and renal function. CT abdomen (Fig. 1) showed a large
retroperitoneal mass with compression of the stomach and infiltration of the
spleen. Upper Endoscopy showed a large friable, ulcerated mass in the fun-
dus. Colonoscopic examination was normal. Histopathological examination
showed diffuse infiltration of the tumor cells into the mucosa, submucosa
and muscularis propria which stained positive for CD 15 and CD 30 (Fig. 2).
A histopathological diagnosis of classical type Hodgkin’s Lymphoma was
made.
Gastric Lymphomas are relatively uncommon comprising less than 10% of
all gastric neoplasms. At least 60% of the gastrointestinal lymphomas arise in
the stomach. Non Hodgkin’s Lymphomas represent 2–8% of all gastric ma-
lignancies. Hodgkin’s disease of the stomach, either primary or secondary to
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systemic disease is rare. Gastrointestinal involvement by Hodgkin’s disease
is reported in fewer than 10% of patients with residual Hodgkin’s disease at
autopsy.[figure1][figure2]
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Iron Pill Gastropathy: A Case Report and Review of the Literature
Nirmal Kaur, MD, Bryan N. Coffing, MD, Joel Greenson, MD, William D.
Chey, MD∗. Division of Gastroenterology, University of Michigan, Ann
Arbor, MI and Department of Pathology, University of Michigan, Ann
Arbor, MI.
Purpose: Despite the widespread use of oral iron supplements, the entity
of “iron pill gastritis” has remained largely unrecognized in the Gastreon-
terology literature. Our patient is an 85 year-old man who presented with a
several-month history of melena. Pertinent medications included daily lan-
soprazole 30 mg and aspirin 81 mg. He had been taking ferrous sulfate
325 mg twice daily for iron deficiency anemia for the prior 8 weeks. History
included coronary artery disease, compensated congestive heart failure, and
hypertension. The patient had a history of an upper gastrointestinal bleed
2 years prior to this evaluation, secondary to aspirin and celecoxib use. Up-
per endoscopy revealed a large esophageal ulcer, multiple duodenal ulcers,
and no gastric ulcers. Testing for Helicobacter pylori was negative. Physical
exam revealed stable vital signs and no orthostasis. Examination was normal
except for guaiac-positive stool. Hematocrit was stable at 36%. Subsequent
upper endoscopy revealed a normal esophagus and multiple sessile diminu-
tive polyps in the gastric fundus. A non-bleeding 4 × 8 mm gastric ulcer with
pigmented material was found in the gastric body. Histopathologic evalua-
tion of gastric biopsies obtained from the ulcer revealed foveolar hyperplasia
with abundant granular brown pigment, consistent with iron pill gastropathy.
The patient was placed on twice daily oral lansoprazole at a dose of 30 mg,
and oral iron was discontinued. A follow-up upper endoscopy performed one
month later revealed no evidence of active ulceration. The patient has been
maintained on lansoprazole 30 mg twice daily and aspirin 81 mg daily. He
has experienced no further gastrointestinal problems. Iron injury is thought
to result from a direct corrosive action on the gastrointestinal mucosa. A
previous study found gastric ulcers in association with oral iron use. Histol-
ogy of these biopsies showed heavy iron deposition within ulcer granulation
tissue, in connective tissue, and in blood vessels of the lamina propria. Ul-
ceration appeared to have preceded the initiation of iron therapy, suggesting
that iron use exacerbated a pre-existing condition. Few clinicians are aware
that oral iron has been associated with gastropathy that can lead to the de-
velopment of peptic ulcer disease. Our case provides an illustration of this
rare but important entity and highlights the importance of co-morbidity and
concomitant use of low dose aspirin.
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Usefulness of Microvascular Diagnoses of Early Gastric Cancer Using
Magnifying Endoscopy
Tomofumi Tanaka, Yasushi Oda∗, Makoto Yasunaga, Eisuke Kaku, Kiwamu
Hasuda, Seiji Ito, Hideyo Goto, Masahiro Hattori. Gastroenterology,
Hattori G.I. Endoscopy and Oncology Clinic, Kumamoto, Japan.
Purpose: In 2001, Yao K et al. reported the characteristics findings
for intestinal-type gastric cancer were an irregular microvascular pattern
(IMVP), and the presence of a Demarcation Line (DL) using magnifying
endoscopy, between the cancerous and non-cancerous mucosa.
The aim of this study was to examine the following two items regarding
the usefulness of microvascular diagnoses of intestinal-type gastric cancer.
(1) Findings of an index that shows, in a more concrete form, IMVP. (2)
Significance of IMVP and DL to serve in the diagnosis of its gastric cancer.
Methods: Period was December 2006 through May 2007. Subjects were 17
cases of intestinal-type gastric cancers which showed depressed in shape,
while control group consisted of 72 cases of benign erosions. Microvascular
patterns were divided into four types: irregularity of vessel arrangements;
vessel caliber disparities; vascular density increases; vessel multibranchings.
If any one of these categories applied, then diagnosis of IMVP was made.
Gastric cancer diagnostic precision were determined according to sensitivity,
specificity, odds ratio (OR), and positive predictive value (ppv).
Results: I. All four categories showed high percentages for gastric cancer,
with statistically significant differences.
II. The gastric cancer diagnostic precision for each vascular pattern were
investigated. As for specificity and ppv, all four categories showed roughly
90% or higher.
As for sensitivity, however, only irregularity of vessel arrangements were as
high as 60%.
III. Used as diagnostic precision in gastric cancer, DL sensitivity and speci-
ficity were 82% (14/17) and 53% (29/55), while IMVP one were 59% (10/17)
and 99% (71/72). DL (+) of ppv for gastric cancer was 26% (14/53), while
IMVP (+) of it was 77% (17/22). The DL OR was 4.4 (14×35/3×37), while
the IMVP one was 101.7 (10×71/7×1)
Conclusion: 1. As an index for grasping IMVP, irregularity of vessel ar-
rangements was useful.
Both the specificity and ppv of it showed high levels of gastric cancer diag-
nostic precision. Sensitivity, however, was 60%. 2. If we perform a biopsy of
depression lesion in which DL is confirmed, we may expect to detect approx-
imately 80% of gastric cancer, but may cause the biopsy of approximately
50% of benign erosion. As for IMVP, while approximately 60% of gastric
cancer will be identified, it is surmised that the findings show that benign
erosion will be mostly unobserved.
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Relationship of Symptoms to Quality of Life in Patients with
Gastroparesis
Pooja Sukhwani, MD, Siva Doma, MD, Henry P. Parkman, MD∗.
Medicine, Temple University School of Medicine, Philadelphia, PA.
Purpose: Understanding symptom severity and the effects of symptoms on
quality of life (QOL) in patients with gastroparesis may provide clinicians
useful information to help guide treatment. The aim of this study was to
identify specific gastrointestinal symptoms that most severely affect QOL in
patients with gastroparesis.
Methods: New patients with gastroparesis in 2006 were given the Patient
Assessment of Upper Gastrointestinal Symptoms (PAGI-SYM) which eval-
uates symptom presence and severity using a 6-point Likert scale from 0
(none) to 5 (very severe) and the Patient Assessment of Upper Gastroin-
testinal Disorders-Quality Of Life (PAGI-QOL) questionnaire which covers
five domains (daily activity, diet, psychological, clothing, relationship) and
associates higher scores with worsening QOL with responses ranging from
scale of 0–5. The PAGI-SYM questionnaire is a 20-item tool, which includes
the 9 Gastroparesis Cardinal Symptom Index (GCSI) questionnaire.
Results: During 2006, 53 new patients with gastroparesis were seen and
filled out both questionnaires. The average age was 40 years, 42 patients
were female (79%), and 17 patients had diabetic gastroparesis (32%). The
GCSI score was 26.3 ± 1.2 and correlated with PAGI-QOL score (r =
0.47). The predominant symptom reported by the patients on the PAGI-SYM
questionnaire was nausea (23 pts; 43%) followed by vomiting (13 pts; 25%)
and abdominal pain (9 pts; 17%). Patients with vomiting as the predominant
symptom had the highest (worse) QOL score (3.28±0.25) when compared to
nausea (3.01 ± 0.21, P = 0.41) and abdominal pain (2.99 ± 0.44, P = 0.55).
Of the five QOL domains, the psychological QOL domain (3.68 ± 0.32) was
highest in patients with vomiting as the predominant symptom, whereas the
diet QOL domain was the highest in patients with the predominant symptom
of nausea (3.61 ± 0.26) or abdominal pain (3.48 ± 0.32). In these patients
with gastroparesis, the QOL questions associated with the worst QOL scores
were: 1) Avoided certain types of food (4.13 ± 0.03); 2) Concern about what
you can and cannot eat (4.11 ± 0.02); and 3) Frustrated about not being able
to do what you wanted to do (4.06 ± 0.03).
Conclusion: In patients with gastroparesis, although nausea was the most
prevalent predominant symptom, vomiting was associated with the worst
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QOL score. Nausea and abdominal pain affected the diet domain, whereas
vomiting affected psychological domain the most. Use of the PAGI-SYM
and PAGI-QOL questionnaires helps to understand the impact of symptoms
on quality of life in patients with gastroparesis.
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Aspirin Use in the Setting of Acute Myocardial Infarction and Peptic
Ulcer Bleeding Does Not Increase the Rebleeding Rate
Justin Cheung, MD, Jennifer Rajala, MD, Daniel Moroz, Gurpal Sandha,
MD∗. Medicine, University of Alberta, Edmonton, AB, Canada.
Purpose: To determine if the use of aspirin or other anti-platelet agents is
associated with adverse outcomes in patients with a bleeding peptic ulcer in
the setting of acute myocardial infarction.
Methods: Patients with a bleeding peptic ulcer and a concurrent acute my-
ocardial infarction were evaluated from 2 tertiary care centers between 1999
and 2007. The pattern of aspirin (ASA) use was determined. Peptic ulcer
rebleeding rates and cardiac outcomes were assessed.
Results: 102 patients were evaluated retrospectively. Seventy nine patients
(78%) received ASA and 46 patients (45%) received clopidogrel during
an acute myocardial infarction. 34 patients (33%) were continued on ASA
therapy after peptic ulcer bleeding whereas the remaining 68 patients (67%)
had ASA held temporarily or discontinued during hospitalization. Patients
who had ASA continued were more likely to have had a STEMI, IIb/IIIa
inhibitor use, percutaneous coronary intervention and/or CABG (P < 0.05).
There was no difference in the rebleeding rate from ulcers with low risk
stigmata between patients who continued ASA compared to those who had
ASA held or discontinued (4.0% vs 7.5%). Among patients with high risk
stigmata, there was also no difference in the rebleeding rate (23% vs 29%).
When ASA was continued, there was no increase in the rebleeding rate when
clopidogrel was used or not (7% vs 11%). Mortality tended to be lower in
patients who had ASA continued compared to those who had ASA held or
discontinued (9% vs 16%).
Conclusion: Aspirin does not appear to increase the rate rebleeding in pa-
tients presenting with peptic ulcer bleeding in the setting of an acute my-
ocardial infarction.
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Implanted Gastric Pacemaker for the Treatment of Diabetic
Gastroparesis: A University Hospital Experience
Rassa Shahidzadeh, MD, John D. Mellinger, MD, Bruce V. MacFadyen,
MD, Ayaz J. Chaudhary, MD, FACG∗. Section of
Gastroenterology/Hepatology, Medical College of Georgia, Augusta, GA
and Section of Gastrointestinal Surgery, Medical College of Georgia,
Augusta, GA.
Purpose: Investigate the efficacy of gastric pacemaker implantation in the
treatment of diabetic gastroparesis (DGP) in symptom control and quality
of life.
Methods: Eleven gastric pacemaker implantation surgeries were performed
from October 2004 to August 2006 at Medical College of Georgia. Five pa-
tients with clearly documented DGP who failed medical management were
treated with gastric pacemaker implantation surgery and available for study.
Mean age was 39.4 years old. Three of the patients were women. Average
duration of symptoms prior to pacemaker impantation was 4.7 years. Patients
were followed for an average of 20 months after gastric pacemaker implan-
tation. Several symptom scoring systems including Total Symptom Score
(TSS) and Vomiting Frequency Score (VFS) were measured in all patients at
baseline and after implantation. Patients were evaluated for subjective signs
of illness according to self-reported VFS (range, 0 to 4) and TSS, measuring
for nausea, vomiting, bloating, abdominal pain, and anorexia (range, 0 to 24
for severity and frequency each). Complications related to surgery or im-
planted device and hospitalizations related to gastroparesis were recorded.
Dependence on medications for motility, nausea, and pain were also recorded
before and after implantation.
Results: All patients except one had significant improvement in symptoms
scores following gastric pacemaker implantation. Mean improvement in TSS
was 54% for severity and 21% for frequency of symptoms. Total TSS mean
improvement was 37%. VFS mean improvement was 61%. Two patients re-
quired at least one hospitalization for DGP-related symptoms after implanta-
tion. One patient required repeat surgery for pacemaker lead dislodgement.
Overall, patients required less antiemetics, motility agents, and pain medi-
cation after implantation. No deaths occurred in these five patients.
Conclusion: Gastric pacemaker implantation provides clinical improve-
ments in patients with DGP who have failed medical treatment.
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Gastric Electrical Stimulation for Gastroparesis – The Temple
Experience
Varadarajan Subbiah, MD, Sean Harbison, MD, John Meilahn, MD,
Vanessa Lytes, CRNP, Robert S. Fisher, MD, Henry P. Parkman, MD∗.
Medicine, Temple University, Philadelphia, PA.
Purpose: Gastric electric stimulation (GES) is used to treat patients with
medically refractory gastroparesis. The aims of this study were: 1) to review
our experience with GES for the treatment of refractory gastroparesis; and 2)
to determine if there are factors that might favorably impact clinical outcome.
Methods: 100 patients with refractory gastroparesis have been treated with
Enterra GES (Medtronic, Inc) at our institution over the last 6 years. At
follow-up visits, patients were given the Patient Assessment of GI Symp-
toms (PAGI-SYM) questionnaire and asked to rank their symptoms using a
Clinical Global Patient Assessment scale (CGPA) ranging from –7 (a very
great deal worse) to +7 (a very great deal better).
Results: Of 100 patients implanted, 75 patients still had an active stimulator
at the time of this analysis. 8 patients have died; 14 patients had stimulators
explanted due to infection (4), gastrectomy (2), lead/pacer erosion (3), MRI
(4), shocks (1); and 3 patients had no follow-up. Average follow-up was 318
days (range 34–1473 days). 63 out of 75 patients (84% per protocol; 63%
intention to treat) currently receiving GES reported symptomatic improve-
ment, 6 remained the same, and 6 worsened. Average CGPA score of the 75
patients was 3.2 ± 0.4 (SEM), falling in the “somewhat better” category. The
33 patients with diabetic gastroparesis had a higher average CGPA score than
the 42 patients in the idiopathic group (4.2 ± 0.5 vs 2.4 ± 0.5; P = 0.005).
The 61 patients with nausea/vomiting as the primary symptom had a higher
CGPA score than the 14 patients with abdominal pain (3.4 ± 0.4 vs. 2.3 ±
0.8; P = 0.020). The 32 patients using narcotic analgesics regularly had a
lower CGPA score than the 43 patients in the non-narcotic group (2.3 ± 0.6
vs 3.9 ± 0.5; P = 0.014). Among the diabetics, those with nausea/vomiting
as their primary symptom felt more improvement than patients with abdom-
inal pain (4.5 ± 0.5 vs. 3.3 ± 0.8; P = 0.027). The same trend was present
among the idiopathic population (2.4 ± 0.6 vs. 0.7 ± 1.2; P = 0.034).
Conclusion: The majority of patients undergoing gastric electric stimula-
tion stated their symptoms were better than prior to stimulation. Patients
with nausea/vomiting as primary presenting symptom responded better than
patients with abdominal pain. Diabetic gastroparetics responded better than
patients with idiopathic gastroparesis. Importantly, this study has delineated
three factors that appear to impact on a favorable clinical response – etiology,
predominant symptom, and narcotic use.
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Ischemic Gastritis; an Unusual Cause of Abdominal Pain and Gastric
Ulcers
Steven Kaptik, MD, Yasser Jamal, MD, B. Kay Jackson, MD, Claudio R.
Tombazzi, MD∗. Medicine, University of Tennessee, Memphis, TN.
Purpose: Ischemic gastritis is considered to be an uncommon cause of gas-
trointestinal symptoms. We are presenting a patient with history of severe
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abdominal pain, celiac artery stenosis and endoscopic findings of ischemic
gastritis, who had complete resolution of pain and endoscopic findings after
celiac artery stenting.
Methods: CASE REPORT:
Results: Patient was a 70 yrs old white male who presented to the emer-
gency room (ER) with a history of chronic epigastric pain for the last several
months. The pain was sharp, moderate in intensity, non-radiated and was
associated with nausea. For the last two weeks before coming to ER the
pain was more intense and persistent. He reported a 100 Lbs of weight loss
for the last five months. Significant past medical history included coronary
artery disease, type II diabetes and hypertension. The physical examination
revealed a soft, nondistended abdomen with mild tenderness in epigastrium
and right upper quadrant. Pertinent laboratory studies included a white blood
cells count of 15,000 with 14% bands and an elevated creatinine of 2.4 mg/dl.
The CT scan of the abdomen showed wide spread atherosclerosis. An upper
endoscopy revealed extensive gastric erythema with large superficial, irreg-
ular ulcers through the body and antrum. Biopsies obtained for the gastric
ulcers were interpreted as ulcerative gastritis by the pathologist. Because of
the endoscopic findings, severe atherosclerosis by abdominal CT and no res-
olution of symptoms with standard treatment with proton pump inhibitors,
patient underwent a magnetic resonance angiogram. The study showed sig-
nificant stenosis of the celiac trunk with atherosclerotic calcification at origin
of celiac axis and superior mesenteric artery. Patient subsequently under-
went stenting of the celiac artery. After the stent was placed, the patient had
a complete resolution of his abdominal pain. A repeated upper endoscopy
performed six weeks later showed almost complete healing of the gastric
mucosa.
Conclusion: This case represents an unusual cause for abdominal pain and
gastric ulceration. The diagnosis of ischemic gastritis should be considered in
patient with a vascular disease history and unexplained upper gastrointestinal
symptoms.
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Comparisons of Alimentary Tract Transit Times among Normal
Subjects from Two Multicenter Trials Using SmartPill Wireless
pH/Pressure Recording Capsule: Its Clinical Implication
I. Sarosiek, MD, J. Sarosiek, MD, S. Rao, MD, H. Parkman, MD, B. Kuo,
MD, J. Lackner, PsyD, L. Katz, MD, M. Sitrin, MD, W. Chey, MD, W.
Hasler, MD, J. DiBaise, MD, J. Wo, MD, K. Koch, MD, J. Semler, PhD, R.
McCallum, MD∗. KUMC, Kansas City, KS; UI, Iowa City, IA; TU,
Philadelphia, PA; MGH, Boston, MA; UB, Buffalo, NY; MC, Scottsdale,
AZ; UL, Louisville, KY; UM, Ann Arbor, MI; WFU, Winston Salem, NC
and The SP Corp., Buffalo, NY.
Purpose: The SmartPill (SP) wireless pH/pressure recording capsule was
approved for assessment of gastric emptying (GET) based on data from a
gastroparesis (GP) trial. In a separate study colonic transit time (CTT) mea-
sured by SP in patients with chronic constipation (CC) was similar to CTT
measured with Sitzmarks. These trials encompassed not only two separate
sets of healthy volunteers, but also two different test meals.
Aim: To compare GET, small bowel transit time (SBTT), CTT, and whole
gut transit time (WGTT) from CC and GP trials utilizing different test meals.
Methods: In CC study, 68 (32 F, mean age of 37 y) and in GP trial 50 (22 F,
mean age of 35 y) controls were enrolled. While fasting, subjects swallowed
the SP with a bar (SmartBar; 260 kcal,) and Sitzmarks capsule in the CC
trial; or, with standardized meal (99TcEggbeaters, 255 kcal,), in GP study.
The WGTT was measured from the time of ingestion of the SP until an
abrupt loss of signal. The time from ingestion to rise of pH exceeding pH
4.0 was defined as GET. A sudden drop of 1 pH unit >5 min. was regarded as
an ileo-caecal (I-C) arrival. By subtracting GET from I-C time, SBTT and
CTT were determined. Based on statistical analysis with Mann-Whitney
Test, results are presented as median and 25%-75% range.
Results: The median WGTT in both groups was similar (27.1, 22.1–45.5
hrs, vs. 28.0, 23.2–36.8 hrs range; P = 0.872). The CTT was also similar
(20.7, 15.4–38.1 hrs, vs. 18.4, 13.0–27.7 hrs range; P = 0.315). The SBTT
in controls from the CC trial was 25% faster (3.5, 2.8–4.4 hrs range) than
GP study (4.7, 3.8–6.2 hrs range; P = 0.001). The GET in CC trial was 17%
faster (2.9, 2.5–3.8 hrs range) than in GP trial (3.5, 3.0–3.9 hrs range; P =
0.045). Of note: the mean values for GET, SBTT, CTT, and WGTT in both
groups were similar.
Conclusion: 1. SP technology represents a new test for assessing TT within
all segments of the GI tract. 2. The difference in the median values of GET
and SBTT is because the data was not normally distributed in CC trial. 3.
Our results provide a reference for normal values for the office use of SP in
the future where SmartBar will be the standard meal.
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Primary Prevention by Omeprazole 20 mg Daily of the Adverse
Gastrointestinal Effects of Short-Term Non-Steroidal
Anti-Inflammatory Drug Use in Healthy Subjects: A Randomized,
Double-Blind, Placebo-Controlled Study
Jay C. Desai, BA, Shefali M. Sanyal, BA, Tyralee Goo, BA, Ariel A. Benson,
BA, Carol A. Bodian, DrPH, Kenneth M. Miller, MD, Lawrence B. Cohen,
MD, James Aisenberg, MD∗. Internal Medicine (Gastroenterology),
Mount Sinai School of Medicine, New York, NY and Anesthesia
(Biostatistics), Mount Sinai School of Medicine, New York, NY.
Purpose: To evaluate in healthy, episodic NSAID users the effectiveness
of omeprazole at the U.S. approved OTC dose (20 mg daily) as primary
prevention of the adverse gastrointestinal effects of short-term NSAID use.
Methods: We performed a double-blind, single-site study of generally
healthy subjects aged 50–75 who had no specific risk factor for NSAID-
related complications, did not take chronic NSAIDs, and had no endoscopic
lesions at baseline. Subjects were randomized to a 6.5 day treatment of
naproxen (NPX) 500 mg BID plus omeprazole (OMP) 20 mg QD or NPX
500 mg BID plus placebo, after undergoing a baseline endoscopic examina-
tion and symptom questionnaire. The primary endpoint was the incidence of
gastroduodenal ulceration (GDU) after completion of treatment; secondary
endpoints included a change in dyspepsia score [by Severity of Dyspepsia
Assessment (SODA)], and the incidence of GDU and/or > 5 erosions. Gas-
troduodenal biopsies were taken at both endoscopies for future molecular
analysis for H. pylori (HP) evaluation.
Results: A total of 70 subjects were randomized and 66 completed the study.
Age, sex, and HP status were similar between the arms. Fewer subjects in the
NPX plus OMP group developed GDUs compared to the NPX plus placebo
group (11.8% vs. 46.9%, RR = .25, P = .002). This protective effect of
co-prescription of omeprazole was greatest in subjects infected with HP.
NPX plus OMP was also associated with a significant decrease in the risk
of GDU and/or >5 erosions. By SODA testing, subjects taking NPX plus
OMP experienced less dyspepsia than those taking NPX plus placebo. HP
was associated with an increased risk of ulcer in the NPX plus placebo group,
while dyspeptic symptoms were associated in both groups with endoscopic
ulcers.
Conclusion: (1) OMP at the U.S. approved OTC dosage of 20 mg daily re-
duces but does not eliminate gastroduodenal ulcers and dyspeptic symptoms
caused by short-term non-selective NSAID use in 50–75 year old intermit-
tent NSAID users; (2) the benefit of co-prescription is greatest in HP-positive
individuals; (3) endoscopic injury related to NSAIDs is associated with dys-
peptic symptoms, and is increased in HP-positive subjects.
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Adjudication of GI Events from Long-Term Placebo-Controlled Trials
Provides Evidence for GI Safety and Tolerability of Celecoxib vs
Placebo
N. Arber, MD∗, D. Lieberman, MD, M. Bertagnolli, MD, E. Hawk, MD, A.
Rustgi, MD, T. Wang, MD, J. Coindreau, MD, C. Eagle, MD, B. Levin, MD.
Tel Aviv MC, Israel; Oregon University; Harvard Cancer Center; National
Cancer Inst.; University of Pennsylvania; Columbia University; Pfizer Inc,
and University of Texas.
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Purpose: To analyze incidence of clinically significant upper or lower gas-
trointestinal adverse events (CSULGIEs) of celecoxib vs placebo, using ad-
judicated gastrointestinal (GI) data from the Adenoma Prevention with Cele-
coxib (APC), and Prevention of Colorectal Sporadic Adenomatous Polyps
(PreSAP) studies.
Methods: In APC, 2035 subjects were randomized to celecoxib 200 mg
BID, 400 mg BID, or placebo for 3 years. In PreSAP, 1561 subjects were
randomized to 400 mg QD or placebo for 3 years. Adverse events (AEs),
bleeds, perforations, obstructions or ulcers were evaluated up to 30 days last
dose by a blinded GI Endpoint Adjudication Committee (GIEAC). Subjects
with GI AEs, GI-related deaths, or Hb fall 3 g from baseline were included.
Time between first dose and CSULGIE was analyzed by a Cox proportional
hazards model, stratified by study, with aspirin as covariate. Age, gender,
clinical history were also analyzed.
Results: Of total population reporting AEs (N = 3588), 97 subjects met
inclusion criteria and were reviewed by the GIEAC. 54 were adjudicated
as having CSULGIEs (1.62% for celecoxib; 1.30% for placebo). Incidence
of CSULGIEs was higher among aspirin-users in both groups (2.99% vs
1.17% celecoxib; 2.83% vs 0.81% placebo). No significant difference was
shown in hazard ratio (HR) or relative risk (RR) of celecoxib vs placebo.
HR of celecoxib vs placebo was 1.24 with upper 0.025 CI at 2.21 (rejects
non-inferiority). There were no significant differences in RR of CSULGIEs
between treatments in either aspirin (RR 1.06, 95% CI 0.48, 2.34, P = 0.894)
or non-aspirin users (RR 1.44, 95% CI 0.64, 3.25, P = 0.374). Aspirin and
age were significant contributors of toxicity.
Conclusion: In this pooled analysis, testing for non-inferiority, incidence
of CSULGIEs was equivalent for celecoxib and placebo. Importantly, there
were few events and the analysis was underpowered. These findings support
celcoxib’s long-term GI safety and tolerability, and show long-term aspirin
use is associated with significant GI toxicity.
P-value HR 95% CI
Celecoxib NS 1.25 0.71–2.23
Aspirin 0.0006 2.63 1.52–4.57
Age (>65 y) 0.0366 1.79 1.04–3.08
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Effect of Helicobacter pylori Infection on Gastric Cancer Development
Marcelo L. Ribeiro, PhD∗, Waldemar Bartchewsky, Jr., MS, Mariana R.
Martini, MS, Marisa C. Alvarez, MS, Daisy M. Salvadori, PhD, Marcelo S.
Ladeira, PhD, Jose´ Pedrazzoli, Jr., PhD. Unidade Integrada de
Farmacologia e Gastroenterologia, Universidade Sa˜o Francisco, Braganc¸a
Paulista, SP, Brazil and Departamento de Clinica Medica, UNESP,
Botucatu, SP, Brazil.
Purpose: Evaluated the effect of H. pylori infection on COX-2, IL-1b, IL-8,
Bax, Bcl-2, MGMT and hMLH1 expression in patients with chronic gastritis
and gastric cancer.
Methods: Gastric biopsies were obtained from two hundred subjects, 155
with chronic gastritis (125 Hp positive and 30 Hp negative) and 45 with
gastric cancer. The expression of COX-2, IL-1b, IL-8, Bax, Bcl-2, MGMT
and hMLH1 was analyzed using real time RT-PCR, and allelic variants of
cagA and vacA were identified by PCR.
Results: mRNA expression of pro-inflammatory COX-2, IL-1b and IL-8,
cellular turnover Bax and Bcl-2, and DNA repair MGMT and hMLH1 genes
were significantly higher in H. pylori-infected patients than in uninfected
patients. The expression of IL-1b, IL-8, Bax, Bcl-2 and MGMT in gastric
adenocarcinoma tissues were not different from those detected in H pylori
negative patients. Regarding COX-2, we found that its mRNA levels were
higher than in uninfected patients; on the other hand hMLH1 expression was
significantly lower. The genotype cagA+/vacAs1 of H. pylori is related with
both, high degree of inflammation and the higher levels of mRNA expression
of COX-2, IL-1b and IL-8. The ratio Bax to Bcl-2 decreased significantly
in gastric adenocarcinoma tissue, which is correspondent with the findings
that apoptosis decreases in tumor tissues.
Conclusion: Our data showed that H. pylori infection up-regulate the ex-
pression of pro-inflammatory genes which increases the synthesis of ROS
causing DNA damage. The up-regulation of DNA repair enzymes observed
in infected patients seems to be a natural response against the increased pre-
mutagenic oxidative DNA adducts generated by the bacteria. Regarding the
cellular turnover, the bacteria could promote expressions of Bax, Bcl-2 and
COX-2, however it might play a different role in carcinogenesis. Initially
H. pylori could upregulate the expression of proapoptotic genes (Bax), and
this effect might be stronger than its upregulatory effect on Bcl-2. During
the development of cancer, upregulatory effects of H. pylori on antiapoptotic
genes (Bcl-2) and on promitogenic genes (COX-2) might counteract the pro-
apoptosis effects of Bax. Additionally, we showed a loss of mismatch repair
hMLH1 expression in patients with gastric cancer which may easily increase
the mutations rate, affecting the carcinogenesis and tumor progression.
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Does Increased Primary Resistance to Recommended Antibiotics
Really Affect Helicobacter pylori Eradication?
Christina C. Eclissato, MD, Sergio Mendonc¸a, PhD, Marcelo L. Ribeiro,
PhD, Jose´ Pedrazzoli, Jr., PhD∗. Clinical Pharmacology and
Gastroenterology Unit, Sa˜o Francisco University, Braganc¸a Paulista, SP,
Brazil.
Purpose: To evaluate the efficacy of two commonly employed treatments
for Helicobacter pylori infection and the impact of bacterial resistance to
antibiotics on eradication rate during a pharmacokinetic study of eradication
therapy.
Methods: Seventy-nine consecutive H. pylori-positive patients were ran-
domly enrolled to receive a 10-day treatment with either lansoprazole 30 mg
plus amoxicillin 1 g and clarithromycin 500 mg (all b.i.d., Group A, N =
40); or bismuth subcitrate 125 mg q.i.d. plus tetracycline 500 mg q.i.d and
furazolidone 200 mg b.i.d. (Group B, N = 39). Patients took the first dose of
the therapy on days 1, 5 and 10 under supervision at our facility. H. pylori
status was reassessed at least 60 days following completion of the therapy
and bacterial resistance to the antibiotics was investigated.
Results: Four patients from group A and 2 patients from group B were
lost to follow up. Both treatments resulted in similar H. pylori eradication
rate: 82.5%–77% (per protocol), 80.5%–73% (intention-to-treat) in Group
A and B, respectively (N.S.). Twelve patients in group A were resistant to
clarithromycin and in one of them resistance to and amoxicillin was also
present. In Group B there were only two patients with resistance to tetracy-
cline. No resistance to furazolidone was detected. Pre-treatment resistance
did not impact eradication rates for both groups.
Conclusion: Primary resistance to clarithromycin or amoxicillin previously
considered a potentially serious problem for the eradication of H. pylori
infection may be not as important as other factors such as compliance for
those patients using these drugs.
150
Helicobacter pylori Virulence Marker from an Area of High
Prevalence with Low Incidence of Gastric Carcinoma
Javed Yakoob, PhD∗, Shahab Abid, FCPS, Zaigham Abbas, FACG, Jafri
Wasim, FACG, Muhammad Islam, MSc, Rustam Khan, FCPS, Zubair
Ahmad, FCPS. Medicine, Aga Khan University, Karachi, Sindh, Pakistan
and Pathology, Aga Khan University, Karachi, Sindh, Pakistan.
Purpose: Helicobacter pylorus (H. pylori) infection leading to peptic ulcer
and gastric carcinoma is more frequent in developing countries. It is acquired
at an early age however, frequency of gastric carcinoma (GC) is low. In the
present study, we aimed to determine the tissue H. pylori virulence marker
cagA and vacA alleles and their association with clinical, endoscopic and
histological findings.
S172 Abstracts
Methods: Two hundred-forty patients with H. pylori infection established
by both rapid urease test and histology were studied. The symptoms of the
patients were recorded and biopsies (antrum and body) were evaluated his-
tologically. The cagA and vacA allelic status was determined by polymerase
chain reaction (PCR). Patients with GC were compared with non-GC.
Results: One hundred and fifty-nine (66%) were males. Abdominal pain
175 (73%) and anemia 21 (9%) were the main presenting features. On en-
doscopy, 169 (70%) had gastritis, 16 (7%) gastric ulcer, 37 (15%) gastric
carcinoma and 18 (8%) duodenal ulcer. CagA was positive in 125 (52%)
whileVacAs1a was positive in 163 (68%), VacAs1b 82 (34%), VacAm1 134
(56%) and VacAm2 122 (51%). On histology, acute on chronic inflammation
was present in 163 (68%) and chronic in 60 (25%). CagA was associated
with diagnosis of GC 29 (83%) P = 0.003, inflammation and metaplasia,
P = 0.01 and P < 0.001 respectively. CagA S1aM1 was positive in 21 (60%)
P < 0.001 and CagA S1a 23 (66%) P = 0.03 with GC. The vacA alleles
S1aM1 was positive in 22 (63%) P = 0.04, S1bM1 in 10 (29%) P = 0.01
with GC.
Conclusion: The majority of our patients presenting with abdominal pain
had cagA positive gastritis. Genotype CagA S1aM1 was more frequently
associated with GC. Further studies are required to look into the activity
of the cagA gene to explain the low incidence of gastric carcinoma in our
population.
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T Regulatory Cells Are Abnormal in Gastroparesis (GP)
Vikram Taruga, MD, William Johnson, PhD, Mark Runnels, MS, Phillips
Jenkins, MD, Gailen Marshall, MD, PhD, Thomas Abell, MD∗. Dept. of
Digestive Diseases, University of Mississippi Medical Center, Jackson, MS.
Purpose: We have previously shown that many patients with the symp-
toms of gastroparesis demonstrate coagulation abnormalities associated with
autoimmune markers, even in the absence of known autoimmune disease.
Many autoimmune conditions have associated immunoregulatory dysfunc-
tions that precede clinical manifestations, but, no controlled studies of cy-
tokines exist in GP.
Methods: To investigate the hypothesis that GP patients can have un-
suspected underlying immunoregulatory abnormalities, we quantitated T
regulatory cells in peripheral blood mononuclear cells (PBMC) from nine
symptomatic GP patients (2 m 7 f mean age 44 years) due to DM (N =
2), post-surgical (N = 1), or idiopathic disease (N = 6) and compared the
results to 25 normal controls. T regulatory 1 (TR1), TH3 cells and TH1/TH2
ratios were quantitated in PBMC from patients with GP and normal controls
by flow cytometry. TR1 cells were defined as CD4+CD25+FoxP3+IL-10+
while TH3 cells were defined as CD4+TGFb +. TH1/TH2 ratios were cal-
culated from TH1(CD4+IFNg +) and TH2 (CD4+IL-4+) values. Results
were compared by t-test and reported as mean and 95% CI.
Results: TR1 and TH3 cell numbers were both lower in patients with GP.
TH1/TH2 ratio was decreased in GP versus normal controls, (See table of
results).
Conclusion: GP patients have multiple T regulatory cell abnormalities, sim-
ilar to those seen in various allergic and autoimmune disorders. Both TR1
and TH3 were lower in GP compared to control. An altered TH1/TH2 ratio
(favoring TH2 predominence) response was also observed in GP patients,
consistent with an established immune imbalance. Further studies of T reg-
ulatory cells in GP seem warranted, and may offer help in understanding
the mechanisms of other reported inflammatory abnormalities often seen
in GP.
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Multiplex PCR To Detect H. pylori in MALToma and Its Role in
Treatment and Prognosis: A Case Series
Xiangwen Meng, PhD, Veerpal Singh, MD, Tat-Kin Tsang, MD∗. ENH
Research Institute, Evanston Northwestern Healthcare, Evanston, IL and
Cytokine Control 95% Conf GP 95% Conf P
CD4+/CD25++ 7.41 6.4–8.4 4.18 2.6–5.8 0.0014
IL-10 (TR1)
CD4+ TGFb (TH3) 0.94 0.8–1.1 0.63 0.4–0.9 0.051
CD4+ IFNg/IL-4 0.87 0.6–1.1 0.33 0.1–0.7 0.0205
Department of Medicine, Northwestern University, Feinberg School of
Medicine, Evanston, IL.
Purpose: Gastric mucosa-associated lymphoid tissue (MALT) lymphoma
develops in Helicobacter pylori-associated chronic gastritis. Current diag-
nostic techniques for H. pylori associated MALToma include CLO rapid
urease test, conventional PCR, histologic studies. However, these methods
are not very sensitive and do not provide accurate treatment guidance or
prognosis. To report a case series in which Multiplex PCR (MPCR) was
applied to detect H. pylori related MALToma and its use to guide treatment
and prognosis.
Methods: We performed MPCR in patients with a diagnosis of MALToma.
Patients were treated and followed till their MPCR reaction became negative.
Results: Four patients with a diagnosis of MALToma demonstrated MPCR
positive reactions with negative or positive CLO, culture and pathology for
H. pylori. In 2 patients, a negative MPCR reaction was used to determine
a treatment endpoint. In one patient, in spite of multiple treatment tissue
was negative for MPCR but positive for MALToma and it was therefore
determined that it might be due to evolved MALToma. In another patient,
the MALToma recurred after 9 months in spite of persisted negative MPCR.
These two patients with MALToma in spite of negative MPCR received
radiation and the MALToma was cured. (Table)
Conclusion: In all patients we noted that MPCR was very sensitive and
specific for diagnosis of H. pylori related MALToma. In all patients, MPCR
was utilized to determine treatment efficacy and prognosis.
After 2 weeks of Repeat 2 weeks of
Patients EGD Prevpac/ EGD Prevpac/ EGD Recurrence
Patient 1 +ve MALToma,
+ve CLO, +ve H.
pylori, +ve
MPCR
+ve MALToma,
−ve CLO, −ve H.
pylori, +ve
MPCR
−ve MALToma,
−ve MPCR
NO
Patient 2 +ve MALToma,
−ve CLO, −ve H.
pylori, +ve
MPCR
+ve MALToma,
−ve CLO, −ve H.
pylori, +ve
MPCR
−ve MALToma,
−ve MPCR (Plus
Flagyl)
Yes after 9
Months. Treated
with radiation,
MALToma
resolved
Patient 3 +ve MALToma,
−ve CLO, −ve H.
pylori, +ve
MPCR
−ve MALToma,
+ve MPCR
−ve MALToma,
−ve MPCR
NO
Patient 4 +ve MALToma,
−ve CLO, +ve H.
pylori, +ve
MPCR
+ve MALToma,
−ve MPCR
+ve MALToma,
−ve MPCR
?? Evolved
MALToma.
Treated with
radiation,
MALToma
resolved
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Helicobacter pylori (Hp) Seropositivity in Patients with Both Negative
Rapid Urease Test (CLO) and No Histopathological Evidence of Hp
Kishore Maganty, MD, Adarsh Varma, MD, Swetha Kandula, MD, Larry F.
Hughes, PhD, Jatinder P. Ahluwalia, MD∗. Division of Gastroenterology,
Internal Medicine, and Surgery, Southern Illinois University School of
Medicine, Springfield, IL.
Purpose: Gastric biopsies are obtained routinely during EGD for CLO and
histology. However, questions have been raised about a decreased diagnostic
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yield of CLO and histology in detecting this organism compared to the
original published reports for several reasons, including a gradual decrease
in Hp infection over the past decade and increase in the use of acid-reducing
medications. The aim of the study was to investigate the role of Hp serology
in patients with negative CLO and no histological evidence of Hp.
Methods: A total of 776 consecutive patients (age 18–95) who underwent a
CLO test at a large tertiary care center in the Midwest between July 2005 to
December 2006 were identified. Fifteen patients were excluded due to lack
of CLO test verification and 5 due to lack of availability of EGD report.
We reviewed the CLO results, EGD reports, available histology (routine
hematoxylin-eosin and/or thiazine stain), and aspirin and other NSAID use.
Available serology was then compared to CLO and histology in the detection
of Hp in patients with and without ulcers and erosions detected on EGD.
The results were analyzed with the binomial distribution using serology test
specificity of 92% provided by the manufacturer (Meridian).
Results: A total of 756 patients were studied: 441 (58.3%) males and 315
(41.7%) females (mean age: males, 59.86 years and females, 61.93 years).
Most patients were Caucasian (N = 669; 88.5%) with more outpatients
(N = 411; 54.4%) than inpatients (N = 345; 45.6%). CLO was positive in
52 (6.88%) patients and negative in 704 (93.12%) patients. Hp serology was
available in 91 patients of which 16 had it done more than 1 year prior to CLO.
In the remaining 75 patients, no gastric biopsies were done on 25 patients.
Of these 50, 49 patients had negative CLO and histopathology but 9 (18.4%)
had positive Hp serology. Exclusion of patients with Hp serology done more
than 4 weeks before or after the CLO identified 26 patients of which 6 had
positive Hp serology with this proportion (6/26) being significant, greater
than the false positive rate (P < 0.05).
Conclusion: CLO is positive in a small percentage of patients undergoing
EGD. Negative CLO and histology may not be sufficient to exclude infection
with Hp. Prospective studies assessing the role of Hp stool antigen testing
and PCR for Hp16S ribosomal DNA on gastric tissue are warranted in this
patient population.
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The Role of Flow Cytometry in the Diagnosis and Surveillance
of Gastrointestinal Lymphomas
Minhhuyen T. Nguyen, MD, Heba Durra, MD, David S. Weinberg, MD,
Harry S. Cooper, MD, Tahseen I. Al-Saleem, MD∗. Fox Chase Cancer
Center, and Temple University Hospital, Philadelphia, PA.
Purpose: We evaluate the accuracy of flow cytometry (FCM) using endo-
scopic biopsies in the diagnosis and surveillance of GI lymphomas.
Methods: We retrospectively analyzed 105 consecutive FCM results on 69
patients with suspicious GI lesions over 11-year period (1996–2007). Eigh-
teen tests (9 patients) were discarded due to inadequate cells for FCM. Of
the adequate specimens, 60 were initial-observation samples and 27 were
follow-up. FCM was compared to the combined group of H&E and IHC
morphology.
Results: Male:female ratio was 1:1, mean age 64.5 years (34–83) and mean
follow-up period 12.1 months (1–96). There were 54 gastric, 21 small bowel,
11 large bowel and 1 liver samples. All were obtained by cold biopsy forceps
except for 3 fine-needle aspirations. Lymphomas diagnosed included 17
MALT, 11 diffuse large B-cell, six follicular, three mantle cell and one
T-cell.
Overall, FCM alone compared to H&E and IHC showed sensitivity 91.4%:
95% CI [75.8%, 97.8%], specificity 90.4%: 95% CI [78.2%, 96.4%], positive
predictive value 86.5%: 95% CI [70.4%, 94.9%] and negative predictive
value 94.0%: 95% CI [82.5%, 98.4%].
Initial FCM results in 60 patients were 21 true positive, 35 true negative, 2
false positive and 2 false negative. One “false positive” had recurrent disease
a year later. Both false negatives had definite disease on further follow-
up. Analysis showed sensitivity 91.3%: 95% CI [70.5%, 98.5%], speci-
ficity 94.6%: 95% CI [80.5%, 99.1%], positive predictive value 91.3%: 95%
CI [70.5%, 98.5%] and negative predictive value 94.6%: 95% CI [80.5%,
99.1%].
Following therapy, 27 FCM results were 11 true positive, 12 true negative, 3
false positive, and 1 false negative. Two “false positives” had recurrent dis-
ease in surveillance (follow-up period: 1–6 months). Analysis showed sen-
sitivity 91.7%: 95% CI [59.8%, 99.6%], specificity 80.0%: 95% CI [51.4%,
94.7%], positive predictive value 78.6%: 95% CI [48.8%, 94.3%] and neg-
ative predictive value 92.3%: 95% CI [62.1%, 99.6%].
Conclusion: Flow cytometry is a highly accurate, affordable, quick and
widely available test for detecting lymphomas in GI endoscopic biopsies.
FCM can be routinely performed as a complementary test to H&E and IHC.
For a few discordant cases in which histology and FCM differ, possible
explanations are small number of biopsies, difficulty in correctly identifying
the involved sites, especially after therapy, and the elusive, complex nature
of lymphomas in general.
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Drug Utilization Review of Acid Suppressants for Bleeding and Other
Indications (Durable) – An Audit To Assess the Utilization of Proton
Pump Inhibitors and Histamine H2-Receptor Antagonists in Canadian
Hospitals
Alan Barkun, MD∗, Robert Enns, MD, Joseph Romagnuolo, MD, Tanja
Muller, MD, Bruce Kalmin, MD, Ian A. Hawes, BSP, Yao Lei, PhD. The
DURABLE Group of Investigators. Division of Gastroenterology, McGill
University, Canada; Division of Gastroenterology, University of British
Columbia, Canada; Division of Gastroenterology, Medical University of
South Carolina, and Medical Affairs, AstraZeneca Canada Inc, Canada.
Purpose: Inappropriate utilization of proton pump inhibitors (PPI) and
H2-receptor antagonists (H2RA) in inpatients is prevalent, but not
well defined due to a lack of standardized grading system of appro-
priateness. We undertook a national audit to better characterize this
situation.
Methods: For in-patients receiving a PPI or H2RA, demographic, clinical,
laboratory, endoscopic, and pharmacological data were collected. Drug reg-
imens were reviewed by experts using standardized adjudication rules. Regi-
mens included intravenous high dose continuous infusion PPI (IVci = bolus
followed by ci), bolus IV PPI (IVb), oral PPI, and IV or oral H2RA, and were
categorized as Endorsed (with dosing accuracy) or not recommended (based
on published guidelines), indeterminate (based on other publications), or not
recognized.
Results: Over 6 months, 1829 patients (age: 63.8 ± 16.9 yrs, 43% female)
were included from 12 institutions (6 academic and 6 community settings)
in 8 provinces. 28% were taking a PPI and 7% an H2RA prior to admission.
Mean length of stay was 15.3 ± 18.7 days. The top indication for PPI or
H2RA use was upper GI bleeding (UGIB) in 28.7%, of which 48% started
while in-hospital and 29% did not undergo endoscopy; the remainder did
within 41.4 ± 58.8 hrs of symptoms onset. Peptic ulcer was seen in 56.6%
(23% with high-risk stigmata).
Conclusion: Non endorsed use is noted in 48.3% Ivci, 36.6% Ivb, and 9.5%
PO PPI/H2RA, while correct dosing is common for endorsed indications
(98.6% Ivci, 85.3% Ivb, and 75.0% PO). These data will help design ap-
propriate educational and behavioural interventions to optimize in-hospital
prescribing of acid suppressants.
Research supported by AstraZeneca Canada Inc.
Categorization of both PPI and H2RA Use
Endorsed Not Not
% % correct Indeterminate Reccomended Recognized
[CI] dosing % [CI] % [CI] % [CI] N
IVci 48.3 98.6 1.4 48.3 2.0 147
[40.4, 56.3] [0.4, 4.8] [40.4, 56.4] [0.7, 5.8]
IVci 38.4 85.3 17.9 36.6 7.1 336
[33.4, 43.7] [14.1, 22.3] [31.6, 41.9] [4.8, 10.4]
PO 46.3 75.0 30.3 9.5 13.9 201
[39.4, 53.2] [24.4, 37.0], 61 [6.1, 14.3] [9.8, 19.4]
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Do Minorities Have a Worse Outcome from Primary Gastric Cancer
Than Whites?
Thomas Birris, MD, Andrew Albert, MD, MPH, Sherri Yong, MD, Stephen
Sontag, MD∗. Gastroenterology, Hepatology, and Nutrition, Loyola
University Medical Center, Maywood, IL.
Purpose: The purpose of this study is to compare the gastric cancer survival
rates of Blacks, Hispanics, and Whites; and to identify factors that may
account for any differences.
Methods: The records of all patients with histological documentation of
primary gastric adenocarcinoma at a single university medical center from
January 2002 through December 2005 were reviewed. Various characteristics
were recorded. The predictor variables on ethnicity included sex, age at
diagnosis, treatment (with surgery, chemotherapy, or radiation), and cancer
stage.
Results: During the four year period from January 2002 through December
2005, 76 patients were diagnosed with primary gastric adenocarcinoma. His-
panics developed adenocarcinoma at a younger age than Blacks and Whites
(mean age of 61.7 years versus 63.3 and 72.9 respectively). Hispanics and
Blacks had significantly more advanced cancer than Whites, as defined by
Stage III or IV disease (68.8% versus 39.2% with a difference of 29.6% and
95% confidence interval of 3.24 to 55.96). Hispanics also had shorter mean
survival (0.58 years) than Blacks (1.05 years) and Whites (1.08 years). The
Cox Proportional Hazards Regression (figure) demonstrated the statistically
significant decrease in Hispanic survival, without significant influence of
the predictor variables (hazard ratio = 1.57 with 95% confidence interval of
1.02–2.43).
Conclusion: Compared to Whites, gastric adenocarcinoma in Hispanics is
more advanced, has worse survival, and develops at a younger age; causes for
these differences are unknown, but warrant further investigation.[figure1]
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Clinical Outcomes, Survival Benefits, and Long-Term Stent Patency in
Patients with Malignant Biliary Obstruction: A Systematic Review
and Meta-Analysis
Faisal A. Bukeirat, MD∗, Rubayat Rahman, MD, MPH.
Medicine-Digestive Diseases, WVU School of Medicine, Moragntown, WV.
Purpose: Endoscopic biliary drainage for malignant obstructive jaundice is
a viable and popular alternative, but its exact role and the clinical outcomes
of the various available stents are subject to debate. The objective of this
study was to review the literature with regard to the clinical outcomes, pa-
tency rates, and quality of life in patients requiring endoscopic palliation for
malignant obstructive jaundice.
Methods: Using PubMed, Medline, Embase, Current Contents, and the
Cochrane Database of Systematic Reviews databases (OVID), a literature
search was performed for papers published from January 1990 to December
2006. All retrieved papers comparing plastic with metallic stents for pallia-
tive biliary decompression, were rated according to the strength of evidence
and carefully analyzed.
Results: A total of 566 patients were included in our analysis. 273 (48%)
patients had plastic stents, and 293 (52%) had metallic stents. In the plastic
stent group 144 patients (53%) were males, and 129 (47%) were females.
In the metallic stent group 155 patients (53%) were males and 138 (47%)
were females. The age of the patients was 21–96 years, with a median age
of 72.50 years. The median age for the plastic stent group was 73.01 years
(36–96), and that of the metallic stent group was 72.09 years (21–94), which
was not statistically significant (P = 0.84).
Based on our meta-analysis, the median time of stent patency was 187.7 days
for the metal stents, and 95.1 days for the plastic stents, which is statistically
significant (P < 0.002). While the quality of life was better for all of the
patients undergoing palliative endoscopic drainage, there was no evidence
of a difference in the technical or therapeutic success, or complication rates
between the two groups. However, the median patient survival was also
statically higher (P < 0.001) in the metal stents group than the plastic stents
group (243 days vs. 190 days).
Conclusion: Palliative endoscopic drainage affords improved quality of life.
With better patency rate and improved patient survival, clinicians should
consider using a metal stent as first preference, when there is no other con-
traindication, in the management of malignant biliary strictures.
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Clinical Outcomes, and Long-Term Stent Patency in Patients with
Malignant Biliary Obstruction: A Systematic Review and
Meta-Analysis
Faisal A. Bukeirat, MD∗, Rubayat Rahman, MD. Digestive Diseases,
WVU School of Medicine, Morgantown, WV.
Purpose: Endoscopic biliary drainage for malignant obstructive jaundice
is a viable alternative, but its exact role and the clinical outcomes of the
various available stents are subject to debate. The objective of this study was
to review the literature with regard to the clinical outcomes, patency rates,
and quality of life in patients requiring endoscopic palliation for malignant
obstructive jaundice.
Methods: Using PubMed, Medline, Embase, Current Contents, and the
Cochrane Database of Systematic Reviews databases, a literature search
was performed for papers published from January 1990 to December 2006.
All retrieved papers comparing plastic with metallic stents for palliative bil-
iary decompression, were rated according to the strength of evidence and
analyzed.
Results: A total of 566 patients were included in our analysis. 273 (48%)
patients had plastic stents, and 293 (52%) had metallic stents. The age of the
patients was 21–96 years, with a median age of 72.50 years. The median age
for the plastic stent group was 73.01 years (36–96), and that of the metallic
stent group was 72.09 years (21–94), which was not statistically significant
(P = 0.84).
The median time of stent patency was 187.7 days for the metal stents, and
95.1 days for the plastic stents, (P < 0.002). While the quality of life was
better for all of the patients undergoing palliative endoscopic drainage, there
was no evidence of a difference in the technical success, or complication
rates between the two groups. However, the median patient survival was
statically higher (P < 0.001) in the metal stents group than the plastic stents
group (243 vs. 190 days).
Conclusion: Palliative endoscopic drainage affords improved quality of life.
With better patency rate and improved survival, clinicians should consider
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using a metal stent as the prefered option in the management of malignant
biliary strictures.[figure1][figure2]
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Prognostic Factors in Patients with Advanced Cholangiocarcinoma:
Role of Surgery, Chemotherapy, and Body Mass Index
Mirna H. Farhat, MD, Ali I. Shamseddine, MD, Kassem A. Barada, MD∗.
Internal Medicine-Division of Hematology/Oncology, American University
of Beirut-Medical Center, Beirut, Lebanon; and Internal
Medicine–Division of Gastroenterolgy, American University of
Beirut-Medical Center, Beirut, Lebanon.
Purpose: Cholangiocarcinoma is an infrequent malignancy that involves
the biliary epithelium. It has a poor prognosis with a survival of less than
5% at five years. Radical surgery is the only potentially curative treatment
modality, while the impact of chemotherapy on survival remains contro-
versial. Due to the small number of patients, determinants of prognosis in
cholangiocarcinoma are not well characterized.
The purpose of this report is to study the factors that may affect survival of
cholangiocarcinoma in Lebanon.
Methods: A retrospective review of the medical records of 55 patients di-
agnosed with cholangiocarcinoma at the American University of Beirut be-
tween 1990 and 2005 was conducted. Univariate and multivariate analysis
were performed to determine the impact of surgery, chemotherapy, body
mass index, bilirubin level and other factors on survival.
Results: The median survival of all patients was 8.57 months (0.03–105.2).
Univariate analysis showed that low bilirubin level (<10 mg/dl), radi-
cal surgery and chemotherapy administration were significantly associ-
ated with better survival (P = 0.012, 0.038 and 0.038, respectively). In
subgroup analysis on patients who had no surgery, chemotherapy admin-
istration prolonged median survival significantly (17.0 vs. 3.5 months;
P = 0.001).
Multivariate analysis identified only low bilirubin level < 10 mg/dl and
chemotherapy administration as independent predictors of associated with
better survival (P < 0.05).
Conclusion: Our data show a significant positive impact of both palliative
and postoperative chemotherapy and a bilirubin level <10 mg/dl at presen-
tation on survival in patients with cholangiocarcinoma.
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Enteral Self-Expanding Metallic Stent (SEMS) for Palliation of
Jaundice in Pancreatic Intraductal Papillary Mucinous Neoplasm
(IPMN)
Eric L. Lever, MD∗, Anshu X. Kumar, MD. Gastroenterology, Kaiser
Permanente Medical Center, Bellflower, CA.
Purpose: There has been one previous report of enteral SEMS placement in
the bile duct (BD) for choledochal cyst with cholangiocarcinoma. We report
a case of IPMN of the pancreas requiring enteral sems.
Methods: A 79 yo male was followed for presumed chronic pancreatitis
with dilated PD when he developed jaundice. ERCP 12/05 revealed IPMN.
Sphincterotomy was done, and a 10 fr plastic stent was placed with improve-
ment. In 10/06 the pt. developed recurrent jaundice and cholangitis. A 10 mm
biliary sems was placed. After 1 week the pt. returned with cholangitis and
no improvement in jaundice. The SEMS had migrated almost completely
into the duodenum. It was removed endoscopically and the BD was swept
with an 18 mm balloon to remove mucin. Symptoms and jaundice persisted.
2 weeks later a 22 mm diameter enteral SEMS was placed.
Results: Patient had persistent relief of symptoms and normalization of
bilirubin after placement of enteral SEMS in the BD.
Conclusion: 22 mm enteral SEMS can provide effective palliation of jaun-
dice and cholangitis in IPMN when obstruction is due to mucin production
and not ductal narrowing.
Table 1. Effect of 22 mm SEMS
ERCP 1 ERCP 2 ERCP 3 POST 22MM SEMS
TOTAL BILI 9.6 6.9 14.4 0.9
ALK PHOS 901 1055 788 350
ALT 230 182 188 48
GGT 730 428 265
CA 19–9 10 117
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Detection of Patients at Increased Risk of Pancreatic Cancer Utilizing
Electronic Databases
Brandon A. Conkling, DO, James T. Sing, DO∗, Richard A. Erickson, MD.
Gastroenterology, Scott&White Hospital, Texas A&M Health Sciences
Center, Temple, TX.
Purpose: Pancreatic cancer is the four and fifth most common cancer in
men and women respectively and has the lowest five-year survival rate
of any cancer. Surgical resection offers the only hope for cure; however
52% of patients have stage IV disease at the time of diagnosis. The cur-
rent problem is there are no means to identify patients who are at risk
of developing pancreatic cancer at an early resectable stage. We hypoth-
esize that there may be certain risk factors which predispose patients for
pancreatic cancer. If a combination of these factors could be determined
then screening exams could be offered to these patients with endoscopic
ultrasonography.
Methods: A retrospective review of our tumor registry was used to iden-
tify 638 patients with pancreatic cancer diagnosed between the years of
1995–2005. Patients that were referred from an outside institution or not
routinely followed at Scott & White were excluded. The remaining 397
patients had their electronic medical records reviewed to determine if the
incidence of certain factors or combination of factors portend a higher risk
of pancreatic cancer. The factors reviewed included: the presence of an el-
evated amylase or lipase, new onset diabetes, chronic pancreatitis, family
history of pancreatic cancer, history of unintentional weight loss, and abnor-
mal pancreatic radiographic imaging. In addition, we also reviewed the same
criteria of age/sex matched controls seen at the GI clinic during this same
period.
Results: Multiple factors on univariate analysis including elevated amylase
and lipase, family history of pancreatic cancer, alcohol use, elevated CEA,
new onset diabetes as well as use of diabetic medications are present more
commonly in patients with pancreatic cancer as compared to their age/sex
matched controls. Multivariate analysis revealed family history of pancre-
atitis, use of diabetic medications, and history of weight loss or abdomi-
nal pain were significantly increased in pancreatic cancer patients versus
controls.
Conclusion: Conclusions: Our results indicate a combination of the above
factors are more common in patients with pancreatic cancer. Patients with
these risk factors should be identified while asymptomatic and offered a
screening exam, either with CT scan or endoscopic ultrasound depending
on local expertise, to find potentially resectable pancreatic cancers.
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Dissociation in the Sensitivity of Magnetic Resonance
Cholangiopancreatography in the Diagnosis of Biliary and Pancreatic
Diseases
Emad Qayed, MD, Qiang Cai, MD, FACG∗. Department of Medicine
Division of Digestive Diseases, Emory University School of Medicine,
Atlanta, GA.
Purpose: Magnetic resonance cholangiopanreatography (MRCP) and en-
doscopic retrograde cholangiopancreatography (ERCP) are the two cur-
rently available important tools in the diagnosis of pancreatobiliary dis-
eases. The aim of this study was to examine the sensitivity of MRCP
in the diagnosis of pancreatobiliary diseases using ERCP as the gold
standard.
Methods: We studied all patients who had ERCP and also MRCP at Emory
University Hospital from January 1st 2002 to January 20th 2007. Those who
had MRCP beyond 3 months of ERCP, who had liver transplant or biliary
surgery between those two tests, and who had incomplete or suboptimal
ERCP or MRCP were excluded from the study. We compared the diagnosis
suggested by those two tests in eligible patients.
Results: 184 patients met the enrollment criteria during the study period.
Of those, 136 had abnormalities mainly in the biliary system, and 48 had
abnormalities mainly in the pancreas in ERCP. In the 136 patients who had
biliary abnormalities, MRCP had the correct diagnosis as ERCP in 111
patients (82% of 136) and incorrect diagnosis in 25 patients (18% of 136).
In contrast, in the 48 patients who had pancreatic abnormalities, MRCP had
the correct diagnosis as ERCP in 46 patients (96% of 37) and incorrect
diagnosis in 2 patients (4% of 48). The dissociation of the sensitivity of
MRCP in diagnosis of the biliary diseases and the pancreatic diseases is
statistically significant (P < 0.05).
Conclusion: In this retrospective study, MRCP had more accuracy in the
diagnosis of pancreatic diseases than that of biliary diseases when ERCP
was used as the gold standard.
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Retrospective Comparison of Magnetic Resonance
Cholangiopancreatography (MRCP) with Endoscopic Retrograde
Cholangiopancreatography (ERCP) in the Diagnosis of
Pancreaticobiliary Diseases
Emad Qayed, MD, Qiang Cai, MD, FACG∗. Department of Medicine
Division of Digestive Diseases, Emory University School of Medicine,
Atlanta, GA.
Purpose: Magnetic resonance cholangiopancreatography (MRCP) is an
alternative to diagnostic endoscopic retrograde cholangiopancreatography
(ERCP) for imaging the biliary tree and investigating pancreaticobiliary
diseases. The aim of the study is to compare the accuracy of MRCP to that
of ERCP in the diagnosis of various obstructive and nonobstructive pancre-
aticobiliary diseases.
Methods: A retrospective analysis was conducted at Emory University Hos-
pital of all patients who underwent ERCP procedures between January 1st
2002 and January 20th 2007. To create a comparison, we looked for MR-
CPs performed within three months of the ERCP. We excluded patients who
had liver transplant or biliary surgery between the two tests, and who had
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incomplete or suboptimal ERCP or MRCP. Comparison was made between
the final diagnosis suggested by each test. Subanalysis was done to investi-
gate the diseases that caused most inaccuracies in MRCP.
Results: Of all patients who had an ERCP performed during this five-year
period, 184 patients met the inclusion criteria of the study. Of those 184
patients, 99 (54%) were males and 85 (46%) were females. Average patient
age was 55 years.
The MRCP diagnosis agreed with the ERCP in 85.3% of cases (157/184) and
disagreed in 14.7% of cases(27/184). Of all comparisons in which MRCP
disagreed with ERCP, 48% were related to choledocholithiasis (13/27),
22% to biliary strictures (6/27), 15% to biliary tree anomalies (4/27) and
7% to biliary malignancies (2/27). There were two cases of chronic pan-
creatitis and ampullary abnormality that were misdiagnosed by MRCP
(2/27, 8%)
Conclusion: In general, MRCP appears to be a relatively accurate tool to
investigate and diagnose pancreaticobiliary disorders. It provided similar
results to ERCP in 85.3% of cases. Inaccuracies in MRCP were most com-
monly related to choledocholithiasis, although a separate study is suggested
to evaluate the sensitivity and specificity of MRCP in detecting choledo-
cholithiasis in our patient population.
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Multiple Biliary Stenting – An In Vitro Comparison Using a Novel
ERCP Mechanical Simulator
Joseph W. Leung, MD∗, Brian Lim, MD, Chhaya Hasyagar, MD, Robert
Wilson, BVD, Felix W. Leung, MD. Gastroenterology, Sacramento VA
Medical Center, Mather, CA; Division of Gastroenterology and
Hepatology, UC Davis Medical Center, Sacramento, CA and
Gastroenteorology, Sepulveda ACC, VAGLAHCS and David Geffen School
of Medicine at UCLA, North Hills, CA.
Purpose: There is a paucity of methods for objective evaluation of ERCP
accessories. In this study, we tested the hypothesis that practice on a me-
chanical simulator allows comparison of performance of different ERCP
accessories.
Methods: Endoscopists at various level of ERCP experience participated
in Hands-on ERCP practice workshops using a mechanical simulator. Ac-
cessories for biliary stenting with (Fusion OASIS, Cook Endoscopy) and
without (RX, Boston Scientific) the capability of intraductal release (IDR)
of the guide wire were compared. Total time taken to insert single or multiple
stents across an artificial bile duct stricture using the ERCP simulator and
simulated fluoroscopy time were recorded.
Results: There was no significant difference in the time required for place-
ment of single stent (Table 1). The accessories that permitted IDR and ex-
change of guide wire required significantly shorter time to complete place-
ment of three stents (Table 2), most likely because of the absence of need
for re-cannulation.
Conclusion: Objective comparison of the function of different ERCP ac-
cessories is made possible by referencing the time taken to complete a spe-
cific task, e.g. single or multiple stenting. The mechanical simulator permits
performance of different accessories by the same group of operators to be
objectively evaluated. How the results of in vitro practice and comparison
using the mechanical simulator will translate in clinical settings remain to
be established.
Comparison of Single Stenting with 2 Short Wire Systems
Balloon Stent Total
IDR N Cannulation Dilation Cytology Insertion Time SFT
Yes 19 1.5 ± 0.2 2.0 ± 0.2 1.5 ± 0.1 2.2 ± 0.3 8.9 ± 0.6 2.6 ± 0.3
No 21 1.8 ± 0.2 1.6 ± 0.1 1.6 ± 0.2 1.5 ± 0.2∗ 8.7 ± 0.7 2.2 ± 0.4
Time in minutes (mean±SEM), IDR= intraductal release, SFT=Simulated
fluoroscopy time, ∗versus Fusion OASIS, P < 0.05, unpaired t test
Comparison of Time Taken for Triple Stenting
IDR N Total Time Down Time Recannulation Time SFT
Yes 9 15.8 ± 1.2 3.5 ± 0.6 0 3.8 ± 0.5
No 9 20.9 ± 1.2∗ 5.1 ± 1.4 4.6 ± 0.9∗ 4.2 ± 0.5
Time in minutes (mean ± SEM), ∗ versus Fusion OASIS, P < 0.05, unpaired t test
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Correlation between MRCP and ERCP Findings in Patients
Undergoing an ERCP at a Tertiary Care Hospital
Rubayat Rahman, MD, Uma Sundaram, MD∗. Section of Digestive
Diseases, West Virginia University School of Medicine, Morgantown, WV.
Purpose: The sensitivity and specificity of endoscopic retrograde cholan-
giopancreatography (ERCP) and magnetic resonance cholangiopancreatog-
raphy (MRCP) have been studied separately. It is very common in the clinical
practice to obtain a MRCP followed by an ERCP. To date, there has been
no study to correlate the findings between these two studies. Aim: Examine
patient characteristics, and outcomes between the MRCP and ERCP findings
in patients in a tertiary care hospital.
Methods: This retrospective study was undertaken after obtaining appropri-
ate IRB exemption. Patients who underwent MRCP followed by an ERCP in
West Virginia University between July 1, 2004 and June 30, 2006 were iden-
tified. Patient’s demographic information, pre-imagining and pre-procedure
relevant laboratory values and diagnostic study outcomes were collected.
Data was entered into MS Access and SAS 10.0 was utilized to analyze the
data. Two tail P-value of 0.05 was considered statistically significant.
Results: A total of 165 patients were identified who underwent a MRCP
followed by an ERCP in West Virginia University Hospital from July 1, 2004
to June 30, 2006. 98 (59%) of these patients were female and 67 (41%) were
male. Baseline demographic characteristics were comparable between male
and female patients. MRCP over diagnosed ductal dilatation significantly
more as compared to ERCP (ERCP 116/165 and MRCP 138/165, P < 0.04).
Similarly, MRCP also over diagnose the presence of a hepatobiliary mass
compared to ERCP (78/165 compared to 61/165, P < 0.01). In contrast,
MRCP under diagnosed bile duct stones (44/165 for MRCP and 59/165
for ERCP, P < 0.01). Similarly, MRCP also under diagnosed both biliary
stricture and obstruction a significant percentage of the time (15% and 18%
respectively, P < 0.05 for both).
Conclusion: In patients presenting with symptoms, signs and laboratory
studies suggestive of hepatobiliary pathology MRCP appears to be a less
sensitive and specific modality than ERCP for ductal dilatation, mass, stones
or obstruction. Thus, ERCP remains the gold standard test for visualization
of the hepatobiliary tree.
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Incidental Bile Duct Stones Diagnosed by EUS
Ognian A. Pomakov, MD, Shahid Mehboob, MD∗. Division of
Gatroeneterology/Department of Medicine, SUNY at Buffalo, NY/Buffalo
VA Medical Center, Buffalo, NY.
Purpose: EUS of the common bile duct is the most accurate minimally
invasive procedure to diagnose choledocholithiasis with accuracy of more
than 90%. The true incidence of asymptomatic common bile duct (CBD)
stones in patients undergoing EUS examination for unrelated indications is
unknown.
Methods: We have retrospectivly reviewed our initial, single center EUS
database for any cases of incidental CBD stones.
Results: Two out of 50 EUS procedures (4%) found asymptomatic CBD
stones. We describe in details both cases of incidental choledocholithiasis,
found on EUS done for unrealted indication.
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Conclusion: Once an EUS study is indicated, we recommend a complete
EUS examination of the upper GI tract (including billiary tree) regardless of
the indication.
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GI Assistants’ Evaluation of the Impact of Hands-On Practice
Workshop for ERCP Training
Joseph W. Leung, MD, FACG∗, Rebeck Gutierrez, RN, Brian Lim, MD,
Kanat Ransibrahmanakul, MD, Robert Wilson, BVD, Felix W. Leung, MD.
Gastroenterology, Sacramento VA Medical Center, Mather, CA; Division of
Gastroenterology and Hepatology, UC Davis Medical Center, Sacramento,
CA and Gastroenterology, Sepulveda ACC, VAGLAHS and David Geffen
School of Medicine at UCLA, North Hills, CA.
Purpose: A successful ERCP requires close coordination between endo-
scopist and assistant. This study evaluates GI assistants’ assessment of a
hands-on practice workshop with mechanical simulators for ERCP training.
Methods: GI assistants (nurses/techs) attended a full day training workshop
with didatic talks and hands-on practice with different accessories using
mechanical simulators including insertion of catheter, guide wire exchange,
basket and balloon stone extraction, biliary dilation and brush cytology,
placement of plastic stent and mechanical lithotripsy. An expectation ques-
tionnaire described by Borkovec et al was modified for mechanical ERCP
simulator practice. Questions included: 1. How logical does this type of
simulator practice seem to you? 2. How confident would you be that this
simulator practice would be successful in improving your ERCP skills? 3.
How confident would you be in recommending simulator practice to col-
leagues who are learning to perform ERCP? 4. Would you be willing to
undergo proposed simulator training for improving your ERCP skills? 5.
How successful do you feel this type of simulator practice would be in en-
hancing the skills of a different endoscopic procedure (e.g. polypectomy,
esophageal stenting, etc)?
Results: 62 GI assistants attended 2 workshops and completed pre and post
practice evaluations. There was a significant increase in mean total credibility
score reported (pre 41.0 ± 1.3 versus post 46.7 ± 0.6, P < 0.05, paired t test).
The assistants were confident that simulator practice would be successful in
improving their skills in assisting with ERCP and that they would recommend
this mode of practice to others.
Conclusion: Hands-on simulator practice offers GI assistants an opportunity
to learn to assist with different ERCP procedures. Improvement in credibility
scores validates assistants’ endorsement of this mode of training.
Pre and Post Credibility Scores
Q1 Q2 Q3 Q4 Q5 Total
Pre 8.0 ± 0.3 7.7 ± 0.3 7.7 ± 0.3 9.1 ± 0.2 8.5 ± 0.3 41.0 ± 1.3
Post 9.3 ± 0.1 9.0 ± 0.2 9.4 ± 0.1 9.6 ± 0.1 9.4 ± 0.2 46.7 ± 0.6
P < 0.05 < 0.05 < 0.05 < 0.05 < 0.05 < 0.05
Data (mean ± SEM), P < 0.05 is significant
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Longitudinal Study of Endoscopic Ultrasound-Guided Celiac Plexus
Blockade (EUS-CPB) for Treatment of Painful Chronic Pancreatitis
(CP)
Tyler Stevens, MD∗, Gregory Zuccaro, MD, John A. Dumot, DO, John J.
Vargo, MD, MPH. Gastroenterology and Hepatology, Cleveland Clinic
Foundation, Cleveland, OH.
Purpose: To prospectively evaluate efficacy and duration of pain relief and
change in opioid consumption obtained by EUS-CPB in pts with CP.
Methods: Consecutive pts who underwent EUS-CPB (triamci-
nolone/bupivicaine) for pain from suspected or established CP were
enrolled into a prospective registry. Information regarding demographics,
imaging severity, opioid consumption (morphine equivalents, MEs), and
EUS technique was collected at baseline. Pts were phoned 7 days post
procedure to assess pain relief based on a 4-point scale (none, minimal,
moderate, and complete) and post-procedure daily MEs. Duration of relief
(time to return to baseline pain) was assessed through subsequent telephone
contact and review of medical records.
Results: 26 pts underwent EUS-CPB between December 2005 and May
2007. 16 (62%) had pain relief (4 minimal, 4 moderate, 8 complete). No
significant change was observed in daily Mes (mean difference 15 mg, P =
0.43). Among the 16 responders, the median duration of pain relief was
27 days (range 1 to 150 days).[figure1]Univariate analysis did not reveal
differences in response based on age (P = 0.66), alcohol abuse (P = 0.11),
baseline opioid consumption (P = 0.40), imaging severity (minimal change
vs. calcific, P = 0.89), or EUS technique (unilateral vs. bilateral, P = 0.85).
Conclusion: Most patients with CP have at least a partial response to EUS-
CPB. However, the duration of response is short (∼1 month) and opioid
consumption does not change.
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Magnetic Resonance Cholangiopanreatography Versus Endoscopic
Retrograde Cholangiopancreatography in the Evaluation of Patients
with Suspected Biliary Strictures and Choledocholithiasis
Emad Qayed, MD, Qiang Cai, MD, FACG∗
Purpose: To determine the diagnostic accuracy of magnetic resonance
cholangiopanreatography (MRCP) in the detection of biliary strictures and
choledocholithiasis using endoscopic retrograde cholangiopancreatography
(ERCP) as the gold standard.
Methods: The medical records of patients who underwent both ERCP and
MRCP for the evaluation of suspected biliary disease between January 2002
and January 2007 were retrospectively reviewed. Patients who had a final
diagnosis of primary sclerosing cholangitis, pancreatic duct obstruction or
biliary tract anomalies were excluded. Patients who underwent ERCP with
stenting before the MRCP were also excluded. In all patients the presence
or absence of choledocholithiasis and biliary strictures, as determined by
MRCP, was correlated with the final diagnosis obtained from ERCP.
Results: 94 patients met the enrollment criteria of the study. The diagnoses
on ERCP were choledocholithiasis in 27 patients, benign and malignant
strictures in 34 patients and normal bile ducts in 33 patients. MRCP diag-
nosed choledocholithiasis with a sensitivity of 89%, specificity of 90% and
accuracy of 89%. It resulted in seven false positive and three false negative
findings when compared with ERCP. MRCP diagnosed the presence of stric-
tures with a sensitivity of 91%, specificity of 98% and accuracy of 96%. It
resulted in one false positive and three false negative findings. The overall
sensitivity, specificity and accuracy of MRCP in the detection of bile duct
lesions were 90%, 76% and 85%, respectively.
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Conclusion: In this retrospective study, MRCP accurately detected the pres-
ence or absence of biliary strictures and choledocholithiasis, with a supe-
rior accuracy in detecting biliary strictures. However, the overall accuracy
of MRCP (85%) in the evaluation of these biliary lesions was somewhat
lower in our patient population than what is reported in other comparative
studies.
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The Severity of Pancreatic Ductal Changes on Standard MRCP
According to Cambridge Classification Correlate with the Maximum
Bicarbonate Level Achieved during Secretin Stimulated Exocrine
Pancreatic Functional Testing (ePFT)
Samer Alkaade, MD, Numan C. Balci, MD, Amir J. Momtahen, MD, Frank
R. Burton, MD∗. Internal Medicine, Saint Louis University School of
Medicine, St. Louis, MO and Radiology, Saint Louis University School of
Medicine, St. Louis, MO.
Purpose: MRCP has shown comparable results to ERCP in detecting pan-
creatic ductal changes of chronic pancreatitis. ePFT is regarded as the gold
standard for the detection of exocrine pancreatic insufficiency. The aim of
this study is to evaluate the correlation between the severity of pancreatic
ductal changes on MRCP according to Cambridge classification and the
maximal bicarbonate levels achieved during secretin stimulated ePFT.
Methods: We retrospectively reviewed all the charts of patients who had
secretin stimulated ePFT at our institution between January 2005 and March
2007. All patients who had MRCP and ePFT within four weeks time period
were included in the study. All secretin stimulated ePFTs were performed in
our endoscopy unite. The MRCP images were evaluated by our radiologist,
who was blinded to ePFT results. Ductal changes of the pancreatic gland
were assessed.
Results: 62 patients had ePFT at our institution between January 2005 and
March 2007. 38 patients underwent MRCP and ePFT within four weeks
time period. MRCP images revealed abnormal pancreatic ductal changes
consistent with chronic pancreatitis (ranging from equivocal to severe ac-
cording to Cambridge classification) in 16 patients. On ePFT testing 26
patients had maximum bicarbonate level above the cut off value of 80
mmol/L, and 12 patients had maximal bicarbonate level of 80 mmol/L
or less. A strong correlation was found between the level of bicarbonate
concentration on ePFT and MRCP scores according to Cambridge clas-
sification (Spearman 0.639, P value 0.00001), also there was a signifi-
cant difference between the mean values of the maximum bicarbonate re-
sults during ePFT in patients with normal (Cambridge 0) and patients with
equivocal/abnormal (Cambridge 1–4) MRCP findings (Mann-Whiney Test,
P = 0.0001).
Conclusion: A high degree of correlation exists between the pancreatic duc-
tal changes as measured on MRCP according to Cambridge classification and
maximum bicarbonate level achieved during ePFT testing. Further studies
are needed to validate this correlation in a prospective manner.
Difference in maximum HCO3 concentration according
to MRCP findings
MRCP N Mean HCO3 (SD) P value
Cambridge 0 22 106.27 (26.3) 0.0001
Cambridge 1–4 16 73.25 (19.4)
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Asymptomatic Common Bile Duct Dilatation in Chronic Hepatitis C
Patients on Methadone
Atif Shahzad, MD, Sirisha Jasti, MD, Ayse Aytaman, MD, Gerald Fruchter,
MD∗. Gastroenterology, State University of New York Downstate Medical
Center, Brooklyn, NY and Gastroenterology, VA NY Harbor Healthcare
System, Brooklyn, NY.
Purpose: An estimated 3.9 million Americans are infected with Hepatitic
C Virus (HCV) with a particularly high incidence in US veterans. The risk
of Hepatitis C progression to cirrhosis is estimated to be approximately
30 percent. Chronic HCV is a known cause of hepatocellular carcinoma
(HCC). Overall lifetime risk of HCC in patients with Hepatitis C cirrhosis
approaches 20%. Therefore, routine screening for HCC in HCV cirrhotic
patients via imaging/AFP monitoring has become standard of care with the
goal of diagnosing early HCC. In the course of performing HCC screening,
we have found several patients with asymptomatic common bile duct (CBD)
dilatation (>6 mm) whose workups did not reveal any underlying CBD ob-
struction. Further evaluation showed that these patients were on methadone.
It has been known for many years that narcotics, particularly, morphine can
increase sphincter of Oddi pressures. A causal association between CBD di-
latation and methadone use has also been previously observed in two reports
in the English language with a total of 9 patients.
Methods: Retrospective review of veterans with HCV undergoing HCC
surveillance in a major metropolitan VA medical center.
Results: A total of 512 patients with HCV who underwent HCC screen-
ing with abdominal sonograms were reviewed. Fifteen patients were found
to have asymptomatic CBD dilatation out of which 12 (80%) were on
methadone. Of the total population screened only 12.7% (N = 65) were
on methadone. The rate of asymptomatic CBD dilatation in methadone vs.
non-methadone users was then analyzed. Out of 65 patients on methadone,
18.5% (N = 12 patients) (mean age 58 ± 8.6) had asymptomatic CBD di-
latation (mean 9.8 mm ± 2), compared to only 0.67% (N = 3 patients) in
the 447 patients not on methadone. All patients in the methadone group with
asymptomatic CBD dilatation had a normal alkaline phosphatase except for
two patients, both of whom had either a normal ERCP or MRCP. The mean
bilirubin was 0.8 ± 0.5, with 2 patients having total bilirubin of 2 and 1.7,
both of which were due to elevated indirect bilirubin. Only 2 out of the 12
patients had cholelithiasis.
Conclusion: Chronic methadone use can predispose to asymptomatic com-
mon bile duct dilatation. Invasive workups may be unnecessary in methadone
users with asymptomatic CBD dilatation undergoing HCC screening in the
absence of clinical suspicion of bile duct pathology.
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Hypertriglyceridemic Acute Pancreatitis Is Different
Jagdish S. Nachnani, MD, Donald R. Campbell, MD∗. Departments of
Medicine – Gastroenterology Divisions, Saint Luke’s Hospital, Kansas
City, MO and University of Missouri/Kansas City, Kansas City, MO.
Purpose: Although hypertriglyceridemia is a well known cause of acute
pancreatitis, there are a limited number of studies characterizing hyper-
triglyceridemic acute pancreatitis (HAP). The aims of this study were to: a)
compare the clinical course and severity of HAP and acute pancreatitis (AP)
secondary to other causes, b) determine whether the admitting triglyceride
level influences or predicts the course of HAP, c) determine how the severity
of HAP in patients with diabetes mellitus (DM) compares to non-diabetics
and d) evaluate serum amylase and lipase values in HAP.
Methods: During a 5 year period all inpatients discharged with pancreatitis
and hypertriglyceridemia from two tertiary academic hospitals were identi-
fied using ICD-9 codes 577.0 and 272.1 respectively.
Results: 2,576 episodes of pancreatitis were identified. A cohort of 27
episodes (1.04%), comprising the fourth largest series of patients with
AP attributable to HAP is characterized and described. Patients with HAP
were younger (38.15 ± 11.24 years) compared to those with AP (45.78 ±
13.87 years, p < 0.005) and had longer hospitalizations (10.44 ± 8.23 days
vs. 3.96 ± 6.83 days, p < 0.0001). The mean admission triglyceride level
was 4,680 ± 3,007 mg/dL (range 728–11,554 mg/dL). There was no corre-
lation between the admission triglyceride level and severity of pancreatitis
(determined by APACHE II score, hospital LOS, and ICU LOS) in HAP pa-
tients. APACHE II scores of non-diabetics with HAP were lower compared
to diabetics with HAP (3.11 ± 2.85 v. 6.06 ± 3.54). However, non-diabetics
with HAP had longer hospitalizations (12.67 ± 12.70 days) and required
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more ICU care (5.33 ± 7.47 days) compared to patients with HAP and DM
(9.33 ± 4.87 hospital days and 2.56 ± 3.92 ICU days). The mean admission
lipase value in patients presenting with HAP was 2,507 ± 3,689 U/L and
mean amylase value was 266 ± 267 IU/L. Serum amylase values were nor-
mal in 33% of the HAP cohort, 30% of the cohort had normal lipase values,
and 11% of the cohort had both normal amylase and lipase values.
Conclusion: Patients with HAP were significantly younger and the length
of their hospitalization was significantly longer compared to patients with
non-HAP. Although 66% of HAP patients had diabetes mellitus, the longer
hospitalizations associated with HAP were not attributable to DM. Up to
one-third of HAP patients have a normal admission amylase or lipase value
and admission lipase values are generally much higher than amylase values.
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The Effects of Alcohol and Substance Abuse on Sedation during ERCP
Ami K. Naik, MD∗, Yasmin Alishahi, MD, Muhammad Bilal, MD, Jim Y.
Wan, PhD, Claudio R. Tombazzi, MD. Department of Gastroenterology
and Hepatology, The University of Tennessee, Memphis, Memphis, TN.
Purpose: Unsuccessful conscious sedation is a limiting factor in endo-
scopic retrograde cholangiopancreatography (ERCP). Some patients be-
come agitated and combative during the procedure. Alcohol and substance
abuse may precipitate these reactions. This study was designed to investi-
gate the effects of alcohol and substance abuse on conscious sedation for
ERCP.
Methods: A retrospective chart review of all patients from the Veterans
Administration Hospital in Memphis, Tennessee who underwent ERCP from
January 2002 until December 2006 were evaluated.
Results: 271 ERCP procedures were done during this timeframe. The indi-
cations for the ERCP ranged from diagnostic studies to therapeutic interven-
tions. Benzodiazepines, narcotics, and anti-emetics were used for conscious
sedation. This study shows that there is a statistically significant inverse cor-
relation between a history of alcohol and substance abuse and success with
conscious sedation during ERCP. Chi-square analysis indicates a statistically
significant inverse correlation between a history of alcohol use and success
with conscious sedation during ERCP (P = 0.0131). In addition, there is a
statistically significant inverse correlation between a history of illicit drug
use and success with conscious sedation during ERCP (P = 0.0021). Fur-
thermore, the lack of illicit drug use was also found to be an independent
predictor of success (P = 0.0101).
The Effects of Alcohol and Substance Abuse on Sedation During ERCP
Unsuccessful Successful
Sedation Sedation
Current Alcohol Use 12 34
No History of Alcohol Abuse 27 198∗
History of Illicit Drug Use 8 11
No History of illicit Drug Use 31 221∗∗
∗P = 0.0131 ∗∗P = 0.0021
Conclusion: This study found that alcohol and substance abuse correlated
with unsuccessful sedation during ERCP. In this patient population, gen-
eral anesthesia may be a safer and more beneficial alternative to conscious
sedation.
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Hepatic Resection Is a Safe and Effective Treatment for Bilateral
Hepatolithiasis
Satoshi Nozawa, MD, Fumio Kimura, MD, Hiroaki Shimizu, MD, Hiroyuki
Yoshidome, MD, Masayuki Ohtsuka, MD, Atsushi Kato, MD, Hideyuki
Yoshitomi, MD, Katsunori Furukawa, MD, Noboru Mitsuhashi, MD, Dan
Takeuchi, MD, Kousuke Suda, MD, Shigetsugu Takano, MD, Masaru
Miyazaki, MD∗. Department of General Surgery, Graduate School of
Medicine, Chiba University, Chiba, Japan.
Purpose: The aim of this study was to evaluate the perioperative and long-
term results of hepatectomy for bilateral hepatolithiasis comparing to that
for unilateral hepatolithiasis.
Methods: From 1985 to 2006, 30 patients underwent hepatectomy for hep-
atolithiasis, and their medical records were reviewed retrospectively for im-
mediate (operative morbidity and mortality) and long-term (stone recurrence
and survival) results.
Results: For the patients with unilateral hepatolithiasis, left side hepatectomy
was performed in 19 cases (76%) and right side hepatectomy was performed
in six cases (24%). Hepatectomy to bilateral lobes was done in three of five
patients with bilateral hepatolithiasis. In the other two patients, left side hep-
atectomy was done and the stones of the preserved liver were eliminated
intraoperatively. All the stones were removed except in a patient who under-
went lateral segmentectomy for bilateral hepatolithiasis. The most frequent
operative complication was biliary fistura, observed in six patients. The op-
erative morbidity was 33.3% (32% in the unilateral stone group, 40.0% in
the bilateral stone group) but there was neither operative nor hospital death.
History of biliary surgery was significantly correlated with the immediate
operative morbidity though the other examined factors were not (e.g. loca-
tion of stones, resected side of the liver, hemihepatectomy or not). With a
median follow-up of 163 months (range 4 to 290), no stone recurrence or
no repeated cholangitis was observed in 29 patients after complete removal
of the stones. Though one episode of cholangitis, ileus, and duodenal ulcer
were observed, respectively, they were treated conservatively. Two patients
died of recurrence of the liver cancer coexisting at the operation, cholan-
giocarcinoma and hepatocellular carcinoma, respectively. One patient died
of HCV liver cirrhosis. Two patients died of unrelated malignancy (gastric
cancer and lung cancer).
Conclusion: Hepatic resection is a safe and effective treatment not only
for unilateral but also for bilateral hepatolithiasis since it has high stone
clearance rate and good long-term results. It might be applied carefully for
patients with previous biliary surgery, the risk factor for higher incidence of
immediate morbidity.
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Two Simple Vital Sign Measurements Plus Serum Albumin Are Strong
Predictors of Disease Severity in Acute Pancreatitis?
Amit B. Sohagia, MD, Raja Masood, MD, Rafiq Rehan, MD∗, Hiliary
Hertan, MD, Nejat Kiyici, MD, Edward Norkus, PhD. Department of
Gastroenterology & Medicine, Our Lady of Mercy Medical Center, Bronx,
NY.
Purpose: Acute Pancreatitis is one of the common causes of hospital and
Intensive care unit admission. It is a potentially serious disease and with In-
tensive Care Management lead to decrease in mortality. The aim of this study
was to determine if simple vital sign measurements combined with routine
lab results can identify acute pancreatitis patients who will be transfers to
the ICU.
Methods: All patients admitted and diagnosed with acute pancreatitis (2005
-2006) were included (N = 101). Data collected were CBCs, SMA7s, LFTs,
serum albumin and vital signs [blood pressure, respiratory rate (RR), pulse
rate (PR) and temperature (T)] on admission, after 24 and 48 hrs. Severity
of disease was classified based on outcome [hospital discharge vs. transfer
to intensive care (ICU)].
Results: Patient mean age was 57 ± 17(sd) years (range = 28–97 yrs), 45%
were females and 24% of the sample were transferred to the ICU. Prelim-
inary statistics (student t-tests & chi-square analysis) identified a number
of variables to be associated with ICU transfer (low and/or worsening al-
bumin, elevated Temperature, PR>89, elevated amylase and/or lipase) and
others that were not (remaining CBCs, SMA7s and vital signs). A logistic
regression model to predict ICU transfer was then developed including age,
sex and either absolute or trend variables (increasing or decreasing values
during 48 hrs) for labs and vital signs (step-wise addition). This approach
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identified three strong predictors of ICU transfer; a 92% decreased risk
of ICU transfer for every 1.0 g/dL (>1.6) increase in albumin by 48 hrs
(P = .014), a 9-fold increased risk of ICU transfer with a PR>89 at 48 hrs
(P = .027) and a T > 98.6◦ F at 48 hrs (P = .017). With the inclusion of
these three predictors to the model no other lab or vital sign measurement
were found to predict ICU transfer. Early ICU management lead to decrease
mortality from 25% to less than 10%. This model had an overall specificity
of 93% with positive and negative predictive values of 75% and 85%, re-
spectively. Patients which were transferred to ICU also meet other Prognostic
criteria such as (Ranson’s and APACHE-II).
Conclusion: These findings suggest that careful monitoring the changes
in body temperature, pulse rate and albumin status during the initial 48
hours following admission can accurately predict patients at risk for ICU
transfer. Monitoring these markers shown decrease mortality from 25% to
less than 10%.
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Comparison of Abdominal Ultrasound and ERCP in Determining the
Etiology of Obstructive Jaundice
Arif Amir Nawaz, FACG, FACP∗, Shahid Sarwar, FCPS, Salwa Hussain,
MBBS, Atiqa Batul, MBBS, Khubaib Shahid, FCPS. Gastroenterology and
Hepatology, Fatima Memorial Hospital Shadman, Lahore, Punjab,
Pakistan.
Purpose: ERCP remains the gold standard for diagnosis and initial treatment
of patients with obstructive jaundice. Accuracy of ultrasound in such patients
and its concordance with ERCP has not been studied in our part of the world.
Objective: To compare the efficacy of abdominal ultrasound and ERCP in
determining the etiology of obstructive jaundice
Methods: Study was carried out at a tertiary care referral center in Lahore,
Pakistan from August 2006 to May 2007. Patients undergoing ERCP for
provisional diagnosis of obstructive jaundice were included. Abdominal ul-
trasonographic examination was conducted before ERCP and all patients
underwent ERCP under conscious sedation. Diagnosis on ultrasound and
ERCP was compared using cross tabulation.
Results: A total of 54 patients (male: female ratio of 0.6 (22/32)) with a mean
age of 47.22 (±14.94) were included in the study. Jaundice and Abdomi-
nal pain were the predominant presenting symptoms in 48 (88.9%) and 42
(77.8%) patients respectively whereas pruritis and fever were present in 27
(50%) and 11 (20.4%) patients respectively. Choledocholithiasis/sludge was
accurately diagnosed in 8 out of nine patients. Ultrasound only diagnosed
50% of the patients with Peri-ampullary tumors and pancreatic carcinoma
accurately; sonographic finding of a distal CBD stricture without any defini-
tive diagnoses were noted in the rest of the patients. Ultrasound was very
accurate in determining the etiology of various proximal CBD lesions. In
the 4 patients with mid-CBD strictures on ultraosound, 2 were found to
have gall bladder carcinoma, 1 common hepatic duct stricture and 1 acute
pancreatitis- diagnoses which are not usually possible on ERCP. Of the 3
patients with Cholangiocarcinoma, 2 cases had been suspected to have this
diagnosis on ERCP and ultrasound alike while the third one had a mid-CBD
stricture on ultrasound. Ultrasound findings had complete concordance with
the ERCP diagnoses in cases of post-cholecystectomy strictures, fistulas and
CBD ligation.
Conclusion: Ultrasound was very accurate in determining the etiology of
various proximal CBD lesions.
The accuracy of Ultrasound in determining the etiology of distal biliary ob-
structive processes is significantly lower but is useful as inital investigation.
Abdominal ultrasound and ERCP are complementary investigations in pa-
tients with obstructive jaundice.
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Prevalence of Fungal Infection in Patients with Severe Acute
Pancreatits and Its Outcome
Rakesh Kochhar, MD∗, Mahiuddin S.K. Ahammed, MD, Arunaloke
Chakraborti, MD, Pallab Ray, MD, Usha Dutta, MD, Jai Dev Wig, MS,
FRCS. Gastroenterology, Microbiology & General Surgery, Postgraduate
Institute of Medical Education and Research, Chandigarh, India.
Purpose: The present prospective study was aimed at exploring prevalence
of fungal infections in patients with SAP, to detect predisposing factors for
the same and to study the outcome of these patients.
Methods: Fifty consecutive patients with SAP were investigated for evi-
dence of fungal infection (F I) by culture of blood, urine, drain fluid (if
instituted) on day 0, 7, 14 and 21 days and thereafter if indicated and cul-
ture of fine needle aspirate (FNA) from pancreatic / peripancreatic tissue
and samples collected at necrosectomy. All patients were managed with
broad spectrum antibiotics, parenteral or naso-jejunal feeding and support-
ive care. Patients with fungal infection were treated with amphotericin or
fluconazole.
Results: The etiology of SAP in 50 patients (mean age 39.66 yr; 37
males) was alcohol 29 (58%), gallstones 11 (22%) and others in 10 (20%).
Fungal infection was documented in 18 (36%) patients, in 9 patients in
the operative specimen, in 3 patients from the FNA sample and in 9
in the blood culture (4 patients had specimens from two sites positive).
In contrast to patients without F I those with F I more often had ev-
idence of respiratory failure (P = 0.031) or hypotension (P = 0.031)
at admission, had prolonged hospital stay (P = 0.01), longer duration
of antibiotics (P = 0.003), antibiotic treatment for > 4 weeks (P =
0.042), TPN (P = 0.005), invasive interventions (P = 0.022) and re-
quired mechanical ventilation (P = 0.001). On logistic regression analy-
sis the independent risk factors for fungal infection were antibiotics ther-
apy for > 4 weeks and hypotension at hospitalization. Of the 18 pa-
tients with FI, 13 received intravenous amphotericin (N = 7) or flucona-
zole (N = 6) and 8 of them survived while all 5 did not receive antifun-
gals died; while in the non-fungal group, 21 of the 32 survived. Patients
who died more often had >50% necrosis of the pancreas (P = 0.045)
had a higher mean APACHE II score (P = 0.001) and respiratory failure
at admission (P = 0.07) and more often required mechanical ventilation
(P = 0.58).
Conclusion: 36% of patients with SAP developed fungal infection. Prophy-
lactic antibiotic therapy emerged as a strong risk factor. Prompt institution
of anti-fungal therapy improved survival in these patients.
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Disconnected Pancreatic Duct Syndrome (DPDS) Requiring Distal
Pancreatectomy Is a New Indication for Pancreatic Islet
Autotransplantation (PIA): Initial Experience in 7 Patients
Santhi Swaroop Vege, MD, Michael B. Farnell, MD, Michael K. Kendrick,
MD, Florencia G. Que, MD, Enrique A. Sabater, MD, Haraldur Bjarnason,
Matthew R. Callstrom, Michael Deeds, Jarret Anderson, Adam Armstrong,
Suresh T. Chari, MD, Yogish C. Kudva, MD∗. Gastroenterology and
Hepatology, Mayo Clinic, Rochester, MN; Endocrinology, Mayo Clinic,
Rochester, MN; Gastrointestinal Surgery, Mayo Clinic, Rochester, MN and
Islet Isolation Laboratory, Mayo Clinic, Rochester, MN.
Purpose: DPDS after severe acute pancreatitis requires distal pancreatec-
tomy, resulting in diabetes in a third to half of patients. PIA has been reported
after total pancreatectomy but not after distal pancreatectomy for DPDS. We
report our initial experience with 7 (3 successful) patients.
Methods: Clinical, radiologic, endoscopic, and surgical details of 7 patients
are shown in table.
Three of 7 patients had successful PIA (one with intrahepatic hematoma
requiring transfusion and embolization). Only factor which predicted low
yield was firm pancreas at surgery in 3 of the remaining 4 patients. Two of
these 4 pts developed postoperative diabetes.
Results: See Table 1.
Conclusion: PIA is feasible for patients with DPDS undergoing distal pan-
createctomy but low islet yield is a problem. PIA needs evaluation in larger
number of patients with longer follow-up.
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Table 1. Clinical, Endoscopic and Surgical Characteristics and Outcomes of 7 Patients Undergoing PIA
#1 #2 #3 #4 #5 #6 #7
Age and Sex 39 M 60 F 36 F 42 M 42 M 28 F 53 F
Etiology Biliary Post-ERCP Biliary Idiopathic Idiopathic Idiopathic Biliary
Interval between onset
and diagonsis of
DPDS (months)
12 11 15 27 13 1.25 1
Interval between
diagnosis and
surgery (months)
12 1 0 4 11 5 4
Preop diabetes + + − − − − −
Preop narcotics + + − + Only for attack + +
Endoscopic, Surgical,
and Pathologic
Characteristics of
Patients
Pre-endoscopic fluid
collection
+ + + + + + +
# Endoscopic
interventions
7 2 5 12 (1 after
surgery)
4 6 2
% resection 50 70 80 60 50 50 70
Pathology CP CP CP Negative for
tumor
CP CP CP
Clinical, Radiologic,
and Endocrine
Outcomes
Total Ischemic time
(hours)
0.75 1.75 1.8 0.75 2.0 1.5 2.0
Islet Equivalents 62,837 183,833 135,043 420 No islets 3563 3643
Pain Relief No narcotic No narcotic No narcotic No narcotic af-
ter few weeks
Acetaminophen On narcotic No narcotic
Post-surgery fluid
collections
No Yes, small Yes + Yes, ERCP
for leak
? No No
Postop diabetes + (insulin) − − + − − +
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Bouveret’s Syndrome
Soujanya Chava, Timothy Griffin∗. Department of Medicine, Creighton
University Medical Center, Omaha, NE.
Purpose: 81 y/o Caucasian male with past medical history significant for
Cholecystitis (25 yrs ago), Diabetes, HTN and hypothyroidism (on replace-
ment) presented to the ER with sudden onset of severe nausea and vomiting
(15 episodes) of 1 day duration. Vomited brownish liquid. Denied any frank
blood. Denied any abdominal pain, bloating, diarrhea, constipation, weight
or appetite changes. Patient does describe of an episode of right upper quad-
rant pain 25 yrs ago when he was diagnosed with with cholecystitis which
was treated with antibiotics, but did not undergo any cholecystectomy at that
time. Did not have any similar episodes since then. Denied alcohol use. Quit
smoking 35 yrs ago. Allergic to sulfa. On examination, vitals were stable.
Age appropriate male with truncal obesity in no acute distress. Abdomen was
soft, non tender and non distended. No scars. Small umbilical hernia noted.
No Murphy’s sign. Bowel sounds were normal. No hepatosplenomegaly. No
shifting dullness. Labs showed a WBC count of 20.4. Rest of CBC was nor-
mal. BMP was normal except bicarb of 35, BUN of 4 and serum creatinine
of 1.8. LFTs, bilirubin and protein were within normal limits. Abdominal
X ray showed a large gall stone and pneumobilia. CT abdomen with oral
contrast and IV contrast showed a big gall stone of 4–5 cm in duodenum,
pnuemobilia, pyloric obstruction suggesting Bouveret syndrome. Treatment
was started with symptomatic control with Zofran. Kept on NG suction and
IV fluids. Gastroenterology and Surgery teams were consulted. Started on
Zosyn empirically. It was decided to remove the stone by endoscopy and
if unsuccessful, plan was to take the patient to surgery. But subsequently
GI service was able to remove the stone by endoscopic lithotripsy. Patient
improved after stone removal and denied any nausea, voming or abdominal
pain. Subsequently, patient underwent elective laproscopic cholecystectomy
within 6 weeks after discharge.
Conclusion: 1.A timely cholecystectomy would have prevented this com-
plication called Bouveret syndrome. We reinforce the importance of inter-
val cholecystectomy in patients presenting with symptomatic gall stones to
prevent future complications.2. Endoscopic lithotripsy can be tried before
surgical approach.
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Prophylactic Pancreatic Stents: Benefit and Frequency of Downstream
Spontaneous Migration
Johanne Rigaux, MD, Vijay Poreddy, MD, Firas Al-Kawas, MD∗.
Gastroenterology, Georgetown University Hospital, Washington, DC and
Gastro-Enterologie, Hoˆpital Erasme ULB, Bruxelles, Belgium.
Purpose: The first objective was to assess the benefit of Prophylactic Pancre-
atic Stent (PPS) in our high risk population and the frequency of spontaneous
migration of PPS. Second objective was to identify any clinical or technical
factors associated with spontaneous migration.
Methods: We reviewed the charts and endoscopic records of all patients
who received a PPS from 2002 to 2006. Data collected included gender, age,
ERCP indication, procedure performed during ERCP, type of PPS, symp-
toms after the initial ERCP, spontaneous stent migration and the need for
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endoscopic removal. Patients were classified in 2 groups according to stent
outcome; spontaneous migration or endoscopic removal, with a compar-
ison for clinical and technical characteristics. Frequency and interval to
demonstrate spontaneous dislodgment or to perform endoscopic removal
were recorded.
Results: From June 2002 to November 2006, we identified 152 PPS that
were placed in 141 patients (99 women and 42 men). The average age
was 48.7 years (range 19–87). Pancreatic sphincterotomy was the most
common procedure performed with 71 cases. Stent average length was 3
cm. Seventeen patients (11.1%) had post-ERCP pancreatitis, with 3 se-
vere episodes. Factors associated with higher rates of post-ERCP pancre-
atitis were younger age (P = 0.03) and pancreatic sphincterotomy of the
major papilla (P = 0.06). Complete follow up data was not available in
6% of the patients. Spontaneous migration was demonstrated in 88 stents
(63.3%). The remaining 51 stents (36.7%) were removed by endoscopy.
No significant difference was observed between these 2 groups of patient.
A trend for higher rates of spontaneous migration was noted in females
(P = 0.06). The mean delay to demonstrate PS migration was 35 days
(range 2–372). Endoscopic removal was performed after a mean of 55 days
(range 6–1119).
Conclusion: PPS placement in high risk patients reduces post-ERCP pan-
creatitis rate, however severe pancreatitis may still rarely occur. Spontaneous
migration of PPS was observed in 63% of cases. This rate may be increased
by the use of stents with smaller caliber. No clinical or technical factors were
identified to help to predict in which situation spontaneous stent migration
will occur, except a tendency for more spontaneous migration in women.
Because of poor patient compliance, long delays for the stent assessment
and removal were observed.
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Biliary Tract Complications in Orthotopic Liver Transplant Patients:
A Single Center Retrospective Observational Study
Victor J. Torres, MD, Glenn W. Gross, MD, Sandeep Patel, DO∗.
Gastroenterology and Nutrition, The University of Texas Health Science
Center at San Antonio, San Antonio, TX.
Purpose: Biliary tract complications (BTC) have been a significant source of
morbidity after orthotopic liver transplantation (OLT). The aim of the study
is to review the incidence and timing of biliary complications in patients
who underwent OLT at The University of Texas Health Science Center at
San Antonio (UTHSCSA).
Methods: 996 patients underwent OLT at our institution between Novem-
ber 1992 to October 2006. Those who had a T-tube placed at the
donor-recipient common bile duct (CBD) anastomosis or had chole-
dochojejunostomy were excluded from our study. BTC were catego-
rized as: i) stone/sludge; ii) sphincter of Oddi dysfunction (SOD); iii)
leaks; and iv) strictures based on cholangiographic findings at ERCP.
Leaks and strictures were further classified as anastomotic (A) or non-
anastomotic (NA) and as early (≤90 days post OLT) or late (>90 days post
OLT).
Results: A total of 899 patients were included in the study, of which 223 pa-
tients (24%) underwent ERCP for suspected BTC. 190 patients (21.1%, PPV
85.2%) were found to have a BTC at ERCP. The incidence of stones/sludge,
SOD, leaks and strictures were 5.3%, 3.2%, 18.9% and 72.6% respec-
tively. Of the 36 patients with leaks; 23 were (A); 12 (NA) and 1 both.
32 presented early and 4 presented late. Of the 138 patients found to have
strictures, 119 were (A); 5 (NA) and 14 both. 109 presented early and
29 late.
Conclusion: ERCP is an effective and accurate approach for the diagnosis
of biliary tract complications after OLT. The overall BTC rate in our large
series was 21%. Early anastomosis strictures were the most common BTC
observed. Bilary leaks generally occurred early and at the anastomosis. De-
spite advances in OLT surgical techniques, BTC remains a significant source
of morbidity in our post-OLT patients.
Table 1. Incidence of biliary tract complication in orthotopic liver transplant
patients.
Total OLT 899
Total BTC 190 (21.1%)
Stones/sludge 10 (5.3%)
SOD 6 (3.2%)
Leaks 36 (18.9%)
anastomotic 23
non-anastomotic 12
both 1
Strictures 138 (72.6%)
anastomotic 119
non-anastomotic 5
both 14
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Pancreatic Cholera
Gushyalatha Boya, MD, Purna C. Kashyap, MD, Rami Hawari, MD,
Rondon Helbert, MD, Willaim H. Nealon, MD∗. Internal Medicine,
University of Texas Medical Branch, Galveston, TX and Surgery,
University of Texas Medical Branch, Galveston, TX.
Purpose: VIPoma is a rare gastrointestinal endocrine tumor seen in 1 in 10
million per year.
Case Report: A 37 year old African American male was initially admitted
to a community hospital with diarrhea and acute renal failure (acute tubular
necrosis) that required hemodialysis. At that time, he was diagnosed with
inflammatory bowel disease based on nonspecific erythema on colonoscopy.
He was started on mesalamine and the diarrhea improved, with recovery of
kidney function. He was discharged to a rehabilitation facility. Two weeks
later, he was readmitted to our hospital with large volume diarrhea. On exam-
ination he was found to be disoriented, hypotensive, tachycardic and tachyp-
neic. Labs showed a leucocytosis 18.4 × 103/mm, potassium 2.7 mmol/L,
BUN 83 mg/L and creatinine 17.05 mg/dl and lipase 779 U/L. ABG revealed
a pH 7.1, PaCO2 7 MM/Hg, PaO2 118 MM/Hg and HCO3− was 2 MEQ/L.
Urine sediment showed muddy brown casts. Stool cultures were negative.
Stool anion gap was 17. He responded well to hemodialysis and recovered
his renal function. Because of the classic presentation, large volume secre-
tory diarrhea (normal stool anion gap), we pursued investigation for possible
VIPOMA.
Workup: CT scan of the abdomen showed 5.7 cm mass in pancreatic tail
and the octreotide scan was positive in the same area. Serum VIP level was
1474 pg/ml, thus confirming the diagnosis of VIPoma.
Management: Octreotide 50 µc SC every 8 hours resulted in control of his
diarrhea. He underwent surgical resection of the tumor. The pathologic spec-
imen was a neuroendocrine tumor. After surgery diarrhea ceased.[figure1]
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Blunt Trauma to the Main Pancreatic Duct: Cut or Stent?
Kalyani K. Shah, MD∗, Kandarp K. Shah, MD, Mandeep Singh, MD, Jasjit
Singh, MBBS, Muhammad Y. Sheikh, MD. Gastroenterology,
UCSF-Fresno, Fresno, CA.
Purpose: Blunt injury to the main pancreatic duct is commonly a result of
motor vehicular accident, trauma, or assault involving the upper abdomen.
With better imaging modalities now available, exploratory laparotomy is not
always necessary to make this diagnosis. However, there is little published
data to help decide the best course of action in the pancreatic duct when
surgical therapy is not needed for other concomitant injuries. We wanted to
determine which approach has led to the best outcome at our institution in
treating cases of blunt injury to the pancreatic duct.
Methods: We reviewed the charts of patients admitted to our institution
between 2001 and 2006 who experienced blunt trauma to the pancreatic
duct.
Results: A total of eight cases were studied. One was lost to follow up after
transfer to another facility. Of the remaining seven patients, only one had a
pancreatic stent placed within 72 hours of the injury. This patient was able to
tolerate oral intake within 48 hours of the stent placement and was discharged
from the hospital five days after the injury. He has been doing well for over
six months and the stent has been removed. The remaining six patients
underwent distal pancreatectomy and had a median hospital stay of 45 days
for the original injury and its complications. Complications occurred in five
of these six patients (83%) in this group and included pancreatic abscess,
pseudocyst, and fistula. One patient continued to show copious leakage of
pancreatic juice into the abdominal cavity during the observation period.
Stent placement was attempted two weeks after the initial injury, but it was
not successful because the proximal part of the main duct was closed off by
then. Pancreatic juice leakage and saponification made the surgical therapy
technically difficult. Distal pancreatectomy was associated with significant
morbidity on a long-term basis. Pancreatic stent placement within 72 hours
of the injury to the main pancreatic duct produced the best outcome, avoiding
distal pancreatectomy and such consequences as diabetes.
Conclusion: At out facility, the best course of action in cases of blunt trauma
resulting in injury to the main pancreatic duct is placement of a pancreatic
stent to seal the leak within 72 hours of the injury. This early endoscopic
intervention was associated at our institution with a shorter hospital stay and
much less short-term and long-term morbidity compared to distal pancrea-
tectomy. This is our institutional experience and larger prospective studies
are needed to confirm our findings.
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Prevalence of Gall Bladder Dyskinesia in Gastroparesis
Savio Reddymasu, MD, Harshal Patil, MD, Richard McCallum, MD∗.
Medicine, Kansas University Medical Center, Kansas City, KS.
Purpose: The aim of this study is to assess the gall bladder ejection frac-
tion (GBEF) by cholescintigraphy in a cohort of gastroparetic patients with
prominent postprandial abdominal pain.
Methods: 17 patients with gastroparesis (14 females) underwent the hy-
droxyl iminodiacetic acid (HIDA) scan to measure their GBEF over the last
2 years. A GBEF between 35%–50% on the HIDA scan was considered as a
borderline positive test for gall bladder dysmotility and a GBEF <35% was
considered as definite evidence of gall bladder dyskinesia. Gastroparesis for
this study was defined as retention of >10% of a standardized low fat isotope
labeled egg beater meal at the end of 4 hours by scintigraphy. Demographic
data, the etiology of gastroparesis, duration of gastroparetic symptoms, and
bowel movement pattern were also recorded.
Results: 11/17 (65%) of patients had a GBEF of <50%, 8 of these patients
had definite evidence of gall bladder dyskinesia, while the other 3 had a
borderline positive test. 7/8 patients with a definitely positive test under-
went cholecystectomy, of which 5 had chronic cholecystitis on pathology.
6/7 patients reported improvement in pain after the cholecystectomy. None
of the patients with borderline evidence of gall bladder dysmotilily under-
went cholecystectomy. Clinical characteristics of patients are summarized in
table. There was no significant difference (p > 0.05) in age, or duration of
gastroparetic symptoms in patients with normal and abnormal gall bladder
ejection fraction. Gall bladder dysmotility was numerically more likely in
females (OR 5; 95% CI: 0.35–72%), idiopathic gastroparesis (OR 5; 95%
CI: 0.6–46), and in patients with constipation (OR 2; 95% CI: 0.2–13)
Conclusion: 1) This pilot study shows that gall bladder dysmotility is present
in a majority of patients with gastroparesis; particularly of idiopathic etiology
2) Underlying neuromuscular dysfunction in gastroparesis may also extend
to the gall bladder, consistent with a neuropathic etiology to explain the gall
bladder dyskinesia. 3) Appreciating the need to diagnose and treat biliary
dyskinesia in gastroparesis could be an important strategy to address the
pain component in this challenging clinical setting.
Clinical Characteristics of gastroparetic patients who
underwent HIDA scan
Gastroparesis with Gastroparesis without
gall bladder gall bladder
Characteristic dysmotility n (%) dysmotility n (%)
Etiology:
Diabetes Mellitus 2 (18%) 3 (50%)
Idiopathic 8 (72%) 2 (33%)
Age (years) 40 (33–47) 38 (28–48)
Duration of 4 (2–6) 7 (3–11)
gastroparetic
symptoms (years)
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Long-Term Follow up of Endoscopic Sphincterotomy for Bile Duct
Stone Removal: A North American Perspective
Milan E. Folkers, MD, Maydeen Ogara, Kathryn Peterson, MD, James
DiSario, MD∗. Gastroenterology, University of Utah, Salt Lake City, UT.
Purpose: Endoscopic sphincterotomy for stone removal is commonly per-
formed for bile duct stones with early morbidity in about 10% of patients.
Late-occurring complications occur in 3% to 24% of patients in Asian and
European studies. There are no published data on long-term outcomes from
North America. The aim of this study is to determine the long term outcomes
of endoscopic sphincterotomy for bile duct stones in a North American pop-
ulation.
Methods: Patients who had endoscopic sphincterotomy for stones between
1991 and 2000 were identified from billing records at the University of Utah
Health Sciences Center and those with 5 or more years follow up were in-
cluded. Patients with sphincterotomy for other indications were not included.
Living participants were contacted by phone to complete a questionnaire re-
garding their biliary and pancreatic health, and the next of kin responded
for the deceased. Chart review was also performed. Any complications that
developed more than 30 days post-procedure were consider late-occurring.
Results: 193 individuals were identified who met inclusion criteria, includ-
ing 43 individuals who were deceased. Follow up was possible on 80 (41.5%)
individuals including from the relatives of 26 who were deceased. The mean
duration of follow up was 7.75 (range, 5 to 14) years. There were 43 females
and 37 males with a mean age of 62 (range, 23–94) years. Cholecystectomy
was performed in 22 (27.5%) individuals prior to ERCP and 30 (37.5%)
afterwards. Eight (10%) persons had late-occurring complications (Table
1). There were no cases of cholangiocarcinoma. All complications occurred
in those who had undergone cholecystectomy before, or within 14 days af-
ter sphincterotomy, and no one had multiple complications. None of the
deceased patients had known pancreatobiliary complications and all died
of unrelated causes. No patient required surgery, radiographic therapy, pro-
longed hospitalization or ICU care, and there were no sphincterotomy-related
deaths.
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Conclusion: In a North American population, endoscopic sphincterotomy
for bile duct stones is associated with complications in 10% of patients over
the long-term, which is comparable to reports from Europe and Asia. These
complications are usually mild and treatable with ERCP.
Late-occurring Complications of ERCP with Sphincterotomy
for Bile Duct Stones
Number ERCP #
Pain 3 1/0/0
Stones 2∗∗ 1/1
Orifice Stenosis 2 1/4
Pancreatitis 1∗∗∗ 0
∗∗Occurred 2 and 7 years post-ERCP
∗∗∗Required 1 day hospitalization
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Perceived Cancer Risk among Patients with Pancreatic Cysts
Ketan Kulkarni, MD, Savreet Sarkaria, MD, Mark Pochapin, MD, Felice
Schnoll-Sussman, MD∗. Division of Gastroenterology and Hepatology,
Weill Cornell Medical Center, New York, NY.
Purpose: The natural history of pancreatic cystic neoplasms has not been
clearly defined and currently available techniques are at times inadequate for
differentiating premalignant cysts from benign cysts. Therefore, surveillance
of these patients is of paramount importance. We conducted a questionnaire
study to evaluate patients’ knowledge of pancreatic cysts and their perceived
risk of developing pancreatic cancer.
Methods: Sixty-eight consecutive patients evaluated by EUS for a pancre-
atic cyst from 2005 to 2006 were contacted by telephone to administer the
questionnaire. Their knowledge of the pancreas and pancreatic cysts was
evaluated. Patients were asked to estimate their risk of developing cancer
from the cyst over 5 years and if they believed surveillance was necessary.
Based upon clinical and endoscopic parameters, each patient’s risk of can-
cer was also estimated by three experienced gastroenterologists who were
blinded to each other and patient responses. Following arrival at a consensus
opinion regarding each individual’s risk for cancer development the agree-
ment in risk perception between patients and the expert panel was assessed
by the weighted kappa statistic.
Results: A total of 48 (71%) patients with pancreatic cysts were successfully
contacted. Only 14 (29%) knew what the function of the pancreas was and
10 (21%) were able to identify the type of cyst they were diagnosed with.
The three gastroenterologists completely agreed or had minor disagreement
in 87% of cases and the kappa value between each pair of gastroenterologists
ranged from 0.69 to 0.77 (good). Agreement between each patient and the
expert panel’s consensus cancer risk was mediocre (kappa of 0.30). Of 16
patients who believed their cancer risk was “zero”, the expert panel agreed
in only 4 cases. Among 32 patients who had at least a “very small” risk
of cancer and would be recommended to undergo surveillance, only 60%
believed surveillance was necessary.
Conclusion: The definitive diagnosis and subsequent treatment of pancre-
atic cystic neoplasms is still poorly defined. If resection is not performed,
surveillance may be essential to protect from later cancer development. Most
patients with these lesions do not have an adequate understanding of the
pancreas or pancreatic cystic neoplasms. Furthermore, there is mediocre
agreement between gastroenterologists and patients regarding their cancer
risk. Patients’ low perceived risk of cancer may have a negative impact on
subsequent adherence to surveillance recommendations.
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Trends and Experiences with ERCP and MRCP in Maryland
Josh Forman, MD, Eric Goldberg, MD, Peter Darwin, MD∗. Division of
Gastroenterology and Hepatology, University of Maryland School of
Medicine, Baltimore, MD.
Purpose: To define practice patterns and perceptions regarding ERCP and
MRCP among community based gastroenterologists in the state of Maryland.
Methods: A survey consisting of 31 multiple-choice and free text entry ques-
tions was developed using a commercial survey website. Questions about
training and utilization of ERCP, perception and utilization of MRCP, and
practice setting were included. The survey was sent by email to Maryland
members of the ACG, AGA, and ASGE. Physicians with email addresses
from academic institutions were excluded.
Results: Forty-nine gastroenterologists completed the survey. Twenty-eight
(57%) currently perform ERCP. During fellowship, 5 (18%) performed >200
cases and 18 (64%) performed <100 cases. Six (21%) completed an addi-
tional year of advanced endoscopic training. Thirteen (46%) reported an
annual volume of <50 cases and 11 (39%) reported an annual volume of
50 to 100 cases. One reported an annual volume of >200 cases. All per-
form ERCP for treatment of obstructive jaundice, choledocholithiasis, and
cholangitis. Nineteen (67.9%) perform ERCP for diagnosis of suspected
pancreatic or biliary tract disease and 22 (78.6%) perform ERCP to es-
tablish the diagnosis of choledocholithiasis. ERCP volume decreased since
entering practice for 16 (57%). Fourteen (87.5%) attributed the decrease to
the introduction and expanding role of MRCP and most (89.3%) believe
the technology has altered their practice. Respondents feel ERCP findings
correlate with MRCP findings always, most of the time, or sometimes in 4%,
68%, and 28% of cases. Of the 21 not currently performing ERCP, 10 (48%)
performed ERCP previously, half within the last 5 years. Common reasons
for abandoning the practice of ERCP were decreasing comfort level (60%),
time constraints (50%), fear of procedural complications (40%), unfamiliar-
ity with new technology (20%) and fear of litigation (20%).
Conclusion: In the state of Maryland, most surveyed gastroenterologists
performed less than the currently recommended 180–200 ERCP’s during
fellowship and nearly all perform < 100 ERCP’s annually. MRCP has de-
creased ERCP volume for most. Despite the belief that MRCP has altered
practice and the feeling that MRCP findings correlate with ERCP findings
most of the time, many still perform ERCP for diagnostic purposes. Those
who abandoned the practice of ERCP did so mostly due to time constraints,
decreasing comfort with the procedure, and fear of complications. A nation-
wide survey is planned.
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Acute Experimental Pancreatitis in Rats Is Ameliorated by Treatment
with Pramlintide, a Synthetic Analogue of the β-Cell Hormone Amylin
Bronislava Gedulin, MD, Pamela Smith, BS, Ginger Toschiaddi, Clara
Polizzi, Andrew Young, MD∗. In Vivo Pharmacology, Amylin
Pharmaceuticals, Inc., San Diego, CA.
Purpose: Acute pancreatitis is a common and major complication of en-
doscopic retrograde cholangiopancreatography (ERCP) and limits the use
of this otherwise safe procedure. Antisecretory drugs such as somatostatin
(SST) and its long-acting analogue octreotide, or protease inhibitors such
as gabexate mesilate, have been tested as therapies for pharmacological
prevention of post-ERCP pancreatitis, but uncertainty still exists over their
clinical benefit. At physiologically relevant doses in animal models, the
β-cell hormone amylin slows gastric emptying, inhibits gastric acid secre-
tion and exocrine pancreatic secretion, and protects the gastric mucosa. The
present study examined the effect of pramlintide (pram), a synthetic human
amylin analogue, on prevention of caerulein-induced acute pancreatitis in
anesthetized Sprague DawleyTM (SD) rats.
Methods: Saline, pram (300 µg/kg/h), SST (10 µg/kg bolus) or pram+SST
in combination (N = 16, 5, 5, 6, respectively) was infused intravenously
from 30 min before until 240 min after caerulein IP injection (10 µg/kg)
into fasted, male, anesthetized SD rats (320–360 g). As an index of acute
pancreatitis, plasma lipase and amylase were measured for up to 240 minutes
after caerulein injection.
Results: Following caerulein injection, plasma amylase increased 2.23-fold
at 240 min in saline-treated controls compared to 1.40-, 1.61- and 1.51-fold
in rats receiving pram, SST or the combination (P < 0.01, P < 0.04 and
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P < 0.01, respectively). Plasma lipase increased by 20.3-fold in the control
saline group compared to 8.1-, 6.1- and 5.0-fold in pram, SST or combination
groups (P < 0.02, P < 0.01 and P < 0.01, respectively). Although each was
different from controls, there were no significant differences between SST,
pram or pram+SST treatments in attenuating caerulein-induced increases
in plasma amylase and lipase in this animal model of pancreatitis.
Conclusion: Pramlintide ameliorated increases in pancreatic enzyme activ-
ity in this rat model of acute pancreatitis. Future studies are warranted to
explore the potential use of pramlintide in the prevention of pancreatitis,
which may occur during ERCP procedures. This research was funded in part
by Amylin Pharmaceuticals, Inc., San Diego, CA.
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Trainers’ Assessment of Mechanical Simulator Practice in ERCP
Training
Brian S. Lim, MD, Joseph W. Leung, MD∗, Robert Wilson, BVD, Felix
Leung, MD. Gastroenterology, UC Davis Med Cntr, Sacramento, CA;
Sacramento VA Med Cntr, Mather, CA and Sepulveda ACC/David Geffen
School of Medicine at UCLA, Sepulveda, CA.
Purpose: There is a paucity of simulator models for ERCP training. We ex-
plored trainers’ evaluation of potential application of a mechanical simulator
for ERCP practice to supplement trainees’ clinical experience.
Methods: At 2007 DDW, ERCP trainers were introduced to new ERCP ac-
cessories by a U.S. manufacturer. Participants tested the accessories using a
mechanical simulator (GIE 2007;65:1056–1062) and completed a modified
expectation questionnaire (Borkovec, J Behav Ther Exp Psych 1972;3:257–
260) before and afterwards. Questions were: (1) How logical does this sim-
ulator practice training seem to you? (2) How confident are you that this
simulator practice would be successful in improving trainees’ ERCP skills?
(3) How confident would you be in recommending simulator practice to
trainees who are learning to perform ERCP? (4) Would your trainees be
willing to undergo simulator training? (5) How successful do you feel this
simulator practice would be in enhancing skills of a different endoscopic
procedure, e.g. esophageal stenting?
Results: Data of 12 completed sets of pre and post evaluations were analyzed
using the paired t test. There was a significant increase in the mean total
credibility score (Table 1) reported by the trainers (pre 41.3 ± 1.3 vs post
44.5 ± 1.8, P < 0.05). In particular, the trainers were significantly more
confident after the use of the simulator that this simulator practice would
be successful in improving the trainees’ ERCP skills and that they would
recommend simulator practice to trainees.
Conclusion: Exposure to simulator practice provided trainers the opportu-
nity to evaluate the use of mechanical simulator for ERCP training. Improve-
ment in credibility scores validates trainers’ endorsement of this mode of
practice to complement clinical training. These endorsements indicate that
impact of mechanical simulator practice on trainees’ clinical performance
deserves randomized controlled assessment.
Table 1. Pre and Post responses to Expectation Questionnaire and Credibility Scores
Q1 Q2 Q3 Q4 Q5 Total scores
Pre 8.3 ± 0.5 7.2 ± 0.4 8.3 ± 0.4 9.7 ± 0.2 7.8 ± 0.5 41.3 ± 1.3
Post 8.8 ± 0.4 8.6 ± 0.3 9.2 ± 0.4 9.8 ± 0.3 8.3 ± 0.5 44.5 ± 1.8
P value n.s. < 0.05 < 0.05 n.s. n.s. < 0.05
Data expressed as mean ± SEM, P < 0.05 is significant, n.s. = not significant
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Wire Controlled Cannulation Reduces the Risk of Post-ERCP
Pancreatitis in Children by Initially Accessing the Bile Duct with a
Soft-Tipped Guidewire, without Contrast Injection
R. Martin Bashir, MD∗, Bryan Fine, MD, Parvathi Mohan, MD, Ali Bader,
MD, Sona Sehgal, MD, Bernard Kerzner, MD. Gastroenterology,
Children’s National Medical Center, Washington, DC.
Purpose: Pancreatitis is the most common and serious complication of diag-
nostic and therapeutic ERCP, occurring in 3–30% of cases overall. However,
limited data on children have been published to date. Patient factors such
as age, prior history of post-ERCP pancreatitis, and technical factors (ex-
perience of the endoscopist and the number of PD injections) are high-risk
predictors for post-ERCP pancreatitis. Traditional training recommendations
for cannulation of the common bile with initial contrast injection are out-
dated and should be revised. This study asked the question: can the incidence
of post ERCP pancreatitis in children be reduced by initially accessing the
bile duct with a soft-tipped guidewire prior to contrast injection?
Methods: Retrospective assessment of all children who underwent ERCP
for selective CBD cannulation by a single endoscopist from July 2002 to
June 2006 was performed. All patients included had initial, selective CBD
cannulation using a soft-tipped guidewire and a sphincterotome. The CBD
was freely cannulated with the wire, after which time the cannulatome was
advanced into the mid CBD, prior to injecting any contrast. Cases requiring
minor ampullary cannulation were excluded.
Results: ERCP was successful in cannulation of the CBD in 99.4% of pa-
tients. A total of 162 ERCPs were performed for selective CBD cannulation
over a 48 month period by single endoscopist. All procedures utilized initial
wire-guided cannulation with a 0.025 soft-tipped guidewire. Two patients
(1.5%) developed clinically identifiable mild post-ERCP pancreatitis; one
(0.7%) developed post-sphincterotomy bleeding which did not require ther-
apy. None had developed pseudocysts or sequellae of chronic pancreatitis
up to 6 months after evaluation. There were NO cases of severe pancreatitis
(0%) or ICU admissions as a result of Post-ERCP pancreatitis.
Conclusion: Accessing the bile duct with a soft-tipped guidewire likely sig-
nificantly reduces the risk of developing post-ERCP pancreatitis in children.
Further study is needed.
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Pancreatic Cyst Size and Malignancy: An Endoscopic Ultrasound
Perspective
Jayaprakash Sreenarasimhaiah, MD∗, Luis A. Armstrong, MD, Luis F.
Lara, MD, Shou J. Tang, MD. Division of Digestive and Liver Diseases,
University of Texas Southwestern, Dallas, TX.
Purpose: Cysts of the pancreas are often found incidentally on many con-
ventional radiographic imaging tests. Often, these rely on size to suggest
significance.
Methods: A retrospective analysis of all pancreatic cysts presenting for
endoscopic ultrasound examination was made. 41 consecutive patients over
a period of 18 months were analyzed. Fine-needle aspiration was performed
of cysts. Cyst fluid was analyzed for CEA level, amylase, and cytology along
with correlation to clinical and endosonographic appearance.
Results: The patient group included 22 men (53.6%) and 19 (46%) women.
Average age was 63 years. Of all cysts, 6 were found by histology and CEA
levels to be malignant. The average size of these cysts were 9.29 cm2. Be-
nign cysts included 35 total with an average size of 12.10 cm2. Of the benign
cysts, 12 were found to be pseudocysts based on the above tests. The aver-
age size of pseudocysts was 16.02 cm2. In comparison of the benign cyst
size to malignant cyst size, no statistical significance was found (P = 0.53).
In comparison of all benign cysts to pseudocysts, no significant difference
was identified (P = 0.31). Additionally, no difference was found as well be-
tween malignant cysts and pseudocysts based on size (P = 0.53). Malignant
cysts include 4 mucinous cystic neoplasms, one intraductal papillary muci-
nous cyst of side-branch variety, and one cystic degeneration of pancreatic
adenocarcinoma.
Conclusion: Cyst size has significant variation. Radiographic prediction of
cyst malignancy cannot be reliably made on size alone. Pseudocysts, benign
cysts, and malignant cysts have no significant differences in size.
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Metastatic Cholangiocarinoma Masquerading as Mesenteric Ischemia
Andrew N. Pearson, MD, Rassa Shahidzadeh, MD, Vinayasekhara Reddy,
MD∗. Section of Gastroenterology, Medical College of Georgia, Augusta.
Purpose: Perihilar Cholangiocarcinoma represents 60–80% of cholangio-
carcinomas. Obstructive jaundice is the presentation in 90% of patients.
Other symptoms include weight loss, anorexia, acholic stools, fatigue and
abdominal pain.
Methods: 60 year old male presented with postprandial abdominal pain,
sitophobia and 30 lb weight loss over 2 months. The pain was constant peri-
umbilical worsened with eating. Abdomen was tender without peritoneal
findings. With mesenteric ischemia in the differential a CT was performed.
Mesenteric vessels were patent but small bowel and colon were diffusely
thickened and mild left intrahepatic ductal dilation was noted. Surgical eval-
uation and review of CT suggested mesenteric ischemia was less likely.
Enteroscopy and colonoscopy with ileoscopy and biopsies were negative.
Liver enzymes were normal except alkaline phosphatase 185, AST 52 and
ALT 104. ERCP to evaluate biliary dilation revealed mild narrowing of
medial branch of right intrahepatic and tight stricture at take off of left in-
trahepatic. Stent was placed across the stricture. Brushings were negative.
Cholangiocarcinoma was suspected when the CA 19–9 of 2000 U/mL re-
turned in conjunction with the ERCP findings. Although CT scan did not
suggest metastatic disease a CT PET scan demonstrated metastasis to the
right lobe, peritoneum, mesentery and bowel. Biopsy of porta hepatis using
biliary stent as landmark was consistent with adenocarcinoma of pancreatic
or biliary origin (CK19 +). The patient opted for hospice care succumbing
2 months later.
Results: Perihilar Cholangiocarinoma typically presents with obstructive
jaundice. This patient presented with abdominal pain, sitophobia and weight
loss, more consistent with mesenteric ischemia. Despite normal bilirubin,
evaluation of intrahepatic duct dilation with CA 19–9, cholangiography and
biopsy was needed for diagnosis. CT PET imaging accurately staged disease
where CT failed. In elderly patients with negative work up for mesenteric
ischemia biliary dilation should be investigated. Cholangiocarcinoma with
metastasis to bowel and peritoneum can present with pain similar to mesen-
teric ischemia from meal stimulated increase in bile flow and/or obstruc-
tion.[figure1]
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Predictors of Morbidity from Local Complications in Severe Acute
Pancreatitis
Hazem Hammad, MD, David Hough, MD, Santhi Swaroop Vege, MD, Bret
T. Petersen, MD∗. Division of Gastroenterology and Hepatology, Mayo
Clinic College of Medicine, Rochester, MN; Department of Radiology,
Mayo Clinic College of Medicine, Rochester, MN and Department of
Internal Medicine, Wayne State University, Detroit, MI.
Purpose: Severe Acute Pancreatitis (SAP) is often complicated by necrosis,
pancreatic duct disruption and fluid collections. These local complications
(LC) cause significant morbidity and often require repeated interventional
procedures.
Methods: Multiple approaches employed to retrospectively identify pa-
tients with SAP presenting to Mayo Medical Center (MMC) within the
first week of onset of pancreatitis included review of: a) CT reports for
the term “pancreatic necrosis”, b) medical ICU data base, and c) global
EMR for Jan. 2002–Dec. 2006. All pts. had at least one of the fol-
lowing indicators of SAP: (1) Pancreatic necrosis on dynamic CT, (2)
APACHE II score ≥ 8, (3) Late development of LC such as pseudo-
cyst or abscess, (4) prolonged ICU admission due to AP, and (5) Length
of hosp.stay (LOS) ≥ 10 days. Pt. medical records were reviewed for
demographics, etiology of SAP, BMI, pertinent lab values and clini-
cal course with particular attention to the eventual need for interven-
tional Rx of LC. The two groups, SAP with and without LC, were
compared with regards to demographics, lab markers and clinical out-
comes.
Results: Eighty-four pts. presented with SAP within 1 week of onset between
Jan. 2002 and Dec. 2006. Among them, 56% (47/84) developed LC and 37%
(31/84) required radiologic (N = 13), endoscopic (17) and/or surgical (11)
intervention for the complication. The mean age of the 47 pts. who devel-
oped LC was 55.1 yrs., vs. 56.9 yrs in pts with SAP but no complications;
66% (31/47) of pts with LC were male, vs. 73% (27/37) of patients with
no complications (both P = NS). The mean BMI was 30 for both groups.
The mean LOS was 35.4 d. for pts. with subsequent local complications
compared to 9.2 d. for pts. without complications (P = < .0001). The mean
admission WBC, hematocrit, and serum creatinine for pts. with complica-
tions were 36.3, 38.9, and 1.5, compared to 16.4, 41.1, and 1.2 in pts. without
complications (all P = NS). The mean peak amylase and lipase levels for
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pts. with and without complications were 1230 and 4196 vs 950 and 3190
(P values NS).
Conclusion: Our data showed no correlation between age, gender, BMI,
admission WBC, hematocrit, serum creatinine, or peak pancreatic enzymes
levels and development of local complications secondary to severe acute
pancreatitis. Local complications of SAP can incur significant prolongations
in hospital stay.
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Long-Term Follow-Up of Endoscopic Papillary Balloon Dilation
Compared to Endoscopic Sphincterotomy for the Extraction of Bile
Duct Stones
James A. DiSario, MD∗, Maydeen M. Ogara, Steven Price, Kristen Hilden,
EDES Group. Internal Medicine GI Division, University of Utah Health
Sciences Center, Salt Lake City, UT.
Purpose: Endoscopic papillary balloon dilation (ED) for the extraction of
bile duct stones is proposed to prevent late-occurring complications com-
pared to endoscopic sphincterotomy (ES). In our previous multi-center study,
237 patients were randomized to have ED or ES. 30 day morbidity occurred
in 18% (7% severe, 2 deaths) of ED and 3% (0 severe) of ES patients (P <
0.001) and the study was terminated at the 1st interim analysis. Our pur-
pose is to determine the long-term outcomes of ED vs. ES in the same
cohort.
Methods: Standardized telephone interviews and medical records review
regarding morbidity beyond 30 days was performed by blinded person-
nel not involved in clinical management. Complications were stratified by
consensus criteria. Patients crossed over from ED to ES were analyzed
as ES.
Results: To date, 131 (55%) participants have been located and 34 (14%) are
known dead. With a mean follow up of 9.7 (8.3–11.0) years, 63 (48%) ED
and 68 (52%) ES participants have been located. 18 (14%) ED and 16 (12%)
ES patients have died, but the causes are known in only 6 and none were
pancreatobiliary-related. Reliable data are available on 97 (41%; 70 women,
27 men) with a mean age of 44 (26–95) years and the treatment groups are
evenly matched. Results are shown in the table. A multivariate regression
analysis was performed on age, gender, cholecystectomy status and peri-
ampullary diverticulum, and none of these factors significantly contributed
to complications in either treatment group.
Long- Term Complications
ED N = 63 ES N = 68 P
Patients with any complications 18 (29%) 14 (21%) P = 0.31
Events
Abdominal pain 15 (24%) 13 (19%) P = 0.53
Jaundice 2 (3%) 3 (4%) P = 0.52
ERCP 3 (5%) 4 (6%) P = 1.0
Recurrent stones 0 3 (4%) P = 0.25
Conclusion: 1. Long-term complications of ED and ES occur at similar
rates. 2. These findings do not support ED as preferential treatment for bile
duct stones to prevent long-term complications of ES.
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Management of Acute Cholangitis with Periampullary Diverticula – Is
Endoscopic Sphincterotomy Really Effective for Recurence
Prevention?
Susumu Shinoura, MD, Tomiaki Kubota, MD, Yutaka Yamaguchi, MD,
Yoshiki Shimabukuro, MD, Kaoru Kikuchi, MD, Yoshihide Keida, MD∗.
Department of Internal Medicine, Division of Gastroenterology, Okinawa
Chubu Hospital, Uruma, Okinawa, Japan.
Purpose: This is an overview on management of acute cholangitis with peri-
ampullary diverticula at Okinawa Chubu Hospital, an educational medical
care institute with 550 beds.
Methods: We reviewd all cases from 7/2003 to 12/2006 (41 months) in
which patients underwent therapeutic endoscopic retrograde cholangio-
pancreatogram (therapeutic ERCP). We compared the treatment outcome
of acute cholangitis cases between those with periampullary diverticulum
and without periampullary diverticulum. Statistical analysis was performed
using chi-square test.
Results: There were 636 cases of therapeutic ERCP in 41 months at our in-
stitute. Of these, 57 cases of acute cholangitis with periampullary diverticula
and 90 cases without periampullary diverticula were noted. No significant
difference in sex, age, common bile duct diameter or status post cholecys-
tectomy were noted between the two groups. 5 cases (8.8%) of recurrence in
the group with acute cholangitis with periampullary diverticula and 9 cases
(10%) of recurrence in the group without periampullary diverticula (N.S.)
were noted. 4 of 5 (80%) recurrent acute cholangitis with periampullary
diverticula and 18 of 57 (31.6%) non recurrent acute cholangitis with peri-
ampullary diverticula were noted (P = 0.03).
Conclusion: There were no significant risk for acute cholangitis in a pa-
tient with periampullary diverticula compared with a patient without peri-
ampullary diverticula.
For an acute cholangitis patient with periampullary diverticula, management
with sole endoscopic sphincterotomy (ES) was not effective in preventing
future recurrent acute cholangitis. Combination of bile duct stenting or en-
doscopic retrograde bile duct drainage (ERBD) before or along with ES were
effective.
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Inferior Vena Cava Compression Due to Biloma: A Case Report
Shailaja Jamma, MD, Michael Aref, MD, Andrew Batey, MD, Thomas
Huber, MD∗. Internal Medicine, University of Illinois at Urbana
Champaign, IL and Gastroenterology, UIUC, IL.
Purpose: Biloma is an uncommon but well known complication of chole-
cystectomy. It varies in sizes from very small inconsequential leaks to very
large collections causing pressure symptoms such as in gastric outlet ob-
struction. However, biloma causing inferior vena cava compression leading
to significant edema has not been reported so far.
Case Report: We report the case of a 55 year old female presenting with
abdominal distention and lower extremity edema, a month after an open
cholecystectomy. Physical examination showed distended abdomen with
hepatomegaly and pitting edema of bilateral lower extremities. Laboratory
data revealed normal hepatic function test except for an elevated alkaline
phosphatase. Contrast enhanced computed axial tomography scan (CAT
scan) of the abdomen revealed a 15 cm × 20 cm fluid collection (open
arrows) displacing the liver far to the left and compressing on the inferior
vena cava (closed arrows). The diagnosis of biloma was established at per-
cutaneous drainage with resolution and relief of her symptoms.
Discussion: Biloma is a localized collection of bile usually from iatrogenic
injury. Laparoscopic cholecystectomy is the most common cause of bile duct
injury leading to biloma formation although it can also occur spontaneously
when gall stones are impacted in the bile ducts leading to disruption. The
incidence varies from 0–7%. Other causes include local infection, cholangio-
carcinoma, transarterial chemoembolization of hepatic malignancy and en-
doscopic retrograde cholangiopancreatography. Postoperative biloma com-
monly manifests within one week after surgery characterized by abdominal
pain, fever, vomiting and jaundice. CAT scan and magnetic resonance imag-
ing are superior to ultrasonography. Continuity between fluid collection and
biliary tree can be determined by radionuclide cholescintigraphy. Chemical
analysis of the aspirate can confirm the diagnosis. Percutaneous drainage is
the treatment of choice for large collections otherwise endoscopic sphinc-
terotomy with or without stent placement is usually adequate. Occasionally
surgery may be needed for a persistent biloma particularly if infection en-
sues.[figure1]
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A Comparison of Ranson’s Criteria Versus Sequential Organ Failure
Assessment Score (SOFA) in Predicting Intensive Care Unit
Admission, Morbidity and Mortality in Acute Pancreatitis in the
Emergency Room
Mirela Meca, MD, Ari J. Wiesen, MD, Arkady Broder, MD, Brian
Schwender, MD, Jonathan Wiesen, MS, Kostas Siderdis, DO, Prasun Jalal,
MD, Steven Helft, MD, Simmy Bank, MD∗. Gastroenterolgy, Long Island
Jewish Medical Center, New Hyde Park, NY.
Purpose: To evaluate the outcome of patients admitted with acute pancre-
atitis and a comparison of Ranson’s score with maximum Sequential Organ
Failure Assessment (SOFA) score to predict the prognosis in the emergency
room.
Methods: Data from consecutive patients admitted with acute pancreatitis
in a referral center in the year 2001–2006 were retrospectively collected.
All charts were reviewed for Ranson’s score at admission and 48 hrs and
SOFA score daily for the first 5 days. The total maximum SOFA score was
calculated summing the highest scores for all six systems. Organ dysfunction
was considered as SOFA score of 1 or 2 points and organ failure as a SOFA
score of 3 or more. The primary outcomes were mortality, admission to the
intensive care unit and duration of hospital stay. Patients with <18 years of
age, known diagnosis of chronic pancreatitis or serum amylase and lipase <
3 times normal were excluded.
Results: 167 patients were admitted to the hospital with a diagnosis of acute
pancreatitis over the 2 year period (90 male, 77 female; median age 52 years,
range 18–96 years). The etiology of pancreatitis was alcohol (42, 25%), gall
stone (68,40%), post-ERCP (9, 5%) or other (48, 30%). The Ranson’s score
at admission was 1.26 ± 1.07. The maximum SOFA score at admission was
1.64 ± 1.76. 32 (19%) patients needed admission to the ICU. 7 patients died
from complications of acute pancreatitis. The median hospital stay for all
patients was 7 days (2–50 days). There was no association between Ranson
score on admission and mortality. However, patients with a SOFA score ≥
3 were 5.9 times more likely to die. (95% CI: 1.1 – 31.4), than those with a
score < 3. 52.6% of those with Ranson ≥3 are admitted to the ICU during
their hospitalization, whereas 16.3% of those with Ranson < 3 are admitted
to the ICU, P < 0.001. 40.4% of those with SOFA ≥3 are admitted to the
ICU during their hospitalization, whereas 10.9% of those with SOFA < 3
are admitted to the ICU, P < 0.0001. An elevated Ranson Score (P < .02)
or SOFA score (P < .001) on admission was predictive of a length of stay
greater than 7 days.
Conclusion: On admission, both Ranson’s score and SOFA score are useful
in predicting the duration of hospital stay. The SOFA score was better in
predicting the overall mortality.
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Clinicopathologic Features of Surgically Resected Pancreatic Cystic
Lesions
Michelle K. Kim, MD, Thomas Curran, BA, Daniel Labow, MD, Myron
Schwartz, MD, Gabriel Levi, MD, Noam Harpaz, MD, PhD, Steven
Itzkowitz, MD∗. Medicine, Mount Sinai School of Medicine, New York, NY;
Surgery, Mount Sinai School of Medicine, New York, NY and Pathology,
Mount Sinai School of Medicine, New York, NY.
Purpose: Pancreatic cysts represent varying degrees of malignant potential.
Because of the limited ability to predict the precise nature of these lesions,
surgical resection is often advised. The aim of this study was to identify clin-
icopathologic features that correlate with malignant potential of surgically
resected pancreatic cysts.
Methods: Using available Gastrointestinal Pathology and Surgical Oncology
databases, we retrospectively reviewed all surgical resections of pancreatic
cysts performed at The Mount Sinai Hospital from August 1995 to June 2006.
We recorded patient characteristics, presenting symptoms, and preoperative
imaging. Among a total of 74 patients, the medical records of 63 patients
were available. Cysts were categorized as benign (N = 35), premalignant
(N = 22), or malignant (N = 17).
Results: Benign, premalignant, and malignant cysts occurred in 47.3%,
29.7%, 23.0% of resected lesions, respectively. After excluding pseudocysts,
we found that patients with premalignant/malignant pancreatic cysts were
more likely to be older and to demonstrate pancreatic duct dilatation on
pre-operative imaging. Malignant cysts were significantly more likely to be
associated with jaundice, to occur in the head or neck of the pancreas, and
to have ductal dilatation on preoperative imaging (Table 1). Malignant cysts
also demonstrated a trend toward increased likelihood of being symptomatic
(P < 0.1).
Conclusion: In this retrospective study, nearly half of pancreatic cyst re-
sections were performed for benign entities. Ductal dilation occurred more
commonly in premalignant and malignant cysts. Malignant cysts were as-
sociated with clinical symptoms, jaundice, and location in the head/neck.
These factors may provide physicians with an improved ability to discrimi-
nate between benign, premalignant, and malignant pancreatic cysts. Using a
newly established Pancreatic Neoplasia Database, we hope ultimately to bet-
ter identify appropriate patients for surgical resection for pancreatic cystic
lesions.
Table 1. Comparison of Nonmalignant and Malignant Pancreatic Cysts
Nonmalignant Malignant
(N = 48) (N = 17) P value
Presence of Symptoms 41% 82.4% P = 0.089
Presence of Jaundice 0% 17.6% 0.009
Ductal Dilation 21.4% 63.6% 0.012
Location in Head/Neck 28.9% 75.0% 0.005
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Lack of Corellation between Liver Enzymes and the Presence of a Bile
Leak Following Laparascopic Cholecystectomy
R. Martin Bashir, MD∗, Biju K. Alex, MD. Gastroenterology, Washington
Hospital Center, Washington, DC.
Purpose: Biliary tract leak following laparoscopic cholecystectomy occurs
in approximately 1–5% of all patients. Most bile leaks are restricted to the
gall bladder bed and perihepatic region; retained calculi may or may not be
present, causing potential elevations in liver function tests (LFTs). Common
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symptoms indicating bile leak are abdominal pain, vomiting, and abdomi-
nal distension. Many surgeons routinely obtain LFTs after all laparoscopic
cholecystectomies, but it is unclear whether liver enzyme elevation is a pre-
dictor of bile leak following lap chole. The purpose of this study was to
determine if routine postoperative LFTs can predict a post operative bile
leak.
Methods: All patients diagnosed as having ERCP documented postoperative
bile leak from April 2003 to May 2007 were identified. Preoperative and post
operative liver enzymes and patient symptoms were obtained through chart
review and retrospective analysis.
Results: Bile leak was observed in 25 patients (0.9%). Among the 25 patients
found to have a bile leak, 9 (36%) had post operative evidence of elevations
of AST, ALT, or Alk Phos (greater than 1.5× normal). Only 6 (24%) had post
operative fever and 5 (20%) leukocytosis. All patients (100%) had evidence
of post operative abdominal pain, nausea or both. There was a statistically
significant difference in pre- and postoperative alanine aminotransferase and
alkaline phosphatase (39 vs 66 U/L; P = 0.01 and 96 vs 133 U/L; P = 0.05,
respectively).
Conclusion: There was no correlation with liver enzyme elevation and pres-
ence of bile leak, with only 36% of patients with bile leak manifesting 1.5×
elevations in Alk Phos, ALT or AST. Postoperative elevations in liver func-
tion tests are frequently seen after laparoscopic cholecystectomy; however,
these elevations do not predict bile leak following laparascopic cholecystec-
tomy. LFTs should be obtained only when clinically indicated.
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Groove Pancreatitis: A Case Report To Illustrate a Little-Known
Entity
Sam J. Samuel, MD, PhD, Albert Pahk, MD, Abha Rani, MD∗. Division of
Gastroenterology, Nutrition and Hepatology, State University of New York
at Buffalo, Buffalo, NY.
Purpose: Groove pancreatitis is a segmental type of chronic pancreatitis
that involves the pancreatoduodenal groove. Recognition of this entity in
the differential diagnosis of pancreatic cancer may avert the extensive and
morbid surgery that is performed to treat pancreatic malignancy.
We present a case report of a 41 year old male with a history of alcohol
dependence who presented with 2 days history of post-prandial abdominal
pain that was relieved by vomiting (sometimes self-induced). His sitophobia
led to a 20 lb weight loss in 2 months. He admitted 2 days of coffee ground
emesis and melena prior to admission. He denied use of NSAIDs. His father
had developed pancreatic cancer at age 50.
He was not anemic on admission, had normal liver function tests and only
mildly elevated lipase and amylase. An abdominal CT with IV contrast re-
vealed a circumscribed hypodense solid mass, 5 cm × 5 cm, that appeared
to arise within the duodenal wall and was located in the duodenal sweep dis-
placing the pancreatic head and causing apparent gastric outlet obstruction.
Extracorporeal ultrasound showed no mass or pseudocyst of the pancreas.
EGD showed a subtotal and impassable postbulbar duodenal stenosis due to
erythematous, edematous polypoid mucosa with surface ulceration. Biop-
sies revealed a lymphoplasmacytic infiltrate confined to the lamina propria
with eosinophils, marked edema and villous blunting.
The patient was managed conservatively and was discharged in 8 days tol-
erating a regular diet. A repeat CT after 1 month showed less distension of
the duodenum and an irregular soft tissue density in the head of the pan-
creas suggestive of pancreatitis. Follow-up EGD showed improvement of the
esophagitis and duodenal wall erythema. Repeat biopsies were negative for
dysplasia or malignancy.
Groove pancreatitis affects the pancreatoduodenal groove. This potential
space is prone to the collection of pancreatic secretions, leading to inflamma-
tion and marked cicatrization in this area. This results classically in duodenal
stenosis.
The pathogenesis is unclear but may involve protein plugs or occlusive tu-
mors in the duct of Santorini, cystic dystrophy of the duodenal wall develop-
ing in a heterotopic pancreas, gastric surgery, peptic ulcer or even dysfunction
of the minor papilla, either primarily or secondary to local inflammatory or
neoplastic processes. Dilation and stenting of the accessory duct has resulted
in the full resolution of groove pancreatitis.
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Comparison of Cyst Fluid DNA Analysis Utilizing Two Different DNA
Interpretations
Mustafa Alnounou, MD, Sirish Sanaka, MD, Jeffrey Tokar, MD, Oleh
Haluszka, MD∗. Fox Chase Cancer Center, Philadelphia, PA.
Purpose: While the utility of a variety of molecular and biochemical mark-
ers in fluid from pancreatic lesions have been reported, the ‘ideal’ marker
remains unknown. A panel of molecular tests is now commercially available
for DNA analysis from cyst fluid (RedPath laboratory, Pittsburgh, PA). In
a small series reported in a previous abstract, we found poor correlation
between the commercial test interpretation and the results of cytology and
surgical pathology. Recently, the result of the PANDA study (GIE 2007;
65:AB101) was reported classifying cysts as nonmucinous, nonmalignant
mucinous and malignant mucinous based on 4 criteria provided by RedPath.
This study was conducted to correlate the results of the criteria used in the
PANDA study in interpreting the results of the molecular analysis with the fi-
nal diagnosis in our previous series as confirmed by cytology and/or surgical
pathology.
Methods: In our small series we identify 12 patients in whom a definitive
diagnosis was made by surgical pathology (8) or cytology (4) from a series
of 154 patients evaluated by EUS-FNA for the presence of cystic pancreatic
lesions. In these patients we reviewed the detailed results of following: The
presence of k-ras mutation, number of mutations, DNA amount (Optical
Density = OD), DNA quality (Cyclic Threshold). In the PANDA study OD
> 10 and CT < 27 with high amplitude mutations are found to be most
consistent with malignant mucinous cysts.
Results: Of the 12 patients in the study k-ras mutation was found in 5
patients, 4 with mucinous lesions and one with neuroendocrine tumor; 4
other patients with mucinous lesion had no k-ras mutation. Six patients had
elevated amount (OD > 10) of good quality DNA (CD < 27.2), of these 4 had
malignant mucinous lesions, one had benign MCA on surgical pathology,
and one had pseudocyst. Three patients with malignant mucinous lesions
had elevated DNA amount, but had low quality DNA (CD > 27). The two
patients with neuroendocrine tumors had low amount of poor quality DNA.
Conclusion: The final pathology results of this small series seem to corre-
late better with the criteria of the PANDA study than with the commercial
interpretation. Their criteria seem to demonstrate greater specificity for the
type of the cyst, whether it is nonmucinous, nonmalignant mucinous or ma-
lignant mucinous, but seem to still lack significant sensitivity. The pattern
we saw in the NE tumors needs to be further studied.
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Epigastric Pain with Very High LFTs and Pancreatic Enzymes – An
Unusual Presentation of Papillary Stenosis
Narayan Dharel, MD, Vijay Arya, MD∗. Division of Gastroenterology,
Wyckoff Heights Medical Center, Brooklyn, NY.
Purpose: The typical case of papillary stenosis is described as middle aged
female who presents with recurrent episodes of right upper abdominal pain
occurring several years after cholecystectomy with mild elevations of LFTs.
Here we report an unusual case of papillary stenosis who presented with
acute pancreatitis like symptoms with very high levels of LFTs and amylase
and lipase followed by rapid improvement.
Methods: A 53-year-old white female s/p cholecystectomy came to the
emergency department because of epigastric pain, nausea and vomiting for
2 days. On physical exam, she had epigastric tenderness but no jaundice
or dehydration. The liver enzymes were grossly elevated, with an aspartate
aminotransferase (AST) level of 2006 IU/L, an alanine aminotransferase
(AST) level of 1359 IU/L, and an alkaline phosphatase (ALP) value of 180
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IU/L. Total and direct bilirubin levels were 2.2 mg/dL and 1.3 mg/dL respec-
tively. Serum amylase and lipase were 1536 U/L and 1915 U/L respectively.
A CT scan of abdomen and pelvis and abdominal sonogram were negative
for pancreatitis or stones in the pancreato-biliary tree. ERCP revealed a nor-
mal papilla. Cholangiogram showed a dilated common hepatic duct of 8 mm
with benign tapering to the ampulla. The cystic duct joined the common
hepatic duct only few millimeters away from the ampulla. Hence the patient
had a very small common bile duct. No stones were noted in the biliary tree.
With the elevated LFTs, biliary pain and dilated duct, this was a case of
type 1 papillary stenosis. Sphincterotomy was performed. Post ERCP fol-
low up labs showed a marked decline in LFTs and amylase and lipase and
there was marked improvement in abdominal pain. At follow up visit one
week after sphincterotomy, the patient remained completely asympomatic
and the LFTs and amylase and lipase were almost completely normalized
(AST = 33, ALT = 154, ALP = 195, amylase = 101, lipase = 46 and total
bilirubiN = 0.3).
Conclusion: Papillary stenosis is not a common condition and often presents
diagnostic dilemma to the clinicians. An ERCP with sphincterotomy is
instrumental in diagnosing and treating papillary stenosis, and should be
considered in postcholecystectomy cases with abdominal pain and elevated
LFTs. Endoscopic sphinceteotomy is a recommended treatment for papillary
stenosis (type 1 SOD) and is very effective and safe in experienced hands.
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Prophylactic Antibiotics in Necrotizing Pancreatitis: A Meta-Analysis
Phil A. Hart, MD, Matthew L. Bechtold, MD, Abhishek Choudhary, MD,
Srinivas R. Puli, MD, Mohamed O. Othman, MD, John B. Marshall, MD,
Praveen K. Roy, MD∗. Division of Gastroenterology, University of
Missouri, Columbia, MO.
Purpose: Acute necrotizing pancreatitis is associated with substantial mor-
bidity and mortality. Prophylactic antibiotics have been used in these patients
to decrease potential infection in an effort to decrease mortality. However,
multiple randomized controlled trials (RCTs) on the subject have shown
mixed results. Based upon these inconsistencies, we conducted a meta-
analysis to analyze the effects of prophylactic antibiotics in necrotizing pan-
creatitis.
Methods: MEDLINE, Cochrane Central Register of Controlled Trials &
Database of Systematic Reviews, PubMed, and recent abstracts from ma-
jor conference proceedings were searched (May 2007). RCTs comparing
prophylactic IV antibiotics to no prophylactic antibiotics in the setting of
necrotizing pancreatitis were included. Standard forms were used to extract
data by two independent reviewers. The effects of prophylactic antibiotics
were analyzed by calculating pooled estimates of mortality, infected pancre-
atic necrosis, length of hospital stay, non-pancreatic infections, and surgical
intervention. Separate analyses were performed for each outcome by using
odds ratio (OR) or weighted mean difference (WMD). Heterogeneity was
assessed by calculating the I2 measure of inconsistency. Publication bias was
assessed by Harbord-Egger, Begg-Mazumdar, and funnel plot methods.
Results: Seven studies (N = 429) which met the inclusion criteria were
included in this analysis. Prophylactic antibiotics for acute necrotizing pan-
creatitis significantly decreased the length of hospital stay (WMD -5.64,
95% CI: −11.01 – −0.27, P = 0.04) and the rate of non-pancreatic infec-
tions (OR 0.55, 95% CI: 0.34–0.88, P = 0.01). No significant differences
between the prophylactic antibiotic and the control groups were noted for
mortality (OR 0.71, 95% CI: 0.41–1.23, P = 0.22), infected necrosis (OR
0.72, 95% CI: 0.45–1.16, P = 0.18), and surgical intervention (OR 0.82, 95%
CI: 0.52–1.30, P = 0.40). Heterogeneity was not statistically significant for
any variable (P > 0.05). No significant publication bias was noted.
Conclusion: Prophylactic antibiotics in necrotizing pancreatitis significantly
reduced the length of hospital stay and rate of non-pancreatic infections.
However, no significant differences were found for mortality, infected necro-
sis, and need for surgical intervention. Prophylactic antibiotics in necrotizing
pancreatitis have a limited role in decreasing length of stay and other non-
pancreatic infections.
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Adenocarcinoma of the Pancreas Presenting as Diabetic Ketoacidosis
Aly Lakhani, MB, BS, Michael Cannon, MD∗. Department of Internal
Medicine, Gastroenterology Division, William Beaumont Hospital, Royal
Oak, MI.
Purpose: Adenocarcinoma of the pancreas (ACP) is often advanced at pre-
sentation and carries a poor prognosis. Infrequently, it presents as diabetes
mellitus (DM.) ACP presenting as diabetic ketoacidosis (DKA) is vanish-
ingly rare.
Methods: A 50-year old Caucasian woman presented to hospital after ten
days of progressive nausea, vomiting, anorexia and fatigue. She was known
to have essential hypertension and major depression, but had no history of
DM. In the emergency department the patient was found to have: glucose
898 mg/dL, anion gap 19, bicarbonate 17 mmol/L, beta-hydroxybutyrate 3.7
mmol/L and both glucosuria and ketonuria. The patient was diagnosed with
DKA and treated with fluid, insulin and potassium. Shortly thereafter the
patient complained of epigastric pain. An abdominal ultrasound revealed
mild dilatation of the common bile duct, signs suggestive of acute chole-
cystitis and a suspicious liver nodule. Further history uncovered a sixty
pound weight loss over the preceding six months. The previously normal
liver indices increased over three days as follows: AST 974 u/L, ALT 425
u/L, total bilirubin 1.8 mg/dL to a peak of 9 mg/dL. Amylase and lipase
remained normal throughout. A CT scan of the abdomen showed a mass in
the head and uncinate process of the pancreas, dilatation of the intra- and
extra- hepatic bile ducts and secondary pancreatitis with atrophic changes.
On MRI the mass was found to encase the Superior Mesenteric Artery. En-
doscopic ultrasound revealed invasion of the Portal Vein. Tissue biopsy of
the head of the pancreas diagnosed the lesion as an adenocarcinoma of the
pancreas of intermediate grade. The cancer was stage IV at diagnosis and
was not amenable to curative surgical intervention. The disease continued
to progress despite radiation therapy and systemic chemotherapy with gem-
citabine and temozolomide. The patient decided to discontinue aggressive
treatment and pursue hospice care.
Results: This case demonstrates that sinister etiologies may underlie DM
or DKA that present in mid to late adulthood. Glucagonomas occasionally
present with DKA, whereas a presentation of ACP with DKA is exceed-
ingly uncommon. Malignancy is an important etiology and early diagnosis
is imperative for successful curative surgical intervention.
Conclusion: Both DKA and DM of late onset in the context of even moderate
weight loss should prompt an evaluation for pancreatic disease.
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Admission Apache II for Prediction of In-Hospital Mortality in Acute
Pancreatitis
Bechien U. Wu, MD, Richard S. Johannes, MD, Xiawu Sun, PhD, Peter A.
Banks, MD∗. Division of Gastroenterology, Center for Pancreatic Disease,
Brigham & Women’s Hospital, Boston, MA and Cardinal
Health-MediQual, Marlborough, MA.
Purpose: To determine the accuracy of the admission APACHE II score
for prediction of in-hospital mortality in acute pancreatitis (AP) using
population-based data. In addition, to determine thresholds for increased
mortality by APACHE II score.
Methods: Patient data was generated from the Cardinal Health Research
Database, a large population dataset that has supported publicly reported hos-
pital performance in Pennsylvania for 20 years. All cases from Jan 2004–Dec
2004 identified by principal diagnosis ICD9-CM 577.0 (AP) were included.
Admission APACHE II scores were calculated for all patients. Missing val-
ues were entered as normal. Performance of admission APACHE II was
measured using area under the ROC curve (AUC). Comparison of APACHE
II score with observed mortality was performed to determine appropriate
cutoffs for high vs. low-risk patient groups.
Results: There were 18,256 cases from 212 hospitals with 225 deaths (1.2%).
Mean age was 55.0 and 49.3% were males. Mean admission APACHE II
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score was 7.0 among all patients. Using our method, admission APACHE II
AUC = .828. Observed mortality by Apache II score is depicted in the table
below.
Conclusion: Our application of the APACHE II scoring system produced an
accurate tool for early prediction of mortality in patients with AP. Mortality
in our AP population did not significantly increase until an APACHE II score
>10.
Observed Mortality by APACHE II score
APACHE II score Observed Mortality (%)
≤10 <1%
11–15 2.75%
16–20 11.0%
>21 32.5%
Overall Mortality = 1.2%
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Septic Pylephlebitis Mimicking Acute Biliary Obstruction
Raffat Jaber, MD, Christain Holand, MD, Natasha Muckova, MD, Ronald
Griffin, MD∗. Division of Gastroenterlogy, Medicine, Loma Linda
University, Loma Linda, CA.
Purpose: Portal and mesenteric vein thrombosis are uncommon. It has been
associated with hypercoagulable state, oral contraceptive use, pregnancy and
septic pylephlebitis. We present a case of septic pylephlebitis mimicking
acute biliary obstruction.
Case Report: 68 year old male presented with fever, chills, left lower quad-
rant abdominal pain, leukocytosis and obstructive biliary picture. There was
no ascites. His work up was negative for cholecystitis, cholangitis and hep-
atitis. Further work up revealed E. coli bacteremia. Contrast enhanced Com-
puted Tomogrophay (CECT) (Fig. 1) showed sigmoid diverticulitis with
thrombus in the inferior mesenteric vein and the portal vein. Hypercoagulable
work up was negative. The patient was treated with piperacillin-tazobactam
and full anticoagulation with warfarin. The patient clinically improved, liver
profile studies normalized and serial CECT (Fig. 2) showed resolution of the
thrombus.
Discussion: Septic pyelphlebitis is difficult to clinically diagnose. The fact
that our patient had abdominal pain with E. coli bacteremia necessitated
CECT of the abdomen and pelvis which revealed inferior mesenteric and
portal vein thrombosis. Condat et al. (1) has reported eight in a series of
33 patients with portal vein or mesenteric thrombosis directly linked to
abdominal sepsis including diverticulitis (N = 2), bacteroides bacteremia
(N = 1) cholangitis (N = 3), hepatic abscess (N = 1) and appendicitis with
peritonitis (N = 1). There were no other identifiable risk factors for hy-
pergoagulable state. Doppler ultrasound and CECT can be used when the
diagnosis is suspected (1). CECT has an advantage in that it is not opera-
tor dependent. In Condat et al series, early anticoagulation lead to 31% of
patients achieving complete thrombus resolution and 46% achieving partial
thrombus resolution. Our patient had partial thrombus resolution within 30
days of the diagnosis. These findings are also comparable to the literature
(2, 3). Furthermore, occurrence or recurrence of intestinal infarction was
not commonly observed on anticoagulation therapy (1, 2, 3). In addition,
treatment of the infectious focus and antibiotics is necessary for optimal
outcome. Antibiotics are recommended for 4–6 weeks in most cases (4).
Our patient received antibiotic therapy for four weeks.
Conclusion: Septic pyelphlebitis should be considered when bacteremia
with an intestinal bacterial species coincides with mesenteric or portal vein
thrombosis. Early anticoagulation is vital for good outcome.
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Early Oral Feeding in Mild Acute Pancreatitis: A Randomized
Prospective Trial
Nison L. Badalov, MD, Zankhana Mehta, MD, Hima Satyavolu, MD, Tejal
Shah, MD, JianJun Li, MD, Robin Baradarian, MD, Kadirawel Iswara,
MD, Scott Tenner, MD, MPH∗. Division of Gastroenterology, Department
of Medicine, Maimonides Medical Center, Brooklyn, NY.
Purpose: One of the pillars of managing patients with acute pancreatitis
has been the concept of “placing the pancreas at rest”. At admission, pa-
tients are typically not allowed to take any food or fluids orally (NPO) while
provided intravenous hydration. Several prospective trials have shown that
early nasojejunal, and more recently, nasogastric feeding is safe and bene-
ficial. When compared to parenteral nutrition, there is a consensus among
the trials demonstrating that enteral nutrition results in decreased infectious
complications, decreased length of stay (LOS) and significant cost savings.
Unfortunately, nasojejunal feeding often requires endoscopic or radiologic
placement of tubes. Nasogastric feeding is uncomfortable and may pose an
increased risk for aspiration.
Methods: In order to determine the safety of early oral feeding in patients
with acute pancreatitis, a randomized prospective study was performed. A
consecutive series of patients with mild acute pancreatitis were invited to
participate (Ranson Score of less than 3, and an APACHE Score less than
6, and with no evidence of organ dysfunction or pancreatic necrosis). After
informed consent was obtained, patients were randomized to one of three
groups. Group 1 was placed NPO, standard of care, until pain resolved and
amylase fell below 3 times normal. Group 2 was placed on a semi-elemental
formula as tolerated starting within 12 hours of admission. Group 3 was
allowed to consume a regular diet as desired starting within 12 hours of
admission. Patients were followed for pain medication requirements, com-
plications, length of stay, and recurrence of disease.
Results: To date, 33 patients have been enrolled in the study. Mean age 52 ±
13, 12 male, 11 female. The three groups of patients did not differ regarding
age, gender and etiology of acute pancreatitis. There were no differences in
narcotic usage, complications and LOS among the three groups of patients.
Morphine use was 6.1 mg ± 2.8 mg per day for the first 3 days in Group
1, 5.5 ± 3.1 mg day in Group 2 and 6.5 ± 2.8 mg per day in Group 3. The
mean length of stay was 4.2 ± 1.1 days, 3.8 ± 2.5 days and 4.1 ± 1.7 days,
respectively.
Conclusion: We conclude that patients with mild acute pancreatitis can
safely be fed a regular diet as tolerated. This study provides further evidence
that “placing the pancreas at rest” is not necessary in the management of
patients with acute pancreatitis.
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Ethanol Pancreatic Injection of Cysts: Results of a Prospective
Multicenter, Randomized, Double Blinded Study
William R. Brugge, MD∗, Kerry Collier, MA, Kathleen McGreevy, RN, C.
Max Schmidt, MD, John DeWitt, MD. Gastroenterology, Indiana
University, Indianapolis, IN; Gastroenterology, Massachusetts General
Hospital, Boston, MA and Surgery, Indiana University, Indianapolis, IN.
Purpose: Pancreatic cystic lesions (PCL) often represent a form of early
malignancy (mucinous cystic lesions).
Purpose: To determine the safety and effectiveness of Endoscopic Ultra-
sound (EUS)-guided ethanol lavage of PCLs.
Hypothesis: The rate of cyst ablation as a result of ethanol (EUS-ETOH
lavage with 80% ethanol) will be greater than the rate achieved with saline
(EUS-SL lavage).
Methods: This was a prospective, randomized, controlled trial that enrolled
patients with a PCL 1–5 cm (0–4 septations). After first lavage, all patients
were offered a second lavage with ethanol. CT was repeated 3 months after
the last EUS. Surgical resection was permitted at any time. The PCLs were
assigned a diagnostic category based upon cytology, cyst fluid CEA and/or
surgery.
Results: From 10/04–6/07, 54 patients were consented, 12 were excluded
prior to initial lavage and 42 (26 F; mean age:69 yrs) with suspected benign
mucinous (35) or nonmucinous pancreatic cystic tumors (4) and pseudocysts
(3) were randomized to EUS-ETOH (25) or EUS-SL (17). Cyst size: median
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19 mm (range: 10–40) and location: head/uncinate (18), body (16) or tail
(8). The change in the size (surface area) and rate of ablation are shown in
Table 1.
Findings: EUS-Ethanol resulted in a significant decrease in cyst size as
compared to saline lavage. 10/23 (43%) subjects had complete ablation of
the PCL as determined by imaging; all as a result of ethanol lavage. Com-
plications from EUS-ETOH: there were two episodes of acute pancreatitis.
Results of surgical pathology in 3 subjects who underwent PCL resection
after lavage: 1) benign 3.5 cm IPMN-50–75% epithelial ablation (ETOH); 2)
benign 2.2 cm mucinous cyst with histology demonstrating 100% epithelial
ablation, (ETOH); 3) 1.5 cm benign mucinous cyst with intact epithelium
(Saline).
Conclusion: EUS-ETOH decreased pancreatic cyst size and resulted in an
ablation rate greater than that achieved with EUS-Saline.
Post Complete Complications
Baseline cyst procedure cyst cyst ablation of EUS
EUS surface area surface area rate (EUS or lavage
Lavage (s) (mean +SEM) (mean + SEM) CT scan) (pancreatitis)
Saline 1.7 cm2 + 0.9 1.4 cm2 + 0.6 0/15 0
N = 15
Ethanol (one) 1.5 cm2 + 0.3 1.1 cm2 + 0.3∗ 2/37 1
N = 36
Ethanol (two) 1.4 cm2 + 0.4 1.0 cm2 + 0.4∗∗ 10/23 1
N = 23
∗P = .002 ∗∗P = .0001 ETOH vs Saline
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Comparison of MRCP with the Gold Standard, ERCP, for Evaluation
of the Hepatobiliary Tract in a Large Urban Community Hospital
Jennifer Lee, MD, Dana A. Sloane, MD, Mahmood Abedi, MD, R.M.
Bashir, MD, Timothy R. Koch, MD∗. Medicine/Gastroenterology,
Washington Hospital Center, Washington, DC and Gastroenterology,
Washington Hospital Center and Georgetown University School of
Medicine, Washington, DC.
Purpose: Endoscopic retrograde cholangiography (ERCP) is the gold stan-
dard in imaging the hepatobiliary tract (HBT). Recent studies have compared
findings from magnetic resonance cholangiography (MRCP) with findings
from ERCP for HBT imaging. Most studies were reported from large aca-
demic tertiary care centers. The purpose of this study is to identify the utility
of MRCP for imaging the HBT in a large urban community teaching hospital
that relies on ERCP.
Methods: This is a retrospective chart review which included all inpatients
and outpatients who had both MRCP and ERCP between August 1, 2006 and
March 31, 2007. Referring physicians included private community physi-
cians and full time hospital staff physicians. For inclusion, both ERCP and
MRCP had to be: 1) completed within a 2 week period, and 2) ordered to
visualize the HBT. A Chi-Squared test of independence was used to examine
the concordance of abnormal and normal findings from MRCP and ERCP.
We determined sensitivity and specificity from MRCP findings compared to
results from ERCP (the gold standard).
Results: Fifty-two joint MRCP and ERCP studies were completed in 48
patients (32 women and 16 men; age range 24 to 89 years). In 52 joint
studies, ERCP was abnormal in 48 (92%) of the cases, while MRCP was
abnormal in 42 (81%). Among 6 cases with normal MRCP in which there was
an abnormal ERCP, the abnormalities included identification of a stricture of
the HBT in 5 cases. Using ERCP as the gold standard, MRCP had a calculated
sensitivity of 83% with a calculated specificity of 50%. Examination of the
concordance of abnormal and normal findings from MRCP and ERCP did
not identify a significant difference (Chi-squared 2×2 contingency table:
P = 0.08).
Conclusion: It is unclear whether results from large academic tertiary care
centers can be applied to community hospitals. In contrast to published
studies, our findings suggest that MRCP may miss a significant abnormality
in 11% of cases. In addition, there was a strong trend (P = 0.08) toward
an increase in the number of cases with abnormal ERCP compared to the
number of cases with abnormal MRCP. ERCP appeared to be a better test for
detecting strictures in imaging of the HBT. In a large community hospital,
MRCP may be an acceptable imaging modality in patients in whom a stricture
of the HBT is less likely.
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Failure of Antibiotics To Prevent Infection in Patients with Necrotizing
Pancreatitis: A Meta-Analysis
Nison Badalov, MD, Robin Baradarian, MD, Ilan Aharoni, MD, Jian Jun
Li, MD, Scott Tenner, MD, MPH∗. Division of Gastroenterology, Dept of
Medicine, Maimonides Medical Center, Brooklyn, NY and Division of
Gastroenterology, State University of New York, Brooklyn, NY.
Purpose: Bacterial infection has been a major cause of morbidity and mor-
tality in patients with acute pancreatitis. Multiple prospective studies have
evaluated antibiotics in the prevention of infection of pancreatic necrosis in
patients with severe acute pancreatitis. The studies have shown conflicting
results. In order to better understand the role of antibiotics in the preven-
tion of infectious complications in patients with necrotizing pancreatitis, the
following meta-analysis was performed.
Methods: A Medline search was performed to identify all trials eval-
uating the efficacy of antibiotic prophylaxis in the treatment of patient
with necrotizing pancreatitis. Studies included in the final analysis were
(1) full length papers published in peer reviewed journals, (2) included
only patients with necrotizing pancreatitis, (4) prospective, (5) placebo-
controlled, and (6) defined outcome as sepsis, infection of pancreatic necro-
sis and mortality. Studies were combined and scored. A pooled analy-
sis of the overall rates of pancreatic infection, sepsis and mortality was
calculated. A weighted mean was utilized. The 95% confidence intervals
were calculated for the placebo and treatment arms. In the analysis, the
absolute risk reduction (ARR) and relative risk reduction (RRR) were
calculated.
Results: Seven randomized, prospective, placebo controlled studies were
identified. Two were double blinded. A total of 455 patients were included in
the analysis, 228 patients given prophylactic antibiotics and 227 patients
given placebo. In combining the studies, using a weighted mean meta-
analysis, there was no significant benefit in using prophylactic antibiotics
compared to placebo in the prevention of pancreatic infection, sepsis and
mortality.
Conclusion: Although earlier studies had suggested that antibiotic pro-
phylaxis can prevent infectious complications in patients with necrotizing
pancreatitis, this meta-analysis, which includes the more recent double-
blinded trials, shows no benefit. The results of this study are consistent
with current guidelines of the American College of Gastroenterology: “pro-
phylactic antibiotics are not recommended in patients with necrotizing
pancreatitis”.
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Prevalence of the Calcium Sensing Receptor (CaSR) Gene
Polymorphisms in Patients with Recurrent Acute and Chronic
Pancreatitis with or without SPINK1 N34S
Venkata Muddana, MD, Michael M. Barmada, PhD, Janette Lamb, PhD,
Beth Elinoff, MPH, Robert H. Hawes, MD, Peter B. Cotton, MD, Michelle
Anderson, MD, Randall E. Brand, MD, Adam Slivika, MD, David C.
Whitcomb, MD∗. Department of Medicine, UPMC Shadyside, Pittsburgh,
PA; Department of Human Genetics, University of Pittsburgh School of
Medicine, Pittsburgh, PA; Department of Medicine, UPMC Presbyterain,
Pittsburgh, PA; Digestive Disorder Center, Medical University of South
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Carolina, Charlestown, PA; Department of Medicine, University of
Michigan Medical Center, Ann Arbor, MI and Department of Medicine,
Evanston Northwestern Healthcare, Evanston, IL.
Purpose: The calcium sensing receptor (CaSR) plays an important role
in calcium homeostasis. It is expressed in pancreatic acinar and ductal
cells, as well as in the cells of the parathyroid gland and kidney tubule.
The CaSR 1011 C>G single nucleotide polymorphism (SNP) is associ-
ated with slightly elevated serum calcium levels in general population.
Felderbauer et al. (Scand Journal of Gastroenterology, 2006; 41: 343–
348) reported three novel CASR gene mutations in a cohort of 19 fam-
ilies with idiopahtic chronic pancreatitis and suggested that CaSR gene
might be a co-factor with SPINK1-mutations in a complex pancreatitis
risk model. To test the hypothesis that the CASR polymorphisms alter
the risk of SPINK1 N34S subjects for recurrent acute (RAP) and chronic
pancreatitis (CP).
Methods: 65 affected subjects with idiopathic and familial pancreatitis and
58 controls were selected, of these 38 patients and 11 controls had SPINK1
N34S polymorphism. The CaSR gene exon 2, 3, 4 and 7, which contains
most of the known functional polymorphisms, were sequenced. Based on
initial results, three nonsynonymous SNPs in exon 7 were genotyped in an
additional 77 affected subjects and 176 controls.
Results: The 3 novel CaSR SNPs (F391F, E790E, and R896H) previously
reported by Felderbauer et al were not identified in our population. In the
exon7 CaSR 1011 C/G SNP the G allele was more common in SPINK1 N34S
subjects (8 of 36, 22%) than either pancreatic patients without SPINK 1 N34S
(8 of 104, 8%, P = 0.034), or controls (16 of 234, 7%, P = 0.012). None of the
11 control subjects with SPINK1 N34S had CaSR 1011 G allele. The other
two common CaSR SNP in exon7 were not associated with pancreatitis.
Conclusion: The CaSR 1011 G allele alone is not a susceptibility
factor for RAP or CP. However, in the presence of SPINK1 N34S,
the CaSR 1011 G allele increases the susceptibility to idiopathic RAP
and CP. These data support a complex genetic model of pancreatitis
susceptibility.
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Efficacy and Safety of a Fully Covered Self Expandable Metal Stents
(CSEMS) for Distal Biliary Neoplasia: Preliminary Data of a
Multicenter Study
Michel Kahaleh, MD, Lee McHenry, MD, Pat G. Northup, MD, Don
Wakelin, MD, Stuart Sherman, MD, Glen A. Lehman, MD, John
Cunningham, MD, Paul Yeaton, MD∗. Digestive Health, University of
Virginia, Charlottesville, VA; Department of Gastroenterology, Indiana
University, Indianapolis, IN and Division of Gastroenterology and
Hepatology, University of Arizona, Tucson, AZ.
Purpose: Partially covered self-expandable metal stents have not clearly
been shown to be superior to uncovered stents in terms of long term patency.
Fully covered metal stents may provide longer patency, but possibly have a
higher rate of complications including stent migration and cholecystitis. We
conducted this multicenter study to analyze the efficacy and complication
rates of fully covered SEMS (CSEMS) in malignant biliary obstruction.
Methods: Between October 2003 and May 2007, 87 Patients (50 males, 66 ±
15 y/o) underwent ERCP with placement of a 10 × 40, 60, 80 or 100 mm
CSEMS (VIABIL, Conmed) for the palliation of distal biliary neoplasia.
Survival, stent patency, complications, and causes of stent dysfunction were
analyzed prospectively. All but 7 patients underwent biliary sphincterotomy
before stent placement.
Results: At the end of the study period, 48 patients were alive and 3 were lost
of follow-up. Twelve CSEMS malfunctioned; 1 migrated and 11 occluded
(10 related to biliary debris and 1 to tumor overgrowth). CSEMS were left
in place and remained patent for a mean of 98 ± 76 days (range: 1–406).
Patency at 90, 180 and 360 days were respectively 90, 64 and 36% (see
Figure). Complications included a self limited wire perforation, 2 post ERCP
pancreatitis and 2 cholecystitis. Six patients underwent curative resection.
Nine patients had their stent removed and replaced in a single session (6 for
tissue sampling, 1 for pancreatic drainage, 2 for occlusion).
Conclusion: Fully CSEMS have acceptable patency rate with minimal short
term complications. Decreased long term patency appears related mainly to
biliary debris. Further long term data is required to confirm this observa-
tion.[figure1]
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A Patient with Choledochal Cyst
Nausheer A. Khan-Bitni, MD, Kaleem M. Rizvon, MD, Omer K. Masood,
MD, Paul J. Mustacchia, MD∗. Gastroenterology, Nassau University
Medical Center, East Meadow, NY.
Purpose: A 29 year old Hispanic woman presented to the ER with complaint
of intermittent right upper quadrant pain of 8 month duration. The pain
started when she was 1 month pregnant, was achy in character and associated
with nausea and vomiting. After she delivered her baby, she noticed yellowish
discoloration of her eyes. She complained of pruritus and anorexia but denied
any fever, chills, diarrhea, or loss of weight. She did not have any significant
medical illnesses and was not taking any chronic medications at home. She
denied smoking, alcohol or drug abuse. Family history was noncontributory.
On physical examination, eyes were icteric and right upper quadrant was ten-
der. Laboratory evaluation showed total bilirubin of 6 mg/dL, direct bilirubin
of 5.2 mg/dL, elevated transaminases (AST-140 IU/L, ALT-126 IU/L) and
elevated alkaline phosphatase (459 IU/L). CT scan of the abdomen showed
severe intra and extrahepatic biliary ductal dilatation and a 10.2×11.7 cm
cyst that was compressing and displacing the pancreatic head, duodenum and
inferior vena cava. MRCP showed significant intra and extrahepatic biliary
ductal dilatation with common bile duct massively distended to 10 cm size.
A diagnosis of choledochal cyst was made.
Choledochal or biliary cysts are cystic dilatations, which may occur singly or
in multiples throughout the bile ducts. They are presumed to be multifactorial
in etiology. An abnormal pancreaticobiliary junction is present in about 70
percent of patients. Choledochal cysts may be complicated by cholelithiasis,
choledocholithiasis, cystolithiasis, pancreatitis, intrahepatic abscess, biliary
cirrhosis and malignancy particularly cholangiocarcinoma. The treatment of
choice is complete excision of the cyst with construction of a biliary-enteric
anastomosis.[figure1][figure2]
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Recurrent Acute Pancreatitis Leads to Chronic Pancreatitis: A
Prospective Case Series
Elie Aoun, MD, Whitcomb C. David, MD, Gleeson C. Ferga, MD,
Papachristou J. Dionysios, MD, Slivka Adam, MD, Papachristou I.
Georgios, MD∗. Medicine, University of Pittsburgh Medical Center,
Pittsburgh, PA; Medicine, Mayo Clinic, Rochester, MN and Medicine,
Pittsburgh VA Health Care System, Pittsburgh, PA.
Purpose: Growing evidence suggests that recurrent acute pancreatitis (AP)
leads to chronic pancreatitis (CP), but this sequence is seldom demonstrated
in human subjects. The Sentinel Acute Pancreatitis Event (SAPE) hypothesis
supports that an initial episode of AP is the first step in a complicated series
of events which ultimately leads to CP.
The aim of this study is to identify patients who evolved from recurrent AP
(RAP) to CP.
Methods: The Severity of Acute Pancreatitis Study (SAPS) database was
reviewed. Patients with their first episode of AP were prospectively followed.
Results: Three of 102 enrolled AP patients fulfilled the above sequence of
events. All 3 patients were teenagers. Upon initial presentation, there was
no evidence of CP on the CT scan performed and no clear AP etiology
was identified. Patients were completely asymptomatic between recurrent
attacks. All patients progressed to CP, as evidenced by CT and ERCP find-
ings, over a relatively short period of time (Table 1). Two patients were
positive for SPINK-1 mutations (N34S), and subsequently underwent total
pancreatectomy with pancreatic islet autotransplantation with good results.
Conclusion: The three patients presented here seem to fulfill the SAPE
hypothesis. Their clinical course supports the concept that pancreatitis may
be a syndrome with a broad spectrum of severity ranging from an isolated
episode of AP to CP. Further studies and the development of additional
disease models are needed in order to fully establish this link.
Patients Characteristics
Patient A Patient B Patient C
Age at first attack
(years)
13 16 13
Gender F M M
Presumed etiology Idiopathic Idiopathic Idiopathic
Family History of
pancreatitis
Brother with RAP None None
AP attacks per year 4 6 5
Time interval
between initial
attack of AP and
development of
CP (years)
1.5 3 3.5
Genetic Testing PRSS1 −/−,
SPINK1 +/+,
CFTR −/−
PRSS1 −/−,
SPINK1 ±,
CFTR −/−
PRSS1 −/−,
SPINK1 −/−,
CFTR −/−
Follow up s/p total
pancreatectomy
and pancreatic
islet cell auto-
transplantation
s/p total
pancreatectomy
and pancreatic
islet cell auto-
transplantation
Enzyme
replacement
and pain
medications
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Cluster of Cases of Gallstone Complications in Patients Less Than 31
Years of Age at UMC, Fresno, CA
Kandarp K. Shah, MD∗, Kalyani K. Shah, MD, Mandeep Singh, MD,
Grace W. Huang, DO, Jasjit Singh, MBBS, Muhammad Y. Sheikh, MD.
Gastroenterology, UCSF-Fresno, Fresno, CA.
Purpose: In the U.S., it is unusual to see gallstone-related complications
in patients below the age of 31 except in Pima Indians and patients with
hemolytic conditions. At the University Medical Center in Fresno, CA, we
have encountered a large cluster of young patients with complications of
gallstones. The nationwide prevalence of gallstones in patients below the
age of 31 is only about 5%. A study was undertaken to further evaluate this
young age group of patients who underwent cholecystectomy.
Methods: The medical records department compiled a list of patients from
January 2004 to August 2006 who had cholecystectomy. The charts of pa-
tients under age 31 at the time of the cholecystectomy were reviewed ret-
rospectively. Data collected included age, ethnicity, body mass index, pre-
dominant complications due to gallstones, and the type of stone found at the
time of surgery. Predisposing factors, including indirect hyperbilirubinemia
and DM, were also assessed.
Results: A total of 1,370 patients had undergone cholecystectomy for gall-
stones in the study period. 370 patients (27%) were below the age of 31.
The medical charts of these 370 patients were reviewed. Cholesterol stones
represented 57.79%, brown stones about 11.92%, green stones 6.42%, and
pigment stones 3.66%. The rest were of undetermined type. About 89.90%
of patients were Hispanic, 7.33% were Caucasian, and all other races con-
stituted about 2.75% of the study population. The average BMI was 31.75,
and the average age was 24.31. Non-Hispanic patients below the age of 31
accounted for more than 20% of the cholecystectomy cases. None of the
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patients had evidence of a hemolytic condition, and only eight cases were
associated with diabetes.
Conclusion: Of all patients undergoing cholecystectomy at our instituion in
Fresno, CA from 2004 to August 2006, an unusually high percentage (27%)
were below the age of 31. The fact that the study population was predomi-
nantly Hispanic does not entirely explain this institutional phenomenon, be-
cause though the Hispanic population is known to have a higher prevalence
of cholelithiasis, the shift to a younger age group for cholecystectomy has
not been reported in the U.S. to our knowledge. This shift to the younger age
group for cholecystectomy affected both the Hispanic and the non-Hispanic
patient population, thus raising the possibility of local factors. These findings
may require further investigation to determine the etiology of cholelithiasis
in this geographic population.
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A Retrospective Comparison of ERCP Complications with
Conventional ERCP vs. Wire Guided ERCP
Gregory J. Ward, MD, Leila Keyvani, MD, Donald R. Duerksen, MD∗.
Internal Medicine, Section of Gastroenterology, University of Manitoba,
Winnipeg, MB, Canada.
Purpose: Endoscopic Retrograde Cholangiopancreatography (ERCP) is an
invasive endoscopic technique which affords both diagnostic studies and
therapeutic interventions. This procedure is associated with potentially se-
vere complications including post ERCP pancreatitis. A factor that may
increase the risk of post ERCP pancreatitis is contrast opacification of the
pancreatic duct. Recently, a wire guided technique has been developed which
avoids opacification of the pancreatic duct. The purpose of this study was
to determine whether there was any difference in post ERCP pancreatitis
requiring hospitalization when conventional cannulation using contrast is
compared with wire guided cannulation.
Methods: A retrospective review of ERCP at a single institution was per-
formed. In 2005 there was a change made from a conventional contrast
injection approach to use of a wire guided approach to ERCP. This latter
technique involves cannulating the common bile duct with a guide wire
prior to injecting contrast. If the pancreatic duct is cannulated, no contrast is
injected. A retrospective chart review of ERCPs performed in April through
September 2004 and January through June 2005 was performed. Data on
procedure length, indication, and complications including pancreatitis was
gathered. Pancreatitis was defined as pain post procedure associated with an
increased lipase and requiring a hospital stay.
Results: A total of 282 ERCPs were performed within the study period by
3 endoscopists, with 14 episodes of post-ERCP pancreatitis (5.0%) docu-
mented. The mean age of the patients was 63 years with 42% being male.
The major indications for ERCP were biliary colic or obstructive jaundice
(75%) and therapeutic intervention was performed in 77% of cases. There
were no differences in demographics between groups.
In the 2005 period, 130 ERCPs were performed, with 3 cases of pancreatitis,
compared with 152 ERCPs in 2004, with 11 cases of pancreatitis [Odds Ratio
0.30 (0.08 to 1.11)]. During the study period, 167 ERCPs were performed
using the wire guided technique, with 4 cases of pancreatitis, compared with
115 ERCPs performed conventionally, with 10 cases of pancreatitis [Odds
Ratio 0.26 (0.09 to 0.79)]. Procedure length was a mean of 32 min and 35
min for conventional and wire guided ERCP respectively. (P = 0.08).
Conclusion: This retrospective study demonstrates that wire guided ERCP
is associated with a lower rate of post-ERCP pancreatitis than conventional
ERCP.
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Efficacy and Safety of ERCP in the Pediatric Population When
Performed by Adult Gastroenterologists: A 6 Year Review
Simona Meca, MD, Brian Schwender, MD, Ari Wiesen, MD, Bernard
Stark, MD, Sideridis Kostas, DO, Simmy Bank, MD∗. Gastroenterology,
Long Island Jewish Medical Center, New Hyde Park, NY.
Purpose: The aim of this study is to evaluate the outcomes of ERCP in the
pediatric population when performed by adult gastroenterologists. Previous
studies have shown that ERCP in the pediatric population is both efficacious
and safe. Little information is available on the safety and efficacy of ERCP
on the pediatric population when performed by an adult gastroenterologist.
Methods: A retrospective chart review was performed at a single academic
center of all 25 patients under the age of 18 that underwent ERCP by an
adult trained endoscopist from 2000–2006. Demographic data was recorded
including age, sex and ethnicity. Clinical data collected included significant
medical history including BMI, clinical indications for ERCP, therapy during
ERCP (such as sphincterotomy, pancreatic or biliary stent placement and
biliary stone extraction), immediate post ERCP complications and hospital
length of stay. BMI was recorded as well.
Results: 25 ERCPs were performed, on patients 18 years of age and younger
from 2000–2006. Of which, 13 were female and 12 were male with an
average age of 13.3 and an age range of 8–18 years old. Significant medical
history included hemoglobinopathies like Sickle Cell Disease (N = 2) and
Spherocytosis (N = 1), PSC (N = 1), IBD (N = 1) and Obesity (N = 5)
Average BMI was 17.37. Average hospital length of stay was 4.8 days with a
range of 0–10 days. Primary indications for ERCP were Cholangitis (N = 2),
Dilated Common Bile Duct (N = 9), Biliary/Pancreatic stent removal (N =
2), Suspected Choledochal Cyst (N = 1), Recurrent Pancreatitis (N = 4),
Pancreatic Pseudocyst (N = 1) and Abnormal Intraoperative Cholangiogram
(N = 6). Sphincterotomy was performed on 19 patients and the common bile
duct was successfully cannulated 96% of the time (22 of 23 cases). CBD
stones were extracted 100% of the time (15 of 15 cases) while pancreatic/bile
duct stents were deployed successfully in 2 of 2 cases. No deaths were
observed. One patient had a post ERCP papillotomy bleed after a needle
knife was used to open a choledococele. This was attributed to a hematologic
disorder (Von Willenbrand Disease). One patient with choledocholithiasis
who underwent ERCP with sphincterotomy and biliary stone extraction had
a mild post ERCP Pancreatitis. No perforations were observed.
Conclusion: In this study, ERCP appears to be a safe and effective procedure
in the pediatric population when performed by an adult trained endoscopist.
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Painless Jaundice and an Extremely Elevated CA 19–9 Secondary to
Choledocholithiasis, Not Malignancy
David L. Ulrich, MD, Saad Jazrawi, MD, Francis Lu, MD, James Robilotti,
MD∗, Prim Chattoo, MD. Gastroenterology, Saint Vincents Medical
Center, New York, NY.
Purpose: Painless jaundice and CA 19–9 levels in the tens of thousands
has been suggested to equate to malignancy with nearly 100% probability.
Here we report a case of a 55 yr-old alcoholic male presenting with painless
jaundice and a CA 19–9 of 62,000 IU/L which normalizes after removal of
a large CBD stone.
Methods: A 55-yr-old hispanic male with an admitted history of heavy
alcohol use presented with jaundice that was recognized by friends over a
2 week period with no complaint of abdominal pain or fever. He stated he
had a decreased appetite for several days and a subjective history of weight
loss, but other than the jaundice had no other symptoms. The results of the
physical examination were unremarkable except for icteric skin and sclera.
Laboratory data on showed a leukocytosis of 23 UL; normal Hgb and Plt.
The bilirubin level was 22.6 mg/dL with a direct of 21.4 mg/dL. Alkaline
phospatase 293 IU/L; AST 62 mg/dL; ALT 166 mg/dL. Amylase and Lipase
were normal. His CA 19–9 was found to be 62,500 IU/L with a CEA and
CA 125 within normal limits.
CT scan of the abdomen showed intra/extra hepatic ductal dilatation with
CBD to 1.6 cm near the pancreatic head. Normal pancreatic duct and no
appreciable mass. An ERCP was performed which showed a large mobile
filling defect in the mid CBD. An extraction of a 2 cm stone was performed.
Results: Follow up studies 3 weeks post extraction showed a normalization
of all liver function tests, negative ANA, ASMA, and AMA; as well as a
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normailization of the CA 19-9 to 18 IU/L. All biliary pathology specimens
were negative for malignancy.
Conclusion: CA 19-9 is a glycoprotein synthesized by normal pancreatic,
biliary, gastric, colonic, endometrial, and salivary epithelial cells. It has
“tumor association” but is not a specific tumor marker. Reports estimate that
CA 19-9 has a sensitivity of 80–90% for pancreatic cancer and 60–70% for
biliary cancer. Non-cancerous lesions such as cholangitis, cholestasis, and
pancreatitis can be associated with elevated CA 19-9 levels, but are thought to
be uncommon higher than 1000 IU/L. Thus, an elevated CA 19-9, even with
high clinical suspicion for malignancy is not always malignancy.[figure1]
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Selected Diagnostic and Therapeutic ERCP and EUS Cases Can Be
Safely and Effectively Performed in an Ambulatory Surgery Center
Setting
Nicholas Karyotakis, MD∗, Rudolph Bedford, MD. Gastrointestinal
Biosciences, Beverly Hills, CA; Linden Crest Surgery Center, Beverly Hills,
CA and Medicine, UCLA, Los Angeles, CA.
Purpose: To evaluate the feasibility and safety of performing endoscopic
retrograde cholangiopancreatography (ERCP) and endoscopic ultrasonog-
raphy (EUS) in a free-standing Ambulatory Surgery Center.
Methods: The first sixteen outpatients undergoing ERCP and/or EUS pro-
cedures in an ambulatory surgery center were evaluated and analyzed for
the purposes of this study. A detailed chart review, phone interview and
follow-up with the treating physicians and the patients to evaluate outcome,
satisfaction and record complications was completed. Equipment and ma-
terials from Olympus Corporation (endoscopes, endosonographic probes,
processors, catheters and sphincterotomes), Microvasive (catheters, sphinc-
terotomes, balloons, plastic stents) and ERBE (Argon plasma coagulator
power unit and peripherals) were used.
Results: Sixteen (N = 16) patients (3 M/13 F, age range: 24–94) underwent
ERCP and/or EUS for a variety of indications. All patients were ambulatory
and had an ASA classification < III. ERCPs were performed in 15 patients
and EUS in 3 (2 patients had a diagnostic EUS followed by therapeutic
ERCP). Three (3) patients underwent only diagnostic ERCP, eleven (11)
patients had ERCP with sphincterotomy and stone extraction, two (2) patients
required plastic stent placement, one (1) patient had ampullectomy following
stent placement and one (1) patient underwent EUS with FNA of pancreatic
mass and adjacent lymph node. Common bile duct cannulation rate was
100% (one patient required pre-cut sphincterotomy). Procedure time ranged
from 18 to 73 min. All patients were observed and discharged within 3
hrs. Complications included one patient with post-ERCP pancreatitis treated
conservatively with pain medications and bowel rest and one patient with an
intravenous site/skin complication. No patient required transfer or admission
to the hospital. Patient satisfaction rates were very high.
Conclusion: Diagnostic and therapeutic ERCP and EUS procedures can be
safely and effectively performed in carefully selected patients in an Ambu-
latory Surgery Center.
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Endoscopic Drainage of Pancreatic Fluid Collections Using Fully
Covered Metallic Stents (CSEMS): A Feasibility Study
Michel Kahaleh, MD, Jayant P. Talreja, MD, Diklar Makola, MD, Tanya D.
Morris, RN, Vanessa M. Shami, MD, Paul Yeaton, MD∗. Digestive Health
Center, University of Virginia, Charlottesville, VA.
Purpose: Endoscopic drainage of pancreatic fluid collections (PFC) has
been proven to be effective, however, the conventional technique of using
plastic double pigtails may require multiple sessions for effective drainage.
Fully covered metallic stents (CSEMS) offer the option of providing a larger
diameter access fistula for drainage and might increase the final success rate.
Methods: Between January 2007 and May 2007, 14 patients (56 ± 5 y/o,
9 male) underwent placement of CSEMS (VIABIL, Conmed) for the
drainage of PFC. Three patients were drained endoscopically and 11 required
EUS-guided drainage. A double pigtail was placed along side (6 cases) or
into the CSEMS (8 cases) to prevent migration. Etiology, indications for
drainage, pseudocyst size, sessions required, complications, follow-up and
final results were prospectively recorded (see table).
Results: Etiology of PFC was gallstone (9), alcohol (3) and other (2). Mean
size was 10 ± 5 cm. A median of 1 session was required to achieve drainage.
Mean time of follow-up until final evaluation was 75 ± 46 days (range
15–180). Complications included, superinfection (4), and bleeding from a
pseudoaneurysm (1). One patient experienced migration of the CSEMS with
resolution of the collection. A total of 13/14 (93%) patients responded suc-
cessfully.
Conclusion: CSEMS seem to offer an efficient and safe alternative for the
drainage of pancreatic fluid collections. A prospective and randomized study
should be performed comparing this technique to conventional drainage with
plastic pigtails.
Details of Cases Drained with CSEMS
Case Indication Size Sessions Complication Results
1 GOO 8 1 None Success
2 Infection 12 1 None Success
3 Infection 15 2 Superinfection Success
4 Infection 13 2 Superinfection Success
5 Pain 12 4 Superinfection Success
6 Infection 5 1 Bleeding Success
7 Infection 7 1 Migration Success
8 Infection 8 1 None Success
9 Pain 17 4 Superinfection Failure
10 Infection 9 1 None Success
11 Infection 9 1 None Success
12 Infection 11 1 None Success
13 Pain 5 1 None Success
14 Infection 5 1 None Success
GOO: Gastric outlet obstruction
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A Single Institution’s Initial Experience with SpyglassTM in the
Diagnosis and Management of Biliary Disease during ERCP
Karen R. Canlas, MD, Malcolm S. Branch, MD, Paul S. Jowell, MD,
Darren A. Pavey, MD, Jorge V. Obando, MD, John A. Evans, MD∗.
Department of Gastroenterology, Duke University Medical Center,
Durham, NC.
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Purpose: To evaluate the clinical utility, safety and ease of use of Spy-
GlassTM (a single-operator peroral cholangiopancreatoscopy system) during
endoscopic retrograde cholangiopancreotography (ERCP).
Methods: A retrospective chart review was performed of the ERCP cases
during which SpyglassTM was used. For each case, the following outcomes
were assessed: success of introducing the device into the bile duct; suc-
cessful identification of filling defects; use and success of electrohydraulic
lithotripsy (if performed); use and success of directly visualized forceps
biopsies; and yield of biopsies.
Results: SpyglassTM cholangiopancreatoscopy was attempted in 6 patients.
A single operator performed each case. Indications for SpyglassTM included:
unexplained abdominal pain of suspected biliary origin (N = 1) and filling
defects seen on initial cholangiogram [suspected choledocolithiasias (N =
3) and malignant stricture (N = 2)]. Cannulation with SpyglassTM was suc-
cessful in 5 of 6 patients (83.3%). The single failed cannulation was due to
difficult anatomy from a suspected malignant biliary stricture in the distal
common bile duct. Identification of filling defects was achieved in 4 of the
5 successful cannulations (3 with stones, 1 with malignancy). Biopsies were
performed in 1 case with a successful diagnosis of a ductal carcinoma. Ther-
apy using electrohydraulic lithotripsy (EHL) via the SpyglassTM device was
attempted in 2 patients (1 with a common bile duct stone, 1 with a cystic
duct stone). Partial clearance was achieved in each case. Failure of success-
ful lithotripsy was due to (1) the size of the common bile duct stone and (2)
inability to maintain good stone to EHL probe contact in the cystic duct. No
procedure related complications occurred.
Conclusion: In this small retrospective review, the Spyglass system demon-
strated adequate visualization of the biliary tree to facilitate the diagnosis
of biliary strictures and lithotripsy of large CBD stones during ERCP. Fur-
ther investigation to identify the optimum patient characteristics for cholan-
giopancreatoscopy with this system is required and ongoing.
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Multiple Biliary Stent Placement Using Conventional Long Wire
(OASIS) and Short Wire (Fusion OASIS with IDR) Stenting Systems
for Benign Bile Duct Strictures (BBDS) – A Retrospective Study
Chhaya Hasyagar, MD, Brian S. Lim, MD, Kanat Ransibrahmanakul, MD,
Erina Foster, MD, Joseph W. Leung, MD∗. Gastroenterology, UC Davis
Medical Center, Sacramento, CA and Sacramento VA Medical
Center/VANCHCS, Mather, CA.
Purpose: Multiple biliary stenting is technically challenging. This retrospec-
tive analysis compared outcomes (success and complication) of conventional
long wire (OASIS, Cook) with short wire (Fusion OASIS with intraductal
release, Cook) stenting systems in multiple stenting for BBDS.
Methods: We reviewed the GI Trac (electronic record system) and hospital
electronic record/imaging as well as patient followup records to identify
patients with BBDS who had undergone multiple stenting, initially with
the OASIS and subsequently Fusion OASIS systems. Sludge/stones formed
above the stricture were removed with basket prior to stent replacement.
Total number of stents, time (minutes) taken and post ERCP pancreatitis
were documented for each ERCP procedure. Data are expressed as (mean ±
SD) and analyzed with Student t-test.
Results: 8 patients underwent a total of 60 stenting procedures between 2000
and 2006, 35 using OASIS and 25 using Fusion OASIS system. There was a
statistically significant difference in number of stents per procedure (1.63 ±
0.731 versus 2.36 ± 0.569, respectively, P < 0.0001). The time required for
first stent placement was 38 ± 19.1 and 46.5 ± 16.2 minutes respectively
(P < 0.14). Mean time for subsequent stents was 7.3 ± 5.29 and 5.95 ± 3.05
minutes respectively (P < 0.2). No post-ERCP pancreatitis was observed in
any patients.
Conclusion: More time is spent on subsequent ERCP’s in removing
sludge/stones that formed above the stricture prior to stent deployment. In-
traductal release (IDR) of guide wire obviates the need for repeat cannulation
and negotiation of the stricture and facilitates multiple stent placement for
BBDS. A prospective trial is needed to confirm the efficacy.
Results of multiple stenting
OASIS Fusion OASIS P∗
# Patients 35 25
Stent /ERCP (mean + SD) 1.63 ± 0.731 2.36 ± 0.569 <0.0001
Time (minutes) first 38 ± 19.1 46.5 ± 16.2 <0.14
stent
Time (minutes) subsequent stents 7.3 ± 5.29 5.95 ± 3.05 <0.2
Post ERCP pancreatitis 0 0
∗Student t-test
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Hemoconcentration Alone Is an Unreliable Predictor of Mortality in
Acute Pancreatitis
Bechien U. Wu, MD, Richard S. Johannes, MD, Xiaowu Sun, PhD, Peter A.
Banks, MD∗. Division of Gastroenterology, Center for Pancreatic Disease,
Brigham and Women’s Hospital, Boston, MA and Cardinal
Health-MediQual, Marlborough, MA.
Purpose: To examine whether hemoconcentration (HC) at admission pre-
dicts in-hospital mortality in acute pancreatitis (AP). To determine whether
a new definition of intravascular volume depletion [Hgb + BUN] is a better
predictor for in-hospital mortality.
Methods: Patient data was generated from the Cardinal Health Research
Database, a large population dataset. All cases from Jan 2004–Dec 2004
with principal diagnosis ICD9-CM 577.0 (AP) were included. Two cohorts of
patients were identified: transferred vs. non-transferred pts. HC was defined
as elevated hgb > 14.6 g/dL (hct 44%). The combination of elevated hgb
> 14.6 g/dL and BUN > 25 mg/dL (Hgb + BUN) was used as a marker
for intravascular volume depletion. Comparison was made between HC and
our newly defined marker of intravascular volume depletion for prediction
of in-hospital mortality in the two cohorts.
Results: There were a total of 202 transferred and 17,852 non-transferred
cases of AP. Overall mortality was 5.5% vs 1.2% in transferred vs. non-
transferred pts respectively (P < 0.001 χ2). HC was a significant risk factor
for mortality only among transferred pts. Combined (Hgb + BUN) was a
significant predictor of mortality in both cohorts. Admission intravascular
volume depletion as assessed by our new criteria was significantly more
common among transferred vs non-transferred pts. (9.4% vs. 2.8%, P <
0.001 χ2).
Conclusion: Hemoconcentration alone is an unreliable predictor of mortal-
ity in AP. Hgb + BUN was a more robust predictor of mortality for both
transferred and non-transferred pts. These findings help explain discordant
results from previous studies of hemoconcentration in AP.
Mortality Comparisons
Transferred (overall Non-Transferred (overall
mortality 5.5%) mortality 1.2%)
% Mortality OR [95% CI] % Mortality OR [95% CI]
HC 11.1% 7.44 [1.56, 35.4] 1.26% 1.05 [0.78, 1.41]
Hgb + BUN 26.3% 10.5 [2.86, 38.9] 5.59% 5.31 [3.51, 8.02]
HC = hemoconcentration, Hgb+BUN = (hgb > 14.6 g/dL + BUN> 25 mg/dL)
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Utility of the SPYGLASS Cholangiopancreatoscope (SCPS): An Initial
Series of 26 Cases at a Tertiary Care Center
Diego I. Kuperschmit, MD, Franklin E. Kasmin, MD∗, Seth A. Cohen, MD,
Jerome H. Siegel, MD. Gastroenterology, Beth Israel Medical Center, New
York, NY.
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Purpose: The SCPS is a recent innovation in which a single endoscopist
is able to perform cholangiopancreatoscopy. The clinical utility of this new
device has not been well studied. The goal of our study was to review our
initial experience with the SCPS and assess its usefulness as a diagnostic
and therapeutic tool.
Methods: We retrospectively examined 26 cases using SPCS. All proce-
dures were performed by one of three biliary endoscopist with experi-
ence in cholangioscopy. Success in imaging the desired ductal structures,
in performing electrohydraulic lithotripy (EHL), and in guiding biopsy was
assessed.
Results: In 20 cases cholangioscopy utilized the Spyscope catheter and
in 6 cases the SPYGLASS video fiber was passed through a triple lumen
sphincterotome. The common duct (CBD) was examined in 25 cases and
the pancreatic duct (PD) in 1. In 13 cases (group 1) the SCPS was used to
evaluate potentially malignant strictures. There were 4 cases (group 2) where
the SCPS was used for EHL of large CBD stones. In 9 cases (group 3) the
SCPS was used in the diagnostic evaluation of various findings in the CBD
or PD.
In group 1 the Spyscope catheter was successfully used in 9/13 cases and
the fiber/sphincterotome was used in 5/13 cases to visualize cbd strictures.
Tissue was obtained in all pts by standard forceps, brushing, or the miniature
Spy forceps (5/13 cases) and was diagnostic of malignancy in 4/13 pts.
Spy forceps provided sufficient tissue in 4/5 biopsies, with 2 demonstrating
mailignancy.
In group 2 stones were visualized well and good placement of the EHL probe
occurred in all cases. Stone pulverization only occurred in 1/3 patients (1/4
cases).
In group 3 the Spyscope catheter was used in 7/9 cases and the
fiber/sphincterotome in 2/9 cases. Examination ruled out stone, mass or
stricture in 7/9 cases. Directed wire guided cannulation of an intrahepatic
duct was performed in one case. A choledochal cyst was successfully sam-
pled with Spy forceps in one case. SPCS examiniation was found to be
clinically useful in all pts in group 3.
Conclusion: Our initial use of the SCPS proved successful in evaluating
complex biliary and pancreatic issues. Excellent visualization was achieved
in all cases. SPCS added to our ability to biopsy malignant strictures, though
the yield was lower than expected in this early experience. EHL was tech-
nically facilitated though two cases of very hard stones proved recalcitrant.
SPCS was found to be clinically useful in the majority of cases.
SMALL INTESTINE/UNCLASSIFIED
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Psychological Correlates of Gluten-Free Diet Adherence in Adults with
Celiac Disease
Jessica B. Edawards George, PhD, Daniel A. Leffler, MD, Melinda D.
Dennis, RD, Ciaran P. Kelly, MD∗, Debra L. Franko, PhD, Jessica
Blom-Hoffman, PhD. The Celiac Center, Beth Israel Deaconess Medical
Center, Boston, MA and Applied Psychology, Northeastern University,
Boston, MA.
Purpose: To determine what set of personality/psychological characteristics
are related GFD adherence in an adult population diagnosed with celiac
disease while further examining the role of depression and anxiety in relation
to adherence with the GFD
Methods: 157 adults with biopsy-confirmed CD on the GFD for > 3 months
completed surveys of depression, anxiety, personality characteristics, self-
efficacy and self-reported GFD adherence, provided a blood sample, and
participated in an evaluation of GFD adherence conducted by an expert
dietician.
Results: Significant correlations were found between bloodwork, self-
reported, and expert evaluation. Logistic regression results indicated that
the following variables were independently associated with GFD adherence:
conscientiousness (B = −.04, S.E. = .01, P < .00), values (B = −.10, S.E. =
.05, P < .05), other food intolerances (odds ratio = .28, 95% CI .10-.78),
and symptoms (B = .05, S.E. = .02, P < .03). A regression model was built
from these significant associations. The resulting model effectively predicted
whether a participant was compliant or non-compliant based on significant
psychological and demographic/disease-specific factors. Successful predic-
tion rates of GFD adherence for the final model was 75.8% for those rated
to be adherent with the GFD and 54.5% for those rated to be non-adherent
with the GFD.
Conclusion: The model of psychological and demographic/disease-specific
characteristics developed can be used to identify patients who may be at
greater risk for poor dietary adherence in order to provide additional support,
education and encouragement.
Regression Model of Variables Associated With GFD Adherence
B or Odds Ratio (P-value)
Values Trait −.10 (0.05)
Conscientiousness −.04 (0.003)
Symptom Severity −.05 (0.03)
Food Intolerances OR .28 (95% CI 0.10–0.78)
[figure 1]
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A Prospective Study of Factors Associated with Increased Gluten-Free
Diet Adherence in Adults with Celiac Disease
Daniel A. Leffler, MD, Jessica B. Edwards George, PhD, Melinda D.
Dennis, RD, Hani Abdullah, MD, Ciaran P. Kelly, MD∗. The Celiac
Center, Beth Israel Deaconess Medical Center, Boston, MA.
Purpose: In recent years increasing number of individuals have been di-
agnosed with celiac disease (CD). The only treatment for CD is lifelong
adherence to a strict gluten-free diet (GFD). Despite its efficacy, adherence
to the GFD is poor and factors which influence this are poorly understood.
We sought to determine which factors influence GFD adherence in adults
with CD.
Methods: A survey of items determined to be important in GFD adherence
was developed by an expert committee and focus groups of patients with
CD. The survey was administered to 154 adults with biopsy proven celiac
disease who then underwent blood testing for IgA tissue transglutaminase
(tTG) levels and a standardized GFD evaluation by a nutritionist skilled
in CD. Univariate and mulitvariate analysis were conducted to determine
factors associated with adherence level.
Results: In the study population, GFD adherence was high with 44.2% fol-
lowing a strict gluten free diet. Gender, Age at participation, age at diagnosis
of CD, length of time on GFD, marital status, educational achievement, and
employment status were not correlated with level of adherence. Factors as-
sociated with GFD adherence are listed in the table below.
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Conclusion: A number of factors were found to be correlated with GFD ad-
herence, including cost, ability to follow the diet outside the home, member-
ship in a celiac disease advocacy group, belief in the importance of following
the GFD, and the ability to follow the GFD despite changes in mood and
stress. These results provide a foundation for the design of educational inter-
ventions that may be used to target individuals at high risk for non-adherence
to the GFD.
Factors Associated with GFD adherence
Factor P Multivariate∗
Cost makes GFD adherence difficult 0.011
Concern with purposeful gluten exposure 0.001
Concern with accidental gluten exposure <0.001
Understanding of GFD 0.002
Ability to follow GFD when traveling 0.012
Ability to follow GFD when dining out <0.001
Ability to follow GFD during social events 0.007
Membership in CD advocacy group 0.008
Comfort following GFD at work 0.003
Belief that avoiding gluten is important for health 0.027
Mood/stress do not affect GFD adherence 0.008
Presence of other food intolerances 0.023
∗Controlling for age, gender, education, age of diagnosis and marital status
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A Prospective Study of Five Measures of Gluten Free Diet Adherence
in Adults with Celiac Disease
Daniel A. Leffler, MD, Jessica B. Edwards-George, PhD, Melinda Dennis,
RD, Detlef Schuppan, MD, Ciaran P. Kelly, MD∗. Gastroenterology, Beth
Israel Deaconess Medical Center, Boston, MA.
Purpose: In recent years increasing number of individuals have been di-
agnosed with celiac disease (CD). The only accepted treatment for CD
is lifelong adherence to a strict gluten-free diet (GFD). Adherence to the
GFD is known to be variable however data guiding the assessment of
compliance is currently lacking. We sought to determine the predictive
value of self-report and four serologic tests compared to expert nutritionist
evaluation.
Methods: 154 individuals between the ages of 22 and 91 followed for
biopsy proven celiac disease were enrolled in the study. All participants
were asked to rate their adherence to a GFD on a likert scale. They then
underwent a standardized evaluation by a nutritionist with expertise in
celiac disease blinded to the participants self-rated adherence. Blood was
then drawn and tested for titers of IgA tissue transglutaminase (tTG) an-
tibody, IgA and IgG deaminated anti-gliadin antibody (dAGA) and con-
jugated IgA-IgG dAGA. ANOVA and ROC analyses were conducted to
determine the value of the different measures in determining adherence
level.
Results: All serologic measures as well as participant reported adherence
were significantly associated with GFD adherence as measured by nutrition-
ist evaluation with Spearman’s correlation, P =< 0.001, 0.002, 0.010, 0.015,
0.017 for self-report, IgA-dADA, IgA-IgG dAGA, IgA-tTG and IgG dAGA,
respectively. On ROC analysis however, no measure performed satisfactorily.
For a set sensitivity of 80%, a cutoff value of 17.0 for IgA dADA yielded a
specificity of 58%, a cutoff value of 10.4 for IgG dADA yielded a specificity
of 54%, a cutoff value of 15.0 for GDP yielded a specificity of 50%, and a
cutoff value of 18.5 for IgA tTG yielded a specificity of 56%. (see Fig. 1)
The performance of all serologic testing but not self-report improved with
increased time on the GFD.
Conclusion: Although current serologic tests have very high sensitivities and
specificities for the diagnosis of celiac disease, they cannot replace trained
nutritionist evaluation in the assessment of GFD adherence.[figure 1]
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Unusual Reasons for Incomplete Colonoscopy
Nirmal S. Mann, MD, FACG∗, Chhaya Hasyagar, MD. Gastroenterology,
Univ. of California, Davis, School of Medicine, Sacramento, CA.
Purpose: A 50 year old woman had h/o chronic constipation for 15 years.
She could not have any bowel movement without the use of laxatives. She
has been using laxatives daily for 15 years but she assured us that she only
used a”safe, natural, herbal” laxative. Therewas no h/o hematemesis, me-
lena or hematochezia. There were no constitutional symptoms. There were
no other GI complaints, there was no F/H of colon cancer. The review of
systems was unremarkablePhysical Examination was normal. CBC & Chem-
istry panel was normal. A screening colonoscopy was per formed after usual
PEG preparation. The rectum and the sigmoid colon were very dark due to
severe melanosis coli. As the scope entered the descending colon, the view
became pitch dark; the endoscopist felt he was in a jungle at night without a
flash light. Manually increasing the brightness to the maximum on the light
source did not help. The procedure was abandoned. Biopsies were obtained
in the sigmoid colon. Later on an elective BE ruled out any masses or polyps
in the rest of the colon. The histologic examination of the biopsy showed
extensive infiltration of the cells in the lamina propria & submucosa with
pigment. On further questioning, the patient informed us that she has been
using Nature’s Secret—Super Cleanse laxative which she said had natural
herbs. An evaluation of the composition of Super- Cleanse showed it con-
tained Cascara sagrada bark which is rich in anthraquinones & anthracene
which are known to cause melanosis coli.
Methods: This is an unusual case in that SEVERE melanosis coli pre-
vented completion of screening colonoscopy. The exact composition of so
called”narural, herbal, safe” laxatives should be ascertained: besides cascara
sagrada other herbs such as Aloe vera and Senna (Swiss Kriss) may con-
tain chemicals which can cause melanosis coli & other serious side effects.
The pigment in melanosis coli is not melanin so it should be called pseudo
-melanosis coli. Melanosis coli involving pericolonic lymph nodes associ-
ated with the herbal laxative Swiss Kriss has been reported in a patient with
colonic adenocarcinoma (Arch Path lab Med128:565–567, 2004). Rarely
melanosis may involve other parts of the GI tract such as the ileum, esopha-
gus & stomach. It may also involve the Vagina & Prostate. Anthraquinone-
induced apoptosis of colonic epithelial cells may be important in pathogen-
esis.(Am J Path, 131:465–476, 1988).
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Treatment of Symptomatic Small Intestinal Bacterial Overgrowth and
Weight Gain after Gastric Bypass Surgery
Hiral N. Shah, MD, Frederick C. Finelli, MD, John R. Kirkpatrick, MD,
Nancy M. Carroll, MD, Timothy R. Koch, MD∗. Medicine, Washington
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Hospital Center, Washington, DC; Surgery, Washington Hospital Center,
Washington, DC and Gastroenterology, Washington Hospital Center and
Georgetown University School of Medicine, Washington, DC.
Purpose: We reported that daily oral thiamine is not effective for treating thi-
amine deficiency after Roux-en-Y gastric bypass surgery (GPS); in contrast,
in those patients with abnormal glucose-hydrogen breath tests, antibiotic
therapy with oral thiamine is effective therapy. Small intestinal bacterial
overgrowth (SIBO) interferes with micronutrient and macronutrient absorp-
tion from the small intestine and may reduce caloric intake. We hypothesize
that antibiotic therapy for SIBO induces weight gain after GBS.
Methods: In this retrospective chart review; 17 female patients (age range
33–65 years; mean age 51 years) had Roux-en-Y GBS in 1999–2005. The
study included: 1) post-operative patients who had both an abnormal glucose-
hydrogen breath test and abdominal symptoms consistent with SIBO, who
2) received an antibiotic to treat bacterial overgrowth. Antibiotic was given
for 7 to 10 days, once monthly. Sex, age, weight before and after receiving
antibiotic, and the presence of or resolution of abdominal symptoms after an-
tibiotic were recorded. Abnormal glucose-hydrogen breath test was defined
by increase in breath hydrogen >20 ppm within 45 minutes after 50 grams
glucose. Patients were seen 8 to 72 months after GBS (mean: 32 months).
Resolution of abdominal symptoms was used to determine effectiveness of
antibiotic therapy.
Results: Eight patients had weight gain (range: 0.5–7.2 kg; mean: 3.2 kg) 2
to 5 months (mean: 3.1 months) after beginning antibiotic therapy. Among
these 8 patients, abdominal symptoms resolved in 7; among 9 patients with
weight loss, only 3 had resolution of abdominal symptoms (Chi-squared
2×2: P = .03). Nine patients had weight loss of 0.5 to 14.4 kg (mean: 4.6
kg) at 2 to 4 months (mean: 3.1 months). Abdominal symptoms resolved in 7
of 13 patients receiving metronidazole, 1 of 2 with amoxicillin/clavulanate,
and 2 of 2 with rifaximin.
Conclusion: Weight gain in patients with SIBO receiving antibiotics was
associated with resolution of abdominal symptoms. This supports our hy-
pothesis that antibiotic treatment of bacterial overgrowth induces weight
gain. Conversely, SIBO may promote weight loss after GBS. Weight gain
noted after antibiotic treatment could be due to: increased caloric intake,
resolution of abdominal symptoms, or increased macronutrient absorption.
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Celiac Disease in the Adult Community; Still a Rare Occurrence
Douglas J. Sprung, MD∗, Gregory M. Sprung. Maitland, FL.
Purpose: To evaluate the prevalence of Celiac disease (CD) in a general
community gastroenterology practice in Orlando, Fl.
Methods: A retrospective computer review of all patient charts in our single
specialty gastroenterology practice, with a diagnosis of CD was undertaken.
Charts from 1/91 – 12/05 were reviewed. A diagnostic small bowel biopsy
(SBB) or positive anti-gliadin Ab plus anti-endomyseal Ab (or anti-tTg Ab)
were requires for the diagnosis of CD. All characteristics, symptoms and
laboratory values were examined.
Results: Of 70 patients with a computer diagnosis of CD, 30 charts were
unavailable because they had been shredded due to inactivityfor 7 years
or more, or left the practice with a former partner. Of the remaining 40
patients, 10 did not meet criteria. 30 charts were reviewed. 11 (36%) were
male, 19 (64%) female. The mean age was 55. The diagnosis of CD was
made by blood tests alone in 4 patients, by SBB alone in 11, and by both
in 15. Diarrhea occurred in 23 (70%), weight loss in 16 (53%) and anemia
in 20 (66%). Anemia was borderline in 10, moderate in 2, severe in 1, iron
deficient in 6 and macrocytic in 1. One patient had concommittent Crohn’s
disease (and dermatitis herpetiformis) and 4 had concommitent microscopic
colitis. None developed cancer, requires steroids or failed to improve on a
gluten free diet. Each physician diagnosed 1.3 patients with CD per year. A
review of all SBB done over a one year period at a single community hospital
revealed 3 cases of CD out of 570 patients, or a prevalence of 1/190. These
were symptomatic patients who underwent gastroscopy.
Conclusion: 1. In a private adult GI practice, CD was a relatively rare diagno-
sis over a 15 year period. The average number of cases per year has remained
stable. 2. The triad of diarrhea, weight loss and anemia was present in over
60% of patients, with 97% of all patients having at least one of these findings.
3. Microscopic colitis was the most common concommitent illness, Crohn’s
disease occurred cocommitently in only one instance. 4. Out of 570 symp-
tomatic patients who underwent SBB to rule out CD, only 3 were positive
(0.5%). 5. CD remains an uncommon diagnosis in the private community
sector, with no evidence of an increasing prevalence over the past 15 years.
It seems unlikely that there are a significant number of patients who go
undiagnosed as has been suggested in the literature.
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Mechanism of Zinc Deficiency in Patients with Roux-en-Y Gastric
Bypass Surgery
Hiral N. Shah, MD, Bikram Bal, MD, Frederick C. Finelli, MD, JD, Nancy
M. Carroll, MD, John R. Kirkpatrick, MD, Timothy R. Koch, MD∗.
Medicine, Washington Hospital Center, Washington, DC; Surgery,
Washington Hospital Center, Washington, DC and Gastroenterology,
Washington Hospital Center and Georgetown University School of
Medicine, Washington, DC.
Purpose: Zinc is an essential component of the catalytic site of hundreds
of different metalloenzymes where it functions as a Lewis acid. The small
intestine is the main site of zinc absorption via transporter expression which
is regulated by dietary zinc intake.
It is has been reported that some patients become zinc deficient after Roux-
en-Y gastric bypass, although the mechanism of this is unknown. Based on
our ongoing work examining thiamine deficiency, we hypothesize that small
bowel bacterial overgrowth can decrease small intestinal zinc absorption.
Methods: This is a retrospective review of 452 patients who underwent
Roux-en-Y gastric bypass surgery from 1999–2005. All patients were iden-
tified who had measurement of serum folate levels. As a marker of small
intestinal bacterial overgrowth (SIBO), elevated serum folate level (>14
ng/dL) has a reported specificity of 79%. Baseline patient demographics
and characteristics including age, sex, BMI were recorded. There were 230
patients who had determination of serum folate level, and 172 patients who
had both serum folate and serum zinc levels.
Results: There were 199 female and 31 male patients with average age of
46 years (range: 21–68 years). The mean body mass index was 53 kg/m2
(range: 40–100). Of these 230 patients, 145 had elevated serum folate levels
supporting a prevalence of 63% for SIBO. Of the172 patients who also had
serum zinc levels, in 54 patients with normal serum folate levels, 43 had
normal serum zinc; among 118 patients with elevated serum folate, 78 had
low serum zinc (Chi-squared 2×2: P < .001).
Conclusion: Elevated serum folate, a marker for small intestinal bacterial
overgrowth, is common after gastric bypass surgery. This study supports
our hypothesis that small bowel bacterial overgrowth can decrease small
intestinal zinc absorption. Since present physiological evidence supports
zinc absorption primarily in the jejunum by a transcellular route involving a
zinc-specific transporter, Zip4, further studies should be directed at potential
post-operative changes in zinc transport and the potential for reversibility
with treatment of small intestinal bacterial overgrowth.
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The Efficacy of the GLP-1 Agonist Exenatide in the Treatment of
Short Bowel Syndrome
Mark Pimentel, MD∗, Benjamin Basseri, MD, Sheila Lezcano, BS,
Kimberly Low, BS, Vicky Lees-Kim, RN, Tess Consantino, RN, Jeffrey L.
Conklin, MD, Edy E. Soffer, MD. GI Motility Program, Cedars-Sinai
Medical Center, Los Angeles, CA.
Purpose: Short bowel syndrome (SBS) is a serious medical problem result-
ing in severe diarrhea and nutritional deprivation. The symptoms result from
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lack of absorptive surface and loss of the braking mechanisms controlling
the proximal gut. One of the missing, distally produced, peptides that control
the proximal gut is glucagon-like peptide-1 (GLP-1). In this study we test the
effect of the GLP-1 receptor agonist, exenatide, on short bowel syndrome.
Methods: SBS subjects were selected based on clinical symptoms and
greater than 50% distal small bowel resection. Before beginning exenatide
treatment, each patient completed a questionnaire documenting stool fre-
quency and consistency. In addition, SBS symptoms, CBC, chemistries and
BMI were also obtained. An antroduodenal manometry study was performed
during fasting, after exenatide, and after a subsequent test meal. Each patient
was then started on exenatide 5 to 10 mcg subcutaneously twice a day. Over
the following month the baseline parameters measured were repeated.
Results: The subjects consisted of 4 males and 1 female, ages 46 to 69
(mean: 57.2). At baseline, all patients had severe diarrhea that ranged from
7 to 15 bowel movements per day, often occurring within 15 minutes of eat-
ing. After exenatide, all 5 patients had an immediate improvement in bowel
frequency and form. In the most severely affected patient, the bowel move-
ments reduced from 15 watery bowel movements per day to 2–3 formed
stool. In all subjects, bowel movements were no longer meal related and
often occurred hours after any meal. At baseline nutritional parameters were
stable due to total parenteral nutrition (TPN) in most cases (N = 3). How-
ever, after exenatide, all 3 patients no longer needed TPN. Despite the lack of
TPN, no weight loss or biochemical nutritional deterioration was observed
in any case. Previous attempts at ceasing TPN had resulted in immediate and
life-threatening dehydraton and malnutrition. Using normal bowel function
as a goal, subjects described their improvement with exenatide as 65–100%
improved. Antroduodenal manometry in 2 out of 5 subjects demonstrated
continuous low amplitude gastric contractions during fasting which com-
pletely normalized after exenatide.
Conclusion: Exenatide is a novel and safe treatment option for SBS. It nor-
malizes bowel function and maintains nutritional status. Successful treatment
with exenatide may significantly reduce the need for parenteral nutrition.
234
Calcium Deficiency Is Associated with Small Intestinal Bacterial
Overgrowth after Roux-en-Y Gastric Bypass Surgery
Bikram S. Bal, MD, Hiral N. Shah, MD, Frederick C. Finelli, MD, JD,
Nancy M. Carroll, MD, John R. Kirkpatrick, MD, Timothy R. Koch, MD∗.
Medicine, Washington Hospital Center, Washington, DC; Surgery,
Washington Hospital Center, Washington, DC and Gastroenterology,
Washington Hospital Center and Georgetown University School of
Medicine, Washington, DC.
Purpose: We have shown that after Roux-en-Y gastric bypass surgery (GBS),
patients frequently have elevated serum folate levels, a marker of small in-
testinal bacterial overgrowth (SIBO). Gastric pouch achlorhydria after GBS
may lead to SIBO. Calcium deficiency with subsequent hyperparathyroidism
and decreased bone mineral density has been reported after GBS. We hy-
pothesize that by altering gut ecology, GBS induces calcium deficiency.
Methods: This is a retrospective chart review of 452 patients who under-
went Roux-en-Y gastric bypass surgery from 1999–2005. Of these patients,
154 had determination of serum folate, serum calcium, and 24 hour urinary
calcium levels. Baseline patient demographics and characteristics included
age, sex, and BMI. Glucose-hydrogen breath testing (HBT) had been per-
formed in 43 patients (abnormal test was: hydrogen concentration >15 ppm
over baseline fasting value or fasting hydrogen level >10 ppm).
Results: In 129 female and 25 male patients, average age was 42 years (21
to 63 years) with BMI range of 40 to 80 kg/m2. Among 43 patients who
underwent HBT, 42 had an abnormal breath test. Of these 42 patients, 38
also had elevated serum folate (90% sensitivity for elevated serum folate as
a predictor of SIBO). Of 42 patients with abnormal HBT, 30 had low 24 hour
urinary calcium (Chi-squared 2 × 2: P < .01). In the154 patients, 48 patients
had normal serum folate levels of whom 38 had normal urinary calcium; in
106 patients with elevated serum folate, 80 had low 24 hour urinary calcium
(Chi-squared 2 × 2: P < .001). Corrected serum calcium was within the
normal range in all patients.
Conclusion: Using HBT as the gold standard, almost all GBS patients who
were tested had abnormal HBT, supporting the belief that SIBO is com-
mon after GBS. Elevated serum folate has a high sensitivity for detecting
SIBO. Serum calcium determination is not accurate in predicting calcium
metabolism in these patients. This study supports our hypothesis that by alter-
ing gut ecology, GBS induces calcium deficiency. Calcium malabsorption
and secondary hyperparathyroidism may increase the risk for developing
osteopenia, osteoporosis, and ultimately osteomalacia. Further studies of
calcium metabolism after treatment of SIBO may support a treatment option
for these patients.
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A Systematic Review of Diagnostic Testing for Small Intestinal
Bacterial Overgrowth
Reza Koshini, MD, Dai Sun-Chuan, MD, Sheila Lezcano, BS, Mark
Pimentel, MD∗. Division of Gastroenterology, Harbor/UCLA Medical
Center, Torrance, CA and GI Motility Program, Cedars-Sinai Medical
Center, Los Angeles, CA.
Purpose: There is a growing body of literature investigating the role of small
intestinal bacterial overgrowth (SIBO) in various disease states. However,
there is much criticism regarding the diagnostic accuracy of testing. The aim
of this study was to systematically review the validity of diagnostic tests for
SIBO.
Methods: We performed an electronic literature search of U.S. National li-
brary of medicine (PubMed) and OVID Medline using key words to identify
and capture a broad series of article titles related to the diagnosis of bac-
terial overgrowth. An a priori set of inclusion and exclusion criteria were
applied to titles, abstracts and subsequently papers to determine those for
final review. The papers included in the final selection were categorized by
type of diagnostic test and evaluated for consistency and design. In the final
step of the review, the studies were compared to published guidelines for
expectations of publications evaluating a diagnostic test (Reid, et al).
Results: With the initial electronic search, 1485 abstract titles met preset
key words. After stepwise application of criteria for abstracts and papers, 71
met the standard for inclusion. Many studies had less than 20 subjects and
often a mixture of diseases predisposing to SIBO. There was no study that
properly validated culture at 105 cfu/mL in upper bowel for SIBO. There was
great variability on culturing techniques and aspirate location. One reason-
ably sized study demonstrated that controls had no bacteria, celiac had 101,
IBS 103 and only Billroth II patients demonstrated levels greater than 105
(Bardhan, et al). Given the lack of gold standard, it was difficult to validate
all other testing such as breath test. Another technique for evaluating the
accuracy of diagnostic testing was to retest after treatment with antibiotic.
23 of the 71 papers studied the test utility in this way and were most convinc-
ing of the clinical utility for the specific test used. Finally, using published
standards for an accurate diagnostic test, none of the 71 publications fulfilled
the full set of criteria.
Conclusion: Diagnosis of bacterial overgrowth has no gold standard since
even culture has not been properly evaluated. In the absence of a gold stan-
dard, this study suggests that clinical correlation in a test, treat and retest
situation is the best method for the management of bacterial overgrowth until
more accurate diagnostic testing is available.
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Genetic Testing Prior to Serologic Screening in Family Members of
Patients with Celiac Disease as a Cost Containment Method
Matthew Chang, MD, Peter H. Green, MD∗. Department of Medicine,
Columbia University College of Physicians and Surgeons, New York, NY.
Purpose: Family members of patients with celiac disease (CD) have
increased rates of developing CD over their lifetime, with up to 3%
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seroconverting 5 years after an initial negative result. Repeat testing of family
members 5 years later would improve CD diagnosis rates, but at significant
cost. Genetic testing prior to screening family members for CD would po-
tentially reduce these screening costs by eliminating HLA-DQ2 and DQ8
negative patients who are at extremely low risk for developing CD.
Methods: Decision analysis was used to compare the costs of screening
family members of patients with CD. The decision tree incorporated three di-
agnostic branches: initial screening with anti-tissue transglutaminase (tTG),
repeat screening with tTG at 5 years later, and genetic testing prior to screen-
ing with tTG. Costs were estimated using Medicare reimbursement fees.
Modeling and sensitivity analyses were performed using Tree Age Pro 2006
(Williamstown, MA).
Results: The cost of an initial screening with tTG of family members of
patients with CD is approximately $434 per person. Repeat screening at
5 years later would cost $683 per person, which is an additional $249, but
would diagnosis an additional 4.4% cases of CD. Genetic testing prior to
screening family members would be slightly more costly, at $750 per person,
but would lower endoscopy workload by nearly 25% when compared to
repeat screening at 5 years without genetic testing. The cost of genetic testing
would have to decrease from $301.40 to $234.40, a difference of $67, to
justify its use prior to serologic testing. As the specificity of tTG approaches
100%, the cost of genetic testing would have to continue to decrease to less
than $200 in order for it to be an affordable option.
Conclusion: Repeat screening with tTG of family members of patients with
CD results in a significant increase in cost, but also an associated increase
in CD cases diagnosed. Genetic testing would potentially eliminate up to
60% of the population to be screened and, if available at a lower cost, would
partially offset costs of repeat serologic screening.
237
Pathomorphologic and Functional Alteration of Duodenal Mucosa in
Patients with Chronic Alcoholic Pancreatitis
Kartar Singh, DM∗, Sonia Bonchal, PhD, K.K. Prasad, MD, Saroj Kant
Sinha, DM, Chander Kamal Nain, PhD. Department of Gastroenterology,
Postgraduate Institute of Medical Education & Research, Chandigarh,
Union Territory, India.
Purpose: Since the pathomorphologic and functional alteration of duodenal
mucosa among chronic alcoholic pancreatitis patients is unknown, therefore
we studied duodenal mucosal morphologic alteration and enzyme activities
of chronic alcoholic pancreatitis patients.
Methods: This prospective study included diagnosed cases of chronic al-
coholic pancreatitis (N = 11) in whom duodenal biopsies were studied for
brush border enzymes (disaccharidases, alkaline phosphatase, LAP, LDH,
GGT), intracellular enzymes (G-6-PDH, ICDH, G-6-P), membranous en-
zyme (Na+-K+ ATPase) activities and pathomorphologic (light microscopic
and ultrastructural) alterations. The duodenal biopsy from patients with
GERD (N = 29) were taken as control. The results were expressed as number
and percentage or mean ± SEM. Appropriate statistical methods were ap-
plied. Informed written consent was obtained prior to participation in study.
The study was approved by the Institute ethical committee.
Results: The mean age (all males) of patients was 41.0 ± 10.7 years. The
mean duration of alcohol intake was 250 ml/day for14 ± 1.3 years. In duode-
nal mucosa of pancreatitis and GERD patients the mean enzymatic activities
(IU/g protein) of lactase was 6.2 ± 0.5 Vs 24.3 ± 1.0 (P < 0.001), sucrase
was 18.6 ± 1.7 Vs 42.4 ± 1.8 (P < 0.001), maltase was 35.4 ± 2.2 Vs
76.1 ± 13.0 (P < 0.001), LAP was 140.0 ± 9.8 Vs 27.7 ± 17.6 (P < 0.01),
LDH was 402.0 ± 40.2 Vs 104.9 ± 4.1 (P < 0.001), GGT was 208.1 ± 11.2
Vs 99.5 ± 4.2 (P < 0.001) and alkaline phosphatase was 267.4 ± 11.3 Vs
180.6 ± 6.5 KAU/g protein (P < 0.01). The mean enzymatic activities in
duodenal mucosa of pancreatitis and GERD patients for G-6-PDH was 4.4 ±
0.4 Vs 11.0 ± 0.2 (P < 0.001), ICDH was 13.8 ± 0.5 Vs 23.2 ± 1.6 (P <
0.05), G-6-P was 0.6 ± 0.06 Vs 1.7 ± 0.05 (P < 0.001) and Na+-K+ ATPase
was 1.1 ± 0.01 Vs 2.5 ± 0.09 (P < 0.001). Chronic alcoholic pancreatitis
patients showed mild villous atrophy (36.4%), intraepithelial lymphocyto-
sis (81.8%) and increased lamina propria infiltrate in the duodenal mucosa.
Electron microscopy showed distorted microvilli, dilated mitochondria, in-
creased rough endoplasmic reticulum in alcoholic pancreatitis patients.
Conclusion: Chronic alcoholic pancreatitis patients showed significant al-
teration in duodenal mucosal enzyme activities indicating injury to ente-
rocytes. These observations were supported by the light microscopic and
ultrastructural alteration of enterocytes.
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Massive Upper GI Bleed and Duodenal Ulcer Caused by Intra-Hepatic
Artery Infusion Catheter Eroding into Duodenum in a Patient with
Metastatic Colorectal Cancer
Khushal Afzal, MD, Weizheng W. Wang, MD∗. Gastroenterology, UMDNJ
New Jersey Medical School, Newark, NJ.
Purpose: Intra-hepatic arterial infusion (HAI) pump placement for selective
hepatic chemotherapy in patients with metastatic colorectal cancer has been
previously used and was associated with many complications. We report for
the first time a case where a HAI catheter eroded into the duodenum causing
ulceration and massive upper GI bleeding.
Methods: A 61-year-old Hispanic female presented for evaluation of mild
abdominal pain and vomiting for three days. Her past medical history was
significant for colon cancer with metastases to the liver. She was treated
with multiple colonic resections, subtotal hepatic resection and eventual
placement of a HAI pump 5 years ago. The patient had repeated episodes of
bowel obstruction over the past several years in addition to multiple series of
sepsis and peritonitis. It was determined upon admission to perform lysis of
adhesions and side-to-side enteroenterostomy. Several days later, the post-
surgical fistula presented with an upper GI bleed with hemostatic instability
and requiring multiple transfusions.
Results: At endoscopy, multiple clean based antral and body gastric ulcers
were noted in addition to diffuse hemorrhagic gastritis (Fig. 1). The previ-
ously placed intra-hepatic artery infusion catheter was seen protruding into
the bulb of the duodenum surrounded by a large clot and ulceration (Fig. 2).
Conclusion: In our finding of duodenal ulceration and upper GI beed, the
catheter was found lodged adjacent to blood clot in a coiled shape. We
believeed that this was a result of direct trauma by the eroding catheter into
the duodenum. It was first time this kind of complication from Intra-heatic
arterial infusion catcheter has been reported in USA.[figure1][figure2]
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A Case of Large Hookworm Infestation
Gourisankar P. Degala, MD, Osama Alaradi, MD∗. Gastroenterology,
Henry Ford Health System, Detroit, MI.
Purpose: A forty-four year old Caucasian female patient presented with few
year history of recurrent abdominal pain and bouts of intestinal obstruction
for which she underwent multiple abdominal surgeries. She was noted to
have microcytic anemia on laboratory studies: Hemoglobin 9.9 g/dL, MCV
78.1 fl, Iron 14 ug/dL and ferritin of 7 ng/ml (Normal 10–120 ng/mL). Her
endoscopic evaluation for GI blood loss included EGD and Colonoscopy.
Both were normal. A small bowel follow-through evaluation showed post-
surgical changes. Subsequently, a small bowel capsule endoscopy (Given
Imaging, Yoqneam, Israel) was performed without any complication. An
interpretation of the images revealed the results seen in Figure A.
Multiple adult worms were seen in the small intestine. Worms, worm frag-
ments, and hooklets were seen in the distal small intestine. There were multi-
ple erythematous areas where the worms were seen. The worms were present
in the study for three hours and thirty minutes. The capsule did not make
it into the colon by the end of the study but a subsequent abdominal film
showed that it passed.
Two separate stool studies for ova and parasites were negative for helminthic
eggs. The patient also denied ever passing worms in her stool. The patient
had no significant travel history but did have worm infestation when she was
seven years old. A microbiologist examined the pictures and confirmed that
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the morphology of the organisms was consistent with hookworms, likely
Necator americanus. She was treated with two courses of albendazole.
This case is a demonstration of a significant abnormal finding in the small
intestine diagnosed only with capsule endoscopy. The high worm load was
clearly the source of iron deficiency anemia. The delayed capsule transit time
also raises questions of whether the worm load delayed motility or caused a
low-grade intestinal obstruction. This is the largest worm load we have seen
compared to previously described cases.[figure1]
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Risk Factors for Small Intestinal Bacterial Overgrowth
Kristen M. Robson, MD∗, Rebecca Liberman, MPH. Gastroenterology,
Lahey Clinic, Burlington, MA and Research, Lahey Clinic, Burlington, MA.
Purpose: Small intestinal bacterial overgrowth (SIBO) has been associated
with various gastrointestinal disorders. Enteric bacterial flora are thought to
play an important role in the pathogenesis of some gastrointestinal diseases.
We aim to determine which patient characteristics, symptoms, and laboratory
values are predictive of SIBO as defined by a positive glucose breath test.
Methods: The records of all patients who were referred for a glucose breath
test between January 1, 2003, and December 31, 2006, were analyzed retro-
spectively. Breath samples were analyzed for hydrogen and methane using a
Model DP Microlyzer (Quintron Instrument, Milwaukee, WI). A breath test
was deemed positive when the baseline hydrogen or methane value increased
by greater than 12 ppm after the ingestion of 50 g of glucose. Chi-square
tests and Fisher’s exact test were used to determine associations between
categorical variables. The independent sample t-test was used to compare
groups of continuous variables.
Results: Of the 167 eligible patients who were referred for a glucose breath
test, 139 patient records were available for analysis (49 male, 90 female;
mean age 54 ± 13 years). There were 40 patients (29%) with positive breath
tests. Patient characteristics that were significantly associated with a positive
glucose breath test were: age greater than 75 years (P = 0.01), low serum
albumin (P = 0.04), and a history of cirrhosis (P = 0.02). The OR for age
greater than 75 was 4.7 (95% CI 1.4, 15.4). A history of irritable bowel
syndrome significantly lowered the risk of a positive test (OR = 0.27, P =
0.02). There was no association between a positive breath test and the use
of proton pump inhibitors, histamine-2 receptor antagonists or antimotility
drugs. Diarrhea was significantly associated with a positive breath test by
hydrogen criteria (OR 2.9, P = 0.01), but no similar association was found
with constipation, abdominal pain, bloating or gas.
Conclusion: In this patient cohort, advanced age, low albumin and a history
of cirrhosis were significantly associated with a positive glucose breath test.
Patients with IBS were less likely to have a positive breath test. Knowledge of
the predisposing factors for SIBO might lead to earlier testing and treatment
in some patients.
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Can Colorectal Cancer Screening Consultations Assist in Evaluating
Physician Adherence to Management of Obese African American
Patients?
Anita Mittal, MD, Rebecca Fausel, Marie L. Borum, MD, MPH, EdH∗.
Internal Medicine, University of Hawaii, Honolulu, HI and
Gastroenterology, The George Washington University School of Medicine,
Washington, DC.
Purpose: Obesity is an epidemic in the United States that causes signifi-
cant morbidity and mortality. It is estimated to cost the nation billions an-
nually. Two thirds of American adults are considered overweight/obese. It
has been suggested that certain ethnic groups, especially African Ameri-
cans, are less likely to receive weight management. This study evaluated the
prevalence of overweight/obese African American patients seeking colorec-
tal cancer screening and the frequency of physician recommended weight
management.
Methods: A retrospective medical chart review was performed where med-
ical records of consecutive patients referred to a continuity GI clinic for
colorectal cancer screening during a three-month period were evaluated.
Documentation regarding demographics and weight management was put
into a database, with patient anonymity maintained. Statistical analysis was
performed with significance determined at P < 0.05.
Results: Our results showed a significant difference in the prevalence of
obesity between African American males and females (P < 0.05), and a
significant difference in the frequency of physician directed weight manage-
ment, with males not receiving as much counseling (P < 0.01).
Conclusion: Literature reveals that African Americans are less likely to
receive preventative health care. Colorectal cancer screening can be used
to find and aid these populations not being counseled, therefore improving
health care and potentially reducing the complications and cost caused by
obesity.
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Absorption and Metabolism of Acetate, Glucose, and Amino Acid in
Metabolic Syndrome
Yoshihisa Urita, Toshiyasu Watanabe, Tadashi Maeda, Kaoru Domon,
Susumu Ishihara, Tomohiro Arita, Asuka Nakayama, Makie Nanami,
Tatsuhiro Yamamoto, Akiro Kugahara, Takamasa Ishii, Hirohito Kato,
Kazuo Hike, Noriko Hara, Yoshiko Honda, Kazushige Nakanishi, Nagato
Shimada, Motonobu Sugimoto∗, Kazumasa Miki. Department of General
Medicine and Emergency Care, Toho University, Tokyo, Japan; Division of
Gastroenterology and Hepatology, Department of Internal Medicine, Toho
University, Tokyo, Japan and Department of Hematology, Toho University,
Tokyo, Japan.
Purpose: The aim of this study is to evaluate the absorption and metabolism
of nutrients in patients suspicious of metabolic syndrome.
Methods: Consecutive 230 subjects presenting diagnostic upper endoscopy
were recruited in this study. 13C-acetate was administrated intraduodenally
in 78, 13C-glycine in 65, and 13C-glucose in 77 patients. At the end of
endoscopy, a tip of endoscope was placed to the second part of the duodenum
and 20 ml of water containing 100 mg of 13C-substrate was sprayed onto
the duodenal mucosa. Breath samples were taken at baseline and at 10-min
interval. Next, 13C-acetate breath test, in which the substrate was orally
S206 Abstracts
administrated with 100 cc of water, was performed in patients with fatty
liver diseases and viral hepatitis.
Results: A delay in the 13CO2 excretion curve in patients with BMI of more
than 26 was found after administration of 13C-acetate, whereas an increased
13CO2 excretion was noted in obese patients after administration of 13C-
glycine. For 13C-acetate breath test, there was a significant delay in 13CO2
excretion in patients with fatty liver as compared with viral hepatitis and
healthy volunteers.
Conclusion: These results suggest that 13C-acetate breath test may be useful
for the screening of metabolic syndrome.
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Can Colorectal Cancer Screening Assist in Evaluating Physician
Adherence to Guidelines for Ordering DEXA Scans?
Anita Mittal, MD, Rebecca Fausel, Marie L. Borum, MD, MPH, EdH∗.
Internal Medicine, University of Hawaii, Honolulu, HI and
Gastroenterology, The George Washington University School of Medicine,
Washington, DC.
Purpose: There are significant health disparities between African Americans
and whites, in the United States. Colon cancer screening can aid in decreasing
the morbidity and mortality from colon cancer, and may also identify other
health risks during gastroenterology consultations. This study evaluated the
prevalence of African American and Caucasian women who require a DEXA
scan seeking preventative care colorectal cancer screening and the frequency
of physician ordered DEXA.
Methods: After IRB approval, medical records of consecutive female pa-
tients referred to a continuity GI clinic for colon cancer screening consul-
tations during a three-month period were evaluated for documentation on
whether a DEXA was ordered, not ordered, or not needed. A Microsoft
Excel database was created, with patient anonymity maintained. Statistical
analysis was performed using chi-square with a significance set at P < 0.05.
Results: 35.5% of Caucasian women did not receive a DEXA who
needed it, whereas 39.3% of African American did not get a DEXA.
The results showed a trend towards African American women being
less likely to receive a screening DEXA when they needed it, with
P-value < 1.
Conclusion: Although there was not a significant difference between the
number of African American and Caucasian women who received a DEXA,
our study revealed that over a third of these women should have received one
regardless of ethnicity, but did not. Colorectal cancer screening can be used
as a tool to detect these women and make sure that they get optimal care.
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Nitazoxanide for the Treatment of SIBO Related Gastrointestinal
Symptoms in Pediatric Population
Youhanna Al-Tawil, MD∗, Alexandra Eidelwein, MD, Clarisa Cuevas, MD,
Anthony S. Jackson, PharmD. Children’s Hospital Pediatric
Gastroenterology, Knoxville, TN and Department of Medical Science,
Romark Laboratories, L.C., Tampa, FL.
Purpose: Many pediatric patients present with symptoms of Small Intesti-
nal Bacterial Overgrowth (SIBO). Intestinal anaerobic bacteria are known
to contribute to the symptoms exhibited by these patients. However, with-
out a definitive test to confirm SIBO, many pediatric practitioners em-
pirically treat these patients with a course of antibiotics with or with-
out probiotics. Nitazoxanide (NTZ) is a first in class thiazolide antibiotic
with a targeted anaerobic antibacterial activity, placebo-like safety pro-
file, high gastrointestinal (GI) concentration, and has limited to no activ-
ity against probiotic species. To date no studies have evaluated the empiric
use of NTZ for the treatment of GI related symptoms in pediatric SIBO
patients.
Methods: A chart review was performed on patients treated with NTZ from
February 2006 to May 2007. The diagnosis of SIBO was made by the attend-
ing physician based on the patient’s history, signs and symptoms. Efficacy
was measured as resolution of the patient’s GI related symptoms, 3–8 weeks
after the end of therapy. Primary markers for resolution included: abdominal
pain, diarrhea, constipation, bloating, and/or flatulence. Overall 22 patients
met the inclusion criteria for review.
Results: Of the 22 patients treated with NTZ, 13 (median age – 6.8 years)
patients returned to the office for adequate follow up. Nine patients were
prescribed NTZ for SIBO and have not returned to the office for any GI
complaints. The range of NTZ doses used was 100 mg – 500 mg BID for
5–10 days depending on age of the pediatric patient. The mean dose and
duration was 422 mg/d for 7.7 days. The most common dose was 200 mg
BID for 10 Days (N = 5). All patients treated with NTZ and a probiotic
(13/13 [100%]) had complete resolution of symptoms that were present at
initial visit.
No clinically significant adverse reactions attributable to NTZ were identified
during the study.
Conclusion: Nitazoxanide appears to be a safe and effective therapy for the
empiric treatment of SIBO related GI symptoms in pediatric patients. Larger
controlled clinical trials are warranted to support these findings.
Results
Symptoms Resolved or Improved No Change / Worsen
Abdominal Pain 13/13 (100%) N/A
Bloating 6/6 (100%) N/A
Diarrhea 9/9 (100%) N/A
Constipation 4/4 (100%) N/A
Flatulence 5/5 (100%) N/A
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Effects of Liquid Meal Ingested Soon after Alcohol Ingestion on
Alcohol Metabolism
Yoshihisa Urita, Toshiyasu Watanabe, Tadashi Maeda, Kaoru Domon,
Susumu Ishihara, Tomohiro Arita, Asuka Nakayama, Makie Nanami,
Tatsuhiro Yamamoto, Akiro Kugahara, Takamasa Ishii, Hirohito Kato,
Kazuo Hike, Noriko Hara, Yoshiko Honda, Kazushige Nakanishi, Nagato
Shimada, Motonobu Sugimoto∗, Kazumasa Miki. Department of General
Medicine and Emergency Care, Toho University, Tokyo, Japan; Division of
Gastroenterology and Hepatology, Department of Internal Medicine, Toho
University, Tokyo, Japan and Department of Hematology, Toho University,
Tokyo, Japan.
Purpose: Alcohol is commonly consumed with, or soon after, a meal that
affects gastric emptying and thus, absorption and metabolism of alcohol.
The aim of this study is to evaluate the effect of liquid test meal ingested
soon after alcohol ingestion on alcohol metabolism, as is common in the
social setting.
Methods: First, a 100 ml of water containing of 100 mg of 13C-ethanol was
administrated orally in 5 healthy subjects and 2 diabetic patients, and 200
ml of liquid meal (Ensure Liquid) was administrates 5 min after 13C-ethanol
ingestion. Breath samples were taken at baseline and at 10-min interval for
150 min. Next, 13C-ethanol breath test was performed without ingestion of
liquid meal. Breath 13CO2 value was measured and expressed as delta over
basline (per mil).
Results: The peak value of 13CO2 excretion (Cmax) was decreased af-
ter ingestion of liquid meal in 5 of 7 patiemts, whereas the time of Cmac
(Tmax) was unchanged. Only one patients had accelrated 13CO2 excre-
tion after ingestion of liquid test meal. The descending gradient of 13CO2
excretion curves after ingestion of liquid meal is parallel to that without
liquid meal.
Conclusion: These results indicated that liquid meal ingested soon after al-
cohol ingestion may not affect elimination but absorption and/or metabolism
of a small amount of alcohol.
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Relationship between Atrophic Gastritis and Fasting Breath Hydrogen
and Methane Levels in the Elderly
Yoshihisa Urita, Toshiyasu Watanabe, Tadashi Maeda, Kaoru Domon,
Susumu Ishihara, Tomohiro Arita, Asuka Nakayama, Makie Nanami,
Tatsuhiro Yamamoto, Akiro Kugahara, Takamasa Ishii, Hirohito Kato,
Kazuo Hike, Noriko Hara, Yoshiko Honda, Shuji Watanabe, Kazushige
Nakanishi, Nagato Shimada, Motonobu Sugimoto∗, Kazumasa Miki.
Department of General Medicine and Emergency Care, Toho University,
Tokyo, Japan; Division of Gastroenterology and Hepatology, Toho
University, Tokyo, Japan and Department of Hematology, Toho University,
Tokyo, Japan.
Purpose: Many factors contribute to inadequate nutrition, including health
status, financial capacities, mobility, and physiologic needs. One of the most
remarkable changes with aging is the frequent development of atrophic gas-
tritis. This process was recently recognized to be due to H. pylori infection.
The aim of this study was to investigate the relationship between atrophic
gastritis and colonic bacterial alteration in the elderly.
Methods: Fasting breath hydrogen and methane levels and serum pepsino-
gens were measured in 560 H. pylori-seropositive patients. Serum pepsino-
gens (PG) were also measured to evaluate the grade of atrophic gastritis and
gastric acid secretion.
Results: The fasting breath hydrogen level was 4.0 ± 7.0 ppm highest in
patients with a serum PG1/2 ratio of 3.5 to 4.0 and 2.5 ± 3.8 ppm in those
with a serum PG1/2 ratio less than 1.0. Similarly, there was no significant
association between the serum PG1/2 ratio and fasting breath methane levels.
When a patient had more than 10 ppm of H2 or CH4 levels, the patient was
considered to have fermentation. The incidences of high intragastric H2
and/or CH4 levels were highest in patients with a serum PG1/2 ratio of 1.0
to 1.5. Among patients with a serum PG ratio less than 2.0, the increased
fermentation was found in the younger group, whereas elder patients had
more frequently increased fermentation among those with a serum PG1/2
ratio of 2.0 to 3.5 than younger groups.
Conclusion: In conclusion, although there was a close association between
atrophic gastritis and bacterial overgrowth in the digestive tract in younger
patients with H. pylori infection, factors other than the lack of gastric acid
may have affect colonic fermentation in H. pylori-positive older patients.
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Nitazoxanide for the Treatment of IBS and SIBO Related
Gastrointestinal Symptoms
Isaac Raijman, MD∗, Susana Escalante-Glorsky, MD, Matthew Bardin,
PharmD. Digestive Associates of Houston, P.A., Houston, TX and
Department of Medical Science, Romark Laboratories, L.C., Tampa, FL.
Purpose: The definitive role of intestinal bacteria in Irritable Bowel Syn-
drome (IBS) has not been elucidated however clinicians routinely treat symp-
tomatic IBS with antibiotics. Furthermore, Small Intestinal Bacterial Over-
growth (SIBO) contributes to the symptoms exhibited by many IBS pa-
tients. Without a definitive test to differentiate the two, many practitioners
empirically treat these patients with a course of antibiotics and at times
probiotics. Nitazoxanide (NTZ) is a first in class thiazolide antibiotic with
a targeted anaerobic antibacterial activity, placebo-like safety profile, high
gastrointestinal (GI) concentration, and limited to no activity against pro-
biotic species. To date studies evaluating the empiric use of NTZ for the
treatment of GI related symptoms in IBS and SIBO patients have not been
presented.
Methods: A chart review was performed on patients treated with NTZ
and assigned the following ICD-9 codes: 536.8, 564, 564.1, 787.3, 787.91,
789.07 between April 2006 and April 2007. The diagnosis of IBS and SIBO
was made by the attending physician based on the patient’s history, signs
and symptoms. Efficacy was measured as improvement or resolution of the
patient’s GI related symptoms, 3–8 weeks after the end of therapy. Primary
markers for resolution included: abdominal pain, abdominal distension, di-
arrhea or constipation, and gas or bloating. A telephone questionnaire was
used to determine resolution of symptoms in patients not followed up in
person. Overall, 14 patients met the inclusion criteria for review.
Results: Of the 14 patients treated with NTZ, 12 were available for follow-
up evaluation. The range of NTZ doses used was 500 mg BID-TID for 5–10
days. The mean dose and duration was 1097 mg/day for 8.2 days, the most
common dose was 500 mg BID for 10 days (N = 6). Resolution of symptoms
are outlined in Table 1. No clinically significant adverse reactions attributable
to NTZ were identified during the study.
Conclusion: Nitazoxanide appears to be a safe and effective therapy for the
empiric treatment of IBS and SIBO related GI symptoms. Larger controlled
clinical trials are warranted to support these findings.
Table 1. Resolution of GI Symptoms
Symptoms Resolved or Improved No Change
Abdominal Pain 73% (8/11) 27% (3/11)
Abdominal Distension 67% (6/9) 33% (3/9)
Gas/ Bloating 83% (10/12) 17% (2/12)
Diarrhea/ Constipation 60% (6/10) 40% (4/10)
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Fine-Needle Aspiration Biopsy of Duodenal Gangliocytic
Paraganglioma: Report of Two Cases
Nilesh P. Patel, MD, Jason D. Conway, MD, MPH, James O. Cappellari,
MD, Kathleen G. Gibson∗. Pathology, Wake Forest University School of
Medicine, Winston-Salem, NC and Internal Medicine, Section on
Gastroenterology, Wake Forest University School of Medicine,
Winston-Salem, NC.
Purpose: Gangliocytic paraganglioma (GP) is a rare neoplasm of uncertain
histogenesis that typically occurs in adults in the second portion of the duo-
denum. We report the first two cases describing the cytologic features of GP
diagnosed using fine-needle aspiration biopsy (FNAB).
Methods: Case 1 was a 43 year-old Caucasian man with an 8.5 cm intralu-
minal, submucosal mass in the second portion of the duodenum adjacent to
the ampulla of Vater. Endoscopic ultrasound-guided FNAB was diagnosed
as a GP and confirmed in the subsequent resection specimen. Case 2 was a
67 year-old Caucasian man with a 2.5 cm submucosal mass in the second
portion of the duodenum adjacent to the ampulla of Vater. An intra-operative
FNAB was diagnosed as a spindle cell neoplasm and the resection specimen
was diagnosed as a GP.
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Results: FNAB smears demonstrated a combination of three distinct cell
types: ganglion cells, epithelioid cells, and spindle cells (Fig. 2A). Both re-
section specimens demonstrated submucosal neoplasms also composed of
these three cell components (Fig. 4A). Immunohistochemical staining results
from the resection specimens included: ganglion cells immunoreactive for
synaptophysin; epithelioid cells immunoreactive for synaptophysin [also im-
munoreactive for somatostatin in Case 1]; and spindle cells immunoreactive
for S100 protein.
Conclusion: In the appropriate clinical and radiographic context, an FNAB
exhibiting ganglion cells, epithelioid cells, and spindle cells is characteristic
of GP.[figure1][figure2]
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Continuous Intravenous Administration of Teduglutide (ALX-0600), a
Glucagon-like Peptide-2 (GLP-2) Analog Induces Intestinotrophic
Activity
Lidia L. Demchyshyn, Nathan Teuscher, David S. Wells∗. Dept of Drug
Discovery, NPS Pharmaceuticals, Toronto, ON, Canada.
Purpose: Teduglutide is an analog of human GLP-2, a naturally occurring
peptide secreted from endocrine L cells predominantly in the distal intes-
tine. Teduglutide has been shown to increase intestinal mass as a result
of increased villus height and crypt depth. In preclinical rodent models,
subcutaneous administration of teduglutide augments the adaptive response
following small bowel resection and reduces the deleterious effects of IBD-
related and chemotherapy-induced intestinal damage. This study compared
the intestinotrophic effects of continuous intravenous to daily subcutaneous
administration of teduglutide in rat.
Methods: Female Sprague Dawley rats were administered teduglutide ei-
ther by continuous intravenous infusion (0.5 mg/kg/day) or subcutaneous
injection (0.5 mg/kg/day, b.i.d.) for 14 days. Morphological changes, in-
cluding intestinal weight and length, were used to measure changes in the
gastrointestinal tract.
Results: Small and large intestinal weights increased significantly, by 125%
and 35% respectively, in animals treated with teduglutide by continuous in-
fusion. Small intestinal weight increased significantly by 88% and a trend
towards increased large intestinal weight was observed in animals receiving
teduglutide by subcutaneous injection. A trend towards increased small in-
testinal length was observed in both treatment groups, however, this effect
only reached statistical significance in animals administered teduglutide by
continuous infusion. Increased villus height was observed in the small in-
testine in animals given teduglutide intravenously and in the small and large
intestine in animals given teduglutide subcutaneously. The pharmacokinet-
ics following intravenous infusion of teduglutide were predictable and the
steady-state plasma concentration of teduglutide was maintained throughout
the 14 days of dosing (40.2 ± 8.8 ng/mL on Day 2 and 50 ± 30.8 ng/mL
on Day 14). The total daily exposure to teduglutide was higher in the in-
travenous group (965–1200 ng-h/mL) than in the group receiving the same
dose of teduglutide by subcutaneous injection (682 ng-h/mL).
Conclusion: Administration of teduglutide by continuous intravenous in-
fusion or subcutaneous injection was associated with increased intestinal
weights and intestinal mucosal mass. Plasma concentrations after continu-
ous intravenous infusion of teduglutide were well predicted. These results
suggest that continuous systemic and intermittent exposure to teduglutide
give similar pharmacological responses.
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Primary Aortoduodenal Fistula Caused by Mycobacterium Avium
Complex
Pallavi K. Rao, MD, Kanan Sharma, MD, Christopher Barde, MD∗.
Department of Gastroenterology, Wright State University, Dayton, OH.
Purpose: A 48 year-old man with history of HIV infection, CD4 count
of 138, on HAART, presented with recurrent episodes of hemetemesis
and hematochezia. He was afebrile, hypotensive and tachycardic. The
laboratory values were normal except for WBC count of 14,000 and
hemoglobin 12.9. A large 3–4 cm duodenal ulcer with blood clot was
seen on emergent EGD. An abdominal CT scan revealed aortoduodenal
fistula in third portion of the duodenum and ruptured aortic abdominal
aneurysm (AAA). An emergent surgery for AAA was performed with re-
pair of the duodenum. The surgical specimen of the aortoduodenal fis-
tula was positive for acid-fast bacilli on ziehl-neelsen stain. Histology
showed scattered non-caseating granulomas, chronic inflammation and scat-
tered foci of acid-fast bacillary organisms, which exhibit a beaded mi-
croscopic appearance. This morphology was consistent with MAC. Blood
cultures for acid-fast bacilli were negative for 6 weeks period. He was
initially treated with intravenous azithromycin, rifampin and levofloxacin
for MAC. Upon discharge he was switched to azithromycin, rifabutin and
ethambutol.
Discussion: Primary aortoduodenal fistula is a rare cause of massive upper
gastrointestinal bleeding. It occurs as a result of spontaneous connection
between the aorta and the third or fourth portion of the duodenum. The re-
ported incidence of primary aortoenteric fistula is about 0.07% in the general
population from a large autopsy series. There are reports of fistula occurring
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due to infection, tumor, radiotherapy and foreign body ingestion. Reported
infectious causes of primary aortoenteric fistula are Escherichia coli, En-
terococcus faecalis, salmonella, Mycobacterium tuberculosis, Clostridium
septicum, Lactobacillus and Klebsiella. We report the first case of MAC as a
cause of primary aortoduodenal fistula causing massive upper gastrointesti-
nal bleeding.[figure1][figure2]
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Positive Predictive Value of Tissue Transglutaminase: A Retrospective
Review at Our Institution
Thomas Park, MD, Ibilola Fashoyin, MD, Marilyn A. Menegus, PhD,
Arthur J. DeCross, MD∗. Division of Gastroenterology and Hepatology,
and Division of Microbiology, University of Rochester, Rochester, NY.
Purpose: To determine: 1) the positive predictive value (PPV) of the IgA
tissue transglutaminase (tTG) assay for celiac disease (CD), with variable
clinical indications for ordering the test; 2) the PPV of the tTG titer; and 3)
the correlation of tTG titer with small bowel histology.
Methods: A retrospective analysis of positive tTG titers from 99 patients,
representing all positive assays at our institution from 2002–2006, for whom
we had concurrent histologic data. Our lab utilizes the human tTG IgA, with
a positive result at >20 units.
Results: The PPV of tTG for biopsy-confirmed CD in patients with:
1. Overall clinical indications listed below, was 78.8% (78/99).
2. Diarrhea with and without iron-deficiency anemia (IDA), was 68%
(17/25).
2a. Diarrhea and IDA, was 71.4% (5/7).
2b. Diarrhea without IDA, was 66.7% (12/18).
3. IDA without diarrhea, was 66.7% (6/9).
4. Non-specific malabsorptive symptoms, weight loss, or failure to thrive,
was 83.3% (15/18).
5. Non-specific gastrointestinal complaints (e.g., abdominal pain, consti-
pation), was 69.2% (18/26).
6. Abnormal liver enzymes and negative standard serologic evaluations for
primary liver disease, was 87.5% (7/8).
7. Unexpected endoscopic findings consistent with CD, was 100% (7/7).
The threshold level at which:
a. 100% of patients had CD was 158.7 units.
b. 95% of patients had CD was 99.6 units.
c. 90% of patients had CD was 41.0 units.
d. 80% of patients had CD was 26.6 units.
The mean tTG level for patients with positive tTG tests and:
i. normal small bowel biopsies was 41.5 units.
ii. biopsies revealing increased intra-epithelial lymphocytes and/or crypt
hyperplasia without villous atrophy (Marsh I and II) was 38.6 units.
iii. biopsies revealing partial villous atrophy (Marsh III) was 106.2 units.
iv. biopsies revealing total villous atrophy (Marsh IV) was 156.7 units.
Conclusion: The positive predictive value of the tTG assay for celiac dis-
ease was unexpectedly robust when applied to scenarios of non-screening,
case-finding by clinical indications, varying from 66.7% – 87.5% de-
pending on the indication. A high PPV of 90% is achieved at a rela-
tively low titer of 41 units. Although there was a correlation between
the titer of tTG and the severity of CD histologic findings on small
bowel biopsies, there was no significant difference in average titer between
normal biopsies and Marsh I and II lesions (infiltrative without villous
atrophy).
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Disparity in Gastroenterology: Is It Just “ACADEMIC” or a
Significant Problem? A 10 Year Prospective Cohort Study
Aparajita Singh, MD, Carol A. Burke, MD∗. For the Women in GI
Committee of ACG, Gastroenterology, Cleveland Clinic, Cleveland, OH.
Purpose: Our previous data demonstrated disparity in income, family
and practice patterns between men and women in GI. We sought to
identify disparities between Private (PP) and Academic practice (AP)
or between men & women within these practice types, 10 years after
fellowship.
Methods: A 36-question survey was sent originally to a cohort of 390 GI
fellows at the time of graduation, and 3, 5 and 10 yr later. We herein ana-
lyzed yr-10 data for practice and gender differences using t-test for contin-
uous, chi square for categorical variables and linear regression for adjusted
income.
Results: 171 individuals (149 men, 22 women) responded. 77% are in PP
and 23% in AP. 81% of men and 50% of women are in PP.
PP vs AP: Compared to PP, academicians were more often married to a
physician (44% vs 22%, P = 0.01) and childless (13% vs 1.5%, P = 0.01).
Respondents in PP worked less hrs/wk but made significantly higher income
than those in AP.
Table 1. PP vs AP
PP AP P-value
Mean income/yr 391K 253K <0.001
Dollars/hr income 148 90 <0.001
Work hrs/wk 52 56 0.04
Call days/month 9 5 <0.001
Vacation wks/yr 5 4 0.07
CME days/yr 6 9 <0.01
Gender Disparity in PP vs AP: In both PP and AP women’s annual income
was lower than men’s. In PP women work less hrs/wk, take less call-days
and more vacation than men. However, in AP, no significant difference in
work-hr or vacation time was noted between men and women.
Multivariate analysis adjusting for work hrs, vacation time, call days and
practice ownership shows the annual income of women is $100K less than
men in AP (P = 0.003), and $60K less in PP (P = 0.08).
Conclusion: Gastroenterologists in AP work longer hours but get paid
significantly less than those in PP. Significant disparities in earnings and
family structure exist for women in both PP and AP. While a greater
proportion of women than men are in AP the disparity in income is
greatest for women in that practice setting. Recognition of these dispar-
ities is imperative and steps to minimize these in both AP and PP are
warranted.
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Table 2. Gender Disparity: PP vs AP
PP AP
Male (N = 121) Female (N = 11) P-value Male (N = 28) Female (N = 11) P-value
Mean income/yr 399K 317K 0.04 282K 179K 0.04
Dollars/hr income 149 142 0.59 97 75 0.09
Work hrs/wk 53 43 <0.01 58 52 0.19
Call days/month 9.7 4.8 0.02 5.4 4.4 0.51
Vacation wks/yr 4.9 8.1 <0.01 4.1 4.2 0.63
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The Yield of Routine Endoscopy with Duodenal Biopsies To Exclude
Celiac Disease
Ramu P. Raju, MD∗, Daniel Moore, MD, Tolga Erim, DO, Fernando
Castro, MD. Gastroenterology, Cleveland Clinic Florida, Weston, FL.
Purpose: Celiac disease is an autoimmune condition that has classically been
defined as a malabsorption syndrome with symptoms of chronic diarrhea,
steatorrhea, abdominal bloating, edema and weakness. However, today, it is
now recognized that there are many “atypical” signs and symptoms which
include dyspepsia, vomiting, reflux, osteopenia, iron deficiency anemia, in-
fertility, and peripheral neuropathy. Many patients will undergo endoscopic
evaluation specifically for the purpose of obtaining duodenal biopsy to rule
out celiac disease. The purpose of this study is to investigate the yield of
routine biopsies as well as the cost per case diagnosed in patients whom
celiac sprue is suspected.
Methods: Patients who had duodenal biopsies taken from January 1, 2004 to
December 31, 2005 at Cleveland Clinic Florida were retrospectively identi-
fied. Patients were selected for the study if they had duodenal biopsies taken
to rule out celiac sprue per written instruction from the gastroenterologist
performing the procedure to the pathologist. The medical chart of these pa-
tients were carefully reviewed with notice to the clinical history, indication
for the endoscopy, appearance of the duodenum, number of biopsies taken,
as well as pathologic findings. Cost-effectiveness ratio was calculated for
each procedure based on Medicare reimbursement from 2006.
Results: A total of 273 patients met the criteria for the study. A positive
diagnosis of celiac disease was made in 7 individuals for a yield of 2.57%.
In patients with classic symptoms of celiac disease, 6 out of 23 patients were
found to have celiac disease for a yield of 26.08% with a cost-effectiveness of
$3021 per case diagnosed. In atypical patients, only 1 out of 250 patients were
found to have celiac disease for a yield of 0.40% and a cost-effectiveness of
$197,000 per case. Nineteen patients were found to have stigmata of celiac
disease in the duodenum on endoscopic examination. Six were found to be
positive for celiac disease. The sensitivity of endoscopic stigmata was found
to be 87.5% and the specificity was 95.1%. The positive predictive value
was 35.0% with a negative predictive value of 99.6%.
Conclusion: Many patients who may have celiac disease will undergo up-
per endoscopy specifically for the purpose of obtaining a duodenal biopsy
specimen to rule out the disease. Due to the low yield and high cost per case
diagnosed in atypical patients, serologic screening may be a better initial
approach.
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Clinical Characteristics and Prevalence of Celiac Disease and
Non-Celiac Gluten Sensitivity Presenting to a Community Based
Private Gastroenterology Clinic
Scot M. Lewey, DO∗. Gastroenterology Associates of Colorado Springs,
Colorado Springs, CO.
Purpose: The prevalence and clinical features of Celiac disease (CD) and
Non-celiac gluten sensitivity in a community based gastroenterology practice
is reviewed.
Methods: The records of all patients with suspected CD presenting to a pri-
vate practice gastroenterologist were reviewed. Comprehensive celiac dis-
ease panel requested on all patients consisted of total serum IgA level, anti-
gliadin (AGA) IgA and IgG, endomysial IgA (EMA) and tissue transglu-
taminase (TTG) IgA antibodies.
Patients presenting for diagnostic upper endoscopy and GI consultation for
symptoms were screened for CD. Those presenting for routine screening and
surveillance colonoscopy with identifiable risk factors for CD were offered
screening. CD was defined using standard criteria.
Results: Records of 367 patients were reviewed. Women outnumbered men
by ratio of 2.8:1 overall but the ratio narrowed to 1.4:1 in patients with CD
and was confirmed in 12.5%. HLA DQ results were obtained in 69% of
patients, 55% of whom were DQ2 positive and 22% DQ8 positive. All with
a positive EMA and TTG in whom DQ was known were positive for DQ2
and/or DQ8 and met criteria for CD. The prevalence of IgA deficiency was
4% overall but 13% in CD.
The average intraepithelial lymphocyte count per 100 epithelial cells was 47
in CD. Those failing to meet strict criteria for CD, but believed to be gluten
sensitive based on clinical presentation and response to gluten free diet had
on average 23 IELs/100 epithelial cells.
Conclusion: The estimated prevalence of CD in the general population of
1% probably significantly underestimates that of patients presenting to a
general gastroenterology practice. Because more than 10% of people with
CD are IgA deficient total serum IgA levels should be checked on all patients
suspected of CD to avoid false negative EMA and TTG IgA tests. AGA tests,
though not specific for CD, may identify patients with elevated IELs, villous
blunting and favorable response to a GF diet. If either EMA or TTG are
positive, DQ2 or DQ8 is likely present. Higher IEL counts are more often
found in CD however, the presence of elevated AGA and IEL counts in the
range of 20–25 are more common in patients failing to meet strict criteria
for CD but who may respond to a gluten free diet, the so-called non-celiac
gluten sensitive (NCGS).
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Double Balloon Enteroscopy: Virginia Commonwealth University
Health System Experience
Amrita Sethi, MD, Doumit S. BouHaidar, MD, Bimaljit Sandhu, MD, Alvin
Zfass, MD∗. Gastroenterology, Virginia Commonwealth University,
Richmond, VA.
Purpose: Review the initial experience with a double-balloon enteroscopy
at VCUHS.
Methods: This was a retrospective review of the first 100 DBE procedures
performed at our center between August 2004 and June 2007 using the
Fujinon EN-405T5.
Results: 100 DBE procedures were performed on 86 patients. 83 DBE were
antegrade (per-oral) and 17 retrograde (per-anal). 85 DBEs were performed
using conscious sedation and 15 were done under general anesthesia. The
most common indication was obscure GI bleeding (overt and occult) as
seen in 88% of patients. Other indications included abdominal pain (5%),
tumor/polyps (5%), and retained capsule (2%). Mean procedure time 83 min-
utes (range 25–210). The first 37 DBEs were performed with fluoroscopy.
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The remaining DBEs were done without fluoroscopy. Complete enteroscopy
was not possible in all patients despite a combined antegrade and retrograde
approach. In 8 patients the procedure could not be completed (6 due to in-
ability to tolerate the conscious sedation and 2 due to inability to advance
the scope through the ileocecal valve for a retrograde DBE). There were
no major complications. All patients were discharged from the endoscopy
suite after a 2 hour recovery period. Findings were seen in 61% of the
DBEs performed. In 39% of the cases the DBE exam was normal. Of those
with positive findings (N = 61) AVM were seen in 63%, erosions or ul-
cers seen in 13%, Dieulafoy lesions in 4%, polyps in 2%. One patient had
a stricture and ulceration; biopsies demonstrated lymphoma. No other case
of malignancy was found. In 40% APC treatment was performed. Biopsies
were performed in 12% of all DBE, clip and injection in 5%, dilation of
a stricture done in 1%. Tattooing to help locate a lesion in the small in-
testine for laparoscopic treatment was performed in 2%. Tattooing to mark
the most distal part of the small intestine reached, was performed in 79%
of cases.
Conclusion: DBE is safe and provides positive findings in the majority of
the cases. AVM is the most commonly found lesions. Therapeutic applica-
tions can be frequently performed (APC, biopsies, injection, clip, dilation
and tattooing). While time consuming, this technique allows the diagnosis
and treatment of lesions in the small bowel. In few cases despite combined
antegrade and retrograde attempt to examine the entire length of the small
bowel, this was unsuccessful.
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Liver and Gastrointestinal Manifestations of Dengue Hemorrhagic
Fever. An Analysis from a Cohort of 263 Hospitalized Patients
Antonio Ramos-De la Medina, MD, Tadeo Ceron, MD, Aurora Diaz-Vega,
MD, Angelica Hernandez, MD, Jose M. Remes-Troche, MD∗.
Gastroenterology and Gastrointestinal Surgery, Veracruz Regional
Hospital, Veracruz, Mexico and Medical-Biological Research Institute,
Universidad Veracruzana, Veracruz, Mexico.
Purpose: Dengue fever result from infection with any of the 4 dengue virus
serotypes (DEN 1–4). Clinical manifestations range from a mild, flulike
and self-limited febrile illness to severe illness with hemorrhage (DHF).
Although, liver abnormalities have been described as a manifestation of DHF,
the prevalence of other gastrointestinal manifestations is unknown. Our aim
was to evaluate the prevalence of liver and gastrointestinal involvement in a
cohort of patients with DHF.
Methods: Dengue fever is an endemic diseases in the state of Vercaruz,
Mexico. We retrospectively review clinical charts from 9005 subjects who
suffered dengue fever in the 2006 epidemic. Patients who where hos-
pitalized because of DHF, at the Veracruz Regional Hospital were in-
cluded for analysis. The diagnosis of DHF was based on serological pos-
itive test and manifestations. Demographic data, clinical manifestations,
laboratory data (peripheral white blood cell count, platelet count, pro-
thrombin time, activated partial thromboplastin time, aspartate and ala-
nine aminotransferase levels, hematocrit, and serum creatinine), and clin-
ical course and outcomes were obtained from the medical records for
analyses.
Results: Among 9005 patients, 263 were hospitalized. Fortyfive percet
were female and 55% were male. Mean age was 30.3 years (range 5–
74) Seventyone patients (27%) had some form of gastrointestinal man-
Table 1. Teduglutide Pharmacokinetics
Teduglutide 20 mg/day sc Teduglutide 80 mg/day sc
AUC (ng.hr/ml) Cmax (ng/ml) tmax (hr) t1/2 (hr) AUC (ng.hr/ml) Cmax (ng/ml) tmax (hr) t1/2 (hr)
Day 1 1781.0 284.2 3.2 2.4 5112.6 562.1 6.5 5.4
Day 2 1688.4 280.8 3.5 2.8 5088.4 554.5 4.5 4.5
ifestation. Fifty of the 71 patients (70%) had abnormal aminotrans-
ferases (ALT and/or AST) during the course of their disease. Four pa-
tients (6%) had a direct billirubin greater than 0.8 mg/dL. All the pa-
tients with gastrointestinal manifestations had less than 105,000 platelets.
Thirty-nine (55%) and 37(52%) had nausea and vomiting respectively.
One patient developed acute pancreatitis. Six patient had gastrointestinal
bleeding of which 5 had upper GI source and 1 patient had lower GI
bleeding. Mean hospital stay was 4.5 days (range 1–14). There were no
deaths.
Conclusion: Most patients with DHF had liver abnormalities. Up to 50%
of the patients had other GI manifestations such as nausea, vomiting, or GI
bleeding. Our findings suggest that in patients with acute fever syndrome with
abnormal liver function tests and GI manifestations, living in an endemic
area, Dengue fever should be suspected.
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Pharmacokinetics and Safety Profile of a Range of Teduglutide Doses
Given for Eight Days in Healthy Volunteers
Nonko Pehlivanov, MD, John Wallens, Jay Yang, PhD, Jane Cyran, PhD,
David Wells, PhD∗. NPS Pharmaceuticals, Parsippany, NJ.
Purpose: Data from animal and human studies indicate that both GLP-
2 and teduglutide (TD) stimulate the growth and proliferation of intesti-
nal epithelial cells. The goal of this study was to investigate the phar-
macokinetics (PK), and safety and tolerability of a range of doses of TD
or volume matched placebo (PL) in healthy volunteers over an eight day
period.
Methods: A Phase 1 single-center, double-blinded, randomized, placebo-
controlled study enrolled 96 healthy volunteers. Seventy two volunteers re-
ceived doses of 10, 15, 20, 25, 30, 50 or 80 mg TD and 23 received PL as
a subcutaneous injection for eight consecutive days with a follow-up visit
seven days after the last dose.
Results: There were 302 adverse events (296 mild, 5 moderate, and 1 se-
vere). Most frequent were gastrointestinal, 94 in the 72 TD subjects and 25
in the23 PL subjects, followed by injection site reactions (86 for TD and
19 for PL). Six subjects withdrew consent (2 on PL, 1 on TD), one with-
drew due to severe adverse event (PL, vasovagal syncope), 2 TD for other
reasons. Eight subjects receiving doses of 15, 20 or 30 mg of TD showed
mild elevations of AST and ALT enzymes by Day 4 of dosing. (defined by
FDA guidance to be less than 2.5 times the upper limit of normal). Among
these eight subjects, seven subjects’ liver enzyme levels returned to nor-
mal by the follow up visit (within 7 days after the last dose), and the other
subject’s liver enzyme level returned to normal within 2 weeks of the last
dose. No dose response in elevated LFTs was observed and none of the sub-
jects receiving the highest doses of 50 and 80 mg showed elevated LFTs.
PK parameters of the 20 and 80 mg/d dose cohorts follow. [Teduglutide
Pharmacokinetics]
Conclusion: Teduglutide appears to be safe in humans for short-term
treatment in doses exceeding up to 10 to 4 respectively times the high-
est dose applied in current clinical trials involving patients with short
bowel syndrome and Crohn’s disease. Mild and reversible changes in
liver enzyme levels are possibly associated with exposure to tedug-
lutide or other factors such as confinement in a Phase 1 clinic in
a dose-independent manner. The PK of teduglutide is predictable and
consistent.
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The Significance of Antineutrophil Cytoplasmic Antibody in Adult
Patients with Henoch-Scho¨nlein Purpura Presenting Mainly with
Gastrointestinal Symptoms
Yan Zhang, MD, Yongkang Wu, MSB, Mattew Ciorba, MD, Qin Ouyang,
MD∗. Division of Gastroenterology, West China Hospital of Sichuan
Universtiy, Chengdu, Sichuan, China; Department of Laboratory
Medicine2, West China Hospital of Sichuan Universtiy, Chengdu, Sichuan,
China and Division of Gastroenterology, Washington University School of
Medicine, St. Louis, MO.
Purpose: This study is to test the clinical significance of ANCA in evaluation
of adult HSP patients presenting mainly with abdominal symptoms.
Methods: Twenty eight consecutive Henoch-Scho¨nlein purpura (HSP) pa-
tients who presented predominantly with abdominal symptoms were enrolled
in this study. Control subjects included 27 age and sex-matched patients with
peptic ulcer disease, colon cancer, acute gastroenteritis, irritable bowel syn-
drome and colonic polyps. ANCA were measured by indirect immunofluo-
rescence (IIF) in all patients; and follow-up ELISA assay was performed in
patients with positive IIF tests.
Results: ANCA was detected in 9 HSP patients by IIF (2 positive for c-
ANCA and 7 positive for p-ANCA). No ANCA was found in the control
group. The sensitivity and specificity of a positive ANCA test (either c- or
p-ANCA) was 32.1% and 100% respectively. Among the 9 patients with
positive ANCA by IIF, only one was positive by ELISA and the antigen was
myeloperoxidase (MPO). The patients with ANCA positivity had higher
HSP clinical scores, and were more likely to have renal function impairment
(table 1).
Conclusion: ANCA is not a sensitive but a specific marker for adult HSP
who presented predominantly with abdominal symptoms. A positive ANCA
test is associated with more severe symptoms.
Table 1. Blood Creatine and 24-hours Urinary Protein in HSP Patients
Blood creatine (µmol/L) 24-hours urinary protein (g/L)
ANCA(+) 320 ± 22 (3.64 ± 0.25 mg/dl) 1.78 ± 0.12
ANCA(−) 104 ± 15∗(1.19 ± 0.16 mg/dl) 0.78 ± 0.32∗
∗P < 0.05 ANCA (+) HSP patients vs. ANCA (−) HSP patients
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Kaposi’s Sarcoma Presenting as Small Bowel Intussusception: Case
Presentation and Review of the Literature
Khursheed Haider, MD, Vijay Nakhate, MD, Shahid Ahmed, MD, Victoria
Bengualid, MD∗. Inernal Medicine, St. Barnabas Hospital, Bronx, NY.
Purpose: KS was rarely seen in the US before the start of transplant medicine
and the HIV epidemic. Bowel intussusception is common in children but rep-
resents only 1% of cases in in adults. Unlike children, adult intussusception
is associated with pathological lesions. In HIV patients the most frequent
GI tumor is KS. However most cases are asymptomatic. Few cases of KS
presenting with intussusception are described in the literature. We present
KS of the small intestine associated with intussusception in an HIV positive
adult.
Case Scenario: A 37 year old homosexual male, HIV positive, presented
with non-radiating sharp abdominal pain associated with vomiting and non-
bloody watery diarrhea. He was non-compliant with HAART.
On exam he was afebrile. Abdomen was soft, diffusely tender. Bowel sounds
were audible. Stool guaiac was negative.
Abdominal X- ray showed multiple air fluid levels suggestive of small bowel
obstruction. Abdominal CT showed ileo-ileal intussusception resulting in
small bowel obstruction. At laparotomy he had telescoping of ileum (intus-
susception). Affected portion of small bowel was removed. Biopsy showed
KS. Recovery was uneventful.
Discussion: In AIDS patients, KS is the most frequent tumor of the GI
tract. It has been reported through out the GI tract, including the orophar-
ynx, esophagus, stomach, small and large intestines, anus, liver, spleen and
pancreas. 50% of cases involve the oral mucosa. It usually remains asymp-
tomatic. In AIDS patients, on autopsy, KS involved the abdominal viscera in
77% of cases. In symptomatic cases, it manifested as GI bleeding, intestinal
obstruction, intussusception, perforation and protein loosing enteropathy.
In the literature we found 9 cases of KS presenting as intussusceptions in
patients with AIDS (see table). Most of the cases involve the small bowel.
50% had skin involvement. Our case illustrates this life threatening but rare
manifestation of a commonly occurring disease in HIV patients. KS should
be considered in the differential diagnosis of an acute abdomen in AIDS
patients.
Published cases of KS intussusception
HIV AREA OF GI SKIN
AUTHOR/YEAR POSITIVE INVOLVED MANIFESTATION
Tedeschi 1947 x Small Bowel Unknown
White 1964 x Colon Unknown
Birch 1967 x Jejujum-ileum No
Coetzee 1967 x Small Bowel Yes
Khorshid 1987 Yes Ileum Yes
Khorshid 1987 Unknown Small Bowel No
Hofstetter 1988 Yes Jejunum Yes
Gulick 1997 Yes Small Bowel Yes
Wang 2002 Yes Ilieum No
This Report Yes Small Bowel No
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Revisiting Capsule Endoscopy in the Diagnosis of Small Bowel
Malignancy
Anthony Aghenta, MD, Ayodele Osowo, MD, Tarun Kothari, MD, FACG,
FACP∗. Internal Medicine, Unity Health System, Rochester, NY.
Purpose: Small bowel malignancy is rare but the diagnostic modalities for
small bowel pathologies in the pre-capsule endoscopy (CE) era were limited
resulting in delayed diagnosis and poor prognosis for malignant tumors. In
evaluating obscure GI bleed recent studies have shown the superiority of CE
in the detection of small bowel tumors.
Case 1: A 74 year old white male presented with a history of GERD and
persistent iron deficiency anemia despite iron therapy and blood transfu-
sions. FOBT was negative. Tests revealed a Hct of 26.4%, Hgb of 8.1 gm/dl,
MCV 88.4fl, platelet count 423,000/cumm, serum iron 14 mcg/dl, TIBC
440 mcg/dl, ferritin 4 mcg/l, and transferrin saturation 3%. EGD, CT scan of
the abdomen and colonoscopy were unremarkable. CE showed an ulcerated
bleeding stricture in the mid ileal region. He underwent laparotomy with
bowel resection. Histology confirmed adenocarcinoma.
Case 2: A 75 year old white female with history of chronic abdominal pain
and iron deficiency anemia presented with hematocrit of 26.2 and MCV of
66.1. FOBTs were negative. Over the preceding 4 years she had several tests
done including 2 abdominal CT Scans, 2 EGDs, SBFT, and colonoscopy.
She remained iron deficient despite iron therapy and blood transfusion. CE
showed bleeding in the distal ileum, intra-operative enteroscopy then re-
vealed a bleeding mass in the distal jejunum that was resected. Histology
confirmed small bowel adenocarcinoma.
Case 3: A 55 year old white male with history of iron deficiency anemia
on iron therapy initially diagnosed 2 years prior presented with fatigue,
palpitations, and shortness of breath. His hematocrit was 19.9, with MCV
of 69.2. FOBT was negative. EGD and colonoscopy were unremarkable. CE
was unremarkable but push enteroscopy revealed fresh blood and organized
blood clot in the proximal jejunum. CT scan of the abdomen showed 4
hypodense lesions in the liver. He underwent laparoscopic exploration with
segmental resection of the jejunum and wedge biopsy of the liver lesions.
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Histology confirmed gastrointestinal stromal tumor (GIST) with metastasis
to the liver.
Conclusion: In the course of iron deficiency anemia, GI bleeding may not be
detected by FOBT even when multiple tests are done. Case 1 and 2 highlight
the utility of CE in diagnosing small bowel malignancy. Case 3 however
attenuates the infallibility of CE. Although only a few studies have reported
clinically significant lesions identified by enteroscopy but missed by CE,
both test modalities are better optimized when complemented.
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Nitazoxanide for the Treatment of SIBO-Related Gastrointestinal
Symptoms
Harry Moulis, MD∗, Gregory J. Stella, MD, Louis M. Agnone, MD, Donato
R. Ricci, MD, Sunil P. Pasricha, MD, David B. Mostellar, PharmD.
Gastrointestinal Associates, P.A., Port Orange, FL and Department of
Medical Science, Romark Laboratories, L.C., Tampa, FL.
Purpose: Small intestinal bacterial overgrowth (SIBO) is a clinical condi-
tion defined as an abnormally high bacterial population in the small intestine.
SIBO symptoms are variable, with abdominal pain or discomfort, bloating,
diarrhea, and flatulence being the most common. Nitazoxanide (NTZ) is
a first in class thiazolide antibiotic with a targeted anaerobic antibacterial
activity, placebo-like safety profile, and high gastrointestinal (GI) concen-
tration. To date no studies have evaluated the empiric use of NTZ for the
treatment of GI related symptoms in SIBO patients. The purpose of this
paper is to report on practice experience utilizing NTZ for the treatment of
SIBO-related GI symptoms in a community setting.
Methods: A chart review was performed on eleven consecutive patients
treated with NTZ for the diagnosis of SIBO. The diagnosis of SIBO was
made by the attending physician based on the patient’s symptoms and positive
lactulose breath test. Patients meeting this criteria were prescribed NTZ 500
mg twice daily for five days. Efficacy was measured as resolution of the
patient’s GI related symptoms 2–4 weeks after the end of therapy; repeat
lactulose breath tests were not performed. The primary markers for resolution
included: abdominal pain, diarrhea, bloating, and/or flatulence.
Results: Of the eleven patients treated with NTZ, seven were available for
follow-up evaluation. The four remaining patients have not returned to the
clinic with any GI related complaints. A complete resolution of symptoms
was reported in five out of the seven patients treated with NTZ. Of the two
patients that did not respond to therapy, one patient was not able to tolerate
the medication due to an unknown reason. The other nonresponder had failed
multiple previous regimens including antibiotics, probiotics, and pancreatic
enzymes. Table one summarizes patient responses to NTZ therapy.
Conclusion: The empiric use of nitazoxanide 500 mg twice daily appears
to be a safe and effective therapy for the treatment of SIBO-related GI
symptoms. To further support these findings, larger controlled clinical trials
are warranted.
Table 1.
symptom resolved or improved No change/Worsen
Diarrhea 5/6 (83%) 1/6 (17%)
Bloating 3/5 (60%) 2/5 (40%)
Abdominal pain 2/2 (100%) N/A
Flatulence 1/1 N/A
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Enteroscopy Using the New 47F Discovery SB and Fujinon
Enteroscope
Paul A. Akerman, MD∗, Daniel Cantero, MD, Jose Avila, MD. University
Gastroenterology, Providence, RI; HospitalFrancais, Ascuncion, Paraguay
and Rhode Island Hospital, Providence, RI.
Purpose: All methods of small bowel enteroscopy have significant limita-
tions. The Discovery SB has been shown to work with the pediatric colono-
scope. Reduced size (58 F to 47 F) and increased length of the enteroscope
may have significant advantages for deep small bowel insertion with min-
imal mucosal damage. The Discovery SB overtube and enteroscope work
by using a rotating raised spiral to pleat small bowel. This pilot study is to
evaluate the new Discovery SB and Fujinon 9.4 mm enteroscope.
Methods: The new Discovery SB overtube is 47 F, 118 cm long with a 5 mm
raised spiral 21 cm long at the distal end. There is a locking collar that allows
spiral pleating or unlocking for push advancement and gathering small bowel.
Indications for the procedure were obscure bleeding or abnormal imaging
studies. Enteroscopy was performed in 7 patients by two endoscopists. In-
formed consent was obtained. Propofol, Fentynal and Versed were used for
sedation. The new 47 F Discovery SB was placed over the Fujinon 9.4 mm
200 cm enteroscope and both were advanced with gentle push and roation
past the Ligament of Treitz (LOT). Once past the LOT the Discovery SB
was rotated and pleating of small bowel was achieved. Further advancement
was achieved with unlocking the Discovery SB and pushing the enteroscope
through the overtube. The Discovery SB was then rotationally advanced over
the enteroscope and the proces repeated. Withdrawal was achieved with an-
ticlockwise rotation of the overtube. Depth of insertion was determined by
endoscopic criteria.
Results: Enteroscopy with spiral advancement was completed in all 7 pa-
tients, 3 M, 4 F. Average age was 47 yrs, average weight/height was 165
cm/70 kg. Average sedation was 80 mg Propofol, 4.5 mg Versed and 90 mcg
Fentanyl. All patients tolerated the procedures well. There were no com-
plications. Minimal mucosa trauma was seen in 2 patients. 2 patients had
AVM’s. 1 patient a small bowel adenocarcinoma. Average depth of insertion
past the LOT was estimated to be 202 cm (Range 60–380 cm) Deepest in-
sertion depth was proximal ileum. Average total time of procedure was 34.5
minutes (Range 21–55 minutes).
Conclusion: The new 47 F Discovery SB and Fujinon 9.4 mm enteroscope
is safe and effective for rapid advancement through the small bowel. Deep
small bowel intubation can be achieved by spiralling the new Discovery SB
and pleating small bowel.
264
Magnetic Resonance Imaging (MRI) of the Small Intestine: Utility of
This Modality in a Large Urban Community Hospital
Nalini K. Sharma, MD, Dana A. Sloane, MD, Jennifer Lee, MD, I.D.
Shocket, MD, Julio A. Salcedo, MD∗, J.D. McFadden, MD.
Gastroenterology/Medicine, Washington Hospital Center, Washington, DC
and Radiology, Washington Hospital Center, Washington, DC.
Purpose: Evaluation of the small bowel is difficult. Current modalities in-
clude computed tomography scan, capsule endoscopy, enteroscopy, entero-
clysis, angiography, small bowel follow through, and surgery. However, each
technique has limitations. Small bowel MRI is an efficient and tolerable tech-
nique with limited availability nationally. This technique is not invasive, does
not involve radiation, and provides detailed information regarding mucosal
and transmural inflammation and wall thickness. The purpose of this study is
to determine the application of small bowel MRI in a large urban community
teaching hospital.
Methods: Small bowel MRI with gadolinium involves administration of
psyllium fiber as an intraluminal agent taken in advance over a 3 hour period,
and the use of glucagon during the examination. This is a retrospective chart
review to determine the indications, results, therapy, and management for 40
patients undergoing small bowel MRI at a large urban community teaching
hospital from January 2006 to January 2007.
Results: Indications for small bowel MRI included abdominal pain (22 pa-
tients), suspected Crohn’s disease (12 patients), anemia (3 patients), gas-
trointestinal bleed (1 patient), and abnormal CT abdomen (2 patients). Small
bowel MRI was abnormal in 14 patients: small bowel thickening (8 patients),
stricture (3 patients), and small bowel obstruction (3 patients). In 17 patients
there had been previous small bowel imaging including capsule endoscopy,
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CT abdomen, small bowel follow through, and abdominal x-ray. In 9 pa-
tients with abnormal findings on a prior study, MRI confirmed the finding
in 5 patients but changed the diagnosis in 4. As a result, 2 patients averted
surgery; 2 patients no longer were given a diagnosis of Crohn’s disease. MRI
did confirm normal small bowel imaging in 8 patients.
Conclusion: Small bowel MRI did confirm normal results in 8 patient with
prior imaging, and more importantly, it did identify false positive results in
4 out of 17 patients with prior imaging. The identification of false positive
results altered patient management. Small bowel MRI is a noninvasive tool
which utilizes an inexpensive and tolerable intraluminal agent, requires no
radiation, and provides detailed imaging. Therefore, small bowel MRI should
be considered for evaluation of the small bowel in large community hospitals.
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Mantle Cell Lymphoma of the GI Tract: Is It Distinctive from Other
Gastrointestinal Lymphomas?
Adrianne LaJoie, MD∗, Williamson B. Strum, MD. Gastroenterology and
Hepatology, Scripps Clinic and Research Institute, La Jolla, CA.
Purpose: Mantle cell lymphoma (MCL) is a relatively new subtype of B-
cell lymphoma that involves the GI tract in up to 88% of patients. MCL is
distinguished by overexpression of the cyclin D1 protein which promotes
cell division, and mucosal affinity for the alpha-4-beta-7 receptor. Our aim
was to examine the clinicopathologic features of MCL compared to follicular
(FL), marginal zone lymphoma of MALT type (MZL) and diffuse large B-
cell lymphoma (DLBCL). We tested the null hypothesis that there is no
difference in site of involvement between MCL and other GI lymphomas.
Methods: Cases of gastrointestinal lymphoma were collected from five com-
munity hospitals in San Diego and identified by histology and flow cytometry.
Age, gender, clinical presentation, site of involvement, endoscopic appear-
ance, and bone marrow involvement were analyzed.
Results: A total of 96 cases were reviewed and included (MCL = 10, FL =
20, MZL = 28, DLBCL = 38). Median age at presentation was similar
(age range 28–97; median age 62–68). 70% of MCL patients were men. En-
doscopic appearances varied from multiple small nodules to large polypoid
lesions to ulcerated masses. There were no characteristic endoscopic findings
for any lymphoma type. Compared to patients with FL, MZL and DLBCL,
patients with MCL had significantly more colonic involvement (P < 0.001)
and were more likely to present with stage IV disease (P < 0.02–0.001).
Greater than 85% of MCL patients were positive for cyclin D1. MZL and
DLBCL were more likely to present with GI bleeding (14.3% and 10.5%,
respectively), while no patients with FL or MCL bled. While 25% of patients
with FL presented with small bowel obstruction, no patients with MCL had
this presentation. These data disprove the null hypothesis.
Conclusion: Clinical markers are available to distinguish MCL from other
lymphomas. Age, sex, and endoscopic appearance are overlapping and not
distinctive. The most helpful distinctions are colonic site of involvement,
advanced disease and presence of cyclin D1. Correct subclassification of GI
lymphoma has important implications for both treatment and prognosis and
even small lesions, should be biopsied.[figure1]
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Clostridium difficile Small Bowel Enteritis
Harry A. Lazarte, MD∗, Syed Bin-Sagheer, MD, Kelli Peterson, MD.
Department of Gastroenterology, Creighton University Medical Center,
Omaha, NE.
Purpose: Clostridium difficile infection is usually localized to the mucosa of
the large intestine. Isolated C. difficile infection of the small bowel mucosa
is a rare finding.
Methods: A 40 y/o male with past medical history of ulcerative colitis, who
underwent a total colectomy with ileostomy in December of 2005 and a take
down of ileostomy and re-anastomosis 6 months later, was admitted in July
of 2006 with complaints of shortness of breath and diarrhea. Abdominal se-
ries showed multiple air fluid levels suspicious for small bowel obstruction.
Further work up, which included a computer tomography of the abdomen
and small bowel series, showed no evidence of obstruction. During this hos-
pitalization, patient developed an urinary tract infection which was treated
with Levofloxacin. Two days after, his diarrhea increased in frequency, at
times with blood. C. difficile toxin test was positive. Metronidazole was
started and the patient improved, eventually leading to discharge. This pa-
tient returned in August with hypotension, tachycardia and diarrhea. Repeat
CT scan of the abdomen showed diffuse mesenteric fat stranding suggesting
mesenteric inflammation. Repeat C. difficile toxin test was positive. At that
time IV Metronidazole and Vancomycin oral was started. Supportive treat-
ment was given. A flexible sigmoidoscopy was done with findings of ery-
thematous small bowel mucosa, but no pseudomembranes observed. Biopsy
results showed small bowel mucosa with preserved villous architecture and
no significant pathology. Patient was discharged with oral Vancomycin and
appropiate follow up.
Conclusion: Clostridium difficile small bowel enteritis is rare and only a few
cases have been reported. A review of the these cases by the Division of In-
fectious Diseases at the Wright Patterson Medical Center in 2001 suggested
that small bowel enteritis caused by C. difficile can be more severe, often
leading to death, than the more commonly known colonic mucosa infection.
In this case, persistence of the infection despite adequate treatment seems
to confirm the aforementioned observations. Our patient developed signs of
sepsis and is our belief that this was due to the C. difficile infection. Recent
reports of ileal perforation secondary to C. difficile small bowel enteritis
make this infection an important consideration in the differential diagnosis
of diarrhea, especially in the setting of colectomy. Therefore, prompt diag-
nosis and use of adequate therapeutic options seems to be imperative in cases
of suspected C. difficile small bowel enteritis.
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Histopathology Predicts Abnormal Liver Function Tests and
Autoimmune Disorders in Celiac Disease
Kavita Singh, MD, Ece A. Mutlu, MD, Mark T. DeMeo, MD∗. Medicine,
Rush University Medical Center, Chicago, IL.
Purpose: Celiac disease (CD) is an immune mediated response to gluten
characterized by lymphocytic infiltration and/or destruction of intestinal villi.
CD has also been associated with extraintestinal manifestations (EIM), un-
related to malabsorption, such as liver dysfunction and autoimmune disease.
EIM may result from a breakdown in the gut barrier. We therefore propose
that the EIM of CD correlates with more advanced histology.
Methods: This was a cross sectional study of 136 patients undergoing en-
doscopy and duodenal biopsy for upper digestive symptoms or suspected
celiac disease. CD was defined as a Marsh III lesion or a Marsh II lesion with
positive serologies (PS) for transglutaminase (tTG) and/or antiendomysial
antibodies (EMA). 48 patients had Marsh III histology, 14 patients had a
Marsh II lesion with PS, while 31 patients had increased intraepithelial lym-
phocytes (IELs) with negative serologies (NS) and 43 control patients had
normal duodenal histology. Presence of elevated liver function tests (LFTs)
and serological or clinically documented evidence of autoimmune disor-
ders (AI) at or near the time of diagnosis of CD were recorded. Patients
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with abnormal LFTs secondary to an identifiable cause of liver disease were
excluded. Statistics was done using SPSS.
Results: In patients with Marsh III lesions, 18 (39%) had elevated LFTs
and 9 (19%) had AI. In Marsh II patients with PS, 2 (15%) had elevated
LFTs, 6 (43%) had AI. In patients with Marsh II lesions alone, 6 (22%)
had elevated LFTs, 7 (26%) had AI. Elevated LFTs were seen in 4 (9%)
controls and 3 (1%) of these patients had AI. Differences in LFTs between
Marsh III lesions and Marsh II lesions with PS and Marsh II lesion without
PS and controls were significant (Chi square, P = 0.009). Abnormal LFTs
were more frequent with advanced Marsh stage. Differences in AI were also
significant between the groups (Chi-square P = 0.018) but were associated
with presence of intraepithelial lymphocytes (IELs) rather han histologic
stage. In our population, the odds ratio (OR) of having increased LFTs with
celiac disease is 4.26 (CI 95% = 1.15–15.76). The OR of having AI with
IELs is 3.08 (CI 95% 1.30–7.27).
Conclusion: In CD, higher Marsh levels are associated with an increased fre-
quency of abnormal LFTs. Though no such association is seen with autoim-
munity there appears to be an increased incidence of AI with the presence
of increased IELs.
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Is Pre-Albumin an Accurate Marker of Nutritional Status in Acutely
Ill Patients?
Kandarp R. Patel, DO, Lin Shu, Richard Gerkin, MD, Rakesh Nanda,
MD∗. Department of Gastronenterology, Carl T. Hayden VA Medical
Center, Phoenix, AZ and Department of Medicine, Good Samaritan
Regional Medical Center, Phoenix, AZ.
Purpose: Pre-Albumin (PAB), a hepatic protein, is the earliest laboratory
indicator of nutritional status and is the preferred marker for “malnutrition”
as it correlates with patient outcomes in a wide variety of clinical conditions.
PAB is also a negative acute phase protein whose plasma concentration
decreases during inflammation. The aim of this study was to determine
if PAB is a valid indicator of the nutritional status in patients with acute
inflammation.
Methods: We retrospectively reviewed all admissions over a 2 year period
from 1/1/2004 to 12/1/2005. Patients included in this study were inpatients
who had PAB and C Reactive Protein (CRP) drawn on the same day. Ad-
missions to all services, including medical, surgical, and ICU were included
in the analysis. Analysis was performed using SPSS software and the ex-
tent of the relationship was found by calculating the Spearman ρ correlation
coefficient. A P-value less than .05 was considered significant.
Results: 176 patients were analyzed. Multiple values were collected on sin-
gle patients for a total of 316 specimens. The Spearman ρ correlation coef-
ficient on day 1 was −.625 (P < .001), day 2 was −.513 (P < .001), day 3
was −.791 (P < .001), day 4 was −.770 (P < .001), and day 5 was −.742
(P < .004). [figure1] All results showed a statistically significant negative
correlation between CRP and PAB levels. As the figure also shows PAB
levels increased only when CRP normalized.
Conclusion: Currently there is no single reliable indicator of patients’ nutri-
tional status and by default PAB is the most widely used because of its ease
to perform. Our study did show there is a negative correlation between acute
inflammation and PAB. Also, as CRP levels normalized the PAB levels in-
creased. Our study suggests PAB may not be an accurate marker of assessing
nutritional needs in acutely ill patients. Future prospective controlled studies
will be needed to confirm our hypothesis.
LIVER
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Problems in Determining the Etiology for High “No-Show” Rate of
Patients Referred for Evaluation of Hepatitis C
Joseph C. Yarze, MD, FACP, FACG FASGE∗. Gastroenterology Associates
of Northern New York, Glens Falls, NY.
Purpose: In a recent prospective study, it has been substantiated that pa-
tients referred for evaluation of hepatitis C are less likely to show for their
initial outpatient consultation, than those referred for the evaluation of “all
other” gastroenterologic/hepatologic diagnoses. This investigation sought to
determine the etiology for this phenomenon.
Methods: In a previously performed prospective study, it was shown that pa-
tients referred to a gastroenterologist (private-practice, single-specialty gas-
troenterology group in a semi-rural community), were less likely to “show”
for their initial office consultation if referred for evaluation of hepatitis C,
than if they had been referred for “all other” gastroenterologic/hepatologic
diagnoses. Over the study period (10/3/03 through 5/6/05), 543 new patients
were scheduled for initial outpatient office consultation. Of these, 66 were
referred for evaluation of hepatitis C, and 477 were referred for evaluation of
“all other” diagnoses. The rate of “not-showing” for initial consultation was
12/66 = 18.2% for patients presenting for evaluation of hepatitis C versus
37/477 = 7.8% for patients referred for evaluation of “all other” diagnoses,
(P = 0.01 by Fischers exact test; odds ratio = 2.65).
From 5/7/05 through 3/21/07 a total of 6 patients referred for evaluation
of hepatitis C did not “show” for initial consultation. A brief questionnaire
(with enclosed self-addressed/stamped return envelope) was sent to these
patients in an attempt to elucidate the reason for this phenomenon.
Results: Of the 6 questionnaires which were mailed to these patients, none
were returned.
Conclusion: The reason why patients with hepatitis C often fail “to show”
for initial outpatient office consultation remains unclear. This uncertainty
remains, despite attempting to contact a cohort of such patients by mail (with
a brief questionnaire and enclosed self-addressed/stamped return envelope).
This “failure to show” for initial subspeciatly consultation is clearly one
major impediment in the pathway to the adequate evaluation and treatment
of patients with hepatitis C.
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Hepatic Neuro-Endocrine Tumor: A Case Report
Sumit Sharma, MD, Preeti Agrawal, MD, Rami Haddad, MD∗.
Department of Medicine, Rosalind Franklin University of Medicine and
Sciences, North Chicago, IL and Department of Oncology, Rosalind
Franklin University of Medicine and Sciences, North Chicago, IL.
Purpose: Primary hepatic neuroendocrine tumor are underreported in liter-
ature as they are thought to represent metastatic lesions. We present a rare
case masquerading as HCC accompanied by high AFP secretion.
Methods: The patient presented with a history of weight loss and abdominal
pain that began in right upper quadrant. Lab work showed: Hgb 12.6 gm/dl,
calcium 10.5 mg/dl, creatinine 1.8 mg/dl, lipase 561 U/L, AST 151 IU/L,
ALT 51 IU/L, T bil.1.2 mg/dl, Alk. phos 262 IU/L, AFP 10313 ng/ml and a
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CEA level of 4.3 ng/ml. Hepatitis panel was non reactive. CT scan showed
enlarged liver with multiple large areas of diminished attenuation consistent
with multiple hepatic masses. An FNAC of liver showed the cell block to
be entirely composed of necrotic tumor with groups of tumor cells demon-
strating high nuclear to cytoplasmic ratio, numerous mitotic figures, granular
chromatin, no visible nucleoli and a vague rosette-like pattern. Percutaneous
liver biopsy specimens were initially reported as hepatocellular carcinoma
but were later revised to neuroendocrine tumor on immunohistochemical
review. A core biopsy was done to further characterize the histology, which
was consistent with neuroendocrine tumor. On immunohistochemistry, the
tumor cells were positive for chromogranin and synaptophysin and nega-
tive for cytokeratin 7 and 20. His serum chromogranin A level was 839.5.
Extensive work up failed to yield a primary site of neuroendocrine tumor
involvement. He was thus diagnosed with an atypical neuroendocrine tumor
and palliative chemotherapy with carboplatin and etoposide treatment was
initiated.
Results: Although an AFP level of >500 is considered diagnostic of Hepa-
tocellular carcinoma, liver biopsy with immunostaining techniques is neces-
sary for proper diagnosis and treatment in cases where a neuroendocrine
involvement is suspected. An apparent hepatic carcinoid tumor may be
metastatic disease, where despite extensive assessment the primary tumor re-
mains obscure. Most primary hepatic neuroendocrine tumors are endocrino-
logically silent. The mainstay of treatment is hepatic resection while oc-
treotide is best suited for metastatic disease from a primary hepatic neu-
roendocrine tumor. Regular clinical review and CT imaging are essential to
detect recurrence. The overall prognosis with this tumor is better than for
other hepatic carcinomas.
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Liver Transplantation and Neurological Manifestations in Wilson
Disease
Sumit Sharma, MD, Preeti Agrawal, MD, Shan-Ching Ying, MD, Kris
Ananad, MD, Arun Verma, MD∗. Medicine, Rosalind Franklin University
of Medicine and Science, North Chicago, IL and Pathology, Mt. Sinai
Hospital, Sinai Health System, Chicago, IL.
Purpose: The role of liver transplantation (LT) in managing the neurological
manifestations of Wilson’s Disease (WD) is not yet conclusive. A 26 year-
old man with WD with cirrhosis experienced a dramatic improvement in
motor function and cognitive testing early after LT, as well as normalization
of copper balance.
Methods: A 26 y/o Hispanic man presented with progressively increasing
abdominal distension, dark urine, clumsiness of gait and cognitive deficits.
He did not have any history of emotional disorder/drug or alcohol depen-
dence/suicidal ideation/hallucinations. On physical examination he had a
tense, distended abdomen with diffuse tenderness, BS+, liver and spleen
could not be palpated. Imaging revealed a large ascites and splenomegaly
(9.5 × 18 × 19 cm) without parenchymal lesions. Liver had a nodular con-
tour and coarse echo pattern. CT of the Abdomen/Pelvis revealed massive
ascites with a small, shrunken, irregular liver with nodular periphery. Patient
was started on lasix, spironolactone and lactulose. EGD showed portal gas-
tropathy and Grade 1 esophageal varices and ophthalmologic evaluation did
not show KF rings. Laboratory studies showed Iron Deficiency anemia with
normal antibody levels of ANA, AMA, alpha 1 antitrypsin and anti Sm Ab.
SAAG>1.1 with 24 Hr urinary copper level of 1835 mcg/l and ceruloplas-
min level of 3 mg/dl, liver copper 974 mcg/gm (dry wt) was consistent with
Wilsons disease. Patient was started on D-Penicillamine and subsequently
put on trientine due to heavy proteinuria and referred for a liver transplant.
He finally got a liver transplant (sibling) and currently is in good health
without any neurological deficits and marked cognitive improvement.
Results: Asonuma et al reported that LRLT from heterozygous carriers of
the WD gene could resolve clinical signs and symptoms of WD and correct
the parameters of copper metabolism. In this case study, Copper metabolism
in the WD recipient was compared before and after transplantation with
marked reduction in urinary copper excretion. Long-term follow-up should
be continued to evaluate this specific therapy.[figure1]
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Etiological, Clinical and Radiological Profile of Suppurative Lesions in
Solid Abdominal Visceras
A.P. Srivastava, MD, Namrata Nigam, MD, A.K. Jain, DM∗, V.K. Dixit, DM.
Department of Gastroenterology, IMS, BHU, Varanasi, Varanasi, UP, India.
Purpose: The profile of abscess is changing over last few decades in the
developing world. A few decades earlier the liver abscess in our country
was invariably amoebic in nature, however, in recent times the pyogenic
and mycotic abscess are being recorded with increasing frequency. This
study aims to evaluate the etiological, clinical and radiological profile of
suppurative lesions in intraperitoneal solid visceral organ like liver and spleen
in our tertiary health care centre in North India.
Methods: A total of 35 patients with intrabdominal abscess were prospec-
tively evaluated over a period of one year in the Department of Gastroen-
terology, IMS, BHU, Varanasi (India). They were studied to detail clinical,
hematological, biochemical, microbiological and radiological examination.
Few special investigations like HIV testing, blood culture and ELISA for E.
histolytica antibody were also carried out in our study.
Results: Of the 35 cases, 30 had liver abscess and 5 splenic abscesses. There
were significant changing trend on the incidence of amoebic abscess (70%)
and pyogenic abscess (30%). Majority of patients with amoebic abscess
presented a decade earlier than pyogenic abscess group. Anemia, moderate
polymorphonuclear leukocytosis, elevated serum bilirubin, increased serum
alkaline phosphatase, increased SGOT, increased SGPT, hypoalbuminemia
were significantly observed in our study group. Most frequently isolated
organism was Klebsiella pneumonia (10%) followed by E. coli (6.6%) and
Staph aureus (3.3%). Amoebic abscess were mostly solitary (size >7 cm),
echofree wall and subcapsular. Males were the dominant group in both liver
and splenic abscess.
Conclusion: Profile of suppurative disease affecting solid abdominal viscera
is changing. Two decades earlier it was invariably involved liver of amoebic
nature. In this study two fifth of cases were due to pyogenic abscess in which
gram negative organism were predominantly isolated, affecting liver (26%)
and spleen (14%), HIV coinfection was an important accompaniant (40%) in
splenic abscess and chronic alcohol is seen in amoebic liver abscess (76.1%).
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Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Budd-Chiari
Syndrome (BCS): Experience at a Tertiary Health Center
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Sanjeev Sachdeva, DM, K.S. Prasanna, MD, S.K. Maurya, MD∗, P.
Mandal, MD, G. Choudhuri, DM, V.A. Saraswat, DM, S.S. Baijal, MD∗.
Departments of Gastroenterology and Radiodiagnosis∗, SGPGI, Lucknow,
UP, India.
Purpose: Transjugular intrahepatic portosystemic shunt (TIPS) is a techni-
cally challenging but efficient therapeutic tool in patients with Budd-Chiari
syndrome (BCS). Results from several small series appear promising but
long-term outcome is not well studied. We aimed to analyze the results of
TIPS as a treatment option in BCS and and compare the outcome of PTFE-
covered stents vs bare stents.
Methods: Of 148 patients of Budd-Chiari syndrome, 115 underwent vas-
cular interventions. 17 patients underwent TIPS/ modified TIPS. Patients
were followed 3–6 monthly with clinical and biochemical assessment, color
doppler and; venography yearly.
Results: 17/18 (94.4%, male-12, median age 30 ± 11.7) patients underwent
successful procedure. Median duration of symptoms to diagnosis was 3
months. Presentation was acute, subacute and chronic in 4, 6 and 7 cases,
respectively. Indications were ascites (15/17) and variceal bleed (2/17) which
were controlled in all. Ten and 7 received PTFE covered and bare stents
respectively. In addition to hepatic vein occlusion, 3 had IVC block for
which IVC stenting was done. Total follow up period was 21 months (range
1–52 m). Five stent dysfunctions and repeat interventions were required in
4 patients with uncovered stents (median 22 months range 2–55 months)
vs 2/10 with PTFE-covered stents (median 18 months range 1–34 m) (P =
0.0339). One year actuarial primary patency rates were 80% vs 57.5% in
PTFE-covered stent group vs uncovered stent group. There were 2 deaths; 1
patient developed intraperitoneal bleed and died 30 days later and the other
patient died 4 months later because of variceal bleed and complications
precipitated by TIPS dysfunction.
Conclusion: TIPS is a useful modality of treatment for BCS with nonre-
canalizable hepatic veins. PTFE Covered stents may be better than uncovered
stents.
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The Effect of Statins on PEG-Interferon/Ribavirin Treatment for
Chronic Hepatitis C
Roy D. Yen, MD, Anoop Prabhu, MD, Thomas Mahl, MD∗. Internal
Medicine/Gastroenterology, VA Western New York Healthcare System,
Buffalo, NY.
Purpose: There is evidence that HMG-CoA reductase inhibitors (statins)
have an effect on hepatitis C virus (HCV) replication in vitro. We hypothesize
there is a syngergistic effect of statins when combined with interferon-based
treatment. We conducted a retrospective review to evaluate the effect of
statins on PEG-interferon (PEG-IFN) plus ribavirin (Rib) treatment response
in treatment-naive patients (pts).
Methods: We identified all pts seen from 2001–06 who had chronic HCV,
were naive to treatment with IFN-based therapy, and were taking a statin
during their course of PEG-IFN/Rib therapy (N = 13). The study group was
matched in 1:3 fashion to 39 control pts for gender, ethnicity, genotype, and
presence of cirrhosis, and we compared these groups for response to first
time treatment with PEG-IFN/Rib. We excluded pts with active HIV/HBV
infection or had received previous IFN-based therapy. We collected data on
age, BMI, and HCV viral load (VL). VLs were recorded at baseline, 12 wks
after start of treatment, end of treatment, and 24 wks after completion of
treatment.
Results: In our study, pts were male (100%) of caucasian ethnicity (76.9%)
with genotype 1 (61.5%) and cirrhosis in 7.7%. Statin group pts had mean
age 51.1 yrs with BMI 30.6 with mean baseline log10VL 5.98 and were
comparable to control pts. In the study group, EVR (2 log decrease in VL
@ 12 wk) was achieved in 100% pts, ETR in 76.9% pts, and SVR in 38.5%
pts. In the control group, EVR was achieved in 86.8% pts, ETR in 52.6%
pts, and SVR in 34.2% pts. There was no statistical difference measured
between proportions of statin pts and control pts achieving EVR, ETR or
SVR. However, the statin group had a higher proportion of undetectable VL
(91.7% vs 55.6%, P = .02) and lower mean log10VL (.4 vs 1.7, P = .04)
at 12 wks after start of treatment. 11 statin pts (84.6%) and 29 control pts
(74.3%) completed the full treatment course.
Conclusion: While there was no difference in proportions between the statin
vs control pts for achieving EVR, ETR, or SVR, there was significantly
higher proportion of statin pts with undetectable HCV VL at 12 wks of
treatment. It is possible that there is a significant synergistic effect of statins
with IFN-based therapy. Higher porportion of complete EVR with statins
may ultimately have significant impact on SVR; however, larger, prospective
trials are needed.
Results
Statin Pts Control Pts P
% EVR 100% 86.8% NS
% Complete EVR 91.7% 55.6% .02
% ETR 76.9% 52.6% NS
% SVR 38.5% 34.2% NS
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The Effect of Statins on Viral Load in Patients with Chronic
Hepatitis C
Roy D. Yen, MD, Anoop Prabhu, MD, Thomas Mahl, MD∗. Internal
Medicine/Gastroenterology, VA Western New York Healthcare System,
Buffalo, NY.
Purpose: There is some evidence that HMG-CoA reductase inhibitors
(statins) have an effect on hepatitis C virus (HCV) replication in vitro, but
there is no in vivo data. We conducted a retrospective review from one large
healthcare network database to evaluate the effect of statins on viral loads
(VLs) in patients chronically infected with HCV.
Methods: We identified all patients seen between 2000–06 who had chronic
HCV, were prescribed a statin, and had HCV VLs measured before and after
the initiation of statins (N = 16). We excluded patients with chronic hepatitis
B or HIV infection or those receiving active treatment for HCV. We collected
data on age, gender, ethnicity, BMI, self-reported alcohol use, specific statin
medication and dose, HCV serology and genotype, LFTs and lipid profile.
We compared the change in HCV VLs before and after initiation of statins
by Wilcoxon Signed Rank test. All significant P values reported for P < .05.
Results: In our study, patients were males (100%) of Caucasian ethnicity
(80%) with mean age 55.5 yrs and BMI 29.7. The median log10VL prior to
initiation of statin was 6.094. Most patients had genotype 1 (80%). Majority
of patients were prescribed simvastatin (87.5%) with mean dose of 35.4 mg.
Patients were taking statins for mean 430.4 days prior to having HCV VL
rechecked with median log10VL 6.103 at that time. There was no significant
difference between HCV VL before and after initiation of statin (P = .96),
and there was also no significant change in LFTs after statins were started.
S218 Abstracts
However, there was a significant decrease in total cholesterol after statins
were started (P < .001).
Conclusion: Our review did not demonstrate a significant change in HCV
levels after initiation of statin. However, larger, prospective studies are re-
quired.[figure1]
Results
Before Statin After Statin P
Log10VL 6.094 6.103 .96
AST 42 49 .33
ALT 64 79 .69
Total Chol 200 149.5 .001
Median values reported
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Results of 5 Years Experience of Liver Secondaries Treated by
Radiofrequency Ablation
Rashmi Jaiswal, MBBS, Ajit Sewkani, MS, Swarna Vyas, MSc, Sandesh
Sharma, MS, Saleem Naik, MS, Dipak Purohit, MS, Vikrant Singh, MS,
K.K. Maudar, MS, PhD, Subodh Varshney∗, Harkirat Bains, PhD. GI
Surgery, Bhopal Memorial Hospital and Research Centre, Bhopal, MP,
India.
Purpose: Radiofrequency ablation (RFA) is a new percutaneous tissue abla-
tive therapy. Role of RFA in treating liver secondaries is not widely studied.
We present our 5 years experience of RFA of liver secondaries.
Methods: Using Berchtold (Tuttlingan, Germany) RF generator (50–60 watt
output), 1500–2000 watts energy/cc tumour was delivered according to the
volume of liver secondaries.
Inclusion criterias were: lesion <5 cm in size, Non-invasion of portal vein,
no proximity to large vessel or duct technically feasible.
Exclusion criterias were: extra-hepatic disease not being treated by
chemotherapy, diminished hepatic function (eg. Child Pugh Class C), re-
fractory coagulopathy, massive ascites.
Between February 2001 and October 2006, 81 patients (52 males and 29
females), aged 39 to 72 years (mean 56 years) had RFA of 252 liver secon-
daries from gall bladder = 22, colorectal = 36, breast = 14, carcinoid or
neuroendocrine = 5, stomach = 4 cancers.
Lesions were sized <3 cm in 69, 3–4 cm in 118 and >4 cm in 65.
RF needle was placed, US guided in 76, CT guided in 1 and at an open
surgery in 4 patients. Follow up was done by contrast enhanced CT scan
between 1–4 weeks after the procedure.
Results: There was no procedure related mortality. All patients were dis-
charged within 24 hours except two. There was no major morbidity. There
were 10/81 (8%) minor morbidity (self limiting ascites = 3, severe abdomi-
nal pain = 3, self limiting pleural effusion = 4). Efficacy: Complete necrosis
was seen in all (100%, 69/69) of lesion up to 3 cm size and (40.6%, 48/118)
of lesion 3–4 cm in size. None of the lesion >4 cm had complete necrosis.
Recurrence at completely treated site at mean follow up of 12 months was
10/117 (8.54%). On more than 12 months follow up, 51/81 (63%) patients
developed new hepatic or systemic recurrence. Survival: One year survival
was 59% and 2 year survival was 24% of whole group.
Conclusion: RFA is safe and effective local tissue ablative method for liver
secondaries. More randomized trials are required to ascertain efficacy of
RFA in improving quality of life and /or survival in patients with liver
secondaries.
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A Single Center Experience of the Use of Mycophenolate Mofetil
(MMF) in the Maintenance Treatment of Autoimmune Hepatitis (AIH)
Jonathan T. Hlivko, MD, Mitchel L. Shiffman, MD, R. Todd Stravtiz, MD,
Velimir A. Luketic, MD, Arun J. Sanyal, MD, Michael Fuchs, MD, Richard
K. Sterling, MD∗. Gastroenterology, Hepatology, and Nutrition, Virginia
Commonwealth University Health System, Richmond, VA.
Purpose: AIH is a common disease in women which has traditionally been
treated with prednisone (P) ± azathioprine (AZA). However, some patients
(pts) are intolerant or do not respond to AZA. MMF, like AZA, is an an-
timetabolite with a somewhat less toxic side effect profile. The objective
of this study was to assess the clinical utility of MMF in the maintenance
treatment (tx) of AIH.
Methods: We performed a retrospective longitudinal analysis of pts fol-
lowed by Hepatology at VCUHS with AIH diagnosed by liver histology
and autoantibodies (ANA and ASMA). Pts with viral hepatitis, overlap syn-
drome and other liver diseases were excluded. Demographic and clinical
data at presentation were collected. Baseline characteristics and effective-
ness of maintaining remission were compared between those who received
to standard therapy (P ± AZA) and those who received MMF.
Results: We identified 126 pts with AIH: mean age 43, 84% female, 69%
Caucasian, 61% + ANA, 48% + ASMA. At presentation, median AST and
ALT were 227 and 261 while bridging fibrosis or cirrhosis were present in
38% and 22%, respectively. After initial induction, maintenance tx included
P + AZA (N = 85), P + MMF (N = 16), low dose P (N = 7), AZA (N =
7), MMF or tacrolimus (1 each). Of the 88 who initially received P ± AZA,
12 were switched to MMF (main reasons for conversion: nausea/vomiting
(N = 4), failure to normalize LFTs (N = 3), and pancreatitis, DVT, rash,
intolerance or hair loss (1 each). Of the 28 on MMF, 10 eventually discon-
tinued MMF due to side effects: headache (N = 3), failure to normalize
LFTs (N = 3), nausea/vomiting (N = 3), and myalgias (N = 1), while 18
remained on MMF either alone (N = 4) or combined with P (N = 12) or P
+ tacrolimus (N = 2). Of the 28 on MMF at any time, remission rates were
similar (86%) to those who remained on standard therapy P ± AZA (81%).
The only independent factor that predicted the eventual need for conversion
to MMF was cirrhosis at presentation (P = .0036).
Conclusion: 1) Use of MMF in the treatment of AIH was well tolerated; 2)
Cirrhosis on presentation was the only independent factor associated with
eventual need for MMF; and 3) Use of MMF was associated with a high
rate of remission (86%). Therefore, we conclude that MMF is an effective
option for salvage therapy for AIH in those who can not tolerate or fail to
respond to AZA.
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The Risk of Analgesics in Cirrhotics
Roger N. Coron, MD, Victor J. Navarro, MD∗. Medicine, Thomas
Jefferson University Hospital, Philadelphia, PA and Gastroenterology and
Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA.
Purpose: Analgesics, including nonsteroidal anti-inflammatory, ac-
etaminophen and aspirin containing compounds may lead to complications
of cirrhosis through a variety of mechanisms. The aim of this case con-
trol study was to assess the association between analgesic use and hepatic
decompensation leading to hospitalization in patients with cirrhosis.
Methods: We prospectively enrolled 90 non-encephalopathic cirrhotic cases
admitted with acute decompensation events, comprising portal hypertensive
bleeding, ascites, peritonitis, and 125 non-hospitalized cirrhotic controls. We
ascertained 30-day analgesic use and potential confounding factors for hep-
atic decompensation such as non-analgesic and alternative medication use,
alcohol use and dietary/medication compliance. All controls had a history of
decompensation, indicating that cases and controls were roughly at similar
risk for decompensation due to cirrhosis alone. Cognitive function was as-
sessed using the Mini Mental State Examination. Univariate and multivariate
logistic regression were used for the analyses. Unadjusted and adjusted odds
ratios were computed, along with corresponding 95% confidence intervals
and P-values.
Results: Hepatitis C, alcohol, and cryptogenic cirrhosis, were the most com-
mon etiologies of cirrhosis, in 168 (79%) of the study patients. The distribu-
tion of etiologies was not significantly different between cases and controls.
Overall, 34% of cases and 44% of controls reported analgesic use over the
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30 days prior to the interview however the difference was not statistically
significant. Multivariate logistic regression indicated that, after controlling
for confounding factors analgesic use was not significantly associated with
decompensation (adjusted OR = 0.69, P = 0.234). These patterns were
consistent for all classes of analgesics (nonsteroidals and acetaminophen
containing). However, there was a trend toward decompensation (adjusted
OR = 2.02) among those who took analgesics 4 weeks prior, although that
effect was not statistically significant (P = 0.112).
Conclusion: Our results suggest that analgesics do not put cirrhotics at
increased risk for decompensation. The lack of an expected deleterious effect
of analgesics may be explained by infrequent use and low doses. However,
the trend toward higher risk for decompensation among those who used
analgesics four weeks prior indicates that an effect may exist and warrants
further investigation.
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Role of Vitamin E & Vitamin C in the Treatment of Nonalcoholic
Steatohepatitis
Kaushikkumar K. Patel, MD, Michael Babich, MD∗, Rad Agrawal, MD.
Department of Gastroenterology, Allegheny General Hospital, Pittsburgh,
PA.
Purpose: To determine whether supplemental vitamin E & C lowers serum
aminotransferases in patients with nonalcoholic steatohepatitis.
Methods: We did a retrospective analysis of NASH patients who were seen
in the AGH Centre for Digestive Health. We evaluated patients age 18 and
75 years with biopsy proven NASH and exclusion of other chronic liver
diseases. A total of 68 patients who met study criteria were assessed retro-
spectively & baseline characteristics including age, sex, weight, BMI, HTN,
DM, lipid profile, AST, ALT, ALP were collected. 68 patients were divided
in two groups: supplemental vitamin E & C (N = 38) or no vitamin supple-
ments (control group) (N = 30). Doses of vitamin E & C were 400 IU–800
IU and 500 mg–1000 mg respectively. AST, ALT, ALP and weight data were
collected between 2–24 months from baseline. The mean follow up period
was 11.96 months and 11.37 months for vitamin group and non vitamin
group respectively. Baseline and follow up data were compared using the
paired t test or Wilcoxon signed rank test. Differences between the groups
were compared by indepedent sample t test or the Mann-Whitney rank sum
test.
Results: Baseline characteristics were similar in the Control and Vitamin C
& E groups. Weight, ALT and ALP were similar in Control subjects between
baseline and follow up; mean AST was higher at follow up. Mean ALT was
99.6 U/L at baseline and significantly decreased to 63.7 U/L (P < 0.001) after
vitamin C & E use. Mean AST was 68.5 U/L at baseline and significantly
decreased to 41.2 U/L after vitamin C and E use (P < 0.001). Mean ALP was
101.3 U/L at baseline and decreased to 83.8 U/L at follow-up (P = 0.09).
Mean weight was comparable between baseline and after use of vitamins C
& E (210.8 lb ± 36.6 vs. 210.8 lb ± 36.0, P = 1.0). Changes from baseline in
mean ALT, AST and ALP were greater in subjects who took vitamins C & E
than in Controls; these differences were statistically significant. Mean ALT
decreased from baseline -35.9 in the Vitamin C & E group and increased
from baseline +9.9 in the Control group (P < 0.001). Mean AST decreased
from baseline -27.3 in the Vitamin C & E group and increased from baseline
+11.2 in the Control group (P < 0.001). Mean ALP decreased from baseline
-16.6 in the Vitamin C & E group and increased from baseline +4.2 in the
Control group (P = 0.049).
Conclusion: Vitamin E & C is effective in lowering serum aminotransferases
in patient with nonalcoholic steatohepatits. Our study showed improvment
in serum aminoransferases within group and between groups.
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To Investigate the Utility of a Week-4 Virological Response for SVR
Prediction in Hepatitis C Virus (HCV) Genotype 3 Patients Treated
with Pegylated Interferon and Ribavirin for 24 Weeks
Shamail Zafar, MBBS, FCPS, Israr Ul Haque Toor, MBBS, FCPS, Nusrat
Ullah Chaudhry, MBBS, MRCP∗. Department of Gastro-Enterology &
Hepatology, Lahore Medical & Dental College, Lahore, Punjab, Pakistan.
Purpose: To investigate the utility of a week-4 virological response for
SVR prediction in hepatitis C virus (HCV) genotype 3 patients treated with
Pegylated interferon and ribavirin for 24 weeks.
Methods: Using a PCR-based quantitative assay we analysed samples ob-
tained at baseline and weeks 4 and 12 from a subset of 50 HCV genotype 3
patients enrolled in a randomized trial of peginterferon a-2a in combination
with ribavirin.
Results: In an intention-to-treat analysis, 84% of patients treated with pegin-
terferon achieved a sustained virological response (SVR). At 4 weeks, 50%
of patients had HCV RNA < 50 IU/ml and 65% had < 600 IU/ml. Of these
rapid responders 86 and 87% achieved a SVR, respectively, with 2 patients
relapsing. In contrast, only 44 and 31% of patients with a week-4 HCV RNA
< 50 or < 600 IU/ml achieved an SVR, respectively, with relapse rates of 23
and 55%, respectively. In multivariate logistic regression analysis a serum
HCV RNA level below 600 IU/ml at week 4 was the strongest independent
predictor of SVR (odds ratio, 11.5; 95% confidence interval, 1.5 to 65.0;
P = 0.015).
Conclusion: Monitoring early viral response may be useful to tailor the
duration of treatment among patients with HCV genotype 3. Patients whose
HCV RNA falls below 600 IU/ml at 4 weeks are at low risk of relapse after
24 weeks of combination therapy.
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Hepatitis B (HBV) Patients Undergoing Chemotherapy: Who Gets
Screened and What Prophylaxis Is Given? A Questionnaire Survey of
Oncologists
Arash Farhadi, MD, James H. Lewis, MD∗, Omar S. Khokhar, MD, Lisa H.
McGrail, MD. Gastroenterology/Hepatology, Georgetown University
Medical Center, Washington, DC and Medical Oncology, Sibley Memorial
Hospital, Washington, DC.
Purpose: Chemotherapy is well-described as a risk factor for reactivation
of HBV infection, although the degree of awareness of this potentially fatal
complication has not been well studied among practicing oncologists.
Methods: We developed a questionnaire that was verbally administered to
131 Heme-Onc physicians in the Washington, DC metropolitan area in early
2007 that sought to assess their awareness of Hep B reactivation, their current
practice of screening for HBV and their recommendations for giving antiviral
prophylaxis to their chemotherapy patients.
Results: Respondent answers as follows: (1) Are you aware that reactivation
of HBV can occur with chemotherapy? Yes 78%; No 22%. (2) Have you
ever seen HBV reactivation in this setting? Yes 30%; No 70%. (3) Which
patients do you screen for HBV: abnormal LFTs 70%; from Asia or Africa
32%; coinfected with HCV 70%; coinfected with HIV or Hx IVDU 58%;
healthcare worker 50%; Hx of transfusions 54%; homosexual men 60%.
(4) Which HBV pt should receive prophylaxis? chronic carrier 46%; ac-
tive infection 76%; resolved HBV 52%. (5) Do you prescribe prophylaxis
yourself? Yes 28%; No 72%. (6) Which antiviral therapy would you use?
Lamivudine 46%; adefovir 14%; not sure 48%. (7) How would you moni-
tor for HBV reactivation? LFTs 46%; viral serology36%; clinical signs/Sxs
32%; not sure 26%. (8) How frequently would you monitor? q2 wk 4%; q4
wk 18%; q6 wk 14%; q8 wk 16%; q12 wk 12%; not sure 36%. (9) How long
should prophylaxis continue after chemotherapy? 4 wk 8%; 8 wk 15%; 12
wk 71%; 16wk 8%. (10) Would you want a gastroenterologist/hepatology to
follow the pt during prophylaxis? Yes 88%, No 12%; and after prophylaxis?
Yes 26%, No 74%.
Conclusion: Most practicing oncologists have not personally encountered
HBV reactivation during chemotherapy, and relatively few currently screen
universally for HBV or are aware that antiviral prophylaxis is available.
Over 80% would defer treatment to a specialist. Raising awareness among
oncologists of current recommendations for screening and providing HBV
propylaxis to chemotherapy patients is clearly warranted.
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Leucocyte Esterase Reagent Strips for the Diagnosis of Spontaneous
Bacterial Peritonitis: A Systematic Review
Anastasios Koulaouzidis, MD, MRCP, Grigoris I. Leontiadis, MD, PhD,
Elmuhtady Said, MBBS, Jaber Gasem, MBBCh, MRCP, Athar A. Saeed,
FRCP∗, Eystratios Maltezos, MD, PhD. Gastroenterology, Bangor
Hospital, Bangor, North Wales, United Kingdom; Gastroenterology,
Medical School ‘Democritus’ University, Alexandropolis, Thrace, Greece
and Gastroenterology, Queen Elizabeth Hospital, Gateshead, Tyne and
Wear, United Kingdom.
Purpose: Spontaneous bacterial peritonitis (SBP) is a potentially life-
threatening complication of decompensated liver disease. Ascitic fluid poly-
morphonuclear (PMN) count ≥ 250/ mm3 objectively confirms SBP. The
existing “gold standard” for the evaluation of ascitic PMN count (manual
count) is however laborious and time-consuming. Recently leukocyte es-
terase reagent (LER) strips (common urine dipsticks) have been successfully
used for the diagnosis of infection in various body fluids. The test is based on
the esterase activity of PMN. Hence, they provide a cheap, easily accessible
and rapid method for the diagnosis of PMN presence in the ascitic fluid.
Aims: We aimed to systematically review the existing evidence on the diag-
nostic value of LER strips in SBP.
Methods: Comprehensive literature search of Medline up to April 2007 for
human clinical trials comparing LER strips with manual count of PMN in
ascitic fluid. MeSH terms used included [“ascites” OR “ascitic fluid” OR
“peritonitis”] AND [“reagent strips” OR “Leuc(k)ocyte esterase strips”].
Abstracts reviewed independently by two authors and full papers of relevent
studies were obtained.
Results: We identified 16 relevant studies (thirteen in English and from 1
in French, Chinese and Korean) comprising 2519 patients. Thirty of them
were Child-Pugh (CP) stage A, 849 CP-stage B, and 1267 CP-stage C. A
total of 4730 paracenteses was performed. A total of 521 SBP was diagnosed.
Various dipsticks were evaluated; Nephur (2 times), Multistix10SG (7 times),
Aution (1 time), UriScan (2 times), Multistix8SG (5 times) and Combur tests
(5 times).
Compared to manual count of PMN (“gold standard”), LER strips were
found to have sensitivity ranging from 45.3% to 100%; specificity ranging
from 84.75% to 100%; positive predictive value ranging from 42% to 100%;
negative predictive value ranging from 87% to 100%.
Conclusion: Use of LER strips in ascitic fluid is a useful method for the
early diagnosis of SBP.
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Splanchnic Hemodynamics in Cirrhotic Patients: Relationship to
Esophageal Varices and the Severity of Hepatic Failure
Tary A. Salman, MD, Inas Kurayim, MD∗, Naglaa A.A. Allam, MD, Khaled
Abuela, MD. Hepatology, National Liver Institute, Shebeen, Menofeya,
Egypt; Radiology, National Liver Institute, Shebeen, Menofeya, Egypt and
Surgery, National Liver Institute, Shebeen, Menofeya, Egypt.
Purpose: The relationship between splanchnic hemodynamics, liver func-
tion, and esophageal variceal grading in cirrhosis remains unclear. The aim
was to determine the value of quantitative Doppler parameters of splanchnic
hemodynamics in assessing esophageal variceal (OV) grading, severity of
liver insufficiency and presence of ascites.
Methods: The following parameters were performed for 153 cirrhotics and
30 controls: portal vein (PV) and splenic vein (SV) – cross sectional area
(CSA), mean velocity (MV), flow volume (FL), PV congestive index; hepatic
artery, splenic artery (SA) and superior mesenteric artery (SMA) pulsatility
index (PI) and resistive index (RI); liver vascular index (LVI), modified
LVI (M-LVI), portal hypertension index (PHI), portal inflow (P-flow) and
collateral inflow (C-flow).
Results: All parameters differentiated between control and cirrhotics except
PV-FL and SV-FL which were significantly lower only in advanced cirrhosis
(Child C). SMA-PI, PHI, P-flow and C-flow were significantly different
among various Child classes. PV-MV was significantly lower in small OV
compared to other groups. All parameters were significantly different in
large OV except PV-FL, SMA-PI and –RI. PV-FL, SA-PI, SMA-RI, LVI, M-
LVI, P-flow and C-flow were significantly different in gastric varices group
compared to other groups. All parameters were significantly different in
ascitic than non-ascitic except PV-CSA, SMA-PI and -RI.
Conclusion: Splanchnic Doppler parameters are significantly related to
stages of liver damage, grade of portal hypertension and presence of as-
cites, and may therefore be used as surrogate markers. We recommend an
optimal scoring system with Doppler parameters integrated for diagnosis
and staging of cirrhosis and portal hypertension.
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Study of Serum Adiponectin in Chronic Liver Disease and Cholestasis
Tary A. Salman, MD, Naglaa A.A. Allam, MD, Gasser I. Azab, MD, Ahmed
Shaarawy, MD, Mona Hassouna, MD, Omkolsoum M. El-haddad, MD∗.
Hepatology, National Liver Institute, Shebeen Al-koam, Menofeya, Egypt
and Clinial Pathology, National Liver Institute, Shebeen Al-koam,
Menofeya, Egypt.
Purpose: Adiponectin is suggested to have a hepatoprotective effect. To date,
there is minimal information available in the literature regarding changes
in serum adiponectin levels in cirrhosis and cholestasis and the associ-
ated metabolic disturbances. Therefore, our aim was to elucidate the role
of adiponectin in chronic liver disease and to correlate adiponectin level
with liver functions &markers of the metabolic syndrome as body mass
index and insulin resistance in these patients.
Methods: 40 patients with different grades of cirrhosis, 30 patients with
cirrhosis & cholestasis and 20 matched controls were studied. They were
subjected to clinical assessment, BMI and Child score calculations, analysis
of ALT, AST, alkaline phosphatase, GGT, C-reactive protein, HOMA index,
adiponectin, abdominal ultrasonography & upper GI endoscopy.
Results: Adiponectin was significantly higher in patients than controls (cir-
rhosis: 15.1 ± 12.14 µg/ml vs 4.7 ± 4.48 µg/ml, P < 0.05 and cirrho-
sis/cholestasis: 21.28 ± 10.2 µg/ml vs 4.7 ± 4.48 µg/ml, P = 0.001).
Adiponectin correlated with bilirubin (r = 0.369, P < 0.05), ALT (r =
0.283, P < 0.05), AST (r = 0.367, P < 0.05), albumin (r = −0.287, P <
0.05), prothrombin (r = 0.278, P = 0.053), ALP (r = 0.394, P < 0.005),
GGT (r = 0.298, P < 0.05), CRP (r = 0.406, P < 0.05). Adiponectin didnot
correlate with presence of ascites or esophageal varices nor did it correlate
with BMI or HOMA index.
Conclusion: adiponectin is elevated in cirrhosis and correlates with degree
of hepatocellular injury and cholestasis. It could serve as a novel marker
indicating cholestasis in liver cirrhosis. Adiponectin in cirrhosis does not
correlate with parameters of body composition or metabolism but exclusively
with reduced liver function.
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Independent Predictors of Histologic Disease Severity in Asian Indian
Patients with Nonalcoholic Steatohepatitis
Deepak Kumar Singh, MD, Puja Sakhuja, MD, Veena Malhotra, MD, Ajay
Kumar Chaudhary, MD, Ranjana Gondal, MD, Shiv Kumar Sarin, MD∗.
Pathology, and Gastroenterology, G. B. Pant Hospital, Delhi, India.
Purpose: The clinical and histological spectrum of non-alcoholic steato-
hepatitis (NASH) is not clearly defined for different races and geographical
areas of the world. Aim: To study the histologic spectrum and to identify the
clinical and biochemical predictors of histologic disease severity in patients
with NASH in Asian Indian Population
Methods: Seventy-one consecutive patients of NASH were included in
the study. Clinical and laboratory data was recorded. Patients were catego-
rized into five BMI based subgroups using Asian criteria. For diagnosis of
NASH on liver histology, criteria given by Matteoni et al and at the AASLD
Abstracts S221
conference (2003) were followed. Histologic features, global necroinflam-
matory grade and fibrosis stage of liver biopsies were scored as per Brunt
et al. (1999), by two pathologists independently, without knowledge of clin-
ical and laboratory data. Univariate analysis using Kruskal-Wallis, Mann-
Whitney and Pearson χ2 tests and multivariate logistic regression analysis
controlled for the effect of age and gender was performed. P value < 0.05
was considered statistically significant.
Results: Fifty-four (76.1%) patients were male and 17 (23.9%) females.
Mean age was 34.9 ± 8 yrs. Mean BMI was 25.7 ± 1.9 Kg/m2. None had
manifest obesity (BMI ≥ 30 kg/m2). Mean waist: hip ratio was higher in
males (0.96 ± 0.07) than females (0.95 ± 0.07). Mean AST was 67.9 ±
25 IU/L and ALT was 106.9 ± 42 IU/L. Five (7%) patients had diabetes
mellitus. Insulin resistance (HOMA-IR>3) was present in 42 (59.15%) hy-
pertriglyceridemia in 62 (87.3%) and hypercholesterolemia in 11 (15.5%)
patients. On necroinflammatory grading, 21 (29.6%) patients had grade 1,
26 (36.6%) grade 2 and 24 (33.8%) grade 3, NASH. Forty-three (60.6%)
patients had stage 1 fibrosis. None had stage 4 fibrosis (cirrhosis). On mul-
tivariate analysis independent predictors of necroinflammatory grade were
BMI (P = 0.009), waist circumference (P = 0.035), waist: hip ratio (P =
0.011) and AST level (P = 0.000); (R2 = 0.52). Independent predictors of
fibrosis stage were female gender (P = 0.02), cholesterol levels (P = 0.048)
and LDL levels (P = 0.025); (R2 = 0.38).
Conclusion: NASH should no longer be considered a disease of obese,
diabetic or hyperlipidemic females. It can present at a young age, in males,
who may be asymptomatic, non-obese and non-diabetic. Female gender,
BMI, waist: hip ratio, AST, hypercholesterolemia and increased LDL are
independent predictors of disease severity in patients with NASH.
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Venous Thromboembolism in Patients with Cirrhosis
David D. Gulley, MD, Evgenia Teal, MA, Naga Chalasani, MD, Suthat
Liangpunsakul, MD, MPH∗. Dept of Medicine, Indiana University,
Indianapolis, IN and Regenstrief Institute, Indianapolis, IN.
Purpose: It is the general notion that cirrhotic patients do not suffer from
DVT/PE as they are naturally anticoagulated. However, there are no studies
that objectively addressed if patients with cirrhosis have lower frequency of
venous thromboembolism (VTE). Therefore, we conducted a case-control
study to examine the relationship between cirrhosis and VTE.
Methods: A case-control study of patients seen at Wishard Hospital between
1995–2005 was performed using the Regenstrief Medical Record System.
Cases were defined as hospitalized patients with biopsy and/or imaging plus
clinical evidence of cirrhosis. Age, gender, and race-matched patients with
no known evidence of cirrhosis seen during the same time period served as
controls. The development of VTE was identified by the ICD-9 codes fol-
lowed by cross referencing studies with Doppler ultrasound, V/Q scan, and
CT chest. Subjects previously hospitalized with VTE were excluded. Charl-
son Index was calculated to determine the comorbidity. Patients with cirrho-
sis were also compared to age, gender, race, and Charlson Index matched
non-cirrhotic patients with other chronic illnesses including chronic kidney
disease (CKD), congestive heart failure (CHF), and five most common can-
cers in the US. Logistic regressions were performed to identify variables
with predictive value.
Results: This study consisted of 963 cirrhotics (51 ± 11 yrs, females 34%,
and Caucasians 60%) and 12,405 controls (51 ± 11 yrs, females 36%, and
Caucasians 60%). Patients with cirrhosis had VTE (1.8%) and this is signif-
icantly higher than the controls (0.9%, OR: 1.78, P = 0.007). The Charlson
Index in cirrhotic patients was higher than that in controls (3.2 ± 1.8 vs.
0.9 ± 1.5, P < 0.001). However, in the combined cohort, cirrhosis (OR
0.87, 95% CI 0.2–2.6) and Charlson index (OR 0.93, 95% CI 0.74–1.16)
were not independently associated with VTE. PTT (OR 0.88: 95% CI 0.84–
0.94) and serum albumin (OR 0.47, 95% CI 0.23–0.93) were the independent
predictors of VTE in the entire cohort. The risk of VTE in cirrhotics was
much lower than those with other medical illnesses: 7.1% in CKD (OR 0.25;
95% CI 0.15–0.41), 7.8% in CHF (OR 0.23, 95% CI 0.14–0.37), and 6.1%
in cancers (OR 0.29, 95% CI 0.17–0.52).
Conclusion: Underlying cirrhosis seems to be protective against VTE when
compared to other chronic illnesses. However, patients with cirrhosis do not
have lower risk of VTE compared to non-cirrhotic controls. PTT and serum
albumin were independent predictors of VTE in cirrhotic patients.
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Pathophysiology of Jaundice in Amoebic Liver Abscess
Virendra Singh, DM∗, Ashish Bhalla, MD, Navneet Sharma, MD, Sushil K.
Mahi, MD, Anupam Lal, MD, Paramjeet Singh, MD. Hepatology,
Postgraduate Institute of Medical Education and Research, Chandigarh,
Chandigarh, UT, India; Internal Medicine, Postgraduate Institute of
Medical Education and Research, Chandigarh, Chandigarh, UT, India and
Radiology, Postgraduate Institute of Medical Education and Research,
Chandigarh, Chandigarh, UT, India.
Purpose: Jaundice in patients with amoebic liver abscess is a frequent oc-
currence. However, pathophysiology of jaundice in these patients is not fully
understood. Hepatic necrosis leads to damage to bile ducts as well as various
vascular structures leading to biliovascular fistula and jaundice. We studied
mechanism of jaundice in patients with amoebic liver abscess.
Methods: We prospectively evaluated 10 patients with amoebic liver abscess
with jaundice from February 2002 to January 2007. All patients underwent
various investigations including imaging studies.
Results: There were 9 males and 1 female patient with a mean age of
39.1 years. Mean duration of illness before presentation was 13.1 days.
All patients had fever and jaundice. We detected damaged hepatic veins and
bile ducts in all patients with amoebic liver abscess causing biliovascular
fistula and hyperbilirubinemia which reverted back to normal after biliary
diversion with nasobiliary drainage.
Conclusion: Jaundice in patients with amoebic liver abscess is due to bil-
iovascular fistula resulting from hepatic necrosis leading to damage to bile
ducts and hepatic veins.
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Cytokeratin 18 Levels as a Noninvasive Biomarker for Nonalcoholic
Steatohepatitis in Bariatric Surgery Patients
Dima Diab, MD, Lisa Yerian, MD, Phillip Schauer, MD, Sangeeta R.
Kashyap, MD, Rocio Lopez, MS, Ariel E. Feldstein, MD∗. Endocrinology,
Cleveland Clinic, Cleveland, OH; Pediatric Gastroenterology, Cleveland
Clinic, Cleveland, OH; General Surgery, Cleveland Clinic, Cleveland, OH;
Anatomical Pathology, Cleveland Clinic, Cleveland, OH and Quantitative
Health Sciences, Cleveland Clinic, Cleveland, OH.
Purpose: Nonalcoholic fatty liver disease (NAFLD) is extremely common
among patients undergoing bariatric surgery. Liver disease may progress
in these patients despite surgical weight loss. Previously, we demonstrated
that plasma concentration of cytokeratin 18 (CK-18) fragments accurately
differentiated NASH from simple steatosis and was predictive of stage of
fibrosis in patients with NAFLD. The aim of this study was to assess the
usefulness of this biomarker in determining NASH in the bariatric surgery
population.
Methods: Our cohort consisted of 99 consecutive patients who underwent
liver biopsy at the time of bariatric surgery. Of these, CK-18 levels were
measured in 86 patients who had plasma available within one week prior
to surgery using a sandwich immunoELISA specific for CK-18 fragments.
Histology was scored by experienced hepatopathologists according to the
NAFLD NIDDK activity score.
Results: Plasma levels of CK-18 fragments ranged from 103 to 1000 U/L
(Median (Q25, Q75): 226 U/L (177, 298)). Compared to either subjects with
no NAFLD, simple steatosis or borderline diagnosis, CK-18 levels were sig-
nificantly higher in subjects with NASH (median (Q25, Q75): 196 (158, 245)
vs. 217 (154, 228) vs. 200 (176, 274) vs. 389 (275, 839), respectively; P <
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0.0001). CK-18 levels were significantly higher in subjects with moderate to
severe fibrosis than in those with mild fibrosis (median (Q25, Q75): 334.5
(240.5, 896) vs. 207 (175, 275), respectively; P = 0.007)). For every 50 U/L
increase in the plasma level of CK-18, the likelihood of having NASH as
opposed to simple steatosis increased 2.45 times (OR (95% CI): 2.45 (1.20,
5.00)). The area under the ROC curve was estimated to be 0.88 (95% CI:
0.77, 0.99). The values with the best combination of sensitivity and speci-
ficity were 252 U/L (sensitivity = 82% and specificity = 77%) and 275 U/L
(sensitivity = 77% and specificity = 100%).
Conclusion: These results demonstrate that determination of CK-18 frag-
ments in the blood accurately differentiates NASH from simple steatosis
and predicts stage of fibrosis in bariatric surgery patients, supporting the
potential usefulness of this test in clinical practice as a noninvasive NASH
biomarker.
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Dysphagia from Hepatocellular Carcinoma Metastases to the
Esophagus Occurring Post-Liver Transplantation
Thalia Mayes, MD, Benedict Maliakkal, MD∗. Division of
Gastroenterology and Hepatology, University of Rochester, Rochester, NY.
Purpose: Introduction: Hepatocellular carcinoma (HCC) commonly metas-
tasizes to the lungs, lymph nodes, musculoskeletal system and adrenal
glands. Metastasis to the esophagus has been reported on rare occasions,
though the diagnosis is usually made at autopsy. Esophageal metastases of
HCC are thought to occur through tumor invasion into the portal system
with subsequently dissemination. We present a rare case of symptomatic
HCC metastasis to the esophagus occurring post-liver transplantation.
Case: A 71 year-old male was referred after evaluation of abnormal liver
tests revealed an alpha-fetoprotein of 4,271 and a 6.5 cm mass in right lobe
of liver suspicious for HCC. There was no personal or family history of liver
disease or HCC, there was no weight loss or history of variceal bleeding,
and examination revealed no signs of decompensated liver disease.
He was not a candidate for partial hepatectomy because the non-tumor part
of the liver appeared cirrhotic on imaging. He underwent extended-criteria
orthotopic liver transplantation about three weeks after his initial consulta-
tion. Explant pathology revealed moderately-well differentiated HCC in right
lobe with small tumor nodules in left lobe. Surgical margins were positive for
HCC at the portal vein and inferior vena cava margins. The non-neoplastic
liver showed minimal steatosis and fibrosis.
Post-transplant course was complicated by liver abscess eventually requiring
re-transplantation, abdominal pain after t-tube removal, and ERCP without
obvious bile leak but with abnormal nodules seen in distal esophagus. He
also developed nausea and dysphagia to solids. EGD revealed multiple pe-
dunculated, ulcerated lesions in mid-distal esophagus, each 1–2.5 cm in size
occurring alongside of varicosed veins. Biopsied were consistent with HCC.
Discussion: Pre-mortem diagnosis of HCC metastases to the esophagus is
extremely rare, but has been reported to occur similarly to our patient with
clinical presenting symptoms of dysphagia and findings of pedunculated
lesions in the esophagus. Our patient was at high risk for HCC recurrence
or metastasis given the positive surgical margins. We believe this is the first
reported case of pre-mortem diagnosis of HCC metastasis to the esophagus
post liver transplantation.
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Limited Value of Leukocyte Esterase Reagent Strips for the Quick
Diagnosis of Spontaneous Bacterial Peritonitis
Matthew Eidem, MD, Sunil Dwivedi, MD, Hector Nazario, MD, Alfredo
Espinoza, MD, Anastacio Hoyumpa, MD∗. Department of Medicine,
Division of Gastroenterology and Nutrition, University of Texas Health
Science Center at San Antonio, San Antonio, TX.
Purpose: The goal of this study was to determine the reliability of leukocyte
esterase (LE) reagent strips in diagnosing spontaneous bacterial peritonitis
(SBP) in the inpatient and outpatient settings.
Methods: One hundred ten patients who underwent a diagnostic or thera-
peutic paracentesis were enrolled in the study. Paracentesis was carried out
in the medical ward or outpatient clinics by interns, residents, or faculty at-
tending physicians. The procedures were done in the usual fashion and sent
for studies as dictated by the ordering physician. The Multistix leukocyte
esterase reagent strip test was performed at the bedside or examing table. The
reagent strip was read by the proceduralist who recorded the results. The re-
sults of the reagent strips were then compared to the laboratory results. SBP
was diagnosed when there was either an ascitic fluid PMN count > 250/mm3
or positive bacterial culture. The reagent strip scores (i.e. Negative, Trace,
1+, 2+, 3+) were recorded to determine the sensitivity, specificity, positive
predictive value, and negative predictive value of diagnosing SBP.
Results: Seventeen of the 110 patients were diagnosed with SBP. Nine had
neutrocytic ascites (PMN > 250/mm3) alone, 4 had positive cultures alone,
and 4 had both neutrocytic ascites and positive cultures. Of these patients,
only five had LE strip results of 1+ or higher (see table). When using 1+
or higher as the cut-off for positive or negative LE strips, the sensitivity was
29.4%, the specificity was 91.4%, the positive predictive value was 38.5%,
and the negative predictive value was 87.6%. When using 2+ or higher as
the cut-off for positive or negative LE strips, the sensitivity was 29.4%,
the specificity was 97.8%, the positive predictive value was 71.4%, and the
negative predictive value was 88.3%.
Conclusion: Contrary to previous reports, the reliability of using LE reagent
strips to rapidly detect SBP was limited when different proceduralists per-
form the test. Thus, this study further illustrates the importance of obtaining
a cell count and bacterial culture when assessing ascites.
LE Strip Results SBP No SBP
Negative 10 78
Trace 2 7
1+ 0 6
2+ 5 2
3+ 0 0
Total 17 93
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Zeaxanthin Reduces Fibrosis in a Gerbil Model of Non-Alcoholic
Steatohepatitis
Sherman M. Chamberlain, MD∗, Manuela Bartoli, PhD, Nancy Rodriguez,
DVM, Jeffrey R. Lee, MD, Jigneshkumar Patel, MBBS, Subbaramiah
Sridhar, MBBS, Dennis M. Marcus, MD. Section of Gastroenterology,
Medical College of Georgia, Augusta, GA; Section of Vascular Medicine,
Medical College of Georgia, Augusta, GA; Laboratory Animal Services,
Medical College of Georgia, Augusta, GA; Department of Pathology,
Medical College of Georgia, Augusta, GA; Department of Medicine,
Medical College of Georgia, Augusta, GA and Southeast Retina Center,
Augusta, GA.
Purpose: Non-alcoholic steatohepatitis (NASH) is characterized by fatty
infiltration and inflammation, causing liver injury and fibrosis by inducing
free radicals in the liver. Zeaxanthin is an anti-oxidant and carotenoid found
in green leafy vegetables and melons. Zeaxanthin is preferentially distributed
to the liver. We hypothesize that zeaxanthin supplementation may reduce the
severity of NASH. In order to test this hypothesis, we established an animal
model of steatohepatitis in Mongolian gerbils (the only known rodents able
to absorb carotenoids from the gastrointestinal tract).
Methods: A methionine-choline deficient (MCD) diet, an established diet
for the creation of steatohepatitis in other rodents, was utilized to induce
steatohepatitis in Mongolian gerbils. A total of 24 weanling male Mongolian
gerbils in 4 groups (6 gerbils in each) were utilized for this experiment.
Three groups of experimental animals were fed for 6 weeks with the MCD
diet ad libitum with gelatin-containing 12.5 mg/kg zeaxanthin (MCD12.5),
or 25 mg/kg (MCD25) or no zeaxanthin controls (MCDC) (note: the MCD
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diet >6 weeks led to gerbil mortality). A non-MCD control group was fed
standard rodent chow ad libitum. Gerbils were euthanized and livers stained
with hematoxylin and eosin (H&E) and trichrome.
Results: On H&E, all MCD gerbils developed significant liver steatosis with
mild inflammation. No difference in steatohepatitis was observed between
MCD12.5, MCD25, and MCDC groups. On trichrome, MCD25 gerbils had
no fibrosis, MCD12.5 gerbils had minimal fibrosis, and MCDC gerbils had
mild fibrosis. The non-MCD control group had no steatosis, inflammation
or fibrosis.
Conclusion: This is the first model of steatohepatitis created in Mongolian
gerbils, and the first controlled study using zeaxanthin to treat steatohepati-
tis. Zeaxanthin reduced fibrosis in our model of steatohepatitis. Zeaxanthin
may protect the liver from developing liver fibrosis in steatohepatitis. Fur-
ther studies are underway to fully evaluate the mechanism of zeaxanthin’s
antifibrotic properties in steatohepatitis.
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Liver Transplant Patients with Hepatitis C Who Do Not Respond to
Pegylated Interferon Plus Ribavirin Do Respond to Consensus
Interferon Plus Ribavirin
Shobha N. Joshi, MD∗, Fredric G. Regenstein, MD. Abdominal
Transplant, Tulane University School of Medicine, New Orleans, LA.
Purpose: Treatment of chronic hepatitis C remains a challenge because of
poor responses to currently available drugs. For example, approximately
80% of patients with hepatitis C have genotype 1, and as many as 50% of
these patients fail to show a sustained response to treatment with pegylated
interferon (Peg-IFN) plus ribavirin (RBV). The aim of the present study was
to examine the efficacy and safety of consensus interferon (C-IFN) plus RBV
in patients with chronic genotype 1 hepatitis C who had failed treatment with
Peg-IFN plus RBV.
Methods: Subjects were 8 patients with recurrent genotype 1 hepatitis C
following liver transplant, who had either failed to respond or had relapsed
after treatment with Peg-IFN plus RBV. Patients were treated with C-IFN
(Infergen; 6–15 µg/day) plus RBV (400–1000 mg/day) for up to 52 weeks.
Adverse events, serum chemistries, complete blood count and hepatitis C
virus RNA (HCV RNA) was measured at baseline, 4, 12, 18, 24, 32, 48, and
52 weeks of treatment and 4, 12 and 24 weeks after completing treatment.
Results: Baseline HCV RNA was 41,200–74,700,000 IU/mL. Six of 8 pa-
tients responded to treatment with a 100-fold decrease in HCV RNA. Serum
HCV RNA became undetectable in 4 patients and this response was main-
tained throughout their treatment ranging from 24 to 52 weeks, and in 1
patient for one month after stopping treatment. One patient failed to respond
at 12 weeks and was discontinued. A second patient failed to respond at 4
weeks and was discontinued at 6 weeks because of proteinuria, increased
serum creatinine and anemia. A third patient responded at 8 weeks, but
was discontinued at 32 weeks because of severe dry skin. All 8 patients
had an initial decrease in serum aminotransferases and bilirubin. Seven pa-
tients developed anemia (hemoglobin < 10 g/dL) and one patient developed
neutropenia (absolute neutrophil count < 700/µL). Anemia was treated sat-
isfactorily with erythropoietin or a reduction in RBV, and neutropenia was
treated satisfactorily with granulocyte colony stimulating factor or a reduc-
tion in consensus interferon.
Conclusion: A majority of liver transplant patients with hepatitis C who have
failed to respond to Peg-IFN plus RBV show a substantial virologic response
when they are subsequently treated with C-IFN plus RBV. Thus, C-IFN plus
RBV represents a novel therapeutic option for patients with hepatitis C who
do not respond to Peg-IFN plus RBV.
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Prevalence and Predictors of Steatosis in Patients with Chronic
Hepatitis C (HCV) Infection
Jagdish S. Nachnani, MD, Alexandra Laya, MD, Esmat Sadeddin, MD,
Owen J. Smith, MD, Laura M. Alba, MD, Wendell K. Clarkston, MD∗.
Internal Medicine, University of Missouri Kansas City, Kansas City, MO
and Gastroenterology, University of Missouri Kansas City, Kansas City,
MO.
Purpose: HCV infection has been described as a risk factor for the devel-
opment of steatosis and steatohepatitis. Steatosis has been associated with
treatment failures in patients receiving combination therapy for HCV and
with acceleration of fibrosis in chronic HCV patients. Few studies have as-
sessed host and viral factors associated with the development of steatosis in
HCV infection.
The aim of our study was to look at: i) The prevalence of steatosis in patients
with chronic HCV infection. ii) Host and viral factors which are associated
with steatosis
Methods: From January 2001 to November 2005, we retrospectively re-
viewed a cohort of 148 consecutive patients with chronic HCV who un-
derwent liver biopsy. Data collected included age, race, gender, BMI, prior
alcohol use, presence of diabetes, family history of diabetes, triglyceride
level, cholesterol level, viral genotype and histopathologic findings on liver
biopsy.
Results: Of the 148 patients with HCV in our cohort, 80 patients (54%)
had steatosis. Mild steatosis was present in 45% and 9% of the patients had
moderate or severe steatosis. Thirteen patients (9%) had cirrhosis. The mean
BMI was 27 ± 5 kg/m2. Out of the 80 patients who had steatosis, 37 (46%)
were females, and 43 (54%) were Caucasians. Upon univariate analysis,
diabetes (P = 0.03) and a BMI ≥ 25 kg/m2 (P = 0.005) were significantly
associated with steatosis in these patients with HCV infection. Race, gender,
age and history of alcohol use were not significant. In multivariate analysis,
BMI ≥ 25 (P = 0.01) was the only factor associated with steatosis. Thirty-
nine (49%) patients had viral genotype 1. Although steatosis was slightly
more common in patients with genotype 3, no statistical difference in the
presence of steatosis between the various genotypes was seen.
Conclusion: In earlier studies, steatosis has been described as an important
risk factor for the severity of liver disease and nonresponse to therapy in
patients with chronic HCV infection. Steatosis was present in 54% of our
cohort of patients with chronic HCV infection. The primary risk factors
for steatosis in chronic HCV infection were diabetes mellitus or BMI ≥
25 kg/m2. Further studies to determine if improved control of diabetes or
weight loss prior to treatment of HCV improves response rates and the effect
of these measures on progression to cirrhosis should be considered.
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High MELD Score and Type of Immunosuppression Are Predictors of
Gastrointestinal Bleeding after Liver Transplantation
Julian Perez, MD, Mauricio Orrego, MD, Oscar Martinez, MD, Ramesh
Koka, MD, Cosme Manzerbeitia, MD, Philip Katz, MD∗. Internal
Medicine, Albert Einstein Medical Center, Philadelphia, PA; Liver
Transplant, Albert Einstein Medical Center, Philadelphia, PA and
Gastroenterology, Albert Einstein Medical Center, Philadelphia, PA.
Purpose: Gastrointestinal bleeding (GIB) after liver transplantation is as-
sociated with significant morbidity and mortality. There is a paucity of in-
formation about the effects of various immunosuppression therapies on GI
bleeding as well as the predictive value of the MELD score in GIB.
The aim of our study was to define the incidence, causes of GIB after liver
transplantation, and to identify the clinical and demographic variables that
are associated with GIB in post liver transplant patients.
Methods: The records of the 522 consecutive primary liver transplants per-
formed at Albert Einstein Medical Center since January of 1995 to December
of 2005 were reviewed retrospectively. A preliminary analysis examined the
association among these variables and the complication of GIB after liver
transplant patients. A logistic regression was used to determine the predictors
of GIB after liver transplant patients.
Results: The incidence of GIB after liver transplant was 8.9%. The most
common causes of bleeding after liver transplant were peptic ulcers 34.5%,
followed by viral enteritis (CMV) (12.7%), portal hypertensive lesions
(10.9%), anastomotic bleeds(4.5%), and other miscellaneous events.
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A MELD score ≥ 32 prior to transplant statistically increases the risk (OR:
6.4; CI: 6.35–6.56: P < 0.001), and immunotherapy with Tacrolimus de-
creases the risk of post transplant bleeding (OR 0.28; CI: 0.26–0.38: P =
0.001). No other variables were associated with GIB post transplant. The
presence of GIB after liver transplant is associated with a higher mortality
Conclusion: Patients with MELD scores >32 are candidates for prophylaxis
against post transplant GIB. Immunosupression with Tacrolimus should be
considered in these patients especially those with high MELD.
Logistic Regression Analysis
Odds Ratio Confidence Interval P Value
MELD > 32 6.42 6.35–6.56 <0.001
TACROLIMUS 0.28 0.26–0.38 0.001
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Severe Pulmonary Sarcoidosis Complicating Hepatitis C Therapy and
Resolving after Treatment Withdrawal
Nalini K. Sharma, MD, Averell H. Sherker, MD∗. Gastroenterology,
Washington Hospital Center, Washington, DC.
Purpose: Current treatment recommendations for hepatitis C include
pegylated-interferon (PEG) and ribavirin (RVN). It is known that interfer-
ons can precipitate a variety of immune-mediated conditions. We describe
a case of pulmonary sarcoidosis in a patient undergoing treatment for hep-
atitis C with PEG and RVN whose pulmonary compromise resolved after
medications were discontinued.
Case: A 45-year-old African-American male presented with several weeks
of dyspnea on exertion. He had a history of genotype 1 hepatitis C for
which he was 24 weeks into treatment with PEG 180 ug SC qweekly and
RVN 600 mg po bid. Physical examination revealed crackles throughout
the lungs. Chest x-ray showed an increased interstitial pattern. Chest CT
showed diffuse interstitial lung disease with a miliary pattern and bilateral
mediastinal and hilar lymphadenopathy. PPD and histoplasmosis antibody
were negative. An angiotensin converting enzyme level was elevated. The
patient underwent a thorascopic lung biopsy which revealed noncaseating
epithelioid granulomas with multinucleated giant cells. Special stains were
negative. The patient was diagnosed with pulmonary sarcoidosis secondary
to PEG ± RVN as he had no findings to suggest preexisting disease. The
patient was advised to stop taking his PEG and RVN and upon followup in
pulmonary clinic six weeks later, he reported resolution of dyspnea. Hepatitis
C viremia returned after treatment withdrawal.
Discussion: Interferons cause an exaggerated Th1-mediated immune re-
sponse and the hepatitis C virus may serve as an antigenic trigger. The
combination of PEG and RVN may further enhance the immune response
to predispose patients to sarcoidosis. RVN monotherapy has not been impli-
cated in the induction of sarcoidosis. This case illustrates that PEG/RVN can
induce symptomatic pulmonary sarcoidosis and withdrawal of therapy with-
out immunosuppressive treatment may be an effective treatment modality.
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Factors Influencing Participation in Hepatitis C Research Trials
Katina D. Robertson, BA, Cynthia A. Moylan, MD, Carla W. Brady, MD,
Andrew J. Muir, MD∗. Division of Gastroenterology, Duke University
Medical Center, Durham, NC.
Purpose: Blacks are disproportionately affected by HCV but have been
underrepresented in clinical trials. The aim of this study was to examine
factors that might impact willingness to participate in HCV trials.
Methods: Subjects with HCV were recruited from the Duke Liver Clinic
and a primary care clinic in Durham, NC. Subjects were interviewed about
attitudes to research. They also completed the Trust in Physician Scale, a val-
idated measure of interpersonal trust in physician-patient relationships, and
the 5-item Duke Religious Index, a validated measure of the major dimen-
sions of religiosity (public/organizational, private/non-organizational, and
intrinsic religiosity). Chi square Analysis and Fisher’s Exact test were used
to assess categorical variables; continuous variables were analyzed using t
tests for normal data and Wilcoxon Rank Sum test for non-normal data.
Results: The study group included 56 blacks and 24 whites with HCV. The
table highlights that black subjects had lower education levels. Black subjects
were less likely to have health insurance coverage and to have their own
transportation. No differences were observed in trust or religiosity scales
between blacks and whites. Black patients were less likely to enroll in a
research study of an experimental medicine than whites (73.2% vs. 25%,
P = 0.0002). Blacks and whites were both likely to participate in a study
of counseling or mental health treatment. Both groups were less likely to
participate in a study with placebo (57% vs. 54%, P = 0.93).
Conclusion: Black subjects with HCV are less likely to participate in studies
of experimental medicines. Differences in trust and religiosity do not explain
these preferences. Limitations in access to health insurance and transporta-
tion to clinics provide significant barriers to Blacks with HCV and may
negatively influence participation in research activities.
HCV Patient Characteristics
Blacks Whites P value
Demographics N = 56 N = 24
Age, years (mean ± SD) 50.4 ± 6.9 50.3 ± 7.0 NS
Gender (% male) 51.8 50.0 NS
Education 0.0005
< grade 12 35.7 0
High school graduate 39.3 45.8
Some college/degree 25.0 54.2
Insurance coverage <0.0001
Private/HMO 21.4 70.8
Medicare 10.7 8.3
Medicaid 39.3 12.5
None 28.6 8.3
Transportation <0.0001
Own car 35.7 79.2
Others drive me 10.7 20.8
Public transportation 41.1 0
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Can Metabolic and Hepatic Abnormalities Be Improved by
Intragastric Balloon Treatment for Obesity?
Giorgio Ricci, MD, Flavia Pigo`, MD, Angelo Rossi, MD, Gianluca
Bersani, MD, Vittorio Alvisi, MD∗. Postgraduate School of
Gastroenterology, University of Ferrara, Ferrara, ER, Italy.
Purpose: In obesity, a cluster of metabolic alterations (Metabolic Syndrome,
MS) is often associated with Fatty Liver (FL). The “bright liver” at abdomi-
nal ultrasonography (US) and, in most cases, increased levels of hepatic en-
zymes, alanine aminotransferase (ALT) and gamma-glutamyltranspeptidase
(GGT), are considered the hallmarks of Nonalcoholic Fatty Liver Disease
(NAFLD) in obese patients. Insulin resistance (IR) is the main link among
obesity, FL and MS. Bioenterics Intragastric Balloon (BIB, Inamed Health,
Santa Barbara, Ca., USA) is considered a safe procedure to prepare patients
to the bariatric surgery. The aim was to evaluate if the weight loss induced
by BIB can improve both IR and liver enzymes.
Methods: From March 2003 through April 2007 in our digestive endoscopy
service, 100 patients (F 65; age 20–63 yrs) with obesity and severe obesity
(BMI 32–62) underwent BIB insertion. The BIB was placed under endo-
scopic control and removed 6 months later. US, clinical and routine labora-
tory investigations were performed before and after BIB. IR was calculated
by the Homeostasis Model Assessment (HOMA-IR), as fasting serum in-
sulin (µU/ml) × fasting plasma glucose (mmol/l)/22.5; values >2.5 indicate
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a state of IR. Exclusion criteria: HBV(+), HCV(+), alcohol consumption
>20 g/day, known drugs in the history.
Results: BMI decreased significantly after BIB (42.7 ± 5.6 vs. 38.4 ± 5.3;
P < .001). BMI reduction higher than 10% (
BMI>10%) was observed
in 50 patients (pts.). US showed FL in the majority (70%). In FL pts. ALT
U/L (48.8 ± 46.5 vs. 31.1 ± 26.9) and GGT U/L (41.5 ± 38.9 vs. 29.5 ±
20.9) significantly decreased after treatment (P < .01). In 30% pts. without
FL at US (noFL), both ALT and GGT ranged normally before and after
BIB. HOMA-IR basal values >2.5 were recorded in 86% FL and in 74%
noFL pts. Values significantly decreased after treatment both in FL (6.03 ±
4.47 vs. 4.21 ± 3.35; P < 0.05), and in noFL pts. (4.71 ± 2.62 vs 2.89 ±
1.39; P < .001). FL and noFL pts. with 
BMI<10%, HOMA-IR, ALT,
GGT values did not significantly change after BIB. Before BIB in FL pts.
a weak correlation (r = 0.37) was found between GGT and HOMA-IR
values. Hypertriglyceridemia in 42.3%, HDL cholesterol levels <40 mg/dL
in 32.4% did not significantly change after BIB.
Conclusion: Weight loss induced by intragrastric balloon reduces IR. The
ALT and GGT decrease suggests an improvement of hepatic lobular inflam-
mation. The benefit depends on a decrease of BMI higher than 10%. We
confirm the pivotal role of IR in FL.
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Retrospective Analysis of Treatment Outcome for Hepatitis C
Genotype 4 in a Community Hospital
Abdullah M. Mallisho, MD, Omar A. Al-Subee, MD, Iyad A. Subei, MD,
FACP, FACG FASGE∗. Gastroenterology, ErfanBagedo Hospital, Jeddah,
Saudi Arabia.
Purpose: Studies on hepatitis C genotype 4 are scares. The wide immigra-
tion movement makes it important to know about the less common genotypes
in the US that are more prevalent in other geographic areas. We aim at ana-
lyzing the current approach and treatment results for patients with hepatitis
C genotype 4.
Methods: Retrospective chart review to collect data on patients who were
treated at our center for hepatitis C virus genotype 4 with Peg-Interferon
and Ribavirin between Jan 02–Jan 07. Patients were identified from the
laboratory logbook for all performed PCR testing. Analysis included patients
who completed 48 weeks of treatment and 24 weeks of follow up.
Results: Out of 77 patients tested positive for Hepatitis C geotype 4, only
51 patients actually received treatment. After initiation of treatment, 30 pa-
tients (59%) achieved early virological response (EVR), while 5 (10%) did
not (nonresponder). Fourteen patients (27%) stopped treatment due to un-
tolerated side effects and 5 were lost for follow up. Twenty-seven patients
completed 48 weeks of combination Peg-Interferon and Ribavirin all of
whom had negative PCR at end of treatment. Sustained virological response
(SVR) was achieved in 19 patients, 5 relapsed, and 3 lost for follow up.
However when analyzing results according to treatment protocol (excluding
the patients who were lost for follow up or withrdrawn) the SVR was 19/29
(66%).
Conclusion: The SVR noticed in this study falls within the range of other
reported studies about HCV genotype 4. The observed withdrawal rate was
very high in this retrospective analysis. However, when patients tolerated
and finished treatment their SVR seemed better than what is published for
genotype 1.
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Erythropoietic Protophyria (EPP) with Acute Hepatic Failure
Xinqing Fan, MD, Gagan Sood, MD, Shuyuan Xiao, MD, Karl Anderson,
MD∗. Gastroenterology and Hepatology, University of Texas Medical
Branch, Galveston, TX and Pathology, University of Texas Medical Branch,
Galveston, TX.
Purpose: Erythropoietic protoporphyria (EPP) is a genetic disorder of the
heme synthesis due to deficiency of the enzyme ferrochelatase and is char-
acterized by overproduction of protoporphyrin, accumulation of protopor-
phyrin in liver results in hepatobiliary injury (Cholestatic cirrhosis) and
rapid increase may result in fatal acute hepatic failure. We report a case of
EPP with cirrhosis presenting with acute liver failure managed successfully
with plasmapheresis, hematin infusion and ursodeoxycholic acid. 17 year
old female with history of photo sensitivity since childhood presented with
jaundice, acute right upper quadrant pain, nausea and vomiting. Laboratory
test revealed T Bil 8.5 mg/dl, Alk Phos 97, AST 736, ALT 283, Albumin
4, PT 23.7, PTT 30, INR 2.1, Platelet 82k, Viral Hepatitis serologies (A, B
and C) were negative. Plasma porphyrins 224µmol/L and RBC protopor-
phyrins 7418 µmol/L were elevated. Liver US revealed no biliary dilatation
but cholelithiasis and hepatosplenomegaly. Liver biopsy demonstrated cir-
rhosis, and severe cholestasis. The liver protoporphyrin was 1287 µmol/gm.
Patient was diagnosed with EPP with acute liver failure and was treated with
plasmapheresis and intravenous hematin infusion as well as cholestyramine
and ursodeoxycholic acid. There was marked improvement in plasma por-
phyrins, RBC protoporphyrins, liver enzymes and total bilirubin. (Fig. 1).
EPP presenting with acute liver failure liver is fatal and transplantation is the
only option. Combined treatment with plasmapheresis, hematin, ursodeoxy-
choilic acid and cholestyramine can stabilize the acute liver injury.[figure1]
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Tolerability of an Optimal PEG IFN Alpha + Ribavirin Regimen for
Patients with Decompensated Liver Disease Due to Hepatitis C
Joseph Ahn, MD, MS, Steven Flamm, MD∗. Hepatology, Rush University
Medical Center, Chicago, IL and Hepatology, Northwestern University,
Chicago, IL.
Purpose: To determine the tolerability of standard dosages of pegylated
interferon alfa (PEG) and Ribavirin (RBV) in patients with HCV and de-
compensated liver disease.
Methods: A retrospective assessment of patients with HCV and decom-
pensated liver disease treated with PEG and RBV initiated between 2002
and 2004. Demographic, virological data, and SVR were collected. Adverse
events including further hepatic decompensation, medication dose reduc-
tions or discontinuations, depression, cytopenias and use of growth factors
were documented.
Results: 16 patients with HCV and decompensated liver disease under-
went therapy with PEG alfa-2b 1.5 mcg/kg/wk or PEG alfa-2a 180 mcg/wk
and RBV 800 to 1200 mg daily. Male to female ratio was 14 to 2. 13/16
(81%) were Genotype 1. 75% were Caucasian. All patients had a history
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of at least one of the following: variceal bleeding 7/16, ascites 9/16, hep-
atic encephalopathy 5/16, hypoalbuminemia 12/16. Three underwent liver
transplantation during the initial 24 wks of therapy. Two discontinued ther-
apy prematurely due to AE (interstitial pneumonitis, asymptomatic jaun-
dice). Two developed significant ascites or hepatic encephalopathy. None
had variceal bleeding. Four had worsening depression requiring the addi-
tion of or increase of anti-depressants. Although the majority developed
cytopenias, only 4 required growth factors (3EPO/2 GSCF). Four required
medication dose reductions. No patients obtained a SVR.
Conclusion: Standard dosage of PEG and RBV was reasonably well toler-
ated in selected patients with HCV and decompensated liver disease. 1) Few
patients developed progression of liver disease or worsening of depression.
2) Expected rates of medication dose reduction/discontinuation were noted.
3) Cytopenias were common but manageable. 4) Larger prospective con-
trolled trials are necessary to determine an accurate SVR for patients with
HCV and decompensated liver disease who receive optimal dosing of PEG
and RBV.
301
HBV Genotype in Northern Portugal
Susana Lopes, MD, Carla Rolanda, MD, Pedro Pereira, MD, Fernando
Branca, MD, Mota Garcia, MD, Guilherme Macedo, MD∗.
Gastroenterology Unit, H.S. Marcos, Braga, Portugal and Clinical
Pathology, H.S. Marcos, Braga, Portugal.
Purpose: Several factors including viral, host and environmental ones have
been reported as determining the progression of liver disease in patients with
chronic hepatitis B (HBV) infection. There is increasing evidence that HBV
genotype may affect its clinical outcome and the response to antiviral therapy.
Currently eight genotypes (A-H) of HBV are identified by a divergence of >
8% in the entire genomic sequence, and have distinct geographic and ethnic
distributions.
We assessed the genotypic profile of HBV infection in Northern Portugal.
Methods: We have determined the genotypes and characterized the sero-
logical profiles of 97 patients. Genotyping was performed with conven-
tional PCR with specific primers (as described by Naito, Hayashi and Abe,
2001). Sequencing DNA open gene with Tgene HBV Genotyping Kit (Bayer
Healthcare) was used as confirmatory test.
Results: In 97 caucasian patients (61 men, 36 women), 70% were genotype
D, 21% genotype A, 6% genotype F, 2% genotype E and 1% genotype C.
Our major cohort of HBV infected replicative patients was HBeAg negative
(77%). In both e-positive and e-negative patients, genotype D predominates
(82% and 67%, respectively) but HBeAg positive patients only had genotype
D and A, with large genotype variety in HBeAg negative patients.
Conclusion: In our HBV infected patients population, predominantly
HBeAg negative, genotype D is the most prevalent (70%) along with a
significant population of genotype A (21%).
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Tumor Necrosis Factor (TNF)/Tumor Necrosis Factor Receptor
(TNFR) Interactions Are Critical for the Development and Effector
Functions of Hepatic and Splenic Cytotoxic T Cells in MHC Class I
Disparate GVHD
Sabina A. Ali, MD, Geri Brown, MD∗. Pediatrics: Division of
Gastroeneterology, Univeristy of Texas Southwestern, Dallas, TX and
Internal Medicine: Division of Gastroenterology, Univeristy of Texas
Southwestern, Dallas, TX.
Purpose: Graft-versus-host disease (GVHD) is increasing in patients who
receive orthotopic liver transplants (OLTx) (1–2% of all OLTx). The mech-
anism of this life threatening disease is unclear, but several risk factors are
considered to be important in its development. Murine models have been
used to determine cause of GVHD. One murine model, in which the transfer
of B6 T cells to MHC class I disparate bm1 × B6 F1 mice leads to the
development of hepatic GVHD. TNF inhibition, with an adenoviral vector
expressing TNFR-Ig chimeric protein (Adv-TNFi) reduces GVHD patho-
logical scores and hepatic CD8+, IFN-γ producing T cells. The present
studies were designed to determine the role of TNF on cytolytic (CTL) ac-
tivity of responder spleen cells (SpC) and intrahepatic lymphocytes (IHL)
from MHC class I disparate GVHD.
Methods: Allospecific killing of H-2bm1 target cells by 51Cr release assays
(CTL assay) utilized SpC and IHL from sublethally irradiated bm1 × B6
F1 who received either B6 purified CD8+ SpC and T cell depleted BMC
and control adenovirus (Adv-βgal) or Adv-TNFi. In specific assays, TNF
antibody (ab) or control ab (R &D Systems) was added at the beginning of
the CTL assay. Levels of effector molecules from responder SpC from MHC
class I disparate mixed lymphocyte culture (MLC) using B6 control or B6.
TNFR1−/− SpC and irradiated bm1 SpC were assessed by real time PCR.
Results: SpC from BMT recipients that had received Adv-TNFi displayed
lower allospecific cytolytic activity than controls [(E:T 1:20 (77%) and 1:50
(80%) vs. 1:20 (13%) and 1:50 (17%)]. Addition of TNFR Ig further reduced
allospecific killing during the cytolytic assay [(E:T 1:20 (45%) and 1:50
(47%) vs 1:20 (0%) and 1:50 (0%)]. IHL from BMT who had received
Adv-TNFi had lower CTL activity than control BMT recipients [(E: T 1:20
(16%) and 1:50 (47%) vs 1:20 (0%) and 1:50 (4%)]. Of importance, the
TNF antibody added prior to the CTL assay also decreased allospecific
CTL activity against bm1 target blasts by IHL. Responder SpC from MHC
class I disparate MLC using B6. TNFR1−/− responder SpC displayed lower
granzyme A, B and perforin expression than control B6 SpC (95%, 39% and
82% lower, respectively).
Conclusion: TNF/TNFR interactions are critical for CTL development and
effector functions in SpC and IHL in MHC class I disparate GVHD.
303
A Case of Hyperemesis Gravidarum
Arthur E. Richert, MD∗, Mark Marino, MD, Rich Awtrey, MD.
Gastroenterology, Louisiana State University Health Sciences Center, New
Orleans, LA.
Purpose: Hyperemesis gravidarum is a clinical diagnosis that has no uniform
criteria. The symptoms typically occur at four to ten weeks gestation. The
diagnosis can be made in females with persisting emesis, weight loss greater
than five percent of prepregnancy body weight and ketonuria beginning in
the first trimester, as well as exclusion of other causes for these symptoms.
A 64 year old G2P1 at 11 1/7 weeks gestational age with no significant past
medical history was admitted to the medicine service for dehydration and
hyperemesis. Patient complained of non-bloody emesis for the past month,
occurring daily with no aggrevating factors. The patient denied jaundice, di-
arrhea, bright red blood per rectum, arthralgias or skin rashes but noted she
had a similar episodes of emesis with her last pregnancy that required hos-
pitalization and resulted in elevated liver enzymes. Physical exam revealed
a patient in no distress, anicteric sclera, abdomen was soft and nondistended
with normal bowel sounds and no lower extremity edema. Lab workup re-
vealed ALT of 1485 U/L, AST of 429 U/L, Alkaline phosphatase of 75 U/L,
Potassium of 2.1 mmol/L, urine ketone of 150 mg/dl and normal platelets,
hemoglobin and hematocrit.
In the hospital the patient was treated symptomatically for her nausea and
emesis, given adequate intravenous hydration and vitamin supplementation.
Further workup, including ANA, smooth muscle ab, Hepatitis panel, HIV,
RPR, HSV IGM ab, CMV IgM ab and right upper quadrant ultrasound
with doppler, were all negative. Throughout the patients hospitalization, her
symptoms improved and her serum aminotransferases improved as well.
After all lab work was obtained, the patient was diagnosed with hyperemesis
gravidarum. The patient was then discharged home after she was tolerating
po and had no complaints of nausea or emesis.
This case demonstrates when the diagnosis of hyperemesis gravidarum
should be considered as well as how the diagnosis should be made. The
diagnosis should be considered when persistent vomiting is accompanied
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by weight loss exceeding five percent of prepregnancy weight and ketonuria
that is unrelated to other causes.
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Hepatic Fibrosis and Steatosis in Treatment Naive Chronic Hepatitis C
Patients of Central California Valley
Muhammad Y. Sheikh, MD∗, Muhammad H. Bashir, MD, Humaira Sadiq,
MD, Jasjit Singh, MBBS, Farheen A. Khan, William C. Pitts, MD, Kandarp
K. Shah, MD. Division of Gastroenterology and Hepatology, University of
California, San Francisco-Fresno Education Program, Fresno, CA.
Purpose: Liver biopsy is traditionally considered the gold standard to assess
hepatic inflammation, fibrosis and steatosis in chronic hepatitis C (CHC)
patients. This study assessed the severity of fibrosis and steatosis in liver
biopsies of treatment naive CHC patients of Central California Valley.
Methods: We retrospectively evaluated 1031 consecutive CHC patients who
underwent a percutaneous liver biopsy between years 2000–2006. Histology
and steatosis were assessed with the METAVIR and Brunt scores respec-
tively. Patients with coinfections and other liver pathologies were excluded
from the study.
Results: Of 1031 patients, 566 (54.9%) were male and 465 (45.1%) were
females. The mean age was 46 years; 46% being Hispanic, 46.8% Caucasian,
3.5% Afro-Americans and 1.8% Asians. The mean body mass index (BMI)
was 29.97. AST and ALT levels and platelets counts were 66.13 ± 8.0 U/L
and 78.9 ± 8.0 U/L and 204.5 × 109 /L respectively. METAVIR F0-F1 was
noted in 521 (50.9%) patients, 234 had F2 (22.8%), 270 had F3-F4 (26.3%)
(Table). Brunt steatosis scores of 0, 1, 2 and 3 were observed in 44.1%,
39.6%, 12.6% and 3.7% of patients respectively. About 80.3% of patients
were genotype 1; among these 42% had low and 18.8% had high steatosis
scores.
Conclusion: The majority of CHC treatment naive patients in the Central
California Valley had early fibrosis (F1-F2) and some degree of steatosis
at the time of biopsy. Severe fibrosis was noted in one fourth of patients at
the time of histologic diagnosis. There was a high prevalence of steatosis in
CHC patients, particularly with genotype 1. Further studies are needed to
evaluate the impact of steatosis on the clinical course and treatment response
in CHC patients.
Baseline histology (METAVIR/Brunt scores)
N = 1031 0 1 2 3 4
Fibrosis # (%) 180 (17.6%) 341 (33.3%) 234 (22.8%) 155 (15.1%) 115 (11.2%)
N = 1025
Inflammation # (%) 15 (1.5%) 253 (24.8%) 493 (48.3%) 239 (23.4%) 20 (1.96%)
N = 1020
Steatosis # (%) 362 (44.1%) 325 (39.6%) 103 (12.6%) 30 (3.7%) —
N = 820
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Frequency of Hepatitis B Core Antibodies in Chronic Active Hepatitis
C Patients in a Pakistani Cohort
Muhammd Umar, FACG, Zahid Mahmood Minhas, MD∗, Muhammad Ali
Asghar, MBBS, Saima Ambreen, FCPS, Muhammad Usman Yaqoob,
MBBS, Hamama Tul Bushra, FCPS, Usman Hakeem, MBBS, Mubashira
Aziz, MBBS, Fiza Binte Ismail, MBBS. Gastroenterology & Hepatology
Division of Department of Medicine, Holy Family Hospital, Rawalpindi,
Punjab, Pakistan.
Purpose: The prevalence of Hepatitis C in Pakistan is about 4% and Hep-
atitis B is 2.5–3%. Estimated community burden is about 11 million people
countrywide. As there was no mass immunization program before 2003 in
the country, therefore, many patients of Hepatitis C had past exposure to
Hepatitis B and recovered uneventfully.
Setting: Gastroenterology & Hepatology Division of Department of
Medicine at Holy Family Hospital Rawalpindi – Pakistan.
Study Design: Reterospective observational study
Methods: PCR positive chronic hepatitis C patients were evaluated for Anti
HBc in their serum. Other patients, who were reactive for HBsAg, excluded
from the study. The information was recorded in a prescribed proforma;
variables studied were patients age, gender, alanine aminotransferase level
(ALT), and Anti HBc status. Anti HBc was done by ELISA third generation
while HCV RNA was done by Roche Real Time. The data was analyzed
using SPSS version 13.
Results: Out of 241 patients 116 (46.89%) were male and 125 (53.11%) were
female. Mean age was 38.05 ± 13.37. Mean ALT level was 70.97 ± 19.58.
Overall frequency of antibodies to Hepatitis B core antigen was 128/241
(53.11%) while in male it was 58/116 (50%) and in female it was 70/128
(54.68%).
Conclusion: Hepatitis B Core Antibodies has high frequency in Chronic
Active Hepatitis C patients. Therefore, it is recommended that all patients
undergoing investigation and treatment for HCV should be checked for Anti
HBc of past exposure to HBV infection particularly in endemic area like
Pakistan.
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13C Breath Tests as Tools for the Assessment of Liver Diseases
Yoshihisa Urita, Toshiyasu Watanabe, Tadashi Maeda, Kaoru Domon,
Susumu Ishihara, Tomohiro Arita, Asuka Nakayama, Makie Nanami,
Tatsuhiro Yamamoto, Akiro Kugahara, Takamasa Ishii, Hirohito Kato,
Kazuo Hike, Shuji Watanabe, Kazushige Nakanishi, Nagato Shimada,
Motonobu Sugimoto∗, Kazumasa Miki. Department of General Medicine
and Emergency Care, Toho University, Tokyo, Japan; Division of
Gastroenterology and Hepatology, Toho University, Tokyo, Japan and
Department of Hematology, Toho University, Tokyo, Japan.
Purpose: It has been difficult to decide the pathogenesis of liver diseases
accurately. 13C breath tests are proposed as tools for the assessment of liver
function and have a great advantage of various 13C-substrate used. Therefore,
different metabolic pathways can be examined by breath tests. Through a
combination of several kinds of breath tests, we evaluate the efficacy of
breath tests to differentiate fatty liver diseases (FLD) from chronic viral
hepatitis (CH).
Methods: 13C-acetate, 13C-phenylalanine, 13C-caffeine, and 13C-valine
breath tests were performed in 23 chronic liver diseases (mean age 67 years)
in a crossover manner. The cause of liver disease was hepatitis C virus (HCV)
in 8 patients, hepatitis B virus (HBV) in 3, and primary biliary cirrhosis
in 1, alcoholic liver disease (ALD) in 4, non-alcoholic fatty liver disease
(NAFLD) in 6. The patients received 100 ml of water containing 100 mg of
13C-substrate in the sitting position after an overnight fast. Breath samples
were collected at baseline and at 10 min-intervals for 150 min after ingestion
to analyze 13CO2.
Results: The 13CO2 concentrations increased from the beginning, and peak
enrichment values were reached at 20 min after administration of 13C-acetate.
A peak value of CO2 excreted was lowest in ALD (19.1 per mil), followed
by NAFLD (21.1 per mil), and CH (48,9 per mil). After administration of
13C-phenylalanine, 13CO2 excretion peaked at 30 min and the peak value
was significant lower in FLD than in CH regardless of the serum albumin
level and the platelet count. There were no significant differences in 13CO2
excretion after administration of 13C-caffeine between FLD and CH. 13CO2
excretion in the first 60 min was significant lower in FLD than in CH after
administration of 13C-valine. 13CO2 excretion at 30 min is closely associated
with the platelet count and the serum albumin level.
Conclusion: 13C-acetate breath test is a useful non-invasive tool for dis-
tinguishing between patients with FLD and those with CH. 13C-valine is
the optimal stable isotope for the assessment of liver function although it is
unable to differentiate FLD from CH.
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Liver Histological Features of Randomly Selected Population with
Abnormal Liver Sonography in Iran
Leila Pasharavesh, MD, Ziba Khorram, MD, Roshanak Roshanfekr, MD,
Kamran Shateri, MD, Ramin Tavafzadeh, MD, Reza Mashayekhi, MD,
Maryam Firoozi, BS, Amir Houshang Mohammad Alizadeh, MD, Farahnaz
Fallahian, MD, Seyed Mohsen Mousavi, MD, Farzaneh Khadem Sameni,
MD, Bahman Talebipoor, MD, Behnaz Mohabbatian, MD, Mohammad
Reza Zali, MD, FACG∗. Research Center of Gastroentrology and Liver
Diseases, Shaid Beheshtee University of Medical Sciences, Tehran, Islamic
Republic of Iran.
Purpose: Non alcoholic steatohepatitis is a word wide public health problem
with no clinical symptom which is in doubt during a random liver enzyme
tests and diagnosed by liver biopsy. This study was down to determine the
Liver histological features of randomly selected population with abnormal
liver sonography in Iran.
Methods: Total of 216 randomly selected non alcoholic subject with ul-
trasonographic fatty liver and no serologic markers of viral or autoimmune
hepatitis and no findings in favor of metabolic liver disease were enrolled
the study in Tehran.
Questionnaire, physical examination, serum biochemical liver tests was com-
pleted for all subjects. For those with persistent liver enzyme elevation and
moderate or moresonographic fatty liver even without liver enzyme eleva-
tion, liver biopsy was performed. Analysis of data was down through SPSS
13 windows statistical package.
Results: 14.06% of subjects had liver enzyme elevation in addition of ultra-
sonographic fatty liver and 2.031% had moderate or more sonographic fatty
liver without enzyme elevation. Both of these two groups were biopsied.
Liver biopsy showed definite steatohepatitis (NASH Activity Score (NAS) 5
or more) in 66.66% and possible steatohepatitis (2 ≤ NAS ≤ 4) in 33.33%.
Steatosis in 33.33% was panacinar and in others azonal. 50% had microvesic-
ular steatosis. 33.33% had moderate perisinusoidal/pericellular fibrosis. 66%
had portal fibrosis. Microgranuloma and vaculated nuclei were seen in 50%
and 88.33% respectively.
Conclusion: Non alcoholic steatohepatitis must not be considered a dis-
ease restricted to specific groups only and its impact might be larger than
what is generally considered. People may have considerable sonographic or
histologic fatty liver in spite of normal liver enzyme tests.
308
Non-Invasive Predictors of Large Varices in Patients Hospitalized with
Gastroesophageal Variceal Hemorrhage
Faisal W. Ismail, MD, Hasnain A. Shah, FRCP, Saeed S. Hamid, FRCP,
Shahab Abid, MD, Wasim Jafri, FRCP∗. Medicine, Aga Khan University
Hoispital, Karachi, Sind, Pakistan.
Purpose: To identify non-invasive factors predicting the presence of large
varices (LV) in patients hospitalized with gastroesophageal variceal hemor-
rhage (GOVH).
Methods: Case records of patients admitted with GOVH between January
1998 to June 2005 were retrospectively analyzed. Relevant clinical param-
eters assessed included Child-Pugh class, clinically detectable ascites, por-
tosystemic encephalopathy (PSE), clinically detectable splenomegaly and
hemodynamic instability, as defined by Baveno. The laboratory parameters
assessed were: hemoglobin, platelet count, prothrombin time, serum biliru-
bin, and albumin. The ultrasonographic characteristics noted were bipolar
splenic diameter, presence of splenomegaly, presence of splenic varies, as-
cites and portal vein diameter. All patients with GOVH were included, and
were divided into 2 groups based on the size of the esophageal varices (EV),
which were classified as small (SV) or large (LV). Patients with gastric
varices without (EV) were excluded.
Data were analyzed using SPSS. Variables with a P value of <0.25 on
univariate analysis were included in step-wise multiple logistic regression
analysis to identify independent risk factors for LV, with P values <0.05
taken as significant.
Results: A total of 420 patients presented with GOVH during the study
period. The mean age, gender distribution, and frequency and etiology of
cirrhosis were similar in the two groups. Liver cirrhosis with hepatocellular
carcinoma (HCC), Child-Pugh class C, clinically detectable ascites, grade 3–
4 PSE, detectable splenomegaly, previous history of GOVH, hemodynamic
instability and platelet count < 91000 were more common in the LV group.
The frequency of radiologically detected ascites, splenomegaly and portal
vein diameter were similar in both groups. On multivariate analysis, inde-
pendent predictors for the presence of LV were: Cirrhosis with HCC (P =
0.029), clinically detectable splenomegaly (P =< 0.001), hemodynamic in-
stability (P = 0.031), a previous history of GOVH (P =< 0.001), platelet
count < 91000 (P =< 0.001), and splenic size ≥158 mm (P = 0.006).
Conclusion: Cirrhosis with HCC, clinical splenomegaly, hemodynamic
instability, a previous history of GOVH, thrombocytopenia <91000, and
splenic size ≥158 mm are independent non-invasive predictors of large
varices in patients with gastroesophageal variceal hemorrhage.
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N-butyl-2-cyanoacrylate in Gastric Variceal Bleeding – A Study To
Determine the Short and Long Term Efficacy of This Agent
Arif Amir Nawaz, FACP, FACG∗, Shahid Sarwar, FCPS, Salwa Hussain,
MBBS, Atiqa Batul, MBBS, Joher Amin, FCPS, Rafia Chaudhry, Asim
Malik, FRCS. Gastroenterology, Fatima Memorial Hospital, Lahore,
Punjab, Pakistan.
Purpose: Catastrophic bleeding from Gastric varices (GV) occurs in 20%
of patients with portal hypertension, either alone or in combination with
esophageal varices. Injection of fundal varices with N-butyl-2-cyanoacrylate
(a tissue adhesive) has been used with varying success in this setting. The
data on the long term efficacy of this modality is very limited.
Objective: 1) To study the short and long-term efficacy of N-butyl-2-
cyanoacrylate in control of fundal variceal bleeding. 2) To determine the
optimal technique and amount of tissue adhesive to be used in this setting.
Methods: This Cohort type of interventional study was conducted in a Ter-
tiary care referral center. Patients presenting with haematemesis and melena
who were found to have fundal varices as source of bleeding were included.
N-butyl-2-cyanoacrylate and lipiodal were injected into the gastric varices
at EGD. Patients were followed six monthly for one year or longer after
endoscopy for rebleed or mortality.
Results: The study population included a total of 56 patients with M/F ratio
of 0.8; predominant age group of 40–59 years. GOV-2 and IGV-1 were seen
in 2/3 and 1/4 of patients respectively. Almost 2/3 of the patients (59%)
also had esophageal varices with high-risk stigmata. The average amount
of N-butyl-2-cyanoacrylate used was 1 cc. Good hemostasis was noted at
initial injection in more than 90% of patients while bleeding leading to
haemodynamic instability was noted in 5 patients. Follow up for 1 year was
possible in 36 patients; clinical and demographic variables were comparable
in both these groups. 6 (17%) out of the 36 patients with long-term follow up
(>1 yr) had rebleeding which was treated with re-injection or band ligation.
Overall mortality was 4(11.1%) with half of this due to rebleeding from
gastric varices. The overall rate of rebleeding at one year was 17% which
is comparable to several other studies. However the average amount of N-
butyl-2-Cyanoacrylate used in our study was significantly lower resulting in
cost-savings.
Conclusion: 1) N-butyl-2-cyanoacrylate is a safe and effective mode of
treatment for the short and long-term control of gastric variceal bleeding.
2) Smaller amounts of N-butyl-2-cyanoacrylate may be used with excellent
efficacy in settings where cost remains a concern. 3) Most cases of rebleeding
may be treated safely with N-butyl-2-cyanoacrylate.
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Screening, Diagnosis and Treatment Strategies Used by the
Gastroenterologists in Ohio for NASH/NAFLD
Abstracts S229
Thomas Sodeman, MD∗, Isam Daboul, MD, Charles Filipiak, MD, Sirni
Hejeebu, DO, Vikas Ghai, MD. Department of Gastroenterology,
University of Toledo, Toledo, OH and Department of Medicine, University
of Toledo, Toledo, OH.
Purpose: Fatty liver disease is now the most common cause for elevated liver
function tests in the United States. Nonalcoholic steatohepatitis (NASH) is a
progressive form of nonalcoholic fatty liver disease (NAFLD) that can lead
to hepatic fibrosis and cirrhosis. As there is not enough data to effectively
diagnose and treat NASH, this study evaluates trends of gastroenterologists
in Ohio on their strategies in dealing with this rapidly escalating disease.
Methods: After approval from the institutional review board (IRB), ques-
tionnaire was send to all 230 gastroenterologists practicing in Ohio. The
content of the questions included methods of diagnosis, number of patient
diagnoses in a year and treatment strategies.
Results: Of the 230 gastroenterologists, 61 responded to the questionnaire
(26% response rate). Almost 50% of the gastroenterologists diagnose more
than 25 new patients every year in Ohio. Most of the gastroenterologists
answered more than one option for screening and treatment. Liver ultra-
sound is used by 75% of the gastroenterologists as the primary modality for
diagnosis followed by laboratory tests, biopsies and Computerized Tomog-
raphy Scan. NASH patients are managed by conservative treatment without
adding Thiazolidinediones, Metformin or Antilipidemic agent by 72% of
the gastroenterologists.
Conclusion: On an average, 50% of gastroenterologists in Ohio see more
than 25–50 new patients in one year. Gastroenterologists in Ohio uses liver
ultrasound as the primary modality for diagnosis and currently use mostly
conservative treatment for NASH. The lack of specific guidelines regarding
the treatment and diagnosis by AASLD Practice Guidelines Committee on
May 24, 2002 is consistent with wide variation in diagnosing and treating
NASH or NAFLD in Ohio.[figure1][figure2]
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The APRI Is a Fair Estimator of Fibrosis in NAFLD, and May Be
Enhanced by the Use of Age
Karen O. Steffer, MD, Shu-Yuan Xiao, MD, John Petersen, PhD, Ned
Snyder, MD∗. Internal Medicine, University of Texas Medical Branch,
Galveston, TX and Pathology, University of Texas Medical Branch,
Galveston, TX.
Purpose: Nonalcoholic fatty liver disease (NAFLD) is increasing in preva-
lence. Many patients with suspected disease do not undergo liver biopsy.
Since it is expensive and invasive, it would be useful if a hepatic fibrosis
index could identify those patients most likely to have significant disease
that might benefit from a biopsy. The AST/Platelet Ratio Index (APRI) has
been shown to be useful in chronic hepatitis C, but there is little data on it
in NAFLD.
Methods: We retrospectively reviewed the pathology database at our insti-
tution from January 1995 to September 2006 using the search keywords of
“steatohepatitis” and “liver biopsy”. Of the 318 patients identified, 210 were
excluded because of a history of HBV, HCV, autoimmune hepatitis, or re-
cent heavy alcohol use. Among the 108 remaining patients we recorded the
AST, ALT, platelet count, demographic data, and when appropriate the liver
biopsy slides were examined blindly. Liver biopsies were staged by F0-F4
criteria with patients with pericellular fibrosis only classified as F1. Mild
fibrosis was defined as F0-F1 and significant fibrosis as F2-F4. The APRI
was calculated as below.∗
Results: The number of patients by stages were F0 (17), F1 (42), F2 (22), F3
(8), and F4 (19). The AUC for the ROC curve for the APRI was 0.758 (95%
CI 0.667–0.836). Using a cutoffs of ≤0.44 and ≥1.0 the APRI predicted 37
of 49 for mild fibrosis and 16 of 17 for a significant fibrosis for a NPV of
75.5% and a PPV of 91.4% respectively. Using logistic regression, and the
APRI and age, we were able to construct a risk ratio. The AUC for the ROC
for the APRI and age was 0.802 (95% CI 0.714–0.873). Using cutoffs of
≤0.84 and ≥0.58 this risk ratio predicted 32 of 39 patients with mild fibrosis
and 22 of 23 patients with significant fibrosis for a NPV of 82.1% and a PPV
of 95.7% respectively. The indeterminate zones were 38.9% for the APRI
and 42.6% for the APRI and age.
Conclusion: The APRI is a fair estimator of fibrosis in NAFLD. It appears
to be most useful in predicting significant fibrosis with a cutoff of ≥1.0. It
may be modestly enhanced by incorporating age. ∗APRI = AST/ULN ×
100/platelets9
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Adequacy of Liver Biopsy Specimens Performed by
Gastroenterologists and Radiologists
Muhammad Y. Sheikh, MD∗, Muhammad H. Bashir, MD, Jasjit Singh,
MBBS, Farheen A. Khan, Humaira Sadiq, MD, Mandeep Singh, MD,
William C. Pitts, MD, Kandarp K. Shah, MD. Division of
Gastroenterology and Hepatology, University of California, San
Francisco-Fresno Education Program, Fresno, CA.
Purpose: Liver biopsy is the gold standard to establish the severity of in-
flammation and fibrosis in chronic hepatitis C (CHC) patients. Specimens
measuring 20 mm long are usually considered optimal to determine grade
and stage reliably. This study looked at the adequacy of biopsy specimens
performed by both gastroenterologists and radiologists at three Hospitals in
the Central California Valley.
Methods: We retrospectively evaluated 1031 consecutive patients with CHC
who underwent percutaneous liver biopsies between years 2000–06. The
pathology reports and other clinical data were reviewed in detail. Biopsy
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specimen size on cut sections and adequacy to interpret fibrosis staging was
assessed.
Results: The study population included 566 (54.9%) male and 465
(45.1%) female patients; 46% being Latinos, 46.8% Caucasian, 3.5% Afro-
Americans and 1.8% Asians. The mean age of patients was 46 years and
mean body mass index (BMI) 29.9. The mean and median length of biopsy
specimens obtained by radiologists (N = 682) was 14.58 and 15 mm and by
gastroenterologists (N = 347) was 14.57 and 13 respectively (P = 0.983).
The majority of biopsies by radiologists were obtained by 14–20 G trigger
(tru-cut) needles, while gastroenterologists predominantly used 16 G aspira-
tion needles. Among the biopsies performed by radiologists 60% (N = 411)
of patients were referred predominantly by primary care providers. Of 1031
biopsies, 15.8% (N = 163) were ≤10 mm in length; among these 65% were
performed by radiologists and 35% by gastroenterologists. Fibrosis staging
was reliably made by the pathologists in 84.2% of specimens measuring ≥10
mm.
Conclusion: The majority of liver biopsies on CHC patients in the Central
California Valley are performed by the radiologists, regardless of BMI of
patients. Among these, most biopsies did not meet the criteria for optimal
length described in the literature. There was no significant difference in
the biopsy specimens obtained by the gastroenterologists and radiologists.
Specimens <10 mm were usually inadequate to accurately establish stage
of fibrosis.
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Iron Reduction by Phlebotomy Reduces alpha Fetoprotein in Patients
with Advanced Chronic Hepatitis C: A Long Term Follow-Up Study
Steven R. Fox, MD, Navakanth Gorrepati, MD, MPH, Mamtha
Balasubramaniam, MS, Tusar K. Desai, MD∗
Purpose: Phlebotomy with iron depletion is known to lower transaminases in
patients with chronic hepatitis C (CHC). We present the results of long term
(up to 9 years) maintenance phlebotomy program in patients with advanced
CHC, high AFP and proven cirrhosis or bridging fibrosis.
Methods: All 18 patients with CHC failed therapy with PEG-interferon/
ribavirin. Liver biopsy showed cirrhosis in 13 patients and bridging fibrosis
in 2 patients. 9 patients were African American. None of the patients demon-
strated HFE mutations. Patients underwent phlebotomy with 300 ml to 500
ml removed every two weeks, with the intent to reduce ferritin while main-
taining hemoglobin above 11.5. Liver enzymes, ferritin, hemoglobin, AFP
Average lab values at different time intervals pre and post phlebotomy
Values prior 3 months 1 year 3 years 5 years
Lab values to phlebotomy PP PP PP PP
Hemoglobin 14.1 SD 1.4 12.7 SD 1.3 13.4 SD 1.4 13.6 SD 2.0 14.2 SD 1.2
(N = 18) (N = 14) (N = 16) (N = 11) (N = 6)
Ferritin 781 SD 610 121 SD 130 108 SD 88 74 SD 68 67 SD 30
(N = 17) (N = 11) (N = 13) (N = 10) (N = 6)
AFP 50 SD 54 27 SD 16 17 SD 14 17 SD 18 15 SD 7
(N = 18) (N = 10) (N = 15) (N = 10) (N = 5)
PP = post phlebotomy, SD = standard deviation
Clinical characterestics of patients with Cryptococcosis
Patient Ascitic Delay in
Age/sex/ Underlying Presenting Fluid Cryptpcoccal diagnosis from Antifungal
Initial MELD Condition Symptoms analysis Cultures initial presentation therapy Outcome
43/Hispanic HCV cirrhosis and no Abdominal Pain WBC = 50 Peritoneal 5 days Amphotericin Anuric renal failure,
M/28 other immunosupressive and Fever (14% segs & fluid and for one day hospice
condition & 56% lymphs) blood and death
58/Caucasian HCV cirrhosis and no Abdominal pain and WBC = 52 Peritoneal fluid 48 hrs Amphotericin Renal failure,
F/23 other immunosupressive worsening (23% segs and blood for 2 days progressive coma
condition ascites & 30% lymphs) and hospice
and platelets were recorded; we rounded to the nearest time interval with
respect to the six-biochemical parameters. The (n) in table 1, for 3 months
and 1 year is <18 because not all patients had labs done at those time points.
Signs and symptoms for clinical decompensation were assessed.
Results: Average ALT, AST and AFP at 3 months, year 1, year 3, and year
5 were all significantly lower than baseline (P < 0.01 for all except AST at
5 years, P = 0.025) (Table 1). There was no significant difference seen in
platelet count or hemoglobin. AFP dropped in all patients. Pre-phlebotomy
AFP was >40 in 7 patients, none of these patients developed hepatoma over
an average of 39 months. No patients developed: encephalopathy, refractory
ascites, variceal bleeding or hepatoma.
Conclusion: In patients with CHC, high ferritin and high AFP, a maintenance
phlebotomy program can lower AFP as well as transaminases, and maintain
the low AFP long term, without inducing anemia. Despite a very high AFP
at the start of the phlebotomy regimen, none of the patients developed a
focal mass or clinical evidence of hepatoma or clinical decompensation.
Maintenance phlebotomy and sustained iron depletion needs to be evaluated
further as a strategy in patients with CHC cirrhosis who have failed anti-viral
therapy.
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Cryptococcus and Cirrhosis. Have We Been Missing the Association?
Rajasekhara R. Mummadi, MD∗, Krishna S. Kasturi, MD, Audrey Nguyen,
MD. Division of Gastroenterology, The University of Texas Medical
Branch, Galveston, TX.
Purpose: Disseminated Cryptococcosis is a disease rarely seen out side
the setting of profound immunosupression such as post- transplant patients,
Acquired Immuno Deficiency Syndrome or malignancy. Less than 30 cases
of systemic cryptococcal infection have described in literature (1965–2006)
in patients with no immunosupressive conditions other than cirrhosis. We
presented one of the cases in 2005 American College of Gastroenterology
(ACG) annual meeting and within 18 months encountered another case. We
hereby suspect that this is an under diagnosed condition and postulate that
cirrhosis per se could be a strong risk factor for disseminated cryptococcosis
and and high index of suspicion needs to be maintained to ensure early
diagnosis of this serious entity.
Conclusion: Both the patients described in this case series had no other
immunosupressive condition other than advanced cirrhosis. The diagno-
sis was made after the peritoneal/blood cultures grew Cryptococcus. Slow
growth of the fungus in cultures usually contributes to delayed (or missed)
diagnosis and initiation of therapy leading to a poor out come.A rapid
and reliable screening test like cryptococcal antigen in serum and or as-
citic fluid would have resulted in prompt initiation of anti fungal therapy.
1. Spontaneous cryptococcal peritonitis should be suspected in patients in
atypical SBP like presentations.(Absent leukocytosis in ascitic fluid, clini-
cal worsening despite antibacterial therapy, lymphocyte predominant leuko-
cytosis). Disseminated cryptococcosis may be an underdiagnosed disease
in cirrhotics. 2. Ascitic fluid and serum for cryptococcal antigen should
be tested in above presentations. 3. Prospective trials to study the rele-
vance of cryptococcal antigen testing in atypical SBP like presentations are
needed.
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Autoimmune Hepatitis: A Risk Factor for Cryptogenic Cirrhosis
Maliha Ahmad, MD, Arun Samanta, MD∗, Kenneth M. Klein, MD,
Baburao Koneru, MD, Dorian Wilson, MD, Fisher Adrian, MD, Andrew
De La Torre, MD, Milie Debroy, MD. Medicine, Univ of Med and Dent of
New Jersey, Newark, NJ; Pathology and Laboratory Medicine, Univ of Med
and Dent of New Jersey, Newark, NJ and Surgery, Univ of Med and Dent of
New Jersey, Newark, NJ.
Purpose: The etiology of cryptogenic cirrhosis (CC) is poorly understood.
It is recognized that a significant number of patients with CC may result
from nonalcoholic fatty liver disease (NAFLD) yet its cause in the others
remains unknown. Occult autoimmune hepatitis or toxic liver injuries have
been the other proposed causes of CC. The aim of the present study was to
identify the clinical, biochemical, immunologic and histologic parameters of
autoimmune hepatitis (AIH) in patients with CC to ascertain whether AIH
is a causative risk factor for the disease.
Methods: Thirty five consecutive patients who had liver transplant for CC
were studied. Clinical, biochemical, immunologic and histologic parameters
were analyzed and the International Autoimmune Hepatitis (IAH) score cal-
culated. Explant histology was reevaluated by a hepatopathologist for the in-
flammation, lymphoid aggregate, plasma cells, interface hepatitis, steatosis,
perivenular and sinusoidal changes, glycogenated nuclei, Mallory hyaline,
bile duct changes, hepatocyte necrosis and fibrosis.
Results: The mean age of patients was 53.7 ± 13 years, BMI was 29.6 ±
6.8 Kg M2 (range 21–42) and 57% were females. Diabetes was present in
42%; obesity in 63%, and 37% had concurrent illness. The liver chemistry
revealed mild to moderate increase in aminotransferases (AST 85.5 ± 105,
ALT 67 ± 70, AST/ALT 1.4 ± 0.6) and Alk Phos (187.7 ± 97.7).
The ANA was positive in 17% and anti-smooth muscle antibody in 31%.
Mean IAH score was 7.0 ± 3.0 and a score of 10 or greater was seen in
14%. However, in 60% of the patients with the high IAH score, the histo-
logic features of residual NAFLD were also present. Liver histology showed
cirrhosis in all. No interface hepatitis or plasma cell infiltrates were seen.
Varying grades of centrivenular sclerosis (27 biopsies) and sinusoidal fi-
brosis (18 biopsies) indicative of residual NAFLD were seen in addition to
Mallory hyaline seen in 23%.
Conclusion: Occult or burnt-out AIH diagnosed by clinical, biochemical and
immunologic criteria may be a risk factor leading to CC in a subset of patients.
In some patients, dual injury from NAFLD and chronic AIH resulting in CC
is a possibility. It remains conjectural that, the classic histology of AIH may
be altered or lost once the disease progresses to cirrhotic stage.
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34 Year Old Pregnant Female Presents with Abdominal Pain
Baseer Qazi, MD, Naser M. Khan, MD, Mani Mahdavian, MD∗.
Medicine, Division of Gastroenterology, Advocate Lutheran General
Hospital, Park Ridge, IL.
Purpose: 34 year old female, gravida 4, para 0, at 16 weeks of gestation
presented with abdominal pain for 3 days, epigastric/right upper quadrant,
severe, with nausea and vomiting. Patient denied fever, arthralgias, or change
in bowel habits. Her past medical history was significant for systemic lu-
pus erythramatosus without active manifestations and antiphospholipid an-
tibody syndrome. She denied any history of smoking, alcohol use, or illicit
drug use. Her medications included asprin, enoxaparin, hydroxychloroquine,
and prenatal vitamins. She was allergic to sulfa and penicillin. Physical
exam revealed elevated blood pressure (150/84 mmhg), tenderness in right
hypochondrium with voluntary guarding and a gravid uterus. Lab studies re-
vealed thrombocytopenia, elevated transaminases (7 times above the normal
value), LDH and decreased haptoglobin. Urinalysis revealed proteinuria with
trace blood. Ultrasound of the abdomen revealed thickened gallbladder wall
without gallstones. CT scan of the abdomen revealed densities throughout
the liver consistent with hepatic infarctions/necrosis. Our patient was di-
agnosed with HELLP syndrome with hepatic infarctions/necrosis. Hepatic
infarction in pregnancy is a rare condition, with an estimated incidence of 1
in 40,000 to 250,000 pregnancies. The hepatic infarction although rare, usu-
ally occurs after the 20th week of pregnancy and usually involves the right
lobe of the liver. The diagnosis is established by abdominal ultrasound, CT
scanning, MRI or angiography. Hepatic rupture is a dangerous complication
that can causes mortality rates as high as 85 percent. Treatment is generally
limited to conservative management and delivery of the fetus. Our case is
unique in that the patient presented with this clinical syndrome in the 16th
week of her pregnancy and her hepatic infarctions included most of her liver
and her medical history included antiphospholipid antibody syndrome. Less
than 30 such presentations have been reported in our literature search. Our
patient had an uncomplicated dilatation and evacuation procedure.[figure1]
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Capsule Endoscopy Can Discriminate between Large/Medium Varices
and Small or No Varices: Defining the Threshold
Kevin P. Meitz, DO, Ian R. Schreibman, MD, Thomas R. Riley, MD, Tri H.
Le, MD∗. Gastroenterology & Hepatology, Hershey Medical Center/Penn
State University, Hershey, PA.
Purpose: Guidelines recommend surveillance endoscopy (EGD) in patients
with portal hypertension. Risk of hemorrhage is correlated to variceal (EV)
size and presence of endoscopic stigmata. Treatment is recommended when
medium/large varices (M/LV) are present. Reports indicate that PillCam
ESO (EC) is a sensitive tool for identifying M/LV when the varix comprises
more than 25% of the circumference of the circular field view. We evaluated
the ability of EC to discriminate small from M/LV using the current grading
scale. In addition, we sought to identify a correlation between varix size by
EC and endoscopic grade.
Methods: Patients underwent EC within 48 hours of EGD. A separate
blinded investigator interpreted capsule findings for size of esophageal
varices (M/LV if >25% of the lumen circumference is occupied; small if
<25%, and absent if no EV detected), exact degree of circumferential occu-
pation if EV present, signs of risk, evidence of prior banding and degree of
portal hypertensive gastropathy (PHG).
Results: 20 patients underwent EC and EGD. One EC was excluded due
to rapid esophageal transit time. Sensitivity, specificity, positive predictive
value (PPV), and negative predictive value (NPV) for EC as compared to
EGD are shown in Table 1. The sensitivity of CE to identify M/LV was 22.2%.
Reduction in the threshold for M/LV to 12.5% of the luminal circumference
results in greater sensitivity, specificity, PPV, and NPV, see Table 2. CE
detected risk signs in 4/9 cases. CE correctly identified PHG in 15/15 cases.
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Four additional cases of PHG not seen on EGD were reported on CE. CE
correctly recognizes 2/5 case with prior banding, did not identify 3 cases
and was false positive in 1.
Conclusion: Our pilot study indicates that discriminating varices by the
current capsule scale is unreliable. However, lowering the grading threshold
improved the ability to discriminate size of EV on CE. EC is a good test for
the detection of PHG. The weakness of CE is in detecting small varices but
this is not of clinical significance. Future studies with larger sample size are
required to further validate our results.[figure1]
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In Hospital Mortality Rates of Patients Admitted for Esophageal
Variceal Hemorrhage over a 15 Year Period: MELD as a Predictor
Amanda D. Fehring, DO, Toan Ngyuen, MD, Kenneth D. Rothstein, MD∗.
Department Gastroenterology & Hepatology, Albert Einstein Medical
Center, Philadelphia, PA.
Purpose: To compare mortality rates amongest two cohorts of patients ad-
mitted for acute esophageal variceal hemorrhage and to evaluate predictors
of in-hospital mortality.
Methods: Retrospective chart review of patients identified by ICD-9 codes
for admission diagnosis of acute esophageal variceal hemorrhage (N = 73).
Cohorts consist of patients admitted between 1990–1997 and 1998–2005.
Data collected included demographic information, etiology of liver disease,
admission MELD, treatment modalities (medical and mechanical therapies),
and patient outcome (death, length of stay). Statistical Analysis was carried
out using Fisher’s exact test, student t-test and receiver operating character-
istic curves.
Results: While mortality between cohorts did not significantly change, 37%
for 1990–1997 vs. 29% for 1998–2005 (P = 0.758), a MELD score greater
than 15 had a sensitivity of 85% for inpatient mortality with an area under
the receiver operating characteristic curve of 0.872 (95% CI: 0.763–0.981).
On univariant analysis, mean MELD score of patients that died during ad-
mission vs. those that survived until discharge were 27 (SD 10) vs. 13 (SD
5), respectively. This difference in MELD was statistically significant with
a P value < 0.001.
Conclusion: While MELD may not always reflect true severity of liver dis-
ease in individuals with cirrhosis-related complications, this study suggests
that it maybe a good prognostic tool in individuals who present with acute
esophageal variceal hemorrhage.
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Metformin Induced Cholangiohepatitis – An Uncommon Presentation
Smitha Battula, MBBS, Erhardt Christopher, MD, Khalil Korkor, MD∗.
Gastroentrology, Gastroentrology of Canton, Canton, OH and Pathology,
Mercy Medical Center, Canton, OH.
Purpose: Metformin hydrochloride is an oral biguanide anti hyperglycemic
commonly used in the treatment of type 2 Diabetes. It improves insulin sensi-
tivity, decreases hepatic glucose production and increases glucose transport
across skeletal muscle membrane. It is not metabolized by the liver and is
excreted unchanged in the urine. The major side effects includes diarrhea,
nausea, vomiting, bloating, flatulence and lactic acidosis. Here, we report a
unique case of acute cholangiohepatitis with metformin use.
Methods: A 63 yr old male presented with fever, right upper quadrant ab-
dominal pain, nausea and vomiting for 4 days. Metformin (500 mg oral
twice daily) was added to his drug regimen four weeks before the onset of
symptoms. His other medications included ASA, glyburide and allopurinol.
Results: Amylase, lipase and hepatitis serologies were negative. AST 38
IU/L, ALT 169 IU/L, alkaline phosphatase 437 IU/L, albumin 3.0 gm/dL and
total bilirubin 4.2 mg/dL. Abdominal ultrasound showed mildly distended
gallbladder with wall thickening with CBD at 5 mm. ERCP revealed absence
of ductal dilatation or filling defects. HIDA scan showed delayed filling of
the gallbladder suggesting chronic cholecystitis. Percutanoeus liver biopsy
demonstrated portal tracts with a mixed inflammatory infiltrate, character-
ized by lymphocytes, neutrophils and abundant eosinophils. Acute inflamma-
tory cells were seen infiltrating bile ductules, with epithelial disruption and
compensatory ductular proliferation. No portal or parenchymal bile stasis
was noted. The histopathologic findings were compatible with mild subacute
cholangitis and the presence of abundant eosinophils raised the possibility
of medication associated cholangitis. Metformin was discontinued.
Conclusion: Continued elevation of alkaline phosphatase led to laparo-
scopic cholecystectomy and liver biopsy 6 weeks after the initial presen-
tation. Biopsy showed moderate chronic portal triaditis with peice meal
necorsis and stage 2 fibrosis consistent with residual medication effect. Cur-
rently his liver function tests are back to normal. This case highlights the
importance of excluding drug induced hepatitis before undergoing chole-
cystectomy.[figure1]
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Statins and Hepatitis C Therapy: A Retrospective Analysis in a
Veteran Medical Center
Andrew Simpson, MD, Kamil Obideen, MD∗, Samir Parekh, MD, Sakaria
Sonali, MD, Patel Minal, MD, Kristina Chacko, MD, Mohamad Wehbi,
MD. Medicinine/Division of Digestive Diseases, Emmory University
School of Medicine, Atlanta, GA.
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Purpose: Hepatitis C virus (HCV) may infect the hepatocytes through the
interaction with CD81 receptors. LDL receptors may serve as coreceptors
for the binding, entry, and internalization of HCV. Statins might be potential
inhibitors for Hep C entry.
Aim: To evaluate the effect of Statins on the outcome of therapy in HCV
infected patients and to assess its tolerability
Methods: We conducted retrospective electronic records review using the
Hepatitis C Registry database at the VA Medical Center from January 2000
to October 2006. Patients with HCV who had completed at least 12 weeks
of therapy with peginterferon and Ribavirin were included in the study. A
subcategory of patients who were on concomitant therapy with Statins was
emphasized.
Data collected: age, gender, ethnicity, BMI, Genotype, Pharmacy prescrip-
tion utilization of Statins, Rebetron, PEG interferon, and Ribavirin, the du-
ration of therapy, ALT level pre and during Statins therapy, HCV PCR at 12
weeks, end of therapy and 6 months after HCV therapy. all follow up notes
were reviewed as well.
Results: 125 patients who completed 12 weeks of therapy were included
in the study. 8 patients (6%) were on statins, all patients of which had an
early virological response (100%). 74 patients in the non-statin group (n
117) had an early virological response (64%). The difference was statistically
significant (P value 0.0007). five patients in the statin group and 74 in the non-
statin group completed 48 weeks of hepatitis C therapy. three patients (60%)
had a sustained virological response (SVR) in the statin group. Twenty-four
(32%) patients had an SVR in the non-statin group. There was a trend towards
significance (RR = 1.756, 95% CI: 0.45 to 6.86). None of the patients in the
statin group had an elevation of transaminases.
Conclusion: In this small sample study, the use of statins during hepatits c
therapy showed no worsening in liver enzyme. In fact, its use might improve
early viral response to therapy. The limiting factor of using statins in HCV
infected patients is the elevated Liver enzyme but no reported incidence of
any complication in our study.
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A Case of Wilsons Disease with Fulminant Liver Failure
Omer K. Masood, MD, Kaleem M. Rizvon, MD, Nausheer Khan Bitni, MD,
Paul J. Mustacchia, MD∗. Division of Gastroenterology, Nassau
University Medical Center, East Meadow, NY.
Purpose: A 22-year-old white female was admitted with one month history
of intermittent bloody diarrhea, increased in severity for four days prior to
admission. Associated symptoms included sore throat, fatigue, abdominal
bloating, fever, chills, nausea and vomiting bilious material. She also com-
plained of recent onset dark, “smoky” urine and yellow discoloration. No
history of pruritis, recent travel, blood transfusion, or easy bruising. On ex-
amination the patient had jaundice and was in slight discomfort, with a fever
of 102.5 F. She was lethargic, but arousable and oriented to person, place
and time. Abdomen was soft and non-tender; no guarding, or hepatomegaly
appreciated. No signs of chronic liver disease. Rectal examination revealed
dark brown stool. Laboratory examination indicated an elevated white count
with bandemia,, hemoglobin of 7.2 (MCV 112; RDW 14). BUN and crea-
tinine were 45 and 2.8. Liver transaminases: ALT 17, AST 193 Alk Phos
<3, Albumin 2.3 and Total bilirubin 19.3 (Direct 12.6). Coagulation pro-
file showed INR 4.2 and PTT 55. Further evaluation demonstrated Coombs
test negative hemolysis; spherocytes, nucleated RBC; left shift of WBC to
promyelocyte stage; Plts 100,000 with large forms on peripheral smear. The
patient was started on antibiotics for an initial diagnosis of infectious di-
arrhea. CT scan of the abdomen showed moderate ascites, splenomegaly,
distended gallbladder and thickening of colonic wall. No liver lesions were
noted. Based upon clinical suspicion a thorough ophthalmological evalua-
tion was performed and revealed dark brown/yellow rings in the peripheral
cornea of the deep stroma consistent with Kayser-Fleischer rings. The patient
was referred for a liver transplant, which she received shortly thereafter.
Wilsons disease is a rare autosomal recessive disorder of copper metabolism
in which excess copper accumulates in the liver, central nervous system and
other tissues. The incidence is approximately 1 in 30,000 with most patients
presenting betweeen the ages of 5 and 40. Fulminant hepatic failure usually
occurs in children or young adults not previously diagnosed with Wilsons
disease. Our case demonstrates a challenging diagnosis based upon clinical
suspicion and laboratory data consistent with fulminant hepatic failure in
this disease: Coombs-negative hemolytic anemia, coagulopathy unrespon-
sive to Vitamin K, rapidly progressive renal failure and a normal or markedly
subnormal Alkaline Phosphatase (<40 IU/L).
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Factors Associated with Low Platelet Count in Veterans with Chronic
Hepatitis C
Samir Parekh, MD, Andrew Simpson, MD, Mohamad Wehbi, MD, Aasma
Shaukat, MD, Kamil Obideen, MD∗. Digestive Diseases, Emory
University School of Medicine, Atlanta, GA.
Purpose: The purpose of this study was to examine liver histology and
virological characteristics as it relates to HCV-associated thrombocytopenia
in a veteran population.
Methods: We conducted a retrospective review of patients with chronic
HCV who had undergone liver biopsy at the Atlanta Veterans Affairs Medical
Center from Jan 1, 1995 to Jan 1, 2006. Data collected included: gender, age,
race, laboratory results (ALT, AST, platelet count, HCV genotype, viral load),
and histology based on the Scheuer histologic scoring system. We defined
low platelet count as <150 × 103/mcL. Means and categorical variables were
compared using ttest and chi square respectively. We used univaraite logistic
regression to explore the relationship platelet count and various variables.
Forward stepwise logistic regression was used to select variables for the final
model
Results: Information was available for 314 patients. 97% were male and me-
dian age was 51 years (range 30–68 years). Median aspartate transaminases
(AST) level was 54 IU/L and platelet count was 213 × 103/mcL. 16% of
patients had platelet counts <150 × 103/mcL. On liver biopsy, a majority of
the patients had grade 1 and 2 lobular and portal inflammation (33% and 47%
for lobular, 47% and 37% for portal respectively) and stage 1 and 2 fibrosis
(32% and 25% respectively). A majority of patients were genotype 1 (89%)
and 52% had viral loads >850,000 IU/mL. Steatosis was reported in 41% of
biopsies. In univariate logistic regression, low platelet count was associated
with higher grade of portal (OR 1.9; 95% CI 1.2, 2.8; P-value 0.001) and
lobular (OR 1.7; 1.2,95% CI 2.6; P-value 0.004) inflammation, higher stage
of fibrosis (OR 1.91; 95% CI 1.4, 2.4; P-value <0.001) and higher odds of
abnormal AST (>35 IU/L) (OR 2.5; 95% CI 1.03, 6.2; P-value 0.04). No
significant relationship was found between low platelet count and viral load,
genotype, or steatosis. In multivariable regression analysis, controlling for
age, gender, and grade of inflammation, low platelet cont was significantly
associated with higher stage of fibrosis. The odds of having low platelet
count for those with advanced stage of fibrosis (Stage 3–4) were nearly 5.5
times the odds of someone with early fibrosis (stage 0–2) (OR 5.5; 95% CI
2.8, 10.1; P-value <0.001).
Conclusion: Our study did not find genotype, viral load, or steatosis to
be predictive of thrombocytopenia in veterans with HCV; however, we did
demonstrate a strong association between thrombocytopenia and advanced
fibrosis.
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Acute Cholecystitis after Percutaneous Liver Biopsy in the Absence of
Hemobilia
Swati Pawa, MD, Nolan Perez, MD, Luis Mejia, MD, Elizabeth May, MD,
PhD, Rakesh Parikh, MD∗. Division of Gastroenterology, Wayne State
University School of Medicine, Detroit, MI.
Purpose: Percutaneous liver biopsy (PCNB) is the standard method for
obtaining liver tissue in the management of acute and chronic liver dis-
ease. Known complications of PCNB include hemoperitoneum, sucapsular
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hematoma, hypotension, pnuemothorax and sepsis. Acute cholecystitis as-
sociated with hemobilia is very rare and is thought to be secondary to ob-
struction of the cystic duct by clotted blood. Herein, we describe a unique
case of cholecystitis after a PCNB in the absence of hemobilia.
Case Report: A 42 year old man underwent an outpatient liver biopsy for
staging of chronic hepatitis C. The liver biopsy was uneventful and he was
discharged home 4 hours later. The patient presented to the ER that same
evening with right upper quadrant pain but was discharged after laboratory
studies demonstrated normal liver tests. He returned 48 hours later with
worsening right upper quadrant pain associated with nausea and emesis. He
was noted to have right upper quadrant tenderness and a positive Murphy’s
sign. He had a leukocyte count of 23,000/mm3, hematocrit of 39%, normal
coagulation profile and normal liver tests. Abdominal ultrasound revealed
a distended gallbladder with diffuse wall thickening and pericholecystic
fluid. There was echogenic material inside. Laparoscopic cholescystectomy
was performed the following morning. The gallbladder was distended with
moderate amount of blood around the liver and gallbladder. The cystic lymph
node was enlarged. On histological examination the gallbladder consisted
of moderate amounts of tan-brown viscous fluid and multiple diminutive
tan black calculi ranging from 0.1 – 0.3 cm in greatest dimension. The
postoperative course was uneventful and the patient was discharged home 2
days later.
Discussion: We report an exceedingly rare complication of acute cholecys-
titis secondary to PCNB. The liver biopsy in our case was performed by a
Trucut needle with one pass made. There was a very strong temporal rela-
tionship between the procedure and the onset of symptoms, which occurred
within 7 hours after the procedure. Although the symptoms and cholecystitis
could have been attributable to hemobilia, none was identified at laparoscopy
or during pathological assessment after cholecystectomy. We hypothesize
that the blood lying around the gallbladder (from the liver biopsy) incited
gallbladder wall irritation which then led to acute cholecystitis.
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Clinical and Histological Differences between Obese and Non-Obese
Cryptogenic Cirrhosis
Shivangi Khara, MD, Arun Samanta, MD∗, Kenneth M. Klein, MD,
Baburao Koneru, MD, Dorian Wilson, MD, Adrian Fisher, MD, Andrew
De La Torre, MD, Milie Debroy, MD. Medicine, Univ Med and Dent of
New Jersey, Newark, NJ; Pathology and Laboratory Medicine, Univ of Med
and Dent of New Jersey, Newark, NJ and Surgery, Univ of Med and Dent of
New Jersey, Newark, NJ.
Purpose: Metabolic syndrome of obesity and nonalcoholic fatty liver dis-
ease constitutes an important segment of patients with cryptogenic cirrhosis
(CC). However, CC is also seen in patients without obesity. The aim of our
study was to characterize the clinical, biochemical and histologic differences
between obese and non-obese patients with CC.
Methods: Thirty two consecutive patients who had liver transplant for CC
were categorized into obese (BMI ≥30 Kg/M2) and non-obese (BMI ≤25
Kg/M2) groups of 16 cases each. Clinical (Age, gender, concurrent ill-
ness, presence of diabetes mellitus) and biochemical parameters (AST, ALT,
AST/ALT ratio, alkaline phosphatase /AST ratio) and liver explant histol-
ogy were compared between the groups. The liver histology was reevaluated
by a hepatopathologist for the inflammation, lymphoid aggregate, plasma
cells, interface hepatitis, steatosis, perivenular and sinusoidal changes, glyco-
genated nuclei, Mallory hyaline, bile duct changes, hepatocyte necrosis and
fibrosis.
Results: Obese cryptogenic cirrhosis: The mean age was 56.6 ± 8.1 years,
BMI was 35.0 ± 3.6 Kg/M2, there were more females (75%), concurrent
illness was present in 50% and diabetes in 37%. Aminotransferases (AST
50.1 ± 23.6 U/L, ALT 40.0 ± 20.7 U/L) were mildly increased. On his-
tology steatohepatitis and steatosis were seen in 25% each and in 50%
no fatty change was noted. Non-obese cryptogenic cirrhosis: The patients
were younger (48.9 ± 15.0 years), BMI was 22.2 ± 1.7 Kg/M2, there
was no gender difference (female 50%), concurrent illness was present
in 43.7% and diabetes in 31%. Aminotransferases (AST 163.3 ± 166.3
U/L, ALT 110 ± 106.3 U/L) were higher and AST/ALT and alkaline phos-
phatase/AST ratios were comparable in the two groups. Steatohepatitis was
uncommon (6%), steatosis was seen in 44% and 50% did not have fatty
change.
Conclusion: Non-obese CC as compared to obese CC is characterized by
younger age at presentation, absence of gender predilection, higher serum
amino-transferases and a very low incidence of steatohepatitis. Steatosis and
higher amino-transferases in absence of obesity in some of the CC patients
may suggest toxic liver injury to be a causative factor in a subset of non-obese
CC.
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Moexipril in Patients with Non-Alcoholic Fatty Liver Disease
Marina G. Silveira, MD, Jay A. Talwalkar, MD, Keith D. Lindor, MD∗.
Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Purpose: The blockade of angiotensin II synthesis attenuates hepatic fibrosis
in different experimental models of chronic liver injury. We aimed to deter-
mine the safety and efficacy of moexipril, an angiotensin-converting enzyme
(ACE) inhibitor, on liver biochemistries in patients with non-alcoholic fatty
liver disease (NAFLD).
Methods: Four patients with biopsy proven NAFLD were enrolled. Oral
moexipril 15 mg/day was administered for 1 year to three patients.
Results: No significant changes in serum alkaline phosphatase (96 ± 32 vs.
93 ± 6 U/L, P = 0.9), total bilirubin (1.5 ± 0.9 vs. 2.1 ± 0.3 mg/dl, P =
0.7), aspartate aminotransferase (48 ± 9 vs. 44 ± 23 U/L, P = 0.4), albumin
(4.4 ± 0.3 vs. 4.2 ± 0.6 g/dl, P = 0.9) were noted after 1 year of treatment.
One of the 3 patients who received medication withdrew from the study at 6
months. No major adverse reactions were observed, but 2 out of 3 patients
complained of increased fatigue.
Conclusion: Moexipril was not clinically beneficial to patients with NAFLD.
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Effect of Diabetes Mellitus on Therapy Discontinuation Rates during
Hepatitis C Therapy
Yasemin S. Aytaman, Edmond Bouassaf, MD, Sabina Kirtich, NP, JoAnn
Comas, NP, Anna Christakos-DiTeodoro, Pharm, Gul Bahtiyar, MD, Samy
I. McFarlane, MD, Ayse Aytaman, MD, FACG∗. Gastroenterology, VA New
York Harbor HCS Brooklyn Campus, Brooklyn, NY; Gastroenterology,
SUNY Health Science Center in Brooklyn, Brooklyn, NY; Division of
Endocrinology, Diabetes and Metabolism, SUNY Health Science Center in
Brooklyn, Brooklyn, NY and Endocrinology, Woodhull Medical and Mental
Health Center, Brooklyn, NY.
Purpose: Hepatitis C is a risk factor for diabetes mellitus (DM). Previous
work from our group demonstrated a four times higher risk of DM among our
hepatitis C patients. Despite availability of effective therapy for hepatitis C,
unacceptably high therapy discontinuation rates remain to be a major barrier
to successful therapy outcomes. We evaluated the effect of DM on therapy
discontinuation rates of our patients.
Methods: A database is established to evaluate the interaction of hepatitis C
and DM. We evaluated the treatment patients in this database with emphasis
on therapy discontinuation rates.
Results: From 1999 – 2006 we had 148 patients in the database treated
with interferon based therapies. Mean age was 53.0 ± 0.5. 98% were male.
51.4% were caucasian, 24.3% were black and 22.3% were hispanic. They
included post-transplant, pre-transplant, re-treatment and tx naı¨ve patients.
65.8% were treated with pegylated interferon/ribavirin, 23.6% with rebetron,
1.9% with concensus interferon/ribavirin and 0.6% with pegylated inter-
feron monotherapy. 64 patients (43%) completed therapy. 52 (35.1%) were
discontinued for non-response. 32 (21.6%) were discontinued prematurely
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secondary to side-effects. In a logistic regression model, using a stepwise
approach, after adjusting for age, gender and race, diabetes did not effect
the rate of discontinuation among hepatitis C patients with an odds ratio of
.066–95% CI (0.28–1.6, P 0.36).
Conclusion: Diabetes Mellitus that is highly prevalent in our Hepatitis C
patient population did not have significant impact on therapy discontinuation
rates.
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Serum Adipokine Profile in Indian Men with Nonalcoholic
Steatohepatitis: Serum Adiponectin Is Paradoxically Decreased in
Lean Versus Obese
M.G. Sanal, Shiv K. Sarin, DM∗, Ajay K. Chowdhary, MD. SpecialCenter
for Molecular Medicine, New Delhi, Delhi, India and Gastroenterology,
GB Pant Hospital, New Delhi, Delhi, India.
Purpose: Asian Indians are prone to central obesity and for same degree of
weight gain are more insulin resistant compared to the West. Hence there is
a need to study adipokine profile in nonalcoholic fatty live disease (NAFLD)
and cryptogenic cirrhosis which are associated with Metabolic Syndrome.
Methods: Body mass indices, insulin resistance and serum adipokine lev-
els were studied in 56 patients; 10 with fatty liver, 30 with non-alcoholic
steatohepatitis (NASH) and 16 with cryptogenic cirrhosis. Eighteen healthy
controls were also included.
Results: The patients were markedly obese than controls (patients-mean
BMI 26.9 ± 4.5; control-22.6 ± 2.5, P < 0.0001). In NASH there was a small
but significant decrease in adiponectin level compared to the controls (NASH
5.4 mg/ml ± 3, controls 7.2 mg/ml ± 2.9, P = 0.037). Obese NAFLD patients
(BMI> = 23, N = 32) were more insulin resistant than lean (BMI<23,
N = 8) patients (HOMA-IR: over weight: mediaN = 2.8, range = 0.8–16.3
and lean- mediaN = 1.05, range = 0.51–2.75, P = 0.003). Lean NAFLD
patients had adiponectin levels lower than over weight patients (3 mg/ml ±
1 in lean and 6.7 mg/ml ± 3.8 in obese, P = 0.003 Fig. 1) All adipokines
tested were raised in cirrhosis patients compared to NAFLD and controls.
Serum resistin was increased in the patient population (3.7 ± 3 ng/ml) than
the controls (2.1 ng/ml ± 1.7 P = 0.007 T test) but the difference was
significant even when cirrhosis patients were excluded (3.4 ± 2.7 ng/ml,
P = 0.03)
Conclusion: We observed a small but significant decrease of serum
adiponectin and an increase in serum resistin and leptin in NAFLD patients
compared to controls. The plasma adiponectin levels in lean NAFLD were
lower than obese NAFLD. This paradoxical decrease of serum adiponectin
as well as low insulin resistance in lean NAFLD suggest a different new
etiology for this subset.[figure1][figure2]
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Incidence and Mortality Trends of Liver Cancer among Puerto
Ricans, US Hispanics and Non-Hispanic US Population
Carlos Romero-Marrero, MD, Ana P. Ortiz, PhD, Graciela Nogueras,
MPH, William Calo, MPH, Eduardo Hernandez, MPH, Nayda Figueroa,
MD, Esther A. Torres, MD, MACG, Erick Suarez, PhD∗. Medicine Division
of Gastroenterology, University of Puerto Rico School of Medicine, San
Juan, Puerto Rico; Biostatistics and Epidemiology, University of Puerto
Rico School of Public Health, San Juan, Puerto Rico and Puerto Rico
Cancer Center, University of Puerto Rico, San Juan, Puerto Rico.
Purpose: Hepatocellular carcinoma incidence rates vary greatly among dif-
ferent ethnic groups. Most of the information regarding the epidemiology of
liver cancer in Hispanics is based on evaluation of databases in which there
is negligible representation of island Puerto Ricans. The aim of this study
was to assess the trends in the incidence and mortality rates of liver cancer in
Puerto Ricans, United States (US) Hispanics and the US general population.
Methods: We analyzed the databases of the Puerto Rico (PR) Cancer Reg-
istry, the US SEER 11, and the PR and US Vital Statistics for all cases of
liver cancer diagnosed in the period 1992–2001. A trend analysis of the
age-standardized liver cancer incidence/mortality rates (per 100,000) was
performed using the direct method (Standard World Population 1960) from
1992–2001. Annual percent change (APC) was estimated with the Poisson
model using as predictor year of diagnosis.
Results: During the study period, Puerto Ricans and US Hispanics (US-
H) showed the highest incidence and mortality trends for liver cancer. The
incidence of liver cancer remained stable for Puerto Ricans (APC = 0.06%)
yet rapidly increased in the US general population (APC = 4.0%) and US-H
(APC = 3.73%). The incidence of liver cancer is increasing in all groups
and sexes, except among Puerto Rican females who showed a decreasing
incidence trend (APC = -1.99%). Puerto Ricans had the highest mortality
rates from liver cancer for both sexes and across all age groups, despite
exhibiting a decreasing trend during the study period (APC = -1.68). An
increasing mortality trend was evident for both US (APC = 1.08) and US-H
(APC = 1.14).
Conclusion: Both US Hispanics and Puerto Ricans are disproportionately
affected by liver cancer having a higher incidence and mortality rates, respec-
tively, in comparison to the US general population. Further studies should
explore the reasons for these ethnic disparities.
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Can Indoleamine 2,3-Dioxygenase Expression in Liver Biopsy Samples
from Hepatitis C Infected Patients Predict Response to Treatment? A
Subgroup Analysis Comparing African-American vs.
Non-African-American Patients
Iryna S. Hepburn, MD, Rassa Shahidzadeh, MD, Theodore S. Johnson,
MD, Andrew Pearson, MD, Jeffrey R. Lee, MD, David Munn, MD, Robert
R. Schade, MD, FACG∗. Sect. of Gastroenterology/Hepatology, Medical
College of Georgia, Augusta, GA; Dept. of Pediatrics, Medical College of
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Georgia, Augusta, GA; Dept. of Pathology, Veterans Affairs Medical
Center, Augusta, GA and Immunotherapy Center, Medical College of
Georgia, Augusta, GA.
Purpose: African-Americans (AA) respond poorly to hepatitis C virus
(HCV) treatment compared to the general population. Indoleamine 2,3-
dioxygenase (IDO), which is induced by interferon-alpha, has been shown
to suppress T-cell proliferation and has been associated with poor response
to HCV treatment in a prior study. We hypothesize that the poor response
seen in AA group may be related to a difference in hepatic IDO expression.
Methods: Immunohistochemical staining for IDO was performed on 107
liver biopsy specimens, obtained prior to treatment, from patients with
HCV. Tissue samples were prepared and incubated with a polyclonal rabbit
anti-human IDO antibody, and then sequentially incubated with a biotiny-
lated anti-rabbit antibody. Biopsies from HCV-negative transplant donor
candidates were used as negative controls. Tumor draining lymph nodes
with IDO+cells were used as positive controls. Both AA and non-African-
American (non-AA) groups received pegylated interferon and ribavirin for
HCV treatment for at least 48 weeks with sustained virologic response (SVR)
defined as viral load undetectable for at least 6 months after end of treatment.
P values were generated using chi-square analysis.
Results: Ethnic cohorts were classified as AA and non-AA subgroups. There
was no significant difference in co-morbidities and HCV genotype between
the two groups. Among non-AA, IDO expression in responders and non-
responders did not significantly predict response to HCV treatment (81%
and 92% respectively, P = 0.39). Among AA, IDO expression in respon-
ders was greater than non-responders, however, this did not meet statistical
significance (31% and 0% respectively, P = 0.27).
Conclusion: IDO expression was associated with HCV treatment non-
responders in a prior study, however, results were not stratified according to
race. In our study, there was a trend towards greater IDO expression among
responders in the AA group (not statistical significant). Hepatic IDO stain-
ing may serve as a predictor of HCV treatment success in AA subgroups,
however, larger studies will be needed to confirm this.
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Effects of Pentoxifylline and Weight Reduction on Liver Histology in
Patients with Non-Alcoholic Steatohepatitis (NASH)
Ajay Kumar, MD, Ashish Kumar, MD, DM, Puja Sakhuja, MD, Deepak K.
Singh, MD, Barjesh C. Sharma, MD, DM, Shiv K. Sarin, MD, DM∗.
Gastroenterology, G B Pant Hospital, New Delhi, Delhi, India and
Pathology, G B Pant Hospital, New Delhi, Delhi, India.
Purpose: We studied the effects of 6-months of pentoxifylline (TNF-α an-
tagonist) therapy on liver histology in patients with NASH.
Methods: Patients of NASH, serum ALT >1.2 × ULN for >6 mo were
enrolled. Excluded: alcohol >20 g/wk, viral/autoimmune hepatitis, PBC,
Responders (N = 8) Non-responders (N = 7)
Parameters Baseline Post-therapy P value Baseline Post-therapy P value
Brunt’s grade 2.6 ± 0.5 1.4 ± 0.5 <0.01 1.7 ± 0.7 2.0 ± 1.0 0.17
Steatosis 2.9 ± 0.4 1.2 ± 0.7 <0.01 1.7 ± 0.8 1.8 ± 0.9 0.6
Ballooning 1.2 ± 0.7 0.6 ± 0.5 0.01 1.4 ± 0.5 1.4 ± 0.8 1.0
Lobular 1.9 ± 0.4 1.1 ± 0.4 <0.01 1.4 ± 0.8 1.4 ± 0.8 1.0
inflammation
Portal 0.9 ± 0.4 0.9 ± 0.4 1.0 0.7 ± 0.5 1.0 ± 0.6 0.17
inflammation
Fibrosis 1.2 ± 0.5 1.5 ± 0.8 0.35 1.0 ± 0.8 1.3 ± 0.8 0.36
BMI 23.9 ± 3.4 21.3 ± 2.4 <0.01 24.2 ± 1.8 23.3 ± 2.2 0.2
AST 77.0 ± 25.5 34.7 ± 16.5 0.02 73.0 ± 24.4 30.9 ± 13.1 <0.01
ALT 118.7 ± 55.2 34.2 ± 8.3 <0.01 115.1 ± 46.2 53.1 ± 41.2 <0.01
HOMA 3.8 ± 1.96 1.6 ± 0.6 0.02 2.6 ± 0.7 2.0 ± 1.2 0.1
TNF-α 40.5 ± 43.6 8.2 ± 1.4 0.47 13.3 ± 8.0 16.8 ± 17.2 0.78
biliary obstruction, Wilson disease, haemochromatosis, cirrhosis, and drugs.
Patients received pentoxifylline, 400 mg tid × 6 mo with weight reduction.
Repeat liver biopsy was done after 6 mo. Brunt’s grade and fibrosis were
compared pre- and post-therapy. Histological response: at least one grade
reduction in Brunt’s grade from the baseline.
Results: 15 patients were included (age 33.1 ± 7.4 yrs, M:F 13:2). Base-
line biopsy: steatosis (grade I in 3, grade II in 4, grade III in 8), lobular
inflammation (grade 0 in 1, grade 1 in 3, grade 3 in 11), portal inflammation
(grade 0 in 3, grade 1 in 12), and fibrosis (grade 1 in 13, grade 2 in 2). Brunt
score was grade 1 in 3, grade 2 in 6 and grade 3 in 6 patients. Post-therapy
Brunt’s grade decreased by at least one grade (responder) in 8 (53%). Portal
inflammation and fibrosis did not decrease even in responders.
Conclusion: Pentoxifylline improves or stabilizes the markers of acute injury
in liver histology like steatosis, and lobular inflammation. Longer periods
of therapy and/or higher dosages may be required for reversal of fibrosis in
these patients.
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The Value of Serum Aminotransferases after Cardio-Pulmonary
Resuscitation
Kavitha Kumbum, MD, David Widjaja, MD, Kalyan C. Kanneganti, MD,
Pradeep R. Atla, MD, Prospere Remy, MD, Sridhar S. Chilimuri, MD∗.
Gastroenterology/Medicine, Bronx Lebanon Hospital Center, Bronx, NY.
Purpose: Liver function tests are commonly done after cardio-pulmonary
resuscitation (CPR). However the clinical value of these measurements in
predicting mortality is unclear and never studied before.
Methods: A retrospective review of medical records of patients ≥18 years
who underwent CPR or were evaluated for clinical instability with antici-
pated cardio-pulmonary arrest at our hospital over a period of one year was
performed. We obtained baseline and post event serum aminotransferases.
Exclusion criteria were unavailability of baseline or post event serum amino-
transferases or if patients did not survive initial resuscitation. Patients were
divided into 2 groups: discharged alive (group A) and died during hospital-
ization (group B).
Results: Sixty patients fulfilled study criteria. The median age was 66 years
and there were 31 men and 29 women. The predominant primary diagnosis
was sepsis (72%, 43/60). Among 23 patients with underlying liver disease,
11 had chronic hepatitis, 2 had fatty liver and 10 had other liver pathology.
Thirty percent (18/60) had cardio-pulmonary arrest and 70% (42/60) had
clinical instability with anticipated arrest. Forty- eight patients (80%, 48/60)
had baseline aminotransferases ≤ upper limit of normal (ULN; 38 IU/mL)
and 3 (4%, 3/60) had baseline aminotransferases more than twice ULN.
There were 34 patients in Group A and 26 patients in Group B. In Group A
mean change in AST was 9 IU/mL and mean change in ALT was 12 IU/mL.
In Group B mean change in AST was 743 IU/mL and mean change in ALT
was 359 IU/mL. In further calculation, six patients with extreme changes in
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aminotranferases (all belonged to group B) were excluded. Among the 20
patients included in Group B, mean change in AST was 42 and mean change
in ALT was 23. Absolute change in AST was significantly higher in Group
B than group A (P = 0.019). Though there was a higher absolute change in
ALT in Group B it did not reach statistical significance (P = 0.39). Among
patients who developed cardiac arrest, HIV patients were 4 times more likely
and chronic hepatitis patients were 8 times more likely to develop ischemic
hepatitis.
Conclusion: As per our review, an increase in AST level after a cardio-
pulmonary resuscitation is associated with higher in-hospital mortality.
These results need to be verified in a larger group of patients. Our study
is the first to report the association between change in serum aminotrans-
ferases and in-hospital mortality after CPR.
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Systemic and Pulmonary Hemodynamics in Patients with
Extra-Hepatic Portal Vein Obstruction (EHPVO)
Ashish Kumar, MD, DM, Sanjeev K. Jha, MD, Barjesh C. Sharma, MD,
DM, Shiv K. Sarin, MD, DM∗. Gastroenterology, G B Pant Hospital, New
Delhi, Delhi, India.
Purpose: Extra-hepatic portal vein obstruction (EHPVO) is a common cause
of portal hypertension and variceal bleeding. Few studies have been done
on hemodynamic alterations in patients with non-cirrhotic portal hyperten-
sion especially EHPVO in contrast to many reports on hemodynamics in
cirrhotics. We evaluated alterations of systemic and pulmonary vascular
system in patients with EHPVO and compared them with patients with com-
pensated cirrhosis. The rationale for this investigation was to study the role
of portal hypertension per se on systemic and pulmonary hemodynamics
in EHPVO as compared to the hemodynamic changes produced by hepatic
dysfunction plus portal hypertension in cirrhotics.
Methods: Consecutive patients of EHPVO, ≥15 years of age were included,
Controls were consecutive patients with compensated cirrhosis and history
of variceal bleed, matched for variceal status (to ensure that they had same
degree of portal hypertension) and body surface area, attending our depart-
ment during the same period. The hemodynamic studies were HVPG, right
atrial pressure (RAP), pulmonary arterial pressure (PAP), pulmonary cap-
illary wedge pressure (PCWP) and mean arterial pressure (MAP). Cardiac
output (CO), systemic vascular resistance and pulmonary vascular resistance
were calculated.
Results: The baseline parameters in the two groups were comparable. Both
EHPVO patients and cirrhotics had similar values in all the measured hemo-
dynamic parameters. The mean cardiac output in EHPVO was 6.5 (±2.6)
L/min while it was 7.9 (±3.2) L/min in cirrhosis (P = 0.212). The sys-
temic vascular resistance in EHPVO was 1242 (±494) dyn.s.cm−5, which
was similar to that in cirrhotics (1018 [± 355], P = 0.167). Similarly the
values of pulmonary vascular resistance were comparable in the two groups
(68 [± 60] vs. 71 [± 70], P = 0.905). A subgroup analysis was done of 8
patients of EHPVO and 8 age matched compensated cirrhotics which also
revealed similar cardiac index, cardiac output, systemic vascular resistance
index, systemic vascular resistance, pulmonary vascular resistance index,
and pulmonary vascular resistance in the two groups.
Conclusion: EHPVO has features of hyperdynamic circulation, ie increased
cardiac output, decreased systemic and pulmonary vascular resistance. These
changes are similar to that seen in patients with cirrhosis. This suggests a
predominant role of increased resistance and thus increased porto-systemic
collateral circulation per se rather than hepatocellular injury in the genesis
of these hemodynamic alterations.
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MyD88-Dependent Bone Marrow-Derived Cells Mediate Sensitization
to Lipopolysaccharide-Induced Acute Liver Injury
Arumugam Velayudham, MD, Istvan Hritz, MD, Angela Dolganiuc, MD,
Pranoti Mandrekar, PhD, Evelyn Kurt-Jones, MD, Gyongyi Szabo, MD∗.
Department of Medicine, Division of Gastroenterology, University of
Massachusetts Medical School, Worcester, MA.
Purpose: Toll-like receptors (TLRs) expressed on both immune cells and
hepatocytes in the liver recognize microbial danger signals and regulate
immune responses. TLR9 and TLR2 play a role in Propionibacterium acnes
(P. acnes)-induced sensitization to lipopolysaccharide (LPS)-triggered acute
liver failure (ALF). Both TLR9 and 2 are dependent on the intracellular
adaptor, Myeloid Differentiation primary response gene 88 (MyD88).
Aim: To determine the differential contribution of immune and parenchymal
liver cells in TLR9 + 2-mediated sensitization to LPS-induced ALF and
assess MyD88 utilization.
Methods: Chimeras were generated in wild type (WT) and MyD88-
deficient mice with WT bone marrow (BM) (referred to as WT/WT and
MyD88−/−/WT, respectively), or in WT mice with MyD88-deficient BM
(WT/MyD88−/−). Mice of WT, MyD88-deficient and the above chimeric
genetic background were primed with TLR9 [2.5µg/g body weight (BW)
intraperitoneal injection (i.p.)] plus TLR2 (LTA 5µg/g BW i.p.) ligands,
heat-killed P. acnes (positive control; 1 mg i.p.) or saline (negative control)
followed 3–7 days later by an LPS challenge (0.5µg/g BW i.p.).
Results: Selective priming with TLR9 + 2 ligands or with P. acnes resulted in
liver granulomas and significant elevations in serum ALT and LPS-induced
serum cytokine levels, namely tumor necrosis factor alpha (TNFα), inter-
leukin 6 (IL-6), IL-12, and interferon gamma (IFNγ ), in WT, WT/WT, and
in MyD88−/−/WT mice compared to LPS stimulation alone without prior
priming. In contrast, MyD88-deficient or WT mice with MyD88-deficient
BM-derived cells (WT/MyD88−/−) were protected from TLR9 + 2 ligand-
or P. acnes-induced granulomas, increase in ALT or sensitization to LPS-
induced elevation of TNFα or IFNγ ; low levels of IL-12 and IL-6 were
induced by LPS. Thus, in the MyD88-deficient and WT/MyD88−/− mice,
priming with TLR9 + 2 ligands or P. acnes did not induce any sensitization
to LPS-mediated ALF.
Conclusion: Bone marrow-derived immune cells play a critical role in TLR-
mediated sensitization and induction of ALF. Thus, MyD88-mediated path-
ways represent a potential target for therapeutic interventions in ALF.
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Long Term Sustained Virological Response among Hispanic Veterans
Successfully Treated for Hepatitis C Virus
Paul J. Nieves, MD, Joel De Jesus, MD, Federico Rodriguez-Perez, MD,
Doris H. Toro, MD∗. Gastroenterology, VA Caribbean Healthcare System,
San Juan, Puerto Rico.
Purpose: Few studies have documented the long term durability of sustained
virological response (SVR) after chronic hepatitis C virus (HCV) treatment
and the optimal follow up for these patients is still not clear. Current studies
have documented relapse rates between 0–5%, but none of these were aimed
at an Hispanic population. Our goal was to assess the long term virological
and biochemical outcome in Hispanic veterans who have documented SVR
after interferon-based therapy.
Methods: Patients with documented SVR after receiving treatment with
standard interferon (IFN) or pegylated interferon (PEG) based regimens,
between 1990 and 2005 were invited to participate. Study consisted of a one
time visit where a questionnaire was administered to evaluate for recent risk
factors for HCV re-infection and blood samples were drawn for AST, ALT
and viral load. Statistical analysis was done using Pearson Chi-Square using
SPSS software.
Results: The study group consisted of 63 patients, 62 males and 1 female
with a mean age of 54.1 years (range 37–70). The average follow up time
after end of treatment was 36.24 ± 13.13 months (range 15–77). 35 (55.6%)
patients had genotype 1, 17 (27.0%) genotype 2, 2 (3.2%) genotype 3 and
1 (1.6%) genotype 4. In 8 (12.7%) patients the genotype was not available.
There was no statistical difference in long term SVR between genotypes.
31(49.2%) patients received IFN and ribavarin, 28(44.4%) PEG and rib-
avarin and 4(6.3%) IFN monotherapy. There was no difference in long term
SVR among these 3 groups. Elevation of AST was seen in only 5 (7.9%)
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patients. ALT at the time of analysis was normal in all. None [0/58 (0%)] of
the patients who presented with normal enzymes had detectable viral load,
whereas 20% (1/5) of those with altered liver function tests had evidence of
viremia (P < 0.001). Overall, only 1(1.6%) patient of our study group had
evidence of virological relapse, which was documented 30 months after the
end of therapy. No risk factors for re-infection were identified by the study
questionnaire.
Conclusion: This study demonstrates that in our Hispanic patients there is
a low relapse rate after SVR is achieved, regardless of treatment or HCV
genotype. The durability of the SVR in our population is similar to that
reported for other ethnic groups. This study supports the evidence that routine
follow up viral loads after SVR has been documented are of low yield, and
probably indicated only in patients with altered liver function tests.
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Large Volume Paracentesis Can Be Performed Safely by a Nurse
Practitioner and Can Reduce Physician Work-Load in a Busy GI
Practice
Kandarp Patel, DO, Erin Tharalson, NP, Tony Merill, Nooman Gilani,
MD, FACG∗. Department of Gastroenterology, Carl T. Hayden VAMC,
Phoenix, AZ and Department of Medicine, Good Samaritan Regional
Medical Center, Phoenix, AZ.
Purpose: Due to time constraints, fewer physicians are performing LVP
resulting in a longer waiting time and more ER and hospital admissions. At
our institution, after initial supervision, a certified nurse practitioner (NP) has
independently performed LVP in a dedicated cirrhosis clinic. The purpose
of our study was to evaluate the feasibility and safety of LVP performed by
a NP.
Methods: Retrospective review of patients records undergoing LVP between
Jan 2003 and May 2007. Baseline information included age, gender, race,
etiology of cirrhosis, child’s score, and biochemical profile obtained clos-
est to LVP. Information on the practitioner performing LVP (physician or
NP), number of attempts, and volume of fluid removed were recorded. Com-
plications including circulatory dysfunction, bleeding, local leakage of as-
citic fluid, infection, perforation, and death were compared between the two
groups.
Results: Baseline characteristics of patients undergoing LVP were similar
in two groups as shown in Table 1.
Baseline Characteristics of Patients Undergoing LVP
Nurse Practitioner Physician
Number of patients 41 43
Age (yr, range) 66(44–82) 60(44–81)
Gender (M/F) 41/0 43/0
Etiology of liver disease
Hepatitis C 4 (10%) 4 (9%)
Alcohol 19 (46%) 22 (51%)
Hepatitis C and alcohol 15 (37%) 12 (28%)
Hepatitis B 2 (5%) 1 (2.5%)
Cryptogenic 0 3 (7%)
Hemochromatosis 1 (2%) 1 (2.5%)
Childs Pugh Class
B 5 (12%) 6 (14%)
C 36 (88%) 37 (86%)
In terms of complications, there was no statistical difference whether LVP
was performed by a physician or a NP as shown below.
Conclusion: Our study shows no difference between physician and NP per-
formance of LVP and complication rates. We found that LVP perormed
by a NP is feasible and has acceptable rate of complications. The cost-
effectiveness of this model needs to be evaluated.
LVP Results and Complications
Nurse Practicioner Physician
Number of paracentesis 245 244
Volume of ascites removed 7796 7004
Number of Needle Attempts 1.06 1.14
Complications (NS) 15(6.1%) 15 (6%)
Post Paracentesis Circulatory 6 (4%) 3 (1.2%)
Dysfunction (NS)
Leakage at site (NS) 4 (1.6%) 4 (1.6%)
Bleeding (NS) 3 (1.2%) 5 (2%)
Infection (NS) 2 (0.8%) 3 (1.2%)
Death 0 0
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Anticoagulation Therapy Using with Danaparoid Sodium for Portal
Venous Thrombosis
Ryushi Shudo, MD∗, Yasuyuki Yazaki, MD, Mitsunori Honda, MD, Kenji
Sugawara, MD, Shuichi Maeda, MD, Haruyasu Yoshizaki, MD, Shigeto
Muranaka, MD, Akihiro Imada, MD. Gastroenterology, Kurosawa
Hospital, Obihiro, Hokkaido, Japan and Gastroenterology, Kobayashi
Hospital, Kitami, Hokkaido, Japan.
Purpose: It is reported that portal venous thrombosis is caused concomi-
tantly with a variety of diseases. However, the adequate treatment for portal
venous thrombosis has yet to be established. In this study, we examined the
effect of anticoagulation therapy using with danaparoid sodium for portal
venous thrombosis.
Methods: Portal venous thrombosis has been confirmed in 22 out of 641
cases of liver cirrhosis in our hospital since 1995. Danaparoid sodium is a
low molecular weight heparinoid whose major component is heparan sul-
fate. Danaparoid sodium enhances the effect of antithrombin that inhibits
coagulation factor. Compared to heparin and low molecular weight heparin,
danaparoid sodium has a higher selective anti-Xa factor activity with lower
risks of hemorrhage. Danaparoid sodium was administered to seven patients
with portal venous thrombosis who were considered to have developed new
thrombosis. One ampule (1250 anti Xa factor units) of danaparoid sodium
was slowly injected intravenously every 12 hours (twice a day). After admin-
istration of danaparoid sodium, follow-ups by abdominal ultrasonography
and CT were performed every two weeks. We studied the effects of dana-
paroid sodium by examining clinical findings, laboratory data, and imaging
findings.
Results: In all seven patients who were administered danaparoid sodium,
patients were safely treated without any adverse effects and complications.
Thrombosis in five out of seven patients disappeared within four weeks.
However, recurrence of thrombosis was found after discontinuation of ad-
ministration of danaparoid sodium in three out of five cases. In order to
prevent recurrence, maintenance therapy by warfarin and aspirin was imple-
mented after discontinuation of danaparoid sodium for some patients. How-
ever, it was not effective. When danaparoid sodium was re-administered to
the recurrence cases, thrombosis disappeared within four weeks in all three
recurrent cases. No adverse effect was found when danaparoid sodium was
re-administered.
Conclusion: It was suggested that danaparoid sodium might become an
effective drug for treatment of portal venous thrombosis, since it was ef-
fective easily administered, and unlikely to cause adverse effects such as
hemorrhage. We intend to examine indications, administration method, and
establishment of maintenance therapy by investigating more cases.
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Efficacy of Recombinant Hepatitis B Vaccine (rHBV) Alone in
Preventing Perinatal Transmission of Hepatitis B Is Similar to
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Combination of rHBV Plus Hepatitis B Immunoglobulin (HBIG): A
Randomized Controlled Trial
Chandana Pande, MBBS, Ashish Kumar, MD, DM, Sharda Patra, MS,
Poppy Hazarika, MBBS, DNB, Shiv K. Sarin, MD, DM∗. Gastroenterology,
G B Pant Hospital, New Delhi, Delhi, India and Obstetrics and
Gynecology, Lady Hardinge Medical College, New Delhi, Delhi, India.
Purpose: HBIG is given along with rHBV to neonates born to HBsAg-
positive mothers to prevent perinatal transmission of Hepatitis B (HBV).
However HBIG is costly and not widely available. We compared the pro-
tective efficacy of combination of HBIG plus rHBV versus rHBV alone for
prevention of perinatal transmission of HBV.
Methods: Neonates delivered of consecutive HBsAg positive mothers re-
ceived either HBIG (0.5 ml) plus rHBV (Group-A) or rHBV alone (Group-
B). rHBV vaccination schedule was 0, 6, 10, and 14 weeks of age in both the
groups and anti-HBs titers were determined at weeks 6 and 18. Development
of anti-HBs >10 IU/ml at any time was considered protective. HBsAg and
HBV DNA were also determined at 18 wks.
Results: 79 HBsAg positive full-term mothers were included (17 [22%]
HBeAg positive, 50 [63%] with serum HBV-DNA >5 pg/ml). 40 neonates
were randomized to Group-A and 39 to Group-B. At 6 wks, protective anti-
HBs titers developed more in Group-A than Group-B (21/28 [75%] vs 7/25
[28%], P = 0.001). However, by 18 wks, protective anti-HBs titers were
similar in both the groups (30/31 [97%] vs 26/29 [90%]; P =0.35). Protection
could not be determined in 19/79 infants (3 died, 16 follow-up awaited). At 18
wks 4/53 (8%) had positive HBsAg and HBV-DNA suggestive of intrauterine
transmission. Protection was similar in both groups regardless of mothers’
HBeAg status and maternal HBV-DNA level.
Conclusion: rHBV alone and rHBV plus HBIG give similar protection
against hepatitis B by 18 wks of age, irrespective of maternal HBeAg status
or HBV-DNA positivity. At 6 wks, combination of rHBV plus HBIG offers
better protection than rHBV alone.
Parameter Baseline 6 Weeks 18 Weeks
Protective (>10 IU/ml) Anti-HBs
Group A – 21/28 (75%) 30/31 (97%)
Group B – 7/25 (28%) (P = 0.001) 26/29 (90%) (P = NS)
HBsAg
Group A 18/39 (46%) 0/27 (0%) 1/26 (4%)
Group B 17/38 (45%) 0/26 (0%) (P = NS) 3/27 (11%) (P = NS)
Detectable HBV DNA
Group A 19/32 (59%) 10/27 (37%) 16/26 (62%)
Group B 21/30 (70%) 12/26 (46%) (P = NS) 11/27 (41%) (P = NS)
HBeAg
Group A 4/38 (10%) – 1/25 (4%)
Group B 2/30 (7%) – 2/25 (8%) (P = NS)
Any marker of HBV present (HBsAg, HBeAg, HBV DNA)
Group A 25/39 (64%) 10/27 (37%) 17/25 (68%)
Group B 27/38 (71%) 12/26 (46%) (P = NS) 11/25 (44%) (P = NS)
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Treatment Outcomes of Transcatheter Arterial Chemoinfusion (TACI)
in Patients with Unresectable Hepatocellular Carcinoma (HCC) Prior
to Orthotropic Liver Transplantation
Whitney de Luna∗, Bo Yoon Choi, MD, Aijaz Ahmed, MD, Daniel Sze, MD,
Emmet B. Keefe, MD, Mindie H. Nguyen, MD. Division of
Gastroenterology and Hepatology, Stanford University, Palo Alto, CA.
Purpose: Transcatheter arterial chemoembolization (TACE) is a common
therapy for unresectable HCC. While both TACE and TACI are generally
well tolerated by patients with compensated liver disease, those with poor
hepatic tend to have higher rates of complications. Compared to TACE, TACI
without embolization may have similar efficacy with fewer side effects and
may allow us to include patients with less hepatic reserve. Our purpose is
to examine outcome of TACI in HCC patients awaiting orthotropic liver
transplantation (OLT) and its efficacy as a bridge towards transplantation.
Methods: We performed a retrospective study of 160 TACI cases in 82 HCC
patients between 4/98–3/07 at single U.S medical center. We examined 30
and 90 day- morbidity following TACI. We also measured overall patient
mortality while waiting on transplantation list.
Results: Mean age was 55 ± 7, 84% were male, 44% were Asian and
41% were white. Most had cirrhosis (88.6%), and either chronic hepatitis
C (62.0%) or B (32.9%). TNM staging of I, II, III and IV were 25%, 57%,
13% and 5%, respectively. Mean MELD score was 10.1 ± 4.1 and mean
CTP score was 6.5 ± 1.7. Number of patients with Child A, B, C was 45,
25, 7, respectively. 40 patients underwent OLT. The average waiting period
to OLT is 6 months. Among 42 patients on waiting list, 7 patients died. The
cause of death for the seven patients include multiorgan failure, metastasis,
recurrent hepatitis C and infection. Only one patient died in 90 days follow-
ing TACI and the other 6 patients died in the one or two years following
TACI. Among the remaining 35 patients, 23 patients are alive and remained
on transplantation list and 12 patients are lost for follow up. Only 7 patients
were hospitalized for >24 hours (6.25% = 10/160 cases) The cause of hos-
pitalization for >24 hours include nausea, vomiting, fever, variceal bleeding
and encephalopathy. One patient (0.63% = 1/160 cases) had worsening of
liver function at the same day following first TACI procedure.
Conclusion: TACI is an effective and safe treatment for unresectable HCC
prior to OLT. Most of our patients required less than 24 hours of hospital-
ization, while patients undergoing TACE generally require longer hospital-
ization. Rate of worsening of liver function following was only 0.63%. Rate
of mortality related to TACI was 1.43% (1/70). TACI may be used as an
effective bridge towards transplantation.
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Factors Associated with Treatment Failure in Patients with Genotype 3
Hepatitis C Virus Infection
Xinyu Zhao, MD, Gulam M. Khan, MD, Tinghui Hsieh, MD, Kumaravel
Perumalsamy, MD, Michael Bernstein, MD, Kadiwarel Iswara, MD, Scott
Tenner, MD, Xiaoli Ma, MD, Jianjun Li, MD∗. Gastroenterology,
Maimonides Medical Center, Brooklyn, NY and Gastroenterology and
Hepatology, Temple University, Philadelphia, PA.
Purpose: Patients with hepatitis C virus (HCV) genotype 3 are believed
to have better response to therapy and only require 24-week therapy. How-
ever recent data showed there is increasing non-response rate up to 20% in
these patients. Little is known about the factors associated with their therapy
failure.
Methods: We conducted retrospective chart review on 34 pts with HCV
genotype 3 infection who were treated with Peg-interferon and ribavirin from
2005 to 2006. Patients were excluded if they were not naive to interferon-
based therapy, were non-compliant, or lost to follow up. Data were collected
on pt demographics (age, sex, and body weight), comorbidities (DM), base-
line HCV RNA levels and baseline ALT levels. HCV RNA and ALT levels
were repeateded at 12 wks and 24 wks of treatment. All pts had follow-up in 6
months post treatment completion to confirm sustained virological response
(SVR). Univariate and multivariate regression analyses were performed to
identify factors associated with treatment response.
Results: Among the 34 patients in our study, 16 (47%) were female. The
mean age was 42.8 ± 10.5 years old; the mean body weight was 80.7 ± 18.3
kg; the mean baseline HCV RNA level was 5.5 ± 0.8 log IU/mL; the mean
baseline ALT was 104.6 ± 79.8 IU/dL. Eighteen pts achieved SVR, and 16
patients failed to respond to therapy. In a univariate analysis, age was found
negatively associated with treatment response (odds ratio [OR] 0.80; 95%
CI 0.70–0.92; P = 0.002), while sex, body weight, baseline ALT levels, and
baseline HCV RNA levels did not have significant association with SVR. In a
multivariate analysis adjusting for sex, body weight and baseline ALT levels,
age remained negatively associated with treatment response (OR 0.66; 95%
CI 0.48–0.92; P = 0.01).
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Conclusion: Therapy response to interferon-based regimen in pts with HCV
genotype 3 infection is negatively affected by increasing age, suggesting
that elderly pts (>50 years old) with genotype 3 infection may need longer
duration of therapy. Further large-scaled studies are needed to confirm these
findings and evaluate potential factors associated with treatment response in
this patient group.
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Improvement of Metabolic Syndrome (MS) in Patients with
Non-Alcoholic Fatty Liver Disease (NAFLD) after Bariatric Surgery
Chunhong Bai, MS, Clare Nugent, MBChB, Michael Garone, Jr., Priya
Gopalakrishnan, Caitlin Quigley, Zarah Younoszai, Mariam Afendy, Arian
Afendy, Rochelle S. Collantes, MPH, MD, Manirath Srishord, RN, BSN,
Hazem Elariny, MD, PhD, Zobair M. Younossi, MD, MPH∗. Center for
Liver Diseases, Inova Fairfax Hospital, Falls Church, VA.
Purpose: Non-alcoholic fatty liver disease (NAFLD) and metabolic syn-
drome (MS) are commonly found in morbidly obese patients undergoing
bariatric surgery.
This study aims to assess the impact of weight loss surgery on the clinical
outcomes of morbidly obese patients with NAFLD.
Methods: 286 morbidly obese patients with biopsy-proven NAFLD who
underwent bariatric surgery were included. Clinical, demographic and his-
tologic data were available at the time of surgery and for a follow-up period
after surgery. MS was defined according to ATP III (The Third Report of
the National Cholesterol Education Program Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults).
Results: Clinical, demographic and laboratory data for the entire cohort are
as follows: age 44.0 ± 11.5, female 78%, BMI 48.7 ± 9.4, waist circumfer-
ence 139 ± 20 cm, AST 23.9 ± 14.9, ALT 30.0 ± 20.1, diabetes mellitus
(DM) 30.1% and MS 39.2%. Patients underwent restrictive, malabsorptive
or combination surgical procedures. Of the entire cohort, 27.3% underwent
malabsorptive surgery, 55.9% underwent restrictive surgery and 16.8% un-
derwent combination restrictive-malabsorptive surgery. Mean weight loss
after restrictive surgery was 33.7 ± 20.1 kg (follow up period 298 ± 271
days). On the other hand, the mean weight loss after malabsorptive surgery
was 39.4 ± 22.9 kg (follow-up period 306 ± 290 days) and after combination
surgery, the mean weight loss was 28.3 ± 14.1 kg (follow up period 281 ±
239 days). The amount of weight loss post-surgery was not significantly dif-
ferent among the three bariatric surgery procedures (P = 0.352). Regardless
of the type of bariatric surgery, significant improvements were noted in DM
(P-values from <0.0001 to 0.0005), MS (P-values from <0.0001 to 0.01),
waist circumference (P-values < 0.0001), BMI (P-values < 0.0001), fasting
serum triglycerides (P-value <0.0001 to 0.001), and fasting serum glucose
(P < 0.0001, except for the combination surgery). Additionally, a significant
improvement in ALT/AST ratio (P = 0.0002) was noted only in those who
underwent restrictive surgery.
Conclusion: Weight loss after bariatric surgery is associated with a sig-
nificant improvement in MS and other metabolic factors associated with
NAFLD.
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Association of Nonalcoholic Fatty Liver Disease with Metabolic
Syndrome in Indian Population
M.G. Sanal, Ajay K. Chowdhary, MD, Shiv K. Sarin, DM∗. Special Center
for Molecular Medicine, New Delhi, Delhi, India and Gastroenterology,
GB Pant Hospital, Delhi, India.
Purpose: Association between non-alcoholic fatty liver disease (NAFLD)
and metabolic syndrome varies among populations. There is a need to eval-
uate this in the Indian subcontinent specially using modified ATP III criteria
with waist circumference lowered to 90 and 80 cm in men and women re-
spectively.
Methods: 76 asymptomatic patients with fatty liver persistenly for an year
or more on US abdomen, with or with out abnormal LFT and 100 age sex
matched healthy controls were studied. The anthropometric measurements,
metabolic parameters, LFTs and liver histology were analyzed in all patients.
Results: 60 men, mean age 40.05 ± 11.4 years, range 18–66. 63 had NASH
and 13 had cirrhosis. 49 (64.5%) patients had raised ALT while 35.5% of
the total patients and 25.4% of the biopsy proven NASH patients had normal
ALT levels. 21% of the patients compared to 8% controls (P < 0.01) had
associated MS as per standard and 42.1% and 12% when the revised ATP-III
criteria used. ROC curve analysis showed waist circumference had the best
power of all ATP-III components in discriminating a patient from control.
35% of nondiabetic patients were insulin resistant with HOMA-IR cutoff
set at 3 In patients compared to controls, the mean BMI (25.2 vs.22.7, P <
0.01) and waist circumferences (92.9 vs.80.8 cm. P < 0.01) were higher. 79%
of the patients and 44% of the controls were over weight. At presentation
Stage 1 fibrosis was seen in 30 (39.5%), stage 2 in 10 (13.2%), stage 3 in 6
(7.9%) and stage 4 in 13 (17.1%) patients. Fibrosis score showed a positive
correlation between FBS (r = 0.25, P = 0.029) and negative correlation
between HDL (r = −0.33, P = 0.004). No significant relation between the
number of positive criteria as per ATP-III and the degree of fibrosis (r =
0.06, P = 0.61) was found.
Conclusion: ALT values could be deceptive in a significant proportion of
Indian NAFLD. Significant proportion are asymptomatic and present at late
stages. While insulin resistance and obesity are common, waist circum-
ference is the most dominant determinant of NAFLD. The association of
NAFLD with MS is not strong enough. This study also shows that in a propor-
tion of patients, NAFLD develops in the absence of evidence of MS.[figure1]
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Sustained Virological Response to Interferon-Based Antiviral Therapy
by Viral Genotype in Recurrent Hepatitis C Patients Following Liver
Transplantation
Anastacia Waechter, MD, Jason Williams, MD, Jason Lee, MPH, Lynn
Shapiro, MD, Maximilian Lee, MD, Ahmad Kamal, MD, MSc, Emmet B.
Keeffe, MD, Aijaz Ahmed, MD∗. Division of Gastroenterology and
Hepatology, Liver Transplant Program, Stanford University School of
Medicine, Stanford, CA; Center for Primary Care and Outcomes Research,
Stanford University School of Medicine, Stanford, CA and Division of
Gastroenterology, Santa Clara Valley Medical Center, San Jose, CA.
Purpose: We conducted a retrospective review of sustained virological re-
sponse (SVR) rates to interferon-based antiviral therapy by viral genotype
at our institution in posttransplant patients with recurrent hepatitis C virus
(HCV) infection.
Abstracts S241
Methods: We identified 224 patients who underwent liver transplantation
at our institution for end-stage liver disease for chronic hepatitis C between
February 1995 and June 2007. Interferon-based antiviral therapy was insti-
tuted in 59 out of 224 with histological evidence posttransplant recurrent
HCV. These patients were treated with pegylated interferon and ribavirin.
Currently, 4 out of 59 patients are undergoing antiviral therapy and were ex-
cluded from our analysis. Data for HCV genotype and SVR were available
for 41 (75%) patients.
Results: SVR was achieved in 16 (39%) patients, and SVR ranged from 0
to 62.5% by genotype. 9 patients (56%) had genotype 1, 14 patients (87%)
were women, and 2 (13%) had diabetes. Average BMI was 29.3 and pre-
treatment viral load was 4.9 × 106 IU/ml. The odds ratio by genotype 1,
female gender, and diabetes was 0.41, 0.71, and 2.72, respectively.
Conclusion: Patients with genotype 1 and diabetes were less likely to achieve
SVR, whereas female patients more likely to achieve SVR.
SVR By Viral Genotype
Genotype Number of Patients SVR No SVR
1 28 9 (32%) 19 (68%)
2 4 2 (50%) 2 (50%)
3 8 5 (62.5%) 3 (37.5%)
4 1 0 (0%) 1 (100%)
Patient Demographics By SVR
SVR No SVR
Number Of Patients 16 25
Genotype 1 (%) 56% 76%
Female (%) 87% 72%
BMI (kg/m2) 29.3 26.4
Diabetes (%) 13% 17%
Pre-treatment Viral Load (IU/ml) 4.9 × 106 3.5 × 106
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Single Dose of Infliximab Is Safe and Effective in Severe Alcoholic
Hepatitis: An Open Label Study
Praveen Sharma, MD, DM, Ashish Kumar, MD, DM, Ajay Kumar, MD,
Hitendra Garg, MD, Barjesh C. Sharma, MD, DM, Shiv K. Sarin, MD,
DM∗. Gastroenterology, G B Pant Hospital, New Delhi, Delhi, India.
Purpose: Severe alcoholic hepatitis (AH) is associated with high mortality.
Tumor necrosis factor-α (TNF-α) contributes to the progression of AH and
TNF-α antagonists like infliximab may help in ameliorating the severity
and complications of AH. There is contradictory data about the efficacy of
infliximab in AH. We evaluated the efficacy of infliximab in improving the
severity and one month mortality in patients with severe AH.
Methods: Consecutive patients with severe AH (Maddrey’s score >32) with
or without hepatic encephalopathy (HE) were included. Patients with serum
creatinine >1.5 mg/dl, severe cardiovascular or cerebrovascular disease, sep-
ticemia, active GI bleed, tuberculosis, malignancy, corticosteroids therapy,
HBV, HCV or HIV positive were excluded. Infliximab was given in a dose
of 5 mg/kg IV at day 0. Conservative therapy including, plasma, albumin,
antibiotics and management of encephalopathy were continued. Maddrey’s
score, peripheral leucocyte count, serum TNF-α levels, C-reactive protein
(CRP) and MELD score were measured at baseline and at day 30. All patients
abstained from alcohol during the study period.
Results: Nineteen patients (mean age 38.0 ± 7.0 yr, all males) fulfilled
the selection criteria. Five (26%) patients had HE (grade 1–2), 17 (89%)
had esophageal varices and 4 (19%) had baseline DF>90. Infliximab was
well tolerated by all the patients. At day 30, compared to baseline, there
was significant improvement in median Maddrey’s score (66 [range 35–140]
vs. 38.4 [range 11.5–182]; P = 0.003), median peripheral leucocyte count
(6792 [range 5500–10,000] vs. 3000 [range 2090–6000] cells/cumm; P =
0.001), median serum TNF-α levels (45 [range 11.2–19880] vs. 20.5 [4–
8600] pg/ml; P = 0.001), median serum CRP (34 [range 14–67] vs. 12
[range 1–82]; P = 0.03), and median MELD score (25 [range 17–36] vs. 21
[range 13–36]; P = 0.001). Two patients (11%) who had H.E developed renal
failure and died in the first week. Seventeen patients (89%) were discharged
from hospital and survived till day 30. However, over a median follow up of
60 (range 7–150) days, 4 additional patients died; 2 had DF>90 and HE at
baseline,(2 patients with massive bleed, HE and renal failure, 1 each with
tuberculosis and sepsis).
Conclusion: In severe AH, single dose infliximab is well tolerated and is
associated with significant improvement in indices of severity. However,
large randomized controlled trials would be needed before infliximab can be
recommended for regular use in AH.
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Role of Pentoxifylline in PRE-Hepatorenal Syndrome State
Pankaj Tyagi, MD, DM, Smruti Ranjan Mishra, MD, Manoj Sharma, MD,
DM, Praveen Sharma, MD, Amarender Puri, MD, DM, Shiv Kumar Sarin,
MD, DM∗. Gastroenterology, G B Pant Hospital, New Delhi, India.
Purpose: Hepatorenal syndrome is one of the major complication of chronic
liver disease with the very high mortality. Pre-HRS stage (creatinine clear-
ance <75 ml/min and >40 ml/min) is the stage when intervention can prevent
development of HRS. Pentoxifylline has been shown in an anecdotal study
to prevent HRS in sever alcoholic hepatitis.
AIM – To assess the efficacy of pentoxifylline in Pre – HRS.
Methods: Chronic Liver Disease patients with Child Pugh score of >7
fulfilling the criteria were included. Patient with HCC, renal failure or active
alcohol were excluded. Patient fulfilling the criteria were randomized to
receive pentoxifylline 400 mg tid (Gr 1) or placebo (Gr 2) for the six months.
Clinical assessment and creatinine clearance was repeated after 6 months.
Results: Twelve patients were enrolled with six patients in each group. Mean
age of the patients were comparable in both groups (Gr 1, 44 ± 12 yr vs Gr
2, 43 ± 13 yr). S. bilirubin was 1.9 ± 0.4 vs 1.8 ± .6 mg% in Gr 1 & Gr
2 respectively (P = ns); S. albumin was 3.2 ± .9 vs 2.8 ± 0.4 mg% in Gr
1 & Gr 2 respectively (P = ns); CTP score was 9 ± 1.7 vs 8.7 in Gr 1 &
Gr 2 respectively (P = ns); baseline creatinine clearance was 57.3 ± 9.6 vs
66 ± 7 ml/min in Gr 1 & Gr 2 respectively (P = ns). In the Gr 1 the mean
creatinine clearance changed from 57.3 ± 9.6 to 84 ± 29 ml/min whereas
the Gr 2 the mean creatinine clearance changed from 66 ± 7 to 62 ± 17
ml/min. Mean serum creatinine changed from 1 ± 0.2 mg/dl to 0.8 mg/dl
in Gr 1 but the serum creatinine worsend from 0.78 ± .28 to 0.8 ± .18 in
Gr 2. One patient died in the Gr 1 due to upper gastrointestinal bleed and no
patient died in Gr 2.
Conclusion: Pentoxifylline improves the creatinine clearance in the patient
in the pre-HRS stage.
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Hepatic Vein Pressure Gradient (HVPG) Is a Predictor of the Degree
of Liver Fibrosis (LF) in Patients with Chronic Liver Disease (CLD)
Due to Hepatitis B Virus (HBV)
Manoj Kumar, MD, DM, Hissar Syed, MD, Ashish Kumar, MD, DM,
Pankaj Jain, MD, Archana Rastogi, MD, Deepak Singh, MD, Puja
Sakhuja, MD, Shiv Sarin, MD, DM∗. Department of Gastroenterology, G
B Pant Hospital, New Delhi, India and Department of Pathology, G B Pant
Hospital, New Delhi, India.
Purpose: Biopsy is considered a gold standard for assessing LF. Sample
variability (30–40%), interobserver variability and allowing only step-wise
evaluation limit its use. HVPG, a measure of portal hypertension (PHT)
correlates with LF in CLD due to HCV. However, correlation between HVPG
and Fibrosis (F) stage has not been fully investigated in CLD due to HBV.
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Aim:To evaluate the utility of HVPG for assessing LF in patients with HBV
related CLD.
Methods: 61 patients with HBV related CLD that underwent both liver
biopsy and hepatic hemodynamic studies were studied
Results: Of 61 (Age: 37.9 ± 15.9 yr, M = 51) patients with treat-
ment naı¨ve HBV related CLD, 49(80.3%) had clinically significant
PHT (HVPG ≥ 10 mmHg), 39(63.9%) had severe PHT (HVPG ≥
12 mmHg), 6(9.8%) had HVPG ≤ 5 mmHg and 6(9.8%) had pre-
clinical PHT (HVPG>5 but <10 mmHg). Distribution of F stages 1/2/3/4
were17(27.9%)/10(16.4%)/20(32.8)/14(23%) respectively. Distribution of
Child stage A/B/C were 46(75.4%)/15(24.6%)/0 respectively. No patient
showed clinical features of clinical decompensation. A positive correlation
between HVPG and F score was found across all ranges of HVPGs (Table).
F score was significantly higher in patients with an HVPG ≥ 10 and ≥12
mmHg than in patients with an HVPG < 10 [Median (range) = 3.0(1.0–4.0)
vs. 1.0(0.0–3.0), P < 0.001] and <12 mmHg [Median (range) = 3.0(1.0–
4.0) vs 1.0(0.0–3.0), P = 0.001], respectively. ROC curve of HVPG for the
prediction of advanced Fibrosis i.e F ≥ 3 had an AUC of 0.906. HVPG
≥12.75 mmHg had a sensitivity of 79% and specificity of 89% for predict-
ing advanced fibrosis on histology. However, 9(36.0%) of 25 patients with
HVPG < 12.75 had F ≥ 3 and 11(30.6%) of 36 patients with HVPG ≥ 12.75
mm Hg did not have F ≥ 3 representing factors other than LF contributing
to higher HVPG and/or sampling limitations of liver biopsy.
Conclusion: HVPG correlates well with the degree of histological LF in
patients with HBV related CLD. It can be a good alternative and /or additive
parameter to liver biopsy in these patients.
Correlations between HVPG and F scores
Group Correlation Coefficient P
All Patients 0.693 <0.001
HVPG < 10 mm Hg 0.603 0.029
HVPG ≥ 10 mm Hg 0.512 <0.001
HVPG < 12 mm Hg 0.887 <0.001
HVPG ≥ 12 mm Hg 0.543 <0.001
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Recent Application of AASLD Practice Guidelines and US Algorithm
for Treatment of Chronic Hepatitis B
Denis V. Kapkov, MD, Trinh B. Meyer, MD, Douglas Meyer, MD, David J.
Clain, MD, Henry C. Bodenheimer, Jr., MD, Albert D. Min, MD∗.
Digestive Diseases, Beth Israel Medical Center, New York, NY.
Purpose: The AASLD practice guidelines (“guidelines”) and US algorithm
by Keeffe et al (“algorithm”) for treatment of the chronic hepatitis B (CHB)
were recently updated. Although the differences have narrowed, the treatment
threshold for ALT and HBV DNA levels showed a few differences between
the two references. We compared the guidelines and the algorithm with the
treatment patterns in patients with CHB at our center.
Methods: Charts of all new and follow-up patients with CHB seen consec-
utively in the GI/Liver clinics at our center between 1/07 and 5/07 were re-
viewed. The patient demographics and baseline disease characteristics were
recorded. Treatment patterns have been reviewed and compared with rec-
ommendations of both references. Statistic significance of the results was
estimated with chi-square and Fisher Exact analysis.
Results: There were 159 patients with 67% male and a mean age of 52.4 years
(range 24–82). 67% were of Asian ethnicity. Overall, 102 of 159 patients
(64%) have been treated. As shown in the table below, 71 of 83 (86%) patients
eligible for therapy based on the ALT and viral load alone per guidelines
and 88 of 109 (81%) patients meeting the algorithm’s criteria received CHB
treatment. The reasons for the non-treatment despite meeting the treatment
criteria included patient refusal, < stage 2 fibrosis by modified Ishak system,
and observation period for the new patients. For the patients with ALT < 2 ×
ULN, the treatment rate was higher in HBeAg- positive patients regardless
of the biopsy status. Among patients recommended for observation, there
were 29 and 13 patients in the guidelines and algorithm groups, respectively.
The presented difference in patient selection method by the guidelines and
by the algorithm appears to be statistically significant (P < 0.05).
Conclusion: Both the updated AASLD guidelines and the US algorithm by
Keeffe et al applied similarly to the current practice of CHB management
at our center. The US algorithm covers a broader spectrum of patients for
initiating treatment than the AASLD guidelines.
Biopsy Considered
before Treatment
Treatment (# of Biopsies Observation
Indicated performed) Suggested
Not- Not- Not-
Treated Treated Treated Treated Treated Treated
AASLD Guidelines 71 12 27 20 4 25
(N = 159) (86%) (14%) (57%)/(10) (43%)/(4) (14%) (86%)
US Algorithm 88 21 14 23 0 13
(N = 159) (81%) (19%) (38%)/(9) (62%)/(2) (0%) (100%)
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Prediction of Histology in Nonalcoholic Fatty Liver Disease: Do
Medications Matter?
Sri Naveen Surapaneni, MD, Charles Katopes, MD, James Wallace, MD,
Peter Nuttleman, MD, Deborah Andris, NP, Behmaran Behnaz, MD,
Richard Komorowski, MD, Franco Jose, MD, Rajiv Varma, MD, Omar
Massoud, MD, Kia Saeian, MD, Samer Gawrieh, MD∗. Medical College
of Wisconsin (MCW), Milwaukee, WI and Zablocki VA Medical Center,
Milwaukee, WI.
Purpose: Various clinical and biochemical variables had been used to pre-
dict histology in patients with NAFLD. However, medications used to treat
different components of the metabolic syndrome, had not been assessed
as potential predictors of histology. Aim: To determine the association of
chronic use of these medications with liver histology in patients undegoing
a liver biopsy for suspected NAFLD.
Methods: Patients who underwent liver biopsy for unexplained elevated
liver tests, suspected NAFLD, or cryptogenic cirrhosis over a 3 year period
at our institution were identified. All liver biopsies were read by an aca-
demic pathologist and categorized as FL, possible NASH, NASH or normal.
Medications chronically used by patients prior to the time of biopsy and rel-
evant clinical and laboratory variables were recorded. Association between
individual variables and diagnoses were studied using the Chi-square test.
Results: 65 patients were identified; 6 (9%) with normal histology, 27
(41.5%) with FL, 27 (41.5%) with possible NASH and 5 (8%) with NASH.
Relevant clinical, laboratory, and medications data are summarized in the
table. Use of insulin and BMI were the only significant variables associ-
ated with NASH. While diabetes, higher triglycerides levels, use of TZD’s,
metformin, statins and ace-inhibitors were more frequent in NASH patients,
these did not reach statistical significance.
Characteristics of the study subjects
Normal Fatty Liver Possible NASH NASH P-
Variable N = 6 N = 27 N = 27 N = 5 value
Age 48 (36–60) 52 (25–70) 46 (23–62) 38 (36–51) ns
BMI 48 (26–58) 32 (25–50) 41 (25–61) 51 (31–58) 0.005
Diabetes 1 (17%) 9 (33%) 13 (48%) 4 (80%) ns
Triglycerides 125 (79–258) 175 (67–360) 219 (71–497) 231 (86–274) ns
ALT 47 (12–104) 51 (13–140) 53 (13–225) 59 (25–104) ns
Metformin 1/17% 6/22% 9/33% 3/60% ns
TZDs 1/17% 3/11% 4/15% 2/40% ns
Insulin 1/17% 1/4% 1/4% 2/40% 0.02
Statins 1/17% 10/37% 6/22% 2/40% ns
Fibrates 0 4/15% 2/7% 0 ns
ACE-I 2/33% 8/30% 9/33% 3/60% ns
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Conclusion: Pharmacotherapy for components of the metabolic syndrome
was more frequent in patients with NASH in this study, but only insulin use
was significantly associated with NASH.
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Treatment Rates in Patients with Chronic Hepatitis B after Liver
Biopsy
Denis V. Kapkov, MD, Trinh B. Meyer, MD, Douglas Meyer, MD, David J.
Clain, MD, Neil D. Theise, MD, Henry C. Bodenheimer, Jr., MD, Albert D.
Min, MD∗. Digestive Diseases, Beth Israel Medical Center, New York, NY.
Purpose: Clinical practice concerns and recent updates of AASLD Guide-
lines (“guidelines”) and US algorithm (Keeffe et al., 2006) on treatment of
chronic hepatitis B (CHB) (“algorithm”) have focused attention on the in-
terpretation of ALT and HBV DNA levels with the utility of liver biopsy in
CHB treatment decisions. Specifically, we focused on the use of liver biopsy
in patients with high viral load having either ALT 1–2 × ULN or normal
ALT. We also assessed the rates of treatment for CHB patients after the liver
biopsy at our center.
Methods: Charts of 159 patients with CHB seen in our ambulatory clinics
between 1/07 and 5/07 have been reviewed. Patient demographics, labora-
tory, histology and clinical data were recorded.
Results: 159 patients were seen (67% males, mean age of 52.4 years, 60%
of Asian ethnicity), and 42 (26%) of them had a liver biopsy. A total of
34 (81%) patients were treated either before or after biopsy (see Table).
Overall, 35 of 42 (83%) patients had liver biopsy prior to making initial
therapeutic decisions, and 27 of the 35 (77%) patients started treatment.
Among 47 patients with ALT 1–2 × ULN, 14 (30%) had a liver biopsy,
including 6 subjects who had > stage 1 fibrosis on modified Ishak system.
Similarly, among 37 patients with normal ALT and HBV DNA > 20,000
IU/mL (HBeAg-positive) or >2,000 IU/mL (for HBeAg-negative), 11 (30%)
had a liver biopsy, including 4 subjects with > stage 1 fibrosis. The majority
of liver biopsy was obtained from the group with ALT > 2 × ULN (24
patients). 14 (58%) of those 24 subjects demonstrated > stage 1 fibrosis.
The overwhelming reasons for non-treatment were minimal fibrosis in 7
of 8 patients. The remaining one patient who had normal ALT and stage
2 fibrosis deferred treatment. Treatment was started in 13 patients with <
stage 2 fibrosis, mainly due to increased ALT values or a family history of
hepatocellular carcinoma.
Conclusion: A liver biopsy was helpful in selecting treatment for patients
with mild ALT elevation. A majority of patients with CHB undergoing liver
biopsy received antiviral therapy afterwards. A large proportion of patients
undergoing liver biopsy with normal ALT and high viral load had significant
liver fibrosis
Fibrosis stage on histology 0 1 2 3 4 Total
# of patients 5 15 10 5 7 42
# of treated patients 2 11 9 5 7 34
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Role of Antigen Processing and Presentation Genes in Development of
Acute and Chronic Hepatitic Viral Infections
Sukriti Baweja, Nirupma T. Pati, Sujoy Bose, Syed S. Hissar, Manoj
Kumar, Puja Sakhuja, Shiv K. Sarin∗. Department of Gastroenterology,
G.B Pant Hospital, New Delhi, Delhi, India and Department of Pathology,
G.B Pant Hospital, New Delhi, Delhi, India.
Purpose: Progression of viral infection to either acute or chronic state de-
pends on the efficacy of the host immune response. Whereas acute viral
hepatitis invites a vigorous, multispecific T-cell response, chronic viral hep-
atitis is associated with a weaker, narrowly focused response. Specific T-cell
hyporesponsiveness in the later could be due to inefficient delivery of anti-
gens to MHC class I molecules. Antigen processing and transport to MHC
class I primarily involves, Low molecular weight protein (LMP);2 and7 and
Transporter Associated with Antigen Processing (TAP)1 and2 genes. Im-
mune system modifies this complex by addition of these subunits induced
by IFN-γ . We hypothesize that proteasome subunits shape the specific T-
cell response and it may be dysfunctionally regulated in peripheral blood
lymphocytes in chronic infections.
Aim: To investigate the expression of antigen processing and presentation
genes in acute hepatitis B (AHB), acute hepatitis E (AHE), chronic hepatitis
B (CHB) and chronic hepatitis C (CHC) patients.
Methods: Fifty subjects were studied:10 of each category, AHB (age 33.3 ±
19.8 yr., M = 7), AHE (age31.7 ± 16.5 yr., M = 7), CHB (age 29.4 ± 13.2 yr.,
M = 8), CHC (age 45.5 ± 18.1 yr., M = 8) and controls (age 27.9 ± 4.6 yr.,
M = 7). Total RNA was isolated from PBMC’s and cDNA was prepared and
mRNA expression of TAP1, TAP2, LMP2 and LMP7 genes was quantified
by Real-Time PCR.
Results: No significant difference in expression patterns between AHB and
AHE was found. LMP2 was upregulated in AHB (P = 0.051) and AHE
(0.059) compared to controls. In CHC, LMP2 was significantly downregu-
lated and TAP2 was upregulated in comparison to AHB and AHE. In CHB,
TAP 1 and LMP 7 were significantly downregulated compared to controls
and AH groups (P = 0.034, 0.006).
Conclusion: i) Downregulation of LMP7 and TAP1 in CHBV and LMP2 in
CHC suggests that the catalytic subunits of proteasome complex and antigen
presentation genes play significant role in HBV and HCV persistence, ii)
Similar profile in AHB and AHE suggests that while viral strains differ,
acute hepatitis invites similar antigen processing pathways.[figure1]
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Does the Stage of Fibrosis or Grade of Inflammation on Liver Biopsy
Predict the Early Response to Combination Treatment with Pegylated
Interferon and Ribavirin in Hepatitis C Patients?
Isam Daboul, MD∗, Vikas Ghai, MD, Srini Hejeebu, DO, Adeel Husain.
Gastroenterology, University of Toledo, Toledo, OH and Medicine,
University of Toledo, Toledo, OH.
Purpose: Using the degree of fibrosis on liver biopsy as a component of the
basis of therapy for hepatitis C patients is proven to be helpful in predicting
response. Treatment is generally advised if the liver biopsy displays a Metavir
score of more than or equal to 2 or an Ishak score of more than or equal to
3. There are no studies available which use the individual role of degree of
inflammation or grade of fibrosis in predicting the response to treatment.
Methods: We conducted a retrospective chart review on 26 naive patients
with hepatitis C genotype 1 [age 39–62 years] who were treated with the
standard approved doses of combination Pegylated interferon and Ribavirin
after having a liver biopsy. The early virologic response (EVR), defined as 2
log or more reduction in the viral count at 12 weeks of therapy, was calculated
in each degree of inflammation group (1–4) and grade of fibrosis (1–4).
Results: The results showed that 53% of patients with grade 1&2 inflamma-
tion were initial responders to the therapy compared to 64% with grade 3&4.
Initial responders of stage 1&2 fibrosis were 59% compared to 56% with
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stage 3&4. Using Fisher’s exact test the difference in the response rate was
not statistically significant for both the grade of inflammation (P = 0.430)
and stage of fibrosis (P = 0.216).
Conclusion: The EVR to treatment of patients with hepatitis C genotype 1
did not show a statistically significant difference between various degrees of
inflammation or different stages of fibrosis on liver biopsy. Neither the stage
of fibrosis nor grade of inflammation accurately predict treatment outcome
in individuals. However these variables may be helpful in counseling patients
and making treatment decisions.[figure1][figure2]
351
Primary Hepatic Lymphoma
Rangan Murali, MD, Bashar M. Attar, MD, PhD∗, Gijo Vettiankal, MD,
Benjamin Go, MD. Gastroenterology, Cook County – John H. Stroger
Hospital and Rush University Medical School, Chicago, IL.
Purpose: Primary hepatic lymphoma (PHL) is a rare malignancy and con-
stitutes about 0.016% of all cases of non-Hodgkin’s lymphoma (NHL). PHL
represents 0.4% of all extranodal non-Hodgkin’s Lymphoma.
A 46 year old man with no significant past medical history, presented with
two weeks history of jaundice, pruritus, epigastric and right upper quadrant
discomfort, loss of appetite and 20 pound weight loss. On examination he
was jaundiced with mild right upper quadrant tenderness. The liver was
enlarged to 5 cm below the right costal margin. No lymphadenopathy or
splenomegaly was noted. Lab values were notable for total bilirubin of 14.1
mg/dl with direct fraction of 9.2, alkaline phosphatase of 646 U/L, GGT of
289 U/L, AST of 202 U/L, ALT of 87 U/L, albumin of 3.0 and LDH of 752
U/L. Alfa fetoprotein, CEA and CA 19–9 were not elevated.
Non-contrast enhanced CT of the abdomen showed a large hypodense mass
in the left lobe of the liver. Contrast enhanced (early arterial phase) CT scan of
the abdomen demonstrated a hypo vascular mass and minimal enhancement
of the mass without distortion of the liver anatomy in the portal venous
phase. Percutaneous liver biopsy revealed diffuse large B cell Lymphoma.
Bone marrow biopsy was normal. Further workup did not reveal disease
involvement elsewhere in the body. The patient was treated with combination
chemotherapy. He responded well to chemotherapy and his liver functions
normalized. After two years of follow up, the patient is asymptomatic with
normal liver function tests and CT scan of the liver.
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Safety of Bioelectrical Impedance Analysis in Evaluation of Patients
with Liver Cirrhosis and Relation with Severity of Disease
Daniele Torres, MD∗, Gaspare Parrinello, MD, Salvatore Paterna, MD,
Pietro Di Psquale, MD, Giuseppe Licata, MD. Internal Medicine
Department, University Hospital, Palermo, Italy.
Purpose: Liver cirrhosis (LC) is characterized by pathological changes in
homeostatic mechanisms which regulate the extracellular fluid volume. The
changes of hydration status are estimate by Bioelectrical Impedance Analysis
(BIA), a simple, inexpensive, non-invasive, patient-bed method. We evaluate
the safety of BIA in LC.
Methods: We enrolled 48 patients (62 ± 9 yr, 27 male) admitted to our
department with diagnosis of LC subdivided in three groups on the basis of
Child-Pugh score (A group: 14 pts; B group: 17 pts; C group: 15 pts). There
were no statistically significant differences in age and gender in each group.
16 healthy volunteers and 16 non-cirrhotic pts with a clear hyperhydration
status (heart failure, kidney failure, nephrotic syndrome), matched for age
and sex, were considered like controls. All the subjects underwent to blood
tests, BIA-101 for detecting whole-body BIA measurements (Resistance: R;
Reactance: Xc) and abdominal ultrasonography.
Results: Showed a significant reduction of parameters from A (R 537 ± 33,
Xc 46 ± 7) to B (R 480 ± 28, Xc 38 ± 6) and C group (R 450 ± 29, Xc
35 ± 5). We observed a statistically significant reduction (P < .001) between
hyperhydrated (R 445 ± 31, Xc 36 ± 8) (R 544 ± 33, Xc 47 ± 8) vs. healthy
controls measurements. No significant differences between hyperhydrated
controls and B or C group was found. These results correlated inversely with
Child-Pugh score (P < .001), serum creatinine (P < .01), directly with albu-
min (P < .01), plasma sodium levels (P < .01), hematocrit (P < .01). When
we classified the pts on the basis of ultrasonography presence of ascites
not significant difference of bioelectrical parameters between moderate and
tense ascites was found. Classifying the pts according to presence of ascites
and to preserved or compromised liver function we observed a more signif-
icant reduction of these values (P < .001) in ascitic pts with compromised
liver function. Analyzing the subgroup of pts with ascites and normal BIA
values we found that all had a preserved liver function.
Conclusion: BIA is a repeatible non operator-dependent method helpful for
evaluation of hydration status in LC and correlates with clinical-functional
class. Thus it is not capable of estimating the entity of ascites because it
is a compartmentalized edema. However this method is useful for rapid
evaluation of severity of disease and selection of pts with ascites for diuretic
treatment (lower BIA values) or paracentesis (normal BIA values).
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Toward Better Prognostic Modeling in Acute Liver Failure
Julie Polson, MD, Nick Rogers, MD, Linda S. Hynan, PhD, A.J. Naylor,
BS, William M. Lee, MD∗. Internal Medicine, University of TX
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Southwestern Medical Center, Dalllas, TX and Clinical Sciences,
University of TX Southwestern Medical Center, Dallas, TX.
Purpose: Previous prognostic scores in ALF have reasonable specificity
but inadequate sensitivity. To improve predictions, we explore a new model
system that controls for the variable of coma severity.
Methods: Prospective data from more than 1,000 ALF patients enrolled in
the United States ALF Study were used to explore whether basic lab val-
ues at time of progression to encephalopathy stage II or III, rather than at
hospital or study admission, might be more useful in predicting outcomes.
We also grouped patients according to ALF etiologies associated with fa-
vorable (acetaminophen, hepatits A and ischemia) versus unfavorable (all
other causes) outcomes. In separate logistic regression analyses we used
standard laboratory measures from the first hospital day that stage II or III
encephalopathy was reached. Patients with missing data for any variable
included in the model were excluded. Pairs of logistic regression models
used lab values and etiology groups to predict the following: death versus
survival at 3 weeks, death or transplantation versus transplant-free (sponta-
neous) survival at 3 weeks, and transplantation versus no transplantation at
3 weeks.
Results: Well-fitting models were developed using standard laboratory pa-
rameters (Table). At arrival to coma grade II or III, death or transplantation
was associated with higher Cr, INR, and total bilirubin, lower pH, and unfa-
vorable etiology compared with spontaneous survival.
Conclusion: Using basic lab values at time of initial coma progression to
stage II or III may yield more accurate prognostic models. Grouping by
etiology is also important. Such a prognostic score should be clinically useful
since predicting need for transplant is crucial at the time of listing, usually
at or near grade II or III.
The US Acute Liver Failure Study Group is supported by U-01 58369; JP is
the recipient of an ACG Research Award.[figure1]
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Clinicopathological Predictors of Sustained Viral Response Rates in
Patients with Chronic Hepatitis C Infection
Jagdish S. Nachnani, MD, Raja Gidwani, MD, Esmat Sadeddin, MD,
Wendell K. Clarkston, MD, Rusell Fiorella, MD, MBA, Laura M. Alba,
MD∗. Internal Medicine, University of Missouri Kansas City, Kansas City,
MO; Pathology, Truman Medical Center, Kansas City, MO and
Gastroenterology, University of Missouri Kansas City, Kansas City, MO.
Purpose: Despite major progress made in treatment of patients with chronic
Hepatitis C virus (HCV) infection, a substantial number of patients fail to
respond or relapse after peginterferon and ribavarin therapy. Peginterferon
and ribavarin has an overall sustained viral response (SVR) rate of 54–63%.
The aim of our study was to identify clinical, laboratory and pathologic pre-
dictors associated with a lack of sustained response to treatment in patients
with chronic HCV infection.
Methods: From December 2002 to November 2005, we included all pa-
tients who had completed interferon therapy for chronic HCV infection and
had a liver biopsy prior to starting interferon therapy. We retrospectively
reviewed the medical records of these patients to access their clinical as well
as pertinent biochemical laboratory results. Liver biopsies were retrospec-
tively reviewed by a single pathologist blinded to the clinical and laboratory
findings.
Results: There were 67 patients in our study cohort. The mean age of the
patients was 46.3 +/– 6.3 years. Of the 67 patients, 36(54%) were males and
31(46%) were females. An early virologic response defined as at least a 2
log(10) reduction in HCV RNA or HCV RNA negativity by week 12 was
present in 73.7% of the patients while 57.8% of the patients had a sustained
viral response. On univariate analysis, absence of EVR (P = 0.0002), Non-
white race (P = 0.008), AST/ALT ratio >/= 1 (P = 0.008), INR >/= 1
(P = 0.02) and presence of steatosis >/= 5% (P = 0.03) on liver biopsy
were negative predictors associated with SVR. In multivariate analysis, only
absence of EVR, Nonwhite race, AST/ALT ratio >/= 1 and presence of
steatosis >/= 5% were significant independent predictors of nonresponse to
treatment.
Conclusion: In conclusion, the treatment rates and options for chronic HCV
infection remain suboptimal. Absence of EVR, Non-white race, AST/ALT
ratio >/= 1 and presence of steatosis >/= 5% on liver biopsy are independent
negative predictors of sustained viral response rates of patients with Chronic
HCV infection on treatment.
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Hepatic Infarct Following TIPS with a ePFTE-Covered Stent and
Review of the Literature
Sandra M. Jara, MD, Joseph McKinley, MD, John M. Coleman, MD,
William Boyd, MD∗. Division of Digestive Diseases & Nutrition, James A.
Haley VA Hospital, Tampa, FL; and Division of Interventional Radiology,
James A. Haley VA Hospital, Tampa, FL.
Purpose: TIPS (transjugular intrahepatic portosystemic shunt) is an ac-
cepted therapeutic modality for gastrointestinal bleeding from portal hy-
pertension that cannot be controlled by either endoscopic or pharmacologic
therapy. TIPS should not be underaken lightly, because the overall procedure-
related mortality can be as high as 1% to 2% and complications including
hepatic encephalopathy, portal vein thrombosis, sepsis, stent migration or
stenosis, and intraperitoneal hemorrhage can occur. Expanded polytetraflu-
oroethylene (ePFTE) covered stents have been developed to improve shunt
patency and reduce TIPS malfunction. On review of the literature, there has
been limited data analysis evaluating the potential for hepatic venous outflow
obstruction related to covered stents with most of the information obtained
from case reports. This abstract presents an interesting case of a segmental
hepatic infarct after TIPS procedure using a GORE VIATORR covered stent.
Methods: A 67 y.o. male with hepatitis B cirrhosis and a history of decom-
pensation with a gastric variceal bleed was scheduled for an outpatient TIPS
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procedure. An ePFTE-covered stent was placed successfully with a hepatic
venous pressure gradient drop of 14 to 6 mm Hg. The patient complained of
mild RUQ and right shoulder pain following the procedure. Physical exam-
ination revealed some liver tenderness without evidence of peritonitis.
Results: Laboratory evaluation revealed severe transaminitis with AST
and ALT >2,000; however, synthetic function was preserved. The patient
did clinically well throughout a brief hospital course with a decrease in
transaminitis and no evidence of liver failure. A triple phase abdominal CT
scan performed 6 days following TIPS procedure revealed a right hepatic
lobe posterior segment infarct.
Conclusion: Segmental hepatic infarct is a potential complication following
TIPS with covered stents.[figure1]
356
Predictive Values of HOMA and Metabolic Syndrome by Different
Definitions in Identifying NASH and Liver Fibrosis in a Population
with High Prevalence of Obesity and Diabetes
Ibrahim A. Hanouneh, MD, Tamali Bhattacharyya, MD, Hesham M.
Elgouhari, MD, Nizar N. Zein, MD, Arthur J. McCullough, MD, Ariel E.
Feldestein, MD∗. Internal Medicine, Cleveland Clinic; Cell Biology,
Cleveland Clinic; Gastroenterology and Hepatology, Cleveland Clinic, and
Pediatric Gastroenterology and Cell Biology, Cleveland Clinic, Cleveland,
OH.
Purpose: Insulin resistance and related metabolic syndrome (MS) have been
closely linked to nonalcoholic fatty liver disease (NAFLD). The progression
from NAFLD to nonalcoholic steatohepatitis (NASH) occurs in substantial
but yet-to-be determined percentage of patients. This study analyzes which
definition of the metabolic syndrome (MS) is more predictive of NASH and
liver fibrosis in population with high prevalence of obesity and diabetes.
Methods: Our cohort consisted of 65 consecutive patients referred for liver
biopsy with clinical suspicion of NAFLD. Histology was assessed blindly
by a pathologist and the clinical data was also collected in blinded fashion.
MS was assessed based on WHO, ATP III, and IDF definitions.
Results: Of 65 subjects, 37 (56.9%) had NASH, 17 (26.2%) had sim-
ple steatosis and 11(16.9%) had normal biopsy. In relation to NASH, the
strongest correlation was observed with WHO definition of MS (r = 0.386,
P < 0.001) > ATPIII (r = 0.371, P = 0.002) > HOMA (r = 0.332, P <
0.001) > IDF (r = 0.283, P = 0.021). However, in association with fibro-
sis, HOMA index was most strongly correlated with degree of fibrosis (r =
0.493, P < 0.001) as compared to the established definitions of MS. Of the
three, WHO showed the strongest correlation with fibrosis (r = 0.411, P <
0.001) as compared to ATPIII (r = 0.36, P < 0.001) and IDF (r = 0.279,
P = 0.013). After adjusting for age, AST, ALT, AST/ALT ratio and diabetes,
HOMA index remained significantly associated with NASH as well as de-
gree of fibrosis (OR: 7.3(2.2–24.4) P = 0.001 and 13.1(2.5–69) P < 0.001
respectively). All three definitions of the MS remained significant in relation
to fibrosis [OR (95% CI) ATPIII: 9.1(1.8–45.0) P = 0.007; WHO: 6.9(1.7–
27.7) P = 0.007 and IDF: 3.9(1.03–14.4) P = 0.044)]. While WHO and
ATPIII remained significantly associated with NASH [OR: 8.4(2.0–34.5)
P = 0.003; and 6.3(1.8–22.0, P = 0.004 respectively], IDF failed to remain
significant [OR = 3.1(1.0–10.0) P = 0.057] after adjusting for confounding
factors.
Conclusion: HOMA and MS are significantly associated with NASH and
liver fibrosis in patients with suspected NAFLD. While the WHO and ATPIII
definitions were strongly predictive of NASH, IDF seemed inappropriate in
identifying the likelihood of having NASH in patients with NAFLD.
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Overview of Hepatitis A in Republic of Armenia
Aregnazan Mkhitaryan, MD∗, M. Shmavonyan, MD, J. Vopyan, MD, G.
Melik-Andreasyan, MD, H. Kazinyan, A. Shahapuni, A. Asoyan, MD.
National Institute of Health, Yerevan, Armenia and Infection Hospital
“NORK”, Yerevan, Armenia.
Purpose: In etiological structure of viral hepatitis, the Hepatitis A (HA),
during 1984–2003 averaged 87.3%. It is known, that disease can have sub-
clinical course, especially at children. Basically, disease comes to an end
recovery, however can be severe and even fulminant courses, with develop-
ment of sympthoms of an Acute Hepatic Encephalopathy (AHE) and a lethal
outcomes.
The research problem is HA percent definition in patients with viral hepatitis,
determination of age-specific characteristics, correlation of severity forms
and HA evaluation in acute fulminant hepatitis.
Methods: A retrospective analysis of patients with viral hepatitis hospital-
ized into the Infectious Hospital during 2002–2006 was performed. The di-
agnosis of HA was formed based on epidemiologic evidence, clinical course
of diseases, blood biochemical analysis data and anti-HAV IgM testing.
Moreover, patients blood had been tested to HbsAg and anti-HCV.
Results: Of all 1919 patients with viral hepatitis, HA was confirmed in 944
(49%) patients. Male was 48.1% and female was51.8%. All of patients had
icteric form of HA. Of them in 12 (1.3%) was diagnosed mixed Hepatitis, at
that HAV+HBV was in 7 patients and 4 patients had HA on the background
of the chronic HCV infection. Age of patients was from several months till
76 years. Patients in age from 6–15 and 16–25 made up the most numer-
ous group: 38.6% and 30.6% respectively. Children up to 6 years old were
6.8%, persons over 46 years old – 2.1% and practically did not suffer from
HA children under 1 years – 0.3% only. Patients admitted to the Hospital
during the whole year, but the most all in autumn-winter season. So during
November – March admitted 532 (56.9%) patients with HA.
In 87.7% patients clinical course was moderate-severe, in 8.8% – severe and
in 3.5% – mild. Fulminant course of hepatitis with AHE was in 4 (0.4%),
at that 3 (0.3%) died due to hepatic coma. Age of patients with AHE was
10–47. All of them were hospitalized within first 10 days from the beginning
of the disease.
Conclusion: Patients with HA are almost half of hospitalized patients with
viral hepatitis. Persons in the age over 16 constitute 49% of HA diseased.
The high percentage of patients with the moderate-severe form, probably,
is conditioned by the fact that treatment in a hospital get patients with the
pronounced symptoms of disease. HAV can also be the cause of fulminant
hepatitis, with a lethal outcome.
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Genetic Variation in the Peroxisome Proliferator Activated
Receptor-gamma Gene Is Associated with NAFLD and Its Histological
Phenotypes
Samer Gawrieh, Miranda Marion, Kristen Smith, Richard Komorowski,
James Wallace, Peter Nuttleman, Deborah Andris, Ahmed Kissebah, Carl
Langefeld, Michael Olivier∗. Medical College of Wisconsin, Milwaukee,
WI; Zablocki VA Medical Center, Milwaukee, WI and Wake Forest
University, Winston-Salem, NC.
Purpose: Peroxisome proliferator activated receptor-gamma (PPAR-γ ) is a
nuclear receptor that regulates adipocyte differentiation, lipid metabolism
and insulin sensitivity and is the molecular target for thiazolidinediones,
agents that enhance sensitivity to insulin. Thus, it is a good candidate gene for
NAFLD. The Ala12 variant of PPAR-γ has been associated with increased
insulin sensitivity, lower body mass and protection from type 2 diabetes.
A second polymorphism C1431T has been associated with increased body
weight.
Aim: To test the association of two PPAR-γ single nucleotide polymor-
phisms (SNP) with NAFLD and its histological sub-phenotypes.
Methods: DNA was extracted from 158 archived, formalin-fixed liver biopsy
specimens from patients with NAFLD and normal controls. Two SNPs of
PPAR-γ (Pro12Ala and C1431T) were genotyped by Taqman assay using
the Biotrove OpenArray system. PPAR-γ haplotypes were predicted us-
ing the program Dandelion, which employs the Expectation-Maximization
(EM) algorithm to obtain maximum likelihood estimates of the haplotype
frequencies and the probabilities of the observed haplo-genotypes for each
individual.
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Results: DNA was successfully isolated and genotyped for 26 controls, 87
FL, and 45 NASH patients. For both SNPs tested, the minor allele frequencies
were decreased in NAFLD compared to controls (10.8 vs 25% for C1431T,
and 9.5 vs 17.3% for Pro12Ala). In subjects with NAFLD, the minor alleles
were enriched in subjects with FL compared to those with NASH (12.5
vs 7.5% for C1431T and 13.3 vs 0.03% for Pro12Ala). Only variation in
C1431T was associated with steatosis (P 0.03). Haplotype analysis revealed
a haplotype consistent of both minor alleles (TG) that is present only in
subjects with NAFLD but not in controls (2.7 vs 0%). This haplotype was
also significantly associated with steatosis, fibrosis, ballooning and lobular
inflammation under an additive genetic model.
Conclusion: Genetic variation in PPAR-γ is associated with NAFLD and its
histological phenotypes. A haplotype shows strong association with histo-
logical findings of NASH, and is more common in individuals with NAFLD
than controls. This haplotype may influence the development of NASH and
its characteristic inflammatory and fibrotic changes.
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Detection of Caspase Activity in the Plasma of Patients with Various
Liver Diseases as a Novel Biomarker of Hepatic Fibrosis
Hesham M. Elgouhari, Nizar N. Zein, Lisa Yerian, Ibrahim A. Hanouneh,
Rocio Lopez, Ariel E. Feldestein∗. Gastroenterology and Hepatology,
Cleveland Clinic; Anatomic Pathology, Cleveland Clinic; Biostatistics and
Epidemiology, Cleveland Clinic; Internal Medicine, Cleveland Clinic, and
Pediatric Gastroenterology and Cell Biology, Cleveland Clinic, Cleveland,
OH.
Purpose: Development of a reliable non-invasive test to predict liver fibrosis
is greatly needed. The expanding knowledge about hepatocellular apoptosis
as a prominent pathological feature in different liver diseases and its sus-
pected role in triggering fibrosis supports apoptosis as a target for biomarker
development. We have recently demonstrated that caspase 3-generated cy-
tokeratin 18 (CK-18) fragments’ level in blood is an independent predictor
of advanced fibrosis in patients with nonalcoholic steatohepatitis. The aim
of our study was to determine the value of this novel biomarker for assessing
hepatic fibrosis in different liver diseases.
Methods: Prospectively, 191 consecutive patients with various liver diseases
or abnormal liver tests referred to our liver biopsy clinic were enrolled. On
the biopsy day, demographic and clinical data were collected along with
blood samples. Histology of all liver biopsies was assessed blindly by an
experienced hepatopathologist and used as the gold standard method for
fibrosis staging scored: 0 for no fibrosis; 1 for early fibrosis; and 2 for
advanced fibrosis. CK-18 fragments’ level was measured in duplicates using
a specific sandwich immunoELISA assay.
Results: Patients with advanced fibrosis (N = 45) had significantly higher
CK-18 fragments’ level than those without advanced fibrosis (Median (Q25,
Q75): 414.4 (207, 748), 214 (122, 400); P < 0.001). The odds of having
advanced fibrosis increased with increasing CK-18 levels. For every 50 U/L
increase in CK-18 fragments’ level, the likelihood of having advanced fi-
brosis increased 5% (OR (95% CI): 1.05 (1.001, 1.1)). Nonetheless, CK-18
level in isolation appeared to be a relative weak predictor of advanced fibro-
sis in these patients with an area under the ROC curve estimated to be 0.67
(95% CI: 0.58, 76). We are in the process of constructing a clinical model for
prediction of advanced fibrosis based on CK-18 levels in conjunction with
other clinical and laboratory tests.
Conclusion: Plasma CK-18 fragments’ level is increased in patients with
advanced fibrosis from various types of liver diseases. Measurement of this
marker in conjunction with other simple clinical and laboratory data may be
useful to predict advanced fibrosis.
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Hepatic Splenosis Mimicking Hepatocellular Carcinoma
Advitya Malhotra, MD, Gagan K. Sood∗. Department of Internal
Medicine, University of Texas Medical Branch, Galveston, TX and
Department of Gastroenterology and Hepatology, University of Texas
Medical Branch, Galveston, TX.
Purpose: Splenosis is heterotropic implantation of splenic tissue after
splenectomy or traumatic rupture of spleen. We report patient with alco-
holic liver disease, who was found to have enhancing hepatic lesion during
surveillance for HCC but was diagnosed as splenosis based on characteristic
imaging, nuclear scintigraphic findings and associated multiple splenules.
A 39-year-old man with alcoholic cirrhosis on routine surveillance for HCC
was found to have small hypoechoic lesion on ultrasound, follow up MRI
revealed a mass in right lobe of liver measuring 4.5 × 5.3 cm with enhance-
ment in early phase and an isodense lesion on late phase (white arrow in
Fig. 1). These findings suggested a diagnosis of hepatocellular carcinoma.
There were also multiple enhancing lesions in mesentery and splenic bud
suggestive of splenules (black arrow in Fig. 1). A Tc-99m sulfur colloid
scan showed uptake in the area of hepatic mass and splenules (marked with
black and white arrow respectively in Fig. 2). Patient had splenectomy in
past after abdominal trauma. Laboratory data revealed Alpha-fetoprotein
3.5, AST 58, and ALT 45. Six months later repeat imaging showed no in-
crease in size of mass. In our case, the presence of concurrent mesenteric
splenosis, normal alpha-fetoprotein, no growth on subsequent imaging and
radio isotope uptake in liver and splenic bed on Tc-99m scan established the
correct diagnosis of splenosis and averted the need for biopsy. Majority of
the time splenosis is an incidental finding at surgery or autopsy, and at times
discovered during computed tomography (CT) or magnetic resonance imag-
ing (MRI). Splenosis being highly vascular mimics other vascular hepatic
neoplasia and presents a dilemma in diagnosis of Hepatocellular carcinoma
(HCC).[figure1][figure2]
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Transmission of Hepatitis B Virus (HBV) Infection Is Predominantly
Perinatal in the Indian Subcontinent: A Large Prospective Study
Hissar Syed, MD, Manoj Kumar, MD, DM, Kazim N. Syed, PhD, Sanjay
Satpathy, MD, DM, Tharun G. Kumar, MSc, Ranjeet Chauhan, MSc, Didar
Singh, MBBS, Puja Sakhuja, MD, Shiv K. Sarin, MD, DM∗.
Gastroenterology, G B Pant Hospital, New Delhi, India and Pathology, G B
Pant Hospital, New Delhi, India.
Purpose: India is in intermediate prevalence zone for HBV infection. Peri-
natal transmission is the predominant mode of transmission in high endemic
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areas. HBV transmission in India is presumed to be predominantly horizon-
tal, but there is scanty data. We conducted a study to test the hypothesis that
chronic HBV infection in India is predominantly due to perinatal transmis-
sion.
Aim: To determine the source of HBV in chronic HBV infected patients.
Methods: Consecutive patients with chronic HBV infection whose relatives
consented for evaluation were enrolled. Family tree was prepared and all
available relatives were tested for HBsAg, anti-HBe, anti-HBs and total
anti-HBc. Vertical transmission was defined when the mother was HBsAg
positive or anti-HBe (suggestive of resolved HBV infection) and/or total
anti-HBc positive (suggestive of past exposure). 254 healthy controls were
also screened for comparison.
Results: 476 index patients (Age 25.7 ± 15.6 yr; Males 363) had 1274
relatives available for screening. In 316 (66.4%) [Age 20.2 ± 14.3 yr; Median
(range) = 18(6 mo.-58 yr.); Males 251] index patients, mother could be
screened. 226/316 (71.5%) mothers and 12/254 (4.7%) of controls were
antibody positive (anti-HBe and/or total anti-HBc) (P < 0.001), 133/316
(42.1%) mothers and 10/254 (3.9%) controls were HBsAg+ve (P < 0.001)
and 90 (28.5%) mothers were negative for HBV markers (Table). Of available
56 (17.7%) spouses (M:F::9:47), 25 (44.6%) were antibody positive (anti-
HBe and/or total anti-HBc), 4 (7.1%) were HBsAg positive. Of 102 available
siblings from 80 (25.3%) families, 27 (26.5%) were found to be antibody
positive, 19 (18.6%) were HBsAg+ve.
Conclusion: Nearly 72% of chronic HBV patients in India acquire HBV
infection through the mother. There is substantial evidence of present or
past HBV infection in mothers of chronic HBV patients, suggesting possible
perinatal transmission. Besides HBsAg, other antibody markers should be
used to identify past HBV infection in the mother
Index patients whose mothers were positive for HBV markers (N = 226)
Perinatal
transmission N %
Mother HBsAg+ve & ≥ 2 siblings
HBsAg+ve
Definite 40 17.7
Mother HBsAg+ve & 1 sibling HBsAg+ve
Or Mother antibody+ve & ≥ 2 siblings
HBsAg+ve
Highly likely 114 50.4
Mother antibody+ve & 1 sibling HBsAg+ve Probable 72 31.9
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Are Ethnicity and Gender Associated with Outcomes in Patients with
Primary Sclerosing Cholangitis (PSC)?
Toyia James-Stevenson, MD, Shaukat Aasma, MD, Fuad Azrak, MD,
Kristina Chacko, MD, Kamil Obideen, MD∗. Medicine/Digestive
Diseases, Emory University SOM, Atlanta, GA; Medicine, GI, University
of Minnesota, Minneapolis, MN and Medicine, William Beaumont
Hospital, Royal Oak, MI.
Purpose: To evaluate the role of gender, ethnicity, age and clinical charac-
teristics in the outcomes for PSC patients. Outcomes were defined as deaths,
compared separately for those who underwent transplant and those who did
not.
Methods: The medical records of patients diagnosed with PSC between
March 1983 and December 2006 were reviewed. The diagnosis was docu-
mented using cholangiographical and/or histological and biochemical crite-
ria. Data collected: age at diagnosis and transplant, gender, race, MELD at
presentation, all laboratory data at presentation, and survival after transplant
using chi-squared test, student t-test, and logistic regression where appropri-
ate. Kaplan-Meier curves and cox proportional hazards models were used to
compare survival.
Results: 56 patients were identified, 33(60%) males and 23(23%) females,
15(27%) blacks, 40(72%) whites. Mean age of diagnosis for blacks was 34.3
yrs compared to 45.4 yrs for whites (P = .001). Total bilirubin (tBili) at pre-
sentation was higher for males compared to females (8.1 vs. 2.9 respectively;
P = 0.01). When stratified by race and gender, black males had significantly
higher MELD scores than black females (19 vs. 12 respectively; P = 0.04).
No such differences were found between white males and females. 34 pa-
tients(61%) underwent liver transplant, 17 males and 17 females (28 whites
and 6 blacks). The mean age at transplant for blacks was 42 yrs compared to
49 yrs for whites (P-value NS). 22 patients died during the follow-up period.
Among those who underwent transplant, age at diagnosis was significantly
associated with survival (HR 1.10; 95% CI 1.02–1.20; P = 0.027). Median
survival was similar among all groups. Among those that did not undergo
transplant, age at diagnosis (HR 1.05; 95% CU 1.01–1.11; P = 0.04), tBili at
presentation (HR 1.05; 95% CI 1.01–1.11; P-value 0.008) and MELD score
at presentation (HR 1.18; 95% CI 1.07–1.30; P = 0.001) were associated
with survival.
Conclusion: Black patients with PSC are diagnosed at a younger age. At
presentation, black males have higher MELD scores and tBili than black
females. Age at diagnosis is associated with survival after transplant. Age
at diagnosis, MELD and total bilirubin at presentation are associated with
survival for those that do not undergo transplant. Larger studies are needed
to evaluate these factors.
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Patients with Hypertension and Diabetes Mellitus Undergoing
Interferon Therapy for Treatment of HCV Are Not at Higher Risk To
Develop Ophthalmologic Complications
James D. Panetta, DO, Camron Kiafar, DO, Elizabeth A. Evanich, NP,
Nooman Gilani, MD, FACG∗. Department of Medicine and Research,
Section of Gastroenterology, Carl T. Hayden VAMC, Phoenix, AZ.
Purpose: To determine the frequency and risk factors related to
interferon-associated ophthalmologic complications during treatment for
hepatitis C.
Methods: Review of records from a cohort of patients undergoing HCV
treatment between January 2005 and May 2007. Patients were treated with
ribavirin in addition to either pegylated INF α-2a, α-2b or consensus INF. A
mandatory, baseline ophthalmologic examination was performed on each pa-
tient prior to initiation of treatment. Data recorded included genotype, treat-
ment duration, type of INF used, presence of prior eye disease/complaints,
presence of DM / HTN, visual complaints during treatment and findings at
baseline and follow-up eye exams. Any visual complaints during therapy
prompted immediate evaluation by an eye specialist.
Results: A total of 183 patients treated for HCV were included in the study
cohort. Seventy-one (38.7%) received interferon α-2a, 100 α-2b (54.6%) and
12 (6.5%) consensus INF. Treatment duration was 1 to 48 weeks (mean =
27.6). Age range was 31 to 72 years (mean = 52.9) and 95% were men.
Twenty-nine (15.8%) had DM, 85 (46.2%) HTN and twenty-one (12.5%)
had both DM and HTN. One patient with DM + HTN had retinopathy
(cotton wool spots) at baseline exam. During treatment 16 (8.7%) had vi-
sual complaints, but only 3/16 (18.75%) found to have retinal changes. In
addition 4 (2.2%) asymptomatic patients had retinopthay on routine follow-
up examinations. Overall 7 (3.82%), (6 during treatment) had documented
retinal changes (6 CWS, 1 optic neuritis). Of 7 with retinal changes, 1
(14.2%) had DM, 3 (42.8%) HTN and 1 (14.2%) had both. Of these, 5
were on α-2b and 2 on α-2a. Three patients required treatment discontin-
uation 44, 20 and 2 weeks earlier than scheduled. These included asymp-
tomatic worsening CWS(1), symptomatic CWS(1) and symptomatic optic
neuritis (1).
Conclusion: In our study, both the incidence of symptomatic retinopa-
thy and resultant treatment discontinuation rate appears very low 3/183
(1.63%) during treatment with PEG INF/ribavirin. The majority of pa-
tients who experienced visual symptoms during treatment had no evidence
of retinopathy (81%). Diabetes and hypertension do not appear to be pre-
dictors for the development of clinically significant interferon-associated
retinopathy.
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A Comparison of Polyethylene Glycol Laxative and Placebo for Relief
of Constipation from Constipating Medications
Jack A. Di Palma, MD∗, Mark B. Cleveland, PhD, John McGowan, Jorge
L. Herrera, MD. Division of Gastroenterology, University of South
Alabama, Mobile, AL and Braintree Laboratories, Inc., Braintree, MA.
Purpose: Medications often cause constipation and little data are available
concerning treatment interventions. This study was designed to evaluate the
safety and efficacy of polyethylene glycol (PEG) 3350 laxative (MiraLax)
for relief of constipation from medicines associated with symptoms of con-
stipation.
Methods: Study subjects were enrolled who met defined criteria for chronic
constipation and were also taking medications that were associated with a
reported side effect incidence of more than 3% constipation. Study subjects
were randomized into a double-blind, parallel, multi-center study where they
received 17 grams per day PEG laxative or placebo for 28 days. The primary
efficacy variable, treatment success, was defined as relief of modified ROME
criteria for constipation over the treatment period. Various secondary mea-
sures were also assessed. Daily bowel movement experience, patient percep-
tion of efficacy and safety information were recorded in a diary. Laboratory
testing was performed at baseline and monthly for hematology and blood
chemistry, including BUN, calcium, electrolytes, and TSH.
Results: 100 patients were enrolled in 4 study centers. Successful treat-
ment according to the primary efficacy variable was seen in 78.3% of PEG
and 39.1% of placebo subjects (P < 0.001). Similar results were observed
in a subgroup of 28 elderly subjects. Secondary measures of number of
bowel movements, complete bowel movements, satisfactory bowel move-
ments, straining at stool and stool consistency also showed statistically sig-
nificant results in favor of PEG compared to placebo (P ≤ 0.001) after the
first week of treatment. There were no differences in patient reported scores
for gas, cramping, or bloating between PEG and placebo. No significant
differences in laboratory findings or adverse events, including the gastroin-
testinal category, were observed. Diarrhea, flatulence, and nausea occurred
more frequently with PEG treatment, although they were not individually
statistically different from placebo. Similar results were observed when these
symptoms were analyzed for differences due to gender, race, or age.
Conclusion: PEG laxative is safe and effective for use in treating constipa-
tion in patients taking constipating medications.
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Expandable Metal Stents for Obstructing Lesions of the Colon as
Bridge Therapy: An Alternative to Emergent Surgery
Aravind S. Vijayapal, MD, Kiely M. James, MD, Brasel J. Karen, MD, Dua
S. Kulwinder, MD∗. Medicine, Division of GI & Hepatology, Medical
College of WI, Milwaukee, WI and Surgery, Medical College of WI,
Milwaukee, WI.
Purpose: Emergent colorectal surgery for colonic obstruction is associated
with higher morbidity and mortality in comparison to elective non-emergent
surgery. Endoscopically placed self expanding metal stents (SEMS) allow
decompression of the colon and are used as palliative treatment obviating
the need for surgery. The use of SEMS in the treatment of acute colonic
obstruction in a resectable operative patient however has not been widely
studied. We hypothesized that SEMS when used as bridge therapy prior to
elective surgery for obstructing colon lesions (malignant or benign) would
be a cost-effective strategy allowing for colon preparation, optimization of
medical condition and a one-stage operation with resection and primary
reanastomosis.
Methods: Review of medical records over a 4-year period identified 11
patients in Group A (mean age 71 ± 10.4, male 9, female 2) and 6 pa-
tients in Group B (mean age 60 ± 12.7, male 1, female 5). Two patients in
Group A had benign strictures. Eight of 11 patients in Group A underwent
elective resection with primary re-anastomosis, 2 underwent resection with
colostomy due to low-lying tumors and 1 patient expired (refused surgery).
Two patients in group B had adenocarcinoma and 4 had benign strictures.
Surgical interventions included sigmoidectomy with colostomy (N = 3) and
diverting loop colostomy (N = 3). Procedural cost data were collected. Cost
and complications of further surgical interventions in Group B were not in-
cluded. Data were compared by the rank sum test and Chi squared test where
appropriate.
Results: There were no technical difficulties in placing the stents. The mean
duration between stent placement and elective surgery was 37.5 ± 57.0 days.
Mean survival in Group A was 507.9 ± 404.4 days. One patient (9%) required
SEMS removal due to stent migration post neoadjuvant chemoradiation. Two
patients (33%) in Group B had post-operative complications. Mean survival
in Group B was 605 ± 644.4 days.
Conclusion: We conclude that SEMS followed by elective surgery for acute
obstructive lesions of the colon in a resectable, operative patient is efficacious
and more cost-effective compared to the traditional alternative of emergent
surgery.
Cost-benefit analysis of SEMS and elective
surgery versus emergent surgery
Cost Morbidity Mortality Overall survival
Group ($) (%) (%) (mean, days)
A 2,500∗ 9.1 0 507.9
B 4,755 33.3 0 605.2
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Views and Practice of Gastroenterologists Regarding High Fiber Diet
and Fiber Supplementation in Patients with Colonic Diverticulosis
Nirmal S. Mann, MD, FACG∗, Suk Seo, MD
.
Purpose: There is no uniformity of practice about the role of high fiber diet
(HFD) and fiber supplementation (FS) in patients with colonic diverticulo-
sis (CD). We wanted to find out how many practising gastroenterologists
recommend HFD & FS for patients with CD.
Methods: Members of AGA or ACG were r contacted by phone or personal
interview about their views & practices on this issue. The trainee members
were not contacted. None of the physicians contacted declined to partici-
pate: participation was 100%. After the survey, information about the age
of respondents was obtained from AMA& ABMS Directories. They were
divided into 2 Groups: group I respondents were 49 years or younger; group
II respondents were 50 years or older.
Results: There were 107 gastroenterologists in this survey. There were 11
(10.2%) women. The mean age was 53.0 yrs (range 32–95). Possible mecha-
nism of CD in lay terms was discussed with patients by 16/107(15%). 10/16
discussed it verbally; 2/16(12.5%) gave written material; 4/16 (25%) gave
both verbal & written discussion. 14/16(87.5%) physicians themselves dis-
cussed it with patient & relatives; 2/16(12.5%) cases nurses discussed it.
91/107(85%0 did not discuss the mechanism of CD; 47/91 thought pa-
tient would not understand it; 62(68.1%) had no time for it. HFD was
recommended by 67/107(62.7%); 31/67 gave such instructions verbally;
13/67(19.4) gave written instructions; 23/67(34.4%) gave both written &
verbal. In 17/67 (25.3%) instructions by physician; 48/67(71.6%) nurses
& 2/67(2.9%) times dietitians gave instructions. 40/107 (37.3%) did not
give HFD instructions; 35/40(87.5%) felt they were not effective & not
needed; 8/40(20.0%) had no time for it; 2/40(5.0%) said it causes gas.
Seedless diet was recommendedby 34/67(50.8%) of those who recom-
mended HFD; 33/67(49.2%) did not recommend seedless diet. FS was
recommended by 55/107(51.4%); 46/55(83.7%) prescribed powder form;
9/55(16.3%) prescribed capsules or tablets. 52/107(48.6%) did not recom-
mend FS; 28/52(53.8%) felt it is not effective; 30/52(57.6%) thought it causes
gas. There were 43/107(40.1%) in Group I; 64/107(59.8%) in Group II.
The mean age of Group I was 40.0 (range 32–49) yrs; the mean age of
Group II was 60.0(range 50–95) yrs. In Group I HFD was recommended
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by 19/43(44%), in Group II HFD was recommended by 52/64(81.2%). FS
was recommended by 16/43(37.2%) in Group I; it was recommended by
41/64(64.0%) inGroup II. These differences are significant (Chi Sq, P <0.05)
Conclusion: Majority of GI docs advise HFD & FS; significant minority do
not. Younger GI docs less likely to advise HFD & FS. Powder form of FS
most common.
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The Effectiveness of Microscopic Colitis Treatments Based on Patient
Demographics
Jennifer J. Fan, Jean Marie F. McGowan, Leslie Bank, MD∗. State
University of New York, Binghamton, Binghamton, NY and
Gastroenterology, United Medical Associates, Binghamton, NY.
Purpose: Our aim was to create a preliminary study that analyzed the overlap
or distinction between effective treatments for MC, LC and/or CC based on
patient demographics and responses.
Methods: Pathology reports of 62 Patients diagnosed with MC, CC, or LC
were compiled into a list from the Pathology department of United Medi-
cal Associates of Binghamton, New York. Patient demographic data were
recorded into charts under the appropriate categories (LC or CC or MC).
Responses to the nine treatments were recorded on a scaling system of 0–4,
with 0 being No Response and 4 being Remission. The proper statistical
tests were performed to find any significant difference in the demographics
of patients with different types of colitis, average patient responses within
the nine treatments, and average patient responses to each of the nine treat-
ments between colitis types. The nine treatments were then organized into
three categories (1-change in diet/fiber supplements; 2-over the counter; 3-
prescribed). The proper statistical analysis was employed to find significant
difference in average patient responses within the 3 treatment categories,
and average patient responses to each of the above three categories between
colitis types.
Results: 28 Patients (mean age = 57.3 ± 14.5) have LC. 21 Patients (mean
age = 62.5 ± 14.4) have CC. 8 Patients (mean age = 53.5 ± 9.96) have MC.
4 Patients (mean age = 62.8 ± 6.65) have both LC and CC. 1 Patient has
CC and MC. There was no significant difference in patient demographics
between treatment groups, and between treatment responses for different
colitis types for patients that underwent each of the nine treatments or the
three treatment categories. There was a significant difference in average
patient responses to Entocort treatment compared to responses to change
in diet or responses to Imodium/Lomotil F(6,87) = 6.044, P < .05, and
average patient responses to prescription drug treatment category compared
to responses to over-the-counter medications or responses to fiber/change in
diet. F(6,87) = 6.044, P < .05.
Conclusion: There was no correlation between types of colitis diagnosed,
patient demographics and effectiveness of treatments. Entocort/Budesonide
was a more effective treatment than diet change or use of anti-diarrhea med-
ications, especially for CC patients. A larger prospective study is planned.
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A Novel Artificial Magnetic Sphincter To Prevent Fecal Incontinence
Mauro Bortolotti, MD∗, Giampaolo Ugolini, MD, Annamaria Grandis,
VD, Giosue Mazzero, MD, Isacco Montroni, MD. Internal Medicine and
Gastroenterology, University of Bologna, Bologna, Italy; Surgical and
Anaesthesiological Sciences, University of Bologna, Bologna, Italy and
Veterinary Morphophysiology, University of Bologna, Bologna, Italy.
Purpose: Fecal incontinence due to low or absent tone of the anal sphincter
represents, especially in the elderly, a problem that to date has not found
yet a satisfactory solution in a not negligible number of patients (Br J Surg
2007;94:134). In this research we propose an original magnetic device to
strengthen the hypotonic anal sphincter and prevent fecal incontinence.
Methods: The device consists in a couple of small magnetic plaques that
are surgically inserted in the wall of the anal canal with the opposite polar-
ities face-to-face, so that, attracting themselves, close the anal lumen. The
study was carried out in 3 swine anatomical preparations. Three couples
of magnets of ovoidal shape made of materials of different magnetic force
(neodimium>ferrite>plastoferrite) were tested. The magnets of each cou-
ple were inserted in two pouches on both sides of the anal canal between the
external and internal anal sphincters. Each couple of magnets was tested in
each preparation by doing, both before and after implantation, 3 trans-anal
pull-throughs of a thin manometric catheter. The mean pressures obtained
before and after magnet insertion were statistically compared with the Stu-
dent t test.
Results: The endoanal pressure after the insertion of neodinium magnets was
79.7 ± 13.1 mmHg (mean ± SD), after ferrite magnets 42.1 ± 5.6 mmHg
and after plastoferrite magnets 21.6 ± 4.6 mmHg, all of them significantly
higher than the pressure recorded in basal conditions (1.72 ± 0.71 mmHg).
Conclusion: The present research demonstrated that the implantation of a
couple of magnets in the wall of the anal canal is able to create a high pressure
zone (HPZ), the value of which may be modulated by choosing magnets
of various attraction force, so allowing a “tailored correction” of the anal
sphincter hypotension. The main advantage of this system lies in the fact that
the magnets create a “dynamic closure”, the mechanism of which has been
previously demonstrated (J Biomechanics 2006;39:564): when the magnets
are detached by the endoluminal pressure increase above the HPZ, they leave
a passage that allows an easy transit of contents. Once verified “in vivo” in
animals the effectiveness and tolerability of this system with magnets of
proper strength covered by biocompatible material, this magnetic sphincter
could represent a simple and effective solution of the fecal incontinence.
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Intravenous Immunoglobulins for Clostridium Difficile Infection – A
Systematic Review
Anastasios Koulaouzidis, MD, MRCP, Syed Habib, MBBS, Saeed Ur
Rehman, MBBS, Naveen Honnappa, MBBS, DVD, John Moschos, MD,
PhD, Athar A. Saeed, FRCP∗. Gastroenterology, Llandudno Hospital,
Llandudno, Cowny, United Kingdom; Gastroenterology, 424 Army
Hospital, Thessaloniki, Greece and Gastroenterology, Queen Elizabeth
Hospital, Gateshead, United Kingdom.
Purpose: Clostridium Difficile enterocolitis (CDE) responds promptly to
oral metronidazole or vancomycin. Twenty to 35% of CDE patients though,
develop refractory infection despite appropriate treatment; this may lead to
colonic perforation, septicaemia and death (14%-25%). 1Emergency colec-
tomy (1.9%) in these circumstances is life saving. 2However, some patients
are unfit for colectomy due to co-morbidities; as well, the mortality rate from
such intervention is extremely high (57%).2 Leung et al., first in 1991, used
intravenous immunoglobulin (IVIG) in six children with relapsing CDE with
good results. Since then, IVIG was used for adult cases of CDE.
Aim: We conducted a systematic review in order to appraise the evidence
for IVIG treatment of CDE.
Methods: Computerized search. We used the MeSH terms [Clostridium
difficile] AND [immunoglobulins, intravenous]. Titles and abstracts were
reviewed and full papers of those considered relevant were obtained. Re-
views, editorials, letters and abstracts were not included.
Results: We found 7 case reports/series (28 subjects) and 1 case control retro-
spective analysis (18 subjects). A total of 46 patients received IVIG for refrac-
tory/recurrent CDE. Mean age of combined group was 70 years. The doses
used range between 150 mg/kg to 500 mg/kg. For 12 patients (26%) multiple
administrations (max. 6) were employed. We used three primary endpoint
measures i.e. CDE related deaths, recurrence/relapse and colectomies. Ther-
apeutic failure was 17.4% (8 deaths), 39.1% (18 relapses/recurrences) and
6.5% (3 colectomies), respectively.
Conclusion: Encouraging case reports for the use of IVIG in severe CDE,
in conjunction with evidence of impaired immune response to Clostridium
Difficile toxins in relapsing/recurrent CDE, have prompted more frequent
use of IVIG. Despite similar recurrence and colectomy rates, the benefit of
IVIG as salvage treatment for severe CDE is such to justify both its ad hoc
use and prospective randomised control trials
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Fermentation of Wheat Dextrin, Psyllium, and Inulin Are Altered but
Not Improved by the Addition of Lactobacillus reuteri
Joanne L. Slavin, PhD, Ashley Januszweski, BS, Alberto Paredes-Diaz,
MD, Vincenzo Savarino, MD, Maria L. Stewart, MS∗. Food Science and
Nutrition, University of Minnesota, St. Paul, MN; Novartis Consumer
Health, Parsippany, NJ and Gastroenterology Unit, Dipartimento di
Medicina Interna, Genova, Italy.
Purpose: Lactobacillus reuteri is a probiotic bacteria that has beneficial
health effects when consumed orally such as decreased cholesterol, de-
creased diarrhea, and improved immunity. However, the interactions between
L. reuteri and dietary fibers in the colon have not been extensively researched.
This study characterized the effect L. reuteri has on the fermentation of wheat
dextrin, psyllium, and inulin.
Methods: In vitro batch fermentation with human fecal inoculum was used
to mimic colonic conditions. Wheat dextrin, psyllium, and inulin were in-
cubated with added L. reuteri (∼1012 cfu/mL, LR+) or in the absence of L.
reuteri (LR-). Samples were removed at 0, 4, 8, 12, and 24 hours for short-
chain fatty acid (SCFA) analysis. Short-chain fatty acid concentrations were
detected by GC-FID, and data was analyzed with SAS statistical software
package (v.9.1).
Results: L. reuteri affected SCFA production by all fibers. Inulin LR+ had
increased total SCFA, propionate, and butyrate concentrations at 4 and 24
hours, compared to inulin LR-. Inulin LR+ had decreased total SCFA, pro-
pionate, and butyrate at 8 and 12 hours compared to inulin LR-. Acetate
production by inulin followed a similar trend, but was not significantly dif-
ferent at 12 and 24 hours. Psyllium LR+ had decreased total SCFA at 12
hours, decreased acetate at 12 hours, decreased propionate at 12 hours, and
increased butyrate at 12 and 24 hours compared to psyllium LR-. Wheat
dextrin LR+ had increased total SCFA at 8 hours, increased acetate at 4 and
8 hours, increased propionate at 4 hours, and increased butyrate at 4, 8, and
12 hours compared to LR-. LR+ favored butyrate production for psyllium
(at the expense of propionate) and inulin (at the expense of acetate) at 24
hours. LR+ favored propionate production for wheat dextrin (at the expense
of acetate) at 24 hours.
Conclusion: L. reuteri acts to improve different aspects of fermentation
dependent on the type of fiber. Fibers should be combined with L. reuteri
based on the desired fermentation pattern. Structural differences between
the three fibers are likely the reason for differences in L. reuteri’s effects
in fermentation. Wheat dextrin was steadily fermented, while psyllium and
inulin were both rapidly fermented, suggesting more flatulence and bloating
in vivo.
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Prevalence of 5-ASA Use in Diverticulitis and Diverticulosis by Age
and Gender
Seymour Katz, MD, Eamonn Quigley, MD, Fergus Shanahan, MD, Antonio
Tursi, MD, Simon Magowan, MD, Neil Accortt, PhD, Kevin Taylor, MSc,
George Parks, MD∗. Nassau Gastroenterology Associates, Great Neck,
NY; National University of Ireland, Cork University Hospital, Cork,
Ireland; Lorenzo Bonomo Hospital, Andria, Italy; P&G Pharmaceuticals,
Mason, OH and The Queens University of Belfast, Ireland.
Purpose: The purpose is to determine the prevalence of 5-ASA use in di-
verticular disease by age and gender.
Methods: This observational study used records of health service utilization
from multiple US health plans within the Thomson Medstat MarketScan
research database. The subjects studied during the period July 2004 to June
2005 were ≥ 18 years of age with a diagnosis of diverticulitis (ICD-9: 562.11,
562.13) or diverticulosis (ICD-9: 562.10, 562.12). Inflammatory disease
activity was determined by calculating the ratio diverticulitis prevalence to
diverticulosis prevalence (D-ratio). 5-ASA use was defined as any use within
6 mos of diagnosis date. Subjects with a diagnosis of inflammatory bowel
disease were excluded from the analysis.
Results: 2,109 (0.75%) patients were found to be on a 5-ASA from a total
population of 281,665 patients with any diagnosis of diverticular disease.
5-ASA use was highest in the 18–29 age group. The ratio of diverticulitis to
diverticulosis was highest among the youngest patients, particularly among
males.
Prevalence Ratesa of Disease and% 5-ASA Use by Age & Gender
Age Group Diverticulitis Diverticulosis D-ratio % 5-ASA Use
(years) Male/Female Male/Female Male/Female Male/Female
18–29 0.53/0.21 0.56/0.32 0.95/0.66 1.65/2.15
30–39 2.14/0.92 2.25/1.45 0.85/0.63 0.88/0.88
40–49 3.97/2.67 7.44/5.76 0.53/0.46 0.67/0.88
50–59 6.13/5.84 27.78/24.45 0.22/0.24 0.52/0.76
60–69 7.72/9.66 40.15/39.54 0.19/0.24 0.58/0.79
70–79 8.97 /12.55 46.78/47.96 0.19/0.26 0.79/1.03
80–99 9.51/12.43 40.65/37.94 0.23/0.33 0.82/0.94
Mean 58.6 yr/63.0 yr 62.6 yr/63.9 yr 0.25/0.28 0.65/0.87
aRates per 1000 population
Conclusion: The higher ratio of diverticulitis to diverticulosis in the younger
population reflects the more aggressive nature of the disease in this patient
subtype. 5-ASA use occurs across all decades of patients with diverticular
disease, albeit at a low level, but is highest in the younger patient popula-
tion indicating increased usage in a subtype often associated with a more
aggressive clinical course.
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5-ASA Treatment Practices among Physician Subspecialties in
HIV-Associated Diarrhea
Maribel Rodriguez-Torres, MD, Joel Scales, MA, Simon Magowan, MD∗.
Fundacion De Investigacion De Diego, San Juan, Puerto Rico and Procter
& Gamble Pharmaceuticals, Mason, OH.
Purpose: 5-ASA has recently demonstrated efficacy in HIV-associated col-
itis. Limited data exists on the pattern of 5-ASA use among physicians. The
purpose of this analysis was to assess attitudes and patterns of 5-ASA use
in chronic noninfectious diarrhea among different physician specialties.
Methods: 301 US physicians treating a large number of HIV(+) patients
from 5 major geographical regions were surveyed from 2 specialties; primary
care (N = 151; 89 internal medicine and 62 family/general practice; PCP)
and infectious disease (N = 150; ID). Physicians were questioned on their
1st, 2nd, and 3rd line treatment practices for noninfectious HIV-associated
Table 1. Clinical Parameter
PCP ID
HIV patients per physician 170 221∗
Chronic diarrhea prevalence 20% 13%∗
Very concerned re:diarrhea 70%∗ 55%
Decreased incidence/5 years 36% 65%∗
Currently use Asacol in these patients 38%∗ 13%
Likely to switch HIV therapies as a first 10% 25%∗
line treatment for chronic noninfectious diarrhea
∗P < 0.05
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chronic diarrhea (HIV-ACD) along with the prevalence and relevance of the
disease in their HIV patients.
Results: There were significant differences in HIV practice patterns (Table 1)
and hierarchal use of 5-ASA between PCPs and ID physicians (Table 2).
PCPs reported a significantly higher prevalence and concern for HIV-ACD
than ID (P < 0.05). This was associated with a significantly higher use of
5-ASA in the 1st and 2nd line of therapy. More than a third (38%) of primary
care physicians use 5-ASA therapy for HIV-ACD, compared to only 13% of
ID (P < 0.05).
Table 2.
PCPs (N = 151) IDs (N = 150)
Treatment 1st 2nd 3rd 1st 2nd 3rd
Options Line Line Line Line Line Line
5-ASAs 15% 22% 25% 1% 1% 11%
OTC Medications∗ 91% 56% 21% 94% 61% 16%
No Treatment 1% 20% 1% 1% 28% 47%
∗Imodium (96% PCP, 98% ID); Lomotil (91% PCP, 95% ID); Bulk agents (89% PCP,
88% ID)
Conclusion: There is a significant disparity in the attitudes and therapeutic
approach for HIV-ACD among PCP and IDs. Further research is needed to
assess the reason for these differences.
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Colonoscopy with Withdrawal Times (WT) > 6 Minutes Detects More
Polyps That Are Mostly Small and Hyperplastic (H) but Also a Few
That Are Larger and Neoplastic (A)
John M. Haydek, MD∗, John P. Haydek, Chris M. Haydek.
Gastrointestinal Associates, Knoxville, TN.
Purpose: Colonoscopy (C) is now an accepted standard as a screening test
for colon cancer (CA). A recent published article demonstrated greater ef-
feciently at polyp detection with colonoscopy withdrawal times >6 min. We
Description Study Group Control Group
age (yrs) 58 ± 12.5 58 ± 12.7
C with no polyps 137/300 (46%) 159/300 (53%)
C with any polyps 163/300 (54%) 141/300 (47%)
C with A polyps 104/300 (35%) 102/300 (34%)
C with H polyps 75/300 (25%) 49/300 (16%)
WT no polyps 6.58 ± 1.7 min ?????
WT with polyps 9.68 ± 3.2 min ?????
Polyps removed-total 322 263
Polyps removed-A 183 (57%) 175 (67%)
Polyps removed-H 112 (35%) 75 (29%)
cancer 5 (1.6%) 1 (0.4%)
other 22 (7%) 12 (5%)
Polyp size-<5 mm total 117 (36%) 52 (20%)
<5 mm-A 46 (39%) 24 (46%)
<5 mm H 61 (52%) 25 (48%)
<5 mm other (CA) 10 (0) 3 (0)
5–10 mm total 189 (59%) 202 (77%)
5–10 mm A 126 (67%) 144 (71%)
5–10 mm H 51 (27%) 49 (24%)
5–10 mm other (CA) 12 (1) 9 (0)
>10 mm total 16 (5%) 9 (3%)
>10 mm A 11 8
>10 mm H 0 0
>10 mm other (CA) 5 (4) 1 (1)
C = colonoscopy, A = adenomatous, H = hyperplastic, CA = cancer
hypothesized that the majority of polyps found would be small and hyper-
plastic.
Methods: 300 consecutive outpatient colonoscopies from Feb 2007 to May
2007 were evaluated and compared to 300 similiarly aged colonoscopies
from Feb 2006 to May 2006. All were performed by a single fellowship
trained gastroenterologist. Study exclusions were incomplete colonoscopy,
colonoscopy associated with complications, previous colonoscopy in the
past 2 yrs, poor prep and previous colon resection. All 2007 colonoscopies
had withdrawal times > 6 min as defined as the time from cecal identification
to withdrawal across the anus. No withdrawal information was available for
2006 data but was assumed to be less then 6 minutes by experience. All
polyps were measured and removed in a standard fashion.
Results: See table below.
Conclusion: Colonoscopy with withdrawal times>6 minutes leads to higher
polyp detection rates, especially for small (<5 mm) hyperplastic polyps.
However, 4 additional cancers and 3 adenomatous polyps > 10 mm were
seen in the study group over the control group. Since 4 of the 5 cancers were
large and obvious, one must suspect an effect of sampling error. Repeating
the study with a higher # of study patients would be beneficial.
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Small (<5 mm) Right Sided Polyps (P) Are More Likely Adenomatous
(A) Then Small Left Sided Polyps during Colonoscopy (C)
John M. Haydek, MD∗, John P. Haydek, Chris M. Haydek.
Gastrointestinal Associates, Knoxville, TN.
Purpose: C with P removal is felt to be key in the reduction of colon cancer.
All P found during C should be removed. A recent article has been published
showing a higher P detection rate with withdrawal times (WT) > 6 min. We
thus set out to determine the distribution and pathology of the increased
amount of P removed.
Methods: 300 consecutive outpatient C from Feb 2007 to May 2007 were
evaluated and compared to 300 similiarly aged C from Feb 2006 to May
2006. All were performed by a single fellowship trained gastroenterologist.
Study exclusions were incomplete C, complicated C, previous C in the past
2 years, poor prep and previous colon resection. All 2007 C had WT > 6
min. All P were measured and removed in a standard fashion.
Results: 322 P were found in 163 study patients (SP) as compared to 263
P in 141 controls. Please see table for P distribution and path breakdown.
In SP, 136 P were right (R) sided (cec/asc/trans) and 186 were left (L) sided
(desc/sig/rec). In controls, 135 P were R sided and 128 were L sided. See
table 2 for P information concerning <5 mm P only.
All polyps removed
Location Study Control
cec 34 27
<5 mm/5–10/>10 19/13/2 10/16/1
A/H/O/CA 25/5/4/1 19/6/2/1
asc 36 56
<5 mm/5–10/>10 13/22/1 11/40/5
A/H/O/CA 30/2/4/0 52/2/2/0
trans 66 52
<5 mm/5–10/>10 17/46/3 3/47/2
A/H/O/CA 57/6/3/1 47/3/2/0
desc 43 23
<5 mm/5–10/>10 10/31/2 4/19/0
A/H/O/CA 22/15/6/1 14/7/2/0
sig 75 57
<5 mm/5–10/>10 27/44/4 10/46/1
A/H/O/CA 36/35/4/0 33/22/2/0
rec 68 48
<5 mm/5–10/>10 31/33/4 14/34/0
A/H/O/CA 13/50/5/2 9/36/3/0
A = adenomatous, H = hyperplastic, O = other, CA-cancer
Abstracts S253
Conclusion: C WT >6 min leads to a higher P detection rate in almost all
sections of the colon, but especially in the L colon. Small P (<5 mm) have
a very high chance of being A in the R colon as compared to the L colon,
especially the rec. Thus endoscopists should spend more time evaluating and
removing small R sided P rather then small L sided P.
<5 mm polyps only
Location (Total #) A H O
cec S (19) 13 4 2
C (10) 6 4 0
CB (29) 19 (65%) 8 (28%) 2
asc S (13) 9 2 2
C (11) 11 0 0
CB (24) 20 (83%) 2 2
trans S (17) 15 2 0
C (3) 3 0 0
CB (20) 18 (90%) 2 0
desc S (10) 3 6 1
C (4) 2 1 1
CB (14) 5 (36%) 7 (50%) 2
sig S (27) 6 19 2
C (10) 1 9 0
CB (37) 7 (19%) 28 (76%) 2
rec S (31) 0 28 3
C (14) 1 11 2
CB (45) 1 39 (87%) 5
S = study, C = control, CB = combined
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C-Reactive Protein and the Risk of Colorectal Adenoma in Apparently
Healthy Populations
Sung Keun Park, Dong Il Park,∗, Hong Ju Kim, Chong Il Shon, Byung Ik
Kim, Woo Kyu Jeon. Internal Medicine, Sungkyunkwan University School
of Medicine, Seoul, Korea.
Table 1. Comparison baseline characteristics between the control group and patients
with colorectal adenoma
Colorectal
Control group adenoma group P
Characteristic (N = 3505) (N = 1982) value
Mean age (years) 54.7 ± 6.6 62.3 ± 6.1 <0.05
Male-no
(%)/Women-no
2074(59.1%)/1431 1404(70.8%)/578 <0.05
Current smokers-no (%) 590(16.8%) 310(16.1%) 0.471
Current user of post
menopausal
hormones
Women-no(%)
110(3.1%) 89(4.4%) 0.512
Current user of aspirin
–no(%)
511(14.5%) 220(11%) 0.184
Current user of
multivitamins-no(%)
87(2.4%) 52(2.6%) 0.861
Body mass index-kg/m2 24.5 ± 2.8 25.0 ± 3.0 0.576
Fasting glucose (mg/dL) 100.0 ± 25.4 104.0 ± 30 0.431
C-reactive protein
(mg/L)
1.4 ± 0.2 1.7 ± 0.25 0.126
Family history of
colorectal
cancer-no(%)
114(3.2%) 75(3.7%) 0.381
Values are expressed as mean ± SE. Current user of post menopausal women (%):
percentage of the women taking the postmenopausal hormones in women. ∗Probability
value < 0.05 was considered significant.
Purpose: The purpose of this study is to evaluate the association between
serum CRP levels and the risk of colorectal adenoma
Methods: 3505 normal control subjects and 1982 patients with colorectal
adenoma were included in the study. The Mean level of CRP was compared
between two groups, and correlation with other variations was analyzed by
multiple regression analysis.
Results: There were significant differences in serum CRP level between two
groups (Table 1). Multiple regression analysis revealed that the CRP level
were not associated with the risk for colorectal adenoma (Table2).
Conclusion: CRP was not predictive of a higher risk for colorectal adenoma.
Table 2. Multiple regression analysis between the presence of colorectal adenoma
and some variables including C-reactive protein
Variables Regression Standard Chai-square P
C-reactive protein 0.403 0.627 0.414 0.520
Age 0.086 0.020 16.899 0.021
Sex −1.011 0.362 7.796 0.042
Body mass index 0.079 0.052 2.275 0.131
Fasting glucose 0.630 0.362 3.032 0.081
Smoking 2.417 0.871 2.934 0.087
Aspirin using 1.861 1.129 2.718 0.099
Postmenopausal 0.559 1.112 0.253 0.615
hormone using
Multivitamine using 0.062 0.730 0.007 0.933
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Colonoscopy Scheduling for Elderly Patients: Morning or Afternoon
Sessions and Does It Make a Difference?
Anthia Gatopoulou, MD, Elmuhtady Said, MBBS, Anastasios
Koulaouzidis, MD, MRCP, Anand Reddy, MRCP, Jitendra N. Singh,
MRCP, Athar A. Saeed, FRCP∗. Gastroenterology, Queen Elizabeth
Hospital, Gateshead, United Kingdom and Gastroenterology, Llandudno
Hospital, Llandudno, United Kingdom.
Purpose: Colonoscopy in the elderly can be a technically challenging pro-
cedure and it may result, in case of incomplete tests, in inconvenience and
extra healthcare costs. Time of colonoscopy is an easily modifiable factor, if
it proved to impact on the completion rate.
The aim of the study was to determine whether the time of a test (morning
or afternoon session) impact on the success rate of cecal intubation.
Methods: We retrospectively reviewed all colonoscopies performed between
March 2006 and 2007 in an endoscopy unit of a District General Hospital
in UK. Patients aged ≥ 75 years old were considered as elderly. Time of
procedure was classified as morning (if before 12:59 hr) or afternoon session
(if after 13:00 hr) and preparation as good or poor, according to report.
Results: A total of 1885 colonoscopies was performed; (morning proce-
dures 630, 347 [female] and 283 [male]; afternoon procedures1255, 698
[female] and 557 [male]). Four hundred eighty three (483) were performed
in elderly patients, ([female] 286, [male] 197) and 324 in afternoon sessions
([female]196, [male]128). In 284 patients (83 morning, 201 afternoon) ex-
amination failed cecal intubation (15%) and in 235 (12.4%) preparation was
poor (78 in morning sessions). Higher incompletion rate was found in el-
derly 93/483 (19.25%) vs. younger patients 191/1402 (13.6%), P < 0.05 and
among women 184/1045 (17.6%) vs. men 100/ 840 (11.9%), P < 0.001; on
the other hand, men ≥75 years old had worse preparation ([female] 28/286
or 9.9% vs. [male] 32/ 197 or 16.2%, P < 0.05). Regarding the afternoon
sessions, [female] ≥75 years old had higher cecal intubation failure rate
than [female] < 75 years old (elderly [female] 46/196 or 23.4% vs. younger
[female] 83/502 or 16.5%, P < 0.05) and than elderly men, as well (elderly
[female] 46/196 or 23.4% vs. elderly [male] 16/128 or 12.5%, P < 0.05). No
differences were observed in preparation either between sessions or between
elderly and younger patients.
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Conclusion: Afternoon colonoscopies have an impact on the completion
rate, especially in elderly women. Scheduling these colonoscopies in morn-
ing sessions might avoid the need for further procedures.
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The Association of Diabetes Mellitus and Colorectal Cancers
Samir L. Habashi, MD, Juan C. Munoz, MD∗, Kenneth Vega, MD.
Gastroenterology, University of Florida Health Science
Center/Jacksonville, Jacksonville, FL.
Purpose: The aim of the study is to determine the association of diabetes
mellitus with the subsequent development of colorectal cancer.
Methods: The endoscopy database at University of Florida /Jacksonville
was reviewed retrospectively to identify all patients with masses discovered
on colonoscopy from June 2003 to November 2005. Inclusion criteria were
the presence of a colonic mass and a histologic diagnosis from the mass.
Study subjects then had their medical records reviewed for the following
information: age, gender, ethnicity, presenting symptoms for colonoscopy,
presence of diabetes, body mass index, endoscopic location of masses and
tumor stage. The data were analyzed using Chi Square & univariate analysis
Results: 230 patients who met inclusion criteria comprise the study popula-
tion. Of the 230 colon masses, 134 were adenocarcinomas, 20 were normal
mucosa & the rest were adenomas. Out of the 230 patients, 57 were diabet-
ics & the rest were non diabetics. The mean age of the patients was 66.62.
123 patients were males and 107 were females. One hundred and nineteen
patients were black, one hundred and six were white, three were Asians
and two patients were Hispanics. Of the 230 patients with colon masses,
31 presented for colon cancer screening, 18 with heme positive stools, 76
with hematochezia, 24 with history of colon polyps, 42 with anemia, 14
with change of bowel habits, 3 with personal history of colon cancer and the
rest had other reasons for colonoscopy (7 with abnormal CT scan, 8 with
abdominal pain, one with family history of colon can & 6 with weight loss).
Forty seven tumors were found in the rectum, 48 were found in the sigmoid
colon, 20 were found in the descending colon, 31 in the transverse colon, 53
were found in the ascending colon, 30 tumors were found in the cecum and
one mass was found in the anal canal. 39% of diabetics with colon cancer
had cancer in the right side of the colon compared to 18.1% of non diabetics
(P = 0.0462) & 71.4% of diabetics with colon cancer had an early stage
cancer (no lymph node /metastasis) compared to 50% of non-diabetics (P =
0.12).
Conclusion: There was no association seen between DM and an increased
risk of colorectal cancer. However, diabetic patients with colon cancer had
proximal lesions more frequently than non-diabetic patients. DM patients
were also noted to have a lower cancer compared to the general population.
This may be due to the health care that diabetic patients receive in comparison
to the general population.
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Nurses Who Assist in Colonoscopy with Sedation On-Demand and a
Novel Technique of Water Infusion without Air Insufflation Evaluate
the Combination as Credible Options for Patient Care
Rodelei Siao-Salera, BSN, RN, Hazel Cabrera, RN, Joseph W. Leung, MD,
FACG∗, Dannie Prather, RN, Lee Toomsen, RN, Surinder K. Mann, MD,
FACG, Kanat Ransibrahmanakul, MD, Felix W. Leung, MD.
Gastroenterology, Sacramento VA Medical Center, VANCHCS, Mather, CA
and Gastroenterology, Sepulveda ACC, VAGLAHS and David Geffen
School of Medicine at UCLA, North Hills, CA.
Purpose: We hypothesize that nurses (being patients advocate) can recognize
impact of new options and methods on work load and are able to assess
credibility of these for CRC screening.
Methods: Veterans underwent colonoscopy using sedation on-demand
(SOD, at patients’ request) and water infusion (without air insufflation) for
CRC screening. 1. Procedure and recovery time in 30 randomly selected
veterans who accepted SOD and their assessment of experience were tabu-
lated. Satisfaction (0 = not satisfied, 10 = satisfied) was rated by veterans
before discharge and at 24 hours. Their willingness to repeat was recorded. 2.
Nine nurses provided anonymous evaluations of experience in assisting se-
dation on-demand and water infusion screening colonoscopy and completed
2 questionnaires using a 10 point scale (1 = no, 10 = yes).
Veterans Who Accepted Sedation On-Demand
Satisfaction Satisfaction Willing
Procedure Recovery Before at 24 to
Time Time Discharge Hours Repeat
Sedated 21.1 ± 2.5 27.7 ± 1.0 9.8 ± 0.2∗ 9.5 ± 0.2∗ 12 of 13∗
(N = 15)
Unsedated 18.9 ± 1.4 9.7 ± 1.0 9.9 ± 0.1 9.7 ± 0.2 14 of 15
(N = 15)
P (unpaired NS <0.05 NS NS NS
t test)
Data (mean ± SEM), time in minutes, ∗ 2 patients did not answer
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Results: Recovery time was shorter for unsedated procedures (Table 1).
Patients could be discharged sooner and this reduces nursing work load.
Nurses’ evaluations showed high credibility scores for both options (Table 2)
Conclusion: Unsedated colonoscopy has shorter recovery time and reduced
nurses’ workload. Nurses witnessed the acceptance by veterans who reported
high satisfaction scores and willingness to repeat. Both may have influenced
the nurses’ evaluations indicating sedation on-demand and technique of wa-
ter infusion without air insufflation are credible options for patient care.
Nurses Evaluations
Nurses Sedation Water Infuion
Evaluation On-Demand Without Air
How logical? 9.3 ± 0.6 9.4 ± 0.3
Improve overall patient satisfaction? 8.2 ± 0.7 8.3 ± 0.6
Recommend to patients? 9.1 ± 0.6 9.4 ± 0.3
How satisfy are you when you assist? 9.0 ± 0.6 9.1 ± 0.3
Improve overall efficiency? 7.8 ± 0.8 8.3 ± 0.5
Overall credibility score (max = 50) 43.4 ± 2.7 44.7 ± 1.2
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Poor Prep Rate for Inpatient Colonoscopies Is Unacceptably High –
Needs Attention
Krishna S. Kasturi, MD, MPH, Rajasekhara R. Mummadi, MD,
Gottumukkala S. Raju, MD∗. Internal Medicine, University of Texas
Medical Branch, Galveston, TX.
Purpose: Poor colon preparation (prep) is an important problem in both
outpatients and inpatients. At our institution, as part of a quality improve-
ment initiative, a series of interventions reduced poor prep rate from 18% to
1% in outpatient colonoscopies during 2002–2007. In this study, we have
undertaken a retrospective review of inpatient colonoscopies to evaluate
the incidence of poor prep and define the problem further so that quality
improvement measures could be implemented to correct the problem.
Methods: I. Incidence of the poor prep was calculated in 850 consecutive
inpatient colonoscopies compared to 5521 outpatient procedures (5/2005–
4/2007).
II. Descriptive analysis of 100 consecutive inpatient colonoscopies with
special reference to the quality of prep (5/2005 -8/2005). [Statistical analysis
was performed using SPSS v.11.0]
Results: I. Incidence of Inpatient Poor Prep: 27% (outpatients: 10%, P =
0.001) [Odds Ratio 3.37, 95% CI 2.8–4.0]
II. Descriptive analysis of 100 consecutive inpatient colonoscopies: Mean
age 61 years (range 25–96); male vs. female: 57 vs. 43; 22% had a prior
colonoscopy; 97% received 4 liters of PEG based electrolyte solution. In-
dication of the procedure: diarrhea (6%), obscure bleeding (33%), overt
bleeding (40%), & other causes (21%). Time of procedure: A.M. procedure
in 68%.
A. Quality of Prep: Poor prep: 27% & Satisfactory prep: 73%. 1. Poor preps
correlated with incomplete examinations (P = 0.001), failure to establish a
diagnosis (P =0.002). 2. No statistically significant association was observed
between the quality of the bowel prep with relation to gender, indication for
the procedure, a.m./p.m. colonoscopies, history of prior colonoscopies, and
the presence of co-morbid conditions.
B. Extent of Colonoscopy: Cecal intubation was successful in 76% (com-
plete examination). Patients with co-morbid conditions were at high risk of
incomplete examination compared to those with none (P < 0.001), irrespec-
tive of the quality of colon preparation.
C. Financial Implications: Repeat colonoscopy during the same hospital-
ization adds approximately $3000 to the cost of care per patient.
Conclusion: The incidence of inpatient poor preps is unacceptably high
(27%). Poor preps are associated with incomplete examinations and failure
to establish the diagnosis. Repeat procedures increase the cost of patient
care. Studies to define the problem and protocols to correct it are currently
being established.
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Excellent Cecal Cleansing with Split Dose of Phosphosoda and 30 mg
of Bisacodyl – A Retrospective Study Using Cecal Photograph as a
Reflector of the Quality of Colon Cleansing
Sahil Mittal, MD, Rajasekhara R. Mummadi, MD, T. Trang, G.S. Raju,
MD∗. Internal Medicine, University of Texas Medical Branch, Galveston,
TX.
Purpose: Poor colon preparation was noted be 18% during an audit of the
quality of colonoscopy preparation using polyethylene glycol based (PEG)
solution in 2002. Since then, a series of changes have been made to our
colon preparation protocol, which reduced the poor preparation rate to 8%
& currently to 1%. Cecum appears to be the last to get cleaned out and is
often obscured by stools despite excellent cleansing of the rest of the colon.
Hence, 300 cecal photographs were graded to assess colon cleansing with
different regimens by a single observer to avoid interobserver reporting bias.
We also analysed the relationship between the quality of cecal image & colon
polyp detection rate.
Methods: 100 consecutive colonoscopies in each group were compared.
Group A: 1 gallon of polyethylene glycol (PEG) the evening before pro-
cedure. Group B: 1.5 ounces phosphosoda (P) the evening before & 1.5
ounces on the day of procedure. Group C: Group B regimen + 10 mg of
bisacodyl at noon and the evening before and on the day of procedure (P +
BIS). Assessment: The cecal photograph was graded on a scale of 1–3: 1 =
stool obscured the mucosa; 2 = 50–100% of mucosa visualized; specs of
stool; 3 = Entire (100%) of the mucosa visualized (excellent prep); no stool.
Endpoints: Mean colon cleansing (MCC) score & polyp detection for each
preparation.
Results: Excellent visualization of cecum (Grade 3) – Clean with 100%
mucosal visualization: 57% in the split dose of P + 30 mg BIS, 20% in the
PEG, & 24% in the split dose of FP (P < 0.001).
MCC Score: 2.47 ± 0.69 in the split dose of P + 30 mg of BIS, 1.98 ± 0.71
in the split dose of P, & 1.92 ± 0.6 9 in the PEG respectively, P < .0001. The
MCC score was higher in the P+BIS group in men (P < .0001); females
(P = 0.04); age < 65 yrs (P < 0.0001) & ≥65 yrs (P < 0.0001).
Polyp detection: In the P+BIS group, there was a correlation between the
quality of cecal image and polyp detection (P = 0.04).
Conclusion: Using the cecal photograph as a reflector of the quality of colon
cleansing, the split dose of phosphosoda & 30 mg bisacodyl proved to be
superior to other regimens.[figure1]
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Increased Risk of Colon Adenomatous Polyps in Patients Infected with
Helicobacter Pylori
Trinh Meyer, MD, Vidushi Golla, MD, Curtis Coley, MD, Albert Min, MD∗.
Division of Digestive Diseases, Beth Israel Medical Center, New York, NY.
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Purpose: A recent meta-analysis suggested an increase in risk of colorectal
cancers associated with H. pylori infection. However, because of selection
biases, small sample sizes and inadequate consideration of potential con-
founding variables in the data analyses, publication bias cannot be ruled out.
The aim of this study is to examine the relationship between H. pylori infec-
tion and colorectal cancer risk utilizing a larger sample size and a diverse
group of patients at a single tertiary medical center.
Methods: We reviewed endoscopic gastric biopsy reports with positive H.
pylori infection of all patients age greater than 40 years between January 2002
and January 2006 at our hospital. Pathology database was then reviewed for
colorectal lesions found by colonoscopy within 6 years of checking H. pylori
infection. Exclusion criteria consisted of age less than 40 years, gastroin-
testinal polyposis, history of malignancies and inflammatory bowel disease.
Data were analyzed using t-test and chi-square test.
Results: There were a total of 410 patients in our data analysis. Of those,
173(42%) were H. pylori (+) and 194 (47%) were men. Mean age of the
patient was 61.1 and 59.9 years in the H pylori (+) and (−) group, respec-
tively (P = NS). In the H. pylori (−) group, 142(60%) patients had normal
colonoscopic finding, 48(20%) had tubular adenoma and 0(0%) had ade-
nocarcinoma. In contrast, in the H. pylori (+) group, 50(29%) had normal
colonoscopic finding, 87(50%) had tubular adenoma and 1(0.6%) had ade-
nocarcinoma. A statistically significant increase in the incidence of tubular
adenoma was seen in the H. pylori (+) group (P < 0.0001). In addition,
among the H. pylori (+) group, significantly more men 63/95 (59%) than
women 44/78 (41%) were seen with tubular adenoma (P = 0.008).
Conclusion: H. pylori infection is associated with an increased risk of col-
orectal adenoma, specifically tubular adenoma. Men with H. pylori infection
may need to have more frequent screening colonoscopy than current guide-
lines recommend.
Helicobacter Helicobacter
positive negative P
N = 173 N = 237 value
Mean age (years) 61.1 ± 8.26 59.9 ± 7.54 NS
Females 78 (45%) 138 (58%) 0.009
Males 95 (54.9%) 99 (41.7%) 0.009
Adenocarcinoma 1 (0.6%) 0 (0%) NS
Villous adenoma 1 (0.6%) 3 (1%) NS
Tubulovillous adenoma 5 (2.9%) 6 (2.5%) NS
Tubular adenoma 87 (50%) 48 (20%) <0.0001
Hyperplastic 28 (16%) 38 (16%) NS
Normal 50 (29%) 142 (60%) <0.0001
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Quantitative Proteomic Profiling of Colorectal Cancer Stratified by
Lymph Node and 8p LOH Status
Ying Lin, MD, Paul F. Meeh, MS, Christopher Farrell, BS, Phillip
Buckhaults, PhD, Robert H. Podolsky, PhD, Jeffrey R. Lee, MD, Robert R.
Schade, MD, William S. Dynan, PhD∗. IMMAG, Medical College of GA,
Augusta, GA; South Carolina Cancer Center & Dept. Pathology &
Microbiology, Univ. South Carolina, Columbia, SC; CBGM, Medical
College of GA, Augusta, GA; Dept. Pathology, Medical College of GA &
VAMC, Augusta, GA; Dept. Medicine, Medical College of GA, Augusta,
GA and Dept. Gastroenterology & Hepatology, 2nd Affiliated Hospital,
Sun Yat-Sen University, Guangzhou, China.
Purpose: An objective of clinical proteomics, as applied to colorectal cancer
(CRC), is to identify patients who are at greater risk of recurrence following
initial resection and thus in need of more aggressive management. We applied
sensitive proteomic technology to identify biomarkers that correlate with
established prognostic indicators including lymph node status and LOH at
chromosome 8p.
Methods: We compared 48 tissue samples: 12 node-positive CRC, 12 node-
negative CRC, and patient-matched normal mucosa. Laser capture microdis-
section (LCM) was used to isolate pure cell populations from standard
frozen sections. About four micrograms of protein was analyzed by two-
dimensional difference gel electrophoresis (2D-DIGE). About 200,000 data
features were quantified, compared and analyzed using a Significance Anal-
ysis of Microarrays (SAM) procedure, which provides a list of candidate
biomarkers ranked by priority. Mass spectrometry for molecular identifica-
tion of candidate biomarkers is in progress.
Results: More than 2100 features per gel have been resolved. We project
that about 1000 features will be matched as common across 90% or more
of the gel images. Interim analysis of 604 well-matched features shows
111 with highly significant changes between cancer and normal (based on
SAM analysis with estimated false discovery rate of <1%). A heat map in
Fig. 1 shows an overview of the interim analysis. In addition, as compared
between node positive and node negative samples, at least one feature has
been identified to date. Characteristics of this and other candidate biomarkers
will be discussed.[figure1]
Conclusion: The combination of LCM and 2D-DIGE provides a compre-
hensive approach for proteomic analysis of very small amounts of CRC
tissue obtained from standard clinical specimens.
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Environmental and Dietary Risk Factors in Microscopic Colitis:
Preliminary Data from a Case-Control Study
Cyrus P. Tamboli, MD, FRCPC∗, Laura Aker, BSc, Jamison J. Engle, MD,
Robert J. Caldwell, PA, M. Bridget Zimmerman, PhD, Frank A. Mitros,
MD. Internal Medicine, Gastroenterology, University of Iowa Carver
College of Medicine, Iowa City, IA; Biostatistics, College of Public Health,
University of Iowa, Iowa City, IA and Pathology, University of Iowa Carver
College of Medicine, Iowa City, IA.
Purpose: To study environmental and dietary factors which may be associ-
ated with lymphocytic or collagenous colitis.
Methods: Cases were identified using a pathology department database
queried for diagnostic terms and confirmed by an expert pathologist. Age &
gender-matched controls were randomly invited from a database of routine
visits to a university Family Care Center with satellite community clinics. A
general questionnaire was completed on demographics, residences, employ-
ment, travel, animal exposures, infections, smoking, immunization, medi-
cations, and family history. A validated food-frequency questionnaire was
used to record dietary habits over the past 1 year. Lymphocytic and collage-
nous colitis cases were analysed together. Statistical analyses included t-test
for continuous variables, Wilcoxon rank-sum test for ordinal data, and Chi-
squared or Fisher’s exact test for categorical data. Significance was at P ≤
0.05. All protocols were first approved by the university ethics committee.
Results: Preliminary data on 38 subjects (23 cases, 15 controls) were avail-
able for demographics, residence, employment, animal exposure, smoking,
immunization, family history and diet. Females comprised 78% of cases and
60% of controls (P = 0.28). Mean age was 65.1 for cases and 57.5 for controls
(P = 0.125). Body mass was lower in cases (mean wt. 70.3 kg) than controls
(mean wt. 87.7 kg) (P = 0.0009). Cases had regular contact with dogs (96%)
more often than controls (67%) (P = 0.027) and had more regular contact
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with fish as pets (43% cases, 0% controls, P = 0.028). There were no differ-
ences in demographics, residence, employment or vaccinations. Cases more
often reported (50%) a (+) family history of chronic diarrheal disease than
controls (0%) (P = 0.002). Cases ate less eggs (P = 0.037) and processed
meat (P = 0.049) but more chicken (P = 0.042) and seafood (P = 0.0007)
than controls.
Conclusion: This preliminary data of environmental risk factors show some
associations with microscopic colitis and body mass, domestic pet exposures,
family history of chronic diarrheal diseases, and meat consumption. The
significance of these findings requires more investigation to determine which
exposures preceded, rather than followed a diagnosis of microscopic colitis.
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Relationship between Sporadic Hyperplastic Polyps and Colorectal
Neoplasia in Hispanic Veterans
Rafael Perez, MD, Arnaldo Lasa, MD, Doris H. Toro, MD∗, Marcia
Cruz-Correa, MD, PhD, Jaime Martinez-Souss, MD. Gastroenterology
Section, VA Caribbean Healthcare System, San Juan, Puerto Rico and
Comprehensive Cancer Center, University of Puerto Rico, San Juan,
Puerto Rico.
Purpose: Hyperplastic polyps (HP) traditionally have been regarded as hav-
ing no malignant potential. Some studies have suggested that HP in the distal
colon may predict presence of adenomatous polyps in the proximal colon.
Other studies have failed to show this relationship. The purpose of this study
is to evaluate for the first time in our Hispanic veterans population if there is
a relationship between the presence of sporadic HP and colorectal neoplasia
(CRN) and to evaluate if proposed risk factors for CRN are also risk factors
for sporadic HP.
Methods: The study consisted of a retrospective review of all the medi-
cal records of patients who underwent a colonoscopy for the first time at
the VA Caribbean Health Care System during the calendar year 2005 and
had a pathologic diagnosis of HP, tubular adenoma (TA), tubulovillous ade-
noma (TVA), villous adenoma (VA) and/or colon adenocarcinoma. Patient’s
age, BMI, smoking and alcohol use history, presence of DM, cholesterol
and triglyceride levels, use of aspirin and the size and location of the le-
sions were recorded. Records with incomplete data and patients with a prior
colonoscopy were excluded.
Results: 861 records were reviewed of which 405 records met the inclusion
criteria (95% confidence interval). 99% of the patients were males, mean age
67.5 (36–87). 121 patients had HP, 331 had TA, 33 had TVA, 12 had VA, 13
had serrated adenomas and 61 patients had adenocarcinoma. The total num-
ber of colonic lesions was 1,065 (240 hyperplastic, 825 CRN). Univariate
analysis using Pearson Chi-Square revealed that patients with HP appeared
to have a lower likelihood of having TA (P < 0.001), adenocarcinoma (P =
0.002), and CRN in general (P < 0.001). Multivariate analysis with logistic
regression revealed that patients with HP had a significantly lower likelihood
of having TA (adjusted OR = 0.21; 95% CI 0.12–0.37), and adenocarcinoma
(adjusted OR = 0.33; 95% CI 0.15–0.73) compared to patients without HP.
No correlation was found between DM, smoking, alcohol or aspirin use and
the presence of HP.
Conclusion: This study demonstrates that sporadic hyperplastic polyps are
not associated with CRN in the Hispanic veteran population. None of the risk
factors proposed for CRN appear to be also risk factors for developing HP.
The results of this study support current colon cancer guidelines in which
surveillance for HP is not recommended.
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Dyssynergia – Key Pathophsyiologic Mechanism for Fecal
Incontinence (FI) in Nursing Home Residents
F.W. Leung, M.H. Beard, V. Grbic, R. Habermann, S.S.C. Rao, J.F.
Schnelle∗. Sepulveda ACC, VAGLAHS, UCLA; Center for Quality Aging,
Vanderbilt VUMC, and U Iowa.
Purpose: We performed anorectal measurements in nursing home subjects
to explain the high prevalence of coexistence of FI and constipation.
Methods: 16 subjects >80 yrs with FI underwent testing. A catheter with 3
solid state pressure transducers was placed in the anorectum with the subject
in the left lateral position. Subjects were asked to squeeze as if to prevent
fecal leakage and to strain as if to have a bowel movement. Rectal sensory
thresholds were assessed by serial balloon distensions.
Results: All 16 subjects had normal rectoanal inhibitory reflex. 2 could not
follow instructions, and 2 were not tested for strain-induced responses. All 12
who were able to strain showed either no relaxation or paradoxical contrac-
tion of the anal sphincter. 3 generated high intra-rectal pressure to produce
defecation indexes of 2.0 ± 0.1 that were normal (> 1.5). The remaining
nine (75%) showed a dyssynergic pattern with significant elevation of anal
sphincter pressure and significantly reduced defecation indexes of 0.9 ± 0.1.
Conclusion: Nursing home residents with FI demonstrate weak internal
and external anal sphincter pressures and severely impaired rectal sensation.
Our novel finding (75% showing a dyssnergic pattern) could explain both
the high prevalence of constipation and incontinence in these elderly nursing
home subjects. [NIH1R02AG23555–01A1-JF Schnelle & VA Clinical Merit
Research Funds-FW Leung].
Results Mean ± SEM Control
Sphincter length (cm) 3.6 ± 0.2 2–4
Baseline intra-rectal pressure before squeeze
(mm Hg)
11.3 ± 2.5
Peak intra-rectal pressure during squeeze
(mm Hg)
25.7 ± 4.2∗
Baseline sphincter pressure before squeeze
(mm Hg)
22.4 ± 2.3 40–70
Peak sphincter pressure during squeeze (mm
Hg)
46.2 ± 8.7∗ 100–180
Squeeze duration (seconds) 8.5 ± 1.8 >30
Threshold for First sensation (ml) 47.5 ± 7.8 10–30
Threshold for Urge to defecate (ml) 99.4 ± 12.5
Maximum tolerable volume (ml) 165.0 ± 14.5 100–300
Baseline intra-rectal pressure before strain
(mm Hg)
17.1 ± 2.9
Peak intra-rectal pressure during strain (mm
Hg)
51.0 ± 7.8∗
Baseline sphincter pressure before strain
(mm Hg)
19.2 ± 1.2
Peak sphincter pressure during strain (mm
Hg)
46.3 ± 6.7∗
∗Vs. baseline before squeeze or strain, P < 0.05, paired t test.
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Two Pathways of Carcinogenesis: MSI vs CIN in Iranian Patinets with
Colorectal Cancer
Mahsa Molaei, MD, Babak Noorinayer, MD, Ali Ghanbarimotlagh, MD,
S. Alireza Emami, MD, Somaye Ghiasi, MD, Mohamadreza Zali, MD∗.
Pathology and Gastroentrology, Research Center for Gastroentrology and
Liver Disease, Shaheed Beheshti University of Medical Sciences, Tehran,
Islamic Republic of Iran.
Purpose: Colorectal cancer (CRC) arising from a complex series of molec-
ular changes that involve at least in two different pathways. These include
microsatellite instability (MSI) pathway and chromosomal instability (CIN)
pathway. The aim of this study was the determination of predominant path-
way involved in carcinogenesis of patients with CRC less than 45 years old
with and without family history (FH) of CRC.
Methods: In our study surgical pathology specimens of 108 patients with
CRC less than 45 years old were immunostained for DNA mismatch repair
proteins (MMRP) including hMLH1, hMSH2, hMSH6 and PMS2. Beta-
catenin and P53 were also examined for CIN pathway
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Results: Totally 108 patients with median age of 40(20 to 45) were evalu-
ated. Fifty seven patients were male and 51 were female. The site of tumor
in 84 patients was colon and in 14 were rectum. Among 96 patients with
known family history, 33(34.4%) had positive FH. The overall rate of abnor-
mal immunostaining were MLH1 8.3%, MSH2 18.5%, MSH6 8.3%, PMS2
11.1%, P53 74.1% and beta catenin 35.2%. Meanwhile abnormal staining
for hMSH2 and hMSH6 were significantly more seen in patients with pos-
itive family history (P = 0.008 and P = 0.032 respectively). Patients with
positive FH for CRC had significantly more abnormal MMRP (54.5% vs.
20.6%, P = 0.001) and less positive p53 (54.5% vs. 81%, P = 0.006) than
patients with negative FH. Patients with early T, N stage tumor had at least
one more abnormal MMRP than advance T, N stage (P = 0.050 for T and P =
0.030 for N stage). Among different factors abnormal hMSH2 had signifi-
cant association with lower cancer related death (P = 0.040). Patients with
rectal cancer had more abnormal MMRP than patients with colon cancer but
not significantly (35.7% vs. 29.8%, P = 0.655) and positive p53 staining for
rectal and colon cancer were 71.4% and 72.6% respectively. Both in colon
and rectal cancer patients with negative family history had more prevalent
positive p53 (80.4% vs. 56.7%, P = 0.022 for colon and 81.8% vs. 33.3%,
P = 0.099 for rectal cancer).
Conclusion: Our study indicate that even in CRC less than 45 years old, the
main pathway for carcinogenesis in patients with negative family history is
CIN, but in positive family history MSI is as effective as CIN. However main
pathway in both colon and rectal cancer is CIN.
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Mismatch Repair Proteins and Clinicopathologic Factors in Colorectal
Cancer
Mahsa Molaei, MD, Babak Noorinayer, MD, Ali Ghanbarimotlagh, MD,
Somayeh Ghiasi, MD, S. Alireza Emami, MD, Katayoon Aghajani, MD,
Mohamadreza Zali∗. Pathology and Gastroentrology, Research Center for
Gasroentrology and Liver Disease, Taleghani Hospital, Shahid Beheshti
University of Medical Sciences, Tehran, Islamic Republic of Iran.
Purpose: Microsatellite instability due to defective mismatch repair proteins
(MMRP) is one of the major pathways for carcinogenesis in colorectal cancer
(CRC). The impact of these proteins in prognosis is not well defined. The
aim of this study were the evaluation of abnormal MMRP prevalence and its
relationship with some clinical and pathologic factors.
Methods: In our study 350 CRC specimens were immunostained for DNA
mismatch repair proteins (hMLH1, hMSH2, hMSH6, PMS2). Patients with
at least one abnormal above factors considered in abnormal MMRP group.
Clinical factors such as sex, tumor site, family history (FH) of CRC and
vital status is considerd. Pathologic factors including grade, T and N stage
in tumor specimen were examined.
Results: 350 patients with median age of 51 were evaluated. The site of
tumor was 270,68 in colon and rectum respectively. Among 329 patients
with known FH, 132(40.1%) had positive FH. The overall rate of abnormal
staining for hMLH1, hMSH2, hMSH6 and PMS2 were 4.4%, 7.2%, 3.5%
and 4.9%. Overall 44 patients (12.7%) had at least one abnormal MMRP.
Abnormal MMRP were not significantly associated with histopathologic
factors (T, N stage, grade). Abnormal MMRP were seen further in colon
than in rectum that was significant for hMLH1 (P = 0.044). Patients with
FH of CRC had more abnormal staining that was significant for hMSH2
(P = 0.041). There was no difference in MMRP according to vital status.
Conclusion: Our results suggest that abnormal MMRP is associated with
clinical factors such as family history of CRC but not with pathologic factors.
Abnormal MMRP is more important pathway for carcinogenesis in colon
than rectal cancer.
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Constipation: Is It a Colonic Versus Generalized Gastrointestinal
Tract Disorder. The Temple Experience
Shabana Shahid, MD, Henry Parkman, MD, Robert S. Fisher, MD∗.
Department of Gastroenterology, Temple University Hospital,
Philadelphia, PA.
Purpose: Constipation is a common clinical condition affecting mil-
lions of Americans. Its prevalence ranges between 2 and 28% de-
pending upon the definition. When the physiology of chronic constipa-
tion is examined, four subtypes exist: slow transit constipation (STC),
dyssynergic defecation (pelvic floor dysfunction; DD), a combination of
both (STC + DD), and normal colon transit with normal pelvic floor
function.
The purposes of this study were two-fold; first, to determine the percentage
of constipated patients with STC, DD, STC+DD, or normal studies at a qua-
ternary motility center; second, to evaluate what percentage of constipated
patients have a diffuse gastrointestinal (GI) motility disorder as evidenced
by a combination of upper and lower GI dysmotility.
Methods: This was a retrospective analysis of 488 patients who underwent
anorectal manometry for the primary symptom of intractable constipation
between 2001 and 2006 at Temple University Hospital’s Motility Center.
Of these patients, anorectal manometry, whole gut transit scintigraphy, anal
electromyography, balloon expulsion testing, and defecography results were
reviewed.
Results: Of the 488 patients with chronic constipation who underwent
AM, 212 patients met the inclusion criteria for the study. Of these, 91/212
(43%) had STC, 25/212 (12%) had DD, 53/212 (25%) had a combination
of STC+DD, and 43/212 (20%) had normal colon transit and pelvic floor
function. Of the patients with STC, 31/91 (34%) had delayed gastric emp-
tying, 9/91 (10%) had delayed small bowel transit, 7/91 (8%) had a de-
lay in both, while 44/91 (48%) had normal upper GI motility. A similar
distribution was seen in patients with DD – 8/25 (32%) had delayed gas-
tric emptying, 2/25 (8%) had delayed small bowel transit, 2/25 (8%) had
transit delays in the stomach and small bowel, whereas 13/25 (52%) had
no abnormality. Examination of the STC+DD group showed 11/53 (21%)
with gastric emptying delay, 7/53 (13%) with small bowel delay transit,
10/53 (19%) with a combination, and 25/53 (47%) had normal upper GI
transit.
Conclusion: Patients presenting with a primary complaint of chronic consti-
pation have a range of colonic motor disorders. The majority of patients had
an identifiable abnormal pattern of colon transit, which included STC, DD, or
a combination of STC and DD. In addition, many patients with chronic con-
stipation have a generalized gastrointestinal tract disorder namely, delayed
gastric emptying and/or delayed small bowel transit.
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Utilization of Nitazoxanide for the Empiric Treatment of Diarrhea of
Unknown Etiology
Isaac Raijman, MD∗, Susana Escalante-Glorsky, MD, Matthew Bardin,
PharmD. Digestive Associates of Houston, P.A., Houston, TX and
Department of Medical Science, Romark Laboratories, L.C., Tampa, FL.
Purpose: Diarrhea of unknown etiology is a common reason patients seek
medical attention. While there are many reasons patients develop diarrhea,
microbial insult has been targeted as a major contributor to this disease. Par-
asites, bacteria, and viruses are part of the spectrum of implicated organisms.
Since testing for a specified organism is often inconclusive, costly, and un-
timely, clinicians often prescribe a trial of empiric antibiotics. Nitazoxanide
(NTZ) is a first in class thiazolide antibiotic with activity against anaerobic
bacteria, protozoans, helminthes, and gastrointestinal viruses. Furthermore,
NTZ has a placebo-like safety profile, high gastrointestinal (GI) concentra-
tion, and limited to no activity against probiotic species. The purpose of this
review is to evaluate the effectiveness of NTZ as empiric therapy for the
treatment of diarrhea of unknown etiology.
Methods: A chart review was performed on patients treated with NTZ
from April 2006 to April 2007 with complaints of generalized diarrhea
not attributed to suspected small intestinal bacterial overgrowth (SIBO), or
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Clostridium difficile-associated diarrhea (CDAD). Efficacy was measured as
patient reported resolution of diarrhea or satisfactory improvement of symp-
toms by the end of therapy. Patients not returning to the clinic were contacted
by telephone to determine resolution of symptoms. Twelve patients met the
inclusion criteria for review.
Results: Of the 12 patients treated with NTZ, 9 were available for follow-
up evaluation. Diarrhea was considered chronic or persistent in 8 of the 9
patients, one patient presented with acute diarrhea. The range of NTZ doses
used was 500 mg BID-TID for 3–10 days, the mean dosing regimen was
1166 mg/day for 7.1 days. Overall 8/9 (89%) patients reported resolution
of diarrhea or satisfactory improvement. Of note, the one patient failure
had been prescribed NTZ 500 mg BID for 7 days, but the patient’s insurance
company would only allow the patient to receive 3 days of therapy (6 tablets).
No clinically significant adverse reactions attributable to NTZ were identified
during the study.
Conclusion: Nitazoxanide appears to be a safe and effective therapy for
the empiric treatment of diarrhea of unknown etiology. Larger controlled
clinical trials are warranted to support these findings.
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Association of GSTM1, P1, T1 and CYP2E1 Single Nucleotide
Polymorphisms with Colorectal Cancer in Iran
Saeideh Ebrahimkhani, MS, Babak Noorinayier, MD, Pedram Kharaziha,
MD, Katoyuon Aghajani, MD, Mohammad Reza Zali, MD, FACG∗.
Shaheed Beheshti Medical University, Research Center for
Gastroenterology and Liver Disease, Tehran, Islamic Republic of Iran.
Purpose: Colorectal cancer rate is very high and common cause of death.
Mortality rate from colorectal cancer can be reduced by identification and
removal of cancer precursors, adenomas, or by detection of cancer at an
earlier stage. We performed this study to determine the association between
genetic polymorphisms of cytochrome P4502E1 (CYP2E1) and glutathione
S-transferases P1, M1 and T1 (GSTP1, M1, T1) and susceptibility to col-
orectal cancer (CRC).
Methods: Genotyping of CYP2E1 and GSTP1, M1, T1 was performed by
using pyrosequencing analysis on DNA isolated from blood sample from
colorectal cancer cases (N = 100) and normal controls (N = 100).
Results: Mean GSTT1 activity was significantly (P < 0.01) higher in cases
as campared to controls (P < 0.0001; OR, 2.43; 95% CI, 1.47–4) on the
other hand there is no significant association between GSTM1, P1, CYP2E1
and colorectal cancer.
Conclusion: GSTT1 measurement may be useful as a colorectal marker
in colorectal cancer and biopsies obtained at colonoscopy can be used to
measure tumor markers.
The genotype frequencies of GSTM1, P1, T1 and CYP2E1 polymorphisms
Wild Heterozygouse Homozygouse
Gene Polymorphism Controls Cases Controls Cases Controls Cases
CYP2E1 rs6413419(A/G) 95(95%) 80(88.9%) 5(5%) 10(11.1%) 0(0.0%) 0(0.0%)
CYP2E1 rs2854140(A/G) 88(96.7%) 83(96.5%) 3(3.3%) 3(3.5%) 0(0.0%) 0(0.0%)
GSTM1 rs17072289(A/T) 68(78.2%) 62 (87.3%) 18(20.7%) 8(11.3%) 1 (1.1%) 1 (1.4%)
GSTM1 rs1065411(C/G) 90(90%) 91(91.9%) 10(10%) 8(8.1%) 0(0.0%) 0(0.0%)
GSTM1 rs1056806(C/T) 87(87%) 91(91.9%) 13(13%) 8(8.1%) 0(0.0%) 0(0.0%)
GSTP1 rs1695(G/A) 53(53%) 54(54.5%) 42(42%) 39(39.4%) 5(5%) 6(6.1%)
GSTP1 rs4986948(G/C) 62(63.3%) 49(61.3%) 30(30.6%) 27(33.8%) 6(6.1%) 4(5%)
GSTP1 rs1138272(T/C) 83(87.4%) 53(72.6%) 12(12.6%) 19(26%) 0(0.0%) 1(1.4%)
GSTT1 rs2234953(A/G) 90(90.9%) 94(95.9%) 9(9%) 4(4.1%) 0(0.0%) 0(0.0%)
GSTT1 rs2266637(A/G) 37(52.9%) 34(37.4%) 26(37.1%) 26(28.6%) 7(10%) 31(34.1%)
GSTT1 rs4630(C/T) 100(100%) 79(98.8%) 0(0.0%) 1(1.3%) 0(0.0%) 0(0.0%)
GSTT1 rs2266633(A/G) 81(81%) 71(75.5%) 11(11%) 19(20.2%) 8(8.0%) 4(4.3%)
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Development of Colon Cancer While in a Screening and Surveillance
Program
Kenneth R. DeVault, MD∗, Andrew D. D’Alessandro, Jeffery B. Albright,
MD, David S. Loeb, MD, Timothy A. Woodward, MD, Michael F. Picco,
MD, Murli Krishna, MD. Medicine, Mayo Clinic, Jacksonville, FL;
Surgery, Mayo Clinic, Jacksonville, FL and Pathology, Mayo Clinic,
Jacksonville, FL.
Purpose: Colon cancer is potentially preventable with screening and surveil-
lance yet no program is 100% effective. We sought to characterize patients
who developed colon cancer within 10 years of an index colonoscopy with
or without other interval screening.
Methods: Retrospective review of patients diagnosed with colon cancer in
2001–2005. Electronic medical record was reviewed for a prior screening
or surveillance colonoscopy performed within 10 years prior to cancer di-
agnosis. Exclusion criteria included high-risk patients (IBD and familial
polyposis). Data extracted included location and stage of tumor, number and
timing of previous colonoscopy and any limitations of the colonoscopy (poor
prep or incomplete exam or incomplete prior polypectomy) and any other
screening test (flexible sigmoidoscopy, fecal occult blood testing or colon
x-ray).
Results: 294 pathology reports reviewed and 37 patients identified with a
colonoscopy within 10 years of cancer diagnosis. 28 (76%) tumors were in
the right colon with remainder (9, 24%) in the left. Cancers were stage 1
(32%), stage 2 (24%), stage 3 (38%) and stage 4 (5%). Patients were classi-
fied as to whether their follow-up was or was not in compliance with current
ASGE guidelines. 13 patients were considered to have been potentially out
of compliance for the following reasons; poor prep on index colonoscopy
(N = 7, although 3 cancers were diagnosed on a repeat exam within one
year of the index colonoscopy), prior incomplete polypectomy (N = 2) and
adenoma > 1 cm without early follow-up (N = 4). The remainder (N = 24)
were in compliance with current guidelines with 7 patients having small ade-
nomas less than 3 years prior to cancer diagnosis, 2 having only hyperplastic
polyps and 15 having normal exams all within 6 years of cancer diagnosis.
In addition, 21 of 37 had additional screening tests in the 10 years prior to
cancer development.
Conclusion: Screening and surveillance are important in the preven-
tion of colon cancer yet some patients will develop cancer. Many,
but not all may be prevented with better follow-up of patients with
poor preparations or complicated lesions. Further study is needed to
determine if the remainder of this problem is due missed adenoma-
tous lesions or if these lesions have a more aggressive course with
progression to cancer despite an appropriate screening exams and
intervals.
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Effect of Exercise and Obesity on Difficulty of Performing Colonoscopy
Syed T. Bin-Sagheer, MD∗, Asma Dajani, MD, Stephen Lanspa, MD, Gleb
Haynatzki, PhD. Division of Gastroenterology, Creighton University
Medical Center, Omaha, NE.
Purpose: To prospectively look at different factors, which may predict dif-
ficult colonoscopy.
Methods: Consecutive patients undergoing outpatient colonoscopies were
assessed for difficult colonoscopies. The main outcome variable, Time re-
quired to intubate the cecum, was used as a measure to assess the techni-
cal difficulty. Obesity was defined as body mass index of 30+. Exercise
was stratified at 3+ times a week for 20+ minutes. Patient variables which
were used as predictors of the main outcome were: age, sex, race, exercise,
obesity, diverticulosis, pelvic surgery, alcohol use, and use of psychiatric
medications.
Results: 128 consecutive patients were examined. 69 patients were obese.
Obese patients took shorter time to reach the cecum (mean = 5.44 minutes)
than non-obese patients (mean = 7.16 minutes). This was statistically sig-
nificant (P = 0.0367) at level 0.05. Only other variable that was statistically
significant was Sex (P = 0.0134), where reaching the secum took longer for
women (mean = 7.21 minutes) than men (mean = 5.29 minutes). None of
the other variables were statistically significant.
Conclusion: Patients who are obese may have easier exam than non-obese
patients. Exercise has no effect on the level of difficulty in performing
colonoscopy. Women have greater difficulty with colonoscopy than men.
Our data clearly contradict anecdotal evidence.
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In-Patient Colonoscopy Preparation – Is Splitting the Dose the
Solution?
Flor Mizrahi, MD, Ramesh Koka, MD, Jorge Uribe, MD, Stacey Zavala,
MD, Girish Anand, MD, Philip Katz, MD∗. Gastroenterology, Albert
Einstein Medical Center, Philadelphia, PA.
Purpose: Colon cleansing (prep) in the inpatient population continues to be a
challenge for the Gastroenterologist. It is well known that the inpatient status
is an independent predictor of inadequate colon prep. Due to multiple co-
morbities, PEG-electrolyte lavage solution (PEG) remains the prep of choice
in this population. In our center the standard 4-liter regimen has been shown
to have 10% lower prep success rates compared to outpatients. Multiple
studies in the outpatient population have shown split dose regimen of PEG
to be superior. There is no published data assessing split dose regimen in
hospitalized patients.
Aim: To evaluate the efficacy of prep for Colonoscopy using the conventional
regimen of 4 L of PEG given the night before (Regimen 1) compared to PEG
given 3 L the night before and 1 L the morning of the Colonoscopy (Regimen
2), and to compare the tolerability measured by the amount of PEG taken.
Methods: IRB approval was obtained for the study. After obtaining informed
consent, patients were randomized using sealed envelopes. Baseline demo-
graphic data including co-morbidities were recorded. Endoscopist blinded to
the regimen rated the colon prep. Rating was based on a validated scale from
previous studies into 4 categories: Poor, Fair, Good and Excellent. Further,
preps rated Excellent and Good were grouped as “Successful”, Fair and Poor
as “Unsuccessful”. The amount of PEG completed was recorded by nursing
staff.
Results: 85 patients have been enrolled to date, 3 patients were excluded:
1 underwent surgery, 1 emergent dialysis and 1 was discharged .51% were
male, 49% female .46% were randomized to Regimen 1, and 54% to Regimen
2. Patients with Diabetes, hypertension, stroke, and Gastrostomy tube were
equally distributed in both groups. 24% of patients in Regimen 1 had an
“Excellent” overall prep compared to 56% of the patients in Regimen 2.
64% of the colon preps were “Successful” in Regimen 2, compared to a 36%
of those in Regimen 1 (P = 0.038). 16% of the patients in Regimen 1 had a
“Poor” prep, compared to an 11% of those in Regimen 2 (P = 0.035).
Conclusion: Split dose regimen is significantly better than conventional
regimen in achieving successful colon prep in the inpatient population based
on our preliminary analysis.
In-patient colonoscopy continues to be a challenge as the safety and effi-
cacy is dependent on achieving an excellent prep. Splitting the dose of the
PEG ensures tolerability and efficacy of colon prep in this difficult group of
inpatients.
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The Impact of BMI and Ethnicity on the Course of Colonic
Diverticulitis
Igal Khorshidi, MD, George Chernis, MD, Rabin Rahmani, MD, Lawrence
J. Brandt, MD∗. Gastroenterology, Montefiore Medical Center, Albert
Einstein College of Medicine, Bronx, NY.
Purpose: To determine whether patients of different ethnic backgrounds
have disparate courses of disease and to evaluate the role of obesity as a
possible risk factor for virulent diverticulitis.
Methods: We conducted a retrospective chart review of 349 patients with
confirmed diverticulitis in two university teaching hospitals in the Bronx,
NY.
Results: Caucasians had a significantly greater risk (76.7%) than African
Americans (52.5%) of developing a complication of diverticulitis on their ini-
tial admission for diverticulitis. African Americans were significantly more
likely (26.1%) than either Hispanics (16.5%) or Caucasians (12.7%) to re-
quire surgery for diverticulitis after at least one medically managed admis-
sion for diverticulitis. A significantly greater percentage of obese patients
(BMI>30) than non-obese patients – 46.7% vs 35.2% – also were likely
to have a recurrence of diverticulitis after an initial non-surgically treated
episode. Non-Caucasians with a BMI<30 also were more likely than Cau-
casians with a BMI<30 to have a recurrent episode of diverticulitis after an
initial medically-managed bout of diverticulitis (39.7% and 21.7%, respec-
tively).
Conclusion: We demonstrated that the course of diverticulitis follow-
ing one medically-managed admission for diverticulitis is more virulent
in African Americans, as manifest by recurrence, the need for surgery,
and development of complications. Caucasians, in contrast, have a more
severe initial presentation of diverticulitis but a less severe course fol-
lowing an initial medically managed admission for diverticulitis than do
non-Caucasions. Finally, we have established obesity as a risk factor for
recurrence.
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Fospropofol Disodium Is Effective and Safe for Sedation during
Colonoscopy
Douglas K. Rex, MD∗, Lawrence B. Cohen, MD. Indiana University
Medical Center, Indianapolis, IN and The Mount Sinai Hospital, New York,
NY.
Purpose: Fospropofol disodium (FP), a water-soluble prodrug of propofol,
possesses a pharmacokinetic profile characterized by a smooth and pre-
dictable rise in propofol plasma concentrations that is unique from its active
metabolite, propofol. This double-blind, multicenter, phase 3 study evalu-
ated the safety & efficacy of FP 6.5 mg/kg & 2 mg/kg in patients undergoing
colonoscopy.
Methods: 314 patients ≥18 years (ASA P1 to P3) were randomized to FP
6.5 mg/kg, FP 2 mg/kg, or midazolam (MD) 0.02 mg/kg in a 3:2:1 alloca-
tion following pretreatment with fentanyl 50 mcg. Patients were permitted
to receive up to 3 supplemental doses of study drug before being consid-
ered a treatment failure & receiving an alternative sedative. Sedation was
assessed using the Modified Observer’s Assessment of Alertness/Sedation
(MOAA/S). The primary endpoint was sedation success, defined by 3 consec-
utive MOAA/S scores of ≤4 after administration of sedative, and completion
of the procedure without use of an alternative sedative medication & without
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manual/mechanical ventilation. Other endpoints included measures of clin-
ical benefit, recovery, memory retention, patient & physician satisfaction,
and safety.
Results: Sedation success (87% vs 26%; P < .001) was higher and the
requirement for supplemental analgesic medication lower (55% vs 77%; P =
.001) in the FP 6.5 mg/kg group than the FP 2 mg/kg group. Patients in the 6.5
mg/kg group were less likely to remember being awake during the procedure
(51% vs 100%; P < .0001). The majority of patients in both groups reported
willingness to use the sedative again (96% vs 91%). Patients in the FP 6.5
mg/kg group had higher memory retention (67%) than patients in the FP 2
mg/kg group (59%). Mean physician satisfaction scores were higher is the FP
6.5 mg/kg group (7.7) than in the FP 2 mg/kg group (4.5), P < .001. FP was
well tolerated, with no serious treatment-related adverse events (TRAEs),
deaths, or AE-related procedure discontinuations. The most common TRAEs
in the FP 6.5 mg/kg and 2 mg/kg groups were paresthesias (68% vs 60%)
and pruritus (16% vs 26%). Six patients experienced transient sedation-
related AEs: FP 6.5 mg/kg (hypoxemia [resolved following repeated verbal
stimulation, N = 1], hypotension [N = 2]); FP 2 mg/kg (hypotension [N =
2]); midazolam (hypotension).
Conclusion: The FP 6.5 mg/kg dosing regimen is safe and effective for
sedation during colonoscopy and is associated with a high level of sedation
success, patient and physician satisfaction, and clear-headed recovery.
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Normal Anorectal Biomechanics Analyzed with Concurrent
Intraluminal Manometry, Surface EMG and Fluoroscopy
Ann Ouyang, MD∗, Sung-Yup Kim, David S. Hartman, MD, James G.
Brasseur, PhD. Medicine, Hershey Medical Center, Penn State University,
Hershey, PA; Mechanical Engineering, Penn State University, University
Park, PA and Radiology, Hershey Medical Center, Penn State University,
Hershey, PA.
Purpose: Evaluations of patients with refractory constipation include de-
fecograms to assess anorectal and pelvic floor (PF) function. Current in-
terpretations are simplistic, involving assessment of anorectal angle and
rapidity of emptying of barium paste. Our aims are to assess the coordina-
tion between anorectal pressures, change in rectal shape, and movement of
rectal content, during a number of specific maneuvers designed to stimulate
muscle groups relevant to anorectal function.
Methods: Surface electrodes were attached to the abdominal (AB) wall and
to the perineum to measure from AB and PF muscle in 8 healthy female
volunteers. Barium paste was inserted into the rectum and a 7F manometry
catheter with 6 solid state transducers was inserted and taped in place to
measure anorectal pressures. Fluoroscopy, pressure, and EMG were recorded
simultaneously on a Kay Elemetrics workstation. The subjects conducted 5
maneuvers to isolate AB PF muscle contraction, including the Kegel and
Valsalva maneuvers. Evacuation was measured with the fluoroscopy table
upright. Pressures were analyzed as space-time isocontours, and in-house
image analysis software was used to quantify the rectal boundary and rectal
area during evacuation.
Results: In all subjects abdominal EMG (AB-EMG) contained periodic
spikes with periods 0.63–0.75 s. Spike activity was not observed in PF-
EMG. The Kegel maneuver was accompanied by well-defined spike activity
in AB-EMG with minimal increase in baseline or rectal pressure, but baseline
PF-EMG and sphincteric pressure increased significantly. By contrast, Val-
salva displayed coordinated increases in EMG baselines, rectal and sphincter
pressures. Fluoroscopy showed ascent of the PF with Kegel. With Valsalva
the rectum stretched downwards as barium was forced into the anal canal.
Evacuation was generally preceded by a period of anorectal pressure insta-
bility and rectal pressure increase. Evacuation was rapid, coincident with
sphincter relaxation, and occurred as a two-part quasi-peristaltic contraction
that separated the anorectal segment in two.
Conclusion: These preliminary data suggest that correlated space-time
changes in anorectal pressure, EMG, and barium movement might distin-
guish normal from abnormal anorectal function.
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Antibacterial and Sporicidal Activity of Silver Against Clostridium
difficile and Impact on Gut Colonization and Disease
Jeffrey B. Lyczak, PhD, Wen Chen, PhD, Nicole Bellefeuille, BS, Katherine
V. Thompson, MPH, Katherine J. Turner, PhD∗. Research & Development,
Nucryst Pharmaceuticals, Inc., Wakefield, MA.
Purpose: To assess the activities of different forms of silver against the
spores and vegetative cells of five strains of C. difficile, and to investigate the
ability of silver-containing formulations to modify the course of C. difficile-
associated disease in vivo.
Methods: The forms of silver included in this study were silver nitrate, silver
(I) oxide, and NPI 32101, a nanocrystalline silver produced by physical
vapor deposition using magnetron sputtering. Efficacy against vegetative
cells of C. difficile was ascertained by a standard anaerobic MIC assay.
Sporicidal activity was determined by exposing spores to test agents for
intervals ranging from 15–120 minutes. Six days of subsequent negative
culture was taken as an indication of sporicidal activity. The ability of silver
to prevent C. difficile colonization and disease was determined by orally
administering silver dispersions or control antibiotics to hamsters previously
colonized with C. difficile after pre-exposure to clindamycin.
Results: The silver MICs against vegetative cells of five different strains
of C. difficile ranged from 8 to 23 µg/ml, which was significantly lower
(P = 0.024 by Mann-Whitney) than MICs obtained against other anaero-
bic species tested. Silver had sporicidal activity that required at least 15
minutes exposure to 50–500 µg silver/ml. Sporicidal activity was more con-
sistent after 1 hour of exposure. This was similar to the concentration- and
exposure time-requirements for the positive control sporicidal agent, glu-
taraldehyde. In vivo studies demonstrated that a single oral dose of silver
reduced colonization by C. difficile to an extent similar to a single oral dose
of metronidazole, but not as well as a single oral dose of vancomycin (P <
0.05 by Kruskal-Wallis, Tukey test). Importantly, pre-exposure of hamsters
to nanocrystalline silver did not render hamsters susceptible to CDAD.
Conclusion: These data show that silver is bactericidal and sporicidal against
C. difficile, and suggest potential utility as a first-line treatment for CDAD.
This work was funded by Nucryst Pharmaceuticals, Inc., Wakefield, MA.
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Colon Cancer: Protein Biomarkers in Tissue and Body Fluids
M. Momeni, MD, P. Pevsner, MD, D. Vecchione, BS, B. Stall, AAS, K.
Zaalook, MD, S. Duddempudi, MD, M. Joseph, MD, S. Anand, MD∗.
Gastroenterology, The Brooklyn Hospital Center, Brooklyn, NY and NYU
School of Medicine Department of Pharmacology, New York, NY.
Purpose: The aim of the study was to validate the concept that potential
biomarkers of colon cancer can be identified from body fluids. We concur-
rently tested multiple body fluid samples (urine, saliva, stool) and tumor
tissue samples to identify concordant proteins. In our Institutional Review
Board approved prospective pilot study, we explored the proteomic diagnosis
of colon cancer by identification of concordant proteins in tumor and body
fluids from the same patient.
Methods: After informed consent, body fluids and tumor tissue samples
were obtained from 20 patients who underwent colonoscopy for tumor biopsy
at The Brooklyn Hospital. Tissue and body fluids from patients with neg-
ative biopsies (10 subjects) were controls. The samples were frozen and
transported to New York University School of Medicine, Department of
Pharmacology for analysis. Proteins were extracted from tissue and stool
with high pressure, 35K PSI, (Barocycler, Pressure Biosciences, Woburn,
MA). Protein separation from tumor, urine, saliva and stool was performed
with either Two-dimensional gel electrophoresis or HPLC (high performance
liquid chromatography). Control and tumor samples were reduced (DTT),
alkylated (iodoacetamide) and trypsin digested. The protein digests were ap-
plied to MALDI (matrix-assisted laser desorption/ionization) target plates
for MALDI MS (MALDI mass spectrometry) and MALDI MS MS (MALDI
tandem) mass spectrometry (Axima TOF, Shimadzu Biotech, Columbia,
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MD). Protein were identified using NCBInr data base interrogation with
Mascot c© software (Matrix Science, London, UK).
Results: The control sample MALDI MS spectra were all similar to each
other as were the tumor sample spectra, however, there were clear differences
between the MALDI MS control and sample spectra. Concordant proteins
were identified from MALDI MS MS spectra in body fluids and tumor.
Conclusion: The apparent tumor signature proteins present in the body
fluids could allow us to develop non-invasive clinical diagnostic tests of
colon carcinoma. To prove the validity of these findings a larger molecular
epidemiolgy study will be undertaken.
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Do ACG Guidelines Still Predict C. difficle Diarrhea in Hospitalized
Patients?
Michael Kaczanowski, MD, David Peretz, MD, Jonathan A. White, MD,
William B. Hale, MD∗. Gastroenterology, Norwalk Hospital, Yale
Univeristy School of Medicine, Norwalk, CT.
Purpose: American College of Gastroenterology (ACG) guidelines pub-
lished in 1997 provide criteria for patient selection for Clostridium difficile
(C. difficile) testing. Since that time, C. difficile has become more preva-
lent in hospitals, more virulent, and new risk factors have been identified.
Furthermore, these guidelines allow for repeat testing after an initial neg-
ative result despite a paucity of data supporting this practice. The purpose
of this study is to determine whether the published guidelines effectively
predict C. difficile infection among patients with multiple samples sent and
to determine the yield of subsequent tests following an initial negative result.
Methods: Retrospective chart review of inpatients who had multiple stool
samples sent to be evaluated for the presence of C. difficile toxin by enzyme
immunosorbent assay (EIA) between January and June 2005. Data were
collected from daily progress notes, nursing flow sheets, medication records,
and computerized physician orders.
Results: 144 patients had multiple assays performed during the study period.
93/144 (64.6%) met ACG guidelines at the time the first sample was sent for
EIA testing; 88/144 (61.1%) met guidelines at the time the second sample
was sent; 39/69 (56.5%) met ACG guidelines at the time the third sample was
sent. When ACG guidelines were met on initial testing, 39/93 (33.3%) had
positive test results for C. difficile toxin. This differed significantly from 9/51
(17.6%) patients with positive EIA results who did not meet ACG criteria for
testing (P = 0.05). Conversely, meeting ACG criteria on subsequent tests
did not improve the likelihood of a positive result (P = 0.9). Only 5/104
(4.8%) patients had an initial negative EIA test which became positive on
subsequent testing.
Conclusion: Among patients who had multiple stool samples sent for anal-
ysis, meeting ACG guidelines improved the pretest probability of a positive
test result for the first specimen sent, but not on subsequent specimens. Using
ACG guidelines alone, however, failed to identify some patients who were,
in fact, positive for C. difficile. In addition, the role of repeated testing for
C. difficile after an initial negative EIA is of unclear benefit.
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Chronic Constipation and Fecal Impaction: Novel but Effective and
Economical Approach for Evaluation, Treatment and Prevention
Tushar C. Chauhan, MD∗, Ketki M. Dadhania, MD, Kieth M. Keefer, MD.
Private Practice, Community Gastroenterolgy Center, Voorhees, NJ;
Medicine, Ancora Psychiatric Hospital, Hammonton, NJ and Medicine,
New Lisbon Developmental Center, New Lisbon, NJ.
Purpose: To check “Carousel Theory” (putting more baggage on faulty
airport carousel will not help it move and may even slow it down further
causing baggage jam) for Chronic Constipation in Patients with Neurogenic
Colon. Chronic constipation is traditionally treated with an advise to increase
dietary fibers. However severely constipated institutionalized patients do not
seem to respond well to this, even when the promotility drugs are added. I
am suggesting a novel and effective strategy for a common problem that is
estimated to have $ 7 billion dollor impact just on our nation and much more
worlwide.
Methods: Total 70 Patients with history of chronic constipation were chosen
for the study. Colonoscopy was scheduled to rule out any anatomical lesion
and as a part of bowel preperation, they all were put on low fiber diet for two
days before the test and were given PEG-3350 for two days. Many pateints
were found to have a surprizing finding- their colon would hold about 800
to 1000 ml of the liquid preperation without any effective persitalsis. One
group of these patients with Neurogenic Colon were put on low fiber diet
and regular PEG-3350 and mild laxative. The other was given traditional
high fiber diet. During follow up the groups were compared for- regularity
and form of bowel movement, follow up abdominal x-rays, need for enema,
need for manual disimpaction, as well as need for transfere to community
hospital for constipation related work up and management.
Results: Contrary to popular belief, the group that was given low fiber was
observed to have lower incidence for all the parameters checked.
Conclusion: This makes physiologic sense, that the colon that can hold 800
ml or more of liquid without generating any peristalsis, obviously can not
generate enough peristalsis to propel solid and often hard stool formed by
high fiber diet. Loading a neurogenic colon with fiber had adversary effect
of bowel functionm therefore it should be limited.
The result of this observation form the institutionalized patients were dupli-
cated in small number of community patients with similar results. but need
to be duplicated in larger numebr of patients. If so, then patient education
and relatively simple dietary modification can help many patients, save many
dollars spent after new research and treatment for this worldwide problem.
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Coloscopy and Colography Are the Appropriate Terms To Use When
Referring to the Endoscopic and Radiological Examination of the
Lower Gastrointestinal Tract
Constantinos P. Anastassiades, MD, Diogenes Hadjinicolaou∗.
Department of Internal Medicine, Mayo Clinic College of Medicine,
Rochester, MN and Greek Department, The English School, Nicosia,
Cyprus.
Purpose: The endoscopic examination of the colon is commonly referred
to as colonoscopy and is currently the dominant modality for colon cancer
screening, a major public health concern. It also forms the bulk of the cur-
rent gastrointestinal endoscopic practice. The endoscopic examination of the
colon is also referred to as coloscopy, especially in Europe.
Despite the evolution of endoscopy, a large proportion of the US population
remains unscreened and attempts are being made to enhance compliance
with colon cancer screening. Part of this effort is the development of the non-
invasive, radiological study of the colon, which is interchangeably referred
to as both colonography and colography. This shows that the rapid advent of
new technology and procedures in the field of gastroenterology has resulted
in the indiscriminate use of medical terminology.
Medical terminology is based on word construction and uses the concept of
the word root in the context of the source language. By applying the rules of
grammar and linguistics, we demonstrate that the desirable word root is col-
(from the Greek col-on, meaning the gut) and not colon- (from the Greek
colon-os, meaning a hill). The correct compound terms col-oscopy, col-
ography, col-itis, col-ectomy and col-ostomy should therefore prevail over the
corresponding terms colon-oscopy, colon-ography, colon-itis, colon-ectomy
and colon-ostomy which would otherwise refer nonsensically to the exam-
ination of the hill, inflammation of the hill, surgical excision of the hill,
etc.
With regard to the two aforementioned ways of examining the lower gastroin-
testinal tract, the only correct terms are therefore coloscopy and colography.
Old habits die hard, and colonoscopy has already become the established
term to describe the endoscopic examination of the gut. However, it would
certainly be appropriate for the term colography to prevail over colonogra-
phy when referring to the more recently developed radiological evaluation
of the gut, e.g. in the form of CT colography, PET colography and virtual
coloscopy.
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Screening Colonoscopy in Average Risk Afro-Caribbean Population
below Fifty Five Years of Age
Manojkumar Singh, MD, Elizabeth Liang, MD, Gemma Rolle, MD, Safak
Reka, MD∗. Gastroenterology, SUNY Downstate, Brooklyn, NY.
Purpose: Recent studies suggest that colorectal neoplasia prevalence may
differ in different population and it may be higher and may present earlier
in African Americans. Committee of Minority Affairs and Cultural Diver-
sity, American College of Gastroenterology issued new recommendations
to begin colorectal cancer screening in African Americans at age 45 rather
than 50 years. The prevalence of colorectal neoplasia in Afro-Caribbean
population in the United States however is not known.
Methods: We retrospectively analyzed consecutive screening colonoscopy
performed in asymptomatic average risk patients of Afro-Caribbean de-
scent below 55 years of age over 6 month’s period. The exclusion criteria
included patients above 55 years of age, history of inflammatory bowel dis-
ease, previous history of adenoma or colorectal cancer and family history of
colon cancer. Patients with hyperplastic polyps or inflammatory polyps on
pathology were also excluded. The patients were analyzed for the size of the
polyps (<5 mm, 5–9 mm, >/= 10 mm), location of the polyps (proximal to
the splenic flexure or distal to the splenic flexure) and histopathology. 95%
confidence intervals were calculated using the exact binomial method.
Results: A total of 218 patients had screening colonoscopy between 50 years
and 55 years of age (mean age of 52.2 years) during the study period. 65%
of the patients were females and 35% were males. 46 patients (21%) [95%
CI (15.9%, 26.8%)] were found to have adenomatous polyps, of these 7
patients (15%) had tubulovillous polyps. 31% of the males had polyps and
19% of the females had polyps. A total of 58 polyps were found, of these 33
(57%) [95% CI (43.6%, 69.67%)] were proximal to the splenic flexure and
25 (43%) were distal to the splenic flexure. 24 polyps (41%) were < 5 mm,
34 polyps (59%) [95% CI (45.5%, 71.4%)] were more than 5 mm, of these
25 polyps (43%) were between 5 mm-9 mm and 9 polyps (16%) were more
than or equal to 10 mm.
Conclusion: In this pilot study overall prevalence of adenomas in asymp-
tomatic average risk Afro-Caribbean population in the United States be-
tween 50 years and 55 years of age was 21%. 57% of the adenomas were
distributed proximally and 59% of the adenomas were larger than 5 mm and
12% of the adenomas were tubulovillous. Although larger cohort is needed
this data suggests that it may be necessary to start screening colonoscopy
below 50 years of age in Afro-Caribbean patient population similar to the
African- Americans.
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Predicting Obstructive Defecation: Symptoms and Physiologic Tests
Kian Makipour, MD, Siva Doma, MD, Henry P. Parkman, MD∗. Medicine,
Temple University, Philadelphia, PA.
Purpose: Constipation can be from a variety of disorders including ob-
structive defecation (OD) and delayed colonic transit. Prior studies have
not shown predictive value of symptoms in identifying patients with OD.
AIM. To determine which physiologic tests and specific questions of the
Rome Pelvic Floor Dyssynergia questionnaire can be used to suggest OD or
delayed colonic transit.
Methods: A retrospective analysis of patients from May to January 2007
was conducted. Each patient underwent anorectal manometry (ARM), anal
electromyography (EMG), balloon expulsion, and whole gut transit scintig-
raphy. OD was defined by the presence of 2 of the following 3 criteria: 1)
inadequate relaxation of the internal anal sphincter (IAS) on ARM; 2) para-
doxical increase in EMG activity on bearing down (simulated defecation); 3)
inability to expel a 50 cc rectally placed balloon within 3 minutes. The mano-
metric defecation index (DI) was defined as the ratio of intrarectal pressure to
external anal sphincter pressure during simulated defecation. Patients were
asked questions from the Rome Pelvic Floor Dyssynergia questionnaire: A)
straining during movements; B) feeling of incomplete evacuation; C) sen-
sation of blocked stools; D) manual maneuvers to facilitate defecation; E)
difficulty relaxing to allow defecation.
Results: Of 76 patients, OD was identified in 55 and nonobstructive consti-
pation (NOC) was present in 21 patients. Abnormal DI (<1.2) was present in
47/55 (85%) OD patients and 9/21 (43%) NOC patients. Paradoxical EMG
response was present in 38/55 (69%) OD patients and only 1/21 (5%) NOC
patients. Abnormal IAS relaxation (<75%) was present in 32/55 (58%) OD
patients and 14/21 (67%) NOC patients. Prolonged balloon expulsion (>3
minutes) was present in 16/55 (29%) OD patients and 3/21 (14%) NOC pa-
tients. Question A was associated with OD (P = 0.054); B was associated
with both OD (P = 0.035) and with delayed colonic transit (P = 0.032); C
was associated with OD (P = 0.060); D was associated with delayed colonic
transit (P = 0.056); E was not associated with either OD or delayed colonic
transit.
Conclusion: The manometric defecation index was sensitive and EMG para-
doxical response was specific in identifying patients with obstructive defe-
cation whereas balloon expulsion did not appear to be useful. Questions
A (straining during bowel movements) and C (sensation of blocked stools)
were associated with obstructive defecation but not delayed colonic transit
whereas D (manual maneuvers to facilitate defecation) was associated with
delayed colonic transit but not obstructive defecation.
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Is Survival for Rectal Cancer Patients Downstaged to Stage I after
Neoadjuvant Radiation Determined by Their Pretreatment Stage? A
10 Year Analysis
Ravi P. Kiran, MD, Naveen Pokala, MD, Victor W. Fazio, MD∗. Colorectal
Surgery, Cleveland Clinic Foundation, Cleveland, OH.
Purpose: Owing to the possibilty of a more advanced initial stage, rectal
cancer patients downstaged to stage I after neoadjuvant radiation may be
expected to have a worse prognosis than patients of comparable stage under-
going surgery alone. We compare survival for patients with pathologic stage
I rectal cancer after neoadjuvant radiation to stage I patients not receiving
preoperative radiation.
Methods: Patients who underwent radical resection of the rectum for stage
I adenocarcinoma of the rectum between 1988 and 1997 were identified
from the prospectively maintained SEER database. Patient and tumor char-
acteristics and survival of patients who underwent preoperative radiation
(PRT) were compared with those who did not receive radiation (NRT). The
Chi-squared, Fisher’s exact and Mann-Whitney tests were used to determine
differences between groups as appropriate. The Kaplan-Meier test was used
to determine survival and the logrank test to determine significance of differ-
ence in survival between groups. P < 0.05 was considered to be statistically
significant.
Results: 2883 stage I patients (58.2% male) underwent radical resection
of the rectum. Tumor grade was well-differentiated (10.5%), moderately
differentiated (78.8%), poorly diffrerentiated (10.2%) or undifferentiated
(0.5%). 127 patients (4.4%) received preoperative radiation, 176 (6.1%)
postoperative and 2571 (89.5%) no radiation. Both RT and NRT groups had
similar gender and tumor grade, but RT patients were significantly younger
(mean 64 vs 68, P < 0.001) than NRT. Median survival was also similar
(median 141 vs 144 months, P = 0.9). The median number of nodes in the
specimen was however significantly lower in PRT than RT (4 vs 7, P < 0.05).
Patients receiving postoperative RT (PORT) had similar gender (P = 0.14),
grade (P = 0.17) and median survival (P = 0.7) compared with PRT. Median
number of nodes in PRT was also significantly lower than PORT (4 vs 6,
P < 0.05).
Conclusion: After neoadjuvant radiation, patients with rectal adenocarci-
noma downstaged to stage I have a lower lymph node harvest but a compa-
rable median survival to patients not receiving preoperative radiation. Thus
such downstaged patients may expect better outcomes determined by their
new stage I status rather than the original stage that prompted neoadjuvant
therpy.
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Comparison of Anorectal Manometry to Endoanal Ultrasound in the
Evaluation of Fecal Incontinence
Savio Reddymasu, MD, Sana Waheed, MD, Shailender Singh, MD,
Benjamin Alsop, Melissa Oropeza-Vail, RN, Richard McCallum, MD,
Mojtaba Olyaee, MD∗.
Purpose: To compare the results of anorectal manometry (ARM) and endo
anal ultrasonography (EAU) in a cohort of patients with fecal incontinence
(FI).
Methods: Retrospective, single center, descriptive study of 27 patients (20
females) referred to the gastrointestinal motility clinic for evaluation of FI.
Patients underwent both ARM to measure anal sphincter function, and EAU
to visualize the morphology of the anal canal. Linear regression analysis
(Pearson’s Correlation Coefficient) was used to correlate findings of ARM
and EUS
Results: Mean age of the patients who completed both studies was 56 years
(Range 26–87 years). Etiology of FI was obstetric trauma in 4, pelvic surgery
in 9, pelvic trauma in 3, pelvic radiation in 1, and idiopathic in 8. Based on
the ARM data, 14/27 had a weak external sphincter squeeze pressure and
3 had impaired rectal sensation, while with the EAU there was thinning of
the external anal sphincter (EAS) in 3 and complete disruption in 1. IAS
thinning was noted in 7/27, scarring of IAS in 2/27 and partial defect of the
IAS in 2. Overall only 2/27 had normal findings by combined ARM and
EAU. There was no correlation (r = 0.48) between EAS function based on
ARM and EAS anatomy as assessed by EAU. Similarly IAS function and
IAS anatomy did not correlate (r-0.26). However, in the three patients with
partial or complete disruption of IAS or EAS on EAU, the ARM showed the
corresponding sphincter weakness
Conclusion: 1) In a cohort of middle aged and older patients of both genders
seeing a gastroenterologist for varying etiologies of FI, only a small percent-
age of patients had a normal ARM or EAU. 2) When there are degrees of EAS
thinning or partial or complete disruption of the anal sphincters on EAU, a
good correlation with ARM is achieved. 3) EAU and ARM are complimen-
tary and important investigations for the thorough assessment of the anal
sphincter apparatus, which in turn will allow for appropriate management
strategies for the majority of patients with FI.
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Outcomes and Risk Factors for Development of Post-Polypectomy
Hemorrhage Requiring Hospitalization
Essam R. Quraishi, MD, Omar Sharif, MD, Kim Brown, MD∗.
Gastroenterology, Henry Ford Hospital, Detroit, MI and Internal Medicine,
Henry Ford Hospital, Detroit, MI.
Purpose: To determine the risk factors related to post-polypectomy hemor-
rhage (PPH) and to determine outcomes of these complications.
Background: PPH is a common complication following polypectomy with
a reported frequency of 0.3 to 6%. Reported risk factors include polyp size,
polyp morphology and patient age.
Methods: All outpatients undergoing colonoscopy with polypectomy be-
tween January 1, 1999 and April 1, 2007 were included. Data pertaining
to the colonoscopy and polypectomy was obtained using the endoscopic
database maintained by the Gastroenterology department and analyzed ret-
rospectively. Corporate data store was queried to obtain the list of patients
that were admitted to the hospital within 30 days following the colonoscopy.
Electronic medical records were reviewed to determine which of these pa-
tients were admitted with a diagnosis PPH. Statistical analysis was conducted
using chi-square analysis.
Results: There were 11,433 patients that had polypectomy performed, of
which 36 were admitted due to PPH (0.31%). PPH varied based on the site
of polypectomy. PPH was 0.62% following polyp removal from the cecum,
0.56% from ascending colon and 0.92% from hepatic flexure compared to
0% in transverse colon or splenic flexure, 0.27% in descending colon, 0.2%
in sigmoid and 0.25% in rectum (P = 0.017 right colon sites compared
with transverse and left colon sites). PPH occurred in 0.21% in patients
undergoing polypectomy during screening vs 0.43% for other indications
(P = 0.026). Bleeding occurred more commonly in males 0.47% vs females
0.19% (P = 0.003). Size of polyp >10 mm was associated with higher risk
of PPH 0.56% vs 0.14% (P = 0.013). There was no association with race or
type of bowel preparation used. 8 patients were admitted to the ICU. 22/36
(61%) patients required endoscopy for hemostasis and the remainder had
spontaneous resolution of bleeding. Mean hospitalization time was 3.7 days.
Conclusion: In our study we found that PPH is significantly higher in men.
PPH occurs significantly more frequently with polyps greater than 10 mm.
PPH appears to occur more frequently with polyps removed from the right
colon as compared with those removed from the transverse and left colon.
Finally, PPH appears to be more frequent following polypectomy in patients
undergoing colonoscopy for a specific indication as compared with those
undergoing polypectomy during screening. PPH was easily controlled in
most patients with either observation or endocospic therapy.
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Complete Resolution of Anemia after Polypectomy of Inflammatory
Fibroid Polyp
Vijay Arya∗, Siddharth Mathur, Niket Sonpal. Div. of Gastroenterology,
Wyckoff Heights Medical Center, Brooklyn, NY.
Purpose: Inflammatory fibroid polyp is an uncommon benign polypoid le-
sion of the gastrointestinal tract. Inflammatory fibroid polyp is more com-
monly found in the stomach or small intestine, and rarely in the colon. We
present a rare case of an 85 year old female (Jehovah’s Witness), presenting
with iron deficiency anemia caused by a benign fibroid polyp in the colon.
Methods: An 85 year old Hispanic female with a past medical history of
HTN, vaginal hysterectomy and family history of colon cancer, was referred
to our hospital (a center for bloodless surgery), after being found to have a
large colonic polyp in ascending colon and iron deficiency anemia. Her Hg
was 10.1, HCT 31.5, MCV 78.2, and her stool for occult blood was positive.
On colonoscopy, diverticulosis was seen from descending to sigmoid colon
and in the ascending colon a large pedunculated polyp with a very thick stalk
was found. At the stalk site 6 cc epinephrine, 1 in 10,000 was injected and the
polyp was removed using snare polypectomy. Pathology reported the mass
as an inflammatory fibroid polyp with multiple erosions measuring 4 × 3 ×
3 cm in size. An EGD showed mild hiatal hernia, gastric erosions and mild
duodenitis. Patient was never given any iron supplements or erythropoietin
injections for the anemia. Follow up labs after 10 months demonstrated
normal levels of Hb of 14.6 and Hct 41.7.
Thus this patient had an iron deficiency anemia secondary to blood loss from
the fibroid polyp which had multiple areas of erosions on its surface, and the
anemia resolved on removal of the polyp.
Conclusion: Inflammatory fibroid polyp is histologically characterized by a
mixture of proliferating fibroblasts and small blood vessels, accompanying
a marked eosinophilic infiltrate. The lesion largely affects adults and is more
common in the antrum of the stomach, but has occasionally been reported
in the small bowel and colon. Although it is generally believed to represent
a reactive, nonneoplastic condition, their histogenesis remains unclear. The
treatment is surgical excision of the polyp, or colonoscopic resection when
it is possible.
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In Vivo Prediction of Polyp Histology Using High
Definition/Magnification and Narrow Band Imaging (NBI)
Anu K. Mathew, MD, Francisco C. Ramirez, MD, FACG, Nooman Gilani,
MD, FACG∗. Gastroenterology, Carl T. Hayden VAMC, Phoenix, AZ.
Purpose: With wide spread use of new generation endoscopes utilizing
wide-angle views, high definition (HD)/magnification (Mag) and NBI, en-
Abstracts S265
doscopists are able to see more diminutive polyps whose clinical significance
remains unclear. Chromoendoscopy can differentiate polyp types with high
sensitivity but is a cumbersome technique. NBI can be utilized for the same
purpose but is less time-consuming. The aim was to predict polyp histology
using a combination of white light endoscopy with HD/Mag and NBI.
Methods: Prospective evaluation of 100 consecutive patients undergoing
screening colonoscopy from Sept 2006–Nov 2006. Olympus H180 colono-
scopes were utilized to examine polyps during adequate insufflation using
white light/HD/Mag followed by NBI mode. Polyp’s histology was then pre-
dicted and polypectomies peformed. The predicted histology was compared
to the true histo-pathological interpretation. The staff endoscopist was mod-
estly familiar with reported patterns visualized under NBI, associated with
adenomatous (Ad) or hyperplastic (HP) polyps.
Results: Of 231 polyps, 190 (82%) were predicted accurately (Ad = 77%,
HP = 89%). A detailed analysis between predicted and true histology of
polyps is shown in Table 1.
Table 1.
Polyp Characteristics Agreement 190 Disagreement 40 Accuracy
≤5 mm 154 35 82%
6–9 mm 22 5 82%
≥10 mm 14 1 93%
L sided lesions 116 28 81%
R sided lesions 74 13 85%
Adenomas 81 24 77%
Hyperplastic 108 14 89%
Other: melanosis,
leiomyoma,
carcinoid, cancer
1 (cancer) 3
Total distal sigmoid
polyps
90 6 93%
Diminutive distal
sigmoid polyps
72 3 96%
Figure 1 shows endoscopist’s accuracy for histology according to the location
and type of polyp. The predicted histological accuracy for HP recto-sigmoid
(≤30 cm from anal verge) polyps was 97% and increased to 98.6% for polyps
≤ 3 mm in size.
Conclusion: By using a combination of NBI and white light with HD/Mag,
we were able to show that polyp histology could be predicted fairly accu-
rately. Up to 99% of the diminutive hyperplastic polyps of recto-sigmoid
were identified correctly. This might help to avoid unnecessary polypec-
tomies.[figure1]
410
Addition of Bisacodyl Tabs Dramatically Reduces the Frequency of
Poor Colon Preps
Stephen J. Sontag, MD∗, Jack Leya, MD, Thomas G. Schnell, MD, Louella
R. Manguba, RN, Petra I. Falk, LPN, Ginger L. Filkas, LPN, Lydia L.
Nimes, LPN, Mclean Karen, RN, Hines-Loyola GI Fellows. GI Section,
Hines Veterans Affairs Hospital, Hines, IL; Department of Nursing, Hines
Veterans Affairs Hospital, Hines, IL and Gastroenterology, Hepatology and
Nutrition, Loyola University Medical Center, Maywood, IL.
Purpose: Poor C-scope preps result in increased complications, costs, and
missed cancers. In the past 4 years, despite 4 different 1 and 3-day prep
concoctions in 3614 exams, 8% of pts had poor preps. In desperation, we sent
out the dove, which returned with an olive branch and 12 tabs of bisacodyl.
Our purpose is to determine whether the new C-scope prep 1) improves
mucosal visualization and 2) reduces the rate of poor preps.
Methods: 100 consecutive pts were prepped by the Nurse Prep clinic in the
same manner as the previous 3614 pts, except for the bisacodyl. Pts were
instructed to commence on the day before the exam (1) the clear liquid diet,
(2) the 12 (5 mg) bisacodyl tabs (3) the gallon of Colyte, (4) the 10 oz of
Mag Citrate and (5) liquids for the rest of the day. Pts read either the story
of Noah or the Book of Job in the Hebrew Bible and reported to the scope
room the next day either by ship or by strips of dry land.
Results: There was an immediate and profound improvement in the quality
of the colon preps and the behavior of the GI fellows and nursing staff. There
was a 33% increase in Good or Excellent preps and a 6% decrease in Poor
preps (95% CI = 23.6–42.4, P < 0.0001). Age was unrelated to the quality
of the prep (P = NS) for all preps. If these results are maintained over the
next 30 years, an entire year of professional services will not have been
squandered.
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Conclusion: Addition of 12 bisacodyl tablets (60 mg) to the already nause-
ating colon prep on the morning prior to the C-scope procedure results in a
stunning increase in the frequency of acceptable preps.[figure1][figure2]
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Diagnostic Yield of Colonoscopy in Patients Referred with Iron
Deficiency Anaemia. Do Patients under 50 Years of Age Merit Such
Indication?
Mahboob Ali, MBBS, Linga Devi Thanasekaran, MBBS, Abdur Rafeh
Khan, MBBS, Irfan Maqsood, MBBS, Nosheen Khawaja, MBBS, Irrum
Tetlay, MBBS, Muhammad Naeem Khan, MBBS, Nicholas Russell, FRCP∗,
Babur Javaid, FRCP. Medicine, North Cumbria Acute Hospitals NHS
Trust, Whitehaven, England, United Kingdom.
Purpose: Iron Deficiency Anaemia (IDA) is one of the common referral
indications for patients undergoing colonoscopy. Colonic cancer (5–10%),
gastric cancer (5%) and coeliac disease (4–6%) are the most important causes
of Iron Deficiency Anaemia, and should be ruled out. British Society of
Gastroenterology (BSG) also recommends that all male patients (irrespec-
tive of age) and female patients aged 50 or more/ postmenopausal should
undergo colonoscopy, besides upper gastrointestinal endoscopy and coeliac
screening.
Methods: Our aim was to assess the diagnostic yield of colonoscopy in
patients referred with iron deficiency anaemia, and to compare the diagnostic
yield in patients under 50 years and over 50 years of age. We were specifically
looking for cancer pick up rate in the two age groups.
This study was carried out in the light of “Guidelines for the Management
of Iron deficiency Anaemia” published by BSG in 2005, which recommends
colonoscopy to rule out cancer in addition to above mentioned screening.
147 cases of Iron deficiency anaemia were identified (ferritin <12 ng/ml
(females) & <17 ng/ml (males), MCV <80 fl) and were finally included in
this study. We collected the data from endoscribe, and patients’ notes were
consulted where required. The data was analysed specifically with regards
to age. Only those patients who had full colonoscopy done were included in
the study.
Results: Eighty eight percent (N = 129) were more than 50 years of age and
18 (12%) were less than 50 years of age. 62.5% (N = 92) of patients were
female and 37.5% (N = 55) were male. Sixty percent (N = 88) of patients
had haemoglobin of less than 9.9 (average 9.6), and 63% (N = 93) had MCV
of 60–79 (average 74 fl). 45% (N = 66) had serum ferritin <10 (average
5.7).
In patients aged more than 50, colonoscopy was normal in 39% (N = 51),
26% (N = 33) had diverticular disease, 13% (N = 17) had colonic polyps,
10% (N = 15) had colon cancer, 6% (N = 7) had haemorrhoids, 2% (N =
2) had crohn’s colitis and <1% (N = 1) had angiodysplasia.
However, in patients less than 50 years of age 84% (N = 15) had normal
colonoscopy and 16% (N = 3) had polyps.
Conclusion: Our study showed that all the cancers were detected in pa-
tients more than 50 years of age. Hence, we recommend that colonoscopy
should not be a routine investigation for patients of less than 50 years of age
presenting with iron deficiency anaemia.
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Narrow – Band Imaging for Differentiating Neoplastic and
Nonneoplastic Colon Polyps during Colonoscopy in Clinical Practice
Ananth Vadee, MD, Colin Swales, MD, Curuchi Anand, MD∗.
Gastroenterology, Saint Vincent Hospital, Worcester, MA and
Gastroenterology, University of Massachusetts Medical Center, Worcester,
MA.
Purpose: All polyps are usually removed during colonoscopy, as it is diffi-
cult to differentiate between neoplastic polyps (NP) and nonneoplastic polyps
(NNP) during standard colonoscopy (SC). Narrow band imaging (NBI) high-
lights the mucosal pit pattern and microvasculature, and may improve the
accuracy of distinguishing NP and NNP.
The aim of this study was to evaluate the accuracy of NBI in distinguishing
NP and NNP, and feasibility of its use during colonoscopy in clinical practice
at an ambulatory surgery center (ASC).
Methods: 240 consecutive patients undergoing colonoscopy at an ASC were
studied. Duration of colonoscopy with application of NBI during the study
period was compared with duration of consecutive colonoscopies performed
by the operator from nursing records of previous examinations. Polyps were
identified using SC and then imaged with NBI. The polyps were desig-
nated as NP and NNP based on SC and NBI. All polyps were resected for
histopathology. The sensitivity, specificity, positive and negative predictive
values of SC and NBI for differentiating NP and NNP was calculated using
histopathology as the reference.
Results: 56 subjects 66% male 34% female, mean age of 61.7 years
had polyps. Indications were screening colonoscopy 77%, abdominal pain
3.5%, anemia 3.5%, heme positive stool 7%, rectal bleeding 4%, others
5%. 80 polyps were identified and resected. 51 polyps were NP (adeno-
mas) and 29 polyps were NNP (hyperplastic or inflammatory) on pathol-
ogy. 45/51 NP were correctly identified on NBI compared to 38/51 NP on
SC. 28/29 NNP were correctly identified on NBI compared to 24/29 NNP
on SC.
The sensitivity for NBI was 88.2% with a specificity of 96.5%, a positive
predictive value of 97.8% and a negative predictive value of 82.3%. In com-
parison SC had a sensitivity of 74.5% with a specificity of 82.7%, a positive
predictive value of 88.4% and a negative predictive value of 64.9%. There
was no significant difference in the duration of colonoscopy with NBI ap-
plication (mean 17.5 min vs.16.4 min, P = 0.12).
Conclusion: NBI is superior to SC in distinguishing NP and NNP polyps.
It can be applied during colonoscopy in a clinical practice setting without a
significant increase in the duration of procedure. However, more studies and
clinical experience with NBI is required; before it can be used as a standard
technique to distinguish NP and NNP during colonoscopy.
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Trainees’ Influence on Polyp Detection (TRIPOD). Does Trainee
Participation Affect Polyp Detection Rates?
Colin T. Swales, MD, Alexander J. Eckardt, MD, Neil P. Phelan, MD,
Sharif Zubair, MD, Nadeem Anwar, MD, Noel Martins, MD, Sunil Patel,
MD, Brian Moquin, MD, Katherine Leung, MPH, Wahid Y. Wassef, MD,
Kanishka Bhattacharya, MD, John M. Levey, MD∗. Division of
Gastroenterology, University of Massachusetts, Worcester, MA.
Purpose: Training future endoscopists is essential to meet increasing de-
mands for colonoscopy. Current standards demand a polyp detection rates
of 15% in male patients and 25% in females. However, it remains unknown
if such criteria are met when trainees are involved during a procedure, or
if trainee- participation leads to a substantial delay in procedure time when
polyps are found.
Methods: We prospectively gathered information about polyp detection rates
during open-access colonoscopy (OAC) in a university-based training pro-
gram. This data was collected as part of a study that aimed to assess patient
satisfaction with OAC, whether there was 2nd- or 3rd-year trainee participa-
tion or not. As part of a quality improvement initiative, we aimed to assess
whether polyp detection rates differed between procedures with or without
trainee involvement. As a secondary aim we analyzed procedure times in the
two groups. Statistical analysis.
Results: 369 patients entered the analysis (181 with trainee participation
and 188 without). Most referrals were for screening/surveillance (87%).
Attending physicians detected polyps in 31% of patients and 34% of trainee-
procedures. In absolute numbers, 96 polyps were detected in the trainee-
group versus 94 in the attending group. The number of patients in whom 3
or more polyps, or polyp greater or equal than 1 cm, were detected, was 14 in
the trainee group versus 20 in the attending group respectively. On average,
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trainee participation during cases with polypectomy delayed the procedure
by 8 minutes (42% relative increase).
Conclusion: Polyp detection rates do not appear to differ during OAC
in our center, whether there was trainee-participation or not, although
trainee-participation led to a (tolerable) delay in procedure duration. There
was a trend towards finding more polyps or polyps greater than 2 cm in
the absence of a trainee, but polyp detection rates were still above na-
tional standards when trainees were present. We believe that such analy-
ses will help improve quality or care and training in university training
programs.
414
Ischemic Colitis Induced by the Combination of Bisacodyl and
Polyethylene Glycol in Preparation for Colonoscopy
Konstantin Vaizman, MD, JianJun Li, MD∗, Kadirawel Iswara, MD, Scott
Tenner, MD. Internal Medicine, Division of Gastroenterology,
Maimonides Medical Center, Brooklyn, NY.
Purpose: Laxatives are frequently used in preparation for lower gastroin-
testinal studies. There have been rare cases of ischemic colitis complicat-
ing colonoscopy preparation. We report two patients who developed is-
chemic colitis immediately following bisacodyl and polyethylene glycol
preparation.
Methods: The first patient is a 56-year-old man with a history of hy-
pertension and mitral valve prolapse who had an outpatient surveillence
colonoscopy. He ingested four tablets of bisacodyl in preparation for his
colonoscopy one day before the procedure. After completing the polyethy-
lene glycol preparation, he reported crampy lower abdominal pain. The pain
was followed by diarrhea and maroon stool. Colonoscopy revealed an area
of patchy submucosal hemorrhage and mucosal edema at the level of the
proximal sigmoid colon. Biopsies of the area showed subacute ulceration
and fibrosis of lamina propria, consistent with ischemic colitis.
Our second case is a 78 year-old female with a history of hyperten-
sion, anemia and osteoarthritis who was admitted to the hospital after an
elective colonoscopy. She had ingested her bowel prep the night before
which included bisacodyl and polyethylene glycol. After developing ab-
dominal pain, followed by bloody diarrhea, she presented to the hospi-
tal. On admission, her abdominal examination revealed lower abdominal
tenderness and distension. Abdominal radiograph revealed a pneumoperi-
toneum. The patient underwent an exploratory laparotomy. Necrotic sig-
moid bowel complicated by perforation was identified. A left hemicolectomy
was performed. Histology of the resected area demonstrated focal ischemic
colitis.
Conclusion: Due to its mechanism of action, bisacodyl may result in colonic
ischemia by transient reduction in the splancnic blood flow. When taken
in conjunction with a polyethylene glycol purgative, resulting in increased
intramural pressure secondary to increased peristalsis, ischemic colitis and
perforation may occur. These two cases suggest that careful consideration
be given to providing biscodyl in combination with polyethylene glycol
preparations.
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Clostridium difficile Colitis: A Shift from a Traditionally Hospital
Acquired Infection to a Community and Nursing Home-Based Disease
Vivek Kumar, MD, Sam Yoselevitz, MD, Sudhir K. Dutta, MD∗.
Gastroenterology, Sinai Hospital, Baltimore, MD and Gastroenterology,
Johns Hopkins University School of Medicine, Baltimore, MD.
Purpose: Until recently, most studies on the incidence and prevalence of
Clostridium difficile-associated disease (CDAD) have focused entirely on
patients hospitalized in the acute care setting. However, CDAD has recently
reached epidemic proportions within the general population and within long
term care facilities such as nursing homes. This study aims to highlight that
the epidemiology of CDAD is shifting from a primarily hospital acquired
disease to an infection arising mostly within our communities and long-term
care environments.
Methods: This was an IRB-approved retrospective study of hospitalized pa-
tients in an inner-city tertiary care hospital in Baltimore, MD. All patients
carried the diagnosis of C. diff colitis (ICD-9 008.45) between Jan 2000
and Dec 2005. We reviewed 410 hospital medical records to verify the diag-
nosis of CDAD by ensuring that all included patients had clinical evidence
of CDAD with a confirmed positive toxin assay. Patients were then divided
into specific categories according to the most likely source of their infec-
tion. Categories included nosocomial, nursing home, community, and other
(i.e assisted living facilities/group homes). The source of infection was con-
sidered nosocomial if patients developed clinical symptoms of CDAD 48
hours or more after admission with a confirmed positive toxin assay. Those
patients with clinical symptoms of CDAD on admission or within 48 hours
(with a positive assay) were accordingly divided into their respective cate-
gories. Special consideration was given to ensure that all included patients
had no previous hospitalizations within the six months prior to diagnosis.
Data was acquired using MS Access and analyzed using SPSS.
Results: A total of 300 toxin assay positive patients were included in the final
analysis. It was found that fifty-three cases (17.7%) were truly nosocomial,
as compared to eighty-six cases (28.7%) which were community acquired,
and one-hundred twenty cases (40%) which were nursing home acquired.
Therefore, two-hundred six cases of CDAD (68.7%) were acquired from a
source outside the hospital setting.
Conclusion: Clostridium difficile-associated disease may be shifting from
a traditionally hospital acquired infection to a primarily community and
nursing home-based phenomenon. Additional epidemiological studies are
needed to further confirm these findings and to develop strategies for limiting
the extent of this disease.
416
Assessment of Methane Breath Testing
Sattar Zubaidi, MD, Sheila Rodriguez-Stanley, PhD, FACG, Susan Riley,
RN, Philip B. Miner, Jr., MD, FACG∗. Oklahoma Foundation for Digestive
Research, Oklahoma City, OK.
Purpose: A positive methane breath test has been associated with constipa-
tion. Bjorneklett and Jenssen (Scand J Gastro1982; 17:985) demonstrated
the presence of methane in the fasting state and in mid-day sampling (non
fasting) in normal volunteers. Le Marchand et al (Environ Health Prospect
1992 Nov; 98:199–202.) demonstrated a clear circadian pattern of excretion
for breath hydrogen while methane excretion was constant throughout the
day.
Aim: To assess change in methane from baseline following lactulose dosing.
Methods: One hundred ninety-nine patients were referred to the OFDR gas-
trointestinal physiology laboratory with chronic lower gastrointestinal com-
plaints for testing for bacteria overgrowth between 8/11/2005 and 6/8/2007.
Patients were stratified by baseline methane values: <2 ppm negative, 2–9
ppm low methane producers, >10 ppm high methane producers. Early in
our experience, methane breath test was considered complete if the baseline
CH4 was elevated (N = 15) (no lactulose was given and no other samples
were taken). The remaining 184 patients were given 10 g lactulose orally.
Methane and hydrogen in the exhaled breath was measured every ten or
fifteen minutes for three hours using Quintron microlyser.
Results: The data is summarized in the table. None of the 149 patients with
no measurable methane became positive after lactulose ingestion. When
the initial breath was positive for methane, patient could have an increase,
No CH3 Low CH3 High CH3
Baseline 149 12 38
Fluctuation 0 10 5
Increased 0 0 20
Discontinued∗ 0 2 13
∗After elevated baseline methane.
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decrease, or fluctuation in breath methane. No patients had a decrease in
methane during the study. 15 were discontinued as mentioned above.
The above table did not include 3 patients (discontinued because of high H2)
Conclusion: 1) An initial BT with low positive methane did not show an
increase in methane following lactulose;
2) An initial BT with high positive methane increases with lactulose 50% of
the time.
3) A negative methane breath test does not become positive after lactulose.
Conclusion
1) Lactulose administration has little effect on baseline breath methane
values.
2) 25% of our patient population have positive tests for breath methane.
417
A Cost Comparison of Metronidazole and Vancomycin in the
Treatment of Clostridium Difficile Associated Diarrhea
Kristen L. Thomas, BS, Kyland R. Holmes, MS, Brian R. Jackson, MD, MS,
Mae Go, MD, John C. Fang, MD, Kathryn A. Peterson, MD, MSci∗.
Gastroenterology, University of Utah, Salt Lake City, UT; Pathology,
ARUP, Salt Lake City, UT and Gastroenterology, VA Medical Center, Salt
Lake City, UT.
Purpose: Clostridium difficile associated diarrhea (CDAD) is currently the
leading cause of antibiotic associated diarrhea. Current guidelines recom-
mend metronidazole as the first line therapy due to its low cost. The emer-
gence of more virulent strains and increasing resistance rates of metronida-
zole have raised questions as to whether vancomycin should be used rather
than metronidazole.
Aim: To determine whether metronidazole or vancomycin provides the most
cost-effective treatment for CDAD.
Methods: TreeAge Pro 8.1 software was used to develop a cost comparison
model of vancomycin versus metronidazole as first line therapy for CDAD.
Separate Markov models were generated to evaluate the drugs’ respective
cost effectiveness for the treatment of CDAD.
Direct outpatient costs associated with CDAD were obtained from the Medi-
care database and included clinic visits, antibiotics (metronidazole and van-
comycin), and stool tests (Toxin A and toxin B). Direct hospital costs were
obtained from the US Medicare DRG’s for enteritis/complications.
Monte Carlo simulation was utilized in the comparison models. Patients
were assumed to have no greater than 6 recurrences.
Results: Using recently reported resistance rates of 20% (metronidazole)
and 1% (vancomycin) and a recurrence rate of 20% for each drug, the
average treatment cost was $561 for metronidazole and $910 for van-
comycin. Using probabilistic sensitivity modeling, equivalent costs be-
tween the groups were attained only once resistance rates of metron-
idazole approached 75%. As determined by cost-modeling, vancomycin
expense would need to be reduced by 88% to achieve superiority to
metronidazole.
Conclusion: Despite increasing resistance rates of CDAD to metronidazole,
metronidazole outperforms vancomycin as first line therapy in the treatment
of CDAD largely due to the expense of vancomycin. First line therapy for
CDAD should remain as metronidazole unless resistance rates become sub-
stantial or the cost of vancomycin is significantly reduced.
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Is Body Mass Index an Important Marker of Complicated
Diverticulitis? A 10 Year Retrospective Review
Serge A. Sorser, MD, Tal B. Hazan, MD, Michael Piper, MD, Luis C.
Maas, MD∗. Gastroenterology, Providence Hospital and Medical Center,
Southfield, MI.
Purpose: Obesity is becoming a growing health concern in the gen-
eral population. The complications of this epidemic affect the endocrine,
cardiovascular and gastrointestinal systems. Multiple studies have linked
diverticular disease to obesity. Furthermore, recent research has shown
fat to be a critical element in the regulation of immunity and the in-
flammatory response. In this study, we sought to determine if body
mass index (BMI) is associated with a higher incidence of complicated
diverticulitis.
Methods: A retrospective review of patients hospitalized with complicated
diverticulitis between 1997 and 2006 was conducted. Medical, surgical and
CT guided interventions were evaluated in reference to age, gender, BMI
and length of hospital stay (LOS).
Results: Charts of 614 patients hospitalized with complicated diverticuli-
tis were reviewed based on specified inclusion and exclusion criteria. Of
those, 36 patients presenting with medically treated diverticulitis with lower
gastrointestinal bleed (LGIB) [group 1], 170 patients undergoing surgical
intervention for simple diverticulitis [group 2], 50 patients with divertic-
ulitis with abscess [group 3], 64 patients with diverticulitis with peritoni-
tis [group 4], and 41 patients with diverticulitis and CT guided drainage
[group 5] were included in this study (N = 325). There was no signif-
icant difference between groups by either gender (P = 0.066) or BMI
(P = 0.648). However, there was a difference in the age between groups
1 and 2 (P < 0.001), 1 and 4 (P < 0.001), 2 and 3 (P = 0.014). Further-
more, differences in the LOS were noted between groups 1 and 3 (P =
0.001), 1 and 4 (P = 0.007), 1 and 5 (P = 0.041). No correlation was
noted between BMI and LOS in any of the groups (group 1: P = 0.061,
group 2: P = 0.650, group 3: P = 0.485, group 4: P = 0.813, group 5:
P = 0.679).
Conclusion: There has been increasing interest in obsesity and its ramifi-
cations in all areas of medicine, including diverticular disease. Numerous
studies have shown a strong correlation between acute diverticulitis and obe-
sity, particularly in the young population. However, little research has been
conducted to conclude what causes complicated diverticular disease and why
it happens to a select group of patients. This study was undertaken to iden-
tify a possible link between complicated diverticulitis and obesity. Anectodal
reports and few studies have found a parallel association. However, in this
retrospective study, no correlation was found between BMI and incidence
complicated diverticulitis.
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How Useful Is Digital Rectal Examination in the Diagnosis of
Dyssynergia?
Priyanka Rao, Kasaya Tantiphlachiva, MD, Ashok Attaluri, MD, Satish
Rao, MD∗.
Purpose: In patients with constipation and difficult defecation, anorectal
manometry (ARM) is regarded as a gold standard for the diagnosis of dyssyn-
ergic defecation. However, it is not widely available and lacks standardiza-
tion. Digital rectal examination (DRE) may provide vital clues regarding
anorectal structure and function that could suggest dyssynergia. However,
DRE is not systematically performed, and its clinical utility in the evaluation
of dyssynergia is not known.
Aim: To examine the diagnostic yield of DRE in pts with constipation and
difficult defecation.
Methods: Patients presenting to a single gastroenterologist with constipa-
tion and difficult defecation (Rome II) were enrolled. All pts completed a
constipation questionnaire and had clinical assessment, including a detailed
DRE: anocutaneous reflex, resting and squeeze anal sphincter tone, perineal
descent, and anal relaxation with straining. A clinical impression of dyssyn-
ergia was noted in the chart. Subsequently, all patients had ARM with a solid
state, 6-sensor probe. Anal sphincter and intrarectal pressures were analyzed
at rest, squeeze and during attempted defecation, and these data were used
to identify dyssynergia. A balloon expulsion test (BET) was also performed.
The diagnostic yield of DRE was compared with ARM, using manometry
as the gold standard.
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Results: We examined 100 pts (F/M: 94/6, mean age: 41 ± 15.3 yrs)
with constipation. Excessive straining, hard stools, incomplete evacuation,
≤ 3 BM/wk and use of digital maneuvers were reported by 84%, 88%,
80%, 75% and 40% of patients respectively. Based on DRE (impaired per-
ineal descent or paradoxical anal contraction or impaired push effort), 76
(76%) had dyssynergia. Subsequently, ARM identified 95 pts (95%) with
dyssynergia. DRE had as sensitivity of 81% and positive predictive value
(PPV) of 99% for diagnosis of dyssynergic defecation. Normal resting tone
on DRE had a sensitivity of 81% and PPV of 69% but a weak sphinc-
ter had a sensitivity of 25% and PPV of 28%. Normal squeeze tone had
a sensitivity of 78% and PPV of 69% whereas a weak squeeze pressure
had sensitivity of 31% and PPV of 40%. Anocutaneous reflex was nor-
mal in 73%, and absent in 27%. BET had a sensitivity of 49% and PPV
of 100%.
Conclusion: In patients presenting with constipation in a tertiary care cen-
ter, DRE has a high sensitivity and PPV in identifying pts with dyssyn-
ergic defecation. DRE has good sensitivity and PPV for detecting a nor-
mal but not an abnormal resting or squeeze sphincter tone. A prolonged
balloon expulsion test is diagnostic but a normal test does not exclude
dyssynergia.
420
Colocutaneous Fistula Causing Diarrhea: A Complication of PEG
Tube Replacement
Shailaja Jamma, MD, Shamant Tippor, MD, Jyothi A. Reddy, MD∗.
Internal Medicine, College of Medicine, University of Illinois at Urbana
Champaign, IL and Gastroenetrology, VA Illiana Health Care System,
Danville, IL.
Purpose: Percutaneous endoscopic gastrostomy (PEG) tube placement lead-
ing to fistula formation is rare and colocutaneous fistula due to PEG place-
ment has been reported in less than ten cases.
Case: A 37 year old male with cerebral palsy and congenital quadriplegia,
with PEG tube for enteral nutrition presented with persistent diarrhea of
2 weeks duration leading to hypokalemia and hypernatremia. Stool studies
including clostridium difficile toxin, ova and parasites, and cultures were
negative. PEG residuals were yellowish and had fecal odor. Further inquiry
revealed there was a bedside replacement of PEG tube 2 weeks ago, which
coincided with the onset of diarrhea. Gastrograffin through PEG tube and
computed axial tomography scan showed the presence of the tube in the
transverse colon and an absence of gastrocolic fistula. Diarrhea resolved
after discontinuing tube feedings.
Discussion: Apart from infection and bleeding, PEG placement can also
cause rare complications such as gastrocolic, jejunocutaneous and colocu-
taneous fistulae. These can occur when loop of intestine gets transfixed
between the stomach and the abdominal wall during tube placement. Also,
these fistulae may remain asymptomatic after initial procedure and become
symptomatic only after PEG replacement. Usually dysfunctional PEG tubes
are replaced at the bed side without any radiologic or endoscopic guidance
and the replaced tube may remain localized in the colon without proper
advancement into the stomach.
Conclusion: After bedside replacement of the gastrostomy tube, a strong
consideration should be given to radiographically confirm the location of
the luminal end. Furthermore, recognize colocutaneous fistula as a cause for
persistent diarrhea after PEG replacement.
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Characterization of Colon Cancer in Patients with Primary Sclerosing
Cholangitis and Ulcerative Colitis
Erin W. Thackeray, MD, Phunchai Charatcharoenwitthaya, MD, Keith D.
Lindor, MD∗. Internal Medicine, Mayo Clinic, Rochester, MN and
Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Purpose: Little is known about the characteristics of colon cancer in patients
with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). The
aims of this study were 1) to describe the histological type, location, and
staging of colon cancers and 2) to determine the influence of PSC on tumor
characteristic in this population.
Methods: A data base identified patients with PSC, UC, and colon cancer
evaluated at Mayo Clinic Rochester (1995–2005). Records were reviewed
for demographics, age at diagnosis of colon cancer, PSC, and UC; and his-
tological grade and location of colon cancer.
Results: Twenty-nine patients with UC and PSC developed colon cancer with
a mean age (standard deviation) of 50.6 (10.6) years (range, 28–83 years)
and 69% were male. Thirteen (45%) patients had a history of PSC before
the diagnosis of colon cancer with a median duration of 44.5 months (range,
1–105 months), while the remaining 16 patients had colon cancer diagnosed
at the same time or prior to the diagnosis of PSC with a median duration
of 1 month (range, 0–57 months). Of the 24 patients who had histological
grading, 17 patients had quiescent to mildly active UC, while only 7 pa-
tients had moderate to severely active UC at the time of the diagnosis of
colon cancer. All of the colon cancers were adenocarcinomas. The majority
(90%) of the cancers were histological grades 2–3 (out of 4). According
to TNM staging system for colon cancer, 10 patients had stage I cancer,
6 had stage II, 7 had stage III, and 5 had stage IV cancer. Twenty can-
cers (69%) were located on the right side of the colon defined as ileocecal
valve to the splenic flexion. The tumor characteristic among patients who
had PSC diagnosed prior to the diagnosis of colon cancer did not differ
from those patients who developed colon cancer prior or synchronous to the
diagnosis of PSC with regard to age at the time of diagnosis of colon can-
cer, gender, activity of UC, tumor grading and staging, and location of the
tumor.
Conclusion: Colon cancer was more likely to develop in the right-sided
colon in young individuals with UC and PSC. The development of PSC
has no impact on the characteristic of colon cancer. This information may be
important in decision making for colon cancer surveillance in this population.
Surprisingly, many cases of PSC were not recognized until after the colon
cancer was found which may suggest a need for more aggressive screening
for PSC in patients with UC.
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Elevated HbA1c Is an Independent Predictor of Aggressive Clinical
Behavior in Patients with Adenomatous Colonic Polyps
Ali A. Siddiqui∗, Haripriya Maddur, Suraj Naik, MD, Byron Cryer.
Gastroenterology, Dallas VA Medical Center, Dallas, TX and University of
Texas Southwestern Medical Center, Dallas, TX.
Purpose: To determine if poor control of DM is associated with with
increased prevalence of colonic adenomatous polyps (AP), especially ad-
vanced AP.
Methods: We performed a retrospective review of 652 patients with DM-
2 and AP. HbA1c levels were evaluated as in index of glycemic control
over the year that preceded diagnosis of AP. 40 factors were assessed in
patients grouped into well controlled (HbA1c < 7.5%) & poorly controlled
DM (HbA1c ≥ 7.5%). Factors in each group were examined by univariate
analysis and logistic regression analysis to determine independent predictors
of aggressive AP behavior.
Results: Our results are summarized in table 1. Logistic regression
showed that patients with HbA1c ≥ 7.5 presented with more advanced
AP, greater right sided AP and a greater number of AP. Patients using
NSAIDS had a lesser incidence of advanced AP (P < 0.01). Concurrent
use of insulin and NSAIDS appeared to negate any protective effect of
NSAIDS.
Conclusion: Poor glycemic control in patients with DM-2 independently
predicts a clinical aggressive course for patients with AP. Small differences
in HbA1c elevation may lead to variations in the behavior of AP.
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Table 1.
Univariate Analysis
Normal HbA1c (N = 339) Elevated HbA1c (N = 313) O.R. (95% CI) P
Present with Advanced Adenomatous Polyp, (%) 13.2 31.2 6.2 (2.4–15.5) >0.005∗
Right Sided Adenomatous Polyp, (%) 15.4 32.9 5.6 (2.2–13.7) 0.001∗
Mean Age at Diagnosis of Adenomatous Polyp 67.8 (52–81) 64.1 (51–76) – 0.001∗
Mean Polyp size, (mm) 6.7 (3–20) 10 (4–30) – 0.001∗
Mean Polyp Number 2.5 (1–7) 5.5 (2–20) – >0.005
Smoker, (%) 42.6 60.5 2.1 (0.89–4.79) 0.05∗
Multivariate Logistic Regression Analysis
DEPENDENT VARIABLES 95% CI P
AP site (Right side = 1) 0.04–0.07 0.69
Polyp Number 0.01–0.15 0.03 ∗
Age at Diagnosis -0.06–0.01 0.21
Smoker -0.14–0.84 0.16
Right Sided Polyps 0.06–1.04 0.03 ∗
Advanced Polyps 0.21–1.36 0.007 ∗
∗Statistically significant
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Simultaneous Assessment of Colonic Transit Using Wireless Capsule
(SmartPill) and Radiopaque Markers in Healthy Subjects and
Effects of Gender
S. Rao, MD, FACG∗, B. Kuo, MD, W. Chey, MD, FACG, J. Dibaise, MD,
FACG, L. Katz, MD, K. Koch, MD, FACG, J. Lackner, PsyD, R. McCallum,
MD, R. Saad, MD, K. Selover, J. Semler, PhD, M. Sitrin, MD, G. Wilding,
PhD, H. Parkman, MD, FACG. SmartPill Research Group
.
Purpose: Colonic transit time (CTT) is used in the evaluation of consti-
pation. Conventionally, CTT is assessed by ingesting radiopaque mark-
ers (Sitzmarks (SZ) followed by abdominal x-ray(s). However, there
is limited normative data, gender effects are unclear, and the tech-
nique is hampered by poor compliance and complex protocols. Re-
cently, the SmartPill (SP) wireless pH and pressure recording cap-
sule has been advocated for assessing CTT. The aim of this multicen-
ter study was to simultaneously assess and compare CTT as measured
by SP with that of SZ in healthy subjects and to assess the effects of
gender.
Methods: After overnight fast, subjects ingested a nutrient bar (260 kcal)
followed by a SZ capsule (24 markers) and a SP capsule. Subjects were
instructed to wear a data receiver for 5 days or until SP was expelled and
to record their bowel habit on a stool diary. Abdominal x-rays were ob-
tained on day 2 and day 5. SP tracing was examined to assess gastric
emptying time (GET) (time to sudden rise in pH >4), small bowel tran-
sit time (SBTT) (time to cecal entry with >1 pH drop after GET), CTT
(time from cecal entry to abrupt temp. drop), and whole gut transit time
(WGTT) (time from ingestion to abrupt temp. drop). The number of re-
tained markers, transit times, and gender differences were assessed and
compared.
Results: Table (mean ± SEM, ∗ = P < 0.05). 70 (36 M (mean age = 25
yrs)/34 F (mean age = 38 yrs), mean age = 37 yrs) were studied. The SP
CTT correlated with% of markers expelled on day 2 (r = 0.72, P < 0.001)
and on day 5 (r = 0.54, P < 0.001). The number of markers retained on
Day 5 were greater (P < 0.001) in females and likewise, the SP CTT was
also slower (P < 0.03) when compared to males. The GET (P < 0.002)
and WGTT (P < 0.03) were also slower in females. All subjects expelled
the SP.
Conclusion: This large prospective study demonstrates very good correla-
tion of colonic transit as measured by SmartPill with conventional SZ
technique. Also, women had slower gut transit time when compared to
men. Thus, gender should be considered when interpreting CTT measure-
ments. SP is a valid technique of measuring colonic and regional gut transit
time.
# Markers # Markers
Day 2 Day 5 GET SBRT CTT WGTT
Whole 8.9 ± 1.0 1.1 ± 0.4 3.6 ± 0.3 3.8 ± 0.2 29 ± 3 37 ± 3
Group
Females 11.2 ± 1.5 1.7 ± 0.8 4.1 ± 0.5 4.0 ± 0.3 35 ± 5 43 ± 5
Males 6.6 ± 1.3 0.4 ± 0.2∗ 3.2 ± 0.3∗ 3.6 ± 0.2 23 ± 3∗ 31 ± 3∗
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Safety of Colonoscopy during Pregnancy
Steven R. Fox, MD, Navakanth Gorrepati, MD, Mitchell S. Cappell, MD∗.
Gastroenterology, William Beaumont Hospital, Royal Oak, MI.
Purpose: Whereas colonoscopy is relatively safe in the general population,
the safety of colonoscopy during pregnancy is inadequately studied with only
15 reported cases. The safety of colonoscopy during pregnancy involves the
unique issue of fetal safety. We analyze the fetal safety of colonoscopy in 23
pregnant patients.
Results: 23 patients (8 primigravida, 15 multigravida) underwent
colonoscopy during pregnancy from 1986 through 2006 at William Beau-
mont Hospitals. Their mean age was 29.7 + 4.7 years (range 20–38 years).
Mean gestational age at colonoscopy was 17.9 + 7.8 weeks (range 2–33
weeks). 4 patients had colonoscopy during 1st trimester, 16 in 2nd trimester
and 3 in 3rd trimester (13 as inpatients). Colonic preps included: oral sodium
phosphate in 5 patients, sodium phosphate enema in 4, magnesium citrate in
3, polyethylene glycol in 4 and other in 5 (no prep in 1). Anesthetic agents
included meperidine (N = 7), fentanyl (N = 6), thiopental (N = 4), mi-
dazolam (N = 2), morphine sulfate (N = 2), and other in 3 (unsedated in
6). Mean duration of endoscopy was 19.4 + 10.3 min (range 8–45). The
procedure was well tolerated in 78%. Primary indications for colonoscopy:
hematochezia in 10, diarrhea in 4, foreign body in 1, and other in 8. Major
new findings/therapy included: new ulcerative colitis in 3, hemorrhoids in
3, ischemic colitis in 3, established IBD in 2, foreign body removal in 1,
new Crohn’s in 1, and other in 4 (normal colonoscopy in 6). The cecum was
reached in 14, transverse colon in 6, hepatic flexure in 2, and near splenic
flexure in 1 pt. Three patients underwent snare polypectomy, and 2 had hot
biopsy. Patients were hospitalized for 2.6 + 4.7 days (range 0–20) after index
colonoscopy. Maternal colonoscopy complications include hypotension in
3 and minor symptoms in 6. Two patients had spontaneous abortions (both
in 1st trimester; 5 days and 5 weeks after colonoscopy). All other infants
were delivered alive with no congenital malformations noted in the infant
nursery. Mean age of gestation at delivery was 37.8 wks + 2.2 (N = 19,
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range 33–40). Mean APGAR score at 1 min was 8.1+ 1.0 (N = 20, range
5–9), and at 5 min was 9.0 + 0.3 (N = 19, range 8–9), birth weight 3.1
+ 0.6 Kg (N = 19, range 1.9–4.2). Fetal outcomes (N = 19) included low
birth weight (< 2500 grams) in 2 infants, twin gestation in 1 and premature
delivery (<37 wks) in 9.
Conclusion: Colonoscopy appears to be relatively safe and can be performed
when strongly indicated in the 2nd and 3rd trimesters of pregnancy.
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Post-Surgical Clostridium difficile Infection
Rabin Rahmani, MD, William Southern, MD, Igal Khorshidi, MD, Andy
Thanjan, MD, Christopher B. Ibrahim, MD, Lawrence J. Brandt, MD,
MACG∗. Gastroenterology, Montefiore Medical Center, Bronx, NY.
Purpose: C. difficile is the most common nosocomial infection and C. dif-
ficile colitis (CDC) is a frequent cause of morbidity and mortality among
hospitalized patients. Although CDC has been studied extensively in medi-
cal patients, the incidence of this infection and this disease hardly has been
investigated in surgical patients. The aims of this study were to identify
the pre-operative risk factors associated with development of post-operative
CDC, and to determine if any predisposing factors were associated with
mortality from this disease.
Methods: We constructed a cohort of all in-patients in 2006 who had under-
gone surgery involving the stomach, small bowel, colon, appendix, anorec-
tum, gallbladder and biliary tract, pancreas, hernia repair or non-otherwise
specified (NOS) abdominal surgery. We performed a retrospective review of
the charts of all patients who had a C. difficile toxin assay post-operatively.
Results: We identified 1214 patients who had undergone one of the specified
surgeries (422 M; 792 F). 45 patients (4%) were found to have at least one
positive C. difficile toxin assay post-operatively. The mean age of the study
population was 57.6 yrs (± 19.4 yrs) for all patients, 63.8 yrs (± 17.7 yrs)
for those suspected to have CDC, and 67.2 yrs (± -17.1 yrs) for those with
a positive toxin assay.
Pre-operative factors associated with post-operative toxin positivity were
age (OR 1.34 for each 10-year increment in age; 95% CI 1.13–1.60); male
gender (OR 1.84; 95% CI 1.01–3.34); proton pump inhibitor (PPI) use within
10 days of surgery (OR 2.00; 95% CI 1.08–3.71; P-value 0.03); antibiotic
use within 30 days of surgery (OR 2.04; 95% CI 1.11–3.77); length of
hospitalization prior to surgery (OR 1.58 for every 5 days of hospitalization;
95% CI 1.30–1.93); and a low serum albumin level on admission (OR 2.00
for each loss of 1 g/dl, 95% CI 1.32–3.03).
Two pre-operative factors were associated with post-operative mortality from
CDC: a low serum albumin level on admission (Hazard Ratio (HR) 3.41 for
each loss of 1 g/dl; 95% CI 2.59–4.49); and a high serum creatinine on
admission (HR 1.55 for each increment of 1 mg/dl; CI 1.02–2.22).
Conclusion: Post-surgical CDC is a significant complication of “abdominal”
surgery that needs to be addressed carefully. Age, male gender, PPI use,
antibiotic use, length of hospitalization, and low serum albumin levels are
important risk factors in the development of post-surgical CDC. High serum
creatinine and low serum albumin levels are associated with higher mortality
rates.
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Symptomatic Mallory-Weiss Tear – A Rare Complication of Peroral
Colon Lavage Preparation
Joseph C. Yarze, MD, FACP, FACG FASGE∗. GI Division, GI Associates of
Northern New York, Glens Falls, NY.
Purpose: To describe a rare symptomatic complication of peroral colon
lavage preparation.
Methods: Colonoscopy is now frequently performed as a primary col-
orectal cancer screening modality. I recently cared for a patient who sus-
tained a rare complication “associated” with the performance of screening
colonoscopy.
Results: A 72 year-old, average-risk patient presented for direct-access
screening colonoscopy. Upon pre-procedure questioning, the patient men-
tioned that she had difficulty ingesting the colon lavage preparation, which
included magnesium citrate, bisacodyl, and polyethylene glycol solution.
Non-bloody vomiting occurred 12 hours prior to the procedure. The pa-
tient volunteered that the rectal effluent turned from yellow to blackish
in color, during the night before which the procedure was performed. She
was taking an NSAID intermittently, but this practice was discontinued 5
days prior to presenting for the procedure. There was no recent iron or bis-
muth ingestion. Physical examination showed slightly pale conjunctivae, but
was otherwise unremarkable. We discussed also performing upper GI en-
doscopy, should it be deemed appropriate upon completing the colonoscopy.
The patient was agreeable, and informed consent was obtained for both
procedures.
The colonoscopy was performed under moderate sedation. The examina-
tion was completed to the cecum and the mucosa was coated with me-
lenic residue (which was suctioned and tested overtly positive for blood).
The terminal ileal mucosa was similarly coated with black, bloody residue.
The colonoscopy was otherwise normal (within the limits of the subop-
timal preparation). Given these findings, upper GI endoscopy was then
performed.
At upper GI endoscopy, a prominent 3 cm nonbleeding Mallory-Weiss tear
was found at the EG junction. No endoscopic therapy was deemed necessary,
and she was discharged home on a proton-pump inhibitor (4 week course),
with instructions to avoid ASA/NSAID use for 4 weeks. A CBC revealed
a Hgb of 10.7 g% (in contrast to a value of 13.8 g%, upon routine blood
testing which had been performed 3 months earlier). The patient recovered
uneventfully.
Conclusion: This case highlights a potential, albeit rare complication, which
can be seen in association with peroral colon lavage preparation, which
was administered prior to screening colonoscopy. Given that screening
colonoscopy is now frequently performed, and nausea and vomiting are not a
rare occurrence during the preparation, it is possible that such symptomatic
events may occur with increasing frequency in the future.
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“Kissing” Patches-An Uncommon Appearance of Cervical Esophageal
Heterotopic Gastric Mucosa
Joseph C. Yarze, MD, FACP, FACG FASGE∗. GI Division,
Gastroenterology Associates of Northern New York, Glens Falls, NY.
Purpose: To describe an uncommon appearance of heterotopic gastric mu-
cosa (HGM) in the cervical esophagus.
Methods: An “inlet patch” refers to a small (usually ∼ 0.5 to 2 cm) island
of red, velvety heterotopic gastric mucosa, which is often conspicuous when
viewed amid the more pink-colored normal esophageal squamous mucosa.
These “patches” are usually found in the cervical esophagus, immediately
below the upper esophageal sphincter. HGM may be found in ∼10% or more
of patients, when the cervical esophageal region is carefully examined.
Results: Over the years, I have found many patients who have had cervical
esophageal HGM, which endoscopically appeared as 2 “kissing” patches,
noted at opposite sides of the lumen. One such case is shown in Figure 1. I
have found that in patients with cervical esophageal HGM, the solitary island
of gastric tissue is most commonly noted at the 7 to 8 o’clock position (which
corresponds to the posterior position). In those in whom I’ve found “kissing”
islands of cervical esophageal HGM, the “accessory” patch is usually smaller
and visualized in the 1 to 2 o’clock position (which corresponds to the
anterior position). I would anecdotally estimate cervical esophageal HGM
to have this less common appearance in ∼ 5% of cases in whom cervical
esophageal HGM is detected.
Conclusion: Cervical esophageal HGM can uncommonly present endoscop-
ically as 2 “kissing” patches, located on opposite sides of the esophageal
lumen.[figure1]
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Massive Bilateral Hepatic Hydrothoraces with Minimal Ascites
Joseph C. Yarze, MD, FACP, FACG FASGE∗, David M. Markowitz, MD. GI
Division, Gastroenterology Associates of Northern New York, Glens Falls,
NY and Department of Radiology, Glens Falls Hospital, Glens Falls, NY.
Purpose: To describe an uncommon presentation of hepatic hydrothorax.
Methods: A 77 yo male presented with recurrent massive bilateral pleu-
ral effusions. Background medical history included systemic hypertension,
atrial fibrillation and a remote history of colon carcinoma. He was initially
evaluated by my associate 9 months earlier, when abnormal liver biochemi-
cal tests were noted. At that time, he had hyperalkalinephosphatasemia (5×
ULN). The serum transaminases were “trivially elevated (<2× ULN). The
serum total bilirubin was normal and the albumin was mildly depressed
at 3.1 g/dl. Full serologic/virologic hepatic investigation was normal aside
from the alpha-1-antitrypsin phenotype revealing MS Pi-type heterozygos-
ity. AMA was specifically negative. An ERCP was performed, which re-
vealed “pruning” of the intrahepatic biliary radicals, most consistent with
underlying cirrhosis (as opposed to PSC). Liver biopsy revealed “bland”
bridging fibrosis. He had no ascites at the time and was to be followed ex-
pectantly. He then presented with massive, symptomatic bilateral pleural
effusions. He underwent multiple thoracenteses, which showed “transuda-
tive” fluid. Pleuroscopy showed no abnormality, and echocardiography was
normal. Consultation was then requested after pleurodesis failed to alleviate
the problem.
Results: During this evaluation, abdominal CT revealed a “scalloped” liver
edge and no appreciable ascites. Ultrasound-guided diagnostic paracente-
sis of a 2 cm RLQ fluid collection confirmed a portal-hypertensive fluid
(SAAG = 1.6 g/dl). Doppler interrogation of the portal and hepatic venous
systems revealed no thrombosis. Radionuclide scanning was performed after
6.2 mCi of TC99m macroaggregated albumin was injected into the peritoneal
cavity (right lower quadrant). This confirmed prompt tracer localization (at
40 min) into both pleural spaces, and a left-sided chest tube, which was
in place at the time. Vigorous sodium restriction and combination diuretic
therapy were unsuccessful in controlling the pleural fluid accumulation. The
patient underwent TIPS placement, which alleviated his bilateral hepatic
hydrothoraces.
Conclusion: This case highlights an uncommon presentation of hepatic hy-
drothorax, where pleural fluid accumulation was both bilateral and occurred
in the absence of significant ascites. Radionuclide instillation into the peri-
toneal cavity was employed to facilitate the diagnosis, and TIPS placement
successfully alleviated the symptomatic pleural effusions.
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“Mark and Clip” in Difficult Cases of Gastrointestinal Hemorrhage
Joseph C. Yarze, MD, FACP, FACG FASGE∗. GI Division,
Gastroenterology Associates of Northern New York, Glens Falls, NY.
Purpose: To describe the use of “mark and clip” method, employed in a case
of recurrent GI hemorrhage.
Methods: An 89 yo patient presented with low-volume hematochezia. Back-
ground history included diverticulosis and she ingested no ASA/NSAID or
anticoagulants. Upon presentation, Hb was 14 g%, she was hemodynami-
cally stable and no further bleeding occurred over 48 hrs. The patient desired
no evaluation, and immediately prior to planned hospital discharge, large vol-
ume, bright-red colored, painless hematochezia recurred. On this occasion,
she became transiently hypotensive and the Hb fell to 6 g%. A bleeding
scan suggested active bleeding from the left colon. EGD was normal. At
colonoscopy, pancolonic diverticulosis was noted, but no active bleeding
was seen, and ileal intubation was normal. A large adherent clot was seen in
the mid-sigmoid. The clot was flushed away and a small-neck diverticulum
was noted beneath. A tiny erosion was noted at the neck of the diverticulum,
but no visible vessel could be seen. Epinephrine solution was injected at the
neck of the diverticulum and the site was marked with ink, as it was thought
to be a potential source of bleeding. Bleeding recurred 48 hours later with
recurrent transient hypotension. Repeat colonscopy again revealed no active
bleeding and no clot was seen in the sigmoid region. A metal clip was placed
in the region of the previously placed ink mark, for possible radiologic identi-
fication of this area of presumed hemorrhage. Hemodynamically significant
bleeding recurred another 36 hours later, and mesenteric angiography was
requested
Results: At angiography, no bleeding site was initially seen on either the
SMA or IMA “runs.” The radiologist then performed a selective contrast
injection in the region of the “sigmoid clip” (IMA distribution) and rapid
extravasation was noted. Hemorrhage was arrested with a third-order “super-
selective” embolization. Bleeding has not recurred after a 10 month period.
Conclusion: In cases of recurrent, “stuttering” gastrointestinal hemorrhage,
one should consider the use of both endoscopic mucosal marking and simul-
taneous clip placement. The former can be used to facilitate identification
during repeat endoscopy or surgery, and the latter can be beneficial during
angiographic investigation. Due to their expense, these maneuvers should
not be employed routinely, but rather as an adjunct under special circum-
stances (e.g. cases of diverticular hemorrhage, Dieulafoy bleeding) where
potential bleeding sites may be difficult to re-identify, if repeat intervention
is required.
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Refractory and Coexistent Crohn’s Disease with ITP: A Clinical
Dilemma
Joseph C. Yarze, MD, FACP, FACG FASGE∗. GI Division,
Gastroenterology Associates of Northern New York, Glens Falls, NY.
Purpose: To describe a novel approach utilized in a case of refractory, co-
existent Crohn’s disease and idiopathic thrombocytopenic purpura (ITP).
Methods: Case Report: 58 yo female was hospitalized with bloody diarrhea
and severe thrombocytopenia. Crohn’s disease spanned 2 decades and she
had previously undergone a partial colon resection. She was hospitalized
on two recent occasions and was cared for by another gastroenterologist.
Recent colonoscopy (done when the platelet count was 242,000/ul), revealed
changes of severe Crohn’s colitis. She was glucocorticoid-dependent (50 mg
of prednisone daily). She had reported questionable allergies/intolerances to
all 5-aminosalicylate preparations, 6MP, methotrexate, and metronidazole.
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Diffuse urticaria occurred after (4) infliximab infusions (despite an excellent
clinical response, and administration of a “pre-treatment” protocol).
ITP (diagnosed 10 years ago) progressed and did not respond to glucocorti-
coids, splenectomy, rituximab, cyclophosphamide and other therapies. She
was seen at a tertiary referral center for opinions from the IBD and hema-
tologic perspectives. No novel approach was recommended, and a surgical
team considered treatment of her IBD contraindicated (platelet count now
∼4,000/ul, despite platlet transfusions). I was asked to see the patient after
transfer back to our community hospital. She was having 12 bloody bowel
actions daily.
Results: The platelet count remained ∼ 4,000/ul. After discussion, I rec-
ommended a trial of oral 5-aminosalicylate, and budesonide was started, in
anticipation of tapering of prednisone. Given prior response to infliximab,
(but severe allergic reaction), a humanized anti-TNF monoclonal antibody
was started (adalimumab 160 mg sc at time 0, 80 mg sc at week 2, then 40
mg sc at week 4, and every 2 weeks, thereafter). All the above interventions
were tolerated and diarrhea improved. Six weeks later, she was discharged,
having 5 soft, non-bloody bowel actions per day. Twelve weeks after start-
ing adalimumab, prednisone was withdrawn. From the IBD perspective, she
remains in clinical remission after 4 months.
Conclusion: Transition to adalimumab was successful in achieving and
maintaining clinical remission with simultaneous, treatment-refractory
Crohn’s disease and ITP, with previously demonstrated severe allergy to in-
fliximab. The ITP remained untreatable, and this limited the ability to utilize
more traditional medical (6MP, MTX) and surgical therapies for the under-
lying IBD. Adalimumab “salvage therapy” was successful in this desperate
clinical situation.
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“Delayed” Sustained Virologic Response after Treatment of Hepatitis
C with Pegylated Interferon and Ribavirin
Joseph C. Yarze, MD, FACP, FACG FASGE∗. GI Division,
Gastroenterology Associates of Northern New York, Glens Falls, NY.
Purpose: To describe a case of “delayed” sustained virologic response (SVR)
after treatment of chronic hepatitis C virus (HCV) infection with pegylated
interferon (PEG-IFN) and ribavirin (RBV).
An otherwise healthy 36 yo male presented for evaluation of chronic HCV
infection in 10/00. Evaluation revealed mild hyperaminotransferasemia and
low-titer (178,654 IU/ml), type 1b viremia. Pre-treatment liver biopsy re-
vealed A3/F3 disease. Treatment with PEG-IFN alpha-2b (150 mcg subcu-
taneous weekly) in combination with RBV (1000 mg orally daily, in divided
doses) ensued, with regular hematological, biochemical and clinical moni-
toring. Serum aminotransferases rapidly normalized, and remained within
normal limits. In 6/01, after 24 weeks of combined antiviral therapy, the HCV
level, however, remained positive at >600,000 IU/ml, by quantitative PCR
analysis. Given this, the patient was characterized as being a non-responder,
and the combination antiviral therapy was withdrawn. The patient was to be
followed clinically, and as he was planning to move, he was to establish care
with another hepatologist in the Midwestern US.
The patient re-presented in 1/07, after moving back to upstate NY. At that
time, he mentioned that evaluation in Iowa, where he had transiently lived,
suggested that he no longer had evidence of HCV infection. In the interim,
he received no other antiviral therapy, and took no herbal, prescribed or OTC
medications. There were no other previous or intercurrent medical illnesses.
Records were obtained for review, and these corroborated that in 10/03,
HCV was undetectable by quantitative PCR (lower limit of detectioN = 200
IU/ml). HCV quantitative PCR was also negative in 1/07 and 2/07. HCV
qualitative PCR was also negative in 3/07 (lower limit of detectioN = 50
IU/ml). The liver biochemical test profile also remained within normal limits.
“Delayed” SVR was ultimately noted to occur in this unusual case, despite
there being firm documentation of a lack of virologic response while on
combination PEG-IFN/RBV for a duration of 24 weeks. “Spontaneous” viral
clearance unrelated to the previous antiviral therapy remains a possibility.
This case highlights an unusual course of sustained HCV clearance, after
what was initially documented to be unsuccessful combination interferon-
based antiviral therapy.
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Atypical “Intramuscular” Colon Lipoma
Kevin J. Herlihy, MD, FACG, Jayant R. Paranjpe, MD, FCAP, Joseph C.
Yarze, MD, FACP, FACG FASGE∗. GI Division, Gastroenterology
Associates of Northern New York, Glens Falls, NY and Department of
Pathology, Glens Falls Hospital, Glens Falls, NY.
Purpose: A 51 yo male presented for screening colonoscopy. The exam
revealed an ∼ 4 cm subepithelial mass in the distal transverse colon re-
gion.[figure1] The lesion was diffusely firm to palpation with closed biopsy
forceps, and a “cushion sign” was unable to be demonstrated. The lesion
was lobulated and endoscopic biopsies revealed only hyperplastic tissue. An
abdominal CT demonstrated the lesion to be hypodense, measuring –113
Hounsfield units. The CT radiographic findings suggested the lesion to be a
lipoma. One section of the CT scan, however, suggested a non-lipomatous,
soft-tissue rim of unclear significance. The patient offered that he had been
experiencing vague left upper quadrant distress. Options of expectant man-
agement, EUS and surgical resection were discussed. Given that the lesion
displayed some characteristics atypical for a lipoma, he opted for surgical
resection.
Laparoscopic transverse colon resection proceeded uneventfully.
Histopathology revealed the lesion to be a lipoma, which was within
the muscularis propria layer. [figure2] The unusual histopathology of
this lipoma accounted for multiple unique aspects of this case. It is
decidedly unusual for a lipoma to be diffusely firm to palpation by biopsy
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forceps. Also, by CT scan, this lesion appeared to have a soft tissue rim
along its border. These findings are likely accounted for by the fact that
histopathology revealed the lipoma to be within the muscularis propria.
This histopathologic finding may also have contributed to this lipoma’s
lobulated appearance.
Colon lipomas can occasionally be associated with atypical colonoscopic and
radiographic features. In this case, such atypical findings were likely related
to the lipomatous lesion being within the muscularis propria, as opposed to
the submucosal layer.
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Systemic Mastocytosis: A Rare Cause of Portal Hypertension
Seth Sweetser, MD, Patrick S. Kamath, MD∗. Division of Gastroenterology
and Hepatology, Mayo Clinic College of Medicine, Rochester, MN.
Purpose: We present a rare case of systemic mastocytosis masquerading
as advanced liver disease. An 80-year-old Caucasian man was referred for
evaluation of ascites and esophageal varices. His history was notable for
frequent watery stools occurring on a daily basis and a thirty pound weight
loss over the past year that had remained undiagnosed despite an extensive
work-up. In the interim, he had been diagnosed with chronic liver disease
of unclear etiology based on the presence of esophageal varices, ascites,
and hypersplenism. He reported intermittent abdominal cramping but de-
nied fever, night sweats, rashes, itching, or flushing. On exam, he appeared
cachectic and his abdomen was distended with shifting dullness. An ab-
domen/pelvis CT showed hepatosplenomegaly, ascites, and punctate scle-
rotic bone lesions. Labs were significant for WBC 5.5 × 10(9)/L with 49%
monocytes, hemoglobin 11 g/dL, platelets 93 × 10(9)/L, ALT 111 U/L,
AST 67 U/L, alkaline phosphatase 601 U/L, total bilirubin 0.9 mg/dL, and
INR of 3.3. Ascitic fluid analysis showed a SAAG of 2.6, total protein of
1.6 g/dL, and 350 cells with 88% monocytes. Gram stain, bacterial cul-
ture, and cytology of the ascitic fluid were negative. Liver biopsy revealed
nodular regenerative hyperplasia. A bone marrow exam was hypercellular
with 20% involvement by systemic mastocytosis. Tryptase immunostain-
ing of the liver biopsy revealed mast cells within the portal areas. Addi-
tionally, a serum tryptase was 243 ng/dL (nl <11.5) which confirmed the
diagnosis.
Conclusion: Systemic mastocytosis is a rare cause of portal hypertension.
Possible mechanisms of portal hypertension in mast cell disease include
increased blood flow in the splenic vein, splenic arteriovenous shunting sec-
ondary to histamine release, increased intrahepatic resistance secondary to
mast cell infiltration, and nodular regenerative hyperplasia. In this case,
portal hypertension was likely caused by nodular regenerative hyperplasia
and infiltration of portal areas by mast cells. The diagnosis of systemic
mastocytosis was considered only after realizing that the diarrhea could
not be explained by the degree of portal hypertension and noting the pres-
ence of sclerotic bone lesions which prompted a bone marrow biopsy and
tryptase measurement. This case highlights the fact that systemic masto-
cytosis should be considered in the differential of causes of portal hy-
pertension in individuals with evidence of advanced liver disease even
when the characteristic cutaneous manifestations of mast cell disease are
absent.
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A Broken Heart from Pancreatitis
Joseph Y. Chang, MD, MPH∗, Gautam Kumar, MBBS. Mayo Clinic
College of Medicine, Rochester, MN.
Purpose: An 83-year-old female presented with a two day history of nau-
sea, vomiting, and epigastric pain. Initial evaluation was consistent with
acute pancreatitis with lipase of 1064 U/L, amylase 1271 U/L; with normal
transaminases, total and direct bilirubins, and alkaline phosphatase. Abdom-
inal ultrasound was negative for gallstones but showed a dilated common
bile duct at 11 mm. She underwent endoscopic retrograde cholangiopan-
creatography with lateral sphincterotomy and placement of pancreatic duct
stent. Due to poor clinical progress, she later underwent computed tomogra-
phy of the abdomen, with findings consistent with severe pancreatitis. She
subsequently developed retrosternal chest pain, dyspnea, diaphoresis and
hemodynamic instability. Electrocardiogram showed new left axis devia-
tion, intraventricular conduction delay and anteroseptal ST elevation. Car-
diac biomarkers were elevated with troponin-T of 0.52 and CK-MB of 24.6.
Transthoracic echocardiogram (TTE) demonstrated reduced ejection frac-
tion at 20%, with new diffuse regional wall motion abnormalities. Manage-
ment for presumed myocardial infarction with aspirin, beta-blocker therapy,
and anticoagulation with unfractionated heparin was started and she was sent
for emergent cardiac catheterization. However, no flow restricting lesions
were found and left ventriculography reported akinesis of the apical septal,
posterolateral, anterolateral, apical and diaphragmatic segments; findings
consistent with the diagnosis of cardiogenic shock secondary to transient
left ventricular apical ballooning, also known as “broken heart syndrome”.
Following this event, the patient had a protracted hospital course requiring
almost 60 days of hospitalization. Her cardiac function normalized with TTE
performed prior to dismissal reporting EF of 55% and resolution of the prior
regional wall motion abnormalities. Acute pancreatitis is an inflammatory
process of the pancreas that is a response to the inappropriate activation
of proteolytic enzymes. Approximately 15–20% of cases can be classified
as severe pancreatitis and these cases can be complicated by systemic in-
flammatory response syndrome (SIRS), sepsis, multiple organ dysfunction,
and death; with mortality rates of 10–30%. This is the first report of severe
pancreatitis complicated by “broken heart syndrome”. One postulated mech-
anism for this disorder is catecholamine induced microvascular dysfunction
resulting in myocardial stunning. It is hypothesized that this case was a result
of sympathetic hyperactivity secondary to the inflammatory response from
severe pancreatitis.
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An Uncommon Cause of Lower Gastrointestinal Bleeding
Gautam Dutta, MD∗, Mukta Panda, MD, FACP. Internal Medicine,
University of Tennessee College of Medicine, Chattanooga Unit,
Chattanooga, TN.
Purpose: Discuss the common causes and investigational modalities for
lower gastrointestinal (LGI) bleeding.
Discuss the common presentation of LGI carcinoid tumors.
Case: A 44 year old male, recent immigrant from India, presented with
copious melena for 1 day without abdominal pain, hematemesis, fever,
weight loss, change in bowel habits. On presentation he was tachycardic
(pulse115/min), and hypotensive (BP 80/55 mmHg). Complete physical
examination was unremarkable. Rectal exam showed frank blood. His
Hb was 8.1 gm/dl and Hct was 25.1%. Panendoscopy revealed an ileal
bleeding mass. Interestingly a colonoscopy done 6 months earlier in In-
dia for anemia workup was normal. Emergent laparotomy revealed nu-
merous smaller intraluminal nodules scattered throughout the small bowel.
Histopathology revealed carcinoid tumor. CT suggested possible metas-
tasis to lymph nodes without liver involvement. He denied symptoms
of carcinoid syndrome and his 24 hr urine 5- HIAA level was 13.1
(diagnostic – > 25 mg/24 hr).
Discussion: The etiology of massive LGI bleeding includes diverticulo-
sis, angiodysplasia, polyps, dieulafoy’s lesion, infectious or inflammatory
bowel disease. Small intestinal carcinoid tumors usually present around sixth
decade of life with abdominal pain or obstruction and rarely with LGI bleed-
ing. Less than 10% patients develop carcinoid syndrome. Our patient was
unique as he was younger, without typical symptoms – rather presented
with massive LGI bleed. Because of substantial false-negatives on initial en-
doscopy as demonstrated in our patient, the fact that small bowel carcinoid
tumors are highly infiltrating; early diagnosis is mandated. An aggressive ap-
proach should be taken which would include repeating routine endoscopies,
enteroscopy, capsule endoscopy, mesenteric angiography, and radionuclide
RBC scan.
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Band of Cacophony
Gautam Dutta, MD∗, Aparna S. Chowdhury, MD, Mukta Panda, MD,
FACP. Internal Medicine, University of Tennessee, Chattanooga, TN.
Purpose: Discuss the complications of Meckel’s Diverticulum (MD), a rare
occurrence in the adult population.
Case: A 55 year old white male presented with progressively worsening ab-
dominal pain for 3 days. The pain started in the mid-lower abdomen and then
became generalized, sharp and colicky, 10/10 in intensity, non-radiating, as-
sociated with nausea but no vomiting. Though he has noticed blood in his
stools occasionally in the past, his last bowel movement was three days prior
with semisolid stool without any blood. His past medical history is significant
for hypertension and peripheral vascular disease, status post aorto-femoral
bypass graft 6 yrs prior. On presentation his vitals were within normal limits,
abdomen was non-distended but tender and rigid all over, more on left lower
quadrant without any rebound tenderness. Bowel sounds were hypoactive.
Rectal exam showed an empty vault. WBC count was 9.0 × 103/mm3 with
94.5% neutrophils, Hb of 9.0 gm/dl and Hct of 31.3%, liver and pancreatic
enzymes were not elevated. ABG didn’t show any acidosis and lactic acid
level was not elevated. X-ray showed a non-obstructive bowel pattern with-
out any free air. Abdominal CT showed findings consistent with complete
mid to distal small bowel obstruction secondary to a closed loop obstruc-
tion. Emergent laparotomy showed a MD that had formed a band around a
portion of small bowel causing it to twist upon itself and become necrotic.
Histopathology showed MD with hemorrhagic necrosis and benign intestinal
tissue with necrosis.
Discussion: Based on autopsy studies and intra-operative evidence, MD oc-
curs in 0.3% to 4% of the population and is the most prevalent congenital
anomaly of the gastro-intestinal tract. The lifetime risk of complications of
MD is 4% which include obstruction, intussusception, inflammation, per-
foration, hemorrhage and neoplasm. Most patients who develop symptoms
are younger than 10 years. So traditionally it is considered a disease of the
pediatric age group and a less common consideration in the adult and geri-
atric population. Misdiagnosis occurs frequently in this age group because
of the poor sensitivity of diagnostic tests, nonspecificity of complaints, and
lack of recognition that this anomaly can present in the older age group.
Physicians need to be cognizant of the multivariate ways of presentation of
this commonly assumed pediatric disease especially when evaluating older
age group patients for unexplained acute or intermittent abdominal pain,
nausea and vomiting, rectal bleeding, peritonitis, or obstruction.
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Gastroduodenal Crohn’s Disease (GDCD): A Case of Dramatic
Response to Selective Granulocyte-Monocyte Apheresis (GMA)
Shivani Sood, MD, MPH, Ira L. Savetsky, BA, Jonathan A. Erber, MD,
William F. Erber, MD, Seymour Katz, MD∗. Gastroenterology, Hepatology
and Nutrition, North Shore Univ. Hospital NYU School of Med.,
Manhasset, NY; Digestive Diseases, SUNY Downstate, Brooklyn, NY and
Gastroenterology, Maimonides Medical Center, Brooklyn, NY.
Purpose: GDCD, a rare and difficult to treat manifestation of Crohn’s dis-
ease. We report the first case of a dramatic clinical, endoscopic and biochem-
ical response of GDCD to selective GMA (Adacolumn).
Case Report: A 37-year-old man presented with cramping abdominal pain,
diarrhea, occasional nausea and vomiting of 2 months’ duration with a nor-
mocytic anemia (Hemoglobin 12 g/dl, MCV 85 fL) and guaiac positive
brown stool. Colonoscopy revealed circumferential and longitudinal deep
ulcerations with cobblestoning of ascending colon and a stenotic ileocecal
valve. Biopsies showed chronic colitis without granulomas. An upper GI
and small bowel (SB) series revealed irregular nodular thickening of the
distal ileal loops, thumb-printing, narrowing and non-distensibility of prox-
imal ascending colon consistent with Crohn’s ileitis and colitis. Labwork
revealed an elevated C-reactive protein (CRP) (97.5 mg/L; normal, 5 mg/L),
erythrocyte sedimentation rate (ESR) (47 mm/hr; normal <15 mm/hr), pos-
itive ASCA IgG/IgA and a negative pANCA. Gastric and duodenal bulb
ulcerations were found on gastroscopy with chronic inflammation without
granulomas or H. pylori. Despite mesalamine, rifaximin and esomeprazole,
at one-month follow-up, the patient’s persistence of cramps and frequent
bowel movements prompted an investigational study of 10 weeks of IRB
approved Adacolumn with informed consent, while continuing his origi-
nal medications. About 10 months after the original gastroscopy, a follow
up gastroscopy showed remarkable disappearance of ulcerations from the
stomach and the duodenal bulb. At this point, the patient had also received
5 weeks of low-dose 6-MP. Repeat ESR and CRP were normal.
Discussion: GDCD is a rare and difficult to treat form of Crohn’s disease.
Investigational technique of GMA involves the extracorporeal passage of pe-
ripheral blood through a column of cellulose diacetate beads (Adacolumn)
or a nonwoven polyester fiber filter (Cellsorba) for “quantitative” removal of
activated circulating leukocytes. We report a dramatic clinical, biochemical
and endoscopic response to GMA, unlikely to be attributable to the 5-week
course of low-dose 6-MP. GMA seems to be a promising “non-drug”, sus-
tained therapeutic approach for treatment of GDCD.
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A Patient with Diarrhea and an Abnormal CT Enterography
Rami J. Badreddine, MD, Conor G. Loftus, MD, Santhi S. Vege, MD∗.
Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, MN.
Purpose: A 35 years- old lady presented to the gastroenterology clinic with
symptoms of early satiety, bloating, nausea, episodic abdominal pain and
a 15 pound- weight loss of several months duration. She reported severe
diarrhea. Workup included a 24 h alpha1- antitrypsin stool clearance which
returned abnormally high.
A CT enterography (Fig. 1) showed prominent gastric mucosal enhancement,
mild enhancement in the duodenum and jejunum with thickening of the bowel
wall suspicious for intestinal lymphangiectasia.
An upper endoscopy showed prominent diffusely scattered white spots in
the first and second parts of the duodenum with a snowflake like appearance
(Fig. 2). Biopsies from the second part of the duodenum were consistent
with intestinal lymphangiectasia.
Discussion: Intestinal lymphangiectasia is characterized by ectasia of en-
teric lymphatic vessels in the mucosa and/or submucosa. When primary, it
is usually associated with abnormal lymphatics elsewhere in the body. Sec-
ondary lymphangiectasia is usually caused by cardiac disease, inflammatory
processes or toxic substances.
Very little information exists on the CT enterography appearances in this
disease. The pattern described above on CT enterography, though not spe-
cific, should raise the suspicion for lymphangiectasia in the right clinical
setting.
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Clinical presentation ranges from diarrhea to significant weight loss, ab-
dominal pain and chylous ascites. Diagnosis relies on clinical, laboratory,
imaging and endoscopic findings. Classic endoscopic findings include dif-
fusely scattered white spots representing dilated lacteals. Treatment re-
lies mainly on dietary modification with a low fat, MCT and a high pro-
tein diet. TPN is sometimes required. Treatment of the primary cause
is essential in secondary intestinal lymphangiectasia. The disease usually
requires long term treatment although occasional remissions have been
described.[figure1][figure2]
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Gastrointestinal Histoplasmosis
Navin Paul, MD, Subramanian Swaminathan, MD, Alka Ganesh, MD,
George Abdelsayeed, MD∗. Bridgeport Hospital [Yale New Haven
Health], Bridgeport, CT and Christian Medical College, Vellore, India.
Purpose: A 43 y/o man from Bangladesh came with 4 month fever, low
appetite and 9 kg weight loss. Investigations in his home country were
noncontributory. He had received antimalarial and antituberculous drugs
with no improvement. Initial examination showed low grade fever, tachycar-
dia, emaciation, and hepatosplenomegaly. Investigations were normal except
for AST 58 U/L, ALT 50 U/L, albumin 2.9 g/L, alkaline phosphatase[ALP]
312 U/L, and GGT 88 U/L. HIV ELISA, ANA, and infective workup were
negative. USG abdomen showed hypoechoic splenic lesions, bilateral adrenal
enlargement with calcification, and enlarged paraaortic nodes. US guided
biopsy of paraaortic nodes revealed Histoplasma capsulatum. Itraconazole
was started and patient became afebrile. While discharge was being planned,
he developed melena. EGD revealed a sinus in the duodenum [Fig. 1], which
was seen to communicate with the right adrenal gland on CT abdomen.
Biopsy of sinus wall showed H. capsulatum. Since he was also noticed to
be icteric, LFT was repeated: total and direct bilirubin 5.5 and 4.7 mg/dL;
AST 67 U/L; ALT 38 U/L; and ALP 743 U/L. ERCP showed hemobilia with
blood clots obstructing the ampulla [Fig. 2]. Clots were removed and CBD
was stented. Subsequent mesenteric angiography showed pseudoaneurysm
of right hepatic artery which was coil-embolised. He was discharged on itra-
conazole. At 6 month follow up, his splenic and adrenal lesions had resolved.
Northeast India and Bangladesh are emerging hotspots for histoplasmo-
sis. GI tract [usually terminal ileum and colon] is involved in over 50%
with disseminated histoplasmosis. Duodenal involvement is rare. Also
fistula formation usually involves thoracic structures. This case repre-
sents the first report of fistulising GI histoplasmosis in an immuno-
competent patient, and also the first report of a mycotic aneurysm in
histoplasmosis.[figure1][figure2]
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A Rare Cause of Rectal Bleeding!
Mitesh B. Patel, MD, Shilpa R. Gowdanapulya, MD, Rosena Custodio, MD,
Jyothi A. Reddy, MD, FACG∗. Gastroenterology and Pathology, University
of Illinois College of Medicine Urbana Champaign, Danville, IL.
Purpose: The presence of gastric mucosa in the rectum is an extremely
rare clinical entity with only 29 cases reported in the English literature. Het-
erotopia refers to the displacement of an organ or part of an organ from its
normal site. Heterotopia is the result of primary displacement or a develop-
mental abnormality where the foreign tissue is termed “heterotopia.” Gastric
heterotopia in the rectum can clinically present with hematochezia, but other
complications such as rectovesical and anocutaneous fistula have been re-
ported. We report a rare case of gastric heterotopia of rectum accompanied
by a brief review of the available literature.
Methods: Chart review and review of literature using Medline and relevant
bibliographies.
Results: A 49 year old man was referred to the gastroenterology clinic
with complaints of rectal bleeding since three months. Approximately 18
months ago, the patient had a normal colonoscopic exam which was per-
formed as a work up for abnormal bowel habits. Upon presentation, a repeat
colonoscopy revealed a 3 mm sessile polyp in the distal rectum. No other
anorectal pathology was evident to explain the symptoms of hematochezia.
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The rectal polyp was resected using electrocautery snare. The pathology
report of the polyp showed fragments of gastric mucosa suggestive of
heterotopia.
Conclusion: The common presentations of gastric heterotopia of rectum are
rectal bleeding and tenesmus, but patients may present with abdominal pain
or incidental mass on colonoscopy. Hematochezia usually responds to treat-
ment with histamine 2 receptor blockers, but endoscopic or surgical excision
is the treatment of choice. The literature suggests that even an incidentally
discovered gastric heterotopia of rectum in an asymptomatic patient should
be removed in view of possible complications such as malignant degenera-
tion and fistula formation.[figure1][figure2]
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Addition of Rifaximin Enema Resolves Colitis Associated with
Clostridium difficile Infection
Donald S. David, MD, FACG∗. City of Hope Cancer Center, Duarte, CA.
Purpose: Rifaximin is a nonsystemic, gastrointestinal-specific antibiotic
and a promising therapeutic agent for C. difficile infections. This is a case
report of a 37-year-old female who developed C. difficile–associated diar-
rhea (CDAD) 32 days after she received an allogeneic stem cell transplant
for acute lymphoblastic leukemia. She had been taking immunosuppressive
therapy (prednisolone, sirolimus, and tacrolimus) and had no prior history of
gastrointestinal disease. The diagnosis of CDAD was established by a posi-
tive result for C. difficile toxin A. The patient developed profound ileus 24
hours after beginning oral vancomycin 125 mg q.i.d. as treatment for CDAD.
Administration of intravenous metronidazole 500 mg and ceftazidime 2 g
every 8 hours was added. However, abdominal pain and distention wors-
ened. A computed tomography (CT) scan revealed colonic wall thicken-
ing consistent with pancolitis, and an exploratory laparotomy revealed a
grossly edematous colon, prompting a loop ileostomy. Postoperatively, in-
travenous metronidazole and ceftazidime were continued, and vancomycin
500 mg was administered t.i.d. by retention enema. Abdominal pain and
distention stabilized but did not resolve. A follow-up CT scan revealed per-
sistent colonic wall thickening, and a sigmoidoscopy revealed persistent
pseudomembranous colitis 10 days postoperatively. In addition, the colonic
fluid remained positive for C. difficile toxin A. Rifaximin 400 mg was added
to vancomycin 500 mg and coadministered t.i.d. as a retention enema. Ab-
dominal pain resolved and distention improved after administration of 4
rifaximin plus vancomycin combination enemas, and colonic fluid was neg-
ative for C. difficile toxin after 8 enemas. In addition, colonic wall thicken-
ing and ileus completely resolved. The patient was discharged 7 days after
beginning combination enema therapy, with instructions to continue admin-
istration of vancomycin enemas on a tapering-off schedule. Eight weeks
after ileostomy, colonoscopy was normal, and uneventful takedown of the
ileostomy was performed 1 week later. Currently, the patient has normal
bowel function and remains asymptomatic. This case represents the first
documented use of a rifaximin enema and suggests that rifaximin 1200
mg/d is a successful treatment option for immunocompromised patients
with CDAD refractory to conventional antibiotic therapy. Large, controlled
clinical studies are warranted to confirm the beneficial role of rifaximin in
CDAD.
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Rectal Bleeding: A Case Report of Localized AL Amyloidosis of the
Colon
Stephanie L. Hansel, MD, Arthur D. Shiff, MD∗. Gastroenterology, Mayo
Clinic Arizona, Scottsdale, AZ.
Purpose: Primary (AL) amyloidosis is usually classified as a systemic dis-
ease involving multiple organ systems. Patients present with weakness, fa-
tigue, and weight loss. Treatment for primary systemic amyloidosis includes
hematopoietic cell transplant, clinical trials, or melaphalan/dexamethasone
and the prognosis is poor. AL amyloidosis can also be a localized disease.
We present a case of localized AL amyloidosis of the colon.
Case Report: A 57 year old male complained of rectal bleeding for the past
3 weeks. He noted frank blood on the toilet paper as well as mixed in his
stool. He otherwise was feeling well and denied joint pain, iritis, and any skin
lesions. He had a similar episode 5 years prior. At that time, he underwent
a colonoscopy with biopsies which were non-diagnostic. He was started on
mesalamine but only took the medication for 3 weeks time as his rectal bleed-
ing resolved. He reported no family history of inflammatory bowel disease.
Laboratory studies including a CBC and CMP were within normal limits.
His colonoscopy revealed patchy non-specific lesions involving the distal
50 cm of his colon. Biopsies were obtained and showed amorphous glob-
ular material in the lamina propria, vessel walls, and muscularis mucosae.
It stained positive for amyloid. Further immunohistochemical stains were
positive for primary or AL amyloidosis of lambda light change type. The
patient was referred to Hematology for further work-up of amyloidosis. He
underwent extensive testing which was negative for systemic amyloidosis,
thus leaving the patient with a diagnosis of localized AL amyloidosis of the
colon.
Discussion: Localized AL amyloidosis of the colon is an uncommon disease.
Unlike systemic amyloidosis, it has an excellent prognosis. Since both lo-
calized and systemic AL amyloidosis can be affect the colon, it is important
to distinguish between the two for prognostic and treatment implications.
Patients found to have only localized disease of the colon may require local-
ized treatment such as argon plasma coagulation to control bleeding but they
do not require systemic treatment. Due to the lack of long-term data, it is
unknown if these patients should undergo periodic surveillance for systemic
amyloidosis.[figure1]
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Microscopic Papillary Adenoma as a Cause of Recurrent Acute
Pancreatitis
Ana Ignjatovic, BMBCh, Anthony S. Mee, MD∗. Gastroenterology, Royal
Berkshire Hospital, Reading, United Kingdom.
Purpose: 10–30% of patients with acute pancreatitis do not have demon-
stratable aetiology and are classified as having idiopathic acute (recurrent)
pancreatitis (IAP or IARP). They should undergo full endoscopic evaluation
in an attempt to delineate the aetiology. We present a case of IARP sec-
ondary to a microscopic adenoma but with normal cross-sectional imaging
and macroscopically normal ERCP.
A 52-year-old man presented with his third episode of acute pancreatitis in a
year. Repeated abdominal USS, CT and MTI scans of the pancreas revealed
changes of acute pancreatitis but no gall stones or structural anomalies of
the pancreas or the biliary tree. There were no risk factors for recurrent
pancreatitis. He went on to have an ERCP. The procedure revealed a macro-
scopically normal duodenal papilla (see Fig. 1) with undilated biliary tree
and a normal pancreatic duct (Fig. 2). Biopsies were taken from the duo-
denal papilla. Histology revealed cytoarchitectural changes compatible with
an adenoma. The patient went on to have a surgical ampullectomy.
A handful of cases of recurrent acute pancreatitis secondary to a benign neo-
plasm of ampulla of Vater have been reported. We present a case of IARP with
a macroscopically normal papilla and biliary tree. The diagnosis and histol-
ogy are usually provided by the ERCP, but in a series of 52 patients in France
who were found to have biopsy proven ampullary adenomas or carcinomas,
37% had endoscopically normal looking papilla. It is well acknowledged
that the patients found to have dilated biliary tree and a macroscopically
normal papilla should have sphincterotomy and intraampullary biopsies and
if papillary adenomas detected it should be resected.
We propose that all patients who undergo ERCP for IARP and in whom no
cause has been found have ampullary biopsies even if the biliary tree, panc-
treatic duct and ampulla appear macroscopically normal.[figure1][figure2]
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Hemobilia Post Intrabiliary Photodynamic Therapy (PDT) for
Cholangiocarcinoma
Rami J. Badreddine, MD, Lewis R. Roberts, MBCB, Joseph J. McBride,
MD, Ganapathy A. Prasad, MD, Lynn S. Borkenhagen, CNP, Lori S.
Lutzke, Todd H. Baron, MD, Kenneth K. Wang, MD∗. Gastroenterology
and Hepatology, Mayo Clinic, Rochester, MN and Interventional
Radiology, Mayo Clinic, Rochester, MN.
Purpose: Case 1: A 61 years old lady presented with jaundice and was di-
agnosed with an unresectable Klatskin tumor. She underwent CBD stenting
and 2 cycles of intraductal PDT. She presented 6 weeks after her second
cycle with severe hematemesis. An EGD revealed hemobilia (Fig. 1). An-
giography showed pseudoaneurysms from both the right hepatic artery and
the accessory right hepatic artery (Fig. 2). These were embolized and the
patient’s bleeding stopped.
Case 2: A 53 years old male with ulcerative colitis and PSC was found
to have a hilar, non resectable cholangiocarcinoma. He underwent a tran-
scutaneous cholangiogram and biliary drain placement. An abdominal MRI
done for staging showed a large left hepatic artery pseudoaneurysm which
was successfully embolized. Two weeks later he underwent transcutaneous
PDT. He presented 48 hours later with massive hemobilia thrpugh his drain.
Angiography revealed bleeding from an aneurysm around the previous em-
bolization site of the left hepatic artery as well as from new collaterals from
the right hepatic artery. This was successfully injected with Ivalon particles.
Discussion: We presented two cases of hemobilia from hepatic artery pseu-
doaneurysms following intrabiliary PDT. When reviewing the literature for
reported complications of intrabiliary PDT we found very few cases of hemo-
bilia.
It is unclear if bleeding is the result of the radiation from PDT itself or
whether other mechanisms are involved. We think that patients with known
or suspected hepatic artery pseudoaneurysms or aneurysms should undergo
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treatment for these by an expert interventional radiologist before proceeding
with PDT. We cannot recommend routine angiography prior to PDT in all
patients at this time.[figure1][figure2]
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Carcinosarcoma: An Unusual Hepatic Metastasis
Anastasia C. Waechter, MD∗. Gastroenterology and Hepatology, Stanford
University Medical Center, Stanford, CA.
Purpose: Carcinosarcomas are rare tumors with malignant epithelial and
mesenchymal components, which most commonly originate in the uterus and
ovary. I describe a case of carcinosarcoma of presumed gynecologic primary
presenting as a symptomatic hepatic metastasis and review the approach to
focal liver lesions.
Methods: A 76-year-old woman presented with right-sided pleuritic sub-
costal pain. A CT angiogram-thorax revealed a 2.7 cm × 2.7 cm hypodense
lesion in the hepatic dome. On biphasic CT-abdomen, this appeared to be
an atypical hemangioma. The patient had no known or suspected extrahep-
atic malignancy. Laboratory evaluation for underlying liver disease and AFP
were normal. A 3-month follow-up CT revealed increased size and new pe-
ripheral areas of enhancement, concerning for malignancy.
One week later, the patient developed recurrent pain. Repeat CT showed
acute hemorrhage into the lesion. She underwent urgent surgical resection
of a hemorrhagic mass from the hepatic dome. Histology revealed high-grade
CK7+/CK20- glands in a high-grade PASD+ spindle cell background con-
sistent with carcinosarcoma, most likely of ovarian or endometrial origin.
Serum CA-125 level was elevated at 336 (normal<35 U/ml). A postoperative
CT chest/abdomen/pelvis and CT-PET scan revealed pathologic right iliac
and inguinal lymph nodes. An FNA of the inguinal lymph node revealed
high-grade carcinoma. No primary tumor was found on CT scan or en-
dovaginal ultrasound. However, this was considered most likely a metastatic
carcinosarcoma of gynecologic origin.
The patient received gemcitabine and carboplatinin with initial response. She
is currently asymptomatic, but her most recent imaging shows increasing
pelvic lymphadenopathy. She is being evaluated for radiotherapy.
Conclusion: Focal hepatic lesions may be found on imaging exams done to
evaluate symptoms but more often are found incidentally. The differential
diagnosis is broad and includes benign causes (cysts, hemangiomas, adeno-
mas, FNH, and abscesses) as well as malignant causes, with metastases being
the most common hepatic malignancies. The correct diagnosis of solitary
liver lesions depends upon the clinical context in which the lesion was de-
tected. Important factors include patient age, gender, symptoms, history or
risk factors for chronic liver disease and history or suspicion of extrahepatic
malignancy. Radiographic features in combination with clinical history and
serum tumor markers can establish the diagnosis in the majority of patients
without the need for fine needle biopsy.
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Human Small Intestinal Anisakiasis Due to Consumption of Raw
Sardines
Masahiro Matsushita, MD∗, Kensuke Kobayashi, MD, Koji Oba, MD,
Raisuke Nishiyama, MD, Akihiko Seki, MD, Yoichiro Kawata, MD,
Hidenori Sakai, MD, Yoshimasa Kobayashi, MD. Gastroenterology,
Haibara General Hospital, Makinohara, Shizuoka, Japan; Surgery,
Haibara General Hospital, Makinohara, Shizuoka, Japan; Radiology,
Haibara General Hospital, Makinohara, Shizuoka, Japan; Medicine,
Kawata Clinic, Yoshida, Shizuoka, Japan; Medicine, Sakai Clinic,
Makinohara, Shizuoka, Japan and 2nd Division, Department of Internal
Medicine, Hamamatsu University School of Medicine, Hamamatsu,
Shizuoka, Japan.
Purpose: Anisakiasis is a human parasitic disease caused by the ingestion
of raw fish. The diagnosis of gastric anisakiasis can be easily confirmed
by endoscopy. However, small intestinal anisakiasis is difficult to diagnose
because of the absence of appropriate diagnostic modalities. We describe two
cases of small intestinal anisakiasis, emphasizing the usefulness of MDCT
(Multidetector-row CT) in the diagnosis.
Case1: A 64-year-old Japanese man was admitted to our hospital because
of sudden abdominal pain and vomiting. Two days prior to admission, he
had eaten raw sardines as sashimi. Abdominal roentgenogram showed air-
fluid levels, suggesting intestinal obstruction. MDCT clearly demonstrated
segmental, symmetrical, and circumferential wall thickening and a small
amount of ascites. Fluid replacement and resting immediately relieved his
symptoms. The anti-anisakis antibody titers in paired sera were measured.
Case 2: A 70-year-old Japanese man was admitted to our hospital because
of sudden abdominal pain and vomiting. Two days prior to admission, he
had eaten raw sardines as sashimi. Abdominal roentgenogram showed air-
fluid levels, suggesting intestinal obstruction. Because of his past history of
appendectomy, a diagnosis of small intestinal obstruction due to adhesion
might have been reasonable. However, considering his recent history of in-
gesting of raw sardines and MDCT findings, a diagnosis of human intestinal
anisakiasis was indicated. Fluid replacement and resting immediately re-
lieved his symptoms. The anti-anisakis antibody titers in paired sera were
measured.
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Discussion: In Japan, there is a long-standing tradition of consuming raw
fish, and gastric anisakiasis accounts for 95.6% of cases, intestinal anisaki-
asis for 4.1%, and that at other sites for 0.3%, according to the analysis
of a series of 15,715 cases. As raw fish dishes are gaining popularity in
many countries, the frequency of anisakiasis is likely to increase. Anisaki-
asis should be considered in the differential diagnosis of small intestinal
obstruction.
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Cholestatic Jaundice as a Paraneoplastic Presentation of Hodgkin’s
Lymphoma
Julia Massaad, MD, Mohammad Wehbi, MD∗. Digestive Diseases, Emory
University School of Medicine, Atlanta, GA.
Purpose: A 21 year old female was transferred to our hospital for the
management of hyperbilirubinemia in the setting of a recent diagnosis of
Hodgkin’s disease. Upon initial assessment, laboratory workup revealed
cholestasis with elevated transaminases, alkaline phosphatase, and no co-
agulopathy. The rest of the workup was negative. Abdominal imaging was
negative. Her bilirubin continued to rise, and a liver biopsy showed pericen-
tral cholestasis and mild non-specific lobular inflammation. She was started
on prednisone with a gradual taper. Six weeks into treatment, her jaundice
resolved.
Hodgkin’s disease-related cholestasis has multiple pathophysiologic mecha-
nisms. The differential diagnosis of jaundice in a lymphoma patient includes
the more common etiologies of sepsis, drugs, viral infections and hepatic
metastasis. These diagnoses can usually be ruled out with an extensive ini-
tial workup. However, liver involvement in Hodgkin’s disease (HD) can be a
more subtle finding that requires a prompt and a more invasive workup. The
three main causes of intrahepatic cholestasis in association with lymphomas
are hepatic lymphoma, vanishing bile duct syndrome (VBDS) and a para-
neoplastic phenomenon. Secondary hepatic lymphoma is almost always an
end-stage manifestation of the disease that can rapidly progress into fulmi-
nant hepatic failure. Primary hepatic lymphoma, on the other hand, occurs
in the absence of extrahepatic disease. It has an extremely dismal prognosis.
VBDS is another cause of cholestasis that has been associated with HD.
Histologically, this entity is characterized by the absence of bile ducts in
the portal triads. Treatment with steroids, ursodeoxycolic acid and IVIG has
been described with not enough evidence to advocate the use of either ther-
apy. The last mechanism is due to a paraneoplastic effect. Stauffer described
a syndrome of nonmetastatic nephrogenic hepatic dysfunction in association
with renal cell carcinoma. Later on a similar paraneoplastic cholestatic en-
tity has been described in association with multiple malignancies including
lymphoma. The proposed mechanism for this rare entity could be overex-
pression of IL-6 by the tumor cells, and hence the reported literature on the
improvement of the cholestasis after treating the malignancy.
Conclusion: In conclusion, the possibility of hepatic lymphoma, VBDS or
a paraneoplastic mechanism should be considered in every case of jaundice
and HD. This can be a life threatening complication that can progress to
fulminant hepatic failure short of early and appropriate intervention.
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Rare Case of Lung Cancer Metastatic to the Colon Incidentally
Discovered at Screening Colonoscopy
Gennadiy Bakis, MD, Matthew M. Baichi, MD∗. Gastroenterology,
Division of Gastroenterology, Hepatology, and Nutrition, Buffalo, NY.
Purpose: The gastrointestinal tract is a rare site for lung cancer metastasis.
Involvement of the colon is especially rare and is usually symptomatic and
discovered after detection of the primary tumor. We report a case of lung
cancer metastatic to the colon discovered at screening colonoscopy.
Methods: Case report
Results: A 71 year old male presented for colonoscopy based on Guaiac
positive stool testing performed as part of routine colon cancer screening.
Laboratory evaluation showed no anemia.
Colonoscopy revealed a transverse colon mass. Biopsy showed colonic mu-
cosa with no evidence of dysplasia. Tumor stains suggested undifferentiated
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carcinoma, likely metastatic. CT scan of chest, abdomen and pelvis showed a
right upper lung lobe soft tissue density. PET scan showed uptake in the right
upper lung as well as right paratracheal and left neck areas. Resection was
performed and pathology revealed the tumor to be submucosal in location
(Fig. 1) with ulceration of overlying mucosa and extension into the subserosa.
Immunohistochemical studies performed on representative tumor sections
reveal a pattern suggestive of lung origin (Fig. 2). One out of seven lymph
nodes showed metastatic carcinoma.
The patient underwent a CT-guided FNA biopsy of the right upper lung
nodule. Immunohistochemical stains and morphologic features were similar
to the colonic tumor; both were consistent with a lung primary.
The patient enrolled in a clinical trial and received Paclitaxel and Carboplatin
chemotherapy. Interval chest CT scan 3 months after initiation of chemother-
apy showed decrease in the size of the lung mass, but treatment was stopped
because of neuropathy. The patient expired 8 months after presentation.
Conclusion: To the best of our knowledge this is the first report of lung
carcinoma with colon metastasis discovered at screening (FOBT positive)
colonoscopy.[figure1][figure2]
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Acute Noncholestatic Azathioprine Induced Hepatotoxicity in a
Female with Crohns Disease
Charles P. Koczka, MD, Juan Diego Baltodano, MD, Robert Levine, MD∗.
Medicine, SUNY Upstate Medical College, Syracuse, NY.
Purpose: The patient is a 34 yo female with ileocolonic Crohns Disease
(CD) since age of 19. She had undergone terminal ileum resection & subto-
tal colectomy with ileostomy & Hartmanns pouch reconstruction 10 years
ago. With complaints of watery rectal drainage, colonoscopy was performed
& suggested acute on chronic inflammatory changes of the pouch. She
was started on Azathioprine (AZA) 100 mg/day. Two weeks later she pre-
sented with 2 days of abdominal pain, nausea, & non-bilious emesis. She
denied use of alcohol, IV drugs, acetaminophen, or herbals. No sick con-
tacts, fever, or recent traveling. On presentation she was hypotensive and
tachycardic. No signs of encephalopathy or jaundice. Abdominal exam re-
vealed shock-fist tenderness & normal liver span. Rectal exam was unre-
markable. Skin examination of extremities revealed tender erythematous
nodules. Lab data revealed transaminitis without cholestasis. Toxicology
screen, serologies for ANA, ASMA, AMA, EBV, viral hepatitis panel were
negative. Iron & copper studies were unremarkable. She was homozygous for
wild-type thioprine methyltransferase. 6-thioguanine nucleotide was 99 (RI:
230–400) & 6-methylmercaptopurine was 1003 (RI: <5700). CT showed
diffuse hepatic steatosis without focal lesions & patent portal and hepatic
veins were seen on Doppler U/S. Skin biopsy showed Erythema Nodosum.
Three days after discontinuing AZA & with supportive care, improvement
was noted in liver biochemistries. This case of AZA-induced hepatotox-
icity was unique in that liver toxicity reflected an abrupt non-cholestatic
hypersensitive mechanism of hepatitis. Furthermore, low levels of 6-TGN
& 6-MMP suggested low risk for toxicity, raising a suspicion for an un-
known metabolic pathway by which AZA induces acute liver injury without
cholestasis.[figure1]
Laboratory Data During Hospital Stay
Day 1 2 3 4
AST 5978 2527 426 114
ALT 4858 3230 1893 1194
Alk. Phos 121 90 83 105
Bilirubin 1.6 1.40 0.9 0.6
Dir Bilirubin 1.2 1.1 N/A 0.4
Albumin 3.3 2.9 2.7 2.7
Creatinine 2.5 1.7 0.7 0.6
BUN 37 28 15 14
WBC 2.5 6.3 8.6 10.1
Hematocrit 44.8 35.1 32.5 30.9
Platelet 231 197 210 180
PT 25.2 28.9 19.1 16.8
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The Use of a Self-Expanding Plastic Stent for an Iatrogenic
Esophageal Perforation
John M. Petersen, DO∗. Gastroenterology, Baptist Medical
Center/Borland-Groover Clinic, Jacksonville, FL.
Purpose: A 48 year old woman was diagnosed with an ascending colon
carcinoma six months earlier. The disease had metastasized to the axial and
peripheral skeleton in numerous locations. Radiation therapy was adminis-
tered to the cervical and thoracic spine with 30 fractions of 180G each. Within
six weeks of completion, the patient developed dysphagia, chest discomfort,
bouts of regurgitation, nausea, and lost 15 pounds. An EGD revealed a tight,
inflammatory, likely radiation-induced stricture in the distal esophagus that
had narrowed the lumen to 8 mm. A CRE balloon dilation was carried out
under direct vision to 13 mm. She developed chest pain in the recovery area,
and a Hypaque esophagogram confirmed a perforation. A naso-gastric tube
was placed endoscopically, and she recieved broad spectrum antibiotics and
IV hydration. Within 24 hours, a Polyflex stent, 18 mm in the body, 23 mm
at the proximal opening, 9 cm long (Boston Sci., Natick, MA) was placed,
and attached to the proximal esophagus with nylon ligatures and Resolution
hemostatic clips. The patient was able to eat soft solids within 48 hours, and
was discharged on the fourth day. She gained weight and had no chest pain
or dysphagia. Chemotherapy was initiated due to an abnormal PET/CT, and
a rising CEA. The stent was removed 7 weeks later, and endoscopically the
perforation had sealed, with an inflammatory mucosa and an intact lumen
left behind.
For years, self-expanding metal stents (SEMS) have been deployed in the
esophagus for malignant obstruction, as well as to cover post-operative leaks
and fistulae. The use of SEMS for benign strictures has been met with a va-
riety of complications and great difficulty in removal. The placement of
removable Polyflex plastic stents across malignant strictures has been well
recored, while utilization for iatrogenic perforations is rare. The Polyflex is a
polyester woven stent with a silicone covering, which makes for easy deploy-
ment, and simple endoscopic removal. Plastic stents are effective in bridg-
ing malignant strictures, fistulae, post-operative leaks, perforation following
atrial fibrillation ablation techniques, benign inflammatory peptic strictures,
and as shown in this vignette, post-endoscopic dilation perforations. The
plastic Polyflex rapidly eliminates contamination of the mediastinum after
perforation, allows for oral hydration and nutrition, and is easily removable.
To avoid migration, which can be as high as 30%, we suggest ligature fixation
with hemostatic clips.
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Collagenous Gastroenterocolitis in a Two Year Old Boy with
Cerebellar Ataxia
Alycia A. Leiby, MD, Seema Khan, MD∗, Diana A. Corao, MD.
Gastroenterology, A.I. Dupont Hosptial for Children, Wilmington, DE and
Pathology, A.I. Dupont Hosptial for Children, Wilmington, DE.
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Purpose: Collagenous colitis is usually diagnosed in adults, with normal
appearance on endoscopy and rarely associated with small bowel inflamma-
tion. In pediatrics there are less than 10 reported cases. We report a case of
collagenous gastroenterocolitis (C-GEC) in a 2-yr-old boy with cerebellar
ataxia. He had a 2-mo history of watery stools and weight loss, 1 mo of
emesis and fevers. Loperamide, and restriction of lactose and refined sugar
did not alter the diarrhea. Initial studies showed low sodium and albumin,
anemia, and elevated ESR. Despite bowel rest he had profuse diarrhea with
a low fecal osmotic gap. All other stool studies were negative. He also had
negative anti-enterocyte Ab, celiac panel, ASCA IgA, ANCA IgG, ANA
and normal lymphocyte enumeration, total IgM and IgA, and complement
levels. Abdominal CT showed dilated fluid filled bowel loops. Endoscopy
revealed erythema and petechiae in the gastric body and increased vascu-
larity, mild edema and erythema in the colon. Biopsies showed thickening
of the subepithelial basement membrane (BM) (>5 µ) in the stomach, duo-
denum and colon. There was also sloughing of the epithelium, abundant
neutrophils in the lamina propria infiltrating the adjacent crypt and surface
epithelium and reactive cellular atypia. Trichrome and immunohistochem-
istry for collagen 3 confirmed collagenous subepithelial thickening. Congo
red staining for amyloid was negative. The diagnosis of C-GEC was made
based on histologic appearance and stains. He was treated with 2 wks of IV
steroids and bowel rest with symptom resolution. Repeat biopsies at the end
of 2 wks revealed less inflammation but persistent presence of thickened
BM throughout. The patient was treated with a PPI, mesalamine and 8 wks
of oral steroids. During this period he tolerated a diet low in lactose and
refined sugar and had resolution of anemia and hypoalbuminemia. 2 wks
after finishing oral steroids, stools increased to 6 times a day. The patient
then started on bismuth subsalicylate, which continued for four weeks with
resolution of his symptoms. We were not able to associate his neurologic
condition with the current problem. This case is unique as most adult cases
have collagenous disease limited to the colon with less common reports
of collagenous gastritis and even rarer reports of collagenous duodenitis.
No other pediatric case has shown small bowel inflammation and duodenal
collagenization.
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Refractory Rectal Ulcer Secondary to Infrared Coagulation Treated
with Canasa Suppository
Yaman Suleiman, MD, Samah Bassas, MD, Mohammad Alsolaiman, MD∗.
Gastroenterolgy Dept, Central Utah Clinic, Provo, UT.
Purpose: Rectal ulcer is an uncommon rectal disorder that can present
with bleeding, passage of mucus, and sense of incomplete evacuation.
Solitary rectal ulcer is the most common type of rectal ulcer. Other
less common causes include infection, ischemia, idiopathic, radiation,
malignancy or medications. Here we report two cases of rectal ulcers
secondary to hemorrhoid treatment, treated successfully with Canasa
suppository.
Methods: Two patients with grade II internal hemorrhoid treated with In-
frared coagulation (IRC). Both patients developed rectal ulcer at the site of
the application with intermittent bleeding. Initially they were treated conser-
vatively with stool bulking agents and Anusol suppository, unsuccessfully.
Canasa suppository were applied QHS for one month. Both achieved com-
plete healing of there ulcers and symptoms.
Results: Both patients achieved complete healing of there ulcers and symp-
toms. Repeat flexible sigmoidoscopy showed complete healing of the ulcer.
No further treatment was required.
Conclusion: Nonsurgical therapy for hemorrhoidal disease grades I and II
with infrared photocoagulation, banding, bipolar and laser coagulation is a
good alternative to surgery; it is painless, suitable as an outpatient procedure
and its cost is low. These treatment are complicated occasionally with delayed
rectal bleeding, urinary retention, pain, and fever. Treating this complication
is very important for the practicing Gastroenterologist. Canasa is a new
addition to our armamentarium for treating refractory rectal ulcers secondary
to such hemorrhoidal treatment.
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Steroid Injection for Benign Refractory Pyloric Stenosis
Yaman Suleiman, MD, Samah Bassas, MD, Mohammad Alsolaiman, MD∗.
Gastroenterolgy Dept, Central Utah Clinic, Provo, UT.
Purpose: Several studies have demonstrated good rates of success for the
relief of symptoms from pyloric stenosis using through-the-scope balloons.
Patients who require more than two dilations are at high risk of endoscopic
failure and the need for surgical intervention. Here we describe two refrac-
tory patients treated endoscopically using steroid ingection and therefore
avoiding surgery.
Methods: Two patients presented with gastric outlet obstruction secondary
to peptic ulcer disease. Both underwent multiple sessions of through the
scope balloon dilation (average 4 sessions) with H. Pylori eradication and
high dose PPI. Patients symptoms recurred with very short improvement
after each dilation. First patient refused surgery, and the other one had severe
comorbidities. 80 mg Kenlog ingection was performed (20 mg in every
quadrant of the pyloric opening) after performing balloon dilation. Both
patients showed significant improvement with no need for further balloon
dilation. Average follow up for these two patients was 18 months. Both
patients were kept on PPI.
Results: Both patients showed significant improvement with no need for
further balloon dilation. Average follow up for these two patients was 18
months. Both patients were kept on PPI.
Conclusion: Endoscopic balloon dilation has been used to treat patients with
gastric outlet obstruction caused by peptic stricture. Surgery is associated
with significant morbidity and mortality and should be reserved for endo-
scopic treatment failures. Benign pyloric stenosis can be readily treated with
endoscopic balloon dilation and should be the first-line therapy. Steroid in-
jection should be considered early in the paradigm of treating benign pyloric
stenosis especially refractory cases and before consideration for surgery.
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Liver Abscess as a Complication of Esophgeal Balloon Dilation
Yaman Suleiman, MD, Samah Bassas, MD, Mohammad Alsolaiman, MD∗.
Gastroenterolgy Dept, Central Utah Clinic, Provo, UT.
Purpose: Despite the increase use of upper endoscopy, the complication rate
has remained low. Infectious complications of EGD include transmission of
infection by contaminated endoscopes or ancillary equipment, bacteremia
and aspiration pneumonia. Here, we are reporting a liver abscess followed a
routine upper endoscopy dilation in patient with gastric bypass.
Methods: A 59 year old patient with history of gastric bypass 19 years
ago presented with intermittent dysphagia has been going on for the last
few months. Her upper endoscopy was remarkable for schatzki ring and
gastric pouch contained undigested food. The gastrointestinal anastomosis
was patent. The schatzki ring was dilated using CRE balloon 15–18 mm
with evidence of breaking the mucosa at 16.5 and 18 mm. Her other past
medical history was significant otherwise for thyroid cancer, thyroidectomy
20 years ago, tobacco and ETOH abuse. Patient presented with right upper
quadrant pain 2 days after the EGD to outside facility. She was treated symp-
tomatically. Pain returned and patient developed fever and chills. CT scan
of the abdomen performed at our facility 2 weeks after the EGD showed left
hepatic lobe abscess. US guided drainage grew Candida Albicans, strepto-
coccus Solivarius, and Beta Hemolytic Strep Group B. Esophagogram failed
to show any leak or perforation. The abscess resolved with IV antibiotic and
percutaneous drainage without the need for surgery.
Results: The timing between the onset of her symptoms and the EGD suggest
causal relationship. This is most likely related to transient bacteremia sec-
ondary to the dilation. Her altered anatomy, gastroparesis and ETOH intake,
probably predisposed her for the bacteremia and the immune suppression
status.
Conclusion: Esophageal dilation has the highest incidence of bacteremia
of all gastrointestinal endoscopic procedures, occurring in approximately
45 percent of cases. In spite of this, complications of bacteremia such as
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endocarditis are rare. The most common reported complication is endocardi-
tis, and less frequently meningitis. Antibiotic prophylaxis is not warranted in
most patients undergoing esophageal dilation except for those at high risk.
People with immunosupressed status or altered anatomy might need to be
considered for prophylaxis.
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EUS in the Diagnosis of Pancreatic Duct Stone Presenting as Pancreas
Divisum and Pancreatic Stricture
Kenneth Belitsis, MD∗, Rajiv Uppal, MD, Steven Gorcey, MD, Dawn
Loveland, ANP. Monmouth Gastroenterology, Eatontown, NJ and
Monmouth Medical Center, Long Branch, NJ.
Purpose: Evaluation of the peri-ampullary common bile duct (CBD) and
pancreatic duct (PD) is notoriously insensitive using standard imaging tech-
niques such as transabdominal ultrasound, CT, and MRI/MRCP. EUS is being
used increasingly to compensate for this deficit and as an excellent means
of imaging this area.
Methods: We present a 49 year old female who had a remote history of
alcohol abuse. She suffered from multiple episodes of acute on chronic pan-
creatitis. An ERCP with brief pancreatic duct stenting performed a year prior
provided temporary relief of her abdominal pain. Two MRCPs performed
were interpreted as pancreatic duct dilation with pancreas divisum (P. divi-
sum). A repeat ERCP attempt failed to successfully cannulate the PD due
to suspected stricture with P. divisum. There was no mention of a stone or a
mass on any of these studies. She presented to our institution with another
episode of acute on chronic pancreatitis. Her serum lipase was 1186 u/L
(normal: 9–50 u/L) and her amylase was 290 u/L (normal: 28–115 u/L).
Liver function tests were normal.
Results: An EUS was performed. A single 8 mm stone was found obstructing
the proximal PD at the peri-ampullary region. This dilated the PD to 8 mm
including a branch within the head of the pancreas (Fig. 1). No strictures, no
masses and no P. divisum were identified. We next performed an ERCP which
revealed a single filling defect in the proximal PD consistent with the stone. A
pancreatic sphincterotomy was performed and the stone was removed using
a 1.5 cm TrapazoidTM Rx retrieval basket (Boston Scientific). The patient
tolerated the procedure well and has been asymptomatic since.
Conclusion: This case demonstrates the superiority of EUS when evaluating
the peri-ampullary area. The MRCPs erroneously interpreted the dilated PD
in the head of the pancreas as P. divisum while the ERCPs erroneously
interpreted the stone itself as a stricture. Both modalities failed to make
the correct diagnosis. EUS should strongly be considered when evaluating
diseases suspected of pancreaticobiliary origin and especially those affecting
the peri-ampullary region.[figure1]
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Superior Mesenteric Artery Syndrome
Angela M. Mills, MD, Dusan Stanojevic, Medical Student, Andrew D.
Mills, MD, Syed T. Bin-Sagheer, MD∗. Internal Medicine, Division of
Gastroenterology, Creighton University Medical Center, Omaha, NE.
Purpose: A 21-year old female with history of methamphetamine use pre-
sented with severe epigastric pain associated with nausea, vomiting, and
rapid weight loss. Basic laboratory, HIV screening, and thyroid studies were
unremarkable. The patient was admitted for symptom management and fur-
ther diagnostic studies. Abdominal ultrasound unveiled massive gastric di-
latation. CT scan revealed severe distention of the stomach and two thirds
of the duodenum which was highly suspicious for SMA syndrome.
The SMA formed an angle of approximately 10 degrees (normal: 38–56
degrees) with the abdominal aorta, and the third part of the duodenum crossed
caudal to the origin of the SMA, coursing between the SMA and aorta. Upper
endoscopy demonstrated antral erosions but failed to reveal any mechanical
causes of stomach and duodenal dilatation. Upper GI and small bowel series
were consistent with SMA syndrome.
Non-bloody gastric fluid (2,500 cc) was removed on the first day of admis-
sion. Treatment was conservative and consisted of: nasogastric decompres-
sion, Hayes maneuvers, and fluids. Her symptoms markedly improved. After
three days, the patient was started on an oral diet and discharged home.
Discussion: SMA syndrome was first described in 1861 by Von Rokitansky
who proposed that duodenal obstruction was caused by arteriomesenteric
compression. Precise incidence of this syndrome in the U.S. is unknown
but some literature cites 0.013%. It is most common in women ages 10–30.
Etiological factors include: anorexia nervosa, exaggerated lumbar lordosis,
or depletion of mesenteric fat caused by rapid severe weight loss due to
catabolic states such as cancer, surgery, burns, or psychiatric problems.
SMA syndrome is characterized by epigastric pain, nausea, voluminous vom-
iting of partially digested food, postprandial discomfort, and early satiety.
The diagnosis requires utilization of CT scanning, upper GI series and upper
GI endoscopy. Endoscopy confirms diagnosis and excludes other etiologies
of duodenal compression.
Conservative treatment is initially recommended in all patients. This includes
adequate nutrition, nasogastric decompression, and positioning of the patient
in a left lateral decubitus position. In some patients, enteral feedings and
parenteral nutrition is needed. Surgical treatment (duodenojejunostomy) is
reserved for the patients not responsive to conservative management as well
as for the patient with gradual onset of SMA syndrome.
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Abdominal Wall Biloma Following Laprascopic Cholecystectomy (LC)
Yaser Al-Solaiman, MD, Yaman Suleiman, MD, Mohammad Alsolaiman,
MD∗. Gastroenterolgy Dept, Central Utah Clinic, Provo, UT and Internal
Medcicine, Rosalind Franklin University, North Chicago, IL.
Purpose: Iatrogenic injury to the biliary tree is a well-documented compli-
cation of Laprascopic CCY (LC). The widespread use of this surgery in the
early 1990s led to increase in the frequency of biliary injury. With increas-
ing experience, the incidence has declined to an overall incidence of 0.5%.
Her we report an interesting case of biloma involving the abdominal wall
following LC.
Methods: A 48 year old morbidly obese man underwent uneventful LC
with normal cholangiogram for gallstone disease. His past medical history
is significant for DM II and HTN. He was readmitted two days later for
abdominal pain, abdominal distension and chills. On his exam, the abdominal
wall was edematous with discoloarization. Initially this was thought to be
secondary hematoma. He was treated symptomatically with pain medication,
IV antibiotics and bed rest. His abdominal pain and distension got worse and
CT scan of the abdomen showed large fluid collection. US guided drainage
proved the fluid to be of biliary nature. He underwent ERCP with stent
placement because of the high clinical suspicion for bile leak. Occlusive
cholangiogram failed to show free bile leak. Patient showed quick clinical
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improvement and was discharged home two days after the ERCP, the stent
was removed in 6 weeks without recurrence of his symptoms.
Results: Common causes of bile leak include cystic duct leak, common bile
duct or hepatic duct injury or GB bed leak. In our case the fluid must have
drained int the abdominal wall as proved by the Ct scan. In contrast to open
CCY, in which all abdominal wall layers are closed, the defects created by
trocars in LC are left open. Also the CO2 insufflated into the peritoneal cavity
during LC ca escape the peritoneal cavity and accumulate in the abdominal
wall creating pseudo-pockets thus facilitating fluid collection. The proximity
of the wound to the biliary ducts and /or GB bed may be contributing factors.
Biloma and bile duct leak should be considered in the differential diagnosis
in addition to the hematoma in patients with abdominal wall edema after
LC.
Conclusion: Successful management of bile duct injury requires a multidis-
ciplinary team approach incorporating biliary endoscopists, interventional
radiologists, and hepatobiliary surgeons. The approach to the patient de-
pends upon the nature and extent of the injury, the presence or absence of
biloma, and the timing of discovery.
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New Method for Esophageal Foreign Body Removal
Yaser Al-Solaiman, MD, Yaman Suleiman, MD, Mohammad Alsolaiman,
MD∗. Gastroenterolgy Dept, Central Utah Clinic, Provo, UT and Internal
Medcicine, Rosalind Franklin University, North Chicago, IL.
Purpose: Accidental foreign body or large food bolus ingestion occur mainly
in children and in edentulous or mentally impaired elderly adults. Meat
bolus impaction above a preexisting esophageal stricture or ring probably
the most common cause of esophageal body obstruction in adults. Meat
bolus disimpaction is one of the most challenging endoscopic procedure for
the Gastroenterologist. Here we describe a new method.
Methods: An 83-year-old man presented with acute dysphagia symptoms
for more than 24 hours duration after chicken meal. Prominent symptoms
included inability to swallow, and cough. EGD revealed a total blockage
of the lumen of the lower esophagus. Multiple attempts using Polypectomy
Snare, Foreign body Forceps, and Roth Nets were unsuccessful to dislodge
the meat bolus. Using Soehendra dilator a passage was created in the middle
of the meat bolus. An 8–10 mm esophageal balloon dilator was passed
distal to the FB through the created passage. After inflating the balloon,
this was pulled proximally allowing the dislodge of the FB which passed
spontaneously to the stomach. Our patient had a recent previous normal
EGD which allowed us to exclude distal obstruction.
Results: Our patient did very well after the procedure. He underwent elective
esophageal dilation later on of his esophageal peptic stricture. He was placed
on long term PPI. He had no recurrent symptoms on one year follow up.
Conclusion: Because of the remarkable variety of articles and situations
may be faced during foreign body removal, the endoscopist must be able to
use various instruments to remove objects that lodge in the esophagus. The
method described here has never been reported previously in the English
literature. This method need to be applied carefully to avoid perforation.
Applying this method under fluroscopy could be useful, in difficult cases.
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A Rare Case of Intraluminal Ureter Metastasis from Rectal Cancer
Vishal Gupta, MD, PhD, Rishi Pawa, MD, Jonathan Saniel, MD, Vaughan
Whitaker, MD, Bryan Donaldson, MD, Jay Cowan, MD, Raja Sabbagh,
MD∗. Division of Gastroenterology, Department of Pathology, and Section
of Colorectal Surgery, Harlem Hospital Center/Columbia College of
Physicians and Surgeons, New York, NY.
Purpose: Intraluminal metastasis to the ureter of rectal cancer is extremely
rare. To the best of our knowledge, this is the third such case report. In
2003, a 49-year-old male was admitted to the hospital for eight-month his-
tory of dark bloody stools. CT scan revealed 3.1 cm circumferential mass
in the rectum with nodules of soft tissue with in the adjacent mesentery.
There was no evidence of metastatic disease. Colonoscopy confirmed the
circumferential mass in the rectum. Biopsy revealed poorly differentiated
adenocarcinoma. The patient underwent low anterior resection with primary
anastomosis. TNM staging was T3N1M0. Due to lymph node involvement,
he subsequently received 3 cycles of 5-FU/Leucovorin and radiotherapy.
Twenty months after the original operation, patient presented with complaint
of left flank pain. His BUN and creatinine were 17 mg/dL (normal range,
7–18) and 1.6 mg/dL (normal range, 0.8–1.4) respectively. Urine analysis
and CEA level were normal. CEA. Follow up CT scan revealed left sided hy-
dronephrosis and hydroureter with no evidence of recurrence. Cystoscopy
did not indicate any abnormality in the bladder. Retrograde ureteropyel-
ography demonstrated abrupt cut off the injected contrast at the L4 level.
A ureteral neoplasm was suspected, and so a left nephroureterectomy was
performed. Macroscopic examination of the resected specimen revealed a
tumor growth infiltrating the lumen of the ureter. Histopathology of the
mass revealed a mucin producing adenocarcinoma involving the mucosal
side of the ureter (Fig. 1). Subsequent immunohistochemical staining re-
vealed: positive for cytokeratin 20 (CK 20), negative for cytokeratin 7 (CK
7) and markedly positive CEA. This pattern of staining strongly suggests
an intraluminal ureter metastatsis from the rectal cancer. Ureter metastasis
in resected colorectal cancer indicates advanced disease and suggest poor
prognosis. Its presentation as hydronephrosis should be taken as an early
indicator of recurrent disease.[figure1]
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Gossypiboma: An Unusual Cause of Gastric Outlet Obstruction
Diagnosed by Endoscopy
Urooj Ahmed, MD∗, Mohy El-Deen Attia, MD, Nouhad Hamade, MD,
Alain Giguere, MD, Shaista Ahmed, MD. Medicine/Gastroenterology,
Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
Purpose: A gossypiboma, or retained surgical sponge is an uncommon sur-
gical complication. Imaging plays a vital role in identifying retained foreign
objects. To the best of our knowledge, it has been been rarely reported for
gossypiboma to cause gastric outlet obstruction. We are reporting a case of
gastric outlet obstruction caused by gossypiboma and diagnosed primarily
by upper GI endoscopy.
Results: A 40-year-old man presented with upper abdominal pain and per-
sistent vomiting for three days prior to admission. The pain was epigastric,
non radiating and without any aggravating or relieving factors. He denied
history of weight loss, melena or hemetemesis. He had a past history of
cholecystectomy done abroad 3 years ago. His general physical examination
was unremarkable. Abdominal examination revealed a healed right subcostal
scar of open cholecystectomy. On palpation, there was an intra-abdominal
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firm mass in the right hypochondrium. His hemogram, biochemical param-
eters, chest x-ray films were normal. After informed consent and overnight
fasting, an upper GI endoscopy revealed stomach partially filled with flu-
ids and food particles. Examination was not completed because of fear of
aspiration. On repeat endoscopy after a longer fasting period, a fixed for-
eign body in the antrum obstructing the pylorus was seen. The foreign body
had an appearance of woven fiber; a few fibers were removed using biopsy
forceps, which suggested a surgical sponge. A contrast-enhanced CT scan
of the abdomen revealed a foreign body with radiopaque segment in the
proximal duodenum and pylorus with local peritonitis causing gastric outlet
obstruction and hyperdistension of the stomach with some free fluid in the
pelvis. There was no free air seen. The patient underwent surgical explo-
ration, which confirmed the diagnosis. The sponge was removed, and the
fistulous communication was repaired.
Conclusion: Although gossypiboma is rarely seen in routine clinical prac-
tice, it should be considered in the differential diagnosis of acute mechan-
ical gastrointestinal obstruction in patients who underwent laparotomy in
the past. Early recognition of this condition may prompt appropriate inves-
tigation and treatment which may reduce morbidity and mortality. The best
known approach in the prevention of this condition is meticulous counting of
radiopaque surgical material in addition to a thorough evaluation of surgical
site at the end of operation.
461
Diffuse Hemangiomatosis of Colon, Liver and Skin
Krishdeep S. Chadha, MD, Shahid Mehboob, MD∗. Department of
Gastroenterology, State University of New York, Buffalo, NY.
Purpose: A 58 yr old man came for routine colonoscopy screening. He
had no history of gastrointestinal bleeding. Prior tests for fecal occult blood
were negative. His past medical history was significant for resection of giant
cavernous hemangioma of the left lobe of liver, 10 year ago and multiple
residual hemangiomas in the right hepatic lobe. Physical exam revealed
multiple cherry red vascular blebs on the back and upper chest, which blanch
with pressure. Colonoscopy showed multiple, red colored vascular blebs,
seen in the cecum and the adjacent ascending colon. None of the lesions
showed active bleeding. The patient demonstrated multiple hemangiomas,
involving the colon, liver and skin. At 1 year follow up, the patient continues
to remain asymptomatic with no gastrointestinal bleeding or increase in size
of liver hemangiomas. To our knowledge, there is no previous case report of
multi-organ involvement by hemangiomas.
462
Atresia of Inferior Vena Cava Presenting as Retro-Peritoneal Masses
Krishdeep S. Chadha, MD, Angelo Delbalso, MD, Shahid Mehboob, MD∗.
Department of Gastroenterology, State University of New York, Buffalo, NY
and Department of Radiology, VA Medical Center, Buffalo, NY.
Purpose: A 52 yr old white male was referred to GI clinic with complaints
of chronic diarrhea, weight loss and abdominal pain for last 3–4 months. Pa-
tient had 2–3 bowel movements/day with variable consistency of the stools.
No history of hematochezia was present. He had been complaining of sharp,
tearing pain in the lower abdomen, radiating to both groins, exacerbated by
movement and relieved by sitting. There was no history of fever or night
sweats. Physical exam revealed soft, non-tender abdomen with no inguinal
or testicular swelling. No inguinal lymphadenopathy was appreciated. Ex-
tremities did not reveal any pedal edema. Colonoscopy revealed edematous
rectal folds without erosions, ulcers, polyps, or arteriovenous malformations.
Biopsy of colonic mucosa showed mild non-specific chronic inflammation of
lamina propria and scattered lymphoid aggregates. Testicular ultrasound re-
vealed bilateral varicocele and no testicular pathology. The CT scan of the ab-
domen showed absence of inferior vena cava; there were multiple collaterals,
which appear as soft tissue densities, initially thought to be retro-peritoneal
masses. The patient subsequently had a veno-gram, which confirmed absence
of the inferior vena cava with multiple dilated retro-peritoneal collateral ves-
sels. Patient was started on as needed regimen of antimotility agents and his
weight has improved at 8 months follow up.
463
Gastric Perforation Due to a Trichobezoar in a Normal Healthy
Woman
Amanpal Singh, MD, Tina Kochar, MD, Advitya Malhotra, MD∗. Internal
Medicine, Uni. of Texas Medical Branch, Galveston, TX.
Purpose: We report a case of a 28-year-old female who presented to emer-
gency department with excruciating epigastric pain that started after she felt
a pop in her stomach. The pain was stabbing in nature and associated with
feeling of nausea. Prior to this episode, she reported history of intermittent
abdominal pain for a period of few months. Her past history was unremark-
able, but her mother and husband reported later that they had stopped her
from pulling and eating her own hair. She was married, had 2 children and
gave no history of any mental illness. A physical examination revealed guard-
ing and rigidity in the epigastric region. Abdominal computed tomography
showed free air under the diaphragm (blue arrow), a break in the anterior
gastric wall (green arrow) and a large heterogeneous mass in the stomach
(yellow arrow) in Figure 1. An initial diagnosis of foreign body/bezoar with
perforated ulcer was made. Patient underwent emergent lapartomy which
revealed a large trichobezoar (Fig. 2) and a perforation on the anterior wall
of the stomach. The bezoar was extracted through an anterior longitudinal
gastrotomy. Both the gastrotomy and the perforation were then sutured with
regional omental patch. The postoperative period was uneventful. Trichobe-
zoar is a rare diagnosis. Our case is unique as the patient described is a healthy
woman with no psychiatric or surgical history. Vague, low grade abdominal
pain is a common complaint and clinicians may tend to overlook it. This
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case emphasizes need for thorough work up in cases of vague unrelenting
abdominal pain.[figure1][figure2]
464
Inferior PancreaticoDuodenal Artery Pseudoaneurysm: A Rare Cause
of Massive GI Hemorrhage
Krishna S. Kasturi, MD∗, Rajasekhara R. Mummadi, MD, Aravind
Sugumar, MD. Internal Medicine, University of Texas Medical Branch,
Galveston, TX and Gastroenterology and Hepatology, University of Texas
Medical Branch, Galveston, TX.
Purpose: A 60-year-old caucasian female with rectal adenocarcinoma (T4
N1 M1) underwent lower anterior resection and segmental ileum resection
and 28 cycles of pelvic radiation therapy. One month after the completion
of XRT, she was admitted to the Intensive Care Unit for tachycardia and
hypotension after an episode of hematemesis. She admitted to having dark
stools over the past 3–4 weeks. Hgb on admission was 8.5 gm/dl and she
was adequately volume resuscitated with IV fluids and packed red blood cell
transfusions. An emergent EGD and Colonoscopy failed to reveal any active
sources of bleeding. The patient continued to have melena, and was soon
passing BRBPR and had 2 more episodes of hematemesis with bright red
blood clots. Her Hgb dropped to 5.5 gm/dl. She then underwent a tagged
RBC study with Tc-99m and which revealed a faint area of radiotracer in the
left upper quadrant region. A subsequent mesenteric angiogram showed an
Inferior Pancreaticoduodenal artery (IPDA) pseudoaneuryam (Fig. 1) and
active bleeding into the bowel wall (Fig. 2) which was embolized using
microcoils, and post-embolization angiograms showed complete occlusion
of the source of bleeding. The patient did not have any further episodes of
bleeding and her her Hgb remained stable for the rest of her hospital stay.
IPDA pseudoaneurysm is a very rare cause of GI bleeding and is usually
a complication of acute or chronic pancreatitis due to auto-digestion of
arterial walls from the release of pancreatic enzymes. Other reported causes
of visceral artery pseudoaneurysms are inflammation, trauma, neoplasms,
or invasive surgical procedures. Aneurysmal rupture can occur into the gut
or the peritoneum and can have devastating results if emergent intervention
is not done.[figure1][figure2]
465
Neutropenic Enterocolitis: An Unusual Complication of Hepatitis C
Virus Combination Therapy
Krishna S. Kasturi, MD, Rajasekhara R. Mummadi, MD, Gagan K. Sood,
MD∗. Internal Medicine, University of Texas Medical Branch, Galveston,
TX and Gastroenterology and Hepatology, University of Texas Medical
Branch, Galveston, TX.
Purpose: A 53-year-old Caucasian female with known HCV infection was
referred for treatment at our institution. She had no history of alcohol in-
take or other co-morbid conditions. Initial physical exam, and laboratory
evaluation including WBC count, chemistries and coagulation parameters,
was unremarkable. HCV genotype 1 A, viral load of 427,883 IU/ml and
liver biopsy grade 3, stage 4 disease were noted on pre-treatment evalua-
tion. She was started on the standard combination therapy with Pegylated
Interferon 180 µg weekly and ribavirin 1200 mg daily. After 12 weeks of
starting treatment, she presented with a one week history of fever (103◦F),
and progressively increasing right lower quadrant cramping abdominal pain.
Physical examination revealed a febrile patient with severe tenderness and
voluntary guarding over the right lower quadrant of the abdomen. Her labs
on admission showed a total WBC count 1100/cmm, Absolute Neutrophil
Count (ANC) 550/cmm, platelet count 57000/cmm, and normal liver func-
tion tests. CT abdomen revealed bowel wall thickening involving the cecum
with dilation (figure) without any evidence of intramural air. Stool stud-
ies were negative for leucocytes and Clostridium difficile toxin. In view of
her neutropenia, clinical presentation, absence of hypotension, and imaging
findings, a diagnosis of neutropenic enterocolitis was made. She responded
well to empiric broad spectrum antibiotics, supportive treatment, and G-CSF
(Filgastrim) and was discharged home after 10 days of inpatient treatment.
Neutropenic enterocolitis is a well known complication of intensive
chemotherapy for various malignancies, but has not been reported with the
neutropenia associated with HCV combination therapy, which is considered
to be well tolerated by most patients. Clinicians should maintain a high index
of suspicion for any signs of infection in cirrhotic patients on HCV therapy
as the physiologic alterations in bowel wall permeability and neutropenia
can act synergistically in causing a serious bacterial infection.[figure1]
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466
Sigmoid Endometriosis Diagnosed by Endoscopic Ultrasound Fine
Needle Aspirate
Bennett S. Hooks, MD, Peter Jelsma, MD, Howard R. Mertz, MD∗.
Gastroenterology, University of South Alabama College of Medicine,
Mobile, AL and St. Thomas Hospital, Nashville, TN.
Purpose: Diagnostic evaluation of submucosal lesions in the sigmoid colon
often requires surgical intervention. The use of endoscopic ultrasound fine
needle aspiration (EUS-FNA) is an accepted method for investigation of
submucosal lesions in the lumen of the GI tract. This case illustrates the
value of EUS-FNA in a submucosal sigmoid colon lesion.
A 36-year-old female presented with one month of left lower quadrant ab-
dominal pain. Her past medical history was only significant for depression.
There was no fever, constipation, diarrhea, or rectal bleeding associated
with the pain. Abdominal exam revealed tenderness in the left lower quad-
rant without mass. A contrasted CT scan showed fatty mesenteric stranding
around the left ovary and sigmoid colon. Pelvic exam and pelvic ultrasound
were unremarkable. She was treated with antibiotics for presumed divertic-
ulitis. Colonoscopy performed six weeks later showed submucosal nodules
in the sigmoid colon, 20 cm from the anal verge. The nodules were smooth
and not mobile. Biopsies showed normal colonic mucosa.
EUS revealed a 20×23 mm nodular hypoechoic mass that involved the mus-
cularis propria of the sigmoid colon. There was a transmural irregular exten-
sion of this mass into the pericolonic tissue. EUS-FNA was performed with
3 passes into the mass for cytology. The cytological studies revealed reactive
appearing glandular epithelial cells with no evidence of goblet cells. There
were focal hemosiderin-laden macrophages present. Immunohistochemical
studies were performed on the tissue and identified the epithelium to be cy-
tokeratin 7 positive and cytokeratin 20 negative. Endometrial stromal cells
present were CD 10 positive and scattered histiocytes were KP-1 positive.
The cytomorphology of the specimen and immunohistochemical profile was
diagnostic of endometriosis.
Diagnosis of colonic mural endometriosis is challenging, and this case illus-
trates the clinical utility for EUS-FNA of submucosal lesions in the sigmoid
colon.[figure1]
467
EWS-CREB 1: A Novel Variant Gene Fusion Transcript in Clear Cell
Sarcoma of the Ileum
Venkata Yalamanchili, MD, Melham Solh, MD, Doina David, MD, Geetha
Krishnamoorthy, MD∗. Department of Medicine, Sinai Grace Hospital,
Wayne State University, Detroit, MI.
Purpose: Introduction: Clear cell sarcoma (CCS) is a rare malignant soft
tissue neoplasm that commonly afflicts tendons and aponeuroses in young
adults. Primary CCS of digestive tract is exceedingly rare and only three
cases of ileum involvement are reported thus far. We hereby report a patient
with CCS of the ileum presenting with abdominal pain and fever.
Case Report: A 40 year old African American woman with a history of ap-
pendectomy and cholecystectomy, presented with a two day history of lower
quadrant abdominal pain and fever. No nausea, vomiting, change in bowel
movements, burning micturition or vaginal discharge was reported. Physical
exam revealed a fever of 100.7 F, bilateral lower abdominal and cervical
motion tenderness. Laboratory data revealed leucocytosis, a negative uri-
nalysis and pregnancy tests. Pelvic ultrasound showed a 7×7×4 cm mixed
echogenic complex mass in the left adnexa. After 72 hours of empiric antibi-
otics for pelvic inflammatory disease, abdominal pain worsened and fever
persisted. CT scan of the abdomen showed a 6 cm soft tissue mass engulfing
the ileum. The patient underwent exploratory laparotomy with small bowel
resection and anastomosis. Surgery revealed a 9.5 × 9.0 × 5.0 cm mass
arising from the terminal ileum. The mass was focally ulcerated and infil-
trating into the mesentery and the bladder. Pathology reported an epithelioid
neoplasm, with small, oval nuclei surrounded by abundant clear cytoplasm
and well defined cell membranes. On immunohistochemical examination,
tumor cells were strongly and diffusely immunoreactive for S-100 while
are negative for melanocytic markers (HMB45, A103) and gastro intestinal
stromal tumor (GIST) markers (CD117 and CD34). Reverse transcription
polymerase chain reaction analysis performed on paraffin embedded tissue
showed EWS-CREB 1 rearrangement, indicating presence of variant t (12;
22) translocation of clear cell sarcoma. Follow up CT scan of the abdomen
showed hepatic lesions, histologically consistent with CCS. The patient was
started on palliative chemotherapy.
Discussion: Cytogenetics and KIT tyrosine kinase stains have a central role
in the diagnosis of this highly malignant tumor which can be mistakenly
diagnosed as GIST or a melanoma. The outcome of metastatic CCS is dismal
despite aggressive surgery and adjuvant therapy.
468
Intestinal Spirochetosis: A Cause of Symptoms Resembling Irritable
Bowel Syndrome
Meghashyam J. Koti, MD, Jawaid Shaw, MD, Jeffrey A. Goldstein, MD,
FACG∗. Department of Internal Medicine, Rochester General Hospital,
Rochester, NY and Department of Gastroenterology, Rochester General
Hospital, Rochester, NY.
Purpose: Intestinal spirochetosis (IS) is an uncommon, but treatable cause
of gastrointestinal symptoms that often resemble irritable bowel syndrome
(IBS). We report a case of IS in a homosexual male presenting with chronic
watery diarrhea.
A 25 year old homosexual male of Asian origin presented with an eight-
year history of watery diarrhea. He denied rectal bleeding, abdominal pain
and weight loss. Physical examination was unremarkable. Biochemical and
hematological parameters were normal. Stool examination did not reveal
conventional pathogens. No gross abnormalities were noted on colonoscopy.
Hematoxylin and eosin (H &E) stained slides of colonic mucosal biopsy
specimens revealed a focally prominent surface epithelial brush border with
basophilic microorganisms adherent to the epithelial surface, suggestive of
IS. The diagnosis was confirmed with Steiner silver stain, which highlighted
surface microorganisms. A seven day course of oral metronidazole was of-
fered as therapy for IS.
IS is an uncommon clinical entity in North America, with an estimated preva-
lence of 2.5% to 6.5%. Higher prevalence rates (11.4 to 64.3%) have been
observed in developing countries, in homosexuals and HIV-infected individ-
uals. Colonization of the colonic mucosa by various species of spirochetes,
including Brachyspira aalborgi and Serpulina pilosicoli, is almost an inci-
dental finding in an asymptomatic patient. Spirochetal invasion of the colonic
epithelium, resulting in epithelial changes and inflammatory infiltrate in the
lamina propria, is associated with symptoms. However, in homosexual men,
regardless of HIV status, symptoms may be present in the absence of epithe-
lial invasion. Persistent diarrhea, abdominal pain or constipation occur either
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alone or in combination, often resembling IBS. The diagnosis of IS is sus-
pected on H & E staining of colonic mucosal specimens, and confirmed by
silver stains, immunohistochemistry or electron microscopy. Due to patchy
distribution of spirochetes, multiple site colonic biopsies are recommended
for a definitive diagnosis. Of the several regimens proposed, metronidazole
seems to be superior in eradicating spirochetes from the intestine.
In conclusion, IS should be considered as a differential diagnosis in pa-
tients with IBS-like symptoms, with an otherwise grossly normal-appearing
colonic mucosa. Metronidazole should be offered as first-line therapy for
the treatment of IS.
469
Recto-Sigmoid Colon Perforation during Retroflexion in a Patient with
Rectal Prolapse: Is This a Safe Practice
Robert P. Svoboda, MD, Kevin W. Olden, MD∗. Gastroenterology,
University of Arkansas for Medical Sciences, Little Rock, AR.
Purpose: Colonic perforation has been well described in the literature as
a known complication of colonoscopy, a commonly performed procedure.
The perforation risk in colonoscopy has been quoted over a wide range. The
rectum is generally felt to be an area of low risk to perforation. We present a
case of a 70 year-old gentleman with recto-sigmoid colon perforation occur-
ring during colonoscopy upon retroflexion in the rectum. To our knowledge
perforation experienced during retroflexion has not been reported. Interest-
ingly, this patient had prolapse of the rectal mucosa identified on digital
rectal examination prior to his colonoscopy. Spontaneous perforation of the
recto-sigmoid colon with evisceration of the small bowel in patients with
rectal prolapse have been reported.
Results: Mr. R. is a 70 year old man referred for a screening colonoscopy.
His medical history included a new diagnosis of prostate cancer. General
surgery had recently seen the patient for evaluation of suspected rectal pro-
lapse. Prior to insertion of the colonoscope, a rectal exam was performed.
There was evidence of rectal prolapse with approximately two centimeters
of rectal mucosa extending beyond the anal sphincter along with external
hemorrhoids. The colonoscopy was performed to the cecum without com-
plication. The entire colonic mucosa appeared normal without evidence of
diverticulosis, stricture, or polyps. Upon retroflexing in the rectum a perfo-
ration occurred. The perforation was suspected to be at the recto-sigmoid
junction after noting blood approximately 15 cm from the anus. The patient
did not complain of any pain and had no abdominal distention, guarding, or
rebound tenderness on examination. Upright abdominal film was obtained
and showed a small amount of free air. Surgery evaluated the patient im-
mediately, and he was started on antibiotics. He was taken to the operating
room and underwent rigid sigmoidoscopy under anesthesia. This did not re-
veal the perforation so an open laparotomy through a small 4–5 cm incision
below the umbilicus was performed. The surgeons identified the mucosal
tear, and he underwent of primary repair of 1–2 cm perforation just above
the peritoneal reflexion.
Conclusion: We hypothesize that rectal prolapse may be a contraindication
to retroflexion in the rectum in patients undergoing colonoscopy.
470
Watermelon Colon: Can This Be an SLE Flare-Up?
Heather Sheets, MD, Krishna S. Kasturi, MD∗, Rajasekhara R. Mummadi,
MD. Internal Medicine, University of Texas Medical Branch, Galveston,
TX and Gastroenterology and Hepatology, University of Texas Medical
Branch, Galveston, TX.
Purpose: A 69-year-old Caucasian female with past medical history of SLE
presented with a two-month history of diffuse abdominal pain, occasional
nausea, vomiting, bloody stools and uncontrolled diarrhea. She denied any
recent travel, change in medications, exposure to contaminated food or wa-
ter, and fevers or chills. Her symptoms initially responded to over the counter
medications, but she was now having severe diarrhea up to 10 times a day
associated with abdominal cramping and bloating. She was on maintenance
steroid therapy for her SLE and her last flare-up was several years ago.
Physical exam was significant for diffuse abdominal tenderness with no
voluntary guarding or organomegaly. Bowel sounds were hyperactive, and
no skin lesions or lymphadenopathy were appreciated. Initial labs includ-
ing CBC, chemistries, LFTs, and thyroid function tests were unremarkable.
Stool studies were negative for C. Difficile, ova and parasites, and leuco-
cytes. The patient underwent an elective EGD that showed mild erosive
gastritis, and a Colonoscopy revealed extensive, reddish, watermelon-like
linear vascular lesions throughout her entire colon extending up to the ileo-
cecal junction, that had the appearance of “Watermelon Colon”. Biopsies
confirmed the vascular nature of these lesions and had features of colitis in
certain regions. The patient was started on high-dose oral steroids and her
symptoms slowly started to resolve. “Watermelon Colon” is an extremely
rare endoscopic diagnosis and very few cases have been reported in the
literature. Prior reported cases were seen in association with scleroderma
or the CREST syndrome and involved focal areas of the colon or the rec-
tum. Only one case describes this entity involving the entire colon, with
cecal sparing, seen with a protein-losing enteropathy. Our case is unique
in its association with SLE and involving the entire colon, including the
cecum. Vasculitis is one of the hallmarks of SLE and it is well-known
to involve the GI tract causing erythematous lesions, ulcers, ischemia, in-
farction, perforation, or inflammatory bowel disease. It is possible that our
patient had a flare-up of SLE that manifested as the Watermelon Colon.
Various treatment modalities have been proposed for such vascular lesions
involving the stomach (Watermelon Stomach) and the colon and include Ar-
gon Plasma Coagulation, sclerotherapy, laser photoablation and endoscopic
cryotherapy.
471
Cola Dissolution Therapy in Gastric Bezoar
Falgun M. Modhia, MD, Camille F. Torbey, MD∗. Internal Medicine,
Marshfield Clinic, Marshfield, WI and Gastroenterology, Marshfield
Clinic, Marshfield, WI.
Purpose: Bezoars are concretions of indigestible material that coalesce usu-
ally in the stomach. In this report, we wished to address one treatment modal-
ity for this often vexing clinical problem.
Methods: A 90-year-old male was admitted to the hospital because of ab-
dominal distention, vomiting, and increased colostomy output. The patient
had a history of dementia and resided in a foster home. Physical exami-
nation revealed an alert but demented elderly male with stable vital signs.
Abdomen was distended with normoactive bowel sounds. Right lower quad-
rant tenderness was present. The patient had been recently admitted with
similar symptoms. Evaluation at that time with plain abdominal films had
revealed a distended stomach with a large amount of food. The patient then
improved spontaneously and was returned home without further testing or
treatment.
Upon admission, abdominal CT scan was suggestive of gastric outlet ob-
struction. Esophagogastroduodenoscopy (EGD) showed a large bezoar oc-
cupying most of the gastric lumen. Several gastric ulcers were seen in the
antrum, away from the pylorus. There was no evidence of gastric outlet ob-
struction. Given the patient’s age and comorbidities, his family wished to
avoid surgery. Papain use was ruled out because of side effects, and cellu-
lase was not available. Therefore it was decided to use gastric instillation of
cola (Coca-Cola) in an attempt to dissolve the bezoar.
Results: Following intragastric lavage with cola for 12 hours, EGD showed
persistence of the bezoar. However, the patient was now able to keep liquids
down. He was discharged to home on proton pump inhibitor therapy, with
instructions to drink 2 cans of cola daily and to follow a liquid diet. Follow-
up EGD 2 months later revealed complete disappearance of the bezoar and
healing of the gastric ulcers.
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Conclusion: After a thorough literature review, we were able to retrieve only
a paucity of articles regarding cola dissolution therapy for gastric bezoars.
Three such reports describe successful dissolution, with varying method-
ologies used. To the best of our knowledge, our report is the first of cola
dissolution therapy in the United States. We propose that cola dissolution
therapy is a valid option for dealing with gastric bezoars. It is anecdotally ef-
ficacious and carries virtually no side-effects. It should be offered to patients
as part of the therapeutic armamentarium. However, this therapy has yet to
be subjected to a randomized controlled trial, and is probably best reserved
for the non-surgical candidate.
472
Gallbladder Remnant: Rare Cause of Abdominal Pain Post
Cholecystectomy
Ganesh R. Veerappan, MD, Matthew C. Wakefield, MD, Gilbert Aidnian,
MD, Eric M. Osgard, MD∗. Gastroenterology, Walter Reed Army Medical
Center, Washington, DC and General Surgery, Walter Reed Army Medical
Center, Washington, DC.
Purpose: Thirty-six year old male presented to gastroenterology clinic with
sharp right upper quadrant pain for a month radiating to his back. He also
described nausea but denied emesis, dysphagia, change in bowel habits,
jaundice, fever, chills, sweats and weight loss. His past medical history was
significant for acute cholecystitis in November 2003 requiring an urgent
cholecystectomy.
Physical exam was remarkable for minimal tenderness in right upper quad-
rant upon palpation. Vital signs and labs were normal. Computed Tomogra-
phy (CT) scan was normal. Ultrasound report commented on a 1.3 cm simple
liver cyst and a 1.2 cm cystic structure containing a 6.7 mm calcification in
the location of the gallbladder fossa.
Gastroenterology recommended evaluation with a Magnetic Resonance
Cholangiopancreatography (MRCP), which revealed a cystic duct rem-
nant with small stones. Endoscopic Retrograde Cholangiopancreatography
(ERCP) was performed to confirm MRCP findings prior to surgical explo-
ration and resection. ERCP revealed normal common bile ducts, no filling
defects, and a long cystic duct with an early take off from the common bile
duct. As contrast continued to be injected, a structure suggestive of a gall-
bladder remnant continued to fill. Gallbladder remnant was identified and
general surgery planned a surgical resection, which revealed a gallbladder
remnant with an impacted stone (Fig. 1).
Retained gallbladder remnant is a rare complication of cholecystectomy and
is more common in the era of laparoscopic cholecystectomy. Symptoms can
occur from new stones forming in remnant or from harboring residual stones.
Patients usually present months to years after initial surgery. Diagnosis is
difficult to make and requires MRCP or ERCP. Treatment in all cases requires
surgical excision with either laparoscopic or open procedure.
In summary, gall bladder remnant is a rare complication of cholecystectomy
and reported in the literature in a number of case series and case reports.
Gastroenterologists should be aware of this diagnosis because it is difficult
to make without a high index of suspicion.[figure1]
473
Gastric Polyps Causing Intermittent Gastric Outlet Obstruction
Jan C. Prazak, MD, Ann Silverman, MD∗. Division of Gastroenterology,
Henry Ford Hospital, Detroit, MI.
Purpose: A 40-year-old Caucasian male with a history of GERD and
Osgood-Schlatter disease presented with acute-onset of abdominal bloat-
ing, nausea and vomiting for one month. His daily symptoms were worse
at night, usually resolving by the next morning. He denied any worsening
heartburn, weight loss, appetite changes, dietary changes or modification of
bowel habits. He had been on long-term proton-pump inhibitor therapy for
GERD and was taking NSAIDs for osteochondritis. Elective gastroscopy
showed multiple large gastric polyps occupying the gastric fundus and body.
Two of these polyps were pedunculated and were prolapsing into the pyloric
channel, presumably causing intermittent gastric outlet obstruction. We en-
doscopically removed two 3.5 cm hyperplastic polyps by snare technique.
The patient’s symptoms completely resolved following this intervention.
Proton-pump inhibitors are widely used in clinical practice and are associ-
ated with an increased incidence of hyperplastic gastric polyps via stimu-
lation of enterochromaffin-like cells. Gastric polyps causing gastric outlet
obstruction should be considered in the differential diagnoses of abdominal
distention.[figure1][figure2]
474
Fleeting Hepatomegaly Due to Glycogenic Hepatopathy in
Uncontrolled Type I Diabetes Mellitus
Rahul K. Chhablani, MD, Maria McIntire, MD, Shriram Jakate, MD,
Stanley M. Cohen, MD, Joseph Ahn, MD∗. Hepatology, Rush University
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Medical Center, Chicago, IL and Pathology, Rush University Medical
Center, Chicago, IL.
Purpose: Glycogenic Hepatopathy (GH) is an under-recognized pathologic
overloading of hepatocytes with glycogen in patients with poorly controlled
type I diabetes mellitus. We present a case of GH and discuss its clinical
presentation, diagnosis, and management.
Case presentation: An 18-year-old woman with Type I diabetes mellitus
since age 5 was admitted via the emergency department for worsening nau-
sea, vomiting, right upper quadrant pain, and increased abdominal girth.
Physical examination revealed tender hepatomegaly 8 cm below the right
costal margin. Laboratory data revealed an AST of 170 U/L, ALT 120 U/L,
alkaline phosphatase 181 U/L, total bilirubin 0.8 mg/dl, HbA1C 12.5%.
Subsequent laboratory screening for viral hepatitis and autoimmune hepatitis
were negative. The patient denied alcohol use. A computed tomography scan
of the abdomen revealed significant hepatomegaly without other abnormal-
ities. An abdominal ultrasound revealed a liver measuring 17.5 cm in length
with increased echogenic parenchyma suggestive of fatty infiltration. The
hepatic vascular indices were normal. A trans-jugular liver biopsy revealed
swollen hepatocytes, pale cytoplasm, and numerous glycogenated nuclei. A
periodic acid-Schiff stain with and without diastase digestion demonstrated
extensive glycogen deposition confirming the diagnosis of GH. Fibrosis,
steatosis, and inflammation were absent. With aggressive glycemic con-
trol, the patient’s abdominal pain, girth, and liver function abnormalities
improved and the patient was discharged. Subsequent follow-up laboratory
data revealed improved HbA1C and normal liver function tests.
Discussion: GH is a complication of uncontrolled type I diabetes mellitus.
Patients often present with liver function test abnormalities and abdominal
pain, hepatomegaly, nausea, or vomiting. Glycogen is not toxic to hepato-
cytes and the elevation in liver enzymes is likely secondary to leakage from
hepatocyte injury rather that cell death. Many physicans often mistake GH
for fatty liver disease. Imaging and laboratory testing cannot effectively dis-
tinguish between these two entities. The diagnosis is made by liver biopsy
which reveals marked glycogen accumulation in hepatocytes. Unlike steato-
sis, GH is not known to progress to cirrhosis. Management strategies for GH
focus primarily on achieving strict glycemic control.
475
Severe Pulmonary Hypertension in Whipple’s Disease
Patricia A. Sanchez, MD, Joel Camilo, MD, Wendell K. Clarkston, MD∗.
Gastroenterology, University of Missouri at Kansas City School of
Medicine, Kansas City, MO.
Purpose: A 49 year-old Caucasian male presented with 6 weeks of dyspnea,
increased abdominal girth, diarrhea and lower extremity edema. Ausculta-
tion disclosed normal heart sounds but decreased breath sounds at the lung
bases. His abdomen was protuberant without masses or organomegaly and
he had bilateral lower extremity edema.
His albumin level was 1.8 g/dL despite normal liver function tests. Imag-
ing studies of his chest and abdomen showed large bilateral pleural effu-
sions, a small pericardial effusion, ascites and edematous loops of bowel.
Echocardiografic evaluation revealed a normal ejection fraction and no
valvulopathies. However, elevated right ventricular pressures led to a cardiac
catheterization which disclosed a pulmonary artery pressure of 90 mmHg,
consistent with severe pulmonary hypertension. The presence of microcytic
anemia (hemoglobin of 8.2 g/dL), prompted upper endoscopic evaluation,
which disclosed mild duodenitis. Small bowel biopsies demonstrated acute
inflammation and numerous Periodic acid-Schiff stained macrophages in
the lamina propria (Fig. 1). PCR confirmatory studies were positive for
Tropheryma whipplei. Antibiotic therapy led to resolution of his symptoms
and normalization of the pulmonary artery pressures over the following 16
weeks.
Discussion: Whipple’s disease is a rare systemic disorder characterized by
arthralgias, weight loss, diarrhea, and abdominal pain. Pulmonary involve-
ment occurs in 30 to 40% of cases, usually as pleural effusions, pulmonary
infiltrates or mediastinal adenopathy. Pulmonary hypertension, however, is
an infrequent finding.
To the best of our knowledge, only three cases of severe pulmonary hyper-
tension in Whipple’s disease have been previously reported in the English
literature. Two of those cases involved patients with valvular heart disease,
probably from blood-culture negative T . whipplei endocarditis.
In our case, we suspected a causal relationship between Whipple’s disease
and pulmonary hypertension, as evidenced by resolution of the latter follow-
ing antibiotic therapy. Direct involvement of the pulmonary vascular bed by
T . whipplei is therefore assumed.[figure1]
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Preventing Recurrent Gastro-Gastric Stricture as a Complication of
Roux-en-Y Gastric Bypass Surgery
Bikram S. Bal, MD, Shilen V. Lakhani, MD, Hiral N. Shah, MD, Frederick
C. Finelli, MD, JD, Timothy R. Koch, MD∗. Medicine/Gastroenterology,
Washington Hospital Center, Washington, DC; Surgery, Washington
Hospital Center, Washington, DC and Gastroenterology, Washington
Hospital Center and Georgetown University School of Medicine,
Washington, DC.
Purpose: Balloon dilation as a treatment for post-surgical anastomotic stric-
tures is minimally invasive and relatively safe. The benefit of through-the-
scope dilators has a reported long-term improvement of 48 to 66%. Place-
ment of a temporary stent is an option that we reported for benign esophageal
stricture. This is a patient wtih gastro-gastric anastomotic stricture which was
treated by injecting triamcinolone (TRIAM) into the stricture, using a pro-
tocol described for esophageal strictures, after multiple balloon dilations
provided short term relief.
Case: A 40 year old female, 4 years after Roux-en-Y gastric bypass surgery,
was transferred following extensive small intestine and right colon resec-
tion following a small bowel volvulus with infarction of the entire jejunum,
ileum, and right colon. A duodenocolostomy was planned as a bridge to
transplantation, but was not feasible due to inflammation. Therefore the
distal duodenum was closed primarily; EEA gastrogastrostomy with dis-
tal decompressive tube gastrostomy was performed. At 1 month she had
nausea and vomiting. At EGD there was a high grade stricture of the gastro-
gastric anastomosis. Under fluoroscopy, the anastomosis was dilated with
through-the-scope balloon dilators. Five additional dilations provided tem-
porary relief. Due to nausea and vomiting, a seventh EGD at day 50 revealed
a residual high grade stricture. During this session, the stricture was dilated
with a balloon dilator to 12 mm and then the stricture was injected circum-
ferentially 5 times with 10 mg of TRIAM. Due to the absence of recurrent
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symptoms she did not require repeat dilation for 3 months; EGD prior to
transplantation revealed a patent gastro-gastric anastomosis. At 3 months
after small intestinal transplantation, she was clinically doing well.
Discussion: This case report demonstrates that injection of TRIAM into an
anastomotic stricture following GI surgery improves long term efficacy of
dilation. TRIAM is preferable to cortisol, as it is locally active for 4 weeks
and is more potent at degradation of collagen fibrils. This novel approach
appears to be an effective method for managing an unusual complication
of gastric bypass surgery without the risk of perforation due to repetitive
endoscopic dilations.
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An Atypical Presentation of Hepatocellular Carcinoma
Christopher C. Canale, MD, William R. Hutson, MD∗. Department of
Gastroenterology, University of Utah, Salt Lake City, UT.
Purpose: This is a 69-year-old Laotian male with a history of prior partial
hepatic resection for unknown reasons, who is admitted to the university
hospital for a palpable right upper quadrant mass causing RUQ pain, 8/10
in severity, and radiating into the back. No factors seem to affect the pain
negatively or positively. Four years ago, he noticed the appearance of a right
upper quadrant mass, which did not cause him significant pain until three
weeks prior to presentation. One week prior to presentation, the patient had
a CT scan done showing a 12.5 × 11.5 cm multilocular liver mass. The
mass appeared mostly cystic with multiple loculations and thick intervening
septa. There was an inferior vena cava thrombus and multiple pulmonary
emboli. Patient’s review of systems was negative. The patient noted mild
weight loss, which he cannot quantify. He reports bilateral ankle swelling
present for the last two days, and frequent drenching night sweats. He moved
to the United States in 1981 from Laos. Physical exam was remarkable for
an afebrile patient with a grapefruit-size, right upper quadrant, tender, firm
mass, a large surgical scar over the right upper quadrant, and 2+ pitting
edema bilaterally. Labs were notable of a WBC of 15,000, Hct 29, Plts 251,
and Eosinophils 25.1%. Basic metabolic panel was within normal limits.
LFTs were notable for an Alkaline Phosphatase of 502, AST 48, ALT 28,
TP 8.7, Alb 2.8, TB 0.8, GGT 334. Hepatitis A, B, and C were negative. AFP
was 4, Alpha-1-AT, ANA, LKM1, ASMA, Stool O&P × 3 were all negative.
His iron percent saturation was 22%. E. histolytica and Echinococcus studies
were negative. Toxocara IgG was positive at 4.1. Serum Fasciola hepatica,
Clonorchis sinensis, and echinococcal serologies were sent to the CDC dur-
ing this hospital course. The patient, due to his multiple pulmonary emboli
and IVC thrombus was started on heparin and bridged to coumadin. The
differential diagnosis included the infectious etiologies tested for, biliary
cystadenocarcinoma, and hepatocellular carcinoma. The patient was started
on albendazole 400 mg p.o. b.i.d. secondary to the elevated Toxocara IgG.
Patient failed to show up for his follow-up appointment, and then presented
to another hospital ten days later in PEA. One hour later, he was pronounced
dead. At autopsy, it was determined that the solid and cystic mass in his liver
was a hepatocellular carcinoma that had occluded the hepatic vein and IVC
via direct extension. One must consider HCC in the setting of an apparent
infectious etiology of a hepatic mass.
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Reactive Thrombocytosis Following Liver Transplant
Christopher C. Canale, MD, William R. Hutson, MD∗. Department of
Gastroenterology, University of Utah, Salt Lake City, UT.
Purpose: Patient is a 66-year-old white male with past medical history sig-
nificant for total colectomy due to ulcerative colitis and primary sclerosing
cholangitis who underwent DCD orthotopic liver transplantation on April
22, 2007, for primary sclerosing cholangitis. The patient was positive for
CMV, and the donor was CMV negative. The patient had a Roux-en-Y
choledochojejunostomy for biliary anastomosis. The patient had an unevent-
ful postoperative course, and was discharged within seven days; however,
the patient then began to develop increasing LFTs, GGT, and total biliru-
bin. On physical exam, vital signs were within normal limits, the patient’s
chevron scar was well healed, and there were no other physical exam find-
ings. Patient was also noted to have a steadily increasing platelet count. A
liver biopsy was done that was consistent with possible biliary obstruction.
Multiple imaging studies were done to evaluate for both biliary and vas-
cular obstruction. No obstruction was seen, but there were multiple areas
of sludge in the common bile duct as well as a tiny splenic remnant. The
patient had a percutaneous drain placed. Since that time, the LFTs gradually
returned to normal limits. The patient has a good appetite and good en-
ergy levels. He was tolerating all PO and denies diarrhea, nausea, vomiting,
chills, fevers, shortness of breath, chest pain, palpitations, headache, blurry
vision, dysuria, or polyuria. His platelets, however, continued to climb to
a peak of 1.08 million. Prior to transplant, the patient’s platelet count was
between 300,000 and 400,000. The peripheral smear was significant for
Howell-Jolly bodies, target cells and spherocytes. It was felt that the pa-
tient was effectively asplenic and had reactive thrombocytosis. Patient was
treated with a ten day course of hydroxyurea and platelet count has remained
under 500,000.
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Anidulafungin Induced Cholestasis Following Liver Transplant
Christopher C. Canale, MD, William R. Hutson, MD∗. Department of
Gastroenterology, University of Utah, Salt Lake City, UT.
Purpose: Patient is a 56-year-old Caucasian male who is status post liver
transplantation on 5/30/06 for chronic hepatitis C, cirrhosis, and concomi-
tant hepatocellular carcinoma. The patient had posttransplant complications
including loculated fungal peritonitis with an organized intraabdominal ab-
scess that has required catheter drainage. His fluid grew out Candida trop-
icalis resistant to voriconazole. Anidulafungin was administered at 200 mg
for the first dose and then 100 mg once daily each day thereafter. Two weeks
after starting this medication, the bilirubin had climbed to 9.1 from 0.6 with
a GGT up from 67 to over 2000. The remainder of the patient’s labs remained
stable including his CBC, coagulation studies and CHEM 14. Patient’s vital
signs were within normal limits. The physical exam was only significant for
a well healed chevron scar and jaundice. While recent liver biopsy findings
were suggestive of large duct obstruction, an MRCP did not show any sig-
nificant extrahepatic duct dilation and ERCP confirmed this finding. It was
felt the cholestatic picture was likely secondary to the anidulfungin and it
was discontinued. Within two weeks, the bilirubin fell to 2.8 and the GGT
dropped to 228. The anidulafungin was restarted due to the severity of the
fungal infection. The bilirubin and the GGT again rose, but the drug was
continued for two more weeks until the infection was eradicated. Following
discontinuation of the anidulafungin, the patient’s labs again returned to nor-
mal limits. The patient is now over one year out from his transplantation and
9 months out from his infection and continues to do well. Prior to reporting
these events to the maker of the drug, there was no evidence reports of el-
evated bilirubin associated with anidulafungin. Now it is a box warning. In
the case of our patient, we were able to successfully treat the Candida tropi-
calis while tolerating the elevated GGT and bilirubin in a newly transplanted
patient.
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A Case of Ileocecal Tuberculosis Found on Screening Colonoscopy
Christopher Fyock, MD, Alyn Adrain, MD∗. Internal Medicine, Brown
Medical School/Rhode Island Hospital, Providence, RI and
Gastroenterology Associates, Providence, RI.
Purpose: While gastrointestinal tuberculosis if often thought of as a disease
of the developing world, clinicians in the United States should not forget
to entertain it as a possibility too. Here we present a case of ileocecal TB
discovered on a screening colonoscopy.
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Methods: A 61 year-old female presented for a screening colonoscopy. She
had no abdominal pain, no change in bowel habits, and no bleeding. The
colonoscopy showed an ileal ulcer 5 cm from the ileocecal valve. The ulcer
was biopsied, and histology showed epithelial granulomas with one acid-fast
bacillus. The cultures were negative for acid-fast bacilli. The patient denied
any known exposure to tuberculosis. The PPD was positive, but the chest x-
ray was negative. An HIV test was negative. This was felt to be consistent with
gastrointestinal tuberculosis. The patient was referred to TB clinic and was
started on a four drug anti-tuberculosis regimen. We performed a literature
search to learn more about this disease that is uncommon in our patient
population.
Results: It is estimated that 50% of the worlds population is infected with
TB, and 5% of these patients have gastrointestinal TB. Gastrointestinal TB
has been rare in the United States, but its prevalence has been increasing
in recent years because of the rise of HIV and the increase of immigration
from developing nations. TB can affect the gastrointestinal tract anywhere,
but the area around the ileocecal valve is the most commonly affected site.
The gut becomes infected by swallowed organisms, which then enter the mu-
cosa and are trapped in the submucosal lymphatic tissue. The most common
presenting complaint is abdominal pain. Fever, diarrhea, and anorexia may
also be present. Colonoscopy is the initial test of choice and may reveal a
deformed ileocecal valve, mucosal nodules, or rounded ulcers surrounded
by inflamed mucosa. The definitive diagnosis is made by isolating acid-fast
bacilli from a biopsy, either by histology smear, culture, or PCR. Abdominal
CT may show wall thickening of the affected bowel. Treatment with a stan-
dard anti-tuberculosis regimen should be initiated if there is high suspicion.
Conclusion: Gastrointestinal tuberculosis can be a difficult diagnosis to
make. However, with the rise in the prevalence of HIV and with a greater
mobility of people from at risk-nations, endoscopists and pathologists should
be aware and maintain a high index of suspicion for this dangerous yet
treatable disease.
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Hiccups: A Subtle Sign of Gastric Volvulus?
David P. McElreath, DO, Farshad Aduli, MD, Kevin W. Olden, MD∗.
Gastroenterology, University of Arkansas for Medical Sciences, Little
Rock, AR.
Purpose: Volvulus is defined as an abnormal twisting of bowel upon itself
resulting in luminal obstruction. This often occurs in the small intestine of
pediatric patients with malrotation leading to obstruction. It is also seen
in the large intestine, most commonly causing obstruction in the cecal and
sigmoid regions. Another less common condition is gastric volvulus.
Acute gastric volvulus is an emergency and an accurate timely diagnosis is
essential. We present two cases of gastric volvulus where a major complaint
of both patients was hiccups. These cases are reported to alert physicians
to the possibility of hiccups as a subtle but important finding to suggest the
diagnosis of gastric volvulus in the appropriate clinical setting. This is impor-
tant because untreated gastric volvulus can potentially lead to incarceration
and mesenteric ischemia with a high mortality.
Results: Case 1: A 63 year old man presented with a one week history
of nausea, vomiting, abdominal pain and progressively worsening hiccups.
Physical exam showed some abdominal distention with mild diffuse ten-
derness. CT of the abdomen showed a distended, fluid-filled stomach with a
twisting pattern consistent with an organoaxial gastric volvulus. Exploratory
laparotomy showed a dilated stomach and paraesophageal hernia. Hernia re-
pair was performed and the patient did well after surgery.
Case 2: An 89 year old man presented with complaints of epigastric pain,
nausea, vomiting, coffee ground emesis, and progressively worsening hic-
cups. Four months prior, an EGD had shown the presence of a large hiatal
hernia. Presenting symptoms and known history of hiatal hernia suggested
a possible diagnosis of gastric volvulus. Abdominal CT was consistent with
a mesenteroaxial gastric volvulus confirming our clinical diagnosis. The pa-
tient was taken to the operating room, and a laparoscopic reduction of his
gastric volvulus was performed.
Conclusion: Gastric volvulus is an uncommon but potentially devastating
condition if not diagnosed in a timely manner. In 1904 Borchadt described
the classic triad of epigastric pain, retching and inability to pass a nasogastric
tube in patients with a gastric volvulus. In our cases, an interesting finding
was the presence of hiccups in both patients. Irritation of the diaphragm
by a sliding gastric volvulus or paraesophageal hernia could theoretically
trigger hiccups. In the presence of signs and symptoms suggestive of gastric
volvulus, it may be appropriate for physicians to inquire about the presence
of hiccups while obtaining the patient’s history.
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A Case of Delayed-Onset Cholestasis Due to Lisinopril Use
Cristina Capanescu, MD∗, Christopher Deitch, MD, Cynthia McCleery,
MD, William Rafferty, MD. Gastroenterology, Cooper University
Hospital, Camden, NJ.
Purpose: A 66-year-old female presented with 1 week-history of painless
jaundice. She denied fever or weight loss and reported no recent travel, al-
cohol use, or dietary exposures. Past medical history was not significant.
Chronic prescription medicines included levothyroxine, esomeprazole, ser-
traline, and lisinopril, which she had taken for 3 years.
Liver chemistries 3 years prior were normal. Serum liver testing showed
alkaline phosphatase 795, total bilirubin 17.1, direct bilirubin 8.8, ALT 304,
AST 392, albumin 4.4, and total protein 6.1. Viral and automimmune hep-
atitis serologies were negative.
MRCP showed three areas of stricturing within the common hepatic duct
(Fig. 1). ERCP was performed, which revealed an irregular common bile duct
and moderate dilation proximally (Fig. 2). Biliary stenting was performed,
and pathology was negative for malignancy. The bilirubin continued to rise to
a maximum level of 26.3. Liver biopsy was performed and was suggestive
of cholestatic hepatitis secondary to drug induced injury. Lisinopril was
discontinued, with a slow resolution of jaundice and normalization in liver
chemistries over three months. ERCP was repeated for stent removal and
cholangiogram revealed a normal biliary tree.
ACE inhibitor-induced hepatotoxicity typically presents within 8 weeks of
drug initiation. In this case the patient had been taking lisinopril for over
3 years without clinical signs or symptoms. This case does not follow the
typical pattern of presentation and suggests that lisinopril may cause chronic
subclinical liver injury, with a delayed onset of symptoms presenting as
severe cholestasis. There is a possibility that chronic inflammation may have
also involved the extrahepatic biliary tree. This is an atypical case in which
identification of drug-induced cholestasis prevented possible life-threatening
hepatic injury.[figure1][figure2]
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Diverticulosis Presenting as Recurrent Bacteremia
Muhannad M. Heif, MD, David Lipschitz, MD, PhD, Sherif
Isshak-Ibrahim, MD, Kevin W. Olden, MD∗. Donald W. Reynolds
Department of Geriatrics, University of Arkansas for Medical Sciences,
Little Rock, AR; Geriatrics, Central Arkansas Veterans Healthcare System,
Little Rock, AR and Internal Medicine/Gastroenterology and Hepatology,
University of Arkansas for Medical Sciences, Little Rock, AR.
Purpose: We present a case of a 71 year old man with a past medical history
of diverticulosis who presented with one month history of dysuria, lethargy
and fever.
Work up initially showed multiple organisms in the urine; however his blood
cultures in 2 bottles grew proteus mirabilis. The patient was treated with
IV antibiotics and after improvement; he was transferred to the geriatric
rehabilitation unit. Subsequently, the patient developed multiple episodes of
UTI and bacteremia. Urinary obstruction secondary to an enlarged prostate
was initially suspected, however, the patient started to report foul smelling
urine and pneumaturia. CT scan of the abdomen showed the possibility of a
fistula between a diverticulum in the sigmoid colon and the bladder with no
evidence of diverticulitis. The patient had no clinical history suggestive of
previous episodes of diverticulitis. Colonocopy was done and malignancy
and IBD were ruled out. Cystoscopy confirmed the presence of the fistula.
Patient underwent successful surgical treatment.
Conclusion: Colovesical fistula (CVF), first described by Cripps in 1888,
is caused by various inflammatory or neoplastic processes. Diverticulitis
is the most common underlying cause, followed by carcinoma, radiation,
Crohn’s disease and ruptured appendix Diverticulosis is a rare but important
cause of CVF. In patients with recurrent UTIs and other symptoms of CVF,
Diverticulosis should be ruled out.
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Twist of Fate: Intestinal Non-Rotation and Intermittent Volvulus in an
Adult Treated with Laparoscopic Lysis of Ladd’s Bands
Sara Hanif, MD, Eric Dozois, MD, Charles Berkelhammer, MD∗.
Gastroenterology, University of Illinois, Oak Lawn, IL and Surgery, Mayo
Clinic, Rochester, MN.
Purpose: Intestinal malrotation or non-rotation is well described in infants
and children, but rare in adults. Most adults with intestinal malrotation are
asymptomatic, and the anomaly is discovered incidentally. In the rare symp-
tomatic adult with intestinal malrotation or non-rotation, mid-gut volvulus
can be life-threatening. We describe an adult with symptomatic intestinal
non-rotation treated successfully with laparoscopic lysis of Ladd’s bands.
Methods: The clinical course of a patient diagnosed with congenital non-
rotation is described. She was studied by CT scans, small bowel follow-
through x-rays, endoscopy, and obstructive series during symptomatic
episodes.
Results: A 45 year old female complained of intermittent episodes of severe
abdominal pain, associated with nausea, vomiting and abdominal disten-
sion, since her teenage years. They would last 45 minutes to several hours,
and would spontaneously subside. Severe episodes necessitated emergency
room visits, where obstructive series would occasionally reveal small bowel
dilation with air-fluid levels. A CT scan revealed that all her colon was
on the left side of the abdomen. Her small bowel was on the right side
of her abdomen, as seen on CT scan and by small bowel follow-through
x-rays. On CT scan, the superior mesenteric artery was on the right side
of the superior mesenteric vein, contrary to normal anatomy. The third
and fourth portions of the duodenum were entirely anterior to the supe-
rior mesenteric artery, rather than posterior to it, and occurred in the right
upper quadrant, rather than the left. At laparoscopy, Ladd’s bands were seen,
as well as a narrow mesenteric pedicle. Ladd’s bands were lysed, appendec-
tomy performed, and the non-rotated positions of the small and large bowel
were left as is. The patient did well without recurrence of symptoms in
follow-up.
Conclusion: Symptomatic adult intestinal malrotation or non-rotation is
rare, but can be associated with life-threatening mid-gut volvulus and in-
testinal infarction. Laparoscopic lysis of Ladd’s band can successfully treat
this rare but potentially life-threatening condition in adults.
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This Is the Pits: A Case of Esophageal Foreign Body Impaction
Ruben D. Acosta, MD, Jason M. Lake, MD, Milton T. Smith, MD, Jonathan
M. Koff, MD∗. Gastroenterology, National Capitol Consortium, Bethesda,
MD.
Purpose: The esophagus is the most common location in the gastrointestinal
(GI) tract for foreign body impactions and endoscopic removal is the best
treatment. While performing endoscopic foreign body removal, it is critical
to protect the airway from inadvertent aspiration of saliva and the object
during extraction. Indications for tracheal intubation prior to endoscopy in-
clude inability to tolerate secretions or finding a radiopaque object within
the esophagus. We present the case of a patient able to tolerate secretions
after swallowing an apricot pit, whose radiographic film was initially read
negative, who during endoscopy was found to have the pit impacted just
distal to his upper esophageal sphincter (UES).
Methods: A 79-year-old Hispanic male presents five hours after ingesting
an apricot pit. The patient initially coughed up pieces of apricot but was
unsure if the pit had been expelled. Initially he felt pain and neck full-
ness but subsequently only experienced odynophagia. On exam, he was
afebrile, with normal blood pressure and pulse, chest without crepitus, and
soft, nontender abdomen. Labs were unremarkable. A neck soft tissue se-
ries was initially read negative. Upon endoscopic esophageal intubation
the apricot pit was seen just distal to the UES. The endoscope was with-
drawn and the patient intubated for airway protection. The endoscope was
reinserted and attempts at removal including use of Roth net, snare, stone
extraction basket, alligator forceps, three prong polyp grabber, and ERCP
stone extraction balloon were unsuccessful. Airway protection and access
were aided by esophageal overtube. After prolonged attempts endoscopy
was aborted. Otorhinolaryngology was consulted who decided to remove
the pit with a rigid esophagoscope in the Operating Room. The pit was suc-
cessfully removed under general anesthesia and inflamed, edematous tissue
was noted. Review of the initial soft tissue film confirmed the radiopaque
pit in the esophagus. Gastrograffin study after removal did not demon-
strate a perforation. Subsequent upper GI barium esophagram was with-
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out obstruction. The patient was discharged without complication two days
later.
Conclusion: The presence of persistent high esophageal obstruction should
be suspected even in the absence of alarm symptoms and despite normal
imaging. Our patient is unusual in terms of his benign complaints and normal
studies. Endoscopic attempts at removal of high esophageal foreign body
impactions are reasonable to attempt as long as adequate airway protection
is in place.
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Severe Systemic Lupus Erythematosus Induced by Antiviral
Treatment for Hepatitis C
Vincent Ho, MBBS, Bsc(Med), Anna Mclean, MBBS, Shaughan Terry,
MBChB, FRCPE, FACP∗. School of Medicine, James Cook University,
Cairns, Queensland, Australia and Gastroenterology, Cairns Base
Hospital, Cairns, Queensland, Australia.
Purpose: There have been only 9 reported cases in the medical literature
of systemic lupus erythematosus (SLE) developing in patients receiving α-
interferon treatment in hepatitis C. We report a case of a 43 year old man
who had SLE develop after receiving pegylated α-interferon and ribavirin
for chronic hepatitis C.
Methods: He had previously been diagnosed with a non-specific inflam-
matory arthritis and was commenced on 15 mg prednisone daily with good
symptom control. He was found to have an elevated HCV RNA viral load
(>800,000 IU) genotype 3 a with elevated ALT. He was commenced on
treatment with pegylated interferon α-2a at a dose of 180 micrograms per
week and ribavirin 400 mg twice daily. His HCV RNA viral load became
undetectable at 12 weeks with normalisation of liver enzymes. However 14
weeks into treatment he presented with a severe flare of arthritis and pleu-
ritis. His interferon and ribavirin were ceased. 4 weeks after discontinuing
antiviral treatment he was admitted to hospital with recurrent arthritis and
pleuritis.
Results: His hospital admission was prolonged and he displayed 8 features
of the American College of Rheumatology (ACR) criteria for SLE – notably
arthritis, pleuritis, florid discoid rash, anaemia and lymphopenia, oral and
aphthous ulceration, glomerulonephritis, the development of high titres of
ANA and anti-double stranded DNA antibodies after antiviral therapy. His
hospital admission was complicated by life-threatening myopericarditis and
vasculitis which necessitated admission to an intensive care unit. He was ad-
ministered pulsed cyclophosphamide, methylprednisolone and intravenous
gammaglobulin.
Conclusion: He made a slow but complete recovery aided by rehabilitation.
Unfortunately his HCV viral load is now detectable and there is evidence
of a mild transaminitis consistent with a recurrent flare of hepatitis C viral
replication. This case is notable for the clinical severity and nature of multi-
organ lupus involvement arising from hepatitis C antiviral therapy.
Autoimmune serological progression and clinical events
Dates Clinical events and ANA levels Anti ds-DNA (<7 IU/ml)
12/7/05 1:640 0
1/4/06 Interferon and ribavirin
commenced
24/4/06 >1:2560 2
26/7/06 Interferon and ribavirin
discontinued >1:2560
90
15/8/06 Admission to hospital with severe
arthritis and pleuritis >1:2560
800
19/9/06 Admission to the intensive care
unit
3/1/07 >1:2560 11
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Pandisaccharidase and IgA Deficiency Diagnosed in Adulthood
Vincent Ho, MBBS, Bsc(Med), John Ombiga, MBBS, FRACP, Peter Boyd,
MBBS, FRACP∗. School of Medicine, James Cook University, Cairns,
Queensland, Australia and Gastroenterology, Cairns Base Hospital,
Cairns, Queensland, Australia.
Purpose: A 40 year old Caucasian lady from a rural community near Cairns
presented to our gastroenterology clinic for investigation of chronic diar-
rhoea since infancy. She passed at least 8 bulky stools per day and her bloat-
ing and flatulence had been worsening recently. Past medical history was
otherwise unremarkable. She was on no medications. Physical examination
was normal. Her family history was significant for a deceased brother who
had diarrhoea since infancy that had also never been investigated. Her dietary
history was notable for avoidance of sugary foods since early childhood.
Results: Her faecal fat test was mildly raised. IgA deficiency was noted
on blood tests 0.77 (1.24–4.16 g/L). HIV testing and her immunoglobulin
subsets apart from IgA were normal. Coeliac serology was negative. She
was started on a gluten challenge prior to endoscopy. Upper endoscopy and
colonoscopy revealed no macroscopic lesions. Duodenal and colonic light
microscopies were completely normal. Evaluation for disaccharidase defi-
ciency revealed pandisaccharidase deficiency (see Table 1). She commenced
a lactose free diet which resulted in partial alleviation of symptoms. Capsule
endoscopy noted a number of small aphthous ulcers in the proximal and mid
small intestine. Abdominal CT scan revealed only mild gas distension of
small bowel loops. A repeat endoscopy 6 months later was normal with no
abnormalities found on small intestinal light and electron microscopies. Test-
ing of duodenal and jejunal disaccharidases reconfirmed pandisaccharidase
deficiency.
Conclusion: Special approval was obtained for sacrosidase enzyme replace-
ment. She was commenced on sacrosidase with lactose dietary restriction.
Her symptoms resolved within 10 days. This lady is thought to have a con-
genital sucrose isomaltase deficiency combined with an IgA and acquired
lactase deficiency. She has consented for genetic analysis of her blood and
intestinal tissue.
Results of disaccharidase testing
Duodenal Duodenal Jejunal
biopsy biopsy biopsy
Small intestinal enzymes 25/9/06 21/3/07 21/3/07
Alkaline phosphatase
(200–1000 U/g protein)
260 220 630
Isomaltase (38–180 L U/g
protein)
8 5 14
Sucrase (26–120 L U/g protein) 2 2 1
Lactase (20–120 L U/g protein) 4 2 9
Maltase (100–400 L U/g
protein)
25 22 72
Trehalase (8–50 U/g protein) – 20 46
Biopsy weight (mg) 8.7 25.2 13.9
Protein (mg/g wet tissue) 36 75 62
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Gastrointestinal Bleeding in a Patient with Pancreatico-Jejunostomy
Diagnosed and Treated with Double-Balloon Endoscopy
Abdo Saad, MD, Michael V. Chiorean, MD∗, Debra Helper, MD, Julia K.
LeBlanc, MD, David Agarwal, MD. Internal Medicine, Indiana University,
Indianapolis, IN; Internal Medicine, Gastroenterology, Indiana University,
Indianapolis, IN and Radiology, Indiana University, Indianapolis, IN.
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Purpose: Diagnosis and therapy of gastrointestinal bleeding in post-surgical
patients can be very challenging due to their altered anatomy. We describe
a patient who developed massive GI bleeding after a Roux-en-Y procedure
and was diagnosed and treated successfully with double-balloon endoscopy
(DBE).
Methods: Case report.
Results: A 50 year old female with history of Roux-en-Y pancreatico-
jejunostomy (Puestow procedure) for chronic pancreatitis four years earlier,
presented with recurrent massive gastrointestinal bleeding, requiring mul-
tiple units of blood transfusions. Standard endoscopies, push enteroscopy,
as well as bleeding scans and mesenteric angiography failed to reveal an
etiology. An urgent capsule endoscopy study, performed during one of the
bleeding episodes, showed blood in the distal small bowel without a clear
source. At DBE, the pancreatico-jejunal anastomosis including the remnant
of the pancreatic duct openings were clearly seen. Active bleeding ensued
about probing the blind end of the jejunal pouch. The bleeding was controlled
after injecting epinephrine and the application of two endoscopic clips. Post-
procedural angiography revealed a possible minute anurysm on a branch of
the dorsal pancreatic artery in the area of the endoscopic clips. The patient’s
hemoglobin normalized over the following weeks and no further bleeding
occurred at 9 months follow-up.
Conclusion: In conclusion, we are presenting a case of delayed bleeding
related to pancreatico-jejunostomy. This report illustrates the constantly ex-
panding spectrum of applications for DBE both in the diagnosis and treat-
ment of patients with altered bowel anatomy following complex surgical
procedures.
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An Interesting Cecal Mass in a Patient with AIDS
Ashutosh Naniwadekar, MD, Advitya Malhotra, MD∗. Internal Medicine,
University of Texas Medical Branch, Galveston, TX.
Purpose: Disseminated histoplasmosis is a common opportunistic infec-
tion in AIDS patients who are severely immunocompromised. Gastrointesti-
nal histoplasmosis (GIH) generally occurs in association with disseminated
histoplasmosis or rarely as localized lesions. GIH is defined by radiological
or endoscopic findings in conjunction with positive gastrointestinal tissue
cultures or histopathologic observation of broad budding yeasts of H. cap-
sulatum in tissue specimens. GIH typically occurs with median CD4 counts
of 35 and patients naı¨ve to anti-retroviral therapy. Common clinical features
include fever, abdominal pain and diarrhea. Colon is the most frequently af-
fected site (67%) followed by the cecum (17%). Endoscopic findings of GIH
are usually multiple ulcers or pseudopolyps; however it can rarely present as
a mass or constricting lesion suspicious for malignancy.
We describe a case of a 45-year-old white male with history of hemophilia A
and AIDS. Patient was admitted to us with a three week history of sharp right
lower quadrant abdominal pain and weight loss. Patient had no history of
opportunistic infection and was naı¨ve to anti-retroviral therapy. On physical
examination, the right lower quadrant was tender to palpation with volun-
tary guarding. Laboratory examination revealed a CD4 count of 17/µL. A
computed tomography (CT) scan of his abdomen showed a non-obstructing
cecal mass with an ‘apple-core’ appearance highly suspicious for malig-
nancy (marked by white arrow in Fig. 1). Subsequent colonoscopy showed
multiple small ulcers in the cecum, ascending colon and the transverse colon
with a three centimeter mass in the cecum (Fig. 2). Histopathology of the
ulcers and the mass showed numerous intracellular budding yeasts consis-
tent with H. capsulatum. Patient was started on itraconazole and reported
resolution of abdominal pain during an outpatient follow-up after a three
week period.[figure1][figure2]
490
Diagnosis of Appendiceal Adenocarcinoma during Screening
Colonoscopy
Jaya R. Agrawal, MD, MPH, John R. Saltzman, MD, FACG∗.
Gastroenterology, Brigham and Women’s Hospital, Boston, MA.
Purpose: Screening colonoscopy allows visualization of the colon and ap-
pendiceal orifice. Careful inspection of the appendiceal orifice can lead to
identification of appendiceal pathology.
Presentation: A 60-year-old man underwent colonoscopy for colon cancer
screening. On inspection, the cecum appeared normal, however when air
was aspirated prior to terminal ileum intubation, the tip of a pedunculated
lesion prolapsed into the cecum from within the appendiceal orifice. Using
a closed snare, a 15 mm polyp was everted from the orifice and removed by
snare cautery.
Clinical course: The post-procedure course was notable for fever and ab-
dominal pain that developed 12 hours after the procedure. An abdominal
CT scan showed stranding around the cecal base, consistent with injury
from the procedure. Symptoms resolved with oral antibiotics. The pathol-
ogy revealed a villous adenoma with high-grade dysplasia. The cauterized
margins were positive for adenomatous epithelium. The CEA level was nor-
mal. An abdominal MRI showed a normal appendix. He underwent repeat
colonoscopy which showed a persistent polyp within the appendiceal orifice.
This was biopsied and the pathology showed villous adenoma. The patient
then underwent an appendectomy with removal of 1.0 cm of the cecum.
Results: Surgical pathology showed a moderately differentiated 0.3 cm mu-
cinous adenocarcinoma present at the appendiceal ostium arising in a villous
adenoma that encompassed the entire appendix and extended into the cecum.
The margins were negative for adenoma or adenocarcinoma.
Discussion: Villous adenoma of the appendix is rare, with a frequency of
0.02% in appendectomy specimens. Adenocarcinoma of the appendix has
been known to arise from within these adenomatous lesions, however there
are only four case reports of appendiceal adenocarcinomas being diagnosed
preoperatively by endoscopy. Early-stage appendiceal adenocarcinomas can
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be cured by appendectomy or appendectomy plus cecectomy, however symp-
tomatic patients are more likely to have unresectable disease. Other neoplas-
tic lesions of the appendix reported to be visualized during colonoscopy
include mucoceles, mucinous cystadenomas and carcinoid tumors. Caution
should be exercised with attempts at mucosal resection; a few case reports
describe appendiceal intussusception or invagination that may appear polyp-
like, and endoscopic removal may lead to complications.
Conclusion: Endoscopists should inspect the appendiceal orifice during
colonoscopy and consider an appendiceal tumor when a polyp or deformity
is seen.
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Primary Pancreatic Non-Hodgkin’s Lymphoma
Pedro R. Abanto, MD, Asif Zamir, MD, FACG, Muhammed G. Nathani,
MD, FACG∗. Internal Medicine, UTHSCSA, Regional Academic Health
Center, Harlingen, TX.
Purpose: Primary pancreatic lymphoma is an extremely rare tumor. We
present an unusual case of a primary large B cell diffuse non-Hodgkin lym-
phoma of the pancreas.
Case Report: This is a 72 year old Caucasian woman with past medical
history of hypertension, depression and GERD who presented with wors-
ening heartburn despite optimum therapy. Her examination and laboratory
tests were unremarkable. The patient had a CT abdomen which suggested a
pancreatic mass (4.5 × 2.5 cm), markedly distended gallbladder and multi-
ple gallbladder stones. ERCP was unsuccessful. She underwent a CT guided
pancreatic mass biopsy and a subsequent EUS guided biopsy. There were
no malignant cells seen. She remained relatively asymptomatic for several
months and refused either a more extensive work-up or a tertiary care center
referral. A year later, she agreed for a second opinion and had an unsuccess-
ful ERCP but now EUS revealed an infiltrative mass involving the head of
the pancreas, the ampulla and the peri-ampullary area with surrounding lym-
phadenopathy. This time pathology reported a diffuse non-Hodgkin’s Lym-
phoma of B cell origin. Immunostains were positive for CD45 and CD20 and
negative for CD2 and chromogranin. After the diagnosis, she also developed
supraclavicular lymphadenopathy. Patient was treated with chemotherapy
(CHOP and rituximab), and did well. Patient is disease free two years after
diagnosis and treatment.
Discussion: Extra nodal lymphoma of pancreas is extremely rare. Diffuse
large-cell lymphoma is the most frequently observed pathological type. It
is usually located in the head of the pancreas. Exact diagnosis is based
on the histology and the immunohistology of the specimen. Our patient
presentation was not typical. Except for an initial mild weight loss and upper
gastrointestinal symptoms, she remained asymptomatic for the most part.
Our initial suspicion was for a neoplastic process but with negative pathologic
findings, it was thought that she may have an alternative diagnosis of chronic
pancreatitis. Regardless, she was followed closely and on repeat evaluation,
the correct diagnosis was made. Our patient was diagnosed more than a year
since the initial symptoms.
Conclusion: In summary, this is a case report of a patient with a primary
pancreatic lymphoma with atypical presentation and minimal symptoms.
This case emphasizes the difficulty in making the diagnosis of pancreatic
lymphoma and the need for persistent follow-up in patients with unexplained
findings.
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Esophageal Lymphagioma
Stephanie L. Hansel, MD, MS, Cuong C. Nguyen, MD∗. Gastroenterology,
Mayo Clinic Arizona, Scottsdale, AZ.
Purpose: Lymphangioma is a soft tissue tumor that may appear in any organ
except the brain. It most commonly involves the skin but has been found in
various areas within the gastrointestinal tract. We present a very rare case of
lymphangioma of the esophagus.
Case Report: A 68-year-old female with a 50-year history of Crohn disease
predominately of the small bowel presented with dysphagia to solid food. Ini-
tial upper endoscopy revealed a 1-cm submucosal nodule at approximately
20-cm from the incisors (Fig. 1). Endoscopic ultrasound revealed a submu-
cosal lesion with normal overlying musoca at 21-cm from the incisor. The
lesion was limited to the mucosal layers, measured 2.7 × 6.9 mm and was
hypoechoic. Lesion was deemed resectable by the endoscopists and patient
later underwent repeat upper endoscopy with jumbo forceps biopsy followed
by total snare polypectomy without complications.
Pathology from the biopsy and polypectomy revealed the submucosa and
lamina propria were occupied by a thin-walled lesion composed of anato-
mizing vessels containing proteinaceous fluid and occasional collections of
lymphocytes. Adjacent tissue in the deeper portions of the biopsy showed
a few benign lymphoid aggregates. No malignancy was seen. The findings
were consistent with lymphangioma.
Discussion: Esophageal lymphangiomas are very rare. This is only the thir-
teenth reported case in the literature. Lymphangiomas consist of dilated
lymphatic vessels and possibly form because of a failure to communicate
with the lymphatic system. Mucosal biopsies may be misleading as these
are submucosal lesions and therefore resection (endoscopic or surgical) is
necessary for the definitive diagnosis. It is important to differentiate these
tumors from other esophageal tumors that have the capability of undergoing
malignant transformation. To date, there have not been any published reports
of recurrence of esophageal lymphangioma tumors or malignant transfor-
mation.[figure1]
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Hemoclip for Severe Post-Prostate Biopsy Rectal Hemorrhage: Case
Series
Joy Tsai, MD, Robert User, MD, Charles Berkelhammer, MD∗.
Gastroenterology & Urology, University of Illinois, Oak Lawn, IL.
Purpose: Minor hematochezia is not uncommon after transrectal prostate
biopsies. However, massive hemorrhage is rare, occurring in less than 1%
of patients in large series. We describe four cases of post-prostate biopsy
rectal hemorrhage in which hemoclip was used as part of combined modality
endoscopic hemostasis.
Methods: Patients with significant gastrointestinal hemorrhage immedi-
ately following transrectal prostate biopsy were stabilized and volume
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rescusitated. Flexible sigmoidoscopy was performed immediately after
hemodynamic stabilization. All patients were treated with combined modal-
ity endoscopic therapy. Initially, epinephrine 1:10,000 was injected directly
into and around the bleeding site. This was followed by placement of three
hemoclips at the bleeding site. Once successfull hemostasis was achieved,
patients were monitored for rebleeding.
Results: Four patients developed rectal hemorrhage immediately following
transrectal prostate biopsy. Three of the cases required hospitalization be-
cause of severe hemorrhage. One patient was managed in the emergency
room and discharged the same day. Two patients developed shock, requiring
emergent volume resuscitation. Three patients required transfusions for a
mean of 5.7 units of blood [range 3 – 9 units]. The endoscopic stigmata
were arterial spurting at the biopsy site in two patients, venous oozing and
laceration at the apex of a large internal hemorrhoid in one patient, and non-
spurting oozing in one patient. Successful hemostasis was achieved with
endoscopic therapy. Rebleeding did not occur.
Conclusion: We describe four cases of post-prostate biopsy rectal hemor-
rhage controlled by combined modality endoscopic therapy. Patients with
post-prostate biopsy hemorrhage, including severe hemorrhage can be suc-
cessfully treated with epinephrine injection followed by hemoclip.
Post-Prostate Biopsy Rectal Hemorrhage
Case Units
Number Hospitalized Transfused Bleeding Stigmata
1 Yes 5 Arterial Spurter
2 Yes 3 Arterial Spurter
3 Yes 9 Venous Ooze/Hemorrhoidal
Laceration
4 No 0 Slow Ooze
Clinical characteristics of patients with post-prostate biopsy rectal hemorrhage.
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Isolated Gastric Varices in Lymphoma
Mohamad Sankari, MD∗, Mark Duff, DO, James Pollack, MD, Angel
Cinco, MD. Thomas Memorial Hospital, South Charleston, WV.
Purpose: A 48 year old man with bipolar disorder was recently treated
with clozapine. He was admitted to the hospital with pancytopenia and an
episode of coffee ground emesis. Upper endoscopy showed patchy erythe-
matous folds in the gastric fundus without evidence of bleeding. He received
blood transfusions and was treated with a proton pump inhibitor. Clozapine
was discontinued and hematology evaluation was in progress. A month later,
he developed massive hematemesis, melena, and hypotension. Emergency
upper endoscopy revealed actively bleeding vascular lesion in the gastric
fundus (Fig. 1). Bleeding was controlled with hemoclips application, intra-
venous proton pump inhibitor, and Sandostatin. Repeat upper endoscopy the
next day clearly demonstrated isolated varices in the gastric fundus (Figure
2). Computerized tomography of the abdomen showed a large splenic mass
invading the capsule medially and encasing hilar vasculature. The next day,
the patient underwent splenectomy with distal pancreatectomy. Pathology
showed Large B-cell lymphoma involving the spleen and the pancreas with
extracapsular and peripancreatic extension. Patient is receiving chemother-
apy consisting of rituximab, cyclophosphamide, vincristine, prednisone, and
doxorubicin.
Conclusion: This case illustrates the dramatic and rapid development of
isolated gastric varices in conditions that induce splenic vein thrombosis.
These conditions include chronic pancreatitis, acute pancreatitis, pancreatic
carcinoma, hypercoagulable states, trauma, and lymphoma as seen in this
patient. Splenectomy is necessary to control the ensuing life threatening up-
per gastrointestinal bleeding in addition to specific therapy to the underlying
disease.[figure1][figure2]
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Combined Hepatocellular Cholangiocarcinoma
Sam M. Nourani, MD, Emma Du, MD, Paul J. Pockros, MD∗.
Gastroenterology, Scripps Clinic, La Jolla, CA and Pathology, Scripps
Clinic, La Jolla, CA.
Purpose: A 60 year-old man presented with abdominal pain in early 2006.
He had a history of cirrhosis due to HCV treated with pegylated interferon
and ribavirin with a SVR in 2000. A liver biopsy in 2005 showed interval
improvement with Grade 0 inflammation and stage 3 (bridging) fibrosis.
Labs revealed a WBC count of 13,200 cells/mm3, platelet count of 202,000
cells/mm3, INR of 1.0, albumin of 4.4 g/dL, bilirubin of 0.5 mg/dL, AST
of 33 U/L, ALT level 47 U/L, and alkaline phosphatase of 104 U/L. The
alpha-feto protein level was 3 ng/ml (normal range 0–15 ng/ml). CT imag-
ing revealed a 5 cm heterogeneous solid mass in the posterior segment of
the right hepatic lobe (Figure A). Examination of the resected tumor re-
vealed combined hepatocellular and cholangiocarcinoma (cHC-CC) with
sarcomatous features (Figure B). Four months later the patient developed
evidence of metastases to his humerus and cervical spine complicated by a
humeral fracture. cHC-CC accounts for 1–6% of all primary liver cancers.1,2
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Tumor heterogeneity and presence of cells intermediate between hepatocel-
lular (HCC) and cholangiocarcinoma (CC) make it difficult to make an exact
histologic diagnosis and predict the biologic behavior of the tumor.2 cHC-
CC is more aggressive than HCC with a natural course of invasion into
the vascular system and metastasis to the lung and lymph nodes, carrying
a poorer prognosis than ordinary HCC.2 Survival of patients after hepatic
resection is poorer than that of those with HCC. Components of cHC-CC
that can be used to predict survival are the quantitative percent of tumor that
is CC as well as the presence of sarcomatous features. 2 It is not known if
adjuvant chemotherapy or liver transplantation are preferable options in the
treatment of this unusual tumor. This patient was initiated on sorafenib, a
novel therapy experimentally used for HCC.[figure1][figure2]
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Spontaneous Large Intramural Hematoma in Roux Limb of Gastric
Bypass
Weitian Liu, MD, PhD∗, John R. Saltzman, MD, FACG. Gastroenterology,
Hepatology and Endoscopy, Brigham and Women’s Hospital, Harvard
Medical School, Boston, MA.
Purpose: Abdominal pain with a significant hematocrit drop may indicate
severe GI bleeding. However, if there is no hematemesis, melena or hema-
tochezia, bleeding from other sources must be considered. We describe a
previously unreported case of spontaneous intramural bleeding within the
Roux limb in a patient with a history of gastric bypass surgery.
Methods: A 34 year old woman, 13 days post bone marrow transplant for
acute myeloid leukemia, with a history of Roux-en-Y gastric bypass surgery
2 years prior, developed moderate abdominal pain with Hct 28%, WBC
0.03 K/µL and platelets 6 K/µL. Esomeprazole and sucralfate were initi-
ated, which did not relieve the pain. Over the next 3 days, the Hct dropped
from 28% to 15%. The patient had more abdominal pain, tachycardia and
hypotension. She had nausea, but no vomiting or hematemesis. She had reg-
ular bowel movements, no melena or hematochezia. After resuscitation with
fluid, blood and platelet transfusions, the patient underwent an abdominal
CT scan.
Results: On CT scan, there was an extensive intramural hematoma confined
within the Roux limb of the gastric bypass with a wall thickness measur-
ing up to 1.7 cm. The abnormality extended from the gastrojejunostomy to
within a few centimeters of the jejunojejunostomy. The patient was given
blood and platelet transfusions to maintain the Hct at 30% and platelet at
50 K/µL. The bleeding gradually stopped over a week. The patient’s symp-
toms of abdominal pain and nausea resolved. A repeat CT scan one month
later demonstrated complete resolution of the intramural hematoma from the
Roux limb.
Conclusion: Spontaneous intramural small bowel wall hematoma has been
reported in patients with excessive anticoagulation or with other risk fac-
tors for bleeding. The jejunum is the most common site of the hematoma,
followed by the ileum and duodenum. Abdominal CT scan is the diagnos-
tic modality of choice to detect an intramural hematoma. CT scan findings
include circumferential or asymmetric wall thickening, intramural hyper-
density, luminal narrowing, and intestinal obstruction. Accurate diagnosis
is crucial because most patients can be treated nonoperatively with a good
outcome. Resolution of the hematoma can be seen as early as 1 week after
onset. In our case, the risk factor for bleeding was the extremely low platelet
count. The patient responded well to conservative management. This is the
first reported case of spontaneous intramural bleeding in the entire Roux
limb of a gastric bypass.
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Successful Multi-Modality Endoscopic Treatment of Bouveret’s
Syndrome without Surgery
Jason N. Rogart, MD, Melissa Perkal, MD, Anil Nagar, MD∗. Section of
Digestive Diseases, Deptartment of Internal Medicine, Yale University
School of Medicine, New Haven, CT and Department of Surgery, Yale
University School of Medicine, New Haven, CT.
Purpose: An 85-year-old man with dementia and diabetes presented with
lethargy, nausea, and coffee-ground emesis. Vital signs were stable and lab-
oratory examination was notable for a leukocytosis, hematocrit of 33%, and
normal liver tests. CT scan showed a distended stomach, pneumobilia, and
a 3 cm gallstone in close proximity to the duodenum. Endoscopy demon-
strated a large gallstone impacted in the duodenal bulb, resulting in gastric
outlet obstruction. Given the patient’s age and comorbitidies, the patient’s
surgeon requested endoscopic management. During the course of three endo-
scopies, the stone was fragmented using a combination of a Holmium:YAG
laser and an intracorporeal electrohydraulic lithotripter (IEHL). IEHL was
more effective in uniformly shattering the stone’s softer outer shell, while
the laser was more effective in weakening the stone’s internal structure by
boring holes into its harder, inner core. The largest fragment was extracted
using a double-snare technique, which provided extra grip and leverage. A
large cholecystoduodenal fistula was visualized with surrounding ulcerated
mucosa, and the gastroscope could be easily advanced into the gallbladder
lumen. The patient was discharged to a nursing home, without recurrence of
symptoms.
Discussion. Gastric outlet obstruction by a gallstone migrating through a
cholecystoduodenal fistula (Bouveret’s Syndrome) was first described in
1896 and is a rare condition, representing fewer than 5% of cases of gall-
stone ileus. Patients are often elderly with underlying comorbidities which
poses significant challenges to both surgeon and endoscopist. Despite mod-
ern surgical techniques, mortality is as high as 30%. Since 1985 there are
only a few reports of successful management with endoscopy alone, with
more than 90% ultimately requiring surgery. Our experience suggests that
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endoscopists should initiate stone fragmentation with IEHL as first line man-
agement, use laser lithotripsy adjunctively, crush stone fragments that are
left in the stomach to prevent migration and ileal obstruction, and prepare
for multiple endoscopic sessions. The choledochoduodenal fistula does not
require closure. With an aging, obese population, we anticipate Bouveret’s to
become more common and recommend endoscopists become familiar with
the multiple options available for effective endoscopic therapy.
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An Unusual Case of Headache in a Patient with Ulcerative Colitis
Wanda Blanton, MD, Paul Schroy, MD, Francis A. Farraye, MD∗. Section
of Gastroenterology, Boston Medical Center, Boston, MA.
Purpose: Cerebral vessel/sinus thromboembolism is a rare complication
of IBD, with DVT and PE accounting for the majority of thromboembolic
complications in patients with IBD. Afflicted patients are usually young and
without other risk factors for thrombosis other than IBD.
Case report: A 21-year-old male with chronic ulcerative colitis (UC) was
admitted with exacerbation of colitis despite therapy with corticosteroids,
oral mesalamine and 6-mercaptopurine (6-MP). Flexible sigmoidoscopy and
biopsies were consistent with severe colitis and negative for infectious eti-
ologies. A CT of the abdomen demonstrated pancolitis. Laboratory values
were notable for an elevated ESR and thrombocytosis. After initiation of
IV steroids, the patient’s colitis improved, but one week after admission, he
developed a new bilateral unremitting headache. Over the next 24–48 hours,
the patient complained of nausea, vomiting, and dizziness with standing.
The neurological exam was significant for increased somnolence, horizontal
nystagmus, right-sided facial weakness, dysmetria, and right upper extrem-
ity drift. MRI/MRV of the head showed venous infarction involving the
cerebellum secondary to venous thrombosis of the bilateral transverse si-
nuses, straight sinus, and bilateral internal cerebral veins. The patient was
started on unfractionated heparin. An attempt at recannulization of the right
cerebral sinus was unsuccessful. Infectious etiologies were excluded, and
additional testing for hereditary hypercoagulable states was negative. The
patient’s mental status gradually improved, with complete resolution of neu-
rologic and GI symptoms. He was discharged on mesalamine, oral steroids,
and 6-MP with plans for a six month course of oral anticoagulation with
coumadin.
Discussion: Cerebral sinus and venous thromboses are rare complications
of IBD, with a reported frequency of ∼ 0.1%. It has been suggested that
this complication is more frequent in UC compared with Crohn’s disease.
MRI/MRV is the most sensitive non-invasive diagnostic imaging technique,
but if the diagnosis is still uncertain, angiography should be considered. An-
ticoagulation with heparin followed by coumadin is a safe, effective therapy.
In a prospective study, 80% patients with cerebral sinus/vein thrombosis
treated with heparin made a complete recovery (ISCVT study). Optimal du-
ration of treatment is unknown, but usually given for six months after a first
episode. To our knowledge, thrombolysis has been limited to case reports
and uncontrolled studies.
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Primary Sclerosing Cholangitis in Association with Multiple Myeloma
Matthew Downey, MD, Christopher O’Brien, MD, Elizabeth Frauenhoffer,
MD, Nasrollah Ahmadpour, MD, Thomas Riley, MD, Ian Schreibman,
MD∗. Gastroenterology and Hepatology, Penn State Milton S. Hershey
Medical Center, Hershey, PA and Division of Hepatology, University of
Miami School of Medicine, Miami, PA.
Purpose: We report the second known case of multiple myeloma (MM)
associated with primary sclerosing cholangitis (PSC).
Methods: CASE REPORT
Results: A 57-year-old man presented with a 6 month history of jaundice
with total bilirubin of 6.3 mg/dL, associated with increased alkaline phos-
phatase to 800 unit/L. Workup included ERCP (Fig. 1) which confirmed PSC
and biopsy confirming cirrhosis. In the course of his pre-transplant evalua-
tion, he developed marked malnutrition with a decrease in serum albumin
from 3.6 to 2.0 g/dL and hypercalcemia. Lytic lesions were identified in
the humerus on routine X-rays. A monoclonal IgG -kappa restricted serum
immunofixation and significant kappa light chains in the urine (1790 mg/L)
were found. Figure 2 is a high power photomicrograph of H & E stained
marrow clot section from a biopsy of the humeral lesion, showing mar-
row replacement by plasma cells- some with binucleation. The inset shows
strong staining for kappa light chains, confirming that lesion is monoclonal
for kappa light chains- consistent with monoclonal plasma cell dyscrasia
(PCD). Given the confirmation of multiple myeloma and advanced cirrho-
sis, palliative care was initiated.
Conclusion: This case is the second report to suggest the possible association
of MM with PSC. PCD encompases a number of disorders with MM being
the most serious. PCD is often associated with other chronic liver diseases
such as chronic active hepatitis, autoimmune hepatitis, and primary biliary
cirrhosis. It is thought that chronic antigenic stimulation by the cirrhotic liver
selects B cell clones which may eventually become malignant. This case
highlights the possible connection between MM and PSC.[figure1][figure2]
500
Concomitant Hemobilia and Hepatic Abscess after Radiofrequency
Ablation
Cristina S. Marin, MD∗, Toyia N. James-Stevenson, MD, James R. Spivey,
MD. Internal Medicine, Emory University, Atlanta, GA and Digestive
Diseases, Emory University, Atlanta, GA.
Purpose: A 79 year-old male with coronary artery disease, hemophilia A,
hepatitis C cirrhosis and hepatocellular carcinoma (HCC) presented ten days
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status post radiofrequency ablation (RFA) with two days of recurrent he-
matemesis, melena, right upper quadrant pain and fever. The patient’s HCC
was previously deemed unresectable due to his comorbid conditions, and the
proximity of the 3.5 cm hepatoma to the bile ducts and the portal vein. On
exam, he was pallid with profuse hematemesis and tachycardia. His WBC
count was 27.1 10 e3/mcL (3.6–11.1) and hematocrit was 30.2% down from
39.9% two days prior. His factor 8 level and platelets were normal, with an
INR 1.29, PTT of 55.2s (25.0–39.0) and minimally elevated liver function
tests. EGD showed blood spewing from the ampulla signifying hemobilia.
Emergent angiography did not show active bleeding, but empiric emboliza-
tion was performed to an irregular branch arising from the left hepatic artery,
which coursed along the needle tract from the recent RFA therapy. A CT scan
showed an 8.4 × 4.8 cm heterogeneous area containing debris, hemorrhage
and air in the medial segment of the left hepatic lobe of the liver, consistent
with an early post-RFA abscess. The patient responded to antibiotics and
volume resuscitation, and was later discharged home. He has subsequently
tolerated a second RFA ablation.
Discussion: RFA is a safe and effective therapeutic option for unresectable
HCC with five year survival rates comparable to surgical resection. Compli-
cations occasionally arise from mechanical and thermal injury to vascular
structures, the biliary tree and adjacent organs. Examples include portal and
hepatic vein thromboses, subcapsular hematomas, and bile duct stenoses.
Hemobilia is a rare complication of RFA with a prevalence of 0.3%. Most
reported cases have favorable prognoses and do not require intervention. In
our case, mechanical injury to the hepatic vasculature during RFA catheter
placement was thought to be the etiology of the patient’s hemobilia, al-
though thermal damage may have also contributed. In addition, our patient
presented with concurrent symptoms and radiological findings consistent
with an early abscess in the post-RFA hepatic tissue. Thus, inflammatory
damage from the concomitant infection may have contributed to the hemo-
bilia. Our case illustrates the importance of early recognition and treatment
of the rare complications of RFA therapy including hemobilia and hepatic
abscess.
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Spontaneous Multiperforation in Lymphomatous Colitis
Masquerading as Crohn’s Disease: Two Cases
A. Mohammed, MD, R. Stein, MD, G. Zalzaleh, MD, J. Grela, MD, C.
Berkelhammer, MD∗. Gastroenterology – Internal Medicine, University of
Illinois, Oak Lawn, IL.
Purpose: Lymphomatous colitis is a rare disorder that can simulate inflam-
matory bowel disease. We describe 2 cases of lymphomatous colitis mimick-
ing Crohn’s disease that were complicated by spontaneous multiperforation.
Case 1: An 82 year old female with a history of chronic lymphocytic
leukemia presented with progressive diarrhea over 5 months, associated with
a 20 pound weight loss. Colonoscopy showed moderately severe pancolitis
with ileal inflammation. Biopsies were reported as inflammatory colitis. She
failed to respond to high dose corticosteroids. Within 4 weeks she required
emergent colectomy for spontaneous multiperforation of her colon. Pathol-
ogy revealed colonic and ileal MALT lymphoma. The colonic lymphoma
was distinct from her chronic lymphocytic leukemia, since the former was
negative to CD5 and did not have chromosomal trisomy 12, whereas the latter
was CD5 positive and positive for trisomy 12. This indicates that the patient
had 2 distinct lymphoproliferative diseases. In retrospect, immunoperoxidase
stains on the initial biopsies did reveal malignant monoclonal lymphocytes.
(See Table)
Case 2: A 49 year old female with a history of ulcerative colitis presented
with severe watery diarrhea and a 50 pound weight loss. Colonoscopy re-
vealed severe pancolitis with skip areas of normal colon. Biopsies were
reported as inflammatory colitis. She failed to respond to high dose cor-
ticosteroids, and refused surgery. Within a number of weeks, she required
emergent colectomy for spontaneous multiperforation of her colon. Pathol-
ogy revealed primary colonic non-hodgkins lymphoma (NHL). In retrospect,
immunoperoxidase stains on the initial biopsies did reveal malignant mon-
oclonal lymphocytes. (See Table)
Conclusion: Lymphomatous colitis can mimick Crohn’s colitis. Lymphoma-
tous colitis should be considered in patients with steroid-refractory inflam-
matory bowel disease. Earlier diagnosis with immunoperoxidase stains look-
ing for monoclonal proliferation of malignant lymphocytes, may prevent
progression of necrotizing lymphoma and spontaneous multiperforation.
Lymphomatous Colitis: 2 cases
Case 1 Case 2
Primary Colonic Lymphoma Disseminated Primary
Prior IBD No Yes
Mimicking Crohn’s Crohn’s
Steroid refractory Yes Yes
Perforation Yes × 3 Yes × 3
Classification of Lymphoma MALT NHL
Characteristics of the two cases of lymphomatous colitis.
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Efficacy Alendronate for Improving Bone Mineral Density in Celiac
Disease
David Widjaja, MD, Kalyan C. Kanneganti, MD, Sridhar S. Chilimuri,
MD∗. Gastroenterology, Bronx Lebanon Hospital Center, Bronx, NY.
Purpose: Currently there is no study or report regarding using bisphospho-
nate in young males with osteoporosis caused by celiac disease.
Case Report: A 32 year old South Asian man initially presented to a gas-
troenterologist after abnormal liver function tests and mild anemia were
detected on a routine office visit. Physical examination was normal. Initial
aminotransferases tests showed aspartate aminotransferase (AST) of 31 U/L
and alanine aminotransferase (ALT) of 56 U/L. Biopsy of the second part of
the duodenum showed villous atrophy with crypt elongation, replacement
of surface epithelial cells by cuboidal cells with loss of brush border and
increase in lymphocytes relative to the number of epithelial cells. Lamina
propria showed increased plasma cells, lymphocytes and polymorphs consis-
tent with celiac disease. Bone scan revealed osteoporosis involving lumbar
spine and osteopenia involving both hips. T and age matched Z scores for
lumbar spine were −2.8 and −2.4; right hip were −1.9 and −1.7; and left
hip were −2.1 and −1.9. Patient was started on a strict gluten free diet and
alendronate 10 mg per oral daily. Repeat biopsies of the duodenum showed
regeneration of villous height and regression of crypt hyperplasia and the
surface epithelium showed increased columnar cells with basal nuclei and
brush borders consistent with partial restoration and improvement in celiac
disease. Repeat bone scan 18 months later showed osteopenia with signifi-
cant improvement of bone mineral density. Post therapy T and age matched
Z scores for lumbar spine were −1.9 and −1.6; right hip were −2.0 and
−1.7; and left hip were −1.7 and −1.4. No significant symptoms related
to side effects of alendronate were reported during the 18 months treatment
period. Repeat aminotransferases tests revealed AST of 26 U/L and ALT of
42 U/L.
Conclusion: The significant increase of BMD in our patient after receiving
alendronate is the first case report of alendronate treatment in celiac disease.
Previous studies of alendronate therapy among men with secondary osteo-
porosis included only patients with long term corticosteroid treatment, low
serum testosterone, and malabsorption syndrome without specific diagnosis
of celiac disease. Study comparing gluten free diet therapy and gluten free
diet therapy with bisphosphonate, especially in non-postmenopausal women,
may reveal the efficacy of bisphosphonate in celiac disease.
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Unusual Cause of Chronic Diarrhea: Cronkhite-Canada Syndrome
Manmeet Padda, MD, Jenica Ryu, MD, Nahid Molaie, MD, Eric Olsen,
MD, Viktor Eysselein, MD, David Chung, MD, Binh V. Pham, MD∗.
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Gastroenterology, Harbor-UCLA Med Center, Torrance, CA; Family
Medicine, and Pathology.
Purpose: Cronkhite-Canada syndrome (CCS) is one of the rare non-familial
causes of multiple polyposis characterized by diffuse gastrointestinal poly-
posis, alopecia, onchodystropy, and hyperpigmentation. Herein, we describe
a case of CCS who presented with chronic diarrhea and weight loss.
Case Report: A 37 year old Filipino man with no PMH presented with a
5 month h/o post-prandial emesis, diarrhea, occasional hematochezia, and
weight loss of 45 lbs. He reported no fevers or other affected family mem-
bers. One week after the onset of his symptoms he noted darkening of palms
and soles, loss of scalp and facial hair, and softening of nails. The patient
appeared pale and cachectic. There were small hyperpigmented macules on
the palate, palms, and soles, hyperpigmentation of hands, feet and back,
dystrophy of the nails, alopecia of scalp and eyebrow, and pitting edema
of lower extremities. His abdomen had diffuse tenderness. Laboratory data
revealed leukocytosis, hypoalbuminemia, deficiency of vitamin A and D.
EGD revealed diffuse polypoid lesions starting from the cardia to the 3rd
portion of the duodenum. Similar lesions carpeted the entire colon (Fig.
1). SBFT revealed only involvement of the duodenum. Histology revealed
polypoid inflammatory mucosa with cystic dilatation of foveloae in the stom-
ach and of colon mucosal glands, confirming the diagnosis. The nutritional
support was given with TPN. The patient was started on oral prednisone,
histamine blocker, proton pump inhibitor, metronidazole, and subcutaneous
octreotide. Vitamins and minerals were supplemented. His condition grad-
ually improved and was sent home on TPN. Follow-up after one month
revealed toleration to oral feeds, normalization of bowel habit, improvement
of alopecia and onchodystropy.
Discussion: CCS is the rare cause of non-familial multiple polyposis. The
diagnosis is based on clinical, endoscopic and pathological findings. Even-
tually, most of the patients develop protein-losing enteropathy and malnu-
trition. The prognosis remains poor, with few patients surviving more than
few months after the diagnosis and 5-year mortality up to 55%.[figure1]
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Metastatic Cholangiocarcinoma Presenting as Left Shoulder Pain
Harshinie Amaratunge, MD, Thomas Tran, MD, Lee Lu, MD, Waqar A.
Qureshi, MD∗. Medicine, Baylor College of Medicine and VA Medical Ctr,
Houston, TX.
Purpose: Cholangiocarcinoma carries a poor prognosis in part due to late di-
agnosis of the condition. Early diagnosis by recognizing the initial symptoms
and risk factors is critical to a better outcome.
Methods: A 52 year-old woman with hepatitis C, tobacco use, and symp-
tomatic cholelithiasis was admitted for elective cholecystectomy. She also
complained of 2 months of severe left shoulder pain and denied any weight
loss. Physical exam revealed RUQ tenderness and severe left scapular pain.
Laboratory results were remarkable for alkaline phosphatase of 449 U/L,
AST 86 U/L, and ALT 206 U/L. Left shoulder X-ray revealed a lytic lesion
in the scapula. MRI showed a 4.5 × 3.8 × 5.0 cm mass in the left scapula.
A CT guided needle aspiration biopsy revealed adenocarcinoma. Abdo CT
showed multiple masses in the liver. An upper endoscopy, colonoscopy, and
CT of the chest were normal. At exploratory laparotomy, a tumor encasing
the perihilar area and portion of the liver was identified. Biopsy revealed
cholangiocarcinoma. Patient opted for hospice care.
Results: Cholangiocarcinoma accounts for 10–15% of hepatobiliary neo-
plasms. This condition should be included in the differential diagnosis of
chronic RUQ pain in patients with risk factors such as primary scleros-
ing cholangitis, choledochal cyst, chronic intraductal stones, and congenital
anomalies of the bile ducts. However, recent findings have suggested addi-
tional risk factors like HCV, HIV, cirrhosis, diabetes and smoking. Our patient
had 2 risk factors: HCV, and smoking history. Cholangiocarcinoma usually
metastasizes to the lungs, adrenal glands, brain, lymphatic system, and the
axial skeleton. Metastasis to appendicular skeleton is rare with 2 cases re-
ported. Traditionally, ERCP is used to assist the diagnosis, but non-invasive
techniques like magnetic resonance cholangiopancreatography (MRCP) are
now preferred. A recent study comparing ERCP and MRCP found that both
were equally effective in diagnosing biliary obstruction. Due to its late pre-
sentation, cholangiocarcinomas have an extremely poor prognosis, with an
average five-year survival rate of 5–10%. Surgical resection is the only cu-
rative treatment and is possible in early extrahepatic cholangiocarcinoma.
Otherwise, chemotherapy with gemcitabine and cisplatin provides a modest
response. Biliary stents are useful for palliation of biliary obstruction.
Conclusion: Cholangiocarcinoma should be considered in patients with
chronic RUQ pain who in addition have risk factors noted above.
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A Case of Vibrio Vulnificus Septicemia in a Patient with Alcoholic
Liver Disease
Mark J. Marino, MD∗, David Matherne, DO, Arthur E. Richert, MD.
Gastroenterology, LSU Health Sciences Center, New Orleans, LA.
Purpose: A 57 year old male commercial fisherman presented to Leonard
J Chabert Medical Center in Houma, Lousiana in the early afternoon com-
plaining of back pain, arm pain and shortness of breath after falling off a
fishing pier into (brackish) water earlier that day and suffering lacerations
to both of his forearms. He also stated that he swallowed a small amount
of water. This patient had no known previous medical history but did not
regularly visit a physician. Through his family it was obtained that he had
an extensive history of alcohol consumption but had never been diagnosed
with advanced liver disease.
Physical exam upon presentation was significant for normal vital signs, spi-
der angiomata on chest wall, and erythematous areas on both forearms con-
sistent with cellulitis. His labs were significant for AST 74, ALT 27, Total
Bilirubin 3.3, and INR of 1.4 and a WBC count of 7300. His platelet count
was 55,000. Cardiac enzymes were negative. He was placed on broad spec-
trum antiobiotics including doxycycline. Within 6 hours blood cultures were
positive for Vibrio vulnificus. In the first 12 hours after admit patient suf-
fered cardiopulmonary arrest but was successfully resuscitated via ACLS
protocol. At the time of this abstract submission, the patient is stiill alive
but critically ill in the ICU approximately one month after admission. His
hospital course has included multi -organ failure including ARDS, renal fail-
ure requiring dialysis, and ischemic hepatitis. He did not develop fulminant
hepatic failure. He did develop ascites and encephalopathy which have been
controlled. His wounds have been extensively debrided and he has undergone
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amputation of several of his digits. Vibrio vulnificus septicemia is a severe
illness often associated in patients with advanced liver disease of any kind
most often with alcoholic liver disease. Patients are infected through open
wounds in estuarine water and consumption and handling of shellfish. The
mortality in patients with advanced liver disease is greater than 50%. It must
be considered in any patients with known or suspected liver disease, diabetes,
or otherwise compromised immune systems.
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MALT Lymphoma of the Duodenum: A Rare Cause for Upper
Gastrointestinal Bleeding and Pancreatitis
Michael Selden, MD∗, Patricia Sanchez, MD, Esmat Sadeddin, MD, Sandra
Laya, MD, Wendell Clarkston, MD. Gastroenterology Department, Saint
Luke’s Hospital/University of Missouri, Kansas City, Kansas City, MO.
Purpose: Mucosa associated lymphoid tissue lymphoma of the duodenum
represents a rare neoplasm. A review by Xiang et al[i] in 2004 highlighted
only 17 previous cases of duodenal MALT lymphoma in the English lit-
erature. We report another rare case of duodenal MALT lymphoma. A 56
y.o. female presented with upper GI bleeding and acute pancreatitis. Upper
endoscopy demonstrated an irregular ulceration in the second portion of the
duodenum (Fig. 1). Endoscopic biopsies revealed acute and chronic inflam-
mation. An abdominal CT scan demonstrated significant circumferential
mural thickening involving the second portion of the duodenum and evi-
dence of pancreatitis. Despite unremarkable endoscopic biopsies, the irreg-
ular appearance of the ulcer and CT findings raised suspicion of underlying
malignancy. The surgical service performed an exploratory laparatomy. A
nodular mass in the second portion of the duodenum extending into the pan-
creas was noted. Biopsy of the mass revealed a low grade MALT lymphoma.
The patient recovered from her episode of pancreatitis and started radiation
therapy. Patel et al.[ii] have previously reported a patient with duodenal
MALT lymphoma with pancreatic infiltration. However, this is the first re-
port of pancreatitis from the extension of a duodenal MALT lymphoma. This
case hopes to expand the current knowledge of the possible presentations
of this rare entity. [i] Xiang Z, Onoda N, Ohira M et al. Mucosa-associated
lymphoid tissue lymphoma of the duodenum: a report of a case resistant
to Helicobacter pylori eradication. Hepatogastroenterology 2004; 51(57):
732–5. [ii] Patel VG, Eltayeb OM, Henderson VJ et al. Primary duodenal
low-grade mucosa-associated lymphoid tissue lymphoma presenting with
outlet obstruction. American Surgery. 2004; 70(7): 613–6.[figure1]
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Gastric Adenocarcinoma in MEN-1
Jessica L. Widmer, DO, Jay P. Babich, MD, Biju Abraham, DO, Phillip
Cassar, MD, Kavita R. Kongara, MD, James H. Grendell, MD∗.
Gastroenterology, Winthrop University Hospital, Mineola, NY.
Purpose: Multiple Endocrine Neoplasm Type 1 (MEN 1) is a familial syn-
drome in which tumors develop in the parathyroid, pancreatic, and pituitary
gland. The frequency of MEN 1 is about 1/30,000. Gastrinomas are the most
common, symptomatic pancreatic endocrine tumor in MEN I, with ZE Syn-
drome and esophageal strictures being known complications.1 A 63-year-old
male was admitted with a one month complaint of dysphagia to solids and
liquids; as well as nausea, vomiting, and a 17 lb. weight loss. He has a known
history of ZES with metastatic gastrinoma, parathyroidectomy, and a diag-
nosis of MEN-1. Prior to admission he had a gastrin level of 13,382 pg/mL
and a CT of the abdomen that demonstrated ascites, soft tissue infiltration
involving the omentum and the mesentery consistent with carcinomatosis.
Admission exam revealed tenderness in the lower quadrants of the abdomen.
Laboratory data were normal. EGD revealed an esophageal stricture that was
subsequently dilated and a large nodular gastric mass that was contiguous
with the g-e junction (Fig. 1). In addition to gastritis biopsies showed inva-
sive poorly differentiated gastric adenocarcinoma with signet ring features
and areas of gastric type epithelium with nodular proliferation of cells sug-
gestive of neuroendocrine tumor. The patient tolerated his dilatation without
complication and was discharged home.
There is no documented association between MEN 1 and gastric adenocarci-
noma. Hoffman et al. hypothesized that patients with MEN-1 with gastrino-
mas have an increased risk of severe esophageal disease including strictures
and Barrett’s.1 Their findings suggest that prolonged inadequately controlled
acid secretion increases the risk of developing advanced esophageal disease
and the possibility of esophageal adenocarcinoma. We hypothesize that when
gastric mucosa is exposed to uncontrolled acid hypersecretion, caused by in-
creased gastrin levels, gastric adenocarcinoma could develop.
REFRERENCE 1. Hoffman, K, et al. Patients with MEN I with gastrino-
mas have an increased risk of severe esophageal disease including stricture
and the premalignant condition, Barrett’s Esophagus. The Journal of Clin
Endocrinology & Metabolism. 2006; 91 (1): 204–212.[figure1]
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Pyogenic Liver Abscess Secondary to Staphylococcus aureus Infection
without Primary Source of Infection
Lokesh K. Jha, MD, Rahaman Mujibur, MD, Samer Alshaeba, MD∗.
Internal Medicine, St. Barnabas Hospital, Bronx, NY.
Purpose: A 46 year old African-American male, migrated from Africa, pre-
sented with chief complaint of productive cough for 2 months associated
with pleuritic chest pain, fever for 3 days, night sweats, mild shortness of
breath and loss of appetite. The patient denied hemoptysis, weight loss, re-
cent travel. Past medical history was significant only for GERD. He reported
a history of Penicillin allergy. He is a smoker, but denied alcohol or drug use.
His vital signs were Temp of 103 F, Pulse 130/min, Respiratory rate 28/min,
Blood pressure of 140/75 mmHg and oxygen saturation was 98% on room
air. Lab values were significant for WBC of 11.7, Hemoglobin/hematocrit
of 14.4 gm/dl/41%, Platelet count of 319. Blood cultures done on admis-
sion were negative. Liver function tests were elevated and chemistry was
normal. He was admitted with the impression of Pneumonia and started on
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intravenous Levofloxacin. Official Chest x-ray report revealed no active pul-
monary disease. Hepatitis B and C serology was negative except for reactive
Anti-Hepatitis B core antibody. Repeat CBC showed a slight decrease in
the WBC count but the LFTS remained elevated. Infectious Disease was
consulted. HIV testing was negative. CT of chest with contrast showed a
7 cm mass in the right lobe of the liver. Triple phase Liver Scan was done
which showed a 7–8 cm fluid filled abscess and a Gastroenterology eval-
uation was requested. Serology testing for Echinococcus granulosa and E.
histolytica were negative. Radiological guided drainage of the liver abscess
showed a purulent material with cell count as follows: WBC 285000, RBC
57500, Neutrophils 27%, Lymphs 65%. Culture grew methicillin resistant
Staphylococcus aureus. The patient was treated with Vancomycin and the
WBC and LFTs started to decrease. Whole body Gallium Scan was neg-
ative and Echocardiography didn’t show any vegetations. The patient was
discharged home on oral Clindamycin. The patient was seen in clinic for
follow up and reported complete improvement in symptoms and repeat CT
scan showed resolution of the Liver abscess. The most striking point in this
case is there was no primary source of infection from Staphylococcus aureus
found.[figure1]
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Dieulafoy’s Lesion of Esophagus Managed with Injection Therapy
Lokesh K. Jha, MD, Fredrick Fallick, MD∗. Department of
Gastroenterology, St. Barnabas Hospital, Bronx, NY.
Purpose: We report the case of a 25-year-old male from Gambia, West
Africa who presented complaining of vomiting bright red blood for 3 days.
He had been seen in emergency department of a different hospital 3 days
prior and sent home, as the vomiting had resolved. He subsequently had 1
episode hematemesis so he came to our ED for further evaluation. He re-
ported passing black stool on one occasion. He denied abdominal pain, fever,
dizziness, and shortness of breath. He denied smoking, alcohol use, or use of
any drugs, except that he had taken a total of 4 Advil tablets prior to seeing
melena. On examination, he was afebrile, slightly tachycardic with a pulse
of108; BP was 142/85 with no orthostasis. The abdominal exam revealed a
soft, non-tender abdomen with normoactive bowel sounds. Stool guiac was
positive. Laboratory values were as follows: hemaglobin and hematocrit
(H&H) 5.7 g/dl/16.3%; INR 1.3; BMP values were within normal limits.
Chest x-ray and plain abdominal film revealed no significant findings. EKG
demonstrated sinus tachycardia at 105 bpm, but was otherwise unremark-
able. GI consultation was requested, and 4 units of PRBC transfusion were
recommended to keep hemoglobin above 9. Subsequently, the patient was
taken for upper endoscopy. Upper endoscopy revealed an actively bleeding
Dieulafoy’s lesion in the mid esophagus, along with a hiatal hernia, which
was controlled with sclerotherapy using epinephrine and cautery with BI-
CAP. The patient was monitored in the ICU, the blood counts stabilized, and
there were no further episodes of hematemesis or melena. The patient was
subsequently discharged home on a proton pump inhibitor. Discharge H&H
were 7.6 g/dl and 21%. Three days later, he returned to the ED complaining
of constipation. On this admission, guiac was positive and the H&H were
was 7.1 g/d and 21.0%. GI consultation was again requested, and the patient
was taken for repeat upper endoscopy which demonstrated both cauterized
lesions in the esophagus to be well-healed with a clean, white base and no
evidence of recurrent bleeding. The H&H remained stable, and the patient
was discharged home on iron tablets and followed in the GI clinic with no
episodes of recurrent bleeding.[figure1]
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Diarrhea: A Presenting Symtpom of HCC
Paul S. Panzarella, MD, Jay P. Babich, MD, Robert Bonasera, MD, Kavita
R. Kongara, MD, James H. Grendell, MD∗. Gastroenterology, Winthrop
University Hospital, Mineola, NY.
Purpose: Hepatocellular carcinoma (HCC) is a primary malignancy of the
liver; most cases are secondary to hepatitis or cirrhosis. The presenting
symptoms of HCC include abdominal pain, jaundice, and bone pain.
We report a case of HCC diagnosed in a patient with a one-month complaint
of watery diarrhea.
A 43-year-old female presented to our institution with one month of abdom-
inal pain, nausea, vomiting and early satiety. Patient had been working as a
missionary in Portugal 8 months prior to presentation; about 1 week after her
arrival, she began to have watery diarrhea (5–6 episodes/day) for which she
states she received “pills.” CT abdomen and pelvis followed by a liver biopsy
were performed while the patient was in Portugal. She was given a diagnosis
of cancer after a mass was seen on CT and liver biopsy exhibited evidence
of malignancy. The patient relocated to the USA. Upon arrival she described
her pain as crampy, radiating to the right flank associated with nausea and
bilious vomiting. She reported as well to have had an unintentional weight
loss of 50 lbs in the last 8 months with loss of appetite.
Pertinent physical exam findings were a palpable liver 7 cm below the costal
margin and diffusely across the entire abdomen.
Laboratory data is shown below in Table 1. A liver biopsy revealed prolifera-
tion of neoplastic cells resembling hepatocytes, arranged in large trabeculae
and nests, giving the impression of a well-differentiated liver carcinoma.
The patient was admitted and based on the extent of the lesions, had bland
particle embolization of the left lobe of the liver with improvement in her
abdominal pain, and was subsequently able to be discharged tolerating oral
feeds.
The literature citing diarrhea as a presenting symptom of HCC is scarce.
In the approach to the patient with a liver mass and diarrhea the clinician
should consider HCC in addition to carcinoid and other neuroendocrine
tumors.
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Laboratory Values
Total Bilirubin 2.0 mg/ul
Direct Bilirubin 1.5 mg/ul
AST 448 U/l
ALT 185 U/l
ALKP 185 U/l
GGTP 868 U/l
Tot Protein 7.6 g/dl
Albumin 3 g/dl
CEA 1 ng/ml
Hepatitis Profile non-reactive
ANA 40
AMA 20
ASMA 20
Ferritin 103 ng/ml
Alpha-1-anti-trypsin 152
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A Case of Multiple Gastrointestinal Stromal Tumors of the Small
Bowel in a Patient with Neurofibromatosis Type 1
Cindy Huang, MD, Jesse Green, MD∗, Kevin Mercure, MD, David
Kuehler, MD, David Jones, MD. Gastroenterology, Albany Medical
College, Albany, NY; Surgery, Albany Medical College, Albany, NY and
Pathology, Albany Medical College, Albany, NY.
Purpose: Gastrointestinal stromal tumors are rare tumors of the gastroin-
testinal tract that arise from primary mesenchymal cells. However, in patients
with type 1 neurofibromatosis (NF-1), GISTs have been reported to occur
with increased tendency. NF-1 is a neurocutaneous disorder that involves
neuroectodermal and mesenchymal derivatives, and it is associated with
GISTs of the small bowel. Clinical behaviors of GIST include abdominal
pain, intestinal obstruction, and acute or occult gastrointestinal bleeding.
We herein report a case of a patient with NF-1 with acute gastrointestinal
bleeding from multiple GISTs of the small bowel.
Case Report: A 57 year-old male with known NF-1 presented with melena
and anemia. His past medical history was significant for gastric angiectasias.
On presentation, he had evidence of neurofibromas on his face and upper
extremities. He denied any abdominal pain. Laboratory analysis showed
severe anemia with a hemoglobin of 9 g/dl. An upper endoscopy revealed
a non-bleeding mass in the second to third portion of the duodenum. A
subsequent colonoscopy and capsule endoscopy were unremarkable. Biopsy
of the duodenal mass demonstrated a spindle-cell neoplasm with positive c-
kit protein, suggestive of a GIST. Computed tomography revealed multiple
masses as large as 3 × 4 cm in the small bowel. Exploratory laparatomy found
multiple duodenal and jejunal tumors with biopsies that were consistent
with GIST of low risk (<2/50 HPF mitotic index). The patient received a
prepyloric-preserving Whipple resection. The rest of his hospital course was
uneventful. His H/H stabilized, and he was discharged.
Conclusion: GISTs of the small bowel are very rare and may present with
massive bleeding. Particularly in patients with type 1 neurofibromatosis with
gastrointestinal bleeding, it should be considered as part of the differential.
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Domperidone for the Treatment of Severe Hyperemesis Gravidarum
Sumona Saha, MD, Rosanna Moura, MD∗. Division of Women’s Digestive
Disorders, Women & Infants’ Hospital, Providence, RI.
Purpose: Hyperemesis gravidarum (HG) is a condition of severe nausea and
vomiting during pregnancy leading to dehydration, nutritional deficiency,
and increased fetal morbidity and mortality. We describe a case of a preg-
nant woman with twin gestation and intractable HG leading to desire to
terminate the pregnancy who was successfully treated with domperidone.
Case: A 33 year-old female, gravida 2, para 1 with twin gestation presented
with severe HG. Intractable nausea and vomiting began at 5 weeks gestation.
Work-up for other causes of nausea and vomiting in pregnancy was nega-
tive. Treatment with standard oral therapy, IV hydration and IV ondansetron
was ineffective. IV metoclopramide was helpful; however, the patient de-
veloped jaw clenching leading to its discontinuation. At 12 weeks gestation
she presented with severe recurrent symptoms, suicidal ideation and desire
to terminate the pregnancy. Domperidone was offered as a therapy of last
resort. The patient was informed of the drug’s risks and benefits, lack of
FDA approval, and limited safety data in pregnancy. After obtaining the
patient and obstetrician’s consent, oral domperidone 10 mg every 8 hours
was started. The patient did well and had no extrapyramidal symptoms. She
was discharged on oral ondansetron and domperidone for hyperemesis and
as needed lorazepam for anxiety. She resumed a regular diet and gained
weight. At 34 weeks gestation she delivered healthy male infants.
Discussion: The goals of treating HG are to maintain fluid and electrolyte
balance, maintain caloric intake and control nausea and vomiting. Anti-
emetics with IV hydration ± parenteral nutrition may be required. Phenoth-
iazines and anti-histamines are first-line therapy. Metoclopramide is also
used; however, its use is limited by central nervous system toxicity. In refrac-
tory cases, ondansetron has been used. Domperidone is a gastroprokinetic
and anti-emetic. In the US, it is not approved by the FDA due to case studies
of arrhythmias, cardiac arrest, and sudden death with IV use. However, oral
domperidone can be obtained from abroad and from compounding phar-
macies. Our report illustrates the use of domperidone for intractable HG to
avoid termination of pregnancy. In women with severe symptoms who are
refractory or intolerant to standard therapy, oral domperidone may allow the
continuation of pregnancy. We present this case to inform physicians of the
potential use of domperidone for severe HG with the understanding that it
is not FDA approved and not widely available in the US.
513
An Unusual Path to the Diagnosis of Crohn’s Disease; from Gastric
Outlet Obstruction to Fat Wrapping of the Terminal Ileum
Michael J. Viksjo, MD, Grace Noh, MD, Clara Yook, MD, Judy Lin, MD∗.
Gastroenterology, UMDNJ New Jersey Medical School, Newark, NJ;
Pathology, VA Medical Center, East Orange, NJ and Gastroenterology, VA
Medical Center, East Orange, NJ.
Purpose: Crohn’s Disease (CD) affects all portions of the GI tract. In familiar
presentations, the diagnosis can be challenged by non-diagnostic histology
and overlapping features. Thus, when CD presents atypically, a multifaceted
approach, with surgeons, radiologists, pathologists, and gastroenterologists
is needed to verify the diagnosis and initiate proper therapy. We report a rare
presentation of CD, with suggestive endoscopic, radiologic, and histologic
findings that, required a virtually pathognomonic laparoscopic feature to
verify the diagnosis.
Case: A 22 yo man with previous dyspepsia came to the GI clinic after 3
months of vomiting, early satiety, and a 25 lb weight loss. He had no diarrhea,
hematochezia, or recent NSAID use. Physical examination was normal, with
no evidence of malnutrition. He was PPD negative. EGD revealed gastric
outlet obstruction with a large quantity of retained food. EGD after a liquid
diet revealed pre-pyloric nodules and erosions with ulceration of the anterior
wall of the duodenal bulb resulting in edema and stenosis. On histology, there
was chronic inflammation, a granuloma and rare H. pylori. Following treat-
ment for H. pylori, a subsequent UGI series with small bowel follow through
revealed slow barium transit through the pylorus and wall thickening of both
the duodenal bulb and terminal ileum (TI). Colonoscopy with TI intubation
uncovered a cobblestone appearance to the mucosa of the TI (severe inflam-
mation and mucosal fibrosis on histology). A third EGD showed unhealed
ulcers and continued gastric outlet obstruction. With persistent vomiting,
weight loss, dehydration, and an inability to tolerate oral medications, the
patient had a gastrojejunostomy. During surgical exploration, fat wrapping
of the terminal ileum was noted. Post-operatively, the patient has regained
weight, has no difficulty eating and is otherwise well on oral mesalamine.
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Conclusion: CD presenting with UGI symptoms is rare, especially as a
gastric outlet obstruction. Histological evidence of UGI CD can be common,
reportedly occurring in 60–70% of patients. Endoscopic evidence, however,
is far less common, occurring in 0.5% to 4% of CD patients. This is an
unusual presentation of CD that required a multidisciplinary approach to
eventually confirm the diagnosis and initiate treatment.
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Hemorrhagic Mantle Cell Lymphoma Diagnosed with Colonoscopic
Cold Biopsy
Jigneshkumar Patel, MBBS, Subbarmiah Sridhar, MBBS, Sherman M.
Chamberlain, MD∗. Medicine, Medical College of Georgia, Augusta, GA
and Section of Gastroenterology, Medical College of Georgia, Augusta,
GA.
Purpose: A 62 year old male admitted with constipation, weight loss and
rectal bleeding, had a colonoscopy showing active bleeding at the colonic
splenic flexure from an extrinsic mass (Fig. 1). With the splenic flexure
mass already bleeding, a single cold biopsy was done at the site. Despite the
cold biopsy being done, his bleeding stopped spontaneously. CT scan of the
abdomen showed thickened colon in the splenic flexure with infiltration of
a large 3 cm mesenteric soft tissue component representing either a primary
carcinoma or a metastatic tumor (Fig. 2).
Methods: Histopathology of the biopsied tissue revealed diffuse infiltrates
of atypical lymphoid cells consistent with a B-cell lymphoma. Bone marrow
biopsy failed to yield further diagnostic information. The original colono-
scopic biopsy was then further evaluated and the patient was diagnosed with
a mantle cell lymphoma. The patient’s mantle cell lymphoma progressed
rapidly despite treatment, and he died within two weeks of his initial presen-
tation.
Results: Mantle cell lymphoma represents only 6% of malignant non-
Hodgkins lymphomas, and involves the colon in 15–30% of patients. The
cold biopsy of the hemorrhagic colonic lesion proved to be critical in di-
agnosing this patient with mantle cell lymphoma. This case highlights the
indication to perform a cold biopsy on a lesion that is already bleeding. Gas-
trointestinal (GI) hemorrhage risk after cold biopsy is extremely low (0.03–
0.14% in prior studies), with no prior study having evaluated the safety of
cold biopsy of an already bleeding GI lesion.
Conclusion: This is only the third case in the literature of a mantle cell lym-
phoma presenting with GI hemorrhage. This case illustrates the diagnostic
information gained from a cold biopsy of an actively bleeding GI lesion
without additional morbidity observed.[figure1][figure2]
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An Unusual Case of Hematochezia in a Healthy 28 Year Old Female
Steven R. Fox, MD, Michael C. Duffy, MD∗. Gastroenterology, William
Beaumont Hospital, Royal Oak, MI.
Purpose: A 28-year-old previously healthy female complained of constipa-
tion for several months and intermittent hematochezia for one week, noting
bright red blood coating her stools. She also noted lower abdominal pain
relieved with a bowel movement. She had no fever, chills, weight loss or
relationship of symptoms to menstrual periods. Physical exam including a
pelvic examination by a gynecologist was normal. The stool was hemoccult
positive. Her CBC was normal. A CT Scan of the abdomen and pelvis was
normal. Colonoscopy showed a firm, multi lobulated 4 × 5 cm broad-based
mass 10 cm from the dentate line that occupied approximately 1/3 of the
circumference of the lumen. Biopsies of the mass showed colonic mucosa
with changes of mucosal prolapse with foci beneath the muscularis mucosa
containing spindle-shaped cells and in one section a small endometrial-
type gland indicative of endometriosis. Immunoperoxidase staining showed
CD10 positive and C-KIT negative cells consistent with endometriosis. The
patient has been referred to a gynecologist specializing in management of
endometriosis and is scheduled for laser ablation and/or excision.
Conclusion: It is estimated that 4–17% of all menstruating women have en-
dometriosis, with 3–34% of these cases involving the gastrointestinal tract.
The rectum and rectosigmoid junction account for 70–93% of all intesti-
nal endometriosis. Colonic mucosal implants are unusual and the disease
is rarely diagnosed by endoscopic biopsy. Although most gastrointestinal
endometriosis is asymptomatic, symptoms may include abdominal pain,
dyschezia, tenesmus, vomiting, diarrhea, constipation, melena or hema-
tochezia. Symptoms do not always correlate with the menstrual cycle. En-
dometriosis is thought to result from retrograde menstruation leading to
implantation on the peritoneum, pelvic viscera, small bowel or colon with
occasional invasion through the submucosa. Gastrointestinal endometrio-
sis may be difficult to diagnose, especially if there is absence of mucosal
involvement. The differential diagnosis includes infection, ischemia, malig-
nancy and IBD. Treatment may involve hormonal manipulation or segmental
resection, particularly with obstructing lesions. We present a case of gas-
trointestinal endometriosis presenting with constipation and hematochezia
in a 28-year-old female diagnosed by colonoscopy and mucosal biopsy. Gas-
troenterologists should be aware of mucosal endometrial implants as a po-
tential cause of rectal bleeding in young women.
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Botulinum Toxin Injection for the Treatment of Gastric Stasis in
Patients with Prior Gastric Surgery
Steven R. Fox, MD, Laith H. Jamil, MD, Tusar K. Desai, MD∗.
Gastroenterology, William Beaumont Hospital, Royal Oak, MI.
Purpose: We report three cases in which Botox injection just distal to the
gastro-enteric anastomosis led to clinical improvement and objective radi-
ologic evidence of improved gastric emptying in patients suffering from
nausea and vomiting after gastric surgery.
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Case 1: A 48-year-old male presented with 3-months of nausea and vomiting.
Upper endoscopy demonstrated pyloric stenosis that could not be traversed.
The patient failed medical therapy and required a pyloroplasty with truncal
vagotomy. Post operatively the patient continued to have nausea and vom-
iting, despite parenteral metoclopramide and avoidance of narcotics. UGI
x-ray showed delayed gastric emptying and marked distention. Botox was
injected at the surgical site. Repeat UGI x-ray showed improvement in gastric
distention and emptying. Fourteen weeks after Botox injection the patient
was symptom free.
Case 2: A 46-year-old female with a history of nausea, vomiting and pyloric
stenosis underwent a pyloroplasty and vagotomy. After her surgery she had
persistent symptoms. During EGD, Botox was injected at the surgical site
which led to improvement in symptoms and the gastric emptying study (Table
1).
Case 3: A 63-year-old female presented with complaints of daily nausea and
vomiting after vagotomy and Roux-en-Y gastrojejunostomy in 1994. The
patient had failed medical therapy. Initial EGD demonstrated a phytobezoar,
with a normal anastomosis. Botox was injected at the surgical site. She has
reported vomiting less than 3 times a month since the Botox treatment. This
has remained constant for the 24 weeks since her therapy. The patient had
gastric emptying studies 14 months before, 2 weeks, and 22 weeks after
Botox therapy (Table 2).
Conclusion: Botox injection just distal to the gastro-enteric anastomosis
improves symptoms of nausea, vomiting and objective parameters of gastric
emptying. Further prospective studies should be considered.
Gastric emptying study after Botox injection
Gastric % retained prior % retained 1 week % retained 8 weeks
emptying to Botox injection after Botox injection after Botox injection
Hour 1 105% 96% 99%
Hour 2 89% 89% 88%
Hour 4 86% 84% 65%
Egg substitute labeled with Technetium-99 m sulfter
Gastric emptying study after Botox injection
Gastric % retained prior % retained 2 week % retained 22 weeks
emptying to Botox injection after Botox injection after Botox injection
Hour 1 100% 38% 41%
Hour 2 101% 30% 30%
Hour 4 97% 18% 2%
Egg substitute labeled with Technetium-99 m sulfer
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Narrow-Band Imaging in the Identification of Sessile Serrated
Adenomas
Manuel Y. Lam, BA, Edward Feller, MD, Baishali Bhattacharya, MD,
Samir A. Shah, MD∗. Department of Medicine, Warren Alpert Medical
School of Brown University, Providence, RI.
Purpose: The narrow-band imaging (NBI) system complements conven-
tional colonoscopy in detecting clinically relevant polyps. Sessile serrated
adenomas (SSA) are important, often subtle, pre-cancerous polypoid lesions.
To demonstrate the clinical utility of NBI, we describe two SSAs identified
by this technology during colonoscopy.
Case: A 53-year-old man had a screening colonoscopy in 2003, revealing
several polyps and an elevated adenomatous area at 50 cm. The latter was not
removed completely. Follow-up colonoscopy in 2005 showed sessile polyps
at 50 cm; one was marked with India ink. Biopsies showed several hyperplas-
tic polyps and one tubular adenoma. In 2007, the patient was referred to a
new gastroenterologist (SAS) overdue for repeat colonoscopy. Past medical
and family history were unremarkable, except that his father had “polyps”
in his fifties. Physical exam was benign. Conventional colonoscopy showed
multiple small and large polyps. The small polyps were removed with snare
electrocautery. Two erythematous folds were visualized by the standard op-
tical filter at 65 and 57 cm. The NBI system revealed extensive gyrus-like
sessile segments of irregular-appearing mucosa. Both lesions were removed
by the saline methylene blue elevation technique. Histopathology of both
specimens revealed SSAs with focal inverted growth patterns. If the NBI
system had not been used, the endoscopist would have chosen to biopsy
the lesions, which may or may not have provided enough tissue to identify
SSAs on histopathology. Follow-up colonoscopy 3 months later revealed no
abnormalities.
Discussion: Sessile serrated adenomas superficially resemble left-sided hy-
perplastic polyps but differ by displaying (1) a higher proliferation index, (2)
dilated crypt architecture, (3) serrations extending to the base of crypts and
(4) an usually right-sided location. These polyps have been termed “adeno-
mas”, even though they lack conventional cytologic dysplasia and differ from
traditional serrated adenomas. They are newly recognized and believed to be
precursors of sporadic colorectal cancers with mismatch repair defects. This
case illustrates the potential of the NBI technology to increase the yield of
significant polyps, including the subtle SSAs—making colonoscopy a more
effective tool in colorectal cancer prevention.
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Achalasia Cardia in an Adult with Acute Renal Failure, Lung Abscess
and Spontaneous Pneumomediastinum, a Rare Combination
Ashok K. Sharma, MD, Lokesh K. Jha, MD, Shraddha Pandey, MD, Carl
Guillaume, MD∗, Christopher Taurani, MD. Gastroenterology, St.
Barnabas Hospital, Bronx, NY.
Purpose: A 24 year old African American male with no significant past
medical history, presented with generalized weakness, cough with brownish
sputum, weight loss of 10 lbs over a period of 2–3 weeks. He complained of
nausea and 3–4 episodes of nonbloody vomiting since 1 week. The patient
denied fever, chills, night sweat, chest pain, shortness of breath or palpita-
tions. On examination, Vitals were stable, he was thin and cachectic. Chest
was clear and pericardial friction rub was heard. Laboratory exam showed
WBC 37.5, Hb/Hct 14.7/43.9, Platelets 598, neutrophils 92%. Chemistry:
Na+ 126, K+ 3.9, Cl- 67, HCO3 22, BUN 225, Creatinine 15.6. Chest
X-Ray revealed a big cavity with air fluid level compatible with abscess in
right lung. He was started on vancomycin and Zosyn for lung abscess and
received hemodialysis for uremic pericarditis. BUN and Creatinine came
down to 151/8.6 next day. CT Scan of chest revealed pneumomdiastinum,
markedly dilated esophagus with air and fluid and a large abscess in right
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lung. Gastrograffin esophagogram revealed markedly dilated esophagus with
smooth tapering distally and no evidence of contrast extravasations. Upper
GI Endoscopy revealed hugely dilated esophagus filled with 1.5 liters of
fluid, highly suspicious for vigorous achalasia. Esophageal biopsy ruled out
any evidence of malignant infiltration and Pseudoachalasia. Bronchoscopy
performed which ruled out any tracheoesophageal fistula and perforation.
He improved gradually with the resolution of the renal failure. He was dis-
charged on Clindamycin with manometry to be scheduled as out patient. He
was much better at follow up in 1 week with significant weight gain awaiting
manometry till we write this case.[figure1][figure2]
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Rectus Sheath Hematoma Following Large Volume Paracentesis
Muhammad M. Amin, MD, Osama A. Yousef, MD, Patricia A. Sanchez,
MD, Wendell K. Clarkston, MD∗. Gastroenterology, University of
Missouri Kansas City, Kansas City, MO.
Introduction: Large volume paracentesis is an accepted method of manag-
ing refractory ascites in patients with cirrhosis. We report the case of a major
hemorrhagic complication of large volume paracentesis with formation of
large rectus sheath hematoma.
Case: 57-year-old Caucasian Male with cirrhosis due to Hepatitis C pre-
sented for large volume paracentesis for refractory ascites. His INR was 2.3
and hemoglobin was 12 g/dl. Abdominal ultrasound to mark the site for para-
centesis revealed large ascites in the left lower quadrant. Approximately 8.5
L of straw-colored ascitic fluid were removed from the marked site. Soon
after the procedure, the patient started bleeding from the puncture site to
which pressure and a suture were applied. The patient also complained of
severe abdominal pain and became hypotensive. He was therefore resusci-
tated with intravenous fluids and blood products as repeat hemoglobin was
7.9 g/dl. A CT of the abdomen and pelvis showed a large left rectus sheath
hematoma (see figure) extending from the level of thoracic cage to pubic
symphysis. The patient was managed conservatively and remained hemo-
dynamically stable after initial resuscitation. A repeat CT of the abdomen 4
days later showed a decrease in the size of the hematoma. The development
of contrast-induced nephropathy complicated his hospital course. He was
discharged to hospice.
Discussion: Bleeding as a complication of paracentesis occurs in less than
1% of cases even in the presence of significant coagulopathy and thrombocy-
topenia. No data exists to support a cutoff value for coagulation parameters
beyond which paracentesis should be precluded. Routine correction of pro-
longed INR and thrombocytopenia before abdominal paracentesis is not
recommended. Conservative management including fluid resuscitation, cor-
rection of coagulopathy and blood transfusion is recommended in such cases.
Invasive measures including therapeutic angiography with embolization and
surgical exploration are reserved for patients who fail conservative mea-
sures. It is important to recognize the existence of this serious complication
as awareness may accelerate the diagnostic process and treatment.[figure1]
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Diagnosis of Shwachman-Diamond Syndrome in a 24-Year-Old
Woman with Abdominal Pain and Fatty Replacement of the Pancreas
Jaya R. Agrawal, MD, MPH, John R. Saltzman, MD, FACG, Elena M.
Stoffel, MD, MPH∗. Gastroenterology, Brigham and Women’s Hospital,
Boston, MA.
Shwachman-Diamond Syndrome (SDS) is genetic disease characterized by
pancreatic insufficiency, fatty replacement of the pancreas, and neutropenia.
It typically presents in childhood, however we describe the diagnosis of SDS
in a young woman presenting with abdominal pain.
Clinical Presentation: A 24-year-old woman presented with post-prandial
abdominal pain, relieved with defecation. The physical exam was normal.
Laboratory evaluation was significant for a WBC of 2400, a platelet count
of 150,000 and a hematocrit of 37.
Evaluation: Further review of pediatric records revealed a history of cyclic
neutropenia and childhood failure-to-thrive. An abdominal CT scan showed
abnormal enhancement of the pancreas, consistent with complete fatty re-
placement. Serum trypsin was <1.2 (normal is 10–57), suggesting pancre-
atic insufficiency. A spot sudan stain for fecal fat was normal. Sweat test
and CFTR gene mutation testing for cystic fibrosis were normal. Genetic
testing revealed a mutation in the SDS gene on chromosome 7, confirming
a diagnosis of SDS.
Differential Diagnosis: The differential diagnosis of pancreatic exocrine
insufficiency in a young person with no alcohol history includes heredi-
tary hemochromotosis, alpha-1 antitrypsin deficiency, pancreatic neoplasm,
malnutrition, diabetes and cystic fibrosis. Rarer genetic disorders in children
include a mitochondrial disorder called Pearsons Syndrome, an ectodermal
dysplastic disorder called Johanson-Blizzard Syndrome, and SDS. Of these
disorders only diabetes, cystic fibrosis and SDS cause extensive fatty re-
placement of the pancreas.
Discussion: SDS is caused by a deficiency in an aspect of RNA metabolism
essential for the development of the exocrine pancreas, hematopoiesis and
chondrogenesis. The disease usually presents in childhood with growth de-
lay, diarrhea and recurrent infections due to cyclic neutropenia. Pancreatic
insufficiency often improves with age, but can be identified by a low serum
trypsinogen or isoamylase level, which may continue to be abnormal even
when steatorrhea resolves. Genetic testing is available to confirm the di-
agnosis of SDS, however a negative test does not rule out the disorder. As
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SDS can be complicated by life-threatening neutropenia, thrombocytopenia,
leukemia and aplastic anemia, hematology follow-up is essential.
Conclusion: A diagnosis of SDS should be considered in young patients
who present with vague GI complaints, leukopenia, and fatty replacement
of the pancreas.
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Experience Using Nitazoxanide in a U.S. Genotype 1 Hepatitis C
Patient
William Kolozsi, MD∗. Salem, OH.
Hepatitis C is the most common chronic bloodborne viral infection in the
United States. It is estimated that 3.9 million (1.8%) of Americans have been
infected with Hepatitis C of which 2.7 million are chronically infected.
Standard treatment today consists of a pegylated alpha interferon (peg-IFN)
in combination with ribavirin (RBV) for 24 to 48 weeks. The goal of therapy
is to clear the hepatitis C virus (HCV) RNA as measured by PCR and to
attain a sustained viral response after treatment is stopped. However, it is now
reported that a quarter of Americans living with HCV have failed standard
treatment. This has opened the door to search for new treatment regimens
that may be beneficial in treating this disease.
Rossignol, et. al. presented a poster “Nitazoxanide in Treating Chronic Hep-
atitis In Vitro Activity and Clinical Case Series” at Digestive Disease Week
2006. This poster detailed the in vitro antiviral properties of nitazoxanide and
included several clinical case reports in treating HCV in Genotype 4 patients.
Nitazoxanide’s outstanding safety profile was confirmed in all hepatitis C
infected patients.
Case report detailing an experience using nitazoxanide along with peg-IFN
in treating HCV in a Genotype 1 patient utilizing the same protocol that was
used in the genotype 4 trial referenced above. Safety parameters, including
liver enzymes and HCV RNA levels via PCR were also monitored.
This patient is a 52 year old male, genotype 1, which was naı¨ve to any
treatments. The patient was started on nitazoxanide 500 mg twice a day on
February 1, 2007. At this time, his HCV RNA was 15,300,000 IU. All other
laboratory parameters were within normal limits (WNL). On April 12, 2007
(approx. 10 weeks post induction) peg-IFN was added to the nitazoxanide.
After four weeks of combination therapy, the patient HCV RNA was 100,000
IU. Thus, the patient had a greater than 2 log reduction in his HCV RNA. No
adverse events have occurred and all other laboratory parameters are within
normal limits. I will continue to treat and monitor this patient in order to
complete the 48 weeks of nitazoxanide and peg-IFN.
This case report details an experience with nitazoxanide induction therapy
followed by a combination of nitazoxanide along with pegylated alpha in-
terferon (peg-IFN α 2a) in a genotype 1 patient with compelling results.
Although this result has shown great promise, larger, randomized trials need
to be conducted in U.S. to confirm and expand upon this finding.
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Development of Lymphomatoid Papulosis in a Patient with Crohn’s
Disease Treated with Infliximab — A Case Report
William Outlaw, MD, Alan Fleischer, MD, Richard Bloomfeld, MD∗.
Gastroenterology, Wake Forest University, Winston-Salem, NC and
Dermatology, Wake Forest University, Winston-Salem, NC.
A 21 year-old white male was diagnosed with ileocolic Crohn’s disease at
age 8. His disease course was complicated by perianal abscess and fistulae
at age 11. Ultimately, he was well on a regimen of azathioprine (150 mg
daily) and infliximab (5 mg/kg IV every 12 weeks) immediately prior to
starting college. Eventually, he developed progressive abdominal pain as-
sociated with anorexia and a 10-pound weight loss. Scattered violaceous
papular nodules erupted on his extremities and buttocks (Fig. 1). A course
of prednisone improved his pain and appetite, but not his rash. Biopsies of
the rash were consistent with lymphomatoid papulosis (Fig. 2). Remicade
was discontinued. He declined methotrexate, so azathioprine was continued
for maintenance of remission. He remains clinically well and his rash has
improved.
Lymphomatoid papulosis (LP) is a rare (incidence <2 per one million pop-
ulation) cutaneous lymphoproliferative disorder characterized by activated
T-cells (usually CD30+). The skin lesions of LP typically are < 3.0 cm in
diameter and usually come and go spontaneously. Overall survival is excel-
lent, approaching 100% over 5 years. Nevertheless, up to 20% of patients
with LP may progress to cutaneous lymphoma (such as anaplastic large T-
cell lymphoma or mycosis fungoides) and there is a 50% cumulative risk of
developing cutaneous lymphoma 25 years after the initial diagnosis of LP is
made.
LP is most frequently reported in immunocompromised patients, especially
those with solid organ or bone marrow transplantation. A LP-like eruption
has been described in one patient on anti-TNF therapy (adalimumab) for
rheumatoid arthritis. To our knowledge, this is the first report of LP in a
patient with Crohn’s disease on infliximab.[figure1][figure2]
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Steroid Unresponsive Sweet’s Syndrome in a Patient with Crohn’s
Disease
Christopher D. Gamble, MD∗, Prema R. Menon, MD. Internal Medicine,
Ball Memorial Hospital, Muncie, IN.
Sweet’s Syndrome, or acute febrile neutrophilic dermatosis, is a condition
characterized by the sudden onset of fever, leukocytosis, and tender, ery-
thematous, well-demarcated papules and plaques which show dense neu-
trophilic infiltrates on histologic examination. Although it may occur in the
absence of known disease, Sweet’s Syndrome can occur with diseases such
as Leukemia, Rheumatoid Arthritis, and Inflammatory Bowel Disease. A
34 year old female presented with an exacerbation of Crohn’s Disease and
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was treated with steroids, fluid rehydration, anti-emetics, pain medication
and azathioprine. On day 5 of hospitalization she was noted to have a low
grade temperature, moderate leukocytosis and a burning, non-pruritic rash.
Scattered vesicles were present on her face, neck, both sides of the upper
chest and back, both lower extremities and the proximal phalanx of her
left middle finger. Some vesicles had central areas of necrosis and one of
her fingers demonstrated a violaceous necrotic plaque. A biopsy revealed a
neutrophilic pustular dermatitis and a diagnosis of Sweet’s Syndrome was
made. Despite treatment with a number of therapies to include colchicine,
prednisone, and infliximab, her rash as well as her Crohn’s symptoms con-
tinued to worsen. Having failed medical therapy for both her Crohn’s Dis-
ease and Sweet’s Syndrome, she ultimately underwent a proctocolectomy,
which subsequently brought about complete resolution of her GI symp-
toms and skin lesions. A literature search failed to reveal a similar case in
which a patient with Crohn’s Disease and Sweet’s Syndrome who failed
medical therapy had such a profound response to surgical therapy. Our
case prompts the idea that patients with Crohn’s Disease and Sweet’s Syn-
drome who do not respond to medical therapy may benefit with regards to
overall morbidity with early surgical intervention. Further investigation is
warranted.[figure1][figure2]
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Acute Liver Dysfunction after Addition of Natalizumab to Interferon
in Two Patients with MS
Michael E. Kader, MD, Thalia Mayes, MD, Philip Katzman, MD,
Lawrence J. Saubermann, MD, Bushra Fazili, MD, Benedict Maliakkal,
MD∗. Department of Gastroenterology and Hepatology, University of
Rochester, Rochester, NY and Department of Pathology, University of
Rochester, Rochester, NY.
Interferon-beta (IFNβ) and natalizumab are commonly employed therapies
for multiple sclerosis. IFNβ has been associated with rare hepatotoxicity,
including autoimmune hepatitis in several patients. To date, serious hepato-
toxicity has not been reported with natalizumab use. Here, we describe two
patients with MS who developed autoimmune hepatitis shortly after being
initiated on natalizumab.
Case #1: A 26 y/o woman was admitted due to new onset of jaundice and
fatigue. Her MS had been treated with interferon-beta-1a. This was discon-
tinued two weeks prior to her presentation because of the development of a
rash. One week prior to her presentation natalizumab was given for her MS.
Initial laboratory data included an INR of 2, total bilirubin of 4.6 mg/dL,
AST of 1863 U/L, ALT of 2212 U/L, and alkaline phosphatase of 74 U/L.
Liver biopsy revealed centrilobular necrosis, lobular disarray with balloon-
ing degeneration, mild canalicular cholestasis, and minimal microsteatosis
(see image 1) thought consistent with AIH.
Case #2: A 52 year-old woman with MS presented to the hospital with
jaundice and abdominal pain. The patient’s MS had been treated for sev-
eral years with interferon-beta-1a and methotrexate. Three months prior to
admission, natalizumab 400 mg was initiated intravenously on a monthly
basis for worsening symptoms. After the second dose of natalizumab, the
patient was noted to have an asymptomatic elevation in her liver function
tests and methotrexate was discontinued. Shortly after the third dose of
natalizumab, she devloped jaundice and worsening right upper quadrant ab-
dominal pain. Laboratory data was significant for a total bilirubin of 6.6
mg/dL, AST 1984 U/L, ALT 1548 U/L, alkaline phosphatase 256 U/L, IgG
1860 mg/dL, anti-nuclear antibody 1:640 titer, and INR of 1.3. Liver biopsy
revealed chronic hepatitis with marked portal inflammation with prominent
plasmacytic infiltrate consistent with autoimmune hepatitis (see image 2).
Discussion: In this report, we describe two cases of autoimmune hepatitis
following the administration of natalizumab for treatment of MS. Based on
these reports, we would strongly suggest that liver function testing be closely
monitored in all patients for evidence of acute hepatitis and liver dysfunction
during treatment with natalizumab.
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Bariatric Surgery in Patients with Crohn’s Disease and Extreme
Obesity
Kerry Wright, MBBS, Donald D. Hensrud, MD, William J. Tremaine, MD∗.
Internal Medicine, Mayo Clinic, Rochester, MN; Preventive Medicine,
Mayo Clinic, Rochester, MN and Gastroenterology and Hepatology, Mayo
Clinic, Rochester, MN.
The clinical course and severity of Crohn’s disease in obese patients is charac-
terized by more disease activity and more frequent peri-anal complications.
The aim of this study was to determine the impact of bariatric surgery and
subsequent weight loss on the course of Crohn’s disease in two patients with
extreme obesity.
Following IRB approval, patients were identified in the Mayo Clinic records
with the following characteristics: extreme obesity, defined as a BMI greater
than 40; Crohn’s disease, documented by the usual clinical criteria; and
bariatric surgery for treatment of secondary complications of obesity. Data
was recorded retrospectively.
Two patients, both female, were identified. Both had Crohn’s disease with
ileo-colonic and perianal involvement, and both were taking azathioprine for
maintenance of remission. Both had a history of lower extremity DVT and
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obstructive sleep apnea. At the time of bariatric surgery, Patient #1 was age
37, weight 165 kg, and her BMI was 68.7. She had undergone one resection
of 20 cm of ileum, 16 cm of cecum and ascending colon, and 12 cm of
sigmoid colon for Crohn’s disease refractory to medical therapy. She had
been in symptomatic remission for 14 mo prior to bariatric surgery. Patient
#2 was age 47, her weight 182.3 kg, and BMI 58.9. She had not undergone
surgery for Crohn’s disease. She had been in symptomatic remission for 18
mo prior to bariatric surgery. The patients had not taken corticosteroids for
Crohn’s disease for 15 mo and 12 mo, respectively. Both had proximal gastric
stapling with Roux en Y gastric bypass. The post-op course in Pt #1 was
complicated by hypotension and in Pt #2 by respiratory acidosis requiring
intubation and mechanical ventilation. Both required re-hospitalization for
nausea and vomiting, and Pt #1 had a wound infection. Patients #1 and #2 lost
20 kg and 73 kg, respectively, by the 10th & 12th month post-op, respectively,
with reductions in BMIs to 62 and 34.8, respectively. The Crohn’s disease
remained in symptomatic remission, on azathioprine, in both for the duration
of follow-up.
Gastric stapling and bypass was safe and beneficial in two patients with
Crohn’s disease and extreme obesity. Neither patient experienced a flare of
Crohn’s disease following surgery.
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Gastrointestinal CMV Disease in an Immunocompetent Host
Christopher Fyock, MD, Melissa Gaitanis, MD, John Gao, MD, PhD,
Murray Resnick, MD, PhD, Samir A. Shah, MD∗. Medicine, Brown
Medical School, Providence, RI and Pathology, Brown Medical School,
Providence, RI.
Gastrointestinal CMV is a well-described problem in patients who are im-
munocompromised. Rarely, gastrointestinal CMV can also affect immuno-
competent patients. Here we report an immunocompetent patient with gas-
trointestinal CMV disease, and we discuss when to treat such patients with
antivirals.
An 83 year-old immunocompetent male with diabetes presented for black
stool. EGD and colonoscopy showed antral ulcers, a duodenal ulcer,
and scattered colonic ulcers. Biopsies came back positive for gastric,
duodenal, and colonic CMV. The patient was referred to immunology
whose initial impression was that the CMV was an innocent bystander.
It was decided not to treat the CMV. He had no further melena. How-
ever, a repeat EGD and colonoscopy ten months later showed persis-
tence of the CMV. A Medline search focusing on when to treat with
antivirals in an asymptomatic immunocompetent patient with CMV was
done.
Most CMV disease occurs in patients immunocompromised by HIV, organ
transplants, chronic steroids, or chemotherapy. CMV disease is exceptionally
rare in the immunocompetent, being the subject of only a few case reports.
Gastrointestinal CMV most often presents as diarrhea, abdominal pain, and
bleeding. Treatment is usually with ganciclovir, but immunocompetent pa-
tients are often not treated with antivirals. A meta-analysis of cases of CMV
colitis in immunocompetent hosts in Digestive Diseases and Sciences by
Gaiatsatos and colleagues found that there was a higher mortality in patients
of male gender who were older than 55 and in patients with chronic diseases.
Among patients younger than 55, 50% had spontaneous resolution without
antivirals, and survival for their group was 100%. However, in those older
than 55, only 32% had spontaneous resolution, and survival for their group
was 45%. Since our patient was both a male older than 55 and also a diabetic,
we treated him with a course of oral ganciclovir. A followup colonoscopy
was normal, but EGD showed persistence of the duodenal ulcer with CMV
present in the biopsies. Re-treatment with IV ganciclovir is currently being
pursued.
Here we present a case of gastrointestinal CMV in a immunocompetent
patient, and we discuss reasons to treat with antiviral therapy versus obser-
vation. The available literature supports the use of antivirals in patients older
than 55 or with co-morbidities.
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The Use of Infliximab To Treat a Patient with Both Familial
Mediterranean Fever and Crohn’s Disease
Alana P. Bunnag, AB, David T. Rubin, MD∗. University of Chicago,
Chicago, IL.
A 23-year old cigarette smoker of Ashkenazi Jewish descent developed ab-
dominal pain, diarrhea and bloody stools. He did not have fevers, back pain,
nausea or vomiting. A colonoscopy showed aphthous erosions throughout
the entire colon, and biopsies revealed cryptitis with crypt abscesses and
some architectural distortion consistent with a diagnosis of Crohn’s disease
(CD). Mesalamine therapy was not effective while treatment with prednisone
showed prompt improvement. However, prednisone tapering was unsuccess-
ful and his abdominal pain and hematochezia reoccured.
The patient came to our center for a second opinion of his CD. Repeat
colonoscopy and biopsies confirmed the diagnosis of CD of the colon, and
a CT scan revealed distal ileal thickening. Azathioprine therapy resulted in
hepatitis and profound nausea. During his two year evaluation and treatment
for CD, he developed intermittent right-sided pleuritic chest pain. Distinct
episodes lasted 1–2 weeks every 2 months and often required ER visits for
analgesia. A thorough work-up with a CT scan and evaluation for pulmonary
embolus were negative. Genetic testing revealed that the patient had Familial
Mediterranean Fever (FMF). Treatment with colchicine improved his pleu-
ritic and abdominal pain, but resulted in treatment-limiting diarrhea. He was
then treated with infliximab (5 mg/kg induction and q 8 week maintenance)
with prompt resolution of all his symptoms and successful steroid tapering.
At 14 months follow-up, he has not had further pleuritic symptoms and is in
stable remission of his CD.
FMF is most commonly seen in Turkish, Sephardic Jewish and Arabic pop-
ulations. The disease is less commonly seen in Ashkenazi Jews, with an
FMF carrier frequency of 1 in 135 and a disease prevalence of 1 in 73,000.
Interestingly, both the FMF gene (MEFV) and the CD susceptibility gene
CARD15 are located on chromosome 16. It has been proposed that inflam-
mation induced by FMF provokes expression of other inflammatory diseases
in genetically predisposed patients. Co-existing CD and FMF is rarely re-
ported. Infliximab therapy was used for this patient’s steroid-dependent CD
but the additional benefit of control of his FMF was not anticipated. The
current mainstay of FMF treatment is colchicine therapy that is limited by
diarrhea and GI upset. TNF-α has been thoroughly described in the patho-
genesis of CD and has also been shown to upregulate the MEFV gene in
FMF. The results of this case suggest that patients with co-existing CD and
FMF may benefit from monotherapy with infliximab.
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FISH-ing for the Correct Diagnosis
Richard W. Awtrey, MD∗, Luis A. Balart, MD. Gastroenterology, Louisiana
State University Health Science Center, New Orleans, LA.
A twenty year old morbidly obese African American female status-post gas-
tric bypass in 2003 presented to the emergency department complaining of
chest pain and increasing shortness of breath. Spiral CT of the chest was
performed as part of her larger work-up that was negative for PE, but re-
vealed a large heterogeneous appearing mass occupying and enlarging the
left lobe of the liver with a single 5 cm mass in the right lobe with pe-
ripheral enhancement. The only risk factor for viral hepatitis was home
tattooing. Labs were essentially normal including AFP and a negative vi-
ral hepatitis profile. CT guided liver biopsy was performed with the initial
interpretation of metastatic thyroid carcinoma to the liver based mainly on
the morphologic appearance that showed a follicular/glandular pattern with
a homogenous eosinophilic material within the lumen. No hepatic tissue
was identified within the biopsy. Second opinion subsequently ruled out thy-
roid carcinoma based on negative TTF-1 and thyroglobulin stains. Patients
care was transferred to two additional institutions that assisted in making a
diagnosis. A second biopsy was suggestive of hepatoblastoma or possibly
cholangiocarcinoma, but no definitive diagnosis was ever made. Her last set
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of biopsies were extensively reviewed by our in house pathology service
and again a second opinion was requested to confirm the diagnosis in this
problematic case. The tumor is focally keratin positive (including CK7) with
strong synaptophysin and focal chromogranin positivity, with corresponding
negative HepPar1, AFP, desmin, and S100. The main differential diagnosis
based on the morphologic appearance and immunohistochemical staining
was neuroendocrine carcinoma or Ewing’s sarcoma/PNET. To definitively
distinguish between the two a FISH (Fluorescence In Situ Hybridization)
was performed on the block for the t(11;22)(q24; q12) translocation which is
found in approximately eight-five percent of patients with Ewing’s sarcoma.
No translocation was identified supporting the diagnosis of neuroendocrine
carcinoma. Further work-up to search for a primary extrahepatic lesion was
pursued and negative. Due to patient’s tumor burden, she was not a candi-
date for surgical resection. Patient was recently started on a chemotherapy
protocol of cisplatin and irinotecan.
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Duodenal Variceal Hemorrhage Treated with TIPS
Kevin S. Jo, MD, William Shaheen, MD, Asad Ullah, MD∗.
Gastroenterology and Hepatology, University of Rochester, Rochester, NY.
Duodenal varices are uncommon in patients with cirrhosis when compared
to esophageal and gastric varices. Hemorrhage from duodenal varices is
rare and treatment is not well documented. We describe a case of bleeding
from duodenal varices in a patient with cirrhosis successfully treated with a
transjugular intrahepatic portosystemic shunt (TIPS).
A 67 year-old Caucasian female with alcoholic cirrhosis presented to an
OSH with bright red blood per rectum. An extensive evaluation including
an EGD, colonoscopy, wireless capsule endoscopy, and enteroscopy did not
locate the source of the bleeding. A tagged-RBC scan localized a potential
source involving the small intestine. A diagnostic laparoscopy with assisted
enteroscopy was negative. The patient had continued bleeding, requiring
>30 units of pRBC over a four month period.
Upon presentation to our institution, the patient continued to have bright red
blood per rectum. An EGD revealed a normal esophagus without varices. The
gastric mucosa showed evidence of portal hypertensive gastropathy without
varices. In the second portion of the duodenum, bulbous lesions were actively
oozing blood (see Fig. 1). Miniprobe ultrasonography revealed serpiginous
hypoechoic lesions with blood flow consistent with varices.
A RUQ ultrasound revealed patent liver vasculature. A TIPS was placed.
The portal gradient was reduced from 19 mmHg to 6 mmHg following
TIPS. Collateral blood flow noted pre-procedure was obliterated.
Following TIPS, the GI bleed stopped. The patient did well after TIPS without
encephalopathy and was discharged after liver transplantation evaluation. At
five month follow-up, the patient denied any further bleeding.
We present a case of duodenal hemorrhage in the setting of cirrhosis. It is a
rare etiology for GI hemorrhage that can be successfully treated with TIPS.
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Type III Choledochal Cyst Variant: First Description of a “Closed
Choledochocele” with Biliary and Pancreatic Drainage Via the
Accessory Duct
John M. Levenick, MD, Timothy B. Gardner, MD, Daniel L. Rath, MD,
Stuart R. Gordon, MD∗. Gastroenterology, Dartmouth-Hitchcock Medical
Center, Lebanon, NH and Gastroenterology, Cheshire Medical Center,
Keene, NH.
Type III choledochal cysts, also called choledochoceles, are rare congenital
or acquired malformations of the terminal biliary tree of unknown etiology.
These cysts can predispose a patient to biliary colic, obstructive jaundice,
or idiopathic recurrent pancreatitis through an obstructive mechanism as the
normal flow of bile is disrupted. They have been described in two anatomic
variants 1) both the pancreatic and bile ducts drain into the choledochocele
2) the choledochocele is a cystic outpouching into the duodenum proximal
to a normal ampulla. Endoscopic ultrasound and ERCP are primary tools
to help diagnosis these anomalous formations and needle-knife sphinctero-
tomy has recently been used to treat these cysts in symptomatic patients. We
report the case of a 23 year-old white female with no previous past med-
ical history who developed acute pancreatitis two weeks after completing
an unremarkable first pregnancy. On EUS, she was found to have a Type III
choledochocele with no apparent drainage into the duodenum. Bile was seen
draining from the accessory duct. Subsequent ERCP via the minor papilla
revealed communication of the ventral pancreatic and common bile ducts
within a choledochocele which did not communicate with the duodenum.
The bile duct appeared to empty retrograde into the ventral pancreatic duct
and subsequently out to the duodenum via the accessory duct. To facilitate
biliary and pancreatic duct drainage, the choledochocele was accessed and
opened with a needle-knife followed by biliary sphincterotomy and tem-
porary plastic biliary stent placement. Six weeks following the procedure,
she continues to feel well. This case represents the first description of a
“closed choledochocele” with biliary and pancreatic drainage via the acces-
sory duct.[figure1]
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Pancreatic Sarcoidosis Diagnosed by EUS with FNA
Kevin S. Jo, MD, William Shaheen, MD, Asad Ullah, MD, Ashok Shah,
MD∗. Gastroenterology and Hepatology, University of Rochester,
Rochester, NY.
We present a case of pancreatic sarcoidosis in a patient with painless jaun-
dice and a pancreatic mass. Definitive diagnosis was obtained by EUS with
fine-needle aspiration (FNA) for sarcoidosis, thereby avoiding surgical ex-
ploration.
A 39 year-old African American male with a history of neurosarcoidosis de-
veloped jaundice and presented for evaluation. The patient denied abdominal
pain, nausea, vomiting, and fever/chills. He noted a 100 lb weight loss over
the last year that was partly intentional. Furthermore, the patient admitted
to pruritis, clay-colored stools, and dark urine color.
Initial laboratory evaluation revealed a total bilirubin 12.3, direct bilirubin
10.3, alkaline phosphatase 311, AST 86, ALT 30, but normal pancreatic
enzymes. MRI revealed a 3.7 cm × 4.8 cm × 4.9 cm mass in head of
pancreas with peripancreatic lymph node enlargement (Fig. 1). Moderate
intrahepatic biliary duct dilatation was noted as well as common bile duct
(CBD) and pancreatic duct dilatation. A Ca 19-9 level was elevated at 367
U/ml.
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An EUS was performed with FNA. An enlarged hypoechoic pancreatic head
pancreas without discrete pancreatic mass was noted. Peripancreatic lym-
phadenopathy was observed. A #22 gauge needle was used to obtain an
FNA of both the pancreatic head and surrounding lymph nodes. An ERCP
was then performed which revealed a 3 cm stricture in the distal CBD. A
sphincterotomy was performed followed by placement of a 10 French/9 cm
CBD stent with resultant bile flow.
Biopsy of the pancreatic head and surrounding lymph nodes was negative
for malignant tumor cells. Non-caseating granulomas were identified in both
the pancreatic head and LAD. Flow cytometry and bile duct brushing were
both negative. The patient was subsequently started on steroids for treatment
of his sarcoidosis after rheumatology consultation.
Sarcoidosis involving the pancreas is rare and is often diagnosed inciden-
tally following surgical resection of a periampullary pancreatic mass. We
describe a case of pancreatic sarcoidosis presenting as a pancreatic mass
concerning for malignancy and diagnosed by EUS with FNA. The use of
EUS in obtaining a definitive tissue diagnosis prevented surgical exploration.
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A Female with a History of Dysfunctional Menstrual Bleeding with an
Uncommon Cause of Fe Deficient Anemia
Homayoun Shojamanesh, MD∗. GI, VANCHCS, Mather, CA.
The purpose of this study was to review an uncommon cause of fe deficiency
anemia in a female with dysfunctional menstrual bleeding. 44 year old pt
with FHx CRC (father dxed age 52) referred to GI service in regard to
history of Fe deficient anemia. Pt also had a history of dysfunctional uterine
bleeding and a more recent history of loose stools. The pt was evaluated
by GI and scheduled for EGD/Colonoscopy. Pt had stool studies that were
negative for fecal wbc and an infectious source. EGD was done and was
normal. Colonoscopy was done and showed over 100 polyps (consistent
with a polyposis condition/syndrome), sessile and pedunculated, ranging in
size from approximately 2 mm to over 15 mm. Colonoscopy was limited
to the transverse colon due to increased polyp number and size and near
obstruction of the lumen. Biopsies were taken and pt was encouraged to
remain on a liquid diet and to go to the ER if any N/V, abdominal pain, or
other problem and a surgical referral was placed. Pt was already being seen
and evaluated by hematology and oncology for anemia. The biopsy result
showed adenocarcinoma at one site and carcinoma in situ at another site.
Other polyp biopsies were adenoma and some were hyperplastic in the distal
colon. Pt was seen and evaluated by surgery and had abdominal colectomy
and ileorectal anastomosis (the distal sigmoid colon and rectum were spared
of any mass or large or adenomatous appearing polyps). In addition, pt had
TAH/BSO for hx of dysfunctional uterine bleeding and large fibroids (two
4–5 cm uterine fibroids). Pt also being referred for further evaluation for
polyposis syndrome for genetic counseling and testing.
Although young and middle aged women with dysfunctional menstrual
bleeding can present with fe deficient anemia, gastrointestinal and other
causes of anemia should also be considered and evaluated for in this pt
population.
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A Novel Endoscopic Treatment of a Gastric Duplication Cyst
Evin J. McCabe, MD, Adam L. Palance, MD, Gregory B. Haber, MD∗,
Stephen Machnicki, MD. Division of Gastroenterology, Department of
Medicine, Lenox Hill Hospital, New York, NY and Department of
Radiology, Lenox Hill Hospital, New York, NY.
A 30 year old previously healthy male presented with one week of severe
chest burning, diminished oral intake, and fifteen pound weight loss. Exam
revealed a non-tender abdomen with left upper quadrant distension. Chest
x-ray showed an air fluid level in the left upper quadrant. CT scan showed
a markedly distended stomach filled with fluid and a round, thick walled
mass with central fluid density at the pylorus measuring 3.2 by 2.4 by 2.6
centimeters. A nasogastric tube was placed for gastric decompression.
The EGD showed an extrinsic bulge occluding the lumen of the pylorus. 8
cc of clear fluid was aspirated via EUS showing benign columnar mucinous
epithelial cells. Provisional diagnosis was gastric duplication cyst.
Endoscopic therapy was undertaken. A needle knife was used to cut through
the wall of the pyloric channel and into the duplication cyst. This allowed
fluid to drain from the cyst and partially collapse the cyst. The track into
the cyst was then dilated with a 10 – 12 mm wire guided CRE balloon. The
interior of the cyst was examined with the endoscope and showed a smooth
wall with an unremarkable lining. Following this, two clips were placed along
the sides of the cut surface to facilitate extension with a needle knife cut.
The opening was then further dilated with a 12 – 15 mm CRE balloon.
In order to marsupialize the cyst, the roof was partially excised as follows.
A double channel endoscope was introduced. A snare was used to grasp one
of the clips and through the second channel a needle knife was used to cut
an elliptical piece of tissue around the clip. Hot biopsy forceps were used
to control bleeding. The forceps were also used to avulse tissue from the
margins of the orifice.
Four weeks post-procedure the patient had regained the fifteen pounds he
had lost and had resumed a regular diet. Currently, twenty six weeks since
endoscopy the patient continues to maintain his weight on a regular diet.
A duplication cyst is an enteric cystic structure that is in intimate contact
with the stomach, sharing with the stomach a common blood supply and
all muscle layers. It is often lined by gastric columnar mucosa and it is
unusual for a duplication cyst to remain asymptomatic until adulthood. In
the past, management of gastric duplication cysts relied primarily on surgical
intervention.
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Eosinophilic Esophagitis in a Patient with Sjogren’s Syndrome
Susan G. Coe, MD, Michelle D. Bishop, MD∗, Dawn D.F. Ferguson, MD.
Internal Medicine, Mayo Clinic, Jacksonville, FL; Gastroenterology, Mayo
Clinic, Jacksonville, FL and Gastroenterology, Mayo Clinic, Rochester,
MN.
A 63 year-old white female with Sjogren’s syndrome complained of recurrent
gingivitis, oral mucosal ulcerations, chronic nausea, dyspepsia, and dyspha-
gia for solids and pills. In the past year she had an unintentional 50 pound
weight loss and had lost her sensation of taste. In recent months she also
developed redness and dryness of her vulva. She had a history of erosive
esophagitis and gastritis documented on two prior endoscopies and multiple
esophageal dilatations were performed in the past to treat her dysphagia. Her
last barium swallow revealed non-specific narrowing of the upper and distal
esophagus with no clear Schatzki’s ring identified.
On exam was a middle aged white female who was not jaundiced. There was
an irregular shaped area of erythema on her right buccal mucosa with white
striations in the pattern of Wickham’s striae. There were no discrete oral ul-
cerations. Cardiovascular and respiratory exams were normal. Her abdomen
was soft and non-tender with no distention, organomegaly or masses. There
was erythema and edema of her external genitalia, particularly of the labia
minora, but no genital ulcerations.
EGD revealed a narrow caliber esophagus with areas of friability and desqua-
mation of the mucosal surface. Biopsies from the mid-esophagus were con-
sistent with the diagnosis of eosinophilic esophagitis (>20 eos/hpf). Small
bowel biopsies were normal, showing no evidence of celiac sprue.
A minor salivary gland biopsy had confirmed the diagnosis of Sjogren’s
syndrome.
Cutaneous immunofluorescence was negative and there was no evidence
of lupus, vasculitis, or autoimmune bullous disorder. Vulvar biopsies re-
vealed marked acute and chronic inflammation that was non-specific with
no eosinophils identified. The patient’s oral mucosal findings were typical
of Lichen Planus however they resolved before they could be biopsied.
Eosinophilic esophagitis (EE), Sjogren’s syndrome (SS) and lichen planus
(LP) share a number of interesting features. They are all immune mediated
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disorders with an association to either allergens or autoantigens. Gastroin-
testinal manifestations are also common in all three disorders. Though they
share a number of similarities, current knowledge about their pathogenesis
supports they are distinct entities. We report our case as an interesting exam-
ple of a patient with three disorders that, although distinct in pathogenesis,
share a number of similarities that may impact her future treatment.
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Obscure-Overt Gastrointestinal Hemorrhage: A Rare Case of Bleeding
Ectopic Ileal Varices Managed by Double Balloon Enteroscopy
Adam L. Palance, MD, Evin J. McCabe, MD, Gregory Haber, MD∗.
Department of Medicine, Division of Gastroenterology, Lenox Hill
Hospital, New York, NY.
A 63 year-old man was seen for obscure-overt gastrointestinal bleeding.
Medical history was pertinent for BPH. There was no history of liver disease,
alcohol intake, bleeding diathesis, abdominal surgery, or use of NSAIDS.
Since May 2006, the patient had many negative workups for obscure bleed-
ing; including endoscopy, colonoscopy and angiography. A capsule en-
doscopy was suggestive of a bleeding lesion in the distal ileum. He was
transfused 29 units of PRBCs over six hospitalizations The patient was re-
ferred for double balloon enteroscopy (DBE). At initial consultation he was
not bleeding. An elective DBE was planned.
The following day the patient presented with dizziness and hematochezia.
There was no abdominal pain, hematemesis, or chest pain. Vital signs were
normal and rectal exam revealed bloody stool. Initial labs were hemoglobin
of 9.1, MCV of 74.2. All other labs were normal. The patient was admitted
and transfused.
Hematochezia continued requiring 10 units of PRBCs during hospitalization.
A transcolonic DBE was performed and no fresh blood was seen through
the first 125 cm of the ileum. The most distal extent of the exam was inked.
The patient continued to bleed and DBE from above was performed. A small
amount of fresh blood was noted in the proximal ileum.
Upon withdrawal of the scope with irrigation, two clusters of varices located
in the mid-ileum were noted. A mucosal break with a platelet plug was noted
on one varix, suggesting an area of recent bleed.
Cyanoacrylate glue was injected into the varix to ensure hemostasis. The
scope was withdrawn slowly without identification of other varices. The
patient was monitored closely without bleeding for 72 hours post procedure.
The patient was discharged and has remained stable 2 months later.
Ectopic varices describes large portosystemic venous collaterals occurring
anywhere in the abdomen except in the cardioesophageal region. Ectopic
varices are an uncommon cause of gastrointestinal hemorrhage, and make up
5% of all cases of variceal hemorrhage. The literature on this topic consists
of small series and case reports. Therapeutics in this arena are based on
expert experience, not on randomized trials. Ileal varices are exceptionally
rare, especially in the absence of portal hypertension. We believe our case
to be the first case of ileal varices treated at DBE with cyanoacrylate.
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Methylnaltrexone (MNTX) for Constipation in a Patient on Opioids
with Malignant Spinal Cord Compression
Neal E. Slatkin, MD, Michelle Rhiner, RN, NP, Robert J. Israel, MD∗.
Palliative Care, City of Hope, Duarte, CA and Medical Affairs, Progenics
Pharmaceuticals, Inc., Tarrytown, NY.
To investigate the effect of MNTX on constipation in a patient (pt) on opioids
with malignant spinal cord compression. MNTX is a peripherally acting
mu-opioid receptor antagonist. In clinical trials, subcutaneous (SC) MNTX
reversed opioid-induced constipation (OIC) in pts with advanced illness (AI)
without reversal of analgesia or causing withdrawal.
A 46-yr-old man with metastatic, NSC lung cancer and spinal cord compres-
sion was referred to the Palliative Medicine service for upper abdominal and
right chest pain. The pt had received numerous chemotherapies as well as
radiation to metastatic lesions from T8 to T10. Surgery for the cord com-
pression was not advised and on admission the pt reported taking MS Contin
100 mg bid and had not had a bowel movement in 3 days. His exam showed
paraplegia and muscle wasting of the lower extremities. The impression was
that he had chest pain due to a paraspinal tumor and spinal compression. His
abdominal pain was felt to be a combination of constipation and paraspinal
tumor. The constipation was felt to be due to opioids as well as cord com-
pression. During hospitalization the opioids were optimized. He had been
on colace and senna without alleviation of constipation. The pt consented to
participate in a trial of SC MNTX in OIC in pts with AI.
Per protocol, the pt was randomized to a double-blind dose of 0.3 mg/kg
of SC MNTX. Within minutes, he experienced abdominal cramping. About
50 min after the SC MNTX, the pt had a spontaneous passage of a very
large amount of stool. After laxation, his cramping subsided and he reported
feeling very much relieved. He also reported improvement in his abdominal
pain from 4/10 prior to treatment to 3/10 after the bowel movement. No
evidence of opioid withdrawal was noted. The pt received an open-label
dose of SC MNTX at 0.15 mg/kg the next day. He again had a spontaneous
passage of stool, although with less cramping. The pt was discharged to
hospice in a much more comfortable state. His underlying disease continued
to progress and he died approximately three weeks later in hospice.
OIC is often a cause of great distress in pts with AI. SC MNTX has been
shown to rapidly induce laxation in AI pts with OIC. This pt responded to
MNTX despite the fact that he had spinal cord compression and was receiving
high-dose opioids. SC MNTX may be useful in OIC in cases where there is
also a neurologic component to the constipation.
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A Rare Cause of Granulomatous Hepatitis Presenting as Fever of
Unknown Origin
Ryan M. O’Connor, MD, Adam L. Palance, MD, Gregory Haber, MD,
Dennis K. Miller, MD∗. Department of Medicine, Lenox Hill Hospital,
New York, NY.
Case: A 73 year old female with a past medical history of diabetes, pre-
sented with fatigue and fever. These symptoms began two months prior to
admission and were noted after a femoral popliteal bypass two weeks prior
to admission. Elevated liver enzymes evaluated by abdominal ultrasound
revealed echogenic foci in the liver. These foci were consistent with hepatic
abscesses, with ring enhancement and surrounding hyperemia on CT and
MRI imaging. Liver biopsy performed on three separate occasions revealed
necrotizing granulomatous inflammation, with histological features highly
suggestive of an infectious etiology. AFB smear was negative, but tissue cul-
ture grew Mycobacterium abscessus one month later. After discharge, she
again developed fever with enlarging abscesses on CT scan. She is currently
doing well on imipenem, ceftriaxone, and amikacin.
Investigation: Our patient underwent extensive investigations that led to the
diagnosis by culture of the liver biopsy. Initial workup for a fever of unknown
origin, revealed WBC of 12.7, AST of 69, ALT of 56, alkaline phosphatase
of 343, albumin of 3.7, an INR of 2.4. Blood cultures were negative on
numerous occasions. Chest x-ray was clear. Tests for cryptosporidium, E.
histolytica, B. burgdorferi, malaria, coccidiomycosis, histoplasmosis, bru-
cella, tularemia, rocky mountain spotted fever and syphilis were all negative.
Viral studies ruled out the hepatitides, CMV, EBV and HIV. The necrotizing
granulomas found on core needle liver biopsy ruled out sarcoid and drug
induced granuloma. Autoimmune etiologies such as Wegeners granulomato-
sis, PBC, PSC, and autoimmune liver disease were also ruled out.
Discussion: Hepatic granuloma is a immune reaction brought on by many
etiologies. Often the causative agent remains unknown. In the United States,
sarcoidosis and tuberculosis are the most common etiological factors caus-
ing hepatic granuloma. Liver biopsy from our patient grew Mycobacterium
abscessus. This infectious agent has been documented in cases of soft tissue
infections in post-surgical and traumatic skin wounds. It has also been iso-
lated in patients with cystic fibrosis. After careful review of the literature, M.
abscessus has never been reported to be responsible in the formation of liver
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granulomata in humans. This case emphasizes consideration of other more
obscure and rare etiologies such as a M. abscessus infection as a possible
cause for granulomatous hepatitis and hepatic microabscess formation.
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Pneumatosis Cystoides Intestinalis in a Patient with Scleroderma and
Idiopathic Pancreatic Exocrine Insufficiency
Karthik Ravi, MD, Dawn D.F. Ferguson, MD∗. Internal Medicine, Mayo
Clinic, Rochester, MN and Gastroenterology and Hepatology, Mayo Clinic,
Rochester, MN.
Case Presentation: A 43 year old female with limited systemic sclero-
derma and chronic diarrhea was admitted to our hospital with dehydration.
At the time of admission the patient was having 10–15 small volume, wa-
tery bowel movements a day. She was afebrile and had no abdominal pain.
She had previously been diagnosed with small bowel bacterial overgrowth
but did not respond to a recent course of broad spectrum antibiotics. Dur-
ing her hospitalization, high stool output and fat soluble vitamin deficiency
were noted. Pancreatic function testing was performed and showed pancre-
atic exocrine insufficiency. An abdominal CT scan was obtained to evaluate
the pancreas and showed no structural pancreatic abnormalities. Inciden-
tally, pneumoperitoneum with jejunal pneumatosis was noted. A diagno-
sis of pneumatosis cystoides intestinalis (PCI) was made. The patient was
managed conservatively with pancreatic enzyme replacement alone. Stool
frequency had decreased to 1–2 bowel movements per day at the time of
discharge.
Discussion: PCI is a rare complication of systemic scleroderma. The clinical
presentation is nonspecific and may involve nausea, diarrhea, constipation
or abdominal pain. Abdominal tenderness on exam is variable. Radiographic
findings typically include bowel wall cysts and pneumoperitoneum. Pneu-
moperitoneum is due to cyst rupture and is typically asymptomatic. Conser-
vative management is recommended.
Systemic scleroderma is characterized by sclerosis of skin and visceral or-
gans. It is divided into three categories: limited, diffuse, and sine sclero-
derma based on the extent of skin involvement. Previous reports of PCI in
association with scleroderma have been in the setting of diffuse systemic
scleroderma, with only one prior case report of PCI in limited systemic
scleroderma.
Interestingly, our patient also had idiopathic pancreatic exocrine insuffi-
ciency and treatment with pancreatic enzymes resolved her diarrhea. To our
knowledge, this is the first case report of these three diseases in the same
patient. The combination of these diseases may represent polyautoimmunity
in this patient.
Conclusion: PCI is a rare complication of limited systemic scleroderma,
with one previous case described in the literature. We describe the first report
of PCI with systemic scleroderma in association with idiopathic pancreatic
exocrine insufficiency.
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Abernethy Malformation – A Rare Case and Method of Detection
Todd W. Kilgore, MD, Jason S. Ogden, MD, Ajitinder Grewal, MD,
Matthew L. Bechtold, MD, Srinivas R. Puli, MD, Mainor R. Antillon, MD,
Jamal A. Ibdah, MD∗. Division of Gastroenterology, University of
Missouri, Columbia, MO.
Congenital absence of the portal vein (CAPV), or Abernethy malformation,
is a rare malformation of the splanchnic venous system. CAPV has been
associated with liver neoplasms, cardiac anomalies, and musculoskeletal
abnormalities. In this case report, a patient with Abernethy malformation
and a hepatic mass is described. The mass was visualized under EUS and
underwent FNA which may represent the first Abernethy malformation vi-
sualized on EUS.
Case: 54 yo female with idiopathic cardiomyopathy s/p cardiac transplant
who presented to an outside hospital with a 3-day progressive cognitive de-
cline. A head CT revealed an abnormality described as a mass or aneurysm.
The patient was transferred to the University Hospital with confusion but
otherwise stable. A head MRI showed an unruptured, 1 cm, right middle cere-
bral artery aneurysm. Serum chemistries, complete urine drug screen, UA
and culture, blood cultures, chest x-ray, and lumbar puncture were obtained
and only remarkable for an elevated alkaline phosphatase (306 U/L) and am-
monia (74 mcmol/L). Viral hepatitis panel, AMA, and ANA were negative.
An EEG showed diffuse bilateral slowing, consistent with encephalopathy.
Lactulose therapy was initiated. An abdominal ultrasound revealed an ab-
sence of her portal vein and a 3.8 × 4.0 cm echogenic mass in the right lobe
of her liver. An abdominal CT showed heterogenous densities in the right and
left lobes, possible cirrhosis, and no portal vein. A mesenteric angiogram
showed the superior mesenteric vein and splenic vein flowing directly into
the IVC with no portal vein. A CT-guided biopsy of the hepatic lesion showed
periportal fibrosis with no malignancy or cirrhosis. The patient’s mental sta-
tus improved with lactulose. Follow-up of her hepatic lesions by ultrasound
revealed no increase in size and serial alpha-feta proteins were normal. EUS
was performed and showed gastric varices, absent portal vein, and a 1.5 cm
left lobe hyperechoic lesion, which underwent FNA revealing only benign
hepatocytes, ductal cells, and stromal cells. The patient continues to be mon-
itored closely with no recurrent encephalopathy or increase in the hepatic
mass.
Conclusions: This case demonstrates a rare finding of Abernethy malfor-
mation in an adult. Even more rare, this case utilized EUS with FNA to
visualize the malformation and biopsy the hepatic mass. With the increasing
use of EUS, more rare pathologies may be identified in the future, improving
our diagnostic abilities.
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Systemic (AL) Amyloidosis Diagnosed on Duodenal Biopsies in a
Patient Presenting with Mucosal Friability, Hepatomegaly and Weight
Loss
Toyia N. James-Stevenson, MD∗, Robert A. Cohen, MD, Marina Mosunjac,
MD. Department of Medicine/Digestive Diseases, Emory University
School of Medicine, Atlanta, GA and Pathology, Emory University School
of Medicine, Atlanta, GA.
Case Report: A 33 year-old African American male presented with a 2 week
history of blood pooling in his posterior pharynx. He also described a 40 lb
weight loss and increasing sharp right upper quadrant pain over the preceding
6 months. Physical exam revealed a chronically ill-appearing young man with
marked nodular hepatomegaly and blood oozing from his oropharynx. Initial
labs were remarkable for a mild normocytic anemia with hematocrit of 30.3,
calcium of 11.7 mg/dl (8.9–10.3), albumin of 2.8 gm/dl (2.5–5), ast of 112
u/l (10–42), ggt of 111 u/l (7–64), alk phos of 585 (38–126) u/l, tbili of 2.1
mg/dl (0.3–1.6), and an inr of 1.6. The patient underwent upper endoscopy,
which showed subtle granular duodenal mucosa and mild diffuse friability.
Duodenal biopsies revealed extensive amyloidosis. Serum and urine protein
electrophoresis showed monoclonal light chains. The clinical presentation
was most consistent with systemic (AL) amyloidosis. The patient was started
on a course of melphalan and dexamethasone and subsequently discharged
home.
Discussion: Systemic (AL) amyloidosis is the most common and also the
most lethal form of amyloidosis. It results from deposition of insoluble
monoclonal immunoglobin light chain fragments in various organs. The
coexisting monoclonal gammanopathy is usually low-grade and otherwise
benign. Common clinical findings include weight loss, congestive heart fail-
ure, proteinuria, neuropathy and hepatomegaly. Despite the infrequency of
GI symptoms, duodenum biopsies are clearly more sensitive than abdom-
inal fat biopsies, which have a sensitivity of only 75%. Duodenal biopsies
have higher yield than other parts of the GI tract, including rectal biopsies
(98% compared to 86%). Characteristic endoscopic findings include multi-
ple polypoid protrusions and fine granular mucosa, but mucosal friability,
erosions and ulcerations are also seen. Our case demonstrates the importance
of upper endoscopy and duodenal biopsies as primary diagnostic tools. In
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patients presenting with friable mucosa, hepatomegaly and weight loss, amy-
loidosis should be considered. Our early endoscopic approach led to a swift
diagnosis, which minimized the number of diagnostic tests and focused most
of the patient’s hospital stay on treatment.
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Hemorrhagic Small Bowel Renal Cell Metastasis Diagnosed by Double
Balloon Enteroscopy
Adam L. Palance, MD, Sejal Patel, MD, Gregory Haber, MD∗, Evin J.
McCabe, MD, Paresh Shah, MD. Department of Medicine, Division of
Gastroenterology, Lenox Hill Hospital, New York, NY and Department of
Surgery, Lenox Hill Hospital, New York, NY.
Recent advances in enteroscopy have made evaluation of the small bowel
feasible. The utility of capsule endoscopy is solely diagnostic. Double bal-
loon enteroscopy (DBE) permits examination of the entire small bowel and
allows for diagnostic and therapeutic maneuvers. Through tattooing DBE
provides a means for rapid laparascopic localization of small bowel lesions.
Case Report: We report a case of a 65 year old woman transferred for melena
without hemodynamic instability. Medical history was remarkable for hy-
pertension, and left nephrectomy for renal cell carcinoma. Upper endoscopy
and colonoscopy were negative. She was transfused three units and dis-
charged with a hemoglobin of 10.6. Four days after discharge, labs revealed
a hemoglobin of 7.2. On readmission, bleeding scan identified a source in
the right upper quadrant small bowel region. Capsule endoscopy revealed a
possible AVM, and ulcers in the ileum. The patient was transferred to our
institution for DBE to specifically localize, identify, and treat the bleeding
source.
The DBE system allowed deep insertion into the small bowel. A mass with
a friable surface was identified on a broad stalk with ulcer at the base.
Multiple small biopsies were obtained. India ink injections were placed 120
degrees apart, 3 cm proximal to the lesion. Biopsy results were consistent
with metastatic renal cell carcinoma and the patient was taken to the OR for
resection.
Discussion: The small bowel is an uncommon source of GI bleed. Approx-
imately 5% of gastrointestinal bleeds cannot be localized after extensive
workup including panendoscopy and capsule endoscopy. Of these, 27% are
small bowel AVMs or tumors. Other small bowel bleeding lesions include
gastrointestinal stromal tumors, carcinoids, and lymphomas.
At our center DBE is utilized in the evaluation of obscure-occult, and
obscure-overt bleeding. We have found DBE to be safe and effective in
diagnosing and treating many unusual lesions of the small bowel.
Renal cell metastasis to the small bowel are rare and scant reports of in-
tussusception and bleeding secondary to these lesions can be found in the
literature. Here we present the first case report of a small bowel renal cell
metastasis diagnosed at DBE, which was subsequently removed laparoscop-
ically. Tatooing of this endoluminal lesion permitted an expeditious and
directed laparoscopic resection of the lesion.
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Successful Late Treatment of Boerhaave’s Syndrome with Esophageal
Stenting
Adam L. Palance, MD, Eric Rosen, DO, Gregory Haber, MD∗, Jeevan
Vinod, MD, Aman Ali, MD. Division of Gastroenterology, Lenox Hill
Hospital, New York, NY.
We report two cases of Boerhaave’s syndrome treated with esophageal stent-
ing. The literature suggests early stenting to be advantageous. Historically, it
was shown that after 24–48 hours, survival was enhanced with surgical repair
of the esophagus to avoid fulminant mediastinitis. We report two successful
cases treated with esophageal stenting beyond 48 hours.
Patient A is a 56 year old male presenting with emesis and abdominal pain
of four days duration. Past history included COPD. Physical exam revealed
subcutaneous emphysema and decreased breath sounds. CT scan revealed
pneumomediastinum, and left pleural effusion. Initial diagnosis of Boer-
haave’s was delayed until day 5 when he decompensated, had an increase in
WBC and required BIPAP. The pleural effusion was drained. An endoscopy
was performed revealing a 2 cm full thickness tear on the posterior-lateral
wall of the esophagus. A Polyflex stent was placed, broad-spectrum antibi-
otics were initiated, and the patient was taken to the OR for mediastinal
debridement. The patient was discharged one week later and returned in five
weeks for endoscopic stent removal with complete healing of the esophagus.
Patient B is a 78 year old female presenting with hematemesis and epi-
gastric pain. Pain radiated to her back after 5 episodes of emesis. Her past
medical history included COPD and GERD. Physical exam revealed coarse
breath sounds in the left lung, and a soft diffusely tender abdomen. CT chest
revealed pneumomediastinum with esophageal perforation and necrotizing
pneumonitis in the left lower lobe. Endoscopy performed revealed an ex-
udative scar with a 3 cm area of perforation. An Alimaxx esophageal stent
was placed at 72 hours after presentation, broad-spectrum antibiotics were
initiated, and the empyema was drained. The patient was discharged one
week later in good health, and returned after six weeks for stent removal.
Placement of self-expanding metal stents successfully beyond the area of
perforation requires fluoroscopic or endoscopic guidance. Polyflex stents
are favored over traditional metallic stents because they minimize granula-
tion tissue formation, and tissue ingrowth, thus promoting minimal trauma to
the esophageal wall during removal. The Alimaxx stent is covered, it causes
minimal granulation tissue formation, and has a suture designed for repo-
sitioning and removal Late endoscopic treatment of Boerhaave’s syndrome
with esophageal stenting is beneficial and should be considered first line
therapy.
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Acute Esophageal Necrosis: Two Cases of a Rare Endoscopic Finding
Leon S. Maratchi, MD, Amnon Gotian, MD∗, Ira A. Tepler, MD, Luoquan
Wang, MD, Albert D. Kramer, MD. Gastroenterology, Montefiore Medical
Center, Bronx, NY and Pathology, Montefiore Medical Center, Bronx, NY.
Acute esophageal necrosis (AEN) is a rare finding and is estimated to occur
in 0.01% of all patients undergoing endoscopy. We aim to report two cases
of AEN.
The first patient, a 79-year-old woman presented with coffee ground emesis.
She was in atrial fibrillation with a rapid ventricular response. Her heart rate
was controlled with diltiazem and an EGD was performed.
The second patient, a 50-year-old woman was admitted for evaluation of
fever, weakness, and facial rash of two weeks duration. During her hos-
pitalization, she developed acute renal failure and pancytopenia. A renal
biopsy established the diagnosis of lupus nephritis. While in the hospital,
she developed severe odynophagia and an EGD was performed.
In both patients, EGD demonstrated circumferential black esophageal mu-
cosa with overlying white exudates and underlying pink granulation tissue
(see figure). There was a sharp transition to normal appearing mucosa at
the GE junction. Esophageal mucosal biopsies in the first patient revealed
fragments of inflammatory and necrotic tissue. Because of her pancytopenia,
biopsies were not obtained in the second patient. Both were started on IV
PPI, sucralfate and were not allowed oral intake. Both patients had a repeat
EGD that demonstrated resolving esophageal necrosis with confluent white
plaques. Four months later, the first patient presented to the emergency de-
partment with a gangrenous right foot and expired two days later. Six months
later, the second patient has not had a recurrence of her odynophagia.
AEN is a rare event the etiology of which is usually unknown. The di-
agnosis is usually made in the appropriate clinical setting with consistent
endoscopic findings. The prognosis for patients who develop AEN is poor
because 60% die with the disease or suffer complications like esophageal
strictures. Most deaths in patients with AEN are due to an underlying medical
condition rather than AEN itself. Because of its rarity there are no prospec-
tive studies of the management of AEN. Management of AEN could include
no oral intake, treatment of the underlying illness, acid suppression, and
sucralfate.[figure1]
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Menetrier’s Disease: Endoscopic Ultrasound Imaging To Support the
Diagnosis
Robert J. Bonasera, MD, Jay P. Babich, MD, David Friedel, MD∗.
Gastroenterology, Winthrop University Hospital, Mineola, NY.
A 57 year old man was evaluated for 6 months of loose, non-bloody stools,
abdominal cramping and nausea. Leg swelling bilaterally was present for
the prior 2 months as well. Stool studies were negative. Colonoscopy per-
formed 4 months prior did not show any colitis or active inflammation, and
albumin level measured 2.8 gms/dl (normal 3.5–4.5 gm/dl). CT scan of
the abdomen showed diffuse thickening of the gastric wall. EGD displayed
markedly enlarged gastric folds, some with a polypoid appearance in the
proximal stomach (Fig. 1)/ Copious viscous mucous and a distinct transi-
tion to normal gastric mucosa near the antrum was observed. EUS (Fig 2)
revealed the hypertrophy was relegated to the mucosa, measuring 14 mm.
Biopsies showed foveolar hyperplasia, glandular cystic dilation with smooth
muscle proliferation in the lamina propria. HEV staining for H. Pylori was
negative. Findings consistent with Menetrier’s disease.
Menetrier’s disease is a rare, acquired, premalignant disorder of the stomach
which occurs more often in men than women (3:1). The presentation is often
insidious, with non specific complaints of abdominal pain, nausea, vomiting,
diarrhea and peripheral edema.1 Characteristics include hypertrophied gas-
tric folds, excess mucous production, hypochlorhydria and hypoproteinemia.
Etiology is unknown.
Gastric biopsies are needed for the diagnosis. Mainstays of therapy include
H2 blockers and anticholinergics which are believed to decrease protein loss.
As per the literature, roughly 15% have been associated with a carcinoma.
A good portion of these patients go on to develop atrophic gastritis, some
will have a self limiting course and others will continue to suffer for years.1
This patient was treated with an H2 blocker and a high protein diet and has
done well.
Ref: 1. Scharschmidt, BF. The natural history of hypertrophic gastropathy.
Am J Med 1977;63:644.[figure1][figure2]
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Early Detection of Diaphragm’s Disease of the Small Bowel and
Impact on Management
Houssam Al Kharrat, MD∗, Sammy Deeb, MD, Omar Shoukfeh. Dept of
Medicine, Covenant Medical Center, Lubbock, Tx and Health Science
Center, Texas Tech University, Medical School, Lubbock, TX.
Since the term ‘diaphragm’s disease’ was first used in 1988, our knowledge
of the disease has expanded.
We are reporting on a patient who presented with intermittent incomplete
small bowel obstruction. He was diagnosed with multiple small bowel stric-
tures on M2A consistent with NSAID induced diaphragm’s disease.
This is a 47 year old male who presented with abdominal pain, nausea and
vomiting. His pain was dull in nature and periumbilical in location. There
were no obvious exacerbating or relieving factors.
His PMHX: hypertension, juvenile rheumatoid arthritis and multiple joints
replacements.
Medications: Norvasc, Maxzide, Naprosyn, Darvocet, Lortab, and Ambien.
On physical exam he has multiple joint deformities consistent with Juvenile
RA. His Abdomen was distended, tender, with hyperactive bowel sound.
He had normal labs.
Abdominal and pelvic CT showed multiple dilated fluid filled loops of small
bowel without an obvious transition zone or wall thickening.
His small bowel follow through showed some dilated loop of bowel in the
ileum. During this admission he was treated with NGT decompression and
his symptoms improved without surgical intervention.
He represented again a few weeks later with similar symptoms. His CT and
small bowel follow through were identical to those of the prior admission. He
was treated in a similar manner as previously; but once symptoms resolved,
we preformed an M2A study. The study showed multiple strictures through-
out the small bowel. The capsule was trapped in one of these strictures for a
short period of time, but did pass through without any complications.
The patient was advised to stop all NSAID’s and was started on (Miralax) 2
for constipation. The patient has been followed for two years, on a regular
basis, and has not required any further hospitalization or treatment for his
GI tract.
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This is a unique case because of the early detection of small bowel di-
aphragm’s disease along with the cessation of NSAID’s saved this debilitated
patient from potential small bowel obstruction and the need for surgical in-
tervention.[figure1]
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Colonic Co-Infection of Histoplama and CMV in a HIV/AIDS Patient
Mimicking Carcinoma
Xinqing Fan, MD, Larry Scott, MD∗, Qiu Suimin, MD. Gastroenterology
and Hepatology, University of Texas Medical Branch, Galveston, TX and
Department of Pathology, University of Texas Medical Branch, Galveston,
TX.
A 45 year old male with known history of hemophilia and HIV/AIDS pre-
sented with right upper quadrant pain for three weeks, associated with
weight loss and fever. He had declined anti-viral therapy. Physical exam
revealed tenderness in the right upper quadrant without rebound and nor-
mal bowel sounds. Laboratory tests included: WBC: 2000, hemoglobin:
11.1, AST: 61, ALT: 46, albumin: 3.7, CD4 count: 17, HCV antibody was
positive. CT scan revealed an apple core lesion at cecum suggestive of car-
cinoma (Fig. 1A&B). Colonoscopy revealed a mass in the proximal ascend-
ing colon, just distal to the cecum (Fig. 1C). There were also ulcers in the
cecum, ascending, and transverse colon. Biopsy of the mass showed histo-
plasmosis and CMV co-infection (Fig. 1D&E). Antimicrobial therapy was
initiated.
In immunocompromised patients, colonic histoplasmosis is well known to
cause mass like lesion, mimicking carcinoma. CMV often causes ulcers
in the colon, but CMV associated mass lesion of the colon has also been
reported in several cases; the finding of both organisms in a mass lesion in
the colon is rare.[figure1]
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A Case of Obscure Gastrointestinal Bleeding
Neal J. Schamberg, MD, Brian Landzberg, MD, Felice H. Schnoll-Sussman,
MD∗. Division of Gastroenterology and Hepatology, New York
Presbyterian Hospital/Weill Cornell Medical Center, New York, NY.
A 20 yo M with no PMH presented to an outside hospital with dark stools
and decreased exercise tolerance. His hemoglobin (Hb) was 7.8 g/dL. EGD,
Colonoscopy, Meckel’s Scan and Small Bowel Series were all unremarkable;
the patient was stable during workup and was discharged. Two months later,
he syncopized due to recurrent bleeding. His Hb level was 7.5 g/dL with
MCV of 68. Workup including enteroscopy, Technetium-labeled RBC scan,
and CT scan were unremarkable. Colonoscopy revealed blood throughout
the colon; he was transferred to our ICU.
Initial evaluation included a normal Meckel’s Scan and RBC scan.
Patient was given a heparin challenge while in the ICU. On heparin, the
patient rebled, but was hemodynamically stable. A repeat bleeding scan was
positive for activity in the ileum or right colon. Colonoscopy revealed blood
throughout the colon but not in the terminal ileum.
Video capsule endoscopy was performed while the patient remained on hep-
arin.
Distal small bowel images revealed a diverticular orifice with surround-
ing blood. [figure1]Exploratory laparoscopy revealed a Meckel’s Diverticu-
lum.[figure2] A diverticulectomy was performed and the specimen revealed
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atopic gastric mucosa within the diverticulum. The patient made an unevent-
ful recovery.
1. Capsule endoscopy is an effective method to diagnose Meckel’s Diver-
ticulum.
2. A heparin challenge in a monitored setting can aid in the localization of
obscure bleeding source.
3. Meckel’s Scan has an approximately 60% sensitivity in the diagnosis of
Meckel’s Diverticulum in the adult populationa; capsule endoscopy and
exploratory laparoscopy should be pursued when clinical suspicion for
Meckel’s remains high.
4. Lin S, et al. Gastrointestinal bleeding in adult patients with Meckel’s
diverticulum: the role of technetium 99m pertechnetate scan. South Med
J 2002;95(11):1338–41.
548
UGI Bleeding Secondary to Pseudoxanthoma Elasticum
Jae Geun Hyun, MD, Lauren K. Schwartz, MD, Aaron Walfish, MD∗.
Gastroenterology, The Mount Sinai Medical Center, New York, NY.
A 39 year old Pakistani man with diabetes, hypertension and a prior CVA
presented to the emergency department with abdominal pain and melena.
The patient had two prior gastrointestinal (GI) bleeding, occurring 6 and
9 years earlier. Each of those events required massive transfusions, the first
requiring 17 units of packed red blood cells (RBCs) and the second 25
units of packed RBCs. During the previous hospitalizations for GI bleed-
ing, he was diagnosed with pseudoxanthoma elasticum (PXE) based on a
biopsy of a skin nodule in the neck. After admission, the patient underwent
four esophagogastroduodenoscopies (EGDs) for melena. The initial EGD
revealed diffuse blood oozing from multiple petechiae and linear erosions
in the stomach, for which argon plasma coagulation was applied without
success. He underwent additional two EGDs, one colonoscopy and a bleed-
ing scan that were all unrevealing. The final EGD showed three ulcers with
a pigmented protuberance in the antrum; hemoclips, epinephrine injection
and BiCAP electrocautery were applied with a short term hemostasis. De-
spite these attempts, he continued to have melena and underwent a total
gastrectomy and Roux-en-Y esophagojejunostomy. The gastrectomy spec-
imen showed a Dieulafoy’s ulcer in the proximal body that was noted in
a background of vascular abnormalities, including fibro-intimal thickening
and sclerosis with fragmentation and calcification of the internal elastic lam-
ina, consistent with PXE. After surgery, the patient was discharged home
without evidence of recurrent bleeding and remains stable. PXE is an auto-
somal recessive, multisystem disorder that affects primarily the skin, eyes
and vascular system. GI bleeding, usually recurrent and of gastric origin,
has been reported in 13% of affected patients. GI bleeding is thought to
result from degeneration of elastic fibers in the arterial wall, which leads
to aneurysmal dilatation and subsequent rupture of the vessels. There have
been two prior published case reports that associated Dieulafoy’s ulcer with
upper GI bleeding in PXE. In our case given the pathologic findings of Dieu-
lafoy’s lesion and continued bleeding despite multiple endoscopic therapies
we postulate that the Dieulafoy’s ulcer was a likely cause of the bleeding. As
in our case, total gastrectomy may be a justifiable alternative when medical
treatment is ineffective. However, we believe that in a subset of patients with
PXE and continued GI bleeding all attempts to rule out a Dieulafoy’s ulcer
should be made prior to undergoing definitive surgery.
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Cytomegalovirus Infection Associated with Esophagitis and
Esophageal Stricture after Liver Transplantation
Joseph Ahn, MD, MS, Ikuo Hirano, MD, Flamm Steven, MD∗. Hepatology,
Rush University Medical Center, Chicago, IL; Gastroenterology,
Northwestern University, Chicago, IL and Hepatology, Northwestern
University, Chicago, IL.
Cytomegalovirus (CMV) esophagitis is a rare entity most often associated
with AIDS and bone marrow transplantation. We report a case of a liver
transplant recipient with severe CMV esophagitis that rapidly progressed to
esophageal obstruction.
A 46-year-old woman with primary biliary cirrhosis underwent a cadaveric
liver transplantation. The patient was CMV – and received a CMV + graft.
Tacrolimus 2 mg twice daily, mycophenolate mofetil (MMF) 750 mg twice
daily, and valganciclovir 450 mg every other day was initiated. The patient
presented 6 months after transplantation with abdominal pain and dysphagia.
An EGD revealed circumferential distal esophageal ulceration that extended
for 3 cm. Esophageal biopsies, viral cultures, fungal cultures, herpes virus
antibodies, CMV DNA and CMV antigen testing were unremarkable. The
patient was placed on a liquid diet with PPIs and carafate slurry. One week
later, an EGD was performed for new onset odynophagia. Persistent circum-
ferential distal esophageal ulcerations were noted. The esophageal brushings
EGD revealed positive rapid cultures for CMV. MMF was discontinued and
IV ganciclovir was instituted. The patient required IV fluid support and was
unable to take oral medications. An EGD performed two weeks later re-
vealed a tight esophageal stricture with an intraluminal diameter of less than
5 mm and a length of 4 cm that could not be traversed with a Pentax 2731
videoendoscope. The stricture was dilated using serial balloon dilations us-
ing a Bard Eliminator through the scope type dilator. Esophageal biopsies
2 months after the initial presentation revealed no evidence of persistent
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CMV infection. Esophageal dilations were necessary at 10-day intervals for
6 sessions until the patient was able to resume a regular diet. Valganciclovir
was continued.
Risk factors for CMV esophagitis included CMV – recipient status, receipt
of a CMV + graft, leukopenia, discontinuation of CMV prophylaxis, and im-
munosuppression. Initial serologic and biopsy examinations were unreveal-
ing. However CMV infection was confirmed with a positive biopsy culture.
This is the first case of CMV esophagitis complicated by rapid esophageal
stricture formation in a liver transplant patient. It would seem prudent to
maintain CMV prophylaxis in liver transplant recipients with multiple risk
factors.
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Thumbs Up: Endoscopist’s Thumb as an Occupational Hazard
Related to High Volume Endoscopy
Joy Tsai, MD, Charles Berkelhammer, MD∗. Gastroenterology, University
of Illinois, Oak Lawn, IL.
Endoscopists performing high volume endoscopies are at risk of developing
occupational injury related to mechanical stress on the tendons at the base
of the thumb. de Quervains’s syndrome, or stenosing tenosynovitis of the
thumb tendon, has been reported as an occupational hazard of endoscopy
[1]. It occurs as a result of repetitive overuse of the left thumb while grasping
and turning the wheels of the endoscope while moving the wrist in radial
and ulnar directions. This leads to thickening, inflammation and eventually
stenosis of the fibrous tendon sheath as it passes over the distal radius. The
friction-induced tenosynovitis can lead to fibrosis and eventually stenosing
tenosynovitis. We describe a case of de Quervains’s syndrome of the left
thumb occurring in a high volume endoscopist that responded to conservative
therapy.
A 50-yr-old right-handed clinical gastroenterologist who had performed
more than 25,000 endoscopies over the prior twenty years, with an increase
in procedural volume in the last six years, complained of severe pain at the
base of his left thumb. Pain would occur with exaggerated thumb move-
ments during endoscopy. This interferred with performance of endoscopy.
The pain would also awaken the physician in the middle of the night and
interrupt sleep. Examination revealed moderate swelling and point tender-
ness over the left thumb tendons at the distal portion of the radial styloid.
A positive Finkelstein’s test was demonstrated, consistent with de Quer-
vains’s syndrome. He was treated with aspirin, thumb rest for one week,
and a thumb splint at night. This treatment regimen resulted in clinical im-
provement such as to be able to continue his regular endoscopy schedule. de
Quervains’s tenosynovitis affecting the tendons of the thumb can occur as an
occupational hazard of high volume endoscopy (1). It is caused by repetitive
overuse of the left thumb during grasping and turning of the wheels of the en-
doscope while moving the wrist in radial and ulnar directions. The syndrome
can respond to conservative therapy, as in our case. Other therapies include
steroid injection with a reported 90% response rate, and surgical incision
of the tendon. Rarely, when this syndrome is advanced, it may terminate an
endoscopic career. (1) Cappell MS. Colonoscopist’s thumb: DeQuervain’s
syndrome (tenosynovitis of the left thumb) associated with overuse during
endoscopy. Gastrointestinal Endoscopy 2006, 64:841–843.
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Interferon-Alpha Induced Thyroid Disease in Patients Being Treated
for Hepatitis C
Erika Grigg, MD, Edward Chin, MD∗, Robert Schade, MD. Medicine,
Endocrinology, and Gastroenterology/Hepatology, Medical College of
Georgia, Augusta, GA.
Introduction: Interferon (IFN)-alpha is indicated for a variety of malig-
nancies and chronic viral illnesses and is associated with an increase in au-
toimmune thyroid disease. IFN-alpha is critical in viral Hepatitis C (HCV)
treatment. Clinically significant thyroid disease induced by IFN-alpha may
result in discontinuing a therapeutic agent shown to improve survival and
decrease morbidity in HCV infected patients. We present two cases to
show the different clinical presentations of thyroid disease secondary to
IFN therapy for HCV treatment and discuss strategies for diagnosis and
management.
Case presentations: Case #1: 48 year-old man with a family history of hy-
pothyroidism was admitted with abdominal pain and coffee-ground emesis.
Six months after initiating therapy with IFN-alpha and ribavirin for HCV
he noted a 50-lb weight loss with fine tremors and palpitations, which he
attributed to anxiety. Thyroid stimulating hormone (TSH) was normal prior
to therapy. Physical examination revealed a thin, slightly anxious male with
fine, resting tremors. The thyroid gland was not enlarged and no masses,
nodules, tenderness, or bruits were noted. Lab work revealed the TSH was
0.03 (normal 0.4–4.7 uIU/mL) and free thyroxine (FT4) was 3.4 (normal
0.58–1.64 ng/dL). Thyroid stimulating immunoglobulin was 2.5 (normal
<1.3) and thyroid peroxidase antibody was <20 (normal is <40 IU/mL). A
123-iodine thyroid uptake and scan showed diffuse homogenous uptake of
17.8% at 4 hours (upper limit of normal is 15%).
Case #2: 48 year-old woman with a family history of hypothyroidism treated
with IFN-alpha and ribavirin for HCV. Before initiating IFN therapy, her
TSH was 4.35 uIU/mL. After 7 months of therapy, patient stated her rings
were getting tight and she was “retaining water”. A repeat TSH level was
321.38 uIU/mL and FT4 was <0.50 ng/dL. Thyroid hormone replacement
was started and her symptoms resolved.
Discussion: Thyroid disease is a frequent complication of IFN therapy with
variable expressions and different long-term outcomes. Early symptoms of
thyroid disease may be wrongly attributed to HCV symptoms and IFN side
effects leading to a delay in diagnosis and discontinuation of IFN-alpha. The
exact mechanism by which IFN induces thyroid autoimmunity is unknown,
but given the high prevalence of this complication physicians need to be
aware of the spectrum of clinical presentations, etiology, and management.
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A Rare Case of Intussusception in a Patient with Typhlitis Managed
Successfully by Barium Enema Reduction
Simon C. Chan, MD, Ashok Shah, MD∗. Department of Gastroenterology,
University of Rochester Medical Center, Rochester, NY.
Intussusception in adults is an uncommon entity associated with an underly-
ing pathologic cause in 70–90% of cases. Surgical resection is the treatment
of choice as up to 50% of adult intussusception are caused by malignancy.
Here we describe a case of a successful reduction of an intussusception with
barium enema in a patient with neutropenic colitis.
A 26 year-old Caucasian male was admitted to Strong Memorial Hospi-
tal for treatment of acute lymphocytic leukemia, and underwent induction
chemotherapy with daunorubicin, vincristine, and prednisone. He did well
until hospital day #15 when he began experiencing right lower quadrant ab-
dominal pain. A subsequent CT scan revealed an ileocolic intussusception
with pericecal fat stranding. [figure1]Because of his profound neutropenia
and thrombocytopenia, he was initially treated conservatively with IV an-
tibiotics. However, a repeat CT scan the following day showed a persistent
intussusception with increasing dilation of small bowel loops. A barium en-
ema was then performed which identified the intussusception at the hepatic
flexure. With administration of additional pressure, contrast advanced prox-
imally within the colon and entered the small bowel, despite a persistent
filling defect in the cecum.[figure2]The concern for a residual intussuscep-
tion prompted an exploratory laparoscopy which revealed normal anatomy
of the ileocolic region. The appendix and cecum were hyperemic with ev-
idence of neutropenic colitis. The patient did well postoperatively and was
discharged fifteen days later.
To our knowledge, only two cases of intussusception in the setting of
neutropenic colitis have been reported in the literature. Although more
commonly used in children, barium enema resulted in the successful re-
duction of this abnormality as confirmed by diagnostic laparoscopy.
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Inflammatory Pseudotumor of the Liver Mimicking Malignancy
Joseph Ahn, MD, MS∗, Joshua E. Melson, MD, Mariano S. Dy-Liacco,
MD, Shiriam Jakate, MD, Stanley Martin Cohen, MD. Hepatology, Rush
University Medical Center, Chicago, IL; Abdominal Transplant Surgery,
Rush University Medical Center, Chicago, IL and Pathology, Rush
University Medical Center, Chicago, IL.
Inflammatory pseudotumor (IPT) of the liver is a rare inflammatory process
often mistaken for hepatic malignancy. We report a case of a patient with
IPT who presented with fever, mental status changes, and a hepatic mass
who was successfully treated with a right hepatectomy.
A 67 year old Asian female presented with 2 weeks of fever and confusion.
Laboratory evaluation revealed alkaline phosphatase 233 U/L, total biliru-
bin 2.2 mg/dL, AST 80 U/L, ALT 113 U/L, WBC 17 × 109 cells/L. An
MRI revealed an 8.6 × 6.2 cm cystic mass in the right lobe of the liver. A
mammogram, EGD, and colonoscopy were unremarkable. FNA of the mass
revealed acute inflammatory cells and benign hepatocytes. The patient was
transferred to our hospital on empiric antibiotics. Laboratory evaluation re-
vealed albumin 2.3 g/dL, alkaline phosphatase 501 U/L, total bilirubin 0.8
mg/dL, AST 39 U/L, ALT 23 U/L, AFP 2.8 ng/mL, CEA 2.8 ng/mL. Sero-
logic testing for chronic liver disease was negative. A CT scan revealed a
10.4 × 6.8 cm heterogeneous mass in the right lobe with multiple areas of
necrosis and pneumobilia suggestive of a necrotic tumor. The patient was
taken for a right hepatectomy and an 8 × 7.5 cm cystic yellow-tan hepatic
mass was found (Figure). Histology showed multiple microabscesses sur-
rounded by reactive and xanthomatous histiocytes (CD68+, S100−) with
hemorrhage and focal cholangitis consistent with IPT. No malignant cells,
viral inclusions, or parasites were seen and special stains for fungi and AFB
were negative. The patient was discharged 9 days after the hepatectomy and
has been doing well more than 6 months later.
IPT should be considered when patients present with clinical and radiolog-
ical features mimicking malignant neoplasm. IPT is often mistaken radio-
logically for hepatocellular carcinoma, cholangiocarcinoma, or metastatic
tumor. Directed biopsy may nondiagnostic. The diagnosis can often only be
made after complete surgical resection. Hence, surgical resection is definitive
for both diagnosis and treatment.[figure1]
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Intestinal Tuberculosis Masquerading as Crohn’s Disease
Jae Geun Hyun, MD, Eric S. Goldstein, MD∗, Patricia Sylla, MD, David
Bub, MD. Gastroenterology, The Mount Sinai Medical Center, New York,
NY and General Surgery, The Mount Sinai Medical Center, New York, NY.
A 30 year old man, presented to another hospital with 2 years of cramp-
ing abdominal pains which had markedly worsened over the last 3 months.
The pain was associated with watery diarrhea and 30 pound weight loss.
Of note, he immigrated to the U.S. from Nepal 4 years ago. His father had
been treated for pulmonary tuberculosis (TB) 8 years ago. On admission,
he was found to be markedly wasted with diffuse abdominal tenderness.
CT showed extensive thickening of the right colon, with mild thickening
of the transverse and descending colon. Small bowel series showed mini-
mal irregularities of the terminal ileum. Colonoscopy at the other hospital
was aborted at the transverse colon due to severe luminal narrowing by
edema and inflammation. There were patchy areas of deep circumferential
ulcerations, pseudopolyps, and erythema from the distal transverse colon
to the rectosigmoid area. Biopsies revealed active inflammation with non-
caseating granuloma and negative AFB staining. Chest X-Ray and PPD skin
test were negative, as were HIV serology and stool studies. He was treated
for Crohn’s disease with oral mesalamine, intravenous methylprednisolone
and intravenous ciprofloxacin and metronidazole. His diarrhea improved
somewhat, but the abdominal pain did not. He continued to lose weight and
required parenteral nutrition. He was ultimately transferred to our institu-
tion for further care. Repeat colonoscopy revealed deep ulcerations in the
descending colon and visualized parts of the transverse colon. Infliximab
was considered, but because of the patient’s worsening clinical condition, he
was referred for surgery. The surgical specimen ultimately revealed AFB-
positive caseating granulomas. After several months of anti-TB therapy, he
underwent reversal of ileostomy. TB is no longer considered a rare disease
in the United States due to influx of immigrants from endemic areas, and
from the growing AIDS population. The signs and symptoms of intestinal
TB are often non-specific and a high index of suspicion must be maintained
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to ensure a timely diagnosis. Diagnosis requires colonoscopy with multiple
biopsies. Colonoscopic findings which favor intestinal TB include a patulous
ileocecal valve in the setting of circumferential ulcers (rather than the often
linear ulcers of Crohn’s disease), scars, and pseudopolyps. If intestinal TB
is suspected, empiric treatment may be warranted despite negative histology
or culture results.
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Hepatic Artery Pseudoaneurysm: A Unique Cause of Obscure Upper
GI Bleeding
Siddharth Mathur, MD, Mukul Arya, MD∗, Niket Sonpal, BS, Mohammed
Aladdin, MD, Sandeep Patil, MD. Internal Medicine, Wyckoff Heights
Medical Center, Brooklyn, NY.
Hepatic Artery Pseudoaneurysm (HAP) is a rare clinical entity and is usu-
ally associated with iatrogenic or traumatic etiologies, and almost always
manifests with hemobilia. We report the first documented case of HAP in a
patient with chronic cholecystitis without any underlying history of trauma
or surgery, presenting as massive upper gastrointestinal hemorrhage (UGIH)
without hemobilia.
A 73 year old Caucasian female with past history of NIDDM, hypertension,
hyperlipidemia presented to ER with non-radiating epigastric pain, nausea
and black melanonic stools for past 24 hours. Pertinent labs on admission
showed a Hb of 10.3 g, WBC 12.3, T.B 2.3 mg, AST 525 U, ALT 451 U,
ALP 133 U, BUN 35 and S.Cr 1.0. Abdominal ultrasound showed multiple
gallstones, and the CT scan showed a large intraluminal echogenic structure
consistent with a gallstone, with thickened GB wall. Over the next day, the
patients Hb dropped to 6 g and upper GI Endoscopy (UGIE) revealed acute
hemorrhage, possibility of a duodenal ulcer was entertained. To investigate
the possibility of GB malignancy in view of the above radiological findings
and CA 19-9 level of 2801, an ERCP was done which showed no hemobilia
or stone, and a CBD stent was placed for patency. Patient continued to have
UGIH with falling Hb, and multiple endoscopies failed to achieve adequate
hemostasis. Subsequent UGIE study showed an adherent clot on the lateral
wall with active oozing. Patient was then taken for selective catherization
and angiogram of the celiac trunk and right hepatic arteries, which yielded
visualization of large extravasations of contrast from the inferior aspect of the
right common hepatic artery and confirmed a pseudoaneurysm, eroding into
the duodenal mucosa. Successful embolization and hemostasis was achieved.
The patient also had a gall bladder biopsy to rule out malignancy, which
revealed chronic active cholecystitis.
This case illustrates a extremely rare association of HAP with chronic chole-
cystitis presenting as UGIH in an unusual form and not as the classical hemo-
bilia. Of the multiple case reports and series submitted for HAP, almost all
have shown a preceding interventional procedure involving the hepatobiliary
and pancreatic systems or history of trauma. HAP due to biliary inflamma-
tion is usually attributed to stone eroding into the artery or due to local
weakness of vessel wall. Awareness of this rare presentation and association
of HAP may allow early diagnosis and timely intervention.
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Unusual Presentation of Acute Abdominal Pain in Polycystic Liver
Disease Patient
James D. Morris, MD, Karen A. Diamond, MD, Luis A. Balart, MD,
MACG∗. Section of Gastroenterology & Hepatology, LSU Health Sciences
Center, New Orleans, LA.
62 y/o man with history of chronic kidney disease Stage V on hemodialysis
(HD) for 22 yrs secondary to polycystic kidney/liver disease with chronic
abdominal pain. He underwent an endoscopic retrograde cholangiopancre-
atography (ERCP) twice for evaluation of a dilated common bile duct (CBD)
and chronic pancreatitis identified on computed tomography (CT), most re-
cently revealing grossly dilated CBD and periampullary diverticulum. Pa-
tient developed acutely more severe abdominal pain 1 month after ERCP
during HD and was admitted to the hospital. Patient was found to have a
temperature of 102◦ F, diffuse to RUQ tenderness, and delirium with white
blood cell count (WBC) of 5.1 × 103/cmm, bands of 33%, total bilirubin 1.2
mg/dL, alkaline phosphatase 277 IU/L, aspartate aminotransferase 150 IU/L
and alanine aminotransferase 132 IU/L. Surgical evaluation did not indicate
an acute abdomen. Noncontrasted CT revealed interval enlargement of all
cysts in the liver with debris, an enormous gallbladder, polycystic kidneys
and diffuse atherosclerotic disease. Subsequently, patient’s abdominal pain
and mental status improved over the next two days with renal-doses of em-
piric antibiotics of levofloxacin, metronidazole, and gentamicin. On day 3,
patient developed severe episode of abdominal pain and became distended
with tympany/hypoactive bowel sounds. Plain radiograph of abdomen was
consistent with small bowel obstruction/ileus. WBC rose to 18.0, temper-
ature was 97.3◦ F, potassium 5.7 mmol/L, plasma bicarbonate 16 mEq/L.
These changes prompted emergency abdominal laparotomy. Intraoperative
exam revealed ruptured hepatic cyst and brown fluid freely floating in the ab-
dominal cavity. Culture of fluid revealed Escherichia coli and Enterococcus
avium. Drainage and washout of hepatic cyst completed at time of laparo-
tomy. Patient subsequently declined clinically, required pressors and later
expired, 2 days following surgical laparotomy.
Discussion: This case represents report of a ruptured infected hepatic cyst
in a patient with polycystic kidney/liver disease presenting with nondistinct
presentation initially, followed by acute cholangitis picture and later sug-
gestion of small bowel obstruction/ischemic bowel presentation with acute
abdomen in a chronically ill patient. Etiology of nidus for infectious pro-
cess in hepatic cysts undetermined at this time, but possibly due to (chronic)
cholecystitis. Hepatic cysts may rupture, but multiple cysts simultaneously
causing morbidity is rare.
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Cystic Duct Remnant as a Cause of Post-Cholecystectomy Syndrome
Diagnosed by Endoscopic Ultrasound
Anthony N. Schore, MD, Seth A. Gross, MD, Timothy Woodward, MD,
Ernest Bouras, MD, David S. Loeb, MD∗, Massimo Raimondo, MD, Barry
Rosser, MD. Department of Gastroenterology and Hepatology, Mayo
Clinic, Jacksonville, FL.
Background: Post-cholecystectomy syndrome can be the result of a cystic
duct remnant. These patients may present with symptoms of cholecystitis in
the setting of an absent gallbladder. The pathophysiology of this condition
may be the result of sludge, stones, or debris in the remnant cystic duct. Its
incidence has been correlated to the length of the remnant cystic duct.
Case: An 86 year-old man status post-cholecystectomy seven years prior
secondary to gallstone pancreatitis presented with several episodes of right-
sided chest discomfort. He had fever, abnormal liver chemistry and leuko-
cytosis. Blood cultures grew gram negative rods. He was placed on intra-
venous antibiotics and underwent endoscopic ultrasound (EUS) to evaluate
his biliary tree. This demonstrated a common bile duct of 7-mm. In the prox-
imal portion of the CBD, there was an outpocket representing a cystic duct
remnant with echogenic debris (Fig. 1). An endoscopic retrograde cholan-
giogram (ERC) was then performed. This revealed a cystic stump greater
than 1 cm in length which contained a small stone. The stone was removed
and a sphincterotomy was performed. The patient’s clinical symptoms and
laboratory abnormalities resolved. Four weeks later, the patient reported no
further episodes of pain.
Discussion: Post-cholecystectomy syndrome may be the sequela of a rem-
nant cystic duct. The incidence is unknown although it is thought to be
more common in the age of laparoscopic cholecystectomy. When suspected,
MRCP is the diagnostic test of choice. In our case, EUS suggested the disease
which was confirmed and treated by ERC. In patients presenting with post-
cholecystectomy syndrome it is important to consider cystic duct remnant
in the differential diagnosis.
Sources: Zhou PH, Liu FL, Yao LQ, Qin XY. Endoscopic diagnosis and
treatment of post-cholecystectomy syndrome. Hepatobiliary & Pancreatic
Diseases International 2003; 2(1): 117–120.
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Shaw C, O’Hanlon DM, Fenlon HM, McEntee GP. Cysic duct remnant and
the ‘Post-cholecystectomy Syndrome.’ Hepato-Gastroenterology 2004; 51:
36–38.[figure1]
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Failed Use of Adalimumab in Maintaining Remission in Crohn’s
Disease during Pregnancy
Brian P. Bosworth, MD∗, Jennifer Inra, Shanti Eswaran, MD, Ellen J.
Scherl, MD. Roberts Center for Inflammatory Bowel Disease, Division of
Gastroenterology and Hepatology, Weill Cornell Medical College, New
York, NY and Division of Digestive and Liver Diseases, New York
Presbyterian Hospital: Columbia Presbyterian Campus, New York, NY.
Background: Active Inflammatory Bowel Disease (IBD) during pregnancy
is a risk factor for low birth weight, poor fetal outcome and premature de-
livery. Maintaining remission is critical, and medications targeting TNF-a,
such as adalimumab, are most effective in treating Crohn’s disease (CD).
However, their safety and efficacy during pregnancy are not fully known.
We report the failed use of adalimumab in maintaining remission during
pregnancy in CD.
Case: RL is a 21-year-old woman who was diagnosed with IBD at age 17
when she experienced bloody diarrhea and weight loss following a miscar-
riage. She developed toxic megacolon necessitating a total proctocolectomy
with ileal pouch anal anastomosis. An anal fistula which progressed into
an abscess ensued. Pouchoscopy showed an ulcerated inflow tract that more
resembled CD than UC. RL was started on infliximab, 6MP and Prednisone
without significant improvement. Infliximab was subsequently discontin-
ued. Repeated pouchoscopy showed ulceration at the ileoanal anastomosis
site and adalimumab was added. At age 20, RL was in remission and be-
came pregnant while taking adalimumab and 6MP. She presented with a
tender right groin lymph node 6 months later. The node developed into a
nonhealing perianal abscess and was thought to be a pouch-vaginal fistula
secondary to CD. Drainage of the abscess was recommended but she elected
to have it deferred until delivery. Fetal development was normal and she had
a C-section at 36 weeks.
Discussion: Adalimumab’s use in active CD during pregnancy has been
described in several case reports, demonstrating success in attaining remis-
sion and preventing complications such as fistulas, strictures or abscesses.
However, there have been no reports describing adalimumab’s inability to
control complications of CD during pregnancy. While adalimumab is rated
pregnancy class B, crosses the placenta and has been identified in breast
milk, it has not been shown to cause any adverse fetal events. Its efficacy
remains unclear, as our patient manifested new fistulizing disease. A com-
parative registry evaluating the efficacy and toxicity of anti-TNF-a drugs is
warranted. At this time, certolizumab, a pegalated anti-TNF-a drug, may be
a good alternative during pregnancy, as it does not cross the placenta.
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Rectal Perforation Caused by a Holistic Colonic Cleansing
Jennifer Lee, MD, Hiral N. Shah, MD, Mario Golocovsky, MD, Timothy R.
Koch, MD∗. Medicine, Washington Hospital Center, Washington, DC;
Surgery, Washington Hospital Center, Washington, DC and
Gastroenterology, Washington Hospital Center and Georgetown University
School of Medicine, Washington, DC.
Introduction: Colonic cleansing, also termed high water enema, colonic
lavage or irrigation, is common in alternative medicine. It involves intro-
duction of up to 50 liters of fluid into the colon through a rectal tube. It is
believed to have a detoxifying effect. Risks include electrolyte imbalances,
bowel perforation, and transmission of disease. We present a case of rectal
perforation after colonic irrigation.
Case: 44-year-old African American lady presented with rectal pain. She
had colonic irrigation at a holistic health center during the previous week.
During irrigation, she felt sharp, severe rectal pain which steadily increased.
She also noted small, loose stools, nausea, vomiting, and hematochezia.
Temperature was 101◦F; pulse 114 bpm. She had an obese, soft and non-
tender abdomen, with bowel sounds present, but no organomegaly, guard-
ing, or rebound tenderness. Rectal examination revealed no mass, normal
anal sphincter tone, and hemoccult negative stool. Physical examination was
otherwise normal. Initial pelvic CT imaging revealed extensive edema and
extraluminal air around the rectum, suggesting a contained perforation, but
no abscess. There was no free intra-abdominal air or ascites. Repeat CT scan
at 1 week revealed a horseshoe shaped abscess at the anterior rectum, with
oral contrast visible in the perirectal space. A defect in the anterior rectal wall
was consistent with persistent rectal tear. The patient was managed nonsur-
gically with IV antibiotics and clinically improved. The patient underwent
a gastrografin enema at 2 weeks but there was no further leak. The patient
was discharged home on oral antibiotics.
Discussion: Colonic irrigation is a holistic procedure based on the concept of
“autointoxication”. Cases of bowel perforation are rarely reported; 3 cases of
rectal perforation in Australia required surgery; 1 case in Singapore resulted
in perineal gangrene. Diagnosis of rectal perforation is made by history,
abdominal x-ray or CT scan. Clinical suspicion demands a careful history.
In this case we treated the patient with intravenous antibiotics and no surgery
was required. Surgical treatment may involve a colostomy, which has major
risks and impact on a patient’s life. Patients may not be aware of the possible
risks; physicians should provide information to patients who participate in
holistic medicine.
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Life-Threatening Hepatic Failure Associated with Entecavir
Resistance Mutations I269I/T and T184L Two Years after
Discontinuation of Lamivudine
Maureen E. Morgan, MD, Walid Ayoub, MD, Aijaz Ahmed, MD, Emmet B.
Keeffe, MD, Mindie H. Nguyen, MD∗. Division of Gastroenterology and
Hepatology, Stanford University Medical Center, Palo Alto, CA.
While entecavir (ETV) resistance is rare in nucleoside naı¨ve HBV patients,
it is more common in the presence of lamivudine resistance (LVDr) muta-
tions. Despite this, ETV is reported to be effective in lamivudine-refractory
patients.
We describe a 47 year old man with history of LVDr who presented with
hepatic failure after being switched from adefovir (ADV) to entecavir (ETV).
The patient initially presented in 1998 as a 38 year old man with chronic
HBeAg positive HBV and cirrhosis and was started on lamivudine (LVD). In
2003, his ALT became elevated, and LVD was stopped and ADV started. Due
to viremia and increasing creatinine, ADV was stopped and ETV started in
2005. His HBV DNA decreased to a nadir of 800 IU/mL in 2006. In February
2007, he developed virologic rebound with HVB DNA >38,000 IU/mL, and
ADV was added. HBV genotypic analysis showed M204V, L180M, I169I/T,
and T184L mutations, as well as a basal core promoter mutation G1764A.
In March 2007, ADV was stopped and tenofovir added, followed by a
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ten-fold decrease in HBV DNA but persistent ALT elevation. In April 2007,
he presented with jaundice, ascites, and abdominal pain, developed septic
shock from spontaneous bacterial peritonitis. Despite aggressive and appro-
priate care, he continued to deteriorate clinically and expired.
This case demonstrates 4 important points: (1) Patients with cirrhosis and
drug-resistant HBV can develop life-threatening hepatic failure while on
therapy, and should be closely monitored. Genotypic mutation analysis
should be considered before starting a new drug; (2) Patients with LVDr sub-
stitutions are at higher risk of ETV resistance than nucleoside naı¨ve patients,
even if ETV is initiated years after LVD is stopped; (3) The I169I/T mutation
has been reported to result in viral breakthrough when it coexists with ad-
ditional entecavir-specific mutations along with LVDr substitutions M204V
and L180M. This case suggests that LVDr substitutions plus the I169I/T
mutation alone or possibly combined with the T184L polymerase mutation
can result in clinical resistance; (4) This patient had HBeAg-positive HBV,
but had a G1764A BCP mutation associated with decreased HBeAg produc-
tion. This suggests infection with a subpopulation of mixed wild-type and
pre-core/core-promoter mutant HBV, which may increase risk of virologic
relapse when treatment is stopped, as seen in HBeAg negative patients.
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Use of Endoscopic Ultrasound Guided Fine Needle Aspiration
(EUS-FNA) with Aspirate Parathormone (PTH) Assay To Diagnose
Mediastinal Parathyroid Adenomas
Duc H. Vu, MD, Richard A. Erickson, MD, FACG∗. Gastroenterology,
Scott & White Memorial Hospital and Clinic, Temple, TX.
Rarely, patients with recurrent hyperparathyroidism have mediastinal
parathyroid adenomas. These lesions often difficult to diagnose, requiring
multiple sophisticated localization techniques. We describe our experience
with diagnosing two patients with mediastinal parathyroid adenomas us-
ing EUS-guided FNA cytology combined with parathormone assay on the
aspirate sample.
Case 1: A 54-year-old white male had a persistently elevated serum calcium
and PTH level despite removal of a right inferior parathyroid adenoma.
Sestamibi CT subsequently revealed a mass superior to the azygous vein.
Radial EUS confirmed the presence of 3 cm solid/cystic lesion which on
subsequent EUS-FNA showed epithelioid proliferation consistent but not
diagnostic of a parathyroid adenoma. However, PTH assay performed on
an aspirate sample diluted in 3 ml of saline was positive at 1800 pg/mL.
Pathology of the resected specimen revealed a 29.7 g parathyroid adenoma.
Case 2: An 86-year-old African-American female had recurrent hyper-
parathyroidism following removal of a left superior parathyroid adenoma.
Chest CT scan revealed enhancing nodule within the right superior medi-
astinum. EUS-FNA showed a 0.6 ×2.0 cm right paraesophageal lesion which
cytologically showed scant epitheliod cell groups. PTH assay on the diluted
aspirate was diagnostic at 6905 pg/mL. She is being managed medical at
present.
Discussion: Preoperative localization of recurrent or persistent hyper-
parathyroidism is often a difficult clinical problem. Transcutaneous ultra-
sonography (TUS), CT, MRI, thalium-technetium, and sestamibi scans have
all be used with predictive values ranging from 40 to 80%. First described
by Doppman in 1983, TUS of suspicious neck lesions with concomitant
PTH assay of the aspirate has become increasingly useful with sensitivities
between 70–100% and a specificity of 100%. Using EUS-FNA with PTH
assay on the aspirate in suspected mediastinal parathyroid adenomas is a
logical extension of this technique. To our knowledge, these cases represent
the first reported examples of this technique. We suggest that this procedure
may be useful in definitively diagnosing patients with suspected mediastinal
parathyroid adenomas.
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Wireless Capsule Endoscopy To Assess Extent of Small Bowel
Involvement in Metastatic Melanoma
Sonia S. Kupfer, MD, David T. Rubin, MD∗. Section of Gastroenterology,
University of Chicago Hospital, Chicago, IL.
A 58-year-old man with metastatic melanoma to the groin presented with
fatigue. He was found to be iron-deficient with a hemoglobin of 6.4 g/dl.
He denied overt GI bleeding but was hemoccult positive. Upper endoscopy
and colonoscopy did not reveal a bleeding source. CT scan of the abdomen
and pelvis showed a stable conglomeration of lymph nodes in the left pelvis
but no other abnormalities. The patient was transfused 2 units of packed red
cells and started on chemotherapy. His fatigue and transfusion-dependence
persisted, so another CT was obtained 8 weeks after the original scan. This
study revealed stable pelvic disease but also 2 new masses in the left upper
and right lower abdomen measuring 6 × 5.3 cm and 3.9 × 4.5 cm respectively
consistent with metastases.
He was referred for possible surgical resection, and a wireless capsule en-
doscopy (WCE) was performed to assess the extent of small bowel involve-
ment. This study showed two large masses in the mid-small bowel corre-
sponding to those seen on CT. Both lesions were multi-nodular with super-
ficial ulcerations. A smaller mass not visualized on the CT scan was found
in the distal small bowel. Several areas of lymphangiectasia were identified
throughout the small bowel suggestive of other sites of metastatic disease.
Given the diffuse involvement, the patient did not undergo surgical excision
and will receive chemotherapy and transfusions as needed.
Malignant melanoma is the most common disease to metastasize to the GI
tract. In autopsy series, GI involvement is found in almost 60% of cases,
though less than 5% of cases are diagnosed antemortem. While metastatic
melanoma has a 5-year survival of only 6%, studies have suggested a sig-
nificant improvement in survival for patients who undergo curative surgery.
Therefore, timely and accurate diagnosis of GI involvement is paramount.
Prior to the advent of WCE, diagnosis relied on radiologic and/or endoscopic
studies with CT scan being the most accurate diagnostic modality. However,
as described in this case, CT may be insensitive to changes associated with
early mucosal infiltration and small masses. Findings of diffuse small bowel
involvement on this patient’s WCE were critical in deeming him a poor can-
didate for surgical cure. Thus, the patient avoided potential morbidity from a
surgery that was unlikely to prolong survival and proceeded with additional
chemotherapy. WCE should be considered part of the standard evaluation of
patients with metastatic melanoma and GI involvement.
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Intracranial Hemangiopericytoma a Rare Liver Biopsy Diagnosis
Carla Rolanda, MD, Fernando Pardal, MD, Guilherme Macedo, MD,
PhD∗. Department of Gastroenterology and Pathology, S Marcos
Hospital, Braga, Portugal and School of Health Sciences, University of
Minho, Braga, Portugal.
A 44-year-old man presented with cervical pain and deficits on motion and
equilibrium. He has a past history of a cerebellopontine angle meningioma
surgically removed 11 years ago and more recently, he has been under oral
hipocoagulation for a venous thrombosis.
Patient was admitted for evaluation: head and cervical MR imaging de-
tected a large recurrent cerebellopontine tumor and a C4 bone lesion; tho-
racic, abdominal and pelvic CT scan imaging revealed numerous hepatic
and vertebral secondary lesions. In this sequence a percutaneous US-guided
liver biopsy was performed and histological diagnosis was hemangiopericy-
toma. Histological reassessment of the first cerebral tumor demonstrated the
same characteristic features. This case was then interpreted as an intracranial
recurrent meningeal hemangiopericytoma with extraneural liver and bone
metastasis and a paraneoplastic thrombotic syndrome. For this, our patient
has been treated with irradiation and is under reevaluation.
Hemangiopericytoma is an uncommon soft tissue sarcoma, and accounts for
only 0,4% of primary CNS tumors having the same distribution of menin-
gioma, these two tumors had been distinguished in 1993. Intracranial tumors
rarely metastasize outside the CNS, except for meningeal hemangiopericy-
tomas, that may undergo late recurrence, many years after the initial onset,
and requires long-term follow-up.
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Strongyloides: A Worm with Lethal Potential
Jawaid Ahmed Shaw, MD, Motaz Al Hafnawi, MD, Meghashyam Koti,
MD, Kevin Casey, MD∗. Gastroenterology/Internal Medicine, Rochester
General Hospital, Rochester, NY.
Introduction: Strongyloidiasis is unique among worm infestations. It can
acquire infective capacity in host’s intestinal tract producing an autoinfective
lifecycle, more so in immuno-compromised patients. Strongyloides hyper-
infection syndrome (HS) has a mortality rate exceeding 85%.
Case 1: A 72-year-old Laotian male, was admitted with a four week his-
tory of profuse watery diarrhea, weight loss and abdominal discomfort.
Examination was significant for hypotension, pallor, abdominal distension
with hyperactive bowel sounds. Labs showed WBCs 17.8 × 109/L, with no
eosinophila(1%). HIV serology was negative. Stool analysis revealed rhab-
ditiform larvae of strongyloides stercoralis (SS) with negative stool cultures
(Fig. 1).
Case 2: A 61-year-old, Puerto Rican male with history of SLE, on steroids
was admitted with abdominal pain and fever of one week duration. He had
abdominal distension, generalized tenderness and hypoactive bowel sounds.
Labs showed WBCs of 7.1 cc/mm with eosinophils of 12%. CT showed di-
lated loops of jejunum. Emergent laparotomy was done which was negative.
Post operative period was complicated by enterobacter septicemia, GI bleed
and ARDS requiring mechanical ventilation. BAL specimen revealed larva
of SS (Fig. 2).
Discussion: Strongyloides HS reflects massive infection with SS with wide
spread dissemination of larva throughout the body. Larval forms can persist
up to 40 years after infection as demonstrated by case 1 who had migrated
to US 25 years ago. The larva of SS carries enteric bacteria on their outer
surfaces which can result in bacterial sepsis as demonstrated by case 2. The
demographic profile of US is fast changing. Hence, physicians taking care
of patients from endemic areas or those who have traveled to these areas in
recent or remote past must have a high index of clinical suspicion to diagnose
and treat this infection which can otherwise be fatal.[figure1][figure2]
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A Rare Liver Tumour and Rather Rare Biopsy Complication
Ana Ignjatovic, BMBCh, MRCP, Chris Akubuine, MBBS, Sam Jalloh,
MBBS, FRCPath, Ravi Madhotra, MBBS, MD, FRCP, MACG∗.
Gastroenterology, Milton Keynes General Hospital, Milton Keynes, United
Kingdom and Pathology, Milton Keynes General Hospital, Milton Keynes,
United Kingdom.
Primary hepatic leiomyosarcoma is a rare tumour of the liver. It usually
arises from intrahepatic vascular structures, bile ducts or ligamentum teres.
We present a patient who presented with right upper quadrant mass and
died of post-liver biopsy haemorrhage. Primary hepatic leiomyosarcoma
was diagnosed on autopsy.
A 67 year old Caucasian woman presented to her primary physician with
a three week history of abdominal pain in June 2006. She was taking as-
pirin, and atorvastatin. She drank little alcohol and did not use any other
drugs. Examination, including breast, was unremarkable apart from a 20
cm firm, non-tender hepatomegaly. She had normocytic anaemia. Liver tests
and viral serology for Hepatitis B and C were normal. Tumour markers were
normal. An USS scan of the abdomen revealed an 18 cm right upper quad-
rant mass arising at the level of the liver. She went on the have contrast CT
scan of the liver, which confirmed a mass arising from the right lobe of the
liver (Fig. 1) with at least two other lesions arising from segment four and
the left lobe, raising the likely possibility of hepatocellular carcinoma. An
USS-guided liver biopsy was non-diagnostic and the patient, unfortunately,
suffered a terminal haemorrhage following the procedure. Autopsy was car-
ried out and histology of hepatic mass confirmed the lesion to be primary
liver leiomyosarcoma (Fig. 2).
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Primary hepatic leiomyosarcoma although rare should be considered in
the differential diagnosis of patients with large hepatic mass in absence of
cirrhosis and other risk factors for hepatocellular carcinoma. Furthermore
it highlights the still appreciable biopsy related morbidity and mortality,
particularly in patients with large hepatic masses.[figure1][figure2]
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Fatal Lactic Acidosis Associated with Combination Oral Antiviral
Therapy for Hepatitis B Reactivation Following Chemotherapy
Ronald M. Levy, MD, Stanley M. Cohen, MD∗, David H. Van Thiel, MD,
Joseph Ahn, MD. Hepatology and Gastroenterology, Rush University
Medical Center, Chicago, IL.
Introduction: Reactivation of Hepatitis B virus (HBV) infection following
the administration of chemotherapy is a potentially lethal complication. Oral
HBV antiviral medications are generally very well tolerated and can be
used both prior to chemotherapy and to treat the actual reactivation. We
report a case of HBV reactivation from chemotherapy and a potentially fatal
complication of the treatment.
Case Report: A 54 y/o Croatian male with chronic lymphocytic leukemia
(CLL) developed severe hepatitis one week after chemotherapy. He had no
known history of liver disease, family history of liver disease, alcohol use, or
use of other medications. All prior LFTs were normal, with no prior testing
for viral hepatitis. Admission examination revealed jaundice. Laboratory
data showed a protein 5.4 mg/dL, albumin 2.7 mg/dL, alkaline phosphatase
112 U/L, bilirubin 20.9 mg/dL, AST 2853 U/L, ALT 3521 U/L, and an INR
of 1.76. Electrolytes, kidney function, and abdominal ultrasound were all
normal. Hepatitis B surface antigen and HBV-DNA were found to be positive.
Serologies for other viral infections and autoimmune hepatitis were negative.
A diagnosis of HBV reactivation was made, and therapy with entecavir,
adefovir, and prednisone was begun. Liver biopsy revealed severe hepatitis,
cholestasis, cirrhosis, and positive HBsAg immunostaining. His laboratory
values improved, and he was discharged home after a 12 day hospitalization.
Ten days later, the patient presented with shortness of breath. He was hy-
potensive, hypoxic, coagulopathic (INR 4.4), in renal failure, with a profound
metabolic lactic acidosis. LFTs revealed bilirubin 32.7 mg/dL, AST 141 U/L,
and ALT 264 U/L. There was no clinical evidence of a perforated viscous. He
was intubated, dialyzed, given broad spectrum antibiotics, and adefovir and
entecavir were discontinued. The patient expired within 24 hours. Autopsy
failed to provide any gross explanation for his lactic acidosis, and all growth
from blood cultures was negative.
Discussion: This case report illustrates that reactivation of HBV after
chemotherapy remains a major clinical issue. Prior to chemotherapy, pa-
tients should undergo testing for HBV. This case may also illustrate a rare
but fatal side effect of HBV nucleoside/nucleotide analogues: lactic acidosis
due to mitochondrial toxicity. Clinicians should be aware that significant
side effects can occur with oral HBV antiviral agents.
567
Rare Extra-Intestinal Manifestation of Ulcerative Colitis
Jeanette Smith, Eric Newton, Petr Protiva∗. Gastroenterology, University
of Connecticut, Farmington, CT.
A 20 year old black male with acne and severe steroid dependant UC for
8 years was admitted for worsening diarrhea after failure to taper steroids.
He was previously doing well on 6-MP, steroids and mesalamine. Other
symptoms included worsening facial and body pustular acne and localized
anterior chest wall swelling. These symptoms were also present during his
last colitis flare and resolved upon improvement of colitis.
Physical exam revealed a striking 4 cm tender, fluctuant swelling over the
right sternal manubrium. He exhibited mild abdominal tenderness and se-
vere facial and truncal pustular acne. Chest CT scan was consistent with
osteomyelitis of right clavicle at the sterno-clavicular joint and fluid collec-
tion in the joint space. Subsequent CT-guided aspiration was performed and
patient was started on broad-spectrum antibiotics for presumed infectious
osteomyelitis. However, Gram stain was negative and no growth in bacte-
rial, fungal, or AFB cultures was detected suggesting diagnosis of sterile
osteomyelitis and antibiotics were discontinued. The patient’s clinical, ra-
diological and histopathological features led to a conclusive diagnosis of
synovitis-acne-pustolosis-hyperostosis-osteitis syndrome (SAPHO), a rare
extra-intestinal manifestation of IBD. In this patient SAPHO was also present
during previous colitis flares and paralleled severity of disease, resolving
upon remission of colitis. The patient was initiated on infliximab therapy
for both steroid dependent UC and SAPHO syndrome with good clinical
response.
The acronym SAPHO was proposed in 1987 to designate a clinical and
radiological entity combining skin, bone and joint manifestations. A ma-
jor component is an inflammatory osteitis with negative cultures and main
site for inflammation is the anterior chest wall. There is an association with
HLA B27 positivity suggesting a link between the SAPHO syndrome and the
spondyloarthropathies. The first line treatment of SAPHO syndrome is with
NSAIDs and analgesics. Other regimens include sulfasalazine, methotrexate
and TNF-α inhibitors. In our patient, we chose to institute TNF-α inhibitor
therapy with infliximab because of the patient’s steroid dependent UC, fail-
ure to improve on immunomodulator therapy and concomitant SAPHO syn-
drome. The association of SAPHO syndrome and IBD is recognized but
reports are extremely rare.
In summary, the SAPHO syndrome is a rarely documented entity and must
be considered in the differential diagnosis when evaluating patients with
extra-intestinal manifestations of IBD.
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Extraluminal Source of Upper Gastrointestinal Bleeding
Kiran Jagarlamudi, MD∗, Rodney Eddi, MD, Walid Baddoura, MD, Alexis
Bobila, MD. Gastroenterology, St. Joseph’s Regional Medical Center,
Paterson, NJ and Seton Hall University School of GME, South Orange, NJ.
Upper gastrointestinal (UGI) bleeding has many etiologies. We present a
unique case of UGI bleeding secondary to an extraluminal source.
A 79 year old Caucasian male presented twenty days after an abdominal
aortic aneurysm (AAA) repair, with a one-day history of several episodes of
black tarry stools, fatigue and dizziness. He denied abdominal pain, nausea or
vomiting. Vital signs were stable. Abdominal exam was completely benign.
Rectal exam revealed black stools. He was started on an IV proton pump
inhibitor. Labs showed: Hb = 8.7, BUN/Cr = 25/1.2. CT scan of abdomen
was significant for a contained air-fluid collection adjacent to the proximal
duodenum. Endoscopy revealed clotted blood in the stomach, and a large
cavity in the distal duodenal bulb with clots but no active bleeding. Bile was
noted in the distal duodenum. On the following day, the patient developed
large amount of bright red hematemesis which prompted emergency surgical
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exploration. There was a large perforation of the proximal duodenum. Upon
evacuation of large clots from the periduodenal collection, active bleeding
was noted to be originating from the right gastric vein located on the serosal
surface. Suture ligation of the superior duodenal artery and right gastric
vein was performed, followed by closure of the duodenal perforation using
an omental patch.[figure1][figure2]
This case illustrates a unique presentation of UGI bleeding. It is likely that
the patient- post AAA repair-developed a contained perforated duodenal
ulcer, thus accounting for paucity of symptoms. It is not clear what initiated
the serosal venous bleeding, but acid and pepsin might have played a role.
To our knowledge, this is the first such reported case.
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Transient Pancreatic Hiatal Herniation Causing Acute Pancreatitis
Gupreet Singh, MD, Charbel Maksoud, MD, Suresh Jayatilaka, MD,
George Pavlou, MD, Walid Baddoura, MD∗. Gastroenterology, St.
Joseph’s Regional Medical Center, Paterson, NJ.
Herniation of the pancreas through a diaphragmatic hiatal hernia is an ex-
tremely rare condition reported in only three cases worldwide, of which two
resulted in acute pancreatitis. Our case describes a transient herniation of
the pancreas that presented with acute pancreatitis.
A 68 year-old man with a prior history of uncomplicated hiatal hernia pre-
sented with an ill-defined epigastric discomfort associated with intractable
nausea and numerous episodes of non-bilious vomiting. Physical exam was
unremarkable. Laboratory workup suggested acute pancreatitis. Abdominal
CT revealed partial pancreatic (body and tail) herniation into the upper me-
diastinum along with a complete herniation of the stomach and transverse
colon. A prior CT had showed only an isolated hiatal hernia without any
evidence of pancreatic displacement. The hospital course was complicated
by sepsis and dehydration. A repeat pre-operative CT showed the pancreas to
be intra-abdominally located. The patient underwent laparoscopic reduction
of the hernia with partial gastric fundoplication. The post-operative course
was uneventful.[figure1]
Hiatal hernia is commonly defined as the protrusion of the upper part of the
stomach into the thorax through a tear or weakness in the diaphragm. Though
the herniation of abdominal organs such as colon, small intestine and spleen
have been well described, pancreatic involvement is rare. Although total or
partial gastric outlet obstruction may complicate a large hiatal hernia, one
has to entertain the rare possibility of pancreatic herniation with or without
pancreatitis, as exemplified by our case.
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Infiltrating Ductal Breast Carcinoma Metastasis to Rectum, an
Uncommon Occurrence
Suresh Jayatilaka, MD, Alka Farmer, MD, Gurpreet Singh, MD, Hossam
Elfarra, MD∗. Gastroenterology, St. Joseph’s Hospital Medical Center,
Paterson, NJ.
Breast cancer is the most common cancer and the second most common
cause of cancer-related mortality in women in the US. Breast carcinoma
usually metastasizes to local and regional lymph nodes, bone, lung, brain,
liver, adrenal glands, and pleura. However, metastasis to GI tract structures
other than liver and peritoneum is an extremely uncommon occurence. We
present a case of established infiltrating ductal carcinoma of the breast with
metastasis to the rectum.
A 55 year-old African-American woman presented with complaints of nau-
sea, vomiting of 2 days duration and constipation. The patient’s medical
history was significant for left breast cancer initially diagnosed by biopsy.
Neoadjuvant therapy was given followed by simple extended mastectomy.
Pathology revealed moderately differentiated infiltrating ductal carcinoma
with negative lymph nodes. Two months later, after restaging PET scan
had demonstrated multiple metastases to the ipsilateral lymph nodes, lung
parenchyma and chest wall, chemotherapy was started. Abdominal examina-
tion was unremarkable; stool was occult-blood positive. CT of abdomen was
normal. A colonoscopy revealed two small sessile polyps in the ascending
colon and rectum, respectively, with resultant polypectomy. Pathology and
immunohistochemistry of the rectal polyp showed poorly differentiated infil-
trating ductal carcinoma, consistent with metastastic breast cancer.[figure1]
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Eighty percent of invasive breast cancers are ductal, but distant metastasis to
unusual locations such as peritoneum, meninges and the gastrointestinal tract
is more frequently seen with infiltrating lobular carcinoma. In one series of 41
patients, GI metastasis in patients with invasive lobular carcinoma was twice
as much as in cases of invasive ductal carcinoma (34% vs 17% respectively).
Rectal involvement by breast cancer is very rare and represents the least
frequent metastatic site in the GI tract. Systemic treatment with hormonal
and/or chemotherapy is usually the only option in these patients because of
multi-organ involvement.
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Autoimmune Pancreatitis Masquerading as Pancreatic Cancer
Rada Shakov, MD, Kiran Jagarlamudi, MD∗, Hossam Elfarra, MD, Walid
Baddoura, MD. Gastroenterology, St. Joseph’s Regional Medical Center,
Paterson, NJ and Seton Hall University School of GME, South Orange, NJ.
Autoimmune pancreatitis (AIP) is a rare form of pancreatitis with mild
attacks of abdominal pain, pancreatic enlargement, and changes of the pan-
creatic duct (PD) and CBD. We present a case of AIP mimicking a cholan-
giocarcinoma.
A 50 year old female presented with 5 days of scleral icterus, pruritus, malaise
and fatigue. She denied nausea, vomiting, weight loss, or abdominal pain.
Vitals were stable and physical exam was benign.
Labs showed T. Bili 8.14, AP 562, GGT 286, AST 264, ALT 427, Amylase
46, Lipase 18, ANA negative, pANCA < 1:20, and ASMA 9 (negative).
Abdominal ultrasound described a heterogenously enlarged pancreatic body,
and a 1 cm common bile duct. MRI showed diffusely enlarged and hetereoge-
nous pancreas with CBD obstruction at the pancreatic head. ERCP revealed
dilated CBD with a distal 4 cm stricture. After sphincterotomy a biliary
stent was placed and antibiotics were begun. Fragments of fibroadipose tis-
sue with lymphoplasmacytic cells and few eosinophils, without evidence of
lymphoma were seen on pancreatic biopsy.
A trial of prednisone 40 mg daily was started and remarkable improvement
was noted within weeks, with jaundice resolution and normalization of LFTs.
Repeat imaging studies, including ERCP showed a normal pancreas and
CBD.[figure1][figure2]
AIP is a chronic pancreatic inflammation characterized histologically by
lymphoplasmacytic inflammation. Elevated IgG and IgG4 are useful diag-
nostic markers. Imaging studies reveal pancreatic swelling with narrowing
of the PD and distal CBD. Whenever considering either cholangiocarcinoma
or pancreatic cancer, AIP must be included in the differential diagnosis to
avoid unnecessary surgery. The dramatic response to oral steroids is the most
useful clue to the diagnosis of AIP, leading to reversibility of pancreatic mor-
phology and dysfunction.
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Prurigo Nodularis in a Patient with Hepatic Sarcoidosis
Suresh Jayatilaka, MD, Habib ElGhoul, MD, Theodore Dacosta, MD,
Robert Spira, MD∗. Gastroenterology, St. Michael’s Medical Center,
Newark, NJ.
Prurigo Nodularis (PN) is a rare skin condition characterized by multiple
pruritic hard crusty excoriated nodules. PN is the end result of chronic
scratching which induces nerve thickening and eventually results in per-
manent skin changes, including nodular lichenification, hyperkeratosis, and
hyperpigmentation. The true cause of this condition is unknown. Factors trig-
gering PN include HIV and other immunodeficiency diseases, liver failure,
renal failure, psychiatric illness, and skin diseases.
A 41-year old female with a past medical history significant for sarcoidosis
of the lung and liver of ten years duration presents with a two year history of
chronic intense pruritis refractory to treatment with topical steroids and ur-
sodiol. A liver biopsy two years prior revealed hepatic granulomas consistent
with sarcoid of the liver. Physical examination was significant for jaundice
and diffuse, hyperpigmented, firm, scaly, and excoriated lesions on the arms,
legs, and torso. Laboratory studies revealed increased alkaline phosphatase
and bilirubin with mild elevations in transaminases. Extensive workup for
cholestasis included negative auto-antibodies, negative viral hepatitis mark-
ers, normal ERCP, and inconclusive imaging studies. A repeat liver biopsy
showed chronic hepatitis, piecemeal necrosis, and moderate fibrosis. Punch
biopsy of the skin showed changes consistent with PN.
A variety of systemic conditions have been reported to be associated with PN,
amongst which is liver disease. Nerve growth factors have been implicated
in the pathogenesis. Topical or intralesional glucocorticoids are considered
to be first-line therapy. Other options include topical vitamin D3, topical
capsaicin, cyclosporin and thalidomide which can improve both appearance
of the skin and pruritus.
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Large Descending Colon Lipoma Causing Intussusception and
Mimicking Malignancy
Patrick D. Martin, MD, Bradford Sklow, MD, Douglas G. Adler, MD∗.
Gastroenterology, University of Utah, Salt Lake City, UT.
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Presentation & History: A 69-year-old previously healthy male presented
with a 1-month history of hematochezia and 10 lb wt loss. The patient de-
nied any changes in bowel movement frequency; he continued to average
1–2 bowel movements per day. The patient denied abdominal pain, nausea
or vomiting. Previous medical history included an appendectomy and her-
nia repair, ankle fracture. The patient took no medications, and denied any
behavioral risk factors. Family history revealed a daughter with ulcerative
colitis, and no colorectal cancer.
Physical Exam & Laboratory Evaluation: Physical exam was unremark-
able. The complete blood count and the basic metabolic panel were normal.
CT revealed a mass in the descending colon with partial intussusception in-
volving the sigmoid colon, suggestive of carcinoma. There was no adenopa-
thy or evidence of metastases.
Treatment & Hospital Course: Colonoscopy revealed a 7 cm, peduncu-
lated, ulcerated, fungating mass with partial intussusception just distal to the
splenic flexure at 70 centimeters from the anal verge. Biopsies only revealed
inflammation.[figure1]A repeat colonoscopy was performed and the lesion
was removed with a large snare and electrocautery. Pathology revealed a
lipoma with no evidence of malignancy. The patient has done well there-
after.
Discussion: This case is unusual for several reasons: First, colonic lipo-
mas are comparatively rare, with a reported incidence less than 5%. Second,
colonic lipomas are positively correlated with distance from the anus. Our pa-
tient’s lipoma was found in the descending colon. Third, colonic lipomas are
most frequently small and asymptomatic. Lipomas larger than 2 cm are more
often symptomatic, potentially causing obstruction, bleeding, or– very rarely
– intussusception. Our patient had both a symptomatic and intussuscepted
lipoma. Fourth, grossly, lipomas are generally covered by smooth mucosa.
Our examination revealed an ulcerated fungating mass that appeared grossly
malignant.
Large lipomas associated with intussusception are not easily differentiated
from malignancies. Our experience shows that lipomas with unexpected
gross appearance can also be easily mistaken for malignancy.
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Recurrent Gastric Telangiectasias Despite Argon Plasma Coagulation
in a Patient with Osler-Weber-Rendu Syndrome
Simon C. Chan, MD, Ashok Shah, MD∗. Gastroenterology, University of
Rochester Medical Center, Rochester, NY.
Osler-Weber-Rendu syndrome is an inherited disorder characterized by re-
current bleeding of mucocutaneous telangiectasias. Argon plasma coagula-
tion (APC) has been used successfully to treat lesions in the gastrointestinal
tract. Here, we report a case of bleeding gastric telangiectasias with an un-
usual pattern of recurrence.
A 71 year-old woman with known Osler-Weber-Rendu syndrome has been
followed in our clinic for over four years. She has a long history of iron
deficient anemia due to intermittent bleeding from gastric telangiectasias.
Over the last three years, she has required periodic blood transfusions to
maintain a stable hematocrit despite APC of these lesions every one to two
months.
Multiple telangiectasias were seen in the distal half of the stomach on ini-
tial endoscopy. An ulcer later developed due to aggressive cautery. During
subsequent sessions, telangiectasias were seen radiating from the periphery
of this ulcer. Despite repeated APC, these telangiectasias increased in size
and new ones were seen in the ulcer bed itself. With further treatment ses-
sions, these lesions became increasingly ectactic and numerous. During her
most recent endoscopic sessions, these lesions continued to bleed despite
long pulses of APC. Adherent clots were seen overlying previously treated
telangiectasias. At this time, the patient required two units of packed red
blood cells each week to maintain a hematocrit of 28 to 30%.
Because of the failure of endoscopic therapy, the patient underwent laparo-
scopic partial gastrectomy with Billroth II anastomosis. The patient did well
postoperatively and has not required any further blood transfusions.
APC has been used successfully to treat vascular ectasias of the gastroin-
testinal tract. A recent report of a patient with Osler-Weber-Rendu syndrome
documented a poor response of gastric telangiectasias to APC. Although
similar results were observed in this case, we have documented progression
of these lesions over fourteen endoscopic sessions. This progression may
represent the natural history of evolution in response to APC and may lead
to insights to more effective treatment of these lesions.[figure1]
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An Unusual Presentation of Eosinophilic Esophagitis
Adam J. Spiegel, DO, Kirk Sperber, MD, David C. Wolf, MD∗. Division of
Gastroenterology, New York Medical College, Valhalla, NY and Division of
Allergy and Immunology, New York Medical College, Valhalla, NY.
Case Report: A 91 year old male presented with severe dysphagia symp-
toms. For six years, the patient noted mild dysphagia to solids. In the three
months leading up to presentation, he complained of severe difficulty swal-
lowing both solids and liquids, with a resulting 15 pound weight loss.
The patient had a history of allergic rhinitis which flared during the spring and
fall. He denied use of NSAIDs or any adverse reactions to foods. Esomepra-
zole was started two months prior to admission, but resulted in minimal
improvement of symptoms.
Physical examination revealed an elderly male with normal vital signs. Ex-
amination of the head, neck, chest, abdomen, and extremities was normal.
On upper endoscopy, the esophagus was edematous, avascular, and had a
cobblestone appearance. There were diffuse white plaques and a scale-like
appearance. There were no signs of stricture, mass, or external compression.
Both the stomach and the duodenum were normal. Biopsies from the proxi-
mal, mid, and distal esophagus all demonstrated greater than 100 eosinophils
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per high power field. The patient was diagnosed with eosinophilic esophagi-
tis (EE). The patient was skin prick and patch tested to a panel of aeroal-
lergens and foods. He was highly atopic to various seasonal and perennial
aeroallergens. However, testing was negative to all food allergens. Treat-
ment was initiated with fluticasone 440 mcg orally twice per day. By seven
days, the patient was tolerating a regular diet with no further complaints of
dysphagia.
Discussion: In previous case reports describing EE in adults, the mean age of
the patients was younger than 50, with only four patients being older than 65.
We report the first case of eosinophilic esophagitis in a nonagenarian. Endo-
scopic evaluation of EE typically reveals mucosal rings, corrugations, stric-
tures, linear furrowing, mucosal fragility, and/or whitish vesicles or plaques.
Our patient had a severely edematous and avascular-appearing esophageal
mucosa with an overlying whitish scale. Although the endoscopic findings
in this case were not typical of EE, the histology was highly consistent with
EE.
This case emphasizes that EE should be considered in the differential diag-
nosis of adults who present with dysphagia, regardless of their age. It also
demonstrates the importance of biopsies from the proximal and mid esoph-
agus, even if the typical endoscopic hallmarks of EE are not encountered.
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An Unusual Case of Three Synchronous Primary Gastrointestinal
Carcinomas
Nan Sandar, MD, SriKrishna Nagri, MD, Zeyar Thet, MD, Richard
Hwang, MD, Khalid Zaalook, MD, Sury Anand, MD, Carl Guillaume,
MD∗. Gastroenterology, The Brooklyn Hospital Center, Brooklyn, NY;
Medicine, Long Island College Hospital, and Gastroenterology, St.
Barnabas Hospital, Bronx, NY.
A 57 year old man presented with complaint of on and off vomiting and 20 lb
weight loss within 8 months. He was treated for prostate cancer with radiation
therapy about a year ago. Family history was significant for prostate cancer
in his uncle and uterine cancer in his sister in their fifties. Lab studies showed
iron deficiency anemia and positive fecal occult blood test. Esophagogastro-
duodenoscopy was unremarkable. Colonoscopy revealed a large fungating
mass in the ascending colon and biopsy showed moderately differentiated
adenocarcinoma. A right hemicolectomy was performed which showed two
separate tumors in the ascending colon measuring 3 cm and 6.5 cm respec-
tively, separated by 1.5 cm of normal mucosa. The postoperative course
was complicated by obstipation and increased amount of nasogastric tube
drainage. Computed tomography of abdomen and pelvis showed markedly
distended stomach and duodenum and abrupt transition point in the proxi-
mal small bowel with no contrast beyond that level. Exploratory laparotomy
showed an obstructing mass in the 3rd portion of the duodenum for which
duodenectomy with primary duodenojuejunostomy was performed. Patho-
logical examination revealed a 3.5 cm circumferential obstructing adeno-
carcinoma of the duodenum. Tumor tissue was tested high for microsatellite
instability and genetic testing showed homozygous MSH 2 mutation.
Small intestinal carcinomas are among the rarest types of cancer account-
ing for only 2% of gastrointestinal carcinomas. Though it is included in
the tumor spectrum of Hereditary Non-Polyposis Colorectal Cancer, its in-
cidence in those patients is rare. To the best of our knowledge, this is the
first case report of three synchronous primary gastrointestinal carcinomas.
[figure1][figure2]
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Localized Aspergillus Esophagitis: A Difficult Diagnosis of Persistent
Odynophagia Leading to a Diagnosis of AIDS
Syed-Mohammed Jafri, MD, Anand Madan, MD∗. Division of
Gastroenterology, University of Texas Health Science Center, Houston, TX.
A forty-seven year old African American female without any significant
medical history presented complaining of a one week history of odynopha-
gia, weight loss, and subjective fevers. A barium swallow study demon-
strated five millimeter ulcers throughout the esophagus. Esophagogastro-
duodenoscopy (EGD) showed white plaques throughout the esophagus.
Brushings were performed which suggested Candidiasis. The patient was
treated with fluconazole for ten days but without any relief. After two weeks
of persistent and worsening symptoms including continued weight loss, re-
peat EGD showed continued white plaques throughout the esophagus. Multi-
ple biopsies were performed which revealed numerous diffuse narrow angle
branching hyphae within the esophageal mucosa consistent with Aspergillus.
There were no signs of any disseminated disease. On further work-up, the
patient was diagnosed with AIDS with a CD4 count of one. An increased
dose of fluconazole was continued for two weeks with improvement in symp-
toms and HAART therapy for HIV/AIDS was initiated. Disease due to tissue
invasion by Aspergillus is uncommon and occurs primarily in the setting of
immunosuppression. Gastrointestinal disease secondary to Aspergillus is
usually seen only in the most severely immunocompromised patients, espe-
cially those with prolonged severe neutropenia. While gastrointestinal tract
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involvement is not uncommon in the context of disseminated disease, it is
rarely a localized site of infection. In a series of 3374 autopsies including a
large proportion of cardiac and oncology patients, Young et al observed inva-
sive aspergillosis in ninety-eight cases with gastrointestinal tract disease in
twenty-one percent. In one series approximately one-third of cases with dis-
seminated aspergillus infection had gastrointestinal involvement including
esophageal lesions in five cases, with no localized gastrointestinal infection.
The histological appearance of typical fungal hyphae with associated tis-
sue damage is sufficient for definitive diagnosis of invasive fungal infection
in accordance with published guidelines. We present a rare case of local-
ized gastrointestinal invasive aspergillosis in the absence of disseminated
disease.
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A Rare Case of Metastasis-Induced Acute Pancreatitis in a Patient
with Small Cell Carcinoma of the Lung
Matthew M. Tsushima, MD, Wichit Srikureja, MD∗. Gastroenterology,
Loma Linda University Medical Center, Loma Linda, CA.
Acute pancreatitis caused by metastatic carcinoma to the pancreas is un-
common. We report a rare case of metastasis-induced acute pancreatitis
with small cell carcinoma of the lung.
A 49 year old female, smoker, with history of small cell carcinoma with
limited disease to the right lung, was admitted with constant epigastric ab-
dominal pain radiating to the back for 4 days. The patient denied any fever,
chills, or nausea. One month earlier she had completed 1 cycle of chemother-
apy with cisplatin and etoposide. She denied any history of heavy alcohol
use or hypertriglyceridemia.
On admission, the patient was afebrile and in mild distress. Temperature
was 98.1◦F, blood pressure was 127/76 mm Hg, pulse was 78/minute, and
respiration rate was 20/min. Physical examination revealed mild bibasilar
crackles. The bowel sounds were normoactive. Mild tenderness to palpa-
tion was noted over the mid-epigastric region without rebound tenderness,
guarding, or palpable mass. Laboratory evaluation revealed a lipase of 2206
IU/dL [10–45 IU/dL], white blood cell count of 32.3 × 103/µL [4.8–11.0
× 103/µL], and hematocrit of 29.1% [37–47%]. Liver tests and creatinine
were all in normal range.
CT scan of the abdomen revealed a 2.3 × 2.2 cm hypodense mass in the head
of the pancreas without associated pancreatic or common bile duct dilatation.
In addition, multiple small liver lesions and a moderate right pleural effusion
were noted. To clarify the lesion seen on the pancreas, EUS-guided FNA of
the mass in the pancreas was performed. The cytology revealed malignant
cells consistent with small cell carcinoma of the lung.
The patient was managed conservatively with dietary restriction, narcotics
for pain control, and parenteral fluids. Although her pain improved, serum
lipase was persistently elevated up to 1000 IU/L. Subsequently, she experi-
enced increasing shortness of breath. She elected for comfort care and died
a few days later. Metastasis-induced acute pancreatitis is rare and can occur
as the initial presenting manifestation of a carcinoma or late in the course of
the disease. Mechanisms of acute pancreatitis in our patient is unclear but
may include mass effect on the pancreas and/or mechanical pancreatic duct
obstruction. Chemotherapy, surgery and endoscopic intrapancreatic stenting
may be considered. However, the overall prognosis, as seen in our case, is
extremely poor.
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Suspected Asymptomatic Large Colon Lipoma: Biopsy?
Pavan Manchikalapati, MD, Brian Moquin, MD, John Levey, MD∗.
Gastroenterology, University of Massachusetts, Worcester, MA.
Lipomas are the second most common benign tumors of the colon, after
adenomatous polyps. Management of incidentally detected asymptomatic
large colon lipomas has not been well studied. To our knowledge, this is the
first case report of asymptomatic colon lipoma that was complicated by both
hemorrhage and bowel obstruction after endoscopic biopsy.
Case report: A 59-year-old female with history of hypertension and hyper-
lipidemia, underwent routine colonoscopy that showed 3.5 cm lipomatous
appearing polyp in the sigmoid colon. Patient was referred to gastroenterol-
ogy clinic for evaluation of the sigmoid mass. At this point, review of systems
was negative. Patient had no previous surgeries and family history was un-
remarkable. Patient was taking Atorvastatin and hydrochlorothiazide. One
year after her initial procedure, a repeat colonoscopy revealed a 3.5 cm, soft,
mobile, pedunculated mass in the sigmoid colon with positive pillow sign
(indents when depressed using biopsy forceps) and was biopsied with cold
forceps. Histopathology revealed smooth muscle prominence and fibrovas-
cular tissue. One week after the procedure patient presented with bright red
blood per rectum and mild crampy abdominal pain. The patient was hemo-
dynamically stable at her baseline hemoglobin level. Physical exam revealed
left lower quadrant tenderness on deep palpation with no peritoneal signs.
The patient underwent immediate flexible sigmoidoscopy that showed com-
pletely obstructing purplish mass in the sigmoid colon with an overlying
clot. Virtual colonoscopy was performed which showed a pendunculated
soft tissue density consistent with lipoma and 2.9 cm mass in the lumen of
sigmoid colon consistent with hematoma. Patient was managed conserva-
tively; bleeding resolved spontaneously and was discharged to home. During
six months of follow-up patient remained asymptomatic.
Conclusion: Colon lipomas, can be diagnosed by colonoscopy by their char-
acteristic features i.e, mobile, soft mass with positive pillow sign and CT
scan appearance of smooth borders and uniform fat equivalent density. In
our review, out of 22 colon lipoma biopsies reported in literature only 4 are
conclusive with a diagnostic yield of 18%. In addition to a low diagnostic
yield, biopsy may result in complications such as bleeding or obstruction. We
report a novel case in which both bleeding and colonic obstruction resulted
from biopsy of a large sigmoid lipoma. For this reason EUS evaluation is
likely preferable to biopsy of these lesions.
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Consequences of a “Dropped Pass”: Liver Abscess Due to Eikenella
corrodens
Joanna M. Peloquin, MD, Gautam Kumar, MBBS, Stephen C. Hauser,
MD∗. Medicine, Johns Hopkins Hospital, Baltimore, MD; Cardiology,
Mayo Clinic, and Gastroenterology and Hepatology, Mayo Clinic,
Rochester, MN.
Case report: A 64-year-old man presented with right upper quadrant pain
and fever for 3 days and a 3 week history of malaise following laparoscopic
cholecystectomy for acute cholecystitis. The operative note described gall-
bladder rupture and spillage and suction recovery of multiple pigmented
stones. On exam, he had stable vitals and a nodular, tender liver edge 3 cm
below the right costal margin. White blood cell count was elevated to 13.2
× 109/L. Computed tomography of the abdomen/pelvis revealed a 6 cm
liver abscess in right, posterior lobe. Following percutaneous drainage, sino-
gram showed a large, rounded filling defect within the cavity consistent with
a retained stone (Fig. 1). Abscess fluid cultures grew Eikenella corrodens
and Prevotella ovis. Blood cultures were negative. Antibiotic coverage of
levofloxacin and metronidazole was switched to ertapenem. The drain was
removed after 18 days, and the patient completed a 1 month course of er-
tapenem. He reported symptom resolution, and follow-up CT demonstrated
near complete resolution of the abscess.
Discussion: During the 375,000 laparoscopic cholecystectomies performed
annually, dropped gallstones occur with a reported incidence ranging from
3–33%. Of these, the risk of complications ranges from 2.3–12% of cases,
presenting 4–9 months post-operatively. Complications described include
bowel obstruction, fistula, and intra-abdominal abscess. As seen in this pa-
tient, pigmented stones and acute cholecystitis are known risk factors for
gallbladder rupture during laparoscopy. Yet, our patient’s presentation on
the 21st post-operative day makes this one of the earliest reported cases of
a post-operative complication secondary to a dropped gallstone. Abscesses
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associated with dropped gallstones most frequently grow Enterococcus, E.
coli, and Klebsiella. Eikenella corrodens is a pathogen usually associated
with bite wounds, and few examples of Eikenella liver abscesses exist in
the literature. Eikenella is commonly resistant to metronidazole, making
recognition of infection particularly important for adequate antimicrobial
therapy.[figure1]
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Endoscopic Diagnosis of Boerhaave’s Syndrome
Travis J. Rutland, MD, John-Paul Voelkel, MD, Herbert A. Phelan, MD,
Reynaldo Rodriguez, DO∗. Division of Gastroenterology, University of
South Alabama, Mobile, AL and Department of Surgery, University of
South Alabama, Mobile, AL.
Case Presentation: A 78 year old male presented with chest pain and dys-
pnea. Four days before he underwent transrectal prostate biopsy and subse-
quently had gross hematuria. On the day of presentation he had micturation
syncope but denied chest trauma.
Physical examination, EKG and cardiac enyzmes were normal. Chest x-ray
showed a layering fluid collection in the left chest. Thoracentesis revealed
600 cc of bright red blood. Chest tube was placed. The patient required me-
chanical ventilation and was hemodynamically unstable, prompting abortion
of planned chest CT and emergent surgical exploration. Anterolateral tho-
racotomy revealed 1500 cc of blood clot which was removed. No significant
injury, other than a bleeding needle tract from the diagnositic thoracentesis,
was observed.
The patient developed massive hematemesis and an upper endoscopy showed
a laceration in the distal esophagus with visualization of pulmonary tissue.
Exploration though a posterolateral thoracotomy widely opening the medi-
atinal pleura, identified the esophageal tear which was primarily repaired in
one layer. Despite critical care and multiple transfusions, the patient expired.
Boerhaave’s Syndrome is a barogenic rupture of the esophagus which clas-
sically has a preceding episode of emesis. Mackler’s triad of vomiting, chest
pain, and subcutaneous emphysema is seen in about 50%. Rapid diagnosis
and treatment is essential.
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MRI Differentiates Anoxic Brain Injury from Liver Failure Associated
Cerebral Edema in Ecstasy (MDMA) Toxicity
Joshua E. Melson, MD, Joseph Ahn, MD, MS∗, Shyam Prabhakaran, MD,
MS, Stanley Martin Cohen, MD. Hepatology, Rush University Medical
Center, Chicago, IL and Neurology, Rush University Medical Center,
Chicago, IL.
“Ecstasy” (3,4 methylenedioxymethamphetamine, MDMA) is a popular
recreational drug associated with acute liver failure, serotonin syndrome,
rhabdomyolysis, cerebral edema, and stroke.
Case: An 18 year old healthy male presented with obtundation following
consumption of ecstasy. On admission, he was intubated for airway protec-
tion and noted to have liver and renal failure. Laboratory testing revealed
WBC 21.3 × 109/L, creatinine 2.1 mg/dL, INR 1.84, CPK 6000 U/L, AST
4551 U/L, ALT 3224 U/L, bilirubin 2.2 mg/dL, alkaline phosphatase 139
U/L, and Factor V 19%. ANA, ASMA, HBsAg, HAV IgM, HCV Ab, and
ceruloplasmin were negative. The patient was started on N-acetylcystine. A
head CT showed well-defined, symmetric hypodensities in the globus pal-
lidi, cerebellum, and cortex. EEG showed diffuse slowing with no seizure
activity. The patient was noted to have decerebrate posturing. MRI showed bi-
lateral restricted diffusion in the globus pallidi and subcortical white matter,
consistent with irreversible cytotoxic injury rather than reversible vasogenic
edema from hepatic encephalopathy. The postulated mechanism of toxicity
was from direct excitotoxicity due to ecstasy. An echocardiogram did not re-
veal a right-to-left shunt or thrombus. The bilirubin, INR, transaminases, and
creatinine normalized over seven days but the patient continued to remain
comatose with decerebrate posturing. Comfort measures were instituted.
Conclusion: This case demonstrates a patient with MDMA toxicity who
presented in liver and renal failure with a coma from anoxic brain injury.
Initially, his coma was attributed to hepatic encephalopathy. He met Clichy
criteria for liver transplantation: Factor V less than 20%, with grade 4 en-
cephalopathy. However, an MRI with diffusion weighted imaging revealed
irreversible brain injury and based on these findings, the patient was not
listed for liver transplantation. In MDMA toxicity, excessive serotonin re-
lease may lead to cerebral vasoconstriction, stroke, and anoxic brain injury.
Thus, anoxic brain injury may occur independent of acute liver failure. In
MDMA associated liver failure, MRI may be useful to distinguish patients
with permanent brain injury who should be precluded from liver transplan-
tation.
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An Unusual Complication of Nissen Fundoplication
Simon C. Chan, MD, Ashok Shah, MD∗. Gastroenterology, University of
Rochester Medical Center, Rochester, NY.
The Nissen fundoplication reinforces the LES by a circumferential wrap
of the distal esophagus with the gastric fundus. Well known complications
include post-operative dysphagia and persistent heartburn. Here we report
an unusual complication in which the patient had a severe gastrointestinal
bleed from an ulcer on the fundoplication wrap.
A 64 year-old man with a history of GERD and three prior Nissen fundo-
plications (1991, 1993, and 2003) was admitted with a four day history of
dizziness and black stools. Initial bloodwork revealed a hematocrit of 32%,
which fell to 19% over the course of 12 hours. Subsequent upper endoscopy
the following day revealed a submucosal mass in the stomach immediately
distal to the gastroesophageal junction associated with an 8 mm clean based
ulcer. Because the patient was a poor historian, we were not aware that the
patient had had prior antireflux surgery.[figure1]Further evaluation with a
linear endoechoscope revealed a hyperechoic lesion arising from the third
layer of the stomach suggestive of a lipoma or GIST tumor. The patient’s
hematocrit remained stable during his hospitalization and a repeat endoscopy
one week later showed no significant changes in the size or appearance of
the lesion or ulcer.
One month later, the patient had a repeat endoscopy. Examination of the
gastric cardia revealed a swirl of gastric folds associated with a Nissen
fundoplication. Examination with a radial echoendoscope revealed multiple
gastric layers associated with such a wrap.
There are rare case reports of gastric ulcers following a Nissen fundopli-
cation. These ulcers often occur in the proximal stomach (an exceptionally
unusual location) and is thought to be a result of anatomical distortion of
the fundoplication. Here we observed an ulcer located on the fundoplication
wrap itself, resulting in gastrointestinal bleeding. To our knowledge, this
S332 Abstracts
is the first report of such a complication. We suspect that fundoplication
wrap may have been misidentified initally due to bleeding within the gas-
tric submocosa and distention of a gastric fold with subsequent mass-like
appearance. The cause of the ulcer is likely local mucosal ischemia.
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An Unusual Case of Heterotopic Gastric Mucosa Followed for 5 yrs
Deepthi Bollineni, MD, Prem Misra, FACG∗. Division of
Gastroenterology, Wyckoff Heights Medical Center, Brooklyn, NY.
Heterotopic gastric mucosa is either a result of abnormal differentiation of
fetal endoderm or a metaplastic process from regeneration of local mucosa.
It can occur throughout the GI tract, most commonly in the esophagus and
meckels diverticulum. Review of literature suggests duodenal heterotopic
gastric mucosa is fairly rare, usually associated with an ulcer and ranges in
size from 3 mm to 10 mm. Here we illustrate a case of a duodenal heterotopic
gastric mucosa not associated with an ulcer measuring 40 mm. An 89 yr old
caucasian male, was admitted for constipation and anemia. Pertinent positive
findings on physical examination was a positive stool hemoccult on digital
rectal examination. Lab data showed Hb-11.9 mg/dl. CT of the abdomen and
pelvis was negative for any pathology. EGD revealed 40 mm sessile polyp in
the duodenal bulb with an associated esophageal ulcer, hiatal hernia, atrophic
gastritis and grade III esophagitis. Multiple biopsies were taken but the
polyp was not removed. The pathological report showed heterotopic gastric
mucosa. Interestingly, approximately 5 years ago this patient underwent EGD
which reported a flat sessile soft villous 10 mm polyp in the duodenal bulb.
Biopsy report was the same. The pathogenesis of gastric gland heterotopia
is controversial. Some investigators advocate a theory of secondary invasion
of the surface mucosa through a defect in the muscularis mucosa, arising as
a result of inflammation or ulceration, others insist on a congenital origin
based on cases in which no microscopic signs of muscularis mucosal injury
or inflammatory cell infilteration of the mucosal layer were demonstrable.
Experimental evidence suggests that downward adenocystic proliferation of
glands is a dysplastic or a precancerous change. Histology shows normal
gastric mucosa including mucinous tall columnar epithelial cells, as well
as chief and parietal cells below the gastric glands, just in an abnormal
location. Complications include obstruction, peptic ulceration, hemorrhage
and perforation. There is no reference in medical literature to malignant
transformation of heterotopic gastric mucosa. Endoscopic resection, surgical
resection and observation by periodic EGD have all been suggested for a
follow up and differential diagnosis. To our knowledge, this is the largest
polypoid heterotopic gastric mucosa in the literature and the patient was
followed for 5 yrs. with significant increase in the size of the mucosa from
10 mm to 40 mm with no change in histopathology. Pictures of endoscopy
will be presented.
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“Downhill” Esophageal Varices Treated with Azygos Vein
Embolization
Garth Swanson, MD, Joseph Ahn, MD, MS, Stanley Martin Cohen, MD,
Hector Ferral, MD, Forrest Dodson, MD, David Van Thiel, MD∗.
Hepatology, Rush University Medical Center, Chicago, IL; Interventional
Radiology, Rush University Medical Center, Chicago, IL and Abdominal
Transplant Surgery, Rush University Medical Center, Chicago, IL.
“Downhill” esophageal varices (DEV) are varices associated with SVC ob-
struction and pulmonary hypertension but not with portal hypertension. We
report a rare case of DEV deriving off the azygos vein in the setting of pul-
monary hypertension and normal hepatic venous pressure gradient (HVPG),
treated with azygos vein embolization and variceal band ligation.
Case Report: A 55 year old female with a history of rheumatic heart disease,
mechanical mitral and aortic valve replacement on warfarin presented with
hematemesis. Laboratory testing revealed Hg 7.5 g/dL, INR 6, and albumin
2.5 g/dl. Band ligation was performed during upper endoscopy which re-
vealed multiple, bleeding grade IV esophageal varices. An echocardiogram
showed an ejection fraction of 65% with severe pulmonary hypertension
and signs of right ventricle overload. A CT scan revealed extensive vascu-
lar changes around the distal esophagus. A transjugular hepatic venogram
revealed a free hepatic venous pressure (FHVP) of 23 mmHg and a wedged
hepatic vein pressure of 27 mmHg with calculated HVPG of 4 mmHg.
Liver biopsy revealed cirrhosis. The patient was discharged on warfarin.
Ten days later, the patient presented again with hematemesis and repeat
esophageal varices band ligation was performed. A direct transjugular portal
venogram revealed no evidence of esophageal varices. Selective catheteri-
zation of the azygos vein demonstrated reversed azygos vein flow and large
distal esophageal varices. Selective embolization and coil placement of the
right and left azygos vein was performed. A EUS confirmed massive parae-
sophageal varices with a markedly dilated azygos vein and thoracic duct.
The patient has remained on warfarin with no further bleeding episodes
three months after discharge.
Discussion: DEV are so labeled because the direction of flow is “downhill”
or retrograde towards the azygos vein from the submucosal venous network
around the esophagus which forms in response to obstruction of the SVC or
pulmonary hypertension. This is in contrast to esophageal variceal bleeding
associated with portal hypertension which is “uphill”. This case demon-
strates the efficacy of combined endoscopic variceal ligation with selective
endovascular azygos vein embolization and coil placement in managing
DEV, a rare cause of upper GI bleeding.
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A Case of 300 Pound Weight Loss, Malabsorption, Malnutrition and
Protein Losing Enteropathy Due to Systemic Lupus Erythematosis of
the Small Intestine
Cindy Huang, MD, Richard MacDermott, MD∗, Jennifer Lindstrom, MD,
Seth Richter, MD. Gastroenterology, Albany Medical College, Albany, NY;
Gastroentereology, Albany Medical College, Albany, NY and Nutrition,
Albany Medical College, Albany, NY.
We report a case of very severe malabsorption and malnutrition due to Sys-
temic Lupus Erythematosis (SLE). A 55 year-old female was transferred
to our hospital, due to a three-year history of chronic diarrhea, profound
weight loss of 300 lbs, and recurrent small bowel obstruction. Previously, a
colonoscopy demonstrated nonspecific colitis of the ascending colon, and a
trial of a gluten-free diet was ineffective. Her past medical history was signif-
icant for lysis of adhesion surgeries. On admission, physical exam revealed
temporal wasting, non-patchy hair loss, anasarca, and loss of subcutaneous
fat. Her BMI was 14: decreased from a baseline of 72. Presenting laboratory
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findings revealed an Hgb of 10 gm/dL. CRP was elevated at 80 mg/L. Al-
bumin was 1.7 g/dL. Zinc was 29 ug/dL. Vitamins A and D were low at 30
ug/dL and 5 pg/mL, respectively. Chemistry and hepatic profiles, amylase,
and lipase were normal. CT scan revealed pleural effusions, ascites, and
dilated small bowel loops. EGD demonstrated atrophied duodenal mucosa
with villous blunting and few intraepithelial lymphocytes that was inconsis-
tent with Celiac disease. The patient’s condition worsened; she was intubated
and transferred to the ICU. Her albumin fell to <1 g/dL and her prealbumin
to 3.9 mg/dL despite being on TPN. Due to low complement levels, she
underwent SLE workup. Lupus serologies revealed positive ANA titer of
1:10240; negative anti double stranded DNA; positive anti Smith antibodies
at 248 U/mL. The patient had small bowel resection, due to her obstruc-
tion. Pathology revealed full thickness inflammation of the small intestine,
with ulceration and myositis. Combined with her serology findings, it was
concluded that she had lupus-associated enteritis. She was treated with IV
solumedrol and TPN. After 5 weeks of treatment, her albumin rose to 2.2
g/dL and prealbumin to 19 mg/dL. The patient was discharged on oral pred-
nisone and azathioprine. This case demonstrates that SLE can be a cause of
profound weight loss, malabsorption, malnutrition, and protein losing en-
teropathy from extensive small bowel inflammation. Recognition of severe
small bowel inflammation due to SLE is important for effective treatment to
improve both short and long term survival.
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Hereditary Gastric Carcinoma: At Management Cross Roads
Jawaid Ahmed Shaw, MD, Motaz Al Hafnawi, MD, Tarun Kothari, MD,
Kevin Casey, MD∗. Gastroenterology, Rochester General Hospital,
Rochester, NY and Gastroenterology, Unity Hospital, Rochester, NY.
Introduction: Hereditary diffuse gastric cancer (HDGC) is an autosomal-
dominant cancer susceptibility syndrome characterized by early onset diffuse
gastric cancer and lobular breast cancer. Germ-line truncating mutations in
the E-cadherin gene (CDH1) have been shown to underlie about 30% of
HDGC families of various ethnic backgrounds. Here, we report a family
with HDGC.
Case 1: A 69- year-old, female with a history of familial gastric and breast
carcinoma, was diagnosed with lobular carcinoma of right breast at 43 years
of age. Genetic screening for BRCA1 and BRCA2 was negative. Full se-
quencing of CDH1 gene done last year was positive for 2287G>T delete-
rious mutation. Since then she is under chromoendoscopic surveillance at
six monthly interval, as she is still weighing the offer of prophylactic gas-
trectomy. Detailed family history was obtained and pedigree constructed
(Fig. 1).
Case 2: A 55-year-old, female presented for consultation about being tested
positive for CDH1 gene mutation. She was found to be the first cousin of
case 1 and having same deleterious mutation of CDH1 gene at the same
locus. She under went EGD and was discovered to have linitis plastica with
histology revealing invasive, poorly differentiated adenocarcinoma, signet
cell type. Patient is now ongoing evaluation for total gastric resection.
Discussion: Germline CDH1-associated gastric cancer develops diffusely
throughout the stomach wall and foci of malignant cells often underlie a
grossly and histologically normal surface epithelium. Therefore serial con-
ventional EGD, chromoendoscopy or endoscopic ultrasound may not be a
useful screen for this patient population. Our cases illustrate the contro-
versies surrounding the optimal management of germline E-cadherin muta-
tion patients and their families. The average age of onset of gastric cancer
in germline CDH1- positive families is 38 years, but it has been docu-
mented in teens as well. The question arises as to what is the ideal timing
for surgical intervention and screening, given our case 1 has been asymp-
tomatic up till now but on the other hand, case 2 being already positive for
malignancy.[figure1]
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Loratidine-Induced Hepatitis with Autoimmune Features Associated
with Small Fiber Peripheral Neuropathy
Muaiad Kittaneh, MD, Sara Hanif, MD, Albert J. Czaja, MD, FACG,
Arthur Itkin, MD, Charles Berkelhammer, MD, FACG∗. Internal Medicine,
University of Illinois at Chicago, Oak Lawn, IL and Internal Medicine,
Division of Gastroenterology, Mayo Clinic, Rochester, MN.
Purpose: Loratidine-induced hepatitis is rare, with only a few case reports in
the medical literature. We describe a patient with loratidine-induced hepatitis
with autoimmune features, associated with small fiber peripheral neuropathy.
Results: A 49 year old male was previously well except for multiple envi-
ronmental allergies. He had been taking loratidine 10 mg/day for 1 year. He
had no other risk factors. He complained of painful paresthesiae to his lower
extremities. His ALT was 492 U/l, AST 233 U/l. Extensive serologies were
negative including cryoglobulins. Celiac disease was excluded by a negative
celiac disease panel, normal small bowel biopsy and negative HLA DQ2 and
DQ8. His only autoimmune markers were positive circulating immune com-
plexes of 45 u/ml (normal less than 8 u/ml) and low level anti-smooth muscle
antibody of 1:80. His anti-nuclear antibody, p-antinuclear cytoplasmic anti-
body, and antibodies to soluble liver antigen and Liver-Kidney Microsomal
were negative, and immunoglobulin IgG, IgM and IgA levels were normal.
HLA typing did not reveal the susceptibility alleles known to be associated
with autoimmune hepatitis. Liver biopsy revealed panacinar hepatitis, grade
4/4 with no cirrhosis. Nerve biopsy and EMG/nerve conduction studies
were consistent with small fiber peripheral neuropathy. Loratidine was dis-
continued. Despite being off loratidine for 6 weeks, his liver biochemistries
progressed to an ALT of 772 u/ml, AST of 277 and bilirubin of 1.9 mg/dl.
He was treated with prednisone 40 mg/day and pregabalin 75 mg bid. His
liver biochemistries rapidly normalized. Prednisone was gradually tapered
and discontinued after 1 year. There has been no recurrence of hepatitis
after 20 months of observation. He remains with symptomatic peripheral
neuropathy.
Conclusion: We describe a rare case of loratidine-induced hepatitis with
autoimmune features associated with small fiber peripheral neuropathy. Im-
mune features included circulating immune complexes, low titer anti-smooth
muscle antibody, and rapid response to corticosteroids. We speculate that lo-
ratidine caused an immune mediated hepatocellular injury and peripheral
neuropathy.
589
Leakage from Surgical Jejunostomy Tube Due to Sharp Angle of
Efferent Limb
Kendrick M. Che, DO, Snorri Olafsson, MD∗. Gastroenterology, Loma
Linda University Medical Center, Loma Linda, CA.
Purpose: 30 year old male with mental retardation, cerebral palsy and
seizures was admitted in October 2004 for respiratory distress from pneumo-
nia. He was intubated and after extubation, he developed dysphagia. A gas-
troenterologist attempted percutaneous endoscopic gastrostomy tube (PEG)
placement but was unsuccessful since no transillumination was seen. Surgery
was then consulted. They tried to do an endoscopic PEG in the operating
room without success. Upon laparotomy the stomach was found to be higher
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than normal in the area under the costal margins and could not be pulled
down. After multiple attempts to reposition the stomach, PEG placement
was determined to be impossible due to a result of increased tension on
the stomach. A jejunostomy tube was therefore placed 20 cm distal to the
ligament of Treitz.
The patient has had about 30 feeding tube changes over the following 3 years
due to chronic tube leakage. He suffered from extensive skin breakdown and
infections surrounding the jejunostomy tube making it difficult for the family
to take care of him. The patient’s father as well as medical staff had changed
the jejunostomy tubing as a standard blind procedure and time after time,
leakage continued to occur. Different sized tubes were attempted without
success.
When he was referred to us we took him to GI lab for endoscopic evaluation
and replacement of the jejunostomy tube. After entering approximately 2
cm through the stoma with a 6 mm slim nasal upper endoscope, a division
with an afferent and efferent limb was seen. The limb slightly to the right and
straight ahead was assumed to be the afferent limb from the stomach. Instead
we took a very sharp left turn and advanced 50 cm down with the endoscope.
A Savary guidewire was placed through the scope, the scope withdrawn, and
then a 45 cm jejunal feeding tube was threaded over it. Radiology confirmed
that this was the efferent limb. Leakage from the feeding tube has since
reduced dramatically and the skin has healed.
When jejunostomy feeding tubes repeatedly leak despite multiple tube
changes, it is recommended to perform an endoscopic guided tube change
with an upper nasal endoscope. In this case, during blind tube changes, the
tube most likely repeatedly entered the pathway of least resistance, which
was in the limb leading towards the stomach. This caused tube feeds to travel
back out the tube or exit the space surrounding the tube.
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Extensive Nonalcoholic Fatty Liver Disease and Cirrhosis in a Single
Family: A Case Report
Stacy K. Tong, MD, Joseph Ahn, MD, Stanley M. Cohen, MD∗. Hepatology
and Gastroenterology, Rush University Medical Center, Chicago, IL.
Purpose: Nonalcoholic fatty liver disease (NAFLD) is a spectrum of dis-
ease ranging from simple fatty liver to nonalcoholic steatohepatitis (NASH)
to cirrhosis. NAFLD appears to be the most common liver disease in
the United States, and may have a higher prevalence within certain fam-
ilies, suggesting a role for genetics. Prior studies have shown that up
to 18% of NASH patients had an affected 1st-degree relative. The lim-
ited prior case reports of familial clustering only showed a small number
of affected family members. We present a family with extensive disease
involvement.
Case report: A 62 year-old patient with cirrhosis who had undergone or-
thotopic liver transplantation, reported an extensive family history of liver
disease. The family tree illustrated below represents the entire 1st and 2nd
generations of the family as well as the affected members of the 3rd genera-
tion. We identified 8 members (5 male, 3 female) of this family with NAFLD
or cirrhosis. The affected family members span two generations. Three of
the family members had uncomplicated NAFLD and 5 had cirrhosis. In the
2nd generation, 3 out of 9 siblings (33%) had cirrhosis. One of the 3 died
awaiting liver transplant and 2 received orthotopic liver transplants. All 3
affected members of this generation were diabetic and overweight, and 2 had
hyperlipidemia. There were 25 total family members of the 3rd generation
and 20% (5/25) had known liver disease. Two members of the 3rd generation
had cirrhosis, 1 of whom was overweight with hypercholesterolemia. The
3 non-cirrhotic NAFLD patients in the 3rd generation all had obesity and
hyperlipidemia.
Discussion: This case illustrates an extensive family history of NAFLD and
cirrhosis, exhibiting the entire spectrum of fatty liver disease. Some family
members have not been evaluated for liver disease, possibly under-estimating
the true prevalence of liver disease within this family. The extensive in-
volvement described in this case report suggests a genetic predisposition
in addition to common dietary and environmental factors in this familial
cluster.[figure1]
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Gastric Antral Vascular Ectasia Associated with Sytemic Sclerosis: A
Case Report and Review of the Literature
Sindu Stephen, MD, Marie L. Borum, MD∗. Department of
Gastroenterology, George Washington University, Washington, DC.
Purpose: The association between GAVE and SSc have been reported infre-
quently in the literature with sporadic case reports. In this paper, we describe
a patient with iron deficiency anemia diagnosed with GAVE and presumed
SSc.
Results: A 51 year old male with a history of hypertension was referred to
rheumatology clinic for skin thickening. Three months prior to admission,
he noticed progressive skin thickening involving the anterior chest, neck and
face. He also noticed some dyspnea on exertion but denied symptoms con-
cerning the gastrointestinal tract. Review of systems was otherwise negative.
On examination he had pale conjunctiva, thick skin over anterior chest, neck
face and arms. His fingers revealed clubbing. Pulmonary and cardiovascular
exams were unremarkable. Fecal occult blood test was positive. He was also
found to be hypoxic with oxygen saturation of 90% on room air. His labs
are shown in Table 1. He had a chest computed tomography which revealed
interstitial fibrosis with prominence at the bases with pulmonary function
tests showing a decreased diffusing capacity. An EGD was performed to
investigate his anemia. The procedure revealed Gastric Antral Vascular Ec-
tasia which was treated with argon plasma coagulation therapy. Due to his
clinical skin fibrosis and internal organ involvement, he was diagnosed with
systemic sclerosis.[figure1]
Conclusion: This case illustrates the importance of recognizing this disease
as a potential cause of upper gastrointestinal bleeding and anemia in sclero-
derma patients. Early recognition of the association between SSc and GAVE
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with prompt referral to a gastroenterologist for iron deficiency anemia in
this patient population is advised.
Labs
9000 +1:80
WBC (cells/ml) cells/ml ANA speckled
Hematocrit (%) 21 ESR 45
Platele count 652 CRP 1.6
BUN (mg/dl) 19 Rheumatoid Factor +1:8
Ferritin (ng/ml) 7 Anti dsDNA negative
TIBC (mcg/dl) 331 Anti Ro & La negative
Iron (mcg/dl) 16 Anti-smooth muscle negative
MCV 60 Anti-centromere Antibody negative
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Ischemic Necrosis of the Terminal Ileum and Cecum with Oral
Kayexalate
Srinivas R. Mummadi, MD, Ashutosh S. Naniwadekar, MD∗, Phong Tang,
MD. Department of Internal Medicine, University of Texas Medical
Branch, Galveston, TX.
Purpose: Sodium polystyrene sulfonate (Kayexalate) is a cation-exchange
resin used with sorbitol for the treatment of hyperkalemia since 1961. There
have been several case reports of colonic necrosis with the use of Kayexalate-
sorbitol enemas and very rarely with oral Kayexalate. The overall incidence
of Kayexalate-sorbitol induced colonic necrosis has been estimated to be
around 0.27%. Clinical manifestations may vary from mild abdominal pain
or gastrointestinal bleeding to bowel perforation presenting with an acute
abdomen. The exact pathogenesis of Kayexalate-sorbitol induced colonic
necrosis is unknown. However it is believed to occur due to severe vasospasm
induced by osmotic mucosal injury from the sorbitol component, on a back-
ground of elevated renin levels in uremic patients.
A 39-year-old African American man with end-stage renal disease secondary
to focal segmental glomerulosclerosis, on hemodialysis, presented to us
with a syncopal episode. He had missed two scheduled days of dialysis.
On physical examination, he had bibasilar crackles with a soft, non-tender
abdomen. Laboratory examination revealed a potassium of 6.2 with no EKG
changes of hyperkalemia. He was given 30 grams of oral Kayexalate (with
sorbitol). Around six hours after ingestion, he started having severe gen-
eralized abdominal pain. Physical examination revealed a tense, rigid ab-
domen with rebound tenderness. An abdominal X-ray showed ileus with
free subdiaphragmatic air. An emergent laparotomy showed a 1 cm cecal
perforation with areas of ischemic necrosis in the terminal ileum. He had a
right-sided hemicolectomy and subsequently got hemodialysis. Histopatho-
logic examination showed multifocal ischemic necrosis of the ileum and
cecum (Fig. 1) with characteristic rhomboid shaped, basophilic crystals in
a mosaic pattern, consistent with Kayexalate (shown by arrow in Fig. 2).
[figure1][figure2]
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Severe Gastrointestinal Bleeding Due to Isolated CMV Enteritis
Diagnosed by Double-Balloon Enteroscopy
Monika Fischer, MD, Michael V. Chiorean, MD∗. Internal Medicine,
Gastroenterology, Indiana University, Indianapolis, IN.
Purpose: Cytomegalovirus (CMV) primary infection or reactivation can
cause serious complications in immunocompromised individuals. However,
isolated CMV enteritis in immunocompetent adults is extremely rare. We
are reporting a case of recurrent massive gastrointestinal bleeding caused by
CMV enteritis in a young female diagnosed by double-balloon enteroscopy
(DBE).
Methods: Case report.
Results: A 38-year-old patient with history of IgA nephropathy on intermit-
tent low-dose steroids (prednisone 5–20 mg/day, 10 days monthly), presented
with recurrent massive gastrointestinal bleeding of obscure etiology. Mul-
tiple initial endoscopic and radiologic tests including upper and lower en-
doscopy, push enteroscopy, wireless capsule endoscopy and bleeding scans
were negative or non-diagnostic. Urgent upper and lower DBE showed sev-
eral large semi-circumferential superficial ulcers extending from the prox-
imal jejunum to ileum. Multiple biopsies were positive for CMV by H&E
stain and immunohistochemistry. The serum CMV antigen was positive. De-
spite adequate antiviral therapy, the patient experienced multiple recurrent
episodes of massive bleeding, at roughly weekly intervals, requiring a total of
46 units of blood. Ultimately, she underwent an intraoperative DBE which re-
vealed a new jejunal ulcer with active bleeding which was treated surgically.
She eventually recovered after prolonged intravenous and oral gancyclovir
therapy and was discharged to a temporary rehab facility. This case illustrates
several unique features: a severe CMV-related illness in a relatively immuno-
competent host; isolated CMV small bowel involvement; recurrent massive
bleeding despite adequate antiviral therapy; diagnosis made exclusively by
DBE.
Conclusion: CMV enteritis should be in the differential diagnosis of pa-
tients with massive gastrointestinal bleeding regardless of age or immune
competency. DBE may be an extremely useful diagnostic test in patients
with massive GI bleeding of obscure etiology.
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Endoscopic Closure of a Gastrocutaneous Fistula
Zahid Afzal, MD∗, Ajay Bajaj, MD. Internal Medicine/Gastroenterology,
Advocate Christ Medical Center, Oak Lawn, IL.
Purpose: A 78 year old nursing home patient was seen in consultation for
a gastrocutaneous fistula. The patient had a PEG tube that was removed
secondary to infection several weeks prior. She subsequently developed a
gastrocutaneous fistula. Conservative measures such as high dose proton
pump inhibitors and promotility agents to help the fistula heal were un-
successful. Furthermore, the patient’s skin around the abdominal wall had
become macerated and exfoliated secondary to frequent leakage of gastric
contents.
The patient underwent an EGD. The fistulous opening was well visualized in
the gastric body. A single Resolution ClipR (Boston Scientific) was applied
to close the fistula. Once applied the stomach could be well insufflated. A
naso-jejunal tube was then placed endoscopically to maintain the patient’s
nutrition. Over the next 2 to 3 weeks there was complete healing of the
patient’s fistula and macerated skin around the PEG site.
Endoscopic closure of gastrocutaneous fistulas has been described in other
reports. Our case exemplifies the ease of closure of gastrocutaneous fistulas
using endoscopic clips. A single clip was successful in closing the gastro-
cutaneous fistula in our patient. This is attributed to the larger size of the
Resolution ClipR and the ability to open and close the clip to ensure optimal
positioning before deployment.
The spectrum of endoscopic practice is expanding and there will be novel
uses for endoscopic accessories in the future. Many of these new techniques
can easily be employed into daily clinical practice by a trained gastroenterol-
ogist.
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Pseudomelanosis Duodeni: An Unusual Rare Finding
Laura H. Yun, MD∗. Gastroenterology, University of California San
Diego, La Jolla, CA.
Purpose: Melanosis coli or pseudomelanosis coli is a common finding and
is a consequence of laxative abuse. Seeing a similar black discoloration of
the duodenal mucosa is an unusual, rare finding and called pseudomelanosis
duodeni.
A 67 year-old female with a past medical history of CAD, HTN, DM, and
chronic renal failure presented with melena. The EGD revealed a few, scat-
tered, nonbleeding antral erosions and an erythematous gastropathy. The
mucosa of the first and second portion of the duodenum was noted to have
a diffuse, speckled pattern of small black dots which was biopsied. On
colonoscopy the mucosa appeared normal, and there was evidence of old
blood in the cecum and terminal ileum. Histopathology of the duodenal mu-
cosa revealed black pigment in the macrophages of the lamina propria. These
findings were consistent with the diagnosis of pseudomelanosis duodeni.
Pseudomelanosis duodeni is a rare condition first described in 1976 by
Bisordi and Kleinman and primarily described in the literature in case re-
ports and case series. It is thought to be a benign condition characterized by
the accumulation of dark pigment in the macrophages of the lamina propria.
On review of the literature, the majority of the patients are noted to be fe-
male and 60 years of age or older. In addition it is associated with certain
medical condition such as chronic renal failure, hypertension, gastrointesti-
nal bleeding, and congestive heart failure. It is also associated with the use
of certain medications including hydralazine, propanolol, hydrochloroth-
iazide, furosemide, and iron supplementation. Of note, this patient was fe-
male and had chronic renal failure, CAD, and hypertension. She was also on
hydralazine, furosemide, and ferrous sulfate.
The exact etiology of the disorder is not known. The pigment is thought to
be composed primarily of ferrous sulfide. The proximal duodenum is the site
of iron absorption, and it is thought that the iron sulfide complexes are un-
able to be mobilized and thus accumulate in the macrophages. Other authors
have suggested that the pigment is melanin-like because of a similar stain-
ing pattern to actual melanin. They hypothesize that certain substances like
furosemide and propanolol contain benzene rings which may be converted to
melanin-like pigments via a tyrosinase-like action within the macrophages.
Pseudomelanosis duodeni is a rare and interesting finding. There is still
no uniform interpretation regarding the nature or source of the pigment.
Luckily, the outcome for these patients is good as this is thought to be a
benign process.
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Meckel’s Diverticulum Active Bleeding Detected by Capsule
Endoscopy
Guilherme Macedo, MD, PhD∗, Artur Machado, MD, Susana Lopes, MD,
Raquel Goncalves, MD, Carla Rolanda, MD, Pedro Pereira, MD, Mesquita
Rodrigues, MD, Mario Marcelino, MD. Gastroenterology Unit, H.S.
Marcos, Braga, Portugal and Surgery Department, H.S. Marcos, Braga,
Portugal.
Purpose: Diagnosing Meckel’s diverticulum (MD) before surgery is still a
challenge, although the clinical, histopathological and imagiologic features
of MD are well known. Several modalities have been proposed for evaluating
patients with gastrointestinal hemorrhage from a presumable small bowel
source. Even in acute bleeding episodes, repeated diagnostic workups and
invasive procedures (angiography, intraoperative enteroscopy) are several
times inconclusive.
We present two cases, a 14 and 16 years old patients, admitted to our hos-
pital due to recurrent severe gastrointestinal bleeding (6 gr/dl drops of
hemoglobin). Both underwent upper gastrointestinal endoscopy and ileo-
colonoscopy, and although no bleeding lesions had been identified, fresh
clots were noticed in terminal ileum. Within the first 24 hours of presenta-
tion both performed capsule endoscopy (Endocapsule Olympus). In 5 and 6
hours respectively, the bleeding source was identified as an active bleeding
oozing from a small diverticulum like orifice in the middle ileum.
Surgical resection of the ileal segment confirmed the presence of the diver-
ticulum with ectopic gastric mucosa. There was no recurrence of bleeding
at follow-up after surgery. Both cases illustrate the usefulness of capsule en-
doscopy availability and its role in investigating acute small bowel bleeding
in this age group.
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Patent Stent 10 Years Post Transjugular Intrahepatic Portosystemic
Shunt (TIPS)
Gurpreet Singh, MD, Ragu Kottam, MD, Suresh Jayatalika, MD, Joseph
DePasquale, MD∗. Gastroenterology, Saint Michael’s Medical Center,
Newark, NJ and Seton Hall University School of GME, South Orange, NJ.
Purpose: TIPS is currently indicated in cirrhotic patients with refractory
ascites and recurrent variceal bleeding, not responsive to medical and/or
endoscopic therapy. The aim of the procedure is to decrease portal hyper-
tension by creating a permanent tract through the liver parenchyma between
the hepatic and portal veins. Common complications include hepatic en-
cephalopathy, shunt dysfunction and occlusion.
Results: A 65 year- old male- with history of diabetes, hypertension and
chronic alcohol buse- presented 10 years ago with upper GI bleeding. Work-
up at that time, including endoscopy, revealed cirrhosis with actively bleed-
ing esophageal varices. After failed attempts at controlling recurrent UGI
bleeding, the patient underwent TIPS in January of 1997. The post-procedure
course was unremarkable with no further bleeding episodes or evidence of
liver decompensation. The patient remained abstinent from alcohol. A rou-
tine Doppler ultrasound performed in January of 2007 confirmed patency of
the shunt with normal flow.
Conclusion: TIPS is now a well recognized treatment for managing sequelae
of symptomatic portal hypertension such as acute or recurrent variceal bleed-
ing, refractory ascites and Budd-Chiari syndrome. Several complications can
occur during and after placement of the stent; after hepatic encephalopathy,
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the most common one is shunt stenosis/ occlusion. This happens with longer
follow-up (52% at 3–9 months and 70% at 9–15 months). Primary patency
after TIPS placement has been reported to be 66% after 1 year, and 42%
after 2 years. To our knowledge, this case may represent the longest reported
graft patency following this procedure.
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Delayed Colonic Perforation after ESD in a Patient with Ulcerative
Colitis
Matthew L. Bechtold, MD, Ajitinder Grewal, MD, Todd W. Kilgore, MD,
Srinivas R. Puli, MD, Mainor R. Antillon, MD∗. Division of
Gastroenterology, University of Missouri, Columbia, MO.
Purpose: Endoscopic submucosal dissection (ESD) removes pre-malignant
lesions and intra-mucosal cancers from the GI tract, offering an alternative to
surgery. As any procedure, ESD has complications. Certain conditions, such
as ulcerative colitis (UC), have not been well-studied with ESD and may
lead to increased complications. This case demonstrates a rare incidence of
delayed colonic perforation after ESD in a patient with UC.
Case: 83 yo male with UC on chronic steroid therapy was found to have a
large lateral spreading tumor in the ascending colon on colonoscopy with
biopsies revealing no adjacent active UC disease. After the patient refused
surgery, he presented for ESD. The 4 × 8 cm mass was identified, raised, and
dissected with a conventional needle knife. Two small defects were closed
with 7 resolution clips. Post-procedure, IV antibiotics and steroids were ini-
tiated and he was admitted to ICU. Lesion revealed a tubulovillous adenoma
with underlying cauterized submucosa and no invasive malignancy. On hos-
pital day 3, he improved with softened abdomen and improved leukocytosis.
On hospital day 4, he had flatus, decreased abdominal distention and pain,
and was extubated. On hospital day 5, he had respiratory distress, increased
abdominal distention, and hematochezia. He was emergently re-intubated
and underwent exploratory laparotomy. A small opening was noted at the
hepatic flexure with bleeding and soilage. A right hemicolectomy with divert-
ing ileostomy was performed. Post-operatively, IV antibiotics and steroids
were initiated. Surgical specimen revealed metal clips with full thickness
necrosis with associated adjacent hemorrhage, cautery artifact involving the
muscularis propria, and acute inflammation with dense inflammatory infil-
trate extending to the subserosal fat with focal microabscesses. No cautery
artifact was noted in adjacent muscularis propria. The perforation was noted
3.5 cm from the clips. On hospital day 8, the patient was extubated. After a
prolonged hospital course, he succumb to sepsis and other co-morbidities.
Conclusions: This case demonstrates a rare delayed colonic perforation
after ESD in the setting of chronic UC and steroid therapy. Although ESD
is an acceptable alternative to surgery, many conditions, such as UC, have
not been fully examined. In this case, the delayed perforation may have
been secondary to anatomically changes in the colonic wall from UC. More
research is required to fully access the safety of ESD in UC.
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Treatment of Symptomatic Cystic Duct Stone in a Pretransplant
Cirrhotic Patient
Timothy M. Saettele, Megan Saettele, Priyanka Tiwari, MD, Matthew L.
Bechtold, MD, Srinivas R. Puli, MD, Mainor R. Antillon, MD∗. Division of
Gastroenterology, University of Missouri, Columbia, MO.
Purpose: Cholelithiasis is prevalent in cirrhotic patients. Laparoscopic
cholecystectomy is used to treat symptomatic cholelithiasis but is not recom-
mended for those with cirrhosis. Endoscopic gallbladder stent placement has
been described for symptomatic cholelithiasis relief in cirrhotic patients, but
is technically difficult or impossible if cystic duct anatomy is not amenable
to cannulation. This case demonstrates the placement of a cystic duct stent,
stent upsizing, and stone removal in a cirrhotic patient with symptomatic
cystic duct cholelithiasis.
Case: 44 yo male with cirrhosis (Child-Pugh C), acalculous cholecystitis,
and prior cystic duct/gallbladder stent presented with biliary pain. ERCP
revealed a 5 mm cystic duct stenosis that could not be traversed and a lack
of contrast in the gallbladder. A 10 cm 10-Fr biliary stent was placed into
the cystic duct proximal to the stricture. Over the next 22 weeks, two ERCs
were performed with the replacement of stents proximal to the stricture. At
22 weeks, ERC revealed the localized stenosis in a tortuous cystic duct and
three previous 10-Fr, 8.5-Fr, and 7-Fr stents were removed. A 0.035” Jagwire
was passed through the stenosis. A 12 cm 5-Fr biliary stent with pigtails was
placed into cystic duct and gallbladder. At 24 weeks, ERC showed the stent
in place, a diffuse 20 mm stenosis of the cystic duct, and a possible 8 mm
gallbladder stone. At 24–32 weeks, two ERCs were performed with upsizing
of the gallbladder stents from 5- to 7-Fr. At 38 weeks, ERC revealed a cystic
duct of 6 mm in diameter with a filling defect. A second 15 cm 7-Fr stent
with pigtails was placed into the gallbladder. At 44 weeks, ERC showed
the two 7-Fr stents which were removed. The cystic duct and gallbladder
were swept using a basket and balloon with sludge and stone fragments
removed. A choledochoscope was passed into gallbladder over a guidewire
and demonstrated clearing of the cystic duct, gallbladder, and CBD by direct
visualization. Over time, the patient has remained asymptomatic.
Conclusions: This case demonstrates a novel technique effectively used
in the treatment of a cystic duct stone in a pretransplant cirrhotic patient.
Cystic duct stenting with systematic stent upsizing enabled stone removal
without surgery. With this approach, cirrhotic patients that are non-operative
candidates may have an endoscopic alternative to allow symptomatic relief.
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Diagnosis of Mediastinal Tuberculoma with EUS Guided FNA
Alla Grigorian, MD, Houssam Mardini, MD∗, Nicholas Nickl, MD.
Division of Digestive Diseases and Nutrition, University of Kentucky,
Lexington, KY.
Purpose: A 65 year old man presented for evaluation of dysphagia and chest
discomfort. Past medical history was significant for diabetes and chronic
kidney insufficiency.
Review of systems and physical examination were not revealing.
Upper GI endoscopy was performed and demonstrated no mucosal abnor-
mality and no obvious endoscopic findings suggestive of pathology that
could explain symptoms. Imaging of the chest revealed calcified granuloma
in the lower lung fields, small mediastinal lymph nodes, and 5.4 × 2.8 cm
hypodense structure adjacent to esophagus with low density center and cal-
cification. Patient was referred to our center for endoscopic ultrasound with
fine needle aspiration of above mass.
EUS findings included extrinsic hypoechoic mass/lesion with some calcifi-
cations inside noted adjacent to the thoracic esophagus and pericardium. This
began from 28 cm from the incisors and extended to 30 cm. Three passes were
made with the 22 gauge ultrasound biopsy needle using a transesophageal
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approach.[figure1]On site cytology evaluation of the material obtained from
the aspirate had a mucoid appearance. Futher staining demonstrated a more
granular appearance consistent with necrosis. A Fite stain was performed
which revealed rare acid fast bacilli.[figure2]Based on above information
diagnosis of tuberculoma was made and patient was referred to infectious
disease clinic for further investigation and treatment.
REFERENCES
1. Le, H S. Oh, J Y. Lee, J H. Yoo, C G. Lee, C T. Kim, Y W. Han, S K. Shim,
Y S. Yim, J J. Response of pulmonary tuberculomas to anti-tuberculous
treatment. Eur Respir J. 23(3):452–5, 2004 Mar.
2. Prytz, S. Hansen, J L. Surgical treatment of “tuberculoma”. A follow-up
examination of patients with pulmonary tuberculosis resected on suspi-
cion of tumour. Scand J Thorac Cardiovasc Surg. 10(2):179–82, 1976.
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Post Herpetic Esophageal Neuralgia: A New Entity?
Kiran Jagarlamudi, MD, Pragathi Ravi, MD, George Protopapas, Ashok
Gupta, MD, Walid Baddoura, MD∗. Gastroenterology, St. Joseph’s
Regional Medical Center, Paterson, NJ and Seton Hall University School
of GME, S. Orange, NJ.
Purpose: Herpes simplex (HSV) esophagitis is frequently seen in immuno-
compromised patients. It responds to treatment with either acyclovir or val-
cyclovir. We describe a case of HSV esophagitis with intractable symptoms
despite treatment and endoscopic resolution, which responded to an empiric
course of gabapentin.
Results: A 75 year-old male- post liver transplant for hepatitis C on
tacrolimus therapy- presented with progressive odynophagia, dysphagia,
atypical chest pain, anorexia and a 25 lb weight loss. He had a history
of herpes esophagitis treated one year prior with IV acyclovir followed by
valcyclovir for a total of three months. Physical examination was unremark-
able. Laboratory studies revealed a normocytic anemia. An esophagogram
and chest x-ray were normal. Upper endoscopy showed minimal focal mu-
cosal irregularity of the distal esophagus; biopsies revealed reactive changes
with no demonstrable herpetic findings. Viral cultures were negative. Car-
diac work-up was normal. The patient was started on a trial of gabapentin
300 mg once daily with a drastic improvement of symptoms. He continues
to do well on therapy, at two–month follow-up.
Conclusion: Herpes esophagitis is commonly seen in immunocompromised
patients. It usually responds well to antiviral therapy. Our patient’s symptoms
could not be explained by recurrent herpetic esophagitis given paucity of
endoscopic findings. The remarkable clinical improvement after initiation
of gabapentin therapy raises the possibility of a post-herpetic neuralgia as
an underlying etiology. The severity of the clinical presentation and negative
history precluded the suspicion of reflux disease as an alternate diagnosis.
To our knowledge, this is the first such reported case.
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Facial Hyperpigmentation in Association with Peginterferon alpha-2a
and Ribavirin Treatment for Chronic Hepatitis C Patient: A Case
Report
Mandeep Singh, MD, Muhammad Y. Sheikh, MD∗, Jasjit Singh, MBBS,
Nazar E. Sanousi, MD, Sonia Garcia, Robert Futoran, MD, Muhammad H.
Bashir, MD, Kandarp K. Shah, MD. Division of Gastroenterology &
Hepatology, University of California, San Francisco-Fresno Education
Program, Fresno, CA.
Purpose: Skin hyperpigmentation is a rare complication of interferon based
combination therapy for chronic hepatitis C (CHC). Lingual hyperpigmen-
tation is described in the past but facial hyperpigmentation has not been
reported. We report an unusual case of facial skin hyperpigmentation in a
CHC patient who received therapy with peginterferon alpha-2a and ribavirin.
A 45 years old Latino patient was started on a combination therapy with
peginterferon alpha -2a and ribavirin for chronic hepatitis C, genotype 1. He
responded well with drop in viral load from his baseline 507494 IU/ml to <10
at week 12. Viral load at week 24 was <25. Dark-brown skin pigmentation
was noted on his face at week 28. He was referred to a dermatologist for eval-
uation. A punch skin biopsy showed chronic inflammation with pigmentary
alteration and actinic keratosis. Immunohistochemical staining with Fontana
Masson stain revealed melanin deposits in the pigmented macrophages. S-
100 protein stain showed increased number of melanocytes along basal layer
of epidermis (Figs. 1 and 2). Patient successfully achieved SVR. His pig-
mentation improved slowly but remarkably over 12 months follow up with
local hydroquinone gel (4%) and a sun screen.
Conclusion: Peginterferon alpha-2a based combination therapy may cause
local skin hyperpigmentation which is possibly reversible. Discoloration of
the face causes significant concern for obvious cosmetic reasons. Physi-
cians should be aware of potential reversibility of such hyperpigmenta-
tion.[figure1][figure2]
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Ischemic Colitis in a Patient Receiving Carboplatin and Paclitaxel for
Non-Small Cell Carcinoma of the Lung
Sumanta K. Pal, MD, Donald David, MD∗. Department of Medical
Oncology, City of Hope National Medical Center, Duarte, CA and
Department of Gastroenterology, City of Hope National Medical Center,
Duarte, CA.
Purpose: We describe a 69-year-old female with a history of metastatic
breast cancer and a newly diagnosed non-small cell lung cancer who elected
to undergo systemic chemotherapy with carboplatin and paclitaxel. One
day after receiving her first cycle of chemotherapy, she presented with nau-
sea, vomiting and hematochezia. She had a normal screening colonoscopy
14 months prior to this event. She had a benign abdomen on examination.
Her hemoglobin was normal at the time of admission (13.0 g/dL; normal,
11.5–15.5 g/dL) and remained stable through the course of her hospitaliza-
tion. Her WBC count was 3600 U/L at the time of admission, with a normal
differential. Her laboratories were only otherwise significant for a slight el-
evation in her transaminases (AST 48 U/L; normal, 15–46 U/L, and ALT
52 U/L; normal 15–46 U/L). Colonoscopic evaluation was performed on the
next hospital day and demonstrated hemorrhagic and ulcerated appearing
mucosa extending in a segment of approximately 20 cm in the area of the
splenic flexure, grossly resembling ischemic colitis. The mucosa proximal
and distal to this area appeared endoscopically normal. Pathologic analy-
sis of the biopsy specimens showed changes consistent with a non-specific
colitis and suggesting ischemia. Viral and bacterial culture of the speci-
mens demonstrate no growth to date. The patient had a gradually improving
course through her hospitalization without any significant intervention, and
two weeks subsequent to her discharge she reported that her symptoms had
completely resolved.
Discussion: Ischemic colitis needs to be strongly considered in the evalu-
ation of hematochezia in the setting of cancer chemotherapy, particularly
in patients who have received taxane-based agents. This report will add
to a small number of published cases of ischemic colitis associated specifi-
cally with taxane-based chemotherapy. Although this outcome was favorable,
some published cases have resulted in significant morbidity and mortality.
It appears most prudent to hold additional doses of taxane-based therapy, as
cases have recurred on rechallenge. Though the precise mechanism remains
unclear, direct drug toxicity to the gastrointestinal epithelium is suspected
to contribute to this phenomenon. Alternatively, inhibition of angiogenesis
could lead to the observed ischemic effect.
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Endoscopic Hemostasis of Massive Hematochezia after Transrectal
Prostate Biopsy: A Case Series
Teresa A. Tacopina, MD, Irwin M. Grosman, MD∗, Adnan Khdair, MD.
Gastroenterology, Long Island College Hospital, Brooklyn, NY.
Purpose: Transrectal ultrasound-guided (TRUS) prostate biopsy is the pre-
ferred method for diagnosing prostate cancer in the US. Overall, the pro-
cedure is safe with a low morbidity and mortality. The incidence of hema-
tochezia after TRUS prostate biopsy varies from 0–37% in published reports.
We report our center’s experience with endoscopic hemostasis in a series of
patients with massive hematochezia after TRUS prostate biopsy.
Results: Case 1: A 55 y/o man presented with massive hematochezia 12 days
after TRUS biopsy. Urgent colonoscopy revealed a visible vessel with adher-
ent clot on the anterior wall of the rectum at the biopsy site. Two hemoclips
were successfully placed to control the bleeding.
Case 2: A 53 y/o man presented 12 days after TRUS with significant hema-
tochezia. Colonoscopy revealed a clot in the rectum at the biopsy site. A
BICAP probe was used to cauterize the bleeding site. No further bleeding
occurred.
Case 3: A 74 y/o man on aspirin presented with massive hematochezia 5
hours after TRUS biopsy. Sigmoidoscopy revealed an area of arterial spurting
at the biopsy site. The APC was used to cauterize the bleeding site with good
hemostasis.
Case 4: A 56 y/o man on aspirin and clopidogrel presented with massive
hematochezia 1 day after TRUS biopsy. Urgent sigmoidoscopy was per-
formed and arterial spurting was seen at the site of prostate biopsy. The bleed-
ing was controlled with epinephrine injection and BICAP electrocautery.
Conclusion: Rectal bleeding is a common complication encountered after
TRUS prostate biopsy and is usually managed by local tamponade. Rarely,
massive bleeding occurs requiring urgent endoscopy to provide hemostasis.
Various endoscopic techniques have been employed including: epinephrine
injection, sclerosant injection, electrocautery, band ligation and hemoclip ap-
plication. Factors predisposing to significant post-procedural hematochezia
include the number and location of core biopsies obtained. Patients with
internal hemorrhoids are reportedly at increased risk for post-biopsy hema-
tochezia. Both immediate and delayed hematochezia have been reported.
Cases 1 and 2 illustrate the unusual occurrence of delayed hematochezia
after TRUS biopsy requiring endoscopic hemostasis. Cases 3 and 4 ques-
tion the reported safety of continued anti-platelet therapy at the time of
prostate biopsy. Our series illustrates the important role of endoscopic hemo-
static interventions in managing massive hematochezia after TRUS prostate
biopsy.
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Endoscopic Management of Esophageal Varices with Band Ligation in
Hepatitis C Patients Receiving Pegylated Interferon/Ribavirin
Therapy: Safety and Success of This Approach in Three Patients
Alexander T. Lalos, MD∗. Gastrointestinal Consultants of NEPA,
Scranton, PA.
Purpose: Hepatitis C (HCV) clearance rates with pegylated inter-
feron/ribavirin are low in patients with cirrhosis. Also, therapy is relatively
contraindicated in decompensated disease. Esophageal variceal bleed is a
sign of decompensation but many HCV patients on transplant lists bleed
from varices or have large varices on screening exams. Therefore, antiviral
treatment is being offered to patients with a known history of large varices or
variceal bleeding. We report three cases where pegylated interferon/ribavirin
therapy was given to patients who were also undergoing endoscopic variceal
ligation (EVL). The experience in these patients patients shows that liga-
tion and antiviral therapy can be undertaken concurrently and may enhance
anti-viral therapy outcomes.
Methods: Three patients with G1 Hep C and cirrhosis were evaluated at a
liver transplant facility. Due to low MELD scores these patients were referred
to our local GI practice for another attempt at anti-viral treatment. All had
previous unsuccessful interferon/ribavirin therapy. Two patients had previous
variceal bleed and the third had large varices on screening EGD. Two patients
underwent initial EVL and after variceal eradication was underway anti-viral
therapy was started. The third started antiviral therapy without EVL but then
elected to undergo prophylactic EVL.
Results: These three patients have been on antiviral therapy for 39, 40 and
58 weeks. There have been a total of 10 EVL procedures performed on
therapy. The average platelet count of the patients during treatment has been
32K, 44K, and 50K. No episodes of variceal bleed have occurred during
or within 72 hours of any EVL procedure. Platelets have not been given
before any procedure and treatment has not been interrupted for procedures.
One patient had a transient anemia that coincided with black stool but no
obvious bleeding occurred. A total of 137 patient-months of antiviral therapy
has been given without variceal bleeding. Two patients have achieved late
clearance of HCV and the third developed low grade relapse following intial
clearance.
Conclusion: 1) HCV clearance with pegylated interferon/ribavirin can be
achieved in patients who are concurrently undergoing EVL for variceal erad-
ication. 2) EVL appears to be safe and feasible during antiviral therapy. 3)
We think that EVL may even enhance outcomes in preventing antiviral treat-
ment cessation/ interruption which may accompany a clinically significant
variceal hemorrhage
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Recurrent Signet-Cell Type Gastric Cancer Simulating Ulcerative
Colitis
Matthew Mukherjee, MD, A. Brodsky, MD, Irwin M. Grosman, MD∗.
Gastroenterology, Long Island College Hospital, Brooklyn, NY.
Purpose: The patient is a 69 year old man from Ukraine, Russia near the
Chernobyl accident. He was evaluated for a six month history of early satiety
and weight loss in 2001. He underwent EGD and was found to have three
benign gastric polyps, multiple serpentine ulcers and severe erythema and
edema in the gastric body. Biopsies revealed poorly differentiated adenocar-
cinoma, signet ring cell-type. Colonoscopy at that time was unremarkable.
Abdominal CT showed a diffuse pattern of infiltration, with a linitis-plastica
type appearance. Laparoscopy demonstrated that the tumor was limited to the
gastric body and cardia and a total gastrectomy with esophagojejunostomy
was performed. Pathology revealed invasive adenocarcinoma with lympho-
vascular invasion, negative surgical margins and positive lymph nodes –
stage IIIb disease. Postoperatively, he received adjuvant chemotherapy with
5-fluorouracil and leukovorin and radiation therapy. He was free from re-
currence of the cancer for four and a half years when he returned with left
lower quadrant abdominal pain and alternating diarrhea and constipation for
several weeks. He underwent colonoscopy which demonstrated inflamed and
ulcerated mucosa in the rectum, sigmoid and transverse colon. A prelimi-
nary endoscopic diagnosis of ulcerative colitis was made and mesalamine
was administered orally and via enema. Stool microbiological studies, ESR,
p-ANCA and ASCA were all normal. Endoscopic biopsies revealed mucosal
infiltration with signet-ring type cells consistent with metastatic gastric car-
cinoma in the hepatic flexure, splenic flexure, sigmoid colon and rectum.
CT and PET scan showed recurrent disease limited to the colon. He was
treated with chemotherapy (5- fluorouracil, Taxotere and cisplatin), which
he tolerated well.
Conclusion: Gastric adenocarcinoma carries a poor prognosis partly be-
cause symptoms often develop after the disease has become locally advanced
or metastatic. The most common sites of metastasis are liver, lung, peri-
toneum and bone marrow. Less common sites include umbilicus (“Sister
Mary-Joseph’s nodule”), ovary (“Krukenberg tumor”), rectum (“Blumer’s
shelf”), kidney, bladder, brain, heart and thyroid. The colon has been de-
scribed in several case reports as a site of local spread (transverse colon)
or distant metastasis. Recurrent gastric cancer presenting as inflammatory
bowel disease is very rare, with only one other previous case reported in the
literature.
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Acute Hemorrhagic Colitis in 25 Year Old Man Treated for Flu like
Symptoms
Dana M. Kaplan, Jianlin Xie, MD, PhD, Anisha Thadani, MD, Sita
Chokhavatia, MD∗. Gastroenterology, The Mount Sinai Medical Center,
New York, NY.
Purpose: A 25-year-old previously healthy male developed nausea, non
bloody vomiting, fever with chills, muscle aches and watery diarrhea. He
was treated for influenza B in an emergency room the next morning with
a 5 day course of a neuraminidase inhibitor – oseltamivir plus other symp-
tomatic treatment. That evening he noted onset of left lower quadrant abdom-
inal pain, cramping and sharp in nature, progressively increasing in intensity
over the next 3 days which was accompanied by an increased frequency of
bloody bowel movements (15 bowel movements of small quantity- “couple
of teaspoons”) and presented to our hospital. No recent travels, sick con-
tacts or prior antibiotics use were reported; no family history of IBD. On
examination he was not in acute distress; had stable vitals and was afebrile;
abdomen exam revealed normal bowel sounds, soft but tender in the left
lower quadrant; no stool in vault but Guiaic positive on rectal exam, no
hemorrhoids or fissures. Stool was negative for WBC and O/P; stool cul-
tures were negative and Clostridium difficile toxins also negative. Thick-
ening of the bowel wall from distal descending to the proximal sigmoid
colon was seen on CT. In addition to intravenous fluids, metronidazole and
ciprofloxacin were started for presumed infectious colitis. Patient had dis-
continued oseltamivir after 2 doses. Sigmoidoscopic examination revealed a
severely inflamed, edematous, and erythematous mucosa from the anal verge
to 40 cm and sparing of the rectal mucosa. Biopsies from the hemorrhagic
sigmoid and normal appearing rectum revealed mildly active chronic coli-
tis suggestive of ischemic/concomitant infectious colitis and normal rectal
mucosa, respectively. The patient’s symptoms began to improve after halting
oseltamivir treatment. Metronidazole was discontinued after 2 day treatment
but he completed a 5-day ciprofloxacin course. Diarrhea significantly im-
proved with decreased frequency and minimal bright red blood per rectum.
His symptoms resolved completely and he was discharged on hospital day
4 (9 days after initial onset of symptoms).
Acuity and short duration of symptoms were suspected secondary to infec-
tious and/or ischemic colitis. However, acute hemorrhagic colitis induced/
exacerbated by oseltamivir could not be ruled out since the symptoms wors-
ened following its administration and improved upon discontinuation. Acute
hemorrhagic colitis induced by oseltamivir was first reported by a Japanese
group in 2006.
608
Isolated Gastric Malakoplakia Associated with Helicobacter Pylori
Infection: A Case Report and Review of Literature
Shoba Mendu, MD, Michael Piper, MD∗, Ved Singla, MD.
Gastroenterology, St. John Providence Hospital, Southfield, MI.
Purpose: Malakoplakia is a rare chronic inflammatory disorder character-
ized by a mass like accumulation of histiocytes and pathognomonic inta-
cellular and extracellular siderocalcific inlusion bodies called Michaelis-
Gutmann bodies. It most frequently involves the genitourinary tract. In-
volvement of gastrointestinal tract, lymph nodes, brain, bone, lungs, adrenal
glands and skin has also been reported. Isolated gastric malakoplakia is
extremely rare. Here we report a case of isolated gastric malakoplakia asso-
ciated with Helicobacter pylori (H pylori) infection with complete histologic
and symptomatic resolution after treatment.
Methods: A 71-year-old African American man presented with dyspep-
sia, epigastric discomfort, diarrhea and weight loss of more than one year
duration. There was no clinical evidence of immunodeficiency or malig-
nancy. Upper gastrointestinal endoscopy revealed mild inflammation with
scattered white plaques in the gastric antrum and body with a 5 mm polyp
in the body. Examination of the biopsy of the plaques revealed lamina
propria replaced by regular, small, round nuclei with eosinophilic cyto-
plasm containing Michaelis-Gutmann bodies diagnostic of gastric malako-
plakia. A moderate number of H pylori like organisms were seen on
Warthin Starry stain. Colonoscopy revealed one cecal and one descend-
ing colon tubular adenoma. There was no evidence of malakoplakia or
malignancy seen elsewhere. He was treated with lansoprazole, amoxicillin
and clarithromycin for ten days and his symptoms resolved. Repeat gas-
troscopy after 4 months showed no evidence of malakoplakia or H pylori
organisms.
Results: Reports of isolated gastric malakoplakia are few in number.
Malakoplakia is associated with concomitant diseases such as leukemia, lym-
phoma, alpha chain disease, immunodeficiency, miliary tuberculosis, villous
adenoma and carcinoma. Infectious agents have been implicated as the cause
of malakoplakia in the majority of cases. To our knowledge this is the first
case reported showing an association with H pylori infection with complete
symptomatic and histologic resolution after treatment. Since malakoplakia
mimics malignancy and can be associated with colorectal carcinoma in 30%
of the cases, a thorough evaluation is essential
Conclusion: Isolated gastric malakoplakia is extremely rare. Diagnosis and
treatment of predisposing conditions is very important to prevent complica-
tions.
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Clincal Utility of Adjunctive Naturopathic Products To Improve the
Tolerability of Interferon Based Regimens for Hepatitic B and C: A
Report on Four Patients
Srinivas S. Vasireddi, MD∗. Advanced Digestive Center, Metuchen, NJ.
Purpose: To observe any clinical utility of adjunctive naturopathic products
like Milk thistle, turmeric, Siberian Ginseng, Schisandra and Bupleurum in
improving the tolerability of standard Interferon based therapies for Hepatitic
C and B patients.
Methods: 3 patients with hepatitis C on standard pegylated interferon alpha-
2b and ribavirin and 1 patient with hepatitis B on pegylated interferon alpha-
2a were instructed to simultaneously take two 220 mg capsules of Milk
Thistle, 1000 mg of turmeric capsules, 1000 mg of Siberian Ginseng, 3
cups tea daily with 1 tsp each of schisandra and bupleurum tinctures respec-
tively for the initial 2 months. They were assessed every 2 weeks for the
side effect profiles including fatigue, energy loss, myalgias, mood swings
and flu like symptoms. Their lab prameters were analysed and the subjec-
tive tolerability of therapy was also graded from 1(Intolerable) to 5(Very
Tolerable).
Results: All four patients receiving the above naturopathic supplements did
not report any serious subjective side effects warranting any dose reduc-
tion or stoppage of standard therapy. They maintained their normal routines
without any fatigue or energy loss. All reported tolerability scores of 3 or
higher. The patients also felt that the natural supplements seemed to help
them subjectively, with no adverse sequelae. The CBC profiles were also
maintained in acceptable ranges and did not warrant any dose reductions of
the standard therapy.
Conclusion: The tolerability profiles of the four patients receiving natur-
opathic supplements with the standard Hepatitic B and C interferon based
therapies was very good, with none of the patients requiring dose reduc-
tions or stoppage of standard therapy. The patients also reported a feeling
of subjective well-being. Whether this could be related to a non-specific
immuno-booster effect or a placebo phenomenon, naturopathic supplements
appear to have a clincal role in improving the patient tolerability of inter-
feron based hepatitis regimens. Further large scale standardized controlled
studies are needed to assess the clinical utility of these unregulated “food
supplements”.
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Gastric Cancer Recurrence in Small Bowel after Subtotal Gastrectomy
with Billroth II Gastrojejunostomy
Albert J. Pahk, MD, Shahid Mehboob, MD∗. Gastroenterology, University
of Buffalo, Buffalo, NY.
Purpose: A seventy-nine year old Caucasian male with gastric adenocar-
cinoma (T2aN1M0) who underwent subtotal gastrectomy with Billroth II
gastrojejunostomy and chemotherapy three years ago was referred by his
oncologist for a nine pound weight loss over one month. An esophagogas-
troduodenoscopy was performed and a five centimeter friable mass was
identified in the efferent loop five centimeters distal to the gastrojejunos-
tomy. A biopsy of the mass revealed moderately to poorly differentiated
adenocarcinoma. Exploratory laparotomy revealed the tumor in the effer-
ent loop which was excised and a second suspicious area of small bowel
was resected. The pathology for both small bowel segments were infiltrating
moderately to poorly differentiated adenocarcinomas. The pathology from
the small bowel was compared with the pathology of the original gastric
adenocarcinoma from three years ago and were identical. The patient there-
fore had recurrence of his gastric cancer in his efferent limb in two separate
locations three years after his surgery.
Locoregional recurrence of gastric cancer is most commonly found in the
gastric stump. There have been rare reports of gastric cancer recurrence in the
J-pouch and in the efferent loop. These cases were reported in patients from
the Far East, where incidence of gastric cancer and gastric cancer recurrence
is higher and surveillance is more extensive. However this is the only reported
case of recurrence in the efferent limb at two separate sites. This is also the
first reported case in North America of gastric cancer recurrence in the small
bowel.
There is no universal consensus for surveillance following curative surgical
resection for gastric cancer. Prognosis for recurrent disease remains poor,
yet there are no guidelines to help detect recurrence at an earlier and more
treatable stage. We propose yearly surveillance with esophagogastroduo-
denoscopy in patients with gastric cancer resection.
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Pneumatosis Intestinalis. The Question Is To Be or Not To Be – A
Polyp!
Aman Ali, MD, Hagit Manor, MD, Eric Rosen, MD, Rukhsar Ahmed, MD,
Knarik Arkun, MD, Gregory Haber, MD∗. Gastroenterology and
Hepatology, Lenox Hill Hospital, New York, NY.
Purpose: 57 year old male with history of diabetes and hyperlipidemia
presented with abdominal distension and flatulence of several months du-
ration. Initial colonoscopy by the referring gastroenterologist revealed mul-
tiple large, broad based, transverse colon polyps. Snare polypectomy was
deferred due to concerns regarding diagnosis and potential complications.
Laparoscopic resection vs. endoscopic resection by a skilled endoscopist
was discussed with the patient who opted for the latter. Colonoscopy per-
formed at our institution revealed many 5–25 mm, sub-mucosal lesions.
The morphology was that of a distinct raised globular lesion or a confluent
multilobulated mass (Fig. 1). The endoscopic impression was pneumato-
sis coli. The largest polyp was partially snared to remove the mucosa and
well biopsies were taken to get deeper tissue. Biopsies revealed numerous
gas filled cysts in mucosa and sub mucosa, lined by epitheliod histiocytes
(Fig. 2).
Pneumatosis intestinalis is characterized by multiple gas-filled intamural
cysts in the small or large bowel. It may be primary or secondary due to peptic
ulcers, IBD, feeding jejunostomy, ruptured diverticuli, clostridium difficile,
AIDS enterocolitides, COPD, mechanical ventilation, post endoscopy and
intestinal ischemia. This finding may be incidental on endoscopy or routine
imaging. Symptomatic patients may present with diarrhea, hematochezia,
abdominal pain, distension or flatulence. Hyperbaric oxygen treatment and
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antibiotics are helpful in some instances. However, in cases of intestinal
ischemia and perforation, pneumatosis is an ominous sign and emergent
surgery is indicated.
Conclusion: Our patient had persistent irritable bowel symptoms likely un-
related to pneumatosis. Endoscopic recognition and confirmatory biopsies
avoided an unnecessary surgical resection, for an otherwise benign condi-
tion.[figure1][figure2]
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MALTOMA of the Colon Presenting as Autoimmune Hemolytic
Anemia
Amanpal Singh, MD, MS, Jack B. Alperin, MD, Alvah R. Cass, MD,
Guillermo Gomez, MD, G.S. Raju, MD∗. Internal Medicine, Family
Medicine and Surgery, Uni. of Texas Medical Branch, Galveston, TX.
Purpose: Gastrointestinal causes of anemia include blood loss, nutritional
deficiency, malabsoprtion of nutrients, hypersplenism, or drug induced bone
marrow suppression or hemolysis. Autoimmune hemolytic anemia is a rare
manifestation of GI disease; when it occurs, consider gastrointestinal lym-
phoma.
Objective: We report a case of MALTOMA of the colon presenting as au-
toimmune hemolytic anemia (first report).
Case Report: A 60 year old man presented with worsening exercise intol-
erance and dizziness for three months and without weight loss, fever, night
sweats or GI symptoms. Examination: icterus, otherwise unremarkable. In-
vestigations: Hemoglobin: 7.2 g/dl, reticulocyte count: 17.22%, haptoglobin
22 mg/dl, unconjugated bilirubin 2.6 mg/dl, LDH 644 U/L; Direct antiglob-
ulin test: weakly positive; Bone marrow biopsy: erythroid hyperplasia (M:
E = 0.3:1); thus confirming a diagnosis of autoimmune hemolytic ane-
mia. Treatment: PRBC transfusions and prednisone. Evaluation of underly-
ing etiology: CT abdomen (Fig. 1): a large mass transverse colon (arrow);
Colonoscopy with high frequency ultrasound probe sonography: a large sub-
mucosal mass in the mid transverse colon. Surgery: Laparoscopic transverse
colon resection. Pathology (Fig. 2): small lymphocytic lymphoma, with im-
munohistologic features consistent with MALT lymphoma of colon. Course:
Patient recovered fully and is currently on prednisone; last hemoglobin:
11.7 g/dl.
Conclusions: Our case demonstrates that value of investigation of under-
lying cause of autoimmune hemolytic anemia. The underlying problem is
MALT lymphoma of the colon without gastrointestinal symptoms.
Literature Search: We did not encounter a case of MALT lymphoma
of the colon with autoimmune hemolytic anemia in the literature.
[figure1][figure2]
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Retrieval of Distally Migrated Esophageal Stent Using Enteroscopy
Raja S. Vadlamudi, MD, Mark F. Young, MD∗. Department of Internal
Medicine, East Tennessee State University, Johnson City, TN.
Purpose: Migration of esophageal stent is an important complication (6%
to 18%). Stent migrations are usually treated with conservative measures.
We present a case where the displaced stent is removed using enteroscopy.
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Case Report: A 48 year old male smoker with intermittent dysphagia to
solids and heartburn underwent esophagogastroduodenoscopy (EGD) with
biopsy which showed squamous cell carcinoma of the distal esophagus con-
firmed by pathology. Exploratory laparotomy showed metastatic involvement
of the celiac lymph nodes. He underwent chemotherapy and radiation ther-
apy without any complications. Later esophagectomy with splenectomy was
done for worsening dysphagia. He developed an esophageal anastomotic
leak postoperatively. An esophageal deficit of 1.5 cm was identified on EGD
and was reduced using surgical clips. A silicone coated polyflex esophageal
stent was also placed at the anastomotic site. Few days before the proposed
stent removal, he developed abdominal discomfort. The abdominal x-rays
showed possible distal migration of the stent in to the left upper quadrant
of the abdomen. He underwent enteroscopy and the stent, initially found in
the jejunum, was pulled into third part of the duodenum (Fig. 1). For lack of
facility to use forceps with enteroscope, a pediatric colonoscope was used
to remove the stent using rat toothed forceps (Fig. 2). Neither small bowel
defects nor distal esophageal deficits were noted on repeat enteroscopy.
Conclusions: This case illustrates the retrieval of distally migrated
esophageal stent using enteroscope with no untoward effects or compli-
cations.[figure1][figure2]
614
Metastatic Melanoma in a Dialysis Patient with Vomiting Diagnosed
by Gastric Polyp Biopsy
Maria Lufrano, DO, Ian Storch, DO∗, Richard Feldstein, MD, John
Costable, MD, Michael Gitman, MD. Gastroenterology, Northshore
University Hospital, Manhasset, NY.
Purpose: Gastric polyps are a common incidental finding on upper en-
doscopy. Although the majority of these polyps are benign, rarely they rep-
resent primary gastric malignancy, lymphoma or even metastatic disease.
We describe a case of metastatic melanoma without a primary cutaneous
lesion diagnosed by endoscopic biopsy of a gastric polyp.
Case Summary: A sixty-three year old Irish female with past medical his-
tory significant for coronary artery disease, hypertension and end stage renal
disease requiring dialysis presented with complaints of intermittent vomit-
ing for two weeks. Her vomiting was not associated with food and she
denied nausea, wretching, weight loss, hematemesis or melena. Physical ex-
amination including a thorough neurologic, ophthalmic and dermatologic
exam was performed which was normal. Comprehensive metabolic panel
and complete blood count were within normal limits. An upper endoscopy
was performed which revealed multiple 5 mm polyps in the body of the
stomach. Histology of the polyps revealed that they were malignant and spe-
cial stains were positive for vimentin, HMB45, S100, Melan A, and CEA
consistent with metastatic melanoma. Computerized tomography (CT) of
the chest/abdomen and pelvis were within normal limits. CT of the brain
revealed calcified/hemorrhagic lesions consistent with metastatic disease.
Conclusion: Gastric polyps are a common finding on upper endoscopy oc-
curring in 2.5% of cases, most of which are hyperplastic. Metastatic disease
to the stomach is rare, but has been described with breast cancer, renal cell
carcinoma and melanoma. Metastatic melanoma is usually from the skin
but, can be secondary to non-cutaneous lesions such as those of ocular and
mucosal origin. Primary gastric melanoma has been reported but usually
is seen as a large ulcerated mass. In our case no primary lesion could be
identified likely, secondary to regression of a primary cutaneous lesion as
occurs in 2% of melanoma cases. Our case highlights that although most
gastric polyps are benign, gastric cancer and metastatic disease must always
be entertained and biopsy should be considered.
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Ciprofloxacin-Induced Acute Cholestatic Liver Injury and Associated
Renal Failure from Acute Tubular Necrosis
Amy J. DiChiara, MD, Matt Atkinson, MD, Kenneth E. Sherman, MD∗.
Department of Internal Medicine, University of Cincinnati, Cincinnati, OH.
Purpose: Ciprofloxacin, a fluoroquinolone antibiotic commonly prescribed
for a variety of infections has generally been well-tolerated; however, there
are rare reports of it causing hepatic failure or renal failure. In this case report,
we describe a 65 year-old man with a history of ischemic cardiomyopathy
and mild renal insufficiency (baseline creatinine 1.2–1.3), who developed
acute cholestatic jaundice and acute renal failure following treatment with
ciprofloxacin 500 mg two times a day for cellulitis. Six days into his treat-
ment course, routine labs showed the following: AST: 319, ALT: 157, AP:
711, bilirubin: 8.5, BUN: 36, creatinine: 2.3, INR: 6.6. The patient had no
history of previous liver disease, alcohol, recent new medications, nor other
toxic/herbal exposure. Total and direct bilirubin eventually rose to 25.3 and
15.6, while AST, ALT, and AP improved to 139, 102, and 226, respectively.
Liver biopsy revealed prominent canalicular and intrahepatocyte cholesta-
sis as well as focal hepatocyte ballooning with surrounding neutrophils and
lymphocytes, but no significant necrosis. Other causes of liver injury were
ruled out. Simultaneously, the patient became oliguric, creatinine contin-
ued to rise, and eventually required regular hemodialysis. Kidney biopsy
revealed acute tubular necrosis (ATN). Within two months of stopping the
ciprofloxacin, the patient was off dialysis and back to his baseline creatinine
in three months. Liver tests normalized by five months.
Discussion: There are 15 reported cases of ciprofloxacin-induced hepatotox-
icity. The time course between initiation of ciprofloxacin and development
of cholestatic liver injury as well as the improvement of this injury with the
removal of the offending agent strongly suggested ciprofloxacin as the cause
of the liver injury. Additionally, the time course and severity of renal failure
suggested ciprofloxacin-induced ATN as the cause of the renal failure. There
are several reports of ciprofloxacin-induced acute renal failure secondary to
interstitial nephritis; however, there has been only a single case report of
ATN from ciprofloxacin. To our knowledge, this represents the first case
report of simultaneous acute cholestatic liver injury and ATN secondary to
ciprofloxacin.
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Elevated Alfa Fetoprotein: Looking beyond Hepatocellular Carcinoma
Mamata Ravipati, MD, Navneet Attri, MD, Rami Y. Haddad, MD∗.
Department of Internal Medicine, North Chicago VA Medical Center,
North Chicago, IL and Department of Hematology/Oncology, North
Chicago VA Medical Center, North Chicago, IL.
Purpose: Carcinoid tumors are the tumors of neuroendocrine system com-
prising 1–2% of all gastrointestinal malignancies. Primary hepatic carcinoid
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is a very rare tumor. Less than 70 cases in English literature are reported so
far. We report on a patient who developed primary hepatic carcinoid tumor
in a non cirrhotic liver with elevated fetoprotein which is a rare association.
54 yr old male presented with six month history of bloating and gaseous
sensation, dull right upper quadrant nonradiating pain 3/10, decreased ap-
petite, weight loss of 20 lbs over 6 month period, distant history of Hepatitis
A, >40 pack year smoking history, without history of alcohol or illicit drug
use. Physical exam revealed non tender hepatomegaly otherwise unremark-
able. CT scan of abdomen showed markedly enlarged liver with multiple
masses. Labs showed CBC and BMP to be normal, total Bilirubin1.2, ceru-
loplasmin 45, Iron 45, HepB core antibody reactive, Hep B surface antigen
and antibody non reactive, Hep C antibody non reactive, AST 151, Alt 51,
Alkaline phosphate 262, Amylase 92, Lipase 561, Alfa fetoprotein 10313.3,
CEA 4.3. Histopathological examination revealed highly cellular smears
with groups of tumor cells demonstrating high nuclear to cytoplasmic ra-
tios, numerous mitotic figures, granular chromatin, no visible nucleoli and
a vague rosette-like pattern. Immunohistochemistry was positive for chro-
mogranin and synaptophysin and negative for cytokeratin 7 and 20. Serial
Octreotide scan showed mild non-homogenous uptake in the left lobe of the
liver and were inconclusive for metastatic carcinoid.
Patient was transferred to Tertiary hospital and was given 6 cycles of
chemotherapy Carboplatin + Etoposide due to extensive liver involvement
and presence of small cells. He achieved partial response without develop-
ment of new lesions on the most recent follow up CT scan of abdomen and
pelvis.
Conclusion: Diagnosis of primary hepatic carcinoid is difficult because of its
rarity and histological similarity to hepato cellular carcinoma. Misdiagnosis
is easy especially with elevation of alpha fetoprotein. Liver masses with AFP
level higher than 4000 are usually treated as HCC, even in Hep B neg patients.
Thus, the diagnosis of HCC should be confirmed with biopsy especially in
liver masses presenting with elevated AFP and negative Hep B serology.
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A Late Presentation of Blue Rubber Bleb Nevus Syndrome Diagnosed
by Laparoscopic-Assisted Double Balloon Enteroscopy
Nidhi Singh, MD, Vivek Prachand, MD, Carol Semrad, MD∗.
Gastroenterology, University of Chicago, Chicago, IL.
Purpose: A 78 year-old man with peptic ulcer disease and new atrial fib-
rillation requiring warfarin presented with weakness and anemia at an out-
side institution. Initial EGD and colonoscopy found no bleeding source. A
tagged RBC scan showed a left upper quadrant blush. An arteriogram had
no arterial or venous abnormalities. Push enteroscopy identified nonbleed-
ing dilated venous structures in the proximal small bowel. Video capsule
endoscopy found round, blue lesions in proximal small bowel, red blood
in mid-distal jejunum, and black fluid obscured the distal small bowel. He
was transferred to our institution for double balloon enteroscopy (DBE). On
physical exam, he had a 2 mm lower lip purple papule and a 4 mm purple
papule on his scrotum. His stool was brown but hemoccult positive. External
exam of the bowel with laparoscopic-assisted DBE identified blue lesions
on small bowel and colonic serosal surfaces. Endoscopically, flat prominent
veins were noted in the distal esophagus and gastric antrum, blue polypoid
lesions were identified in the small bowel with relative ileal sparing, and
red blood with clot was found in the mid-jejunum. Despite vigorous warm
water washes, no active bleeding lesion was identified to warrant endoscopic
or surgical intervention. Blue Rubber Bleb Nevus Syndrome (BRBNS) was
diagnosed based on characteristic cutaneous venous malformations and as-
sociated visceral lesions. Given late age of presentation, bleeding provoked
by anticoagulation, and extent of bowel involvement, he has been treated
conservatively with octreotide without a subsequent bleed for 8 months.
BRBNS is a rare disorder in which cutaneous lesions, often present in early
childhood, tend to be multiple, blue, compressible lesions that rarely bleed
unless traumatized. In contrast, GI lesions, usually evident in early adulthood,
extend from the oral cavity to anus with easy bleeding. Conservative medical
management has been reported using corticosteroids, interferon, octreotide,
and iron supplements. Endoscopic therapy has included sclerotherapy, band
ligation, laser photocoagulation, and polypectomy. Most recently, a combi-
nation of radical endoscopic and surgical local excision of lesions has been
reported to be successful and sparing of extensive bowel resections. To our
knowledge, this is the first use of DBE in the diagnosis and management of
BRBNS deep in the small bowel. With the first bleeding episode at age 78,
it is also one of the latest presentations of BRBNS ever diagnosed.
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Massive Upper GI Bleed Secondary to Splenic Artery Pseudoaneurysm
Susan Ramdhaney, MD, Ajay Malhotra, MD, Safak Reka, MD, Michael
Herskowitz, MD, Frank Gress, MD∗. Gastroenterology, Radiology, SUNY
Downstate Medical Center and Kings County Hospital, Brooklyn, NY.
Purpose: 22 year old male, history of abdominal trauma, presented with sud-
den onset of 3 episodes of hematemesis associated with abdominal pain and
loss of consciousness. He denied previous episodes of GI bleeding. Two years
prior, he had multiple stab wounds to the abdomen and subsequently under-
went exploratory laparotomy and ostomy with reversal for perforated bowel.
Reports heavy alcohol use on weekends and smokes 1 ppd × 6 years. Upon
arrival to the emergency room, vital signs were stable: P73, BP 122/68 with
no orthostasis. Abd exam: + BS, NT, ND, + midline and ostomy scars, no
organomegaly. Rectal exam: brown stool, guaiac positive. NG lavage was
not performed. Labs: WBC 11,900 mm3, Hg 12.5 g/dL, Hct 37.9%, Platelets
323/mm3, BUN/cr ratio19 with normal coagulation profile and liver tests. An
EGD was performed. A large fresh clot was seen in the gastric body which
could not be suctioned. In addition, fresh blood was seen in the second por-
tion of the duodenum, but no source of bleeding was identified. During en-
doscopy, the patient had several more episodes of hematemesis and was taken
to interventional radiology. A 5 F catheter was placed in the celiac axis and
an angiogram was performed. A pseudoaneurysm off the mid splenic artery
was identified as the source of bleeding and coils were deployed and packed
into the pseudoaneurysm. Repeat angiogram showed no residual flow with
good thrombosis. Subsequently, the patient was discharged with no further
episodes of GI bleeding and Hct 35%. Few cases have reported GI bleeding in
patients where pseudoaneurysms have been thought to spontaneously erode
into the GI tract secondary to compression/stress/trauma. Since this patient
had sustained prior abdominal trauma in the same anatomical location as
the formation of the splenic artery pseudoaneurysm, spontaneous fistular-
ization of the pseudoaneurysm and the gastric wall could have occurred thus
explaining his presentation. A thorough review of the literature has reported
pseuodocyst and pseudoaneurysm fistularization to arteries supplying the GI
tract or to the pancreatic duct in patients with chronic pancreatitis resulting
in upper GI bleeding. However, to date, there is no reported case of a pseu-
doaneurysm of the splenic artery caused as a result of prior abdominal and
presenting as trauma hematemesis. Hence, as gastroenterologists, we must
be aware of the increasing role of angiographical methods for diagnosing
and controlling acute GI bleeding.
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Fever and Sepsis as an Unusual Complication of Erosion of an IVC
Filter into the Duodenum
Syed R. Latif, Edward Feller, MD∗, Jeremy Spector, MD, Samir A. Shah,
MD. Division of Gastroenterology, The Warren Alpert Medical School of
Brown University, Providence, RI.
Purpose: Erosion of an inferior vena cava (IVC) filter into the GI tract is rare.
Similarly, fever and sepsis is an underappreciated complication of intravas-
cular device migration. We report a patient with an unexpected duodenal-
caval fistula detected endscopically as the postulated cause of unexplained
recurrent sepsis.
Case Report: A 67-year-old presented with one week of confusion. He
denied abdominal complaints. He had been discharged 2 weeks earlier
with Klebsiella pneumoniae sepsis. Past medical history was significant for
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multiple pulmonary emboli with placement of a non-retrievable IVC filter
2 years previously. Two months prior to the current admission, UGI en-
doscopy for Barrett’s esophagitis screening lead to the seemingly incidental
discovery of a thin, metallic foreign body protruding into the duodenum. On
exam, temp. = 101.6◦F, blood pressure = 140/80 without postural change,
pulse = 74/min. Cardiac, pulmonary and abdominal exams were normal.
WBC count = 16,000; 4 out of 4 blood cultures were positive for Staphylo-
coccus aureas.
Progressive dysphagia due to Parkinson’s disease required percutaneous en-
doscopic gastrostomy tube placement. At UGI endoscopy, a thin metal wire
was protruding through the wall of the second portion of the duodenum. A
clean-based, non-bleeding ulcer was on the opposite wall. The finding was
consistent with migration or erosion of a non-retrievable IVC filter through
the duodenal wall. CT scan confirmed this finding. He declined further treat-
ment.
Discussion: Perforation of an IVC filter into the GI tract is rare. Other po-
tential mechanisms of IVC-duodenal fistula are penetrating injury; erosion
of tumor, abcess or pseudocyst. Clinical manifestations of filter migration
into the duodenum are diverse, including chronic abdominal pain, GI bleed-
ing of any magnitude, fever or sepsis. Clinical signs of infection, such as
confusion in our patient, may be non-specific and misleading, mimicking
more common disorders. Delay in diagnosis is common. We postulate that
duodenal ulceration and sepsis were complications of an IVC filter. Fever
and bacteremia are rare, reported complications of duodenal migration or
perforation of these devices. Filter erosion should be considered in any pa-
tient with a history of filter placement and unexplained chronic abdominal
pain, GI bleeding, fever or sepsis.
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Recurrrent Hematochezia – A Rare Presentation of the
Klippel-Trenauny-Weber Syndrome
Bhavesh B. Shah, MD, Geanina Anghel, MD, Joseph C. Young, MD,
Anthony R. Lupetin, MD, Katie F. Farah, MD∗. Division of
Gastroenterology, Allegheny General Hospital, Drexel University College
of Medicine, Pittsburgh, PA; AGH Surgery, Allegheny General Hospital,
Pittsburgh, PA and Dept. of Diagnostic Radiology, Allegheny General
Hospital, Pittsburgh, PA.
Purpose: A 27 year old male presents with 8–10 episodes of painless hema-
tochezia per month over the past 9 years. Physical examination revealed hy-
pertrophy and large varicose veins in the right thigh. PMHx was significant
for a port-wine stain on his right thigh early in childhood. At age 8, he devel-
oped oozing of his right thigh and underwent laser therapy. At age 12 he noted
a “bumpy” consistency of his right thigh and underwent a right leg venec-
tomy. Pathology revealed arteriovenous malformations (AVMs). His first
episode of hematochezia occurred at age 18; work-up at that time included
normal EGD, colonoscopy, and capsule endoscopy. Our repeat colonoscopy
showed grade 1 internal hemorrhoids and prominent rectal veins to 10 cm
from the anal verge. CT scan showed calcified phleboliths in the peri-rectal
fat relating to multiple dilated venous structures. MRI/MRV of the pelvis
showed an enlarged fetal lateral limb-bud vein extending into the right lateral
thigh, enlarged peri-rectal veins and hemangiomatosis. Right leg venogram
revealed extensive venous collaterals and an aberrant sciatic vein extend-
ing from the right lateral thigh. Additionally a direct communication from
the common femoral vein and deep system to the large venous collaterals
in the knee and thigh was noted. These findings prompted a diagnosis of
Klippel-Trenauny-Weber Syndrome (KTWS). He then underwent endove-
nous ablation of his right sciatic vein and a large collateral vein, followed by
U/S-guided sclerotherapy with foam injection. Follow-up flexible sigmoi-
doscopy revealed near complete ablation of rectal varices 6 months from
first presentation. There have been no further episodes of hematochezia.
KTWS is a sporadic congenital anomaly characterized by the presence of a
port-wine stain, varicose veins, hypertrophy of bony/soft tissues and AVMs.
Rectal bleeding is a rare complication of KTWS and there have been few
reported cases of hematochezia secondary to rectal varices from KTWS. The
diagnosis is supported by histologic demonstration of AVMs. Treatment op-
tions include debulking, radiotherapy, sclerotherapy or surgery. This case
illustrates the importance of endoscopic recognition of rectal varices as it
may unmask manifestations of a severe underlying systemic disorder.
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An Unusual Cause of an Abdominal Mass
Freddy Caldera, DO, Lisbeth Selby, MD∗, Heather L. Rutledge, MD.
Gastroenterology, University of Kentucky, Lexington, KY.
Purpose: A 29 year old white male had been having worsening abdominal
pain and distention over two months. During this time he had nausea, early
satiety, and night sweats. He had noticed a painful mass near his epigastrium.
He had not had any weight loss, jaundice, or change in bowel pattern. On
physical exam he had a firm, distended abdomen with normal bowel sounds
and a large mass extending from the epigastrium to his pelvis. A CT of ab-
domen was obtained that showed a large 27 cm mass in diameter arising from
the retroperitoneum, involving the liver, and extending to the pelvis. There
were multiple omental and liver metastases along with extensive retroperi-
toneal lympadenopathy. A needle biopsy was performed that was consistent
with Ewing sarcoma. The patient was treated with vincristine, doxorubicin,
cyclphosphamide and actinomycin D. Surgery was not an option due to ex-
tensive metastases.
Ewing sarcoma is a neuroectodermal tumor of the bone that may metasta-
size to other bones and lungs, and very rarely spreads to other organs. It is
usually found in children, with average age at diagnosis of 10–20 and an
incidence of 1 per 3.3 million. Extra-osseous Ewing sarcoma is rare and has
been described in the retroperitoneal cavity, stomach, gallbladder and small
bowel. Retroperitoneal origin of the cancer is rare only 15 cases have been
reported worldwide. Adverse predictors for survival are metastatic disease
at presentation, primary extraosseous tumor, or age older than 26. He is cur-
rently undergoing a second regimen of chemotherapy with ifosfamide and
etoposide, due to poor response with first chemotherapy regimen.
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Isolated Cecal Infarction with the Radiological Picture of a Mass
Lesion in a Patient with an Acute Abdomen and No Obvious
Predisposing Factors
M. Momeni, MD, P. Basi, MD, G. Martin, MD, S. Anand, MD, V. Rovito,
MD∗. GI, LMC, BK, NY.
Purpose: Isolated cecal infarction is an uncommon entity, which can be
due to vasculoocclusive or nonocclusive causes. Here we present a case of
a healthy elderly female with abdominal pain who was found to have an
isolated cecal gangrene.
An 82 year old Caucasian female presented to the emergency room with the
acute onset of right lower quadrant abdominal pain. Her medical history was
pertinent only for well-controlled hypertension and a surgical history of a
left breast lumpectomy. At the time of admission, the patient was febrile with
no hemodynamic instability; lab values revealed only leukocytosis (WBC
13,800/mm with 90% neutrophils). Computed tomography-intended to rule
out appendicitis- revealed focal wall thickening of the cecum and ascending
colon suggestive of a cecal mass (Fig. 1). Colonoscopy was not recommended
because of the possibility of perforation. Due to the clinical picture and CT
scan findings of a possible cecal mass, the patient underwent exploratory
surgery. Intraoperatively, gangrene isolated to the cecum with full thickness
necrosis was found. No free perforation was noted. Mesenteric pulses were
palpable. The patient underwent right hemi-colectomy and had an uneventful
postoperative course.
Histopathology revealed severe ischemia of the cecum with transmural in-
farction of the cecal wall and acute peritonitis of the cecal serosa. Proxi-
mal (ileal) and distal (colonic) resection margins and appendix showed no
evidence of ischemia. The cecal vessels showed no atherosclerosis as well
as no evidence of vascular occlusion or vasculitis. Work-up with cardiac
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echocardiography revealed no focus of embolic disease. The patient was
discharged in stable condition one week after surgery.
To our knowledge, this is a unique case report of isolated cecal gangrene in
a patient with no predisposing cause. Isolated cecal gangrene may present
as a diagnostic dilemma owing to its uncommon occurrence and atypical
presentation-in this case the radiological impression was that of a cecal
mass (was read by four radiologists). Therefore, gastroenterologists should
entertain the diagnosis of cecal gangrene in a patient with acute right lower
quadrant pain.[figure1]
623
Case Series on Hepatic Portal Venous Gas
Debapriya De, MD, Mitesh Patel, MD, Rishi Pawa, MD, Krishnarao V.
Tangella, MD, Davendra P. Ramkumar, MD∗. Internal Medicine,
University of Illinois at Urbana Champaign, Urbana, IL;
Gastroenterology, Columbia University College of Physicians & Surgeons,
Harlem Hospital Center, New York, NY; Pathology, Provena Covenant
Medical Center, Urbana, IL and Gastroenterology, University of Illinois
College at Urbana Champaign, Urbana, IL.
Purpose: Hepatic portal venous gas (HPVG) is an important, but rare radio-
graphic finding of gas in the portal venous system. It is a valuable clue to a
serious intraabdominal pathology. We present 2 contrasting cases of bowel
ischemia causing HPVG.
Methods: Review of literature using Medline.
Results: A 62 year old male presented with diffuse abdominal pain, associ-
ated with abdominal distension, constipation, nausea & vomiting for 3 days.
He was found to be in septic shock. CT of the abdomen and pelvis showed
air in the portal venous system, distended loops of small bowel with air fluid
levels, along with air in the mesenteric veins. At surgery, perforated ap-
pendix & cecum with purulent peritonitis was found & compromised bowel
was resected. Histopathology revealed acute appendicitis; the small bowel
segment showed extensive hemorrhage, with ischemic necrosis of the mus-
cularis propria. Vascular structures were free of thrombi or emboli. A 68
year old female presented with dizziness & lightheadedness for a day. She
reported feeling of mild abdominal discomfort in the left lower quadrant.
Initial blood pressure was 78/34. CT scan of the abdomen & pelvis revealed
gas in the left hepatic lobe in a branching pattern within the intrahepatic
portal venous radicals. Repeat CT scan 3 days later, revealed bowel wall
thickening at the cecum with pericolonic inflammatory changes. Because of
worsening leucocytosis and acidosis, surgery was done. This revealed a cecal
inflammatory mass without perforation. Histopathology revealed ischemic
changes of the cecum. Cecum is considered a watershed zone vulnerable to
ischemia. HPVG was caused by localized cecal ischemia due to severe hypo-
tention caused by her antihypertensive medications. The first case presented
with dramatic clinical features versus the second case, which showed mini-
mal clinical signs and symptoms. Ischemia caused by hypotention was the
initiating event in both patients, with sepsis & overtreatment of hypertension
being the primary causes in respective cases.
Conclusion: HPVG is a serious diagnostic clue indicating bowel compro-
mise. The cause of HPVG should be thought of as a surgical emergency until
proven otherwise, as a delay in surgical intervention can be fatal.
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Isolated Polypoid Ganglioneuroma of the Sigmoid Colon
Debapriya De, MD, James Kumar, MD, Srikanth Vallurupalli, MD,
Krishnarao V. Tangella, MD, Davendra P. Ramkumar, MD∗. Internal
Medicine, University of Illinois at Urbana Champaign, Urbana, IL;
Pathology, Provena Covenant Medical Center, Urbana, IL and
Gastroenterology, University of Illinois at Urbana Champaign, Urbana, IL.
Purpose: Ganglioneuromas (GN) are rare tumors and seldom arise in the
gastrointestinal tract. GN are often located in the posterior mediastinum,
retroperitoneum, adrenal glands, pelvis, cervix & parapharyngeal region.
We report a case of isolated polypoid GN in a 56-year-old caucasian male
who underwent a screening colonoscopy.
Methods: Review of available literature using Medline.
Results: Patient’s past medical history & physical examination was unre-
markable. Family history was noncontributory. All hematological & bio-
chemical investigations were normal. Colonoscopy revealed a sessile 15
mm submucousal polyp located about 20 cm proximal to the rectosigmoid
junction. Macroscopically, the specimen was a 20 × 20 × 20 mm pale brown
polyp. Microscopic examination demonstrated the presence of ganglion cells
and spindle cells. Immunoperoxidase staining with S-100 protein showed
positive areas in the spindle cell regions, ganglion cells & prominent nerve
fibers. The pathological diagnosis was made as polypoid GN. A surveillance
colonoscopy after 2 months showed no other abnormalities. Polypoidal GN
differ from diffuse intestinal GN in that the neural proliferation lies within
the lamina propria, thus giving the clinical impression of a ‘micropolyp’.
Differential diagnoses include neurofibroma & schwannoma, which are no-
table for the absence of ganglion cells. Isolated GN does not produce any
specific symptoms & are usually noted incidentally at colonoscopy, surgery
or necropsy. There have been some reports of abdominal pain, obstruction,
constipation, ileus, appendicitis & weight loss as presenting clinical sce-
narios based on the size and the position of the tumor. The lesions can be
dumb-bell shaped & luminal resection can increase the risk of perforation.
Patients with isolated polypoid GN do not require long-term follow-up since
they do not develop systemic disease. Diffuse GN is however associated with
Von Recklinghausen’s disease, Cowden’s disease, Multiple Endocrine Neo-
plasia (MEN) type 2B & non familial adenomatous polyposis. They have
been shown to be caused by a single mutation in the RET proto-oncogene,
with a methionine to threonine substitution at codon 918 (M918T).
Conclusion: Because of the potential risk of perforation of the colon by
GN, gastroenterologists must therefore be aware of this rare but important
identity.
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Complicated Periappendiceal Abscess Diagnosed on Colonoscopy
Raja S. Vadlamudi, MD, Puneeth Goenka, MD∗. Department of Internal
Medicine, East Tennessee State University, Johnson City, TN.
Purpose: Appendicitis with its complications like periappendiceal abscess
is diagnosed with 93% to 98% accuracy using CT. In several reported cases,
appendicitis with atypical symptoms and/or nondiagnostic imaging was di-
agnosed during colonoscopy. We present a case of complicated periappen-
diceal abscess diagnosed on colonoscopy.
Case Report: A 37 yr old female presented to our clinic being referred
for an abnormal CT scan showing mass extending into the cecum. She had
intermittent right lower quadrant pain for past 2–3 months, increasing in
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intensity with menstruation. She had no change in bowel movements, no
urinary symptoms, no nausea or vomiting. CT abdomen showed right pelvic
cystic mass attached to the uterus, adnexa, cecum and sigmoid colon with no
visualization of appendix (Fig. 1). Colonoscopy showed edematous cecum
with clear pus extruding from the appendiceal orifice confirming appendicitis
(Fig. 2). Laparotomy showed large mass in the pelvis covered with omentum
and small bowel. Pus was expressing from necrotic base of the appendix and
from the right ovarian cyst. Appendectomy and hysterectomy with bilateral
salphingo-oophorectomy were performed. Pathology confirmed appendicitis
with abscess formation along with the ovarian abscesses on both sides. The
culture from the pus was positive for Bacteroides fragilis indicating bowel
as the source of infection. Our patient had appendicitis with abscess that
disseminated causing infection of the ovarian cysts. The infection was walled
off by omentum causing atypical symptoms, thus misleading physicians till
colonoscopy.
Conclusion: This unusual case illustrates a key role played by colonoscopy in
diagnosing a complicated periappendiceal abscess presenting with atypical
symptoms and non diagnostic radiologic workup.[figure1][figure2]
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Cisplatin Induced Ischemic Colitis: A Case Report
Kanwar R.S. Gill, MD, Seth A. Gross, MD, Mohammad Al-Haddad, MD,
Tejal Patel, James S. Scolapio, MD∗. Division of Gastroenterology &
Hepatology, Mayo Clinic, Jacksonville, FL.
Purpose: Ischemic colitis (IC) is caused by a reduction in intestinal blood
flow, which most commonly arises from occlusion, vasospasm, and/or hy-
poperfusion of the mesenteric vasculature. The development of IC in setting
of chemotherapy is rare. We report a case of a 68-year-old woman who devel-
oped IC involving the descending colon after chemotherapy with Cisplatin.
Case: A 68-year-old woman who was on Cisplatin for invasive thymoma pre-
sented with 4-day history of nausea, vomiting, left sided crampy abdominal
pain and bloody diarrhea. The symptoms started 2 days after the first cycle
of chemotherapy. Her past medical history included asthma, bronchiectasis,
colonic diverticulosis, peptic ulcer disease and migraines. The patient was
taking premarin, omeprazole, and denied any NSAID use. The patient also
denied personal or family history of inflammatory bowel disease. The pa-
tient had stable vital signs, and the physical examination demonstrated mild
left lower quadrant abdominal tenderness. Laboratory studies revealed mild
leukocytosis. A CT scan of the abdomen revealed diffuse thickening of the
colon wall with edema and fat stranding in pericolic region from the level
of the splenic flexure through the upper sigmoid colon, and the abdominal
vasculature was patent. A colonoscopy revealed areas of diffuse mucosal
edema and errythema with superficial exudates from 30 cm to 80 cm from
anal verge. The stool studies and colonic biopsies were negative for an in-
fectious etiology, and the biopsies were consistent with IC. The patient was
thought to develop IC secondary to Cisplatin chemotherapy.
Discussion: IC after systemic chemotherapy has been described, but is ex-
ceedingly rare after Cisplatin. There is only one published case report in
English literature of IC related to cispatin by Mauya et al. Their patient re-
ceived Docetaxal with Cisplatin. Although rare, IC should be considered in
patient with colitis symptoms after Cisplatin chemotherapy.
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A Rare Mimic of Colon Cancer: Ameboma
Malini Madhavan, MBBS∗, Chenni S. Sriram, MD, Gautam Kumar, MBBS,
MRCP (UK). Department of Internal Medicine, Mayo Clinic, Rochester,
MN and Molecular Pharmacology/Experimental Therapeutics, Mayo
Clinic, Rochester, MN.
Purpose: To appreciate the diagnostic challenge posed by ameboma in a
patient encumbered with multiple ailments as well as to gain a brief insight
into its clinico-pathological features and treatment options.
Results: A 76-year-old male from Minnesota, with history of non-small
cell lung cancer and prostate cancer, presented with subacute intestinal ob-
struction and hematochezia. He had recently started prednisone for radiation
pneumonitis. Computed tomography of the abdomen revealed circumferen-
tial colonic wall thickening and exophytic masses extending from the cecum
to the proximal transverse colon. Colonoscopy revealed multiple, partially
obstructing, necrotic luminal masses in the same distribution. The differen-
tial diagnoses included extensive colon cancer, metastatic cancer, lymphoma,
tuberculosis, and Yersinia colitis. A biopsy done to ascertain colon cancer
showed instead hemophagocytic Entamoeba histolytica in flask-shaped ul-
cers confirming the diagnosis of ameboma. High serum anti-E. histolytica
antibody titers and trophozoites and cysts in the stool provided corroborative
evidence. The clinical enigma was resolved when subsequent questioning
revealed that he was a frequent traveler to Central America and China, the
last visit being 5 years ago. Treatment with Metronidazole for 3 weeks fol-
lowed by Paromomycin for a week culminated in clinical and colonoscopic
resolution.
Conclusion: E. histolytica, a leading cause of parasitic death in develop-
ing nations, represents a significant health hazard for international travel-
ers. Intestinal amebiasis is typified by colonic ulcero-inflammatory lesions
and manifests as a clinical spectrum ranging from asymptomatic infection,
through colitis, ameboma and toxic megacolon. Ameboma, a rare presenta-
tion even in endemic countries, is characterized by an inflammatory colonic
mass indistinguishable from colon cancer. Complications include bleeding,
bowel obstruction and perforation. As exemplified here, immunosuppression
may precipitate severe symptoms in asymptomatic carriers several years after
the sentinel infection. Metronidazole is the cornerstone of therapy followed
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by a luminal amebicide such as Paromomycin or Diloxanide furoate to erad-
icate colonization. Colonic mass in the setting of immunosupression and a
history of travel to developing countries, even in the remote past, should raise
the possibility of ameboma. Prompt diagnosis and treatment is imperative
to prevent complications and unnecessary surgery.
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Two Primary Adenocarcinomas in a Crohn’s Patient with Infliximab
Therapy
Christina A. Tennyson, MD, Divyesh Sejpal, MD, Daniel Labow, MD,
Michael Lewis, MD, Maria T. Abreu, MD∗. Gastroenterology, Mount Sinai
School of Medicine, New York, NY; Surgery, Mount Sinai School of
Medicine, New York, NY and Pathology, Mount Sinai School of Medicine,
New York, NY.
Purpose: A 55 year old woman with a six year history of Crohn’s disease
presented with recurrent episodes of pancreatitis. The patient was initially
diagnosed with Crohn’s disease of the stomach and duodenum, without in-
volvement of the colon and remainder of the small bowel. One year following
diagnosis, the patient had continued progressive obstructive symptoms and a
loop gastro-jejunostomy was performed for a duodenal stricture. Following
surgery, she received therapy with azathioprine and eventually infliximab.
After approximately three years of therapy with infliximab, the patient de-
veloped severe abdominal pain and was diagnosed with pancreatitis. Aza-
thioprine was discontinued; however, she experienced a recurrent episode of
pancreatitis the following month. A CT scan revealed mild dilatation of the
pancreatic duct without a discrete mass, intra/extrahepatic biliary dilatation,
and wall thickening with enhancement in the second portion of the duode-
num. An MRCP confirmed wall thickening just proximal to the ampulla,
without a ductal filling defect. An endoscopy was performed to locate the
ampulla and characterize Crohn’s disease involvement. While the stomach
appeared grossly normal, a stricture of the duodenum was appreciated 5 cm
past the pylorus and biopsied. The efferent limb of jejunum appeared nor-
mal, but the afferent limb contained an area of stricturing disease and the
ampulla could not be located with a side-viewing endoscope. Biopsies of
the duodenal stricture revealed adenocarcinoma. A pancreaticoduodenec-
tomy was performed with resection of a portion of the gastric antrum. A
Stage I (pT1, N0) well to poorly differentiated adenocarcinoma of the pe-
riampullary duodenum was found in a background of segmental Crohn’s
duodenitis with inflammatory stenosis and polypoid/flat high grade dyspla-
sia. In addition, a signet ring cell adenocarcinoma of the pyloric channel
was found, Stage IB (pT2a, N0), in a background of chronic gastritis with
high grade dysplasia. There was no tumor invasion of the pancreatic/biliary
ducts and 33 regional lymph nodes were negative for adenocarcinoma. This
case of two adenocarcinomas in a young patient with a short duration of
Crohn’s disease raises concern about the relationship between infliximab and
tumorigenesis.
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Primary Sclerosing Cholangitis and Autoimmune Hemolytic Anemia:
A Casual Association?
Marie B. Wiles, PA-C, Charles H. Parker, MD, Alastair D. Smith, MB,
ChB∗. Medicine, Halifax Regional Hospital, South Boston, VA and
Medicine, Duke University, Durham, NC.
Purpose: Primary sclerosing cholangitis (PSC) is a progressive and incur-
able condition characterized by inflammation, fibrosis, destruction and loss
of interlobular-sized bile ducts, leading to biliary cirrhosis and liver failure.
It is more common among men, is frequently associated with chronic in-
flammatory bowel disease (IBD) and with the following HLA haplotypes,
-A1, -B8, and -DR3. Patients with PSC have increased prevalence of other
autoimmune disorders, e.g. celiac disease. Autoimmune hemolytic anemia
(AIHA) has been described in association with PSC, albeit uncommonly.
A 55 year-old man with stable PSC, confirmed the previous year, and treated
hypothyroidism but without chronic IBD, complained of increasing fatigue,
chest pain and dyspnea of two weeks’ duration. He denied overt blood loss,
fever, pruritus or jaundice. The principal examination findings were pallor
and icterus. Vital signs were stable. Heart sounds were normal, there was
no pericardial friction rub and both lung bases were clear. Neither liver nor
spleen was palpable, and he had no clinical evidence of ascites. Laboratory
data were as follows: Hb 6.7 g% (normal range [NR]: 14–18), and MCV
108.6 fL (NR: 80–94), with normal white cell and platelet counts. The retic-
ulocyte count was 6.2% (NR: 0.5–4). LDH concentration was 164 IU/L (NR:
91–180). However, the serum haptoglobin was 2 mg% (NR: 36–195). His
polyspecific, direct antiglobulin test was positive. Serum concentrations of
ferritin, folate and vitamin B12 were normal. Total serum bilirubin (BR)
was 3.5 mg% (NR: 0.4–1.2), of which the indirect component was 2.6 mg%.
The alkaline phosphatase was 420 IU/L (NR: 42–121), but aminotransferase
concentrations were normal. Albumin was 4 g% (NR: 3.2–5.5), and his pro-
thrombin time was 12 seconds (NR: 9–13.1). Although his EKG revealed new
left bundle branch block, cardiac enzymes were not elevated. A presump-
tive diagnosis of AIHA was made and treatment with methyl prednisolone
begun. Concentrated red cells were transfused cautiously. Four weeks after
commencing corticosteroid therapy his Hb had risen to 13.2 g%, and the hap-
toglobin to 37.8 mg%. His BR was 1.3 mg%. The daily dose of prednisone
was 40 mg.
Reports of the co-existence of PSC and AIHA include the sequence described
above, and vice versa. This is the first report to our knowledge of a patient with
PSC, AIHA and autoimmune hypothyroidism. The corticosteroid exposure
demands careful attention to minimization of bone density loss.
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Henoch-Scho¨nlein Purpura with Terminal Ileitis Masquerading as
Crohn’s Diseae
Eric R. Wollins, MD, Antoinette Saddler, MD, Marie L. Borum, MD∗.
Division of Gastroenterology and Liver Diseases, George Washington
University Medical Center, Washington, DC.
Purpose: An 18 year-old Korean male presented with a 1-week history of
colicky abdominal pain, non-bloody diarrhea and painful swelling of his
right ankle. His PMH, FHx and SHx were unremarkable. Upon initial eval-
uation, he was febrile, tachycardic and tender with palpation of his RLQ.
His right ankle appeared warm and swollen without any evidence of rash.
Admission labs: WBC:18, H/H: 18/ 48, Plt: 400, BUN:11, Cr: 1.0. AXR was
normal. ABD CT scan revealed a mildly dilated and thickened terminal ileum
with a normal appendix. Initial differential diagnosis included: Crohn’s dis-
ease with extra-intestinal manifestations, infectious colitis and diverticulitis.
Additional labs: ESR: 6, CRP: 4.4. Colonoscopy showed a normal rectum
and colon and terminal ileitis with localized edema, erythema and puru-
lent, superficial ulcerations. Given these findings, a presumptive diagnosis
of Crohn’s disease was made and the patient was started on a 5-ASA regimen.
Biopsies from the terminal ileum revealed chronic active ileitis with ulcer-
ation and fibropurulent exudate. Additional labs: ASCA(+), p-ANCA (−),
negative blood, urine and stool cultures. Seven days after discharge, the pa-
tient represented appearing toxic with RLQ pain and a new bilateral lower ex-
tremity purpura with associated polyarthritis. Labs revealed:WBC:14, H/H:
14/42, Plt:450, Eos:2, ESR:53, CRP:6.7, BUN:77, Cr:2.5 with nephrotic
range proteinuria and a normal coagulation profile, peripheral smear, hep-
atitis panel and rheumatologic serologic evaluation. An IgA level was mildly
elevated at 464. Kidney biopsy showed large irregular mesangial subepithe-
lial deposits and a skin biopsy demonstrated small vessel leukocytoclastic
vasculitis. Given the constellation of these new findings including palpa-
ble purpura in the absence of coagulopathy, abdominal pain, arthritis and a
biopsy with predominant IgA deposition, a diagnosis of Henoch-Scho¨nlein
purpura (HSP) with terminal ileitis was made. The patient was started on
prednisone with a rapid clinical improvement and normalization of renal
function.
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HSP is a small-vessel vasculitis that commonly affects the skin, joints, kid-
neys and gastrointestinal tract. GI manifestations typically occur up to 8 days
after the onset of purpura. However, as in this case, the diagnosis of HSP
may be delayed not only when the GI manifestations mimic other entities
such as Crohn’s disease, but also, when the GI manifestations precede the
characteristic purpuric rash.
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Acute Pancreatitis: An Unusual Complication of Double Balloon
Enteroscopy
Rahul Pannala, MD, Ganapathy A. Prasad, MD∗, Suresh T. Chari, MD,
Louis M. Wong Kee Song, MD. Gastroenterology and Hepatology, Mayo
Clinic, Rochester, MN.
Purpose: 76 year old male with critical aortic stenosis presented for eval-
uation of transfusion-requiring iron deficiency anemia. As esophagoduo-
denoscopy, colonoscopy, capsule endoscopy, and CT enterography were un-
remarkable, a double-balloon enteroscopy (DBE) was performed and re-
vealed a moderate sized jejunal vascular ectasia that was treated with argon
plasma coagulation. There were no immediate procedure-related complica-
tions.
Approximately 4 hours later he presented with severe abdominal pain. Sig-
nificant laboratories included a markedly elevated lipase (924 U/L [10–73
U/L]) and amylase (380 U/L [26–102 U/L]). CT abdomen revealed inflam-
matory changes in the body and tail of the pancreas and significant edema
in the peripancreatic fat (Fig. 1) but there was no evidence of necrosis. He
improved gradually over the course of the next week with conservative treat-
ment. CT abdomen 2 months (Fig. 2) later demonstrated persistent inflamma-
tory changes in the pancreatic body and tail and ill-defined fluid collections
in and around the pancreatic tail. However, the patient was asymptomatic.
Repeat CT 6 weeks later noted decrease in size of the fluid collections and
pancreatic inflammation. He had an uneventful aortic valve replacement at
this point. CT performed 4 months later demonstrated a normally enhancing
pancreas with minimal residual fluid collection. Our report adds to previous
case reports from Japan and Netherlands of this uncommon complication
of DBE. Though there are no prospective series, the estimated prevalence
of pancreatitis following DBE is around 1%. The etiology of pancreatitis
following DBE is unclear but may be related to duodenal reflux or transient
sphincter of Oddi dysfunction, which may occur during a long procedure
such as DBE with compression of the ampulla. Prospective evaluation of the
complications of DBE is needed.[figure1][figure2]
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Insulin Therapy for Hypertriglyceridemia (>6,000 mg/dl) and
Hyperglycemia (>500 mg/dl) in the Setting of Acute Pancreatitis
Wayne Tsuang, Luis Ruiz, MD, Smruti Mohanty, MD, Jesse Hall, MD∗.
Pritzker School of Medicine, University of Chicago Medical Center,
Chicago, IL; Section of Pulmonary and Critical Care Medicine, University
of Chicago Medical Center, Chicago, IL and Section of Gastroenterology,
University of Chicago Medical Center, Chicago, IL.
Purpose: Hypertriglyceridemia (HTG) accounts for 2% of acute pancre-
atitis. The most common presentation of HTG pancreatitis is uncontrolled
diabetes. Control of triglyceride levels is essential to avoid exacerbation of
pancreatitis. Insulin therapy for HTG in the setting of pancreatitis is not
widely reported.
Results: A 25 year-old female with Type II diabetes and hypertension with
poor medication compliance presented to the emergency room complaining
of abdominal pain and several episodes of non-bloody, non-bilious emesis.
She denied fevers or chills. She also denied alcohol or drug use. Family his-
tory was unremarkable. Exam revealed a distended, tender abdomen without
guarding or rebound and decreased bowel sounds.
Blood sample was grossly lipemic and showed: HTG (6,280 mg/dl), elevated
lipase (7,430 u/l), and hyperglycemia (566 mg/dl). Pregnancy and toxicology
tests were negative. Abdominal CT confirmed pancreatitis without evidence
of gallstones or biliary ductal dilatation/obstruction.
An insulin (0.1 u/kg/hr) intravenous (IV) drip was started and enteral nu-
trition withheld. Twenty hours later, triglyceride levels decreased to 1,658
mg/dl and to <500 mg/dl by hospital day 5. Serum glucose levels decreased
to 82 mg/dl after 24 hours. Serum lipase levels decreased to <60 u/l in one
week.
Conclusion: Reported treatments of HTG pancreatitis include combinations
of IV insulin, IV heparin or apheresis. We managed HTG with IV insulin,
which activates lipoprotein lipase and degrades triglycerides into glycerol
and fatty free acids. In addition, IV insulin also treated hyperglycemia. Hep-
arin has been used with insulin for HTG for its ability to release lipoprotein
lipase from endothelial surfaces. However, lipase released by heparin is more
liable to hepatic degradation, depleting plasma stores. Apheresis can rapidly
remove triglycerides. However, the efficacy of apheresis in HTG pancreatitis
has limited data and conflicting reports. We felt apheresis was unnecessary
in our patient due to the decrease in triglyceride levels after 24 hours of IV
insulin.
IV insulin can successfully manage HTG and hyperglycemia in the setting
of acute pancreatitis and uncontrolled diabetes. However, definitive recom-
mendations for therapy in HTG pancreatitis requires further study.
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Reported cases of C. difficile bacteremia and sepsis
Age Clinical Other isolated Stool Suspected
Author (yr)/ Sex presentation organisms toxin source Treatment Outcome
Feldman et al. 85 F Fever, hypotension,
diarrhea
Enterococcus faecalis Pos Colon Vancomycin/ Gentamicin iv Ventilator
dependent
Wolf et al. 18 M SBO Candida parapsilosis NR Unknown NR Favorable
Wolf et al. 33 F Pelvic abscesses,
rectovaginal fistula
C. cadaveris, B.
melaninogenicus,
Fusobacterium species
NR Pelvic abscesses NR Death
Wolf et al. 77 M Sigmoid perforation Eubacterium lentum NR Colon NR Death
Cid et al. 3 M Tonsillitis, pericarditis None NR Unknown Vancomycin iv Favorable
Byl et al. 18 M Fevers, abdominal pain,
diarrhea
None Pos Colon Vancomycin oral Favorable
Byl et al. 78 M Peumonia, diarrhea None Neg Colon Vancomycin oral and iv Death
Spencer et al. 65 M Gangrenous toe,
diarrhea
Bacteroides fragilis Neg Unknown Cefuroxime/ Metronidazole iv Death
Sanchez et al. 51 F Hepatic abscess, biliary
obstruction
Enterococcus casseliflavus NR Unknown Daptomycin/ Metronidazole iv Favorable
SBO = Small bowel obstruction, Pos = Positive, Neg = Negative, NR = Not reported
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Clostridium difficile Sepsis Associated with an Enterococcal Hepatic
Abscess
Patricia A. Sanchez, MD, Michael Selden, MD, Owen J. Smith, MD,
Wendell K. Clarkston, MD∗. Department of Medicine, Division of
Gastroenterology, University of Missouri at Kansas City School of
Medicine, Kansas City, MO.
Purpose: A 51-year-old female with metastatic gallbladder carcinoma and
recurrent biliary obstruction presented with fevers, hypotension, right upper
quadrant tenderness and jaundice. She denied diarrhea and other gastroin-
testinal complaints. Blood cultures identified Vancomycin-resistant Entero-
coccus casseliflavus and Clostridium difficile.
Laboratory data included a WBC of 22,000/µL an ALT of 168 IU/L, alkaline
phosphatase of 513 IU/L and a total bilirrubin of 8 mg/dL.
Imaging revealed a 9-cm hepatic abscess and dilated bile ducts both of
which were percutaneously drained by interventional radiology. Cultures of
the biliary aspirate grew Enterococcus faecium but no anaerobes. The patient
responded to intravenous daptomycin and metronidazole.
Discussion: C. difficile is a major nosocomial enteric pathogen that results in
significant morbidity. While its primary presentation is that of acute colitis,
extraintestinal manifestations have been described (Table 1). Whether the
source of the bacteremia in our case was colonic or biliary is difficult to
determine.
Physicians should be cognizant of the potentially invasive nature of this or-
ganism. Extraintestinal manifestations may become more frequent given the
increased incidence and virulence recently associated with this microorgan-
ism.
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Delayed Post-Polypectomy Bleeding Associated with Use of Bilberry
(Vaccinium Myrtillus) Extract
Mitchell Duterte, MD∗, Shawn Waugh, PA-C, Rizwana Thanawala, MD.
Lake City, FL.
Purpose: The use of herbal medications is becoming more common. Since
these are considered dietary supplements, they are not subject to stringent
regulations by the Food and Drug Administration. Published data on the
adverse effects of herbal medications are scanty and this may have significant
implications on the perioperative care of patients.
A 66 year old man with history of diabetes mellitus and hypertension under-
went colonoscopy for colorectal cancer screening. He takes several medica-
tions, none of which are anticoagulants, antiplatelets or anti-inflammatory
drugs. The patient also takes bilberry extract 500 mg once a day, suppos-
edly to improve his vision. Since the adverse effects of bilberry extracts are
not known, the patient was told to stop taking it one week before the pro-
cedure. Colonoscopy showed multiple colon polyps, the biggest of which
was a 1 cm sessile polyp in the tranverse colon. These were removed by
snare cautery using standard technique. The immediate post-colonoscopy
course was uneventful. Two weeks after colonoscopy, the patient resumed
taking bilberry extracts. Two days later, he started to have hematochezia. His
hemoglobin dropped from 13 g/dl to 6.8 g/dl. The platelet count was 139
thou/cu mm. Bleeding time was prolonged at >15 minutes. The patient was
transfused a total of 11 units pRBC. Repeat colonoscopy revealed that the
bleeding was from the polypectomy site at the transverse colon, where an
ulcer with active oozing of blood was seen. The bleeding site was cauterized
with gold probe and clipped with three hemoclips. The bleeding ceased for
24 hours. However the patient started to bleed again. Because of failure of
endoscopic hemostasis, he subsequently underwent subtotal colectomy. The
post-operative course and the remainder of the patient’s stay in the hospital
was unremarkable.
Extracts of bilberry (V. myrtillus) have been used for many years in the
treatment of diarrhea, dysmenorrhea and a variety of visual disorders. It has
several bioactive components but most of the studies have been on antho-
cyanosides. Anthocyanins are purported to have antioxidant, hypoglycemic
and lipid-lowering properties. It has also been shown to inhibit platelet aggre-
gation and inhibit the synthesis and release of pro-inflammatory agents like
prostaglandins, leukotrienes and histamine. Theoretically it may increase
the risk of bleeding. However human studies proving its efficacy and safety
are lacking. Therefore it may be prudent to stop this medication in patients
undergoing procedures where the risk of bleeding is high.
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Mycophenolate Mofetil (MMF) Induced Cecal Ulceration in a Patient
with Lupus Nephritis
Ehteshamul H. Anjum, MD, Prabodh Ranjan, MD, Jinil Yoo, MD∗, Pramod
Joseph, MD. Nephrology, Our Lady of Mercy Medical Center/New York
Medical College, Bronx, NY and Gastroenterology, Our Lady of Mercy
Medical Center/New York Medical College, Bronx, NY.
Purpose: Lupus nephritis (LN) remains a major cause of renal failure in
women of child bearing age. In comparison to cyclophosphamide, MMF has
an excellent safety profile. MMF is usually associated with gastrointestinal
(GI) side effect, especially diarrhea is a major concern. More serious events
such as GI bleeding or colon perforation were reported in transplantation
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group. We describe a case of cecal ulceration and GI bleed with the use of
relatively high dose of MMF in a patient with LN.
A 38 year old African American woman with systemic lupus for 8 years
developed active LN class IV/V. She was initially placed on oral cyclophos-
phamide 2 mg/kg and methylprednisolone 16 mg daily. Cyclophosphamide
was switched to MMF 2 grams/day because of leucopenia. The dose of MMF
was increased to 2.5 gm/d for the persistent nephrotic syndrome, with im-
provement of the proteinuria. However she developed diarrhea and severe
anemia requiring blood transfusion. Colonoscopy revealed erythematous
mucosa from hepatic flexure to cecum with two oozing linear ulceration in
cecum. With a temporal association between the dose increment of MMF
and the event, MMF was discontinued. Her GI bleeding resolved in 3 days.
Colonoscopy was repeated in 4 weeks revealing complete resolution of the
ulcers. Severe GI adverse effects like upper GI bleeding and ulcerations
are reported with the use of MMF but there are very few reports of cecal
ulceration in the literature.
The frequency of adverse effects seems to be related to higher blood level of
MMF, whereas immunosuppressive activity is related to the total exposure
(Area under the curve). High dose of MMF inhibits the proliferation of basal
epithelial cells of intestine in mice.
Owing to its safety and efficacy as shown in recent trials, MMF is gaining
popularity as a therapeutic option both for induction and maintenance of
severe LN. Even with use of higher doses of MMF, monitoring of drug level
is not routinely used. In view of increasing use of MMF the likelihood of en-
countering these serious side effects are higher. Future studies are needed to
determine both effective and safe therapeutic targets to make this promising
agent more safe and predictable.
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Intragastric Balloon for Obesity Causing Gastric Outlet Obstruction
Natalee S. Sansone, MD, Liberato Salvatore, MD∗. Internal Medicine,
Division of Gastroenterology, New York Hospital of Queens, Flushing, NY.
Purpose: Intragastric balloons are indicated for treatment of moderately
obese patients. Major complications include immediate gastric outlet ob-
struction, spontaneous deflation causing obstruction, and gastric perforation.
We report a case of delayed gastric outlet obstruction.
A 59 yo female presented with nausea, vomiting and abdominal pain for
5 days. The patient had an intragastric balloon (BioEnterics Intragastric
Balloon – BIB, INAMED Health, Santa Barbara, CA) placed 9 weeks prior
in Mexico having lost 30 lbs with a BMI of 35 kg/m2. Past history included
GERD and laparoscpic cholecystectomy.
Her vital signs were stable. Her RUQ and epigastrum were firm and tender.
Serologies showed: Na 137, K 2.6, Cl of 91, CO2 35, glucose 127, BUN 18,
and creatinine 1.4. Upper GI series showed positional barium passage (Fig.
1).[figure1]Endoscopy, using Olympus GIF 140 (Olympus Corp), showed a
fundal balloon occluding the lumen (Fig. 2). A scleroneedle and a rat tooth
forcep were used to puncture the balloon and drain its contents. The en-
doscope was reinserted with an overtube (Bard Endoscopic Overtube). A
jumbo snare was used to impact the balloon into the overtube at 10 cm. All
were removed in unison with anesthesia on standby.[figure2]The following
day, the patient complained of a sore throat and chest pain and had a tem-
perature of 38.8. The leukocyte count was 11.93 K/uL (normal 4.8–10.8
K/uL). CT scan of the neck and chest showed a small amount of air in the
paraesophageal space and mediastinum.
The patient was treated with piperacillin/tazobactam 4.5 grams q8◦ IV,
metronidazole 500 mg q6◦ IV, gentamicin 240 mg IV daily and made NPO.
She was discharged 10 days later.
In conclusion, a delayed gastric outlet obstruction occured after intra-gastric
balloon placement. Endoscopic balloon removal with overtube assistance
was complicated by a small esophageal perforation, managed conservatively.
637
Heat Stress and Excercise Induced Ischemic Colitis in a 21 Year Old
Riffat Meraz, MD, Namita Chittoria, MD, Preeti Mehta, MD, Uma Murthy,
MD∗. Internal Medicine, SUNY Upstate Medical University, Syracuse, NY.
Purpose: A 21 year old healthy caucasian male presented with vomiting,
diarrhoea and LLQ abdominal pain within 2 hours of vigrous game of frisbee
on a hot day of July with T Max of 88◦ F. Stools were loose, brown with
bright red bloody streaks and vomitus was large volume containing food.
He denied ingesting restaurant or undercooked food, use of antibiotics or
NSAIDs, recent travel, ano rectal intercourse, h/o joint pain, skin rash, eye
symptoms or any such previous episode.
Exam was significant for dry oral mucosa with poor skin turgor and LLQ
tenderness with DRE postive for occult blood. Labs were significant for
CPK of 719, Alk Phosphatase 174, WBC 22.6. Stool studies, vasculitis
panel and coags were negative. His CT abdomen showed increased soft tis-
sue stranding and thickening of transverse and descending colon suggestive
of infammation or infection. Colonscopy showed severe segmental inflam-
mation characterized by congestion, erythema, friability with granularity at
the transverse colon and splenic flexure, with multiple linear bluish lesions
suggestive of Ischemic Colitis. Biopsy was done and results were consistent
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with Ischemic Colitis. [figure1]Patients clinical condition and biochemical
parameters improved with IVFs and bowel rest within two days, and he was
discharged home in a stable condition.
Heat stress causes acute-phase, thermoregulatory responce with cutaneous
vasodilation and splanchnic vasoconstriction. One of the most serious com-
plications include Intestinal ischemic or infarction, usually in children and
elderly.1 And elevated body temperature alone may not be the sole cause
of fatal outcomes in heat stroke but that toxic chemicals released in this
accelerated thermogenesis may also be involved.2
The threat of heat-related illnesses is increasing with global warming and
although they are treatable and preventable, at least 688 persons die of them
in the US each year.3 Ischemic colitis must be suspected in heat stressed
patients even if they are young and even if their core temperature is <40◦ C
at presentation.
1. NEJM, Vol. 346, No. 25 – June 20, 2002
2. J Sci Med Sport. 2007 May 22
3. Heat-related deaths–US, 1999–2006. MMWR 2006; 55(29):796–8.
638
Intra Abdominal Pathology in Polymyalgia Rheumatica Presenting as
Exacerbation of Rheumatic Disease
Punyanganie de Silva, MRCP, Nagarajan Pranesh, MRCS, Guy Vautier,
FRCP∗. Department of Gastroenterology, James Paget University
Hospital, United Kingdom and Department of Surgery.
Purpose: A 73 year old lady with polymyalgia rheumatica presented with
a month’s history of right hip and thigh pain and stiffness. She had had
intermittent diarrhoea with no bleeding or mucus.
Examination revealed reduced right hip and knee flexion only. She was
apyrexial with elevated white cell count and inflammatory markers.
Hip, pelvic xrays, stool culture were normal. Sigmoidoscopy revealed mild
proctitis and mild diverticulosis. Ultrasound scan abdomen was also normal.
She had been commenced on steroids 3 weeks prior to admission.
A diagnosis of polymyalgia exacerbation was made and steroid dose in-
creased. Antibiotics were also commenced.
Diarrhoea was not recorded during admission but limb weakness and hip
pain deteriorated and inflammatory markers continued to rise, so an MRI
spine and pelvis was arranged on day 5.
This revealed multiple gluteal abscesses extending around the right femoral
head along with a perforated diverticulum and presacral abscess.
Despite attempted radiologically guided drainage with a view to hemi-
colectomy if required, and escalating antibiotic therapy, she became increas-
ingly septic and died.
Case 2: A 69 year old lady with polymyalgia presented with a 3 week
history of left thigh pain. She had had left sided abdominal pains for 6 months
treated by oral analgesia. Bowels chronically alternated between constipation
and diarrhoea with no rectal bleeding. She had loss of appetite and weight
over three months. Examination revealed mild weakness of left hip flexion.
White cell count and CRP were elevated. A diagnosis of exacerbation of
polymyalgia was made and steroid dose increased.
She was admitted a week later with severe abdominal pain, tachycardia
and pyrexia. Examination revealed generalized peritonitis. After aggressive
resuscitation, laparotomy was performed. This revealed faecal peritonitis
due to obstructing proximal sigmoid tumour with a perforated descending
colon and a large retroperitoneal abscess. She had a prolonged stay in the
intensive care unit following Hartmann’s procedure, but was later found to
have liver metastases.
Discussion: These cases highlight how patients with polymyalgia may have
perforated intrabdominal disease which mimics their rheumatic pathology.
Steroid therapy which is the mainstay of polymyalgia therapy can be detri-
mental.
In the presence of diarrhea/abdominal pain, a high degree of clinical suspi-
cion should be maintained for an alternative gastrointestinal cause.
639
Enteryx Revisited
Matthew Weed, MD∗, Steven A. Gorcey, MD, Shannon Hammond, FNP.
Gastroenterology, Monmouth Medical Center, Long Branch, NJ and Brody
School of Medicine, Greenville, NC.
Purpose: Enteryx was voluntarily recalled due to adverse events including
one death due to an aorto-enteric fistula. During training, endoscopists are
instructed to inject the polymer at the Z-line.
Methods: Our technique, namely injecting at or below the diaphragmatic
hiatus, rather than at the EG-junction, significantly reduces the risk of com-
plications. We present three patients that, when used appropriately, could
benefit from Enteryx.
Results: LM presents with retrosternal burning, dysphagia, recurrent URI.
She had been treated with PPIs and cycles of antibiotics. pH study demon-
strated significant reflux. EGD revealed esophagitis and a 2 cm sliding hiatal
hernia. She was referred for a fundoplication but opted for the Enteryx. Two
weeks later she had a decrease in her GERD and URI symptoms. AH has
severe reflux, severe asthma and retrosternal chest pain. Cardiac work up was
negative. EGD showed erosive esophagitis. Manometry showed ineffective
peristalsis. pH study demonstrated significant acid reflux. High dose PPI
and promotility agents provided no relief. She was referred for laparoscopic
fundoplication. She could not be cleared for general anesthesia. Enteryx
was performed. Three weeks later there was marked improvement in her
chest pain and asthma symptoms. She decreased Nexium from 80 mg twice
daily to 40 mg once daily. Within 9 months she had recurrence of her symp-
toms. Work-up revealed loss of polymer. Repeat Enteryx would have been
considered but unavailable due to the recall. MD presents with a history
of chronic GERD and two Nissen fundoplications. The first fundoplication
had “slipped.” He reported recurrent regurgitation and substernal discomfort
despite high dose PPI and promotility agents. Endoscopy was unrevealing.
Manometry showed normal motility with presence of a high-pressure zone
consistent with fundoplication. The Enteryx procedure was offered to the
patient. The polymer was injected just distal to the diaphragmatic hiatus.
The patient had almost immediate response. Over several months he had
recurrence of symptoms. EGD and X-ray revealed loss of polymer. The En-
teryx procedure was performed using the same techinque. The patient again
reported immediate relief of symptoms.
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Conclusion: Enteryx complications could be avoided by altering the in-
jection site. It should be limited to those with advanced endoscopic skills.
And training should be lengthened before being certified. Enteryx should be
reconsidered for select patients with GERD.
640
Mesalazine Induced Aplastic Anemia in a Patient with Crohn’s Disease
Ari Wiesen, MD, Jonathan Wiesen, MS, Sewanti Priyadarshi, MD, Kaushik
Neeraj, MD, Simmy Bank, MD∗. Albert Einstein College of Medicine,
Bronx, NY and Department of Medicine/Gatroenterology, Long Island
Jewish Medical Center, New Hyde Park, NY.
Purpose: A 52 year old woman with a past medical history of Crohn’s
Disease presented with several months of progressive lethargy, fatigue and
one day of bright red blood per rectum. She had lived in Haiti until 1 week
prior to admission and she noted that she had been transfused a week before
her trip. The patient had been taking 1,000 mg daily of Mesalazine for
several years.
She appeared comfortable and physical examination reveaeled small pe-
techia on her palate and lower extremities. Her initial WBC count was
3.4×109 and hematocrit was 27%. Her platelet count was 1×1069/L. ANC
was 550. Absolute reticulocyte count was 0.02×10612/L. ESR was 90 MMS.
PT, PTT and INR were normal. The patient was transfused with platelets.
EGD, colonoscopy and capsule endoscopy were unremarkable. Serologic
tests for Hepatitis, Parvovirus, CMV, EBV, HIV and PNH were negative.
Immunofixation showed no clonal spikes. Bone marrow biopsy revealed a
hypocellular marrow. A diagnosis of aplastic anemia was made. The patient
was given 1 cycle of cyclosporine and ATG (anti thymocyte antiglobulin)
and was discharged on prednisone. Her blood work remains consistent with
marrow depression.
The hematological effects of mesalazine are potentially fatal. Initial phar-
macological tests in 4000 patients reported no hematological complications.
Since then several reports have associated it with severe hematologic anemias
as well, including aplastic anemia, neutropenia and thrombocytopenia.
The ages of the patients with aplastic anemia attributed to mesalazine have
ranged from 20 to 75 years of age. The dosage and the length of treatment
also varied, with one patient experiencing the effect after only 28 days. Pa-
tients may present with purpura, bruising, epistaxis or with severe infectious
processes precipitated by neutropenia.
The exact mechanism of the aplastic anemia is unclear. Mesalazine may
induce immunologic suppression of the of hematopoetic stem cells or effect
a direct toxic effect upon those cells. The treatment for mesalazine associated
aplastic anemia is a combination of ATG, cyclosporine and granulocyte
colony – stimulating factor (G–CSF).
Conclusion: Aplastic anemia secondary to mesalazine is a rare but rec-
ognized phenomenon. Further studies are needed to identify its frequency.
Addition to the side effect profile of mesalazine may affect its choice for
therapy of patients with inflammatory bowel disease.
641
Ulcerative Colitis Diagnosed in a Patient with Venous
Thromboembolism
Seong K. Choi, MD, Afshin Tavakoly, MD, Leelavathi Kasturi, MD, Henry
Safier, MD∗. Internal Medicine, Mount Sinai School of Medicine at
Queens Hospital Center, Jamaica, NY.
Purpose: Thromboembolic episodes, either in the form of deep venous
thromboembolism (DVT) and/or pulmonary embolism (PE), are infrequently
observed in inflammatory bowel disease (IBD). The incidence of venous
thromboembolism (VTE) in IBD is 3–3.6 times greater than control groups
and is one of the serious complications of IBD, associated with high mor-
bidity and mortality. The underlying mechanisms of increased VTE in IBD
are multifactorial and still unclear. The infrequent but serious outcome of
such IBD complications demands a challenging diagnosis.
A 61-year-old male with unremarkable past medical history, presented to
ED, complaining of dyspnea of one month’s duration. On admission, patient
was noted to have profound anemia with a Hb 8.0 g/dL, unilateral calf tender-
ness, significant weight loss and heme positive stool. On system review, he
related 3 month history of intermittent diarrhea with blood admixture. Subse-
quently, Doppler US revealed DVT of the left lower extremity. The extensive
pulmonary embolism involving left main pulmonary artery was detected on
Spiral chest CT. The patient was transferred to intensive care unit, transfused
with packed RBCs and started on low molecular weight heparin (LMWH).
After improvement of his anemia, a gastrointestinal work up was under-
taken due to strong suspicion of possible malignancy. Colonoscopy showed
friable edematous and erythematous mucosa, and shallow scattered ulcera-
tions throughout the large bowel from rectum to cecum. Biopsies revealed
moderate to severe active chronic pan-colitis, consistent with ulcerative col-
itis, without evidence of dysplasia. P-ANCA (anti-neutrophilic cytoplasmic
antibodies) was elevated and thrombophila evaluation showed normal ho-
mocysteine, protein C, S level, and anti-cardiolipin antibody, but decreased
Antithrombin III level. The patient was treated with mesalamine (Asacol)
800 mg po three times a day and mesalamine 4 g retention enema at bedtime.
After unremarkable hospital course, the patient was discharged and returned
to his country, precluding our follow up.
The case illustrates a patient who was admitted to our hospital with massive
PE and DVT, and eventually found to have active UC as an underlying etiol-
ogy. Albeit uncommon, IBD has been established as a specific manifestation
and risk factor which shoud be included in the differential diagnosis of VTE.
642
Pulmonary Nodules in Ulcerative Colitis
Thanhtam N. Nguyen, BA∗, Chris Shepela, MD, Patnaik Mrinal, MD.
Gastroenterology, Hepatology and Nutrition & General Internal Medicine,
University of Minnesota, Minneapolis, MN.
Purpose: Inflammatory bowel disease (IBD) exhibits a wide spectrum of
pulmonary manifestations. Pulmonary nodules, however, are infrequently
reported in the literature as an extraintestinal manifestation (EIM) of IBD.
We report a case of a patient who presented with ulcerative colitis (UC) and
multiple pulmonary nodules as an EIM of UC.
A 23-yr-old female with a family history of UC was referred to our hospital
for acute onset of persistent dry cough and worsening bloody diarrhea. CT
of the chest, abdomen, and pelvis revealed multiple bilateral pulmonary
nodules, some of which were cavitary in nature, measuring up to 2 cm in
diameter and bowel wall thickening involving the entire colon consistent
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with pancolitis (Fig. 1). Flexible sigmoidoscopy revealed a diffuse area of
congested, friable mucosa in the rectosigmoid region and descending colon.
Biopsies showed colonic mucosa with abundant active inflammation and
crypt abscesses. CT-guided biopsy of one of the nodules revealed a pattern
and distribution consistent with non-specific interstitial pneumonitis (NSIP)
(Fig. 2). An extensive autoimmune, immunological, and infectious workup
was negative except for a positive IBD serology panel strongly suggestive
of UC. The patient was started on IV prednisolone with improvement of
pulmonary nodules on repeat CT scan. Repeated chest x-ray at 2 months is
back to normal.
To our knowledge, this is the first case of acute UC with pulmonary nodules
as the initial presentation. Histologically, pulmonary nodules as an EIM of
IBD vary from being necrobiotic, granulomatous, to focal aggregates of
lymphocytes. The NSIP pattern observed in our patient’s lung biopsy is
distinct from what has been reported in the literature and may constitute
a new addition to the spectrum of histological patterns seen in pulmonary
nodules linked to IBD.[figure1][figure2]
643
Hemochromatosis and Ankle Arthritis
Gennadiy Bakis, MD, Matthew Baichi, MD∗. Division of
Gastroenterology, Hepatology, and Nutr, SUNY at Buffalo, Buffalo, NY.
Purpose: Sixty eight year old male with hypertension, glucose intolerance,
hyperlipidemia, obesity and history of severe ankle osteoarthritis was re-
ferred to gastroenterology for evaluation of elevated liver enzymes. Prior to
evaluation he had a nine year history of bilateral ankle pain and swelling
which was investigated with multiple radiological studies showing severe
degenerative joint disease. Sedimentation rate and ANA were unremark-
able. Ankle pain was treated with non-steroidal agents, COX-2 inhibitors,
braces, physical therapy and steroid injections with intermittent minimal
improvement. Symptoms of bilateral wrists and shoulder pain were also
present but much less prominent. The patient also had chronically elevated
transaminases that had been attributed to alcohol use. Viral hepatitis serolo-
gies, anti-smooth muscle antibodies, alpha-1 antitrypsin were unremarkable.
Ferritin was elevated at 6500, iron saturation 85% and patient was C282Y
homozygous. Liver biopsy showed 4+ iron and macronodular cirrhosis.
Arthropathy is one of many clinical manifestations of hereditary hemochro-
matosis. Wrist, shoulder, knee and hip joints are most commonly affected.
Our patient’s long-standing severe ankle osteoarthritis is rare manifestation
of hereditary hemochromatosis.
644
Toxic Megacolon with Perforation: A Complication of Salmonella
Colitis in the U.S.
Isam Daboul, MD∗, Vikas Ghai, MD, Adeel Husain, Srini Hejeebu, DO.
Gastroenterology, University of Toledo, Toledo, OH and Medicine,
University of Toledo, Toledo, OH.
Purpose: Intestinal perforation as a life-threatening complication of toxic
megacolon following non-typhoid Salmonella infection has not been re-
ported in the United States according to current literature reviews. The dis-
ease is rapidly progressive, and death may ensue due to septicemia and/or
perforation.
Methods: A 48-year-old gentleman presented to the ER with bloody, watery
stools every hour associated with a crampy abdominal pain that progressively
worsened with eating. A week prior, the patient presented to an outlying fa-
cility where he was prescribed Dicyclomine and Imodium which did not
improve his condition. On this presentation, CT scan revealed multiple air-
fluid levels and follow up colonoscopy showed necrotic areas throughout
the colon with thick white discharge and ulcers. The patient was started on
steroids and Flagyl. The stool was negative for Clostridium Difficile and later
grew Salmonella group D isolate found to be susceptible to Ciprofloxacin
which was then started. The patient’s abdominal distention, pain and dis-
comfort began to resolve. He was started on a clear liquid diet and then
discharged on treatment.
Results: Two days later, the patient again presented to the ER with worsening
abdominal pain. Plain films showed severe colonic distention with free air
Abstracts S355
under the diaphragm which suggested toxic megacolon with perforation. The
patient then underwent a total colectomy with ileostomy.
Conclusion: Dicyclomine and Loperamide should not be used in cases of
dysentery as it may predispose to toxic megacolon. Identification of patients
with toxic megacolon associated with non-typhi Salmonella infections is
important as they are at risk for further intestinal perforation. Early effec-
tive fluid resuscitation, antibiotics, steroids and rectal tube insertion may be
helpful to prevent the occurrence of intestinal perforation.[figure1][figure2]
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A Case of Interferon-Induced Anti-Jo1 Positive Polymyositis with
Pulmonary Fibrosis
Matthew B. Chandler, MD, David L. Jager, MD, Mary Reyes, MD, Marie
L. Borum, MD∗. Gastroenterology, George Washington University,
Washington, DC.
Purpose: Interferon therapy for hepatitis C is rarely complicated by the
onset of autoimmune diseases. Thyroid disease, hemolytic anemia and TTP
are better known autoimmune diseases complicating interferon therapy. We
present a case of anti-Jo1 positive polymyositis with pulmonary fibrosis
induced by interferon therapy.
A 54-year old female with hepatitis C and biopsy consistent with mild ac-
tivity and mild fibrosis was treated with pegylated interferon and ribavirin.
After starting therapy, she complained of flu-like symptoms. Four weeks
later, she complained of worsening flu-like symptoms, shortness of breath
and weakness in her arms and legs prompting admission to the hospital. At
admission, her blood pressure, pulse and temperature were normal. She was
dyspneic with increased work of breathing. On exam, she had bilateral coarse
breath sounds and weakness in the proximal muscle groups in all extrem-
ities. Labs at admission were ALT93, AST115, Alkp144, TB0.2, Alb2.8,
CPK2637, Aldolase33.8, ANA<1:40, dsDNA<30, C4<8, C3<9, RF14,
and ESR70. Anti Jo1 was positive. SSA, SSB, pANCA, anticardiolipin,
ASMA, and AMA were negative. Chest x-ray showed bilateral interstitial
infiltrates. The patient underwent bronchoscopy with biopsy demonstrating
interstitial organizing pneumonitis and chronic bronchitis. Pulmonary func-
tion tests demonstrated moderate chest restriction with reduced DLCO to
30% of predicted. Clinical presentation suggested a diagnosis of anti-Jo1
positive acute polymyositis with interstitial pneumonitis. This constellation
of clinical features comprises the antisynthetase syndrome. Interferon ther-
apy was discontinued and the patient was treated with cyclophosphamide and
prednisone. She had gradual improvement in her weakness and pulmonary
function. The serum aldolase and creatine phosphokinase levels returned to
normal.
Interferon therapy is rarely complicated by the development of autoimmune
diseases. There have been few reports of acute polymyositis with pulmonary
fibrosis associated with interferon therapy. The presence of anti-Jo antibody
in patients with acute polymyositis is associated with the development of
pulmonary fibrosis. An association between Anti-Jo1 positive polymyositis
and hepatitis C has been previously described in patients without exposure to
interferon therapy. Because of the temporal relationship between interferon
therapy and the development of symptoms of this rare disease, the patient
presents with interferon-induced antisynthetase syndrome.
646
Sign of Leser-Tre´lat
Audrey H. Calderwood, MD, Robert C. Lowe, MD∗. Gastroenterology,
Boston Medical Center, Boston, MA.
Purpose: An 86 year old man complained of abdominal discomfort and
early satiety. He noted an increase in size and number of lesions on his
right flank that had been stable for decades prior. On exam, he was deeply
jaundiced with an enlarged, firm epigastric mass that was tender to palpation.
There were multiple, lichenified lesions on his right flank consistent with
eruptive seborrhoeic keratoses (Figs. 1, 2). Laboratory evaluation showed a
total bilirubin of 17.9 mg/DL, alkaline phosphatase of 987 U/L. Computed
tomography showed a large mass in the porta hepatits with replacement of
liver parenchyma by tumor and compression of the common bile duct. Liver
biopsy revealed poorly differentiated adenocarcinoma of bile duct origin.
Consideration was given to ERCP with palliative common bile duct stent
but the patient refused. He was also evaluated by oncology but declined
further treatment. One month after diagnosis, he was referred for hospice
care.
The sign of Leser-Tre´lat was first described in 1890 and is characterized by
the abrupt appearance of multiple seborrhoeic keratoses that rapidly increase
in size and number. This paraneoplastic syndrome is seen most often in ade-
nocarcinoma of the gastrointestinal tract (stomach, colon, liver, pancreas),
but can also occur in breast and lung cancer, renal cell carcinoma, lymphoma
and leukemia. This cutaneous finding may be the first sign of visceral ma-
lignancy and should prompt further investigation.[figure1][figure2]
647
The Buried Bumper Syndrome in Children
Sabina A. Ali, MD, Meghana Sathe, MD, Michael A. Russo, MD∗.
Pediatrics, Division of Pediatric Gastroenterology and Nutrition,
University of Texas Southwestern/Children’s Medical Center of Dallas,
Dallas, TX.
Purpose: Case #1: A 10 month old former 25 week preterm newborn with
a history of chronic lung disease and gastroesophageal reflux (GER). At 2
months a Nissen fundoplication with surgical gastrostomy tube (GT) was
performed due to severe GER. The infant consumed adequate calories by
mouth and initially never required use of the GT. Due to worsening respira-
tory issues he underwent a video swallow study which revealed aspiration.
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Feeds were discontinued by mouth, replaced by GT feedings. Abdominal
distention and fussiness were noted with GT use. A fluoroscopic GT study
showed the GT balloon to be within the gastric antrum with partial gastric
outlet obstruction. This led to surgical revision of the GT with a 14 French
mushroom tube. Four weeks after the revision he presented with fever. A
fluoroscopic study revealed a small gastrocutaneous fistula tract adjacent to
the GT site with edema. Antibiotics were started and an esophagogastro-
duodenoscopy (EGD) performed. The endoscopic images demonstrated a
“buried bumper” with incomplete intragastric visualization of the gastros-
tomy device. The GT was removed.
Case #2: A 7 year old with Hurler’s syndrome had a Gastro-jejunostomy
(GJ) tube placed at 1 year of age due to concern of aspiration and poor
oral feedings. He presented with a 3 week history of redness and bulging
around the GJ tube site and swelling with use of the GJ tube. Around the site
there was an 8 cm circumferential area of erythematous, indurated tissue.
An ultrasound of the area revealed a 4 cm balloon with surrounding edema.
Subsequently an EGD demonstrated the balloon buried completely under
granulation tissue. The balloon was deflated and the GJ tube was removed
successfully.
Conclusion: Buried bumper syndrome (BBS) is caused by internal migration
of the internal bumper into the gastric wall usually due to excessive tension
applied to the tube. The internal bumper may become completely overgrown
by gastric mucosa and is usually a late complication. Most reported cases
have been in adults. Prevalence ranging from 1.5% to 6.1%. It may present
as increased leakage around the site, immobility of the catheter, resistance
of infusion, or abdominal pain. Once diagnosed the solution is removal of
the tube. Failure to recognize this complication may result in GI bleeding,
gastric perforation, peritonitis, and even death.
648
Fine Needle Aspiration Biopsy (FNAB) of a Rare Case of Malignant
Seeding of Percutaneous Endoscopic Gastrostomy (PEG) Tract: Direct
Implantation during PEG Insertion or Seeding Via Hematogenous
Spread?
Anwer M. Siddiqi, MD, Robert D. Hamilton, MD, Mithra Baliga, MD,
Rhyne Flowers, MD, Anil Minocha, MD∗. Pathology, University of
Mississippi Medical Center, Jackson, MS; Medicine, Division of Oncology,
University of Mississippi Medical Center, Jackson, MS and Medicine,
Division of Gastroenterology, University of Mississippi Medical Center,
Jackson, MS.
Purpose: PEG insertion is routinely performed in patients with potentially
obstructive head and neck cancers, during surgery for tracheostomy place-
ment or prior to definitive radiation therapy. We describe a case of one such
patient who developed metastasis at the gastrostomy stoma possibly as a
result of PEG placement. The diagnosis was made by FNAB.
A 56 year-old African American woman with a prior history of ethanol and
tobacco abuse presented with the complaints of dysphagia and odynophagia.
She was diagnosed with cT3N2bM0 Squamous Cell Carcinoma (SCC) of
the right aryepiglottic fold.
A PEG tube was placed to relieve her symptoms and to provide a mechanism
for nutrition and hydration during subsequent therapy. A Pull technique
was employed for the procedure. Radiation and chemotherapy were then
administered. Later, she underwent neck dissection and six out of twenty
three lymph nodes were found positive for carcinoma. She was also found
to have venous involvement by SCC.
Approximately seven months after the placement of the PEG tube, localized
swelling was noted around the gastrostomy site. A FNAB was performed
around the opening which revealed SCC, and was found similar to the pa-
tient’s previous surgical neck dissection and biopsy lesion.
A CT scan revealed extension of the lesion across the abdominal wall into
the stomach. EGD showed the tumor mass in the gastric wall. The patient
expired approximately nine months following her initial diagnosis of SCC.
Although PEG placement for head and neck cancers is common, the metas-
tasis to a PEG tube exit site is extremely rare. While direct implantation
with a variable-sized initial tumor burden may explain many of the cases of
PEG site metastasis, it is controversial whether this metastasis occurs as a
result of direct implantation of the malignant cells during PEG placement or
from vascular seeding of tumor cells at the vulnerable incision site. This case
emphasizes the importance of FNAB in diagnosis of such tumor metastasis.
649
A Pancreatic Pseudocyst Presenting as Dysphagia and Review of the
Literature
Sandra M. Jara, MD, Francene Martin, MD, Patrick Brady, MD∗. Division
of Digestive Diseases, University of South Florida, Tampa, FL.
Purpose: Pancreatic pseudocysts are a common complication of acute and
chronic pancreatitis. Very rarely a pseudocyst may extend into the medi-
astinum by way of the esophageal or aortic hiatus and present with dyspha-
gia. This abstract reports an unsual case of dysphagia as the leading symptom
in a patient with chronic pancreatitis.
Methods: A 46 y.o. male with a history of chronic alcoholic pancreatitis
and chronic pain syndrome presented with solid food dysphagia and weight
loss. A CT scan of the chest revealed a large, lobulated 10 cm ×16 cm fluid
collection within the posterior mediastinum which displaced the liver, heart,
IVC, and left atrium (Fig. 1). An abdominal CT scan showed a pancreatic
pseudocyst which communicated with the retrohepatic fluid collection and
extended into the inferior portion of the posterior mediastinum through the
diaphragmatic hiatus. An ERCP with sphincterotomy was performed to eva-
lute communication of the pseudocyst with the pancreatic duct; however,
successful cannulation of the pancreatic duct was not achieved. A 2D car-
diac echo was performed to evaluate potential cardiac compromise from
cystic structure without evidence of cardiac tamponade seen. The patient
was followed by GI, cardiothoracic and trauma surgery services during his
hospitalization. Once his nutrition was appropriate he underwent a pancreatic
cystogastrostomy and did well following the surgery.
Conclusion: A mediastinal pancreatic pseudocyst is a rare and potential
cause of dysphagia. Pancreatic pseudocysts should be considered in the
differential diagnosis of mediastinal cystic lesions.[figure1]
650
An Unusual Case of Dysphagia Caught on 3-D CT
Brian S. Lim, MD, Walter Trudeau, MD∗, John Rosenquist, MD.
Gastroenterology & Radiology, UC Davis Med Cntr, Sacramento, CA.
Purpose: 64 year old female with chronic cough, which has gotten worse
in last 1.5 years and failed treatment with inhalers for presumed asthma and
PPI for presumed GERD. Patient started to have progressively worsening
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cough after almost every meal. She had mild dysphagia to solids more than
liquids for unknown period of time and denied any abdominal pain, weight
loss, melena or hematochezia. Patient’s past medical history included hy-
pothyroidism, hypertension, thymectomy, tonsillectomy/adenoidectomy and
cholecystectomy. Physical exam revealed normal neck, abdominal, and pul-
monary exams except for the fact that the patient had minimal cough during
the exam.
Video fluoroscopic exam showed circumferential narrowing of the esopha-
gus at the level of the aortic arch. Endoscopy via naris showed a ring in the
cervical esophagus at 30 cm from the nasal vestibule. 3-D CT scan revealed
double aortic arch as the reason for the patient’s symptoms (see figure). Pa-
tient had surgical division of the left aortic arch with improvement of her
symptoms.
Early in embryonic morphogenesis, 6 pairs of pharyngeal arch arter-
ies develop. Normally, left fourth arch becomes the aortic arch and the
right fourth arch contributes to the innominate artery. Vascular rings are
formed when this process of regression and persistence does not occur
normally, and the resulting vascular anatomy completely encircles the tra-
chea and esophagus. Pathogenesis is unknown. Among patients with vas-
cular rings, those with double aortic arch present earlier than those with
other anatomic variations. Esophageal symptoms include emesis, choking,
or dysphagia and are more common in older infants and children. Occa-
sionally, patients may reach older childhood or adulthood before developing
persistent or progressive symptoms of dysphagia, respiratory symptoms,
or both.
Chest radiograph can show indentation of the tracheal air column. Bilateral
indentation of the esophagus is observed on the AP view of barium esopha-
gram and posterior indentation on the lateral view. MRI and CT are the best
single imaging studies.
Treatment is surgical division of the ring to relieve compression of the trachea
and esophagus achieved by dividing the minor arch through an ipsilateral
thoracotomy.[figure1]
651
Jejunal Varices Detected on Capsule Endoscopy as the Cause of
Recurrent GI Bleed
Brian S. Lim, MD, John Rabine, MD, Surinder K. Mann, MD∗.
Gastroenterology & Hepatology, UC Davis Medical Center, Sacramento,
CA; Gastroenterology, Sacramento VA Medical Center, Mather, CA and
David Grant USAF Medical Center, Travis Air Force Base, CA.
Purpose: We present a case of a 45 year old male with history of abdominal
gunshot wound in 1980’s and small wedge resection of the liver for lacera-
tion. Patient developed GI hemorrhage in 2004, and workup revealed hep-
atic hemangiomas as the likely source. Patient reportedly had embolization
with coils without success and continued to have bleeding episodes. Several
months later, he had right hepatectomy and Roux-en-Y hepaticojejunostomy
since hepatic hemangiomas were still the suspected etiology of his GI bleed.
However, he continued to have bleeding. At some point around this time, he
was diagnosed with portal vein thrombosis and portal hypertension, though
the exact details of this diagnosis are not known. He had extensive evalua-
tions including multiple endoscopies at two teaching medical centers with
no definitive conclusion. Patient was then seen at a different hospital for a
massive GI hemorrhage in 2006. During that admission, EGD/enteroscopy
showed grade I esophageal varices, questionable gastric varices, and mild
portal gastropathy. Colonoscopy showed mild portal colopathy and small
internal hemorroids. Tagged RBC scans and angiogram did not locate the
source of bleed. CT scan suggested the possibility of varices within jejunum.
This is when the patient was referred to our facility for capsule endoscopy,
which demonstrated four clusters of varices in jejunum with fresh blood
approximately 2 hours and 40 minutes into the study. The patient was not
a candidate for TIPS because of his extensive portal vein thrombosis and
underwent surgery for splenorenal shunt with an associated splenectomy.
He currently remains stable without any further episodes of gastrointestinal
bleeding.
Bleeding from jejunal varices is an uncommon manifestation of portal hy-
pertension. Recently, capsule endoscopy has been used in the workup of
obscure-overt GI bleed as in our case. Our case represents one of the first
reports of jejunal varices detected on capsule endoscopy as the cause of GI
hemorrhage.[figure1]
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A Case of Thyrotoxic Crisis Leading to Fulminant Hepatic Failure
Thomas Birris, MD, Michael Heavey, MD, Ashish Arora, MD, Sonu
Dhillon, MD, Claus Fimmel, MD∗. Gastroenterology, Hepatology, and
Nutrition, Loyola University Medical Center, Maywood, IL.
Purpose: The goal of this clinical vignette is to illustrate the relationship
between thyrotoxicosis and liver failure.
Methods: Hepatology was consulted on a patient admitted to Cardiology at
a university medical center.
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Results: A 49 year old male, without known medical history, presented to
the Emergency Department complaining of swelling and shortness of breath.
Associated symptoms included anxiety, weight loss, cough, and diarrhea.
The patient’s family history was significant for a “thyroid problem.” Physical
examination revealed exophthalmos, jugular venous distension, irregularly
irregular tachycardia, bibasilar rales, abdominal distension, and bilateral
lower extremity pitting edema. The patient’s initial laboratory evaluation
revealed AST of 81, ALT of 55, alkaline phosphatase of 249, total bilirubin
of 2.5, INR of 1.7, free T3 of 1605, and free T4 of 7.0.
The patient was dosed with methimazole, as the clinical picture met criteria
for thyrotoxic crisis. Subsequently his transaminases increased to greater
than 25 times the upper limit of normal. Total bilirubin, alkaline phosphatase,
and INR also increased further. Apheresis was utilized, given the patient’s
apparent inability to tolerate methimazole. Follow-up thyroid hormone levels
were improved as were the transaminases, despite mental status changes and
worsening congestive heart failure.
Thyroid hormone levels again began to increase despite additional sessions
of plasmapheresis; therefore, the patient was redosed with methimazole. The
transaminases continued to decrease, but thyroid hormone levels improved
only slightly. Given the patient’s multisystem organ failure, his sister opted
for comfort care. The patient passed away on the eighth day of hospitalization.
Conclusion: The patient suffered from fulminant hepatic failure secondary
to thyrotoxicosis. An increase in transaminases has been reported in 25–
40% of patients in thyroid storm; however, there are few reports of thyro-
toxicosis presenting with fulminant hepatic failure. It is difficult to establish
which features of thyrotoxic liver injury are of multifactorial etiology. In
this patient methimazole may have been a contributing factor. Rare cases
of methimazole-induced liver injury have been reported, but are usually
cholestatic in nature and occur over a longer time course. In the vast major-
ity of cases, the hepatic abnormalities associated with hyperthyroidism are
reversible following early recognition and treatment of the disorder.
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Azathioprine Induced Sweets Syndrome in a Patient with Crohn’s
Disease
Nicholas C. Boetticher, MD, El-Azhary A. Rokea, MD, Carryer W. Peter,
MD, Santhi S. Vege, MD∗. Gastroenterology and Hepatology, Mayo Clinic
– Rochester, Rochester, MN and Dermatology, Mayo Clinic– Rochester,
Rochester, MN.
Purpose: Sweets syndrome, or acute febrile neutrophilic dermatosis, is a
condition typified clinically by the abrupt onset of fever, leukocytosis, and
painful red papules or plaques. Histologic examination shows dense neu-
trophilic infiltrates. It may be associated with inflammatory, infectious, or
neoplastic diseases as well as multiple medications.
Our patient, a 31 year old Kuwaiti man, presented for evaluation of a 10 year
history of fistulizing Crohn’s colitis, treated with chronic steroids. Azathio-
prine (AZA) had been trialed seven years prior, but was discontinued after
he developed a skin infection within a week. At initial evaluation, setons
were placed in two peri-rectal fistulas and AZA was again started at 100
mg per day. His chronic prednisone at 10 mg a day was continued with an-
ticipation of a future taper. Six days later, the patient developed fever and
tender erythematous plaques over the dorsum of his hands and feet as well
as his face. The patient was admitted to hospital, where his temperature was
39.2 C, pulse 104, and blood pressure 98/58. White blood cell count and C
reactive protein were elevated at 23.4×109/L and 19.4 mg/dL respectively.
Broad spectrum antibiotics for a presumptive cellulitis were begun. Despite
this, the patient continued to be febrile over the next three days. His rash pro-
gressed, with pustules developing over his previous plaques. A skin biopsy
was taken from one such lesion, from which cultures and stains were nega-
tive for infection. Histology showed neutrophilic infiltration of the stratum
corneum and microabscesses. Given the absence of infectious agents and
characteristic biopsy findings, Sweets syndrome was diagnosed. Antibiotics
and AZA were stopped, and prednisone was increased to 40 mg per day. He
promptly defervesced and the skin lesions began to improve within two days.
Complete resolution, after desquamation of the affected areas, was seen at
three weeks.
Sweets syndrome is a rare complication of inflammatory bowel disease, with
fewer than 50 cases reported in the literature. A single case of possible drug
induced Sweets has been reported in association with AZA administration,
but the association is complicated by the presence of underlying IBD. How-
ever, given the temporal association of AZA dosing and symptoms in this
episode, as well as seven years ago, this most likely represents a case of drug
induced Sweets syndrome.
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Case of Chronic Hepatitis C Presenting with Right Axillary
Lymphadenopathy
Biju K. Alex, MD, Roshan M. Bashir, MD∗. Department of Medicine,
Washington Hospital Center, Washington, DC.
Purpose: Chronic hepatitis C is the most common cause of chronic liver dis-
ease. Most patients with chronic infection are usually asymptomatic or have
mild nonspecific symptoms such as fatigue, myalgias, arthralgias, weak-
ness, and weight loss. Extrahepatic manifestations have been associated with
chronic hepatitis C infection. We present an unusual case of a patient with
hepatitis C presenting with right axillary lymphadenopathy.
Case Presentation: This is a 52 year old African-American male with his-
tory of hepatic C who noticed an enlarging mass under his right armpit for
2 1/2 months. He reports no night sweats, fevers, fatigue or weight loss. He
denied any abdominal pain and review of system was otherwise negative.
Physical exam was notable for 6 cm area of adenopathy in his right axilla.
All other areas including supraclavicular, cervical, groin and left axillary
were negative for adenopathy. Abdominal exam was nontender without hep-
atosplenomegaly. Liver enzymes including AST, ALT, Alk Phos were nor-
mal. The right axillary lymph node was excised. Pathology revealed florid
follicular hyperplasia (Fig. 1). There was no evidence of Reed-Sternberg
cells or variants. Immunostain for hepatitis C virus showed multiple foci
of scattered positive intranuclear staining of macrophages and lymphocytes.
The final diagnosis was florid reactive follicular hyperplasia associated with
hepatitis C viral infection.
Conclusion: To our knowledge, this is the first case of a patient with chronic
hepatitis C presenting with right axillary adenopathy associated with the
disease.
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Carcinoid Tumor of Small Bowel and Colonic Adenocarcinoma, a
Concurrent Occurrence in a 77 Year Old Male
Alka Farmer, MD, Howard Benn, MD∗. Internal Medicine, St. Joseph
Regional Medical Center, Paterson, NJ.
Purpose: Carcinoid tumors are the most frequent GI neuroendocrine tumors.
It is thought that carcinoid tumors and adenocarcinoma arise de novo from
the same pluripotent stem cell, however the incidence of adenocarcinoma is
higher. We present a case of a patient presenting with synchronous carcinoid
tumor and colon adenocarcinoma, 25 year after resection of a primary small
bowel carcinoid tumor.
Methods: A 77 year old male presented with 2 month complaint of flush-
ing, nausea, vomiting, diarrhea and weight loss (25 lb). His medical history
was significant for small bowel resection for a primary carcinoid tumor in
1981, with complete resolution of obstructive and neuroendocrine symp-
toms. Physical examination revealed hypertension, cutaneous flushing, gen-
eralized abdominal tenderness and ascites. CT scan demonstrated bowel
obstruction.
Subsequent colonoscopy revealed a polyp in the sigmoid colon and an ob-
structing friable splenic flexure mass. Labs revealed elevated serotonin -605,
Chromogranin A- 300 and normal CEA. A subtotal colectomy with ileorec-
tal anastomosis was performed. Small bowel pathology was consistent with
carcinoid tumor. Colon pathology was significant for typical carcinoid with
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concurrent well differentiated adenocarcinoma. Chemotherapy was initiated.
Patient died within one month due mainly to metabolic complications asso-
ciated with short bowel syndrome.
Conclusion: GI carcinoids, especially those arising within the small
bowel have been associated with increased incidence of synchronous and
metachronous de novo adenocarcinoma. However, because of the great dis-
parity in tumor cell growth rates, carcinoid tumors requires 40 years doubling
time, compared to adenocarcioma which requires 17.8 years, synchronous
presentations are rare. The current patient may represent a de novo carci-
noid/adenocarcinoma synchronicity or recurrent carcinoid/adenocarcinoma
pathology.[figure1][figure2]
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Multifocal Splenic Steatosis in End Stage Cholestatic Liver Disease
Jeffrey Tang, MD, Chetan Pai, DO, Stuart C. Gordon, MD∗. Internal
Medicine, Division of Gastroenterology, Henry Ford Hospital, Detroit, MI.
Purpose: The multifocal variant of diffuse hepatic steatosis frequently mim-
ics metastatic disease on imaging studies, but similar condition involving the
spleen is not described. We report a case of multifocal splenic steatosis mas-
querading as primary splenic lymphoma.
Methods: A 47-year old man with end stage primary sclerosing cholangitis
underwent orthotopic liver transplant (OLT) evaluation and was found at rou-
tine magnetic resonance imaging (MRI) to have multifocal splenic lesions.
His past history included ulcerative colitis and hyperlipidemia, with recent
weight loss and muscle wasting. Physical examination showed jaundice, hep-
atosplenomegaly, and diffuse xanthalasmas. Laboratory data showed a total
cholesterol of 1,311 mg/dL and an low density lipoprotein of 1,238 mg/dL.
MRI showed four hyperintense enhancing splenic masses ranging in size
from 2.6 cm to 3.5 cm, highly suspicious for lymphoma. Prior to formal
OLT listing the patient underwent diagnostic splenectomy. Microscopically
the focal lesions showed infiltration of red and white pulp consistent with
nodular and diffuse lipidosis without evidence of malignancy.
Conclusion: Splenic fat infiltration may result from intravenous fat emul-
sions, but its occurrence in hyperlipidemic liver disease has not been previ-
ously described. In cholestatic disorders, high serum levels of lipoprotein X
require an intact reticuloendothelial system (RES) for removal from circu-
lation. We speculate that in this patient with advanced cirrhosis, his splenic
RES may have led to disordered lipid deposition. The MRI appearance in
this case was not consistent with usual steatosis, thus the aberrant lipoprotein
of advanced cholestasis may have created an atypical imaging finding. In the
setting of advanced cholestatic liver disease with hyperlipidemia, knowledge
of the entity of focal splenic fat could broaden the differential diagnosis of
splenic lesions.[figure1]
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An Unusual Case of Right Upper Quadrant Pain
Christopher B. Keller, DO, Jorge L. Herrera, MD∗. Internal Medicine,
University of South Alabama, Mobile, AL and Division of
Gastroenterology, University of South Alabama, Mobile, AL.
Purpose: The differential diagnosis of nausea, vomiting and right upper
quadrant pain is broad. We present a case presenting with an unusual cause
of these symptoms.
A 47 year old female presented with back and chest pain after falling in the
shower approximately 2 hours prior to arrival. The pain was worse with deep
inspiration. She reported a recent history of subjective fevers, chills, nausea,
vomiting and decreased appetite. On exam vital signs were stable and she
was afebrile. Breath sounds were decreased at the right base, and dullness
to percussion with decreased fremitus was noted. Bowel sounds were nor-
mal, hepatomegaly with tenderness to palpation in right upper quadrant was
present. Laboratory data revealed hemoglobin of 11.2 g/dL, white blood cell
count of 8,900/mcL with 17% bands, sodium130 meq/dL, albumin 2.8 g/dL,
INR 1.2, and PTT 39 sec. Chest x-ray showed elevated right hemidiaphragm
(Fig. 1). CT scan revealed an enlarged liver with numerous cysts throughout
and a single left renal cyst (Fig. 2). Two dominant cysts were accessible
for drainage with ultrasound guidance. Despite high fevers during her stay,
no positive cultures were obtained. The patient was treated with empiric
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antibiotic therapy for the duration of her stay with resolution of fever and
leukocytosis. She was discharged on amoxicillin clavulanate for 6 weeks.
Patient has remained afebrile and asymptomatic in follow up visits.
Polycystic liver disease (PCLD) is an inherited disease that was once thought
to be only associated with polycystic kidney disease. It is now known to
be a distinct genetic syndrome. Isolated PCLD is usually asymptomatic
and under diagnosed. When symptoms develop in these patients it’s usually
due to mass effect of large cysts or from cysts infection or rupture. The
liver usually remains functionally normal, although portal hypertension may
develop. Clinical presentation includes abdominal distention, early satiety,
dyspnea, and back pain. Fever and chills are associated only with infected
cysts. Valvular and vascular abnormalities are some of the extra hepatic
manifestations of PCLD.
Asymptomatic patients should receive no treatment. Patients with infections
need draining of the infected cyst and antibiotic therapy. Complications from
portal hypertension may require a liver transplant.
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Liver Transplantation for Infliximab-Induced Fulminant Hepatic
Failure
John L. Gosserand, MD, Shamita Shah, MD, K. Shiva Kumar, MD∗.
Division of Gastroenterology & Hepatology, Ochsner Clinic Foundation,
New Orleans, LA.
Purpose: Infliximab (Remicade) is a chimeric monoclonal antibody that
binds TNFα and is indicated for Rheumatoid arthritis, Crohn’s disease,
Ankylosing spondylitis, Psoriatic arthritis, and Ulcerative colitis. Potential
adverse effects of Infliximab include infusion reactions and risk of serious
infections including tuberculosis. Hepatotoxicty has recently been recog-
nized as a potentially serious adverse effect of Infliximab. We report a case
of Infliximab-induced fulminant hepatic failure resulting in orthotopic liver
transplantation.
Methods: A 53 year old African-American female with Rheumatoid arthri-
tis was initially treated with systemic steroids and methotrexate. She had no
history of chronic liver disease and all baseline laboratory studies, includ-
ing liver panel, were within normal limits. Since she continued to remain
symptomatic, methotrexate was stopped and infliximab was initiated. She re-
ceived four infusions over 12 weeks and presented two weeks after the fourth
infusion with progressively worsening jaundice. Infliximab was then discon-
tinued. Laboratory studies revealed: Total Bilirubin 4.3 mg/dl, AST 1797
U/L, ALT 1807 U/L, Alkaline phosphatase 193 U/L, PT/INR 15.3/1.6. Since
her laboratory studies continued to worsen, a liver biopsy was performed.
This revealed marked bile duct damage, diffuse ballooning degeneration of
hepatocytes with lobular disarray and cholestasis with a scattered mixed in-
flammatory infiltrate. Over the course of the next several days, there was
continued deterioration of hepatic synthetic function (Total Bilirubin 19.9,
PT/INR 27.7/3.1) with onset of hepatic encephalopathy. She was then listed
and underwent orthotopic liver transplantation ten weeks after the last infu-
sion of infliximab. The explant showed submassive necrosis with large areas
of hepatocyte dropout, collapse of hepatic lobules and marked bile ductular
proliferation with cholestasis. She had an uneventful post-operative course
and remains well six months after transplant.
Conclusion: The precise mechanism of hepatotoxicity of TNFα inhibitors
remains unclear. Unlike many of the reported cases of hepatotoxicity re-
lated to use of Infliximab, our patient was not on concomitant therapy with
immunsuppresants or other potentially hepatotoxic medications. Our case
highlights the potential for severe cholestatic liver injury from Infliximab.
Clinicians should be aware of this possibility with prompt discontinuation
of the drug in patients who develop progressive liver test abnormalities.
659
Carcinoid Liver Metastasis “Cured” by Cholecystokinin (CCK)
Rajasekhara R. Mummadi, MD, Manoop S. Bhutani, MD∗. Division of
Gastroenterology, The University of Texas Medical Branch, Galveston, TX
and Department of GI Medicine and Nutrition, UT MD Anderson Cancer
Center, Houston, TX.
Purpose: Octreotide scintigraphy is widely used in imaging of neuroen-
docrine tumors which express a high rate of somatostatin receptors. It is
considered to be highly sensitive and specific in diagnosing hepatic metasta-
sis of carcinoid tumors. We here by present an unusual cause of false positive
hepatic metastasis that can potentially be overlooked.
A 52 year old female underwent an EGD for work up of dyspepsia. EGD
revealed a nodule in the duodenum the biopsy of which revealed it to be
a carcinoid tumor. An EUS revealed the tumor to be localized to the deep
mucosa/submucosa area with an intact muscularis prorpria. EMR was done
with histopathology of the resected tumor confirming it to be carcinoid. Oc-
treotide scintigraphy (In-111 Octreotide), done to evaluate for the presence
of metastatic disease revealed a 3.5 cm area of increased activity in the liver
compatible with hepatic metastasis where as Computerized Tomography
(CT) scan and Magnetic Resonance Imaging (MRI) scans of the liver did
not show any abnormality. Due to this discrepancy and since there was a case
report describing intense gall bladder concentration that caused diagnostic
confusion (Kipper and Krohn 1997), it was decided to repeat the Octreotide
scintigraphy with cholecystokinin (CCK) administration during the test. A
repeat Octreotide scan before the administration of CCK showed findings
similar to previous scan (presence of the 3.5 cm hot spot in liver). CCK was
administered to empty the gall bladder. The area was found to diminish in
activity with in minutes after CCK was administered and was totally absent
in images obtained 24 hours later. The scan was read as normal.
Traditionally, presence of Octreotide tracer in gall bladder was considered
to be diagnostic for presence of neuroendocrine tumors since only 2% of
In-111 Octreotide is cleared through hepatobiliary excretion. But there have
been at least five published reports of false positive octreotide scans that
were interpreted as normal after repeating the scan following a fatty meal.
Awareness of this potential source of diagnostic confusion is very important
in interpreting hepatic metastasis of neuroendocrine tumors and findings
should be correlated with cross sectional imaging. Since gastroenterolo-
gists/hepatologists are involved in the care of patients with gastrointestinal
carcinoid tumors we felt it was important to present this case of “hepatic
metastasis” cured by CCK.
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An Usual Cause for Rectal Mass
Mahindrakar Shruti, MD, Saad F. Jazarwi, MD, Nicholas Gualtieri, MD∗,
James Robilotti, MD, Peter Bloom, MD. Internal Medicine –
Gastroenterology, Saint Vincent Hospital – Manhattan, New York Medical
College, New York, NY.
Case Report: A 77 yo Female was found to have a rectal mass on evaluation
of occasional rectal bleed after bowel movement. She had a long history knee
arthritis (treated occasionally with non-steroidal) and dyspepsia (resolved on
over the counter antacids). Physical exam was unremarkable except for the
rectal lump felt on digital exam, with no inguinal lymph nodes appreciated.
She had positive stool guaiac (heme-occult) testing. Lab test did not show
anemia. Colonoscopy showed a large non-ulcerated 3×3 cm firm rectal mass
noted 8 cm into the rectum. The remainder of the colon showed diverticu-
lar disease and internal hemorrhoids. Biopsies showed diffuse infiltration
by small to medium sized atypical lymphoid cells. Immunohistochemical
staining and flow cytometric analysis showed a monoclonal lamba B-cell
population and CD markers highly indicative of Extranodal Marginal B-cell
lymphoma of MALT type. Imaging showed bilobed rectal hypervascular
mass, which is continuous with the posterior wall of the rectum. No evidence
of metastasis. PET CT confirmed the findings. Upper endoscopy showed gas-
tritis and the presence of H pylori. This was successfully eradicated (C-14
urea breath test negative), but the rectal tumor did not regress.
MALT lymphoma constitutes 5% of all NHL. The stomach is the most com-
mon site, but it can also be found in the lung, thyroid, breast, orbit, skin &
soft tissues. Systemic symptoms rarely occur. These tumors are slow grow-
ing and metastasis occurs late. Localized lymphomas of the stomach respond
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well to H pylori therapy while non-gastric ones can be cured with local ther-
apy (surgery or radiation). These options were offered to the patient and she
opted for local radiation. She received a total of 45 Gy of 3D conformal ex-
ternal beam radiation therapy. Repeat colonoscopy and PET scans for 2 years
have not shown recurrence, and the only complaint has been occasional rec-
tal bleed from newly developed angioectasia which were managed by argon
plasma coagulation.
This is only the third case report of primary MALT lymphoma of the rectum
here in the US and we describe the role of non-surgical approach in this case
(unique to ours).[figure1]
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A Rare Case with a Rare Presentation
Thomas R. VanderHeyden, DO, Jonathan Williams, DO∗, Thomas Schnell,
MD, Stephen Sontag, MD. Internal Medicine, Loyola University Medical
Center, Maywood, IL and Gastroenterology, Hines Veteran Hospital,
Hines, IL.
Case: A 71-year-old male presents to his primary complaining of leftsided
low back pain radiating to the mid-abdomen. CT scan showed a 5 cm soft
tissue mass. Subsequent exploratory laparotomy with biopsies leads to a
diagnosis of sclerosing mesenteritis. The patient was discharged following
G-tube decompression. He remained relatively asymptomatic until one year
later when he developed worsening left sided low back pain radiating to the
epigastrium. The pain is unrelenting, intensified postprandially and asso-
ciated with nausea. He finds no relief with conservative therapy. Physical
exam shows normal active bowel sounds, and a tender mid-epigastric pal-
pable mass. Abdominal x-ray does not demonstrate bowel obstruction. CT
scan reveals a calcified mass now measuring 10 cm encasing portions of the
superior mesenteric artery. Concern for mesenteric ischemia is entertained,
and a selective superior mesenteric angiogram is performed. Results yield
an encased ileocolic artery, and jejunoileal branches which are small and
irregular. Findings are suggestive for mesenteric ischemia.
Discussion: Sclerosing mesenteritis is a rare disorder that affects the small
bowel mesentery of predominately middle aged men. Symptoms include
abdominal pain, bloating, distention, diarrhea and weight loss. The presen-
tation is usually a manifestation of an impinging mesenteric mass resulting
in symptoms of bowel obstruction. The pathophysiology remains largely
unknown. Currently, there is no optimal treatment strategy. Consequently,
treatments have ranged from conservative management in asymptomatic
patients, medical therapy, and surgical intervention in non-responders.
Sclerosing mesenteritis is frequently a relatively benign condition, although
it can be a debilitating disease. Symptoms are usually a result of bowel ob-
struction; however patients may infrequently develop mesenteric ischemia
as a result of mechanical compression of the abdominal vasculature. In this
case, angiography suggests that our patient has developed compromised arte-
rial blood flow leading to symptoms of ischemia. Our patient was initiated on
Azathioprine four weeks earlier and levels of the metabolite 6-Thioguanine
(6-TG) were being monitored. This case illustrates that alternative therapy,
which includes revascularization or tailored medical therapy may be needed
to prevent further complications in patients with sclerosing mesenteritis re-
sulting in mesenteric ischemia.
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Evaluation of an Inpatient with Obscure Gastrointestinal Bleeding in
the Community Hospital Setting
Keith S. Sultan, MD∗, Joseph S. DeVito, MD, Robert J. Ward, MD.
Gastrointestinal Associates, Plainview, NY; Massepequa, NY and Lake
Success, NY.
The evaluation of obscure gastrointestinal bleeding has been revolutionized
by the use of Capsule Endoscopy (CE). Studies have consistently shown
the superiority of the capsule over small bowel series and traditional push
enteroscopy. Though widely available, it is not however available in all lo-
cations. Older but more widely available studies for obscure gastrointestinal
bleeding still have value.
A 67 year old male presented to a community hospital emergency room
with syncope, lethargy, and shortness of breath with exertion. The patient
reported one day of dark stools. He had no abdominal pain and denied the
use of aspirin, NSAIDS, clopidogrel, or warfarin. Initial lab work showed a
hemoglobin of 4.8 g/dl and an mcv of 64. Abdominal exam was benign. Rec-
tal exam confirmed melena. The patient was admitted to a monitored unit and
resusitated with IV fluids and transfusion of packed red blood cells. Inpatient
EGD the next morning was unremarkable. Colonoscopy after polyethylene
glycol preparation showed black stool and dark clot in all colonic segments.
During cecal washing, blood clot was observed passing through the ileocecal
vavle.
Once stabilized, since CE was not available in the hospital, the patient was
discharged without further study. Outpatient CE performed seven days fol-
lowing initial presentation revealed an erythematous small bowel mass one
hour into the recording. CT scan two days later identified a 5 cm mass in
the abdomen. Surgical pathology of a proximal jejunal mass was consistent
with a GIST. Post operatively the patient did well. Six month follow up blood
counts were normal.
Though the weight of clinical evidence heavily favors CE as the most sensi-
tive test for small bowel bleeding, clearly each case exhibits its own special
considerations. While capsule endoscopy availability has expanded in the
community, most CE units are outside the hospital, and therefore most stud-
ies are performed in an office based setting. For our patient, given the size
and location of the lesion, it is very likely that further inpatient workup such
as push enteroscopy or small bowel series would have made the diagnosis.
While this patient’s good outcome was not compromised by the diagnostic
delay, this may not be the case for others. Our eagerness to provide the best
and most up to date testing for our patients should not make us overlook the
other valuable diagnostic tools at our disposal.
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False Negative Test for Gastropresis from Technicium (Tc) Oatmeal
Radionuclide Gastric Emptying (GE) Study; Lack of Standardized
Updated Protocols for Tc GE in Community Hospitals
Jennifer L. Wellington, Jon Kotler, MD, Soumendu K. Das, MD, V. Alin
Botoman, MD∗. Biological Sciences, Florida Atlantic University, Boca
Raton, FL; Nuclear Medicine, Holy Cross Hospital, Fort Lauderdale, FL;
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GI Institute of Fort Lauderdale, Fort Lauderdale, FL and Gastroenterology,
University of Miami, Miami, FL.
We present a case of a strikingly false negative TcGE study, using oatmeal, a
semi-solid, in a patient with signficant gastroparesis, as well as results of an
initial small survey of radionuclide TcGE protocols in local hospitals most
of which were outdated, and did not conform to more recent standardized
data.
A 42 yo man was referred for a second opinion for refractory dyspepsia
and GERD. He had a 2–3 yr history of chronic recurrent nausea, episodic
vomiting and errosive esophagitis which had responded poorly to bid PPI’s,
H2 blockers, and metoclopromide. Bravo pH testing had shown signficant
residual GERD on PPI therapy. A Tc oatmeal GE study off metoclopromide,
done at the referring hospital, was interpreted as normal (T 1/2 31 min).
Physical exam showed a succusion splash. The GE study repeated at a our
tertiary referral hospital with standard 2 hour Tc egg sandwich technique
showed severe gastroparesis (T 1/2>180 min). Patient was started on dom-
peridone 10 mg qid, and lanasoprazole solu-tabs 30 mg twice daily with
marked improvement.
The Tc GE technique is the most widely used test for gastroparesis. Substrate
type greatly affects the rate of emptying. Most published normal values for
GE use a solid Tc egg substrate. Semi-solid oatmeal mixed with Tc has
been used in pts who are allergic to eggs, with scant normal data, and no
comparative data with standard egg sandwich technique. Yet oatmeal is the
only substrate used for GE studies at the large hosp chain which referred
our patient. A multi-center study published in 2001, has provided simplified
reproducible 2&4 hr Tc egg GE methodology, requires few measurements
and is reproducible. We initially polled 10 other hospitals, in the area and
found none that followed recent published standard methodology, with wide
variation. We found that patients with gastroparesis respond at times poorly
to conventional PPI’s. A solu-tab type PPI preparation signficantly improves
the GERD response. 1) Oatmeal is a poorly studied semi-solid substrate
for Tc based gastric emptying study, and should be used only in true egg
allergic patients. 2) The effect of gastroparesis on PPI bioavailabilty, should
be further investigated.
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An Unsual Case of Severe Pill Esophagitis Mimicking Herpetic
Esophagitis, Caused by a New OTC NSAID – Containing Sleeping Aid
Jennifer L. Wellington, Darlene Bonior, RN, V. Alin Botoman, MD∗.
Biological Sciences, Florida Atlantic University, Boca Raton, FL; GI
Institute of Fort Lauderdale, Fort Lauderdale, FL and Gastroenterology,
University of Miami, Miami, FL.
We present a case of severe NSAID induced esophagitis, mimicking severe
herpetic esophagitis, caused by a new sleeping aid OTC preparation that
combines naproxen and diphenhydramine. This type of preparation caused
severe injury to the esophagus, its use as a bedtime sleeping aid, greatly
increasing the risk of pill induced esophagitis. We could find no product
labeling warning patients of this potential complication.
This 37 yo man with a hx of dyspepsia, IBS, and chronic insomnia, developed
acute severe odynophagia, which did not respond to PPI’s, or antacids, only
able to swallow small amounts of liquids. He repeatedly denied taking any
pills associated with pill induced esophagitis. Urgent EGD revealed very
severe discontinuous ulcerations with almost complete slough of the distal
esophageal mucosa, suggestive of severe herpetic esophagitis. Biopsies and
viral cultures were negative for herpes. Patient improved with the addition
of liquid sucralfate qid. On subsequent questioning he remembered taking a
naproxen containing sleeping aid (Advil-PM) at bedtime with little water
for several days prior to the symptoms. The preparation was stopped, syptoms
resolved, and repeat endoscopy showed healing of the ulcerated esophageal
mucosa.
Many patients take sleeping aids for insomnia, that typically have ace-
tominephen and diphenhydramine, such as Tylenol PM. We were suprised
to learn of the existence of a similar OTC NSAID preparation (Advil
PM). In our previous case-controlled study (Gastrointest Endoscopy 2004;
59:AB240) NSAID’s were the most common cause of pill induced esophagi-
tis. A preparation that combines an NSAID with a sleeping aid, carries par-
ticular risk for inducing pill-induced esophagitis, due to its bed-time use.
Patients need to be cautioned about this potential side effect of this type of
preparation. The injury was particularly severe, but responded to NSAID
cessation, and PPI and sucralfate therapy.
Clinicians need to be aware of new sleeping aid OTC preparations that
contain NSAID’s, caution patients about their potential for inducing pill
esophagitis, and question patients with unexplained esophageal ulcerations
and odynophagia about their use.
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Asymptomatic Meckel’s Diverticulum with Multi-Tissue Heterotopia
Debapriya De, MD, Rishi Pawa, MD, Krishnarao V. Tangella, MD,
Sandhya Sarwate, MD, Davendra P. Ramkumar, MD∗. Internal Medicine,
University of Illinois at Urbana Champaign, Urbana, IL;
Gastroenterology, Columbia University College of Physicians & Surgeons,
Harlem Hospital Center, New York, NY; Pathology, Provena Covenant
Medical Center, Urbana, IL and Gastroenterology, University of Illinois at
Urbana Champaign, Urbana, IL.
Meckel’s Diverticulum (MD) is a congenital intestinal blind pouch resulting
from an incomplete obliteration of the omphalomesenteric duct during the
fifth week of gestation. It is present in 2% of the population with a male:
female ratio of 3:1. Patients may be asymptomatic, with MD being iden-
tified intraoperatively, or symptomatically, with MD causing obstruction,
intususseption, volvulus, bleeding & diverticulitis. We present a case of MD
with unusual form of heterotopic tissue found incidentally.
Review of literature using Medline.
A 76 year old female was admitted for nausea, vomiting, crampy abdominal
pain & obstipation for a day. Her past history was significant for abdominal
hernia with mesh repair 5 years prior. A CT Scan of the abdomen revealed
multiple air-fluid levels suggestive of small bowel obstruction. She under-
went abdominal exploration with adhesionolysis. A 3 cm × 2.5 cm × 2 cm
normal looking MD was incidentally identified & was resected. Histopatho-
logical examination showed gastric heterotopia, exocrine & endocrine com-
ponents of the pancreas. Pancreatic endocrine component was confirmed
with immunoperoxidase stains namely, pancytokeratin, synaptophysin &
chromogranin. The incidence of ectopic mucosa in MD varies from 15%
to 50%. Ectopic gastric tissue is found in 60% to 82%, pancreatic in 1%
to 16% & both in 5% to 12% of the cases. Meckel’s scan is 80% sensitive
in identifying MD, with sensitivity increasing with intravenous pentagas-
trin administration. Ectopic gastric mucosa is the commonest ectopic tissue
in MD leading to hemorrhage and diverticulitis, whereas pancreatic tissue
predisposes to bowel obstruction due to mass effect & leads to intussuscep-
tion & volvulus. Surgery is recommended for incidental MD found during
laparotomy in patients younger than 80 years. In our case, intestinal obstruc-
tion was caused by adhesions secondary to the previous hernia surgery &
not due to MD.
Although, asymptomatic MD is of pathological interest for the complexity
of tissue heterotopia which is involved, physicians should be aware of this
entity because of its varied clinical manifestations when symptomatic.
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Insulin and Dextrose in the Treatment of Hypertriglyceridemia
Induced Pancreatitis (HIP)
Debapriya De, MD, Rishi Pawa, MD, Benjamin L. Jacobson, MD, Ali
Alizadehsovari, MD, Davendra P. Ramkumar, MD∗. Internal Medicine,
University of Illinois at Urbana Champaign, Urbana, IL;
Gastroenterology, Columbia University College of Physicians & Surgeons,
Harlem Hospital Center, New York, NY and Gastroenterology, University of
Illinois at Urbana Champaign, Urbana, IL.
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Hypertriglyceridemia is thought to be the etiology in 3% of patients with
acute pancreatitis, often associated with poorly controlled diabetes mellitus
or chronic alcohol abuse. We present a case of HIP, treated using insulin &
dextrose.
Review of literature using Medline.
We report a case of a 36 year-old male who presented with severe diffuse
abdominal pain, nausea, vomiting & flexed contracture of his upper ex-
tremities. Patient did not have any past medical history or prescribed home
medications. He had consumed moderate amounts of alcohol in the past
with an episode of binge drinking prior to admission. Relevant physical
findings included tachycardia, scleral icterus, epigastric tenderness & up-
per extremity tetany. White blood cell count was 9300/uL with 29% bands.
Chemistries were significant for corrected calcium of 5.9 mg/dl & an anion
gap metabolic acidosis with bicarbonate of 15 mM/L. Liver function tests
revealed total bilirubin 3.1 mg/dl, AST 339 U/L, ALT 140 U/L & alkaline
phosphatase of 253 U/L. Amylase was 256 U/L & lipase could not be assayed
because the specimen was grossly lipemic. Abdominal ultrasound showed
biliary sludge with no cholelithiasis. Computed tomography of the abdomen
revealed peripancreatic fat stranding. Lipid profile showed triglycerides of
6850 mg/dl. Patient’s pancreatitis was attributed to his hypertriglyceridemia.
He was treated with intravenous fluids, prophylactic antibiotics, pain con-
trol & bowel rest. Calcium chloride infusion corrected the hypocalcemia
& tetany. A novel therapy was employed to reduce triglyceride levels by
starting an insulin & dextrose infusion. Insulin drip was started at 4 U/hour
along with 100 ml of 10% dextrose infusion. Triglyceride levels decreased
dramatically from the initial value to 1920 mg/dl the next day and 159 mg/dl
on day 4 with resolvement of pancreatitis.
Insulin is known to stimulate lipoprotein lipase activity and accelerate chy-
lomicron degeneration thereby reducing serum triglycerides. This was the
rational for insulin use in this case. The patient’s response to this treatment
is consistent with a few other rare reports in the literature which suggests
that insulin/glucose infusions should be further evaluated in cases of HIP.
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Rare Anatomic Variation of Ampulla of Vater
Patricia Laurel, Rahat Hussain, Muhammed G. Nathani∗. Internal
Medicine, UTHSCSA, Regional Academic Health Center, Harlingen, TX.
Introduction: Ampulla of Vater refers to a confluence of distal common bile
duct and main pancreatic duct in second portion of duodenum. In 10–15% of
patients, the pancreatic duct and common bile ducts have separate openings
into the duodenum. However, in most cases, the openings are within the same
papilla (ampulla). We report a very unusual anatomic variation of Ampulla of
Vater with evidence of duplication of ampulla. The pancreatic duct opening
was in the the main ampulla and the common bile duct had a completely
separate opening within a smaller ampulla about 2 cm proximal to the main
papilla.
Case Report: A 29 year Hispanic female presented with a 3–4 month his-
tory of recurrent abdominal pain with occasional fever and chills. Physical
examination was unremarkable. Laboratory data was within normal limits.
Abdominal ultrasound suggested dilated common bile duct and cholelithi-
asis, with suspicion of choledocholithiasis. An ERCP was performed. The
ampulla was identified but only pancreatic duct could be cannulated. Further
careful exploration revealed another ampulla like structure 2 cm proximal
to the main ampulla. This was cannulated and led to a dilated common bile
duct with multiple filling defects. A relatively small sphincterotomy was
performed because of smaller size of the ampulla and stones were extracted.
Discussion: This case presents a rare anatomic variation. Although she had
recurrent biliary colic and ERCP confirmed choledocholithiasis, she did
not deveop pancreatitis. Choledocholithiasis is the most common cause of
pancreatitis. However, our patient was protected from developing pancre-
atitis due to the separate opening of the common bile duct. If not correctly
identified, this patient may have had serious complications from an access
(precut) sphincterotomy of the main papilla, including severe pancreatitis
and possible perforation.[figure1][figure2]
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Long Biliary Stent Causing Sigmoid Colon Perforation
Pavan Manchikalapati, MD, Noel Martins, MD, Kanishka Bhattacharya,
MD∗. Gastroenterology, University of Massachusetts, Worcester, MA.
Distal biliary stent migration occurs in 5–10% of the cases; usually, the stent
passes spontaneously through the rectum. Cholangitis, perforation, obstruc-
tion, and fistula formation are the reported complications. In our patient,
biliary stent migration resulted in sigmoid colon perforation. We describe
the clinical presentation, associated risk factors for colon perforation and
review the published literature.
Case report: 70-Year-old male with Hepatitis C, Childs classA cirrhosis and
unresectable hepatocellular carcinoma was referred for ERCP and stenting
of segmental biliary obstruction caused by the tumor. Radio frequency ab-
lation (RFA) was planned later in the week, but it was thought that the
segmental biliary obstruction should be drained to prevent cholangitis after
RFA. He has past history of open cholecystectomy 38 years ago, sigmoid
diverticulosis and left inguinal hernia repair. Patient underwent ERCP and
stent placement across the area of obstruction in the left intrahepatic duc-
tal system. A10-Fr and 15 cm plastic biliary stent with a single external
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flap and single internal flap was inserted uneventfully. 2 days after the stent
placement, patient underwent RFA. 10 days later patient presented to the ER
with worsening abdomen pain for 6 days and with signs of peritonitis. CT
scan revealed free air in the abdomen, sigmoid diverticulae and a migrated
stent in the abdomen outside the lumen of the sigmoid colon. Patient un-
derwent laparotomy, which revealed ascites with fecal staining, a sigmoid
resection with colostomy and peritoneal toilet was performed. The stent was
found to be floating freely in the peritoneum and was removed. The patient’s
postoperative course was complicated by hypotension, respiratory failure,
renal failure, and sepsis. Despite aggressive therapy he did not improve and
was made comfort measures. Patient died on post operative day 8.
Conclusion: Although rare, intestinal perforation should be considered in
patients presenting with acute abdomen and radiology findings confirming
stent migration. In our review of literature, most of colon perforations oc-
curred between 1–3 weeks after the biliary stent placement. Straight stents,
papillary stenosis, adhesions, diverticular disease, colonic strictures and her-
nias were associated conditions. Our case illustrates the point that long
(>7 cm) straight biliary stents may not spontaneously pass with feces should
they become dislodged and double pigtail biliary stents should be considered
to minimize the risk of perforation.
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TB or Not TB: An Atypical Etiology of Colitis
David H. Kerman, MD, Jeffrey B. Raskin, MD∗. Medicine –
Gastroenterology, University of Miami/Jackson Memorial Hospital,
Miami, FL.
Bloody diarrhea is a common presentation in clinical practice. In the US, in-
flammatory bowel disease, ischemic colitis, and bacterial infections are most
commonly responsible for these findings. Our aim is to present a case of col-
itis with bloody diarrhea with a rare etiology amongst long-term inhabitants
of the United States.
A 42 year-old Haitian woman with a past medical history of cadaveric re-
nal transplant secondary to glomerulonephritis was referred for consultation
with complaints of bloody diarrhea, fevers, and chills. Eight months prior,
she presented to an outside institution with similar complaints. Workup at
that time yielded a diagnosis of Crohns colitis and the patient was started
on oral mesalamine and a prednisone taper. Her symptoms never resolved.
She was hospitalized at our institution with right upper lobe pneumonia for
which she was started on broad-spectrum antibiotics. She denied abdomi-
nal pain or anorexia. Physical examination revealed a temperature of 101.3
Farenheit, right basilar crackles, and mild right-sided abdominal tenderness
without rebound. CT scan of the abdomen demonstrated a 4 × 2 cm fluid
collection without air-fluid levels adjacent to the transplanted kidney and
thickening of the terminal ileum and cecum. Repeat colonoscopy showed
right-sided ulcerations with the most prominent ulceration at the ileocecal
valve. Biopsies showed acute colitis with lymphocytic infiltrates and no gran-
ulomas. Special stains for CMV, flow cytometry for lymphoma, and fungus
were all negative. Stool studies were positive for acid-fast bacilli. Review
of biopsies from the cecal ulceration showed AFB positivity as did sputum
from the bronchoscopy. Subsequent PCR studies confirmed Mycobacterium
tuberculosis in the sputum.
This case highlights several important points. In an immunocompromised
patient with bloody diarrhea, atypical causes should be entertained. Similar-
ities in the clinical presentation between Crohns colitis, CMV colitis, and TB
colitis make a definitive diagnosis difficult, as they may mimic each other.
With the burgeoning increase in immunocompromised patients as well as
the advent of biologic therapies for IBD, there has been a marked resurgence
in mycobacterial disease. Mycobacterial tuberculosis should be considered
in these patients presenting with bloody diarrhea.
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EUS with Trucut Biopsy for Diagnosis of Intra-Abdominal
Tuberculosis
Kaumudi Somnay, MD∗, Natalya Belova, MD. Department of
Gastroenterology, New York Hospital Queens, Flushing, NY.
An 80-year Italian old male presented with left upper quadrant pain, exces-
sive fatigue, weight loss and normocytic anemia. EGD revealed thickened
and inflamed gastric mucosa and 2 submucosal gastric impressions. CT scan
of the abdomen showed low attenuation lesions in the omentum adjacent to
the stomach and low attenuation gastrohepatic ligament lymph nodes.
The working diagnosis was lymphoma. Using linear EUS and fine needle
aspiration, tissue was collected for cytology and microbiology. Cytology was
initially non-diagnostic, so Trucut needle biopsy was performed. Perigastric
lymph nodes cytology was positive for necrotic material with numerous
lymphoid cells. AFB and fungal studies were negative.
Trucut biopsy on pathology revealed necrotizing granuloma without acid-
fast bacilli. 4 weeks later AFB culture grew M. Tuberculosis complex.
Another patient who was a 44-year-old male with AIDS presented with fever,
dysphagia, vomiting, weight loss and intermittent non-bloody diarrhea.
On admission he was febrile and tachycardic. Physical exam revealed cachec-
tic ill-appearing male. Abdominal examination was unremarkable. There was
no palpable lymphadenopathy. Patient was anemic; CD4 cell count was 5.
EGD revealed extrinsic compression of the stomach. CT scan of the abdomen
showed a mass in the splenic hilum, indenting the posterior aspect of the
stomach, and smaller masses in the paragastric region. EUS was performed
with multiple fine needle aspirations of the lesions and but it did not provide
definitive diagnosis, so EUS was repeated with Trucut biopsy.
Histology revealed necrotic tissue mixed with lymphoid cells, histiocytes,
caseating granuloma with presence of AFB, further identified as Mycobac-
teria tuberculosis. Patient was treated with four-drug regimen; his condition
improved and he was discharged.
Diagnosis of abdominal tuberculosis presents a challenge because it is un-
common, inaccessible, and yields few numbers of bacilli on FNA.
It is important to realize, that TB seems to be resurging and abdominal TB
needs to be considered in the differential in both immunocompromised and
immunocompetent patients.
In the above 2 cases we show that EUS with Trucut needle tissue acquisition
can be an accurate and safe method of diagnosing lesions accessible through
the gastrointestinal tract. EUS guided Trucut biopsy played crucial role in
diagnosis of intra-abdominal tuberculosis in both the immunocompromized
and immunocompetent patient.
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A Case of Fatal Polycystic Liver Disease
Swetha Kandula, MD, Raymond L. Farrell, MD, Stuart A. Torgerson, MD∗.
Division of Gastroenterology, Department of InternalMedicine, Southern
Illinois University School of Medicine, Springfield, IL.
Autosomal dominant polycystic kidney disease (ADPKD) is the most com-
mon hereditary renal disease which affects 1/400 to 1/1000 live births. Liver
involvement is the most common extra-renal manifestation. The prevalence
and number of hepatic cysts in patients with ADPKD increase with age,
female sex, severity of renal disease and use of exogenous female steroids.
Polycystic liver disease (PLD) occurs alone as autosomal dominant polycys-
tic liver disease (ADPLD) or in combination with ADPKD. Jaundice and
hepatic failure are unusual features of PLD. Here we present a case of an
advanced PLD.
A 79 yr old female with history of PLD, ADPKD presented with fatigue,
anorexia, abdominal pain and distension, ten pounds weight loss, dark urine
and itching. No history of alcohol, hepatotoxic drugs, tattoos or viral hepati-
tis. Examination showed icteric sclerae and mucous membranes, distended
abdomen with fluid wave, hepatomegaly and pedal edema.
Pertinent laboratory results included hb 10.1 g/dl, hct 31%, plt 279 k/cumm,
BUN 22 mg/dl, creatinine 0.7 mg/dl, alk phos 366 IU/L, AST 53 IU/L,
ALT 22 IU/L, total bilirubin 9.1 mg/dl, direct bilirubin 5.5 mg/dl, indirect
bilirubin 3.6 mg/dl, PT 16.6 sec, INR 1.4, albumin 1.5 g/dl. CAT scan of
abdomen showed multiple hepatic cysts with compression of surrounding
parenchyma and bilateral renal cysts. MRCP revealed compression of extra
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hepatic biliary ducts by a large left lobe cyst. As the patient was not a
candidate for transplant, a cholecystectomy and choledochoduodenostomy
were done to alleviate the distal obstruction. Post-operatively the patient
succumbed to overwhelming sepsis and encephalopathy.
While most patients with PLD are asymptomatic, some patients may expe-
rience abdominal pain, early satiety, and shortness of breath due to massive
liver enlargement. Rarely patients such as ours can have ascites, hepatic
failure and encephalopathy. Treatment of symptomatic liver cysts is com-
prised of somatostatin analogues, aspiration, sclerotherapy, unroofing, inter-
nal drainage with cystojejunostomy or fenestration. In extreme cases hepatic
resection or liver transplantation are options.[figure1]
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The Misplaced Shoe Polish Bottle!
Rohit Jindal, MD, Edmond Bouassaf, MD, Ayse Aytaman, MD∗.
Gastroenterology, VA NYHHS, Brooklyn, NY and Gastroenterology, SUNY
Downstate Medical Center, Brooklyn, NY.
Rectal foreign bodies of various shapes and sizes have been reported. Such
patients usually present with pain and obstructive symptoms however presen-
tation is often delayed due to embarrassment. Morbidity is due to bleeding,
laceration or perforation and is usually complicated with multiple attempts
at self removal. We present the case of a patient with a considerably large
foreign body impacted proximal to the rectosigmoid junction which was
successfully removed by endoscopy.
Case Presentation: A 43 y man presented with rectal pain and mild rectal
bleeding for two days. He admitted to using objects for rectal insertion
two days prior to presentation. The patient had made several unsuccessful
attempts to evacuate the rectum using digital manipulation and laxatives. On
rectal exam, the smooth edge of a foreign body was palpable. Abdominal xray
was suggestive of a metallic spring device in the sigmoid. Sigmoidoscopy
revealed the base of a large plastic bottle at 5 cm from the dentate line [Fig. 1].
The scope was carefully advanced along the side of the bottle and its proximal
end was noted to be at 30 cm. Attempts to grab the bottle with forceps of
various sizes were unsuccessful. It was also not possible to snare the bottle as
its diameter was larger than the largest available endoscopic snare. Finally,
9.5 in Foerster forceps with serrated jaws were inserted carefully alongside
the scope and under visual guidance, the base of bottle was grasped. The
forceps were slowly pulled out as the patient bore down. The object turned out
to be a plastic liquid shoe polish bottle 20 cm long and 4.5 cm in diameter. A
check sigmoidoscopy revealed minimal mucosal trauma at the rectosigmoid
junction but no perforation. Repeat abdominal xray was normal and the
patient discharged after observation for a few hours. Review of literature
revealed this to be a unique case of a liquid shoe polish bottle recovered
from the rectum using endoscopy.
Discussion: Transanal removal of large objects impacted above the rectosig-
moid junction is difficult. However, endoscopic removal should be preferred
and attempted prior to open surgical approach as it is safe, less morbid and
cost effective.[figure1]
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DIC as a Complication of HHT or Osler-Weber-Rendu Syndrome
Houman Javedan, MD, Nausheen Naz, MD, Manish Tandon, MD, Julio C.
Ayala, MD∗. Internal Medicine, Mount Auburn Hospital, Harvard
Medical School, Cambridge, MA.
The possibility of disseminated intravascular coagulopathy (DIC) as a com-
plication of hereditary hemorrhagic telangectasia (HHT) has been described
in the past[1]. However, due to the low incidence of HHT, information on
the topic is scarce. We present a case of HHT complicated by DIC to support
the clinical awareness needed with regards to DIC resulting in bleeding as a
presentation of HHT.
A 72 year old female presented with a severe episode of epistaxis and was
found to be in DIC. She had been suffering from recurrent episodes of epis-
taxis for over 5 years. Her past medical history included pulmonary embolus,
COPD, hypertension and diverticulosis. Her family history included recur-
rent epistaxis in her father and son. Physical examination on presentation
demonstrated a telangectetic lesion on the tongue and fingertips and dried
blood in her right nares. Laboratory data revealed WBC 7.67, HCT 37, MCV
86.2, Platelets 114, PT 24, INR 2.1, Fibrinogen <70, and DDimer >5250.
BUN 8, Cr 0.8.
Endoscopy performed for hematemesis confirmed gastric arterio-venous
malformations (AVMs). CT angio of abdomen and chest demonstrated pul-
monary, liver, and gastrointestinal tract AVMs. Small bowel capsule study
confirmed gastric AVMs with no small bowel AVMs. Genetic testing demon-
strates single nucleotid (A) deletion at position 364 of the ALK-1 gene
causing a truncated ALK-1 protein.
A clinical diagnosis of HHT was confirmed.
This case adds to the literature in support of the clinical relevance of DIC as
a complication of HHT. Furthermore, in this case it was a part of the acute
presentation which led to the diagnosis of HHT. [1] Ann N Y Acad Sci,
1981;370:851–4
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Primary Duodenal Mucosa-Associated Lymphoid Tissue Lymphoma
Treated with Rituximab
Brent J. Prosser, MD, Praveena G. Velamati, MD, Mack C. Mitchell, MD∗.
Department of Digestive Diseases, Johns Hopkins Bayview Medical
Center, Baltimore, MD.
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MALT lymphoma is the most common primary lymphoma of the GI tract.
Though gastric MALT lymphoma is well described, only 17 cases of primary
duodenal MALT lymphoma are reported. The use of rituximab has never
been reported.
A 64 year old man with hypertension had three years of intermittent GI
bleeding. Multiple endoscopies showed duodenitis with ulceration. Biopsies
of the stomach and duodenum on five occasions showed peptic duodenitis
without H. pylori. Work-up for Zollinger-Ellison syndrome was negative
and all NSAIDs were discontinued without improvement. Despite a highly
selective vagotomy, the duodenitis and ulcerations persisted, prompting re-
ferral.
On presentation, the patient was taking esomeprazole twice daily and ran-
itidine nightly. Four weeks after an empiric course of H. pylori therapy,
endoscopy showed duodenal erosions with biopsies revealing duodenitis.
Sucralfate was started and endoscopy three months later showed duodeni-
tis with an eosinophilic infiltrate. Cromolyn was prescribed and endoscopy
four months later was unchanged. However, biopsies revealed a dense CD20-
positive lymphocyte infiltrate. MALT lymphoma was confirmed by flow cy-
tometry. PET scan showed increased radiotracer uptake in the duodenum
with no metastases. The patient did not want extensive chemotherapy, radi-
ation therapy, or surgery; therefore, a one month course of rituximab was
given. A follow-up PET scan showed persistent, though notably less, uptake
in the duodenum. An endoscopy revealed persistent MALT lymphoma. In
the setting of only a partial response to rituximab, the patient underwent
radiation therapy.
Of the reported cases of primary duodenal MALT lymphoma, only three
patients responded solely to H. pylori eradication. All other cases were
treated with either chemotherapy or surgery. Different chemotherapeu-
tic regimens include oral cyclophosphamide; CHOP followed by vinblas-
tine/etoposide/epirubicin/prednisone; CVP; and clarithromycin monother-
apy. In the remainder of cases, surgery was the preferred. We avoided more
toxic regimens for rituximab, a chimeric monoclonal antibody to CD20-
positive lymphocytes. Rituximab has demonstrated efficacy in a variety of
lymphomas and with response rates as high as 64% in gastric MALT lym-
phoma. There are no reports of its use in primary duodenal MALT lymphoma.
Given rituximab’s ease of administration and reasonable side effect profile,
it may be a viable alternative for treatment in the absence of response to
H. pylori eradication.
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Fatal Small Bowel and Colonic Ischemia after Sodium Phosphate
Bowel Preparation
Praveena G. Velamati, MD, Kimberley E. Steele, MD, Mack C. Mitchell,
MD∗. Department of Digestive Diseases, Johns Hopkins Bayview Medical
Center, Baltimore, MD and Department of Surgery, Johns Hopkins
Bayview Medical Center, Baltimore, MD.
A 69 year old woman with a history of breast cancer, COPD, osteoporo-
sis, and hypertension was scheduled for a colonoscopy for heme positive
stools and constipation. Serum creatinine, electrolytes, and hepatic enzymes
were normal, and she was instructed to use a sodium phosphate (NaP) bowel
preparation. On the day prior to her procedure she ingested 45 ml of an oral
NaP solution, and subsequently developed nausea, vomiting and abdominal
pain. Upon presentation, she was slightly tachycardic but her blood pressure
was normal. Her abdomen was moderately distended with decreased bowel
sounds. Serum sodium was 136 mEq/L, potassium 3.6 mEq/L, chloride 96
mEq/L, bicarbonate 16 mEq/L, blood urea nitrogen 12 mg/dL, creatinine 1.3
md/dL, lactate 1.7 mmol/L, phosphate 13.6 mg/dL, and calcium 9.9 md/dL.
Computed tomography of the abdomen showed marked feces in the colon
with no free air or obstruction. Nasogastric and rectal tubes were placed, and
non-phosphate based laxatives administered, without improvement in her
abdominal pain. Thirty-six hours later she developed cardiopulmonary dis-
tress and was transferred to the intensive care unit. Flexible sigmoidoscopy
showed dusky mucosa and she was taken emergently to the operating room.
The entire colon and a small portion of the terminal ileum appeared non-
viable, and a total colectomy with ileostomy was performed. The following
day her lactate had risen to 4.3 mmol/L, the ileostomy appeared necrotic
and she was taken back to the operating room for a revision with resection
of approximately fifteen centimeters of ischemic ileum. The pathology was
consistent with diffuse ischemia and mucosal necrosis. Her hospital course
was complicated by nosocomial infection, pneumonia with bilateral effu-
sions, poor wound healing, refractory hypotension, and inability to wean
from the ventilator. Her family decided to withdraw support and the patient
died. There have been multiple cases of acute phosphate nephropathy re-
sulting from NaP use that led to an FDA warning in 2006. However, in this
case despite the hyperphosphatemia the patient never developed significant
renal failure. In fact, her phosphorus levels and creatinine normalized and
her urine output remained adequate. Fatal small bowel and colonic ischemia
related to the use of a NaP bowel preparation has not been reported in the
absence of renal failure.
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Strongyloidiasis Manifesting as Colonic Polyps Successfully Treated
with Ivermectin
Edmond Bou Assaf, MD, Nassim El-Hajj, MD, Ayse Aytaman, MD, Andrew
W. Seymour, MD, Jie Ouyang, MD, Gerald Fruchter, MD∗. State
University of New York, Brooklyn, NY and New York Harbor VA, Brooklyn
Campus, Brooklyn, NY.
A 75 year old male well compensated cirrhotic presented for surveillance
colonoscopy three years after undergoing a left hemicolectomy for a large
villous adenoma with HGD. Patient also with History of prostatic Ca treated
with RT. He has had intermittent diarrhea over several years. He was found
to have peripheral eosinophilia of 39%.
Colonoscopy revealed 20–30 polyps, scattered throughout the colon, ranging
in size between 3 mm and 1 cm. Eight of these polyps were either biopsied or
removed endoscopically. Pathology from all samples showed inflammatory
polyps with marked eosinophilia, eosinophilic cyrptitis and cryptal abcesses.
Exam of stools showed few Strongyloides Stercoralis larvae. Accordingly,
the patient was treated with two doses of Ivermectin at 24 hours interval.
At eight-week follow up, there was resolution of the diarrhea and hema-
tochezia. CBC showed improvement of the peripheral eosinophil count to 7%
of CBC. Colonoscopy revealed one 3 mm polyp, which, on biopsy showed no
eosinophilia. Random colonic biopsies showed mild chronic inflammation
with no eosinophilia.
Conclusion: Strongyloides infection should be considered in patients with
a history of chronic diarrhea and multiple polyps on endoscopy. A history of
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travel to an endemic area is suggestive. Two consecutive doses of Ivermectin
can be considered as an effective treatment regimen.[figure1]
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Certolizumab Pegol Treatment of Crohn’s Disease in a Patient Who
Had an Adverse Reaction to Infliximab: A Case Report
Markus Sedlak, MD∗. Internal Medicine, Linz City Hospital, Linz, Austria.
Patient history: A 34-year-old male patient (weight 69 kg; height 179 cm)
was admitted to hospital in October 2004 with severe abdominal pain and
diarrhea. At admission, he had a Crohn’s Disease Activity Index (CDAI)
score of 243 points and reported more than five loose bowel movements
per day (often with blood). Endoscopic examination and CT scans revealed
moderate to severe lesions in the terminal ileum and colon ascendens, but
there were no fistulae or stenoses.
Initial therapy: Treatment with azathioprine and oral cortisone for 5 months
failed to achieve a satisfactory response (2–3 intense, loose bowel move-
ments/day, with spasms and blood; CDAI score of 209 points).
Infliximab therapy: Therapy with infliximab (300 mg iv infusion at 0, 2,
and 8 weeks, and then every 8 weeks) was initiated in February 2006. After
the third infliximab infusion, the patient developed signs of severe acute pan-
creatitis and hypotension, accompanied by massive diffuse abdominal pain,
fever, and vomiting. The patient was hospitalized and examinations indicated
serious pancreatitis with swelling in the pancreatic head, ileum terminalis,
and colon ascendens. Antibodies against infliximab were not measured. Fol-
lowing treatment with analgesics, parenteral nutrition, and metronidazole,
the patient’s condition stabilized and he was subsequently discharged. Al-
though 5% of infliximab infusions are associated with nonspecific adverse
reactions, severe acute reactions such as acute pancreatitis are rare.
Therapy with certolizumab pegol: After discharge from hospital, the pa-
tient’s clinical condition soon worsened (severe diffuse abdominal pain, 5–7
loose bowel movements/day, with blood; CDAI score of 214 points). The
patient began treatment with certolizumab pegol (induction with 400 mg
subcutaneously at Weeks 0, 2, and 4, and then 400 mg every 4 weeks). The
patient’s condition improved after the second certolizumab pegol injection
(2–3 loose bowel movements/day, very few pain episodes, and CDAI score of
134 points). After 6 months’ certolizumab pegol therapy, the patient showed
significant improvement (almost no diarrhea, only occasional pain, some
weight gain, and CDAI score of 92 points).
Certolizumab pegol provided effective treatment of Crohn’s disease for this
patient who had previously reacted badly to treatment with infliximab. This
case illustrates that certolizumab pegol may offer a viable rescue therapy for
a patient with Crohn’s disease who experiences such a reaction to infliximab.
Certolizumab pegol was provided by UCB.
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Delayed Life Threatening Rectal Bleeding after Trus-Guided Prostatic
Biopsy
Wael El Darawy, MD∗, Won Sohn, MD, Maurice A. Cerulli, MD.
Methodist Hospital, Brooklyn, NY.
Rectal bleeding is one of the complications of TRUS-guided prostate biopsy,
but is usually mild and stops spontaneously. We report a case of delayed se-
vere rectal bleeding after TRUS-guided prostate biopsy that required emer-
gency colonoscopy and clipping of the bleeding vessel.
A 56 year-old man presented with dysuria, fever and chills. Three days
earlier he underwent TRUS-guided prostate biopsy which was uneventfull.
His medical history included hypertension and dyslipidemia. His tempra-
ture was 105.1, pulse was 144 and BP was 106/75. He also had distended
urinary bladder and tender prostate. Blood tests showed a WBC count of
15.4, hemoglobin of 11.9, and platelet count of 253. Coagulation profile
was normal. Urine analysis showed 269 WBC and 116 RBC per HPF. A
Foley’s catheter was inserted and he was treated with antibiotics. He im-
proved over the next 3 days. However, on the fourth day, he passed a large
bowel movement of bright blood and developed hypovolemic shock. While
being resuscitated emergent colonoscopy was done. Colonoscopy showed a
large bleeding vessel at the biopsy site and the bleeding was successfully
controlled using hemostatic clips. The patient was stabilized with 2 units of
PRBC and had no further bleeding since then.
Mild hemorrhagic complications are common problem after transrectal
prostate needle biopsy. Bleeding commonly occurs directly after the pro-
cedure and is usually controlled by applying pressure at the biopsy site.
Only few cases of severe rectal bleeding which required invasive procedures
were reported. We also found one case report of delayed rectal bleeding af-
ter 5 days. Our patient developed rectal bleeding 7 days after biopsy, which
represents secondary hemorrhage due to urinary infection. Our literature re-
view found no prior results of colonoscopic treatment of bleeding site with
clipping of the blood vessel. We propose this useful procedure in similar
cases.
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Bread Bag Clip Ingestion: A Rare Cause of Upper Gastrointestinal
Bleed
Suzanne K. Morrissey, MD, M. Lance Weaver, MD, Katie Farah, MD∗,
Shyam J. Thakkar, MD. Division of Gastroenterology, Allegheny General
Hospital, Drexel University College of Medicine, Pittsburgh, PA and
Department of General Surgery, Allegheny General Hospital, Drexel
University College of Medicine, Pittsburgh, PA.
An 83-year-old man with a history of macular degeneration and atrial fibril-
lation on coumadin was admitted to an outside hospital with hematemesis
and profound anemia. EGD revealed a 1 cm clean-based cratered ulcer in
the duodenal bulb. He was discharged off coumadin and presented to our
institution two days later with an acute stroke. Prior to the reinstitution of
anticoagulation, EGD was performed to evaluate the prior ulcer. A side-
viewing endoscope was used for full visualization and showed a foreign
body eroding into the posterior duodenal wall with an underlying deep ul-
ceration. Endoscopic removal was not possible due to strict adherence to
the duodenal mucosa. Exploratory laparotomy revealed a bread clip erod-
ing into the duodenal wall in close proximity to a duodenal diverticulum.
Duodenotomy and extraction of the clip was performed. The patient did not
recall having ingested the bread clip.
Bread clips are rarely found as foreign bodies in the gastrointestinal tract.
When present, the clip can adhere to the mucosa causing obstruction, per-
foration, or bleeding. There have been twenty three reported cases of bread
clips found in the gastrointestinal tract. Bowel obstruction and perforation
are the most common clinical presentations. Our patient is the second re-
ported case world-wide of gastrointestinal bleeding caused by a bread clip.
The small bowel is the most common site of impaction thought to be due to
the smaller diameter and irregularly folded mucosa. Esophageal and colonic
impactions have also been described. Complications may arise up to years
after ingestion. As there was no expiration date on our patient’s clip, it was
impossible to estimate the time from ingestion. Most cases of ingested bread
clips are elderly, edentulous patients. Our patient’s accidental ingestion was
due to his severe vision impairment. Diagnosis is often difficult secondary to
unawareness of ingestion and radiolucency on x-ray. Therefore, impaction of
a radiolucent foreign body should always be considered in the differential of
gastrointestinal bleeding. Given the significant morbidity and mortality re-
lated to bread clip ingestion, some countries have eliminated their use while
others are looking for a newly-designed clip.
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Mycobacterium Avium Complex Infection of the Duodenum
Josh Forman, MD, Roderick Kreisberg, MD, Eric Goldberg, MD∗.
Division of Gastroenterology, University of Maryland School of Medicine,
Baltimore, MD.
A 31-year-old woman with AIDS was admitted with abdominal pain, non-
bloody diarrhea, and recurrent fever. She reported fatigue, weakness, and
weight loss of 14 kg over six months. Laboratory testing revealed normo-
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cytic anemia, minimally elevated transaminases and alkaline phosphatase,
and hypoalbuminemia. The total bilirubin and LDH were normal. Upper en-
doscopy revealed a normal esophagus and stomach. The duodenal mucosa
was granular and firm with tan-yellow nodules and plaques. Microscopic
examination of biopsy specimens prepared with periodic acid-Schiff (PAS)
and Fite’s acid fast stains revealed abundant histiocytes within the lamina
propria containing a dense array of filamentous inclusions. DNA probe of a
positive acid-fast blood culture confirmed Mycobacterium avium complex
(MAC) infection.
The prevalence of gross GI mucosal involvement in disseminated MAC has
not been clearly defined and endoscopic findings are variable. In a review
of 55 cases of disseminated MAC infection in patients with AIDS where
endoscopic findings were reported, the most common finding was multiple
raised nodules that were yellow, white, yellow-whitish, or pink in color in
38%. The mucosa was normal in 36%. Other non-specific findings such
as erythema, edema, and ulcerations were encountered less frequently. The
duodenum was involved in > three quarters of the cases described, while the
rectum was involved in nearly 25%.
Histologic examination of biopsy specimens is essential when endoscopi-
cally evaluating patients with suspected disseminated MAC as similar clini-
cal manifestations, endoscopic findings, and histologic findings are encoun-
tered in Tropheryma whipplei infection. In contrast to MAC, organisms in
Whipple’s disease are rounded and sickle-shaped, intracellular and extracel-
lular, and resist acid fast staining. Whipple’s disease is rarely reported in
patients with AIDS.[figure1][figure2]
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Metastatic Soft Tissue Sarcoma Detected by Small Bowel Video
Capsule Endoscopy
Jennifer Weiss, MD, Sharon Weber, MD, Mark Reichelderfer, MD, Deepak
Gopal, MD∗. Section of Gastroenterology & Hepatology & Dept. of
General Surgery, University of Wisconsin – School of Medicine & Public
Health, Madison, WI.
To be familiar with the diagnosis, treatment, and prognostic factors for sar-
comas in the GI tract.
Case: A 50 year old female was referred for evaluation of obscure GI bleed-
ing presenting with melena and iron deficiency anemia. Past medical history
revealed a diagnosis of soft tissue sarcoma involving the buttocks, with sub-
sequent spread to her heart, colon, and adrenal gland. She completed multiple
courses of chemo-radiation therapy and underwent a right hemicolectomy. At
the time of referral, medical oncology felt that her disease was stable based
on whole body CT scan imaging. Physical exam revealed pale conjunctiva
and sacral changes consistent with a prior resection and radiation. Labo-
ratory data confirmed anemia (Hgb 7.8 g/dL, Hct 25%, iron 10 mcg/dL).
Upper GI endoscopy with small bowel enteroscopy to the proximal jejunum
and colonoscopy failed to demonstrate any active GI bleeding source. Cap-
sule endoscopy was performed and revealed 2 large, ulcerated submucosal
lesions with active bleeding from the mid-jejunum to the distal ileum (Fig-
ure). Intraoperatively an area of intussusception with 2 intraluminal masses
was located approximately 1 1/2 feet from the ileocolic anastomosis and was
resected. Pathology confirmed metastatic high-grade sarcoma.
Discussion: Soft tissue sarcomas are rare malignant tumors, accounting for
<1% of all new cancers/year. They arise from mesenchymal tissue with
approximately 80% arising from soft tissue and 20% from bone. Besides
metastatic spread to the small intestine, sarcomas can present as primary
small bowel malignancies. In prior case series, clinical presentations of sar-
comas of the small intestine (metastatic or primary) include an abdominal
mass, pain, weight loss, GI hemorrhage, obstruction, intussusception, and
perforation. The treatment of choice is surgical resection with intent to ob-
tain adequate negative margins. The role of adjuvant chemotherapy remains
controversial with studies showing varying results. With regards to progno-
sis of these tumors, histologic grade has borne out to be the most significant
factor affecting survival.[figure1]
682
Four Different Presentations of a Rare Disease – Whipple’s Disease
Bogdan Cristescu, MD, Safak Reka, MD∗. Digestive Diseases, SUNY
Downstate Medical Center, Brooklyn, NY.
Whipple’s disease (WD) is a rare chronic infectious multisystem disease
caused by bacterium Tropheryma whipplei. Only about 1000 cases have
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been reported to date. We describe our experience with 4 cases diagnosed
with WD between 2002 and 2007: first 3 cases from Brooklyn, New York
and case #4 from Western Massachusetts.
Case #1: A 72 year-old (yo) Caucasian male from Spain, living in Brook-
lyn since 1975, presented with 30 lbs weight loss, pulmonary nodules
and retroperitoneal lymphadenopathy. Lymph node biopsy revealed foamy
macrophages (FM) containing periodic acid-Schiff (PAS) positive (+) mate-
rial and negative Ziehl-Neelsen stain (ZN). Retrospectively, he had arthralgia
for 10 years and developed intermittent diarrhea, epigastric pain and progres-
sive cognitive decline for the last 6 months. Laboratory data were significant
for anemia and evidence of malabsorbtion. On upper endoscopy (EGD) duo-
denal mucosa had small lymphangiectasia and biopsy was consistent with
WD with PAS + FM in lamina propria (LP).
Case # 2: A 61 yo Caucasian male from Russia, living in Brooklyn for the
last 7 years, with long history of arthralgia was evaluated for iron deficiency
anemia. Colonoscopy was unrevealing and EGD showed normal appearing
duodenal mucosa with distended villi by FM PAS + and negative ZN on
biopsies, consistent with WD.
Case #3: A 25 yo African American male presented with diarrhea for 1
year. Colonoscopy with ileoscopy revealed erythema of the terminal ileum
mucosa with PAS + FM on biopsies. EGD confirmed the diagnosis of WD
with similar findings on duodenal biopsy.
Case #4: A 41 yo Caucasian male of Irish descend, with history of seroneg-
ative polyarthritis on treatment with high doses of aspirin and intermittent
steroids presented with an episode of diarrhea for 4 weeks with negative
work-up including colonoscopy. The episode resolved, but subsequently the
patient had recurrence of diarrhea and weight loss. On EGD duodenal mu-
cosa appeared flat, pale and biopsies showed PAS + FM in LP suggestive of
WD. The diagnosis was confirmed by a PCR assay.
All patients were treated with Ceftriaxone for 2 weeks followed by Trimetho-
prim -sulfamethoxazole for 1 year. Diarrhea and anemia resolved and arthral-
gia was significant improved in all patients. Patient in case #1 had weight
gain and improvement in adenopathy and cognitive function.
Discussion: WD has a variety of clinical manifestations and should be con-
sidered in patients who present with migratory arthralgias of the large joints,
weight loss, diarrhea, and abdominal pain.
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Metastatic Lobular Breast Cancer to the Gastrointestinal Tract: An
Unusual Case Report
Jianfeng Cheng, MD, PhD, Joseph McNelis, MD, Dragoslava Zamurovic,
MD, FCAP, Srinivas Kalala, MD, Jeffrey Brensilver, MD, FACP∗. Internal
Medicine, Sound Shore Medical Center, New Rochelle, NY;
Gastroenterology, Sound Shore Medical Center, New Rochelle, NY;
Pathology, Sound Shore Medical Center, New Rochelle, NY and
Gastroenterology, New York Medical College of Westchester, Valhalla, NY.
We report a rare case of lobular breast carcinoma metastatic to the stomach
and colon. A 54-year-old patient had undergone left lumpectomy with ax-
illary dissection and postoperative radiation therapy two years earlier. Cur-
rently, the patient presented with anemia (Hgb/Hct: 9.0 g/L/27.1%). Gas-
troscopy showed hiatal hernia while colonoscopy revealed nodular changes
in the mucosa and diverticulosis. Biopsies from the gastric antrum and
colon showed poorly differentiated carcinoma within the lamina propria
with some of the tumor cells showing signet ring cell features. Histolog-
ically the carcinoma was similar to the invasive lobular breast carcinoma
from two years ago. Immunohistochemical analysis revealed positive stain-
ing for CK7 and GCDFP-15 and few cells weakly positive for progesterone
receptors, confirming breast origin of metastatic tumor. Staining for estro-
gen receptor marker and CK20 was negative. Nuclear Medicine bone scan
showed no evidence of bone metastasis. The patient received aggressive
systemic chemotherapy.
Breast carcinoma is the most common malignancy in women and metastatic
breast cancer typically involves lymph nodes, lungs, bones, brain and liver.
Gastrointestinal metastases is less common and usually derive from lobular
rather than ductal breast carcinoma, remain asymptomatic for a long time and
present as a late event in the progression of the disease. Since lobular breast
cancer has an unpredictable metastatic pattern such as hematogenous spread
to distant organs prior to regional lymph node involvement, any specific
or nonspecific symptoms in patients with known lobular breast carcinoma
should cause a high suspicion of metastasis. Endoscopic exploration, ade-
quate biopsies should be followed by histological and immunohistochemical
analysis of gastric and colonic mucosal malignancies, further comparing with
the histological features of original breast carcinoma. In summary, evalua-
tion of any gastrointestinal symptoms in patients with history of invasive
lobular breast carcinoma followed by pathologic and immunohistochemical
analysis is essential in establishing an early diagnosis of metastatic lobular
carcinoma and avoiding unnecessary surgical treatment.
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C difficile Enteritis in Ileostomy Patients: Report of Three Cases and
Review of the Literature
Laith H. Jamil, MD, Amulya Konda, MD, Lynne Dieterle, PA-C, Karim
Tazi, MD, Gregg Polidori, MD, Michael C. Duffy, MD∗. IM/GI, William
Beaumont Hospital, Royal Oak, MI.
C. difficile (CD) is the most common cause of nosocomial infectious diarrhea
and is generally considered a colonic pathogen. CD small bowel enteritis
(CDSBE) has only rarely been reported. We describe the clinical course and
treatment of 3 ileostomy patients with diarrhea due to CD.
Case #1: 48 YOM s/p colectomy and ileostomy for Crohn’s disease 2 yrs pre-
viously presented with fever, nausea, vomiting, abdominal pain, increased
ileostomy output, and marked dehydration. Antibiotics had been adminis-
tered 3 months previously. Ileostomy CD toxin was positive by ELISA. He
responded to a standard course oral metronidazole and vancomycin with
resolution of symptoms and negative repeat CD toxin after treatment.
Case #2: 72 YOM s/p colectomy and ileostomy for ulcerative colitis 24 yrs
earlier presented with a low-grade fever and non-bloody diarrhea of 1-month
duration. There was no antecedent antibiotic use. Ileostomy CD toxin was
positive by ELISA. He was initially treated with metronidazole, which was
switched to oral vancomycin. He responded to 2 weeks of vancomycin,
but relapsed following discontinuation and received a 1-month course of
vancomycin with clearance of the toxin.
Case #3: 39 YOM with severe acute alcoholic pancreatitis required a to-
tal abdominal colectomy and ileostomy for colonic ischemia. He required
multiple courses of antibiotics and subsequently developed a high ileostomy
output. Ileostomy fluid CD toxin was positive and he responded to a standard
course oral metronidazole and vancomycin
Discussion: CDSBE has been reported in 20 patients in the literature, but
only previously in ten ileostomy patients, most of whom were detected in
the early post-operative period (<90 days). In only 3 cases in the literature
was CDSBE diagnosed > 90 d following surgery in ileostomy patients. We
report 2 more such cases, and a third in the early post-operative period.
Most patients have a history of antibiotic use and present with increased
ileostomy output. Most respond to standard therapies (oral metronidazole or
oral vancomycin). Relapses may occur.
Conclusion: C. Difficile enteritis is a potential cause of high ileostomy output
and should be in the differential diagnosis. Treatment with oral metronida-
zole or vancomycin is generally effective.
685
An Undiagnosed Case of Cholecystitis and Salmonella Vertebral
Osteomyelitis: From Gut to Bone
Constantinos P. Anastassiades, MD, Abinash Virk, MD∗. Department of
Medicine, Mayo Clinic College of Medicine, Rochester, MN.
A 66-year-old female was transferred to our institution complaining of a
3-month history of back pain, left leg numbness and weakness. She had
initially been diagnosed with sciatica and received a steroid injection in her
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left buttock. Her symptoms got progressively worse. During a local work-up,
she had also been diagnosed with a urinary tract infection (UTI) and treated
with a 7-day course of trimethoprim/sulfamethoxazole.
Magnetic resonance imaging (MRI) of the spine was then performed at her
local facility and this showed a mass. The abnormal tissue was surgically
excised but the pathology report commented on the absence of malignancy
only. She continued to feel unwell and she was transferred to our institution,
where a new MRI of the lumbar spine showed a probable infectious process
in the L3 and L4 vertebral bodies with near-total collapse anteriorly.
New urine and blood cultures grew Gram negative bacilli. The same organism
was grown from a lumbar spine biopsy. All cultures eventually grew non-
typhoid Salmonella. It emerged that the diagnosis of UTI a month earlier
had been based on a urine culture growing Salmonella. CT of the abdomen
showed evidence of cholecystitis but no evidence of an abdominal aortic
aneurysm.
The patient denied any gastrointestinal symptoms. She and her husband
admitted to frequent ingestion of rare-cooked beef, though not poultry or
eggs. She underwent cholecystectomy and a number of neurosurgical and
orthopedic procedures. Gallbladder pathology revealed acute and chronic
cholecystitis with focal abscess formation. She required a prolonged hospi-
talization and was discharged home on intravenous antibiotics.
Salmonella vertebral osteomyelitis (SVO) primarily involves the lumbar
spine. The dominant features are fever and back pain. Diarrhea is uncom-
mon in SVO, although gastroenteritis is the most common clinical syndrome
associated with salmonella infection. Salmonella is frequently harbored in
the gallbladder. Blood cultures are positive in 48% of the SVO cases. The
condition requires long-term antibiotic management and some cases require
surgery. Infected abdominal aortic aneurysms are associated with high mor-
tality and need to be excluded in patients older than 50 years of age with
Salmonella bacteremia or evidence of deep organ infection. The presence of
Salmonella in the urine should not be treated as a UTI and should prompt
immediate work-up for bacteremia and other tissue involvement.
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Jejunal Ulcerations and Ascites as Presenting Manifestations of
Henoch-Schonlein Purpura
Suzanne K. Morrissey, MD, Katie Farah, MD∗. Division of
Gastroenterology, Allegheny General Hospital, Drexel University College
of Medicine, Pittsburgh, PA.
A 59-year-old man presented with a five day history of melena, hemateme-
sis and progressive abdominal distention. There was no prior history of
gastrointestinal bleeding. Physical exam was significant for mild abdominal
tenderness with shifting dullness. Rectal exam revealed melena. CT scan
of the abdomen and pelvis showed moderate ascites, patent mesenteric ves-
sels, normal liver morphology, and segmental jejunal wall thickening with
mild dilatation. Paracentesis revealed clear fluid with a serum-ascites al-
bumin gradient of 0.9 consistent with a non-portal hypertensive etiology.
Enteroscopy was significant for multiple cratered ulcers extending from the
proximal to mid-jejunum with stigmata of recent bleeding. Biopsies of the je-
junal lesions were consistent with mucosal ulceration. Intravenous steroids
were initiated for a presumptive diagnosis of Crohn’s disease. One week
later, the patient developed acute renal failure and a purpuric rash involving
the hands, bilateral lower extremities and buttocks. Skin biopsy showed a
leukocytoclastic vasculitis. Immunofluorescence stain was positive for IgA.
A diagnosis of Henoch-Schonlein Purpura (HSP) was made. There was mild
improvement in renal function and complete resolution of rash with no sub-
sequent episodes of gastrointestinal bleeding. The patient was discharged to
home on azathioprine therapy and has been asymptomatic to date.
HSP is an IgA-mediated vasculitis characterized by gastrointestinal tract,
kidney, skin and joint involvement. Gastrointestinal symptoms may precede
cutaneous findings up to 40% of the time. Since the incidence of HSP in the
adult population is rare, there may be a delay in diagnosis especially in the
absence of skin manifestations. Typical and well-described endoscopic man-
ifestations of HSP include duodenal erosions, ulcerations and hemorrhages.
There are very few reported cases of jejunal ulcerations as the cause of gas-
trointestinal bleeding. To date, there have been only five reports of ascites
as a manifestation of HSP in the adult population. Recognition of diffuse
jejunal ulcerations, with or without ascites, should raise clinical suspicion
for HSP so that appropriate treatment can be initiated in a timely fashion.
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Endoscopic Ultrasound (EUS) Findings in Tropical Pancreatitis
Laith H. Jamil, MD, Amulya Konda, MD, Steven Fox, MD, Gehad Ghaith,
MD, Veslav Stecevic, MD∗. GI, William Beaumont Hospital, Royal Oak,
MI.
Introduction: Tropical Pancreatitis (TP) is an idiopathic Chronic Pancre-
atitis (CP) unique to nonindustrialized countries. Large intraductal calculi,
marked dilatation of the main pancreatic duct, and gland atrophy, charac-
terize it. This is the first report describing Endoscopic Ultrasound (EUS)
features.
Case: A 26 YOF recently arrived from South India, presented with epigastric
pain radiating to the back, nausea and vomiting of 5 days duration. She has
had similar episodes since age 15. They usually resolve within 4–5 days
with restricting diet, antiemetics and painkillers. Previous EGD showed
doudenitis and she was treated for H Pylori. There was minimal ETOH use
and no family history of a similar condition or of GI malignancies. Lipase
was 87. Triglyceride levels were normal. CT scan of the abdomen showed
an ill-defined pancreas with surrounding inflammatory changes, a dilated
pancreatic duct, and multiple calcifications. EUS of the pancreas showed
parenchymal calcifications, hyperechoic strands, hyperechoic foci, lobular-
ity, and cysts. The pancreatic duct was dilated, up to 6 mm, with hyperechoic
walls, visible side branches, with a tortuous/ecstatic appearance.
Discussion: EUS is increasingly being utilized to diagnose diseases of the
pancreas; including CP. EUS features of CP are echogenic foci, strands,
lobularity, cysts, stones, duct dilatation, duct irregularity, hyperechoic duct
margins, and visible side branches. These features were all present in our
patient, consistent with CP.
TP, first described by Geevarghese, as a disease with pain during childhood,
diabetes during puberty, and with death occurring at the prime of life. It
initially was thought to be restricted to areas within 30◦ of latitude from
the equator. More than 90% of patients have the illness before 40 years. The
overall prevalence in an endemic area is 1 in 500 to 1 in 800 in Southern India.
Endocrine insufficiency is an inevitable consequence. The pathophysiology
of TP is unknown. Genetic mutations of the SPINK1 gene, particularly the
N34S missense mutation, are seen in up to 50%.
Conclusion: EUS features of TP are similar to those of CP, in our patient,
who demonstrated all 9 features.[figure1]
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Small Bowel Metastsis from Lung Cancer
Mario Tapia, Bielose C. Konwe, Margie Cornwell, Muhammed G.
Nathani∗. Internal Medicine, UTHSCSA, Regional Academic Health
Center, Harlingen, TX.
Introduction: Symptomatic small bowel metastasis from primary carci-
noma of the lung is considered a rare clinical entity. We report two distinct
clinical presentations of non-small-cell lung carcinoma with gastrointestinal
involvement.
Case 1: A 68 year old Hispanic male with a non-small-cell lung cancer pre-
sented to the ED with shortness of breath, fatigue, anorexia, emesis, and dark
stools. Physical examination revealed a pale elderly male, with epigastric
fullness and crepitations in the right lung field. Laboratory tests suggested
severe anemia with Hemoglobin level of 5.2 gm/dl. Upper endoscopy and
colonoscopy failed to identify the etiology of the anemia. CT scan suggested
a filling defect in the jejunum with suspected intussusception, requiring par-
tial small bowel resection. Histopathology confirmed malignancy consistent
with metastasis from the primary non-small-cell lung carcinoma. He deteri-
orated clinically with worsening metastasis and died within a few weeks.
Case 2: A 74 year old Hispanic male presented with left knee pain. He
had anorexia, weight loss, fatigue and occasional dark stools. Physical ex-
amination revealed a pale elderly male with tachycardia. His hemoglobin
was 7.7 gm/dl with fecal occult blood positive. Endoscopies revealed raised,
friable, vascular, superficially ulcerated mucosal lesions in the stomach, je-
junum, cecum and rectum. CT scan of the chest was noted for 6 cm size
right lower lobe lung mass. There was evidence of extensive bone metasta-
sis. Histopathology report from gastrointestinal lesions revealed large cell
poorly differentiated carcinoma. He opted for hospice care and died within
a few weeks
Discussion: Cancers of the lung often disseminate early, but small bowel
metastasis of a primary lung carcinoma is rarely encountered, with a re-
ported incidence of 0.5% in one series. Large cell carcinoma is the most
common histopathologic type. Usual presentation includes intestinal ob-
struction, perforation and rarely bleeding and peritonitis. Surgical resection
may be pursued in patients with excellent primary tumor control in the ab-
sence of concurrent other metastatic involvement. The prognosis for patients
with small bowel metastasis of non-small-cell lung carcinoma is poor with
reported survival ranging from weeks to months .
689
Medical Management of Jejunal Diverticulitis
Valerie J. Rader, MD, Noel Fajardo, MD, John A. Schaffner, MD∗. Internal
Medicine, Mayo Clinic School of Graduate Medical Education, Rochester,
MN and Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Case Report: A 79 year-old woman with cardiac and renal disease was
transferred to St. Marys Hospital for intra-abdominal abscesses. She com-
plained of left lower quadrant abdominal pain and two weeks of fever and
chills. Abdominal CT demonstrated two abscesses, one 5 cm, interspersed
between small bowel loops and anterior to the left kidney and a second,
3.5 cm, anterior to the descending colon at the level of the pelvic brim.
On transfer, she was afebrile with normal bowel sounds. She was tender in
the left periumbilical region without rebound or guarding. Rectal exam was
normal. Leukocyte count was normal. Hemoglobin was 9.6 g/dL.
CT of the abdomen repeated three days later showed multiple jejunal diver-
ticula with two abscesses in the jejunal mesentery. The superior collection
had decreased in size and the inferior collection was stable, both measuring
4 cm.
She completed a 14-day course of metronidazole and levofloxacin. Twenty-
one days later, she was asymptomatic and CT of the abdomen revealed
resolution of the superior abscess with a thin-walled diverticulum. The infe-
rior abscess was markedly decreased in size with residual diverticular wall
thickening and adjacent soft tissue infiltration. At one month, the patient re-
mained asymptomatic and follow-up CT abdomen at eight months revealed
no evidence of abscess.
Discussion: Jejunal diverticulosis has been reported to be found in 4.6% of
autopsy specimens1. Patients can present with chronic complaints or acute
complications including diverticulitis with perforation and abscess forma-
tion. Acute jejunal diverticulitis occurs in up to 6.4% of patients with diver-
ticulosis2. Most cases of jejunal diverticulitis have been treated with surgical
resection2, but there are a limited number of reported cases of patients with
abscess treated non-surgically3. In our patient, who presented with diver-
ticulitis with two areas of abscess formation, resolution of symptoms and
CT findings occurred with conservative treatment alone. Based on the out-
come of our patient, surgery may be avoided when jejunal diverticulitis with
abscess is detected early with institution of conservative measures. 1Noer
T. Non-Meckelian Diverticula of the Small Bowel. Acta Chir Scand 1960;
120: 175–179. 2Palder SB, Frey CB. Jejunal Diverticulosis. Arch Surg 1988;
123: 889–894. 3Novak JS, Tobias J, Barkin JS. Nonsurgical Management
of Acute Jejunal Diverticulitis: A Review. Am J Gastroenterol 1997; 92:
1929–1931.
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Mystery in the Desert
Shayan Alam, MD, Jonathan A. Leighton, MD∗, Jerry Smilack, MD,
Thomas Colby, MD. Internal Medicine, Mayo Clinic Arizona, Scottsdale,
AZ; Gastroenterology, Mayo Clinic Arizona, Scottsdale, AZ; Infectious
Disease, Mayo Clinic Arizona, Scottsdale, AZ and Pathology, Mayo Clinic
Arizona, Scottsdale, AZ.
A 74 yo caucasian male from Phoenix, AZ presents with one month of ab-
dominal pain, diarrhea and anorexia. He was recently evaluated at the VA
and thought to have a stricture from diverticulitis. His symptoms continued
and he presented to Mayo for further evaluation. He had a history of hyper-
tension and diabetes and continued to smoke. His family history was non-
contributory. His vital signs were stable and his only physical exam finding
was a palpable mass in the abdomen. His labs showed anemia, thrombo-
cytosis and hyperglycemia. His initial CT scan showed an 8 cm infiltrating
mass in the sigmoid colon. The differential diagnosis included neoplasm,
lymphoma or abcess. A colonoscopy was then attempted but could not be
completed secondary to a 5 mm stricture. The patient was then referred
to surgery. The lesion was removed successfully. The lesion was adherent
to the jejunum, spleen and abdominal side wall. The pathology from the
specimen showed a palisading pattern of histiocytes with a center of hyphal
elements surrounded by a ring of immunoglobulins. This pattern is known
as the Splendore-Hoeppli phenomenon and is highly suggestive of an infec-
tion from Basidiobolus ranarum, an environmental saporophyte normally
found in subtropical climates. It normally causes subcutaneous infection
and visceral involvement is rare. However, there have been 15 cases of gas-
trointestinal basidiobolus diagnosed in Arizona since 1994. The diagnosis
usually requires culture, however it can be made by serology or histology.
Treatment requires surgical resection and prolonged antifungal therapy. This
patient required three months of therapy with itraconazole and did well in
follow up.
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Infectious Colitis Mimicking Crohn’s Disease
Thomas Park, MD, Ashok N. Shah, MD∗. Division of Gastroenterology
and Hepatology, University of Rochester, Rochester, NY.
There have been rare case reports of infectious diarrhea mimicking Crohn’s
disease. We present two cases of infectious colitis in which the endoscopic
and radiographic features, and in one case, biopsies, mimic Crohn’s disease.
Case #1: A 46 year-old woman presented with 4 days of bloody diarrhea up
to 10 times a day and lower abdominal cramps, nausea, and vomiting. She
was afebrile and had mild tenderness in her right upper abdomen. She had
a normal WBC and a HCT of 27. Multiple stool cultures, including for C.
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difficile, and ova and parasite tests were negative. CT scan showed diffuse
colitis from the sigmoid to the cecum with pericolonic infiltrative changes.
Colonoscopy revealed patchy erythema, edema, and ulcers in the cecum and
the ascending colon. She was started on mesalamine and IV steroids, as well
as antibiotics. Colon biopsies revealed just mucosal erosions. Viral stool
cultures were ordered, and were positive for adenovirus.[figure1]
Case #2: A 34 year-old man presented with 6 days of nausea, vomiting,
and diarrhea up to 15 times a day, with fevers and chills. WBC was normal,
fecal leukocytes were >20, and stool cultures were negative. Abdominal
CT revealed thickening and stranding around the right colon and terminal
ileum. Colonoscopy revealed edema, erythema, and petechiae in a patchy
distribution from the rectum to the cecum. A small superficial ulcer was
seen in the rectum. The patient was started on mesalamine and antibiotics.
Biopsies revealed active, chronic inflammation in the terminal ileum and
colon, with glandular architectural distortion. Blood cultures were positive
for Salmonella.[figure2]
Discussion: These two cases highlight the rare, but very real, possibilities
of infectious colitis mimicking Crohn’s disease. These would seem to favor
delaying steroids and other aggressive options considered in the “top-down”
approach until infectious etiologies are ruled out.
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Isolated Elevation of Serum Lipase Caused by a Sub-Centimeter
Neuroendocrine Tumor Diagnosed by EUS-FNA
Maria Lufrano, DO, John Costable, MD, Ian Storch, DO∗.
Gastroenterology, North Shore University Hospital, Manhasset, NY.
Introduction: Elevations of serum lipase can be seen in pancreatitis and less
commonly in cholecystitis, bowel ischemia, renal insufficiency, hepatic dys-
function, alcohol abuse, intracranial events, sarcoidosis, macro-lipasemia,
IBD and prolonged ICU stay. We describe a patient with a prior history of
acute pancreatitis and a chronically elevated serum lipase caused by a sub-
centimeter pancreatic neuroendocrine tumor (P-NET) diagnosed by EUS-
FNA.
Case Summary: A sixty–three year old black female with a past medical
history significant for hypertension and glaucoma presented after a recent
hospitalization for an acute bout of pancreatitis with subsequent persistence
of abdominal pain, bloating and a chronically elevated lipase. The patient
denied recent history of blunt trauma, weight loss, nausea, vomiting or diar-
rhea. Physical exam was unremarkable. Laboratory evaluation revealed an
elevated serum lipase level of 517 U/L (4× ULN) while amylase, complete
blood count and comprehensive metabolic panel were within normal limits.
An abdominal ultrasound, computerized tomography with pancreatic pro-
tocol and magnetic resonance imaging with cholangiopancreatography, and
chest x-ray were normal. Repeated lipase levels over the subsequent three
months confirmed persistent elevation ranging from 3–5 X ULN. An endo-
scopic ultrasound was performed which revealed a 5 mm, round, hypoechoic
mass in the neck of the pancreas. The main pancreatic duct was within nor-
mal limits and not compressed by the lesion. Fine needle aspiration of the
mass was performed with cytology favoring a neuroendocrine tumor versus
well-differentiated adenocarcinoma. This diagnosis was confirmed by a sec-
ond pathologist. Chromogranin A, insulin, VIP and glucogon levels as well
as an octreotide scan were all within normal limits.
Conclusion: Elevated serum lipase in a patient without radiographic or clin-
ical signs of pancreatitis can be a diagnostic dilemma. Lipase levels above
three to five times the upper limit of normal are more specific and suggest a
pancreatic source. Our patient had a history of pancreatitis and a persistent
lipase of four to five times the upper limit of normal which was likely caused
by tumor compression of a small pancreatic side branch duct. The lesion
was beyond the sensitivity of CT or MRI and visualized only by endoscopic
ultrasound. Our case suggests that EUS should be considered in patients
with an isolated, elevated level of lipase when no other cause is identified.
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Uncommon Presentation of PTLD in the Esophagus
Syed Abbas Fehmi, MD, Sameer Saini, MD, Wiliam Chey, MD∗.
Gastroenterology, University of Michigan, Ann Arbor, MI.
75 year-old man with diffuse B-cell lymphoma was found to have new
thickening of mid-esophagus on a CT. Questioning revealed progressive
solid/liquid dysphagia. GI was consulted.
Patient underwent kidney transplant 1 yr ago. Approx. 5 mths later, he pre-
sented with abd. pain and weight loss. CT revealed 2 mesenteric lesions
and multiple small nodules in liver, spleen, and lung bases. Lung biopsy
revealed diffuse B-cell lymphoma, EBV+. Patient was diagnosed with post-
transplant lymphoproliferative disorder (PTLD). Immunosuppressive med-
ications were tapered.
On day of admission, pt. developed acute mental status changes. Imaging
revealed progression of brain lesions. Chest CT revealed new thickening of
mid-esophagus prompting GI consultation.
Upper endoscopy showed a lt. 4 × 3 cm ulcerated mass in middle third
of esophagus. Fig. 1. Path showed necrotic debris, bacteria, and inflamma-
tory cells. Sirolimus was discontinued and repeat endoscopy planned. 6 wks
later, CT chest showed 39 × 31 mm necrotic mass in the middle medi-
astinum. Patient developed worsening dysphagia, odynophagia and caugh-
ing. Ba esophagram showed extraluminal flow of contrast in mid third of
esophagus. This cavity measured 4 × 1 × 1.8 cm.
Upper endoscopy was repeated. Fig. 1.
Pathology. Fig. 2. Ulcer with subadjacent B-cell neoplasm consistent with
PTLD. Stains for CD20 and CD3 confirmatory.
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PEG tube was placed for nutritional support. Rituximab was considered,
however given overall poor prognosis the patient opted for hospice care.
PTLD should always be suspected in patients with solid organ transplanta-
tion. GI tract involvement provides an opportunity for endoscopic diagnosis.
The unique aspect of this case is the esophageal presentation after kidney
transplant in an adult. Most case reports in literature are of pediatric patients
with liver, intestinal, lung or heart transplantation with PTLD affecting the
colon, small bowel or stomach.[figure1][figure2]
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Fusobacterium Nucleatum: An Uncommon Cause of Pyogenic Liver
Abscess
Amil P. Patel, MD∗, Jesse Jacob, MD, Mohammad Wehbi, MD, Kamil
Obideen, MD. Department of Gastroenterology, Emory University,
Atlanta, GA.
A 35 year old previously healthy African American male presented with re-
current fevers, chills, and diffuse abdominal pain for 3 weeks. He denied any
nausea, vomiting, diarrhea, or recent travel. Physical exam was significant
for a temperature of 38.7 C, mild epigastric and right upper quadrant ten-
derness without rebound or guarding, and a normal liver span. Laboratory
data indicated a leukocyte count of 13,700 and minimally elevated alkaline
phosphatase. CT scan of the abdomen revealed a 9 cm × 5.1 cm abscess
in the right hepatic lobe. Entamoeba histolytica serologies, blood cultures,
and a HIV test were all negative. The patient underwent CT guided percu-
taneous aspiration of the abscess with drainage placement. He was started
empirically on ampicillin/sulbactam awaiting culture results, which even-
tually grew Fusobacterium nucleatum. Repeat CT scans revealed that the
abscess was diminishing in size. He was subsequently discharged on amox-
icillin/clavulanate to complete 6 weeks of therapy. Additional history later
revealed that he had a routine dental cleaning 2 weeks prior to initiation of
his symptoms.
The majority of pyogenic liver abscesses are the result of contiguous spread
from infections in the biliary tree or peritoneal cavity while a much smaller
number involve hematogenous seeding of the liver. The most common
pathogens are mixed facultative and anaerobic gastrointestinal flora with
E. coli and Klebsiella pneumoniae being the most frequently isolated. Fu-
sobacterium nucleatum is an anaerobic Gram negative rod that is part of the
oral flora and typically causes only dental and upper respiratory tract infec-
tions. It is not commonly associated with hepatic abscesses. In this case, the
patient likely had a transient bacteremia from his recent dental cleaning that
seeded the liver. This case illustrates the importance not only of obtaining a
thorough history but also the importance of covering for anaerobic bacteria
in intraabdominal abscesses. Although Fusobacterium nucleatum is a rare
cause of hepatic abscesses, it and other anaerobes should be considered in
patients who have undergone recent dental work.
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Extensive Portal Venous Gas and Pneumatosis Intestinalis in the
Absence of Small Bowel Ischemia or Infarction
Pavan K. Pinnamaneni, MD, Parupudi V.J. Sriram, MD∗, David Hodges,
MD, Ari Halldorsson, MD. General Surgery, Texas Tech Univ Health Sci
Center, Lubbock, TX and Internal Medicine (Gastroenterology), Texas Tech
Univ Health Sci Center, Lubbock, TX.
Portal venous gas and pneumatosis intestinalis are usually associated with
transmural small bowel ishemia or infarction and are generally fatal. We
present here a case with negative laparotomy and successful outcome.
A 66 y male with multiple co-morbidities like hypertension, diabetes, coro-
nary artery disease, advanced COPD, who was a recent hospital discharge
following bronchopneumonia and respiratory failure, presented to the ER
with sudden severe abdominal pain. On clinical examination he had frank
signs of peritonitis. He had leukocytosis with bandemia (21%). An abdom-
inal CT showed extensive pneumatosis intestinalis and portal venous gas
(Fig. 1A–C). He was resuscitated and taken up for emergency laparotomy.
Per op there was no evidence of any bowel ischemia, infarction or perforation.
Diffuse pneumatosis was noted throughout the small intestine. Mesenteric
pulses were well palpable. Colon, Liver and gall bladder were normal. He
was managed in ICU, initially with TPN and 2 weeks later he was initiated on
tube feeding. He gradually recovered and was discharged. Repeat CT scan
showed complete resolution of portal venous gas and pneumatosis (Fig. 1D).
Portal venous gas and pneumatosis intestinalis generally denote mesenteric
ischemia with grave prognosis. Patients with negative laparotomy are likely
to recover uneventfully.[figure1]
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Massive Pleural Effusion as Initial Presentation of Advanced Liver
Cirrhosis
Michelle Rivera, Jahaira Serrano, Yohanna de Jesus, Victor L. Carlo∗.
Internal Medicine, Division of Gastroenterology, UPR Medical Science
Campus, Shool of Medicine, San Juan, Puerto Rico.
Hepatic hydrothorax is seen in 5–10% of patients diagnosed with liver cirrho-
sis, and is rarely present in the absence of ascites. The diagnosis is considered
in the presence of a pleural effusion in a cirrhotic patient without pulmonary
or cardiac disease.
A 24-year-old woman without history of prior liver disease developed a
massive exudative right pleural effusion that required a tube thoracostomy
for a suspected pneumonic process with associated effusion. The patient re-
quired a second intervention and chest tube placement. An extensive work up
failed to find the etiology of the effusion, but revealed altered liver function
tests, increased CA-125 and Ca 19-9 tumor markers and a positive hepatitis
C virus antibody with ongoing viral replication. Imaging revealed hepato-
splenomegaly without ascites. Fluid analysis evolved from an exudate to a
transudate and alerted to the possibility of a hepatic hydrothorax. Rapid tran-
sit of fluid from the abdominal cavity to the right lung was demonstrated using
Tc-99 sulfur colloid. An Enterococcus fecalis was recovered from the fluid.
Salt restriction and aggressive diuresis decreased the thoracostomy output,
but she developed massive ascites once the tube was removed suggesting
closure of the hemi-diaphragm porus connections. Ascites was refractory
to medical treatment. A Transjugular intrahepatic porto-systemic shunt was
successful in decreasing portal vein pressure from 16 to 6 mm Hg, and the
patient is undergoing evaluation for a liver transplant.
A massive pleural effusion led to the diagnosis of chronic liver disease as-
sociated to hepatitis C in this patient. Hepatic hydrothorax from porous
diaphragm syndrome was a therapeutic challenge in this young female with
no prior history of liver disease or ascites. Radiotracer study confirmed a
peritoneal origin of the fluid. Spontaneous bacterial empyema has been re-
ported and could explain the initial fluid findings. In addition, tumor markers
CA 19-9, CA-125, which have been reported increased with liver fibrosis,
were helpful in suggesting the presence of cirrhosis or advanced fibrosis
accounting for her clinical presentation.
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Severe Copper Deficiency in a Patient with History of Gastric Bypass
Leading to CNS Demyelinaton, Severe Ataxia and Peripheral
Neuropathy
Motaz K. Al-Hafnawi, MD, Jawaid Shaw, MD, Kevin Casey, MD∗.
Department of Medicine, Gastoenterology Division, Rochester General
Hospital, Rochester, NY.
Copper is an essential micronutrient necessary for the hematologic and neu-
rologic systems. Acquired copper deficiency in humans has been described,
causing a syndrome similar to the subacute combined degeneration of vi-
tamin B12 deficiency. Copper deficiency is being increasingly recognized
in adult populations due to various causes including high zinc levels, cop-
per chelating agents and after gastric bypass surgery. We present a case
patient with sever hypocupremia leading to profound neurological symp-
toms to stress the importance of this clinical entity and its early diagnosis
and treatment. We present a 52 year-old white male who had Roux-en-Y
gastric bypass surgery. He was maintained on multivitamin supplements in-
cluding Vitamin B12, iron and zinc. Fifteen years after his gastric bypass
he started having worsening sensory ataxia and worsening paresthesias of
the lower extremities, and was hospitalized for severe weakness in his lower
extremities. On admission his nutritional evaluation revealed normal serum
levels for Vitamin B12, zinc and iron. However he was found to have an ex-
tremely low serum copper level. MRI of the spine showed T-2 hyperintensity
within the dorsal spinal cord from C2 through C5 which has been described
in patients with copper deficiency. The patient was started on copper sup-
plements, showed significant clinical improvement, and was maintained on
copper supplements after his discharge. Copper deficiency is a rare compli-
cation following gastric bypass surgery. Copper is primarily absorbed from
stomach and proximal small bowel. It is not clear why copper deficiency oc-
curs in some but not all patients after gastric surgery. Iron and zinc have been
described to inhibit copper uptake in the proximal bowel. Zinc and copper
compete for absorption in the digestive tract so that a diet that is excessive in
one of these minerals may result in a deficiency in the other. Bariatric proce-
dures such as gastric bypass surgery result in a similar functional anatomy
of the proximal gut and may place more patients at increased risk of copper
deficiency. Early recognition and therapy with copper supplements may lead
to a decrease in both neurologic and other known hematologic consequences
of hypocupremia. Oral copper should to be taken in a different time prefer-
ably earlier to the oral multivitamins or oral zinc to prevent the chelating
effect of zinc on copper.
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Benign Small Bowel Thickening with Lymphadenopathy: A
Manifestation of Celiac Disease
Jerry Martel, MD, MPH, Daniel A. Sussman, MD, Robert I. Goldberg,
MD, Jamie S. Barkin, MD∗. Division of Gastroenterology, University of
Miami Miller School of Medicine, Miami, FL and Division of
Gastroenterology, Mount Sinai Medical Center, Miami Beach, FL.
Introduction: Celiac disease (CD) is the most common inheritable GI dis-
order with an overall prevalence of 1:250. Small bowel lymphoma with lym-
phadenopathy is a well-documented entity complicating the clinical course
of patients with CD. This accounts for one-half to two-thirds of malignancies
associated with CD. However, small bowel thickening with lymphadenopa-
thy does not always represent malignancy.
Aim: The aim of these case reports is to present small bowel thickening and
lymphadenopathy on CT scan as an unusual part of the spectrum of CD.
Table 1.
Patient Information Patient A Patient B
Age, Sex,
Presentation
40 y/o woman with
abdominal pain and
diarrhea
76 y/o man with weight
loss and diarrhea
CT Scan Reported
Findings
Multiple prominent
lymph nodes in left
abdominal
mesentery; Small
bowel thickening
with partial transient
intussusception
Mild mesenteric
lymphadenopathy
and thickening of a
portion of the small
bowel
Diagnostic Modality Diagnostic Laparoscopy Enteroscopy & Biopsy
Biopsy Results Reactive lymphoid
hyperplasia with
small intestinal
mucosa with mild
villous blunting and
striking
intraepithelial
lymphocytosis
Intestinal mucosa with
complete blunting of
villi with increased
surface epithelial
lymphocytes
consistent with sprue
Positive Serologies IgA TTG IgA antiendomysial Ab
Management Gluten-free Diet Gluten-free diet &
Prednisone
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Discussion: Only one prior case is reported in the literature presenting with
small bowel thickening and lymphadenopathy of benign etiology in a pa-
tient with CD. We report two patients who presented with CT findings of
small bowel thickening and mesenteric lymphadenopathy. (Table A). The
patients have CD confirmed by biopsy and/or serologies. The benign nature
of thickening and lymphadenopathy was confirmed by laparoscopic biopsy
in one case and endoscopic biopsy with clinical and imaging follow-up in
the other. Upon initiation of celiac treatment, the patients had clinical im-
provement, reversion of their small bowel thickening, and regression of their
lymphadenopathy.
Conclusion: Small bowel thickening and mesenteric lymphadenopathy may
be the initial finding of CD and may be of a benign etiology.
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A Case of Metastatic Adenocarcinoma Presenting with Fulminant
Hepatic Failure and Elevated Alpha Fetoprotein Level
Nirmala M. Sivaprakasapillai, MD, Nabil Fayad, MD, Louis Chaptini,
MD∗, Christopher Deitch, MD, Joseph Depenbusch, MD.
Gastroenterology, Cooper University Hospital, Camden, NJ and
Pathology, St. Francis Hospital, Wilmington, DE.
Fulminant hepatic failure (FHF) most commonly occurs due to viral hepatitis
or drug toxicity and rarely occurs as the initial presentation of malignancy. We
report the case of a patient without prior history of malignancy who presented
with FHF, was found to have metastatic adenocarcinoma and interestingly,
had a very high alpha fetoprotein (AFP) level.
A 59 year old woman was admitted with progressive jaundice, abdominal
pain, ascites, and lower extremity edema. She denied any new medications,
alcohol or drug use. Laboratory data revealed alkaline phosphatase of 1279
IU/L, alanine aminotransferase of 88 IU/L, aspartate aminotransferase of
280 IU/L, total bilirubin 5.4 mg/dl, low albumin, and prolonged prothrom-
bin time. No etiology for FHF was apparent on intial evaluation including
ultrasound.
Serum AFP and carcinoembryonic antigen (CEA) were elevated at 1439
ng/ml and 9.3 ng/ml respectively. Liver biopsy revealed moderately differ-
entiated adenocarcinoma arising from the gastrointestinal tract, most likely
of colonic origin. [figure1]Unenhanced CT scan at the time of biopsy re-
vealed metastatic disease.[figure2]Unfortunately, the patient’s condition de-
teriorated and she died 9 days after admission.
A review of the literature revealed initial presentation of FHF due to
metastatic cancer to be rare and reported cases were primarily diagnosed at
autopsy. The clinical presentation and laboratory findings are non-specific.
Although primarily used to aid in the diagnosis of hepatocellular carcino-
mas and yolk sac tumors, elevated AFP levels have been rarely reported in
gastrointestinal malignancies. Mortality rates are high and treatment options
are limited, especially since liver transplantation is contraindicated.
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Ischemic Hepatitis Arising in the Setting of Hitherto Undiagnosed
Cirrhosis Secondary to Hemochromatosis
Alastair D. Smith, MB, ChB∗, Nadia S. Sanford, MD, Carla W. Brady, MD,
MHS. Medicine, Duke University, Durham, NC.
Ischemic hepatitis (IH) is characterized by an abrupt, marked but reversible
increase in serum aminotransferase concentration(s) arising within a clinical
setting of circulatory failure and systolic hypotension, in which other possible
causes of hepatocellular necrosis can be excluded reliably. The histological
hallmarks are centrilobular hepatocyte necrosis, central vein congestion and
distortion of adjacent hepatic sinusoids. Prompt recovery may follow but
the overall course is governed by underlying disease. It is unclear if the
presence of end-stage liver disease (ESLD), whether as the result of hepatic
congestion or otherwise, predisposes patients to develop IH more readily.
A 45 year-old man with non-ischemic cardiomyopathy was transferred for
management of cardiogenic shock. He was intubated, and had an intra-aortic
balloon pump in situ. Despite inotropic support he remained hypotensive
(mean BP: 82/46 mm Hg). Physical examination demonstrated no external
evidence of ESLD. Laboratory data were as follows: aspartate aminotrans-
ferase 1860 IU/L (normal range [NR]: 10–60), alanine aminotransferase
1494 IU/L (NR: 10–60), prothrombin time 23.8 s (11.1–13.1) and total serum
bilirubin 2.3 mg% (NR: 0.2–1.2). Acute hepatitis A, B and C virus infec-
tions were excluded on the basis of appropriate serologic testing. His antin-
uclear antibody titer was weakly positive (1:40). The serum ceruloplasmin
concentration was 39 mg% (NR: 20–60). His serum ferritin concentration
was 7774 ng/mL (NR: 30–300), and the iron saturation 68% (NR: 14–50).
Liver histology revealed cirrhosis (Masson trichome stain), and grade 4/4
iron overload involving hepatocytes, Kupffer cells and the biliary epithelium
(Prussian blue iron stain). In some centrilobular areas prior hepatocyte loss
consistent with ischemic injury was evident, but not chronic passive con-
gestion. Testing for the commonest mutations in the hemochromatosis (HC)
gene was negative. Despite improvement in liver tests with further support-
ive care, he developed renal dysfunction. Continued systolic hypotension
precluded hemodialysis, and the patient died 21 days after transfer from
complications of ESLD.
This man’s clinical and laboratory picture at the time of transfer was entirely
consistent with IH. However, cirrhosis secondary to HC was the dominant
histologic abnormality, almost totally obscuring changes of IH. The diagno-
sis of HC, although unexpected, was important so as to avoid unnecessary
efforts at cardiac transplant evaluation.
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Unusual Complication of a Colonic Interposition with an Unusual
Solution
Paramvir Singh, MD, Andres Gelrud, MD∗. Digestive Diseases, University
of Cincinnati, Cincinnati, OH.
A 30 year old woman underwent an esophagectomy with colonic interpo-
sition for management of lye induced esophageal stricture. Unfortunately,
the surgery was complicated by recalcitrant stricture at both the esophago-
colonic and colo-gastric anastomoses. These esophageal strictures have been
managed with multiple dilations (approximately once a month) using a
Savary-Gilliard systems as well as needle knife stricturoplasty and injec-
tion of steroids into the lesion. However, the stricture at the colo-gastric
anastomosis persisted. This was most recently managed with placement of a
12 cm long by 25 mm wide Polyflex stent (Boston Scientific, Natick MA) to
achieve tissue re-modeling at the anastomosis site. Prior to assembly of the
stent, a non-absorbable suture was affixed through the proximal aspect of the
stent. This was anchored to the colonic mucosa proximal to the anastomo-
sis using a resolution clip (Boston Scientific, Natick MA) to prevent early
distal migration. Two weeks later the Polyflex stent migrated distally into
the stomach. This was extracted using a rat-toothed forceps and standard
endoscopy. Since the stent was extracted nine months ago she has done well
and not required any more dilation.
Discussion: Approximately 5000 caustic ingestions occur annually in the
United States and is the leading cause of esophageal strictures in the pe-
diatric population. Urgent upper endoscopy is recommended to assess the
degree of mucosal injury which has a bearing on immediate management
as well as prognosis. Up to one-third of patients develop esophageal stric-
tures usually in those with severe mucosal injury. Although management
of caustic strictures usually requires multiple sessions of esophageal dila-
tions, temporary placement of self expanding plastic stents (SEPS) has also
been successful in case series. In patients with refractory esophageal stric-
tures, esophagectomy with colonic interposition may be required. To our
knowledge this is the first case of a Polyflex stent placement with success-
ful resolution of a colo-gastric anastomotic stricture. VIDEO and IMAGES
available for presentation.
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Pancreatic Cysts in a Patient with Von Hippel-Lindau Disease Causing
Common Bile Duct Obstruction
Michael J. Viksjo, MD, Robert J. Bierwirth, MD, M.J. Sterling, MD∗.
Gastroenterology, UMDNJ New Jersey Medical School, Newark, NJ.
Von Hippel-Lindau Disease (VHL) is characterized by the formation of mul-
tiple vascular tumors (primarily in the CNS) in response to the uninhibited
action of hypoxia inducible factor (HIF). Normally an adaptive response to
ischemia, HIF is regulated by the VHL protein. In individuals with muta-
tions in both genes coding for the VHL protein, there is unregulated action
of HIF with subsequent angiogenesis and tumor formation. Among other
complications of VHL are pancreatic tumors and cysts. Though pancreatic
lesions reportedly occur in up to 77% of VHL patients, symptoms are rare.
We present a patient with VHL who developed CBD compression and ob-
structive jaundice requiring ERCP and stent placement due to diffuse cystic
involvement of the pancreas.
Case: A 37 yo woman with no previous history presented to another facility
with ataxia, dysphagia and headache. After a CT scan revealed two vascular
cerebellar lesions, consistent with hemangioblastomas, the patient was trans-
ferred to our institution for arterial embolization. Her stay was prolonged
by post surgical complications. While recovering, she developed abdominal
pain and cholestatic jaundice. Abdominal ultrasonography showed intra- and
extra-hepatic biliary ductal dilation, a CBD diameter of 13 mm and multiple
cystic lesions in the pancreas. The patient developed fever and leukocytosis,
and then underwent an ERCP. The cholangiogram revealed a distal CBD
stricture, with obtuse angles suggestive of extrinsic bile duct compression.
Brushings of the stricture for histology revealed degenerative bile duct cells
and no evidence of malignancy. The stricture was managed with a graduated
dilating catheter and a 10 fr stent was placed, which resulted in rapid endo-
scopically apparent drainage of the biliary tree. The patient’s symptoms and
liver tests improved and she was discharged to a rehab facility.
Comment: Pancreatic lesions can be common in VHL (depending on the
family and genetic mutation studied). The most common lesions found in
VHL are simple cysts, serous cystadenomas, and neuroendocrine tumors,
but adenocarcinoma, metastatic renal carcinoma, and hemangiomas have
all been reported. While early satiety and pain from pancreatic cysts occur,
CBD obstruction from external compression by a pancreatic cyst in VHL is
extremely rare. In summary, this was an unusual case of VHL with pancreatic
cystic lesions causing extrinsic biliary obstruction, which was able to be
palliated with ERCP and stent placement.
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Spontaneous Choledochoduodenal Fistula in a 64 Year Old Lady with
a Remote History of Cholecystectomy
Savio John, Manju P. Paul, Juan D. Baltodano, Ronald D. Szyjkowski∗.
Medicine, SUNY Upstate Medical University, Syracuse, NY.
We report the case of a 64-year-old Hispanic lady with h/ocholecystectomy
10 years ago who presented with intermittent abdominal pain ever since
then. The abdominal pain was described as aching in quality, epigastric in
location and radiated up to the right shoulder and back. She has had nausea
but no vomiting, fevers or chills. Past medical history was significant for hy-
pertension, dyslipidemia and choledocholithiasis. Her medications included
ursodiol, esomeprazole, verapamil, amitriptyline, and aspirin. There was no
history of substance abuse or NSAID intake or duodenal ulcer. Physical
examination was within normal limits except for diffuse tenderness in the
epigastric region with no guarding or rebound tenderness. CT of the abdomen
showed a moderate amount of air within the intrahepatic biliary system with
mild dilation of the intrahepatic ducts with extension of the dilation to an
even more dilated extrahepatic duct, which measured 2.5 cm in its maxi-
mal AP dimension. Multiple foci of air consistent with pneumobilia were
identified. ERCP, occluded cholangiogram as well as EGD were done which
showed a fistula of 7–8 mm in diameter from the upper third of the main bile
duct into the duodenal bulb. The symptoms of the patient were attributed to
this fistula, as a result of ingested food going into her bile duct. Clipping
of the fistula via ERCP, though attempted, was unsuccessful and hence a
choledochojejunostomy with Roux-En-Y loop was performed. The post op-
erative course was uneventful with the patient reporting no symptoms in a
1 year follow-up period. Bilioenteric fistulae are usually incidental findings
and arise as a complication of chronic duodenal ulcer disease, cholelithiasis,
previous instrumentation to the biliary system or malignancy. The presence
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of a fistula by itself does not equate to necessity for surgery and treatment
of the uncomplicated fistula appears unnecessary.[figure1]
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Adult T-Cell Leukemia/Lymphoma with Terminal Ileal Involvement
Biju K. Alex, MD, Atoussa Farough, MD, Roshan M. Bashir, MD∗.
Department of Medicine, Washington Hospital Center, Washington, DC.
Introduction: Adult T-cell leukemia/lymphoma (ATLL) is an uncommon
highly aggressive non-hodgkins lymphoma. Secondary gastrointestional in-
volvement has been documented in literature, predominately the gastrum.
This rare case describes a pt with ATLL involving the terminal ileum with
endoscopy findings.
Case Presentation: The patient is a 64 yo old male from Ghana who was
admitted with symptoms of fatigue, weight loss and skin rash × 1 month. He
initially presented 2 wks ago as outpatient with diarrhea and vague abd pain
which resolved at the time of admission and denied any acute GI complaints
upon presentation. Pt had tender right supraclavicular and b/l nontender
cervical lymphadenopathy measured 2×2 cm. Abd exam was nontender,
nondistended with active bowel sounds. Liver span measured 40 cm and no
splenomegaly. On skin exam, there was pruritic scaly hyperkeratotic papules
involving the palms, soles, chest, abdomen, back with hyperpigmentation.
On laboratory examination he had hypercalcemia and renal insufficiency.
Western blot was positive for HTLV1. Skin, bone marrow and lymph node
biopsy revealed ATLL.
Endoscopy Findings: EGD showed a diffuse congested mucosa with ul-
cerative lesions in the proximal gastric and fundus. Colonoscopy revealed
diffuse mucosal erythema in the sigmoid and descending colon; terminal
ileum evaluation demonstrated polypoid mucosa with cobblestone appear-
ance. Biopsies of the colon, terminal ileum and gastric mucosa were all
diagnostic of ATLL.
Discussion: ATLL is associated with human T-cell lymphotrophic virus type
I (HTLV-I). HTLV-1 affects 10–20 million people worldwide and carries a
life time risk of 2–5% of developing ATLL. GI infiltration with gastrum is
more commonly involved with the frequency much lower for large and small
intestine.
Conclusion: This is a rare case of ATLL involving the terminal ileum. Only
two cases of terminal ileal involvement have been described in Japan. It can
be suggested that routine endoscopic surveillance of the upper and lower
GI tract in all newly diagnosed patients with ATLL is recommended for
prognostic purposes and in evaluating response to chemotherapy.[figure1]
705
Perforated Meckel’s Diverticulum Mimicking Crohn’s Disease
Presenting with Bowel and Urinary Obstruction
Banny S. Wong, MD, David W. Larson, MD, Schuyler O. Sanderson, MD,
Amy S. Oxentenko, MD∗. Department of Internal Medicine, Division of
Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN;
Department of Surgery, Division of Colon and Rectal Surgery, Mayo
Clinic, Rochester, MN and Department of Anatomic Pathology, Mayo
Clinic, Rochester, MN.
To describe an unusual case of Meckel’s diverticulum presenting with com-
bined bowel and urinary obstruction.
All data, including those from patient history, physical examination, labora-
tory tests, imaging, endoscopy, surgery, and pathology, were obtained in the
course of patient care and presented with the consent of the patient.
Meckel’s diverticulum is a common congenital anomaly of the gastroin-
testinal tract, but an uncommon cause of serious complications in adults.
While reports of hemorrhage, bowel obstruction, and perforation associated
with Meckel’s diverticulum exist, there have been no prior reports of com-
bined urinary and bowel obstruction due to abscess formation. We report
the case of a 21-year-old man, with history of recurrent papillary thyroid
cancer, but no prior abdominal surgery, who presented with a one-month
history of rectal pain and new onset obstipation and urinary retention. He
reported night sweats and weight loss, and had a second-degree relative with
known Crohn’s disease. Digital rectal examination was notable for marked
tenderness with proximal induration. CT of the abdomen revealed a large,
complex, circumferential, perirectal abscess compressing the rectal lumen
and base of the urinary bladder, associated with thickening of the terminal
ileum and an ileocecal fistula. Flexible sigmoidoscopy with endorectal ultra-
sound displayed a complex abscess with extensive mucosal and surrounding
inflammation. At exploratory laparotomy, a Meckel’s diverticulum, with a
large perforation at its base, was discovered near the ileocecal fistula and
immediately superior to the perirectal abscess. The section of small bowel
containing the Meckel’s diverticulum, terminal ileum, and cecum were all
resected, and the abscess was debrided. No gross or pathologic evidence for
malignancy or Crohn’s disease was seen. The patient’s symptoms resolved
post-operatively.
This is the first reported case of a perforated Meckel’s diverticulum with
secondary pelvic abscess formation and fistulization, mimicking Crohn’s
disease, presenting with combined bowel and urinary obstruction.
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A Rare Case of Biliary Synovial Sarcoma
Advitya Malhotra, MD, Raju S. Gottumukkala, MD∗. Internal Medicine,
University of Texas Medical Branch, Galveston, TX and Gastroenterology
and Hepatology, University of Texas Medical Branch, Galveston, TX.
A 51-year-old Hispanic male was referred to our hospital with obstructive
jaundice and a possible cholangiocarcinoma. At the other hospital patient
had undergone laboratory examination, CT scan and ERCP. Laboratory ex-
amination showed leucocytosis, elevated liver function tests (total bilirubin
14 mg/dl, conjugated bilirubin 10 mg/dl, and alkaline phosphatase of 800
U/per liter). Computed tomography (CT) abdomen showed dilated CBD and
a mass obstructing the neck of gall bladder. During endoscopic retrograde
choledochopancreatography (ERCP) lots of mucus membrane like material
was expressed and sent to histopathology. No definitive pathological diag-
nosis could be made because of the complexity of the tissue. Patient contin-
ued to be symptomatic and had persistently elevated LFTs. After transfer,
MRCP with gadolinium revealed an intraluminal mass within the common
bile duct with probable extension into the gallbladder, most consistent with
cholangiocarcinoma (Fig. 1). Patient underwent Whipple’s procedure for this
suspicious mass. Gross pathology of the resected specimen revealed two sep-
arate unconnected polypoid masses in common bile duct and gall bladder.
Histopathology revealed whorls of small darkly staining cells arranged in
sheets suggestive of synovial sarcoma vs. small cell carcinoma vs. periph-
eral neuroectodermal tumor (PNET) (Fig. 2). Various immunohistochemical
stains were performed on the tumor specimen (positive for CD 99, Bcl-2 and
synatophysin) favoring a poorly differentiated synovial sarcoma. Slides were
reviewed with two other pathologists who concurred with the interpretation
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of the tumor as synovial sarcoma. To the best of our knowledge this is one
of the first rare cases described in literature. Patient was lost to follow-up
before initiation of chemotherapy.[figure1][figure2]
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Syncope Secondary to the Metastasis of Hepatocellular Carcinoma
Ari J. Wiesen, MD, Daniel Klein, MS, Kadam Jaydeep, MD, Sideridis
Kostas, MD, Davidof Samuel, MD, Simmy Bank, MD∗. Gastroenterology,
Long Island Jewish Medical Center, New Hyde Park, NY and Albert
Einstein College of Medicine, Bronx, NY.
A 73 year old male with history of hemochromatosis and cirrhosis presented
after an episode of syncope. He was found to be hypotensive and EKG showed
sinus bradycardia. An echocardiogram showed a right atrial mass presumed
to represent an atrial myxoma. A CT of the chest (Fig. 1) further demonstrated
the mass to be extending through the tricuspid valve into the right ventricle.
Prior to excision, a CT of the abdomen was performed (Fig. 2) revealing
multiple hepatic hyperdense nodules, suggesting hepatocellular carcinoma.
AFP was found to be 1237.5. The patient declined biopsy and therapeutic
measures. He returned home with palliative treatment.
Cardiac metastasis is a more common manifestation than is perceived. There
is a reported 10% incidence in patients with hepatocellular carcinoma,
0.67%–3% present as an intracavitary lesion. The carcinoma can either in-
vade the IVC with extension into the RA or form a neoplastic thrombus
embedding in the cavity.
Two mechanisms have been shown to cause syncope in cases of Cardiac
Metastases. Intracavitary lesions may obstruct blood flow via ball valve
mechanism or cause tricuspid insufficiency by inhibiting closure of the
valve. Echocardiography showed a huge mas in the right ventricle protruding
through the tricuspid valve into the right atrium kand keeping it from clos-
ing. Color Doppler showed evidence of tricuspid insufficiency and reduced
cardiac output, the likely cause of syncope in our patient.
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Isolated Neurofibroma of the Pylorus Presenting as “Idiopathic”
Gastroparesis, Refractory to Standard Medical Management
Irene Sarosiek, Jameson Forster, Savio Reddymasu, Pernilla Foran,
Katherine Roeser, Jerzy Sarosiek, Richard McCallum∗. Motility Center,
KUMC, Kansas City, KS and Surgery, KUMC, Kansas City, KS.
We report a benign isolated neurofibroma of the pylorus resulting in pyloric
stenosis, presented with epigastric pain, nausea, vomiting, and severe weight
loss. After extensive evaluations patient was diagnosed with idiopathic gas-
troparesis (IGP), without any response to medical treatment. Remarkable
recovery followed implantation of gastric electrical stimulator (GES) with
simultaneous resection of serosal nodule (histologically diagnosed with neu-
rofibroma) and pyloroplasty.
A 24 year old male, developed severe diarrhea, nausea, vomiting, and weight
loss of 100 lbs over 1 year, following his trip to South America. EGD evalu-
ation showed narrowing of the pylorus addressed with 2 injections of botox.
Due to the lack of symptom relief, gastric emptying test (GET), CT scan,
SBFT results suggested partial gastric outlet obstruction and enlarged stom-
ach. Exploratory laparoscopies (X2) were inconclusive. Extensive testing
for various diseases was negative.
He was referred to us in Nov. 06 for further evaluation of isymptoms of IGP
with severe malnutrition. 4 hour GET proved delayed emptying (44% re-
tained at the end of 4 hours; normal: 0–10%). USG of the abdomen and HIDA
scan suggested some sludge and cholelithiasis. During this time, patient was
treated for GI symptoms with metoclopramide, tegaserod, erythromycin,
domperidone, scopolamine patch and desipramine. As the patient continued
to lose weight despite oral nutritional supplementation, liquid diet, and pres-
ence of GI symptoms it was decided to implant the GES. CT of the abdomen
showed a 3 cm intramural mass near the gastric pylorus. Placement of GES,
pyloroplasty, J-tube placement, and a cholecystectomy was done in Jan, 07.
Intraoperatively, the thickening of the muscle around the pylorus with serosal
nodules was found and resected. Pathology report confirmed presence of a
neurofibroma, without involvement of peritoneal lymph nodes. Patient was
discharged in stable conditions with a good control of his GP-like symptoms.
During subsequent follow up visit in April 2007 it was observed that patient
regained 70 lbs and he was not in a need for continuous J-tube feeding which
was removed at that time. This case is presenting a very complicated and
rare clinical condition of isolated neurofibroma of the pylorus which was a
challenging task for caring physicians due to the symptoms suggestive of
IGP.
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Granulocytic (Myeloid) Sarcoma of Stomach Presenting with Upper
Gastrointestinal Bleeding
M. Singh, MD, D. Baltodano, MD, C. Zanardi, MD, P. Holtzapple, MD∗.
Gastroenterology, Pathology, SUNY Upstate Medical University, Syracuse,
NY.
Introduction: Granulocytic sarcoma (GS) is a localized extramedullary tu-
mor of neoplastic immature myeloid cells. GS is the “tissue phase” of some
forms of myeloid leukemia. We present a patient with upper GI bleed sec-
ondary to GS of the stomach.
Case Summary: 66 yr/F with myelodyplastic syndrome (MDS) for
18 months presented with dark tarry stools. She received thalidomide and
azacytidine therapy but had refractory anemia (RAEB). At admission she
was hypotensive, tachycardic with mild abdominal tenderness. Labs show
hematocrit of 20, platelets count of 59,000 with WBC count of 71,000 and
9.3% blasts and normal LFT. She received multiple PRBCs and platelets
transfusions. CT scan of abdomen showed a 6.4 × 5.5 cm mass within the
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gastric antrum. Upper gastrointestinal endoscopy revealed a submucosal,
non-circumferential mass partially occluding the gastric antrum (Fig. 1).
Histopathological and immunochemical staining of biopsies showed an atyp-
ical cellular infiltrate that expressed CD43, lysozyme, myeloperoxidase and
positive Leder stain (chloroacetate esterase) (Fig. 2). Repeat bone marrow
biopsy was consistent with AML.
Discussion: GS commonly involves periosteum/bone, soft tissue, lymph
nodes and skin. Gastrointestinal tract is rarely involved with small intestine as
the more common site than stomach. Acute GI bleed as in our case, has been
reported as the most common presentation. Endoscopically gastric GS have
appearance of superficial ulceration, hemorrhagic rugal folds, multiple small
nodules and more commonly as a polypoidal mass. Diagnosis is based on
tissue biopsy, immunochemical and Leder’s staining. Management involves
chemotherapy, local radiation or surgical intervention.
Conclusion: It’s prudent to endoscopically screen patients for gastrointesti-
nal involvement from myeloproliferative or leukemic disorder in the presence
of GI symptoms.[figure1][figure2]
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Cronkhite-Canada Syndrome Presenting as Acute Colitis; Confirmed
by Colonoscopy, Upper Endoscopy, Capsule Endoscopy, and Pathology
Greg Nesmith, MD, Ryan Ford, MD, Kelly Crawford, MD∗. Digestive
Diseases, Emory University School of Medicine, Atlanta, GA.
Cronkhite-Canada syndrome is a rare disease first described in 1955. The
clinical features include diarrhea, nail dystrophy, alopecia, and hyperpig-
mentation of the skin. We describe a case of Cronkhite-Canada Syndrome
presenting as acute colitis with evidence of disease found on upper en-
doscopy, sigmoidoscopy, and capsule endoscopy.
A 49 year old male presented to the Emory University GI clinic with total
body hair loss and bloody diarrhea which began suddenly six weeks prior to
presentation. He described the diarrhea as loose, predominantly liquid stool
with red blood mixed in occuring 4–5 times per day. The diarrhea also occurs
at night and wakes the patient from sleep. He was seen by a gastroenterologist
who performed a colonoscopy and was found to have erythema throughout
his colon. He was diagnosed with indeterminate colitis from a biopsy show-
ing mucin filled crypts and chronic active inflammation without malignancy
and started on 5-ASA therapy without improvement. At the time of presen-
tation to our clinic, he had no remaining hair on his head and had also lost
his eyelashes and body hair including his pubic hair. He also reported that
he had lost his finger nails and toe nails. In addition he had a fifty pound
weight loss and systemic fatigue. He also reported alterations in his sense
of smell and a decreased appetite because food no longer tasted good. Phys-
ical exam was notable for diffuse hair loss including loss of his eyelashes,
loss of his finger nails and toe nails but was otherwise unremarkable. Upper
endoscopy and flexible sigmoidoscopy were repeated in addition to capsule
endoscopy for additional evaluation. The upper endoscopy was remarkable
for nodular, friable, erythematous gastic mucosa. There was also duodenitis
with erythema and ulcerations noted. The esophageal mucosa was normal.
The flexible sigmoidoscopy demonstrated erythematous and friable mucosa
from the rectum to the transverse colon with exudative ulcerations. Capsule
endoscopy showed diffuse, nodular erythematous mucosa throughout the
entire small bowel. After a thorough review of the patient’s history, physical
exam and discussion with our pathologist the diagnosis of Cronkhite-Canada
Syndrome was made and treatment was started. The patient was treated with
antihistamines, H-2 blockers, prednisone, and the first reported use of the
antibiotic Rifaximin for the treatment of Cronkhite-Canada Syndrome with
a good response.
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Agenesis of the Gallbladder: A Preoperative Diagnosis
Using 4 Imaging Modalities
Alfonso H. Waller, MD, Jennifer L. Goralski, MD, Kiran Rao, MD, Michael
Jaker, MD, Zamir S. Brelvi, MD∗. Department of Medicine, UMDNJ –
New Jersey Medical School, Newark, NJ.
Agenesis of the gallbladder is a rare biliary congenital anomaly, with an
incidence rate of 0.01–0.06%. Awareness of this entity by clinicians and
radiologists is essential because approximately 23% of affected individuals
present with biliary symptoms, including 90% with right upper quadrant
pain, 60% with nausea and vomiting, and 35% with jaundice. Agenesis of
the gallbladder will frequently be misinterpreted as cholecystitis with cystic
duct obstruction, therefore subjecting these patients to undergo unneces-
sary surgical procedures. We present a case of a 35-year-old female with
right upper quadrant pain, nausea, and vomiting, but no jaundice, pruritis, or
fever. Physical examination revealed right upper quadrant tenderness with
voluntary guarding but without rebound tenderness or Murphy’s sign. There
were no surgical scars on the abdomen or back. Pertinent laboratory val-
ues included a white blood cell count of 4,600 /mm3, albumin 4.2, alkaline
phosphatase 163, total bilirubin 0.6, direct bilirubin 0.2, AST 98, ALT 93,
and GGTP 627. A HIDA scan suggested the diagnosis of acute cholecystitis;
however, the gallbladder could not be visualized on ultrasonography or com-
puted tomography of the abdomen. An MRCP was then performed which
also failed to visualize the gallbladder but noted an otherwise normal biliary
tree, confirming the diagnosis of agenesis of the gallbladder. Even though
agenesis of the gallbladder is rare, it should be considered preoperatively
in a patient presenting with symptoms of cholecystitis to avoid unnecessary
surgery.
712
Dramatic Decrease of Gastrin Levels after Extirpation of Metastatic
Gastrinoma Lymph Nodes in a Patient with Multicentric Carcinoid
and MEN 1
Alejandra Castillo-Roth, MD, Jonathan Erber, MD, Wilbur Bowne, MD,
Rosemary Wieczorek, MD, Gerald Fruchter, MD∗. NY VA NY Harbor
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Health Care System, Brooklyn, NY and SUNY Downstate Medical Center,
Brooklyn, NY.
Case Report: A 57-year old male presented with epigastric pain and heart-
burn. He had two loose bowel movements daily; no weight loss. He had
a history of Zollinger Ellison syndrome (ZES) with multiple endocrine
neoplasia-1 (MEN-1); medical records indicated that he had undergone a
partial parathyroidectomy for hypercalcemia and recurrent renal stones in
1985; in 1992, he was found to have multiple gastric ulcers and a gastrin of
2000 pg/ml; he underwent resection of two duodenal gastrinomas in 1993.
He was treated with high dose omeprazole since.
We performed EGD, which revealed over 100 gastric polyps in the stomach,
0.5-cm to 2.5-cm in diameter, and approximately 20 polyps in the first and
second portion of duodenum; Gastric pH was 8 on high dose omeprazole.
Pathology and immnunopathology were consistent with carcinoid tumor.
Gastrin level was 21,712 pg/ml.
Abdominal CT demonstrated an enhancing lesion in the tail of the pancreas
and multiple enhancing nodules between the pancreas and second and third
portion of duodenum; the gastric wall had a thickened, enhancing nodular
appearance. Octreotide scan showed uptake in the stomach and duodenum.
Gastrin level prior to surgery was 24,332 pg/ml. He underwent resection
of peripancreatic, periduodenal, and perigastric lymph nodes and enucle-
ation of the pancreatic lesion. Multiple carcinoid lesions were noted in the
stomach and duodenum. No liver metastases were detected. Pathology and
immunopathology were consistent with gastrinoma. 1-week later, gastrin
level was 8.897 pg/ml. He was started on Octreotide daily, and is now main-
tained on monthly IM injections. Five months post-op, EGD revealed slight
regression of gastric and duodenal nodules; gastrin was 2,359 pg/ml.
Conclusion: Gastric carcinoid tumors occur in 15 to 50% of patients with
MEN-1 and ZES, and are usually benign. Gastric carcinoids in patients
with longstanding MEN-1/ZES may become symptomatic, aggressive, and
metastasize to the liver. Surgical excision of gastrinomas in patients with ZES
decreases the incidence of hepatic metastases, however long-term biochem-
ical cure is achieved in fewer than 30% of cases. Our patient successfully
underwent lymphadenectomy and enucleation of remaining gastrinomas fol-
lowed by Octreotide therapy with dramatic reduction in his gastrin level as
well as symptomatic improvement and regression of his carcinoids.
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Ischemic Duodenal Ulceration in a Sickle Cell Patient with Sickle Cell
Crisis
Rahul N. Julka, MD, Laura W. Lamps, MD, Kevin W. Olden, MD∗.
Gastroenterology/Hepatology, University of Arkansas for Medical
Sciences, Little Rock, AR and Pathology, University of Arkansas for
Medical Sciences, Little Rock, AR.
Introduction: Sickle cell disease (SCD) is caused by molecular abnormali-
ties in the formation of hemoglobin causing pain crisis from vascular occlu-
sion by sickling. Impaired flow in the microvasculature can lead to ischemia,
infarction, and ulceration. We present a case of sickle cell crisis (SCC) caus-
ing a duodenal ischemic ulcer.
Case Report: A 35 year old woman with SCD presented in SCC with
abdominal pain (atypical symptom for her). She began narcotics, fluids, O2,
and DVT prophylaxis, but her abdominal pain continued. She had 3 episodes
of hematemesis. Hgb dropped from 12.9 to 9.8 and she denied NSAID
use. She started on a PPI, got 2 units of RBC’s, and DVT prophylaxis was
stopped, despite risk factors for DVT (cigarette smoking and OCP use). EGD
showed hemorrhagic duodenitis and 1 cm ulcer in the bulb (Fig. 1). Ulcer
biopsy revealed mucosal capillaries with sickled RBC’s and no H. pylori.
On day 4, her O2 saturation dropped from 97% to 89%. CT of the chest
showed bilateral PE, she became hemodynamically unstable, and died of
cardiac arrest.
Discussion: Abdominal pain is common in SCD, with etiologies from splenic
sequestration to hepatobiliary disease. With epigastric pain, ischemic ulcer
of the duodenum is possible. Ischemic ulcers in SCD are due to primary
mucosal infarctions caused by sickling. At low O2 tension, hgb S tends to
polymerize, causing a distorted RBC with poor deformability leading to
arteriolar occlusions causing poor healing of infarcted areas.
Conclusion: Complications of ischemic ulcers of the GI tract due to SCD
must be in the differential diagnosis of abdominal pain in SC patients. Urgent
endoscopic and surgical intervention need to be considered, as PPI’s do not
heal this ulcer. Use of anti-coagulants needs to be balanced between the risks
of PE and increased GI bleed; aggressive endoscopic hemostatic treatment
of the ischemic ulcer may be warranted.[figure1]
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Ascites Still a Dilemma!
Mukesh Kumar, MD, Gaurav Alreja, MD, Robert Spira, MD∗. Internal
Medicine, Trinitas Hospital, Seton Hall University, Elizabeth, NJ.
Introduction: Ascites is a common finding in clinical practice. It is typically
due to liver disease. The etiologic approach of ascites is relatively easy but
patients with a mixed picture can sometime complicate the workup.
Case Report: Our patient is a 34-year-old previously healthy non-alcoholic
Portuguese man who was admitted to Trinitas Hospital on 12/02/2006 com-
plaining of abdominal distension, epigastric pain and significant weight loss.
Patient denied any history of illicit drug use, blood transfusion or TB expo-
sure. Physical examination revealed massive ascites with tender abdomen,
no jaundice. Preliminary studies included LFTs, INR, amylase, lipase, UA
WNL, Hepatitis B, C, HIV, ANA and RF negative. USG and CT abdomen
showed massive ascites, normal biliary tree and liver. Paracentesis revealed
normal appearing ascitic fluid with SAAG <1.1, wbc 81(Lymph 90%).
Gram stain, culture, AFB culture were negative with normal cytology. MRA
showed normal portal vein and 2D Echo was WNL. Stool studies did not
show any infection or evidence of malabsorbtion. Peritoneal biopsy was neg-
ative for malignancy and tuberculosis. Esophageal, gastric and small bowel
biopsies were non-revealing. Patient was treated with multiple paracente-
sis and empiric antibiotics. Patient improved with resolution of ascites and
discharged home.
Discussion: Although cirrhosis is the cause of ascites formation in most
patients, approximately 15 percent have a cause other than liver disease, in-
cluding cancer, heart failure, tuberculosis, or nephrotic syndrome. Review
of literature revealed that ascites without obvious cause has been associated
with dialysis, previous abdominal surgery, hypothyroidism, constrictive peri-
carditis and mesothelioma. In our case despite extensive workup, it was still
a dilemma!
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Endoscopic Therapy of a Difficult To Treat Pancreatic Duct Stone in a
Pediatric Patient
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Gopal Narasimhan, DO, Diego Kuperschmit, MD, Franklin E. Kasmin,
MD, Seth A. Cohen, MD, Jerome H. Siegel, MD, MACG∗. Division of
Digesive Diseases, Beth Israel Medical Center, New York, NY.
A 15-year-old male pt with no significant pmh visiting the US from India
presented to a PCP for evaluation of acute abdominal pain. He was found
to have mid epigastric tenderness and anorexia with frequent episodes of
vomiting. The initial work-up revealed elevated serum amylase and lipase
levels 2× above the upper limits of normal. An MRCP was performed which
showed a stricture in the pancreatic duct (PD) at the head of the pancreas
with a large 3 cm stone within the duct proximal to the stricture. An ERCP
was performed (Fig. 1) which revealed similar findings as the MRCP with a
dilated PD. A pancreatic sphincterotomy was performed, and the PD stric-
ture was dilated to 6 mm using a balloon dilator system. Several attempts
were made to perform mechanical lithotripsy and remove the stone with both
a balloon and basket. These attempts were unsuccessful, and a pancreatic
stent was placed extending distal to the stone. The patient underwent extra-
corporeal shock wave lithotripsy (ESWL) after which a repeat ERCP was
performed. The stricture was dilated to 6 mm. The remaining stone and many
stone fragments were successfully removed during the procedure (Fig. 2).
The pancreatic duct was irrigated with saline, and clear effluent was accom-
plished. Two large caliber stents were placed during the procedure to modify
the anticipated course of pancreatitis. After the procedure, the patient was
pain free with amylase and lipase levels now within the normal range.
This vignette is an example of successful endoscopic therapy of a dif-
ficult to treat pancreatic stone. An alternate treatment strategy consid-
ered during the initial consultation included surgical management of the
stone by pancreatico-jejunostomy. This more invasive procedure and it’s
related morbidities was avoided by utilizing a combination of ESWL and
ERCP.[figure1][figure2]
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Segmental Arterial Mediolysis: An Unusual Cause of Ischemic Colitis
Robert E. Kraichely, MD, Amy S. Oxentenko, MD∗. Division of
Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Case: A 25-year old female presented with acute severe abdominal pain
that awoke her from sleep, located in the mid and lower abdomen. It was
associated with nausea and diaphoresis. Within hours, she began to have di-
arrhea, followed by hematochezia, prompting an emergency room visit and
hospital admission. Examination revealed no fever, normal bowel sounds,
abdominal tenderness without peritoneal signs, and gross blood on rectal
exam. CBC, electrolytes, liver chemistries, pancreatic enzymes, β-hCG, and
cultures were within normal limits. Colonoscopy revealed erythema and ul-
cerations around the splenic flexure, with biopsies consistent with ischemic
colitis. She received supportive care and symptoms resolved. Upon out-
patient consultation, her past medical history was unremarkable. Her only
medication was an oral contraceptive. She denied smoking, and had no per-
sonal or family history of hypercoagulable conditions. She was tested for
hypercoagulable disorders, with none found. Because of her age and absence
of an obvious etiology, a CT angiogram was performed which demonstrated
focal dissection of the superior mesenteric artery adjacent to the origin of the
middle colic and pancreaticoduodenal arteries, with the origin of the middle
colic artery narrowed. These findings were consistent with segmental arte-
rial mediolysis as a cause of her ischemic colitis. There was no extension of
the dissection or further blood flow compromise upon repeat CT. There was
no evidence for a connective tissue or collagen vascular disease. She was
placed on beta-blocker therapy and had her oral contraceptive discontinued.
Plans were made for follow-up imaging in six months.
Discussion: Segmental arterial mediolysis (SAM) is a rare, nonarterioscle-
rotic, noninflammatory vascular condition characterized by vacuolar degen-
eration with lysis of the outer tunica media vasorum of the arterial wall. SAM
predominately involves the abdominal visceral arteries, although renal, cere-
bral and coronary arteries can also be affected. Incidence is unknown. SAM
can lead to aneurysms, dissection, thrombosis or rupture of the splanchnic
and renal arteries. Hemorrhage and shock are most commonly reported, and
bowel ischemia or infarction is less frequent. The natural course of SAM is
not known, although some speculate it may be a precursor to fibromuscular
dysplasia. This case demonstrates that SAM can manifest at a young age,
and should be in the differential diagnosis of the patient presenting with
bowel ischemia without other known risk factors.
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Chronic Diarrhea, Alopecia Totalis and Muscle Cramps in a 36 Year
Old Female
Samar Harris, MBBS, Kathrin Czarnecki, MD, Harris V.K. Naina, MBBS∗.
Internal Medicine, Mayo Clinic, College of Medicine, Rochester, MN.
To report a case of Satoyashi syndrome occuring in a Caucasian female.
A 36-year-old Caucasian female developed painful muscle cramps of both
lower extremities along with bilateral hip pain since the age of 9 years.
She was later found to have bilateral femoral head deformities. She attained
menarche at the age of 14 years along with development of secondary sexual
charateristics. At the age of 16, her symptoms were further complicated with
diffuse hair loss in her scalp, axilla and pubic regions.
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She became pregnant at the age of 26, and there was complete resolution of
her symptoms including reversal of her hair loss. Shortly after an uneventful
pregnancy and vaginal delivery of a term baby, her symptoms returned with
progressively increasing severity. Two years prior to presentation she devel-
oped intermittent self limiting episodic watery diarrhea with each episode
lasting for 1 to 2 weeks. There was no associated abdominal pain, nausea,
vomiting, or fever. However she did note a 20 pound weight loss.
A clinical diagnosis of Satoyshi syndrome was made in 2006, and she was
started on treatment with prednisone. Her diarrhea and muscle cramps got
better. A susbsequent EGD and colonoscopy were unremarkable. Mucosal
biopsies from small bowel were negative for celiac disease. The biopsies
from the colon showed mild chronic colitis.
Satoyashi syndrome is a very rare systemic autoimmune disease involving
the nervous, endocrine, and gastrointestinal systems. The majority of patients
with Satoyoshi syndrome has been reported from Japan. Rarely has it been
reported in Caucasians. A recent study has shown a common antibody against
brain, stomach, and duodenal tissue, in the sera of two patients with this
syndrome. GAD antibodies in Satoyoshi syndrome has been reported, but it
was negative in our patient. She had symptomatic and clinical improvement
with steroids but her alopecia totalis did not resolve completely.
Satoyashi syndrome should be considered as a differential diagnosis in pa-
tients with neurological symptoms and chronic diarrhea with alopecia. These
patients would benefit from immunosuppressants.
718
Tanned Lady with Skin Lesions and Liver Disease
Rajeswari Anaparthy, MD∗. Internal Medicine, University of Texas
Medical Branch, Galveston, TX.
We illustrate a case of porphyria cutanea tarda manifested as a result of
heterozygous hemochromatosis gene mutation.
46 year old female presented with increasing pigmentation of face and blis-
ters on bilateral hands and feet. She had no past medical history, substance
abuse and was on no medications. Physical examination showed hyper pig-
mentation/ hypertrichosis of the face, bullous lesions on the dorsal surfaces of
hands and feet and accompanied by crusted erosions, atrophic scars, abdom-
inal distension, with positive shifting dullness and bilateral lower extremity
edema.
Evaluation: Skin biopsy of the bullous lesions revealed Sub epidermal Blis-
ter. Urine Wood lamp examination yielded pink fluorescence. Plasma por-
phyrin level was elevated with fluorescence emission maximum at neutral
pH near 619 nm. Urine porphyrin level was elevated. Urine porphobilinogen,
detla aminolevulenicacid were normal. Fecal porphyrin levels were elevated.
Hepatic panel showed elevated ALP, ALT, AST, Right upper quadrant ul-
trasound showed findings of cirrhosis. Hepatitis serologies and ANA were
negative. Ferritin and serum iron level was elevated with normal TIBC.
Liver biopsy revealed Iron Overload with severe Fibrosis. Genetic studies
for hemochromatosis showed heterozygous H63D mutation.
Conclusion: Diagnosis of Porphyria cutanea Tarda was made. Herterozy-
gous H63D mutation being the inciting factor for iron overload.
PCT results from deficiency of the uroporphyrinogen decarboxylase in heme
biosynthetic pathway. Exposure to hepatotoxins that result in hepatic iron
overload is one of the major mechanism. HFE mutations and hepatitis C
virus infection are important causes.
Porphyria cutanea tarda should always mandate workup for underlying hep-
atic iron overload. Mutation analysis for hemochromatosis and liver biopsy
may be necessary. Heterozygous hemochromatosis gene mutations, although
rare could manifest as iron over load syndromes.
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Recurrent Colonic Abscesses: A Rare Presentation of Colonic Cancer
Subaila Zia, MD, Malvinder Singh, MD, Jaya P. Buddineni, MD, Carl
Guillaume, MD∗. Internal Medicine, Saint Barnabas Hospital, Bronx, NY.
Colorectal cancer rarely manifests as colonic abscess. Here we have a pa-
tient who presented with recurrent colonic abscesses and was diagnosed
with adenocarcinoma of the cecum. The literature review did not show any
other documented case of colorectal cancer presenting as recurrent colonic
abscesses.
A 67 years old African American female with hypertension, anemia, and
uterine fibroids was admitted with right lower quadrant abdominal pain for
one week. The pain was associated with dark brown watery diarrhea, nausea
but no fever, chills or vomiting. She had right lower quadrant tenderness
with no rebound or rigidity. Fecal occult blood test was negative.
Two months prior to admission, patient had similar pain and CT scan ab-
domen revealed right lower quadrant abscess measuring 7.4 cm × 6.8 cm.
She underwent CT guided drainage with indwelling catheter for six weeks.
Cultures showed enterococcus fecalis and beta hemolytic streptococcus.
Antibiotics given. After indwelling catheter removal, patient had recur-
rent right lower quadrant pain, repeat CT scan abdomen revealed recurrent
colonic abscess measuring approximately 6.1 cm × 7.8 cm and repeat CT
guided drainage of right lower quadrant abscess was done. Culture showed
Aeromonas hydrophilis and Streptoccocus viridans. Patient was discharged
on antibiotics. Colonoscopy revealed large friable mass in cecum and a small
polyp in proximal transverse colon. Cecal mass biopsy showed moderately
differentiated adenocarcinoma, and transverse colon biopsy showed tubu-
lar adenoma. Right hemicolectomy was performed, and its biopsy showed
stage 2, moderately differentiated invasive adenocarcinoma, located in ce-
cum centered on appendiceal orifice extending into the pericolic fat forming
a 4 cm mass. Obstruction of appendiceal orifice was seen due to the tumor
extension causing dilatation of distal appendix with mucinous dissection
of its muscle layer and perforation of mid portion of appendix forming a
fistula tract into retrocecal region. Pericolic lymph nodes were negative for
metastasis. CEA level was 1.8 prior to surgery and repeat CEA level after
surgery was 1.2. Six months post operatively, a surveillance colonoscopy was
normal.
Colorectal carcinoma is common in the USA. Its presentation varies there-
fore, it is a diagnostic challenge for. Above we have reported colonic car-
cinoma presenting as recurrent colonic abscess Our patient had normal
colonscopy two years ago.
Recurrent colonic abscesses can be an indicator of an occult colorectal car-
cinoma.
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VIPoma – A Case of Abrupt Onset Diarrhea in an Elderly Patient
Amil P. Patel, MD∗, Mohammad Wehbi, MD, Kamil Obideen, MD.
Department of Gastroenterology, Emory University, Atlanta, GA.
An 85 year old previously healthy Caucasian female presented with a 2 month
history of a sudden onset diarrhea involving 7–10 large, watery, non-bloody
bowel movements per day. The diarrhea was unaffected by fasting, and she
denied any abdominal pain, fevers, sick contacts, or recent travel. Physi-
cal exam was significant for orthostasis. Laboratory data demonstrated hy-
pokalemia and a non-anion gap metabolic acidosis. Common infectious eti-
ologies were initially ruled out with negative fecal leukocytes, stool gram
stain and culture, Clostridium difficile toxin, ova and parasites, and Giardia
studies. A colonoscopy was unremarkable, and an EGD revealed no evi-
dence of celiac sprue. Stool electrolytes revealed a low stool osmotic gap
suggesting a secretory diarrhea. Subsequent studies for gastrin and 5-HIAA
were normal, and the patient denied any laxative use. However, a VIP level
was found to be elevated at 359. A subsequent CT and MRI showed no
masses or evidence of metastasis. An iodine 123 meta-iodobenzylguanidine
(I-123 MIBG) scan ultimately indicated an area of increase uptake in the
fourth part of the duodenum. The patient refused surgical intervention, and
she was placed on octreotide injections, which significantly improved her
diarrhea. A follow-up VIP level showed a decrease to 28.
VIPomas are extremely rare neuroendocrine tumors with an incidence of
1:10,000,000 per year. The hypersecretion of vasoactive intestinal peptide
results in the Verner-Morrison or WDHA syndrome, which includes large
Abstracts S383
volume watery diarrhea, hypokalemia, and achlorhydria. VIPomas are typi-
cally found in adults 30–50 years of age and have a gradual onset of symp-
toms. The majority of these tumors are located in the tail of the pancreas
and are often metastatic at the time of diagnosis. Treatment usually involves
octreotide to inhibit hormonal secretion. This particular case represents an
uncommon presentation as the patient was considerably beyond the nor-
mal age range and presented with a sudden rather than gradual onset of
symptoms. In addition, the tumor was ultimately located in the duodenum.
Although neuroendocrine tumors such as VIPomas are an exceedingly rare
cause of diarrhea especially in the elderly, they should be considered as a
potential etiology in any secretory diarrhea.
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Idiopathic Hepatic Angiosarcoma
Michael J. Grupka, MD, John Polio, MD∗. Transplant Program, Hartford
Hospital, Hartford, CT and Gastroenterology, University of Connecticut,
Farmington, CT.
A 47 year old white male was referred to evaluate rapidly progressing liver
disease. The patient complained of 6 months duration of dull, constant, mid-
epigastric abdominal pain with radiation to the back. The onset was gradual
with a persistent progression in severity requiring escalating doses of ac-
etaminophen and naproxen. Other symptoms included anorexia, weight loss,
and nausea. Exam revealed a middle aged man with a sallow complexion.
He had signs of temporal wasting, palmer erythema and spider angiomata.
His liver span was 10 cm with a firm smooth edge. He had mild abdominal
distention without focal tenderness and a positive fluid wave.
Laboratory data revealed non-specific abnormalities in his liver function
tests. CT scan of his abdomen demonstrated a nodular liver with several
small enhancing nodules. A non-contrast CT scan ten months prior revealed
a normal appearing liver. Extensive serological work up was negative. Tumor
markers were within normal limits. MRI had diffuse signal abnormalities in-
cluding a 2.5 cm area near the dome of the right lobe of the liver. Biopsy of
the right dome mass came back as nondiagnostic soft tissue and blood clot.
A random liver biopsy was noted for sinusoidal dilation without evidence for
fibrosis. Repeat MRI two months after the biopsy showed an additional 4 cm
infiltrating mass straddling the hepatic vein. The paracentesis showed thick,
vibrant green ascites with negative cytology. The hepatic gradient pressure
was increased. Transjugular biopsy revealed acute centrilobular necrosis,
severe sinusoidal dilation, and a single area of atypical hepatocellular regen-
eration. Due to diagnostic uncertainty a laparoscopy with ultrasound guided
liver biopsy was performed. The liver grossly appeared cirrhotic. There were
nodules seeding the peritoneal wall as well as a posterior wall bladder mass.
Biopsies confirmed the diagnosis to be a high grade metastatic epitheloid
hepatic angiosarcoma.
Hepatic angiosarcoma is a rare malignant vascular tumor. The diagnosis can
be difficult due to the rarity of the tumor. This tumor mimics more common
disorders and lacks pathognomonic signs. The finding of a thick, vibrant
green ascites had not been reported before. Open biopsy is often needed to
make the diagnosis. The clinical course is aggressive and there are minimal
treatment options available.
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Dissection of an Unusual Gastric Mass Using Rat-Tooth Forceps
Patrick J. McDevitt, DO, Arnab Biswas, DO, Abraham Mathew, MD∗.
Department of Internal Medicine, The Penn State Hershey Medical Center,
Hershey, PA and Department of Gastroenterology and Hepatology, The
Penn State Hershey Medical Center, Hershey, PA.
A 71 yr old Asian male with a history of renal cell carcinoma is referred
for EUS evaluation of a 3 cm mass located in the gastric cardia. Biopsies at
previous EGD were negative for evidence of neoplasm. EUS was performed
with a radial and linear scope. The lesion was confined to the submucosa
separate from the muscularia propria. The complex lesion was 22 mm ×
20 mm with anechoic and hypoechoic regions. FNA and tunneled biopsies
were negative. Endoscopic resection was performed given the documented
ultrasonographic properties. Saline was injected circumferentially adjacent
to the lesion. Needle-knife was used to incise three-quarters around the base.
Rat-toothed forceps were then used to enter the submucosal plane. Dissec-
tion was accomplished by opening and closing movement of the forceps.
The endoscope was retroflexed to repeat this sequence on the distal aspect
until the lesion was completely elevated. Using standard snare polypectomy
technique, the nearly excised mass was detached from the gastric wall. Mi-
nor bleeding was controlled with epinephrine injection and hemostatic clips.
The pathology report showed the lesion to be a buried inverted fundic gland
polyp.
Submucosal masses are a frequent finding at endoscopy. Common submu-
cosal lesions include leiomyomas, leiomyosarcomas, lipomas, stromal tu-
mors, carcinoid tumor, granular cell tumors, duplication cysts or varices.
While fundic gland polyps are a common finding, inverted polyps are a rare
occurrence.
Endoscopic mucosal resection (EMR) has been used for the removal of intra-
mucosal neoplasms of the gastrointestinal tract with success. This procedure
relies on the snare technique and has been limited to lesions less than 20 mm.
Endoscopic submucosal dissection (ESD) is a newer technique developed
to overcome the limits of EMR. The snare technique is not used for ESD
and this procedure relies on a needle knife for en bloc resection. We present
a unique approach for the removal of a submucosal lesion found to be an
uncharacteristic fundic gland polyp.[figure1]
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Hepatic Adenomatosis: A Rare Clinical Entity with Unique
Characteristics
Kashif Ahmed, MD, Muslim Atiq, MD, Kamran Safdar, MD, Nyingi
Kemmer, MD, Guy Neff, MD∗. Division of Digestive Diseases, Dept of
Internal Medicine, University of Cincinnati, Cincinnati, OH.
Introduction: Hepatic adenomatosis (HA) is a rare entity. Complications
can ensue and may be related to hemorrhage, excessive growth with pain
and malignancy. We present a case in a 33-year old female suffering from
persistent growth of HA despite past surgical intervention.
Case: Caucasian female presents with right upper quadrant tenderness
(RUQ), nausea, and vomiting worsening over three days. Past history signif-
icant for a right lobectomy and left lateral segmentectomy of the liver after
a fall 20 years earlier. The patient used oral contraceptives for less than a
year as a teenager. On exam, she was tachycardic and hypotensive. Abdomen
was distended, firm, RUQ tenderness, and hepatomegaly. Bowel sounds were
present. Laboratory data revealed H&H 12/36, AST 216 U/L, ALT 216 U/L,
albumin 3.8 g/dl, alkaline phosphatase 138 U/L, INR 1.1, AFP 1.5 ng/mL,
and lactic acid 2.9 mmol/L. Initial CT scan demonstrated extravasation of
contrast in the caudate lobe suggestive of a bleed. Angiogram showed an
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irregular branch of the hepatic artery to the caudate lobe which was em-
bolized. Repeat CAT scan revealed multiple hepatic lesions and hemorrhage
(subcapsular, retroperitoneal, and intraperitoneal). Her condition worsened
thus she was listed and received a cadaveric liver transplant. The explanted
liver showed presence of a 17×10×5 cm hematoma in the liver. It also con-
tained 50–100 adenomas ranging in size from 0.5 cm–4.5 cm. Pathology
revealed hepatic adenomatosis.
Discussion: Hepatic adenomatosis is a rare entity characterized by greater
then 10 adenomas. Unlike solitary hepatic adenoma, there is lack of fe-
male predominance or association with glycogen storage diseases. Lesions
do not have a tendency towards influence by steroid or estrogen use. The
etiology is poorly understood and is associated with congenital or acquired
abnormalities of hepatic vasculature.
Clinically, these lesions are more painful and result in significant hep-
atomegaly. Bleeding and malignant transformation occurs in 62% and 13% of
cases respectively. Due to the risk of hemorrhage and malignancy, resection
of the largest and most vulnerable lesion is often required. Surgical resection
has been shown to decrease abdominal pain and lead to longer hemorrhage
free intervals and need close surveillance. Patients who progress despite
radiological and surgical interventions require liver transplantation.
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Obstructive Jaundice Secondary to a Pancreatic Plasmacytoma
Adam J. Spiegel, DO, Roshan Patel, MD, Shireen Pais, MD∗. Department
of Gastroenterology, New York Medical College, Westchester Medical
Center, Valhalla, NY and Department of Pathology, New York Medical
College, Westchester Medical Center, Valhalla, NY.
Case Report: A 37 year old male recently diagnosed with multiple myeloma
and on therapy with thalidomide presented with epigastric pain and jaundice.
At the time of presentation, the pertinent positives on physical exam were
jaundice and a mildly distended abdomen with epigastric tenderness. Total
bilirubin was 4.2 mg/dL with direct fraction 3.3 mg/dL, alkaline phosphatase
250 U/L, AST 107 U/L, and ALT 160 U/L. Other blood tests including tumor
markers were normal. A CT scan of the abdomen revealed a large pancre-
atic mass measuring approximately 8 cm × 8 cm encasing the celiac axis
and abutting the superior mesenteric artery. Endoscopic ultrasound demon-
strated a heterogeneous and diffusely hypoechoic mass replacing the head,
uncinate process, neck, and proximal portion of the body of the pancreas. In
the mid body of the pancreas there was a demarcation between the infiltrating
tumor and the distal pancreas. The common bile duct could not be identified
in the head of the pancreas. FNA of the mass revealed hemorrhagic smears
containing sheets of plasma blasts and cells consistent with myeloma. The
patient was diagnosed with pancreatic plasmacytoma in the setting of mul-
tiple myeloma. Treatment was initiated with bortezomib. By the third cycle,
symptoms had improved and hepatic blood tests had normalized.
Discussion: Extramedullary myeloma is rare and most commonly mani-
fests in tissues rich in reticuloendothelial cells such as those found in the
head, neck, and upper respiratory tract. Gastrointestinal involvement has
been reported in approximately 10% of cases and usually involves the liver
or spleen. The pancreas is only rarely involved and the diagnosis is often
made postmortem with an incidence rate of 2.3% based on autopsy studies.
Obstructive jaundice and abdominal pain are the most common symptoms
characterizing myeloma of the pancreas.
Previous case reports of pancreatic plasmacytoma have described laparotomy
as the method of choice in obtaining a tissue diagnosis. This case highlights
the utility of EUS as a surgery-sparing diagnostic modality in a patient with
a large pancreatic mass. We also are reminded that pancreatic plasmacy-
toma should be considered in the differential diagnosis of a heterogeneous
pancreatic mass, especially in the setting of multiple myeloma.
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Ischemic Colitis Masquerading as Crohn’s Colitis in a Patient with
Protein C Deficiency
S. Gopaluni, MD, V. Muthu, MD, M. Singh, MD, N. Mehta, MD,
P. Holtzapple∗. Medicine, SUNY Upstate Univ, Syracuse, NY.
Introduction: Acute mesenteric ischemia from mesenteric vein thrombo-
sis[MVT] is a rare manifestation of a hypercoagulable state like protein-C
/S deficiency. We report a case of protein-C deficiency with ischemic colitis
mimicking the radiological and endoscopic features of Crohn’s colitis.
Case Description: 29 yr/F with protein-C deficiency with no prior complica-
tions presented with abdominal pain, tenesmus and bright red blood per rec-
tum. She denied fever or any constitutional symptoms. CBC, liver function
tests and coagulation profile were normal. CT scan of the abdomen/pelvis
with contrast showed diffuse thickening from mid-transverse colon to the rec-
tum and ruled out MVT. Stool studies including bacterial cultures, clostrid-
ium difficile toxin were all negative. Sigmoidoscopy showed skipped areas of
bleeding ulcerated mucosa with inflammatory changes in the recto- sigmoid
colon suggesting Crohn’s colitis and the patient was started on mesalamine
[Fig. 1]. Rectosigmoid biopsy showed ulceration, coagulative necrosis and
inflammation with fibrin thrombi consistent with ischemic colitis secondary
to MVT [Fig. 2]. There was no evidence of chronic changes to suggest
inflammatory bowel disease.
Discussion: MVT should be suspected when acute abdomen develops in pa-
tients with prior thrombotic episodes or a documented thrombophilic state. It
was postulated that in our patient protein-C deficiency led to MVT which was
not revealed on the CT scan and the bleeding was secondary to mesenteric
ischemia. CT scan is considered the diagnostic test of choice and anticoagu-
lation is the standard of care. High index of clinical suspicion, early diagnosis
and treatment can prevent progression to gangrenous bowel.
Conclusion: Our case underscores the association of mesenteric vein throm-
bosis with prothrombotic disorders and brings to attention that it can be
missed on imaging studies.[figure1][figure2]
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GI Classification Systems: Spanning the Globe
Kenneth M. Banner, MD∗, Jaydeep S. Kadam, MD, Kostas Sideridis, DO,
Simmy Bank, MD. Division of Gastroenterology, Long Island Jewish
Medical Center – Albert Einstein College of Medicine, New Hyde Park, NY.
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Gastroenterology is replete with classification systems and criteria. These
systems have sometimes been named for the cities in which they were cre-
ated to facilitate easy recall by clinicians. To our knowledge, a report of
classifications based on place of origin has never been published. A Med-
line search was conducted to identify geographically named classification
systems. Twenty-one such classifications/criteria were identified.
We present the criteria/classifications listed below in the format of a world
map, all with in-depth descriptions; each system is illustrated on the map
corresponding to the place where it was first published.
Esophagus
– Seattle Protocol for Barrett’s Esophagus
– LA Classification for Esophagitis
– North Italian Endoscopic Club for the Study and Treatment of Esophageal
Varices
Stomach
– Sydney Classification for Gastritis
– Glasgow Dyspepsia Severity Score
Colon
– Bethesda Criteria for Testing Colorectal Tumors for Microsatellite Insta-
bility
– Amsterdam Criteria for HNPCC
– Paris Classification for neoplasia of the GI mucosa
Liver
– Milan Criteria for Liver Transplantation for Hepatocellular Carcinoma
– Barcelona Criteria for Liver Transplantation for Hepatocellular Carcinoma
– UCSF Criteria for Liver Transplantation for Hepatocellular Carcinoma
– Pittsburgh Criteria for Liver Transplantation for Hepatocellular Carcinoma
– King’s College Criteria for acetaminophen-induced and non-acetamino-
phen induced acute liver failure
Biliary
– Mayo Risk Score for Primary Biliary Cirrhosis
– Oslo Risk Score for Primary Biliary Cirrhosis
– Milwaukee Classification for Sphincter of Oddi Dysfunction
Pancreas
– Atlanta Criteria for Pancreatitis
– Cambridge Classification for diagnosis of chronic pancreatitis based on
ERCP
IBD/IBS
– Vienna Classification for Crohn’s Disease
– Montreal Classification for Ulcerative Colitis
– Rome Criteria for Irritable Bowel Syndrome
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A Tale of Two CTs
David J. Cozzi, DO, Robert E. Smith, MD∗. Gastroenterology, Geisinger
Medical Center, Danville, PA.
A 52 year old male with no significant past medical history underwent further
evaluation of a right retroperitoneal soft tissue mass found on CT measuring
20 cm in its greatest dimension. He had been complaining of right flank
discomfort with an associated 15 pound weight loss over the past 6 weeks.
Coincidentally, his wife had noted a small lump on the right anterior abdomen
that had been progressively enlarging. The patient underwent a CT guided
biopsy of the mass that favored a myxoid liposarcoma.
He was arranged for surgery shortly thereafter, however the patient cancelled
the procedure and his whereabouts were unknown. Multiple attempts were
made to contact the patient, without success. Three months later, the patient
re-established contact and underwent a preoperative abdominal CT (Fig. 1).
His findings dramatically worsened. His mass extended from the inferior
aspect of the liver to the lower pelvis and from the right chest wall to the
left mid abdomen. There was evidence of disseminated disease and massive
displacement of the internal organs.
He underwent a radical surgical resection, including a right nephrec-
tomy/adrenalectomy, partial right hepatectomy with cholecystectomy and
right hemicolectomy. The excised mass measured 42 × 32 × 20 cm and
weighed 11.8 kg. His only post-surgical complication was a perihepatic ab-
scesses that was successfully treated with antibiotics and drainage. A repeat
CT was obtained and marked improvement was noted (Fig. 2).
Discussion: Liposarcomas are soft tissue sarcomas arising from mesenchy-
mal tissue with its location in the retroperitoneal region accounting for
20% of all sarcomas. Early metastases are uncommon, with the lungs
being the most frequent site. This case demonstrates a rapidly growing,
disseminated liposarcoma with extraordinary imaging revealing extreme
displacement of the internal organs and dramatic postoperative improve-
ment.[figure1][figure2]
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An Uncommon Occurrence of Intestinal Spirochetosis in an
Immunocompetent Host
Teena Chopra, MD, Gebreselassie Nida, MD, Suneetha Duttala, MD,
Rodger MacArthur, MD, Firdous Siddiqui, MD∗. Internal Medicine,
Wayne State University/Detroit Medical Center, Detroit, MI.
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Introduction: Intestinal spirochetosis (IS) is a condition defined morpho-
logically by the presence of spirochetal microorganisms attached to the api-
cal cell membrane of the colonic and rectal epithelium. It is a rare disease
and difficult to diagnose, as its symptoms resemble those seen in many
other common diseases. It has an increased prevalence in immunocompro-
mised hosts particulary homosexual men and HIV-infected individuals but
few symptomatic cases in immunocompetent hosts have been described.
Clinical significance in individual cases has remained unclear. There is still
controversy as to treatment with antibiotics (metronidazole or Penicillin G)
and eradicating organisms will result in symptomatic improvement.
Case Report: We report a case of a 54 year old African American male
with a 10 year history of intermittent watery diarrhea. He reported upto 4
bowel movements per day with no associated abdominal pain or cramping.
He also reported intermittent hematochezia. Patient’s only other medical
problem included hypertension. Our patient is a painter and also involed
in maintainence work on old roofs and claimed to have frequent contact
with excreta from birds and rodents including mice. Physical examination
of the patient was unrevealing. An initial laboratory workup that included
complete blood count, basic metabolic panel, and liver function tests was
normal. Stool cultures were negative; however, the presence of bright red
blood and diarrhea prompted a colonoscopy which showed a normal appear-
ing colonic mucosa throughout and moderate sized internal haemorrhoids.
Random colon biopsies were obtained to evaluate for microscopic colitis
which revealed the presence of spirochetes on the surface of colonic ep-
ithelium which were confirmed by positive staining with Dieterle stain. The
patient was treated with metronidazole 500 mg 3 times per day for 14 days,
and showed improvement.
Intestinal spirochetosis should be included in the differential diagnosis of
chronic diarrhea not only in immunocompromised but also in immunocom-
petent patients. A colonoscopy with biopsy will aid in the diagnosis of this
disorder. Treatment with metronidazole or penicillin G should be considered
in symptomatic patients with intestinal spirochetosis.
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Successful Endoscopic Dilation of Cervical Esophageal Webs: Two
Case Reports
Ali Lankarani, MD, Vivek Kumar, MD, Sam Yoselevitz, MD, Sudhir K.
Dutta, MD∗. Gastroenterology, Sinai Hospital, Baltimore, MD and
Gastroenterology, Johns Hopkins University School of Medicine,
Baltimore, MD.
Esophageal rings and webs are the most common structural abnormalities
in the esophagus. We present two elderly females with dysphagia and sig-
nificant weight loss secondary to Cervical Esophageal Webs (CEW). Here
we review our recent successful experiences with endoscopic controlled and
fluoroscopic guided rupture of these webs.
Two females at the ages of 76 and 87 presented with a six month period
of progressive dysphagia and significant weight loss. A barium swallow
study demonstrated a thin area of circumferential narrowing in the cervical
esophagus, suggestive of CEW.
Because of the high location of the lesions in these two cases, all of the
treatment options including surgical resection of the web were considered.
Pneumatic dilatation of the web was performed after endotracheal intuba-
tion. During the endoscopy, the esophageal web was visualized and under
fluoroscopy a guide wire was passed through the narrowing. The balloon was
positioned across the web, dilated to 10-mm and subsequently to 13-mm in
diameter. Rupturing of the webs was confirmed by bleeding from the site of
the cervical web. The scope was then passed through this area without re-
sistance. Brush cytology and mucosal biopsies were then obtained from the
web area, which did not demonstrate any malignant process. Patients were
discharged the day after the procedure with no complications. During the six
month follow up none of the patients complained of recurrent dysphagia.
The first proposed treatment option for benign structural abnormalities of the
esophagus is lifestyle modification, including modifying eating habits. One
or multiple attempts of esophageal dilation can be implemented in persistent
cases via pneumatic, Savary, or Maloney dilators. Endoscopic electrosurgical
incision or Nd:YAG laser incision of the esophageal rings have also been
used in refractory cases. Removal of the ring surgically is rarely necessary
for persistent dysphagia.
Our successful management of these patients suggests the need for a close
multidisciplinary approach for optimal patient care. We think less invasive
interventional treatments like pneumatic dilation can be used initially. Endo-
tracheal intubation should be considered to reduce the risk of aspiration and
asphyxiation. In the event of treatment failure or in case of complications,
esophagotomy and surgical resection of the web can be considered.
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Endophthalmitis Complicating Klebsiella Pneumoniae Liver Abscess:
An Infrequently Recognized Complication
David W. Victor, MD, Rebeckah Lemann, MD, Jacob Feagans, MD,
Virendra Joshi, MD∗. Section of Gastroenterology, Tulane School of
Medicine, New Orleans, LA.
Endogenous endophthalmitis is a well described metastatic complication of
pyogenic liver abscess that can lead to devastating ocular complications es-
pecially in immunocompromised host. Its diagnosis is often delayed due to
the sub-clinical presentation. We report one of the few cases in Western liter-
ature of metastatic endophthalmitis in the setting of Klebsiella pneumoniae
liver abscess.
A 50 year old South Asian male presented to his primary care physician with
4 days of flu like symptoms and fevers up to 40◦C. Initially, he complained of
new onset right eye pain, photophobia, and blurred vision. Ophthalmologic
evaluation noted hypopyon and iridocyclitis of the right eye. Vitreal tap Gram
stain revealed Gram negative bacteria. Laboratory data at that time included
a leukocyte count of 12,900 with eighty percent neutrophils; AST 43 and
ALT 98. The patient was admitted to the hospital three days after initial
presentation for aggressive broad spectrum antibiotic therapy. Suspicion of
a gastrointestinal source led to a liver ultrasound that demonstrated multiple
abscesses in the right hepatic lobe. Percutaneous drainage returned grossly
purulent fluid which yielded Klebsiella pneumoniae upon culture. Despite
resolution of his sepsis, his ophthalmologic condition worsened requiring
enucleation 20 days after initial presentation.
First described in Taiwan in the early 1990s, hepatic abscess secondary to
Klebsiella pneumoniae is now an emerging disease in western countries.
Reports in the literature have been steadily increasing, and cases have been
described in all races. The virulence of K. pneumoniae is notable, and early
detection of this pathogen is essential. Endophthalmitis is the most common
metastatic complication of Klebsiella hepatic abscess. Intravenous antibi-
otics commonly employed to treat hepatic abscesses are often insufficient to
treat this grave ocular complication. Successful treatment regimens for Kleb-
siella endophthalmitis often include intravenous and intravitreal antibiotics
as well as early vitrectomy to attempt preservation of visual acuity.
1. K. pneumoniae needs to be recognized as a highly invasive organism caus-
ing ocular complications in immunocompetent hosts with pyogenic hepatic
abscess
2. Early ophthalmic intervention needs to be emphasized in patients with
Klebsiella pneumoniae hepatic abscesses and ocular symptoms to prevent
permanent visual impairment.
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Schistosoma Mansoni in the Stomach – A Rare Find!
Rohit Jindal, MD, Jie Ouyang, MD, Rosemary L. Wieczorek, MD, Mohit
Jindal, MD, Ayse Aytaman, MD∗. Gastroenterology, VA NYHHCS,
Brooklyn, NY; Gastroenterology, SUNY Downstate Medical Center,
Brooklyn, NY and Pathology, VA NYHHCS, Brooklyn, NY.
Schistosomiasis occurs as a result of immune response to the schistosome
ova in the tissues of the body. The ova of various schistosomes have been
reported in biopsy specimens of rectum, liver, intestine, bladder and rarely
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from ectopic sites as bronchial biopsy. We present a very rare case of gastric
schistosomiasis caused by Schistosoma mansoni.
Case report: A 65 year old man, originally from Puerto Rico, who had
lived in the US for four decades but travelled frequently to the Carribean
was being followed up for compensated hepatitis C cirrhosis. He under-
went elective esophagogastroduodenoscopy to rule out esophageal varices.
On EGD, there was no evidence of esophageal or gastric varices or portal
gastropathy suggestive of portal hypertension. A small shallow pre-pyloric
ulcer was seen and the mucosa in the body of the stomach was noted to have
a salt and pepper appearance. Biopsies were obtained and pathology from
the body of the stomach revealed several granulomas with S. mansoni ova
in the lamina propria [Fig. 1]. The patient admitted walking bare foot in wa-
ter several times over the years in Puerto Rico. He denied having abdominal
pain, nausea, vomiting, diarrhea or bleeding. Stool was tested multiple times
and did not reveal any ova or parasites. The patient was treated for gastric
schistosomiasis with Praziquantel at a dose of 20 mg/kg. Repeat EGD done
two months later did not show schistosoma ova in gastric biopsy. The patient
was advised to avoid walking bare foot in water in the endemic areas.
Discussion: Schistosomiasis can be diagnosed by detecting ova in feces
or urine, from various tissues of the body or by serological testing. The
ova of different species can be identified by their characteristic appearance-
S. mansoni ova have a prominent lateral spine. Schistosomiasis is usually
asymptomatic as was the case in our patient but intestinal schistosomiasis
can present as abdominal pain, diarrhea and iron deficiency anemia. Gas-
troenterologists should be aware of gastric schistosomiasis as a rare entity
that can be successfully treated with Praziquantel.[figure1]
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Collagenous Colitis Associated with Common Variable
Immunodeficiency
Soren Gandhi, David M. Chaletsky, MD, Christopher C. Ashley, MD∗.
Gastroenterology, Albany Medical College, Albany, NY.
Common Variable Immunodeficiency (CVID), a group of 20–30 heteroge-
neous disorders, is associated with a broad spectrum of clinical manifes-
tations including gastrointestinal diseases. Common manifestations include
nodular lymphoid hyperplasia, inflammatory bowel disease (Crohn’s, ulcer-
ative colitis), giardiasis, pernicious anemia, and sprue-like illness. In this
report, a rare case of collagenous colitis associated with CVID is described.
A patient with an 11 year history of CVID, stable on monthly IV gamma-
globulin therapy, presented to the clinic with progressively worsening loose
bowel movements over a course of 3 years. Stool culture was negative for ova
and parasites, blood and mucus. Upper gastrointestinal endoscopy showed
normal appearing esophagus, stomach, duodenum and jejunum as well as a
normal colonoscopic appearance. Duodenal biopsies showed no evidence of
giardiasis and terminal ileum biopsies were unremarkable. Random colonic
biopsies demonstrated microscopic colitis consistent with collagenous col-
itis. Immunostaining for CD3 highlighted numerous intramucosal lympho-
cytes, and trichrome stain revealed a thickened subepithelial collagen band.
Collagenous colitis, a rare entity itself, occurs in small percentage of patients
who present with chronic diarrhea. The prevalence of CVID is approximately
1 in every 50,000 and to discover this combination is unusual, as there has
only been one reported case thus far in the reviewed literature. This report
highlights the presentation, diagnostic workup and clinical course in this
patient with a rare combination of unusual conditions.
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A Challeging and Unusual Presentation of a Case of Acute Pancreatitis
Lavanya R. Petchetti, MD∗, Pavan Kumar Gona, MD, Bangaru Raju
Kolanuvada, MD, Chandra Padmaraju, MD. Internal Medicine, The
Mount Vernon Hospital, Mount Vernon, NY.
Introduction: The most common causes of acute pancreatitis is from bile
stones, alcohol abuse and some uncommon causes being drug-induced, id-
iopathic, trauma, pancreatic cancer, post-ERCP, ischemia, vaculitis, inflam-
matory bowel disease. However acute pancreatitis in the setting of uncon-
trolled rapid atrial fibrillation with systemic embolization should be one of
the differential diagnoses to be considered during the work up of Idiopathic
pancreatitis.
Case Presentation: We report a case of 83 y/o male who presented to the
emergency room with abdominal pain radiating to the back. Labs on admis-
sion showed elevated amylase and Lipase. Past medical history significant for
Atrial Fibrillation. For some medical reasons patient was not on coumadin.
Intial CT abdomen did not show any significant pathology in the abdomen.
Over the next 24 hrs there was a significant change in the patient’s mental
status, so we repeated a CT abdomen and CT head which actually showed
significant infarcts in the spleen, pancreas and also acute ischemic infact in
the cerebral cortex. This patient probably had Acute pancreatitis secondary
to the emboli from rapid atrial fibrillation which is an unusual entity. Though
this patient was started on standard anticoagulation, it had to be discontinued
as the ischemic infarcts converted to hemorrhagic lesions.
Discussion: This was a challenging case because, what was initially thought
to be an ‘idiopathic’ acute pancreatitis turned out to be an ischemic pancre-
atitis. Our patient had a very deleterious course with a fatal outcome and
ended up with ARDS. Management of such cases is a real challenge!
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Zenker’s Bezoar as a Cause of False-Negative Modified Barium
Swallow in a Patient with Dysphagia
Andrew N. Pearson, MD, Rassa Shahidzadeh, MD, Sherman M.
Chamberlain, MD∗. Section of Gastroenterology, Medical College of
Georgia, Augusta, GA.
Zenker’s diverticulum occurs when abnormally high intra-bolus pressures
generated during swallow leads to protrusion of mucosa through an area
of anatomic weakness in the pharynx. Patients may experience dysphagia,
aspiration, choking, regurgitation, voice changes and weight loss as a result
of Zenker’s diverticulum.
A 93 year old female was admitted to our hospital for aspiration pneumo-
nia. Modified barium swallow demonstrated oropharyngeal dysphagia with
lingual and pharyngeal weakness and retropulsion of the bolus from the
esophagus into the pyriform sinuses leading to aspiration. Of note, there
was no Zenker’s diverticulum identified. These findings made placement of
a percutaneous endoscopic gastrostomy tube (PEG) requisite. On upper en-
doscopy we found a large left-sided Zenker’s diverticulum with an impacted
bezoar (Zenker’s bezoar). The Zenker’s bezoar was successfully removed
with a Roth Basket (Fig. 1), and the PEG subsequently placed by a push
method over a wire to facilitate passage of the tube beyond the Zenker’s
diverticulum (Fig. 2).
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This case demonstrates that a modified barium swallow may fail to demon-
strate a Zenker’s diverticulum when a Zenker’s bezoar is present. The
Zenker’s bezoar likely contributed to the oropharyngeal component of this
patient’s dysphagia.
This is only the third reported case of a Zenker’s bezoar. This is the first
reported case of a Zenker’s bezoar leading to a false-negative modified bar-
ium swallow. We recommend considering the presence of Zenker’s bezoars
in debilitated elderly patients who appear to have oropharyngeal dyspha-
gia on modified barium swallows, without prior histories of neuromuscular
compromise.[figure1][figure2]
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A Rare Case of Hepatotoxicity
Sohail Asfandiyar, MD, Chan Ma, MD, Mary Ann H. Sherbondy, MD∗.
Gastroenterology, Henry Ford Hospital, Detroit, MI and Pathology, Henry
Ford Hospital, Detroit, MI.
Medications, both prescription and complementary, are increasingly recog-
nized causes of hepatotoxicity. Hepatic injury from drug accounts for ap-
proximately 2–5% of hospitalizations for jaundice, and is the most common
cause of fulminant hepatic failure in the United States. We present one such
case.
A 57 yo man presents to the hospital with a 1 week history of nausea,
vomiting, and dark urine. Evaluation in the emergency room revealed AST
239, ALT 497, alkaline phosphatase 231, and total bilirubin of 5.4. He was
admitted, and evaluated by the gastroenterology consult service for a possible
ERCP. Workup included hepatitis serologies, autoimmune serologies, iron
studies, and an abdominal ultrasound. There was no cholelithiasis or biliary
dilation, so the case was referred to hepatology.
On further questioning of the patient, he admitted to taking a variety of over-
the-counter herbal formulations, and had been taking them for over 2 years. In
addition, his primary care physician started atenolol for hypertension within
the last month. The patient underwent a liver biopsy to rule out autoimmune
hepatitis versus viral hepatitis. The biopsy showed granulomatous hepatitis
with an unusual number of eosinophils suggestive of drug induced liver
injury. The patient was instructed to stop all herbal medications and the
atenolol was changed to amlodipine. Follow-up in clinic revealed that his
liver enzymes and bilirubin normalized.
Idiosyncratic drug reactions typically occur within the first 6–12 months
after initiation of the medication. In this patient’s case, the complementary
medications were first on our list of potential culprits. However, he had been
taking them for over 2 years which places this group of medications further
down the list. The initiation of atenolol for treatment of hypertension, which
occurred one month before his presentation to the emergency room, is a more
likely suspect, perhaps by interaction with the complementary medications.
Antimicrobials and anticonvulsants are the two most common medication
groups that cause drug-induced liver injury. However, all clinicians should
be cognizant of the fact that any prescribed or complementary drug may
cause hepatotoxicity, and a thorough medication history is vital.
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Choledochal Semi Volvulus with Normal LFTs: A Complication of
Paraesophageal Hernia, with Literature Review
Sayeeda A. Jabeen, MD, Raymond L. Farrell, MD∗. Internal Medicine,
Southern Illinois University, Springfield, IL.
86 year old lady presented with sudden onset of sub-sternal and epigas-
tric pain, with radiation to the neck and the back, associated with nausea,
palpitation, diaphoresis, and vomiting dark material. PMH: Long standing
hiatal hernia with bloating, belching, and chest discomfort. BP 220/110. All
labs normal except troponin slightly elevated 0.06. Initial diagnosis: Acute
Coronary Syndrome. Urgent Cardiac catherization was normal. CT of the ab-
domen revealed a large paraesophageal hernia with all of the stomach located
intra-throacically, with possible incarceration, along with a hugely distended
gallbladder, with dilation of CBD to 13 mm with no gallstones. Patient was
taken to OR for reduction and fixation of hernia. An abdominal approach
was taken, upon opening of the abdomen a large hemorrhagic, gangrenous
gallbladder was seen along with hiatus hernia with pulled cholodocal ductal
system along with the tenting of duodenum. Intraoperative cholangiogram
showed no filling defect or gall stones. Patient underwent cholecystectomy
along with reduction and fixation of hiatus hernia.
Literature Review: 4 similar cases have been reported.
Miller and Thompson (1977): Intermittent dislocation of Liver; A syn-
drome associated with volvulus of stomach, transverse colon and obstructive
jaundice.
Llaneza PP et al. (1986): Extrahepatic obstruction of CBD at the di-
aphragmatic hiatus in association with intrathoracic volvulus. Lamouliatte
et al. (1992): Biliary obstruction complicating diaphragmatic hiatus her-
nia with jaundice due to choledochal dislodgement and torsion. Caldiero
et al. (2001): Choledochal semi volvulus with jaundice due to hiatal her-
nia. All the 4 cases presented with cholestatic syndrome secondary to either
obstruction or stretching of CBD in the diaphragmatic hiatus and hiatus her-
nia was diagnosed retrospectively. By contrast, our patient presented with
chest/ epigastric pain with normal LFTs and was subsequently found to have
gangrenous acalculous cholecystitis in association with incarcerated hiatus
hernia. This observation emphasizes the possibility of direct relationship of
gangrenous cholecystitis and hiatus hernia even with normal LFT, could be
due to intermittent stretching or tension of CBD. If time permits HIDA scan
is recommended to confirm the diagnosis. But, if the clinical suspicion is
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high, an abdominal approach is recommended to repair the volvulus and at
the same time explore the gallbladder to reduce the added mortality of these
coexisting clinical entities.
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Metastatic Breast Cancer Mimicking Small Bowel Crohn’s Disease
Mariam S. Sauer, MD, Sherri Yong, MD, James Richter, MD, Khondker
Islam, MD∗. Department of Medicine, Loyola University Medical Center,
Maywood, IL and Department of Pathology, Loyola University Medical
Center, Maywood, IL.
Introduction: Small bowel involvement of metastatic breast cancer is a rare
but recognized entity. It can present in a number of ways and can often
be confused with primary disorders of the gastrointestinal (GI) tract such as
Crohn’s disease. We present a case of metastatic breast cancer to the terminal
ileum initially presenting as abdominal pain.
Case: A 62 year old Caucasian female with metastatic breast cancer to bone
presented with left lower quadrant pain for 6 months. The pain was dull
without radiation and no aggravating or relieving factors. She complained
of no other GI related symptoms such as constipation, diarrhea, nausea,
vomiting, weight loss or blood in stool. There was no known family history
of colon cancer or inflammatory bowel disease. Initial workup included a
CT scan which showed nonspecific wall thickening of the terminal ileum.
A small bowel follow through was subsequently done and revealed mu-
cosal effacement and nodularity of the last 15 cm of the terminal ileum.
A colonoscopy to the terminal ileum was then done. Endoscopically, the
terminal ileum appeared grossly abnormal with several ulcerations and sur-
rounding erythema and edema. The colonic mucosa appeared normal except
for scattered diverticulosis. Biopsies of the terminal ileum revealed chronic
inflammation.
At that time the patient was suspected to have Crohn’s disease but was not
treated as she did not follow up with a gastroenterologist. One year later as
she remained symptomatic, the patient’s primary care physician referred her
to a gastroenterologist for suspected Crohn’s disease. She underwent repeat
colonoscopy to confirm the diagnosis. Terminal ileal ulcers were again seen
and biopsy results revealed metastatic breast cancer.
Discussion: Breast cancer may metastasize anywhere within the GI tract. In
one retrospective review, it was estimated that breast cancer metastasizing to
the GI tract involved the small bowel in 19% of patients. The most common
presentations that are reported are abdominal pain, obstruction and bowel
perforation.
The differential diagnosis of terminal ileal ulcers is broad. The most common
etiologies are inflammatory bowel disease, infections and ischemia. How-
ever, metastatic breast cancer may affect the small bowel although it is rare.
Clinicians should have a high index of suspicion in patients with metastatic
breast cancer presenting with terminal ileal ulceration.
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Dysphagia in a Patient after Cervical Spine Surgery
Ravi V. Nadimpalli, MD, Mark Blumenkehl, MD∗. Gastroenterology,
Henry Ford Health System, Detroit, MI.
Case: A 66 year-old gentleman with a history of stroke and cervical spine
surgery is referred for evaluation of dysphagia. His symptoms have been
present for 10 days, and occur with solid food and pills. He reports some de-
creased oral intake and mild weight loss but denies odynophagia, abdominal
pain or melena. His past history is significant for cervical spine spondylolis-
thesis for which he underwent cervical discectomy and stabilization via an
anterior approach, performed 8 months prior to this presentation. On exam,
his abdomen was benign and no cervical lymphadenopathy was noted. An
upper endoscopy was performed which showed a normal stomach and duo-
denum. On withdrawal, the esophagus was examined carefully, revealing the
finding below (Fig. 1). The image shows a screw from the patient’s cervical
hardware eroding into the upper esophagus, with the lumen seen at the bot-
tom of the image. A subsequent swallow study shows pooling of contrast in
the area of erosion. The patient underwent surgical repair of the defect using
a sternocleidomastoid flap.
Discussion: Pharyngo-esophageal perforation is a rare complication of cer-
vical surgery. It is primarily associated with anterior-approach cervical
surgery. The incidence is unknown, but in four large studies of anterior cer-
vical surgery a total of 7 cases of perforation were noted. The presentation of
this complication can range from complete lack of symptoms to mediastini-
tis and sepsis. Due to the wide variability in presentation, diagnosis can be
difficult and a high index of suspicion should be maintained in patients with
esophageal symptoms and a history of anterior cervical surgery. Perforation
is thought to be mediated by recurrent infections or chronic compression
of the esophagus and subsequent ischemia. Investigation can include lateral
spine films, CT scan, swallow study or endoscopy. Management remains
controversial, and ranges from conservative treatment with nasogastric tube,
NPO status, and intavenous antibiotics to surgical intervention with an SCM
flap. Given the rare nature of this complication, definitive guidelines for ther-
apy have not been outlined, and further study is necessary before a standard
approach can be recommended.[figure1]
739
Endotherapy for Massive GI Bleeding Due to Duodenal Lipoma
Parupudi V.J. Sriram, MD, Easwaran Variyam, MD∗. Internal Medicine
(Gastroenterology), Texas Tech Univ Health Sci Center, Lubbock, TX.
Massive gastrointestinal bleeding due to duodenal lipoma is uncommon. We
present here a case to demonstrate the feasibility of endoscopic treatment.
A 64 y male presented to the ER with acute shortness of breath. He is obese,
hypertensive, chronic smoker and has advanced COPD. He was hypotensive
and cyanotic on admission. He was immediately intubated and transferred
to ICU. Further workup revealed severe pulmonary embolism (PE). He was
started on anticoagulation and was considered for thrombolysis. Within 6
hours he developed massive hematemesis and had a drop in hemoglobin by
3 gms/dL. There was no prior history of abdominal pain, NSAID ingestion,
liver disease or alcoholism. He was immediately transfused with PRBCs, IV
PPI. An EGD showed fresh blood clots in fundus and duodenum that could
not be cleared. He was continued on PPI infusion and anticoagulation was
continued without thrombolysis. Hematocrit was maintained with PRBCs. A
repeat EGD revealed a polypoidal lesion with surface ulceration in 2nd part
of duodenum (Fig. 1A). An upper endoscopic ultrasound (EUS) showed a
well-defined, hyperechoic lesion arising from the submucosa, suggestive of
lipoma. In view of significant bleeding and ongoing need for anticoagulation
due to PE, this lesion was resected endoscopically. Histopathology confirmed
it as a lipoma.
Submucosal lesions causing massive GI bleeding is uncommon but not rare.
The differential diagnosis for submucosal lesions causing bleeding include
S390 Abstracts
varices, vascular malformations (Dieulafoy’s lesion), stromal tumors arising
from muscularis mucosa and lipomas. Endoscopic appearances can some
times be suggestive – arterial lesions may be pulsatile; varices may be in-
dentable with the tip of a biopsy forceps; benign tumors may be firm and mo-
bile under the mucosa. Echomorphology on EUS is generally confirmatory.
Endotherapy of lesions detected incidentally on endoscopic examination is
debatable. Endoscopic resection, avoiding surgery, is the treatment of choice
for symptomatic patients.
Massive gastrointestinal bleeding due to duodenal lipoma is uncommon.
Confirmation of echomorphology on EUS facilitates safe removal of these
tumors by endoscopic resection.[figure1]
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Trouble Shooting in the Endoscopy Unit: Successful Management of
Gastro-Gastric Fistula and Gastro-Jejunal Anastomosis Obstruction
Using a Polyflex Stent
Paramvir Singh, MD, Thomas Sonnanstine, MD, Andres Gelrud, MD∗.
Digestive Diseases, University of Cincinnati, Cincinnati, OH and Tristate
Surgical Weight Loss Center, St. Luke Hospital, Florence, KY.
A 50 year old man underwent Roux-en-Y gastric bypass (RNY GBP) for mor-
bid obesity. Immediately post-op the patient was diagnosed with an anasto-
motic leak requiring revision of the gastro-jejunostomy anastomosis (GJA).
Eight months later, he presented with protracted nausea and post-prandial
emesis. An upper endoscopy revealed an obstructing giant marginal ulcer
involving approximately 75% of the GJA. Despite optimal medical ther-
apy (sucralfate, PPI, misoprostol, liquid diet) the ulcer persisted on repeat
endoscopy 3 months later. During this endoscopy a second lumen was visu-
alized in the gastric pouch which represented a gastro-gastric fistula (GGF).
This tract was dilated followed by placement of a percutaneous endoscopic
gastrostomy (PEG) tube for enteral nutrition in the excluded stomach. Subse-
quent endoscopy 2 months later showed a stenotic GJA with persistent ulcer.
In an effort to facilitate resumption of oral intake and reverse the bariatric
anatomy, we decided to place a Polyflex stent (Boston Scientific, Natick MA)
across the GGF. To alleviate the sharp angulation between the gastric pouch
and the excluded stomach a biliary guidewire was passed through the gas-
trostomy tube and subsequently withdrawn through the mouth. Keeping this
wire in a state of constant tension at both ends (mouth and gastrostomy), a 23
mm wide × 90 mm long stent was successfully deployed across the GGF. To
prevent stent migration the proximal aspect of the stent was affixed to the gas-
tric mucosa using a resolution clip and a suture loop that was placed through
the stent prior to assembly. The patient’s symptoms abated completely after
this procedure. The stent was successfully removed six months later. During
his four months follow up, he continues to maintain good nutritional status
with oral feeding alone.
Discussion: Prior to divided RNY GBP, GGF occurred in up to 50% of
patients. Currently the incidence is 6%. GGF may be asymptomatic or present
with failure to lose weight or weight regain. Marginal ulcers secondary to
GGF necessitate addition of a PPI. Smoking and the use of NSAIDs are
contraindicated to enhance mucosal healing. This case represents a novel
successful off label use of the retrievable Polyflex stent with endoscopic
reversal of bariatric anatomy to facilitate healing of an obstructing marginal
ulcer and assure PO intake.
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A Case of Common Variable Immunodeficiency Mimicking Refractory
Celiac Sprue
Tanvi A. Dhere, MD∗, Alexander Lee, Mohammed Wehbi, MD, Kamil
Obideen, MD. Department of Digestive Diseases, Emory University,
Atlanta, GA.
Case presentation: A 57 year old Caucasian male with a history of common
variable immunodeficiency (CVID) presented to our clinic for management
of his celiac disease. The patient had been diagnosed in 2001 after pre-
senting to an outside gastroenterologist with complaints of diarrhea and
had evidence of scalloping and villous blunting on an EGD. The patient
did not respond to a gluten free diet and lost 40 lbs despite the gluten re-
striction. Given the weight loss, radiological workup was performed (CT
and small bowel follow through) but showed no abnormalities except for
splenomegaly which may be found in patients with CVID. A repeat small
intestinal biopsy in our institution showed evidence of extensive inflamma-
tory infiltrate and submucosal fibrosis with no evidence of villous blunting.
Flow cytometry was negative for lymphoma. A capsule endoscopy showed
villous atrophy, decreased folds, mucosal erythema, and granularity along
with lymphangiectasia. The patient’s gastrointestinal symptoms as well as
endoscopic and histologic findings were attributed to CVID and not celiac
disease. He was started on intravenous immunoglobulin therapy. His symp-
toms improved, and he noted an increase in his weight after being taken off
the gluten free diet. Discussion: Among the primary immunodeficiency dis-
orders, gastrointestinal manifestations tend to predominate in patients with
CVID. Histologically, CVID can mimic endoscopic findings suggestive of
celiac disease. There are subtle differences, however, that gastroenterolo-
gists should be aware of in order to delineate between the two diseases as
the management strategies are different. Plasma cells are absent from the in-
testinal biopsy specimens of patients with CVID, like our patient described
above. Apoptotic bodies are common in CVID. A gluten free diet improves
villous atrophy in approximately 50% of patients with CVID, while it nor-
malizes villous architecture in the majority of patients with celiac sprue.
Unlike CVID, celiac sprue, is associated with increased amounts of IgM
and IgA. Treatment with immunoglobulin (IVIG) does not always appear to
improve the rate of infection or improve GI symptoms in CVID, unlike our
patient. Supportive treatment with fluids as well as repletion of vitamins and
minerals remain a central part of therapy. In conclusion, this case illustrates
the need for searching for alternative causes for diarrhea and malabsorption
in a patient that is refractory to treatment for celiac disease.
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Unusual Presentation of a Cecal Volvulus
Sohail N. Shaikh, MD, Hamed Shaaban, MD, Robert S. Spira, MD, Joseph
R. DePasquale, MD∗. Gastroenterology, Seton Hall University School of
Graduate Medical Education, South Orange, NJ.
Introduction: Cecal bascule is a rare type of volvulus where the cecum
folds anteriorly, displacing the appendix into the RUQ. Although colonic
obstruction usually presents as a surgical emergency, the diagnosis is usually
not made preoperatively without radiography. This is an unusual presentation
of cecal bascule.
Case Report: 81 y/o black female with diabetes presented with 4 days of
“crampy” constant lower abdominal pain, constipation, vomiting and poor
appetite. She denied bleeding, viral illness, smoking, antibiotic use, or prior
abdominal surgery. Examination revealed tachycardia, diffuse abdominal
tenderness especially RLQ, no peritoneal signs with a negative guaiac. After
a bowel movement her pain improved (8/10→2/10).
Labs: Hgb 11.2 (nl MCV); WBC 7.7 (n-69%); Lactate 2.1; nl-AST /ALT;
Amylase 67; Lipase 21.
The next 48 hours yielded alternating exam findings from a benign to surgical
abdomen. Labs remained unchanged.
CXR: Right hemidiaphragm elevation with marked bowel distension in the
RUQ.
CT scan: 9 cm cecum with an air-fluid level [figure1]Day two: Increasing
pain with peritoneal signs warranted surgery. A dilated cecum was found
folded onto the ascending colon into the RUQ, completely obstructed at the
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fold with patchy necrotic areas requiring a right hemicolectomy. [figure2]Her
post-op course was uneventful.
Discussion: Bascule is a French term meaning seesaw. This is appropriate
as the cecum flips upward on itself causing a deep crease across the bowel
and an occlusion of the gut lumen. Cecal bascule differs from volvulus in
that its injury is not caused by vascular compromise, but by a one way flap-
valve with pressure building against the fold distally. This case illustrates a
unique condition and presentation of waxing and waning pain, reminding us
that cecal bascule must be considered in patients with abdominal pain and
distension.
743
Adenocarcinoma of the Colon Associated with Esophageal Dysmotility
M. Mukherjee, MD, A. Khdair, MD, T. Soora, MD, I.M. Grosman, MD∗.
Gastroenterology, Long Island College Hospital, Brooklyn, NY.
An 80 year old woman presented with a 2 week history of worsening nausea
and vomiting of gastric contents. She reported anorexia and 20 lb weight
loss over one month. She denied dysphagia, odynophagia, globus sensation
or regurgitation. A prior EGD showed gastritis with evidence of H. pylori
that was treated. She was scheduled for colonoscopy but developed abdomi-
nal pain and vomiting with the bowel prep. Initial evaluation revealed stable
vital signs and no fever. Physical exam was significant for a benign abdomen
and fecal occult blood. There was mild anemia. A CT scan of the abdomen
showed distention of the distal esophagus and no evidence of bowel obstruc-
tion. A gastric emptying study demonstrated no transit of solid food from
the esophagus into the stomach at 90 minutes after ingestion. A repeat EGD
showed a dilated distal esophagus with retained food particles and no evi-
dence of stricture. The stomach and duodenum were normal. Biopsies were
unremarkable. The vomiting persisted despite metoclopramide therapy. Sub-
sequent colonoscopy showed a circumferential mass in the sigmoid colon.
The patient underwent sigmoid resection and pathology revealed adenocar-
cinoma. Post-operatively the patient experienced no further symptoms and
she was discharged home in stable condition.
GI dysmotility is a rare paraneoplastic syndrome that occurs most often in
association with small cell lung carcinoma. Rarely lung adenocarcinoma,
leiomyosarcoma, lymphoma, melanoma and cancers of the kidney, breast
and prostate have been implicated. Patients often suffer from intestinal pseu-
doobstruction. Dysphagia, bladder dysfunction, autonomic insufficiency and
peripheral neuropathy have also been described. The onset of symptoms may
precede the discovery of the primary tumor by several years. It is thought
to have an autoimmune basis and histology typically demonstrates marked
lymphocytic infiltration of the myenteric plexus. The interstitial cells of Cajal
may be a target in the pathogenesis of this disorder. Cross-reacting autoan-
tibodies found in the sera of these patients bind to the primary tumor cells
and to neuronal cells in the myenteric plexus, resulting in inflammation and
destruction. The detection of circulating anti-neuronal nuclear antibodies in
the serum may aid in the diagnosis of this condition.
We report here a case of colonic adenocarcinoma associated with esophageal
dysmotility as a paraneoplastic syndrome which resolved after resection of
the tumor. This has not been previously reported in the literature.
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Chlorzoxazone as the Cause of Fulminant Hepatic Failure
Adam Levy, MD∗, Gaurav Mehta, MD, Stacey Zavala, MD, Malek Ashraf,
MD, Kenneth Rothstein, MD, Santiago Munoz, MD. Hepatology, Albert
Einstein Medical Center, Philadelphia, PA.
A 48-year-old Caucasian woman with a past medical history of anxiety pre-
sented to the emergency room complaining of 3 weeks of jaundice, nausea,
and right upper quadrant pain. She had no significant family history. She
rarely drank alcohol and did not use illicit drugs. Medications were esci-
talopram, which she had been on for several years, and chlorzoxazone 250
mg three times daily, which she had been taking for the last 4 months for
shoulder pain.
On exam the patient was jaundiced, with scleral icterus. She had a tender
right upper quadrant. She had no stigmata of chronic liver disease. She did
not have evidence of encephalopathy on admission.
Laboratory data: WBC 9,600 mm3; Hgb 12.7 g/dL; Platelets 243×103/uL;
PT 37 sec; INR 3.8; Creatinine 0.9 mg/dL; Albumin 2.7 g/dL; Total bilirubin
18 mg/dL; Direct bilirubin 12.9 mg/dL; AST 923 U/L; ALT 1391 U/L;
AlkP150 U/L. HBsAg, Hep C Ab and HCV PCR were negative. Hepatitis
A IgM negative, IgG positive. ANA and SMA negative. AMA positive at
1:160, LKM and SLA were negative. CMV negative. Acetaminophen level
was undetectable on admission.
Ultrasound revealed a mildly heterogeneous liver with no focal masses and
appropriate flow in all vessels.
Transjugular liver biopsy: Sub massive hepatic necrosis with severe interface
activity and widespread reticulin collapse, severe cholestasis, intense ductu-
lar proliferation, marked neutrophilic infiltrate due to chemotactic response
to ductular proliferation, occasional eosinophils and few plasma cells, not
suggestive of autoimmune hepatitis, moderate ductopenia, no cholangitis.
CMV, herpes, and hepatitis B immunostains were negative.
The patient was admitted for evaluation of acute liver failure. Chlorzoxazone
was discontinued. Over the course of 8 days, transaminases decreased but PT
remained elevated. She had very low Factor 5 and 7 levels which continued
to decrease during her stay in the hospital (down to <1%). Patient developed
stage 2 encephalopathy and was listed for liver transplantation. Seven days
after being listed, the patient underwent successful liver transplantation.
Chlorzoxazone is a centrally acting muscle relaxant introduced nearly
fifty years ago. Hepatotoxicity is a known rare adverse reaction. Literature
review reveals two deaths attributed to liver failure from chlorzoxazone, and
one other patient survived after liver transplant from chloroxazone-induced
S392 Abstracts
liver failure. This case reemphasizes the need to monitor for hepatotoxity in
patients taking chlorzoxazone.
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Ulcerative Jejunoileitis – An Uncommon Cause of Gastrointestinal
Bleeding and Adenopathy
Daniel S. Mishkin, MD, CM∗, Stephen Sentovich, MD. Gastroenterology,
Boston University, Boston, MA and Surgery, Boston University, Boston,
MA.
A 66 year old man presented for unexplained gastrointestinal bleeding. He
had noticed bright red blood per rectum and had a syncopal event upon
getting up from the toilet. His initial evaluation included an EGD and a
colonoscopy without any significant findings. He required 5 units of blood
and was discharged and sent to Boston University Medical Center for a small
intestinal evaluation. Of note, he was noticed to have a 45 pound weight loss
over the prior months and he had an albumin of 2.7 g/dl. His past medical
history was significant for hypertension, coronary artery disease and dia-
betes, and he was not taking any NSAIDs. On exam, he was tender at a site
of fullness in the right lower quadrant. His laboratory evaluation revealed an
elevated WBC of 11.6 and ESR of 87 with a normal tTG and IgA level and
HIV negative. A CT enterography was performed showing multiple enlarged
paraaortic lymph nodes up to 2.6 cm. Additional prominent less than one
centimeter lymph nodes were noted within a region of swirling mesentery
anterior to the pancreas. Concentric wall thickening was noted in multiple
loops of the distal ileum and less so in some loops of jejunum. The patient
underwent a CT-guided lymph node biopsy. The pathology, flow cytometry
and PCR of the lymph node biopsy were inconclusive (non-specific inflam-
mation). All other laboratory cell-typing evaluations for lymphoma were
negative.
Without a definitive diagnosis, a capsule endoscopy was performed and
demonstrated multiple ulcerations scattered throughout the small intestine.
The proximal ulcerations were within the reach of a push enteroscope and
were biopsied. The pathology was inconclusive (normal small bowel mu-
cosa). The patient underwent a CT/PET scan that was essentially negative
except for a mild uptake presumed to be from the jejunal biopsies.
After another bleeding episode, the patient was taken to the operating room.
An area of significant ileal inflammation and adjacent adenopathy was easily
identified and was resected laparoscopically. Pathology demonstrated mu-
cosal ulcerations with reactive adenopathy without granulomata, lymphpro-
liferative disease or carcinoma, suggestive of primary ulcerative jejunoileitis.
Ulcerative jejunoileitis is a rare disease entity and can be seen without the
presence of associated celiac disease. The significance of the adenopathy,
weight loss, and hypoalbuminemia suggested a neoplastic process that re-
quired an operation to make a definitive diagnosis.
746
Lung Cancer Presenting with Dysphagia Due to Esophageal Metastasis
Vineeta Sood, MD, Fred L. Hardwicke, MD, Parupudi V.J. Sriram, MD∗.
Internal Medicine, Texas Tech Univ Health Sciences Center, Lubbock, TX;
Internal Medicine (Hematology & Oncology), Texas Tech Univ Health
Sciences Center, Lubbock, TX and Internal Medicine (Gastroenterology),
Texas Tech Univ Health Sciences Center, Lubbock, TX.
Esophageal metastases are rare and majority of them originate in the larynx,
hypopharynx, trachea, bronchus and stomach. We report a case of lung cancer
presenting with dysphagia.
A 58 year old white male complained of intermittent dysphagia to solids for
7 weeks. He denied anorexia, but lost 15 lbs in 6 months. He is a chronic
smoker (100 pack years) but denied any alcohol or drug use. Chest x-ray
showed left sided pleural effusion. EGD revealed extrinsic compression in
mid esophagus and a 2 cm cratered ulcer (Fig. 1A). Thoracic CT revealed
left pleural effusion (pl.eff)), T12 vertebral metastases impinging on the
cord (>>) and mediastinal lymphadenopathy (Fig. 1B). Esophageal ulcer
biopsy showed atypical cells in the sub-epithelial stroma (Fig. 1C). Immuno-
histochemistry was consistent with lung primary. Metastatic spread was also
confirmed from vertebral lesion and the pleural fluid. He was treated with
steroids, spinal irradiation and chemotherapy with Docetaxel. However, pa-
tient succumbed to an acute coronary event one week later.
Tumors metastasizing to the esophagus include gastric, renal, hepatocellular,
prostate, testicular, skin and bone. Autopsies in patients dying of cancer
suggested an overall incidence of 3 to 6%, with breast and lung as the most
common primary tumors. Secondary esophageal involvement occurs due
to (i) direct extension (most common), (ii) lymphatic or, (iii) hematogenous
spread. 1–2% of lung cancer patients initially complain of dysphagia. Spread
to the esophagus results in sub-mucosal infiltration with normal overlying
mucosa and endoscopic biopsies are usually non-diagnostic. However, in the
present case esophageal ulcer biopsies were diagnostic of metastases from
lung.
Recent onset dysphagia in a chronic smoker warrants urgent EGD to exclude
esophageal cancer or rarely metastases from lung cancer.[figure1]
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Endoscopic Treatment of a Small Bowel Obstruction – Removal of an
Apricot-Pit Bezoar
Daniel S. Mishkin, MD, CM∗, David B. Mcaneny, MD. Gastroenterology,
Boston University, Boston, MA and Surgery, Boston University, Boston,
MA.
A 94 year old woman developed acute onset of nausea, vomiting, significant
abdominal distention, and chest pain. Her history was limited by progressive
memory loss and limited short term recall. However, her daughter (a physi-
cian) reported that she may have swallowed an apricot pit. Her past medical
history is noteworthy for severe coronary artery disease with congestive
heart failure, cerebrovascular accidents and hypertension.
On examination, the patient was hemodynamically stable, and she had a
distended, tender abdomen, and a succussion splash. While ruling out cardiac
causes of her pain, radiographs of the abdomen demonstrated several mildly
dilated loops of small bowel with little to no gas in the colon, suggesting
a small bowel obstruction. A subsequent CT scan demonstrated moderate
dilatation of the stomach and loops of proximal small bowel, with collapse of
the terminal ileum. There appeared to be a short segment of narrowing in the
ileum that likely represented the mechanical obstruction; a heterogeneous
intraluminal collection of gas and soft tissue was located proximal to this
site, and its appearance was compatible with a bezoar.
The patient’s cardiopulmonary conditions were treated during the next
24 hours, and her abdomen became progressively more distended while
her discomfort increased. In addition, her lactic acid level rose to 2.6 (ULN
2.0). A repeat CT scan revealed increasing dilatation of the proximal small
intestine. The patient and her daughter ardently hoped to avoid an operation,
so we proposed an attempt at removing the bezoar via endoscopy.
Following two tap water enemas, an endoscope was passed through the stool-
filled colon and into the terminal ileum under minimal sedation. Anticipating
a poorly prepped colon, the plan was to start with a pediatric colonoscope
with the double balloon endoscope as a back-up that was subsequently not
needed. About 40 cm proximal to the ileocecal valve, an obvious obstructing
foreign body was identified and dragged into the colon with a snare. This
8-cm long bezoar was compatible with the apricot pit, and her abdomen
immediately deflated. The endoscope was re-inserted and we observed no
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strictures or mucosal narrowing; some superficial erosions most likely re-
flected ischemic changes from the formerly impacted bezoar.
This poor surgical candidate underwent an endoscopic removal of an apricot-
pit bezoar, with immediate relief of an acute small bowel obstruction. She
has been subsequently well.
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A Case of Painless Jaundice as the Primary Presenting Symptom for
Renal Cell Carcinoma
Paula M. Dionisio, MD, Ananya Das, MD, Suryakanth Gurudu, MD∗.
Gastroenterology, Mayo Clinic Scottsdale, Scottsdale, AZ.
Introduction: Renal cell carcinoma (RCC) is regarded as one of the great
masqueraders in medicine. This is a case of an unusual presentation for this
malignant entity.
Case: A 69-year-old male presented with a 3 week history of diffuse pruritis,
progressive jaundice, dark urine, and clay colored stools. The patient had no
abdominal pain or fever. Laboratory studies were consistent with cholesta-
sis: AST 237 U/L, ALT 245 U/L, Alk Phos 689 IU/L, total bilirubin of 16.7
mg/dL, and direct bilirubin of 11.2 mg/dL. The patient was afebrile, diffusely
jaundiced, and had no abdominal tenderness on exam. Magnetic resonance
imaging of the abdomen and magnetic resonance cholangiopancreatography
revealed a 10 cm × 8 cm × 7 cm left renal mass and retroperitoneal and
portocaval lymphadenopathy. A 3 cm × 2 cm retropancreatic node displaced
the pancreatic head and mechanically obstructed the extrahepatic common
bile duct (CBD) causing intra- and extrahepatic biliary ductal dilation. En-
doscopic retrograde cholangiopancreatography (ERCP) was performed the
following day. A very tight mid-CBD 2 cm long stricture consistent with
extrinsic compression was found (see Figure). Biliary stricture dilation was
performed and a biliary stent (10-French 9-cm straight Cotton-Leung bil-
iary stent) was placed in position across the stricture with excellent biliary
drainage. Subsequently (2 weeks later) the patient had left radical nephrec-
tomy and mobilization of the liver and partial lymphadenectomy. The patient
is currently undergoing chemotherapy and has had one planned biliary stent
change since surgery.
Discussion: Painless jaundice has been infrequently reported in the litera-
ture as a presenting or associated complaint with renal cell carcinoma. Re-
ported causes have included metastases to: pancreas or surrounding lymph
nodes (2 cases and 2 studies of 5 patients each), intraluminal common bile
duct (2 cases), and duodenum (one case). Additionally, 2 cases of jaundice
secondary to a paraneoplastic syndrome associated with RCC have been
reported. This case, along with those previously reported, demonstrates that
while rare, an inclusive differential for painless jaundice may uncover alter-
native primary pathology.[figure1]
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Successful Removal of a Migrated Esophageal Self-Expanding
Metallic Stent from the Stomach with the Aid of an Esophageal
Self-Expanding Plastic Stent
Gene L. Chang, MD, Yogesh Patel, DO, Timothy Laurie, DO, Mani
Mahdavian, MD∗. Gastroenterology, Advocate Lutheran General
Hospital, Park Ridge, IL.
Self expanding metallic stents (SEMS) have been useful for palliative treat-
ment of malignant esophageal obstruction, however, occasionally migration
of the stent occurs. Extraction of migrated metal esophageal stents can be a
challenging procedure with complications including esophageal perforation
and hemorrhage. We describe an innovative way of successfully extracting a
migrated esophageal SEMS from the stomach 7 weeks after initial deploy-
ment, using a self expanding plastic stent (SEPS) as a funnel to protect the
strictured distal esophagus.
A 63 year old male with stage IV esophageal adenocarcinoma causing stic-
ture of the distal 5 cm of the esophagus, underwent successful deployment of
an Ultraflex SEMS (12 cm in length) across the stricture. Seven weeks after
deployment, the stent was seen migrated into the stomach. A pediatric upper
endoscope was unable to traverse the stricture, thus a balloon dilation was
performed of the stricture and the scope was then advanced into the stom-
ach. The SEMS was too large to be pulled through the stricture. Attempts
to cross the stricture with overtubes and a foreign body hood protector were
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unsuccessful due to the anatomy of the stricture. The initial procedure was
terminated and a repeat attempt was performed two days later. A self ex-
panding plastic stent (SEPS) was deployed with the proximal flare (21 mm
diameter, 9 cm length, 25 mm diameter flare) in towards the stomach to act
as a funnel, as well as to protect the esophageal mucosa (Fig. 1). The stent
was successfully placed across the stricture. The endoscope was advanced
through the stent and the end of the SEMS was grabbed with a jumbo snare.
The SEMS was pulled through the SEPS and out of the patient returned to
recovery in stable condition (Fig. 2).[figure1][figure2]
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Is It Time To Perform HIV Screening among Patients Prior to
Receiving Infliximab (Remicade) Therapy?
Ketul Patel, MD, Shoba Mendu, MD, Michael Piper, MD∗.
Gastroenterology, Providence Hospital Medical Center, Southfield, MI.
Background: Infliximab (Remicade), a TNF-alpha inhibitor, is primarily
used in the treatment of autoimmune disease, as well as inflammatory bowel
disease. We describe a case of infliximab therapy initiated in a man with
ulcerative colitis (UC), who developed cytomegalovirus (CMV) retinits, due
to undiagnosed HIV/AIDS.
Case report: A 65 year old Caucasian man with past medical history of
hypertension, diabetes mellitus and otherwise healthy, was referred to the
gastroenterologist office for complaints of diarrhea, rectal bleeding and re-
cent weight loss. Infectious etiology was ruled out with negative stool studies;
he then underwent a colonoscopy, revealing diffuse erythema and exudate
consistent with panulcerative colitis. Subsequent treatment with prednisone,
mesalamine, and 6-MP gave some symptomatic relief. Due to an inability
to completely wean off prednisone the decision was made to start infliximab
therapy after a negative tuberculin skin test. After initial induction with in-
fliximab the patient showed marked improvement of his GI symptoms. He
was continued on a maintenance regimen of infliximab. Several months later
he presented to his physician’s office with the complaint of decreased vision,
and seeing floaters in his right eye. After a referral to a specialty ophthalmol-
ogy center the diagnosis of CMV retinitis was made. Since CMV retinitis is
associated with HIV/AIDS, he underwent testing for HIV. The test was posi-
tive with a viral load of 201,000-copies/ml and CD4 count of 68-cells/mm3.
By this time, infliximab had been stopped; he received treatment for his
CMV retinitis, which eventually necessitated the placement of a ganciclovir
intraocular implant, and antiretroviral therapy for HIV/AIDS.
Discussion: An increased risk of developing serious infections is seen in
patients on an immunosuppressive agent such as infliximab. Currently it
is recommended that all patients be screened for TB prior to iniatiation of
therapy. Our patient was a healthy man with no obvious risk factors for
HIV/AIDS. The immunosuppressive effects of infliximab could potentiate
opportunistic infections in patients with HIV. Patients are not always forth-
coming with details of their sexual history, or may not be aware of potential
risk factors for HIV. Mandatory HIV testing prior to initiation with infliximab
would have prevented the CMV opportunistic infection in this patient.
We propose that HIV testing should be offered to all patients prior to initiating
therapy with infliximab.
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Hepatocelluar Carcinoma in a Patient with Hepatitis C in the Absence
of Cirrhosis
Javid Fazili, MD∗, Mohammad Madhoun, MD, Lary Pennington, MD.
Digestive Diseases/Internal Medicine, University of Oklahoma Health
Sciences Center, Oklahoma City, OK and General Surgery, University of
Oklahoma Health Sciences Center, Oklahoma City, OK.
Chronic infection with hepatitis C virus (HCV) is regarded as a risk factor for
hepatocellular carcinoma (HCC). Current guidelines recommend screening
patients with HCV for HCC only if there is evidence of cirrhosis. HCC has
been described in HCV patients without cirrhosis, but to our knowledge data
has been very limited.
We report this case of an 81- yrs old African American female with a history
of HCV infection, the only risk factor being a blood transfusion in 1970. She
presented with abdominal pain, and was found to have 4.2 × 4.6 cm enhanc-
ing lesion in the left lobe of the liver by computed tomography (CT-scan) of
the abdomen. Subsequently, a CT-guided fine needle aspiration (FNA) was
positive for malignant cells. Testing for hepatitis B surface antigen (HBsAg)
was negative, patient had no history of exposure to toxins and denied alcohol
intake. The patient had no evidence of cirrhosis clinically or by labs (Total
Bilirubin; 0.6 mg/dl, international normalized ratio (INR); 1.1, albumin of
3.7 g/L and platelet count of 220 × 109/L). Since the patient was not consid-
ered a candidate for liver transplant given her age, she underwent surgery, and
was found to have a 6 cm hepatoma for which she had a left hepatic lobec-
tomy. Pathology revealed mild to moderately differentiated hepatocellular
carcinoma with cancer free margins. Histological examination of the cancer
free hepatic tissue showed mild chronic inflammation with hepatosteatosis
and no evidence of cirrhosis or fibrosis. One year post surgery, patient con-
tinues to be fully functional and has normal synthetic liver function with no
evidence of recurrence.
This case raises the possibility that patients with chronic hepatitis C infection,
without evidence of cirrhosis who are currently considered to be at low risk
for HCC may also develop HCC. Whether the long duration of infection
has a role, needs to be evaluated further. The natural history of hepatitis C
is still evolving and as longer follow up after the initial infection becomes
available, new long-term effect of the infection may be observed.
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Encapsulating Peritoneal Sclerosis: A Rare, but Recognized Cause of
Ascites in Patients with Renal Failure
Alastair D. Smith, MB, ChB∗, Andrew I. Wolf, MD, Keyur Patel, MD.
Medicine, Duke University, Durham, NC.
Encapsulating peritoneal sclerosis (EPS) is a rare but devastating complica-
tion of peritoneal dialysis (PD), occurring typically, but not exclusively after
renal transplantation (RT). Clinical features include abdominal distention
with ascites and/or intermittent small bowel obstruction (SBO). Diagnosis
may be difficult to establish because the condition is rare and the index of
suspicion may not be sufficiently high.
A 37 year-old man underwent live donor RT during 1995 for hyperten-
sive nephroclerosis. Immunosuppressive therapy comprised cyclosporin,
azathioprine and prednisone. Four years later, renal failure recurred after
repeated episodes of allograft rejection; he underwent transplant nephrec-
tomy and started PD, converting to hemodialysis in 2006. He complained
of increasing abdominal distention, early satiety, intermittent vomiting of
two months’ duration and 15 lb. weight loss, earlier this year. There was
no remote history of jaundice or family history of liver disease; he had no
risk factors for hepatitis B or C virus exposure. Phenytoin was being taken
for seizure prophylaxis. Physical examination revealed evidence of recent
weight loss, and ascites, but no icterus or other clinical features of cirrhosis
and portal hypertension. Mental state was normal. Laboratory data were as
follows: Albumin 2.8 g% (normal range [NR]: 3.4–4.5), bilirubin 0.2 mg%
(NR: 0.2–1.2), prothrombin time 12.2 sec (NR: 11.1–13.1), aspartate amino-
transferase 11 IU/L (NR: 10–60) and alkaline phosphatase 162 IU/L (NR:
30–135). His calcium concentration was 8.6 mg% (NR: 8.7–10). There was
no evidence of chronic hepatitis B or C virus infection; his serum ferritin
concentration was 667 ng/mL (NR: 30–300). Liver histology revealed no
inflammation or fibrosis, but the presence of some iron within Kupffer cells
consistent with dialysis-dependent renal failure. The serum-ascites albumin
gradient was 1.8 g%. Contrast-enhanced CT scan confirmed the presence
of large, loculated intrabdominal fluid collections, causing compression of
the second duodenal part. Thickening of the peritoneum consistent with a
chronic inflammatory process was evident also. A presumptive diagnosis
of EPS was made. Treatment with prednisone (30 mg/day) and tamoxifen
(20 mg, bid) was begun, pending possible surgery.
Abstracts S395
The clinical features of EPS may suggest other potential diagnoses, e.g.
mechanical SBO or end-stage liver disease. However, the combination of
PD, before or after RT, abdominal distention and vomiting should not be
overlooked.
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The First Reported Case of Disseminated Coccidioides Involving the
Esophagus and Presenting with Severe Iron-Deficiency Anemia
Julie T. Yang, MD, Hanson Kwok, MD, David S. Condon, MD∗. Internal
Medicine/Gastroenterology, Loma Linda University Medical Center, Loma
Linda, CA.
Introduction: Coccidioides infections have been documented in many or-
gans of the body, but the only case of gastrointestinal tract involvement re-
ported thus far is a single case of retropharyngeal abscess. Here, we present
a case of disseminated Coccidioides affecting the esophagus.
Case: A 68-year-old Hispanic man presents with 3 years of progressive
worsening weakness and fatigue, and 40 pound weight loss in the last 3
months. He has also taken 3-years of naprosyn for chest pain. He did not
report any hematochezia, melena, or hematemesis. Past history included
Billroth II for peptic ulcer disease. Patient reports history of suspicious
lung mass on chest radiograph 8 months ago when he was found to have
pneumothorax. Patient lived near the border of Arizona and Mexico for
30 years as a lemon farmer prior to moving to San Bernadino, California
recently.
On exam, the patient was very thin. His Hgb was 4.6, ferritin 4.5, TIBC
407, and iron 8, and he required 6 units of PRBC transfusion. EGD and
colonoscopy were performed and revealed a 1.5 cm deep esophageal ulcer
with raised borders at 35 cm with pathology showing acute and chronic ulcer-
ation containing fungal spores of Coccidioides immitis. Chest CT revealed
multiple deep neck and chest lymphadenopathy, left clavicular soft tissue
mass, and soft tissue mass adjacent to T6, T7 and L2 vertebral bodies. A cal-
cified lymph node was also seen adjacent to the deep esophageal ulcer at 35
cm. Bronchoscopy and ultrasound-guided FNA of perijugular lymph nodes
reported only inflammatory changes and no malignancy. Coccidioides Ab
serology was 1:128. CSF Coccidioides serology and cultures were negative.
HIV screen was also negative. The patient was treated with 10 days of IV
diflucan followed by oral diflucan and subsequently discharged home with
infectious disease, gastrointestinal and neurosurgery follow-up.
Conclusion: This is the first reported case of disseminated Coccidioides
infection involving the esophagus and the second case in literature involving
the gastrointestinal tract. The CT scan suggests a localized dissemination
of Coccidioides from chest lymphadenopathy to the esophagus, causing a
deep esophageal ulcer. The initial finding of severe anemia is also a unique
presenting feature of this case.
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Pancreatic Pseudocyst Dissecting into the Psoas Muscle
Kalyani Vallurupalli, MD, Raymond Farrell, MD∗, Andrew Varney, MD.
Internal Medicine, Southern Illinois University, Springfield, IL and
Gastroenterology, Southern Illinois University, Springfield, IL.
We describe an unusual extension of a pseudocyst into the psoas muscle.
A 56 year old male with history of chronic pancreatitis presented with epigas-
tric pain and tenderness. His serum amylase and lipase were within normal
limits. A CT scan of the abdomen demonstrated several cystic structures
with peripheral enhancement in the lesser sac consistent with pseudocyst
formation and cystic lesion within the psoas muscle. An MRCP demon-
strated the connection between these cysts.[figure1] Percutaneous drainage
of the pseudocyst was performed.
A follow up CT scan 15 days later showed a reduction in size of the pseu-
docyst within the psoas as well as that in the lesser sac as shown in the
figure which compares the size of the psoas pseudocyst before and after the
Aspirate Fluid analysis
Amylase 7,190 u/L
Lipase 11,883 u/L
Culture No growth
Cytology Negative for malignant cells
procedure.[figure2]The drain was removed after a few days and the patient
had an uneventful recovery.
Although pancreatic pseudocysts are usually found in the vicinity of the
pancreas, there are reports of them occupying unusual sites such as the
mesentery, mediastinum and spleen. A review of literature revealed three
cases of pancreatic pseudocyst extending into the psoas muscle. Two of
them were alcoholics who presented with pain in the hip without any signs
or symptoms of pancreatitis. Both were diagnosed by CT of the abdomen
and were treated by percutaneous drainage. Fluid analysis yielded a negative
culture with amylase of >10,000. The third case presented as a swollen and
painful left thigh and raised serum amylase which was treated by laparotomy.
Our case adds to the existing literature regarding the feasibility of percuta-
neous drainage in the management of pseudocyst pancreas extending into
the psoas.
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Rifaximin for the Treatment of Newly Diagnosed Crohn’s Disease
Ira Shafran, MD∗, Patricia Burgunder, ARNP. Shafran Gastroenterology
Center, Winter Park, FL.
An aggressive immune response to commensal enteric bacteria is thought
to contribute to the pathophysiology of Crohn’s disease in genetically pre-
disposed individuals. Rifaximin is a nonabsorbable antibiotic with broad-
spectrum activity against intestinal pathogens, and multiple studies have
demonstrated a clinical benefit with rifaximin in patients with mild-to-
moderate Crohn’s disease. This case series evaluated the effectiveness of
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rifaximin monotherapy in patients (N = 2) with newly diagnosed Crohn’s
disease. Case report 1: a 25-year-old female presented with a 4-month history
of chronic abdominal pain and diarrhea. A colonoscopy revealed a healthy
colon to the ileum; however, a colonic biopsy was positive for non-caseating
granuloma active ileitis. Small bowel capsule endoscopy showed numerous
aphthous ulcerations, fissuring, and denudation of the small intestinal mu-
cosa. Based on gastrointestinal (GI) symptoms and endoscopic findings, the
patient was diagnosed with a baseline Crohn’s disease activity index (CDAI)
score of 260. The patient began therapy with oral rifaximin 400 mg twice
daily (b.i.d.). After 5.5 weeks of rifaximin treatment, the patient experienced
complete relief of GI symptoms, and endoscopic findings revealed substan-
tial healing of the small intestinal mucosa (CDAI score = 18). The patient
has remained asymptomatic with rifaximin 800 mg/d for 7 weeks. Case re-
port 2: a 25-year-old female presented with severe iron-deficient anemia as
her only symptom. However, a colonic biopsy was positive for lymphoid
nodular hyperplasia and her C-reactive protein (CRP) serum level was sub-
stantially increased (14.7 mg/L), indicating inflammation. Small bowel cap-
sule endoscopy findings were characteristic of Crohn’s disease, including
numerous aphthous ulcerations, fissuring, edema, and active bleeding in the
small intestine. The patient began therapy with oral rifaximin 400 mg b.i.d.
After 4 weeks of rifaximin treatment, the patient’s CRP level improved sub-
stantially (1.3 mg/L) and capsule endoscopy demonstrated healing of the
small intestinal lesions. After 5 weeks of rifaximin 800 mg/d, the patient
remains free of GI symptoms and has experienced stabilization of her severe
anemia. In summary, rifaximin effectively improved clinical symptoms and
promoted healing of the small intestinal mucosa for 2 patients with newly
diagnosed Crohn’s disease. These findings provide further evidence of the
beneficial role of rifaximin for treatment of inflammatory bowel disease,
warranting further investigation in controlled clinical trials.
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Exophytic Splenic Cyst Mimicking a Gastric Mass
Christine Carter-Kent, MD, Pramodha Muniyappa, MD, Matthew
Wyneski, MD, Orhan Atay, MD, Lori Mahajan, MD∗. Pediatric
Gastroenterology, Cleveland Clinic, Cleveland, OH.
A 15 year old male with a four year history of Crohn’s Disease presented with
unrelenting nausea, severe abdominal pain, anorexia, and a 15 lb weight loss.
Despite therapy with Prevacid, azathioprine, and oral steroids, symptoms
persisted. He underwent EGD and colonoscopy. During EGD, a 1.5-cm firm
submucosal nodular lesion was visualized in the gastric cardia. Remainder
of upper endoscopy was normal. The colon appeared diffusely erythema-
tous with deep erosions and ulcerations present throughout. Gastric biopsies
over the lesion revealed chronic active gastritis with H. pylori. Based on
the appearance of the submucosal gastric mass, the differential diagnosis in-
cluded enteric duplication cyst, stromal tumor, leiomyoma/leiomyosarcoma,
pancreatic rest, and splenic cyst. To further classify this lesion, MRI of the ab-
domen was performed. The MRI revealed a 1–1.5 cm exophytic splenic cyst
in the left upper quadrant which appeared to impress on the posterolateral
aspect of the gastric fundus. No abnormality of the gastric wall was identi-
fied. The patient was subsequently admitted and treated with IV steroids and
Infliximab for the diagnosis of Crohn’s flare. The patient was also started
on therapy to treat H. pylori. Symptoms improved and the patient was dis-
charged. Given the small size of the splenic cyst and improvement in symp-
toms, the lesion was not surgically removed.
Splenic cysts are an unusual finding in the pediatric population; however,
they should be considered in the differential of a gastric submucosal mass.
There are no previous reports of a splenic cyst in a pediatric patient mim-
icking a gastric mass at the time of upper endoscopy. These lesions may be
congenital or secondary. Secondary causes include chronic parasitic infec-
tion and abdominal trauma. It is important to recognize these lesions due risk
of spontaneous rupture or abdominal pain caused by impingement on other
intra-abdominal structures. The definitive treatment of these lesions involves
partial or total splenectomy. Decision about surgical intervention is based
upon the location and size of the cyst. In this case, the decision was made
the monitor the patient closely with serial imaging studies as abdominal pain
improved significantly with treatment of underlying Crohn’s disease and H.
pylori. Should this splenic lesion grow rapidly, surgical consultation may be
advised.
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Endometriosis Presenting as Recurrent Massive Ascites
Hui Hing Jack Tin, MD, Hima Satyavolu, MD, Jai Mirchandani, MD,
Kadirawel Iswara, MD, JianJun Li, MD, Scott Tenner, MD, MPH∗.
Division of Gastroenterology, Department of Medicine, Maimonides
Medical Center, Brooklyn, NY.
Endometriosis typically presents as dysmenorrhea, pelvic pain, dyspareunia,
and infertility. Less common clinical presentations of endometriosis from
implantation on the kidney, lung, or colon include hematuria, pleural ef-
fusions and hemoptysis and gastrointestinal bleeding. Ascites complicating
endometriosis is rare. We report an unusual case of endometriosis presenting
as recurrent massive ascites.
A 30 year old African-American woman with worsening abdominal pain and
distension over 2 months presented to the emergency room. The patient had
a history of abdominal distension and pain occuring with every menses for
several years. the symptoms had always resolved at the end of each menstrual
cycle. Over the two months prior to presentation, the abdominal distension
did not subside. After developing worsening abdominal pain, she presented
to the emergency room for evaluation. She denied any nausea, vomiting,
diarrhea, jaundice, or fever. Past medical history was significant for an elec-
tive abortion 7 years prior. Menarche had occured at age 13 with subsequent
regular cycles, no excessive bleeding. On physical examination, she was a
healthy female in mild distress. She has a grossly distended abdomen with
mild diffuse non-localizing abdominal tenderness, no stigmata of liver dis-
ease and no lower extremity edema. Laboratory studies were significant for
a mild normocytic anemia. The remainder of the laboratory findings, in-
cluding liver function tests, was normal. CA-125 was within normal limits.
Pregnancy test was negative. Computer assisted tomography of the abdomen
and pelvis revealed ascites, but no other significant intra-abdominal pathol-
ogy. A paracentesis was performed. Four liters of serosanguinous fluid was
aspirated. Fluid white cell count was 1650 cells/mm3 with a differential of
88% neutrophils. Red blood cell count in the fluid was 110,000 cells/mm3.
Fluid albumin was 3.2 g/dL. total protein 5.4 g/dL. Cytology was negative.
With an absence of an etiology for the ascites, the patient underwent diag-
nostic laparoscopy. Laproscopic exam was grossly normal, random biopsies
revealed endometrial proliferative tissue.
This case demonstrates that endometriosis should be considered in the dif-
ferential diagnosis of ascites. The diagnosis may be difficult, and as this
case demonstrates, random biopsies of the peritoneum may be necessary in
establishing the diagnosis.
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Enteryx: Migration into the Lymphatics and beyond
Ganesh R. Veerappan, MD, Jonathan M. Koff, MD, Milton T. Smith, MD∗.
Gastroenterology, Walter Reed Army Medical Center, Washington, DC.
Introduction: Endoscopic implantation of a biocompatible nonresorbable
copolymer (Enteryx; Boston Scientific Corp, Natick, MA) was approved by
the FDA in April 2003, as an effective therapy for gastroesophageal reflux
disease (GERD). This technique injects 3–6 cc of Enteryx through a scle-
rotherapy needle into the lower esophageal sphincter (LES). The solution
polymerizes into a spongy material shortly after injected and is not remov-
able. In September 2005, the FDA recalled Enteryx due to complications
associated with these polymer injections.
Case: A 39 year old white male with a history of GERD refractory to proton
pump inhibitor (PPI) therapy presented with atypical chest pain for 2 years.
Two years prior to presentation, patient underwent an Enteryx injection with
good initial success. However, the patient has complained of intermittent,
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sharp chest pain that has worsened since his procedure. Pain is not consistent
with GERD symptoms and cardiac work up was negative. Past medical
history, physical exam and labs were unremarkable.
With concern for a potential Enteryx-related complication, an appropriate
work up was initiated. Upper endoscopy and upper gastrointestinal series
were normal. A Computed Tomography scan of the chest, abdomen and
pelvis, as expected, revealed polymer around the gastroesophagal junction.
Unexpectedly, there was a hyperdense focus seen in the subcarinal region
(Fig. 1) and another seen in the right hilum, consistent with polymer migra-
tion. Polymer was also found in small bowel wall.
Discussion: Polymer migration is a known complication of Enteryx, but
no known reports of migration into the lymphatic system. Unrecognized
tramsmural injections are a serious adverse event of Enetryx, as endoscopists
may blindly inject into adjacent structures. Our patient likely had Enteryx
injected into his lymphatic system, which quickly migrated to the subcarinal
and right hilar regions before solidifying. It is unclear whether the polymer
is responsible for our patient’s current symptoms, but it is a possibility. Even
though this product is no longer being used, it is important for gastroenterol-
ogists to be aware of the associated complications and appropriate work up
of these patients.[figure1]
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A Rare Case of Solid Pseupapillary Tumor of the Pancreas in a Young
Girl with Celiac Disease
Maria Luisa Forchielli, MD∗, Nunzio C. Salfi, MD, Francesca Poli, MD,
Mario Lima, MD, Massimo Masi, MD. Pediatrics, Med School of Bologna,
Bologna, Italy; Pathology, Med School of Bologna, Bologna, Italy and Ped
Surgery, Med School of Bologna, Bologna, Italy.
Solid papillary cystic tumors of the pancreas are rare entities and occur more
frequently in women aged 20–40.
We report a case of a 11-year old girl followed for celiac disease (CD) with
a secondary diagnosis of a pseudocystic pancreatic tumor.
This young girl was diagnosed with CD at the age of 9 after complaints
of abdominal discomfort in the previous two months. Her sibling had been
diagnosed with CD a few years earlier. Both her immunological work up
and histological specimens were consistent with CD. In the following year
her immunological tests progressively normalized, but her weight did not
improve and her spine had to be evaluated for severe scoliosis. During work
up an abdominal mass was noted.
Subsequent evaluations identified a solid papillary cyst tumor of the pan-
creatic head. She was then operated on and the mass was fully enucleated.
Histological findings confirmed the diagnosis and showed that the margins
were free of disease. The latest abdominal ultrasounds have showed regular
findings apart from two residual portal lymphatic nodes. She is now receiving
pancreatic enzyme supplementations on the regular basis.
This is the first case of a rare solid papillary tumor of the pancreatic head
occurring in a young girl who also carries the diagnosis of CD.
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Progressive Liver Involvement with Multiple Myeloma Causing
Non-Obstructive Cholestasis Despite Thalidomide and Dexamethasone
Therapy
Fadi E. Rahhal, MD, Robert R. Schade, MD∗. Department of
Gastroenterology and Hepatology, Medical College of Georgia, Augusta,
GA.
A 49 year old male was diagnosed with kappa light chain multiple myeloma
by bone marrow biopsy after presenting with acute renal failure and circu-
lating plasma cells in the blood. He was started on thalidomide and dex-
amethasone. After receiving four cycles over a 3 months period, he had
improvement on the peripheral blood smear but no response on repeat bone
marrow biopsy. One month after initiation of therapy he started developing
a gradual increase in total and direct bilirubin. The treatment was stopped
2 months later and the patient was admitted to the hospital for further work
up after a total bilirubin reaching 9.4 mg/dl. Ultrasound of abdomen showed
significant liver enlargement over a period of 2 months with no evidence of
biliary obstruction. HIDA scan showed delayed hepatic uptake consistent
with severe hepatocelluar dysfunction. Transjugular liver biopsy demon-
strated massive involvement with plasma cells. The immunoprofile in the
liver biopsy was similar to that in the bone marrow biopsy supporting the
diagnosis of hepatic multiple myeloma. During his 2 weeks of hospitaliza-
tion the patient rapidly developed hepatic failure and was discharged home
on hospice.
Plasma cell infiltration of the liver can be detected in 30 to 40% of patients
with multiple myeloma. Also up to 50% of autopsies done on these patients
showed hepatic involvement. However, only rare cases have been reported of
multiple myeloma leading clinically to non-obstructive cholestasis and pro-
gression into liver failure. Our patient was receiving treatment for myeloma
and despite that his liver involvement was getting worse leading to severe
cholestasis followed by progression into liver failure after the medications
were stopped.
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Metastatic Melanoma Presenting as Massive Upper Gastrointestinal
Bleeding
Nison L. Badalov, MD, Matthew Tangorra, DO, Anita Torok, MD, JianJun
Li, MD, Kadirawel Iswara, MD, Scott Tenner, MD, MPH∗. Division of
Gastroenterology, Department of Medicine, Maimonides Medical Center,
Brooklyn, NY.
Symptomatic gastrointestinal involvement of malignant melanoma is seen
in less than 5% of patients. We present a patient with massive upper gas-
trointestinal bleeding, found to have malignant melanoma as the cause.
A 66-year-old gentleman presented with epigastric pain, nausea, melena and
coffee ground emesis. Past medical history included diabetes mellitus and
hypertension, both well controlled with glyburide, enalapril and amlodip-
ine. The patient denied any similar episodes in the past or any history of
NSAID use. An upper endoscopy was performed revealing multiple black-
pigmented lesions in the antrum and duodenum (Fig. 1). Biopsies were
obtained. Pathology revealed duodenal mucosa with nests of cells in the
lamina propria (Fig. 2). The cells demonstrated uniform nuclear features
with occasional intra-nuclear cytoplasmic protrusions. Melanin pigmenta-
tion was identified. The findings were consistent with metastatic malignant
melanoma. On further questioning, the patient reported an excision of a mole
a year prior. Review of the pathology from that time revealed a melanoma
that has been completely excised.[figure1]
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Approximatelly 2–5% of patients with metastatic melanoma will have clini-
cally significant GI symptoms, such as nausea, vomiting, abdominal pain, ob-
struction, and gastrointestinal bleeding. However, most patients are asymp-
tomatic and have metastatic melanoma identified incidentally on endoscopy.
Autopsy series of patients with advanced melanoma has shown that 60%
have evidence of metastasis to the gastrointestinal tract. The most common
locations for metastatic disease in the gastrointestinal tract include the small
bowel (50%), colon (31.3%), and anorectum (25%). This case demonstrates
that malignant melanoma to the stomach can be a cause of massive upper
gastrointestinal bleeding.
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Effectiveness of EUS in Liver Lesions of Unclear Etiology
Priyanka Tiwari, MD, Timothy M. Saettele, Matthew L. Bechtold, MD,
Srinivas R. Puli, MD, Mainor R. Antillon, MD∗. Division of
Gastroenterology, University of Missouri, Columbia, MO.
Endoscopic ultrasound (EUS) has assumed an important role in the diagnosis
and staging of malignant GI tumors over the past few decades. EUS has
widespread applications in the imaging of the GI tract, but has not been
comprehensively studied in characterizing liver lesions. This case report
describes the application of EUS in one such case.
Case: 24 yo male with hypoplastic kidneys s/p renal transplant × 2 (last be-
ing 7 years prior), chronic transplant nephropathy, and chronic pancreatitis
presented with a 3-week history of epigastric pain. CT of abdomen without
intravenous contrast (due to the patient’s renal function) revealed a 3–4 cm
mixed density lesion in the anterior segment of the right hepatic lobe which
was biopsied under CT-guidance with aspiration of 10–15 ml of serosan-
guinous fluid. Biopsy cultures grew Enterococcus for which the patient was
prescribed intravenous ampicillin/sulbactam for 6 weeks. The patient left the
hospital AMA. Two weeks later, he returned to the hospital and underwent
an MRI without contrast and a trans-abdominal ultrasound with equivocal
findings. A repeat CT-guided biopsy was performed and revealed a bloody
aspirate. EUS was performed and showed a 30 × 40 mm vascular structure
in the right lobe of the liver with turbulent flow with a doppler characteris-
tic of an arterial structure, consistent with an arterio-venous malformation.
Four weeks later, the patient presented with sharp epigastric pain, melena,
and icterus. Labs revealed a total bilirubin of 22.5 mg/dL and a significant
decrease in hemoglobin (10 to 5.9 g/dL). An EGD revealed esophagitis.
Side-view endoscopy (duodenoscope) demonstrated blood-tinged bile from
the major papilla. Contrast injection revealed blood clots obstructing the
CBD, which was cleared and stented with a 10-Fr 10 cm plastic stent. The
cause of the upper GI bleed was determined to be hemobilia.
Conclusions: This case report suggests the use of EUS as the imaging modal-
ity of choice for the liver prior to any therapeutic endeavor for patients who
have contraindications for radiological contrast. Although scant information
is available on the use of EUS as a primary imaging modality in cases such
as these, this report suggests EUS may serve an important role in identifying
liver lesions and preventing potential iatrogenic complications.
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Endoscopic Mucosal Resection of H. Pylori Negative Esophageal
MALT Lymphoma
Michael J. Gilbert, MD, Ashok Shah, MD∗, Asad Ullah, MD.
Gastroenterology and Hepatology, University of Rochester, Rochester, NY.
Introduction: MALT lymphoma is a cancer of gastrointestinal mucosa as-
sociated with H. Pylori infection. Less than 1% of MALT lymphoma occur
in the esophagus. Esophageal MALT lymphoma has previously been treated
with radiation therapy. We describe a case of Endoscopic Mucosal Resection
as therapy for the treatment of esophageal MALT lymphoma confined to the
mucosa.
Case: A 38 year old female presented with 3 months of GERD symptoms
despite treatment with a variety of medications. She denied hematemesis,
melena, hematochezia or unintended weight loss. She denied alcohol or to-
bacco use. Her family history is significant for a father with colon polyps.
Physical exam was unremarkable. Laboratory analysis: WBC 8, HCT 43,
Plts 275, K 4.0, Cr 0.7, LFT normal. H. Pylori IgG Negative. An EGD
was performed that demonstrated a 4.4 mm∗1.8 mm nodule 4 cm above
the GE junction. Biopsies of the nodule demonstrated lymphoma. Gastric
biopsies demonstrated no evidence of H. Pylori or malignancy. EUS demon-
strated a hypoechoic lesion with 2 mm of depth localized to the mucosa. CT
scan showed no evidence of lymphadenopathy or other disease. The nod-
ule was removed with an EMR technique. It was first raised with 10 cc of
normal saline. An oblique 16 mm hard EMR cap was attached to a single
channel therapeutic endoscope and the nodule was removed using a snare.
Histopathology showed extranodal monoclonal kappa restricted marginal
cell lymphoma with normal surrounding mucosa. Immunohistochemistry
demonstrated: LCA+/CD20+/CD79a+Bcle-2 staining demonstrated resid-
ual reactive germinal center.
Discussion: Extranodal MALT lymphomas arise in mucosal organs of the
gastrointestinal tract, usually in the stomach and colon. H. Pylori infection
is the usual underlying etiology of MALT lymphoma in the stomach and
eradication of H. Pylori is the initial treatment of choice for gastric MALT
lymphoma. This patient demonstrated no evidence of H. Pylori infection
on either gastric biopsy or serology. MALT lymphoma in the esophagus is
very rare. MALT lymphomas are confined to the primary site and tend to
disseminate slowly. There have been two previously documented cases of
MALT lymphoma arising in the esophagus. In these reports EMR has been
demonstrated to be an effective technique to remove MALT lymphoma that
has not invaded the muscularis. Complete removal of esophageal MALT
lymphoma with EMR precludes further treatment with radiation therapy.
764
An Unusual Presentation of Pemphigus Vulgaris
Jesse P. Houghton, MD, Monica Ianosi-Irimie, MD, Stacey B. Trooskin,
Hazar Michael, MD∗. Gastroenterology & Hepatology, UMDNJ-Robert
Wood Johnson Medical School, New Brunswick, NJ.
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Pemphigus vulgaris (PV) is a potentially life-threatening autoimmune dis-
ease targeting skin and mucous membranes. The disease is characterized
by disruption of adhesion of the keratinocytes termed acantholysis (1,2).
Although oral and pharyngeal involvement is very common, esophageal
involvement is reported to be less common and is mostly confined to
case reports and case series. Esophageal involvement usually manifests as
odynophagia and dysphagia, while hematemesis is rare. Here, we report a
case of PV involving the esophagus and presenting as hematemesis, requiring
endoscopic intervention for hemostasis.[figure1][figure2]
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Uveal Melanoma with Hepatic Metastases: A Case Report
Eric R. Wollins, MD, Showkat Bashir, MD∗. Division of Gastroenterology
and Liver Diseases, The George Washington University Medical Center,
Washington, DC.
A 44 year-old female presented with a one-week history of RUQ abdomi-
nal pain without nausea, change in bowel habits or weight loss. PMHx was
unremarkable and FHx was significant for colorectal cancer in her father
who died at age 50 and a brother with multiple polyps at age 40. There
was moderate RUQ tenderness and rectal exam showed hemoccult pos-
itive brown stool. Labs: Hgb:8.8, Hct:27.6, MCV:65, AST:80, ALT:128,
ALK:101, T.Bili:0.1.CT ABD: multiple hypodense hepatic lesions suspi-
cious for metastatic disease. Based on these findings, our initial differential
diagnosis included colorectal cancer with hepatic metastases given the pa-
tient’s presentation of hemoccult positive stool with microcytic anemia in
the setting of a family history of colorectal cancer and colonic polyps in
two first degree relatives. Additional studies revealed normal tumor markers
and an unrevealing EGD and colonoscopy. As a result, our revised differ-
ential for hepatic metastases of an unknown primary included malignancies
of the lung, breast, kidney, ovary, thyroid and lymphatics. Liver biopsy was
performed and stained positive for HMB-45, MART-1 and S-100 consistent
with metastatic melanoma. Additional patient history revealed a significant
history of sun exposure, irregular nevi and as a result, the primary site of
melanoma was assumed to be cutaneous in origin. However, during this
time the patient was also evaluated by her ophthalmologist for progressively
worsening visual acuity. On exam, the patient was determined to have a
lesion consistent with ocular melanoma of the iris. The patient was subse-
quently treated with intra-hepatic chemotherapy for uveal melanoma with
hepatic metastases without any improvement and died 67 days after initial
presentation.
Malignant melanoma of the uveal tract (iris, ciliary body, choroid) is rare
and the most common non-cutaneous melanoma in adults. The liver is the
predominant organ involved in up to 95% of cases with metastatic disease.
Approximately 60% of patients with metastases are asymptomatic and 30%
may have normal LFT’s. Although liver involvement tends to be the first
manifestation of metastatic disease, the role of systemic screening is contro-
versial because of the paucity effective therapy. Metastatic uveal melanoma
is very aggressive with a poor prognosis and a median survival less than
six months. This case illustrates the aggressive nature of metastatic uveal
melanoma and highlights the importance of including melanoma in the dif-
ferential for hepatic metastases.
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Conservative Management of Inadvertent Colon Penetration during
Percutaneous Gastrostomy Tube Placement
Hansen Kwok, MD, Wichit Srikureja, MD, Ronald Griffin, MD∗.
Gastroenterology, Loma Linda University Medical Center, Loma Linda, CA
and Gastroenterology, Loma Linda VA Medical Center, Loma Linda, CA.
Percutaneous endoscopic gastrostomy (PEG) is the preferred method for
long-term enteral nutrition access. Major complications are infrequent. One
complication often requiring surgery is inadvertent colonic perforation. We
report 2 cases of PEG-related colon injury with benign courses that did not
require surgery.
Case 1: 57 year-old male, with dysphagia from an intracranial hemorrhage,
was consulted for PEG placement. His only relative contraindication for PEG
was a prior partial gastrectomy for peptic ulcer disease. A PEG was easily
placed after seeing clear transillumination and distinct finger indentation in
the gastric wall; the tube placement was endoscopically confirmed. Follow-
up exam on days 1 and 3 were normal. Eleven days later, the patient had
feculent material in the PEG tube. At this time, the abdominal exam was
benign. WBC was 15.1 and KUB showed the PEG traversing the colon into
the stomach. Follow-up abdominal CT revealed the PEG bumper was in the
transverse colon. No pneumoperitoneum, abscess, or gastrocolic fistula was
seen. The PEG was removed 17 days after placement and subsequent exams
and labs were normal. The PEG tract closed without incident and the patient
expired 1.5 months later from pneumonia.
Case 2: 80 year-old male was evaluated for PEG placement to prevent recur-
rent aspiration pneumonia from Parkinson’s related dysphagia. There were
no contraindications for the PEG. The procedure was uncomplicated and
the follow-up exam was benign. The patient was discharged home tolerating
tube feedings. He returned to the emergency room 40 days later after inad-
vertently pulling out the PEG. A replacement tube was inserted, but could not
be advanced. A Gastrografin tube-study showed contrast filling the colon at
the splenic flexure, without reflux into the stomach. At this point, the abdom-
inal exam was benign. There was no leukocytosis. The PEG was removed
and the patient was observed. No problems occurred and the tract closed
spontaneously.
These cases illustrate the indolent course of transverse colon penetration
during PEG placement. Although there is a risk for peritonitis, many cases
may be silent unless the PEG becomes dislodged. Given this observation,
one could surmise that PEG-related colon injury is more frequent than pre-
viously reported. However, in light of these benign outcomes, conservative
management may be considered if no acute findings exist.
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Acute Myelomonocytic Leukemia Manifesting as Ileus
Tal B. Hazan, MD, Fernando N. Gamarra, MD, James C. Shanks, MD,
Luis C. Maas, MD, Robert Bloom, MD∗. Gastroenterology/Hepatology,
Providence Hospital and Medical Centers, Southfield, MI; Internal
Medicine, Providence Hospital and Medical Centers, Southfield, MI;
Hematology/Oncology, Providence Hospital and Medical Centers,
Southfield, MI; Gastroenterology/Hepatology, Providence Hospital and
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Medical, Southfield, MI and Hemotology/Oncology, Providence Hospital
and Medical Centers, Southfield, MI.
Introduction: Acute Myelomonocytic Leukemia (AMML) is a malignancy
of myeloid stem cells with monocytoid differentiation which predominantly
involves the marrow and blood. It often involves the gingiva but can also
occasionally involve other extramedullary sites such as lymph nodes, medi-
astinum, uterus and rarely the small intestine. We present a rare case of a pa-
tient with known but untreated, chronic myelomonocytic leukemia (CMML)
which converted to AMML. The patient was subsequently found to have
motility impairment due to leukemic infiltration of the small bowel.
Case: Patient was a 70 yr. old male with a one year history of asymp-
tomatic CMML which converted to AMML. He presented to the hospital
with complaints of abdominal distention and diffuse constant abdominal
pain. The clinical presentation and imaging studies supported a diagnosis
of small bowel obstruction vs ileus. Subsequent endoscopic intervention
demonstrated no evidence of gross obstruction, with small bowel biopsies
consistent with leukemic infiltration of the bowel wall.
Discussion: Extramedullary involvement of the gastrointestinal tract by
myeloid leukemia leading to dysfunction is a rare phenomena. In our pa-
tient there was conversion of CMML to AMML, a more aggressive myeloid
leukemia with predilection to tissue infiltration of sites such as the small
intestine. Lymphoid leukemic involvement of the GI tract is more common
and often involves the ileum, stomach and proximal colon. There is a wide
variety of clinical presentations ranging from appendicitis, intussusception
to small bowel obstruction. The literature is sparse with reports of myeloid
involvement. The pathophysiology behind this patient’s symptoms is thought
to be secondary to motility dysfunction from leukemic blast infiltration of
the neuromuscular layer of the small bowel leading to an ileus. Leukemic
involvement of the gastrointestinal tract should be considered in a patient
with leukemia who presents with unusual gastrointestinal symptoms.
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Delivery of Agile Patency Capsule Using an Endoscopic Delivery
Device
Janice Freeman, RN, Deepika Koya, MD, Brenda J. Hoffman, MD∗.
Division of Gastroenterology and Hepatology, Medical University of South
Carolina, Charleston, SC.
The Agile Patency Capsule is an ingestible dissolvable non-video capsule,
which has been in use in U.S since 2006. It is indicated in patients with
suspected intestinal obstruction prior to ingestion of the Pillcam. Ingestion
of the Agile Patency Capsule is contraindicated in patients with swallowing
disorders. Theoretically, this limitation could be overcome by passing the
capsule endoscopically, using a capsule delivery device (US Endoscopy).
Because of the circumference and the consistency (barium makeup) of the
Patency Capsule there are concerns about whether the delivery device would
be functional. To report our clinical experience with successful delivery
of the Agile Patency Capsule using the capsule delivery device and the
difficulties encountered in the deployment of the capsule.
Two patients underwent attempted deployment into the small bowel because
of gastric retention. Both patients had a suspicion of partial small bowel
obstruction. Prior to intubation, the delivery device was passed through the
biopsy channel of the endoscope and the Agile Capsule was inserted into
the device. The endoscope was then passed through the mouth under direct
visualization and advanced into the 2nd portion of the duodenum.
One deployed without difficulty. In the second patient, upon releasing the
capsule, the deployment cable of the device lodged in the distal end of the
Agile Capsule, preventing the release of the capsule. Release of the capsule
was quickly achieved by simply jiggling the endoscope.
This is the first reported experience utilizing the delivery device for the
Agile Patency Capsule. The Agile Capsule’s make-up and size are different
from the Pillcam but still acceptable for deployment. Endoscopists should be
aware of the potential for the cable to penetrate and lodge within the capsule.
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Sclerosing Cholangitis and B-Cell Lymphoma in a Patient with
Chronic Hepatitis C
Ivan Cubas, MD, Serge A. Sorser, MD, Tal Hazan, MD, Allen Stawis, MD,
Kimberly Brown, MD, Michael H. Piper, MD∗. Providence Hospital and
Medical Centers, Southfield, MI; St. John Macomb Hospital, Warren, MI
and Henry Ford Hospital, Detroit, MI.
Introduction: Diffuse large B-cell lymphoma (DLCL) commonly presents
in the seventh decade of life and spreads aggressively to extra-nodal tissues.
DLCL, when responding to therapy, has a long-term survival rate of 50%.
The complications of DLCL are multifold. A literature review has revealed
only one report of sclerosing cholangitis (SC) as a complication of B-cell
lymphoma. In contrast, a recent meta-analysis has described an association
between hepatitis C virus (HCV) infection and DLCL. We present a patient
with chronic HCV infection, who was diagnosed with DLCL and secondary
SC.
Case Report: A 45-year-old Caucasian female with a six-year history of
HCV infection, genotype 1b, presented with vague acute abdominal pain.
Physical examination revealed jaundice, pruritus and choluria. The patient
experienced mild dyspnea, but denied fevers or sweats. Laboratory analysis
showed a total bilirubin (TB) of 4.5 mg/dL, with direct predominance, alka-
line phosphatase (AP) of 272 mg/dL and AST of 59 mg/dL. An abdominal
CT scan showed scattered, hypodense hepatic foci, suggestive of a diffuse,
infiltrative process. There was extensive abdominal lymphadenopathy and
mild ascites. A CT-guided liver biopsy showed DLCL. Due to progressive
cholestasis (TB = 22.5 mg/dL and AP = 330 mg/dL) an ERCP was per-
formed, showing several areas of narrowing interspersed with dilations in the
intra-hepatic bile ducts, consistent with diffuse SC. No dominant stricture
was seen; therefore, endoscopic intervention was not performed. Following
chemotherapy, the patient achieved an excellent response with resolution of
clinical, radiographic and laboratory abnormalities.
Discussion and Conclusion: Secondary SC refers to a radiological and
clinical syndrome that is similar to primary SC but results from a known
pathogenesis or injury, including obstructive, toxic, ischemic, and neoplastic
causes. In this report, we describe a patient with chronic HCV infection who
developed DLCL complicated by secondary SC. In conclusion, secondary
SC should be suspected with unexplained cholestasis complicating DLCL.
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Oriental Hepatolithiasis in an African Patient Presenting with
Subfulminant Hepatic Failure
Satya M. Mishra, MD, Bashar M. Attar, MD, PhD, Melchor V. Demetria,
MD∗. Gastroenterology, Cook County–John H Stroger Hospital and RUSH
University Medical Center, Chicago, IL.
Background: Oriental hepatolithiasis, also known as recurrent pyogenic
cholangitis, is a disease characterized by intrahepatic pigment stone forma-
tion, dilatation and stricturing of biliary tree. Patients usually present with
recurrent episodes of cholangitis leading to chronic biliary obstruction, liver
abscess, liver atrophy and eventually secondary biliary cirrhosis. To our
knowledge, there are no case reports of Oriental hepatolithiasis in African
patients presenting with subfulminant hepatic failure.
Methods: We describe a 28 year old African female from Nigeria who
presented with a 1 month history of progressive scleral icterus, abdominal
distension and lower extremity edema. Liver enzymes were elevated with
Bilirubin: 20.8 mg/dl, Alkaline Phosphatase: 514 U/l, AST-297 U/l, ALT-
104 U/l, INR-2.03. Workup for chronic liver disease showed ANA>1:160,
Anti SM(-), Anti LKM1(-). MRI/MRCP showed cirrhotic liver with moder-
ate intrahepatic biliary dilatation. Patient was given a trial of steroids ther-
apy for possible Auto-immune hepatitis without any clinical response. Tran-
sjugular liver biopsy was non-diagnostic. Patient underwent OLT for hepatic
failure within 2 months of her presentation. Histopathology of explanted
liver showed mixed nodular cirrhosis and diffuse severe intrahepatic bile
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sludging and hepatolithiaisis, marked cholangiolar proliferation, foamy cells
and distended bile ducts suggestive of “oriental hepatolithiaisis”.
Conclusion: Although many patients with Oriental hepatolithiasis present
with a chronic progressive course, our patient presented with subfulminant
hepatic failure. Liver transplantation should be considered as an additional
therapeutic modality in these patients.
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Wireless Capsule Endoscopy in a Patient with Intermittent
Obstructive Symptoms – A New Indication
Daniel A. Sussman, MD, Jamie S. Barkin, MD∗. Gastroenterology,
University of Miami/Leonard Miller School of Medicine, Miami, FL and
Gastroenterology, Mount Sinai Medical Center, Miami Beach, FL.
Background & Aims: Wireless capsule endoscopy (WCE) has emerged as
a valuable tool for the diagnosis of small intestinal pathology. A previous
relative contraindication to WCE was administration of the capsule device
to patients with a history of obstructive symptoms. The aim of this report
is to describe a patient with recurrent small bowel obstruction in whom no
intra-luminal etiology could be found by standard imaging and endoscopic
techniques, but was discovered by WCE.
Case Presentation: A seventy year-old man with history of chronic nons-
teroidal anti-inflammatory medication (NSAID) use, recurrent small intesti-
nal obstruction, and iron deficiency anemia had previously undergone seven
abdominal surgeries with exploration and lysis of adhesions, each with only
transient relief of symptoms. Computer tomogram of the abdomen showed
distended loops of small bowel consistent with partial small bowel obstruc-
tion. However, small bowel series showed no abnormality of mucosal pattern
or contour of the jejunum and ileum. Transit time was also normal at 2 hours.
WCE was performed due to persistent symptoms. The WCE examination
was incomplete with retention of the capsule in the distal jejunum or ileum.
Review of the images from the wireless capsule device revealed an endo-
luminal stricture in the distal small intestine and associated clean-based
ulcer with two small, nonbleeding erosions believed secondary to chronic
use of NSAIDs. Delayed abdominal plain films fifty-seven days after WCE
demonstrated the capsule retained in the distal ileum. A laparoscopic small
bowel resection with end-to-end anastomosis was performed to remove the
retained capsule and resect the area of stricturing. Gross specimens showed
small intestinal luminal narrowing proximal and distal to the capsule. Pathol-
ogy revealed luminal narrowing with focal areas of erosion consistent with
NSAID diaphragms. The patient is now symptom free.
Conclusions: This report lends credence to a new indication for wireless
capsule endoscopy in order to identify occult sources of bowel obstruction
while simultaneously visualizing these areas to discover endoscopic pathol-
ogy.
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Giant Hyperplastic Gastric Polyps: Precursor Lesions to
Adenocarcinoma?
Vivek Kumar, MD, Ali Lankarani, MD, Sam Yoselevitz, MD, Gerald
Hofkin, MD∗. Gastroenterology, Sinai Hospital, Baltimore, MD and
Gastroenterology, Johns Hopkins University School of Medicine,
Baltimore, MD.
Purpose: Genetic analyses and histopathological studies in the past have
proposed a possible progression of both Focal Foveolar Hyperplasia (FFH)
and Hyperplastic polyps (HP) to adenocarcinoma.
Methods: In this case report we present a 31 y/o male who was followed for
a period of 12 years secondary to intractable GERD. Initially he was man-
aged medically with proton pump inhibitors, but despite prolonged treatment
there was only partial relief in his symptoms. For further investigation an
upper endoscopy was performed which showed FFH in the antral region of
the stomach and the decision was made to continue medical management.
Ten years after the initial presentation an endoscopy was repeated due to
intractable vomiting, weight loss, and dyspepsia. Endoscopy showed multi-
ple gastric polyps, the most prominent of which measured about 12 cm in
diameter arising from the initial site of FFH.
The decision was made to remove the giant polyp due to the fact that his
symptoms were attributed to the overall size of the polyp. The biopsy of the
giant HP showed fragments of tubular adenoma with high-grade glandular
dysplasia in the background of mucosal hyperplasia, and without any signs
of invasive malignancy. The patient underwent partial gastrectomy in order
to completely remove the polyp, after which he had partial relief of his
symptoms.
After a period of 1 year he presented again with severe dyspepsia and early
satiety. Repeat endoscopy demonstrated that the entire gastric mucosal sur-
face was carpeted by polypoid structures ranging from barely visible up to
11 cm in diameter. Random biopsy specimens confirmed high-grade dys-
plasia. Due to the fact that random biopsy may have missed areas of invasive
malignancy, a decision was made to perform a total gastrectomy. During
the operation the stomach was found to be 90 cm × 60 cm with dilated
and thickened walls, secondary to the presence of numerous polyps. The
wall thickening was localized to the stomach and did not extend beyond the
GE junction or the pylorus. Pathology specimens from the total gastrectomy
showed focal high-grade dysplasia with foci suggestive of intramucosal ade-
nocarcinoma.
Results: The above case report highlights a possible association between
both FFH and hyperplastic polyps and their progression to invasive malig-
nancy. The rapid transformation of the hyperplastic polyps in our case report
suggests a need for earlier and more aggressive interventions in patients with
these findings.
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Therapeutic Success of Rifaximin in the Setting of Clostridium Difficile
Diarrhea Refractory to Metronidazole and Vancomycin: Case Report
George C. Tannous, BA, Guy Neff, MD∗, Terry O’Toole, MD, Nathan
Schmulewitz, MD, Christopher Duncan, MD, Victoria Zacharias, MS,
Nyingi Kemmer, MD. Division of Digestive Diseases, University of
Cincinnati College of Medicine, Cincinnati, OH.
Purpose: Diarrhea following the use of antibiotics is an infrequent compli-
cation. We report a case of a 42 year-old Caucasian male that suffered from
chronic diarrhea following a two-week course of fluoroquinolone therapy
for pneumonia. The patient’s complaints included bloating and at least 10
episodes of watery diarrhea per day. Stool studies were positive for Clostrid-
ium difficile and psuedomembranes were found on endoscopy. The acute
diarrhea was treated with a two-week course of metronidazole. Although
the diarrhea resolved while on therapy, it recurred within days of stopping
the medication. This sequence of events took place for a second time as
the patient suffered a recurrence following another two-week regimen of
metronidazole. Subsequently, the patient was treated with a two-week course
of vancomycin, during which the diarrhea resolved. However, following dis-
continuation of the vancomycin treatment, the diarrhea recurred once again.
During this last episode of recurrent diarrhea, which lasted 10 days, the pa-
tient developed signs of dehydration and renal dysfunction. He was admitted
for intravenous fluid replacement and treated with rifaximin 400 mg orally
three times per day. The diarrhea and associated symptoms resolved within
24 hours and the patient was discharged home to complete a 4 week reg-
imen of rifaximin. Three months after completion of therapy, the diarrhea
remained suppressed. There are few case reports demonstrating the role of
rifaximin in the treatment of C. difficile colitis, but its role in refractory cases
is unknown. This report describes a dramatic clinical response to rifaximin
in the setting of refractory Clostridium difficile diarrhea and demonstrates
this regimen as an alternative treatment.
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Celiac Disease and Chronic Infectious Enteritis
William P. Stuppy, MD∗. Private Practice, Los Angeles, CA.
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Purpose: Gliadins are polypeptides found in wheat, rye, oats, barley, and
other grains and glutens. They are toxic to the intestinal mucos in suseptable
individuals. The purpose of this report is to demonstrate the presence of
salivary antibodies to gliadin (GliadinAb, SIgA) in patients with chronic
infectious enteritis.
Methods: Two hundred thirty four (234) patients (ave. age 33 yrs., M/F
102:132) found to have infectious enteritis with one or more pathogens
(Blastocystis hominis, Giardia lamblia, Cryptosporidium parvum, Amoeba
histolytica, Helicobacter pylori) were simultaneously tested for GliadinAb-
SIgA (Diagnos-Techs, Inc.).
Results: The mean GliadinAbSIgA in the 234 cases of chronic infectious en-
teritis was >20 U/ml. (normal <13 U/ml., borderline 13–15 U/ml., positive
>15 U/ml.).
Conclusion: Patients with chronic infectious enteritis have elevated levels of
GliadinAbSIgA. This suggests these individuals are rendered suseptable to
Celiac Disease on this basis; a cause and effect relationship. Further studies
to determine the effect of successful treatment of chronic infectious enteritis
on production of GliadinAbSIgA are warrented.
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Peroral Cholecystoscopy-Directed Electrohydraulic Lithotripsy of
Symptomatic Cholecystolithiasis in Poor Surgical Candidates
Priyanka Tiwari, MD, Matthew L. Bechtold, MD, Srinivas R. Puli, MD,
Jamal A. Ibdah, MD, John B. Marshall, MD, Mainor R. Antillon, MD∗.
Division of Gastroenterology, University of Missouri, Columbia, MO.
Purpose: Laparoscopic cholecystectomy is the treatment of choice for symp-
tomatic gallstones, but not for those who are poor surgical candidates.
Choledoscopy-directed electrohydraulic lithotripsy (EHL) using a “baby
scope” passed through a side-viewing duodenoscope is effective for treat-
ing choledocholithiasis. However, this technique has not been reported for
the treatment of symptomatic cholecystolithiasis in patients unable to un-
dergo surgery. This report describes two cases that demonstrate, for the first
time, the feasibility of peroral cholecystoscopy-directed EHL (PC-EHL) for
treating symptomatic cholecystolithiasis in non-surgical candidates.
Case 1: 78 yo female with severe COPD and cholecystostomy tube for
recurrent cholecystitis presented with symptomatic cholelithiasis. A laparo-
scopic cholecystectomy was attempted and aborted due to severe gallbladder
inflammation. The patient was a poor surgical candidate based on poor pul-
monary status and prior failed surgery. She underwent a PC-EHL of a 3
cm gallstone and multiple smaller gallstones. Subsequently, a 10-Fr, 10 cm
cystic duct stent and a 7-Fr CBD stent were placed. After 12 weeks, a repeat
ERC showed only fragments of the stones which were washed and removed.
A 7-Fr double pigtail gallbladder stent was placed. With follow-up, she has
experienced an uneventful recovery and a marked improvement in her symp-
toms.
Case 2: 65 yo male with ischemic cardiomyopathy (NYHA class IV) and
recurrent cholangitis s/p cholecystostomy and gallbladder stenting presented
with symptomatic cholelithiasis. The patient was a poor surgical candidate
based on poor cardiac status. He underwent PC-EHL of a 5 cm gallblad-
der stone. Subsequently, a 10-Fr double pigtail stent was placed into the
gallbladder. After 2 weeks, a repeat ERC demonstrated a 2 cm fragment of
the prior stone. A 10-Fr, 10 cm and a 7-Fr, 10 cm double pigtail stents were
placed into the gallbladder. The patient is scheduled for cholangioscopy with
repeat EHL. With follow-up, he has experienced an uneventful recovery and
a marked improvement in his symptoms.
Conclusion: These cases represent the first successful demonstration of
PC-EHL in the management of symptomatic cholecystolithiasis. This novel
technique offers an endoscopic approach to managing patients with symp-
tomatic cholecystolithiasis who are not surgical candidates.
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Adenocarcinoma at the Colostomy Site in a Patient Presenting for
Ulcerative Colitis Dysplasia Surveillance
Amitpal S. Johal, MD, Michael J. Komar, MD∗. Gastroenterology,
Geisinger Medical Center, Danville, PA.
Purpose: A 60 year-old man with 26 year history of ulcerative colitis pre-
sented for routine surveillance colonoscopy. He underwent a partial colec-
tomy at an outside hospital in the remote past with remaining descending
colostomy and rectal stump. His last colonoscopy was 2 years prior with no
dysplasia on biopsy. Follow-up colonoscopy was performed which revealed
quiescent colitis from the cecum to the descending colostomy. However, upon
closer inspection of the stoma, a 5 mm lesion, thought to be an inflammatory
nodule, was found on the periphery of the stoma. A biopsy was taken, which
showed a moderately differentiated adenocarcinoma. He subsequently was
seen by general surgery and underwent a total proctocolectomy with end
ileostomy.
Discussion: Patients who have had ulcerative colitis for 8–10 years should
have a surveillance colonoscopy with a minimum of 32 biopsy specimens
from the cecum to the rectum every 1–2 years.1 Primary adenocarcinoma
arising from a colostomy site is very rare and has been reported in the lit-
erature only a few times. This case demonstrates the importance of careful
visual inspection of the stoma during surveillance colonoscopy; and recog-
nition that the stoma itself should be included in dysplasia surveillance.
REFERENCE
1. Itzkowitz SH, Present DH. Crohn’s and Colitis Foundation of America
Colon Cancer in IBD Study Group: consensus conference: colorectal
cancer screening and surveillance in inflammatory bowel disease. In-
flammBowel Dis 2005;11:314–21.
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Chronic Mesenteric Ischemia Presenting as Helicobacter
pylori-Negative Duodenal and Gastric Ulcers. Case Report and
Literature Review
M. Fuad Azrak, MD, Gihad Gaith, MD∗. Department of Internal Medicine
Medicine, William Beaumont Hospital, Royal Oak, MI.
Purpose: Vascular insufficiency syndromes involving arterial supply can
rarely present with peptic ulceration that is unrelated to H. Pylori infection
or NSAID use. Gastric ischemia is extremely rare, given the rich arterial
supply to the stomach.
We are reporting an 80-year-old female who presented to our hospital with
approximately 10 week history of postprandial nausea, abdominal discom-
fort and occasional vomiting. She described the pain as dull band-like dis-
comfort in the periumbilical region. She denied any diarrhea, constipation,
melena orhematochezia. Esophagogastroduodenoscopy three weeks prior to
admission revealed multiple gastric and duodenal ulcers. H. Pylori wor up
was negative. Colonoscopy revealed right-sided diverticulosis.
Her pain was progressively getting worse without improvement with the
use of a proton-pump inhibitor. She lost 15 pounds over 3 months and had
multiple visits to the emergency department. The patient had history of hy-
pertension, hyperlipidemia and pelvic vein thrombosis. She had a history
of tobacco smoking and did not consume alcohol or illicit drugs. Her med-
ications included rabeprazole, Lipitor, Coumadin and metoprolol. She was
recently taken off her Alendronate. She denied any use of corticosteroids or
NSAIDs.
No icterus was present. The abdomen was soft, nondistended and had nor-
mal bowel sounds. There was tenderness in the periumbilical and epigastric
region to palpation without palpable masses or rebound tenderness. The
patient had guaiac-negative stool. Laboratory studies revealed normal li-
pase, amylase and liver function tests. Gastrin concentration was 376 pg per
milliliter (normal range 0–110). Abdominal CT was unremarkable. Abdom-
inal Doppler, Abdominal MRA and later traditional angiography demon-
strated occlusion of the proximal aspects of the celiac artery and superior
mesenteric arteries. The patient underwent repair of her celiac and superior
mesenteric axis by anterograde bypass. She tolerated the surgery well and
was discharged in a stable condition.
Ischemic peptic ulcer disease is seldom diagnosed. Certainly, the reconsti-
tution of the patient’s well-being after revascularization suggest that this
very unusual combination was responsible for her clinical picture and the
endoscopic findings.
Conclusion: This case suggests that ischemia as an etiology for peptic ulcer
disease should be considered in H. Pylori negative ulcers even in gastric
ulcers.
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Nitazoxanide and Treatment of Helicobacter pylori
William P. Stuppy, MD∗. Private Preactice, Los Angeles, CA.
Purpose: Out of hundreds of patients seen in consultation for chronic gas-
trointestinal infection/parasitosis 212 were found to have H. pylori infection
by salivary testing. The purpose of this report is to present a novel diagnostic
and theraputic strategy for H. pylori utillizing a single theraputic agent, Nita-
zoxanide, along with pre- and post-diagnostic monitoring utilizing salivary
antibody testing (HpSIgG).
Methods: Seventy nine (79) patients (mean age 49 yr., M/F = 30:49) with H.
pylori infection detected by HpSIgG (Diagnos-Techs, Inc.) were prescribed
one drug, Nitazoxanide (1 gram, PO, BID, for two weeks). Patients were not
allowed to take any acid inhibiting agents of any sort. Carafate was permitted
on a PRN basis for relief of symptoms. Post therapeutic testing with HpSIgG
was obtained (2–4 months) in all cases.
Results: Of the seventy nine patients treated with Nitazoxanide alone post
therapeutic HpSIgG testing indicated eradication of infection in seventy
three (73/79; 92%).
Conclusion: Nitazoxanide is a very effective one drug therapy for H. pylori.
An added advantage is that it is also simultaneusly effective against a host of
concommitant enteric infectious agents and parasites. Salivary testing for H.
pylori is a convenient and non-invasive method for pre- and post-therapeutic
detection of H. pylori infection.
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The GIST (Gastrointestinal Stromal Tumor) of the Gastroesophageal
Junction (GEJ)
Wanwarat Ananthapanyasut, MD, Sammy Nawas, MD, Jue-lin Tang, MD,
Andrea Blumenstein, MD, Charles Berkelhammer, MD∗.
Gastroentrology/Internal Medicine, University of Illinois, Oak Lawn, IL.
Purpose: The histology of primary GEJ tumors is most often adenocarci-
noma, and less often, squamous cell carcinoma. Rarely, GEJ tumors are due
to other primary epithelial malignancies (small cell carcinoma, melanoma
or carcinosarcoma) or nonepithelial neoplasms (lymphoma, sarcoma such as
GIST, or other mesenchymal tumors). Metastases to the GEJ can also rarely
occur. We describe a patient with a GIST of the GEJ.
Case: A 75-year-old man was evaluated for iron deficiency anemia and stools
that were postive for occult blood. He noted dysphagia and early satiety. An
upper endoscopy showed a submucosal mass at the GEJ extending into the
gastric cardia. The mass measured 10 cm. There was central ulceration with
a necrotic tumor cavity, best seen on retroflexion. Biopsies of the ulcer-
ated area showed a spindle cell neoplasm which stained positive for CD117
(c-kit), confirming a GIST. Computed tomography and positron emission
tomography confirmed the GEJ mass, while no metastases were detected.
He underwent a trans-thoracic open partial esophagogastrectomy. Pathology
confirmed a high grade GIST of the GEJ, with negative nodes. There has
been no recurrence as of 9 months of follow up.
Discussion: Our patient had a GIST of the GEJ. It most likely arose from the
gastric cardia, based on location of the tumor’s epicenter and pathological
evaluation. The vast majority of esophageal primary mesenchymal tumors
are leiomyomas. In contrast, the most frequent site of gastrointestinal GISTs
is the stomach, most commonly the gastric fundus. These tumors, including
those involving the GEJ, are amenable to laparoscopic resection. The gist
of this patients GEJ is that GISTs should be included in the differential
diagnosis of GEJ neoplasms.
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Pneumatosis Intestinalis of Small Bowel Due to Acute Pancreatitis
Induced Ileus
Suresh Jayatilaka, MD, Gurpreet Singh, MD, Chintan Modi, MD, Robert
Spira, MD∗. Gastroenterology, St. Michael’s Medical Center/Seton Hall
University, Newark, NJ.
Purpose: Pneumatosis intestinalis (PI) is a condition characterized by the
presence of gas within the wall of the small or large intestine. Common con-
ditions responsible for pneumatosis intestinalis include inflammatory bowel
disease, infectious gastroenteritis, intestinal obstruction, chronic obstruc-
tive pulmonary disease, and AIDS. In rare instances, PI may portend a life
threatening intra-abdominal catastrophe.
Methods: A 52 year-old African American male with history of HIV on
retroviral therapy, hepatitis C, hypertension, alcohol abuse, and a ventral her-
nia repaired six months prior was admitted for mid epigastric pain associated
with nausea and vomiting. On physical exam, the patient had a reducible ven-
tral hernia, hypoactive bowel sounds, epigastric tenderness, and voluntary
guarding without rebound or rigidity. Laboratory studies revealed amylase
1065, and lipase 1130. An abdominal obstructive series revealed moderate
gaseous distension of small bowel loops and right colon. A CT scan of the
abdomen was significant for markedly distended stomach and small bowel
loops with pneumatosis in one of the dilated loops of the small bowel in the
left lower quadrant; the large bowel was also partially distended. The liver,
spleen, gallbladder, and pancreas were unremarkable. An ultrasound of the
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abdomen revealed mildly prominent intrahepatic biliary ducts. The common
bile duct was 8 mm in diameter. The patient was treated conservatively with
subsequent improvement.
Results: [figure1]
Conclusion: We report a case of PI due to acute pancreatitis-induced ileus.
For patients who are asymptomatic or minimally symptomatic, the recom-
mended management includes hyperbaric oxygen, antibiotics, elemental
diet, and treatment of the underlying cause. Intramural gas cysts usually
resolve spontaneously.
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Profound Gastroparasis Presenting with Isolated Intraperitoneal
Amyloidosis
Hui Hing Jack Tin, MD, Jai Mirchandani, MD, JianJun Li, MD, Kadirawel
Iswara, MD, Scott Tenner, MD, MPH∗. Division of Gastroenterology, Dept
of Medicine, Maimonides Medical Center, Brooklyn, NY.
Purpose: Amyloidosis of the gastrointestinal tract usually results in either
mucosal or neuromuscular infiltration. Mucosal infiltration causes mucosal
friability, erosions, ulcerations or thickening of the the intestinal wall, which
in turn causes nausea, vomiting, gastrointestinal bleeding, and malabsoption.
Neuromuscular infiltration may cause gastrointestinal motility disorders. We
present a patient with profound gastroparesis found to have intraperitoneal
amyloidosis as the cause.
Methods: A 51 year old male presented with complaints of nausea, vom-
iting, and epigastric pain. Due to early satiety, there had been a significant
weight loss, but no fever, diarrhea or constipation. The patient’s past medi-
cal history was significant for schizophrenia and glaucoma. His medications
included risperidone, clozapine. pilocarpine, metoclopramide, timolol and
megestrol. Physical examination revealed a catatonic male of moderate build
with diffuse abdominal distension and tenderness. No hepatomegaly was
noted. Rectal examination was normal and fecal occult blood test negative.
An abdominal radiograph showed massive gastric distension. A computer
assisted tomography scan of the abdomen and pelvis revealed a grossly dis-
tended stomach with an abrupt tapering at the duodenum, no obvious mass.
Prior to endoscopic evaluation, an Ewald tube was inserted with removal
of feculent material from the stomach. Endoscopic evaluation to the dis-
tal duodenum revealed irregular large ulcers in the stomach and a normal
duodenum. The patient had a complicated hospital course with respiratory
distress, intubation, and sepsis. Progressive gastric dilatation resulted in is-
chemic ulceration and perforation of the stomach. Exploratory laparotomy
was performed. A wedge resection of the gangrenous, perforated area of the
stomach was performed. Pathology showed gastric mucosa with extensive
necrosis, transmural inflammation and perforation. Extensive granulation
tissue with diffuse amyloid in the perigastric fat.
Conclusion: This case represents the first case of gastrointestinal intra-
peritoneal amyloidosis causing gastroparesis. Our case is unique in that the
site of the amyloid deposit was found in perigastric fat rather than in the
mucosa, vascular endothelium, or the nerve tissue. Based on our findings,
in patients presenting with idiopathic gastroparesis, a full thickness biopsy
should be performed to rule out amyloidosis.
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Sinusoidal Occlusion Syndrome Following Exposure to Gemtuzumab:
Unsuccessful Treatment with Defibrotide
Alastair D. Smith, MB, ChB∗, Daniel J. Hampton, MD, Joseph O. Moore,
MD, Louis F. Diehl, MD. Gastroenterology & Hepatology, Duke
University, Durham, NC and Hematology, Duke University, Durham, NC.
Purpose: Sinusoidal occlusion syndrome (SOS) is a rare, life-threatening
disorder characterized by abdominal distention, weight gain, tender hep-
atomegaly, ascites, and elevated aspartate aminotransferase (AST) and crea-
tinine (Cr) concentrations. Ultrasonography (US) demonstrates patent portal
and hepatic venous circulations. SOS arises most commonly in the setting
of bone marrow transplantation (BMT). Gemtuzumab, an anti-CD33 mono-
clonal antibody, is a new agent for the management of relapsed acute myeloid
leukemia (AML). Abnormal liver tests occur in 1/3 of gemtuzumab-treated
patients, but only 1–2% have documented SOS.
A 24 year-old man, diagnosed with AML 13 months after receiving
chemotherapy for a mediastinal germ cell malignancy failed to respond to
initial protocol chemotherapy with amonafide, cytarabine and mitoxantrone.
Salvage chemotherapy with gemtuzumab was initiated in standard dose and
schedule. Five days after first exposure to gemtuzumab the patient began
gaining weight, and by day 9 his weight gain was 4 kg. His abdomen was
distended and uncomfortable, and he required oxygen for dyspnea. Labora-
tory studies were as follows: AST 6733 IU/L (normal range [NR]: 10–60),
alkaline phosphatase 162 IU/L (NR: 30–135), prothrombin time 17.7 s (NR:
11.1–13), total bilirubin 1.9 mg% (NR: 0.2–1.2) and Cr 5.9 mg% (NR:
0.4–1.4). US scan confirmed the presence of splenomegaly and ascites; the
hepatic and portal vein branches were patent. However, the direction of flow
in the latter was reversed. Both the vena cava and hepatic artery were patent.
Relevant acute viral, metabolic and immune forms of liver disease were ex-
cluded on the basis of appropriate serologic studies. Given the symptom com-
plex, compassionate approval was sought for use of the non FDA-approved
drug, defibrotide. However, despite this intervention, continuous veno-veno
hemodialysis, and further antimicrobial therapy, the patient developed acute
liver failure and died 26 days after first gemtuzumab exposure.
This man’s clinical, laboratory and US findings met diagnostic criteria for
SOS. While experience with SOS in the BMT setting is well recorded, other
etiologies are rarely recorded. This patient’s clinical course was virtually
diagnostic of gemtuzumab-induced SOS. Although use of defibrotide has
been reported to improve 1/3 of patients having SOS in the BMT setting,
experience among patients with SOS after gemtuzumab therapy is very lim-
ited.
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Penetrating Gastric Ulcer: An Usual Route for Liver Biopsy
William A. Mourad, MD∗, Stacy Prall, DO, Komar Mike, MD.
Gastroenterology, Geisinger Medical Center, Danville, PA.
Purpose: There are multiple complications associated with peptic ulcer dis-
ease (PUD). Gastric penetration secondary to complicated ulcers have been
reported to the pleura, pericardium, and small bowel. We report an unusual
case of hepato-gastric penetrating ulcer confirmed by endoscopic imaging
and biopsy.
Case: A 93 yo female presented with complaints of non bloody vomiting pre-
ceded by 2 weeks of dark stools. The patient had recently started coumadin
for atrial fibrillation as well as diflunisal for arthritis. Abdominal exam re-
vealed hypoactive bowel sounds, mild epigastric tenderness without rigidity
or guarding. X ray did not reveal free air. EGD demonstrated multiple gastric
and duodenal ulcers without acute bleeding. 1 large cratered prepyloric ulcer
was biopsied and can be seen in Figure 1. This tissue demonstrated normal
hepatocytes with mild inflammation. H. pylori stool antigen was negative.
Surgical consultation was obtained. Given the pt’s age and comorbidities the
decision was made to treat her conservatively with strict bowel rest, proton
pump inhibitor, and TPN. Repeat endoscopy in 5 weeks demonstrated com-
plete healing of the gastric ulcer. In Figure 2 the healed gastric mucosa can
be seen.
Discussion: Asymptomatic PUD is seen most commonly in the elderly.
Unlike perforated ulcers, which typically present with a surgical abdomen,
penetrating ulcers are more subtle in presentation because they communicate
with adjacent organs. However, most penetrating ulcers ultimately require
surgery. The most frequently identified organs include duodenum, pancreas,
and rarely left lobe of the liver. This patient did remarkably well with ag-
gressive medical management. This is a rare complication of PUD and very
unusual route for liver biopsy.[figure1][figure2]
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De Novo Common Bile Duct Stones Mimicking Malignant Biliary
Obstruction
Rafal G. Ciecierski, MD, Rajat Gulati, MD, Nasreen Jalil, MD, Hareth
Raddawi, MD∗. Internal Medicine/GI, University of Illinois/Advocate
Christ Med Ctr, Oak Lawn, IL.
Purpose: Here, we present an unusual case of a 78 y/o female presenting
with significant weight loss, abdominal pain, jaundice and sitophobia. Her
Past medical history was significan for osteoarthritis and hypertension. Phys-
ical Exam was remarkable for evidence of recent weight loss, mild icterus,
a normal liver size and no peripheral lymphadenopathy. Laboratory inves-
tigations suggested cholestasis. Imaging studies included a contrast CT of
abdomen showing Extrahepatic biliary obstruction and a 9 mm”mass” in the
common bile duct with no evidence of any gall bladder stones.
The patients Primary care Physician had requested tumor markers: CEA, and
CA 19–9 Both were moderately elevated. The Patient was referred for an
ERCP with a tentative diagnosis of Malignant Biliary Obstruction. However,
on ERCP, surprisingly, the patient was found to have a 9 mm isolated common
bile duct stone, the cystic duct was patent and no stones could be visualized
in the gall bladder. An Endoscopic Sphincterotomy was done and the solitary
CBD Stone was extracted. The patient had a sonogram the of the abdomen
to definitively exclude gall bladder stones which confirmed absence of any
stones in the gall bladder. Patient had a dramatic clinical improvment with
resolution of her symptoms, recovery of her weight and normalization of her
liver chemistries within a few weeks.
Results: Here, we present an unusual case of 78 y/o female with significant
weight loss, jaundice, and abdominal pain who on initial investigation of the
complaints by a contrast CT of abdomen was reported to have a 9 mm mass
in the common bile duct with no evidence of any gall bladder stones. A de
novo solitary CBD stone was identified on ERCP and extracted.
Conclusion: De novo stones of the common bile duct arise in the setting
of 1) recurrent cholangitis 2) congenital anomalies like Caroli’s disease 3)
sclerosed or strictured ducts 4) very rarely due to mutations in MDR3 gene.
Mostly common bile duct stones are a findings associated with cholelithiasis
that is a stone arising in the gall bladder passes down the bile duct and be-
comes symptomatic. Solitary De novo CBD Stones may mimick Malignant
biliary obstruction and may falsely elevate tumor markers.
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Gastric Myeloma
Aman Ali, MD, Louis Rosainz, MD, Eric Rosen, MD, Knarik Arkun, MD,
Peter J. Baiocco, MD∗. Gastroenterology and Hepatology, Lenox Hill
Hospital, New York, NY.
Purpose: A 46 year old female with history of SLE, migraine headaches
and CVA presented with nausea, vomiting, progressive solid and liquid dys-
phagia and headache. Physical examination was unremarkable except for a
small, tender, firm mass, palpable in the left submandibular region and left
hypoglossal nerve paresis. Pertinent labs revealed macrocytic anemia with
normal vitamin B12 and folate levels. LDH was elevated at 810 U/L. A
Modified barium swallow revealed oropharyngeal dysfunction. CT scan of
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the head and abdomen were normal. Patient continued to vomit for several
days and endoscopy was advised.
EGD revealed mild atrophy with linear erosions in the gastric body. A 5
mm, raised, friable lesion was seen in gastric cardia with a “pasted on” ap-
pearance (Fig. 1). An excisional cold biopsy was obtained. CT and MRI
to evaluate the neck mass revealed an abnormally enhancing, hypervascu-
lar mass eroding through the left clivus, jugular foramen and hypoglossal
canal (Fig. 2). A stereotactic trans-sphenoidal biopsy of the clivus lesion
was planned, however biopsies from gastric lesion reveal atypical mononu-
clear cells with marked pleomorphism, mitotic activity, multinucleation and
positive immunohistochemical staining for CD138 (Fig. 1). These findings
are consistent with gastric plasma cell myeloma. Subsequently a bone mar-
row biopsy revealed sheets of plasma cells. The patient was treated with
thalidomide and dexamethasone and transferred to a tertiary center for the
remainder of her care.
Conclusion: We present an unusual case of multiple myeloma with gastroin-
testinal manifestations. Although the nausea and vomiting in our patient was
most likely from a CNS lesion, endoscopy helped in making a prompt, less
invasive, histological diagnosis and contributed significantly to the patient’s
care.[figure1][figure2]
786
Periampullary Carcinoid Causing Billary Obstruction
Dara L. Grieger, MD, James Peacock, MD, Adad Ullah, MD, Ashok Shah,
MD∗. Surgery, University of Rochester, Rochester, NY and
Gastroenterology, University of Rochester, Rochester, NY.
Purpose: This is a case of a 71 year old female who presented to her pri-
mary care physician after experiencing dark urine and clay colored stool for
one week. She had no other symptoms. Past medical history includes only
hypertension and hypercholesterolemia. Physical exam was unremarkable
except for slight scleral icterus. Initial laboratory data revealed a total bil-
rubin of 5.3, AST 166, ALT 278, Alkaline Phosphatase 311, amylase 163,
lipase 275 and CA 19–9 267. She underwent abdominal ultrasound which
showed dilated intra and extra hepatic ducts, and a hypoechoic structure in
the pancreatic head with blood flow. Follow up CT showed a 1.3 cm hyper-
vascular mass in the common bile duct near the head of the pancreas, and
extensively dilated intra and extra hepatic ducts. She then underwent outpa-
tient ERCP. A friable mass was protruding from the ampulla, with a filling
defect in the mid to distal common duct. The tumor began to bleed with
instrumentation, and sphincterotomy with stent placement was performed.
A small mucosal tear was clipped. The patient was admitted for observation
and serial hematocrits. On hospital day 3 the patient’s hematocrit had drifted
down to 25 from 42, and she was transfused and underwent repeat ERCP.
The tumor was noted to still be oozing. The following day, the patient under-
went pylorus preserving Whipple procedure. The patient had an uneventful
postoperative course and was discharged on postoperative day 10. Pathol-
ogy revealed a 4.4 cm periampullary carcinoid tumor with extension into
the pancreas and no nodal disease. Carcinoid tumors of the peirampullary
region are rare. Current treatment of choice is resection. Patients who un-
dergo Whipple procedure for carcinoid tend to have fewer complications
than those with adenocarcinoma. There may be some role for local excision
with smaller tumors < 2 cm.[figure1][figure2]
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A Rare Cause of Nausea, Vomiting and Diarrhea: Eosinophilic
Gastroenteritis
Amer Skopic, DO, Joel Moncur, MD, Jonathan Koff, MD∗.
Gastroenterology, NNMC, Bethesda, MD; Pathology, WRAMC,
Washington, DC and Gastroenterology, WRAMC, Washington, DC.
Purpose: Eosinophilic gastroenteritis (EG) is rare disease of unknown etiol-
ogy defined by the presence of gastrointestinal symptoms, eosinophilic infil-
tration of the gastrointestinal tract, peripheral eosinophilia, and eosinophilic
ascites without evidence of parasitic or extra-intestinal disease. EG is classi-
fied into mucosal, muscularis, and serosal types. Clinical symptoms include
nausea, vomiting, abdominal pain, diarrhea, intestinal obstruction and as-
cites. Corticosteroids are the treatment of choice.
A previously healthy 27-year old AA female was referred to GI with a two
week history of abdominal pain, nausea, vomiting and diarrhea. She did
not endorse constitutional symptoms, was on no medications and had not
recently traveled. Her physical examination was unremarkable.
Laboratory evaluation: WBC 13,000 (34% eosinophils); stool cultures, O&P,
c diff toxin A and B, Entamoeba and Strongyloides were all negative. EGD
and colonoscopy were unremarkable. Biopsies of squamous-lined esopha-
gus were notable for 17–20 eosinophils/ hpf. Eosinophils were also notable
in lamina propria of the duodenum (90/hpf) and colon (75/hpf). One week
after endoscopy the patient was seen in a local ED. Abdominal CT scan
demonstrated diffuse thickening of small intestinal wall and moderate as-
cites. Diagnostic paracentesis was significant for 4,128 WBCs with 93%
eosinophils. Culture and cytology were negative and evaluation by GYN
was unremarkable. Serum IgE levels were elevated.
The patient was placed on oral corticosteroids and at the time of writing this
abstract, was responding well.
EG is rare disease that can present in different ways depending on the pre-
dominant location of eosinophils. Our patient had transmural involvement
based on clinical presentation, endoscopic biopsies and eosinophilic ascites.
Although the most common sites of involvement are the stomach and duo-
denum, our patient had evidence of eosinophilic infiltration throughout the
entire gastrointestinal tract from proximal esophagus to distal colon. Talley
et al (1990) proposed three main diagnostic criteria for EG: presence of GI
symptoms, biopsies showing eosinophilic infiltration in one or more layers
and the absence of parasitic infection. Corticosteroids continue to be the
preferred treatment. This case demonstrates a rare diagnosis and need for
continuous re-evaluation as EG was not in our original differential.
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Type I Acute Autoimmune Hepatitis in a Male Patient
Navakanth Gorrepati, MD, Atulkumar Patel, MD∗. Department of Internal
Medicine, William Beaumont Hospital, Royal Oak, MI and Division of
Gastroenterology, William Beaumont Hospital, Royal Oak, MI.
Purpose: Introduction: Autoimmune hepatitis (AIH) is an unresolving in-
flammation of the liver of unknown cause. Women develop AIH more often
than men (3.6:1). AIH is characterized by interface hepatitis, hypergamma-
globulinemia, and autoantibodies. The serologic tests utilized for diagnosis
are antinuclear antibodies (ANA), smooth muscle antibodies (SMA) and an-
tibodies to liver-kidney microsome type I (anti LKM-1). We present a rare
case of acute AIH in a male patient with elevated SMA titers only.
Case Report: A 57-year-old male patient was referred for evaluation of ab-
normal liver function tests. Liver function tests revealed AST of 752 U/L,
ALT of 999 U/L and Alk Phos of 117 U/L. He denied jaundice, abdomi-
nal pain, abdominal distension, fatigue, malaise or fevers. He had a history
of diabetes mellitus, Raynaud’s disease, mitral valve prolapse and deep ve-
nous thrombosis. His liver enzymes measured nine months ago were within
normal limits. He had no recent travel. There was no significant alcohol
consumption. Medications included warfarin and exenatide. Physical exam-
ination was unremarkable. Iron studies, serum ceruloplasmin and markers
for viral hepatitis were negative. ANA, P- ANCA and Anti LKM-1 antibodies
were within normal limits. Patient had elevated SMA titers (1:320) and hy-
pergammaglobulinemia (3.06 gm/dL). CT scan showed mild splenomegaly
and porta hepatic lymphadenopathy. Liver biopsy showed active interface
hepatitis consistent with AIH. He was started on prednisone and azathio-
prine. Liver enzymes improved remarkably within two months.
Summary: AIH is considered a disease of middle age women. ANA and/or
SMA characterize Type I AIH. The present case of a male presenting with
SMA as the sole markers of Type I autoimmune hepatitis is considered rare –
3.74% (4/107). SMA and ANA commonly disappear and reappear. Greater
importance should be given to laboratory and biopsy evaluation in selected
cases.
Conclusion: Acute AIH should be considered in the evaluation and work up
of men with acute hepatitis of unknown origin even though ANA is negative.
REFERENCE
1. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoim-
mune hepatitis. Journal of Hepatology. 1999 Mar; 30(3): 394–401.
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Choledochoduodenal Fistula (CDF) in a Patient Presenting with
Seizure
M. Momeni, MD, V. Kurupath, MD, S. Heydayati, MD, K. Zaalook, MD, G.
Martin, MD, S. Anand∗. GI, Brooklyn Hospital, BK, NY and GI, LMC, BK,
NY.
Purpose: A 59 year-old Haitian man presented to our hospital with chronic
intermittent vomiting for nearly 10 years. On admission, the patient devel-
oped an episode of grandmal seizures for the first time. The patient had a
history of hypertension, hypercholesterolemia, chronic renal insufficiency
and no prior surgeries. He was on antihypertensive medications and a lipid
lowering agent. The laboratory studies revealed: Hgb12.0 g/l, HCT36.0%,
WBC 9.1 K/mm3 and PLT 306 K/mm3. His serum electrolytes: Sodium 140
mEq/l, potassium 3.1 mmol/l, chloride 68 mmol/l, bicarbonate 58 mmol/l,
calcium 9.9 mg/dl, blood urea nitrogen 55 mg/dl, serum creatinine 4.6 mg/dl.
The liver profile was normal. The blood PH was 7.41, and urine PH was 9.0.
Abdominal sonogram – was intended to evaluate his kidneys – discovered the
presence of Pneumobilia. Abdominal CT scan confirmed this finding, and
displayed gastric wall thickening with distended duodenum. EGD grossly
showed deformed duodenal bulb with an abnormal aperture of 3–4 mm in
diameter in the posterior part of the bulb of duodenum. Upper GI series
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subsequently showed reflux of contrast material in the non-dilated biliary
tree, confirming the presence of CDF (Fig). Later, gastric biopsies indi-
cated positive invasion of helicobacter pylori. During the following days of
hospitalization: the renal function improved, the alkalosis resolved, and he
was discharged on anti-helicobacter pylori treatment (ampicillin, lansopra-
zole and clarithromycin). Unfortunately, the patient failed to appear for his
follow up appointments.
Conclusion: Bilioenteric fistulas are usually incidental findings because they
seldom produce clinical symptoms. While Cholecystoduodenal fistulas ac-
count for ninety percent of bilioenteric fistulas, choledochoduodenal fistulas
are rare. Based on our literature search and findings, this is the first case
of CDF presenting with grand-mal seizure. The severe metabolic alkalo-
sis, induced by vomiting in the setting of biliary fistula, appeared to be the
contributing disorder. Therefore, physicians should be aware of atypical pre-
sentations of CDF and prevent a potentially serious complication.[figure1]
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Adalimumab (ADA) Treatment of Hidradenitis Suppurativa (HS) in a
Crohn’s Disease (CD) Patient
Jeffrey T. Wenzke, MD, Ashok Shah, MD∗. Gastroenterology and
Hepatology Division, University of Rochester, Rochester, NY.
Purpose: HS is a chronic inflammatory disease often causing cutaneous
fistulas and scarring. Several reports have associated it with CD. Current
therapy for refractory HS is limited and may involve multiple surgeries; how-
ever, off-label use of anti-TNF agents has shown some promise. We present
a 36-year-old female with a history of CD diagnosed in 1995, started on sul-
fasalazine and azathioprine who developed HS five years later on her groin,
central chest, and under her breasts. Over the next year, she had multiple
courses of antibiotics, PO and topical, with little success. She was given
three infusions of infliximab (INF) with good resolution in 2001. Her sul-
fasalazine and azathioprine were stopped during her pregnancy in 2006, and
her HS relapsed with painful, malodorous, draining fistulas. She was started
on antibiotics, creams, and spironolactone with only minor improvement.
INF was restarted; however, she had an infusion reaction with her second
dose. The decision was made to start her on ADA, a human monoclonal anti-
body directed against TNF-α, at 40 mg SC q2W. Over the next five months,
her course fluctuated requiring her to receive occasional courses of steroids
and one course of antibiotics for possible secondary infection. Meanwhile,
she had a surveillance colonoscopy revealing no active disease on biopsy.
Her lesions have since ceased draining and causing her pain, however they
have unfortunately left her with scars. This report shows that the prior suc-
cess of treating HS in CD patients with INF can likely be seen with ADA,
however further studies are needed to assess the role anti-TNF agents have in
the treatment of cutaneous manifestations of CD. According to our literature
search of the database, this is the first case of successful treatment of HS
in a CD patient with ADA, and only one of a few successful reports of HS
treated with ADA.[figure1][figure2]
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Chronic Intestinal Schistosomiasis
Rishi Pawa, MD, Vishal Gupta, MD, PhD, Rohan Clarke, MD, Jay Cowan,
MD, Lisa Ozick, MD∗. Department of Gastroenterology, Columbia
University College of Physicians and Surgeons, Harlem Hospital Center,
New York, NY.
Purpose: Schistosomiasis is a common parasitic disease in the tropical and
subtropical regions of Asia, Africa and South America. The disease is caused
by a parasitic blood fluke that resides in fresh water. We report a case of a
24 year old male from Ghana without previous bowel problems, who pre-
sented with a history of diarrhea of six months duration. The diarrhea was
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non-bloody and watery in nature with an estimated frequency of four to
six episodes per day, associated with rectal tenesmus, abdominal discom-
fort and a five lbs weight loss. There was no history of fever, arthralgias,
skin lesions or visual symptoms. Physical examination was remarkable for
mild abdominal tenderness located primarily in the hypogastrium with no re-
bound. Laboratory studies including a complete blood cell count, chemistries
and stool studies for ova and parasites were unrevealing. Colonoscopy per-
formed subsequently showed erythematous mucosa of the distal sigmoid
colon and the rectum. [figure1] Histological examination of rectosigmoid
biopsy showed multiple giant cell granulomas and a single Schistosoma egg
with a terminal spine. [figure2] Biopsies obtained from the remainder of the
colon and terminal ileum were within normal limits. Patient was treated with
a single dose of Praziquantal (40 mg/kg) with complete resolution of symp-
toms. Thus, we conclude that even though schistosomiasis is not endemic
in the United States, it should be considered in the differential diagnosis of
patients with gastrointestinal symptoms, particularly in travelers and former
residents of endemic areas.
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The Buried Bumper Syndrome and Gas in the Portal Venous System
Jocelyn V. de Jesus, MD, Dean Silas, MD∗. Gastroenterology, Advocate
Lutheran General Hospital, Park Ridge, IL.
Purpose: A case of Buried Bumper Syndrome accompanied by gas in the
hepatic portal venous system is reported. A 77 year-old man with a recent
stroke and percutaneous gastrostomy (PEG) tube placement two months
previously for dysphagia was admitted to our institution with complaints
of acute pain at the PEG tube site. An abdominal computed tomography
revealed that the internal bumper had migrated from the gastric lumen into
the abdominal wall, otherwise known as the Buried Bumper Syndrome. In-
cidentally, gas was also discovered in the portal venous system. With the
advancement of CT imaging, the incidence of detecting hepatic portal ve-
nous gas has risen. Traditionally associated with a grim prognosis, hepatic
portal venous gas has now been linked to a wider array of pathologies. After
undergoing an endoscopy, with removal of the buried internal bumper and
replacement of the PEG tube, the patient had an uneventful recuperation. To
our knowledge, there have been no cases reported of gas in the portal venous
system coinciding with the Buried Bumper Syndrome.[figure1][figure2]
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Whose Call Is This? Could There Be a Common Explanation for All
These Seemingly Unrealted Tragedies? Since the Root Cause Is
Preventable and Related to Liver, Let Us Try To Elucidate It
Tushar C. Chauhan, MD∗. Private Practice, Community Gastroentrology
Center, Voorhees, NJ.
Purpose: To increase awareness about MCAD. MCAD is very common
metabolic disease (1 in 80). Still not well-known even among physicians.
There are many precipiating factors (like fasting, starvation, excessive phys-
ical actitivies, infection, alcohol consumtion or surgery) and protean clinical
menifestation -vomitting, lethargy, confusion, unexplained techicardia and
fatal ventricular arrythmia, it is still a mysterious illness. It is very well
written about, quite common but still not often entertained in differntial
daignosis.
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Methods: WHAT COULD BE COMMON IN ALL THESE ASES? 29 years
old runner dropped dead after Philadelphia half arathon. -Philadelphia In-
quirer.
Confusion and vomiting for 3 days before death-is it Reye’s syndrome? Is it
Meningitis? -Grand Round at Teaching Hospital. 19 years old Texan Woman
died in Tertiary Care Center. -Journal of Emergency Medicine A Hiker found
confused after being lost for 4 days, Plant poisoning suspected. -Outdoor life.
A Nurse mother held in unexplainable death of teenage girl.-West Varginia
Court Case.
An 18 year college athlete collapsed after practice, died of Ventricular Ar-
rythmia. -National News Media.
Results: To avoid these tragedies, we need to understand “METABOLIC
END POINT”. With physical trainning, one can improve the cardiopul-
monary reserve, but cannot change this MEP. The stressors mentioned above
leads to depletion of carbohydrate as energy source and ketotic pathway of
metabolism kicks in. During this the long chained stored fat molecules are
broken into acetoacetate and b-hydroxybutyrate. While in a person with
MCAD deficiency, the break down of long chained fat is halted to 6 to 10
carbon chain particles. This increased production of medium chained fat par-
ticles accumulates in varios body organ causing variety of clinical presntaion
mentioned above.
Conclusion: The best way to avoid this kind of tregady is to create public
awarenes and avoid the events that lead to MEP.
To avoid the tregady in the people who wants to push their limit of physical
activities, Maintain proper hydraion, supply of glycogen for enenrgy and
avoide ketogenic diet, are other important factor.[figure1]
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Proton Pump Inhibitors Masking a Zollinger Ellison Syndrome
David N. Socoloff, DO∗, Patrick Brady, MD, Daas Adel, MD, Alexander
Rosemurgy, MD. Digestive Diseases and Nutrition, University of South
Florida, Tampa, FL and Tampa, FL.
Purpose: Zollinger Ellison syndrome is a well described clinical entity man-
ifested by hypersecretion of gastric acid, proximal small bowel ulceration,
and non-beta islet cell tumors of the pancreas with aggressive metastatic
potential. Initial symptoms are often vague and can mimic benign ulcer dis-
ease or functional abdominal pain. Response to empiric antisecretory ther-
apy often results in delayed workup with potential serious implications. We
present a case of 42-year-old female with classic symptoms of ZE syndrome
including dyspepsia, GERD, and diarrhea that drastically improved on high
dose PPI therapy. Because she responded well to empiric therapy, no further
workup was pursued. She presents four years later with painless jaundice
and recurrence of symptoms after PPI therapy is halted. Further evaluation
with abdominal imaging reveals a 6 cm calcified pancreatic head mass ob-
structing her biliary tree with a single liver lesion suspicious for metastatic
disease. Therapeutic ERCP reveals multiple small bowel erosions raising the
suspicion of a ZE syndrome. Baseline serum gastrin levels are 3852 pg/ml
off PPI, with normal IgG4 levels. Octreotide scan reveals intense activity in
the pancreatic head and in a focal area of the liver worrisome for metastatic
disease. Whipple procedure with wedge resection of the liver lesion con-
firms the diagnosis of a metastatic gastrinoma. This case demonstrates the
pitfalls that can occur with empiric treatment of dyspepsia without complete
evaluation especially when diarrhea is one the chief complaints. Although
Zollinger Ellison syndrome accounts for less then 1% of peptic ulcer disease
in the United States, early diagnosis is crucial to avoid development of peptic
ulcer disease complications and metastatic disease.
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Amebiasis Mimicking Metastatic Colon Cancer
Aman Ali, MD, Mylon Satchi, MD, Adam Palance, MD, Berhanu Geme,
MD, Sujit Kulkarni, MD, Eric Rosen, MD, Peter Kim, MD∗.
Gastroenterology and Hepatology, Lenox Hill Hospital, New York, NY.
Purpose: A 66 year old male with no past medical history presented with 2
days of crampy, non-radiating, right lower quadrant pain. The patient denied
fever, change in bowel pattern, abdominal distention, nausea, vomiting or
rectal bleeding. The patient had traveled to West Africa three months ago
where he admitted to drinking well water and having a self-limited diarrheal
illness. However since his return to United States, he was asymptomatic. On
physical examination, he was afebrile, abdomen was soft and non-distended
but right lower quadrant was tender on deep palpation. There were no peri-
toneal signs, palpable masses or viscera. Rectal exam was normal.
CBC revealed WBC count of 18.1 without eosinophilia. A CT scan of ab-
domen and pelvis displayed wall thickening in the cecum and ascending
colon, minimal stranding of the pericecal fat and a few low attenuation lesions
in the liver (Fig. 1). These findings were worrisome for colon neoplasm with
metastasis to the liver. He underwent colonoscopy that revealed numerous
non-bleeding serpiginous ulcerations in the cecum and right colon (Fig. 2).
The ulcers were well circumscribed with raised margins and central necrotic
base and in conjuction with his travel history, were suspicious for amebic
infection. Biopsies did not show amebic organisms but displayed marked
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chronic active inflammation, increased eosinophils, paneth cell metaplasia,
crypt distortion, and fibrinopurulent exudates and were considered consis-
tent with amebic infection. Amebic antibody titers were abnormally high.
Patient was treated with metronidazole and paromomycin for 10 days with
a remarkable clinical recovery. Colonoscopy and CT scan performed two
months later confirmed resolution of the infectious process (Figs. 1 & 2).[fig-
ure1][figure2]
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Methotraxate in Autoimmune Hepatitis
Roger Montenegro, MD, Gijo Vettiankal, MD, Melchor Demetria, MD,
Bashar M. Attar, MD, PhD∗. Gastroenterology, Cook County-John H.
Stroger Hospital and Rush University Medical School, Chicago, IL.
Purpose: Methotrexate has been used in patients with cholestatic liver dis-
ease and granulomatous hepatitis, however there has been only three pub-
lished reports on its use in Autoimmune hepatitis (AIH). Standard treatment
regimens for AIH includes corticosteroids and purine analog azathioprine.
Treatment options for patients refractory or intolerant to standard therapy are
limited. This includes medications as Mycophenolate Mofetil, Tacrolimus,
Cyclosporine and Methotrexate. METHODS: We describe a 44-year-old His-
panic female with no history of alcohol abuse who presented with jaundice,
ascites, elevated liver enzymes AST: 525, ALT: 275, positive ANA: >1:5120
and SMAB >1: 80. Viral hepatitis serology and rest of chronic hepatitis
work-up was negative. Liver biopsy was consistent with autoimmune hep-
atitis and cirrhosis. Liver enzymes did not normalize with prednisone alone.
Patient was started on azathioprine but developed pancreatitis. Mycopheno-
late Mofetil was also tried but patient developed intolerable side effects and
was discontinued. Methotrexate at 7.5 mg po per week resulted in normal-
ization of liver enzymes and maintenance of remission with a steroid sparing
effect. Patient refused repeat liver biopsy. To date, 18 months after starting
methotrexate, patient is asymptomatic with normal liver function tests, res-
olution of ascites and off steroids. COCLUSION: In this case methotrexate
was used successfully with normalization of liver function tests and steroid
sparing effect with no documented side effects. These findings suggest that
methotrexate may be useful in treatment of autoimmune hepatitis intolerant
or refractory to standard therapy.
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Recurrent Lymphoma Presenting as Incarcerated Umbilical Hernia
Eyong J. Ly, BA, Edward R. Feller, MD∗, Fred J. Schiffman, MD.
Department of Medicine, Warren Alpert Medical School of Brown
University, Providence, RI.
Purpose: Tumor-associated incarcerated umbilical hernia is rare. Similarly,
this severe complication is an exceptional initial manifestation of recurrent
malignancy. We report a patient with acute incarcerated hernia as the pre-
senting feature of relapsed lymphoma.
Case report: A 62-year-old woman with a history of large-cell lymphoma
in remission for 2 years presented with increasing epigastric pain and mild
nausea for 5 days. She had a known, asymptomatic umbilical hernia for
many years. On exam, she was afebrile, tachycardic, and normotensive.
Abdominal exam revealed a soft, mildly distended abdomen with an in-
carcerated hernia that was erythematous and exquisitely tender to palpation.
Ascites was not present. Laboratory studies showed Hgb=12 Gm%; WBC=
14,400 with 78% Neutrophils, 1% Bands, and 15% Lymphocytes. Abdomi-
nal upright and lateral decubitus x-rays revealed no air-fluid levels. At urgent
laparotomy, she had an incarcerated hernia containing edematous, inflamed,
viable omentum without bowel. Histology of the hernia sac showed a clonal
lymphoid population present within the sac that was consistent with recur-
rent diffuse, large B-cell lymphoma. The patient did well post-operatively
and was discharged home one week after admission.
Discussion: Malignancy may involve the umbilicus by contiguity, lymphatic
or venous spread or by arterial emboli. Palpable, non-tender skin or sub-
cutaneous metastasis, termed Sister Mary Joseph’s nodule, may rarely occur.
Pain and tenderness may also be sub-acute, or slowly progressive. Tumors
in incarcerated hernias are rare, reported in intra-abdominal or pelvic car-
cinoma as well as by uterine fibroids, umbilical varix, endometriosis, and
pseudomyxoma peritonei. Increased pressure due to pregnancy, ascites or
tumor may potentiate incarceration. Skin ulceration, necrosis, strangulation
or hernia rupture may occur. Incarcerated hernia is an exceptional presenting
feature of an undiagnosed or recurrent tumor. As illustrated in this case, clini-
cians should consider underlying malignancy when a chronic, asymptomatic
umbilical hernia suddenly incarcerates.
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Safe Use of the PillCam ESO in a Patient with an Implantable
Cardioverter Defibrillator
Daniel S. Mishkin, MD, CM∗. Gastroenterology, Boston University,
Boston, MA.
Purpose: There has been concern regarding the use of capsule endoscopy
in patients who have an electromedical device based on the fact that both
agents work on a similar radiofrequency. While it is a contraindication to use
the PillCam in a patient with an implantable electromedical device, many
are performing the test on a case-by-case scenario. This is the first published
report using PillCam ESO in such a patient.
A 62 year old man presents for evaluation of his progressive liver disease
that is secondary to Hepatitis B and excessive alcohol use. He serologically
has evidence of cirrhosis and no history of gastrointestinal bleeding. His past
medical history is significant for a dilated cardiomyopathy with an ejection
fraction of 15% for which he takes coumadin and he had an automatic
implantable cardioverter defibrillator (Guidant Contak Renewal 3-CRT-D)
implanted. An evaluation of his esophagus was recommended regarding the
potential for primary prophylaxis, should he have varices. After a discussion
with the patient about the different options of evaluation, he chose to swallow
the PillCam ESO. In light of his cardiac status, risk of bleeding, inability to
get a ride home, and patient preference, there were multiple reasons why he
chose to avoid an esophagogastroduodenoscopy.
During the time of the procedure, the patient was closely monitored. The
pulse generator was located in the left upper chest wall, in relative close
proximity to the 3 sensors for the study. There were no apparent cardiac
changes, both clinically and on the monitor in this pacemaker dependent
subject. After completion of the exam marked by the change in the lights on
the data recorder signifying no further transmission, he was monitored for
an additional 5 minutes.
The images acquired demonstrated an abnormality in the esophagus that
on further evaluation was consistent with high grade dysplasia in a short
segment Barrett’s esophagus and no varices. There was no loss of images
acquired during the examination.
Several series have performed capsule endoscopy in such patients without
interference to the implantable electromedical device or image acquisition.
In one study there was a loss of the images while the capsule was in close
proximity to a patient’s abdominal pacemaker pulse generator. This was a
specific concern as in a study using the PillCam ESO, as the sensor arrays
are in the vicinity of the pulse generator. However, in this case, there was no
loss or alterations of the images during the 22 minutes of the study.
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A Simple Twist of Fate?
Ryan M. Ford, MD, Kristina R. Chacko, MD, Tanvi Dhere, MD, Greg
Nesmith, MD, Henry Olejeme, MD∗. Division of Digestive Diseases,
Emory University School of Medicine, Atlanta, GA.
Purpose: A 19 year old Hispanic female who was 28 weeks pregnant was
admitted for seizures and recurrent post-prandial nausea, vomiting, and ab-
dominal pain. Her symptoms had been present throughout the entire preg-
nancy. Her past medical history included a diagnosis of epilepsy at age 11.
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She had no known drug allergies. Her medications included anti-epileptics,
prenatal vitamins, folic acid, and anti-emetics. Family history was notable for
hypertension and diabetes. She did not smoke or drink alcohol. Vital signs
were notable for a mildly elevated blood pressure and a mild tachycardia.
Physical exam revealed a gravid abdomen with mild epigastric tenderness
and mild lower extremity edema. Labs revealed low albumin, electrolyte ab-
normalities, acute renal failure, mild proteinuria, and elevated liver enzymes.
A previous right upper quadrant ultrasound showed sludge in the gallbladder,
and a single view chest radiograph showed moderate gastric distension. Out
of concern for pre-eclampsia and an atypical HELLP syndrome, the patient
underwent an urgent C-section.
Five days post-operatively, the patient developed recurrent nausea and vom-
iting while receiving narcotics. She was given anti-emetics but she expe-
rienced an episode of coffee ground emesis after a nasogastric tube was
placed. Vital signs were stable and physical exam was again only notable
for mild epigastric tenderness. Repeat bloodwork was unremarkable. Chest
and abdominal radiographs were normal. Upper endoscopy revealed a dis-
tended stomach containing greater than two liters of retained fluid, as well as
a sharp turn in the second portion of the duodenum. A CT scan showed mul-
tiple embryological defects in addition to findings consistent with intestinal
malrotation. An upper GI series confirmed the diagnosis. The patient went
to the operating room for a laparoscopic appendectomy and duodenocolonic
dissociation (LADD procedure). She was discharged five days later.
Intestinal malrotation requiring surgery usually presents in the first month
of life. It is less common to present in adulthood. In this case, we hypothe-
size that pregnancy, with its associated changes in intra-abdominal anatomy,
precipitated the clinical presentation of intestinal malrotation. This case also
demonstrates many of the classic findings, work-up, and treatment of this em-
bryological defect. Intestinal malrotation is a rare disorder that may present
with common symptoms in adults.
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Cholestatic Hepatitis Associated with Hyperthyroidism, and
Exacerbated by Methimazole Therapy
Erick H. Chinga-Alayo, MD, Bashar M. Attar, MD, PhD∗, Frida
Abrahamian, MD. Gastroenterology, Cook County – John H. Stroger
Hospital, Chicago, IL and Gastroenterology, Rush University Medical
School, Chicago, IL.
Purpose: Cholestasis can be caused by multiple drugs and systemic disor-
ders. It is clinically important that reversible conditions are detected rapidly
and corrected. A 28-year-old Pakistani man presented with 1 month history
of progressive jaundice. He had a medical history of hyperthyroidism diag-
nosed recently for which he was treated with methimazole 10 mg PO TID
for one month. No history of alcohol use. Clinical chemistry parameters
two weeks prior to methimazole therapy were as follow; total bilirubin 5.8
mg/dL, direct bilirubin 3.2 mg/dL, alkaline phosphatase 227 U/L, AST 43
U/L, ALT 51 U/L, Free T4 4.19 ng/dL, and TSH 0.03 uIU/mL. On admission
his total bilirubin level was 40.4 mg/dL, direct bilirubin 26.1 mg/dL, alkaline
phosphatase 256 U/L, AST 36 U/L, ALT 42 U/L, lipase 32 U/dL, Free T4
3.5 ng/dL, TSH 0.03 uIU/mL. Markers for autoimmune hepatitis and viral
hepatitis A, B, and C were negative. A CT scan and ultrasound of abdomen
were normal with no biliary dilatation. Liver biopsy showed prominent bile
stasis, and minimal portal and occasional parenchymal neutrophilic infil-
trate. No fibrosis was found. At the time of admission, methimazole was
discontinued and we observed a rapid decrease in the levels of bilirubin,
alkaline phosphatase and liver enzymes, however these were still above nor-
mal values. The patient was subsequently started on lithium to control his
hyperthyroidism. As he remained hyperthyroid he received radioablation of
the thyroid gland two months after lithium was started. Six months after
this procedure his levels of bilirubin, alkaline phosphatase, and liver en-
zymes decreased to normal levels. Hyperthyroidism has been associated
with cholestatic hepatitis that is usually not clinically evident. The liver in-
jury described with hyperthyroidism is reversible after appropriate treatment
of the disease. Methimazole is rarely associated with cholestatic liver injury
that is reversible within months after its discontinuation. In patients with
hyperthyroidism and baseline liver enzymes abnormallities, it is important
to monitor the liver enzymes after methimazole is started.
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Dyspagia Lusoria Due to an Aberrant Right Subclavian Artery and a
Dilated Diverticulum of Kommerell
Srikanth Vallurupalli, MD, Juan Jimenez, MD∗. Internal Medicine,
University of Illinois at Urbana Champaign, Urbana, IL and Radiology,
University of Illinois at Urbana Champaign, Urbana, IL.
Purpose: We describe an uncommon vascular cause of dysphagia in the
elderly.
Methods: A 72 year old woman complained of intermittent dysphagia
to solid food. She reported no loss of appetite or weight loss. Physical
examination was unremarkable. A barium esophagogram revealed mass
effect at the junction of the proximal and middle thirds of the esopha-
gus.[figure1]Computed tomography of the chest was performed and demon-
strated the presence of a left sided aortic arch and an aberrant right subcla-
vian artery arising from a diverticulum of Kommerell.[figure2] The dilated
diverticulum and the artery displaced and compressed the esophagus and
trachea. Surgical correction was not attempted due to the minimal nature of
symptoms.
Results: Bayford in 1787 described extrinsic compression of the esophagus
by aortic vascular abnormalities as a result of “Lusus Naturae” meaning
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a freak of nature which eventually lead to the term dysphagia lusoria. An
aberrant right subclavian artery occurs in about one percent of the population
but is usually asymptomatic. This aberrance is the result of the persistence of
the seventh intersegmental artery during the involution of the fourth aortic
arch resulting in its retro-esophageal course. Kommerell in 1936 described
a diverticulum at the origin of the aberrant artery in a patient with a left
sided aortic arch as a remnant of the primitive right dorsal aorta. With the
development of atherosclerosis, the aorta and its vessels become rigid and
tortuous leading to symptoms in the elderly. Several surgical techniques
have been described to relieve the compression but are only performed after
careful consideration of the risks and benefits.
Conclusion: Clinicians should be aware of this rare cause of dysphagia
which as the population ages, may present more often.
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Emphysematous Gastritis Due to Infection from a Non Gas-Producing
Bacteria!
Manju P. Paul, MD, Savio John, MD, Nilesh Mehta, MD, Preeti Mehta,
MD, Uma K. Murthy, MD∗. Medicine, SUNY Upstate Medical University,
Syracuse, NY.
Purpose: Emphysematous gastritis is a rare condition in which gas collects
within the stomach wall secondary to infection by gas-producing bacteria. We
report the case of 25 year old female with neurofibromatosis who developed
diffuse abdominal pain and distension after C-section. There was no history
of alcohol or substance abuse, ingestion of corrosive substances or NSAIDs.
Patient was febrile, tachycardic, and tachypneic and appeared toxic. Ab-
domen was markedly distended and tender with absent bowel sounds. Blood
work showed WBC count of 25,000 with 91% neutrophils. CT of the ab-
domen showed gastric pneumatosis along the entire greater curvature and bil-
iary tree, diffuse dilatation of the stomach, small bowel and large bowel. EGD
showed diffuse severe mucosal abnormality with congestion, discoloration,
granularity, texture change, decreased vascular pattern and ulceration on the
posterior wall and greater curvature of the stomach. Gastric biopsy revealed
transmural necrosis and streptococcus viridans and stomatococcus were iso-
lated. Patient was started on clindamycin and piperacillin/tazobactam as well
as IV hydration and TPN from the first day. Patient improved with the above
measures and was discharged home after 10 days of hospital stay. Follow
up CT scan and EGD showed resolution of the previous findings. It is im-
portant to differentiate emphysematous gastritis from gastric emphysema as
early institution of antibiotic therapy covering anaerobes and gram negative
bacilli, along with IV hydration and institution of nutrition is the mainstay
of treatment. The stomach is a very uncommon site of involvement, due to
abundant blood supply, acidity and efficient mucosal barrier. Currently, CT
is the best imaging study for diagnosis of emphysematous gastritis. Surgery
is avoided during the acute phase of infection due to friability of the gastric
mucosa.[figure1][figure2]
803
Identification of Unsuspected Parasitic Disease on Video Capsule
Endoscopy
Nirmala M. Sivaprakasapillai, MD, Thomas Judge, MD∗.
Gastroenterology, Cooper University Hospital, Camden, NJ.
Purpose: Parasitic infection has been rarely identified utilizing video capsule
endoscopy (VCE). We report the case of a 41 year old Puerto Rican male
who underwent VCE for evaluation of hematochezia and was found to have
parasitic infection.
Methods: Complete blood count was in the normal range. The patient un-
derwent VCE after an unrevealing upper endoscopy and colonoscopy. At the
time of the VCE, the patient was noted with 2 parasites in the colon. [figure1]
They were colorless and estimated to measure approximately 2–3 mm. He
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was asymptomatic and three stool samples failed to isolate the organism.
There was no peripheral eosinophilia.
Results: Based on the appearance of the parasite and history of travel to
Puerto Rico, Strongyloides infection was suspected. Strongyloides antibody
titer by ELISA was 1.58 which was in the equivocal range (titer of 2.11
or greater is a positive test). The patient was treated with two doses of
Ivermectin, given two weeks apart and repeat antibody titer by ELISA had
decreased to 0.68 (titer of 1.49 or less is a negative test).
Conclusion: Review of the literature revealed rare reports of parasite iden-
tification by VCE. When identified, it is typically an incidental finding that
is beneficial in treatment of an otherwise asymptomatic patient.
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Intermittent Jejunosotomy Tube Obstruction Due to Ascaris
Lumbricoides Infection
Camron Kiafar, DO, Deepa Shah, MD, Nooman Gilani, MD, FACG∗.
Medicine and Research, Section of Gastroenterology, Carl T. Hayden VA
Medical Center, Phoenix, AZ.
Purpose: Ascariasis is the third most frequent helminthic infection in the
US. The female worm can measure up to 40 cm in length. We describe a
patient who presented with J-tube occlusion from A. lumbricoides infection.
Case: A 45-year-old Costa-Rican woman was referred due to jejunostomy
tube malfunction. Initially, she was admitted after sustaining a closed head
injury in a MVA near the Arizona-Mexico border. She remained nonverbal
and required assisted ventilation and a J- tube placement for nutrition. Since
her tube placement, multiple episodes were noted where nutritional formula
could not be administered through the tube. No residual tube feeds were
noted. There was no visible kink or damage and no clinical or radiologi-
cal evidence of small bowel ileus/obstruction. She was afebrile with stable
vital signs and abdomen was benign with normo-active bowel sounds. Her
jejunostomy site appeared clean and intact. The WBC count was 6,400 with
5% eosinophils, hemoglobin 10.6, MCV 85 and platelet 351,000. Her LFTs
were normal.
A gastrograffin injection of the J-tube revealed no evidence of leak and the
tube was in appropriate position. An EGD revealed a mobile roundworm
in D2 extending distally.[figure1]Upon endoscopic removal this measured 5
inches in length. Pathology confirmed this to be A. lumbricoides. She was
treated with mebendazole 100 mg BID × 3 days and subsequently had no
further episodes of tube obstruction.
Discussion: More than 1.4 billion people are infected with Ascaris world-
wide with the highest prevalence in tropical countries. Transmission occurs
mainly via ingestion of water/food contaminated with eggs. Adult worms
inhabit the lumen of the small intestine, but may be found anywhere in the
GI tract. Common GI manifestations of infection include abdominal pain;
intestinal, hepatobiliary and pancreatic duct obstruction.
Intermittent occlusion of this patient’s jejunostomy tube was likely the result
of obstruction from ascariasis infection, which was treated both medically
and endoscopically. Although infections in adults are rare in the US, unusual
manifestations of parasitic infections should be considered in those from
endemic areas.
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Colonic Polyps in the “Esophagus”
Jessica Widmer, DO, Paul Panzarella, MD, William Gusten, MD, Kavita
Kongara, MD∗, James Grendell, MD. Gastroenterology, Winthrop
University Hospital, Mineola, NY.
Purpose: Esophageal atresia is a condition in which the proximal and distal
portions of the esophagus do not communicate. Etiologies of these anomalies
are still largely unknown; however, vascular insufficiency, genetic factors, vi-
tamin deficiencies, drug and alcohol exposure, viral, chemical, and physical
events have all been linked to embryologic developmental aberrancy.
Our patient is a 32 y.o. male with esophageal and duodenal atresia cor-
rected by gastrojejunal anastomosis and colonic interposition as an infant.
He presented with nausea, melena, hematemesis, and a syncopal episode. His
medical history was remarkable for dysphagia and recurrent pneumonias.
On admission, UGI and SBS revealed colonic interposition with segments
of the jejunum anastomosed to the stomach, proximal duodenum, and biliary
system. Gastric varices, an ulcer in the fundus, and inflammatory changes
in the duodenal bulb were suspected. Upper endoscopy however, revealed a
non-bleeding 1.5 cm neo-esophageal /gastric ulcer at the anastomosis site,
and a 1 cm sessile polyp in the proximal neo-esophageal transposed colon.
This was removed via snare cautery polypectomy and was later histologically
confirmed as a juvenile retention polyp.
Multiple studies of patients with interposition report post-operative compli-
cations such as motility problems, gastroesophageal reflux, and respiratory
complications.1 The endoscopic findings and history of recurrent pneumo-
nia in our patient confirm these findings. Cases of adenomatous polyps and
adenocarcinoma in transposed colonic segments to correct esophageal atre-
sia have also been reported. This illustrates the need and re-emphasizes the
importance of colon cancer screening wherever colonic tissue is found. 1.
Deurloo et al, “Esophageal function after correction of esophageal atresia:
follow-up after more than 18 years.” Eur J Gastroenterol Hepatol. 2005;
17(1): A27.[figure1][figure2]
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Oro-Nasal Fistula: An Usual Etiology of Dysphagia after Treatment
for Tonsillar Cancer
Joseph M. McKinley, MD, Brice Taylor, MD, Prasad Kulkarni, MD∗.
Department of Gastroenterology, University of South Florida, Tampa, FL.
Purpose: Surgery and chemo-XRT are commonly used to treat tonsillar
cancer.
Post-XRT dysphagia is common, and results acutely from mucositis and xe-
rostomia. Late complications include trismus, dental decay, osteoradionecro-
sis, proximal esophageal strictures and cranial nerve dysfunction. We present
an unusual patient who presented with dysphagia and nasal regurgitation sec-
ondary to an oro-nasal fistula following chemo-XRT for recurrent tonsillar
cancer, diagnosed by endoscopy.
Case report: This 59 y/o Hispanic male with a history of T1N0 SCCa, of
the left tonsil was treated initially with wide local resection. Chemo-XRT
was administered for recurrent cancer at 1 year. He presented with gradually
progressive solid food dysphagia and left nasal regurgitation.
A complete physical examination was unremarkable. ENT evaluation in-
cluding a flexible endoscopy was negative for recurrent cancer. An MRI of
the neck (Fig. 1) found no evidence of enhancement in the upper neck, skull
base, or within the cranium.
DVE showed slightly diminished swallowing function but was otherwise un-
remarkable. An upright barium swallow (Fig. 2) was completed and initially
reported to be normal. An EGD was performed to exclude a metachronous
esophageal cancer and other stenoses. EGD showed normal esophagus, stom-
ach and duodenum. In the oropharynx, on the left and lateral of the uvula an
opening was visualized (Fig. 3). The scope was easily passed through this
opening to the nasopharynx where the turbinates were clearly visualized,
confirming the finding of an oro-nasal fistula. Although the diagnosis was
elusive, management was relatively simple and included prescription of a
palatal obturator to be placed to occlude the fistula.
Oro-nasal fistula is an inadequately recognized consequence of surgery and
XRT for tonsillar Ca. Awareness and timely recognition of this entity is
crucial in managing these patients as a simple prosthetic device makes a
tremendous difference to the patient’s suffering and allows meeting nutri-
tional goals.
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Case Report: Argon Plasma Coagulation for the Treatment of
Hemorrhagic Radiation Sigmoiditis
Mindy C.W. Lam, MSc, Clarence K.W. Wong, MD, FRCPC∗.
Gastroenterology, University of Alberta, Edmonton, AB, Canada.
Purpose: Radiation colitis is not an uncommon consequence of pelvic ra-
diation, such as in patients treated for gynecologic cancers. Some of these
patients may suffer from anemia requiring transfusion due to chronic bleed-
ing. Many of these patients are managed with rectal medications, which is
often inadequate for control. Argon plasma coagulation (APC) has been well
described for its efficacy in treating radiation proctitis. Here, we present two
cases in which APC therapy was used to treat radiation sigmoiditis.
Methods: We followed two cases originally seen at our regional cancer
centre (Cross Cancer Institute) in Edmonton, Alberta, Canada. Both pa-
tients received pelvic radiation for endometrial cancers and were referred
for active bleeding secondary to radiation colitis that had required numerous
transfusions.
Results: Radiation induced telangiectasias were found from 10–50 cm in
the sigmoid colon. Both patients had significant improvement of symptoms
after one session of APC treatment set at 40–60 W and gas flow of 2.0 L/min.
To assess the efficacy of treatment, a second endoscopy with APC was per-
formed. There were no complications from the procedures. Neither patient
require blood transfusions after the initial treatment with improvement in
their hemoglobin levels and were doing well at four and ten-month follow
up.
Conclusion: Argon plasma coagulation can be used effectively to provide
immediate and sustained resolution of symptoms in patients with radiation
sigmoiditis (colitis).
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Intestinal Occlusion Caused by Meckel’s Diverticulum with Ileoileal
Intussusception in an Elderly Patient: A Rare Case Report
Jianfeng Cheng, MD, PhD, Naga Vemula, MD, Jeffrey Brensilver, MD,
FACP∗. Internal Medicine, Sound Shore Medical Center of Westchester,
New Rochelle, NY.
Purpose: We present a successfully treated case of small bowel obstruc-
tion secondary to Meckel’s diverticulum with ileoileal intussusception. A 75
year old male with chronic constipation presented with confusion, vomiting
and diarrhea. On admission he had hypotension, tachycardia and tachypnea.
There were some rhonchi and few crackles in both lungs. His abdomen was
diffusely distended, non-tender with normal bowel sounds. Investigations
revealed WBC of 6300/mm3 (78% neutrophils), CK: 605 U/L (N: 22–269
U/L), arterial blood gas showed hypoxemia, blood urea nitrogen of 77 mg/dl
(N: 7–18 mg/dl) and Creatinine of 3.9 mg/dl (0.5–1.2 mg/dl). Hepatic panel
and serum electrolytes were normal. Chest radiograph showed bilateral in-
filtrates and abdominal CT revealed high grade distal partial small bowel
obstruction. He was started on Piperacillin/tazobactam and Zithromax for
sepsis secondary to aspiration pneumonia, fluid resuscitation and nasogas-
tric suction for partial small bowel obstruction. His blood cultures and urine
culture were negative. C. difficile toxin, mycoplasma and legionella were
negative. Repeated abdominal CT showed high grade small bowel obstruc-
tion proximal to the middle ileum with moderate wall thickening. Laprotomy
showed small bowel obstruction secondary to Meckel’s diverticulum with
ileoileal intussusception. A small bowel resection was performed and the
patient recovered very well.
Discussion: Meckel’s diverticulum, the most common congenital anomaly of
the gastrointestinal tract, occurs in 1–3% of the population. Majority of pa-
tients with Meckel’s diverticulum are asymptomatic and only less than 5% of
these patients have clinical presentations, such as intestinal obstruction, in-
tussusceptions, inflammation and bleeding. Further, symptomatic Meckel’s
diverticulum is primarily found in pediatric age and virtually nonexistent
in elderly. It is difficult to diagnose Meckel’s diverticulum before opera-
tion. Meckel’s diverticulum should be searched in the laparotomy due to
S416 Abstracts
acute abdomen and it can be the cause of serious abdominal complications.
We considered our case interesting because of its rarity and of preoperative
diagnosis difficulty.
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An Unusual Case of Disseminated Histoplasmosis in an
Immunocompetent Patient
Elliot Joo, MD, Matthew M. Tsushima, MD, Michael Walter, MD∗.
Internal Medicine, Loma Linda University Medical Center, Loma Linda,
CA and Gastroenterology, Loma Linda University Medical Center, Loma
Linda, CA.
Purpose: Although histoplasmosis in the immunocompetent patient has
been reported, dissemination is rare. We report an unusual case of an im-
munocompetent patient with disseminated histoplasmosis who presented
with abdominal pain and bloody diarrhea.
Results: A 27 year old Caucasian male with a history of poor oral hygiene
presented with tachycardia and daily fevers up to 103◦F for nine months
following a molar extraction. He initially developed a recurrent oral abscess
despite treatment with clindamycin. He then failed to improve with a 10-
day course of oral steroids. The patient presented to the emergency room
with a temperature of 102.9◦F, heart rate of 160/minute. On exam, ulcerated
red lesions in the buccal mucosa and gingiva were noted. White blood cell
count was 16.0 × 103/µL. The remainder of his blood tests including an
HIV test was negative. Blood cultures were drawn and he was started on
ampicillin/sulbactam and vancomycin.
The patient was diagnosed with acute necrotizing ulcerative gingivitis and
was taken for teeth extraction and debridement. Mandibular biopsy showed
findings consistent with osteomyelitis. Biopsy culture was only positive for
coagulase negative Staphylococcus.
The patient continued to have sinus tachycardia and fevers despite a vari-
ety of antibiotic regimens. He then developed abdominal pain and bloody
diarrhea. Pseudomembranous colitis was suspected and appropriate treat-
ment was started with no improvement. A colonoscopy revealed numerous
ulcerations throughout the colon. Biopsies of the ulcers revealed extensive
infiltration with macrophages engorged with Histoplasma capsulatum. The
previous mandibular biopsy slide was then reviewed and it demonstrated the
same organism. Further history taking revealed that the patient was a former
resident of Missouri, and had moved to California 3 years ago.
Within several days of starting amphotericin B, his fevers subsided for the
first time in nearly 10 months, and his tachycardia markedly improved. He
was eventually discharged home with itraconazole.
Conclusion: Approximately two-thirds of patients with disseminated histo-
plasmosis do not have a clear etiology for their hematogenous spread. In
our patient, steroid therapy could have led to him being momentarily im-
munocompromised, promoting hematogenous spread of the fungal spores
and consequently, disseminated disease.
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Henoch-Schonlein Purpura in an Adult Presenting Initially as Acute
Gastrointestinal Illness without Skin Manifestations
Swetha Kandula, Raymond L. Farrell, Stuart A. Torgerson∗. Division of
Gastroenterology, Department of Internal Medicine, Southern Illinois
University School of Medicine, Springfield, IL.
Purpose: Henoch-Schonlein purpura (HSP) is a systemic vasculitis that
affects small caliber vessels. Patients present with arthralgias, purpuric rash
on the lower extremities, and renal involvement. Gastrointestinal symptoms
(abdominal pain, nausea, vomiting, diarrhea, bleeding) are more common
in children than adults and usually follow skin manifestations. We present
a case of HSP in an adult with gastrointestinal involvement documented
endoscopically preceding the onset of skin lesions creating a diagnostic
dilemma.
A 25 year old healthy woman presented with five days of abdominal pain,
nausea, vomiting, diarrhea and haematochezia with a prior upper respira-
tory tract infection. She denied fever, rash or antibiotic use. Family history
was significant for Crohn’s disease. Examination showed diffuse abdominal
tenderness.
Abnormal laboratory data were: WBC 34 k/cumm, ESR 51 mm/hr, CRP
2.4 mg/dl. The following laboratory data were negative or within normal
limits: hb, hct, platelets, BUN, creatinine, urinalysis, serum IgA, IBD serol-
ogy, ttgIgA, stool leucocytes and cultures. Immuno-serological workup was
negative. CAT scan of the abdomen showed multiple thickened small bowel
loops and edema of stomach and terminal ileum raising possibility of Crohn’s
disease. Small bowel follow through showed dilated and ulcerated loop of je-
junum. Esophagogastroduodenoscopy and colonoscopy were significant for
gastritis, erosions and edema of duodenum, sigmoid colon and rectum. Biop-
sies revealed acute inflammatory changes consistent with immune-mediated
vasculitis.
Patient subsequently developed arthralgias and diffuse non blanching pe-
techial rash on the lower extremities. Mesenteric angiogram was normal.
Skin biopsy showed leucocytoclastic vasculitis. Immunoflourescence stain
showed vascular deposits of fibrin and granular IgA. She was diagnosed
with HSP and treated with corticosteroids with remarkable improvement.
This case illustrates the potential for diagnostic uncertainty when HSP in
adults presents with gastrointestinal symptoms preceding skin manifesta-
tions.[figure1]
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Coil Migration and Cholestatic Jaundice: An Uncommon Late
Complication of Hepatic Artery Pseudoaneurysm Embolization
Rahul Pannala, MD, Baron H. Todd, MD, Vege S. Santhi, MD∗.
Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Purpose: 51-year-old White male with neurofibromatosis, and history of
pylorus-preserving radical pancreaticoduodenectomy nine years ago for
peri-ampullary islet cell cancer and post-operative hepatic artery pseudoa-
neurysm that was successfully treated by coil embolization presented for
evaluation of jaundice. He complained of persistent diarrhea, jaundice and
weight loss. Liver chemistries included total bilirubin of 9.2 mg/dL, AST
121 U/L, ALT 119 U/L, alkaline phosphatase of 922 U/L. MRCP revealed
marked left hepatic lobar atrophy, intrahepatic bile duct dilatation through-
out the left hepatic lobe, several intra-hepatic ductal stones, and changes
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suggestive of cholangitis. ERCP confirmed these findings and also noted a
partially strictured choledochojejunostomy. Balloon dilatation of the chole-
dochojejunostomy, extensive stone extraction, and biliary stenting were per-
formed. Repeat ERCP 6 weeks later noted recurrent severe stone burden in
the common and left hepatic ducts. Remarkably, a partially uncoiled wire
neighboring the right hepatic duct was intraductal possibly causing stric-
turing and stone formation. The coil was also noted to be intermittently
exiting the choledochojejunostomy suggesting the possibility that it can be
retrieved endoscopically. However, immediately thereafter the patient suc-
cumbed to severe cholangitis. Autopsy revealed left hepatic lobar atrophy
and a migrated coil in the right hepatic duct.
We report an unusual and previously unreported late complication of coil
embolization of a hepatic artery pseudoaneurysm. Our case is unique in the
delayed problems from coil migration, the nature of the migration, i.e., into
the hepatic duct, and consequent hepatic lobar atrophy, extensive intrahepatic
and CBD stone burden with associated stricture of the choledochojejunos-
tomy. As pseudoaneurysms do not contain all the layers of the arterial wall
there may be an increased propensity for coil erosion and migration. Al-
though ERCP may be the diagnostic method of choice, the present case
also highlights that if there is significant stone burden it may be difficult to
identify the presence of coils in the hepatic or common bile duct.[figure1]
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Unusual Pulmonary Complication from Maloney Dilation
David S. Hodges, MD∗, Rishi Raj, MD. Internal Medicine, Texas Tech
University Health Sciences Center, Lubbock, TX.
Purpose: Complications from bougie dilation of the esophagus are uncom-
mon; most are related to perforation. We describe a case of breakage of
Maloney dilator tip during dilation which was silently aspirated and pre-
sented with persistent cough.
Results: A 70 year old white male presented with intermittent dysphagia to
solid food. Upper endoscopy revealed a Schatzki ring at the gastroesophageal
junction. Dilation was performed using a 58 French Maloney dilator with
minimal resistance. He recovered in the endoscopy unit without incident
and discharged home. Late that evening the patient developed dry cough.
The cough persisted the following day and patient presented to local minor
care center. Localized wheezing was present in right lower lobe; antibiotics
were prescribed and patient sent home. Dry cough persisted the next day and
patient came to our hospital emergency room. There was no fever, wheezing
was audible in right lower lobe. Chest X-ray revealed a 3 cm linear radiopacity
in the right lower lobe bronchus, suspicious for a foreign body (Fig. 1).
The Maloney dilator used was inspected; the distal tip was missing and
corresponded to the length and contour of the suspected pulmonary foreign
body. The patient was admitted; at subsequent bronchoscopy a foreign body
was seen and removed from right lower lobe bronchus. Upon inspection,
it was the dilator tip (Fig. 2). The patient recovered well with cessation of
wheezing and cough. Upon further inspection of our dilators, it was found
that the more commonly used dilators had shallow transverse furrows in
the tapered tips, resulting from frequent use and disinfectant cleansers. The
smaller, less commonly used dilators had no such changes. The complete
dilator kit was replaced.
Conclusion: Frequently used bougie dilators should be periodically in-
spected for signs of damage that could result in possible breakage during
dilation.[figure1][figure2]
813
Case Series: Lactulose Retention Enema Associated with Massive
Gastrointestinal Hemorrhage in Three Patients
William R. Kessler, MD∗. Gastroenterology, Indiana University Medical
Center, Indianapolis, IN.
Recently at our institution we observed 3 cases of severe lower gastroin-
testinal hemorrhage associated with use of the Lactulose Retention Enema
(LRE). Practicioners must be aware of the potential complications of using
such a device in critically ill, cirrhotic patients.
Part I: Chart review, including endoscopic reports, laboratory data, imaging
studies and discharge summaries was performed.
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Part II: Diameter as well as bulb pressure was measured using a retention
enema set attached to a manual sphygmomanometer. Once fully deflated the
system was closed and measurements were obtained for sequential pumps.
This was repeated twice.
Part I: During a three month period three patients were identified as having
severe lower gastrointestinal hemorrhage associated with the administration
of LRE.
Case 1: 52 year old male with Hepatitis C Cirrhosis (Child’s C) was trans-
ferred for management of variceal hemorrhage. LRE was administered
for HE. After massive lower gastrointestinal hemorrhage, flexible sigmoi-
doscopy revealed a 10 cm rectal tear with clot. Patient expired within twenty
four hours.
Case 2: 51 year old male with Hepatitis C/Alcoholic Cirrhosis (Child’s B)
was admitted due to Hepato-Renal Syndrome (HRS) and HE. LRE was
administered with subsequent massive lower gastrointestinal hemorrhage.
Colonoscopy revealed a one-third circumferential rectal tear with clot. Imag-
ing revealed no perforation. Patient survived to discharge.
Case 3: 76 year old female with Hepatitis C Cirrhosis (Child’s B) was admit-
ted HE following TIPPS procedure. LRE was administered and subsequently
massive lower gastrointestinal hemorrhage ensued. Colonoscopy revealed a
large rectal mucosal defect and possible ulcer. Imaging revealed no evidence
of perforation. Patient survived to discharge.
Part II: The mean pressure (mm Hg) and (diameter (cm)) for one, two, three
and four pumps was; 107 (4), 195 (4.3), 242 (4.3) and 260 (4.8), respectively
(See Table).
Based upon this study we conclude that LRE should be avoided in cirrhotic
patients in the critical care setting due to significant morbidity and mortal-
ity associated with traumatic complications related to the high intra-bulbar
pressures generated in the enema retention system. Our institution favors
the use of intravenous antibiotics for HE and has abandoned the practice of
LRE.
Pressure and Diameter Measurements
Number Pumps Mean Pressure (mm Hg) Mean Diameter (cm)
1 110 4
2 195 4.3
3 242 4.3
4 260 4.8
814
Refractory Peptic Ulcer Disease: A Rare Presentation of Annular
Pancreas
Laith H. Jamil, MD, Michael C. Duffy, MD, Mitchell S. Cappell, MD,
PhD∗. GI, William Beaumont Hospital, Royal Oak, MI.
Case: A 28-year old Caucasian male presented with epigastric pain, nau-
sea, and vomiting. There was no history of NSAID use. He had normal
LFTs, amylase and lipase. EGD revealed an ulcerated mass/narrowing in
the descending duodenum. Biopsies showed duodenitis, H. pylori negative.
An UGI series showed a focal constriction in the descending duodenum.
Abdominal CT showed an incomplete annular pancreas (AP) encircling the
anterior and lateral aspect of the descending duodenum with narrowing of
the duodenal lumen. The patient’s symptoms initially responded to high dose
PPI, but recurred four months later. Repeat EGD showed severe narrowing
of the descending duodenum. The patient underwent gastrojejunostomy with
relief of the symptoms. Repeat EGD revealed healed ulcers/erosions.
Discussion: AP is a rare congenital anomaly (incidence 1:20,000) charac-
terized by a ring of pancreatic tissue surrounding the descending duodenum.
It results from failure of the ventral anlage of the pancreas to rotate with
the duodenum. There are two main etiologic theories: (1) Lecco’s Theory
– adherence of the ventral bud to the duodenal wall prior to rotation re-
sults in its persistence and encirclement of the duodenum, and (2) Baldwin’s
theory – persistence and enlargement of the ventral bud. It can present at
any age, including infants. Most adults present between 20 and 50 years of
age. Most are asymptomatic. Presenting symptoms include abdominal pain,
nausea, postprandial fullness, vomiting, UGI bleeding (from peptic ulcer),
acute or chronic pancreatitis, and rarely biliary obstruction. 15% of adults
with AP have duodenal stenosis. 33% have PUD. PUD is believed to be due
to prolonged stasis of antral contents. The treatment is bypass surgery of
the annulus, by duodenojejunostomy, duodenoduodenostomy, or a gastroje-
junostomy.
Conclusion: This is an unusual presentation of AP in adulthood as a DU and
constriction refractory to PPI therapy, which responded to gastrojejunostomy.
AP should be strongly considered in the differential diagnosis of a benign
idiopathic PUD in the descending duodenum associated with severe focal
duodenal narrowing, and refractory to PPI therapy. AP should be excluded
by appropriate imaging studies.[figure1]
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Pyogenic Liver Abscess Complicating Colonoscopic Polypectomy
Rebekah G. Gross, MD, Bruce Reiter, MD, Mark A. Korsten, MD∗.
Gastroenterology, Mount Sinai School of Medicine, New York, NY;
Radiology, James J. Peters Veterans Affairs Medical Center, Bronx, NY and
Gastroenterology, James J. Peters Veterans Affairs Medical Center, Bronx,
NY.
Flexible colonoscopy is the “gold-standard” for diagnosis and treatment of
colorectal pathology. However, there remain serious, albeit rare, risks of this
invasive procedure, including infectious complications.
A 68 year old man with coronary artery disease and diabetes mellitus pre-
sented with a three-day history of abdominal cramps, vomiting, and non-
bloody diarrhea. The patient had undergone screening colonoscopy one
week previously, during which a 2 cm × 3 cm pedunculated polyp was re-
moved from the hepatic flexure using snare cautery. Pathology had revealed a
moderately differentiated invasive adenocarcinoma arising in a tubulovillous
adenoma.
The patient was febrile to 39 degrees Celsius and physical exam was re-
markable for a distended, tender abdomen with decreased bowel sounds.
Laboratory studies showed a white blood cell count of 13,400/µL and ele-
vated transaminases to twice the upper limit of normal. Abdominal CT was
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obtained, revealing an abscess measuring 8.1 cm in maximum dimension in
the posterior segment of the right hepatic lobe. Blood cultures grew E. coli
and alpha hemolytic streptococci.
The patient was treated with intravenous antibiotics and underwent CT-
guided placement of a percutaneous drainage catheter to assist with res-
olution of the abscess. He ultimately proceeded to right hemicolectomy for
resection of the adenocarcinoma.
Presence of colonic tubulovillous adenoma alone, like active inflamma-
tory bowel disease, is considered a risk factor for hepatic abscess devel-
opment, presumably by causing mucosal defects that allow spontaneous
micro-perforation. However, given the brief time-course from colonoscopy
to onset of symptoms and location of the polypectomy at the hepatic flex-
ure, we believe our patient’s abscess was caused by micro-perforation during
the procedure. This case serves to raise our consciousness of the infectious
potential of therapeutic colonoscopy, while not diminishing our belief in its
power to diagnose and treat gastrointestinal pathology.[figure1]
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Fever of Unknown Origin: Pylephlebitis
Julie Yang, MD, Eugene R. Schiff, MD, MACG∗. Division of
Gastroenterology and Hepatology, University of Miami Miller School of
Medicine, Miami, FL.
Background: Pylephlebitis, or septic thrombophlebitis of the portal vein, is
a rare complication of any intraabdominal infectious process that is associ-
ated with significant morbidity, including hepatic abscess, bowel ischemia,
portal hypertension and death. We describe a case of a patient who presented
with fever of unknown origin (FUO), later found to be due to pylephlebitis
secondary to clinically silent sigmoid diverticulitis. Case: 56 year old male
physician presented to an outpatient facility with complaints of fevers, rig-
ors, and myalgia for 5 days. Routine fever work-up revealed a leukocytosis
(17,300/µL), but negative blood cultures, urinalysis, and CXR. Viral causes
were also excluded. High-spiking fevers and rigors continued and empiric
antibiotic therapy (levofloxacin) was initiated. Despite treatment, the pa-
tient’s symptoms persisted for the next 2 weeks and he was subsequently
admitted for further evaluation. On admission, his temperature was 103 ◦F,
but physical examination was unremarkable. Laboratory investigations were
notable for an increased WBC (18,700/µL, 90% polys, 17% bands), ESR
(120 mm/hr), AST (92 IU/L) and ALT (82 IU/L). Alkaline phosphatase (105
IU/L) and total bilirubin (0.5 mg/dL) were normal, but albumin (2.2 g/dL)
was decreased. Abdominal US with dopplers revealed a thrombus in the
portal vein and right branch, without signs of portal hypertension, cirrhosis,
or collateralization. CT of the abdomen/pelvis with contrast confirmed ex-
tensive thrombosis and demonstrated sigmoid diverticulitis. The patient was
placed on broad-spectrum IV antibiotics (piperacillin/tazobactam) and anti-
coagulation therapy. Admission blood cultures grew anaerobic peptostrepto-
coccus and the diagnosis of pylephylebitis was made. The patient ultimately
defervesced and his WBC normalized. His aminotransferases subsequently
trended down, and he was discharged on hospital day 6. The patient was to be
maintained on long-term IV antibiotic therapy (4–6 weeks of ertapenem) and
anticoagulation. An outpatient hypercoagulabilty work-up, echocardiogram
and colonoscopy were all negative. Follow-up CT demonstrated improve-
ment of the pylephlebitis. Conclusion: The diagnosis of pylephlebitis should
be considered in patients with FUO. Imaging studies are required, not only
to demonstrate thrombus, but to identify the underlying source of infection.
A high index of clinical suspicion is required in this scenario because ag-
gressive antibiotic therapy can be promptly initiated, avoiding potentially
serious complications.
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Pancytopenia in a Patient Treated with 6MP and Fluconazole: A Novel
Drug Interaction
Jonathan Z. Potack, MD, Lloyd Mayer, MD, Thomas A. Ullman, MD∗. Dr.
Henry D. Janowitz Division of Gastroenterology, Mount Sinai School of
Medicine, New York, NY.
An 83 year old woman with a history of ulcerative colitis was admitted with
increased diarrhea and rectal bleeding. Colonoscopy revealed active colitis
from the anal verge to the splenic flexure. Prednisone was added to her stable
dose of 6 mercaptopurine (6MP). The prednisone was gradually tapered as
her symptoms improved. Five months later the patient was readmitted with
fatigue and dysphagia. Upper endoscopy revealed white exudates throughout
the esophagus consistent with Candida esophagitis. Treatment was initiated
with oral fluconazole 100 mg daily. The patient’s dysphagia improved and
she was discharged. Five days later the patient was readmitted with fatigue.
A complete blood count revealed a leukocyte count of 1,600/ul with an ab-
solute neutrophil count of 850/ul, hemoglobin of 8.5 g/dl and platelet count
of 44,000/ul. Her baseline leukocyte count ranged from 4,600/ul to 7,200/ul,
baseline hemoglobin range;10.5 g/dl to 12 g/dl and baseline platelet range;
210,000/ul to 300,000/ul. Measurements of her 6MP metabolites revealed
a 6 Thioguanine (6TG) level of 924 (>400 = high risk of leukopenia) and
the 6 methylmercaptopurine (6MMP) level was undetectable. The patient’s
dose of 6MP was stable and her family verified she had not taken an in-
advertent overdose. The fluconazole was discontinued and the hematologic
abnormalities resolved over five days.
6MP is metabolized by xanthine oxidase to 6 thiouric acid (6TU). 6 TU
is then metabolized by thiopurine methyltransferase (TPMT) to 6TG and
6MMP. Higher levels of 6TG correlate with leukopenia but also with re-
sponse to therapy. Patients who are homozygous for inactivating mutations
of TPMT are at high risk for increased 6TG levels and leukopenia. This
patient had tolerated 6MP over many years without developing leukopenia.
She rapidly developed leukopenia after the introduction of fluconazole and
the leukopenia resolved with the withdrawal of fluconazole. We hypothe-
size that fluconazole led to a decrease in TPMT activity resulting in high
6TG levels and leukopenia. No previous interaction between 6MP and flu-
conazole has been described. A significant number of IBD patients receive
corticosteroids which puts them at increased risk for fungal infections. Many
of these patients may receive fluconazole while concurrently on 6MP. We
recommend careful monitoring of the blood count during therapy given the
risk of leukopenia in patients receiving 6MP and fluconazole.
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Severe Anemia as the Presenting Feature of Small Bowel Melanoma
Rushabh J. Modi, BA, Samir A. Shah, MD, David Schreiber, MD, Edward
Feller, MD∗. Medicine, Division of Gastroenterology, The Warren Alpert
Medical School of Brown University, Providence, RI and The Warren
Alpert Medical School of Brown University, Providence, RI.
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Introduction: Melanoma, the most common tumor metastasizing to the GI
tract found post-mortem, is rarely symptomatic. Similarly, this cutaneous
malignancy is a rare etiology of severe, occult GI bleeding. We report a case
of unexplained chronic anemia due to recurrent melanoma in the absence of
other suggestive complaints.
Case Report: A 70 year-old man with known melanoma diagnosed 3 years
previously was sent to the emergency department after routine tests demon-
strated severe anemia. Bloodwork was done to prepare for a duodenal biopsy
after PET scan for routine metastatic surveillance demonstrated hyperactiv-
ity in the duodenum. He gave no history of trauma, bleeding, or GI com-
plaints. Review of symptoms revealed mild fatigue and dyspnea on exer-
tion of unclear duration. Physical exam: blood pressure = 152/90; pulse =
90/minute with minimal postural change. No skin lesions were present. The
rest of the exam was unremarkable except stool was positive for occult
blood. Hgb. was 6 gm% and iron studies were consistent with a microcytic,
hypochromic anemia. Colonoscopy was normal. Upper endoscopy using a
pediatric colonoscope demonstrated a 2–3 cm, pigmented, ulcerated mass in
the distal duodenum- proximal jejunum. Histology: malignant melanoma.
He was referred to medical oncology for treatment options.
Discussion: Melanoma is an aggressive tumor; the GI tract is the second
most common site of metastasis after the lung. An ante-mortem diagnosis
is made in only 1.5% to 4.4% of patients. Diagnostic challenges include
(1) small bowel recurrence as late as 21 years after resection of a primary
skin lesion, (2) occurrence without a cutaneous site; (3) presentation as a
non-pigmented lesion or mimicking a typical benign polyp; (4) non-specific
symptoms suggestive of more common disorders. Endoscopically, small
bowel lesions manifest as single or multiple mucosal or intramural nodules,
ulcerated masses, or as diffuse bowel involvement. This patient underscores
the need to consider recurrent, extra-cutaneous tumor in all individuals with
a history of melanoma and evidence of GI bleeding of any magnitude. Such
patients undergoing endoscopy should have all lesions biopsied to detect
possible metastatic disease.
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Investigation of the Excluded Stomach after Roux-en-Y Gastric
Bypass: The Role of Percutaneous Endoscopy
Kanwar R.S. Gill, MD, Mark J. McKinney, MD, Ernest P. Bouras, MD∗.
Gastroenterology, Mayo Clinic, Jacksonville, FL.
Background: The bypassed portion of the stomach is difficult to access
and evaluate after Roux-en-Y gastric bypass. We report a case of obscure
gastrointestinal bleeding where successful endoscopic examination of the
bypassed stomach and small bowel was made through percutaneous access.
Case: A 66-year-old man status post Roux-en-Y gastric bypass surgery for
morbid obesity 6-years prior presented to an outside institution with melena
and hemodynamic instability. His hemoglobin (Hgb) was 10 gm/dl, a drop
from baseline Hgb of 15 gm/dl. The patient was taking aspirin 81 mg daily.
Upper endoscopy revealed expected post-surgical changes and colonoscopy
showed diverticulosis with no bleeding. A tagged RBC scan revealed a focus
of activity in the right upper quadrant. The aspirin was stopped and the patient
was discharged following cessation of clinical bleeding and a stable Hgb.
He was readmitted five days later with recurrent melena and a Hgb of 8.5
gm/dl. A repeat bleeding scan was negative and capsule endoscopy revealed
bleeding at 4 hours into the recording (suspected jejunum). The Roux-en-Y
anastomosis was not specifically identified. The patient was transferred to
our institution for double balloon endoscopy, but the Roux-en-Y anastmosis
was not reached and no proximal source of bleeding was identified. Based
on the suspicion that bleeding was coming from the excluded stomach (ES),
a percutaneous endoscopy was performed. Once localizing the ES with ul-
trasound, the stomach was filled with air and a 22 French gastrostomy tube
was inserted into stomach with the assistance of fluoroscopy. Through the
percutaneous access, we were able to examine the ES and Roux limb to
beyond the surgical anastmosis. No source of bleeding was identified, so a
button PEG was left in place for future access. The patient experienced no
recurrent bleeding over a 3-month period, and the PEG was subsequently
removed.
Discussion: Percutaneous examination of the ES with contrast was first
described by McNeely et al in 1987, and an endoscopic examination with
a bronchoscope was first used in 1998. Since then, only few case reports
have been published utilizing percutaneous endoscopy to evaluate suspected
pathology in the ES. New techniques like double balloon endoscopy have
been shown to be useful but the examination may be limited by difficult
access, as with our patient. This case highlights the value of percutaneous
endoscopy to examine the ES after Roux-en-Y gastric bypass.
820
Rectal Stent Revision Using Argon Plasma Coagulation
Amil Patel, MD, Kamil Obideen, MD∗. Medicine/Division of Digestive
Diseases, Emory University School of Medicine, Atlanta, GA.
A 66 year old male was referred for evaluation of heme positive stools and
constipation. A colonoscopy ultimately revealed an obstructing rectal mass 7
cm from the anal verge (Figure A), and the biopsy was consistent with mod-
erately differentiated rectal adenocarcinoma. A subsequent computed to-
mography scan and endoscopic ultrasound confirmed a stage IIIB, T3N1M0
rectal adenocarcinoma. A Boston Scientific Wallflex enteral colonic stent
size 25 mm × 90 mm was then successfully deployed for symptomatic re-
lief while he underwent neoadjuvant chemoradiation therapy. However, 6
weeks later, the patient began to experience rectal pain, bleeding with bowel
movement and intense tenesmus. A repeat flexible sigmoidoscopy revealed
that the distal portion of the metal stent was imbedded within the rectal mu-
cosa resulting in irritation (Figure B). Over the course of two subsequent
flexible sigmoidoscopies, argon plasma coagulation was utilized at 80 watts
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and 0.8 liters/minute to remove the distal portion of the stent and blunt the
sharpened edges (C-D). The remnants of the stent were successfully re-
moved using forceps. There was little to no mucosal irritation as a result
of the procedure, and the patient’s symptoms had dramatically improved at
follow-up.[figure1][figure2]
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Balantidium Coli and Trichuris Trichiura Co-Infection Presented with
Lower Gastrointestinal Bleeding – A Case Report
Bogdan Cristescu, MD, Safak Reka, MD∗. Digestive Diseases, SUNY
Downstate Medical Center, Brooklyn, NY.
Balantidium coli (B coli), primarily an intestinal parasite of pigs, is an un-
common protozoan cause of infectious colitis in the United States. Three
forms of B coli infection can occur: asymptomatic cyst excretion, acute col-
itis with prominent bloody diarrhea and chronic infection. We present a case
of co-infection with B coli and Trichuris trichiura presented as acute colitis.
Case report: A 46 year-old female from Bangladesh living in Brooklyn,
New York for the last 8 years presented with an episode of bloody diarrhea
and lower abdominal pain. Her medical history was significant for diabetes
mellitus (DM) on insulin therapy. Patient traveled to Bangladesh 6 months
ago, stayed at a farm in a remote village and drank water from a weld. Phys-
ical exam was unremarkable. Laboratory data revealed iron deficiency ane-
mia and uncontrolled DM. Stool studies were negative. Colonoscopy showed
patchy 0.5 – 0.7 cm discrete ulcers throughout the sigmoid, descending, trans-
verse colon and cecum. A 2 cm live white worm with a whip-like appearance
was retrieved from the cecum. Colonic biopsies showed colonic balantidi-
asis with acute inflammation, superficial ulcerations, inflamed granulation
tissue and trophozoites of balantidium coli. The worm was identified as
Trichuris trichiura (whipworm).
The patient was treated with Albendazole 400 mg daily for 3 days and
Tetracycline 500 mg four times daily for 10 days. She had complete resolution
of her symptoms and repeated colonoscopy at 6 weeks was normal.
Discussion: B coli infection should be considered in patients presenting with
bloody diarrhea and history of travel in endemic countries. Patients with other
infections or debilitating diseases are more likely to develop symptomatic
infections. Co-infection with B coli needs to be considered when other
pathogenic parasites are present including nematodes.[figure1][figure2]
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The Importance of Belching: Pharmacologic Inhibition of Eructation
Presenting as Bloating and Abdominal Pain
Andrew D. Rhim, MD∗. Gastroenterology Division, Department of
Medicine, University of Pennsylvania School of Medicine, Philadelphia,
PA.
Excessive eructation, or belching, has been looked upon as crass in cer-
tain social contexts. Further, this response has been implicated, in part, in
the pathophysiology of intractable GERD. Hence, the act of eructation fre-
quently is cast in a negative light. However, the eructation response serves
an important role in the alleviation of elevated pressures in the stomach,
especially in cases of aerophagia. Here we present an interesting case where
the importance of eructation is highlighted, giving rise to a discussion of the
mechanism of eructation.
The patient is a 46 year-old male, with a past medical history notable for
polysubstance abuse, diabetes mellitus type 2, hypertension, and obesity,
admitted to an inpatient medical service for treatment of a septic joint. During
his admission, he noted a 2 week history of increasing bloating and transient,
sharp epigastric pains. During the same time frame, the patient enrolled in
a substance abuse program in which baclofen was initiated and increased.
These symptoms totally resolved when made NPO. CT scan of the abdomen
and pelvis were negative for any gross pathology, including obstruction, fat
stranding, or free air. On exam, multiple bottles of diet carbonated beverages
littered the patient’s bedside. He admitted to habitually drinking up to 4 L of
diet cola a day for the past 2–3 years (preceding the initiation of baclofen).
Upon cessation of carbonated beverages, the symptoms completely resolved.
However, since the patient refused to continue abstinence of carbonated
beverages, the dosage of the baclofen was slowly titrated down. With the
removal of the baclofen, the patient was able to continue his habit without
symptoms.
Ingested carbonated beverages elaborate a large amount of gas in the stom-
ach. When gastric intralumenal pressures are high due to ingested air, the
rate of transient lower esophageal relaxations (TLESR) increases, leading
to the eructation response. It has been shown that baclofen, a GABA(B)
receptor agonist, inhibits TLESRs by modulating gastric mechanoreceptor
and CNS-Vagus nerve transduction. Hence, when baclofen was started, the
patient’s eructation response was inhibited, leading to increased gastric pres-
sures and, presumably, the described symptoms. Discontinuation of the ba-
clofen allowed for return of the proper stimulation of TLESRs and eventual
alleviation of the patient’s pain.
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Autoimmune Pancreatitis (AIP) – A More Younger and Diverse Disease
Matthew Behme, MD, Girish Anand, MD, Ramesh Koka, MD, Philip O.
Katz, MD, Jorge R. Uribe, MD∗. Gastroenterology, Albert Einstein
Medical Center, Philadelphia, PA.
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AIP was first proposed as a distinct entity of chronic pancreatitis in 1995. The
incidence, prevalence and clinical characteristics worldwide are yet being
investigated. Common age of presentation is between of 45–75 years with a
distinct male predominance.
We present a 23-year-old African American, HIV + obese male (BMI 47.5)
with one week of painless jaundice, unintentional 20 pound weight loss in the
last 3 months and symptoms of cholangitis 24 hours prior to admission. Liver
chemistries revealed elevation with clear cholestatic pattern: Direct hyper-
bilirrubinemia (22 mg/dl) alkaline phospatase more than three times upper
normal limit, normal transaminases, inversion of the albumin to globulin
ratio. Pancreatic enzymes were normal as well as electrolytes and glucose.
Liver ultrasound showed intra and extra hepatic ductal dilatation. Triple
phase CT of the pancreas revealed a diffusely enlarged pancreas without
phlegmonous changes, calcification, or pseudocysts and a narrowed, irreg-
ular pancreatic duct. The arterial enhanced images demonstrated a hypo
dense pancreas with increased peripheral attenuation in delayed phase. Tra-
ditional auto-immune markers were negative except for a weakly positive
SMA (1:20). Total serum Gammaglobulins were elevated with IgG Sub-
class 4 normal. CD4 count was normal.
ERCP identified a smooth, 4 cm distal common bile duct stricture. A per-
cutaneous pancreatic biopsy confirmed the diagnosis of sclerosing lympho-
plasmacytic pancreatitis. Treatment with oral prednisone at 40 mg/ day led
to rapid normalization of liver chemistries and full cholangiographic resolu-
tion of the stricture. This case illustrates that AIP is not limited to the older
age group and can be seen in younger African American patients.
This is the first reported case of AIP in a patient with HIV. Whether this is
a chance association is unclear and will need to be looked at with further
reports of this interesting disease.
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Gastrointestinal Stromal Tumor and Papillary Renal Cell Carcinoma:
A Case Report
Ilysa Diamond, DO∗, Saphwat Eskaros, MD, Chethana Kanaparthi, MD,
Andrea Culliford, MD, Sury Anand, MD. Gastroenterology, Brooklyn
Hospital, Brooklyn, NY and Gastroenterology, St. Barnabas, Bronx, NY.
There are only 4 reported cases of GIST found with concomitant PRCC. A
50 y o male with HTN presented after a presyncopal episode, with dizzi-
ness, and black stool for 1 month. PE remarkable only for melena. Iron
deficiency anemia was seen on labs, large hiatal hernia on EGD and a nor-
mal colonoscopy. A 9 × 5 cm right pelvic mass was seen on CT scan with a
meniscal sign of the oral contrast suggesting ileal neoplasm (Fig. 1), and a
5 × 4 cm right kidney mass. Laparoscopic excision of a 6 × 8 cm ileal tu-
mor showed malignant GIST, with spindle cells, vesicular nuclei and a 5/50
hpf mitotic rate. Histochemical staining was postive for CD117. CT guided
biopsy of the renal mass showed PRCC. The patient underwent a total right
nephrectomy without post-op chemotherapy. GISTs are differentiated from
other smooth muscle neoplasms by the identification of the CD117 antigen
on immunohistochemical staining. CD117 is part of the c-kit receptor, a
membrane tyrosine kinase and a product of the c-kit or KIT proto-oncogene.
Other non-GIST spindle cell neoplasms of the GI tract do not carry this
mutation, which is clinically relevant because the c-kit mutation is sensitive
to imatinib, a selective tyrosine kinase inhibitor. Surgical resection is the
treatment of choice, but only half are recurrence free for five years. Ima-
timib is successful as adjuvant therapy in advanced disease and an option for
unresectable disease. Both PRCC and GIST have been connected to muta-
tions in the proto-oncogenes c-MET and c-KIT however this association is
only seen in recurrent familial tumors, not sporadic as seen in this patient.
A case report describes a patient with metastatic GIST and PRCC, treated
with imatinib. Six months later, all hepatic lesions had regressed.
However, the renal masses increased in size, raising questions regarding
the effect of imatinib for treatment of GIST on PRCC. In this situation,
perhaps sunitinib should be considered as first-line treatment as it has been
FDA-approved for treatment in imatinib refractory patients with GIST and
in patients with advanced renal cell carcinoma.[figure1]
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Autoimmune Cholangitis in a Patient without AIP
N. Thorne, MD, V. Korapati, MD, J. Grendell, MD∗. Division of
Gastroenterology, Winthrop University Hospital, Mineola, NY.
A 42 year-old male, presents with fatigue, pruitus, 20 lb weight loss and
RUQ discomfort. Laboratory data is shown in Figure 1. MRCP revealed
a 9 mm focal stricture at junction of CHD & proximal CBD. The typical
beaded appearance of PSC was not noted. Liver biopsy revealed patchy lob-
ular and portal chronic inflammation without cirrhosis. Treatment included
prednisone and ursodiol. Following therapy, the patient clinically improved.
After the steroids were discontinued he again became symptomatic. Table
1 shows the trend of liver enzymes, IgG and CRP levels throughout the
treatment course.
Table 1.
Tx Alk-phos IgG IgG4 CRP
Pre Tx 881 2297 210 —–
Pred40 mg 382 1500 114 2.0
Off Pred 316 2192 189 3.2
Pred30 mg 263 1620 129 2.0
Discussion: AIP is characterized by an inflammatory process in which
prominent lymphocyte infiltration with associated fibrosis of the pancreas
causes organ dysfunction. The current diagnostic criteria is based on the
Japanese criteria including: 1) narrowing of >1/3 of the pancreatic duct on
ERCP as well as enlargement of the pancreas; 2) elevated levels of serum
IgG4 or the presence of autoantibodies, and 3) evidence of lymphoplasma-
cytic changes within the pancreatic parenchyma on biopsy1. Biliary strictures
may be present as diffuse monomorphic or long segmental strictures of the
intrapancreatic portion of the CBD, irregular narrowing of the extrahepatic
bile ducts and less frequently, enlarged intrahepatic bile ducts2. Patients with
SC typically associated with AIP have a better prognosis than classic PSC
patients. Both SC and pancreatic lesions respond well to steroids and in some
cases, stenting3. 1Japan Pancreas Society. Diagnostic Criteria for AIP 2002.
Journal of Japan Pancreas Society 2002;17;585–7. Dmitry et al; AIP, NEMJ
2006; 355; 2670–6. 3Takahiro Nakazawa, MD, et al, Clinical Differences
Between Primary Sclerosing Cholangitis and Sclerosing Cholangitis With
AIP.
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Isolated Histoplasma Colitis Masquerading as Idiopathic
Inflammatory Bowel Disease
Pavan Chepyala, MD, Prasuna Madhavaram, MD, Kevin W. Olden, MD∗.
Gastroenterology & Hepatology, University of Arkansas for Medical
Sciences, Little Rock, AR.
To recognize histoplasma infection as a cause of gastrointestinal bleeding
and colitis in high risk subjects.
A 41 year old BW presented to UAMS Medical Center for evaluation of
fatigue, low grade fever, abdominal pain and bloody diarrhea of 3 weeks
duration. Physical exam showed a well nourished lady in no apparent dis-
tress. Abdomen was mildly distended with diffuse tenderness to palpation,
without guarding or rebound. Rectal exam revealed hemoccult positive red-
dish brown stool. Labs revealed H/H 5.3/17.7. LFT, BMP, PT/ INR were
with in normal limits. Stool studies for leucocytes, ova and parasites and
C. difficle were negative. After initial stabilization, upper and lower GI en-
doscopy was performed. EGD was normal, and colonoscopy revealed diffuse
ertythema with clean based ulcers at the hepatic flexure and transverse colon.
Histopathology revealed active colitis. Bloody diarrhea subsided and she was
discharged on oral Metronidazole and Mesalamine.
Two months later, she returned with worsening abdominal pain, fever and
hematochezia. CT of the abdomen showed a thickened ascending colon and
parts of the transverse colon. Repeat colonoscopy showed several superfi-
cial mucosal ulcerations scattered through out the ascending and transverse
colon. Gomori-methenamine-silver stain (GMS) of the biopsy revealed nu-
merous yeast forms, consistent with histoplasma infection. Urinary antigen
for Histoplasma was strongly positive. Cultures from the specimen were
positive for Histoplasma capsulatum, confirming the diagnosis. Treatment
with liposomal amphotericin B and Itraconazole was initiated. On follow
up visit she remained symptom free. Clinical manifestations of gastroin-
testinal histoplasmosis range from asymptomatic to nonspecific like nau-
sea, vomiting, diarrhea and abdominal pain. Colonic involvement can be
the first clinical sign of disseminated histoplasmosis. The terminal ileum
and cecum are the most commonly involved. Ulcers are the most common
lesions. Typically ulcers appear as annular shaped lesion with raised bor-
ders and necrotic base. Other lesions include mucosal erythema, nodules,
polyps, hypertrophied folds and Mass lesions. Detection of histoplasma
antigen in the urine is a rapid method of diagnosis. Direct microscopic
examination of clinical specimen stained using GMS aids in rapid diag-
nosis. Amphotericin B is the appropriate initial Treatment. Itraconazole
200 mg once or twice daily for 6 to 18 months is used for maintenance
therapy.
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Advanced Liver Disease in a Patient with PiMZ alpha-1 Antitrypsin
(A1AT) Phenotype and Normal Serum A1AT Level
Meena Narayanan, MD, Swetha Kandula, MD, Frank A. Mitros, MD,
Jatinder P. Ahluwalia, MD∗. Internal Medicine, Southern Illinois
University School of Medicine, Springfield, IL and Pathology, Univ. of
Iowa, Iowa City, IA.
A 23 year old woman with a history of diabetes mellitus since age 12 and
incidentally-noted thrombocytopenia was seen for recurrent abdominal pain
and was found by abdominal ultrasonography to have splenomegaly with
prominent vascularity in splenic hilum. An abdominal CT confirmed marked
splenomegaly and revealed a small lobulated liver and vascular structures
suspicious for abdominal collaterals. She denied icterus, jaundice, pruritis,
rash, confusion, sleep abnormalities, fatigue, poor appetite or weight loss.
She also denied alcohol use, injection drug use, cocaine snorting or blood
transfusions, but had some tattooing 2 months ago.
Physical examination revealed bronzing of skin, spider nevi, and a systolic
ejection murmur. Abdominal was soft and protuberant. The liver tip could not
be appreciated, the spleen was enlarged and there was no shifting dullness.
Laboratory studies: WBC 3200, platelets 48,000, albumin 3.6 g/dl, AST 53
U/L, ALT 36 U/L, total bilirubin 2.4 mg/dl, direct bilirubin 1.2 mg/dl, al-
kaline phosphatase 780 U/L, and GGT 1538 U/L. Further workup included
normal ceruloplasmin, iron studies, A1AT and alpha-fetoprotein, and was
negative for viral (A, B and C) and autoimmune hepatitis, raising the possi-
bility of NASH.
A liver biopsy revealed cirrhosis with PAS-positive inclusions in hepatocytes
and minimal steatosis. A1AT phenotyping revealed MZ phenotype. Subse-
quently, she developed ascites and was worked up for liver transplantation.
A1AT is a protease inhibitor (Pi) secreted predominantly by the liver and
its deficiency leads to liver disease in a small percentage of patients due to
intracellular retention of the mutant protein. Several mutant alleles involving
a single amino acid substitution have been identified. PiZZ homozygosity is
most commonly associated with A1AT deficiency and involves accumulation
of mutant A1AT in the liver in PAS-positive globules. Although patients
carrying a single Z allele (Pi∗Z) have been reported to be at a higher risk
of developing cirrhosis, the role of PiMZ in the development of advanced
liver disease is not widely known. This case highlights the importance of
considering PiMZ phenotype in patients with normal A1AT level presenting
with liver disease of unclear etiology.
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HIV-Associated Non-Hodgkin’s Lymphoma of the Small Intestine
Amjad Mreyoud, MD, Paula Burkard, MD, PhD∗. GI, University at
Buffalo, Buffalo, NY.
The diagnosis of small bowel tumors is often difficult due to the rarity of
these lesions, and the nonspecific and variable nature of the presenting signs
and symptoms.
A 59 year old white male with a history of HIV \ AIDS (CD4 = 73) who
presented to the hospital with 1 week history of generalized weakness, poor
oral intake, non productive cough and mental status changes. He denied any
fever, chills, dyspnea, or GI complaints.
His initial work up demonstrated WBC 16.7 (Neutrophils 25%, Bands 8%,
and Lymphocytes 22%), thrombocytopenia (29000), anemia (Hgb 11.8 g/dl),
and elevated LFTs (Ast 175 U/L, Alt 98 U/L, Bilirubin 1.1 mg/dl, Alkaline
phosphatase 1078 U/L).
He had Head CT scan which was unremarkable, abdominal U/S which re-
vealed fatty liver with two liver cysts in the right lobe and splenomegaly,
and abdominal CT scan which showed 9 cm mass like mural thickening
involving the terminal ileum, moderate retroperitoneal and abdominal lym-
phadenopathy, splenomegaly, and small ascites.
Colonoscopy was done which showed an exophytic bulky mass in the ter-
minal ileum extending to the ileocecal valve with friable overlying mucosa.
Biopsies showed Non Hodgkin’s lymphoma – B cell type. The Bone mar-
row biopsy demonstrated bone marrow diffusely involved by non Hodgkin’s
lymphoma. Patient became hypoxic and more confused, the family refused
any further investigations or treatments and he expired two days later.
Discussion: Small bowel malignancies account for only 2–3% of all gas-
trointestinal (GI) neoplasms, and less than 0.4% of all cancers in the United
States. Primary GI lymphoma is the most common extranodal form of lym-
phoma; the stomach (75%) and small bowel (9%) are most often involved.
Small bowel lymphoma occurs predominantly in male adults, peaking in the
seventh decade. Most tumors are focal and involve the distal small intestine.
The incidence of primary intestinal lymphoma in the United States doubled
between 1985 and 1991. Among the factors implicated in this increase is
the increasing number of immunocompromised patients (eg, AIDS, trans-
plantation recipients), and the increasing immigration from Third World
countries.
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Ischemic Liver Insult in a Patient with Sickle Beta Thalassemia 0:
First Reported Case
S424 Abstracts
Rajat Gulati, MD, Tasma Harindhanavudhi, MD, Imran Ali, MD, Rafal G.
Ciecierski, MD, Hareth Raddawi, MD∗. Internal Medicine/GI, University
of Illinois/Advocate Christ Med Ctr, Chicago/Oak Lawn, IL.
A 34 years old African American lady with a past medical history of Sickle
Beta Thalassemia 0 (hemoglobin electrophoresis revealed a hg A1:0%, A2:
3.2%, S: 73.2%, F: 23.6%), Hepatitis A Exposure and immunity, and hy-
pertension who presented with jaundice and right upper quadrant abdominal
discomfort. She was not on any known hepatotoxic medications and there
was no history of either hypotension or cardiac dysrythmias. Physical ex-
amination showed a normal blood pressure, significant jaundice, no sign of
encephalopathy, a normal liver size with no stigmata of chronic liver dis-
ease. Complete blood count revealed hemoglobin of 11.5 g/dL, hematocrit
of 33%, WBC 4.9 and Platelet of 134,000. Liver function test showed an
INR 1.1, AST 1519, Alt 1413, Alkaline phosphatase 158, total bilirubin 5.6
and conjugated bilirubin of 3.9, LDH 697. Further serological investigation
included a negative anti-mitochondrial and anti-smooth muscle antibodies.
Her jaundice worsened and further radiological investigations including an
ultrasound and a CT scan of the Abdomen revealed a homogenous liver with
an irregular contour along the anterior aspect of the right lobe of the liver.
These were followed by an MRI/MRA of the liver, which reported capsular
retraction with abnormal signal enhancement in the anterior aspect of the
liver. Later, a diagnostic liver biopsy disclosed the presence of ischemic hep-
atitis with marked congestion, fibrosis and presence of sickled cells within
dilated sinusoids.
Liver involvement is common in Patients with Sickle cell disease. Hep-
atic lesions in sickle cell disease have been reported in many patterns con-
sisting of sinusoidal dilatation, perisinusoidal fibrosis and acute ischemic
necrosis. However, Sickle Beta Thalessemia 0 is known to have a rela-
tively/comparatively benign course in relation to severity and frequency
of vaso-occlusive crises. This case is particularly unique for significant is-
chemic hepatitis in a patient with Sickle Thalassemia 0, which is yet to be
described in the literature.
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Endoscopic Management of a Large Pancreatic Duct Stone
Victor J. Torres, MD, Sharon Davidson, RN, Robert Marcovich, MD,
Sandeep N. Patel, DO∗. Gastroenterology and Nutrition, The University of
Texas Health Science Center at San Antonio, San Antonio, TX and Urology,
The University of Texas Health Science Center at San Antonio, San
Antonio, TX.
Background: Pancreatic duct stones (PDS) are found in approximately 35%
of patients with chronic pancreatitis. Large PDS can lead to obstructive
pancreatopathy and consequent recurrent attacks of pancreatitis. Endoscopic
extraction of large or complicated pancreatic duct stones have routinely
yielded mediocre results. Extracorporeal shock wave lithotripsy (ESWL)
has demonstrated efficacy as a salvage therapy in such patients who are
not sugical candidates. We report a case of a large pancreatic duct stone
extraction utilizing endoscopic therapy in conjunction with ESWL obviating
the need for surgery.
Case: A 34-year-old woman was referred for the evaluation and manage-
ment of idiopathic acute recurrent pancreatitis. An endoscopic ultrasound
(EUS) was performed revealing changes consistent with chronic pancreati-
tis, incomplete divisum, and a 2.7 × 1.9 cm stone in the ventral pancreatic
duct (Wirsung). The patient underwent two attempts of Endoscopic Retro-
grade Cholangiopancreatography (ERCP) yielding unsuccessful pancreatic
duct cannulation due to impaction of the stone at the pancreatic orifice. A
few months later she presented to our institution with another bout of acute
on chronic pancreatitis prompting surgical evaluation for decompression
surgery. Alternatively, the patient underwent ESWL using a Medstone STS-
TC Shock Wave Generator with 2400 shocks at 20 KV directed at the radio
opaque stone in the RUQ. Post ESWL, cannulation of the pancreatic duct
was achieved revealing a tight stricture in the head with a downstream 2.5
cm stone. Despite performing a pancreatic septotomy, balloon dilation of the
stricture and mechanical lithotripsy we were unable to extract the stone. Two
5 Fr/5 cm pancreatic duct stents were then deployed in the ventral duct. A
second course of ESWL with similar settings was then performed directed
at the stents. On follow up ERCP, the pancreatic stents were removed. The
pancreatogram revealed small fragments of stone in the ventral duct which
were easily extracted with a balloon. The patient has been pain-free during
her fourth month of follow up with no recurrent bouts of pancreatitis.
Conclusion: ESWL in conjunction with endoscopic therapy is a safe and
effective approach for large or complicated pancreatic duct stones and should
be considered early in the management of this entity.
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EUS Guided Diagnosis of New-Onset Sarcoidosis in a Patient with
Cervical Cancer
Rabin Rahmani, MD, David Hass, MD, Sammy Ho, MD∗.
Gastroenterology, Montefiore Medical Center, Albert Einstein College of
Medicine, Bronx, NY.
Case: A 36-year-old Hispanic woman with squamous cell cervical cancer,
stage IIIb, presented to the emergency department with pleuritic chest pain,
a persistent non-productive cough and new-onset dyspnea-on-exertion for
5 days. She denied dysphagia, odynophagia, abdominal pain, fever, night
sweats, hemoptysis or hematemesis. Social, family, and travel history were
non-contributory. Review of systems was positive for 10 pound weight loss
in 4 months.
Physical exam only revealed tachycardia and fine basilar rales in the posterior
lung fields.
Initial lab data showed: Hb 8 (12–16 g/dl), MCV 73 (80–100), Iron 53
(65–175 ug/dl), and ACE level of 77(12–68 u/l). SMA 7, liver tests, and co-
agulation profile were normal. HIV serology was negative. CT chest demon-
strated mediastinal lymphadenopathy. A PET scan showed intense medi-
astinal lymph node uptake suggestive of metastatic disease. An endoscopic
ultrasound (EUS) was subsequently performed to make a definitive diagno-
sis.
EUS of the mediastinum revealed a large hypoechoic subcarinal lymph node
with irregular borders. EUS-guided fine needle aspiration (FNA) was nega-
tive for malignant cells but showed scattered non-caseating granuloma con-
sistent with sarcoidosis (Figure 1). Steroid therapy was initiated which re-
sulted in significant symptomatic and radiographic improvement.
Discussion: EUS-FNA was first proposed as an accurate and simple diag-
nostic modality for sarcoidosis in 1999. Since then, several studies have
demonstrated the efficacy of EUS-FNA in obtaining a definitive diagnosis
in patients with mediastinal lymphadenopathy.
Despite these promising reports, EUS-FNA currently is underused for defini-
tive diagnosis of mediastinal lymphadenopathy. We report a case which
demonstrates the clinical utility of EUS-FNA as a diagnostic modality in
a woman with cervical cancer and new-onset sarcoidosis.[figure1]
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The Koch Pouch Revisited: Traumatic Ulcerations in a Koch Pouch
Thomas Park, MD, Ashok N. Shah, MD∗. Division of Gastroenterology
and Hepatology, University of Rochester, Rochester, NY.
The Koch pouch, invented by Dr. Nils Koch in the late 1960s, was the first
type of continent ileostomy. It was created to provide a better lifestyle for
patients who had to have their colons removed for treatment of colitis and
other diseases. Its popularity has decreased over time, due to the fact that
it is a technically demanding construction and sometimes associated with
complications. We describe a case of a patient with a Koch pouch who was
found on endoscopic examination to have complications associated with the
management of his pouch.
This is a 64 year-old man who had a Koch continent ileostomy for ulcerative
colitis in 1975. He inserts a catheter through his one way nipple valve to
empty his pouch six to seven times a day. He has been feeling well and
denies any gastrointestinal complaints. He presents for annual dysplasia
surveillance of his pouch.
On exam, he is afebrile and vitals are stable. His nipple valve on the right side
of his abdomen appears unremarkable, without signs of infection. The patient
is brought to the endoscopy suite and medicated for moderate sedation. A
gastroscope is inserted through the valve orifice. The general mucosa of
the pouch appears unremarkable. However, advancement of the scope to the
distal end of the pouch reveals several clean-based ulcers in close proximity
to each other (see Figure 2). These are attributed to traumatic injury from
the patient’s frequent catheterizations. Retroflexion reveals a narrowed, but
patent, lumen of the afferent limb (see Figure 2). Surveillance biopsies of
the pouch are negative for dysplasia.[figure1][figure2]
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Laser Lithotripsy for Removal of a Difficult To Treat Common Bile
Duct Stone: A Collaborative Effort among Gastroenterology, Urology,
and Radiology Departments
Thomas Park, MD, Erdal S. Erturk, MD, Ashok N. Shah, MD∗. Division of
Gastroenterology and Hepatology, and Department of Urology, University
of Rochester, Rochester, NY.
Laser lithotripsy is being increasingly utilized to remove difficult to treat
common bile duct (CBD) stones. These procedures are usually performed at
referral centers that have the equipment and volume of patients to perform
these procedures. We describe a case of a patient with a retained CBD stone
that failed multiple types of treatment, but was finally dissolved through a
collaborative effort of the departments of Gastroenterology, Urology, and
Radiology.
This is a 58 year-old man with a history of cholelithiasis for thirty years.
Eleven months ago, he was admitted to an outside hospital for febrile jaun-
dice. An ultrasound revealed intra- and extrahepatic duct dilatation, several
small stones in the cystic duct and a large stone in the CBD. Endoscopic ret-
rograde cholangiopancreatography (ERCP) restored some flow in the CBD,
but the CBD stone remained. He was scheduled for a repeat ERCP to attempt
to remove the stone again, but he was lost to follow-up. Five months ago, he
underwent a cholecystectomy, and was found to have a trapped CBD stone.
An attempt by the surgeon to remove the stone through the percutaneous
transhepatic drain was unsuccessful. The patient then came to our institution
and had an ERCP with extension of the sphincterotomy. However, attempts to
remove the stone with a trapezoid basket were unsuccessful. Next, extracor-
poral shock wave lithotripsy (ESWL) was performed, but without apparent
fragmentation of the CBD stone. Finally, it was decided to perform laser
lithotripsy.
The gastroenterologist, urologist, and radiologist, working in collaboration,
performed a percutaneous laser lithotripsy. Cholangiogram through the bil-
iary catheter revealed a large CBD stone approximately 2 cm in size. With
the guidance of fluoroscopy, a ureteral access catheter was inserted over a
wire into the CBD. A ureteroscope was advanced into the CBD to the level of
the stone. A 200 micron holmium laser fiber was used to perform lithotripsy.
Pulverization of the stone was confirmed through a contrast study.
Discussion: We demonstrate a case of successful laser lithotripsy on a dif-
ficult to remove CBD stone through a collaborative effort of Gastroenterol-
ogy, Urology, and Radiology. Using this model, laser lithotripsy may be
performed successfully not only in referral centers, but in community-based
hospitals as well.
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Improvement of Cardiomyopathy after Infliximab Treatment for
Crohn’s Disease (CD)
Roberto E. Mera, MD, Hector Banch, MD, Esther A. Torres, MD, MACG∗.
Department of Medicine, Division of Gastroenterology, University of
Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico.
Rare instantes for cardiovascular complications of Inflammatory Bowel Dis-
ease have been reported, including valvular insufficiency, conduction dis-
orders, pericarditis, myocarditis, pericardial tamponade, dilated cardiomy-
opathies (DCM) and endomyocardial fibrosis. Caution has been advised
when using infliximab (INF) in patients with heart disease, especially DCM,
because of an increased risk of sudden death.
We report a 17 y/o male with CD diagnosed at 9 yrs age, when he presented
bloody diarrhea, weight loss and abdominal pain. He had many hospitaliza-
tions for exacerbations and perianal fistulizing disease treated with courses
of steroids and 5-ASA. In 2004, progressive shortness of breath leading to
mechanical ventilation prompted a diagnosis of DCM, with ejection frac-
tion (EF) of 22%. Treatment with carvelidol and ACE inhibitors stabilized
his heart disease. In 2005, he developed a retroperitoneal abscess requir-
ing drainage and antibiotics. An colocutaneous fistula required a segmen-
tal colectomy with end colostomy and mucous fistula. In early 2006, he
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presented with an acute abdomen. Exploratory revealed a jejunal volvulus
with necrosis and severe colonic disease, requiring segmental small bowel
resection, subtotal colectomy and end ileostomy. Because of the aggressive
disease, infliximab therapy was considered. EF was 36%. With close car-
diac monitoring, IFX at 5 mg/Kg for a dose of 170 mg/infusion was started.
Induction therapy was completed uneventfully, and 2 months later he had
gained 10 lbs, steroids were discontinued, perianal fistula had closed, and
EF 46%. IFX dose was adjusted by weight. By 6 months, he had 25 lbs
and EF was 56%. He has continued doing well on maintenance IFX and
azathioprine.
Complications of the cardiovascular system by Crohn’s disease are uncom-
mon. Most of the reported complications related to CD are myocarditis and
pericarditis but dilated cardiomyopathy has been described. Vasculitis is part
of the pathological spectrum of inflammatory bowel disease and the most
probable mechanism for cardiovascular injury. We successfully treated a pa-
tient with CD and DCM with improvement of systolic function and clinical
status. We wonder whether his DCM is an undiagnosed manifestation of CD
or an unrelated complicating illness.
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Vaginal Crohn’s Disease Successfully Treated with Adalimumab
Patricia L. Kozuch, MD∗, Anthony J. DiMarino, MD, Kent Wilson, BS,
Cynthia Miller, RN, Anthony Infantolino, MD. Digestive Disease Institute,
Thomas Jefferson University Hospital, Philadelphia, PA.
The patient is a 36 year-old woman with a 15-year history of colonic and pe-
rianal Crohn’s Disease (CD) complicated by rectovaginal fistula, status-post
a total proctocolectomy with end-ileostomy in 2004 for medically-refractory
disease, including incomplete responses to infliximab and cyclosporine. The
patient enjoyed a surgically-induced remission until May 2006, when she de-
veloped vaginal pain, swelling, and ulceration; she had no gastrointestinal
symptoms, fevers or weight loss but was fatigued and had left knee swelling
and pain. Physical exam was notable for diffuse edema, induration, ulcers
and mucopus of the vaginal introitus, labia minora, and inner labia majora
in addition to left knee suprapatellar tenderness, edema and small effusion.
Laboratory tests were significant for Hgb 5.9 g/dL, ferritin 6 ng/mL, and
CRP 3.9 mg/dL. Herpes simplex, Haemophilus ducreyi, and AFB cultures
were negative as were Chlamydia, RPR and HIV serologies. Vaginal biop-
sies revealed dense, diffuse mixed inflammation with multinucleated giant
cells and granulomas consistent with CD; special stains for fungi and bac-
teria were negative. Pelvic MRI showed vaginal distention, thickening and
a possible fistula from the posterior inferior vagina to the perineal soft tis-
sue. Small bowel series was normal. Knee aspiration was consistent with
an inflammatory effusion. A diagnosis of vaginal CD with early fistula and
peripheral arthropathy was made. She was transfused packed RBCs to a Hgb
10.3 and treated with intravenous steroids and antibiotics with no improve-
ment. She was subsequently enrolled in an open-label adalimumab study for
patients with previous infliximab exposure (the CHOICE trial): she received
an induction regimen with 160 and 80 mg subcutaneously at 0 and 2 weeks,
followed by 40 mg every other week. She was started on concomitant 6-MP
50 mg/day. Within 1 week, she reported markedly decreased vaginal and
knee symptoms. Six weeks after starting treatment, exam revealed nearly
normal vaginal mucosa, with only 2 small ulcer scars. Her knee edema and
effusion had resolved, and her Hgb was stable without further transfusions.
She has remained well on maintenance adalimumab every other week for
7.5 months. This case is the first known report of successful treatment of
mucocutaneous vaginal CD with adalimumab.
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An Unusual “PPI-Refractory” Symptomatic Gastric Ulcer
Successfully Treated with Corticosteroids and Azathioprine:
Eosinophilic Mural Ulcer
Tasma Harindhanavudhi, MD, Wanwarat Anathapanyasut, MD, Waqar
Mian, MD, David Olmstead, MD, Rogelio G. Silva, MD, Hareth Raddawi,
MD∗. Internal Medicine/GI, University of Illinois, Advocate Christ Med
Ctr, Chicago/Oak Lawn, IL.
A 23-year-old female was evaluated for chronic abdominal pain and iron
deficiency anemia. She was initially diagnosed with peptic ulcer disease
and was treated with a proton pump inhibitor (PPI). An initial upper en-
doscopy demonstrated a large antral gastric ulcer. Biopsy showed mixed
inflammatory cell infiltration and no Helicobacter pylori organisms were
seen. However, she continued to have rather severe epigastric pain requiring
narcotic analgesics despite continuous aggressive therapy with a PPI. Past
medical history included asthma. Physical examination was unremarkable
except for epigastric tenderness. Laboratory studies showed a hemoglobin of
8 g/dl, MCV 69 fL, white blood cell count 6,100/uL with 11% eosinophils.
Abdominal imaging studies looking for other causes of her pain were nega-
tive. The possibility of noncompliance with PPI treatment or OTC NSAID
use was raised. However, repeat endoscopy in June 2007 revealed a larger
prepyloric penetrating ulcer and an adjacent smaller antral ulcer. Multiple
biopsies were obtained and demonstrated abundant eosinophilic infiltration.
Serum gastrin was normal. Colonoscopy was unremarkable. The diagnosis of
eosinophilic mural gastric ulcer was made and she was started on prednisone
50 mg daily concomitantly with Azathioprine 50 mg to be increased to 100
mg daily in addition to a proton pump inhibitor. Dramatic symptomatic and
clinical improvement occurred shortly after medical therapy was initiated.
Eosinophilic gastric ulcer is believed to be a rare/localized manifestation of
the entity of eosinophilic gastroenteritis. This case uniquely illustrates (1)
a refractory large, gastric ulcer with a smaller adjacent ulcer. (2) clinically
manifesting as persistent problematic upper abdominal pain and iron defi-
ciency anemia, and (3) immediate improvement with corticosteroid/immune
modulator therapy without the need for surgical intervention. Clinicians and
Gastroenterologists should suspect this readily treatable entity in cases of
ulcers with unusual clinical behavior.
OUTCOMES RESEARCH
837
Proton Pump Inhibitors vs. Histamine2 Receptor Antagonist in
Treatment of Non Variceal Upper Gastrointestinal Bleed: A
Meta-Analysis
Ruchi Gupta, MD, Praveen Garg, MD∗. Medicine, University of Florida
College of Medicine, Jacksonville, FL.
Purpose: To evaluate whether proton pump inhibitors (PPI) are more effec-
tive than histamine2 receptor antagonist (H2RA) in treatment of non variceal
upper gastrointestinal bleed (UGI) and to compare the impact on mortality,
rate of rebleed, surgical intervention, length of stay and need for transfusion.
UGI bleed is a frequent problem in United States with an annual incidence of
100 per 100,000. Randomized control trials on UGI bleed have conflicting
results and are heterogeneous with above mentioned outcomes.
Methods: Metanalysis of comparative randomized control trials of PPI vs.
H2RA in non variceal UGI bleed from 1990–2006 using Pubmed, Medline,
Embase databases. The included trials indicated one of the outcomes as
mortality, rebleed rate, surgical intervention, length of stay or transfusion
requirement. Two reviewers independently reviewed a total of 31 trials with
3,846 patients. These trials fulfilled the inclusion criterion and contained
data for atleast one of the outcomes.
Results: Recurrent bleed was noted in 7.3% (95% CI 5.5–9.2) of patients
treated by PPI vs. 13.9% (95% CI 11.4–16.3) of patients treated with H2RA
(OR 0.5 95% CI 0.42–0.69). Surgical intervention was needed in 4.8% (95%
CI 2.9–6.0) of patients treated with PPI vs. in 7.1% (95% CI 5.2–9.3) of
patients treated with H2RA (OR 0.6 95% CI 0.50–0.84). Mortality as an
endpoint was seen in 1.8% (95% CI O.9–3.1) patients treated with PPI vs.
2.5% (95% CI 1.5–3.9) in patients treated withH2RA (OR 0.71 95% CI 0.59–
2.10). 21% of patients treated with PPI required blood transfusion (95% CI
16.2–26.9) vs. 29% of patients (95% CI 24.7–32.0%) treated with H2RA
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(OR 0.4 95% CI 0.6–0.92). Length of stay was 6.1 days for PPI (95% CI
3.4–7.8) vs. 6.9 (95% CI 3.9–8.2) for patients treated with H2RA (OR 0.9
95% CI 0.78–1.18).
Conclusion: Treatment with PPI reduces rebleed rate and need for surgical
intervention when compared with H2RA for treatment of non variceal UGI
bleed. At best the evidence suggests limited superiority of PPI over H2RA
when comparing transfusion requirement. Use of PPI has no benefit on length
of stay and overall mortality when compared to H2RA in patients treated for
non variceal UGI bleed.[figure1]
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Timely Confirmation of Gastroesophageal Reflux Disease Via pH
Monitoring: Budget Impact on Managed Care Organizations
Yu-Chen Yeh, MS, Won Chan Lee, PhD, Brian E. Lacy, PhD, MD, John E.
Pandolfino, MD, Joel V. Brill, MD, Michael L. Weinstein, MD, Angeline M.
Carlson, PhD, Mary Jo Williams, BS, Michael R. Wittek, MSW, Chris L.
Pashos, PhD∗. HERQuLES, Abt Associates Inc., Lexington, MA;
HERQuLES, Abt Associates Inc., Bethesda, MD; Section of
Gastroenterology, Dartmouth Hitchcock Medical Center, Lebanon, NH;
Department of Gastroenterology, Northwestern University Medical School,
Chicago, IL; Predictive Health, LLC., Phoenix, AZ; Metropolitan
Gastroenterology Group, P.C., Chevy Chase, MD; Data Intelligence
Consultants, LLC., Eden Prairie, MN and Medtronic, Inc., Minneapolis,
MN.
Purpose: The ACG guidelines recommend the use of pH monitoring to
confirm the diagnosis of acid reflux in patients with a normal endoscopy. This
analysis evaluated the financial impact of pH monitoring with the wireless
pH capsule on a managed care organization (MCO) in the United States.
Methods: A decision model was constructed to project total 1-year costs
to manage GERD symptoms with and without the adoption of wireless pH
capsules in a hypothetical MCO with 10,000 eligible adult enrollees. Costs of
GERD diagnosis, treatments, and symptom management for those in whom
a GERD diagnosis was ruled out by pH monitoring were assessed. The
incremental per-member-per-month (PMPM) and per-treated-member-per-
month (PTMPM) costs were the primary outcomes. Data sources included
literature, expert input, and standardized fee schedules.
Results: An increase of 10 percentage points in the use of pH monitoring
with wireless pH capsules yielded incremental PMPM and PTMPM costs
of $0.029 and $0.481, respectively. The costs of PPI therapy to the plan
dropped to $236,363 from $238,086, while increases were observed in pH
monitoring (from $16,739 to $21,973) and non-GERD therapy costs (from
$1,392 to $1,740). The results were sensitive to the percentage of patients
requiring repeat endoscopy before wireless pH monitoring and the cost of
PPIs.
Conclusion: Timely and increased use of pH monitoring as recommended
in the ACG guidelines improves clinical practice and patient care. It leads
to more accurate diagnosis and less unnecessary use of PPIs with only a
modest budgetary impact on health plans.
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Gastroenterology and CME: How Do We Want To Learn in an Urban
Landscape?
Seth F. Tatel, MD, Justin R. Boike, BS, BS, Christopher J. Shoemaker, MEd,
Ben M. Stickan, MBA, Jay L. Goldstein, MD∗. Department of Medicine,
University of Illinois at Chicago, Chicago, IL.
Purpose: The purpose of this study is to objectively measure physician
preference regarding the format, content, & timing of educational programs.
Methods: A survey was developed containing 38 questions with multiple
choice and/or open-ended responses & mailed to 1052 referring physicians to
the Section of Digestive Diseases & Nutrition at the University of Illinois at
Chicago. The survey included participant demographics, preferred learning
style & format, & factors that may influence attendance. Respondents could
complete the survey by mail or via the web.
Results: Of the 101 responses [13% web (N = 13); 87% by mail], the
majority of respondents practiced GI (97%) as opposed to Internal Medicine
(3%). Responses were received after two mailings separated by 1 month,
with a total response rate of 9.6%; 81% were male, 17% were female while
2% preferred not to specify. Formal didactic lectures (N = 72, 71%) &
case presentations (N = 56, 55%) are the preferred form of learning, in
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contrast to teleconferences (N = 7, 7%). The majority of respondents (N =
75, 74%) prefer face-to-face interaction while only 28% prefer web-based
learning. Driving distance to programs does not appear to be a major barrier
to attendance as 71% (N = 72) are willing to travel > 10 miles. Wednesday
(N = 38, 38%) & Saturday (N = 43, 43%) are the most preferred days.
Evening (N = 57, 56%) is the preferred time for live programs with the
start time of 7 p.m. (N = 48, 48%). Those who prefer Saturday favored
morning programs, 30% (N = 30) desired programs two hours in length,
& 39% (N = 39) favored a program half-day in length. 64% (N = 65)
of responders felt CME credits were either important or very important in
the decision to attend a conference. 75% (N = 76) and 37% (N = 37) felt
that both content & the speaker, respectively, would most likely cause them
to attend a CME activity. The preferences & results do not differ based
on years in practice. Unexpectedly web learning is not the preferred method
of learning for younger physicians & there is a clear preference for hard
copies of materials vs. web-based materials.
Conclusion: Despite advancement in educational technology (i.e. web learn-
ing, video & tele-conferencing), the majority of respondents still prefer tra-
ditional learning formats. CME credits seem to play a significant role in the
decision to attend a conference, while the most important factors influencing
attendance at CME activities are the content of the program & the speaker
responsible for conveying the information.
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Gastric Acid Analysis Is a Reliable and Reproducible Measure of Acid
Secretion in GERD Patients Treated with Placebo or Pantoprazole
Vijaya Pratha, MD∗, Daniel L. Hogan, MD, Richard B. Lynn, MD, Gail
Comer, MD, David C. Metz, MD. Clinical Applications Laboratories, San
Diego, CA; Wyeth Pharmaceuticals, Collegeville, PA and University of
Pennsylvania Medical Center, Philadelphia, PA.
Purpose: To compare the results of 3 separate studies using gastric acid
output to assess the consistency of results and the ability of pantoprazole to
suppress gastric acid secretion in similar patient populations.
Methods: Three different multi-center, randomized, double blind studies en-
rolled patients with a history of erosive esophagitis and symptoms of GERD
who underwent an antisecretory therapy wash out prior to randomization.
Although the study designs differed among the three studies, each had an
arm that received oral pantoprazole 40 mg tablets for 7–10 days and 2 stud-
ies had placebo arms (one with 2 separate placebo arms). Basal acid output
(BAO) and maximal acid output (MAO; pentagastrin stimulated, 6.0 µg/kg,
sq) were measured at Hour 22–23 and Hour 23–24 after the last dose, re-
spectively, after 7–10 days of therapy. Acid output is the product of [H+]
× gastric volume for each of four 15-minutes collections, which are added
together to provide a one-hour BAO or MAO measurement.
Results: In studies with placebo arms the MAOs were 30.5 ± 12.8 (N =
7)1; 29.2 ± 13.0 (N = 8)2; 20.9 ± 14.5 (N = 24)2 and the BAOs were 4.1 ±
5.2 (N = 7)1 and 3.2 ± 1.9 (N = 8)1; 2.8 ± 3.0 (N = 23)2, respectively. The
results of the patients treated with oral pantoprazole 40 mg tablets for 7–10
days are in table below.
Conclusion: When performed by experienced operators, gastric acid output
measurements are remarkably consistent across different studies in similar
patient populations. Acid suppression by pantoprazole is also consistent and
reproducible. Gastric acid analysis is a reliable method for quantifying acid
secretion and its inhibition. 1 Am J Gastro 2000, 95:626–633 2 Dig Dis &
Sci 2006, 51:1595–1601 (and data on file) 3 Am J Gastro 2006 (Abstract
143), 101(S2): Page S90 (and data on file)
Study N MAO mEq/hr (mean ± SD) BAO mEq/hr (mean ± SD)
A1 31 6.5 ± 5.6 0.8 ± 1.3
B2 22 6.3 ± 6.6 0.6 ± 0.8
C2 52 7.3 ± 4.8 0.6 ± 0.6
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Prevalence of Gastroesophageal Reflux Disease as Assessed by the
National Ambulatory Medical Care Survey
Frank K. Friedenberg, MD∗, Dawit Nehemia, BBA, Melissa Xanthopoulos,
PhD, Deborah B. Nelson, PhD, Joel E. Richter, MD. Gastroenterology,
Temple University School of Medicine, Philadelphia, PA and Graduate
School of Public Health, Temple University, Philadelphia, PA.
Purpose: Estimates of the prevalence of GERD have previously used large
surveys of the general population. These surveys are unlikely to accurately
estimate the prevalence of patients seeking medical care for GERD. This
information would be especially useful for future economic estimates of the
overall cost of GERD to the US healthcare system.
Methods: The U.S. Census Bureau acts as the data collection agent for
the NAMCS. Each primary sampling unit consists of physicians randomly
assigned to a 1-week reporting period during a calendar year. During this
period, a sample of patient visits are recorded using a standardized encounter
form. For this study the NAMCS codes for diagnoses and symptoms com-
patible with GERD were combined into a single categorical variable.
Results: From 1995–2004 there were 266,339 ambulatory care encounters
for all diagnoses recorded in the NAMCS. Of these, 2,827 (1.1%) were
for GERD. Prevalence in both genders was identical. GERD patients were
significantly older (53.4 vs. 45.5 years, P < 0.001) than non-GERD patients.
There was an increase in cases from 1995 (583/100K) to 2004 (1369/100K;
P < 0.001). This increase was seen in both genders and among whites and
blacks. Race was not an independent risk factor for GERD (P = 0.51). There
was a significant difference in regional rates of GERD (range 883/100,000
in Western U.S. to 1195/100K in Midwest U.S.), however, after adjustment
for age, this difference was not significant (P = 0.36). GERD was associated
with tobacco use (12.6% vs. 9.9% for non-smokers; P = 0.028). GERD was
not associated with more physician visits per year (3.1 vs. 3.4; P = 0.26), and,
although statistically significant, office visits for GERD patients averaged
only 72 seconds longer (20.5 vs. 19.3 min; P < 0.001). Not surprisingly,
patients with GERD were far more likely to be prescribed a PPI (OR = 43.7;
95% CI 40.2–47.5, P < 0.001).
Conclusion: The prevalence of ambulatory care visits for GERD is rising,
paralleling the data from other population-based studies. The prevalence
is rising for both genders, as well as blacks and whites and is associated
with regular tobacco use and increasing age. Frequency and duration of
ambulatory care office visits appears unrelated to this diagnosis. Future
NAMCS surveys will include BMI data allowing the capability to determine
the effects of obesity on trends in GERD-related visits.
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Statin Use and the Risk of Cholecystectomy in Women
Chung-Jyi Tsai, MD∗, Michael Leitzmann, MD, Walter Willett, MD,
Edward Giovannucci, MD. Div. of Digestive Diseases and Nutrition,
University of Kentucky Medical Center; Div. of Cancer Epidemiology and
Genetics, National Institute of Health, and Channing Lab., Dept. of
Medicine, Harvard Medical School.
Purpose: Statins are recently shown to exert beneficial pleiotropic effects
beyond reducing serum cholesterol levels. Statins can reduce biliary choles-
terol secretion independent of inhibition of cholesterol synthesis, and have
been shown to prevent gallstone formation in animals. The effect on gallstone
disease in humans is unclear.
Methods: We examined the relation of statin use to the risk of cholecystec-
tomy in a large cohort of women. As part of the prospective cohort study
on women’s health in U.S., the women who had no history of gallstone
disease reported biennially if they had undergone cholecystectomy, a surro-
gate of symptomatic gallstone disease. A validation study was conducted.
Based on when the exposures of interest were queried, two follow-up peri-
ods were used. In 2000 women were first asked to report separately if they
regularly used statins. Statin users were asked to further specify duration of
use in two-year categories up to six or more years. Retrospective analysis
Abstracts S429
for statins using data collected in 2000 to define use from 1994 forward.
Prospective analysis for general lipid-lowering drugs was conducted dur-
ing the same study period. Responses to the 2000 questionnaire indicated
that by that year approximately 93% of the cholesterol-lowering drugs used
in this cohort were statins. Analysis of statin use included 53,611 women,
and analysis of general lipid-lowering drugs use included 56,953 women.
Multivariate relative risks were assessed using the Cox model.
Results: In the statin analysis we ascertained 2,581 cases of cholecystec-
tomy during 305,197 person-years of follow-up. The multivariate relative
risk (R.R.) for current statin users, compared with nonusers, was 0.82 (95%
confidence interval (C.I.), 0.70 to 0.96). Among diabetic women, longer
duration of statin use (≥ 2 years) was associated with a seventy-five per-
cent risk reduction. Compared with diabetic nonusers, the R.R. for current
diabetic users for two or more years was 0.25 (C.I., 0.07 to 0.88). In the
general cholesterol-lowering drugs analysis, we ascertained 2,434 cases of
cholecystectomy during 298,726 person-years of follow-up. Compared with
nonusers, the R.R. for current users of general cholesterol-lowering drugs,
mostly statins in this cohort, was 0.86 (C.I., 0.75 to 0.99).
Conclusion: Our findings suggest that statin use, particularly among diabetic
women, may reduce risk of cholecystectomy.
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A Model To Predict Rebleeding Following Endoscopic Therapy for
Nonvariceal Upper Gastrointestinal Hemorrhage
Anne T. Wolf, MD, Sharmeel K. Wasan, MD, John R. Saltzman, MD∗.
Gastroenterology, Brigham and Women’s Hospital, Boston, MA and
Medicine, Brigham and Women’s Hospital, Boston, MA.
Purpose: Following endoscopic therapy, recurrent bleeding occurs in up to
20% of patients with nonvariceal upper gastrointestinal hemorrhage. The
objective of this study was to develop a rebleeding score to predict recurrent
hemorrhage in these patients.
Methods: This was a retrospective cohort study of consecutive patients ad-
mitted to a tertiary care hospital between July 1, 1999, and June 30, 2004, with
nonvariceal upper gastrointestinal hemorrhage. Patients were evaluated for
rebleeding within 30-days of successful therapeutic endoscopy. Two hundred
thirty-six patients were identified using the hospital’s endoscopic database.
Factors for inclusion in the rebleeding score were identified using multivari-
able logistic regression with stepwise selection. The regression coefficients
were converted into integers for score calculation. Internal validation was
performed using bootstrapping.
Results: Six factors were included in the rebleeding score: Proton pump
inhibitor use (-8 points, P = 0.056), Endoscopically demonstrated bleeding
(5 points, P = 0.053), Peptic ulcer (6 points, P = 0.018), Treatment with
epinephrine monotherapy (7 points, p = 0.0026), Intravenous or low molec-
ular weight heparin use (15 points, P = 0.0014), and moderate or severe
Cirrhosis (10 points, P = 0.032) (PEPTIC). The area under the curve for
the score predicting rebleeding was 0.71. Cutoffs were chosen to stratify pa-
tients as “low-risk” (score ≤−3; 7.6% rebled), “average-risk” (score −2 to 0;
15.7% rebled), “high-risk” (score 1 to 7; 32.6% rebled), or “very high-risk”
(score ≥8; 68.2% rebled).
Conclusion: We have developed an easily calculated rebleeding score that
predicts recurrent hemorrhage following endoscopic therapy for nonvariceal
upper gastrointestinal hemorrhage.[figure1]
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Effects of Lubiprostone, a Chloride Channel Activator, on Cardiac
Parameters in Dogs
Birgit Roerig, PhD, Hiroyoshi Osama, Ryuji Ueno, MD∗. Sucampo
Pharmaceuticals, Inc., Bethesda, MD and Sucampo Pharma, Ltd., Osaka,
Japan.
Purpose: Treatment with lubiprostone, a type-2 chloride channel (ClC-2)
activator used for the treatment of adults with chronic constipation, does not
result in QTc prolongation in human subjects treated with supratherapeutic
doses (up to 144 mcg) (Sprenger et al, Gastroenterology 132[4 Suppl 2]:A-
325, 2007). Studies were performed to assess cardiac effects of lubiprostone
in dogs.
Methods: In an in vitro assay to evaluate lubiprostone effects on cardiac
action potential, isolated canine Purkinje fiber preparations were exposed to
increasing doses of lubiprostone (7.5, 75, and 750 pg/mL; 1.5–150 times the
highest observed plasma concentration in humans) at 3 stimulus intervals,
results of which were compared to time-matched vehicle control sequences.
An in vivo study evaluated the effects of a single intraduodenally adminis-
tered (ID) dose of lubiprostone (0, 10, 100, or 1000 mcg/kg) in male dogs.
Blood pressure, heart rate, femoral artery blood flow, and electrocardiograms
(ECGs) were collected at 7 time points over 2 hours post-dose. A second in
vivo study evaluated the effects of repeated oral dosing of lubiprostone (up
to 50 mcg/kg/day) in male and female dogs over a 39-week treatment period.
ECGs were collected prior to dosing and at Weeks 13, 26, and 39.
Results: The in vitro assay showed no remarkable changes in action potential
duration or amplitude, resting membrane potential, or maximum rate of rise
of the action potential at any of the concentrations tested. ID administration
of lubiprostone had no effect on any cardiac parameter at any dose, with
the exception of decreased mean blood pressure (34% maximum) between
10 and 120 minutes post-dose at 1000 mcg/kg, which is 1,250 times the
recommended single dose in humans. Over 39 weeks of lubiprostone treat-
ment at doses up to 50 mcg/kg/day (>31 times the recommended daily dose
in humans) no abnormal changes in heart rate, QRS duration, QT interval,
QTc, PR interval, or R wave were observed in male or female dogs.
Conclusion: In vitro and in vivo testing of lubiprostone in dogs demonstrates
a favorable cardiac profile at clinically relevant and supratherapeutic doses.
This research was fully funded by Sucampo Pharmaceuticals, Inc.
845
Antispasmotics Are Safe for Treating Irritable Bowel Patients Age 65
and Older in the Community
Douglas J. Sprung, MD∗. GI, Florida Hospital, Altamonte Springs, FL.
Purpose: GI antispasmotics are generally not recommended for patients
65 years and older because of the perception that the elderly are particularly
prone to the CNS side effects of these agents and their effectiveness at
doses tolerated by this age group is questionable. This has not been our
experience, but since HMO’s and pharmacies recently have been rejecting
or questioning such presciptions in patients over 64 years, an outcomes study
was undertaken to assess this bias against antispasmotics in the elderly.
Methods: An outcomes study was set up including all patients (pts) with
IBS seen between 1/06–10/06 in our private clinical GI practice in Orlando,
Fl. Of 545 pts seen with IBS, 104 pts aged 65 and above were encountered,
and their characteristics studied from chart review.
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Results: 85% (88/104) of pts were much better after antispasmotic treatment.
12% (13/104) were somewhat better, and only 3% (3/104) were not any bet-
ter. Medications used included hyoscyamine, clidinium/chlordiazepoxide,
belladona/phenobarbital and dicyclomine. Dosages were in the usual rec-
ommended adult dosage range. Side effects were rare, except for dry mouth
(30%) and sleepiness (8%). Interstingly, 87% (90/104) of these pts were
considered to suffer with significant stress, anxiety disorder or depression.
23% pts took medications for < 1 year, and 52% of the total population took
medications for <5 years. Of the pts with IBS who were over age 65, their
symptoms began before age 35 in 9.6%, age 36–55 in 15.4%, age 56–65 in
27.9% and over age 65 in 47.1%.
Conclusion: 1. Antispasmotics and anticholinergics were extremely effec-
tive in 85% of pts and somewhat effective in 12%. 2. Antispasmotics were
safe when used in this age group and side effects did not limit usage in this
cohort, and were essencially those of dry mouth and rarely fatigue. 3. 87%
of these pts had significant stress factors, anxiety disorder or depression. 4.
Medication usage was usually short lived or intermittent in 75% of pts. 5.
IBS symptoms began most commonly over age 65 in this cohort (47%) with
75% of pts developing symptoms over age 55.
846
The Readability of Hepatitis C Health Education Materials
Noel M. Lee, MD, Andrew J. Muir, MD, MHS, Carla W. Brady, MD, MHS∗.
Department of Medicine, Duke University Medical Center, Durham, NC
and Division of Gastroenterology, Duke University Medical Center,
Durham, NC.
Purpose: Brochures educate patients with hepatitis C virus (HCV) infection
about all aspects of their disease. Government regulations require many doc-
uments to be written at an eighth-grade level or lower to ensure readability.
Data from the National Health and Nutrition Examination Survey suggests
that most Americans with HCV infection have an education level of high
school or less. Many of these people may lack adequate literacy skills to
benefit from such educational tools.
Aim: To determine the readability of HCV educational brochures.
Methods: Using computer software, Flesch-Kincaid Grade Levels and
Flesch Reading Ease scores were measured for selected HCV educational
brochures to determine brochure readability. Reading ease scores range from
0 to 100; lower scores indicate increased difficulty in readability.
Results: Flesch-Kincaid Grade Levels and Reading Ease scores for
brochures were: National Institutes of Health: What I Need to Know About
Hepatitis C (6, 68.5), American Liver Foundation (ALF): If you have Hep C
(7.3, 65.7), Centers for Disease Control (CDC): Living with Chronic Hep C
(7.4, 65.5), CDC: Getting Tested for Hep C (7.4, 65.6), ALF: Coping with
HCV Infection (8.9, 54.7), Hepatitis C Connection: Hepatitis C Fact Sheet
(9.6, 55), Hepatitis Foundation International: Hepatitis C (11, 45.4), ALF:
Hepatitis C (12.5, 36.5), and ALF: Hep C, An Information Source (12.7,
34.4).
Conclusion: HCV educational brochures have a wide range of readability
scores. Several currently available brochures were rated above the recom-
mended eighth grade reading level. Brochures from government agencies
had generally higher readability scores than brochures from other groups
and therefore may be more useful to the larger population of HCV patients.
Future studies are needed to better characterize the health literacy of patients
with HCV infection in order to guide clinicians working with patients with
HCV infection.
847
Stress Ulcer Prophylaxis for the Acutely-Ill Patient: What Do
Residents Know?
Bassel Atasi, MD∗, Henri Godbold, MD, Kurtis Moodie, MD, Louay
Shawesh, MD, Soley Seren, MD, Jorge Guzman, MD. Internal
Medicine/Pediatrics, Wayne State University, Detroit, MI.
Purpose: Several risk factors for developing stress ulcers (SU) have been
identified: mechanical ventilation, head injuries, organ transplant, coagu-
lopathies, and severe burns. In spite of that, unwarranted use of Stress Ulcer
Prophylaxis (SUP) is widespread in US hospitals due to the lack of knowl-
edge in this area. Such improper use of medications is costly.
Methods: Questionnaires consisting of multiple-choice and short-answer
questions were distributed to 125 residents at the Detroit Medical Center,
with a response rate of 80% (100). The aims were to gauge residents’ un-
derstanding of risk factors for developing SU, assess the process in selecting
agents, and compare demographic trends. Three forms were excluded from
final analysis for being incomplete.
Results: Of the 97 respondents, 34% were interns and 66% were more senior
residents; 35% were pediatric residents, 42% were internal medicine (IM)
residents, 14% were combined pediatrics/IM residents, and 9% were rotat-
ing residents from other specialties. Risk factors for developing SU most
commonly identified were: high-dose steroid therapy (86% of participants),
burns (80%), previous PUD (77%), and recent alcohol/drugs abuse (65%).
Established risk factors, such as organ transplant (16%), mechanical venti-
lation (37%), and head injury (40%), were not as commonly selected. No
resident would initiate SUP for patients with coagulopathies. The routine use
of SUP for all types of admissions was indicated by 14% of all participants.
Receiving high-dose steroids was the most common reason to initiate therapy
among pediatric residents (70%), followed by having burns (46%); whereas
IM residents chose burns most commonly (57%), followed by high-dose
steroids (50%). Proton pump inhibitors were selected as the most effective
therapy by 58% of residents, followed by H2-Blockers (35%). Diarrhea was
the most commonly selected adverse outcome of therapy, followed by pneu-
monia. Cost of therapy was an interest to only 4% of all respondents.
Conclusion: Knowledge on the topic of risk factors for SU, comparison of
effectiveness of therapy, and adverse outcomes is lacking among residents.
Using steroids by far was the most common reason to initiate therapy, even
though it is not an established risk factor in the literature. Most residents
did not seem to be aware of some major risk factors. An institution-wide
protocol for SUP therapy may need to be in place to minimize the cost of
unwarranted therapy and prevent possible adverse outcomes.
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Patient Phone Calls: Acitvity-Based Cost Analysis Related to
Outpatient GI Practice
Raj T. Majithia, MD, David A. Johnson, MD, FACP, FACG∗. Internal
Medicine/Gastroenterology Division, Eastern Virginia Medical School,
Norfolk, VA.
Purpose: Phone calls to a physician’s office from patients occupies the time
of many personnel in a gastroenterology practice. The objective of this study
was to evaluate the time impact and cost effect of these phone calls on an
out-patient GI practice with focus on medication related questions.
Methods: Prospective blinded study involved 100 consecutive calls that
were passed to the nursing staff by the receptionist. Nurses were blinded as
to the intent of the study and were told it was a quality assurance program.
Time logs were assessed for each stage of the consecutive calls including
the receptionist, nurse and physician stages. Standard office policy was that
the physician review all telephone call communications.
Results: Call times for medication related calls were analyzed with time
rounded to the nearest min. 30% of calls were medication related. Of these,
10% were due to side effects of medication prescribed, 50% due to lack of
efficacy, 5% due to questions concerning medication dose, 20% related to
cost and availability, and 15% for other reasons. Medication categories for
the calls were IBD: 26%, hepatic: 22%, acid/peptic: 21%, IBS: 20%, and
other: 11%.
Please refer to Table 1.
The average cost incurred to the practice by a medication related call was
$20.29. Other additive potential costs such as overtime or other “opportunity
costs” were not assessed by this analysis.
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Conclusion: Using an activity based cost accounting analysis, these data
show that medication related patient calls to physician offices have con-
siderable indirect related costs that are expenses incurred by the physician
practice. Studies are underway, using similar survey data to compare these
results to the impact of electronic medical records.
Table 1. Average Time per Call
Personnel Mean Time (min) Time Range (min) Payscale ($/Hr)
Receptionist 1 1–3 15
File Clerk 3 2–5 12
Nurse 10 3–25 26
Physician 3 1–15 300
Transcription∗ 2 1–4 17
∗(20% of Calls)
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Patient Underreported Use of NSAIDs in GI Practice: A Prospective
Office-Based Survey
Raj T. Majithia, MD, David A. Johnson, MD∗. Internal
Medicine/Gastroenterology Division, Eastern Virginia Medical School,
Norfolk, VA.
Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the
most commonly used classes of medications worldwide. It is estimated that
more than 30 million people take NSAIDs daily. We examined the underre-
ported use of NSAIDs on a preliminary office intake assessment question-
naire of patient reported medications.
Methods: A prospective questionnaire was administered to patients follow-
ing written and verbal confirmed report of “current medications” to nursing
staff. 100 patient surveys performed for consecutive patients seen in a private
GI practice. After patients listed their “current medications”, they were given
a survey and asked to acknowledge any use of 30 non-prescription formula-
tions that contained NSAIDs. Patients filled these surveys while waiting for
M.D. The educational level of all participants was assessed.
Results: Of the 100 surveys completed, 6% of patients had not completed
high school, 19% had completed high school, 8% had started but not finished
college, 54% had completed college, 2% had started but not finished gradu-
ate school, and 11% had completed graduate school. The educational level
of the patients did not correlate with underreporting of NSAID usage. On
the survey, 18% of patients noted use of an NSAID listed that had not been
reported verbally to nursing staff. 8% of those patients reported daily use,
15% weekly use and 76% reported use within the last month. Patients were
then asked in the questionnaire as to the reason for not reporting medication
intake to nurse. 14% stated they were never asked about the specific med-
ication, 22% did not think the medications were important enough to list,
34% bought the medication with prescriptions, and 30% noted their reason
as their doctor did not prescribe the medication to them.
Conclusion: Using a prospective questionnaire in a private practice GI office,
these data show that patients underreport use of non-prescription NSAIDs.
Based on the data, it is clear that this underreporting can have a detrimental
effect on procedure related as well as long-term patient care. Future studies
would be needed to examine the incidence of side effects due to underre-
porting of NSAIDs.
850
Derivation and Validation of an Algorithm To Identify Helicobacter
pylori Infected Patients Using Administrative Data
Neena S. Abraham, MD, MSCE∗, Ranil DeSilva, MD, Peter Richardson,
PhD. Gastroenterology, Baylor College of Medicine; Micheal E. DeBakey
VAMC, Houston, TX; Health Services Research, Houston Center of Quality
of Care and Utilization Studies; Micheal E. DeBakey VAMC, Houston, TX
and Department of Medicine, Baylor College of Medicine, Houston, TX.
Purpose: To validate VA administrative data for the diagnosis of H. pylori
infected patients.
Methods: National pharmacy, inpatient and outpatient administrative
databases identified patients with an ICD-9 code for H. pylori (041.86) and
those with prescriptions for eradication therapy from 01/01/03 to 12/31/03.
Primary chart abstraction was used to confirm diagnosis of H. pylori based on
antibody serology, urease breath testing, histopathology, or progress notes.
Multivariable regression assessed predictors of H. pylori infection consider-
ing: prescription of eradication drug therapy, ICD-9 code, EGD procedure
code, source of diagnostic code (inpatient or outpatient), age, gender and
race. The c-statistic was calculated to assess the discriminant ability of the
algorithm. Once derived this algorithm was validated in a cohort of patients
from calendar year 2005 (N = 312).
Results: The test cohort consisted of 581 patients (378 potential cases;
203 random controls) who were primarily male (94%), Caucasian (59%)
and elderly (67 years [SD 10]). ICD-9 code 041.86 had the greatest posi-
tive predictive value (PPV) for H. pylori (PPV 100% if from an inpatient
encounter; PPV 97.4% if from an outpatient encounter). Evidence of eradi-
cation drug therapy was associated with a PPV of 73.7% (triple therapy) and
97.7% (quadruple therapy). Multivariable regression revealed the strongest
predictors to be outpatient ICD-9 code 041.86 (OR 8.1; 95% CI: 7.0–9.1);
eradication drug therapy (OR 7.4; 95% CI: 6.6–8.3); EGD (OR 3.5; 95% CI:
3.3–3.6); and age ≥ 70 (OR 1.2; 95% CI: 1.1–1.4). A diagnostic algorithm
including eradication drug therapy, ICD-9 diagnostic code 041.86 and age
≥ 70 yielded a c-statistic of 0.93, suggesting excellent discriminant ability.
When this algorithm was tested in a validation cohort from calendar year
2005, the PPV was 97.9% with a NPV of 98.8%.
Conclusion: Administrative data can be used to accurately diagnose H. py-
lori infected patients. The optimal diagnostic algorithm includes presence of
eradication drug therapy overlapping with an outpatient ICD-9 code 041.86
among elderly adults.
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Cost-Benefit of PPI Gastroprotection among Elderly NSAID Users
Neena S. Abraham, MD, MSCE∗, Jennifer Hasche, MSc, Christine
Hartman, PhD. Gastroenterology, Micheal E. DeBakey VAMC; Baylor
College of Medicine, Houston, TX and Health Services Research, Houston
Center of Quality of Care and Utilization Studies; Micheal E. DeBakey
VAMC, Houston, TX.
Purpose: Our aim was to quantify national cost-benefit of proton pump
inhibitor (PPI) gastroprotection in a cohort of elderly NSAID users.
Methods: Veterans ≥ 65 years prescribed an NSAID or coxib at a VA facil-
ity (01/01/00–12/31/02) were identified from national prescription fill data
and records linked to VA and Medicare inpatient, outpatient and death files.
Using our published algorithm, we defined UGIE and assessed related endo-
scopic, radiological or surgical procedures, ambulatory visits and inpatient
hospitalization days. The VA National Average Cost Dataset was used to as-
sess healthcare utilization costs, apportioned as recommended by published
methodology. Pharmacy costs, from the VA Pharmacy Benefits Management
program, were considered cumulative from the index NSAID prescription
to the UGIE. Each person-day of follow-up was assessed for exposure to
NSAID, coxib and overlapping PPI. Regression models assessed whether PPI
gastroprotection resulted in reduced healthcare use, while adjusting for de-
mographics; UGIE risk factors; co-morbidity; prescription channeling (i.e.,
propensity score); geographic location and multiple time-dependent phar-
macological covariates, including aspirin, anticoagulants, antiplatelets and
statins.
Results: In 481,495 veterans, 3,205 UGIE (97.3% male; 78.6% white; mean
age, 73.9 [SD 5.7]), occurred in 293,594 person-years of follow-up. Of
these UGIE, 36.9% were treated by the VA (i.e., VA-UGIE), costing $5.05
million, 97% of which ($4.9 million) was related to medical resource use and
$150,000 to pharmacy costs. Of VA-UGIE patients, 50% were hospitalized;
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the 33.8% prescribed a PPI were less likely to be hospitalized (OR 0.39;
95% CI: 0.30–0.52) and had a lower median total medical cost than those
not prescribed a PPI ($522.14 [IQR 1935] vs. $1,268.91 [IQR 4176]; P <
0.001). PPI prophylaxis for an NSAID-related UGIE requires an additional
$234 per veteran. However, this increase is offset by a $2,019 reduction in
total medical costs per veteran.
Conclusion: PPI gastroprotection for high-risk elderly patients is associated
with fewer NSAID-related UGIE and reduced hospitalization and associated
resource costs. Reduced resource costs offset higher pharmacy-related costs,
making PPI gastroprotection beneficial for elderly veterans.
852
Healthcare Costs and Clinical Sequelae Associated with Constipation
in a Managed Care Population
Debanjali Mitra, MA∗, Keith L. Davis, MA, Robert W. Baran, PharmD.
RTI Health Solutions, RTP, NC and Medical Outcomes Research, Takeda
Global Research & Development, Deerfield, IL.
Purpose: In addition to a high cost burden, patients with constipation are
likely to suffer from a high incidence of gastrointestinal (GI)-related clinical
sequelae. We examine changes in health care costs and sequelae in patients
with constipation before and after initial diagnosis compared to matched
controls.
Methods: The i3 Innovus LabRx database was retrospectively analyzed.
Patients diagnosed with constipation (ICD-9 564.0×) between 1/1/03 and
12/31/05 were identified (N = 48,585) and demographically matched in
a 1:2 ratio with controls (N = 97,170). An index date for the constipation
group was defined as the date 3 months prior to the first observed constipation
diagnosis. For controls, the index date corresponded to that of their respective
match in the constipation group. Per patient charges for medical services and
prescriptions, and rates of GI-related sequelae were assessed over 12 months
prior to and following the index date.
Results: Total health care charges per patient with constipation were $9,305
pre-index compared to $17,799 in the post-index period (+$8,494; P <
0.0001). Total charges for controls were $5,967 pre-index and $7,151 post-
index (+$1,183; P < 0.0001). After controlling for comorbidities, preva-
lence of cancer, opioid use, and Charlson Score between the pre- and post-
index periods via linear regression, total charges per patient with constipation
remained substantially higher (+$3,664; P < 0.0001) post-index vs. pre-
index. Charges for controls remained $701 higher post-index (P < 0.0001).
Logistic regression showed that patients with constipation had a substantially
and significantly (P < 0.0001) greater likelihood of intestinal impaction
(odds ratio [OR] = 6.6), anal fissures (OR = 5.0), hemorrhoids (OR = 4.2),
volvulus (OR = 10.3), intestinal obstruction (OR = 4.1), and rectal ulcers
(OR = 4.8) during the post-index period compared to pre-index. Overall,
patients with constipation were 4.5 times more likely to have any clinical
sequelae post-index (OR = 4.5; P < 0.0001), while no significant change
was found among controls.
Conclusion: Persons with constipation have greater health care costs and
GI-related sequelae post-index period compared to pre-index. Demograph-
ically similar patients without constipation have a lower prevalence of these
sequelae with no pre- to post-index change. Increased prevalence of these
sequelae may contribute to the total cost burden of constipation. Current
standards of care may not be sufficient to reduce this burden.
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Outcomes of Recurrent Abdominal Pain (RAP) in Children and
Responses to a Multidimensional Measure for RAP (MM-RAP): A
Follow-Up Study
Hoda M. Malaty, MD, PhD∗, Suhaib Abudayyeh, MD, Kimberly O’Malley,
PhD, David Y. Graham, MD, Mark A. Gilger, MD. Department of
Medicine, Baylor College of Medicine, Houston, TX; Medicine, Veterans
Affairs Medical Center, Houston, TX and Pediatrics, Baylor College of
Medicine, Houston, TX.
Purpose: Recurrent abdominal pain (RAP) is a common problem in chil-
dren and adolescents. The aims are: 1) to characterize the course of children
with RAP, 2) to evaluate the diagnostic outcomes of RAP, 3) to compare
responses of a newly developed measure for RAP across the different diag-
nostic categories of RAP.
Methods: We conducted a prospective 2 year study of children diagnosed
with RAP during their first visit to the Pediatric Gastroenterology Clinic at
Texas Children’s Hospital and who were followed-up. At their initial visit, the
eligible child/ parent completed a multi-dimensional measure for RAP (MM-
RAP) consisting of 4 scales (pain intensity scale, symptoms scale, disability
scale, and satisfaction scale). The final diagnosis was defined as the diagnosis
at their last visit. Outcomes were classified into 3 categories: functional RAP,
organic RAP, and Gastroesophageal Reflux Disease (GERD). The responses
of the MM-RAP were analyzed by One-Way ANOVA analysis among the 3
RAP outcome groups.
Results: One hundred and forty one children ages 4 to 18 years (44% boys)
participated. The mean follow-up period was 50 weeks. The final diagnoses
were functional RAP in 46%, organic RAP in 24%, and GERD in 30%.
Neither age nor sex predicted the outcome. The total scores for the pain
intensity scale were significantly higher among children with functional RAP
than organic RAP or GERD (19.7 (±3.5) vs. 14.2 (±4.7) and 13.1 (±4.2);
respectively, P = 001). Although the non-pain symptoms total score did
not differ between the three outcome groups, independent items within the
scale, i.e. diarrhea, vomiting, and heartburn were significantly higher among
children with organic RAP and GERD compared to functional RAP. The
scores for pain disability and health satisfaction scales were similar among
the three outcome groups.
Conclusion: The MM-RAP discriminated between functional and organic
RAP across the studied population. Children with functional RAP report
more intense pain than children with organic RAP or GERD. Neither the
disability scale nor the satisfaction scale differentiated between the func-
tional and organic RAP.
854
Sequential Therapy Is Superior to Standard Therapy for Treatment of
Helicobacter pylori Infection: A Systematic Review and Meta-Analysis
Nadim S. Jafri, MD, Carlton A. Hornung, PhD, Colin W. Howden, MD∗.
University of Louisville, Louisville, KY and Northwestern University,
Chicago, IL.
Purpose: Authorities continue to recommend standard PPI-based triple or
quadruple therapy for the treatment of H. pylori infection despite failure of
eradication in around a quarter of patients. Sequential therapy (ST) (5 days
of PPI + 1 antibiotic followed by 5 days of PPI + 2 other antibiotics) may
be more efficacious.
Methods: We performed a systematic search for randomized controlled tri-
als (RCTs) comparing ST with standard therapy for H. pylori infection in
Medline, EMBASE, and the Cochrane Central Register of Controlled Trials
using Pubmed, Google Scholar and Ovid as search engines without language
restriction. We also hand searched the references of original/review articles
and evaluated symposia proceedings, poster presentations and abstracts from
major gastrointestinal meetings. Relative risks (RR) were calculated for in-
dividual trials; data were pooled using a fixed effects model. Relative risk
reduction (RRR), absolute risk reduction (ARR) and number needed to treat
(NNT) were calculated and are reported with 95% confidence intervals (CI).
Study quality was assessed with the Jadad scale. Results were subjected to
sensitivity analysis.
Results: 8 RCTs comprising 2202 patients (1071 men) met eligibility cri-
teria. Mean age ranged from 9.9–70 years. 1095 patients were randomized
to sequential therapy and 1107 to standard therapy. ST was superior with
respect to eradication rates; RRR = 22% (95% CI: 18–27%), ARR = 17%
(14–20%), NNT = 6 (5–7), and for ulcer healing; RRR = 17% (10–25%),
ARR = 11% (7–16%), NNT = 9 (6–14). Compliance was similar in both
arms (RR 0.99, 95% CI: 0.97–1.01). ST was superior in adults (RRR = 22%
(18–27%), ARR = 17% (14–20%), NNT = 6 (5–7)), as well as in smokers
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(RRR = 25% (9–43%), ARR = 19% (9–29%), NNT = 5 (3–11)); and in
patients with non-ulcer dyspepsia (NUD) (RRR = 25% (18–33%), ARR =
19% (14–23%), NNT = 5 (4–7)). When evaluating only RCTs of high qual-
ity (Jadad score ≥ 3) there was still a benefit to ST (RRR = 17% (11–24%),
ARR = 14% (9–18%), NNT = 7 (5–11)). Lack of significant heterogeneity
was noted among RCTs, except for ulcer healing. Side effect profile was
similar in both arms.
Conclusion: ST appears superior to standard therapy for eradication of
H. pylori infection and ulcer healing. It also produced superior eradication
rates in smokers and in patients with NUD. These outcomes were consistent
by sensitivity analysis. However, all identified RCTs were from Italy, and
results may not be replicable in the US. This approach should be tested in
US-based RCTs.
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GI Endoscopy Nurse Experience Predicts Polyp Detection during
Screening Colonoscopy
Evan S. Dellon, MD, Robert S. Sandler, MD, MPH, Nicholas J. Shaheen,
MD, MPH∗. Medicine, University of North Carolina, Chapel Hill, NC.
Purpose: While factors that predict polyp detection during screening
colonoscopy have been described, the effect of GI endoscopy nursing ex-
perience level on polyp detection is unknown. The aim of this study was
to determine whether nurse experience is associated with rates of polyp
detection.
Methods: We performed a retrospective analysis of screening colonoscopies
at the University of North Carolina Hospitals between August 2003 and 2005.
Procedures were limited to those performed by attendings without trainee
involvement. Nurse experience was measured in weeks from the initial start
date to the procedure date for each endoscopy nurse. The primary outcome
was the detection of any polyp. The secondary outcome was the detection of
multiple polyps. Additional variables related to both the procedure (bowel
preparation quality, cecal intubation rate, withdrawal time) and the patients
(age, gender, ASA score, BMI, comorbidities, and past surgical history) were
extracted from our electronic endoscopy database. Descriptive statistics, bi-
variate analysis, and multivariable logistic regression were performed. The
study was approved by the Institutional Review Board of UNC.
Results: Any polyp was detected in 44% of the eligible 3,631 screening
colonoscopies. Multiple polyps were detected in 23%. Twenty-nine nurses
were employed in our endoscopy unit during the study period, 19 of whom
were new to gastroenterological nursing. Increased polyp detection was asso-
ciated with increased withdrawal time, reaching the cecum, increased patient
age, increased patient BMI, and better quality bowel preparation. For nurses
with 6 months of experience or less, any polyp was detected in 40.3% of
procedures compared with 46.0% of procedures for nurses with more than 6
months of experience (OR 1.3, 95% CI: 1.1–1.5, P = 0.002). Similarly, for
nurses with 6 months of experience or less, multiple polyps were detected
in 18.2% of procedures compared with 25.5% of procedures for nurses with
more than 6 months of experience (OR 1.5, 95% CI: 1.3–1.8, P < 0.001).
These relationships held after adjusting for potential confounding patient
and procedure variables.
Conclusion: Nursing experience of six months or less is associated with
lower rates of polyp detection, independent of physician withdrawal time,
bowel preparation, cecal intubation rate, and other factors that might in-
fluence detection. These findings may have implications for nurse train-
ing as well as quality of colorectal cancer screening programs that utilize
colonoscopy.
856
Persistence with Infliximab Therapy Reduces Crohn’s Disease Related
Medical Costs
H.C. Thompson, MBA∗, M.I. Rahman, MD, B. Meissner, PhD, B. Tang,
MD, O. Dabbous, MD. Health Economics & Clinical Outcomes Research,
Centocor, Inc., Horsham, PA and Applied Health Outcomes, Xcenda, LLC,
Palm Harbor, FL.
Purpose: To evaluate the impact of persistence with infliximab treatment on
medical costs among patients with Crohn’s disease (CD), utilizing a managed
care database.
Methods: A retrospective study using PharMetrics managed care plan
database in the United States from July 1, 1999 through June 30, 2005, was
conducted. Patients newly initiated on infliximab, continuously enrolled for
12 months before and after their index infliximab claim, and having at least
2 diagnoses of CD, one of which occurred in the pre-index period were
included. Persistence (%) was defined as the number of days between the
first infliximab claim and the last infliximab encounter, divided by 365 and
multiplied by 100. Two mutually exclusive cohorts were defined based on
their levels of infliximab persistence: patients who were persistent greater
or equal to 80%, and those who were persistent less than 80%. CD-related
medical costs (those in which CD was the diagnosis on the claim) in the
12-month post-index period were computed for each patient. The cost of
adverse events could not be identified separately in this analysis. Univariate
differences between the persistent and non-persistent cohorts were assessed
using Mann-Whitney and chi-square tests.
Results: 480 patients were included, 251 (52.29%) with a persistency ratio
≥80% and 229 (47.71%) with a persistency ratio <80%. 55% were fe-
male and the mean age was 36.9 years. The ≥80% persistency cohort had
lower CD-related medical costs compared with the <80% persistency cohort
($4,380.21 vs $8,570.11; ns), primarily driven by inpatient costs ($2,014.31
vs $5,981.51; P < 0.001). Costs were also higher for emergency room and
outpatient levels of care in the lower persistency cohort.
Conclusion: This study indicates that a higher persistence rate with inflix-
imab therapy is associated with lower CD-related medical costs, primarily
driven by decreased inpatient hospital costs. Future studies to examine the
impact of persistence with infliximab on clinical and humanistic outcomes
are recommended.
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Increased Inpatient Utilization Following Colectomy in Ulcerative
Colitis in the Medicare Population
H.C. Thompson, MBA∗, M.R. Kugel, MS, M.I. Rahman, MD, G.J. Watson,
MS, O. Dabbous, MD, B. Tang, MD. Health Economics & Clinical
Outcomes Research, Centocor, Inc., Horsham, PA and Health Outcomes,
The Moran Company, Arlington, VA.
Purpose: To examine inpatient hospital utilization following colectomy in
pts covered by Medicare who have ulcerative colitis (UC).
Methods: A retrospective analysis was conducted using claims from the
Medicare Standard Analytic Files 5% sample database between Jan 1, 2001
and Dec 31, 2005. Pts were identified as having UC using diagnostic codes
(ICD-9 codes 556.x) and were limited to those who had a procedure code
indicating colectomy (45.7×), and a diagnosis of UC prior to that date.
Pts with a subsequent diagnosis of Crohn’s disease were eliminated from
this analysis. The first procedure was chosen if the beneficiary had multiple
45.7× procedures (these are partial excisions, so a beneficiary could have
multiple procedures over time). The study design consisted of a 12-mo pre-
colectomy period and 12-mo post-colectomy period. Medicare participation
was required for the year prior to the colectomy, and the pt had to be alive
during the 12-mo post-colectomy period. Inpatient hospital costs and re-
source utilization were evaluated 12 mos before and 12 mos after the quarter
in which the colectomy occurred. All costs are presented in 2005 US dollars.
Results: A total of 905 pts with UC who had a claim for colectomy were
included in the analysis. Total inpatient costs ($19,778 vs $23,765) and
average length of stay (ALOS) (15.2 days vs 18.3 days) increased following
colectomy, while mean number of admissions did not increase significantly.
Conclusion: Inpatient hospital utilization and subsequent costs increased
during the 12-mo period following colectomy in the Medicare population.
Although the mean number of admissions was similar, length of stay and
costs were higher. Additional analyses along with larger samples are needed
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to determine the extent of these services and reasons for increased inpatient
utilization.
Mean Inpatient Cost and Utilization Pre- and Post-Colectomy
Pre-colectomy Post-colectomy P-Value
Total Inpatient (N = 222)
Costs ($) $19,778 $23,765 0.0001∗
Mean number of admissions 2.2 2.3 0.0534
ALOS 15.2 18.3 0.0011∗
∗P < 0.05; paired t-test
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Collagenous and Lymphocytic Colitis in Celiac Disease: Evaluation of
Standardized Morbidity Ratios
Jianfeng Cheng, MD, PhD, Jun Yang, MD, Govind Bhagat, MD, Peter
Green, MD∗. Internal Medicine, Sound Shore Medical Center, New
Rochelle, NY; Medicine-Digestive and Liver Disease, Columbia University,
New York, NY and Pathology, Columbia University, New York, NY.
Purpose: Celiac disease (CD) and microscopic colitis (MC) occur together
in some patients, however the actual prevalence of MC in CD is not known.
Using a large data base of patients with CD seen in a university based
center we investigated if the occurrence of MC and its subtypes: lymphocytic
colitis (LC) and collagenous colitis (CC) is higher in CD than in the general
population, via analysis of standardized morbidity ratios (SMR).
Methods: Our prospectively maintained database of 1009 patients (seen
between 1981 and 2006) with CD at the Celiac Disease Center of Columbia
University was analyzed. We calculated SMRs for overall MC, LC, CC
and gender-specific MC, LC and CC by using the epidemiological study in
general population conducted in Minnesota between 1985 and 2001 as the
reference group.
Results: Forty-four patients (4.3%) with MC were identified (CC: 11 [1.1%]
and LC: 33 [3.2%]). Mean age of diagnosis of CD in those without MC was
significantly younger than those with MC (42.7 ± 17.9 vs 53.2 ± 14.7, P <
0.0001). There was no difference in the gender distribution in the MC group
compared to the whole CD cohort (female:male: 2.1/1 for CD vs 3.9/1 for
MC, P = 0.13). However, among the two subtypes of MC, CC showed a
striking female predominance (female: male ratio-2.7:1 for LC and 11:0 for
CC, P = 0.05). Based on the data from an epidemiological study of MC in the
general population conducted in Minnesota, the SMR was 72.39 (95% CI:
52.52–95.36) for MC; 46.70 (95% CI: 23.05–78.13) for CC and 88.65 (95%
CI: 60.87–121.32) for LC. Among females, the SMR was 72.25 (95% CI:
50.30–98.17) for MC, 51.57 (95% CI: 25.45–86.28) for CC and 88.53 (95%
CI: 56.66–127.50) for LC; while among males the SMR was 72.93 (95% CI:
33.06–128.36) for MC; 0 for CC and 88.98 (95% CI: 40.34–156.60) for LC,
respectively. Of 44 MC patients, 63.6% were diagnosed after CD, because
of persistent diarrhea despite a gluten-free diet while 25% were diagnosed
simultaneously with CD and 11.4% diagnosed prior to CD.
Conclusion: Our study demonstrated that MC is more prevalent in CD than
in the general population and occurs in those diagnosed with CD when they
are older. LC has a stronger association with celiac disease than CC. CC
occurs only in females with CD, while LC occurs in both genders. MC should
be suspected in CD when there is a poor response to a strict gluten-free diet.
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Patients That Do Not Speak English Miss Fewer Clinic Appointments
Than English Speaking Patients
Justin L. Sewell, MD, MPH, John M. Inadomi, MD, Hal F. Yee, Jr, MD,
PhD∗. Medicine, University of California, San Francisco, San Francisco,
CA.
Purpose: Prior studies of healthcare outcomes reveal inequities among vul-
nerable populations; however, it has not yet been established whether deficits
in access or utilization are the source of disparity. This study aimed to deter-
mine whether non-English speakers and minority patients with established
care access exhibit lower rates of utilization of gastroenterology care than
English speakers and white patients.
Methods: Case-control study performed in a diverse urban population
served by an established safety net health system. Subjects included all
patients referred and scheduled for a gastroenterology clinic appointment
between 05/2005 and 08/2006. The primary outcome was whether a subject
showed for their clinic appointment. Predictor variables included age, gender,
race/ethnicity, language, socioeconomic measures, appointment wait time,
substance abuse and psychiatric history, and primary clinic type. Multivari-
able logistic regression and classification tree analysis were used to analyze
the data.
Results: 1,833 subjects were included (683 no-shows and 1,150 shows). In
a multivariable analysis, subjects speaking primarily Spanish or an Asian
language were more likely to show for a clinic appointment (odds ratio
for missing the appointment = 0.42 and 0.56, respectively, P < 0.001),
than English speakers (see table). Results for race/ethnicity were mixed.
In the classification analysis, language was the variable most predictive of
utilization.
Conclusion: Surprisingly, among patients with established care access, not
speaking English was associated with improved rates of gastroenterology
care utilization. This unexpected association suggests that language may be
a surrogate marker for mechanisms underlying these findings, such as cul-
tural identity, patient-provider communication, or immigration status. Fur-
ther study is indicated to uncover the role of such mechanisms in vulnerable
populations.
Logistic regression of factors associated
with not showing for a clinic appointment
Independent Variables Adjusted Odds Ratio (95% CI) P Value
Language∗ <0.001
–Spanish 0.42 (0.28, 0.63)
–Asian language 0.56 (0.38, 0.82)
Ethnicity† 0.001
–Black 1.55 (1.15, 2.08)
–Hispanic 1.53 (1.06, 2.22)
–Asian 0.95 (0.66, 1.38)
Odds ratios represent odds of not showing for a clinic appointment. ∗Languages are
compared with English. †Race/ethnicity is compared with white.
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Esophageal Adenocarcinoma and Barrett Esophagus Registry
Consortium
Mary Fredericksen, CCRP, Deb Geno, CCRP, Michael B. Wallace, MD,
Virender K. Sharma, MD, EABE Work Group, Yvonne Romero, MD∗.
Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN;
Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL;
Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ;
Otolaryngology, Mayo Clinic, Rochester, MN and GI Outcomes Unit,
Mayo Clinic, Rochester, MN.
Purpose: Progression from Barrett esophagus (BE), a premalignant epithe-
lium, to esophageal adenocarcinoma (AC) likely involves the accumulation
of genetic events that impact signals important for cell proliferation, survival,
angiogenesis, immune escape, and invasion. Identification and validation of
markers requires the resources of a large bank of serially collected, well-
characterized fresh-frozen and formalin-fixed tissue, blood, demographic,
symptom and risk factor data.
Aims: Resource created to facilitate the identification of: 1) genetic path-
ways important in the neoplastic transformation from BE to AC; 2) novel
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biomarkers of risk, early detection, response to treatment; and 3) novel ther-
apeutic or chemoprevention targets.
Methods: Since 2001, at Mayo Clinic Rochester (MCR), and 2005, at Mayo
Clinic Jacksonville (MCJ), participants provide demographic/clinical infor-
mation and complete baseline/annual questionnaires. Blood collected once;
tissue collected at every clinically indicated endoscopy/surgery. Mayo Clinic
Arizona is in the process of joining this effort.
Results: As of June 2007, at MCR, 2838 unique patients have met entry
criteria of which 1602 (56%) have been enrolled, 651 (23%) declined, and 426
are being processed. Enrolled patients include: 841 BE alone, 291 BE with
AC, 189 AC alone, 108 squamous cell carcinoma (SCC) patients (controls),
3 patients with AC and SCC, 4 patients with BE, AC and SCC features,
and 157 AC of the gastroesophageal junction. Blood and tissue have been
collected at least once from 1380 and 673 unique participants, respectively.
At MCJ, 55 of 85 (65%) patients have been enrolled.
Conclusion: The Esophageal Adenocarcinoma and Barrett Esophagus
(EABE) Registry Consortium is a multi-center multi-disciplinary Academia-
NIH-Industry collaborative effort designed to prospectively enroll consecu-
tive patients with Barrett esophagus and esophagus cancer, to collect fresh-
frozen/formalin-fixed tissue, blood, demographic, symptom and risk factor
data to facilitate bench-to-bedside translational discoveries.
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Use of Acid Suppression Therapy in Hospitalized Patients – Going
beyond the Indications
Ruchi Gupta, MD, Ravi Kottoor, MD∗, Juan C. Munoz, MD, Louis R.
Lambiase, MD. Medicine, Division of Gastroenterology, University of
Florida College of Medicine, Jacksonville, FL.
Purpose: Acid suppression medications are among the top 5 medications
prescribed in hospitalized patients. There are unequivocal indications out-
lined for their usage by FDA. We postulate that many patients are inappro-
priately started and discharged on acid suppression therapy (AST). The aims
of our study is to determine the frequency and validity of such prescriptions
on General Medicine wards.
Methods: Chart review of 500 patients admitted consecutively to a Uni-
versity Hospital was done. Patients who received at least a dose of AST
were included. Patients who spent any time in ICU or who were on AST
on admission were excluded. Accepted indications were as outlined by the
FDA. Categorical variables like demographics, admitting diagnosis, comor-
bidities, LOS were analyzed with ‘starting the patient on acid suppression
therapy’ and ‘discharge on acid suppression’ as outcome variables. Those
discharged on AST were followed up at 3 months.
Results: 230/500 (46%) patients were started on AST on admission. 184/230
(80%) of the patients lacked an indication for initiation of AST. No known
cause documented (39%) followed by stress ulcer prophylaxis in low risk
patients (23%) were top 2 reasons for inappropriate usage. Most common
reasons for admission were infectious disease (26%) and gastroenterology
(15%) related diagnosis. 83/184 (45%) of patients were discharged on inap-
propriate AST. No significant difference in categorical variables in patients
who were discharged on unnecessary AST vs. in whom it was discontinued.
On 3 months follow up 68% of these patients were still on inappropriate
AST.
Conclusion: Our study reveals that not only AST is over prescribed in hos-
pitalized patients but a significant number of patients are also discharged
on it without a valid indication. Given the cost and recent data associating
AST with complications, its prescription needs to be critically questioned.
Educating house staff, strict guidelines for starting AST and emphasizing the
importance of medication reconciliation are some of the simple interventions
that can help prevent unnecessary prescription of AST.[figure1]
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The Direct and Indirect Cost Burden of Crohn’s Disease
Eliza Ng, MD, Teresa B. Gibson, PhD∗, Ronald J. Ozminkowski, PhD, Ron
Z. Goetzel, PhD, Wayne Burton, MD, Sara Wang, PhD, Ross MacLean,
MD. Global Outcomes Research Strategy, Bristol-Myers Squibb,
Princeton, NJ; Health and Productivity Research, Thomson Healthcare,
Ann Arbor, MI; Institute for Health and Productivity Studies, Cornell
University, Washington, DC and Division of General Internal Medicine,
Northwestern University, Chicago, IL.
Purpose: To estimate the direct medical costs and indirect costs (productivity
related) for commercially-insured patients with Crohn’s Disease.
Methods: Data were obtained from the 1999 to 2005 MarketScan Commer-
cial Claims and Encounters (CCAE), Medicare Supplemental, and Health
and Productivity Management databases. Patients with a diagnosis of Crohn’s
Disease and at least a 1-year disease-free pre-period were found resulting in
6,569 nonelderly patients with Crohn’s Disease and 1,628 elderly patients
with Crohn’s Disease.
12-month direct medical care expenditures (medical and prescription drug)
for patients with Crohn’s Disease were compared to expenditures among
an equal number of propensity-score matched comparison group members.
Propensity scores were estimated via demographic characteristics and co-
morbidities. Indirect costs, as measured by absenteeism and short-term dis-
ability costs, were compared for a sub-sample of employees in each group.
Regression analysis controlled for demographic and case mix factors. A
range of cost burden estimates were produced by varying the estimation and
matching techniques.
Results: Average 12-month direct medical care expenditures were $5,299
for nonelderly and $8,348 for elderly comparison group members. Average
estimated direct medical expenditures for patients with Crohn’s Disease ex-
ceeded comparison group members by as much as $16,388 for nonelderly
patients and $8,648 for elderly patients (all P < .01).
Absenteeism costs were $5,097 for employees with Crohn’s Disease, al-
though this was not significantly different from the comparison group.
Short term disability expenditures were about $1,700, which was double
the amount for the comparison group (P < .05).
Conclusion: Crohn’s Disease is a very costly disorder and merits consider-
ation as interventions are developed to manage the burden of disease and
improve productivity.
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Increased Healthcare Utilization Following Colectomy in Ulcerative
Colitis
Heidi C. Thompson, MBA∗, Brian Meissner, PhD, Mirza I. Rahman, MD,
Omar Dabbous, MD, Boxiong Tang, MD. Health Economics & Clinical
Outcomes Research, Centocor, Inc., Horsham, PA and Applied Health
Outcomes, Xcenda, LLC, Palm Harbor, FL.
Purpose: To examine healthcare resource utilization in patients with ulcer-
ative colitis (UC) following colectomy.
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Methods: A retrospective analysis was conducted using medical and phar-
macy claims from the PharMetrics database between January 1, 2000 and
June 30, 2005. Patients were required to have 2 distinct claims for UC (ICD-
9 codes 556.x) and were limited to those who had a CPT code indicating
colectomy (44140–44160), and a diagnosis of UC prior to that date. The
study design consisted of a 12-month pre-colectomy period and 12-month
post-colectomy period. Continuous enrollment was required for the entire
two-year period. Healthcare resource utilization was evaluated 12 months
before and 12 months after the colectomy date. The outcomes of interest
included healthcare encounters for the following levels of care: inpatient,
outpatient, emergency room, physician, laboratory, and drug costs. Basic
population characteristics were also examined, including demographics and
overall patient comorbidity burden (Charlson Comorbidity Index).
Results: A total of 411 patients with UC who had a claim for colectomy were
included in the analysis. Over half of the patients were male (51.7%) and the
mean age was 46 years. The mean Charlson Comorbidity Index score was
4.4. Total utilization of services increased following colectomy, including
inpatient encounters and outpatient encounters, all at significant levels (P <
0.05).
Mean Resource Cost and Utilization Pre- and Post-Colectomy
Pre-colectomy Post-colectomy P-Value
Total Healthcare Visits 26.6 (19.3) 39.4 (33.6) <0.0001
Inpatient encounters 0.9 (1.1) 1.8 (1.7) <0.001
Outpatient visits 8.7 (10.9) 19.4 (24.9) <0.001
Emergency Room visits 0.8 (1.4) 0.9 (1.6) 0.2583
Physician visits 13.9 (11.7) 14.9 (13.9) 0.1595
Laboratory visits 2.1 (3.3) 2.2 (4.3) 0.7790
Conclusion: Healthcare utilization increased during the 12-month period
following colectomy, driven by increases in inpatient and outpatient visits.
Additional analyses are needed to determine the extent of these services and
reasons for increased service utilization.
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Maintenance Therapy with Infliximab Reduces Hospitalization and
Surgery in Crohn’s Disease
H.C. Thompson, MBA∗, J.A. Pesa, PhD, N. Zhao, PhD, C. Han, PhD, M.I.
Rahman, MD, B. Tang, MD, O. Dabbous, MD. Health Economics &
Clinical Outcomes Research, Centocor, Inc., Horsham, PA; Medical
Affairs, Ortho-McNeil Janssen Scientific Affairs, LLC, Superior, CO and
R&D, Centocor, Inc., Malvern, PA.
Purpose: To assess the impact of maintenance versus episodic infliximab
therapy on hospitalizations and surgery in patients with Crohn’s disease
(CD).
Methods: A retrospective analysis of claims data was conducted from the
Marketscan Commercial Claims and Encounters database from 2000 to 2003
for claimants with CD (ICD-9 codes, 555.0, 555.1, 555.2 or 555.9) who
had an induction regimen (3 infusions) of infliximab in 2003. Continuous
enrollment for 12-months pre and 12-months post the index infusion date in
2003 was required. Patients were excluded if they had infliximab infusions in
2001 or 2002. Cohort analyses were conducted for three distinct cohorts: 1)
1–2 infliximab infusions; 2) 3–4 infliximab infusions; 3) 5 or more infliximab
infusions.
Results: Analyses were conducted on 126 patients who met the inclusion
criteria. The majority of patients were female (53.2%) and the mean age was
49.5 years. Among the cohort with 5 or more infliximab infusions (N = 34),
20.6% required hospitalization, as compared to 37.5% of the cohort with
1–2 infusions (N = 48) and 34.1% of the cohort with 3–4 infusions (N =
44). The cohort with 5 or more infliximab infusions also had fewer mean
hospitalizations (1.29 vs. 1.83 and 1.47, ns), and shorter lengths of stay (5.11
days vs. 5.64 days and 5.91 days, ns). In addition, the percentage of patients
requiring surgery was decreased for the 5 or more infusion cohort (24%) as
compared with the other cohorts (40% each).
Conclusion: Although non-significant, the results of this analysis indicate
that when treating CD with a maintenance schedule of infliximab, the num-
ber and length of hospitalizations are reduced, and the percentage of patients
requiring surgery decreases. Infliximab should be used on a maintenance
schedule rather than episodically (ie: treat flares) in order to optimize treat-
ment outcomes.
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Patient Reported Quality of Life Following Surgery in Ulcerative
Colitis
H.C. Thompson, MBA∗, D. Eisenberg, PhD, M. Bala, PhD, M.I. Rahman,
MD. Health Economics & Clinical Outcomes Research, Centocor, Inc.,
Horsham, PA and Worldwide Health Economics & Pricing, J & J
Pharmaceutical Services, Malvern, PA.
Purpose: To assess the impact of surgery on quality of life (QOL) in ulcer-
ative colitis (UC).
Methods: A random digit dial phone survey of 1,000 pts with UC in the
US was conducted. Respondents were selected from an opt-in database of
17 million US consumers, of which 40,000 self-identified as having UC.
Of the 40,000 potential respondents, about 19,000 had confirmable contact
information, and were used as targets to arrive at the desired sample of 1,000.
Contact was attempted with 7,900 potential respondents, and the overall
response rate was 13% (1000/7900). The survey consisted of an interview
lasting about 27 minutes. Information was gathered regarding prior surgeries
for UC, including total colectomy and various QOL indicators. Summary
statistics were calculated.
Results: Of the 1,000 respondents,19.7% (197) had UC-related surgery in
the past 5 yrs, with an average of 2.3 surgeries per respondent. The mean time
from diagnosis to first surgery was 39.6 months. Of the respondents who had
undergone surgery, 37.1% had their entire colon removed and 31% reported
that they were required to wear an ostomy bag. Almost equal percentages of
respondents indicated that their lives were better before surgery as opposed
to better after surgery (49.2% vs. 45.0%). This was also true for those who
had a total colectomy (32.6% vs. 30.4%). However, QOL was still affected by
UC following surgery (Table). Pts who had undergone surgery also reported
a substantial number of workdays missed (9.3 in the past 30 days) and less
productive workdays (24.7 in the past 30 days) due to UC symptoms.
Mean number of days in the past 30 days with UC-related symptoms
UC Surgery
Because of UC, during Other than Total
the past 30 days, how many days. . . Total Colectomy Colectomy
Did PAIN make it hard for you to do
your usual activities, such as work
or recreation?
9.8 8.6
Have you felt SAD, BLUE, or
DEPRESSED?
8.6 8.5
Have you felt WORRIED, TENSE,
or ANXIOUS?
10.6 10.0
Have you felt you did NOT get
ENOUGH REST or SLEEP
because of your UC?
12.1 10.9
Have you felt STRESSED? 13.8 12.1
Conclusion: Almost 20% of respondents reported having surgery for UC,
and those who had surgery still reported feelings of pain, depression, anxiety,
sleeplessness and stress due to their disease. Work life following surgery
was still negatively affected. Further studies are needed to better understand
optimal management and outcomes in UC.
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Infliximab Is Clinically Effective in Reducing the Need for Steroids in
Inflammatory Bowel Disease
H.C. Thompson, MBA∗, B. Meissner, PhD, M.I. Rahman, MD, O.
Dabbous, MD, B. Tang, MD. HECOR, Centocor, Inc., Horsham, PA and
Applied Health Outcomes, Xcenda, LLC, Palm Harbor, FL.
Purpose: To determine the influence of infliximab (IFX) on steroid use in
pts with inflammatory bowel disease (IBD), including Crohn’s disease (CD)
and ulcerative colitis (UC).
Methods: A retrospective analysis was conducted using medical and phar-
macy claims from the PharMetrics database btw Jan. 1, 2000 and June 30,
2005. Pts were required to have 2 distinct claims for CD (ICD-9 codes 555.×)
or UC (ICD-9 codes 556.×) and were limited to those started on IFX therapy
before June 30, 2004. Corticosteroid use was evaluated 12 mos before and
12 mos after the first IFX claim (IFX index date). Continuous enrollment
was required. Outcomes of interest included: the% of pts with at least 1
prescription for an oral steroid; mean number of steroid prescriptions per pt;
and mean number of days in which a steroid was theoretically available per
pt. Basic population characteristics were examined including demographics
and overall pt comorbidity burden (Charlson Comorbidity Index).
Results: Of the 971 CD pts and 274 UC pts that received IFX, over half of the
pts were female and the mean age was 40 for CD and 39 for UC. The mean
Charlson Comorbidity Index score was 1.9 for CD and 2.4 for UC. In the yr
prior to the IFX index date, 58.6% (569) of pts with CD had a prescription
for an oral steroid vs 45.1% (438) in the yr following the index date (P <
0.05). In the yr prior to the IFX index date, 69.7% (191) of pts with UC
had a prescription for steroids vs. 52.1%(143) in the yr following the index
date (P < 0.05). Significant reductions in the mean number of corticosteroid
prescriptions for both CD (2.5 vs 1.8; P < 0.05) and UC (1.9 vs 1.4; P <
0.05) and the number of days in which a corticosteroid was available for CD
(70.3 vs 48.6; P < 0.05) and UC (49.9 vs 36.2; P < 0.05) were documented
during the post-IFX period.
Steroid use pre- & post-IFX
CD UC
Pre-IFX Post-IFX Pre-IFX Post-IFX
% of pts with
steroid
prescription
58.6(569)∗ 45.1(438)∗ 69.7(191)∗ 52.1(143)∗
Mean # of
steroid
prescriptions
1.9(2.5)∗∗ 1.4(2.4)∗∗ 2.5(2.6)∗∗ 1.8(2.6)∗∗
Mean # of
steroid days
49.9(73.1)∗∗ 36.2(69.7)∗∗ 70.3(82.6)∗∗ 48.6(72.4)∗∗
∗P < 0.05 chi square test ∗∗P < 0.05 paired t-test
Conclusion: This analysis indicated that IFX use resulted in a reduction in
overall corticosteroid use in pts with IBD. Consequently, use of IFX should
be considered for IBD pts who are dependent on corticosteroids, have steroid
toxicity, and who are not responding adequately to treatment with steroids.
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The Pre-Operative Utility of Dobutamine Stress Echocardiography in
Patients Undergoing Liver Transplantation
Lynn Shapiro, MD, Maximilian Lee, MD, Jason Lee, MPH, Alex S.
Lapasaran, MSN, APN, William Fearon, MD, Ahmad Kamal, MD, MSc,
Aijaz Ahmed, MD∗. Division of Gastroenterology and Hepatology, Liver
Transplant Program, Stanford University School of Medicine, Stanford,
CA; Center for Primary Care and Outcomes Research, Stanford University
School of Medicine, Stanford, CA; Division of Cardiovascular Medicine,
Stanford University School of Medicine, Stanford, CA and Division of
Gastroenterology, Santa Clara Valley Medical Center, San Jose, CA.
Purpose: To determine whether dobutamine stress echocardiography (DSE)
is sufficient to rule out significant coronary artery disease (CAD) in patients
undergoing liver transplantation (LT).
Methods: At our institution, 281 adults underwent LT between January 1,
2000 and June 30, 2006. Pre-operative DSE was performed in 121 (43%)
out of 281 adult LT recepients to screen for CAD. Patients (N = 121) who
underwent DSE were either >50 years in age and/or with presence of 1 or
more major cardiac risk factors. We conducted a retrospective review of any
subsequent angiography and survival.
Results: 109 (90%) patients had a normal DSE and 12 (10%) patients had
an abnormal DSE, including 3 with stress-induced wall motion abnormal-
ities and 9 with resting wall motion abnormalities. Coronary angiography
was performed in 24 patients with a normal DSE: 6 patients were found to
have significant lesions and 4 required intervention. Angiography was also
performed in 4 patients with an abnormal DSE: only 1 patient had a signifi-
cant lesion and it required intervention. DSE had 14% sensitivity and 85%
specificity for CAD, with 25% positive predictive value and 75% negative
predictive value. After a median follow-up of 1.8 years (range, 0 to 5.5 years),
survival was higher in those patients who had undergone coronary angiog-
raphy despite a normal DSE, than in those were assumed to have no CAD
based on a normal DSE alone (100% versus 80%, P = 0.04).
Conclusion: A normal DSE may be insufficient in ruling out CAD in high
risk patients undergoing LT. The lower mortality in those patients who un-
derwent angiography despite a normal DSE suggests that significant lesions
may be missed with non-invasive testing and that cardiac intervention prior
to transplant may improve outcomes.[figure1]
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An Exploratory Analysis of Healthcare Utilization and Costs in
Pediatric Crohn’s Disease
H.C. Thompson, MBA∗, E. Teng, PharmD, M.I. Rahman, MD, R. Ferrer,
BS, B. Tang, MD, O. Dabbous, MD, J. Pulicharam, MD. HECOR,
Centocor, Inc., 800 Ridgeview Drive, Horsham and Clinical Research &
Outcomes, Healthcare Partners, Inc., Torrance, CA.
Purpose: To evaluate healthcare utilization costs associated with pediatric
Crohn’s disease (PCD) from a payor perspective.
Methods: An analysis using data from 2003 through 2006 containing claims
for HMO pts assigned to HealthCare Partners Medical Group from 6 com-
mercial health plans in S. CA was conducted. Newly diagnosed pts age <18
with Crohn’s disease (CD; ICD-9 555.×) were identified. Pts were required
to have 6-mos pre- and 12-mos post continuous eligibility from their disease
index date. Cost and resource utilization were compared to a cohort without
CD who were matched to the pts with PCD on age, sex, and birthday (within
30 days of age/sex matched pts with PCD). Statistical significance was not
assessed due to the small sample size.
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Results: 62 pts with PCD were identified, with 30 meeting the continuous
eligibility criteria. Most were female (56.7%) and the median age at dx
was 13 yrs. The comparator grp consisted of 10,864 children. The total per
member per month (PMPM) cost for pts with PCD was $2,547.32, with 70%
attributable to PCD, vs a PMPM cost of $166.07 for the non-PCD cohort.
There were 500 admissions per 1,000 members per yr (PTMPY) for the PCD
grp vs 11.2 for the comparator cohort. The average length of stay (ALOS)
was also longer for the PCD cohort (7.6 days vs 4.4 days). The PMPM cost
of inpt stays was $1,409.41 for the PCD cohort vs $18.16 for the comparator
cohort.
Conclusion: PCD is associated with much higher levels of resource utiliza-
tion and costs of care, primarily driven by inpt stays. Treating PCD appropri-
ately before the disease progresses to a level requiring hospitalization may
help reduce some of the costs in PCD.
PCD
Comparator
Costs $ Total PMPM % with PCD Dx Total PMPM
Outpt Office Visits 106.06 50 13.91
Outpt Office-Based
Procedures
28.24 96 5.10
ER 69.15 61 6.12
Day Surgery 544.30 89 0.83
Lab 44.53 28 2.67
Inpt 1,409.41 75 18.16
Pharmacy 293.13 32 18.32
Total 2,547.32 70 166.07
Utilization Total PTMPY % with PCD Dx Total PTMPY
Outpt Office Visits 10,733 47 1,971.2
Outpt Office-Based
Procedures
2,000 52 293.7
ER 400 75 72.6
Day Surgery 1,800 65 0
Lab 13,000 39 1,034.3
Inpt Admits 500 73 11.2
Inpt ALOS 7.6 4.4
ALOS-PCD Admits 7.8 N/A
ALOS-Non-PCD
Admits
7.0 N/A
Pharmacy (Per
Member Per Year)
20.3 30 2.3
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Current Physician Extender Utilization Patterns in Community Based
GI Practice
Naresh Gunuratnum, MD∗, Ravi Juluri, MD, Andrew Catanzaro, MD,
Steve Carpenter, MD. Department of Internal Medicine, St. Joseph Mercy
Health System, Ann Arbor, MI and Department of Internal Medicine,
Mercer University School of Medicine, Savannah, GA.
Purpose: Various pressures in medicine demand increased efficiency of
GI patient care models. Physician extenders Nurse Practitioners (NP) and
Physician Assistants (PA) have become essential components in both the
inpatient and outpatient setting. There is a lack of useful data regarding
extender use pattern in community based GI practices.
Methods: Extender use was compared between two busy active gastroen-
terology practices in different geographic locations within the U.S.
Results: Huron Gastroenterology (HG) is a 13 physician practice. This prac-
tice utilizes 5 physician extenders (4 PA’s and 1 NP’s). HG uses one PA
exclusively in the hospital, 3 PA’s in the office and hospital, and the NP
is dedicated to a liver clinic. The Center of Digestive and Liver Health
(CDLH) is an 8 physician practice utilizing 7 physician extenders (3 NP’s
and 4 PA’s). One extender is assigned to inpatient services. 3 extenders
are assigned to assist the primary physician in the office. One extender is
assigned to see urgent follow up patients who have called seeking care.
One NP is dedicated to pediatric gastroenterology. The last extender cov-
ers extender vacations and, also, assists with urgent care. CDLH does not
currently utilize physician extenders for on call coverage or weekends. Pay
range is from 57K-82K depending on experience at both locations. The
ratio of physicians to extenders varies between these two groups due to
group preference (HG: 5 extenders/13 MD’s (38.7%), CDLH: 7 extenders/8
MD’s (87.5%).
Conclusion: Physician extenders may be utilized in all non-endoscopic
phases of community based GI practice to improve access for patients and
facilitate care, yet little data is readily available. As demand for endoscopic
services increases, the utilization of extenders may increase. Salaries for ex-
perienced extenders are considerable, but generally, the cost is made up via
increased patient volume and subsequent revenue. More widely disseminated
information would be useful for GI practices to make informed decisions
regarding the optimal number and utilization of physician extenders, thereby
enhancing practice efficiency and improving patient care delivery. Prospec-
tive studies of quality of care rendered, reimbursement for services, and
patient satisfaction will be beneficial to practices considering expanding the
role of physician extenders in practice.
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Management of Iron Deficiency Anaemia: Are We Meeting the
Guidelines?
Sindhu Ramamurthy, MBBS, Peter Reid, FRCP∗. Department of Medicine,
Countess of Chester Hospital NHS Foundation Trust, Chester, Merseyside,
United Kingdom.
Purpose: Iron deficiency anaemia (IDA) accounts to upto 15% of all referrals
to gastroenterologists. Inspite of the avilability of well establised guidelines
the management of IDA is often suboptimal with most patients, if not at
all being incompletely investigated. The diagnostic criteria for IDA vary
between published studies. This study was done to review the management
of patients with IDA at a district general hospital in UK and determine the
pitfalls in the diagnosis and treatment of these patients.
Methods: A proforma was devised based on the guidelines laid by the British
Gastroenterology Society (BSG) for the management of IDA. Retrospective
review of case notes of all patients with a new diagnosis of IDA between
January 2005 and December 2006 was carried out. Patients with obvious
source of blood loss (melaena, haemtemesis, PR bleed) were excluded form
the study. Elderly and infirm patients who were deemed to be not fit for
further investigations were also excluded from the study.
Results: This retrospective study included 110 patients (24 male, 66 female)
with age ranging from 22 yr-80 yr (median age 66 yr). About a third of the
patients (29%) presented with gastro-intestinal (GI) symptoms. A majority
of the patients (47%) were asymptomatic and IDA was diagnosed following
routine blood tests. In 38% of the patients IDA was secondary to GI causes.
Non GI causes like menorraghia, epistasis, mechanical heart valve attributed
to 12% of cases. 24% of patients with a normal upper GI endoscopy were
discharged without any lower GI investigations. In 18% of patients no further
investigations were arranged after a normal upper and lower GI endoscopy.
20% patients found to have refractory anaemia were referred to specialist
centres for further investigation Most of the patients were managed medically
with oral iron (96%) and parenteral iron (29%) therapy. 24% patients received
blood transfusion, two thirds of which were not indicated as per hospital
blood transfusion guidelines. Long term proton pump inhibitor therapy was
indicated in 49% of patients but was presecribed in only 30% of the patients.
Conclusion: Overall adherence to the BGS guidelines was poor. A care
pathway to guide physicians for investigating and treating patients with iron
deficiency anaemia was recommended. If a GI cause for IDA is not found
after a bidirectional endoscopy then it is necessary to proceed with further
investigations to look for non GI causes.
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Does FNA Improve the Accuracy of Endoscopic Ultrasound in
Evaluating Mediastinal Lymphadenopathy? A Meta-Analysis and
Systematic Review
Srinivas R. Puli, MD, Jyotsna Batapati Krishna Reddy, MBBS, Matthew L.
Bechtold, MD, Jamal A. Ibdah, MD, Mainor R. Antillon, MD∗.
Department of Gastroenterology and Hepatology, University of
Missouri-Columbia, Columbia, MO.
Purpose: The published data on accuracy of endoscopic ultrasound (EUS)
to differentiate inflammatory from neoplastic process in a lymph node has
been varied. This differentiation is crucial for appropriate therapy. The im-
pact of EUS-fine needle aspiration (FNA) in the evaluation of mediastinal
lymphadenopathy is not clear.
Aim: To evaluate the accuracy of EUS alone and EUS with FNA in evaluating
mediastinal lymphadenopathy
Methods: Study Selection Criteria: Only EUS and EUS-FNA studies con-
firmed by surgery or with prolonged follow-up were selected.
Data collection & extraction: Articles were searched in Medline, Pubmed,
Ovid journals, CINAH, and Cochrane controlled trials registry. Two review-
ers independently searched and extracted data. The differences were resolved
by mutual agreement.
Statistical Method: Meta-analysis for the accuracy of EUS was analyzed
by calculating pooled estimates of sensitivity, specificity, likelihood ratios,
and diagnostic odds ratios. Pooling was conducted by both fixed and random
effects models.
Results: Initial search identified 3610 reference articles, in which, 460 rele-
vant articles were selected and reviewed. Data was extracted from 76 studies
(N = 9310) which met the inclusion criteria. Of these, 44 studies used EUS
alone and 32 studies used EUS-FNA. The pooled estimates are shown in table
1. All the pooled estimates, calculated by fixed and random effect models,
were similar. The P for chi-squared heterogeneity for all the pooled accuracy
estimates was > 0.10.
Conclusion: EUS appears to be a good diagnostic tool to evaluate medi-
astinal lymphadenopathy. This meta-analysis shows that FNA substantially
improves the accuracy of EUS in evaluating mediastinal lymphadenopathy.
EUS with FNA should be the diagnostic test of choice in evaluating medi-
astinal lymphadenopathy.
Table 1. Showing the pooled estimated for accuracy of EUS and EUS-FNA in eval-
uating Mediastinal Lymphadenopathy with 95% confidence intervals.
EUS EUS-FNA
Studies 44 32
Pooled sensitivity 84.7% (82.9–86.4) 88.0% (85.8–90.0)
Pooled specificity 84.6% (83.2–85.9) 96.4% (95.3–97.4)
Positive likelihood ratio 3.3 (2.6–4.3) 11.2 (5.9–21.2)
Negative likelihood ratio 0.24 (0.9–0.3) 0.1 (0.1–0.2)
Diagnostic odds ratio 19.1 (12.7–28.5) 106.9 (54.4–210.3)
Area under the curve 0.91 0.97
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Diagnostic Accuracy of Endoscopic Ultrasound in Detecting Distal
Metastasis of Esophageal Cancers: A Meta-Analysis and Systematic
Review
Srinivas R. Puli, MD, Jyotsna Batapati Krishna Reddy, MBBS, Matthew L.
Bechtold, MD, Ajitinder Grewal, MD, Christoper Bartalos, MD, Jack D.
Bragg, MD, Jamal A. Ibdah, MD, Mainor R. Antillon, MD∗. Department
of Gastroenterology and Hepatology, University of Missouri-Columbia,
Columbia, MO.
Purpose: Distal metastasis in patients with esophageal cancer predicts prog-
nosis and guides therapy. The published data on accuracy of endoscopic
ultrasound (EUS) for diagnosing distal metastasis (M1) in patients with
esophageal cancer has been inconsistent.
Aim: To evaluate the accuracy of EUS in diagnosing distal metastasis of
esophageal cancers.
Methods: Study Selection Criteria: Distal metastasis was defined as metas-
tasis to peritoneum, liver, cervical lymph nodes, celiac axis lymph nodes, or
abdominal lymph nodes. Only EUS studies confirmed by surgery were se-
lected. EUS criteria used for nodal invasion were: larger than one centimeter,
hypoechoic, and round.
Data collection & extraction: Articles were searched in Medline, Pubmed,
Ovid journals, and Cochrane controlled trials registry. Two reviewers inde-
pendently searched and extracted data. The differences were resolved by
mutual agreement.
Statistical Method: Meta-analysis for the accuracy of EUS was analyzed
by calculating pooled estimates of sensitivity, specificity, likelihood ratios,
and diagnostic odds ratios. Pooling was conducted by both fixed and random
effects models. The heterogeneity among studies was tested using Cochran’s
Q test based upon inverse variance weights.
Results: Initial search identified 2630 articles, in which, 336 relevant arti-
cles were selected and reviewed. Data was extracted from 25 studies (N =
2029) that met the inclusion criteria. Pooled sensitivity of EUS in diagnosing
nodal involvement by esophageal cancers was 67.2% (95% CI: 62.6–71.6).
EUS had a pooled specificity of 97.9% (95% CI: 97.1–98.6). The posi-
tive likelihood ratio of EUS was 18.5 (95% CI: 10.1–33.9) and negative
likelihood ratio was 0.3 (0.2–0.5). The diagnostic odds ratio, the odds of
having metastasis in positive as compared to negative EUS studies, was 68.9
(35.4–134.1). All the pooled estimates, calculated by fixed and random effect
models, were similar. SROC curves showed an area under the curve of 0.91.
The P for chi-squared heterogeneity for all the pooled accuracy estimates
was > 0.10.
Conclusion: This meta-analysis shows that EUS has a high specificity but
low sensitivity to evaluate distal metastasis of esophageal cancers. Improve-
ments in technology or diagnostic criteria are needed to enhance the sensi-
tivity.
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Efficacy of Proton Pump Inhibitors in Reflux Laryngitis: A
Meta-Analysis and Systematic Review
Srinivas R. Puli, MD, Abhishek Choudhary, MBBS, Jyotsna Batapati
Krishna Reddy, MBBS, Matthew L. Bechtold, MD, Ajitinder Grewal, MD,
Christoper Bartalos, MD, Jack D. Bragg, MD, Praveen K. Roy, MD∗.
Department of Gastroenterology and Hepatology, University of
Missouri-Columbia, Columbia, MO.
Purpose: Gastro-esophageal reflux disease (GERD) can present with atypi-
cal manifestations such as reflux laryngitis (RL). Patients with RL may have
symptoms like hoarseness, chronic throat clearing, and excessive phlegm
and laryngoscopy shows findings indicating posterior laryngeal inflamma-
tion. The efficacy of proton pump inhibitors (PPI) for resolution of laryngeal
symptoms and laryngoscopic findings in RL pts has been varied. The aim of
this meta-analysis was to determine the efficacy of PPI’s in RL.
Methods: We searched for articles in Medline, Pubmed, Ovid journals,
and Cochrane controlled trials registry. Only randomized, double-blind, and
placebo-controlled trials were selected. Pts selection criteria included: age
18 to 80 yrs, use of twice daily PPIs, with symptoms suggestive of RL and
laryngoscopic signs of inflammation, dual probe pH testing documenting
acid reflux, no acid suppressive therapy 2 wks prior to start of trial and
treatment for a minimum of 8 to 12 wks.
Statistics: Pooled effect sizes for mean difference in symptom scores
and laryngoscopic scores were calculated by both fixed and random ef-
fect models. Pooled effect size was expressed as weighted mean difference
(WMD).
Results: 6 randomized, placebo-controlled trials met the study criteria. Of
these, 5 studies (N = 167) reported a mean score of symptoms and laryn-
goscopic findings and were included in this analysis. Treatment follow-up
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periods were 16 weeks in 1 study, 12 weeks in 2 studies and 8 weeks in the
remaining two studies. The WMD between PPI and placebo for laryngeal
symptoms was -0.467 (95% CI = −3.40 to 2.47; test of heterogeneity, P =
0.76). The pooled estimate of WMD in laryngoscopic scores between PPI
and placebo was 0.157 (95% CI = −0.101 to 0.414; test of heterogeneity,
P = 0.98). I statistic gave a 0% insistency (95% CI = 0% to 64.1%). Publi-
cation bias calculated using Begg-Mazumdar bias indicator gave a Kendall’s
b tau value of 0 (P = 0.82) and Egger bias indicator gave a value of −0.12
(95% CI = −1.40 to 1.1, P = 0.81).
Conclusion: Twice daily PPI therapy leads to an improvement in the mean
scores of both laryngeal symptoms and laryngoscopic scores, but the differ-
ences are not significant when compared to placebo. There is a large placebo
effect in patients with RL. Better risk stratification of RL patients including
improved diagnostic tools are needed for this group of patients.
874
Impact of Post-Operative Ileus (POI) on Hospital Length of Stay in
Colectomy Surgery Patients
Shrividya Iyer, PhD∗, William Saunders, PhD. Global Health Outcomes
Assessment, Wyeth Research, Collegeville, PA and Premier Research
Services, Premier, Inc, Charlotte, NC.
Purpose: To study the impact of postoperative ileus (POI) on hospital length
of stay in colectomy patients.
Methods: A retrospective cohort study design was used. Adult patients with
a principal procedure code for partial excision of large intestine (ICD-9
code: 45.71–45.79), discharged between Jan 2004–Dec 2004 were identi-
fied from Premier’s Perspective Comparative Database, an inpatient records
database from over 500 hospitals in the United States. The colectomy pa-
tients were further classified for the presence of POI, by the presence of
paralytic ileus (ICD-9 code 560.1) and/or digestive system complications
(ICD-9 code 994.1) during the study period. Multivariate hierarchical re-
gression analysis was performed with log-transformed length of stay as the
dependent variable. Patient demographics, mortality risk, disease severity,
admission source, payment type, and hospital characteristics were used as
covariates.
Results: A total of 17,896 patients with a primary procedure code for colec-
tomy were identified, of which 3,115 (17.4%) patients had a secondary di-
agnosis of POI, including paralytic ileus (N = 2,732; 15.3%) and digestive
system complications (N = 1,899, 10.6%), with significant overlap between
the two (N = 1516, 8.5%). The majority of colectomy patients with POI
were male (54.9%), Caucasian (70.9%) and in the 51–64 year age group
(51%). The crude average hospital length of stay was significantly higher
(P < 0.001) in colectomy patients with POI (13.75 ± 13.33 days) compared
with patients without POI (8.85 ± 9.49 days). Presence of POI was found to
significantly increase hospital length of stay (antilog b = 1.29, P < 0.001) in
the regression model. Gender (P < 0.01), severity level (P < 0.001), admis-
sion source (P < 0.05) and hospital size (P < 0.05) were other significant
predictors of hospital length of stay.
Conclusion: Postoperative Ileus (POI) is associated with a significant in-
crease in the hospital length of stay in colectomy patients. Prevention of POI
in colectomy patients could potentially decrease hospital length of stay and
reduce costs.
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Long-Term Outcomes of H. Pylori Infection That Was Undiagnosed or
Untreated at First EGD
Stephen J. Sontag, MD∗, Kapil R. Mehta, MD, Thomas G. Schnell, MD,
Jack Leya, MD, Hines-Loyola GI Fellows. GI Section, Hines Veterans
Affairs Hospital, Hines, IL and Gastroenterology, Hepatology and
Nutrition, Loyola University Medical Center, Maywood, IL.
Purpose: Patients with GI Sx are treated with PPI’s, scheduled for EGD,
scoped at a later date, and invariably found to have a “normal” exam. Bx for
H. pylori (HP) infection is not routine. If HP is present, the patient will not
know from the EGD. We claim that ignoring potential HP infection allows
survival of HP sleeper-cells, which may in due course result in HP terror
attacks. The purpose of this study is to investigate the validity of that claim.
Methods: The At-Risk Study Group comprises outpts that had EGD with
gastric Bx at any time during a 4-yr Recruitment Period (RP) from Jan-1998
through Dec-2001. The Study Group was formed from 2 pathways: (1) Pts
who had EGD before the RP and again later in the RP [Began with EGD
before the RP]; and (2) Pts who had EGD in the RP and then again later
some time in the future [Began with EGD in the RP].
Results: The At-Risk Study Group comprises 1207 pts with gastric Bx: 408
have known outcomes (good and bad) and 799 have yet to declare them-
selves. HP-Pos pts had worse outcomes in all parameters. HP-Pos pts had
3.3× greater risk of “any” (major or minor) complications (Hazard Ratio =
0.3; CI:0.2–0.4; P < 0.0001), 5.6× greater risk of “major” complication,
and 1.3× greater “all-cause” mortality. Age, NSAIDs, H2RAs (Multiple
Regression) did not contribute to outcome. PPIs were protective (OR =
3.1).
Conclusion: In Pts having EGD for any reason, the failure to diagnose silent
HP infection or the failrue to treat those patients who tested positive exposes
patients in the decade to come to a 5–6× greater frequency of major GI
complications.[figure1]
Long-Term Complication Rate of HP Neg and Untreated HP Pos
Any Major All-Cause
Complication Complication Mortality
HP-Pos 55.9% 26.3% 29.9%
HP-Neg 18.7% 4.4% 20.2%
Diff (95% CI) 37.2% 21.9% 9.7%
(CI: 30%–40%) (CI: 14%–38%) (CI: 1.4–18%)
P-Value <0.0001 <0.0001 = 0.03
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cag PAI in H. pylori Isolated from Dyspeptic Patients in Tehran, Iran
Leila Shokrzadeh, MSc∗, Keveh Baghai, MSc, Hosein Dabiri, PhD,
Fereshteh Jafari, BS, Navid Sahebekhyri, BS, Mehdi Bolfion, BS,
Mohammad Yaghoobi, MSc, Daryush Mirsattari, MD, Homayun Zojaji,
MD, Noshin Belar, BS, Mohamad Reza Zali, MD, FACG. Food Borne
Disease and Diarrheal, Research Center for Gastroenterology and Liver
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Diseases, Shaheed Beheshti University of Medical Science, Tehran, Islamic
Republic of Iran.
Purpose: The aim of this study was to investigate the prevalence of cagPAI
in H. Pylori isolated from gastritis patients in Tehran, Iran.
Methods: A total of 70 H. pylori strain with positive PCR results for glmM
gene were selected from dyspeptic patients in Tehran, Iran. DNA extraction
from biopsies was performed by QIAamp DNA Mini Kit (QIAGEN GER-
MAN). PCR amplification was used for four loci (cagA, cagG, cagM, cagT)
of cag PAI.
Results: Out of 70 biopsy samples with glmM-positive gene, cagA were
detected in 74.3% (52 of 70) of patients. The prevalence of cagT, cagG
genes were 15%, 10% respectively. cagM gene was not detected in studied
isolates. Co-existence of cagA/cagT , and cagA/cagG were detected in 12 and
7 isolates respectively. We detected 6 H. pylori isolates with cagA negative;
however they carried either cagG or cagT genes. There were 4 isolates which
had three genes (cagA/cagG/cagT) together.
Conclusion: The pathogenic role of the cag PAI as a whole or in part,
in disease development, is not yet completely understood. Although the
most studies were reported that there are correlations between genotyping
of cagPAI and PUD or GC. Finding of this study showed all of isolates from
NUD patients were carried at least one of cagG/cagT/cagA genes. According
to result, the cagA gene could be served as a better marker for the cag PAI.
However, the presence of this single gene does not necessarily indicate the
presence of a complete set of cag PAI genes. Low prevalence of PUD samples
may relate to lack of cagM , whose product is essential for type IV secretion
system. At the end we suggest studding of more genes of cagPAI in patients
with PUD and gastric cancer in large population.
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Prevalence of Gastrointestinal Symptoms and the Influence of
Demographic Factors
Afsaneh Zarghi, MD, MPH∗, Mohamad Amin Pourhoseingholi, PhD,
Manijeh Habibi, MS, Ali Akbar Haghdost, MD, PhD, Ali Solhpour, MD,
Mehdi Moazezi, MD, Ali Ramezankhani, PhD, Mohammad Rostaminejad,
BS, Mohammad Reza Zali, MD, FACG. HSR, Research Center for
Gastroenterology & Liver Diseases, Shaheed Beheshti Medical Sciences
University, Tehran, Islamic Republic of Iran.
Purpose: In this study, we obtained the prevalence of some important gas-
trointestinal symptoms such as nausea, vomiting, rectal bleeding, anorexia,
and weight loss which may point to a structural GI disease. The prevalence
of some of gastrointestinal symptoms relevance with demogrphic factors.
Methods: This is a cross- sectional study with a reliable questionnaire that
was performed during six months in 2006, on random sampling of 1304 peo-
ple of Tehran. After interviews one physician was consulted for symptoms in
respondents. We invited people for an interview and a clinical examination.
Questionnaire was completed in two urban and rural areas.
Results: Mean age of the responders was 34.8 ± 16.6 years (range 12–70).
A mean of 19.6% of subjects reported experiencing at least one of the 11 GI
symptoms. Women were significantly more than men to experience relevant
symptoms. Overall, 100,000 of Iranian population (48.7% men and 51.3%
women). Mean age of the responders was 34.8 ± 16.6 years (range 12–
70). Prevalence of gastrointestinal symptoms included: abdominal pain was
10.1%, constipation 6.2%, diarrhea 1.1%, abdominal bloating 10% dyspep-
sia 11.3% proctalgia 1.5%, nausea and vomiting 1.2%, incontinence o.5%,
GI bleeding 0.7%, weight loss 0.9% dysphagia 0.6%. Some of gastroin-
testinal symptoms were common in married as dyspepsia 14.5%, abdominal
bloating13.2%, abdominal pain 13%, constipation 8.3%, incontinence 0.5%.
We obtained relevance between education & gastrointestinal symptoms as
dyspepsia increased by education: Primery 18.9%, lowerdiploma 10.5%,
diploma 9%, upper diploma 6.5%, Ms or upper 0%. In these population
12–35 age group was 42.9% and 36–70 age group was 57.1%. All of GI
symptoms are common in those of >35 years except diarreh, vomiting,
incontinence.
Conclusion: Dyspepsia is the most common (M = F = 11.3%). Constipa-
tion (F = 7.6% & M = 4.7%) and proctalgia (F = 2.1% & M = 0.8%) are
common in female (P-value < 0.05), and other symptoms are statistically
equal in both female and male. Dyspepsia and constipation are common in
>35 years of female and male but in female is more. Gastrointestinal symp-
toms and symptom complex are common in older people in Iran community.
Gastrointestinal symptoms were common in married and low education. It is
no relevance between insurance and gastrointestinal symptoms in this study.
878
The Role of cagE, oipA, cagA and vacA Genes of Helicobacter pylori
in Iranian Dyspepsia Patients
Kaveh Baghai, MSc∗, Leila Shokrzadeh, MSc, Hosein Dabiri, PhD,
Fereshteh Jafari, BS, Mehdi Bolfion, BS, Mohammad Yaghoobi, MSc,
Daryush Mirsattari, MD, Homayon Zojaji, MD, Mohammad Reza Zali,
MD, FACG. Departement of Food Borne and Diarrheal Disease, Research
Center of Gastroenterology and Liver Disease, Shaheed Beheshti
University of Medical Sciences, Tehran, Islamic Republic of Iran and
Biology Faculty, Shaheed Beheshti University of Medical Sciences, Tehran,
Islamic Republic of Iran.
Purpose: The aims of this study was determination of the association be-
tween the cagE, oipA, cagA, vacA, genes and clinical manifestations.
Methods: A total of 60 gastric biopsies from 60 patients who were qualified
for endoscopies of the upper gastrointestinal were included in this study.
The genomic DNA was extracted from biopsy samples by Qiagen tissue kit.
The status of the cagE, oipA cagA, vacA genes was studied by using the
polymerase chain reaction (PCR) method.
Results: In all of selected specimens, glmM gene was used as a screening
test for confirmation of helicobacter pylori. cagA, cagE, and oipA genes
were present in 42(70%), 17(28%), and 37(61%) of 60 samples respectively.
11 (18.3%) of patients were classified in PUD group and 49(81%) were
in NUD group. in PUD patients, 5(45%) were positive for cagA whereas
6(54%) were positive for cagE. five of ulcerative samples have oipA. genes.
Interestingly all of cagA positive samples were positive for cagE and oipA
too. All of ulcerative samples were vacA m2 positive. s1m2 was predominant
genotype in all PUD patients.
Conclusion: Current study demonstrated high frequency of cagA and low
prevalence of cagE in studied samples which shows may in spite of some
other studies, cagA is better marker of cagPAI than cagE. Since cagE was
positive in 54% of PUD in compare to 22% in NUD patients, this study
suggest that presence of cagE is better probe for prognosis of ulcer formation.
Overall we conclude presence of cagE and oipA beside of vacA s1m2 may
be helpful in prediction of ulcer formation in H. pylori infected patients.
Finally we suggest performing this kind of study in large scale.
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Clinical Outcomes of Helicobacter pylori Infection in Relation to vacA
and cagA Genotypes in Iranian Patients
Hosein Dabiri, PhD∗, Fereshteh Jafari, BS, Leila Shokrzadeh, MSc, Kaveh
Baghai, MSc, Mohammad Mehdi Aslani, PhD, Mahsa Molaei, MD,
Homayun Zojaji, MD, Faramarz Derakhshan, MD, Mohammad Reza Zali,
MD, FACG. Department of Food Borne Disease, The Research Center of
Gastroenterology and Liver Disease of Shahid Beheshti University, Tehran,
Islamic Republic of Iran and Department of Medical Microbiology, Iran
Pasture Institute, Tehran, Islamic Republic of Iran.
Purpose: The aims of this study were to evaluate the role of vacA genotyping
with respect to gastric inflammation and injury, and clinical presentation in
Iranian populations.
Methods: Genomic DNA from biopsy specimens from patients with gas-
tritis, peptic ulcer disease and gastric cancer were characterized by ureC
(glmM), cagA and vacA genotyping by polymerase chain reaction (PCR).
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Results: Our results showed that 96 (57%) of 167 patients with gastro duo-
denal diseases, 19 of 33 gastroduodenal ulcer and 3(60%) of 5 gastric cancer
were infected with H. pylori. In this study 19.8% strains were isolated from
patients with PUD and 68.7% from patients with NUD.s1m2 genotype was
observed in 36.8%, of PUD and 40.5% NUD patients.
Conclusion: Prevalence of cagA positive (76%) in Iran is close to that of
Europe and North America (60–70%) than Asian countries (90%). Regarding
the vacA gene, 97% (93 of 96) of H. pylori positive patients determined
by ureC (glmM) PCR were successfully detect the vacA gene. The vacA
s1m2 was predominant genotype in Iran (41%). The prevalence of s2m1
(8.3%) was high in Iranian isolates. Although individuals who infected with
H. pylori possessing the cagA (+) gene and vacA m2 genotypes were more
sensitive to development of gastroduodenal disease but we could not find
any significant correlation between cagA status and PUD, because of similar
high cagA gene positivity in the H. pylori strains isolated from PUD (78.6%)
and NUD (74.3%). CagA status cannot be used as a useful marker to predict
the outcome of the infection in patients in Iran.
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Non-Cutaneous Head and Neck Cancer in Solid Organ Transplant
Recipients
Saurabh S. Dhawan, MD, Thomas H. Costello, MD, Agnes Lo Costello,
BSP, PharmD, Merry E. Sebelik, MD, Brea Olson, BSc∗, A. Osama Gaber,
MD. Internal Medicine, University of Tennessee Health Science Center,
Memphis, TN; Otolaryngology, Head and Neck Surgery, University of
Tennessee Health Science Center, Memphis, TN; Pharmacy, University of
Tennessee Health Science Center, Memphis, TN and Transplant Surgery,
University of Tennessee Health Science Center, Memphis, TN.
Purpose: Head and neck cancer is the most common site of cancer in the
transplant population. The goal of this study was to examine the nature and
behavior of non-cutaneous head and neck cancer (NCHNC) in solid organ
transplant recipients at the University of Tennessee Health Science Center.
Methods: Cases of post transplant de novo non-cutaneous head and neck
cancer diagnosed between 1995 and 2002, were compared with the general
population (SP) using data from the National Cancer Institute.
Results: During the 8 year period, 1120 solid organ transplantation (TXP)
were carried out. Six cases of NCHNC were identified. The incidence of
SCC of the head and neck was 0.5% (6/1120). 5/6 patients had history of
smoking and 5/6 of post-transplant diabetes mellitus. The median age at TXP
was 51 years (41 to 59 years). 5/6 patients were Caucasian and 1/6 African-
American. 5/6 patients were male and 1/6 female. The median time to first
diagnosis of cancer was 2.5 years (4 months to 13 years) after TXP. NCHNC
was the first de novo cancer in all patients. All the patients died. 4/6 patients
died of causes related to non-cutaneous head and neck cancer and 2/6 died
of other cancers. The median survival after diagnosis of cancer was 14.7
months (90 days to 2.9 years). The median age at diagnosis of NCHNC in
the GP was 62.8 years and survival after diagnosis was 26 months. Although
the median age at diagnosis of NCHNC is not statistically different from the
GP (P value = 0.156), the survival curve of these patients is poor compared
to the GP (P value = 0.0217).
Conclusion: Although, the incidence NCHNC was 0.5%, it was the first post-
transplant malignancy to be diagnosed in all our cases. History of smoking
and post-transplant diabetes was commonly found in NCHNC in solid organ
transplant recipients. These patients should undergo routine screening for
NCHNC, which if occurs may be the first post-transplant malignancy in
these patients, has a shorter survival and higher mortality compared to the
GP.
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Statin Use and the Risk of Colorectal Cancer in Patients with Diabetes
Christine Yeh, MD, Robert Morgan, PhD, Michael Johnson, PhD, Mark
Kuebeler, MS, Hashem El-Serag, MD, MPH∗. Health Services Research,
Baylor College of Medicine, Houston, TX.
Purpose: Colorectal cancer (CRC) is one of the leading causes of cancer
deaths worldwide. Experimental data indicate a possible prevention effect for
statins in CRC. However, the available epidemiological data are conflicting.
Methods: We conducted a nested case-control study within a cohort of vet-
erans with diabetes identified by ICD 9 codes or medication use in national
VA databases. The records were also linked to Medicare files to maximize
the probability of capturing health care encounters among dual VA-Medicare
users. Cases were defined as incident CRC during 1/2001–12/2002 without
prior history of lung, pancreas, stomach, esophagus, breast, or liver cancer
prior to index date. Cases were individually matched on age and incidence
density to four controls without CRC. Patients with incomplete Medicare
enrollment, HMO-Medicare enrollment, or no VA pharmacy use were ex-
cluded. VA Pharmacy Benefits Management files were used to identify filled
statin prescriptions including type, dose, and duration. Multivariable con-
ditional logistic regression models were used to estimate odds ratios after
adjusting for confounding variables.
Results: The cohort comprised of 763,807 veterans with diabetes. A to-
tal of 6080 cases and 24,320 matched controls were examined. The mean
age was 74 and the majority of patients were Caucasian (88%) and/or male
(99%). The mean duration between entry into cohort and CRC index date was
2.3 years. Filled statin prescriptions were recorded less frequently in cases
(49%) than in controls (52%); OR, 0.88; 95% CI 0.83–0.93. This inverse
association remained significant after adjusting for inflammatory bowel dis-
ease, severity of diabetes, cholecystectomy, liver disease, use of aspirin or
NSAIDs, or colon evaluation by endoscopy, imaging, or fecal occult blood
testing. Longer durations of filled statin prescriptions were associated with
greater risk reduction in CRC: OR, 0.89; 0.84–0.94 (6 months), OR, 0.86;
0.81–0.92 (12 months), OR, 0.85; 0.79–0.91 (18 months), OR, 0.83; 0.76–
0.90 (24 months). Simvastatin comprised the majority of statin use (87%)
and the findings were very similar to those of any statin. No significant asso-
ciations were observed between CRC and non-statin cholesterol (OR, 1.02;
0.88–1.18) or triglyceride lowering medications (OR, 0.96; 0.87–1.05).
Conclusion: The use of statins was associated with a significant reduction
(∼10%) in the risk of CRC in patients with diabetes. This risk reduction
seems to be greater in patients with longer duration of statin use.
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Influence of Esophagogastroduodenoscopy (EGD) on Prescription (Rx)
Fill Patterns for Proton Pump Inhibitors (PPIs) and Nonselective
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) among Type-2
Diabetic (T2D) and Nondiabetic Patients
Linda C. Koo, PhD, Roger Luo, PhD, Jeremy Levinson, John T. Monyak,
PhD, Debra G. Silberg, MD, FACG∗. AstraZeneca LP, Wilmington, DE.
Purpose: To examine the effect of EGD on Rx fill patterns for PPIs and
nonselective NSAIDs in T2D and nondiabetic patients.
Methods: Data on patients aged ≥18 y in the MarketScan administrative
claims database with full enrollment data for 180 d pre- and post-EGD from
2000–2005 were extracted (D9612L00108). EGD was identified by CPT
codes; T2D patients were identified as having ≥2 medical claims for T2D
by ICD-9 codes or ≥2 oral antidiabetic Rxs; and nondiabetic patients were
identified as having no ICD-9 codes for any type of diabetes or Rxs for
antidiabetic medications. PPI and nonselective NSAID use were defined by
national drug codes. T2D patients who underwent EGD were matched 1:1
with nondiabetic patients by age and gender. McNemar’s test was used for
proportion differences pre- and post-EGD; χ2 tests were used for differences
between independent cohorts.
Results: Of the 10,546,828 patients in the MarketScan database, 9,373,650
had no diabetes; 953,766 had T2D; 219,412 had other types of diabetes.
In the matched population (N = 39,636 for each group), post-EGD, Rx
fills increased for PPIs and decreased for nonselective NSAIDs (Table).
Among patients already taking PPIs, 80.3% continued to use them post-
EGD. Among patients not taking PPIs pre-EGD, 38.3% began using them
post-EGD. The percentage of patients adding a PPI post-EGD was higher
(P < .0001) for patients using (44.6%) than not using nonselective NSAIDs
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(37.9%). Of patients who took nonselective NSAIDs, 56.7% discontinued
use post-EGD, and this proportion was lower (P < .0001) in patients who
took (52.4%) than those who did not take concomitant PPIs (59.9%). No
meaningful differences were seen between the T2D and nondiabetic groups.
Conclusion: PPI use increased and nonselective NSAID use decreased post-
EGD. Most patients who took only a nonselective NSAID pre-EGD discon-
tinued NSAID use or had a PPI added to their regimen post-EGD. These
results suggest that EGD findings had a direct effect on Rx fill patterns.
Rx Fills for PPIs and Nonselective NSAIDs Pre- and Post-EGD
Absolute Percentage
Pre-EGD Post-EGD Change Change
EGD patients (%) (%) (%) (%)
PPIs
T2D (N = 39,636) 36.7 54.2 17.5∗ 47.7
Nondiabetic (N = 39,636) 35.9 53.0 17.1∗ 47.6
Nonselective NSAIDs
T2D (N = 39,636) 7.6 6.2 −1.4∗ −18.4
Nondiabetic (N = 39,636) 6.2 5.0 −1.2∗ −19.4
∗P < .0001
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Frequent Nighttime Symptoms and Increased GERD Symptom
Severity Are Associated with Impaired Functioning
James McGuigan, MD, Lawrence Johnson, MD, Daniel Aguilar, MPH,
Bonnie Dean, PhD∗, William Orr, PhD, Ronnie Fass, MD, Ning Yan, MD,
Diana Morgenstern, MD, Robert Dubois, MD. Cerner LifeSciences,
Beverly Hills, CA; University of Alabama, Birmingham, AL; University of
Florida, Gainesville, FL; Lynn Health Science Institute, Oklahoma City,
OK; University of Arizona, Tucson, AZ and Wyeth Pharmaceuticals,
Collegeville, PA.
Purpose: To assess health-related quality of life (HRQOL) among GERD
patients stratified by symptom severity and by nighttime symptoms.
Methods: A sample of US adults participated in a web survey including a
validated GERD screener. Frequency and severity of nighttime and daytime
heartburn and acid regurgitation during the previous 3 months were each
assessed. The highest value reported for symptoms during the daytime or
nighttime was assigned to assess severity (10-point Likert scale). Severity
classification was: mild (1–4), moderate (5–7) and severe (8–10). Nighttime
GERD (NTG) cases were defined as: (a) symptoms ≥2 nights/wk with or
without daytime symptoms, or (b) cases without daytime symptoms but
at least one night/wk with symptoms. SF-36 Mental Component Summary
(MCS) and Physical Component Summary (PCS) scores were calculated and
mean scores were compared for NTG vs Daytime GERD (DTG) (t-tests),
and by severity (ANOVA). Lower scores signify worse HRQOL.
Results: 2,805 of 18,213 invited to participate responded. 2,603 (mean age =
46 years, 55% women) satisfied the study criteria. Among 668 cases with
current GERD symptoms, 303 had NTG and 365 had DTG; 664 cases had
severity data: 155 were mild, 341 moderate, and 168 severe. GERD cases with
NTG had lower MCS and PCS scores compared with DTG cases (Table 1;
P < 0.05). Among individuals with GERD, as GERD severity increased,
MCS and PCS scores significantly decreased (Table 2; P < 0.05). Differences
between moderate and severe groups were twice as large as differences
between mild and moderate groups.
Conclusion: HRQOL is significantly worse in patients with nighttime GERD
symptoms. Symptom severity is also associated with decreased HRQOL.
These findings suggest that even partial improvement in symptom severity or
reduction in nighttime symptoms may lead to improved mental and physical
functioning among symptomatic GERD patients.
Table 1. Mean MCS and PCS Scores for NTG vs DTG
NTG (N = 303) DTG (N = 365)
MCS 40.8 43.2
PCS 41.6 43.5
Table 2. Mean MCS and PCS Scores by GERD Severity
Mild (N = 155) Moderate (N = 341) Severe (N = 168)
MCS 44.6 42.8 38.2
PCS 44.8 43.4 39.0
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The Relationship between Atypical GERD Manifestations and Sleep
Impairment
Ronnie Fass, MD, Brian Calimlim, MS, Daniel Aguilar, MPH, Bonnie
Dean, PhD∗, James McGuigan, MD, Lawrence Johnson, MD, William Orr,
PhD, Ning Yan, PhD, Diana Morgenstern, MD, Robert Dubois, MD.
Cerner LifeSciences, Beverly Hills, CA; University of Alabama,
Birmingham, AL; University of Florida, Gainesville, FL; Lynn Health
Science Institute, Oklahoma City, OK; University of Arizona, Tucson, AZ
and Wyeth Pharmaceuticals, Collegeville, PA.
Purpose: To assess sleep impairment among GERD patients experiencing
frequent nighttime atypical manifestations of GERD.
Methods: A sample of US adults participated in a web survey including a
validated GERD screener. Frequency of nighttime atypical GERD manifes-
tations during the previous 3 months was assessed. Frequent symptoms were
defined as atypical manifestations ≥2 nights per week for each manifesta-
tion. Sleep impairment during the previous 3 months was assessed using a
five-category ordinal scale. The proportion with sleep impairment (ie, those
reporting sleeping poorly often or most of the time) was compared for GERD
cases with versus those without each nighttime atypical manifestation using
the chi-square adjusting for multiple comparisons.
Results: 2,805 of 18,213 invited to participate responded. 2,603 satisfied
the study criteria (mean age = 46 years, 55% women); 701 were GERD
cases. Overall, 74% of GERD cases reported at least one nighttime atypical
manifestation. For almost every daytime and nighttime atypical manifesta-
tion assessed, more than 20% of GERD patients reported their occurrence
as frequent (≥2 days or nights per week). For 8 of the 9 nighttime atypi-
cal manifestations assessed, the proportion of GERD cases reporting sleep
Percent with Sleep Impairment for GERD cases
with vs without frequent atypical manifestations
Infrequent or Frequent
no manifestation manifestation
% with sleep impairment P-value
Fullness in Throat 35.5 62.1 <.0001
Sinusitis 35.1 51.7 .0001
Coughing 35.7 54.2 <.0001
Throat Clearing 33.7 53.2 <.0001
Sore Throat 37.0 59.2 <.0001
Snoring 39.9 44.6 NS
Wheezing 37.9 56.7 <.0005
Choking 39.1 63.1 <.0004
Non-cardiac Chest Pain 35.8 62.2 <.0001
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impairment was significantly higher for GERD cases with the atypical man-
ifestation compared with GERD cases without the atypical manifestation.
Conclusion: Most atypical GERD manifestations affected quality of sleep
as perceived by individuals with GERD. Awareness of this relationship may
assist in the management of these patients.
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Prevalence of Sleep Impairment among Adults with GERD
William Orr, PhD, Brian Calimlim, MS, Daniel Aguilar, MPH, Bonnie
Dean, PhD∗, Lawrence Johnson, MD, Ronnie Fass, MD, James McGuigan,
MD, Ning Yan, PhD, Diana Morgenstern, MD, Robert Dubois, MD.
Cerner LifeSciences, Beverly Hills, CA; University of Alabama,
Birmingham, AL; University of Florida, Gainesville, FL; Lynn Health
Science Institute, Oklahoma City, OK; University of Arizona, Tucson, AZ
and Wyeth Pharmaceuticals, Collegeville, PA.
Purpose: To identify and characterize possible sleep impairment among
patients with GERD.
Methods: A general population of US adults participated in a web-based
survey including the GERD Symptom & Medication Questionnaire, a val-
idated GERD screening tool to determine GERD status. Nighttime GERD
(NTG) cases were defined as: (a) symptoms ≥2 nights/week with or without
daytime symptoms, or (b) individuals without daytime symptoms but at least
one night/week with symptoms. Daytime GERD (DTG) cases were GERD
cases not satisfying NTG criteria. Respondents not meeting the above cri-
terion served as controls. Sleep impairment was compared for GERD cases
versus controls and for NTG versus DTG during the previous 3 months using
the chi-square test for trend.
Results: 2,805 of 18,213 invited to participate responded. 2,603 satisfied the
study criteria (mean age = 46 years, 55% women); 701 were GERD cases.
Among symptomatic GERD cases (N = 668); 303 met NTG criteria and 365
met DTG criteria. GERD cases had a higher prevalence of sleep impairment
than controls (41.9% vs 19.4%; P < 0.0001) (Table 1). NTG cases reported
significantly more sleep impairment than DTG cases (49.5% vs 36.7%; P =
0.0003)(Table 2).
Conclusion: GERD in general, and especially NTG symptoms, is associated
with significant sleep disruption. Awareness of nighttime reflux and associ-
ated sleep complaints should allow more complete evaluation and treatment
of GERD patients.
Distribution of sleep impairment by GERD vs Controls
GERD Controls
(N = 701) (N = 1902)
Sleep impairment % distribution
Slept well almost all of the time 9.8 23.8
Slept well most of the time 19.3 30.8
Occasionally had trouble sleeping 29.0 26.1
Often had trouble sleeping 26.1 12.9
Slept poorly most of the time 15.8 6.5
P < 0.0001 for chi square test of distribution
Distribution of sleep impairment by NTG vs DTG
NTG (N = 303) DTG (N = 365)
Sleep impairment % distribution
Slept well almost all of the time 6.0 11.5
Slept well most of the time 17.8 20.0
Occasionally had trouble sleeping 26.7 31.8
Often had trouble sleeping 29.7 23.8
Slept poorly most of the time 19.8 12.9
P = 0.0003 for chi square test of distribution
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Exploratory Study Examining the Risk of Gastrointestinal Bleeding
for Patients on Selective Serotonin Reuptake Inhibitor Therapy
Smita Kothari, PhD, Michael Jones, MD∗, Stacey Long, MS. TAP
Pharmaceuticals Products, Inc., Lake Forest, IL; Northwestern University,
Chicago, IL and Thomson Healthcare, Cambridge, MA.
Purpose: Selective Serotonin Reuptake Inhibitors (SSRIs) are highly used
in the treatment of depression; however their use has been associated with
bleeding. There is current debate in the literature whether SSRIs are asso-
ciated with gastrointestinal bleeding (GIB). This exploratory, retrospective
claims-based analysis aimed to compare the incidence of GIB in patients
continuously using SSRIs for at least 6 months compared with age and sex
matched controls and examine factors that may be associated with the risk
of GIB among SSRI users.
Methods: The MarketScan database (2001–2005) was used to identify pa-
tients ≥ 18 years, newly initiated on SSRI therapy. Inclusion criteria: con-
tinuous enrollment in the 12 months before and after the first SSRI pre-
scription (index claim); consecutive SSRI use without a gap of >31 days
between prescriptions for at least 6 months. Exclusion criteria: received an
SSRI prescription or had a GIB diagnoses within 1 year before the index
claim. Logistic regression examined impact of age, gender, exposure (days
supply of filled prescriptions) of SSRI, NSAID, gastrotoxic agents (GTAs;
warfarin, corticosteroids, antiplatelets and calcium channel blockers), and
gastroprotective agents (GPAs; proton pump inhibitors, histamine2-receptor
antagonists) on odds of GIB.
Results: Sample had 149,647 SSRI users that met the inclusion criteria; mean
SSRI exposure in follow-up period was 358 days (SD 79). SSRI incidence
of GIB was 8.3/1000, compared to 6.4/1000 in controls. Percent use of
NSAID, GTA, and GPA in SSRI patients ranged from 24–36% in the pre
or post period. Mean days (across all patients) of NSAID, GTA, and GPA
exposure was 39, 63, and 53 in the pre-period, and 48, 89, and 75 days in the
follow-up period. Compared to 18–34 year old SSRI users, those 65+ years
were 12 times(x) more likely to have GIB, rates were 6× and 3× higher for
those aged 55–64 and 45–54. Female SSRI users were 1.4× more likely to
have GIB compared to males. GTA users were 2% more likely to have GIB
for each additional 30 days of exposure (pre-period or follow-up period).
Conclusion: New SSRI users were 1.3× more likely than controls to ex-
perience GIB. Among SSRI patients, older age, females, and use of GTAs
were associated with having GIB. Additional research will investigate time
to onset of GIB, and the influence of GIB events on subsequent SSRI, GTA,
NSAID, and GPA use in the SSRI population.
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Impact of Sleep Difficulties on Economic and Humanistic Outcomes in
GERD/Heartburn Sufferers
Reema Mody, PhD∗, Susan Bolge, PhD, Hema Kannan, MPH. TAP
Pharmaceutical Products Inc., Lake Forest, IL and Consumer Health
Sciences, Princeton, NJ.
Purpose: To study the association of GERD/heartburn (HB) and timing
of its symptoms with sleep difficulties and the impact of sleep difficulties
on health-related quality of life (HRQOL) and resource use in GERD/HB
sufferers.
Methods: Data were from the 2006 US National Health and Wellness Survey,
a nationally representative, Internet-based survey of the health status, atti-
tudes, behaviors, and outcomes of adults. Those reporting GERD/HB in the
past 12 months (N=21,250) were compared with non-sufferers (N=41,583)
on 3 sleep difficulties outcomes: induction (difficulty falling asleep), main-
tenance (difficulty staying asleep/waking too early), and sleep-related diffi-
culties (self-report of insomnia, sleep difficulties, induction or maintenance)
for 2+ times a week. Among GERD/HB sufferers, those with GERD/HB
problems during the day only (DO)[13.3%], at night only (NO)[28.2%], or
during both day and night (DAN)[58.5%] were compared. Regression mod-
els were used to determine the independent effects of GERD/HB and its
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timing on sleep difficulties and the impact of sleep difficulties on resource
use and HRQOL, assessed by SF-8.
Results: GERD/HB sufferers were significantly (P < 0.001) more likely to
experience sleep-related difficulties(73 v 56%), induction(47 v 32%) and
maintenance(63 v 46%) than non-sufferers. Controlling for demographics
and comorbidities, GERD/HB sufferers were more likely to experience sleep-
related difficulties (OR = 1.54, 95% CI = 1.48–1.60), induction (OR = 1.41,
CI = 1.36–1.47), and maintenance (OR = 1.45, CI = 1.40–1.50) than non-
sufferers. GERD/HB sufferers with sleep difficulties had significantly lower
SF-8 physical and mental summary scores and reported more ER visits, days
hospitalized, and provider visits in the past 6 months than those without sleep
difficulties. A greater proportion of DAN sufferers experienced sleep-related
difficulties(77 v 66 v 70%), induction(52 v 38 v 42%) and maintenance(67
v 55 v 59%) than DO or NO sufferers (P < 0.001). Controlling for de-
mographics, comorbidities, and GERD/HB treatment, DAN sufferers were
more likely to experience sleep-related difficulties (OR = 1.43, CI = 1.30–
1.57), induction (OR = 1.45, CI = 1.32–1.58), and maintenance (OR =
1.44, CI = 1.32–1.57) compared to DO sufferers.
Conclusion: Those with GERD/HB, chiefly DAN sufferers, are more likely
than non-sufferers to experience sleep difficulties, mainly maintenance. The
study provides quantitative evidence about the negative impact of sleep dif-
ficulties on resource use and HRQOL in GERD/HB sufferers.
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Utility of Screening Coagulation Studies in Gastrointestinal Bleeding
Patients without Risk Factors for Coagulopathy Admitted to the
Intensive Care Unit
Angelo H. Paredes, MD, Viet-Nhan H. Nguyen, DO∗, Corrine L.
Maydonovitch, BS. Department of Gastroenterology, Walter Reed Army
Medical Center, Washington, DC.
Purpose: Measurement of prothrombin time (PT), international normaliza-
tion ratio (INR) and partial thromboplastin time (PTT) for patients admitted
to the ICU with gastrointestinal bleeding (GIB) is routinely done regardless
of risk factors for bleeding. This is a retrospective study to determine the per-
centage of abnormal PT/PTT/INR requiring correction prior to endoscopy
in a cohort without risk factors for bleeding, and to evaluate if abnormal val-
ues are independent risk factors for rebleeding, hospital mortality, prolonged
ICU and hospital stay.
Methods: Retrospective chart review of 300 consecutive admissions from
the ED to the ICU for gastrointestinal bleeding. A total of 175 patients
were identified as not having risk factors for bleeding disorders (defined as
alcohol abuse, liver disease, and active use of anticoagulants). These patients
were divided into normal (INR≤1) and abnormal (INR>1) cohorts. The
percentage of patients requiring correction of coagulopathy was calculated.
Also, length of stay in the ICU, total days in the hospital, rebleeding, and
hospital mortality among the cohorts were compared.
Results: Five (5) of 175 admissions (3%) without risk factors for bleeding
disorders underwent correction of their INR with fresh frozen plasma at
time of admission. Cause of abnormal INR in all patients was attributed to
malnutrition. Seventy-three patients had normal INR, and 102 had abnormal
INR on admission. These two cohorts did not differ significantly in age,
gender, and comorbidities as measured by the Charlson Comorbidity Index.
There was no statistically significant difference in hospital mortality, inhouse
rebleeding, and total days in the hospital between the two groups. The cohort
with abnormal INR had a statistically signficant longer length of stay in the
ICU (3.6 vs 2.7 days, P = 0.002).
Conclusion: It is uncommon for GIB patients without risk factors for bleed-
ing disorders to present with abnormal coagulation tests that require cor-
rection. Abnormal INR is an independent risk factor for prolonged stay in
the ICU by our observation. Prospective trials are needed to validate these
findings.
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Is Obesity the Cause of Reduced Healing Rates in Advanced Grades of
Erosive Esophagitis (EE)?
Nimish Vakil, MD, FACG, Prateek Sharma, MD, FACG, John T. Monyak,
PhD, Debra G. Silberg, MD, FACG∗. University of Wisconsin Medical
Center, Milwaukee, WI; University of Kansas Medical Center, Kansas City,
MO and AstraZeneca LP, Wilmington, DE.
Purpose: Obesity increases the transgastric pressure gradient and thereby
predisposes to acid reflux. To determine whether BMI affects healing of
different grades of EE in patients treated with proton pump inhibitors
(PPIs).
Methods: This was a pooled analysis of 5 randomized, double-blind, mul-
ticenter clinical studies of similar design that compared esomeprazole 40
mg once daily to either omeprazole 20 mg once daily (SH-QBE-0013, -
0016, and –0052) or lansoprazole 30 mg once daily (D9612C00083 and
D9612L00046). Eligible patients were aged 18 to 75 y and had EE verified
within 1 week of randomization by endoscopy and graded using the Los An-
geles (LA) classification system. Endoscopy was repeated at 4 and 8 weeks to
assess healing of EE, defined as no esophageal erosions. Healing rates were
combined for all PPIs, assessed according to baseline LA grade (A, B, C,
or D), and grouped according to BMI category. Logistic regression models
(LRMs) were fit with healing of EE at the end of the study as the dependent
variable and BMI as a continuous independent variable. The LRM adjusted
for treatment, study, baseline LA grade, age, sex, race, H pylori result, and
presence of hiatal hernia. A second LRM was also fit to test for interaction of
BMI with the other factors. A χ2 test was performed to test for differences
in the percentage of patients in each BMI category with severe (LA grade C
or D) EE.
Results: This analysis included 11,027 patients. Healing rates at 8 weeks
were comparable among the BMI categories (Table). The LRMs showed
no significant effect of BMI on healing: P = .2286; odds ratio, 1.006 (95%
CI, 0.996–1.016). However, baseline LA grade was significantly (P < .0001)
associated with healing, with decreased odds of healing for higher LA grades.
No interaction effects with BMI were found.
Conclusion: BMI had no detectable effect on healing of EE in patients
treated with PPIs. Lower rates of healing after 8 weeks of treatment in patients
with high grades of EE are not likely due to obesity.
Healing rates by BMI and baseline LA grade categories
Baseline EE BMI Group N Healing Rate (%)
A < 25 785 89.0
25 to < 35 2,186 91.4
≥35 506 91.5
B < 25 635 83.5
25 to < 35 2,629 86.9
≥35 683 85.4
C < 25 278 81.7
25 to < 35 1,944 79.5
≥35 437 78.7
D < 25 107 72.9
25 to < 35 614 70.4
≥35 123 71.5
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Impact of Steroid Discontinuation on Health Care Resource
Utilization in Crohn’s Disease
B.G. Feagan, MD∗, E.V. Loftus, MD, M.A. Kamm, MD, J. Chao, P. Mulani.
London Health Sciences Centre, University of Western Ontario, London,
ON, Canada; Mayo Clinic College of Medicine, Rochester, MN; St. Mark’s
Hospital, Harrow, United Kingdom and Abbott, Abbott Park, IL.
Purpose: Steroid use (SU) is associated with considerable morbidity, there-
fore the economic impact of SU in Crohn’s disease (CD) could be important.
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Steroids could also be surrogates for disease severity. This study determined
whether discontinuation of SU among patients (pts) with CD lowers CD-
related health care costs.
Methods: 9,811 pts with CD-related SU were selected from an Integrated
Health Care Information Services (IHCIS) managed-care database (1999–
2005). Index date is the first date of CD-related SU (CD within the past 30
days) after 3-month continuous insurance coverage eligibility. Pts with SU
60–90 days after the index date were steroid maintainers (SM). All others
were steroid discontinuers (S-). Health care costs (total and CD-related) of S-
and SM were evaluated over 3 months and compared descriptively. The same
groups were then controlled for baseline (BL) characteristics (demographics,
comorbidities, BL CD-related and non-CD related costs) using a regression-
adjusted (Reg-Adj) model and compared. Costs were inflation-adjusted to
year 2005 in US dollars ($).
Results: Of the 9,811 CD pts selected, 5,614 were S- and 4,197 were SM.
Mean age was 43.1 years for both groups, with 44.4% (S-) and 46.7% (SM)
males. Both groups had similar prior total and CD-related costs. In the follow-
up period, both total and CD-related costs were statistically significantly
lower for S- when compared with SM (both P < 0.01) (table). Total and
CD-related Red-Adj costs were statistically significantly lower for S- when
compared with SM (both P < 0.01). Significantly lower CD-related costs
were observed for all components of S-, including inpatient, outpatient, and
prescription drug costs.
3-Month Health Care Costs by Steroid-Use Status
Descriptive Costs, US $ Reg-Adj Costs, US $
Total CD-related Total CD-related
SM (N = 4,197) 10,786 5,270 9,513 5,352
S- (N = 5,614) 7,759∗ 3,275∗ 8,477∗ 3,209∗
∗P < 0.01, S- vs. SM for respective cost groups.
Conclusion: Significant total costs were observed for patients with contin-
uous steroid use. Steroid discontinuation was significantly associated with
lower total and CD-related health care costs. These results demonstrate that
continuous steroid use may have significant cost implications for society and
third-party payers. Therapies that help patients taper off steroids may yield
cost savings.
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Gender Differences and Bariatric Surgery Outcome
Inessa Khaykis, MD, Christine J. Ren, MD, George A. Fielding, MD,
Warren Huberman, PhD, Barrie Wolfe, RD, Heekoung Youn, RN, Stefanie
Hong, Fritz Francois Francois, MD, Elizabeth Weinshel, MD∗.
Gastroenterology, New York University Hospital, New York, NY; Surgery,
New York University Hospital, New York, NY and Psychiatry, New York
University Hospital, New York, NY.
Purpose: Bariatric surgery is an effective treatment for obesity, however it
does not lead to equal results in every patient. Although the prevalence of
obesity in women in the US parallels the increase in men, little data exists
on differences in predictors of bariatric surgery outcome between men and
women. The aim of this study was to identify gender differences in predictors
of weight loss success in the first year after bariatric surgery.
Methods: The charts of all patients who underwent laparoscopic adjustable
gastric banding (LAGB) or Roux-en Y gastric bypass (RYGB) between
10/1/2000 and 10/31/2005 were reviewed. Demographic data, social his-
tory, past psychiatric history, personal and family history of obesity, self and
professionally assessed eating behavior, as well as post-op data on excess
body weight loss at 1, 3, 6 and 12 months follow-up were collected for each
patient. Post-op weight loss success was defined as >50% of excess weight
loss (EWL) at 12 months.
Results: A total of 1,722 patients were evaluated and 635 without follow-up
data at 12 months were excluded. Among the 1,087 analyzed individuals,
994 (88%) had the LAGB and 136 (12%) had RYGB. Women made up 73%
and 83% of patients in the LAGB and RYGB groups respectively. The mean
age was 41 ± 12 y and 44 ± 12 y for women and men respectively. The racial
distribution was similar in both groups. The initial mean BMI was 44.8 kg/m2
and 47.7 kg/m2 for women and men. 70% of men were married, compared
to only 48% of women (P < 0.001). Women had a higher number of negative
pre-op social psychiatric factors compared to men (7.4 ± 3 vs. 6.3 ± 3, P <
0.001), but were more likely to achieve successful EWL compared to their
male counterparts (53% vs. 38%, P < 0.001). Factors that were predictive
of successful EWL among women included late night eating (P = 0.018),
not eating carbohydrates (P = 0.020), being socially avoidant (P = 0.029),
and having a marriage that was impacted by obesity (P = 0.016). None of
these factors were predictive of post-op weight loss success in men.
Conclusion: In this cohort we identified significant gender differences in
bariatric surgery outcome as well as in the predictors of successful post-op
weight loss. Further evaluation is warranted to better understand the impact
of these factors on long-term weight loss outcome.
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Are Proton-Pump Inhibitors (PPIs) Associated with an Increased Risk
of Community-Acquired Pneumonia (CAP)? A Nested Case-Control
Study Investigating Recent PPI Exposure and CAP
Monika A. Sarkar, MD, Sean Hennessy, PharmD, Yu-Xiao Yang, MD∗.
Department of Medicine, Univeristy of Pennsylvania, Philadelphia, PA and
Center for Clinical Epidemiology and Biostatistics, Department of
Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia,
PA.
Purpose: Limited data suggest that proton-pump inhibitor use may increase
the risk of developing community-acquired pneumonia. We aim to further
assess the effect of recent PPI use on the risk of developing CAP in a large,
population-based cohort.
Methods: We conducted a nested case-control study in the General Prac-
tice Research Database (GPRD) (1987–2003). The GPRD is a computer-
ized medical record system from the United Kingdom containing complete,
prospectively-collected prescription data. The study cohort included all pa-
tients aged ≥ 18 years and with ≥ 6 months of pneumonia free follow-up in
the GPRD. Cases included all patients with an incident CAP diagnosis. Up
to 10 controls were selected for each case using incidence density sampling,
matching on practice site, calendar period, and duration of follow-up prior
to the index date. The primary exposure was the presence or absence of
any PPI prescription in the 30 days prior to the index date. In a secondary
analysis, we compared the effect of once daily versus twice daily PPI dos-
ing. Adjusted odds ratios (AORs) were estimated using conditional logistic
regression adjusting for age, sex, measures of healthcare utilization, alcohol
use, smoking, BMI, a comprehensive list of co-morbid conditions, and med-
ications that may alter immune status or compromise CNS or oropharyngeal
function. Effect modification was also examined for patients ≥ 65 versus <
65 years of age.
Results: When adjusted for sex and age, the OR for CAP associated with
recent PPI use was 1.8 (95% CI 1.7–1.9). After adjusting for all additional
confounders, recent PPI exposure showed a minimally increased risk of CAP
(AOR 1.1 95% CI 1.0–1.2). This small increase in risk was limited to patients
< 65 years old (AOR 1.3 95% CI 1.2–1.5), while patients ≥ 65 years old
were at no increased risk (AOR 1.0 95% CI 0.9–1.1). Twice daily PPI dosing
was also associated with a higher risk of CAP (AOR 1.3 95% CI 1.1–1.6)
than once daily dosing (AOR 1.1 95% CI 1.0–1.1).
Conclusion: Recent PPI use was associated with an increased risk of de-
veloping CAP after adjusting for sex and age. However, after adjusting for
multiple measured confounders, the increased risk of CAP was minimal.
This increased risk was primarily seen with twice daily dosing and younger
PPI users.
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Coffee Grounds Emesis: Always an Underlying Gastrointestinal
Bleeding Problem?
Jad Bou-Abdallah, MD, Preeti Mehta, MD, Sami Beg, MD, Uma Murthy,
MBBS∗. Internal Medicine, Upstate Medical University, Syracuse VA
Medical Center, Syracuse, NY.
Purpose: Acute GI blood loss manifests as hematemesis, melena and/or
hematochezia. Initial management is identical irrespective of nasogastric
(NG) aspirate results. Current practice includes early upper endoscopy. Sig-
nificantly fewer high-risk bleeding lesions are found on endoscopy in patients
with coffee grounds vs. bloody NG aspirates GIE 2004;59:172–78.
We present a case series to illustrate that patients with coffee grounds emesis
(CGE) and coffee grounds NG aspirate often have other unsuspected medical
illnesses that may be overlooked by pre-occupation with the GI bleed.
Methods: Retrospective chart review of six patients presenting with CGE
who were admitted for the upper GI bleeding.
Results: All patients were hemodynamically stable at admission.
NG lavage showed coffee grounds that cleared easily.
None of the patients rebled or required blood transfusions during their hos-
pital stay.
See table 1 for demographics, associated illness, endoscopic findings and
outcome.
Pt.1: Referred for endoscopy which was deferred, pt. deemed unstable from
new onset atrial fibrillation. Acute myocardial infarction ruled in.
Pt.2: Constipation at presentation overlooked and diagnosis of small bowel
obstruction delayed by work-up of CGE.
Pt.3: Diagnosis of urosepsis made after septic shock developed 12 hours
after admission.
Pt.4: Admitted for CGE. Extensive pulmonary emboli found subsequently
on evaluation of dyspnea which was present on admission.
Pts.5 and 6: Admitted to ICU because of large volume of CGE despite no
drop in BP and Hb/Hct. Pt.5 had acute renal failure.
Conclusion: Priority with work-up of GI bleeding including endoscopy de-
layed the diagnosis of serious, even life threatening illnesses. Hemodynam-
ically stable patients who present with coffee grounds NG aspirate and no
fall in Hb/Hct should be evaluated for other associated non-GI bleeding
conditions.
Age Sex/ Associated
Patient Age Race Disease Endoscopy Outcome
1 70 M/W Myocardial
Infarction
not done discharged
2 55 M/W Small Bowel
Obstruction
Gastric Erosions discharged after
surgery
3 82 M/W Urosepsis not done recovered with
antibiotics
4 89 F/W Pulmonary
Emboli
not done discharged after
recieving IVC
filter
5 63 F/W Acute Renal
Failure
normal resolved with
hydration
6 60 M/W no major illness normal discharged after
endoscopy
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Comparison of Resource Consumption in GERD Care by Primary
Care Providers and Gastroenterologists
Jay L. Goldstein, MD, FACG∗, Smita Kothari, PhD, Rachel Halpern, PhD.
Univ Illinois at Chicago, Chicago, IL; TAP Pharmaceutical Products, Inc.,
Lake Forest, IL and i3 Innovus, Eden Prairie, MN.
Purpose: Driven by our hypothesis that the medical approach to gastroe-
sophageal reflux disease (GERD) and (&) resource consumption differ for
primary care providers (PCPs: general practitioners, internists) & gastroen-
terologists (GEs), the purpose of this study is to define, quantify & compare
resource consumption for patients (pts) with GERD treated by PCPs and
GEs.
Methods: Retrospective medical & pharmacy claims data from a national
health plan with 14 M lives. Pts with ≥2 GERD-related diagnoses (ICD9
530.1×, 530.2×, 530.3, 530.81, 530.85, 787.1) or medications (proton
pump inhibitors (PPIs), H2 receptor agonists (H2RAs), or other (sucral-
fate, bethanechol, metoclopramide)) were identified from 11/1/01–10/31/04
& observed for ≥1 year. Episode Treatment Group software created episodes
(eps) of integrated comprehensive GERD-related care in defined timeframes.
Eps were labeled PCP or GE if ≥55% of claims in eps were associated with
PCP or GE, respectively. Procedures, prescriptions (rx) & sequences of PCP
& GE care were measured.
Results: Sample included 270,325 pts with 54% female & mean age 46(±
14) years. There were 228,719 PCP eps & 46,241 GE eps. Among all PCP
& GE eps, pts had mean 0.8(± 0.4) eps/year with mean episode length of
5.4 months. PPIs alone were the main drug therapy; 70% & 68% of all PCP
& GE eps, respectively, had rx for PPIs only. The 2nd most common rx was
H2RA for PCPs (9% eps) versus GEs, who added other rx to PPI (5%). Pts
were sent to GEs during PCP eps (PCP-GE referral (ref)); after PCP eps
(PCP-GE transfer); or before PCP eps (GE-PCP transfer). PCP-GE ref eps
and GE eps were more likely to have physician visits & endoscopies versus
non-PCP-GE ref eps; all chi-square significant at P < 0.01.
GERD Care Resource Consumption
PCP-GE PCP-GE GE-PCP
Referral Transfer Transfer
No GE Ref GE Ref PCP Ep GE Ep GE Ep PCP Ep
# (%) all pts 5,521 (2%) 1,859 (0.7%) 1,874 (0.7%)
# eps 220,051 8,668 2,100 2,265 2,189 2,247
% eps with
physician
visit
54% 85% 64% 82% 78% 51%
% eps with
endoscopy
2% 60% 2% 37% 31% 3%
Eps with GE care were more likely (P < 0.01) to have esophagoplasty, fundo-
plasty, other tests (e.g., Bernstein) although <4% eps had those procedures
(data not shown).
Conclusion: Pts transferred or referred to GEs had relatively high resource
consumption via physician visits & endoscopies. Pts transferred to PCPs
after GE eps appeared to use fewer GERD-related visits versus pts who went
to PCPs before GEs.
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Infliximab Persistence: Treatment of Crohn’s Disease from a Payor
Perspective
O. Dabbous, MD∗, M. Lee, MBA, H.C. Thompson, MBA, R. Delise, AB, B.
Tang, MD, M.I. Rahman, MD. HECOR, Centocor, Inc., Horsham, PA;
Market Research, Centocor, Inc., Horsham, PA and Trinity Partners, LLC,
Waltham, MA.
Purpose: To evaluate the persistence of infliximab (IFX) maintenance ther-
apy for the treatment of patients (pts) with Crohn’s disease (CD) utilizing
the Wolters Kluwer (WK) and PharMetrics claims databases.
Methods: Longitudinal claims data from PharMetrics and WK were ana-
lyzed. Pts enrolled in the same plan for 12 mos after the initial claim were
evaluated. The first IFX treatment (index date) among pts with CD in the
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period Dec 1 2003 – Feb 28 2004 was identified. Only pts in the PharMet-
rics database who were eligible for continuous coverage for at least 12 mos
following the initial claim were evaluated. Pts were included in the main-
tenance regimen group only if their first 2 infusions were within the study
period and were between 5–10 wks apart, or if the first 2 infusions were <5
wks apart and the third infusion was 5–10 wks after the second. A cohort
was developed based on the first IFX treatment date. IFX persistence (%)
was defined as the% of pts in the cohort that either had an IFX claim in the
calendar month 12 mos after the index date, or had a claim within 56 days
prior to the calendar month 12 mos after the index date. Beginning with the
Feb 2004 cohort, PharMetrics-derived persistency rates were updated based
on a trend analysis of WK claims data for index dates of Feb 2004, Mar &
Sep 2005, and Mar 2006.
Results: 891 pts receiving IFX were analyzed. In the Feb 2004 cohort, the
IFX persistence rates decreased over a 12 mo time period from 89% at 3 mos,
80% at 6 mos, and to 73% at 12 mos; 95% CI (70–76%). Based on a trend
analysis of WK data cohorts initiating on Feb 2004, Mar 2005, Sep 2005,
and Mar 2006, IFX persistence appears to be similar, and is estimated at 89%
at 3 mos, 86% at 6 mos, and at 79% at 12 mos; 95% CI (76–82%). After the
third month of treatment, IFX persistence was over 88% (79%/89%) for the
duration of the yr. [figure1]
Conclusion: IFX persistence in pts with CD is high (> = 73% in both) over
a 12-month time period in analyses conducted on 2 databases. Moreover,
persistence was much higher after the first three mos of therapy (> 88%).
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Development and Validation of the pH-Metry Impact Scale (pHIS) and
pH-Metry Symptoms Scale (pHSS)
Angela G. Bradley, MD∗, Hack J. Kim, MD, John K. DiBaise, MD,
Virender K. Sharma, MD, Michael D. Crowell, MD. Internal Medicine,
Mayo Clinic Scottsdale, Scottsdale, AZ and Gastroenterology, Mayo Clinic
Scottsdale, Scottsdale, AZ.
Purpose: Ambulatory wireless pH-metry has gained popularity because of
improved patient tolerability and decrease restrictions on normal diet and
activity. Few studies have quantified patient’s experiences during wireless
or catheter-based pH-metry and no validated questionnaires exist for the
quantification of the impact of pH-metry on daily activities or symptoms.
Primary aim was to develop and validate the pHIS and pHSS to assess
patient’s changes in activities of daily living and symptoms during pH-metry.
Methods: The pHIS included seventeen items selected by literature review
and expert consensus to reflect the impact of pH-metry on activities of daily
living. Item responses were coded on a 7-point Likert-type scale anchored
with ‘none of the time’ to ‘all of the time’. The survey was administered
to out-patients undergoing pH-metry. Principal Component Analysis (PCA)
with Varimax rotation and Kaiser Normalization (SPSS v15) was completed.
Internal consistency was assessed according to Cronbach’s alpha. The pHSS
quantified pH-metry associated changes in 12 symptoms by their frequency,
severity and bothersomeness on 5-point Likert-type scales. Non-parametric
Mann Whitney tests were used for preliminary comparisons.
Results: Sixty seven consecutive patients (51 F; 59 ± 16 yrs and 16 M;
64 ± 11 yrs) undergoing wireless (N = 51) or catheter-based pH-metry
(N = 16) completed the pHIS and pHSS. PCA of the pHIS suggested a
3-component solution that accounted for 72% of total variance: “Social-
Emotional Impact” (46%), “Impact on Daily Activities “(16%), and “Dietary
Impact” (10%). Cronbach’s alphas ranged from 0.86–0.92, supporting good
internal consistency. Wireless pH-metry patients experience less melancholy
when compared to catheter-based (0.49 vs 1.19, P < 0.01), were less likely to
be socially impacted (P < 0.01) and more likely to continue daily activities
(0.61 vs 1.56, P < 0.05). Foreign body sensation in chest was increased in
wireless patients (1.60 vs .25, P < 0.01), whereas foreign body throat was
more frequent in catheter patients; 2.94 vs 1.02 P < 0.01.
Conclusion: The pHIS and the pHSS demonstrated good psychometric prop-
erties and can provide a validated instrument for assessment of the impact on
activities of daily living and patient’s symptoms during pH-metry. Assessing
changes in daily activities and symptoms during pH studies may improve
clinical interpretation of these diagnostic tests.
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Can the Occurence of Septic Complications after Restorative
Proctocolectomy Be Predicted?
Ravi P. Kiran, MD, Feza H. Remzi, MD, Victor W. Fazio, MD∗, Andre D.
Moreira, MD, James M. Church, MD, Ian C. Lavery, MD, Tracy L. Hull,
MD, Scott A. Strong, MD. Colorectal Surgery, Cleveland Clinic
Foundation, Cleveland, OH.
Purpose: To evaluate preoperative and operative factors that might be asso-
ciated with the development of septic complications after restorative proc-
tocolectomy (RP).
Methods: From a prospectively maintained pouch database, patients devel-
oping abdominal and pelvic septic complications after RP were identified.
The association of patient, disease and technical factors and the develop-
ment of septic complications was determined. Complication rates within
subgroups were analyzed with Kaplan-Meier analyses, and comparisons per-
formed using log rank tests. P < 0.05 was considered to be significant.
Results: There were 3215 patients (56.1% male) in the database. Final patho-
logic diagnosis was inflammatory bowel disease 92%, FAP 6%, cancer 0.8%,
dysplasia 0.4%, and others 0.8%. 84.2% underwent diversion proximal to
pouch. 251(7.8%) patients who developed septic complications were iden-
tified. There was no association between septic complications and age (P =
0.9), gender (P = 0.3), primary indication (P = 0.06), presence of anal
findings (0.22), prior colectomy (0.08), pouch anastomosis type (0.06) or
proximal diversion (P = 0.47). Comorbidity (P < 0.05), hypoalbuminemia
(P < 0.01), final pathological diagnosis (P < 0.001) and intra-operative
transfusion (P < 0.01) were significantly associated with the development
of septic complications. Perioperative immunosuppressant use (P < 0.001)
was significantly associated with the devlopment of septic complications.
Amongst the patients on immunosupression, Remicade (P < 0.01) and Imu-
ran use (P < 0.05) was significantly associated with sepsis in contrast to
steroid use (P = 0.2), which was not associated with sepsis.
Conclusion: Patients treated perioperatively with Remicade and Imuran,
and those with associated comorbidity, hypoalbuminemia, and requiring in-
traoperative transfusion are more likely to develop septic complications after
RP.
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Systemic Antibiotic Prophylaxis for Percutaneous Endoscopic
Gastrostomy: A Meta-Analysis
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Abhishek Choudhary, MD, Matthew L. Bechtold, MD, Mohamed O.
Othman, MD, Srinivas R. Puli, MD, John B. Marshall, MD, Praveen K.
Roy, MD∗. Division of Gastroenterology, University of Missouri,
Columbia, MO.
Purpose: Percutaneous endoscopic gastrostomy (PEG) tube placement is
associated with a risk of infection. Despite numerous guidelines recom-
mending prophylactic antibiotics prior to PEG tube placement, their use
remains controversial. We performed a meta-analysis to establish whether
prophylactic use of systemic antimicrobials reduces the risk of peristomal
and systemic infection in patients undergoing placement of PEG tubes.
Methods: MEDLINE (1966–2007), PubMed, Cochrane Central Register of
Controlled Trials & Database of Systematic Reviews, and abstracts from gas-
troenterology scientific meetings (last 5 years) were searched (June 2007).
Only randomized controlled trials (RCTs) of adult subjects comparing pro-
phylactic antibiotic to no prophylactic antibiotic for PEG tube placement
were included. Study quality was accessed by assigning a quality score. Two
independent reviewers used standard forms to extract data and the differ-
ences were resolved by mutual agreement. Meta-analysis for the effects of
prophylactic antibiotic was analyzed by calculating pooled odds ratio for
peristomal infections, systemic infections, and mortality using both fixed
and random effects models. Heterogeneity among studies was assessed by
calculating I measure of inconsistency. Publication bias was assessed by
constructing funnel plots.
Results: Ten RCTs (N = 1,051) met the inclusion criteria. Five trials used
cephalosporins, 3 trials used penicillin, and 2 trials used either penicillin or
cephalosporins. Prophylactic antibiotic with PEG tube placement resulted
in a significant reduction in the incidence of peristomal infection (OR 0.42,
95% CI: 0.30–0.59, P < 0.01) and systemic infection (OR 0.22, 95% CI:
0.13–0.39, P < 0.01). No significant difference was noted for mortality (OR
0.67, 95% CI: 0.35–1.26, P = 0.21). Heterogeneity among studies was not
significant. Funnel plots revealed no significant publication bias. All studies
received a high score for quality.
Conclusion: Administration of prophylactic antibiotic prior to PEG tube
placement is effective in reducing the incidence of peristomal infections and
systemic infection.
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Missed Cancers vs Procedure-Related Complications: Balancing the
Medico-Legal Risks of Surveillance Colonoscopy
Sameer D. Saini, MD, Sandeep Vijan, MD, Philip S. Schoenfeld, MD∗.
Gastroenterology, University of Michigan, Ann Arbor, MI and Internal
Medicine, University of Michigan, Ann Arbor, MI.
Purpose: Data suggest that gastroenterologists perform surveillance
colonoscopy more often than recommended by guidelines. This practice
may be driven by medico-legal concerns over missed cancers. Though more
frequent colonoscopy may reduce the risk of missed cancers, it also increases
the risk of procedure-related complications. According to malpractice data,
such complications, particularly colonic perforation, are the most common
reason for litigation against gastroenterologists. Yet, no study has compared
the frequency of missed cancers and colonic perforations in patients under-
going “intensive” vs recommended colonoscopic surveillance.
Methods: We developed a Markov model to determine the number of op-
portunities for litigation in a cohort of 1000 men/women ≥50 yrs of age with
a new diagnosis of colon adenomas. We modeled 2 surveillance strategies:
(1) an “intensive” strategy with colonoscopy every 3 years in all patients;
and, (2) a “recommended” strategy with colonoscopy every 3–5 yrs based
on current guidelines. The base-case assumptions (and ranges for sensitiv-
ity analysis) were: (1) risk of colonic perforation: 0.25% (0.1%-0.4%); (2)
relative risk of litigation due to missed cancer vs perforation: 1.0 (1.0–3.0);
and, (3) advanced adenoma miss rate: 6% (0%-12%).
Results: In the base-case analysis, the “intensive” strategy resulted in 46
opportunities for litigation over the lifetime of the cohort (22 perforations
& 24 missed cancers). In contrast, the “recommended” strategy endorsed
by current guidelines resulted in only 40 opportunities for litigation (14
perforations & 26 missed cancers). In sensitivity analysis, the number of
opportunities for litigation under the “intensive” strategy was greater than
under the “recommended” strategy even when the perforation rate was re-
duced (0.1%), when the relative risk of litigation due to an interval cancer was
increased (3-fold), or when the advanced adenoma miss rate was increased
(12%).
Conclusion: Compared to the recommended strategy, more intensive
surveillance is associated with slightly fewer missed cancers but substan-
tially more colonic perforations, resulting in more opportunities for litiga-
tion. This result was robust to a wide range of assumptions in sensitivity
analysis. Endoscopists who disregard current guidelines and perform more
intensive surveillance out of concern for missed neoplasia should carefully
weigh the competing risk of procedure-related complications.
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Knowledge of Hepatocellular Carcinoma (HCC) Screening Guidelines
and Current Practices: Results of a National Survey
Pratima Sharma, MD, Sameer Saini, MD, Rubenstein Joel, MD, Latoya
Bernard, Darrell Pardi, MD, Jorge Marrero, MD, Phillip Schoenfeld,
MD∗. Internal Medicine, University of Michigan, Anna Arbor, MI and
Internal Medicine, Mayo Clinic, Rochester, MN.
Purpose: HCC is the fifth most common cancer in the world. The AASLD
recommends HCC screening for high risk patients. Previous survey studies
have demonstrated that many gastroenterologists either do not know or disre-
gard guideline recommendations about colon polyp surveillance even when
they do understand them. However, no prior studies have evaluated prac-
ticing gastroenterologists’ knowledge of HCC screening recommendations,
including management of positive screening tests.
Methods: A 12-item multiple choice survey about HCC screening was devel-
oped based on 2006 AASLD guidelines. Content validation was performed
with expert review. For each question, respondents reviewed a clinical sce-
nario, identified the appropriate intervention based upon guideline recom-
mendation, stated if they were certain about guideline recommendation for
this question, and identified their usual practice. The survey was distributed
to physicians attending two major GI certification and recertification exami-
nation review courses (Mayo Clinic GI Board Review and William Steinberg
Board Review in GI).
Results: 42% (224/537) of potential respondents completed the survey. 71%
(160/224) were attending physicians with median age of 41 yrs and median
practice of 11.5 yrs. 8% had never heard of HCC guidelines. 97% correctly
identified that AFP alone or alternating with ultrasound was inappropriate
for HCC screening. 94% used ultrasonography for HCC screening. 85% of
respondents correctly identified the high risk patients for HCC screening,
however, only 33% knew the appropriate age to start HCC screening among
female Asian chronic hepatitis B carriers. 30% did not know that the guide-
line recommendation for ≥ 2 cm hypervascular lesion suspicious for HCC
was referral for liver transplantation. Among those who knew guidelines,
virtually 100% self-reported that they followed the guidelines in their own
practices.
Conclusion: The majority of physicians correctly identified the common
high risk scenarios, methods and duration of HCC screening. However, 30%
of gastroenterologists did not know that Child B cirrhotic patient with ≥ 2 cm
lesion suspicious for HCC should be referred for liver transplantation. As
opposed to previous data on colon polyp surveillance, gastroenterologists
appear to know most HCC screening guidelines and apply most of these
recommendations in their own practice.
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Cost-Effectiveness of Lubiprostone in a Managed Care Population
with Chronic Idiopathic Constipation
S.R. Earnshaw, PhD∗, C.L. McDade, A.W. Mangel, MD, R.W. Baran, PhD.
RTI Health Solutions, RTP, NC and Takeda Global Research &
Development, Deerfield, IL.
S450 Abstracts
Purpose: Treatment of chronic idiopathic constipation (CIC) can be costly.
Recently, medications used to treat CIC over longer time periods have been
approved and have been consistently reimbursed. Understanding the eco-
nomic consequences of these treatments as currently prescribed in managed
care health plans is important to decision-makers. To assess cost effectiveness
of treating patients with lubiprostone from a United States (US) healthcare
payer perspective.
Methods: We developed a Markov model to compare treatment with lu-
biprostone to tegaserod in adult patients with history of CIC (per Rome II
Guidelines). Perspective of the third party payor was modeled. Age and gen-
der distributions of CIC patients were taken from an analysis of managed
care claims data. Treatment patterns were applied as observed in managed
care claims data which included treatment with tegaserod in patients over
65 years of age. Treatment efficacy data, rescue medication use, and symp-
toms scores were extracted from FDA Approved Clinical Trials and product
labels. Direct cost data were drawn from standard US costing sources (WAC
prices) and published analyses of claims data. The model was projected over
a one-year time horizon.
Results: Among CIC patients prescribed lubiprostone or tegaserod within
a managed care health plan, those treated with lubiprostone had lower
drug costs ($1,547 versus $1,746) and fewer medical costs ($2,330 ver-
sus $2,486) than patients on tegaserod. Patients on lubiprostone had more
symptom-free days than patients on tegaserod (326 versus 301, respectively).
Fewer lubiprostone-treated patients required rescue medications than those
on tegaserod (35.3% versus 47.1%, respectively). As a result, treating with
lubiprostone was dominant compared to tegaserod. In probabilistic sensitiv-
ity analyses, 91.4% of 1000 simulations demonstrated dominant results.
Conclusion: Based on analyses of managed care treatment patterns, lubipro-
stone is less costly and more effective than tegaserod for treatment of CIC.
Cost-effective options for reimbursement remain available.
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Healthcare Utilization and Cost in Pediatric Gastroesophageal Reflux
Disease (GERD) Patients on Continuous vs. Intermittent Proton Pump
Inhibitor (PPI) Treatment Regimens
Suzanne P. Nelson, MD∗, Smita Kothari, PhD, Eric Q. Wu, PhD, Bjorn
Persson, PhD, Nicolas Beaulieu, MA, Mateo Arana, MA, Mei Lu, MA. The
Feinberg School of Medicine, Northwestern University, Chicago, IL;
Health Economics & Outcomes Research, TAP Pharmaceutical Products,
Inc., Lake Forest, IL and Analysis Group, Inc, Boston, MA.
Purpose: To compare healthcare utilization and costs in two distinct PPI
treatment regimen groups in the pediatric GERD population: continuously
treated with PPIs vs. intermittently treated with PPIs.
Methods: Patients were identified from a privately insured claims database
(1999–2005) using the following criteria: age < 18 years at date of first PPI
prescription (index) and one GERD diagnosis (ICD-9-CM: 530.11, 530.81,
787.1) in the 6-month period before the index. A 1-year washout period
was used to ensure that no other PPIs had been used prior to index date.
The continuous group (CG) was identified as patients having a PPI episode
longer than 30 days starting at index. The intermittent group (IG) was iden-
tified as patients having a first PPI episode of 30 days or less followed by a
discontinuation of 30 days or more, and then another PPI episode. Health-
care utilization rates and costs were measured for the 1-year period prior
to index date (baseline) and 1-year post index date (follow-up), and com-
pared between the two regimens using Student and Wilcoxon tests. Patients
concomitantly using PPIs and H2 Receptor Antagonists during either the
baseline or follow-up period were excluded.
Results: The samples included 1,026 continuous and 310 intermittent PPI
users. CG and IG patients had similar demographic and comorbid charac-
teristics at baseline. The mean length of treatment for CG group during
follow-up was 170 days (mediaN = 120 days). On average, IG patients had
2.1 episodes (mediaN = 2 episodes), and were off treatment for104 days (me-
diaN = 91 days). CG patients experienced an average reduction of $4,351
in total cost (medical + pharmacy) in the follow-up compared to baseline,
while IG patients experienced an average increase of $686 in total cost (dif-
ference $5,037, P = 0.009). The CG patients also experienced a reduction
by 0.11 GERD-related inpatient stays compared to a 0.06 increase for the
IG patients (P = 0.006).
Conclusion: The results suggest that pediatric GERD patients who are con-
tinuously treated with PPI experience a relatively larger benefit in terms of
total cost savings than do patients treated intermittently. Further studies are
needed to assess the impact of different age and risk groups on these cost
savings.
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Use and Abuse of Proton Pump Inhibitors
Erika Grigg, MD, J. Carter Balart, MD, Dianne B. Williams, PharmD,
Robert R. Schade, MD∗. Medicine, Gastroenterology/Hepatology,
Pharmacy, Medical College of Georgia, Augusta, GA.
Purpose: To determine the utilization of proton pump inhibitors (PPIs) at
an academic medical center we evaluated the indications for PPI use in
hospitalized patients, and the frequency in which patients placed on a PPI
during hospitalization were discharged on a PPI.
Methods: We performed a prospective analysis of 502 consecutive patients
admitted at the Medical College of Georgia (MCG) and the Children’s Med-
ical Center (CMC) who received a PPI. Patients who were on a PPI at home
and not placed on one at the time of admission were not accounted for in
this study. We recorded demographics, indication for use, hospital service
prescribing PPI, route of administration, PPI use prior to admission, and
discharge PPI medication for each admission.
Results: Between May 6th and June 19th, 2005, a total of 2,497 patients
were admitted to MCG and CMC. 502 were prescribed a PPI. Analysis of
the adult population revealed 463 (26%) patients admitted to MCG were
prescribed a PPI. Patients received a PPI for the following indications: stress
ulcer prophylaxis (SUP)-53%, GERD-30%, not documented -15%, GI bleed-
5%, continuation of home medication-4%, other-4%, esophagitis-0.1%, and
peptic ulcer disease-0.1%. 37% of patients were on a PPI prior to admission.
Although 246 patients (53%) were placed on a PPI for prophylactic purposes,
only 18% were admitted to the intensive care unit. Overall, 300 of the 463
patients (∼65%) were prescribed a PPI without a documented appropriate
indication. Upon discharge, 50% of patients were prescribed a PPI. 22% of
patients placed on a PPI for prophylactic purposes were discharged on a PPI.
Overall, about 55% of patients were discharged on a PPI without appropriate
indication or documentation.
Conclusion: There is significant overuse of PPIs in the inpatient setting at our
institution with about 26% of patients receiving a PPI on admission, and 55%
of patients discharged on a PPI without any clear indication or documenta-
tion. Caution must be used when initiating PPI therapy in the hospital setting;
long-term therapy often continues unnecessarily after discharge leading to
increased healthcare costs, polypharmacy, and increased risk for potential
adverse effects including Clostridium difficile diarrhea, community-acquired
pneumonia, and intestinal bacterial overgrowth. Therefore, physicians need
to be aware of the indications and possible consequences of PPI use in hos-
pitalized patients.
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Comparison of Lactose Versus Lactulose Breath Tests in Subjects
Suspected with Small Intestinal Bacterial Overgrowth
Kelly Cushing, BS, Rana Abraham, MD, Mary Kwasny, ScD, Ali
Keshavarzian, MD, Ece Mutlu, MD∗. Digestive Diseases, Rush University
Medical Center, Chicago, IL and Rush College of Nursing, Chicago, IL.
Purpose: Evidence for comparative utility of various carbohydrate sub-
strates in hydrogen breath testing (HBT) for the diagnosis of small intestinal
bacterial overgrowth (SIBO) is scant. The aim of this study was to compare
the yields for lactulose vs. lactose HBT in suspected SIBO. We determined:
1) the frequency of SIBO; 2) the level of rise in hydrogen (H) & methane
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(CH3); & 3) the time to rise in H or CH3 with the highest sensitivity for
SIBO with each carbohydrate substrate.
Methods: All subjects who underwent HBT from 2003–06 at Rush Univer-
sity Medical Center were identified using the HBT database, cross referenced
to a billing database. Subjects were excluded if they had HIV, immunosup-
pression, antibiotic use, widespread malignancy or terminal illness. For HBT,
25 gm of lactose or 20 gm of lactulose were used. Two baseline samples &
samples every 15 mins were taken up to 165 mins and analyzed using the
Quinton Microlyzer for H, CH3 & carbon dioxide (CO2). The clinical data
& the HBT results were obtained via chart review and were analyzed with
chi- square, Fisher exact tests for categorical data, & Kruskal-Wallis tests for
continuous variables, using SPSS v. 11.5 & S+7.0. HBT were considered
positive for SIBO if there was a double peak in H or CH3 in lactose or lac-
tulose HBT; or the hydrogen level was > 20 ppm before 90 min in lactulose
HBT. The tests were read by a single experienced gastroenterologist.
Results: Patient related variables such as age, gender, pre- or post- test symp-
toms or diagnosis, past medical or surgical history, medications, endoscopic
or histological findings from EGD &/or colonoscopy, hemoglobin & albu-
min did not differ significantly between the patients receiving lactose HBT
(N = 110) vs. lactulose HBT (N = 85). There was no statistically signifi-
cant difference in the frequency of SIBO in subjects who underwent lactose
(36.7%) versus lactulose (40%) HBT (P = 0.221). There was no statistically
significant difference between mean CH3 levels at any time interval with
either substrate, although there was a trend towards higher CH3 levels at
all time intervals in lactulose HBT. Mean CH3 levels in lactose vs lactulose
peaked at 30 mins vs 60 mins, respectively in those with SIBO.
Conclusion: Lactose and lactulose HBT yield similar results in SIBO di-
agnosis. Use of the lactose substrate could be considered in those patients
suspected to have lactose intolerance and SIBO.
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Differences in Health Care Visits Coded for Potential Proxy
Conditions/Symptoms of Gastroesophageal Reflux Disease (GERD)
before and after a GERD Diagnosis: A Pediatric Database Study
Suzanne P. Nelson, MD∗, Susan R. Orenstein, MD, Hashem El-Serag, Eric
Q. Wu, PhD, Smita Kothari, PhD, Bjorn Persson, PhD, Nicolas Beaulieu,
MA, Mateo Arana, MA. The Feinberg School of Medicine, Northwestern
University, Chicago, IL; School of Medicine, University of Pittsburgh,
Pittsburgh, PA; Baylor College of Medicine, Houston, TX; Analysis Group,
Inc., Boston, MA and Health Economics & Outcomes Research, TAP
Pharmaceutical Products, Inc., Lake Forest, IL.
Purpose: To examine changes in frequency of medical visits coded for
potential proxy conditions and/or symptoms of GERD (PPCSG) before and
after a GERD diagnoses in a large pediatric claims database.
Methods: All children aged 2–18 years coded for a GERD diagnosis
(ICD-9-CM: 530.10–12, 530.81, 787.1) twice within a six month period
in the MarketScan1 claims database (2001–2005) and continuously in the
database for 6-month before (pre) and after (post) the first GERD diagnosis
(index) were included. One control patient, matched by gender, birth year
and state of residence, was identified for each GERD patient, assigned the
index date of the matched GERD patient, and confirmed to be retained in the
database continuously for 6-month pre and post index date. Experts in the
field generated a list of ICD-9 codes representing PPCSG. For each PPCSG,
the mean number of visits coded for each PPCSG were compared for the pre
and post periods.
Results: The sample included 17,123 GERD patients and their 17,123 con-
trols. For most of the selected conditions, no significant changes were found
in the mean number of visits pre and post index for the control sample (P >
0.05). For the GERD sample, significant reductions in the mean number of
visits were identified for several selected conditions: acute sinusitis (P <
0.01), cough (P = 0.04), croup (P < .01), otitis (P < .01), and pneumonia
(P < .01). Significant increases were found in several others: abdominal pain
(P < .01), chest pain (P < .01), nausea/vomiting (P < .01), and unspecified
anorexia (P < .01).
Conclusion: The results show that visits for many PPCSG which are poten-
tial extraesophageal manifestations of GERD decreased after a GERD di-
agnosis, suggesting the possibility that recognition and treatment of GERD
resulted in improvement of outcomes of these conditions. Potential PPCSG
with increases in visit numbers after the GERD index were generally more
typical gastrointestinal GERD symptoms. Further study is required to under-
stand this finding. 1http://www.medstatmarketscan.com. Accessed on June
11, 2007.
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The Economics of Gastrointestinal Bleeding in US Managed Care
Setting: 12-Month Costs and Outcomes
Byron L. Cryer, MD∗, Charles M. Wilcox, MD, Henry J. Henk, PhD,
Gergana Zlateva, PhD. UT Southwestern Medical School, Dallas, TX; i3
Innovus, Eden Prairie, MN; Pfizer, Inc, New York, NY and UAB,
Birmingham, AL.
Purpose: Gastrointestinal (GI) bleeds require intensive medical interven-
tion and could lead to escalated health resource utilization (HRU) over the
patient’s lifetime. This study estimates the incremental cost of GI bleed-
ing and associated outcomes compared to a control cohort over a 12-month
follow-up.
Methods: US national health-plan claims data (1999–2004) were used to
identify patients hospitalized with an upper GI bleeding event. These pa-
tients were propensity matched to control patients from 10% sample taken
from the same US health plan, without evidence of GI bleeding, based on
a nearest neighbor matching method. The propensity score model included
age, gender, date of index date (quarter/year), Charlson Comorbidity Index,
geographic region, and prior medical utilization. Expenditures are the sum
of health plan and patient paid amounts.
Results: 8,823 GI bleed patients and 579,018 control patients meeting inclu-
sion criteria were identified. Propensity score matching yield 7,646 matched
pairs. Mean age was 53 in both cohorts and 50.2% of patients with GI bleed
were male compared to 56% in the control group. Charlson comorbidity
index was 0.54 and 0.48 respectively, for the GI bleed patients and controls.
Among the GI bleed patients, total health care expenditure averaged $24,036
in the year following hospital admission compared to the annual average of
$5,111 per person in the general population (P < 0.001). Main cost drivers
for the GI bleed cohort were inpatient hospitalizations while outpatient vis-
its and prescription pharmacy accounted for 23% of expenditures (Table 1).
Risk of re-hospitalization among GI bleed patients was 24%. Patients with
GI bleed had on average, an additional 0.7 ER and 4.5 outpatient visits
compared to controls (P < .001).
Conclusion: 12-month HRU for patients experiencing GI bleed was signif-
icantly higher than that of controls without GI bleed. Additional research is
necessary to document GI bleed recurrence over a longer timeframe.
Table 1. Annual Health Care Expenditures.
GI Bleed General Population P-value
Total $24,036 $5,111 <0.001
Medical $21,769 $3,303 <0.001
Inpatient $14,844 $1,090 <0.001
Outpatient $3,270 $1,374 <0.001
ER $411 $103 <0.001
Other Medical $3,244 $736 <0.001
Pharmacy $2,267 $1,808 <0.001
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Medical, Pharmacy, and Sick Leave Costs for Constipation and for
Irritable Bowel Syndrome with Constipation in the 6 Months before
and after Diagnosis: An Employer Perspective
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N. Kleinman, PhD, R. Brook, MS∗, A. Melkonian, MD, R. Baran, PharmD,
N. Talley, MD. HCMS, WY; JeSTARx, NJ; Takeda R&D, IL and Mayo
Clinic, MN.
Purpose: Both constipation (C) and irritable bowel syndrome with C
(IBS+C) are known to be very costly. However, whether the costs of C are
driven by the same factors that drive IBS+C costs is unknown. We aimed to
assess the cost of illness (COI) for C without and with IBS (IBS+C) among
US-based employees.
Methods: A retrospective analysis was conducted using the Human Capital
Management Services Research database, which represents multiple US-
based employers and contains employee health claims data from 2001–2005.
Data included medical, pharmacy, payroll, work absence, and demographics.
ICD9 Codes were used to include employees in the C cohort: 564.0 (Con-
stipation), 564.00 (Unspecified), 564.01 (Slow Transit), and 564.09 (Other).
Employees with C and an ICD9 for IBS (564.1×) at any time were included
in the IBS+C cohort. Propensity scores based on demographics, job-related
variables, region, existence of medical claims, and Charlson Comorbidity
Index Score were used to match 5 C employees to each IBS+C cohort em-
ployee. For the C cohort the index date was the date of the first C claim. For
the IBS+C cohort the index date was the date of the first IBS claim. Mean
costs for each cohort were adjusted to 2006$ and compared by category for
medical, prescription drug (Rx), and sick leave costs in the 6-months before
and after index diagnosis (dx).
Results: Data were available for 1854 employees. Demographics for both
cohorts were similar (P > .05). All between cohort COI comparisons (Fig-
ure) were similar (P > .05), except for Rx costs after dx ($26 higher for
IBS+C, P = .036). Within cohort comparisons (6-months before vs. after
dx) identified significant increases in medical and Rx costs for both cohorts
(P ≤ .05). Sick leave costs and days increased after dx in both C and IBS+C
cohorts (P > .05). Persons with IBS+C averaged an additional 1.3 sick leave
days during the 6-month period after dx when compared with the C cohort
(P < .03).
Conclusion: Costs of illness for IBS+C and C are very similar. Total costs
and sick leave days for both cohorts increased after dx.[figure1]
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Infliximab Therapy for Patients with Crohn’s Disease: Analysis of
Health Care Utilization
Patrick D. Meek, PharmD, Nilay D. Shah, PhD, Holly K. Van Houten, BA,
Bora Gumustop, MD, Marjorie Rosenberg, PhD∗. Department of
Pharmacy Practice, and the Research Institute for Health Outcomes,
Albany College of Pharmacy, Albany, NY; Division of Health Care Policy
and Research, Mayo Clinic, Rochester, MN; Albany Gastroenterology
Consultants, PC, Albany, NY and Biostatistics and Medical Informatics,
School of Business, University of Wisconsin at Madison, Madison, WI.
Purpose: We sought to evaluate the relationship between infliximab and
subsequent health resource use and costs in privately insured patients with
Crohn’s disease (CD) using observational data from the 1999–2003 Medstat
MarketScan commercial claims and encounters databases.
Methods: We undertook a 12-month pre-post (before and after infliximab),
and 2-year prospective risk adjusted case-control analysis of integrated inpa-
tient, outpatient, and prescription drug claims. Three-hundred and ninety-six,
and 7,938 plan participants older than 18 years of age with a diagnosis of
CD were included in the pre-post, and case-control analysis, respectively.
Results: We found no differences in mean number of admissions (0.49 versus
0.51 admissions; P = 0.79) or length of hospitalizations (2.6 versus 3.3 days;
P = 0.16), or in mean number of emergency department [ED] visits (0.62
versus 0.65 visits; P = 0.74) during the 12-month periods before and after
infliximab, respectively. Increases were seen in mean number of outpatient
visits (
 = +2.4 visits; P < 0.001) and mean number of prescription drug
fillings (
 = +5.1 fillings; P < 0.001) when counts of events were compared
12-months after infliximab to counts before infliximab (
 = post minus pre).
Infliximab therapy was associated with a mean increase of $15,524 in total
12-month expenditures (P < 0.001). In the 2-year prospective case-mix
adjusted models, with a propensity score covariate to account for disease
severity, no significant differences in rates of hospitalization (rate ratio [RR]
of 0.82; P =0.183) or ED visits (RR of 1.05; P =0.550) were seen. Infliximab
was associated with a higher rate of outpatient office visits (RR of 1.54; P <
0.001). Case-mix adjusted mean total expenditures during the 2-year follow-
up period were higher for infliximab users than for those who did not receive
infliximab ($40,686 versus $22,109, respectively; P < 0.001).
Conclusion: Taken together, the results of the pre-post and case-mix adjusted
analyses suggest that infliximab therapy is not associated with an overall re-
duction in direct healthcare resource utilization when used in actual practice
by privately insured patients with CD.
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Effect of a Liver Psychology Team on Mental Health Related
Treatment Discontinuation Rates
Yasemin S. Aytaman, Edmond Bouassaf, MD, JoAnn Comas, NP, Shalini
Sehgal, PsyD, Daniel Feld, PsyD, Gul Bahtiyar, MD, Samy I. McFarlane,
MD, Ayse Aytaman, MD, FACG∗. Gastroenterology, VA New York Harbor
HCS Brooklyn Campus, Brooklyn, NY; Division of Endocrinology,
Diabetes and Metabolism, SUNY Health Science Center in Brooklyn,
Brooklyn, NY; Division of Endocrinology, Diabetes and Metabolism,
Woodhull Medical and Mental Health Center, Brooklyn, NY and
Gastroenterology, SUNY Health Science Center in Brooklyn, Brooklyn, NY.
Purpose: Hepatitis C (HCV) has a higher prevalence in veterans. Despite
availability of effective therapies, unacceptably high therapy (tx) discontinu-
ation rates remain a significant barrier to successful outcomes with combina-
tion tx. Veterans have increased mental health co-morbidities and decreased
rate of tx candidacy, as well as premature discontinuation of HCV tx sec-
ondary to mental health side-effects. The overall discontinuation rates in
registration trials were reported to be 13–15%. Mental health related discon-
tinuation rates as high as 15% have been reported with IFN based treatments.
The effect of a liver psychology team on treatment discontinuation rates is
not well established.
Methods: A database was created to evaluate the interaction of hepatitis
C and diabetes. Out of this database 148 patients were identified to have
received tx for hepatitis C between 1999 and 2006. We evaluated the mental
health tx discontinuation rates in this very diverse group of patients, including
post-transplant, pre-transplant, re-treatment and tx naı¨ve patients.
Results: From 1999–2006 148 patients were identified in the database that
were treated with interferon based therapies. Mean age was 53.0 ± 0.5.
98% were male. 64 patients (43%) completed therapy. 52 (35.1%) were
discontinued for non-response. 32 (21.6%) were discontinued prematurely
secondary to side-effects. Of the 32 patients, who discontinued tx for side
effects, 7 (21.9%) had mental health reasons. Overall 4.3% of the patients
were discontinued for mental health reasons. 17.9% of patients seen by liver
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psychology had MH discontinuations as opposed to 50% of the patients not
seen by liver psychology. 7 out of 96 patients treated prior to 2003 as opposed
to 0 out of 45 patients treated after 2003 had treatment discontinuation for
MH reasons.
Conclusion: Mental health co-morbidities leading to decreased therapy can-
didacy and treatment discontinuations represent a significant barrier to ther-
apy. An integrated liver psychology team can have a significant impact on
therapy discontinuation rates.
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Gastrointestinal Bleeding in Biopsy-Proven Graft-Versus-Host Disease
of the GI Tract: Risk Factors and Effect on Mortality
Hazem T. Hammad, MD, Nataliya Razumilava, MD, Nolan E. Perez, MD,
Murray N. Ehrinpreis, MD∗. Division of Gastroenterology, Wayne State
University, Detroit, MI.
Purpose: Graft-versus-host disease (GVHD) is the leading cause of mor-
bidity and mortality after allogeneic bone marrow transplantation. Gastroin-
testinal tract (GIT) involvement presents with diarrhea, abdominal pain,
vomiting, and upper or lower GI bleeding. Risk factors for GI bleeding and
its effect on mortality have not been described. The purpose of this study is
to identify the risk factors for GI bleeding in GVHD and determine its effect
on survival.
Methods: We reviewed the medical records of patients with biopsy-proven
GVHD of the GIT after allogeneiec hematopoietic stem cell transplantation
(HSCT) from 1/2000 to 12/2006 at our institution.
The patients were grouped into those with no evidence of GI bleeding, pa-
tients with mild bleeding (< 6 units of PRBC’s transfused) and patients with
severe bleeding (> 6 units).
Results: We identified 73 of 489 patients (15%) with HSCT and biopsy-
proven GVHD of the GIT; 39 patients (53%) were male.
Nineteen patients (26%) had severe GI bleeding, 4 (5%) had mild bleeding
and 50 (68%) had no bleeding.
Mean age for patients with severe bleeding was 41 years compared to 42 years
in patients with no bleeding. 73% of patients (14/19) with severe bleeding
were male compared to 46% of patients (23/50) with no bleeding (P =
0.039).
There was a trend toward more endoscopic finding of erosions, ulcers, necro-
sis or bleeding in patients with severe bleeding, 73%, compared to 50% of
patients with no bleeding (n = 25, P = 0.076).
Of the patients with severe GI bleeding, 95% (n = 18) had clinical grade 3
or 4 GVHD compared to 48% of patients with no bleeding (n = 24) (P =
0.0003). 79% of patients with severe bleeding (n = 15) had histological
grade 3 or 4 compared to 58% of patient with no bleeding (n = 29, P =
0.001).
The average onset of GIT GVHD symptoms after HSCT was 8 days earlier
in patient with severe bleeding (26 vs. 34, P = 0.46).
The overall 6 month-mortality rate in patients with severe bleeding was 79%
(n = 15) compared to 54% (n = 27) in patients with no bleeding (P = 0.096).
Conclusion: Our data suggest that male gender, clinical grade of 3 or 4,
and histological grade 3 or 4 were associated with the development of GI
bleeding in GVHD of the GIT. Patient age and onset of symptoms showed no
correlation with increased risk of bleeding. Endoscopic findings, however,
seemed to suggest more risk of bleeding.
There was a trend toward increase in overall 6 month-mortality rate after
HSCT in patients with severe GI bleeding.
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Patients Discharged from a Chest Pain Center – Are They Followed up
and Treated Appropriately?
Mark Mellow, MD∗, Charles Bethea, MD, Gayle Sturgis, RN, Linda
Pitchford, RN. Digestive Health Center, INTEGRIS Baptist Medical
Center, Oklahoma City, OK.
Purpose: Chest pain (CP) centers represent an important advance in the
diagnosis and rapid treatment of patients presenting with chest pain of cardiac
ischemic origin, as patients undergo a structured protocol to rapidly identify
and treat acute cardiac ischemic injury. What happens to patients discharged
from the chest pain unit with acute ischemic injury having been “ruled out”
is the subject of this report.
Methods: We were able to contact 44 consecutive patients, ages 36 to 84
(mean age 61) discharged from our CP center 30 to 60 days previously. They
were asked to consent to a phone interview. 39 of 44 agreed to participate.
We described symptoms that would likely relate their CP to a gastrointestinal
origin (heartburn, dysphagia, upper abdominal pain, regurgitation, nausea
or vomiting) and inquired whether these symptoms were present. We de-
termined whether physician follow-up was obtained. We inquired whether
diagnostic tests had been performed, whether GI consult had been obtained,
and whether presenting symptoms were still present at the time of our inter-
view.
Results: 33 of the 39 patients had followed up with their primary care
provider (PCP). 23 of 39 had concurrent symptoms strongly suggestive of a
gastrointestinal origin of CP and had discussed this with their PCP. Only 2 had
been referred to a Gastroenterologist. Additionally, 22 of the 39 continued
to have the symptom that prompted their visit to the CP Center.
Conclusion: GI symptoms (and, hence, likely CP origin) are common in
patients discharged from a CP center. While most patients had medical follow
up with their PCP, diagnostic tests were rarely performed, and, in the majority
of patients, symptoms persisted. As a result of this information, we have
initiated a protocol whereby all patients discharged from the CP center will
have structured follow up with a GI consultant, contact being established
with an “on call” Gastroenterologist prior to their discharge from the chest
pain unit.
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Prospective Assessment of Electronic Health Record (EHR)
Implementation on Community Based GI Practice
Steve Carpenter, MD, Soha Taheri, MD, Lynn Marini, RN, MBA, Naresh
Gunuratnam, MD∗, Andrew Cantanzaro, MD. Internal Medicine, Mercer
University School of Medicine, Savannah, GA and Internal Medicine, St.
Joseph Mercy Hospital, Ann Arbor, MI.
Purpose: EHRs are increasingly utilized in GI practices with the promise of
increased practice efficiency, improved safety, and decreased cost. There is
limited data on the ability of EHRs to achieve these intended endpoints. This
abstract compares the impact of EHR implementation on two community
based GI practices.
Methods: Huron Gastro (HG) is an 18 provider practice in Michigan that
installed the NextGen EHR in 2004 and was fully implemented in 2006. The
Center for Digestive and Liver Health (CDLH) is a 15 provider practice in
Georgia that implemented the Allscripts EHR in 2005. Clinical outcomes
and costs pre and post implementation were assessed.
Results: Prior to implementation, the average time for a referring doctor
to receive a dictated consultation was 14 days (range 7–28 days). Post im-
plementation, this time decreased to hours after completion of the consul-
tation at both practices. HG medical records FTE preimplementation was
1 per 3 providers, post implementation 1 per 4 providers. CDLH medical
records FTE preimplementation was 5 per 6 providers, post implementation
3 per 8 providers. HG annualized pre-implementation transcription costs
were 112K compared to 12K post implementation. CDLH annualized pre-
implementation transcription costs were 71K compared to 29K post imple-
mentation. HG postage costs decreased from $20K to $6.5 during the same
comparative period. When the drug Zelnorm was withdrawn from the mar-
ket due to safety concerns, all patients using Zelnorm at both practices were
identified within 24 hours and contacted by mail or phone to discontinue
the drug. Similar efforts to identify patients when Cisapride was withdrawn
took over a week in 2000 at HG.
Conclusion: Community based GI practice EHR implementation resulted
in reduction in the time for referring physician to receive consultation notes
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by an average of 2 weeks at both practices, decreased medical record FTEs,
decreased transcription costs, and decreased postage costs. These finding
suggest EHR implementation improves the efficiency of communication
and decreases practice costs. Allowing easy database searches to identify
patients at risk for drug toxicity may enhance patient safety. The cost savings
achieved by EHRs are countered by the significant cost associated with
implementation and the hiring of dedicated IT staff.
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Frequency and Indications for Performance of Repeat Colonoscopy
within Sixty Days
Hazem Hammad, MD, Bret T. Petersen, MD∗, Beverly Ott, Felicity Enders,
PhD. Division of Gastroenterology and Hepatology, Mayo Clinic College
of Medicine, Rochester, MN and Internal Medicine, Wayne State
University, Detroit, MI.
Purpose: Overuse of colonoscopy affects the availability, quality, and cost
of care. We sought to evaluate the frequency and indications for repeat
colonoscopy within 60 days, and to evaluate whether baseline patient char-
acteristics or the course during the first colonoscopy predicted the need for
repeat procedures.
Methods: We identified 781 patients who had more than one colonoscopy
within 60 days, among 51559 patients (1.5%) who underwent colonoscopy
during Jan 2004 to Dec 2006. Control patients who did not have repeat
exams were matched with the study population with respect to procedure
date and location. Medical records were reviewed for patient demographic
and historical data and numerous procedural characteristics. Univariate and
multivariate logistic regressions were performed to assess the association
between the repeat colonoscopy and patient age, gender, BMI, history of
abdominal surgery, procedure tolerance, size of largest polyp, endoscopist
experience, inpatient vs. outpatient status, and use of anticoagulants, nar-
cotics or benzodiazepines.
Results: The most common reasons for repeat colonoscopy included poor
bowel preparation (32%), “Need for Complex Therapy” (21%), bleeding
management (13%), pathology follow-up (12%), stricture therapy (6%), fail-
ure due to intolerance (4%), failure due to anatomy (4%), and anticoagulant
or antiplatelet agent mgmt (2%). Multivariate logistic regression showed sta-
tistically significant differences between the study and control populations
in regard to age (OR = 1.01; 95% CI 1.003–1.017; P < 0.005), history of
abdominal surgery (OR = 1.68; 95% CI 1.34–2.11; P < 0.0001), procedu-
ral tolerance level (OR = 4.01; 95% CI 2.20–7.30; P < 0.0001), inpatient
versus outpatient status (OR = 1.78; 95% CI 1.31–2.41; P < 0.001), largest
polyp size ≥ 2 cm (OR = 10.70; 95% CI 5.08–22.56; P < 0.0001), and use
of anticoagulants (OR = 1.58; 95% CI 1.12–2.22; P < 0001). Endoscopist
experience, and patient gender, BMI, or use of narcotics or benzodiazepines
did not correlate with repeat procedures.
Conclusion: Poor bowel preparation and referral for complex therapies are
the dominant indications for repeating colonoscopy within 2 months. Vari-
ables associated with performance of repeat colonoscopy included older age,
history of previous abdominal surgery, inpatient status, poor procedure tol-
erance, largest polyp size more than 2 cm, and use of anticoagulants at the
time of the first colonoscopy.
914
Impact of an Internet-Based Educational Program on Colonoscopy
Attendence and Quality
Tojo Thomas, MD, Prashant Kedia, MD, Russell D. Cohen, MD∗.
Medicine/Gastroenterology, The University of Chicago, Chicago, IL.
Purpose: Poor patient compliance with attendance for scheduled colono-
scopies leads to inefficiencies in scheduling and potential delays in diagnosis.
Patient education techniques such as pre-procedural visits and telephone re-
minders have been shown to improve attendance rates. Poor compliance with
the pre-procedural preparative regimen may lead to cancelled procedures or
insufficient visualization of the colonic mucosa.
EMMITM (Expectation Management and Medical Information; Emmi So-
lutions, Illinois) is an online program that allows patients to learn about
colonoscopy and its preparation prior to their procedure. This study aims to
measure its utility in improving attendance and preparation quality.
Methods: Consecutive English-speaking competent adult patients sched-
uled for an outpatient colonoscopy upon referral from the primary care
group at our institution were assigned an EMMI number and instructions to
access the system prior to their procedure. Computer workstations were avail-
able for patient use. The primary outcome was attendance at the scheduled
colonoscopy date; secondary assessments included quality and impact of the
preparative regimen, and timing and reasons for cancellations. Fisher-exact,
Chi-square, T-test, ANOVA, and logistic regression tests were performed,
where appropriate.
Results: 333 patients were assigned EMMI numbers (65% female, mean
age 60, range 25–93 years). 45 patients (13.5%) viewed the program prior to
colonoscopy, predicted by younger age (mean 57 vs. 61, P = 0.04) but not
gender. Watching EMMI was predictive of attending scheduled colonoscopy
(89% vs. 68%, P = 0.005; irrespective of gender or age in regression analy-
sis). 16.9% of patients who attended their colonoscopy had watched EMMI
as compared to 5.2% of non-attendees. Too few patients who watched EMMI
subsequently cancelled their colonoscopy (5) to allow for comparison of can-
cellation times and reasons between the two groups. Cancellation due to poor
preparation was more common in older patients (mean age 60 vs. 48, P =
0.208), irrespective of gender or EMMI status. Quality of preparation and
impact on cecal intubation rates were not predicted by gender, age, or EMMI
status.
Conclusion: Patients who watched an Internet-based education program
prior to their colonoscopies were more likely to attend their colonoscopies
than non-viewers. In an increasingly technological society, Internet-based
pre-procedural education programs may help improve procedure attendance
and other outcomes.
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Primary Sclerosing Cholangitis Is a More Common Indication for
Orthotopic Liver Transplantation among African American Than
Non-African American Patients
Alastair D. Smith, MB, ChB∗, Judith W. Gentile, RN, ANP. Medicine, Duke
University, Durham, NC.
Purpose: Primary sclerosing cholangitis (PSC) is a progressive, incurable
condition of unknown etiology, characterized by inflammation, fibrosis, de-
struction and loss of interlobular-sized bile ducts, leading to biliary cir-
rhosis and liver failure. Orthotopic liver transplantation (OLT) is the only
life-extending intervention for patients with end-stage PSC. Recent US Sci-
entific Registry of Transplant Recipients (SRTR) data indicate that among
patients with PSC being added to the United Network for Organ Sharing
(UNOS) waiting list the proportion of African Americans (AA) was greater
than non-AAs, compared to other disease indications. This suggests that
PSC may run a more aggressive clinical course. It was our aim to determine
whether the proportion of AA patients with PSC undergoing OLT per unit
time was different from the proportion of non-AA patients undergoing OLT
for PSC.
Methods: The SRTR was reviewed between 1998 and 2002 inclusive for all
adults (18 – 80 years) who were added to the UNOS waiting list for OLT. The
proportions of AA and non-AA patients undergoing OLT for PSC within 1
year, 1–2 years, 2–3 years, and > 3 years of being added to the waiting list
were calculated, and compared using the Chi-square test.
Results: From 1998 to 2002 inclusive 39,878 patients were added to the
UNOS waiting list for OLT. 2173 (5.45%) had PSC. Of these, 262 (12.1%)
were AA. The proportions of AA patients with PSC who underwent OLT
within 1 year, 1–2 years, 2–3 years, and >3 years of being added to the
waiting list were: 28.2% (74/262), 13.7% (36/262), 8.8% (23/262) and 5.7%
(15/262). 114/262 (43.5%) AA patients with PSC did not undergo OLT
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during the study period. The proportions of non-AA patients with PSC who
underwent OLT within 1 year, 1–2 years, 2–3 years, and > 3 years of being
added to the waiting list were: 33.5% (640/1911), 11.5% (220/1911), 4.7%
(89/1911) and 4.9% (93/1911). 869/1911 (45.5) non-AA patients with PSC
did not undergo OLT during this period. Except for the period < 1 year from
the time of OLT listing, the proportion of AA patients with PSC undergoing
OLT was significantly greater than the porportion of non-AA patients with
PSC who underwent OLT (P = 0.026).
Conclusion: These outcomes for AA patients with PSC suggest that their
disease course may be more agressive, given that patients underwent OLT
sooner from the time of listing than did non-AA patients. An alternative
explanation is that AA patients with PSC were simply sicker than non-AA
patients at the time of listing for OLT.
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Economic and Humanistic Outcomes Associated
with Timing of GERD/Heartburn Symptoms
Reema Mody, PhD∗, Hema Kannan, MPH, Susan Bolge, PhD.
TAP Pharmaceutical Products Inc., Lake Forest, IL and Consumer Health
Sciences, Princeton, NJ.
Purpose: To study the impact of timing of GERD/heartburn (HB) symptoms
on economic and humanistic outcomes, specifically health-related quality of
life (HRQOL), work productivity/activity impairment, and resource use.
Methods: Data were from the 2006 US National Health and Wellness Sur-
vey, a nationally representative, Internet-based survey of the health status,
attitudes, behaviors, and outcomes of adults. Among respondents who re-
ported experiencing GERD/HB in the past 12 months, the GERD/HB symp-
toms were categorized as occurring during the day only (DO), at night only
(NO), or during both day and night (DAN). The 3 groups were compared
on: HRQOL assessed by SF-8, work/activity impairment measured by Work
Productivity and Activity Impairment Questionnaire and resource use. Chi-
square and ANOVA were used to test for significant differences among cat-
egorical and continuous variables, respectively. All comparisons were tested
for significance at P < 0.001 level.
Results: Of the 21,250 individuals who reported experiencing GERD/HB,
13.3% reported DO symptoms, 28.2% NO symptoms, and 58.5% DAN
symptoms. DAN sufferers were significantly more likely to be female,
younger, experienced more frequent and severe symptoms, and are more
likely to use pharmacotherapy than DO or NO sufferers. DAN sufferers re-
ported significantly lower physical and mental HRQOL (43.92, 45.38 respec-
tively) than DO (47.15, 48.70) and NO (47.28, 48.08) sufferers. Among those
employed full-time, DAN sufferers reported significantly greater percentage
work productivity loss in the past 7 days compared to DO and NO suffer-
ers (18.57 v 14.94 v 14.99%), with impairment while at work contributing
more than absenteeism. DAN sufferers reported significantly greater activity
impairment compared to DO and NO sufferers (37.12 v 27.40 v 27.01%).
In the past six months, DAN sufferers reported significantly higher number
of hospitalizations and physician visits (0.67, 6.35 respectively) than DO
(0.44, 4.80) and NO sufferers (0.40, 4.60). Using linear regression models
to control for demographics and comorbidities, the significant differences in
HRQOL, work/activity impairment and resource use remained.
Conclusion: More than half of GERD/HB sufferers experience symptoms
both during the day and night. Due to the worse HRQOL, higher resource
utilization and greater work/activity impairment associated with DAN symp-
toms, GERD/HB sufferers with DAN symptoms may have a significant eco-
nomic and humanistic impact on patients, employers and society.
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Does Abnormal Computed Tomography (CT) of the Gastrointestinal
(GI) Tract Correlate with Endoscopic Findings?
Rekha Cheruvattath, MD, Stacy G. Prall, DO, Robert E. Smith, MD,
Michael J. Komar, MD, Nicholas A. Inverso, MD∗. Gastroenterology,
Geisinger Medical Center, Danville, PA.
Purpose: To determine the clinical significance of incidental GI tract abnor-
malities identified on CT.
Methods: A single center retrospective study identified patients undergoing
endoscopic evaluation for luminal GI tract abnormalities detected on CT.
Patient selection utilized a search of the electronic medical record for ICD-9
code 793.4 (nonspecific abnormal findings of GI tract on radiology exam).
Only patients with abnormal CT were included.
Results: 77 patients underwent endoscopy specifically for GI tract abnor-
malities noted on CT. The most common indication for the CT scan was
abdominal pain. Contrast (oral and iv) was used in 66 patients. CT findings
included thickened appearance of the bowel wall, mass lesions and stenoses.
Subsequent endoscopic findings are:
Colonoscopy (43/77 patients)
Gender (M/F) 22/21
Age (years) (Avg ± SD) 56.65 ± 19.9
Abnormal findings
a) Terminal ileum/Ileocecal valve) 5/9 (55.5%)(ileitis-4,
malignancy-1)
b) Right colon
(cecum/ascending/hepatic flexure)
4/12 (33.3%) (ischemia -1, colitis
-1, adenoma-2)
c) Proximal left colon (splenic
flexure/descending
3/5 (60%) (malignancy-1,
adenoma-2)
d) Rectosigmoid 10/17 (58.8%)(malignancy-3,
adenoma-2, miscellaneous∗-5)
(∗miscellaneous: proctitis-1, volvulus-1, colitis-2, stenosis-1)
Esophagogastroduodenoscopy (34/77 patients)
Gender (M/F) 13/21
Age (years)(Avg ± SD) 63 ± 12.8
Abnormal findings
a) Distal esophagus 5/16 (31.2%) (hiatal hernia-3, fundoplication-1,
varices-1)
b) Stomach (body) 3/8 (37.5%) (malignancy-1, adenoma-2)
c) Antrum 0/7 (0%)
d) Duodenum 2/3 (66.6%) (adenoma-1, granulation tissue-1)
Conclusion: Gastroenterologists routinely perform endoscopy to address
abnormalities discovered on imaging. This study addresses our center’s expe-
rience and found differences from previously published data which primarily
identified correlation in the rectosigmoid and distal esophagus. In our study,
the highest correlation between CT findings and endoscopic abnormalities
occurred in the terminal ileum, proximal left colon, rectosigmoid area and
duodenum. Although not all findings revealed sinister pathology, endoscopy
remains the primary modality to investigate radiologic abnormalities of the
GI tract.
918
Single-Dose Crossover Pharmacokinetic/Pharmacodynamic Study of
Fospropofol vs Propofol in Healthy Volunteers
Ajit Shah, PhD∗, Jo¨rg Fechner, MD, Michel Struys, MD, Bipin Mistry,
PhD. MGI Pharma, MGI PHARMA, Inc, Bloomington, MN; Department
of Anesthesiology, University of Erlangen-Nuremberg, Erlangen, Germany
and Department of Anesthesia, Ghent University Hospital, Ghent, Belgium.
Purpose: Fospropofol disodium (FP, AQUAVAN) is a water-soluble pro-
drug of propofol being developed for sedation in adults undergoing diagnos-
tic and therapeutic procedures. FP is rapidly and completely metabolized to
propofol (PFP) in vitro. This study compared the PK/PD and safety profiles
of FP versus propofol (P, DIPRIVAN) in 12 healthy subjects (20–40 yr).
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Methods: In this open-label, 2-period, crossover study, each subject received
a 10 mg/kg IV bolus of FP in the 1st period. The resulting maximal EEG
effect was recorded by minimal bispectral (BIS) index. Depth of sedation
was scored using the Modified Observer’s Assessment of Alertness/Sedation
(MOAA/S) scale. After a 7-day washout, in the 2nd period subjects received
a 50-mg/min infusion of P titrated to produce a similar EEG effect as with
FP. For PK evaluation, venous plasma samples were obtained during both
periods, predose and up to 4 h postdose. Samples were assayed for FP by
LC/MS/MS and for both PFP and P by HPLC with fluorescence detection.
BIS measurements were obtained at 1 min predose, 1 min postdose, and
at 2-min intervals until 20 min postdose or until the subject became fully
alert.
Results: PK and PD parameters[figure1]PK and PD parameters for PFP
differed from P, displaying a longer onset and duration of response, consistent
with the observed concentration-time profile of PFP. Mean t1/2 values for
P were similar for both treatments. The most common treatment-emergent
adverse events (AEs) after FP (paresthesias and pruritis) were mild and self-
limited; the most common AE after P treatment was mild dizziness.
Conclusion: FP dosing was well-tolerated, with no serious AEs. FP displays
distinct differences in PK and PD compared to P, including a longer time to
peak effect and a greater duration of effect.
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Efficacy and Safety of Teduglutide in Parenteral Nutrition
(PN)-Dependent SBS Subjects: Update of a Current Multinational
Trial
Richard Gilroy, MBBS, Nonko Pehlinov, MD, Jane Cyran, PhD, Nancy
McGraw, Roxanne Kapikian, DrPH, Lidia Demchyshyn, PhD, John
Caminis, MD∗. Nebraska Medical Center, Omaha, NE and Dept of
Clincial Development, NPS Pharmaceuticals, Parsippany, NJ.
Purpose: Massive small intestinal resection creates malnutrition, diarrhea,
and dehydration as a consequence of reduced intestinal capacity to absorb
nutrients, and this can lead to dependence on parenteral nutrition (PN) ther-
apy. Unfortunately use of PN is also associated with serious complications,
however, it is vital for many short bowel syndrome (SBS) patients. Tedug-
lutide, an analog of glucagon-like peptide-2 (GLP-2), is being evaluated for
safety, tolerability, and efficacy in reducing PN dependency in SBS patients.
We present the design and baseline characteristics of this multinational trial.
Methods: Eligibility criteria included: 18 years and older; SBS resulting
from major intestinal resection; PN dependency for at least 12 months; PN
required at least 3 times weekly; and preserved renal and hepatic function.
Subjects then entered into an intensive stabilization period to optimize PN
volume before being randomized to placebo or 0.05 or 0.1 mg/kg/day of
teduglutide for a 24-week treatment, with follow-up 4 weeks post-treatment.
Reduction in PN usage at 24 weeks of therapy was the primary endpoint, cal-
culated as an ordered categorical response. Additional assessments included
plasma citrulline, 72-hour balance studies, villous height, crypt depth, bone
density, and quality of life.
Results: A total of 139 subjects were screened and 84 randomized (37 male),
with 13 withdrawing. Up to 71 patients are expected to complete the study.
Forty percent of subjects were recruited from the US and Canada, 60% from
the EU. Subjects developed SBS due to surgical resections for: CD (37%);
vascular accidents (30%); trauma (11%); and volvulus (13%). Sixty seven
percent of subjects had a colon in continuity and 35% had a stoma. The
average remaining length of small bowel was 66 cm and 69 cm of colon.
Of the 20% of subjects with a distal/terminal ileum, 53% had an ileocecal
valve. The DSMB reviewed safety throughout the study and found no specific
concerns.
Conclusion: The target of randomizing at least 80 PN-dependent SBS pa-
tients in the teduglutide study was achieved, making this the largest clinical
trial to evaluate a treatment to decrease PN requirements in SBS patients.
The ability to reduce PN by enhancing enteral function, the therapeutic goal
of teduglutide, has the potential to lead to improved quality of life in the
SBS population.
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Impact of Adalimumab (HUMIRA) on Patient-Reported Outcomes
E.V. Loftus, MD∗, B.G. Feagan, MD, J.F. Colombel, MD, E.Q. Wu, PhD, A.
Yu, PhD, P.F. Pollack, MD, J. Chao, PhD, P. Mulani, PhD. Mayo Clinic
College of Medicine, Rochester, MN; Robarts Research Institute, London,
ON, Canada; CHU Lille, Lille, France; Analysis Group, Inc., Boston, MA
and Abbott, Abbott Park, IL.
Purpose: Adalimumab (ADA) is approved for the treatment of adults with
moderate to severe Crohn’s disease (CD). Limited research has been re-
ported on the impact of anti-TNF therapy on depressive (D) and fatigue (F)
symptoms.
Methods: To assess the effect of ADA maintenance on F and D symptoms
and traditional patient-reported outcomes (PROs), among randomized re-
sponders (RR) [pts with ≥70 point decrease from baseline CDAI score at
Week (Wk) 4] in CHARM. All pts received a starting regimen of open-label
(OL) ADA: 80 mg at BL (Wk 0), 40 mg ADA at Wk 2. At Wk 4, pts were
stratified by response and randomized to a maintenance regimen: 40 mg ADA
EOW or EW, or PBO. Differences in PROs [SF-36, IBDQ, FACIT-Fatigue
(F), and Zung Depression scale (ZD)] at Wks 0, 4, 12, 26, and 56 were eval-
uated for those receiving ADA induction only (IO) and ADA maintenance
(IM) therapy among RR. Fatigue was measured by FACIT-F (scale range
0–52), a 3–4 point change was considered clinically meaningful. Depressive
symptoms were measured by ZD (scale range 20–80, with >50 = D state).
Results: 499 responders were randomized at Wk 4 (IO, N = 170; IM,
N = 329). Week 0 PROs indicated impaired health-related quality of life
(HRQOL). The mean Wk 0 FACIT-F score = 23, similar to cancer pts with
anemia. The mean Wk 0 ZD score (IO = 55, IM = 56) suggested depres-
sion among CD pts. Pts improved across all 4 PROs during the IO phase
(Wk 4 vs. Wk 0). PROs from Wks 12–56 showed significantly improved
HRQOL for pts in the IM group vs. the IO group. FACIT-F scores showed
F symptoms were reduced in the IM group (P < 0.01 vs. IO). Reductions
in ZD scores showed statistically significantly reduced D symptoms in the
IM group (P < 0.01 vs. IO). SF-36 Physical Component (PCS) and Mental
Component (MCS) Summary PROs were greater for the IM group at Wks
26 and 56 (all P ≤ 0.05 vs. IO). Disease-specific IBDQ score improvements
were highly significant and sustained for the IM group (P < 0.01 vs. IO)
throughout the study.
Conclusion: Substantial and sustained benefits were observed for fatigue
and depression outcomes in CD patients receiving ADA maintenance ther-
apy. Adalimumab maintenance therapy also resulted in significant and sus-
tained improvements in CD-specific (IBDQ) and general (SF-36, PCS and
MCS) HRQOL measurements, compared with induction only therapy.
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Impact of Adalimumab (HUMIRA) on Patient-Reported Outcomes
among Patients with Fistulizing Crohn’s Disease in the CHARM Trial
J.F. Colombel, MD∗, E.V. Loftus, MD, B.G. Feagan, MD,
D.A. Schwartz, MD, E.Q. Wu, PhD, A. Yu, PhD, P.F. Pollack, MD,
J. Chao, PhD, P. Mulani, PhD. CHU Lille, Lille, France; Mayo Clinic
College of Medicine, Rochester, MN; Robarts Research Institute, London,
ON, Canada; Vanderbilt University Medical Center, Nashville, TN;
Analysis Group, Inc., Boston, MA and Abbott, Abbott Park, IL.
Purpose: Fistulas occur in 17–43% of patients with Crohn’s disease (CD),
and fistulizing disease is associated with worsening quality of life. Com-
plete and sustained fistula closure has been associated with adalimumab
(ADA) therapy in the CHARM trial, a Phase III randomized, double-blinded,
placebo-controlled assessment of ADA in maintaining clinical remission in
patients with CD.[1]
Methods: We assessed the impact of ADA maintenance therapy on CD-
specific health-related quality of life (HRQOL) among randomized patients
with draining fistulas observed at screening visits and at baseline (BL) of the
CHARM trial. Inflammatory Bowel Disease Questionnaire (IBDQ) evalua-
tions were conducted at BL and at Weeks 4, 12, 26, and 56 of the CHARM
trial. IBDQ scores over time between groups receiving ADA, 40 mg ev-
ery other week (EOW) or 40 mg every week (EW), or placebo (PBO), were
compared using analysis of covariance. The proportions of patients achieving
≥16-point improvement in IBDQ from BL, the minimum clinically mean-
ingful improvement, were compared using chi-square tests.
Results: The baseline CDAI and IBDQ were similar for fistulizing patients
and non-fistulizing patients (mean CDAI: 314 vs. 311; IBDQ: 123 for both
groups). Of 117 patients with fistulizing CD who entered the study, 75 had
IBDQ measurements after Week 4 and were followed through Week 56.
Statistically significant and clinically meaningful results observed with ADA
maintenance were sustained through Week 56. Mean changes in IBDQ scores
from BL and the percentage of patients achieving ≥16-point improvement
in IBDQ from BL at Week 56 are presented (table).
Change From Baseline IBDQ and% of Patients With
≥16-Point Total IBDQ Gain at Week 56
Improvements PBO 40 mg ADA EOW 40 mg ADA EW
from BL (N = 26) (N = 21) (N = 28)
Total IBDQ (mean) 21.6 43.5∗ 46.8∗
≥16-point IBDQ (%) 46 76∗ 86∗∗
∗P < 0.05, ∗∗P < 0.01, both vs. PBO.
Conclusion: Adalimumab maintenance therapy is associated with sustained
and clinically meaningful improvement of CD-specific quality of life among
patients with fistulizing Crohn’s disease as measured by the IBDQ. [1]
Colombel JF, et al. Gastroenterology. 2007;132:52–65.
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CMT vs. IO/R at Wk 56
IO/R CMT-EW CMT-EOW
Wk 56 CDAI (median) 183 154∗ 147∗
Remission, n/N (%) 99/261 (38) 125/257 (49)∗ 132/260 (51)∗
Total IBDQ, n (median) 261 (159) 257 (168)∗ 260 (168)∗
Complete fistula closure, n/N (%) 13/33 (39) 20/31 (65)∗ 11/22 (50)
CD-related hospitalization∗∗∗ Reference group 0.52 (0.32–0.83)∗∗ 0.63 (0.40–0.99)∗
All-cause hospitalization∗∗∗ Reference group 0.53 (0.36–0.78)∗∗ 0.55 (0.37–0.80)∗∗
Flares (mean) 0.98 0.85∗ 0.80∗
LOCF. ∗P < 0.05 and ∗∗P < 0.01 vs. IO/R. ∗∗∗Hazards Ratio (95% CI).
Continuous vs. Induction Only/Reinitiated Adalimumab Maintenance
Therapy Yields Optimal Results for Moderate to Severe Crohn’s
Disease: Subanalysis of CHARM
J.F. Colombel∗, W.J. Sandborn, P. Rutgeerts, A. Yu, E. Wu, P.F. Pollack, J.
Chao, P. Mulani. CHU Lille, Lille, France; Mayo Clinic, Rochester, MA;
Univ. Hospital of Gasthuisberg, Leuven, Belgium; Analysis Group, Inc.,
Boston, MA and Abbott, Abbott Park, IL.
Purpose: Fully human monoclonal antibody, adalimumab (ADA), with
demonstrated efficacy and safety in CHARM, is approved for treating mod-
erate to severe Crohn’s disease (CD). In this subanalysis, we compared
ADA efficacy of continuous maintenance therapy (CMT) vs. Induction
Only/Reinitiation (IO/R) therapies.
Methods: In CHARM, 854 pts received ADA, 80 mg/40 mg at Weeks (Wks)
0/2. At Wk 4, 778 pts were randomized to receive ADA 40 mg every other
week (EOW; N = 260) or weekly (EW; N = 257), or placebo (PBO; N = 261)
through Wk 56. At/after Wk 12, pts could switch to open-label (OL) ADA 40
mg EOW and increase to EW for flare/non-response. Pts on OL EW could not
de-escalate to EOW. ADA efficacy (remission [CDAI < 150], total IBDQ,
fistula closure, flare occurrence, and hospitalization risk) was compared
with CMT vs. IO/R—pts who received IO therapy followed by PBO, or
pts randomized to PBO and later reinitiated on OL ADA. The CMT group
included pts on randomized ADA who either remained on blinded therapy or
subsequently went to OL. A Cox proportional hazard model, after stepwise
confounder selection, estimated the effect of ADA on hospitalization risk,
controlling for Wk-4 responder status, stenosis/stricture history, and age.
Results:
Conclusion: CMT ADA therapy resulted in significantly greater remission
rates, quality of life improvements, fewer flares, and reduction in all-cause
and CD-related hospitalizations vs. IO/R therapy. The preponderance and
consistency of these analyses collectively suggest CMT with ADA yields
superior results for pts with moderate to severe CD when compared with
IO/R dosing.
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Feeding Decisions in Patients with Advanced Dementia – Formative
Research
Donald A. Garrow, MD∗, Jane G. Zapka, ScD, Elaine Amella, PhD, Mark
DeLegge, MD. GI and Hepatology, MUSC, Charleston, SC.
Purpose: To understand feeding decisions in the elderly with late-stage de-
mentia from perspectives of caregivers, primary-care physicians, gastroen-
terologists and nursing home staff, to guide strategies to improve care through
informed, shared-decision making.
Methods: In-person interviews were held with caregivers, primary-care
physicians, gastroenterologists and nursing home staff. A semi-structured
interview was designed for each group. With caregivers, interviewers were
particularly mindful of the need to not infer caregivers made “uninformed”
decisions but focused on having them “tell their stories”. Notes were sum-
marized by the two interviewers (DG and JZ).
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Results: In discussions with caregivers, the theme of “starving to death” was
clear and strong. Caregivers saw “no choice”, and a feeding tube is necessary
“when it is time”. Hand-feeding was not discussed with caregivers as an
option to tube-feeding. The primary-care physicians and geriatrician report
few of their dementia patients have feeding tubes, indicating dissonance with
general practice. All acknowledged poor efficacy of feeding tubes, “they may
increase quantity, but not quality time.” “I often do not present the option
of a feeding tube to patients.” A nursing home administrator felt it took less
time to care for a patient with a feeding tube. He appeared uncomfortable
when asked for the relative reimbursement rate for tube-feeding vs. hand-
feeding. Interestingly, the nursing-home nurse stated that there is no time
saved by tube-feeding when all skilled care is included. A gastroenterologist
felt there was pressure from nursing homes to insert feeding tubes stating
he acquiesced to a nursing-home previously on this issue. He noted that
suggestion by a gastroenterologist toward not placing a feeding tube may
be met with resistance by a family who has already made a decision for
placement. He often feels “like a mechanic” and not an active participant in
the decision-making process.
Conclusion: These pilot interviews reinforce issues of communication for
individuals involved in feeding of elderly, late-stage dementia patients.
Primary-care doctors have the challenge of communicating options in sit-
uations of emotion in the context of difficult decisions about prognosis.
Gastroenterologists are often removed from the decision-making process,
even though they have vast experience in feeding issues. A team-oriented ap-
proach, with more consideration of the primary-care challenge and gastroen-
terologist’s knowledge of nutrition and feeding, may help improve shared and
informed decision-making.
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Characteristics and Outcomes of Gastroparesis-Related
Hospitalizations in the United States, 2004
Yize Wang, MD, PhD, Robert S. Fisher, MD, FACG, Henry P. Parkman,
MD, FACG∗. Gastrointestinal Section, Department of Medicine, Temple
Univeristy School of Medicine, Philadelphia, PA.
Purpose: Gastroparesis is an increasingly recognized disorder in patients
with nausea and vomiting. In a previous analysis, we found that gastroparesis-
related hospitalizations increased 138 percent in the United States during
1995–2004 (DDW 2007; T1119). We aimed to examine the characteristics
and outcomes of gastroparesis-related hospitalizations in 2004 and com-
pare gastroparesis to common upper gastrointestinal (GI) conditions includ-
ing gastroesophageal reflux disease, gastric ulcer, gastritis, and non-specific
nausea/vomiting.
Methods: The publicly available Healthcare Cost and Utilization Project
Nationwide Inpatient Sample 2004, a nationally representative sample of 8
million hospital stays, was used. Gastroparesis-related hospitalizations were
defined as those with the primary diagnosis or a secondary diagnosis of
gastroparesis (ICD-9-CM code 536.3). Multivariate regressions were used
to control for age, sex, type of primary insurance, admittance through the
emergency department, diabetic status, number of diagnoses, and/or number
of procedures and compare differences in outcomes including length of stay,
total charges, and in-hospital deaths.
Results: Of all gastroparesis-related hospitalizations (N = 29,083), 7 per-
cent had gastroparesis as the primary diagnosis. Of hospitalizations with
gastroparesis as a secondary diagnosis, the top 3 primary diagnoses were di-
abetes with neurological manifestations (24.0%), diabetes with ketoacidosis
(5.9%), and congestive heart failure (2.8%). Compared to hospitalizations
with a common upper GI condition as the primary diagnosis, hospitalizations
with gastroparesis as the primary diagnosis were more likely to be diabetic
(27% for gastroparesis vs. 14.2–21.0% for common upper GI conditions).
The latter also had the longest length of stay (+15.4% to +66.2%, all P <
0.001) and the highest or second highest total charges (-7.2% to +60.6%, all
P < 0.01) in multivariate regressions. In 2004, it was projected gastroparesis
as the primary diagnosis led to 62,296 hospital days, $208 million hospital
charges, and 57 in-hospital deaths in the United States and that gastropare-
sis as a secondary diagnosis led to 849,667 hospital days, $3,292 million
hospital charges, and 1,709 in-hospital deaths.
Conclusion: Compared with common upper GI conditions, gastroparesis
had the longest length of stay and the highest or second highest total charges.
The economic impact of gastroparesis-related hospitalizations is significant
in the United States.
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Administrative Data for Colonoscopy with Polypectomy Have a High
Level of Accuracy
Collins N. Okolie, MD, Gregory Cooper, MD∗. Department of
Gastroenterology, University Hospitals of Cleveland Case Medical Center,
Cleveland, OH.
Purpose: Guidelines from the ACG consider colonoscopy to be the proce-
dure of choice for colorectal cancer screening. One method for monitoring
the use of colonoscopy and associated polypectomy is through the use of
administrative or billing data, which are typically recorded with Current Pro-
cedure Terminology 4th Edition (CPT-4) and International Classification of
Diseases 9th Revision (ICD-9) codes. However, the accuracy of these codes
for identifying polypectomy has not been validated in clinical practice. We
hypothesized that colonoscopy with polypectomy billing codes as recorded
by medical coders correlated well with the actual physician procedure report.
Methods: We used physician practice administrative data from 2002 and
2003 to select a random sample of 502 patients aged 65 and older with
CPT-4 codes for colonoscopy with biopsy (N = 226), hot biopsy (N =
42) or polypectomy (N = 143). We included procedures performed at a
freestanding ambulatory surgery center (ASC) as well as the endoscopy
unit of a tertiary care hospital. The corresponding endoscopy reports were
reviewed and considered to be the gold standard in the analysis. In addition,
the pathology reports were reviewed and the predictive accuracy of various
codes for identifying adenomatous polyps was determined. We measured
the sensitivity (Sens) and positive predictive value (PPV) of the procedure
codes.
Results: There was a high level of concordance between the physician billing
codes and procedure notes for snare polypectomy (Sens 99%, PPV 100%),
biopsy (Sens 98%, PPV 95%) and hot biopsy (Sens 82%, PPV 93%). To
identify adenomas 5 mm or greater, codes for snare had the highest accuracy
(Sens 75.5%, PPV 82.6%), followed by hot bx (Sens 16%, PPV 80.9%) and
cold bx with polyp diagnosis (Sens 6.9%, PPV 13.4%). To identify adenomas
of size 10 mm or greater, snare polypectomy codes had a Sens and PPV of
98.3% and 88%, respectively, with the sample size too small for cold and hot
bx. No differences in accuracy were noted between the two practice sites.
Conclusion: In this two facility study, billing codes have high level of ac-
curacy for identification of colonoscopy with biopsy, hot biopsy and snare
polypectomy. In addition, codes for snare polypectomy have the highest ac-
curacy for identification of large adenomas. These data support the use of
administrative data for studies of the use of colonoscopy and its applications.
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Beclomethasone Diproprionate + Mesalamine Enemas for Refractory
Ulcerative Proctitis. A Retrospective Analysis
Mario Guslandi, MD, FACG∗, Patrizia Giollo, MD, Pier Alberto Testoni,
MD. Gastroenterology Unit, S. Raffaele University Hospital, Milan, Italy.
Purpose: Active ulcerative proctitis is usually treated with local adminis-
tration of either mesalamine or corticosteroids. Cessation of rectal bleeding
can be already observed within a couple of weeks, but occasionally patients
do no respond to standard local therapy.
Purpose of our analysis was to establish the therapeutic role of enemas com-
bining mesalamine and beclomethasone dipropionate in patients resistant to
rectal administration of beclomethasone dipropionate alone
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Methods: We re-examined retrospectively 34 outpatients with rectal local-
ization of ulcerative colitis treated in our Unit during the last four years.
The subjects, aged 29–47 years, had experienced a clinical flare-up of the
disease during oral maintenance with mesalamine 1600 mg daily and had
been treated with rectal beclomethasone diproprionate 3 g/100 ml at bedtime
for up to 15 days with persistence of rectal bleeding.
Sixteen patients continued the ongoing local treatment with beclomethasone
enemas for further two weeks and increased the oral dose of mesalamine to
3.200 mg daily (group A). The remaining eighteen subjects maintained oral
mesalamine 1.600 mg daily and were treated for two weeks at bedtime with
a rectal enema where beclomethasone 3 g/100 was mixed with a powder
containing 1.5 g of mesalamine (group B).
Results: In group A, five patients reported no more bleeding at the end of
the treatment period, whereas eleven patients with persistent bleeding at two
weeks were switched to oral corticosteroids.
In group B sixteen of the eighteen subjects experienced disappearance of
rectal bleeding.
The difference between the two treatment groups is statistically significant:
P = 0.002 by chi-square test
Conclusion: Our preliminary, retrospective analysis suggests that: 1) rectal
administration of a mixture of beclomethasone and mesalamine is effec-
tive in patients refractory to rectal beclomethasone alone; 2) adding rectal
mesalamine to the beclomethasone enema is more effective than increasing
the dose of oral mesalamine.
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Rifaximin Improves Symptoms in Patients with Crohn’s Disease or
Ulcerative Colitis
Paul L. Berenbaum, MD, FACG∗. Hahnemann University Hospital,
Philadelphia, PA and Drexel University College of Medicine, Philadelphia,
PA.
Purpose: Inflammatory bowel disease (IBD) is a chronic intestinal disor-
der with multiple etiologies. In IBD, including disease refractory to stan-
dard first-line therapies, inflammation is likely caused by an exaggerated
immune response to commensal enteric bacteria in genetically predisposed
individuals, suggesting that antibiotic therapy may be beneficial. Systemic
antibiotics and immunomodulators are frequently administered to treat IBD.
However, systemic antibiotics may not adequately target the intestinal lu-
men, and immunomodulators do not affect the underlying pathogenic cause
of the disease. Rifaximin is a nonsystemic, gastrointestinal-specific antibi-
otic that provides targeted treatment to resolve bacterial insult and improve
IBD symptoms.
Methods: This retrospective chart review evaluated outcomes in patients
with mild-to-moderate refractory Crohn’s disease (CD) or ulcerative colitis
(UC) who received adjunctive therapy with rifaximin 400 mg 3 times daily
for 2 to 4 weeks during the period from the end of 2004 through 2005. Chart
reviews assessed disease location, previous antibiotic therapy, concomitant
medications, clinical response (>50% symptom improvement) or clinical
remission (100% symptom resolution) after initiation of rifaximin treatment,
and incidence of adverse effects.
Results: Fourteen adult patients were identified (mean age, 43 y); 3 patients
had UC and 11 patients had CD. Eleven patients (79%) had received treat-
ment with systemic antibiotics in the previous 2 weeks. Prior to rifaximin
treatment, 10 patients had been taking immunomodulators, 13 had been tak-
ing oral mesalamine, and 5 had been taking oral steroids, all with suboptimal
results. Thirteen patients (93%) had a clinical response with rifaximin, and
9 of these 13 responders (69%) experienced complete remission of IBD
symptoms. Median time to complete remission after initiation of rifaximin
treatment was 10 days. A higher rate of clinical remission was observed in
patients with IBD localized to the colon (6 of 7 patients) or ileocolon (3 of
4 patients) versus the ileum (0 of 3 patients). Concomitant treatments were
well tolerated, with only 2 reports of nausea and 1 report each of flatulence,
dyspepsia, and headache, none of which resulted in treatment discontinua-
tion.
Conclusion: These findings suggest that rifaximin 1200 mg/d for up to
4 weeks is a potentially beneficial therapy for patients with IBD. Large,
well-designed, controlled trials are warranted to confirm these promising
preliminary clinical findings.
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Gender Influences Time to Diagnosis for Patients with Crohn’s Disease
Confined to the Ileum
Sunanda V. Kane, MD, MSPH∗, Erin Aronson, BSc. Department of
Medicine, University of Chicago, Chicago, IL and Department of Medicine,
Mayo Clinic, Rochester, MN.
Purpose: Crohn’s Disease (CD) is an idiopathic inflammatory disease that
can occur anywhere along the digestive tract, with one-third of cases limited
to the distal ileum. CD of the terminal ileum causes non-specific symptoms
that can easily be mistaken for other conditions, including Irritable Bowel
Syndrome (IBS). Our aims were to assess for differences in time to diagnosis
between women and men with CD limited to the terminal ileum as well as
quantify the number of diagnostic tests until correct diagnosis for both sexes.
Methods: This was a single-center, retrospective study. Thirty-five women
with Crohn’s disease limited to the terminal ileum were matched by age
of diagnosis with 40 men also with disease limited to the terminal ileum.
Patients with any colonic or perianal disease, or who presented with acute
perforation or obstruction were excluded. Symptoms, time to diagnosis from
symptom onset, number of physician visits and number of diagnostic tests
performed were recorded.
Results: There was no difference between men and women for the age at
onset of symptoms. There was a significant difference for the length of time
of undiagnosed symptoms for women compared to men (76.7 months vs.
35.5 months, P = 0.007). Women were also more likely to have undiagnosed
symptoms for more than 36 months prior to diagnosis (OR = 3.9, 95% CI =
1.23–12.4). Women were found to be at greater risk of undergoing more
than 3 diagnostic tests prior to diagnosis (OR = 4.2, 95% CI = 1.25–14.1),
and for undergoing more diagnostic tests than men (3.85 vs. 2.55 tests, P =
0.01).
Conclusion: Women are diagnosed significantly later after symptom onset
than men and undergo more diagnostic tests before CD is diagnosed. Work
up for gastrointestinal complaints should include full assessment of the small
intestine before a diagnosis of IBS is made.
Women Men
(N = 35) (N = 40) P-value
Mean age at sx onset yrs (SD) 22.5 (4.2) 23.6 (5) NS
Mean time from symptom onset 76.7 35.5 0.007
to diagnosis (months)
Time of undiagnosed 46.4% 18.2% 0.026
symptoms > 36 mo
Mean # diagnostic tests 3.86 2.55 0.01
done pre-diagnosis
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The Different Expression of Pro-Inflammatory Cytokines and a
Pro-Apoptotic Protein, in Pelvic Ileal Pouches for Ulcerative Colitis
and Familial Adenomatous Polyposis
Raquel Franco Leal, MD, Maria de Lourdes Setsuko Ayrizono, MD, Joao
Jose Fagundes, MD, Marciane Milanski, MS, Mario Jose Saad, PhD, J.
Ricardo Navarro Goes, MD, Licio Augusto Velloso, PhD∗, Claudio Saddy
Coy, MD. Dept of Surgery, Coloproctology Unit, Campinas State
University, Campinas, Sao Paulo, Brazil and Dept of Internal Medicine,
Cellular Signalization Laboratory, Campinas State University, Campinas,
Sao Paulo, Brazil.
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Purpose: Pouchitis after total retocolectomy is the commonest complica-
tion in ulcerative colitis (UC), while is quite rare in familial adenomatous
polyposis (FAP).
Objective: To evaluate the inflammatory activity in endoscopically normal
ileal pouch mucosa, by determining the expressions of IL-1β, IL-6, IL-
8, TNF-α, a pro-apoptotic protein p-Bad, and the activation of NF-KB in
patients with UC and FAP.
Methods: Twenty patients submitted to total retocolectomy and J pouch,
asymptomatic, were evaluated, 10 patients with UC and 10 with FAP. The
control group consisted of ten individuals with normal ileo-colonoscopy
examinations. The specimens were snap-frozen in liquid nitrogen and the
expressions of TNF-α, IL-1β, IL-6, IL-8 and p-Bad were determined by
immunoblot of total protein extracts. NF-KB was evaluated by immunopre-
cipitation and immunoblot. The absence of pouchitis was assessed clinically,
histology and endoscopically, according to the Pouchitis disease activity In-
dex. All biopsies were taken after the approval by regional ethic commit, and
informed consent from the patients.
Results: TNF-α, IL-1β, IL-6, IL-8 and p-Bad expression was increased in
patients with UC, when it was compared with FAP (P < 0.05). Otherwise,
NF-KB activation was similar in both groups. The control group had little
TNF-α expression (P < 0.01) when compared with UC and FAP. There were
no statistical difference in NF-KB activation (P > 0.1) and IL-1β, IL-6, IL-8
and p-Bad expressions (P > 0.05) when compared control group with UC
and FAP.
Conclusion: This study is important because there are, to our knowledge, few
studies that evaluated inflammatory activity in asymptomatic ileal pouches,
and whether there is any relationship with pro-apoptotic proteins. The pa-
tients with UC had increased levels of the studied cytokines, even without
clinic and endoscopic evidence of pouchitis. Moreover, there was increased
p-Bad expression. These findings may suggest a higher susceptibility to
this inflammatory complication in patients with UC, and could explain the
increased epithelial cell apoptosis, that could correlates with the mucosa
atrophy in patients with pouchitis.
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Biological Therapy with Infliximab in Ulcerative Colitis:
Personal Experience
Barbara Bizzarri, MD, Fabiola Fornaroli, MD, Nicola de’ Angelis, MD,
Valentina Maffini, MD, Francesca Vincenzi, MD, Gian Luigi de’ Angelis,
Prof∗. Gynecological, Obstetrical and Neonatal Department, Pediatric
Gastroenterology Unit, Parma, Italy and Surgery, Abdominal Surgery,
Parma, Italy.
Purpose: Clinical experience of therapy with Infliximab in patients with
Ulcerative Colitis (UC) is still not well known. We report our personal ex-
perience with Infliximab in 3 patients with UC not responder or dependent
to high dosage of steroid therapy.
Methods: 3 male patients with UC were enrolled. G.E., 7 years, presented
iperacute UC (pre-mega toxic colon stage) not responder to steroid treatment.
C.D., 9 years, dependent to high dosage of steroid and with arthralgic symp-
toms and functional limitations not improved by metothrexate. I.V., 16 years,
dependent to high dosage of steroid and not improved by azatioprine started
6 months before. The classic therapeutic scheme with induction remission
therapy followed by maintenance therapy at 5 mg/kg/dose was administrated
intravenously. All patients took steroids and antihistamine therapy 3 days be-
fore the infusion and steroid was administrated intravenously just before the
infusion of Infliximab.
Results: In the first patient a progressive improvement of pre-mega toxic
colon permitted to avoid an urgent surgery. After 3 Infliximab infusions a
viral infection worsened general conditions and abdominal symptoms, de-
termining the necessity of surgery in election with colectomy by Soave with
ileo-ano anastomosis and ileostomy, after 15 days from the last infusion.
Now the patient, after reconstitution of intestinal continuity, is in good gen-
eral condition and asymptomatic. In the second patient therapy with Inflix-
imab determined a complete clinical endoscopical/histological remission of
UC and a complete remission of arthralgias after 3 infusions. This patient is
still receving biological therapy. In the third patient after 3 months from last
Infliximab infusion a rectal-sigmoidal relapse of UC was observed although
he is still in therapy with azatioprine.
Conclusion: Infliximab therapy in patients with UC is effective, but we don’t
know if and how it can condition the future natural course of the disease.
In one patient, Infliximab therapy was effective as a “bridge drug” to avoid
urgent surgery but it was not able to avoid surgery in election. In the second
patient it was useful to control the intestinal and arthralgical symptoms but
the evolution after the suspension of the therapy is not foreseeable. In the last
patient Infliximab well controlled the iperacute disease but after 3 months
from the last infusion a mild relapse occurred.
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Exposing the Weaknesses: A Systematic Review of Azathioprine
Efficacy in Ulcerative Colitis
Yvette Leung, MD, Remo Panaccione, MD, Brenda Hemmelgarn, PhD,
Jennifer Jones, MD∗. Medicine, Division of Gastroenterology, University
of Calgary, Calgary, AB, Canada and Medicine, Division of Nephrology,
University of Calgary, Calgary, AB, Canada.
Purpose: We performed a systematic review and meta-analysis to evaluate
the clinical efficacy of azathioprine or 6-mercaptopurine after standard in-
duction with corticosteroids. We also sought to explore potential sources of
clinical trial heterogeneity that may have influenced the results of previous
trials.
Methods: A comprehensive search of online databases was conducted. Only
randomized controlled trials with azathioprine or 6-mercaptopurine within
a minimum duration of follow-up of 6 months were selected. Pooled rel-
ative risk estimates were calculated for the primary outcome “success of
treatment”, defined as clinical remission or significant clinical response or
failure to relapse.
Results: In total, 6 trials were included in the systematic review and 5 in
the meta-analysis. The pooled relative risk estimate, using a random effects
model, for “success of treatment” with AZA compared to 5-ASA and/or
placebo was 1.42 (95% CI 0.93–2.17, P = 0.109). Using only trials of higher
methodology quality (Jadad score >2), the pooled relative risk estimate was
2.05 (95% CI 1.30–3.23, P = 0.002).
Conclusion: In summary pooling the results of the two trials of highest
methodologic quality demonstrated a modest efficacy of azathioprine com-
pared to 5-ASA and/or placebo for the successful treatment of ulcerative
colitis. These results must be interpreted with caution as they are based on
two relatively small trials. Therefore, although the use of azathioprine is
common in the management of UC this practice is not based on high quality
evidence.
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Mycobacterium Paratuberculosis in Crohn’s Disease Granulomas
Sonia Toracchio, PhD, Hala El-Zimaity, MD, Carlos Urmacher, MD,
Seymour Katz, MD, David Y. Graham, MD∗. Medicine, Baylor College of
Medicine, Houston, TX; Pathology, CBLPath, Inc, Rye Brook, NY;
Gastroenterology, Great Neck, NY and Medicine, VAMC, Houston, TX.
Purpose: Crohn’s disease is a chronic inflammatory bowel disease of as
yet unknown and possibly heterogeneous aetiology. A possible infectious
aetiology has also been repeatedly discussed. One of the most plausible
candidates is Mycobacterium avium subspecies paratuberculosis (MAP).
Numerous authors have explored the link between MAP and Crohn’s disease
using various methods on biopsies, resections, fresh, frozen, and paraffin-
embedded tissue, with variable results.
Aim: To examine the detection rate of MAP in patients with Crohn’s disease
using paraffin-embedded tissues and a semi-nested IS900 specific PCR.
Methods: Paraffin-embedded tissues of patients with Crohn’s disease were
analyzed. Microdissection of granulomas and peri-granulomas (normal) was
performed. On the basis of sequence reported in GenBank alignments, we
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designed primer sets specific for M. avium subsp. paratuberculosis. The
presence of the MAP was examined by semi-nested IS900 specific PCR.
Results: Human beta-actin gene was amplified in all cases, indicating suc-
cessful DNA quality. Detection rate of MAP specific IS900 DNA by PCR
was appropriately identified from two controls (paraffin-embedded tissue
and bacteria culture) confirming the specificity and sensitivity of designed
primers. The presence of MAP was found in 1/20 (5%) patients with Crohn’s
disease; in this case the semi-nested PCR targeting IS900 was positive in
microdissected granuloma.
Conclusion: We designed a PCR assay that permits the detection of short
DNA fragments of the MAP specific IS900 gene in paraffin-embedded sam-
ples. Furthermore, the use of microdissection permitted to detect MAP DNA
in granulomas in one patient with Crohn’s disease. Detection of MAP DNA
within granuloma might suggest an infectious etiology in a small subset of
patients with Crohn’s disease.
Acknowledgments: Dr. Sonia Toracchio was supported by a fellowship from
Fondazione Italiana per la Ricerca sul Cancro (FIRC), Milan, Italy.
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Surveillance Pouch Endoscopy for the Detection of Dysplasia in
Ulcerative Colitis Patients with Ileal-Pouch Anal Anastomoses Is
Cost-Effective (IPAA)
Bo Shen, MD∗, Alex Z.H. Fu, PhD, Bret Lashner, MD, Feza H. Remzi, MD,
Victor W. Fazio, MD. Digestive Disease Center, Cleveland Clinic,
Cleveland, OH.
Purpose: Dysplasia or cancer can still occur in the anal transitional zone
(ATZ) or ileal pouch mucosa after IPAA for ulcerative colitis (UC). Whether
surveillance pouch endoscopy is needed is controversial. The aim of the
study is to evaluate the cost-effectiveness of pouch endoscopy with different
surveillance strategies using Markov decision-tree models.
Methods: The target population was adult IPAA patients with underlying
UC. One year was used as the transitional cycle in the model. The yearly
transitional probabilities, i.e., the annual incidences, were derived from a
literature review. A hypothetical population size of 1000 with an average
starting age of 40 was followed for 30 years. Only costs associated with
surveillance (from payers’ perspective) were considered. The effectiveness
outcome in the analysis is measured in person-year that surveillance would
advance the diagnosis of dysplasia. High-risk patients were defined as those
with chronic pouchitis; severe villous atrophy of pouch mucosa; cuffitis; pri-
mary sclerosing cholangitis; pre-operative diagnosis of backwash ileitis, dys-
plasia or cancer; and family history of colon cancer. The cost-effectiveness
threshold of $50,000 per life-year was applied for the decision analysis.
Results: The estimated incidence rates for dysplasia of any grade in the
ATZ or pouch mucosa were 0.34% and 1.93% for average-risk and high-risk
patients, respectively. Sensitivity analysis was conducted within the ranges
specified for costs and annual incidences. The surveillance strategy is very
sensitive to the estimated annual incidence.
Conclusion: Surveillance pouch endoscopy is cost-effective for average-risk
patients (Q 3 yrs) and for high-risk patients (Q 1 yr), which was sensitive to
change in incidence rates.
Cost-effectiveness Analysis of Surveillance for dysplasia (N = 1000, T = 30 years):
Total Cost Person-year Advanced Incremental Cost-Effectiveness ratio,
(C, million$) Dx of Dysplasia (E) $ per person-year
No surveillance, average/high risk 0/0 0/0 NA
Q 10 yr surveillance, average/ high 1.6/1.6 1006/4994 1,596/322
Q 5 yr surveillance, average/high risk 3.2/3.2 1254/6153 6,475/1,385
Q 3 yr surveillance, average/high risk 5.4/5.4 1353/6607 21,668/4,717
Q 2 yr surveillance, average/high risk 8.0/8.0 1402/6832 54,264/11,906
Q 1 yr surveillance, average/high risk 16.1/16.1 1451/7055 162,978/35,974
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The Influence of Immune Modifier Therapy on the Development of
Non-Melanoma Skin Cancer in Patients with Crohn’s Disease under
Age Fifty
Garfield Grandison, MBBS, William J. Tremaine, MD∗, Clark C. Otley,
MD. Internal Medicine, Mayo Clinic, Rochester, MN; Dermatology, Mayo
Clinic, Rochester, MN and Gastroenterology and Hepatology, Mayo Clinic,
Rochester, MN.
Purpose: A few case reports have identified the use of immune suppressive
drugs for treatment of inflammatory bowel disease as a risk for the develop-
ment of skin cancer. Non-melanoma skin cancer (NMSC) is more common
in men and usually occurs in those older than age 50. The aim of this study
was to investigate the relationship of NMSC to immune suppression therapy
among patients with Crohn’s disease less than age 50.
Methods: With IRB approval, a retrospective chart review of patients at
Mayo Clinic, Rochester, MN, who had documented CD diagnosed between
1975 and 2004 and who were subsequently diagnosed with NMSC. Inclusion
criteria were: age less than 50 at the time of skin cancer diagnosis; diagnosis
of skin cancer at least 2 years after CD diagnosis; no prior history of skin
cancer or pre-malignant skin disease; and residence in Minnesota, Iowa,
Illinois, Wisconsin, N. Dakota, or South Dakota.
Results: 15 patients (7 Caucasian males, 8 Caucasian females), who met
the inclusion criteria were identified: 7 received either no medical therapy or
only mesalamine for CD prior to developing NMSC while 8 received immune
suppressive drugs (steroids only = 2, Azathioprine/6-MP = 6). None of the
patients had received infliximab or other biologic therapies. The median
ages for those who did not and those who did receive immune suppression
were 43 years and 46 years, respectively, P = 0.327. The median time from
diagnosis of CD to diagnosis of NMSC was 14.1 years in the group receiving
no immune suppressives and 15.5 years in the immune suppressive group,
P = 0.921. All 7 patients (4 males, 3 females) who did not take immune
suppressives developed basal cell carcinomas (BCCs), and 2 also developed
squamous cell cancers (SCC). Among the 8 patients (3 males, 5 females)
who took immune suppressives, 6 developed SCCs (2 also had BCCs), and
2 other patients had BCCs only. No patient developed more than 2 NMSCs
over the study period.
Conclusion: Among patients with Crohn’s disease who developed non-
melanoma skin cancer before age 50, there was no gender predominance,
and treatment with immune suppression was not associated with an increased
risk of skin cancer.
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MMXTM Mesalamine Is Effective for the Maintenance of Remission of
Mild-to-Moderate Ulcerative Colitis Irrespective of Patients’ Previous
Relapse History
William J. Sandborn, MD∗, Robyn Karlstadt, MD, Karen Barrett, MSc,
Raymond E. Joseph, MD. Inflammatory Bowel Disease Clinic, Mayo
Clinic, Rochester, MN; Shire Pharmaceuticals Inc., Wayne, PA and Shire
Pharmaceuticals Inc., Basingstoke, Hampshire, United Kingdom.
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Purpose: To investigate the effect of relapse history in patients with mild-to-
moderate ulcerative colitis (UC) on the efficacy of maintenance therapy with
MMX Multi Matrix System (MMX) mesalamine (LIALDATM [MEZA-
VANTTM XL in the UK and Ireland, MEZAVANTTM elsewhere]).
Methods: Patients with active, mild-to-moderate ulcerative colitis (UC) in
two phase III, randomized, placebo-controlled studies (SPD476–301 and -
302), received MMX mesalamine 2.4 or 4.8 g/day, or placebo, for 8 weeks. An
ASACOL (mesalamine) delayed-release tablet (Procter & Gamble Phar-
maceuticals, Cincinnati, OH, USA) 2.4 g/day internal reference arm was also
included in study 302. Patients not in remission after study 301 or 302 could
receive an additional 8 weeks’ high-dose (4.8 g/day) MMX mesalamine
therapy as part of a long-term, open-label study (SPD476–303). Patients in
remission at the end of study 301, 302 or the 8-week extension phase of
303 could enter the 303 maintenance phase and receive MMX mesalamine
2.4 g/day for 12 months. Remission was defined as a modified UC Dis-
ease Activity Index score of ≤1, calculated as: rectal bleeding and stool
frequency scores of 0, a combined Physician’s Global Assessment score and
sigmoidoscopy score of ≤1, no mucosal friability; and ≥1-point reduction
in sigmoidoscopy score from baseline.
Results: 438 evaluable patients with complete relapse records prior to the
parent studies’ baseline entered the 12-month maintenance phase. Overall,
290 patients (66%) achieved remission at 12 months. Of patients who previ-
ously experienced <3 relapses in the two years prior to parent study baseline,
70.1% (192/274) achieved remission at 12 months. In comparison, 59.8%
(98/164) of patients who previously experienced ≥3 relapses in the two years
prior to parent study baseline achieved remission at 12 months.
Conclusion: Relapse history may identify patients with difficult-to-control
UC in whom long-term remission rates may be reduced. Nevertheless, about
60% of patients who experience ≥3 relapses in the two years prior to re-
ceiving treatment with MMX mesalamine are likely to be in remission up
to one year later when receiving MMX mesalamine 2.4 g/day maintenance
therapy. Further studies are needed to determine if a higher maintenance
dose of MMX mesalamine is warranted in patients who are prone to relapse.
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MMXTM Mesalamine Is Effective for the Maintenance of Ulcerative
Colitis Remission in Both Left-Sided and Extensive Disease
Gary R. Lichtenstein, MD∗, Michael A. Kamm, MD, Robyn Karlstadt, MD,
Ron Diebold, PhD, Karen Barrett, MSc, Raymond E. Joseph, MD.
Division of Gastroenterology, University of Pennsylvania, Philadelphia,
PA; Department of Gastroenterology, St. Mark’s Hospital, London, United
Kingdom; Shire Pharmaceuticals Inc., Wayne, PA and Shire
Pharmaceuticals Inc., Basingstoke, Hampshire, United Kingdom.
Purpose: A combined analysis of two phase III, placebo-controlled studies
(SPD476–301 and -302) has demonstrated mesalamine with MMX Multi
Matrix System (MMX) technology (LIALDATM, also known as MEZA-
VANTTM XL in the UK and Ireland, and as MEZAVANTTM elsewhere; here-
after referred to as MMX mesalamine) to be efficacious for the induction of
remission of active, mild-to-moderate ulcerative colitis (UC), in patients with
left-sided (distal to the splenic flexure) or extensive (involving the transverse
colon) disease. In a subsequent 12-month extension study (SPD476–303),
MMX mesalamine 2.4 g/day has demonstrated efficacy for maintenance of
UC remission. Here we present a post-hoc analysis of 12-month remission
rates with MMX mesalamine therapy in patients with a medical history of
either left-sided or extensive UC.
Methods: Patients were randomized to MMX mesalamine 2.4 g/day given
once daily (QD) or 1.2 g given twice daily (BID) for 12 months. Remission
was defined as a modified Ulcerative Colitis Disease Activity Index score ≤1,
calculated as: scores of 0 for rectal bleeding and stool frequency, a combined
Physician’s Global Assessment and sigmoidoscopy score of ≤1, no mucosal
friability, and a sigmoidoscopy score reduction of ≥1 from baseline.
Results: In total, 451 patients were included in the efficacy population. Of the
450 with known extent of disease, 67.0% (233/348) and 64.7% (66/102) of
patients with left-sided or extensive disease, respectively, were in remission
at month 12. The results were similar with once- or twice-daily treatment in
patients with left-sided (QD = 65.5%, BID = 68.4%, P = 0.570) or extensive
disease (QD = 60.4%, BID = 68.5%, P = 0.393).
Conclusion: MMX mesalamine 2.4 g/day is effective for the maintenance of
remission of mild-to-moderate UC in both left-sided and extensive disease.
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Long-Term Remission Rates in Patients with Mild-to-Moderate
Ulcerative Colitis Who Require an MMXTM Mesalamine Dose
Increase To Induce Initial Remission
Stephen B. Hanauer, MD∗, Michael A. Kamm, MD, Ron Diebold, PhD,
Karen Barrett, MSc, Raymond E. Joseph, MD. Section of
Gastroenterology and Nutrition, University of Chicago, Chicago, IL;
Department of Gastroenterology, St. Mark’s Hospital, London, United
Kingdom; Shire Pharmaceuticals Inc., Wayne, PA and Shire
Pharmaceuticals Inc., Basingstoke, Hampshire, United Kingdom.
Purpose: MMX Multi Matrix System (MMX) mesalamine (LIALDATM
[US] MEZAVANTTM XL [UK and Ireland] and MEZAVANTTM [else-
where]), is a novel high-strength, once-daily 5-aminosalicylic acid therapy
that has been shown to be efficacious for the induction and maintenance of
remission of mild-to-moderate ulcerative colitis (UC) in a phase III clinical
trial program. Here we examine long-term remission rates in patients who
required a MMX mesalamine dose escalation to induce remission.
Methods: In two placebo-controlled, phase III clinical trials (SPD476–
301 and -302), patients with active, mild-to-moderate UC received MMX
mesalamine 2.4 or 4.8 g/day for up to 8 weeks to induce remission. Those
patients not in remission at the end of these trials could opt to receive a
further 8 weeks’ treatment with MMX mesalamine 4.8 g/day (as part of a
two-phase, open-label trial [SPD476–303]). Patients who achieved remis-
sion in these studies could choose to receive MMX mesalamine 2.4 g/day
maintenance therapy for 12 months (second phase of study 303). In this ret-
rospective analysis, we determined 12-month remission rates for (a) patients
who received MMX mesalamine 2.4 g/day as induction therapy and then
entered the maintenance study directly; and (b) patients who received 2.4
g/day plus a further 8 weeks of high-dose MMX mesalamine therapy before
entering the maintenance phase (2.4 g/day).
Results: Seventy-nine patients received MMX mesalamine 2.4 g/day in stud-
ies 301 and 302 and entered the maintenance phase directly. A total of 53
patients received MMX mesalamine 2.4 g/day for 8 weeks, plus a further 8
weeks’ MMX mesalamine 4.8 g/day and then entered the 12-month main-
tenance phase of study 303. Twelve-month remission rates were 73.4% for
patients who directly entered the maintenance phase, and 50.9% for those
who entered via the 8-week extension phase.
Conclusion: In this analysis, in patients initially treated with MMX
mesalamine 2.4 g/day, the requirement for further treatment at a higher dose
to achieve remission was associated with reduced long-term remission rates.
These patients may represent a difficult-to-treat subgroup who may require
a higher maintenance dose of MMX mesalamine. Further studies are needed
to test this hypothesis.
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Time to Initial Symptom Resolution with MMXTM Mesalamine
Therapy for Active, Mild-to-Moderate Ulcerative Colitis
William J. Sandborn, MD∗, Robyn Karlstadt, MD, Karen Barrett, MSc,
Raymond E. Joseph, MD. Inflammatory Bowel Disease Clinic, Mayo
Clinic, Rochester, MN; Shire Pharmaceuticals Inc., Wayne, PA and Shire
Pharmaceuticals Inc., Basingstoke, Hampshire, United Kingdom.
Purpose: An important endpoint for both patients and physicians when
treating active, mild-to-moderate ulcerative colitis (UC) is the time between
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initiation of therapy and initial symptom resolution. Here we present the
median time to initial resolution of rectal bleeding and normalization of
stool frequency from a post-hoc analysis of pooled data from two phase
III, placebo-controlled, double-blind, double-dummy studies (SPD476–
301 and -302) of MMX Multi Matrix System (MMX) mesalamine
(LIALDATM [MEZAVANTTM XL in the UK and Ireland, MEZAVANTTM
elsewhere]).
Methods: Patients with active, mild-to-moderate UC were randomized to
MMX mesalamine 2.4 g/day (given once or twice daily) or 4.8 g/day (given
once daily) or placebo, for 8 weeks. Time to initial resolution of symptoms
(i.e. resolution of rectal bleeding, normalization of stool frequency, or both
combined) was defined as the time between first dose of study medication
and the first day of symptom resolution (defined for rectal bleeding and stool
frequency as a score of 0).
Results: A total of 517 patients were included in the intent-to-treat popu-
lation. Median time to resolution of symptoms (stool frequency and rectal
bleeding) was 25, 26 and 44 days, in the MMX mesalamine 2.4 g/day, 4.8
g/day and placebo groups, respectively (Kaplan-Meier log-rank test: P =
0.0001). For the resolution of rectal bleeding median times were 7, 8, and
16 days, respectively (Kaplan-Meier log-rank test: P < 0.0001). For the
normalization of stool frequency median times were 19, 20, and 34 days,
respectively (Kaplan-Meier log-rank test: P = 0.0001).
Conclusion: Once- or twice-daily MMX mesalamine offers initial resolution
of UC symptoms within weeks of starting the medication.
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Once- or Twice-Daily MMXTM Mesalamine for the Maintenance of
Remission of Mild or Moderate Ulcerative Colitis
Remo Panaccione, MD∗, Michael A. Kamm, MD, Robyn Karlstadt, MD,
Ron Diebold, PhD, Karen Barrett, MSc, Raymond E. Joseph, MD.
Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, AB,
Canada; Department of Gastroenterology, St. Mark’s Hospital, London,
United Kingdom; Shire Pharmaceuticals Inc., Wayne, PA and Shire
Pharmaceuticals Inc., Basingstoke, Hampshire, United Kingdom.
Purpose: Mesalamine with MMX Multi Matrix System (MMX) technol-
ogy (LIALDATM, also known as MEZAVANTTM XL in the UK and Ireland,
and as MEZAVANTTM elsewhere) is a novel, high-strength formulation of
5-aminosalicylate (5-ASA; 1.2 g per tablet), designed to release 5-ASA
throughout the colon. An analysis of combined data from two randomized,
phase III trials (SPD476–301 and -302) demonstrated the efficacy of MMX
mesalamine for improving remission rates in patients with active, mild (Ul-
cerative Colitis Disease Activity Index [UC-DAI] score 4-<6) or moderate
ulcerative colitis (UC-DAI score 6–10). In a subsequent 12-month extension
study (SPD476–303), in patients achieving remission, MMX mesalamine 2.4
g/day was shown to be efficacious for maintenance of remission. Here, data
from study 303 were analyzed to assess the efficacy of MMX mesalamine
for the maintenance of remission in patients with either mild or moderate
ulcerative colitis.
Methods: Patients were randomized to receive MMX mesalamine 2.4 g/day
(given once daily [QD]) or 2.4 g/day (1.2 g given twice daily [BID]).
Data were analyzed to assess remission rates by baseline disease sever-
ity. Remission at 12 months was defined as a modified UC-DAI score of
≤1 calculated as: rectal bleeding and stool frequency scores of 0, a com-
bined Physician’s Global Assessment and sigmoidoscopy score of ≤1, no
mucosal friability, and ≥1-point reduction in sigmoidoscopy score from
baseline.
Results: In the efficacy population (N = 451), 12-month remission rates
were 70.5% (117/166) for patients with mild disease at baseline, and 64.2%
(183/285) for patients with moderate disease at baseline. Remission rates
were not significantly different in patients receiving MMX mesalamine 2.4
g/day QD or BID for mild disease (69.0 vs 72.2%, P = 0.653) or moderate
disease (61.4 vs 66.7%, P = 0.352).
Conclusion: MMX mesalamine 2.4 g/day, given QD or BID, is efficacious
for the maintenance of remission of both mild and moderate ulcerative colitis.
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The Effect of Prolonged Therapy with MMXTM Mesalamine in
Patients with Acute, Mild-to-Moderate Ulcerative Colitis
Gary R. Lichtenstein, MD∗, Michael A. Kamm, MD, Remo Panaccione,
MD, Karen Barrett, MSc, Kirstin Lees, MA, Raymond E. Joseph, MD.
Division of Gastroenterology, University of Pennsylvania, Philadelphia,
PA; Department of Gastroenterology, St. Mark’s Hospital, London, United
Kingdom; Division of Gastroenterology, University of Calgary, Calgary,
AB, Canada; Shire Pharmaceuticals Inc., Basingstoke, Hampshire, United
Kingdom and Shire Pharmaceuticals Inc., Wayne, PA.
Purpose: MMX mesalamine (LIALDATM [US] MEZAVANTTM XL [UK
& Ireland] MEZAVANTTM [elsewhere]), a novel, high-strength formulation
of 5-aminosalicylic acid (5-ASA), has demonstrated induction of remission
of mild-to-moderate ulcerative colitis (UC) in two phase III, placebo (pb)-
controlled studies (SPD476–301 and -302 [parent studies]). The purpose of
this analysis was to determine the proportion of patients (pts) not responding
to acute treatment in these parent studies who could achieve remission in an
8-week extension study.
Methods: Pts in the parent studies received MMX mesalamine 2.4 g/d (once
daily [QD; 302] or 1.2 g twice daily [BID; 301]), 4.8 g/d (QD [301 and
302]), ASACOL (mesalamine) delayed-release tablets (Procter & Gamble
Pharmaceuticals, Cincinnati, OH, USA) 2.4 g/d (0.8 g three times daily
[TID; 302]) or pb [301 and 302] for 8 weeks. Pts not in remission after the
parent studies could receive an additional 8 weeks’ high-dose (4.8 g/d [2.4 g
BID]) MMX mesalamine therapy in the extension phase of this open-label
trial (SPD476–303). Remission rates (modified UC Disease Activity Index
score of ≤1, calculated as: rectal bleeding and stool frequency scores of 0; a
combined Physician’s Global Assessment and sigmoidoscopy score of ≤1;
no mucosal friability; and ≥1-point reduction in sigmoidoscopy score from
baseline) were calculated at week 8 of the extension study.
Results: A total of 304 pts entered the 8-week extension phase and were in-
cluded in the efficacy population. Overall, 59.5% of pts achieved stringently
defined remission. Remission rates were similar regardless of previous treat-
ment in the parent studies: pb = 57.0%; MMX mesalamine 2.4 g/d (QD or
BID) = 61.5%; MMX mesalamine 4.8 g/d (QD) = 60.3%; ASACOL 2.4
g/d (0.8 g TID) = 61.0%.
Conclusion: An additional 8 weeks’ MMX mesalamine therapy was able to
induce stringently defined remission in a large proportion of pts failing an
initial 8 weeks of 5-ASA therapy. Some pts may therefore avoid therapeutic
escalation by continuing 5-ASA treatment beyond 8 weeks; although further
studies are required to confirm this.
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Predictors of 5-ASA Prescription Persistence during the Chronic
Phase in Patients with Ulcerative Colitis (UC)
Sunanda Kane, MD, Simon Magowan, MD, Neil Accortt, PhD, Diana
Brixner, PhD∗. University of Chicago, Chicago, IL; P&G
Pharmaceuticals, Mason, OH and University of Utah, Salt Lake City, UT.
Purpose: To identify predictive factors for 5-ASA non-persistence in pa-
tients with UC (defined as no 5-ASA refill at 12 mos).
Methods: This retrospective cohort study used records of health service uti-
lization from the Thomson Medstat MarketScan research database. Treat-
ment initiation (index date) was defined as 5-ASA use between Oct 2002–
Sept 2004 with no 5-ASA use in the prior 6 mos. Study subjects were patients
≥18 years of age with a diagnosis of UC (ICD-9:556) in the period of inter-
est and had refilled their prescription at 3 mos post index date. Subsequent
5-ASA prescription refill activity was captured at 12 mos; chronic keepers
were defined as individuals who refilled their 5-ASA prescription at 12 mos
(+/−30 days) whereas quitters did not refill at 12 mos (+/−30 days). Pa-
rameters of interest were captured from the 3 mo time point until the 12 mo
time point and compared between keepers and quitters. Logistic regression
modeling was used to identify independent predictors of non-refill persis-
tence.
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Results: 2,044 UC patients with 5-ASA prescriptions were identified; 920
patients (45%) did not refill their 5-ASA at 12 mos. GI hospitalization, co-
morbid illness, mail order, and younger age were among the parameters
significantly associated with non-persistence. Factors not found to be sig-
nificantly associated with persistence were gender, endoscopy, psychiatric
history, steroid or immuno-modulator use, number of GI office visits, and
non-UC concomitant medications.
Significant Factors Associated with
Risk of Not Refilling 5-ASA at 12 Months
Parameters Odds Ratio P-value
Higher risk of not
refilling
GI hospitalization (6.3%) 1.59 0.02
Mail order of 3-month script
(16.5%)
1.50 0.001
Co-morbid conditions 1.04 <0.0001
Lower risk of not
refilling
Age (per 1 year increase) 0.99 0.02
Use of rectal 5-ASA (16.7%) 0.63 0.0004
Switched to a different
5-ASA (7.7%)
0.53 0.0008
aParentheses denote the percentage of total study population with specific characteristic
Conclusion: Persistence of maintenance therapy among UC patients taking
5-ASAs is multifactorial, though the factors related to persistence during
the chronic disease phase differ somewhat from those of the acute phase,
particularly sex and psychiatric history. Clinical knowledge of these factors
can help with patient management.
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Rapid Clinical Remission Is Significant for the Well-Being of
Ulcerative Colitis Patients Treated with Delayed-Release Mesalamine
E. Jan Irvine, MD, Simon Magowan, MD, Margaret Pasquale, PhD,
Seymour Katz, MD∗. St. Michael’s Hospital/University of Toronto,
Toronto, ON, Canada; P&G Pharmaceuticals, Mason, OH and Nassau
Gastroenterology Associates, Great Neck, NY.
Purpose: Rapid improvement in bowel symptoms is a key treatment goal for
ulcerative colitis patients experiencing a flare, and has important implications
for overall patient satisfaction with treatment. However, there is a paucity of
data reporting quality of life benefits for the patient achieving rapid clinical
remission.
The purpose of this analysis is to quantify the improvement in social, emo-
tional, systemic, and bowel domains associated with clinical remission at 3
weeks using the Inflammatory Bowel Disease Questionnaire (IBDQ).
Methods: Combined data from two large multi-center, randomized, double-
blind, active-controlled trials of similar design (ASCEND I & II) were an-
alyzed for mildly and moderately active UC patients treated with Asacol
(mesalamine) delayed-release tablets 2.4 g daily and who completed the
IBDQ at 3 weeks after initiation of therapy (N = 274). Clinical remission
was defined as patients achieving both a rectal bleeding score = 0 and a stool
frequency score = 0 at 3 weeks. The change in IBDQ scores from baseline
to 3 weeks for Responders to therapy (those patients who achieved clinical
remission at 3 weeks) were compared to the scores of Non-responders to
therapy (those patients who did not achieve clinical remission at 3 weeks).
Results: All domain scores (social, emotional, systemic, and bowel) for
Responders were statistically significantly better relative to Non-responders
at 3 weeks (Fig. 1). Additional improvement in the IBDQ scores for each
domain is observed for the Responders at 6 weeks (P < 0.005).[figure1]
Conclusion: These results indicate that an early time to clinical remission is
significantly associated with improvement in patient well-being, as measured
by changes in IBDQ scores.
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Rapid Symptom Resolution with Delayed Release Mesalamine in
Mildly and Moderately Active UC
William J. Sandborn, MD, Seymour Katz, MD, David Ramsey, MS, Daniel
H. Present, MD∗. Mayo Clinic, Rochester, MN; Nassau Gastroenterology
Associates, Great Neck, NY; P&G Pharmaceuticals, Mason, OH and
Mount Sinai School of Medicine, New York, NY.
Purpose: To evaluate time to clinical remission in patients with mild and
moderate active UC receiving 2.4 g/d of Asacol (mesalamine) delayed-
release tablets.
Methods: Data from 2 multi-center, randomized, double-blind, active-
controlled, 6-wk studies of similar design (ASCEND I&II) were combined
and analyzed. The studies included patients with mild (PGA = 1) and mod-
erate (PGA = 2) active UC. This analysis includes data from the 2.4 g/d
active control arms of these studies. Clinical remission was defined as res-
olution (score = 0) of both rectal bleeding (RB) and stool frequency (SF).
Resolution of RB was defined as the absence of visible blood in stools
and resolution of SF was defined as a patient’s return to his/her normal
number of stools/day. To be included in analysis patients had to have symp-
toms at baseline. Time to clinical remission was defined as the first day
of 3 consecutive days of complete symptom resolution based on symp-
toms recorded by patients daily through an integrated voice response system
(IVRS).
Results: 687 patients were randomized in the 2 studies, of which 349 received
2.4 g/d. Based on IVRS data, the median time to clinical remission in patients
with mild and moderate active UC was 26 days (95% CI 24,33). Time to
clinical remission by disease severity is shown below:[figure1]In addition,
results of the time to complete resolution analysis by individual symptoms
and disease severity are shown below:
Mild and Moderate Mild UC Moderate
UC (Median) (Median) UC (Median)
RB 15 days 4 days 21 days
(95% CI, 10,18) (95% CI, 3,5) (95% CI, 17,28)
SF 21 days 10 days 26 days
(95% CI, 16,24) (95% CI, 7,15) (95% CI, 22,38)
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Asacol 2.4 g/d was well-tolerated, with adverse events consistent with those
described in the current prescribing information. In pivotal clinical studies
of active UC, the most frequent adverse events reported for Asacol were
headache, abdominal pain, and eructation.
Conclusion: In active UC, rapid symptom relief is a key treatment goal.
Asacol 2.4 g/d provided rapid symptom relief in patients with mild and
moderate active UC.
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Comparable Pharmacokinetics (PK) of Two Delayed Release
Formulations of Oral Mesalamine
William J. Sandborn, MD, Guhan Balan, PhD, Barbara Kuzmak, PhD,
Stephen B. Hanauer, MD∗. Mayo Clinic, Rochester, MN; P&G
Pharmaceuticals, Mason, OH and University of Chicago, Chicago, IL.
Purpose: Both Asacol and LialdaTM are delayed release mesalamine
preparations for topical action in the colon with a pH dependent coating
that controls mesalamine release at pH ≥ 7. Lialda also contains lipophilic
and hydrophilic excipients. According to labeling, Asacol is dosed TID and
Lialda is dosed QD for mild to moderate active UC. The purpose of this
study is to evaluate the PK parameters from 2.4 g/d of oral mesalamine
administered as Lialda QD, Asacol QD and Asacol TID.
Methods: 37 healthy volunteers completed the randomized, open-label, par-
allel group, steady state PK study. All doses were taken within 30 minutes
of a meal/snack, and subjects were dosed for 7 consecutive days. Plasma
samples were obtained once daily up to day 7 and for 48 hrs after the first
dose on day 7. Urine was collected over 8 hr intervals for 24 hrs after the first
dose on day 7. Plasma and urine samples were analyzed for 5-ASA & N-
Ac-5-ASA using a validated LC/MS assay. PK parameters were calculated
using non-compartmental methods.
Results: 5-ASA plasma PK parameters and profile of all 3 treatment arms
are shown in the following Table and Figure:
[figure1]The plasma PK parameters for 5-ASA & N-Ac-5-ASA were com-
parable across all treatment arms. The total (5-ASA & N-Ac-5-ASA) urinary
excretion was 18%, 17.7%, and 15.2% for Lialda QD, Asacol QD, and Asacol
TID, respectively.
5-ASA Day 7 PK Parameters – Least Square Geometric Means (95% CI)
Lialda QD Asacol QD Asacol TID
AUC24 ng.hr/mL 13556 (7616,24128) 14358 (8132,25350) 10679 (6168,18491)
Cmax ng/mL 1553 (857,2812) 1420 (790,2550) 1145 (651,2016)
t1/2(hrs) 10.2 (5.8,17.9) 9.6 (5.6,16.5) 8.5 (5.0,14.7)
Fluctuation Index(%) 240 (163,352) 182 (125,266) 206 (143,297)
Conclusion: Overall, Asacol and Lialda dosed QD exhibited a similar PK
profile in healthy volunteers. These results suggest no apparent differences
in the release profile of Lialda or Asacol given once daily. In addition, al-
though not statistically significant, the Asacol TID arm shows less fluctuation
relative to the Lialda QD arm (P = 0.56); clinical significance unknown.
945
Previous History of Steroid Use Does Not Preclude Treatment
with Mesalamine in Ulcerative Colitis (UC)
Seymour Katz, MD, Bruce R. Yacyshyn, MD, David L. Ramsey, MS, Gary
R. Lichtenstein∗. Nassau Gastroenterology Associates, Great Neck, NY;
Procter & Gamble Pharmaceuticals, Mason, OH and Hospital of the
University of Pennsylvania, Philadelphia, PA.
Purpose: To determine effect of high dose delayed-release oral mesalamine
(4.8 g/d) in patients with moderately active UC previously treated with oral
or IV steroids.
Methods: Data from 2 multi-center, randomized, double-blind, active-
controlled studies of similar design (ASCEND I&II) were combined and
analyzed. Efficacy and safety of delayed-release mesalamine 4.8 g/d (in-
vestigational 800 mg tab) was compared with 2.4 g/d (Asacol, marketed
400 mg tab) for treatment of mildly and moderately active UC. The pri-
mary efficacy variable in the combined analysis was treatment success in
patients with moderately active UC (defined as baseline Physician’s Global
Assessment [PGA] score = 2). Treatment success was defined as improve-
ment from baseline at week 6 in PGA accompanied by improvement in
at least one clinical assessment (stool frequency, rectal bleeding, patient
functional assessment [PFA], or sigmoidoscopy findings) and no worsen-
ing in any of the remaining clinical assessments. Improvement was de-
fined as a decrease from baseline of at least 1 point based on a 4-point
scale (0–3). Improvement in the individual clinical assessments was also
assessed.
Results: A total of 423 analyzable patients with moderate UC were random-
ized in the 2 studies, of which 137 patients had received previous oral or IV
steroid therapy. The incremental benefit of 4.8 g/d over 2.4 g/d was apparent
in patients previously treated with steroids:
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Treatment Success at Week 6 in Moderate UC Patients
2.4 g/d (N = 223) 4.8 g/d (N = 200)
Previous Steroid Users 52% 79%∗
∗P < 0.01 stratified by protocol using CMH test
Improvement in the individual clinical assessments further support the re-
sponse of 4.8 g/d in patients previously treated with steroids:
Improvement at Week 6 In Moderate UC Patients
Previously Treated with Steroids
2.4 g/d (N = 75) 4.8 g/d (N = 62)
PGA 72% 91%∗
Stool Frequency 64% 80%
Rectal Bleeding 66% 89%∗
Sigmoidoscopy 65% 82%∗
∗P < 0.05 stratified by protocol using CMH test
The 4.8 g/d dose of mesalamine was well tolerated, with adverse events
comparable to 2.4 g/d.
Conclusion: A previous history of steroid use does not preclude treatment
with mesalamine. There is a role for mesalamine in moderate UC patients
previously treated with steroids. UC patients with moderately active disease
previously treated with oral or IV steroids respond better to higher initial
doses (4.8 g/d) of mesalamine.
946
Authorship and Industry Sponsorship in Treatment Trials in
Inflammatory Bowel Disease
William J. Tremaine, MD∗. Gastroenterology and Hepatology, Mayo
Clinic, Rochester, MN.
Purpose: The International Committee of Medical Journal Editors (ICMJE)
criteria for authorship may not be uniformly applied. Purpose: To examine
the relationship between the funding source, authorship, and journal impact
factor of published therapeutic trials in IBD.
Methods: Prospective drug and device treatment trials for IBD published
in English between April 1, 2005 and March 31, 2007 were identified on
PubMed. The source of funding, journal name and ISI impact factor, affil-
iation of authors, disease studied, study design and outcome, statements of
conflict of interest (COI), and acknowledgement of non-author writers were
recorded.
Results: Seventy-four studies were published in 18 medical journals: 52
(70%) were multi-center and 50 (68%) did not have U.S. authors. There were
32 Crohn’s disease stuides, 27 ulcerative colitis studies, and 5 of both. There
were 43 (58%) industry-sponsored studies, 13 (18%) studies sponsored by
governments or foundations, and in 18 (24%) the funding source was not
stated. Industry studies were more commonly randomized controlled trials
(86%) than non-industry studies (42%). The experimental treatment effect
was positive in 63 (85%) trials and negative in 11, and 9 of the 11 negative
trials were industry-sponsored. The median impact factors for the journals in
which positive and negative studies were published was the same, 3.43, P =
0.774. The median impact factor for the journals in which industry sponsored
studies were published was 3.43, the same as for non-industry studies. The
median impact factor was higher (7.69 vs. 3.01, P = 0.001) for the 35
trials with COI statements compared to the 39 without statements. There
was no significance difference in the median impact factors (5.12 vs. 3.01,
P = 0.11) of journals for the 30 industry-sponsored studies with industry
employee authors compared to the 13 industry-sponsored studies without
employee authors. Non-author professional writers were acknowledged in
23% of industry studies.
Conclusion: The majority of treatments trials in IBD are Industry sponsored,
and most industry studies have industry employee co-authors. IBD treatment
studies with COI statements are published in journals with higher impact
factors. The median impact factors for journals that published postive com-
pared to negative studies was the same. Nearly a fourth of IBD treatment
trials do not identify the funding source. Differences may be due to lack
of uniformity in use of the ICMJE criteria for authorship and non-uniform
journal guidelines for publication.
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Isolated Gastroduodenal Crohn’s Disease Presenting with Acute
Pancreatitis
Kiran V. Rao, MD, Mark J. Sterling, MD, FCAP∗, Kenneth Klein, MD.
Gastroenterology, University of Medicine and Dentistry of NJ, Newark, NJ.
Purpose: Gastroduodenal Crohn’s disease (GCD) occurs in 0.5–4% of pa-
tients with ileocolonic disease, but very rarely does it occur as an isolated
identity and according to various studies is frequently difficult to treat with
medical and surgical interventions. In addition acute pancreatitis has occa-
sionally been associated with Crohn’s disease, but the exact etiology remains
unclear. We present a patient with multiple episodes of acute pancreatitis,
nausea, vomiting, and weight loss who was found to have gastric granulomas
on EGD and was treated with medical therapy.
Methods: We present a case of a 50-year-old male with no past medical
history who initially presented to the out-pt GI clinic with the history of a
recent episode of pancreatitis 2 months prior, where the patient had com-
plaints of nausea, vomitting, and a 15 pound wt loss. At this presentation the
patients’ lipase was 1195 and amylase was 187. An EGD was done which
showed severe acute and chronic erosive gastritis, with focal tendency to-
ward superficial aphthous ulcers, focal microgranulomas, with no evidence
of malignancy or H. Pylori. A colonoscopy showed no endoscopic evidence
of Crohn’s disease in the ileum or colon or any bleeding. Our patient was
started on prednisone taper, mesalamine, and prilosec after which improved
significantly even though there was no evidence of ileal of colon involve-
ment. Prednisone was tapered down to 5 mg/day and he developed vomitting
and weight loss. Our patient was taken off mesalamine and was placed on
6-MP 100 mg daily.
Results: The patient has been continued on 6-MP for more then 7 years
now and his gastroduodenal crohn’s disease has remained clinically asymp-
tomatic.
Conclusion: Isolated GCD is rare; this is demonstrated by the fact that only
1 of 940 Crohn’s patients from a major Dutch university referral center had
isolated proximal CD and that the largest series ever published of isolated
GCD comprised only 7 patients. Granulomas on biopsy in isolated GCD is
an even rarer finding. In a series of 49 patients with CD and gastroduodenal
involvement, more than 75% of the patients showed abnormal gastroduo-
denal biopsies, only 9% of patients had granulomas. Also worth noting is
that when CD does involve the upper gastrointestinal tract, there is nearly
always concomitant disease in the small bowel or colon, to which there is no
evidence in our patient. The association of the GCD presenting with acute
pancreatitis is a rare occurance. And our patient was treated with 6-MP and
had good response.
948
Transplantation of Human Cord Blood Mononuclear Cells on
Reversion of Experimental Inflammatory Bowel Disease
Xiao Cang Cao, PhD∗, Hui Zhao, PhD, Bin Liu, Zhongchao Han, PhD,
Qingyu Zhang, Yu Long Yang, Bangmao Wang. Dept. of Gastroenterology,
Tianjin Medical University General Hospital, Tianjin, China; National
Research Center for Stem Cell Eng and Technol, TEDA, Tianjin, China and
State Key Laboratory of Experimental Hematology, Institute of
Haematology, Chinese Academy of Medical Sciences and Peking Union
Medical College, Tianjin, China.
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Purpose: Inflammatory bowel disease (IBD) is a chronic intestinal inflam-
mation, including Crohn’s disease and ulcerative colitis, with epithelial in-
jure. Many different reagents have been tried in last decade but there is still
no effective therapy. Recently, stem cell transplantation (SCT) has been stud-
ied as therapy for IBD. Although accumulating data indicate that SCT may
serve as a very promising approach, the mechanisms of how it works are
still largely unknown and the limitation of auto-BMHSCT and mobilized
PBHSCT makes it difficult to generalize these therapies. Cord blood is easy
to get and could be an ideal resource of donor cells for SCT. In this study, we
investigate the effects of transplantation of cord blood cells on experimental
IBD and its mechanism.
Methods: To induce colitis in mice, CD4+CD25- T cells were isolated
by magnetic separation from spleen of Balb/c mice and transferred into
Balb/c.SCID mice i.p. The recipient mice were then administrated i.v. with
human CBMNs or with saline as control. To determine whether hCBMNs
are present in intestinal tissues of the recipient mice, hCBMNs were labeled
with CM-DiI prior to transfer. The mice were sacrificed five weeks later
and the various tissues were removed and processed for paraffin-embedded
sections.
Results: Three to five weeks after first cell transfer, the recipient mice devel-
oped intestinal inflammation with characterization of colitis similar to hu-
man patients. The lesions in the mice treated with hCBMNs were improved
than that of control mice. Four weeks later after second transplatation, many
CM-DiI+ hCBMN-derived cells were distributed in intestinal mucosa and
submucosa of the recipient mice, indicating that hCBMN-derived cells were
involved in regeneration of the colon.
Conclusion: Put all together, our data indicated that systemically admin-
istrated hCBMNs responded to an adequate tissue lesion and resulted in
accelerated tissue repair in mouse IBD. hCBMNs could be potentially used
as therapy of the patients with IBD.
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Crohn’s Disease Diagnosed by Capsule Endoscopy in Patients
with Obscure Gastrointestinal Bleeding
Sakeitha Crowder, MD, Richard Bloomfeld, MD∗. Gastroenterology, Wake
Forest University Baptist Medical Center, Winston-Salem, NC.
Purpose: The purpose of this study is to describe and compare cases of
Crohn’s disease diagnosed by capsule endoscopy performed for the evalua-
tion of obscure gastrointestinal bleeding.
Methods: We retrospectively reviewed the records of all patients who under-
went Video Capsule Endoscopy at Wake Forest University Baptist Medical
Center from January 2004 to September 2006 for the evaluation of ob-
scure gastrointestinal bleeding. All patients had overt or occult bleeding
unexplained by findings on colonoscopy, upper endoscopy, or other imag-
ing modality. We then identified all patients with small bowel ulceration
suspicious for Crohn’s disease and collected relevant data from the medical
records. Patients with small bowel erosions not felt to be due to Crohn’s
disease were not included.
Results: From a total of 238 capsule endoscopies performed, 198 studies
were for the evaluation of obscure gastrointestinal bleeding. Six patients
(3%) were identified with small bowel ulceration suspicious for Crohn’s
disease. Five of the six patients were not taking NSAIDS at the time of
the examination. 83.33% of the six patients had a positive IBD serology
(Prometheus Labs, San Diego, CA). Mean age was 35 years and four were
females (66%). All six patients diagnosed with Crohn’s Disease by capsule
endoscopy were being evaluated for iron deficiency anemia requiring multi-
ple blood transfusions. Only two patients had mild symptoms of abdominal
pain and diarrhea. The duration of anemia to diagnosis was from 11 months
to 15 years. The mean follow up of these six patients was 14 months. Sub-
sequent therapy included iron supplementation for all patients. Mesalamine
was initiated in 5 patients and budesonide in one. Two patients subsequently
required immunomodulators and another began infliximab, however none
required surgery.
Conclusion: Crohn’s disease can present with obscure gastrointestinal bleed-
ing with or without typical symptoms of abdominal pain and diarrhea. At
our medical center, we found that 3% of patients being evaluated for ob-
scure GI bleeding by capsule endoscopy had Crohn’s disease isolated to the
small bowel. Of these patients, 66.67% were young females. These cases
can generally be managed medically and may represent a subset of patients
with mild disease.
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High Rates of Vitamin D Deficiency and Osteopenia in Crohn’s
Disease Are Associated with Abnormal Absorption of Oral Vitamin D
Kleanthis G. Dendrinos, MD, Arthur F. Stucchi, PhD, James Becker, MD,
Timothy Heeren, PhD, Zhiren Lu, MS, Jeffrey Mathieu, MS, Tai C. Chen,
PhD, Michael F. Holick, MD, Francis A. Farraye, MD∗. Section of
Gastroenterology, Boston University School of Medicine, Boston, MA;
Department of Surgery, Boston University School of Medicine, Boston,
MA; Biostatistics, Boston University School of Public Health, Boston, MA
and Section of Endocrinology, Boston University School of Medicine,
Boston, MA.
Purpose: Crohn’s disease (CD) patients have high rates of vitamin D defi-
ciency that may result in poor bone mineral density (BMD). However, the
causes of vitamin D deficiency in CD are unclear. As vitamin D is absorbed
in the small bowel, it has been proposed that CD patients cannot absorb vita-
min D adequately. The aims of this study were to assess vitamin D nutritional
status, vitamin D intestinal absorption capacity, and BMD in CD patients.
Methods: 21 consecutive adult patients with CD presenting for routine office
visits to Boston Medical Center were enrolled from January 2007 to April
2007. In addition to demographic and clinical factors, baseline serum levels
of 25(OH)D, an indicator of vitamin D nutritional status, were measured.
To assess vitamin D absorption, patients ingested 50,000 IU of vitamin D2.
Serum vitamin D2 levels were measured via HPLC 12 hours later. Vitamin
D deficiency was defined as serum 25(OH)D levels of ≤ 20 ng/ml. A change
in the serum D2 level of ≥ 50 ng/ml 12 hours after ingestion of 50,000 IU
of vitamin D2 was considered normal absorption (Holick et al, Am J Nutr
1985). Bone density scans of hip and spine were also obtained.
Results: This cohort was young (mean age 44 ± 14 y), predominantly with-
out active disease (by CDAI, ESR, CRP), and well nourished (by albumin,
Hct) and may not routinely be screened for vitamin D deficiency or osteope-
nia. Of the 21 CD patients that completed baseline and absorption testing,
61% (13/21) were vitamin D deficient (14.2 ± 3.7 ng/ml). 85% (11/13) of
patients with vitamin D deficiency showed evidence of vitamin D malab-
sorption (34.3 ± 12 ng/ml). Of the 18 patients who underwent bone density
scans, 56% (10/18) were found to have osteopenia (N = 8) or osteoporosis
(N = 2) as defined by the WHO classification. 70% (7/10) of patients with
low BMD were vitamin D deficient and 86% (6/7) had abnormal absorption
of vitamin D. Among the 10 low BMD patients, two were on corticosteroids
and one is a smoker.
Conclusion: Patients with CD have high rates of vitamin D deficiency
and reduced BMD which may be associated with abnormal absorption of
vitamin D.
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Absence of NOD2 Polymorphisms in Crohn’s Disease Patients
with Uveitis
LuLu Iles-Shih, MD, Elisa Takalo, Judith F. Collins, MD, Tamara M.
Martin, PhD∗. Casey Eye Institute, Oregon Health and Science University,
Portland, OR; Department of Medicine, Oregon Health and Science
University, Portland, OR and Department of Gastroenterology, Oregon
Health and Science University, Portland, OR.
Purpose: NOD2 (also called CARD15) mutations have been found to cause
a rare autosomal dominant form of uveitis called Blau syndrome (BS).
Polymorphisms in NOD2 distinct from those found in BS predispose
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individuals to Crohn’s disease (CD). Previous studies suggest the presence
of specific NOD2 polymorphisms may have an effect on the presentation of
extraintestinal manifestations of CD, such as uveitis. It was hypothesized that
NOD2 polymorphisms influence the presence of uveitis in a CD population.
Methods: Uveitis patients diagnosed with CD seen at the Casey Eye In-
stitute Uveitis Clinic and CD patients with no ocular involvement seen at
the Gastroenterology Clinic at Oregon Health and Science University were
recruited into the study. All 12 exons of NOD2 were genotyped either by di-
rect sequencing or by denaturing high performance liquid chromatography.
Statistical analyses were performed using Fisher’s Exact Test to compare the
frequency of NOD2 CD specific polymorphisms in CD patients with versus
without uveitis.
Results: A total of 37 CD patients were genotyped: ten patients (seven
female, three male) with uveitis related to CD, and the other 27 with no ocular
involvement (18 female, nine male). All patients were Caucasian, including
one Hispanic, one African American/Caucasian, and two patients with mixed
Caucasian and Native American ancestry. The group with uveitis was older
(mean age 48, range 35–79) compared to the patients without uveitis (mean
age 38, range 19–70). Of the 10 patients with both CD and uveitis, seven had
colitis and three had ileocolitis. Among the 27 CD patients without uveitis,
there were 12 with ileitis, seven with ileocolitis, and eight with colitis alone.
The three most common NOD2 polymorphisms (corresponding to amino
acid changes R702W, G908R and 1007fs) were identified in 12 of the 27
patients without uveitis (at a combined allele frequency of 32%) but were
absent in the 10 patients with uveitis. This difference, 32% versus 0%, was
statistically significant with a p-value = 0.015.
Conclusion: Mutations in NOD2 that contribute to the genetic predisposition
of CD are absent from the subset of CD patients who develop uveitis. This
absence is consistent with the colitis phenotype observed in the uveitis cohort
compared to CD patients with no ocular involvement.
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Efficacy and Safety of Rifaximin as Maintenance Therapy for
Mild-Moderate Crohn’s Disease Refractory to Multiple Medical
Therapies
Asher Kornbluth, MD∗, Michele Kissous-Hunt, RPA, James George, MD,
Peter Legnani, MD. Gastroenterology, Mt. Sinai Medical Center, New
York, NY.
Purpose: Rifaximin is a nonabsorbable antibiotic with broad-spectrum ac-
tivity against intestinal pathogens. Previous studies, including our report
of clinical improvement with rifaximin in 55% of 55 patients with mild-
moderate Crohn’s disease (CD), have suggested benefits of rifaximin in CD.
However, limited data are available on the efficacy of antibiotics for main-
taining CD remission. This retrospective review evaluated rifaximin as main-
tenance therapy in patients with mild-moderate CD refractory to multiple
medical therapies.
Methods: Medical records for patients who received open-label rifaximin
for active mild-moderate CD refractory to prior therapies were reviewed.
Those who exhibited clinical improvement during rifaximin treatment and
continued rifaximin as maintenance therapy were included. Patients received
200 mg twice daily (b.i.d.), 200 mg three times daily, 400 mg b.i.d., or 600
mg b.i.d. Concomitant medications were permitted.
Results: The analysis included 28 patients (mean age 40 y) with a mean CD
duration of 13 years; 14 had isolated ileitis, 10 had ileocolitis, and 4 had iso-
lated colitis. Prior to initiation of rifaximin maintenance therapy, patients had
been receiving a mean of 1.9 CD drugs per day. Concomitant medications
during maintenance included aminosalicylates (N = 18; 64%), ciprofloxacin
or metronidazole (N = 11; 39%), budesonide (N = 4; 14%; mean dose 6.7
mg/d), prednisone (N = 3; 11%; mean dose 15.3 mg/d), immunomodula-
tors (6-mercaptopurine, azathioprine, or methotrexate; N = 9; 32%), and
infliximab (N = 3; 11%). Mean dose of rifaximin during maintenance was
685 mg/d; 6 patients received 400 mg/d, 8 received 600 mg/d, 12 received
800 mg/d, and 2 received 1200 mg/d. Overall, patients maintained clinical
improvement for a mean duration of 5.2 months (range, 3–23 months). Mean
duration of response was similar for each disease location: 6.1 months for
patients with ileitis, 4.8 months for those with ileocolitis, and 7.8 months
for those with colitis. Drug-related adverse events (AEs) were oral thrush
(N = 1) and nausea (N = 2). No patients discontinued rifaximin therapy due
to an AE.
Conclusion: In this open-label study, rifaximin (400–1200 mg/d) effec-
tively and safely maintained clinical improvement for a mean duration of 5.2
months in patients with mild-moderate CD refractory to multiple therapies.
Maintenance duration did not depend on disease location. Dose-ranging,
placebo-controlled trials of rifaximin as maintenance therapy in CD are
warranted.
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Adenocarcinoma in Ileal Pouch-Anal Anastomosis: The Cleveland
Clinic Experience
Revital Kariv, MD, Ana Bennett, MD, Yehuda Kariv, MD, Victor Fazio,
MD, Ian Lavery, MD, Bret Lashner, MD, Bo Shen, MD, Feza Remzi, MD∗.
Digestive Disease Center, Cleveland Clinic, Cleveland, OH.
Purpose: Total proctocolectomy with ileal pouch-anal anastomosis substan-
tially reduces the risk for dysplasia and cancer associated with ulcerative
colitis (UC). Cancer in ileal pouch-anal anastmosis (IPAA) patients with un-
derlying UC is a rare, which has only been reported as single cases. Natural
history of IPAA cancer in these patients and its risk factors have not been
investigated and there is lack of consensus for endoscopic cancer surveil-
lance for these patients. The aim of the study was to characterize the natural
history and clinical features, and histology in a group of patients with cancer
of IPAA.
Methods: Pouch database of 2,750 cases was searched. All patients had a
preoperative diagnosis of UC or indeterminate colitis. Patients with cancer
from the pouch and/or anal transitional zone (ATZ) were identified. Clinical
features of these patients were characterized.
Results: Eight patients (0.29%) with adenocarcinoma of the pouch and/or
ATZ were identified from the database. Average age at cancer diagnosis was
56.8 ± 12.5 (SD) years. The mean duration from IBD diagnosis to cancer
and from ileostomy take-down after IPAA to cancer diagnosis was 22.8 and
8.7 years, respectively. Most [5/8(62.5%)] had regular pouch endoscopic-
surveillance after IPAA. Six cases had ATZ cancers and 2 had cancers of the
pouch.
Conclusion: The risk for cancer of IPAA is small but real, which can occur
in UC patients without pre-colectomy diagnosis of dysplasia or cancer. A
disproportional high number of these patients had post-operative Crohn’s
disease of the pouch. The majority of the patients had histologic poorly-
differentiated cancer. Mucosectomy does not necessarily prevent cancers of
the ATZ or pouch.
Demographic and Clinical Features of the 8 Patients with Cancer of IPAA
Cases %
Proctocolectomy performed for dysplasia or cancer 3 42.8
Pancolitis 6 75.0
Family history of colon cancer 1 12.5
Staged pouch surgery 7 87.5
Hand-sewn anastomosis with mucosectomy 3 42.8
Crohn’s disease of the pouch 4 50.0
Poorly differentiated cancer 5 62.5
Tumor metastasis at diagnosis 2 25.0
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Nutritional Changes in Crohn’s Disease Patients Treated
with Infliximab
Dawn Wiese, BS, Bret Lashner, MD, Douglas Seidner, MD∗.
Gastroenterology, Cleveland Clinic, Cleveland, OH.
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Purpose: To assess the nutritional changes, particularly enterocyte func-
tion and body composition that occurs in Crohn’s disease patients beginning
infliximab, we evaluated Crohn’s disease patients immediately before inflix-
imab administration and again after 6 weeks and 6 months of therapy.
Methods: Crohn’s disease patients beginning infliximab for ileocolonic,
non-fistulizing disease were entered. Assessment included parameters of:
1) Disease activity, such as Inflammatory Bowel Disease Questionnaire
(IBDQ), 2) A combined index of inflammation and enterocyte function:
Prognostic Inflammatory and Nutrition Index (PINI), 3) Enterocyte func-
tion, such as plasma folate and citrulline, and 4) Body composition, such
as lean muscle mass (LMM) measured by DEXA scans, BMI, and resting
energy expenditure (REE) measured by indirect calorimetry.
Results: The study enrolled 7 patients, 6 of whom had active inflammation
characterized by CRP > 1.0 mg/dL. Most patients had an improvement in
disease activity. All of the patients had a drop in their PINI after 6 weeks
or 6 months of infliximab treatment (-3.35, P = 0.04). Those with active
inflammation at enrollment had a greater drop in PINI (-4.65, P = 0.03).
Plasma folate significantly increased after 6 months of infiliximab therapy.
There was an increase in BMI and LMM, but only the change in BMI was
significant. Changes in citrulline and REE were inconsistent among subjects.
Conclusion: These findings suggest that Crohn’s disease patients have im-
provements in both inflammation and nutrition (PINI) with infliximab ther-
apy. An improvement in enterocyte function could account for the improved
nutritional status. BMI increased significantly and was partly accounted for
by an increase in LMM. Whether infliximab alters body composition or
merely increases absorption is yet to be determined. These finding also sup-
port the use of PINI in Crohn’s patients as an overall marker of inflammation
and nutrition and possible measure of response to infliximab therapy.
Change in Nutritional Parameters after Infliximab Initiation
Variable Change P-value
IBDQ +38.0 0.058
PINI −3.35 0.044
Folate (ng/ml) +2.14 0.046
Citrulline (umol/L) −1.43 0.792
LMM (g) +872.33 0.440
BMI +2.21 0.034
REE (kcal/kg/day) −0.64 0.423
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Crohn’s Disease-Associated Colonic Dyplasia & Cancer:
Lessons Learned from 93 Cases
Revital Kariv, MD, Ana Bennett, MD, Yehuda Kariv, MD, Mary Bronner,
MD, Bo Shen, MD, Victor Fazio, MD, Ian Lavery, MD, Scott Strong, MD,
Bret Lashner, MD, MPH∗. Digestive Disease Center, Cleveland Clinic,
Cleveland, OH.
Purpose: Endoscopic surveillance is not always employed for patients with
colonic Crohn’s disease (CD). In addition, management of CD-associated
colonic dysplasia or cancer, once detected, is debatable. The aims of the study
were to characterize clinical, endoscopic, and histologic features & natural
history of CD-associated dysplasia/cancer as a source of information for 1)
surveillance recommendations; 2) risk factors for progression from dysplasia
to cancer; & 3) surgical treatment.
Methods: Database search was performed for patients with CD-associated
dysplasia/cancer during the last 30 years. Biopsies and surgical specimens
were reviewed by an expert GI pathologist. Demographic, clinical, endo-
scopic and surgical variables were studied.
Results: 93 patients with CD-associated dysplasia/cancer were identified:
32 (34%) had dysplasia, 22 (24%) had dysplasia and cancer and 39 (42%)
had cancer without dysplasia. High-grade dysplasia (HGD) was found in
49/93 (53%) [72% of the dysplasia group and 43% of the cancer group]
and was multifocal in 27/49 (55%) [57% in dysplasia group, and 54% in
cancer group]. Low-grade dysplasia (LGD) was found in 29/93 (31%) [59%
in dysplasia group, and 16.4% in cancer group] and was multifocal in 13/29
(45%) [47% in dysplasia group, and 40% in cancer group]. 18/61(30%) of
cancer patients had dysplasia found in at least 1 preoperative endoscopy. CD
characteristics are shown in Table 1. Patients with dysplasia who were treated
with 5-aminosalicilates (5ASA) at any time, were less likely to progress to
cancer (OR 2.94, 95% CI 1.22–7.12 P = 0.016) than those without 5ASA
treatment.
Conclusion: 1) Dysplasia in colonic CD often is multifocal; 2) Concurrent
dysplasia was found in a substantial number of CD-associated colon cancers;
and 3) 5ASA use may protect from progression of dysplasia to cancer. Our
findings support routine endoscopic surveillance for colonic CD as in ulcer-
ative colitis and chemoprevention with 5ASA. Colonic CD with dysplasia
may require radical surgery due to the multifocal nature of dysplasia and the
risk for future cancer.
Risk Factors for Dysplasia Progression to Cancer
Cancer(+/
Dysplasia only -dysplasia) P value
CD duration before dysplasia/ 14.7 (0–46) 17 (0–63) 0.45
cancer diagnosis
Pancolitis 27/32 (84.3%) 43/61 (70.5%) 0.21
5ASA treatment 21/32 (65.6%) 24/61 (39.3%) 0.016
Primary sclerosing cholangitis 5/32 (15.6%) 7/61 (11.4%) 0.45
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Biopsy Practices Following the Diagnosis of Neoplasia in Patients
Undergoing Surveillance Colonoscopy in Ulcerative Colitis (UC)
Thomas Ullman, MD∗, Deepthi Deconda, MD, Yevgenia Pashinsky, MD,
Noam Harpaz, MD, Steven Itzkowitz, MD. Medicine, The Mount Sinai
School of Medicine, New York, NY and Pathology, The Mount Sinai School
of Medicine.
Purpose: Current guidelines recommend that a minimum of 32 biopsies
(bxs) be taken at each surveillance colonoscopy (SC) to exclude dysplasia
in patients with longstanding UC. Previous questionnaire and retrospective
studies suggest that this target is not being met.
Aim: To determine whether endoscopists change their bx practices after the
discovery of epithelial dysplasia.
Methods: The Mount Sinai UC-Dysplasia Surveillance Database is an IRB-
approved project that contains clinical, endoscopic, and pathologic informa-
tion on UC patients who have undergone 2 or more SCs between 1994 and
2006. To determine whether bx practices were influenced by previous SC
findings, the number of specimens available for histopathologic review from
each segment were tabulated according to the descriptions of the pathology
lab technician for each separate jar submitted. The number of specimens for
all jars was summed and constituted the bx number for each SC. Bx numbers
from SCs without prior dysplasia were compared to bx numbers from SCs in
patients with findings of indefinite for dysplasia (IND), low-grade dysplasia
(LGD), or high-grade dysplasia (HGD). The number of colorectal cancers
(CRCs) without previous IND, LGD, or HGD were tabulated. Comparisons
were made using Student’s t-test with P < .05 significant.
Results: We identified 187 patients who met our stated criteria. Their average
duration of disease was 17 years, and their average age at first SC was
48 years. Among the 1083 SCs for which bx number was calculated, 523 were
exams with no prior dysplasia (NoD). 332 SCs took place after IND, 177 after
LGD, and 51 after HGD. Bx numbers per SC were less than recommended in
surveillance guidelines. However, for patients who had previous dysplasia,
more bxs were taken during SCs (see Table). Breathrough CRC without
previous dysplasia occurred in 1 case.
Conclusion: While not meeting current recommendations, endoscopists typ-
ically altered their bx practice in response to abnormal findings. Break-
through CRC after SCs in which all prior bxs were dysplasia-free was un-
common (N = 1), suggesting that current SC practices as performed in
routine practice are adequate for preventing the development of advanced
pathology.
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# SCs Bxs per SC P-value
NoD 523 13.7 ± 5.8 –
IND (no prior LGD, HGD, CRC) 332 16.7 ± 6.8 <.001
LGD (no prior HGD, CRC) 177 17.4 ± <.001
HGD (no prior CRC) 51 18.1 ± 6.8 <.001
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Enterocutaneous Fistula after Closure of Temporary Ileostomy,
Incidence, Management and Outcome
Renyu Zhang, MD, Victor Fazio, MD∗, Feza Remzi, MD. Colorectal
Surgery, The Cleveland Clinic Foundation, Cleveland, OH.
Purpose: Diverting ileostomy is commonly used for temporary fecal diver-
sion protecting lower gastrointestinal anastomosis. One of the less reported
serious complications is the formation of enterocutaneous fistula (ECF) at
the ileostomy site after its closure. Choosing a surgical or medical approach
may be a dilemma for the surgeon. The aim of this study is to evaluate ECF
incidence, management and outcome.
Methods: All patients who had temporary ileostomy for primary diversion
following pelvic surgery between 1983 and 2006 were reviewed from the
institutional colorectal surgery databases. Cases of ECF were identified; and
clinical information was extracted.
Results: Total of 4116 patients (3165 pelvic pouch, 951 colorectal cancer)
received temporary ileostomy. Eleven patients with ECF at the ileostomy
site were identified (0.27%). Ten were from ileal pouch patients, one from
the cancer group. For these patients, the mean ileostomy duration was 115
days (12–302). The mean presentation time of the ECF was 15 days post
ileostomy closure (range 3–53). Eight patients had ECF daily output >200
cc. 4 of 8 had output higher that 900 cc/day (range 950–3800). Nine of
10 patients had fistula closure following bowel rest, with/without parental
nutrition. The average duration to closure following medical therapy was 31
days (range 9 -79). The only patient with Crohn’s disease in this series failed
conservative therapy and required abdominal surgery for fistula closure.
Conclusion: Enterocutaneous fistula at old ileostomy site occurs rarely. Most
ECF will resolve promptly with medical management.
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Is Laparotomy Warranted at the Closure of Temporary Ileostomy? A
Review of 571 Patients with Bowel Obstruction Following Restorative
Proctocolectomy with Ileal Pouch
Enterocutaneous Fistula at Old Ileostomy Site
Age/ Ileostomy Closure Time to Fistula Daily Fistula
Patient Gender Diagnosis Duration Type Presentation (days) Output Duration (days)
1 57/M Ulcerative Colitis 114 Hand sewn 3 1000 cc 33
2 69/M Ulcerative Colitis 98 Stapled 6 950 cc OR closure
3 48/F Ulcerative Colitis 12 Hand sewn 7 60 cc 9
4 40/M Indeterminate Colitis 137 Stapled 53 40 cc 9
5 49/M Indeterminate Colitis 109 Hand sewn 4 450 cc 12
6 63/M Ulcerative Colitis 141 Hand sewn 28 225 cc 16
7 47/M Ulcerative Colitis 83 Hand sewn 7 1525 cc 79
8 54/M Indeterminate Colitis 92 N/A 12 3800 cc 47
9 34/M Crohn’s Disease 89 Hand sewn 6 200 cc OR
10 44/F Ulcerative Colitis 94 Hand sewn 34 30 cc 38
11 52/F Colon Cancer 302 Hand sewn 9 450 cc 32
Renyu Zhang, MD, Victor Fazio, MD∗, Feza Remzi, MD, James Church,
MD. Colorectal Surgery, The Cleveland Clinic Foundation, Cleveland,
OH.
Purpose: Small bowel obstruction (SBO) is a usual complication following
major abdominal surgery, which frequently requires surgical intervention.
Temporary ilestomy is commonly employed for fecal diversion, which re-
quires a second surgery, albeit small, for closure. At the time of ileostomy
takedown, instead of a local excision, would a full laparotomy beneficial in
reducing the risk of recurrent bowel obstruction?
Methods: Patients with SBO were identified from the institutional ileal
pouch anal anastomosis (IPAA) database of 3176 cases during a 23-year
period. Clinical details reviewed and analyzed included timing of ileostomy
closure and incisions used.
Results: 794 episodes of SBO from 571 patients were identified following
IPAA. Surgical intervention was required in 229 episodes (29%). Seventy six
patients were excluded because no ileostomy was utilized (49), or ileostomy
not closed (3) or closed at another institution. For the remaining 495 patients,
average ileostomy duration was 120 days. The study group numbered 140
patients who had 1st episode of SBO before ileostomy closure. Depending
on the incision type at the ileostomy takedown, the study group was divided
into three subgroups: A) peristomal incision at the regular time of ileostomy
takedown (> 7 wks), 102 patients; B) laparotomy at the regular time of
takedown, 15 patients; C) laparotomy before the regular time of takedown, 23
patients. SBO recurrence was lower in patients who underwent a laparotomy
(23.7%) than those who had peristomal incision (30.4%).
There were 130 patients (26.2%) who developed their 1st SBO within 60 days
following ileostomy closure. Of these, 101 (77.7%) had only one episode
of SBO. 80 of the 101 (80%) patients were managed medically without
recurrence.
Conclusion: The ileostomy take down presents a valuable opportunity for
patients who already display signs of obstruction. Laparotomy with full
exploration at this point can safely reduce the risk of future bowel obstruction.
The majority of bowel obstruction cases occurring immediately following
take down can be successfully managed medically without recurrence.
Small Bowel Obstruction Recurrence after Ileostomy Takedown
All laparotomy
A B C (B+C)
Number of patients 102 15 23 38
SBO Recurrence 31 4 5 9
Recurrent Rate 30.4% 26.7% 21.7% 23.7%
P value – NS NS NS
Recurrence require surgery 15 1 4 5
Re-op rate 14.7% 6.7% 17.4% 13.2%
SBO: small bowel obstruction.
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Severe Crohn’s Disease Symptoms Are Relieved by Certolizumab Pegol
Brian G. Feagan, MD∗, Geoffroy Coteur, PhD, Dorothy L. Keininger, MS.
Robarts Clinical Trials, Robarts Research Institute, London, ON, Canada;
SGS, SGS Life Science Services, Mechelen, Belgium and Global Health
Outcomes Research, UCB SA, Braine-l’Alleud, Belgium.
Purpose: Certolizumab pegol (CZP) is the first Fc-free PEGylated anti-TNF
Fab’ fragment. Lack of an Fc portion potentially avoids side effects.1 The
efficacy and safety of subcutaneous CZP 400 mg in patients (pts) with active
Crohn’s disease (CD) was shown in a large Phase III trial (PRECiSE 2).2
There were significant improvements in all domains of the Inflammatory
Bowel Disease Questionnaire (IBDQ).3 The present analysis of PRECiSE 2
IBDQ results by item and domain is presented to describe the ability of CZP
to relieve symptoms frequently reported by pts as severe.
Methods: In PRECiSE 2, a 26-week (wk) double-blind study, pts with a
clinical response at Wk 6 following induction therapy with CZP were ran-
domized to CZP (N = 215) or placebo (PBO, N = 210) every 4 wks up to
Wk 24. Pts completed the IBDQ4 at Wks 0, 6, 16, and 26. The proportion of
pts reporting severe or extremely severe impact was calculated at baseline
for each IBDQ item. Analysis of covariance was used to compare IBDQ item
scores at Wk 26 between groups.
Results: At baseline, 35–62% of pts reported the following CD symptoms as
severe: loose bowel movements; abdominal cramps; abdominal pain; fatigue;
lacking energy; sleep problems; not feeling relaxed; and feeling generally
unwell. By Wk 26, all these items were significantly improved in the CZP
group compared with PBO (P ≤ 0.042). Emotional problems were also
less common in the CZP group at Wk 26 than in the PBO group: feeling
frustrated (P = 0.006), afraid of not finding a washroom (P = 0.013), feeling
depressed (P = 0.008), worried (P = 0.047), embarrassed (P = 0.007) or
irritable (P = 0.024), and feeling a lack of understanding from others (P =
0.003). Compared with PBO, pts receiving CZP were less inclined to delay
or cancel a social engagement because of bowel problems (P = 0.022).
Conclusion: CZP improved the majority of CD symptoms, including those
that were frequently reported by pts as being severe. Several bowel and
systemic symptoms were significantly improved by CZP maintenance treat-
ment, as measured by the IBDQ. CZP treatment also relieved the burden of
CD on emotional and social aspects of pts’ lives.
REFERENCES
1. Fossati G, et al. Am J Gastroenterol 2005;100(Suppl. 9):s299.
2. Schreiber S, et al. Gut 2 005;54(Suppl. VII): A82.
3. Feagan B, et al. Gut 2006;55(Suppl. V):A124.
4. Irvine EJ. J Pediatr Gastroenterol Nutr 1999;28:23–27.
This research was funded by UCB.
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Sustained Efficacy and Tolerability of Certolizumab Pegol over 18
Months: Data from PRECiSE 2 and Its Extension Studies
(PRECiSE 3 and 4)
Stefan Schreiber, MD∗, Julian Panes, MD, David Mason, MD, Gary R.
Lichtenstein, MD, William J. Sandborn, MD. Medicine,
Christian-Albrechts University, Kiel, Germany; Gastroenterology, Hospital
Clinic de Barcelona, Barcelona, Spain; Clinical Development, UCB,
Slough, United Kingdom; Gastroenterology, University of Pennsylvania
School of Medicine, Philadelphia, PA and Gastroenterology and
Hepatology, Mayo Clinic, Rochester, MN.
Purpose: Certolizumab pegol (CZP), a PEGylated Fc-free Fab’ anti-TNF,
was effective and well tolerated in a 26-week (wk) open-label induction,
double-blind maintenance trial in active Crohn’s disease (CD; PRECiSE
2 [P2]).1 Patients (pts) could enter open-label extension studies evaluat-
ing long-term continued maintenance of response (PRECiSE 3 [P3]) or re-
induction and maintenance after relapse (PRECiSE 4 [P4]). P3 and P4 are
ongoing studies; results after 12 and 18 months’ treatment are given here.
Methods: P2 pts with a clinical response to CZP 400 mg induction (Wks
0, 2, and 4) at Wk 6 (64.1%) were randomized to CZP 400 mg (N = 215)
or placebo (PBO; N = 210) every 4 wks Wk 8–24. Pts who completed P2
and entered P3 received 4-weekly CZP 400 mg for up to 5 years. Pts who
relapsed (CD Activity Index [CDAI] increase ≥70 or CDAI ≥350) after
randomization in P2 and entered P4 received re-induction with CZP 400 mg
(Wks 0, 2, 4) then maintenance dosing every 4 wks, ie, re-induction from P2
into P4 was a single dose. In P3 and P4, efficacy was assessed by the Harvey–
Bradshaw Index (HBI: remissioN = HBI score ≤4; response = HBI decrease
≥3).2 Pts lost to follow-up or withdrawn were treated as nonresponders.
Adverse events were monitored.
Results: Remission at the end of P2 (Wk 26) was achieved by 47.9% (CDAI)
and 48.4% (HBI) of pts receiving CZP (N = 215). Of these, 41.9% (N = 90)
and 37.2% (N = 80) were in remission after 12 and 18 months, respectively,
of continued treatment in P3. Of pts re-induced with CZP in P4, 29% (N =
14) achieved remission. The remission rate was stable (35% at Month 6
and 12 [N = 17] of P4). Among pts from the P2 PBO group re-induced
with CZP, 44% achieved remission. Remission rates were 44% (Month 6)
and 36% (Month 12). Re-exposure of P2 PBO pts to CZP raised no safety
concerns.
Conclusion: Sustained long-term efficacy was observed with CZP in the
treatment of CD. Re-induction with a single supplemental dose of CZP 400
mg after loss of response was a well-tolerated, successful therapeutic strategy.
REFERENCES
1. Schreiber S, et al. Gut 2005;54(Suppl. VII): A82 (Abstract).
2. Vermeire S, et al. Gastroenterology 2007(Abstract).
This research was funded by UCB.
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A Comprehensive Evaluation of the Impact of Crohn’s Disease and Its
Treatment on Patients Is Achieved Using a Combination of the CDAI
and IBDQ
Brian G. Feagan, MD∗, Geoffroy Coteur, PhD, Dorothy L. Keininger, MS.
Robarts Clinical Trials, Robarts Research Institute, London, ON, Canada;
SGS, SGS Life Science Services, Mechelen, Belgium and Global Health
Outcomes Research, UCB SA, Braine-l’Alleud, Belgium.
Purpose: Diarrhea, abdominal pain, and weight loss are common symptoms
of Crohn’s disease (CD); the most commonly used measure for these symp-
toms is the CD Activity Index (CDAI). CD also greatly impacts patients’
physical, emotional, and social functioning.1 These aspects are measured
using the Inflammatory Bowel Disease Questionnaire (IBDQ).2 This analy-
sis compared and contrasted CDAI and IBDQ information using data from
PRECiSE 2.
Methods: In PRECiSE 2, patients with a clinical response at Wk 6 following
induction with certolizumab pegol (CZP) were randomized to CZP (N=215)
or placebo (PBO; N = 210) every 4 wks up to Wk 24.3 CDAI and IBDQ
data were collected at Wks 0, 6, 16, and 26. Correlations were evaluated at
Wk 26, or at baseline, using Pearson’s correlation for CDAI total score and
IBDQ total or domain scores, and Spearman’s rank correlation for CDAI and
IBDQ items scores. Missing data were not imputed. Correlation coefficients
(R) were termed moderate (≥0.3) or high (≥0.5).4
Results: CDAI and IBDQ total scores correlated moderately at baseline
(R = −0.344; N = 255) and highly at Wk 26 (R = −0.603). CDAI total
score (N = 255) correlated more with the bowel (R = −0.593) and systemic
(R = −0.566) symptom domains of IBDQ than with the IBDQ emotional
(R = −0.517) and social (R = −0.469) function domains. Abdominal pain,
diarrhea, and general well-being, assessed in both measures, were highly
correlated (R = −0.610 to −0.721; N = 244). Weakly correlated items
(R <0.3) included CDAI clinical objective measures (taking medication for
diarrhea, abdominal mass, hematocrit, and low body weight) and some IBDQ
emotional and social function items (passing gas, rectal bleeding, accidental
soiling, weight problems, and lack of understanding from others).
Conclusion: The CDAI and IBDQ assess interrelated but nonidentical as-
pects of CD. The CDAI reflects physical more than emotional or social
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aspects, while the IBDQ covers all aspects but is less comprehensive than
the CDAI for clinical objective measures. Both instruments in combi-
nation provide a comprehensive evaluation of the impact of CD and its
treatment.
REFERENCES
1. Casellas F, et al. Dig Dis 1999;17:208–218.
2. Guyatt G, et al. Gastroenterology 1989;96:804–810.
3. Schreiber S, et al. Gut 2005;54 (Suppl. VII):A82.
4. Cohen, J. Lawrence Erlbaum Associates, Hillsdale, NJ, USA. 1988.
This research was funded by UCB.
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Minimally Important Difference for WPAI:CD Scores: Defining
Relevant Impact on Work Productivity in Active Crohn’s Disease
William J. Sandborn, MD∗, Margaret C. Reilly, MA, Martin C.J. Brown,
MSc, Yves Brabant, MSc, Laetitia C. Gerlier, MSc. Gastroenterology and
Hepatology, Mayo Clinic, Rochester, MN; Margaret Reilly Associates Inc.,
New York, NY; Global Health Outcomes Research, UCB Celltech, Slough,
United Kingdom; AXEN, Brussels, Belgium and Keyrus Biopharma,
Levallois-Perret, France.
Purpose: Crohn’s disease (CD) causes significant economic burden, espe-
cially productivity losses.1 Certolizumab pegol, a PEGylated Fc-free Fab’ is
effective in CD (PRECiSE trials2,3). Clinical response (CD Activity Index
[CDAI]) was associated with improved health-related quality of life (Inflam-
matory Bowel Disease Questionnaire [IBDQ]) and increased productivity
(Work Productivity and Activity Impairment questionnaire [WPAI:CD]).4
We estimated the smallest changes in WPAI:CD scores in PRECiSE 1 per-
ceived as beneficial by patients/clinicians — minimally important difference
(MID).
Methods: Using an anchor-based method (relationship between WPAI:CD
and independent measures), regressions compared changes in WPAI:CD
with those for CDAI and IBDQ between Weeks 0 and 26. Known meaningful
changes in CDAI (50 points) and IBDQ (16 points) were used to derive 2
MID estimates. Using a distribution-based method, 3 MID estimates were
derived from small (0.2) to moderate (0.5) effect sizes (ES, magnitude of
change in WPAI:CD /variability in baseline scores). The 5 MID estimates
gave the first MID assessment in WPAI:CD.
Results: IBDQ correlated more closely than CDAI with WPAI:CD (Spear-
man coefficients 0.44–0.65 vs 0.35–0.52); CDAI yielded the lowest MID
values. A moderate ES of 0.5 gave outlying values. Mean MID estimates
were 6.5% (absenteeism), 6.1% (presenteeism), 7.3% (overall work impair-
ment) and 8.5% (activity impairment) (Table).
Conclusion: MID provides a useful benchmark to interpret treatment out-
come beyond statistical significance. Changes in WPAI:CD scores >7% can
be regarded as sizable changes in workplace productivity.
REFERENCES
1. Bodger K. Pharmacoeconomics 2002;20:639–652./
2. Sandborn W, et al. Gastroenterology 2006;130(Suppl. 2):745.
3. Schreiber S, et al. Gut 2005;54(Suppl VII):A82.
4. Feagan B, et al. Gut 2006;55(Suppl V):Abstracts MON-G-219 and 291
This research was funded by UCB.
MID Estimate (%)
WPAI:CD scores CDAI 50∗ IBDQ 16∗ ES = 0.2 ES = 0.3 ES = 0.5
Absenteeism (N = 321) 1.5 2.2 5.8 8.6 14.4
Presenteeism (N = 324) 3.0 2.8 4.9 7.3 12.2
Overall work impairment (N = 290) 4.9 5.8 5.2 7.7 12.9
Activity impairment (N = 614) 8.7 8.8 5.0 7.5 12.5
∗P-value factor “change in anchor scores”<0.001;  variation
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Comparison of the Penetration of Certolizumab Pegol and
Adalimumab in Inflamed and Noninflamed Mouse Tissue
Andrew M. Nesbitt, PhD∗, Roger T. Palframan, PhD, Alex D. Vugler, MSc,
Adrian R. Moore, PhD, Mark B. Baker, MSc, Roland Foulkes, PhD, Neil
Gozzard, PhD. Celltech Antibody Biology Division, UCB, Slough, United
Kingdom.
Purpose: PEGylated molecules diffuse relatively slowly out of the blood.
The disposition of such molecules may therefore alter during inflamma-
tion. Certolizumab pegol is an Fc-free PEGylated Fab’ of a humanized anti-
TNFα monoclonal antibody. The attachment of polyethylene glycol (PEG)
increases its tissue bioavailability to a level equivalent to or greater than that
of conventional anti-TNFs such as adalimumab. This study compared the in
vivo disposition of certolizumab pegol and adalimumab in noninflamed and
inflamed mouse tissue using a novel noninvasive biofluorescence method.
Methods: Certolizumab pegol and adalimumab, labeled with the low-
molecular weight dye Alexa 680, were administered separately by intra-
venous injection (2 mg/kg) to naı¨ve DBA/1 mice and to DBA/1 mice with
ongoing collagen-induced arthritis. Drug accumulation was measured in the
hind paws at multiple time points up to 26 hours using a Xenogen IVIS200
biofluorescence imager. ELISA was used to assay for drug serum levels in
tail blood samples.
Results: The penetration of both agents was higher into inflamed tissue
than into noninflamed tissue. Certolizumab pegol penetrated more effec-
tively into inflamed arthritic paws than adalimumab: the maximum in-
flamed:noninflamed tissue ratio achieved by certolizumab pegol was 3.9:1
(at 6 hours post-administration) compared with 1.9:1 (at 3 hours) for adali-
mumab. Certolizumab pegol had an elimination half-life in inflamed tissue
of 27.8 hours; the corresponding value for adalimumab was 5.5 hours.
Conclusion: Certolizumab pegol displayed higher and more prolonged ex-
posure in inflamed tissue than adalimumab in this animal model. Cer-
tolizumab pegol, unlike adalimumab, appears to readily enter edematous
inflamed tissue, while sparing noninflamed tissue. This is a property that
may be conferred by PEGylation. Adalimumab’s short period of exposure in
the inflamed tissue is possibly because it is readily recyled out of the tissue
by the FcRn receptor. In comparison certolizumab pegol has a prolonged
exposure because it is Fc free and cannot be recycled by the same mecha-
nism. In the treatment of inflammatory disorders such as Crohn’s disease,
increased drug exposure at the site of inflammation might be an important
consideration.
This research was funded by UCB.
964
Measurement of Urinary Excretion of 40 kDa Polyethylene Glycol
(PEG) after Subcutaneous Administration of Certolizumab
Pegol in Rats
Andrew M. Nesbitt, PhD∗, Ted A. Parton, PhD, Lloyd M. King, BSc, Judith
van Asperen, PhD. Celltech Antibody Biology Division, UCB, Slough,
United Kingdom.
Purpose: Certolizumab pegol, an Fc-free PEGylated Fab’, binds human
tumor necrosis factor (TNF) α with high affinity. The PEG component
of certolizumab pegol comprises two 20 kDa chains of PEG-monomethyl
ether attached covalently and site-specifically to a hinge thiol on the Fab’.
Hemodynamic properties of proteins are altered by PEGylation, leading to
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preferential penetration into diseased versus normal tissue.1 In this study we
monitored metabolism of PEG in rats following subcutaneous administration
of certolizumab pegol.
Methods: Subcutaneous injections of certolizumab pegol 400 mg/kg were
given to nine female Lewis rats. The rats were housed in groups of three in
metabolism cages for four 1-week periods (total study duration: 84 days).
Daily urine and feces collections were weighed, and stored at −70◦C until
analysis. PEG levels were quantified using proton nuclear magnetic reso-
nance (1H NMR) in urine samples purified by ultrafiltration.
Results: The mean recovery of PEG from urine and feces combined was 91%
of the dose. PEG was detected in all urine samples; concentrations reached a
maximum (198 µg/mL) on Day 4, and then declined in a first-order manner
to 14 µg/mL in Week 12. The mean daily excretion in urine (as a proportion
of the dose) was maximal (1.9%) on Day 6, declining in a first-order manner
to 0.21% per day in Week 12. After 84 days, the mean cumulative amount
of dose excreted in urine was 65%. Using a first-order increase/decrease
model, the total urinary excretion was 73% and the half-life for the decrease
in daily urinary excretion was 23 days. The molecular weight of the PEG
excreted in urine was estimated by SDS PAGE to be 40 kDa. Up to Day 42,
PEG equivalent to 18% of the dose was detected in feces (much of the fecal
PEG is thought to be a result of urine contamination).
Conclusion: The innovative method of 1H NMR spectroscopy shows that,
in the rat, the 40 kDa PEG moiety of certolizumab pegol is cleaved from the
Fab’ and excreted unchanged in a first-order process, predominantly in the
urine. The half-life for excretion of a single dose determines the time taken to
reach steady-state excretion on multiple dosing. The rate of excretion during
multiple dosing matched the rate of dosing at steady-state as cumulative
excretion was near-quantitative.
REFERENCE
1. Chapman AP. Adv Drug Deliv Rev 2002;54:531–545.
This research was funded by UCB.
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The Apparent Increase in Apoptosis Reported for Adalimumab,
Etanercept, and Infliximab Is Actually a Reduction in Cell
Proliferation
Andrew M. Nesbitt, Ph.D.∗, Gianluca Fossati, Ph.D., Derek T. Brown,
Ph.D.. Celltech Antibody Biology Division, UCB, Slough, United
Kingdom.
Purpose: Induction of apoptosis in lymphocytes and monocytes by signaling
through membrane tumor necrosis factor (TNF) is a proposed mechanism
of action for anti-TNFs in Crohn’s disease (CD). However, certolizumab
pegol, an Fc-free PEGylated Fab’ anti-TNF, is efficacious in CD but does
not mediate an apparent increase in apoptosis in vitro. Although etaner-
cept was initially reported not to cause apoptosis (and this was cited as the
reason for its lack of efficacy in CD) three groups have now shown that
etanercept does mediate apoptosis in a similar manner to infliximab and
adalimumab. The precise mechanism of the apoptotic effect of some anti-
TNFs and its importance to efficacy are unclear. This study investigated the
apparent pro-apoptotic effects of adalimumab, etanercept, and infliximab in
activated monocytes and lymphocytes.
Methods: Positive selection with MACS beads was used to separate mono-
cytes from human peripheral blood mononuclear cells. The negatively se-
lected population was used as the lymphocyte preparation. Monocytes were
activated with GM-CSF and interleukin-4 for 3 days; lymphocytes were ac-
tivated with CD3/CD28 for 2 days. Anti-TNFs or appropriate controls were
then added (final concentration: 10 µg/mL) for a further 24 hours. The Vi-
aCount assay system (Guava Technologies) was used to ascertain absolute
cell counts and cell viability.
Results: The absolute number of apoptotic cells did not increase above the
levels seen in the respective control samples after treatment of monocytes or
lymphocytes with any of the anti-TNFs. However, adalimumab, etanercept,
and infliximab reduced the number of viable monocytes (36.3%, 35.6%, and
38.3%, respectively) and lymphocytes (31.7%, 32.7%, and 32.5%, respec-
tively) relative to controls. In contrast, certolizumab pegol did not cause a
significant reduction in the number of viable cells compared with control
treatment.
Conclusion: The anti-TNFs adalimumab, etanercept, and infliximab do not
appear to increase apoptosis in isolated monocytes and lymphocytes; instead,
they reduce the proliferation of these cells. However, since certolizumab pe-
gol treatment does not reduce cell proliferation, anti-proliferative activity
against monocytes and lymphocytes does not seem to be required for effi-
cacy in CD. The mechanism of this effect is unclear and requires further
investigation.
This research was funded by UCB.
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MR Enterography in Crohn’s Disease: A Preliminary Experience
Samir A. Shah, M.D.∗, David J. Grand, MD. Medicine, Division of
Gastroenterology, Brown Medical School, Providence, RI and Department
of Radiology, Brown Medical School, Providence, RI.
Purpose: Patients with Crohn’s disease often require multiple radiologic
examinations throughout their lives beginning at a young age. MRI of the
abdomen and pelvis can provide all of the necessary imaging information
required for clinical management of Crohn’s disease without the ionizing
radiation associated with CT or SBFT as well as with a safer intravenous
contrast medium (gadolinium vs. iodinated contrast). Here we report our
initial experience with MR enterography in 11 patients with established or
suspected Crohn’s disease.
Methods: MR enterography was ordered at the discretion of the referring
gastroenterologist. All examinations were performed on a 1.5 Tesla MRI
scanner using a surface coil. Axial and coronal images were obtained us-
ing the following pulse sequences: steady-state free precession (an adapted
cardiac imaging sequence), single-shot fast-spin echo (typically used for
MRCP), as well as 3D fat-saturated gradient echo. 900 cc VolumenTM plus
450 cc of water were used for oral contrast to optimally distend the small
bowel. Intravenous gadolinium was administered to all patients to delineate
increased mucosal enhancement indicative of inflammation, as well as fis-
tulae, phlegmons and abscesses. Total exam time was twenty minutes or
less. The clinician then assessed the utility of the information provided by
the MRI in managing the patient on a 3 point scale: 0 useless, 1 somewhat
useful, 2 very useful. The first 11 patients referred for MR enterography are
included.
Results: All the clinicians rated the MR enterography as very useful (2)
in managing their patient(s). Findings included mucosal and mesenteric in-
flammation, small bowel strictures and fistulae. No abscesses were present.
One MR exam was normal in a patient whom the clinician felt had been
previously misdiagnosed. In this case, the normal study helped refute the
diagnosis.
Conclusion: MR enterography was very useful in evaluating known or sus-
pected Crohn’s disease while eliminating patient exposure to ionizing radi-
ation in this preliminary study. The examinations were well tolerated and
provided diagnostic information directly relevant to patient management.
Future, larger studies are needed to confirm our experience and also to de-
termine whether MR can assess response to treatment in an accurate and
timely fashion. This information, obtained without additional risk to the
patient, could ensure that patients receive the optimal treatment for the ap-
propriate duration.
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Prevalence of Epstein-Barr Virus in Patients with Inflammatory Bowel
Disease
Kanat Ransibrahmanakul, MD, Pouria Kashkouli, MD, Erina Foster, MD,
Thomas Prindiville, MD∗, Sumathi Sankaran, PhD, Irina Grishina, Satya
Dandekar, PhD. Gastroenterology, University of California, Davis,
Medical Center, Sacremento, CA and Medical Microbiology and
Immunology, University of California, Davis, Davis, CA.
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Purpose: Inflammatory bowel disease (IBD) (Crohn’s Disease and Ulcera-
tive Colitis) is characterized by chronic inflammation of the gastrointestinal
tract. IBD is often treated with steroids, mesalamines, immunomodulators
and biologics. With the increasing use of immunomodulators and biologics,
concerns have been raised regarding the risk of development of lymphoma in
IBD patients. The incidence of lymphomas in IBD is controversial. Studies
from tertiary care centers seem to associate lymphomas with IBD. Epstein-
Barr Virus (EBV), a herpes virus, has been associated with lymphomas in
post-transplant and immunosuppressed patients. One major barrier to un-
derstanding etiology of this increased risk is delineating between disease
activity, treatment and the possible role of oncogenic viruses. Our aim is
to determine the prevalence of EBV in patients who are currently being
followed in our IBD clinic compared to a selected group of controls.
Methods: 79 patients with IBD and 25 control subjects were studied. DNA
was extracted from peripheral blood mononuclear cells (PBMC) of patients
with IBD and from healthy IBD negative controls. Cell numbers were cal-
culated using a CCR5 standard curve. EBV loads per million PBMC were
determined using a real-time PCR assay.
Results: A higher incidence of EBV DNA was observed in the IBD positive
group compared to the IBD negative group. EBV was detected in 49% of
IBD patients and in 32% of controls. Results indicate higher average levels
of EBV DNA in IBD positive patients (1.29∗108 compared to 1.76∗103
copies/million PBMC).
Conclusion: The prevalence of EBV is higher in patients with IBD than
that of controls. EBV viral load averaged 5 logs greater than that of controls.
Contributing factors to these findings may include immunosuppressive med-
ications, biologics and the severity of disease activity. Due to our smaller
control sample size, the difference in EBV detection was not statistically
significant (P = 0.13). The significance of higher prevalence of EBV and
higher EBV viral load will need to be determined in a prospective matter.
968
NOD2/CARD15 Gene Exons Sequencing in Iranian Patients with
Crohn’s Disease
Nosratollah Naderi, MD∗, Alma Farnood, MD, Manijeh Habibi, Msc,
Elham Vali Khojeini, MD, Hedieh Balaii, BS, Faramarz Derakhshan, MD,
Farzad Firouzi, MD, Mohammad Reza Zali, MD, FACG. Research Center
for Gastroenterology and Liver Disease, Shaheed Beheshti University of
Medical Sciences, Tehran, Islamic Republic of Iran.
Purpose: In this study all the exons of NOD2/CARD15 gene were sequenced
in Iranian Crohn’s patients to find any probable defect in this gene.
Methods: Sixty non-related Crohn’s patients were enrolled from a tertiary
center in a one year period (2006–2007). All 12 exons of NOD2/CARD15
gene were amplified by PCR (Polymerase Chain Reaction) and evaluated by
direct sequencing.
Results: Of 9 sequence variations identified among 12 exons of
NOD2/CARD15 gene, 4 had an allele frequency >10%. Four new muta-
tions (1 in exon 2 and 3 in exon 4) were observed, which account for less
than 5% of NOD2/CARD15 mutations. The three main variants (R702W,
G908R, and 1007fs) represented 32%, 5%, and 6%, respectively, in Iranian
CD patients. Considering the whole sequence, mutations were mostly present
in exon 4 of this gene.
Conclusion: Different mutations observed in NOD2/CARD15 gene demon-
strated its importance in Iranian CD patients as western populations; though
the affected parts would be different compared to other ethnicities.
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Non-Adherence to Surveillance Colonoscopy in Patients with
Inflammatory Bowel Disease: Assessing the Risk
Sonia Friedman, MD∗, Adam Cheifitz, MD, Francis Farraye, MD.
Medicine, Brigham and Women’s Hospital, Boston, MA; Medicine, Beth
Israel Medical Center, Boston, MA and Medicine, Boston Medical Center,
Boston, MA.
Purpose: Patients with longstanding, extensive UC or Crohn’s colitis have an
increased risk of colon cancer and require colonoscopic surveillance every
2 yrs. The purpose of this study is to determine the non-adherence rate to
surveillance colonoscopies in our patient population and to determine the
risk factors that are associated with non-adherence.
Methods: 259 patients with UC or Crohn’s colitis for at least 7 yrs and at
least 1/3 of the colon involved participated in this cross-sectional question-
naire study. A chart review was also performed for each patient. Part of
the questionnaire included a self-efficacy scale as it related to the ability to
adhere to surveillance colonoscopy.
Results: Median age was 48 and median disease duration 20 yrs. 44% of
patients had UC, and 51% were female. 49% of patients had waited more than
2.5 yrs in between exams and 40% of patients had waited longer than 3 yrs in
between exams. Self-reported adherence was higher than chart-documented
adherence for all times in between exams. Patients who self-reported less
than 6 months in between exams had a mean chart-documented adherence
of 2.16 yrs in between exams. For self-reported frequencies of 1,2, and 3
yrs or more in between exams, the chart documented mean time intervals
between exams were every 2.08, 3.16, and 4.32 yrs respectively.
We validated our large self-efficacy (SE) scale and divided it into 4 subscales,
all significant and valid: Social SE (ability to schedule, tell people, avoid
embarrassment), Calm SE (ability to avoid anxiety associated with colono-
scopies), Prepare SE (ability to take and to tolerate the preparation), and
Doc Comm SE (ability to get doctor’s attention and to ask questions). Both
Calm and Social SE were associated positively with adherence, and Prepare
and Doc Comm SE correlated positively with lower average time between
screenings. Patients reporting that they have trouble with the preparation
and scheduling, that they felt good and did not think the test was needed,
and that they have had inadequate insurance coverage were less likely to ad-
here. By logistic regression, being Jewish, having high Social SE, and using
alternative health care methods were positively related to adherence.
Conclusion: At least 40–49% of patients do not adhere to surveillance
colonoscopies. Many factors relate to adherence including demographic and
clinical factors, doctor message, and self-efficacy.
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Younger Age at Diagnosis Predicts Disease Severity
in Ulcerative Colitis
Lee Roth, MD, Nilesh Chande, MD, Agatha Lau, MD, Maya Roth, MA,
Terry Ponich, MD, Jamie Gregor, MD∗. Division of Gastroenterology,
London Health Sciences Centre, London, ON, Canada.
Purpose: Canada has one of the highest incidences of ulcerative colitis (UC)
in the world, with 3500 new cases each year and a prevalence of over 60, 000†.
Previous studies have examined the natural history of UC, however, this is
the first to examine it in Southwestern Ontario (SWO). London is uniquely
situated with a catchment area of nearly all of SWO, and the London Health
Sciences Centre – South Street Hospital (LHSC-SSH) Inflammatory Bowel
Disease (IBD) clinic is set up to longitudinally follow patients who are
diagnosed and treated there. The goal of the current study is to understand
the demographic characteristics of this population in order to predict disease
severity. †Am J Gastro 2006;101:1559–68.
Methods: Records from 1996 to 2001 were examined to create a database
of UC patients seen in the LHSC-SSH IBD clinic. To be included, patients’
charts were required to have information of their disease presentation and a
minimum of five years of follow-up. Charts were reviewed using standard-
ized data collection forms. Disease severity was generated during the chart
review process, and non-endoscopic Mayo Severity Index‡ criteria were col-
lected into a composite. ‡NEJM 1987;317:1625–9.
Results: 102 consecutive patients’ data were entered into the database. De-
mographic analyses revealed that 51% of the patients were male, the mean
age at diagnosis was 39 years, 13.7% had a first degree relative with IBD,
61.8% were nonsmokers and 24.5% were ex-smokers. In 22.5% of patients
the disease was limited to proctitis, 21.6% had proctosigmoiditis, 22.5% had
left-sided colitis, and 32.4% had pancolitis. Standard multiple regression
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analysis which regressed a composite of physician global assessment of dis-
ease severity, average number of bowel movements, and average amount of
blood in bowel movements on year of diagnosis and age at time of diagnosis
was significant, R2 = .306, F (7, 74) = 4.66, P < .01. Delay from symptoms
to diagnosis of UC, gender, family history of IBD, smoking status and disease
severity at the time of diagnosis did not significantly predict the composite
measure.
Conclusion: A composite of UC disease severity, blood in bowel move-
ments, and number of bowel movements is associated with younger age at
diagnosis as well as year of diagnosis in a longitudinal cohort of UC patients
in SWO. This suggests a potential mechanism for predicting disease sever-
ity at diagnosis and may be a step towards the identification of prognostic
indicators of UC.
971
Efficacy and Safety of Certolizumab Pegol Do Not Appear To Be
Affected by Neutralizing Antibodies in Patients with Crohn’s Disease
Sue Stephens, PhD, Ralph Bloomfield, MSc, Donna M. Devine, MSc,
Andrew M. Nesbitt, PhD∗. Clinical Assay Department, UCB Celltech,
Slough, United Kingdom; Biometrics, UCB Celltech, Slough, United
Kingdom and Antibody Biology Division, UCB Celltech, Slough, United
Kingdom.
Purpose: Anti-TNF agents are effective in the treatment of Crohn’s disease
(CD). However, development of neutralizing antibodies can potentially re-
duce the clinical response rate.1 Certolizumab pegol, a PEGylated Fc-free
Fab’ with high potency for human TNFα, was evaluated in two recent pivotal
Phase III trials in CD (PRECiSE 1 and 2) in which the effect of neutralizing
antibodies on efficacy and safety was analyzed.
Methods: Subcutaneous certolizumab pegol 400 mg was administered at
Weeks 0, 2, 4, then every 4 weeks up to Week 24. Plasma samples were
considered neutralizing if they reversed the ability of certolizumab pegol to
block interleukin-6 production in response to TNFα in HeLa cells. Patients
with ≥1 neutralizing sample were classed as antibody positive (Ab+). Clin-
ical response was defined as a decrease in CD Activity Index (CDAI) score
of ≥100 points (at Weeks 6 and 26 PRECiSE 1 and Week 26 in PRECiSE 2).
Influence of antibody status on the incidence of adverse events (AEs) was
also examined.
Results: Clinical response rate by neutralizing antibody status was deter-
mined for patients who received continuous treatment with certolizumab
pegol (Table). There was no reduction in the proportion of responders in the
Ab+ cohort relative to the antibody negative (Ab-) cohort in either trial. Most
AEs occurred with a similar incidence regardless of neutralizing antibody
status. AEs that occurred more frequently in patients after development of
antibodies were viral gastroenteritis (3% [Ab+] vs 1% [Ab-]) and anemia
(5% vs 3%). AEs occurring more frequently in Ab- patients were nausea
(9% [Ab-] vs 2% [Ab+]), pyrexia (8% vs 4%), and headache (17% vs 5%).
No hypersensitivity signals (eg, injection-site reactions, injection-site pain,
influenza-like illness or rash) were associated with the presence of antibod-
ies.
PRECISE 1 PRECISE 2
(Weeks 6 and 26) (Week 26)
Ab+ Ab− Ab+ Ab−
Clinical response, 6/21 (28.6) 69/304 (22.7) 10/12 (83.3) 123/201 (61.2)
n/N (%)
Conclusion: The development of neutralizing antibodies to certolizumab
pegol does not appear to have a marked effect on clinical response rates
in patients with CD. The frequency of AEs was similar in Ab− and Ab+
patients. Patients in this trial showed no indication of hypersensitivity reac-
tions.
REFERENCE
1. Baert F. N Engl J Med 2003;348:601–608.
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PROTECT-1: A Prospective Randomized Trial of CCX282-B
(Traficet-EN), a Novel Oral Therapy Targeting Chemokine Receptor 9
in Crohn’s Disease
Satish Keshav, MD, Robert Petryka, MD, Tomas Vana´sk, MD, Yaron Niv,
MD, Krzysztof Marlicz, MD, PhD, Ole Haagen-Nielsen, MD, Marta
Machado, MD, Jens Dahlerup, MD, Stefan Schreiber, MD, Pirow Bekker,
MD, Sujata Sankar, PhD, Thomas J. Schall, PhD∗. Gastroenterology,
Oxford University, Oxford, United Kingdom; Gastroenterology, NZOZ
Vivamed, Warsaw, Poland; Hepato-Gastroenterologie, Edvarda Benee
1549 – Poliklinika III, Hradec Kralove, Czech Republic; Gastroenterology,
Rabin Medical Center, Petach Tikva, Israel; Gastroenterology, Klinika
Gastroenterologii i Choro´b, Szczecin, Poland; Gastroenterologisk Dept,
Herlev Hospital, Herlev, Denmark; Gastroenterology, Hospital Sa˜o Lucas,
Porto Allegre, Brazil; Medical Dept, A˚rhus University Hospital, A˚rhus,
Denmark; Institute for Clinical Molecular Biology,
Christian-Albrechts-University, Kiel, Germany and ChemoCentryx,
Mountain View.
Purpose: CCX282-B represents a new class of highly specific chemokine
receptor antagonists. It targets chemokine receptor 9 (CCR9), a key homing
signal for intestine-specific T cells. In a 28-day phase 2 study, CCX282-
B induced clinical responses (CDAI70) in 58% of Crohn’s disease (CD)
patients with a baseline CDAI >250 and elevated CRP, vs. 31% on placebo.
CRP decreased 11 mg/L in the CCX282-B group relative to placebo. These
results prompted PROTECT-1, a large, randomized, placebo-controlled trial
in CD.
Methods: This study involves >100 sites in 16 countries. The primary ef-
ficacy endpoint is CDAI decrease over 12 weeks. Maintenance of response
is assessed over 36 weeks. Adults with moderate to severe CD (CDAI 250–
450), are randomized 3:2:2:2 to receive placebo, CCX282-B 250 mg/day,
500 mg/day, or 250 mg twice daily (bid) for 12 weeks followed by a 4-week
Active Treatment period (250 mg CCX282-B bid). CDAI70 responders
are then re-randomized 2:3 to receive either placebo or 250 mg CCX282-B
bid for 36 weeks (Maintenance period).
Results: As of May 2007, 163 subjects have been enrolled into the Induc-
tion Period. 56 subjects have enrolled into the Active Treatment period. 39
subjects have completed the Active Treatment period, of which 29 (74%)
have achieved a CDAI70 response, 27 (69%) a CDAI100 response, and
16 subjects (41%) were in remission (CDAI < 150). No serious unexpected
adverse events related to CCX282-B have been observed, and overall more
than 250 subjects have received CCX282-B in clinical trials, with no adverse
safety concerns.
Conclusion: CCX282-B, a highly specific, oral CCR9 antagonist, and the
first chemokine-based inhibitor of leukocyte trafficking tested in IBD, shows
promise in CD.
973
Prevalence and Predictors of Sexual Dysfunction in Patients
with Inflammatory Bowel Disease
Viral Patel, Houssam Mardini, MD∗, Willem de Villiers, MD. Division of
Digestive Diseases and Nutrition, University of Kentucky, Lexington, KY.
Purpose: Little is known about sexual dysfunction in pts with inflamma-
tory bowel disease (IBD). Our aim was to assess the prevalence and factors
associated with sexual dysfunction among pts with IBD.
Methods: A clinical sample from a tertiary referral center was interviewed
during their routine clinic visit. The Sexual History Form and questions
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that assess sexual well-being from the National Health and Social Life Sur-
vey were used to determine the prevalence and severity and a global sex-
ual functioning score (GSFS) was calculated (0.11 = perfect functioning;
1 = significant dysfunction). IBD severity was assessed using the Short
Form IBDQ (S.IBDQ). The cohort results were compared to historic con-
trols from both surveys. Non-parametric tests were used to assess asso-
ciations and multivariate analysis was performed to control for potential
confounders.
Results: 62 IBD pts; 46 (75%) pts with CD and 16 (25%) with UC with
a mean age of 44 (range 18 to 74 years) with a mean S.IBDQ score of
50 (range of 22 to 70 at the time of the survey) were surveyed. Sexual
dysfunction was more prevalent in patients with IBD than the general public
(68% vs 31% with any degree of dysfunction; P = 0.002 and 38% vs. 12%
with significant dysfunction; P =< 0.0001). Mean GSFS was significantly
worse among IBD pts compared to values reported in general public (0.51
vs 0.22; P = 0.008). Multivariate analysis showed that this dysfunction did
not correlate and was independent of underlying IBD activity as measured
by the S.IBDQ, steroid use in the past 6 months, disease duration and history
of previous surgery. Furthermore, only one pt received counseling regarding
this problem (self-referred).
Conclusion: Sexual dysfunction is an important concern in patients with
IBD, and must be addressed while treating the patient for their disease. This
dysfunction appears to be independent of disease activity and other dis-
ease related factors. Further studies to determine potential causes including
psychiatric and / or endocrine evaluation should be considered.
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The Direct and Indirect Cost Burden of Illness of Ulcerative Colitis
Eliza Ng, MD, Teresa B. Gibson, PhD∗, Ronald J. Ozminkowski, PhD, Ross
MacLean, MD, Wayne Burton, MD, Sara Wang, PhD, Ron Z. Goetzel,
PhD. Global Outcomes Research Strategy, Bristol-Myers Squibb,
Princeton, NJ; Health and Productivity Research, Thomson Healthcare,
Ann Arbor, MI; Institute for Health and Productivity Studies, Cornell
University, Washington, DC and Division of General Internal Medicine,
Northwestern University, Chicago, IL.
Purpose: To estimate the direct medical costs and indirect costs (productivity
related) for commercially-insured patients with Ulcerative Colitis.
Methods: Data were obtained from the 1999 to 2005 MarketScan Commer-
cial Claims and Encounters (CCAE), Medicare Supplemental, and Health
and Productivity Management databases. Patients with a diagnosis of Ul-
cerative Colitis and at least a 1-year disease-free pre-period were found
resulting in 8,970 nonelderly patients with Ulcerative Colitis and 2,958 el-
derly patients with Ulcerative Colitis. 12-month direct medical care expen-
ditures (medical and prescription drug) for patients with Ulcerative Colitis
were compared to expenditures among an equal number of propensity-
score matched comparison group members. Propensity scores were esti-
mated via demographic characteristics and comorbidities. Indirect costs,
as measured by absenteeism and short-term disability costs, were com-
pared for a sub-sample of employees in each group. Regression anal-
ysis controlled for demographic and case mix factors. A range of cost
burden estimates were produced by varying the estimation and matching
techniques.
Results: Average 12-month direct medical care expenditures were $4,982
for nonelderly and $8,572 for elderly comparison group members. Average
estimated direct medical expenditures for patients with Ulcerative Colitis
exceeded comparison group members by as much as $11,331 for nonelderly
patients and $6,609 for elderly patients (all P < .01).
Average absenteeism costs were $6,021 for employees with Ulcerative Coli-
tis, although this was not significantly different from the comparison group.
Average short term disability expenditures were $1,386, which was almost
three times the amount for the comparison group (P < .05).
Conclusion: Ulcerative Colitis is a costly disorder and merits consideration
as interventions are developed to manage the burden of disease and improve
productivity.
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Clinical Predictors of Elevated C-Reactive Protein (CRP)
among Patients with Active Inflammatory Bowel Disease
Houssam Mardini, MD∗, Razvan Arsenescu, MD, Trevor Winter, MD,
Willem de Villiers, MD. Department of Digestive Diseases and Nutrition,
University of Kentucky, Lexington, KY.
Purpose: CRP is a useful inflammatory marker frequently used in the man-
agement of inflammatory bowel disease (IBD) pts. However, certain groups
of pts have either normal or slightly elevated CRP despite significantly active
disease.
Our aim was to identify determinants of CRP levels in IBD pts.
Methods: Pts with confirmed IBD and at least 2 of the following indica-
tors of active disease (radiologic, endoscopic, pathologic or clinical) were
included in the study. CRP level at the time of disease activity was measured.
Demographics and disease characteristics including location, modifiers and
phenotype were assessed. Non-parametric tests were used to assess associa-
tions and multivariate analysis was performed to find independent predictors.
Results: 92 pts (64 with CD and 28 with UC), mean age 36 yrs (14–68) and
mean age at diagnosis 27 yrs (9–62) were included in the study. Mean CRP
level in the cohort was 3.9 mg/dl (0.3–21.4) and 14 pts had levels >10. CD
and UC pts had comparable mean CRP level (3.2 vs 5.5; P = ns) Univariate
analysis showed that among CD pts, colonic involvement was associated
with higher CRP level compared to ileal disease only (1.7 vs 3.8; P = 0.01)
and active perianal disease compared to no perianal involvement (1.4 vs 4.9;
P = 0.005). Stricturing phenotype was associated with lower mean CRP (1.1)
compared to fistulizing (5.3) and inflammatory (3.7) phenotypes (P = 0.02).
Among UC pts, pancolitis was associated with higher CRP level compared
to pts with lt sided or proctitis (5.1 vs 2.7; P = 0.02). In the entire group,
older age at diagnosis was associated with higher CRP (P = 0.02). Neither
smoking nor family history were associated with CRP level. All associations
remained significant in the multivariate analysis.
Conclusion: Colonic and perianal involvement in CD pts is associated with
high CRP levels while stricturing phenotype and ileal disease are associated
with lower levels. Among UC pts, pancolitis is associated with higher CRP
levels. In IBD pts, in general, older age at diagnosis is associated with higher
CRP levels. These characteristics may help to identify a group of patients
in whom CRP can be used reliably to assess activity and follow response to
treatment.
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Predictors of Short and Long Term Response to Azathioprine
in Crohn’s Disease
Alla Grigorian, MD, Houssam Mardini, MD∗, Razvan Arsenescu, MD,
Trevor Winter, MD, Willem de Villiers, MD. Division of Digestive
Diseases and Nutrition, University of Kentucky, Lexington, KY.
Purpose: Azathioprine (AZA) is widely used in the treatment of pts with
Crohn’s disease (CD). Despite appropriate dosing and the use of metabolite
levels monitoring to guide therapy many pts fail to respond to AZA or have
short remission periods.
Aim: To identify factors associated with short and long term response to
AZA.
Methods: Using our IBD database we identified CD pts treated with AZA
for at least 3 mos. Short-term response was defined as adequate subjective
and objective control of disease (determined by IBDQ scores and the global
assessment of pt and physician) and the ability to wean off steroids in pts
requiring steroids. Long-term response was defined as quiescent disease
for ≥1 year. Pts requiring other therapeutic modalities (including surgery)
during the time frames outlined were also considered to have had no or
lost response. AZA dose used in our institution is 2–2.5 mg / kg/ day or its
equivalent of 6-MP. Pts with TPMT phenotype other than wild were excluded.
A case-control design was implemented. Non-parametric tests and logistic
regression models were used to assess the associations, estimate the odd ratio
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(OR) and 95% confidence intervals (CI) of these associations and control
for potential interactions (AZA dose and concomitant medications).
Results: 148 CD pts treated with AZA were identified for assessing short-
term response to AZA and 97 pts for long-term response. Among pts assessed
for short term response, 106 (72%) had short term response while 42 (28%)
did not and had to be treated with another immunomodulator. Among pts
assessed for long term response, 62 (64%) pts had sustained response while
the rest (35; 36%) did not. Smoking was associated with decreased short and
long-term response (OR 2.4 & 1.8; 95% CI:1.6–5.9 & 1.4–5.2 respectively).
Infliximab maintenance therapy was associated with long-term response (OR
2.0; CI:1.6–7.8) while concomitant use of 5-ASA compounds was associated
with short term response: OR: 1.5; CI:1.1–2.9. Long term responders were
significantly older at diagnosis than non responders (median age was 32 vs.
25 yrs; P = 0.02).
Conclusion: Smoking is associated with decreased short and long term
response to azathioprine in Crohn’s disease patients while Infliximab main-
tenance therapy and older age at diagnosis are associated with a longer
response.
977
Mesalamine Protects Against Colorectal Cancer in Inflammatory
Bowel Disease
Jeffrey Tang, MD, Gena Kucera, PhD, Omar Sharif, MD, Chetan Pai, DO,
Ann L. Silverman, MD∗. Internal Medicine, Division of Gastroenterology,
Henry Ford Hospital, Detroit, MI.
Purpose: Individuals with ulcerative colitis (UC) and Crohn’s disease (CD)
are at increased risk of developing colorectal cancer (CRC) compared to
the general population. CRC risk in inflammatory bowel disease (IBD) is
associated with dysplasia, extent of disease, type of therapy, duration of
disease, and degree of inflammation. This study evaluates the influence of
multiple factors on CRC risk in IBD.
Methods: We identified all IBD patients who developed CRC at our insti-
tution from 1970 to 2005. Cases were matched to controls by type of IBD,
age at diagnosis, sex, race, extent of disease and disease duration. We com-
pared BMI, family history of IBD, family history of CRC, smoking, and use
of mesalamine, mercaptopurine, folic acid, steroids, and nonsteroidal anti-
inflammatory drugs (NSAIDs). Total cumulative dose and average daily
dose were calculated for each prescription drug class. Covariates were com-
pared using Chi-square and Student’s t-tests. Odds Ratios (OR) and 95%
confidence intervals (CI) were estimated using conditional logistic regres-
sion models to examine the relationship between drugs and risk of colorectal
cancer.
Results: A total of 30 CRC patients (25 UC [16 male, 9 female; 37.8 mean
age] and 5 CD [3 male, 2 female, 42.2 mean age]) were identified. After
reviewing 1484 patients (605 UC and 879 CD), 16 patients (13 UC and
3 CD) were matched to 23 controls (19 UC and 4 CD). The CRC cases
and controls were similar in BMI (mean, 27.5 vs. 25.0), family history of
IBD (18.8 vs. 8.8% positive history), family history of CRC (18.8 vs. 8.8%
positive history), and smoking use (66.7 vs. 52.2% nonsmoker). There was
no difference in use of mercaptopurine (6.3 vs. 13.0%), NSAIDs (6.7 vs.
21.7%) and steroids (80.0 vs. 82.6%). More controls used folate compared
to the CRC cases (56.5 vs. 20.0%, P = 0.025). Mesalamine use in UC showed
a decrease in CRC when comparing the cases and controls (76.9 vs. 100%,
P = 0.028). Conditional logistic regression showed that a mesalamine total
dose of ≥5068 grams was associated with an 89% reduction in CRC risk
Ascending Colon/ Transverse Descending
Location Cecum Colon Colon Sigmoid Rectum
Number of specimen jars from site 955 1361 550 677 736
% Positive for HGD/CRC 1.3 1.2 1.5 5.6 9.4
(OR 0.11; CI 0.01–0.91). Folate use at cumulative dose of ≥ 2823 mg did
not show a significant reduction in CRC risk (OR 0.47, CI 0.09–2.50).
Conclusion: Our data suggest that mesalamine use among UC patients leads
to a significant risk reduction in CRC. In our study we found that patients
that did not develop CRC used folate more often that those with CRC but
this was not associated with a reduction in risk of CRC.
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Distal Location of Dysplasia and Colorectal Cancer in Longstanding
Ulcerative Colitis (UC)
Thomas Ullman, MD∗, Deepthi Deconda, MD, Yevgenia Pashinsky, MD,
Noam Harpaz, MD, Steven Itzkowitz, MD. GI/Medicine, The Mount Sinai
School of Medicine, New York, NY and Pathology, The Mount Sinai School
of Medicine.
Purpose: Current guidelines recommend that surveillance for dysplasia be
performed by taking 4-quadrant biopsies every 10 cm throughout the colon in
patients with longstanding UC. Such a strategy, however, may be ineffective
if neoplastic lesions arise only in particular segments of the colorectum.
Aim: To determine where in the colorectum advanced neoplastic lesions are
detected in the practice of surveillance colonoscopy.
Methods: The Mount Sinai UC-Dysplasia Surveillance Database in an IRB-
approved project that contains clinical, endoscopic, and pathologic informa-
tion on more than 700 patients at our instutution who have undergone 2 or
more dysplasia surveillance exams between 1994 and 2006. To determine the
location of biopsies containing advanced neoplasia (AN; colorectal cancer
(CRC) or high-grade dysplasia (HGD)) the database was queried. Pathology
reports were then reviewed and the locations of all the AN lesions were tab-
ulated. In instances where distances were used to describe biopsy location,
jars labeled 0–20 cm were considered rectal in origin; 21–40 cm sigmoid;
41–60 descending colon; and ≥ 61 cm transverse colon. The frequencey
with which any segment was positive was then compared to other segments.
Comparisons were made using Fisher’s exact testing with P < .05 significant.
Results: We identified 54 patients who progressed to AN. They underwent
a total of 283 exams. The mean age of the patients at first surveillance was
49.6 years; the mean duration of disease was 18.3 years; 80% of the patients
had UC proximal to the splenic flexure. The percent of biopsies that were
positive for AN by location is listed in theTable. Biopsies positive for AN
were much more common in the rectum and sigmoid colon than in more
proximal segments (P < .0001 for all two-way comparisons).
Conclusion: The majority of HGD and cancer detected in a surveillance pro-
gram was detected in the rectum and sigmoid. Endoscopists should consider
taking a greater precentage of their biopsies from these segments.
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A Pilot Study of the Efficacy and Tolerability of AST-120 in the
Treatment of Active Pouchitis
Bo Shen∗, Darrell Pardi, Ana Bennett, Kerry Sherman. Gastroenterology,
Cleveland Clinic, Cleveland, OH and Gastroenterology, Mayo Clinic,
Rochester, MN.
Purpose: Bacterial toxins and increased production of deconjugated bile
acids are speculated to play a role in the pathogenesis of pouchitis. While
the majority of patients with pouchitis respond to antibiotics, relapse is
common and non-absorbable and non-antibiotic-based agents are desirable
to reduce bacterial resistance and systemic adverse effects associated with
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long-term antibiotic use. AST-120 is comprised of highly adsorptive, porous,
carbon microspheres with the ability to adsorb small molecular weight toxins,
inflammatory mediators, and harmful bile acids. The aim of this pilot study
was to evaluate efficacy and tolerability of AST in the treatment of active
pouchitis.
Methods: Inclusion criteria: 1) active pouchitis patients with underlying ul-
cerative colitis (UC) with Pouchitis Disease Activity Index (PDAI) scores ≥
7; and 2) discontinuation of antibiotic therapy for at least 2 weeks. Exclusion
criteria included Crohn’s disease of the pouch, and isolated cuffitis. In this
open-label study, all eligible patients received AST-120 in 2 g sachets PO tid
for 4 weeks. The efficacy endpoints were remission (PDAI score < 7) and
clinical response (reduction of PDAI score of ≥ 3). Cleveland Global Quality
of Life (QOL) and Short Inflammatory Bowel Disease Questionnaire were
also assessed before and after the trial.
Results: Ten patients were enrolled the trial: 9 completed the trial (mean
age = 50 ± 10 yrs, SD; mean duration of UC = 16 ± 9 yrs; mean duration
of ileal pouch = 7 ± 5 yrs) and one dropped out of the trial due to a viral upper
respiratory infection 2 days after entry. Of the 9 patients, 4 (44%) had clinical
remission and 5 (56%) achieved clinical response and (AST-120 effect on
components of the PDAI illustrated below). There was numerical, but not
statistically significant improvement in QOL scores. The agent was well
tolerated; one patient had transient mild elevation of alkaline phosphatase.
Conclusion: AST-120 appears to be effective and well tolerated in treat-
ing patients with active pouchitis. A randomized, placebo-controlled trial is
warranted to assess long-term efficacy and safety of AST-120 in this indica-
tion.[figure1]
980
A Pilot Study of the Effects of Dietary Soy Supplementation
on Crohn’s Disease
William Outlaw, MD, Angela Boaz, Richard Bloomfeld, MD∗.
Gastroenterology, Wake Forest University, Winston-Salem, NC.
Purpose: Crohn’s disease is a chronic inflammatory disorder of the gastroin-
testinal tract and dietary therapy has been studied to modulate the inflam-
matory cascade and treat Crohn’s disease. Soy contains several substances
with anti-inflammatory activity such as isoflavones. The aim of this study is
to investigate the efficacy and tolerability of dietary soy supplementation in
patients with Crohn’s disease.
Elevated CRP and Risk of Ileitis
Crohn’s Disease Ulcerative Colitis
Ileitis ± Colitis No Ileitis ± Colitis Ileitis ± Colitis No Ileitis ± Colitis
CRP < 2 (mg/dL) 25 (66%) 13 (34%) 4 (15%) 23 (85%)
CRP > 2 (mg/dL) 13 (87%) 2 (13%) 4 (36%) 7 (7%)
Odds Ratio 3.38 3.29
Methods: Patients with Crohn’s disease, active or inactive, who were seen
at the Wake Forest University Digestive Health Center were asked to partic-
ipate in a prospective open-label pilot study of soy supplementation. After
a full history and physical with labs, each subject had a C-reactive protein
(CRP) recorded, a Crohn’s Disease Activity Index (CDAI) calculated, and
an Inflammatory Bowel Disease Questionnaire (IBDQ) performed. Subjects
were asked to ingest a proprietary, flavored soy shake (Physicians Laborato-
ries, Kernersville, NC) twice a day for 12 weeks. Subjects were followed by
telephone every 3 weeks and with a clinic visit every 6 weeks. CRP, CDAI,
and IBDQ were followed at 6 and 12 weeks. Any subject with worsening
Crohn’s disease requiring new drug therapy was withdrawn from the trial.
Results: Ten patients were enrolled, and then enrollment was halted. Five
patients were unable to tolerate two shakes a day and discontinued the study
by week 6 and one additional patient discontinued the study after week 6. Of
the 4 patients who completed the study, 3 were in remission at baseline and
stayed in remission, while one patient with mildly active disease continued to
have mildly active disease at week 12. No changes in CRP, CDAI, or IBDQ
were seen.
Conclusion: While dietary therapy is an appealing strategy in the manage-
ment of Crohn’s disease, the preparation and dose used in this study was not
well tolerated and the study was unable to show benefit.
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Elevated CRP (C-Reactive Protein) Levels Can Predict Ileal
Involvement in Patients with Inflammatory Bowel Disease
Prabhakar P. Swaroop, MD∗, Naishadh Raghuwanshi, MD. Digestive and
Liver Diseases, UT Southwestern Medical Center, Dallas, TX and
Gastroenterology and Hepatology, Saint Louis University Hospital, Saint
Louis, MO.
Purpose: The advent of high-sensitivity CRP (hs-CRP) has enabled us to
detect disease activity in patient with IBD. We sought to examine the rela-
tionship between hs-CRP (CRP) and location of disease in IBD based upon
endoscopic, histologic, and radiographic activity.
Methods: All IBD patients at our institution between July 2000 and June
2006 who had a CRP, and colonoscopy with biopsy and/or small bowel follow
through (SBFT) performed with 90 days were identified, retrospectively.
The diagnosis of Crohn’s disease (CD) or Ulcerative Colitis (UC) must have
been made or confirmed at our institution. Those patients who underwent
proctocolectomy with IPAA were excluded from the study. The patients with
CD and UC were separately identified and the odds ratio (OR) for an elevated
CRP was determined based upon location of disease.
Results: A total of 218 patients with a confirmed diagnosis of IBD were
identified of which 93 patients fulfilled the inclusion criteria. Of the 53
patients with CD, the mean CRP was 2.80 mg/dL, regardless of disease
location. Using a cutoff CRP level of 2.0 mg/dL, the odds ratio (OR) for
terminal ileum involvement was 3.38, suggesting that those CD patients with
a CRP greater than 2.0 mg/dL are more prone to have ileal involvement. Of
the 40 patients with UC, the mean CRP was 3.18 mg/dL, independent of
location of disease. Again, using a cutoff CRP level of 2.0 mg/dL, the odds
ratio (OR) for ileal involvement was 3.29. The data suggests that a CRP level
greater than 2.0 mg/dL predicts backwash ileitis in those patients with UC.
Interestingly, those patients who had CRP levels greater than 7.0 mg/dL were
found to have Cytomegalovirus infection in the colon, Clostridium difficile
infection, or another underlying systemic infectious process.
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Conclusion: CRP elevation in Inflammatory Bowel Disease is associated
with active disease determined endoscopically, histologically, or radiograph-
ically. In both CD and UC, a CRP > 2.0 mg/dL predicts findings of active
ileal disease at ileocolonoscopy. Ileitis may play a crucial role in the inflam-
matory cascade of IBD.
982
A Randomized Prospective Trial of Endoscopic Ultrasound (EUS) To
Guide Combination Medical and Surgical Treatment for Crohn’s
Perianal Fistulas
Natalie M. Spradlin, MD, Paul Wise, MD, Alan Herline, MD, Roberta
Muldoon, MD, David A. Schwartz, MD∗. Gastroenterology, Vanderbilt
University Medical Center, Nashville, TN and Colon and Rectal Surgery,
Vanderbilt University Medical Center, Nashville, TN.
Purpose: To prospectively determine if rectal EUS can guide combination
medical and surgical therapy and improve outcomes for patients (pts) with
perianal fistulizing Crohn’s disease.
Methods: 10 pts with perianal Crohn’s disease were prospectively enrolled
in a randomized prospective pilot study. Pts were randomized to either the
EUS cohort or control group. All pts underwent a rectal EUS to delineate fis-
tula anatomy followed by an exam under anesthesia by a colorectal surgeon
with seton placement and/or incision and drainage as indicated. The surgeon
was blinded to the initial EUS results of pts in the control group. Medical
treatment was maximized with 6-MP or azathioprine, cipro or metronida-
zole, and infliximab [5 mg/kg at 0, 2, 6 weeks (wks) and q 8 wkly]. For pts in
the control group, additional interventions (seton removal, repeat surgery)
were at the discretion of the surgeon (without EUS guidance). Pts in the EUS
cohort had EUS performed every 16 wks with additional surgical interven-
tions based on EUS findings. The primary endpoint was complete cessation
of drainage at wk 54. All pts had a repeat EUS performed at wk 54 to de-
termine fistula status on EUS (secondary endpoint). The need for additional
surgery was defined as a treatment failure.
Results: 10 pts enrolled in the study. One of the control pts by 3.5 mos
into the study period required multiple repeat surgeries for recurrent fis-
tulas/abscesses and is considered a treatment failure. 1/5 (20%) in control
group and 4/5 (80%) in the EUS group have had complete cessation of
drainage. From the control group, 3 pts failed due to repeat surgery (2 for
persistent/recurrent fistula and 1 for abscess), and 1 had persistent drainage
at wk 54. In the EUS cohort, 1 pt had recurrent abscess after his seton fell
out prematurely.
In the EUS cohort, the median time to cessation of drainage was 99 days and
the time to EUS evidence of fistula inactivity was 229 days.
Conclusion: In this pilot study, using EUS to guide combination medical and
surgical therapy for perianal fistulizing Crohn’s disease improves outcomes
983
Inflammatory Bowel Disease in Afro-Caribbeans: Does It Differ from
Other Ethnic Groups?
Alejandra I. Castillo-Roth, MD, Joanne M. Matthews, MD, Kapil Gupta,
MD, Safak Reka, MD, Swaminath Iyer, MD∗. Gastroenterology and
Hepatology, SUNY Downstate, Brooklyn, NY.
Purpose: Recent studies in inflammatory bowel disease (IBD) have found
phenotypic differences among ethnic groups. Limited data have been pub-
lished about IBD patients of Afro-Caribbean (AC) origin. This study com-
pares Afro-Caribbean IBD patients with three other ethnic groups.
Methods: Retrospective study of 73 AC IBD patients, first and second gener-
ation, followed in the GI clinic. Data were compiled based on sex, diagnosis,
age at onset/diagnosis, family history of IBD, disease distribution and pat-
tern, and extra-intestinal manifestations. Results were compared to those of
the large North American Cohort Study of IBD patients, which included
African Americans (AA), Whites and Hispanics. Data on Crohn’s disease
(CD) and ulcerative colitis (UC) distribution, pattern, and extent were ex-
tracted using the same criteria described by the large North American Cohort
study.
Results: Differences were noted between AC patients and White, AA and
Hispanic patients in regard to diagnosis, age at onset/diagnosis and family
history of IBD (table).
AC have significantly less ileo-colonic CD compared with Hispanics and
significantly more CD colitis compared with the other groups. No upper
gastrointestinal involvement was seen in AC; this significantly differs from
Whites and AA. No significant difference was found in CD pattern or UC
disease extent among AC and the other groups.
IBD Phenotype in AC Compare with other Ethnic
Groups from The Large North American Cohort Study
White AA Hispanic AC
Race distribution 809 116 168 73
Age at diagnosis, 26.6 (12.8) 26.6 (13.3) 25.4 (13.2) 38.5 (14.4)
mean (SD)a
Female, No (%) 427 (51.5)b 80 (63) 77 (45.6)c 50 (68.5)
Family history 237 (29.3) 23 (19.8) 28 (16.7) 1 (1.5)
of IBD (%)d
CD (%)e 510 (63) 81 (69.8) 106 (63.1) 26 (35.6)
UC (%)e 299 (37) 35 (30.2) 62 (36.9) 47 (64.4)
a Bonferroni-adjusted P < 0.001 comparing AC with any of the other groups. b P =
0.013 comparing AC with Whites. c P = 0.003 comparing AC with Hispanics. d P <
0.0001 comparing AC with Whites; P = 0.0003 comparing AC with AA; P = 0.0013
comparing AC with Hispanics. e P < 0.0001 comparing AC with Whites and AC with
AA; P = 0.0002 comparing AC with Hispanics.
Conclusion: This is the largest series of AC IBD patients described in the
literature. We found phenotypic differences among AC with IBD compared
with other ethnic groups. The differences are likely related to genetic and
environmental factors. A better understanding of these differences may in-
fluence patient management and disease prognosis.
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Infliximab Reduces Colectomy in Patients with Moderate-to-Severe
Ulcerative Colitis: Analysis from ACT 1 and ACT 2
W.J. Sandborn, MD∗, P. Rutgeerts, MD, B.G. Feagan, MD, W. Reinisch,
MD, A. Olson, MD, J. Johanns, PhD, J. Lu, PhD, D. Rachmilewitz, MD, S.
Hanauer, MD, G. Lichtenstein, MD, W. de Villiers, MD, D. Present, MD, B.
Sands, MD, J. Colombel, MD. Gastro, Mayo Clinic, Rochester, MN;
Gastro, Univ Hosp Gasthuisberg, Leuven, Belgium; Robarts Research
Institute, Univ Western Ontario, London, ON, Canada; Internal Medicine,
Univ Hosp Vienna, Vienna, Austria; R&D, Centocor, Inc., Malvern, PA; Pr,
Shaare Zedak Medical Center, Jerusalem, Israel; Gastro & Nutrition, Univ
Chicago, Chicago, IL; Center for IBD, Univ Penna, Phila, PA; Internal
Medicine, Univ Kentucky, Lexington, KY; Medicine, Mt. Sinai, New York,
NY; Gastro Unit, MGH, Boston, MA and Pr Gastro-Enterologie, Hopital
Huriez, Lille, France.
Purpose: We assessed the incidence of colectomy through 54 wks, a follow-
up to ACT 1 & ACT 2.
Methods: The prespecified primary analysis was time to colectomy in pts
treated with infliximab (IFX) compared w/ placebo (PBO) (combined stud-
ies & IFX grps). Data were collected in ACT 1 & 2, ACT extension, &
RESULTS-UC. Missing data were collected retrospectively. Rates of colec-
tomy, UC-related hospitalizations, and UC-related surgeries and procedures
were compared btw combined IFX and PBO. Stratified log-rank test was
used for time to colectomy analysis, and Kaplan-Meier (K-M) product-limit
estimated cumulative incidence of colectomy.
Results: 630 (86.5%) pts had complete colectomy follow-up; more IFX
pts had complete colectomy follow-up (90.1%, 5 mg/kg; 86.8%, 10 mg/kg)
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than PBO pts (82.8%). 81 pts (36, PBO; 27, 5 mg/kg; 18, 10 mg/kg IFX)
had a colectomy thru 54 wks. The proportion of PBO pts who received
commercial IFX prior to colectomy was higher than that for combined-IFX
pts (15.7% vs 6.6%) in ACT 1, but similar in ACT 2 (6.5% vs 5.0%). Primary
endpt: Cumulative incidence of colectomy (K-M) was significant favoring
the combined-IFX grp, P = 0.012. The hazard ratio btw PBO and combined-
IFX grps was 0.57 (95% CI: 0.37, 0.89), a 43% risk reduction in colectomy
thru 54 wks. Major secondary endpts: A significantly greater proportion of
PBO pts (14.8%) had colectomy than combined-IFX pts (9.3%, P = 0.028)
thru 54 weeks. The proportion of UC-related hospitalizations and surgeries
were significantly higher in the PBO grp than those in the combined-IFX
grp (P = 0.003 vs P = 0.022) through 54 wks after first infusion.
Conclusion: IFX significantly reduced the incidence of colectomy and de-
creased UC-related hospitalizations and UC-related surgeries/procedures
compared with PBO in UC.
985
Gastroenterologists’ Practices and Attitudes Regarding Inflammatory
Bowel Disease
Andrea Altschuler, PhD, Fernando Velayos, MD, James E. Allison, MD,
Liyan Liu, MD, Lisa J. Herrinton, PhD∗. Division of Research, Kaiser
Permanente Northern California, Oakland, CA and Internal Medicine;
Division of Gastroenterology, University of California, San Francisco, CA.
Purpose: To assess organizational and MD-based aspects of IBD practice
variation within a multi-site integrated care delivery system and the extent
to which physicians are interested in adopting a chronic care model and/or
nurse assistance to manage IBD patients.
Methods: As part of an observational cohort study to understand variation
in IBD care and outcomes, we conducted semi-structured, open-ended inter-
views with 17 gastroenterologists and 1 gastroenterology nurse at 6 clinics in
1 Northern California integrated care delivery system. All interviews were
tape recorded and transcribed. We coded and analyzed transcripts using stan-
dard qualitative methods.
Results: Physicians reported a range of IBD practice among and between
clinics. Data analysis showed most notable differences in 4 domains: 1)
primary care involvement: the extent to which internists conduct initial
work-ups and co-manage patients with mild disease; 2) gastroenterologists’
practices: the extent to which gastroenterologists utilize practice guidelines
and on-line sources; the degree to which colleagues confer with each other,
surgeons, and acknowledged IBD experts; varying practices and attitudes
regarding health education materials that are distributed and/or should be
available for newly diagnosed patients; varying practices prescribing inflix-
imab; and estimates ranging from < 5% to 50% for medical hospitalizations;
3) patient factors: use of alternative medicine is typically non-problematic
and limited to urban areas; 4) physician attitudes toward ancillary support:
the degree to which gastroenterologists feel there is potential for IBD spe-
cialty clinics or chronic care management and how this reflects physicians’
beliefs that IBD is very much an “art of medicine” disease; and the potential
value of using RNs for patient tracking.
Conclusion: 1. Standardized algorithms on how to care for IBD patients do
not exist. 2. There is opportunity to improve or optimize IBD care by having
initial work-ups and management of patients in remission in primary care
and creating and maintaining opportunities for gastroenterologists to confer
Cumulative Risk of any Complication
Yr (95% CI) Yr 1 Yr 5 Yr 10 Yr 15
TPC-IPAA 44.8 (23.4–60.7) 78.4 (53.2–90.0) 83.8 (57.8–94.6) ND
SC-ileostomy 66.7 (0–93.3) 66.7 (0–93.3) ND ND
TPC-ileostomy 35.7 (5.0–56.5) 51.0 (15.5–71.6) 59.2 (21.6–78.7) 59.2 (21.6–83.8)
PC 43.1 (26.9–56.0) 68.0 (50.1–79.4) 73.8 (55.8–85.4) 73.8 (55.8–89.9)
ND, no data.
with local colleagues, surgeons, and acknowledged local experts. 3. There is
value in nurse coordination regarding medications and labs and/or some type
of specialty IBD clinic for especially sick and/or newly diagnosed patients.
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Incidence of Post-Surgical Complications among Ulcerative Colitis
(UC) Patients (Pts): A Population-Based Study
Salma Akram, MD, Steven B. Ingle, MD, Shamina Dhillon, MD, W. Scott
Harmsen, MS, Alan R. Zinsmeister, PhD, William J. Tremaine, MD, William
J. Sandborn, MD, Edward V. Loftus, MD∗. Mayo Clinic, Rochester, MN.
Purpose: We sought to describe the incidence of and factors associated with
post-colectomy complications among UC pts in Olmsted County, Minnesota.
Methods: We identified all pts who had undergone ≥1 surgery for UC in a
cohort diagnosed with UC between 1970–2001. Colectomies were classified
as: total proctocolectomy (TPC) with ileal pouch-anal anastomosis (IPAA),
subtotal colectomy (SC) with ileostomy, TPC with ileostomy, and partial
colectomy (PC). We examined post-colectomy complications by colectomy
type. The association between colectomy type and time to first complication
was assessed with proportional hazards regression analysis.
Results: A total of 47/316 UC pts (14.8%) underwent colectomy during the
follow-up (f/u) period. The colectomy distribution was: TPC-IPAA 60%,
SC-ileostomy 5%, TPC-ileostomy 33%, and PC 2%. Within the first 2 yrs
of f/u, a variety of complications were observed, including (rate/1,000 pt-
yrs): wound infection (204.9), anastomotic leak (56.9), fistula (22.8), abscess
(68.3), small bowel obstruction (148.0), anastomotic stricture (56.9), ileus
(11.4), pouchitis (148.0), and stomal problems (45.5). During the same pe-
riod, the crude rate of infective and non-infective complications was 296 and
512 per 1000 pt-yrs, respectively. The total crude rate was 808/1000 pt-yrs.
See table for cumulative risk of any complication following colectomy. Re-
gression analysis indicated that, relative to TPC-ileostomy, IPAA patients
had a 1.7 times greater risk of experiencing an infective complication (95%
CI, 0.5–6.3) and a 2.4 times greater risk of experiencing a non-infective
complication (95% CI, 0.98–6.1), but only the latter was of borderline sig-
nificance.
Conclusion: In this population-based study of UC pts undergoing colectomy,
a number of post-surgical complications were observed, for a crude rate of
over 800 per 1,000 pt-yrs of f/u in the first 2 yrs, and a cumulative risk of
68.0% at 5 yrs. There was a borderline significant association between IPAA
and time to first non-infective complication.
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Risk Factors for Ulcerative Colitis (UC) Surgery in a
Population-Based Cohort
Steven B. Ingle, MD, Shamina Dhillon, MD, W. Scott Harmsen, MS, Alan
R. Zinsmeister, PhD, William J. Tremaine, MD, William J. Sandborn, MD,
Edward V. Loftus, MD∗. Mayo Clinic, Rochester, MN.
Purpose: We sought to identify clinical and demographic features influenc-
ing initial and subsequent surgery in a population-based cohort of UC.
Methods: Medical records of Olmsted County residents diagnosed with UC
from 1970–2001 were reviewed to identify all surgeries. Colectomies were
classified as: total proctocolectomy (TPC) with ileal pouch-anal anastomosis
(IPAA), subtotal colectomy (SC) with ileostomy, TPC-ileostomy, and partial
Abstracts S481
colectomy (PC). Planned 2nd-stage surgeries were excluded in counting
unplanned follow-up surgeries. Cumulative incidences of initial colectomy
from time of diagnosis (dx) and follow-up surgeries from time of colectomy
were estimated actuarially. Proportional hazards regression was used to as-
sess association of clinical/demographic features with time to colectomy and
time to follow-up surgery (after colectomy).
Results: 316 UC pts (57% males) were followed for 3,698 person-yrs. Fifty-
three pts (17%) had a surgery for UC, of whom 37 (70%) underwent >1
procedure. See table for cumulative risks of initial colectomy and selected
subtypes. Males were more likely to undergo colectomy (hazards ratio[HR],
2.2; 95% CI, 1.1–4.1). Extensive UC was not significantly associated with
colectomy (HR, 1.4;95% CI, 0.7–2.6) relative to proctitis/left-sided UC. Use
of steroids within 90 days of UC dx was strongly associated with colectomy
(HR, 3.2; 95% CI, 1.6–6.5). Initial colectomy subtypes were: TPC-IPAA
(62%), SC (6%), TPC-ileostomy (30%), and PC (2%). Second colectomy-
related surgeries were common, including ostomy closure in 60%; this var-
ied by colectomy type. The 10-yr cumulative risk of subsequent unplanned
surgery was 44.1% overall and varied by colectomy type (see table). Those
undergoing TPC-IPAA compared to TPC-ileostomy were 1.9 times more
likely to have unplanned follow-up surgeries, but this difference was not
significant(95% CI, 0.6–5.9).
Conclusion: In this population-based cohort of UC pts, the 20-yr cumu-
lative incidence of colectomy was ∼ 20%. Male gender and early need for
corticosteroids were significantly associated with colectomy. The most com-
mon surgeries were TPC-IPAA and TPC-ileostomy, and frequent unplanned
surgeries post-colectomy were observed.
Cumulative Risks
IPAA TPC-ileostomy Total
10-yr colectomy from dx 10.7 (6.6–14.7) 4.9 (2.1–7.6) 16.6 (11.7–21.3)
20-yr colectomy from dx 12.1 (7.6–18.4) 5.9 (2.5–10.2) 19.6 (14.0–26.5)
10-yr unplanned 49.7 (25.0–68.8) 34.1 (0–56.9) 44.1 (25.7–59.3)
surg from colectomy
988
Validation of an Algorithm for Predicting IBD, CD and UC in a
Comprehensive Population
Augusto Lois, PhD, Susan Carroll, PhD, Bruce Neri, PhD∗. Prometheus
Laboratories, San Diego, CA.
Purpose: Prometheus has developed a novel algorithmic approach
(Prometheus IBD Serology 7) to IBD serologic marker analysis. The algo-
rithm is a sophisticated computation in which learning statistical classifiers
sequentially analyze a patient’s serologic test results. The tests include as-
says for ASCA, anti-OmpC, anti-CBir1, and ANCA. The algorithmic anal-
ysis does not compare the patient’s values to a standard reference range but
rather to disease and non-disease serologic patterns. Previously we have de-
tailed the algorithm performance in a validation cohort of 500; in this study
we describe a new expanded cohort of 740 subjects which includes pediatric
samples.
Methods: The algorithm was trained to recognize serologic patterns using
a cohort of 1813 patients (including 60 pediatric samples) with confirmed
diagnoses of CD (N = 646), UC (N = 431), GI disease controls (N =
366), and no disease (N = 370). The ability of the algorithm to predict CD,
UC and non-IBD was tested in a validation cohort. The validation cohort
consisted of 740 patients (590 ≥ 18 years and 150 <18 years) with known
Categories Mild Disease Moderate/Severe Disease DD ≤ 10 yrs DD > 10 yrs
n 39 11 36 14
Preferred Medication 5ASA (53.8%) 5ASA (36.4%), antiTNF(36.4%) 5ASA (50%) 5ASA (50%)
Disfavored Medication Surgery (43.6%) Surgery (36.4%) Surgery (38.9%), Oral Steroids (38.9%) Surgery (50%)
diagnoses, including CD (N = 246), UC (N = 115), GI disease controls
(N = 172) and no confirmed disease (N = 207). The prevalence of IBD in
the validation cohort was 49%. None of the samples used in the development
of the algorithm was used for its validation.
Results: Performance characteristics of the algorithm are shown below. In
addition ROC analysis indicates that the algorithm accurately discrimintates
IBD from non-IBD and CD from UC with area under the curve calculations
of 0.9 for both comparison.
Conclusion: Algorithmic analysis of serologic marker data in a cohort of 740
subjects (including 20% pediatric patients) results in accurate predictions of
CD, UC and non-IBD and discrimination between CD and UC.
Algorithm Performance Characteristic
Validation cohort (740) IBD CD UC
Sensitivity 91% 87% 90%
Specificity 85% 91% 96%
Positive Predictive Value 85% 83% 81%
Negative Predictive Value 91% 93% 98%
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Influence of Disease Duration and Severity on Inflammatory Bowel
Disease Patients’ Medication Preference
Deepthi Deconda, MD, Tamar Taddei, MD, Hannah L. Miller, MD, Judy
H. Cho, MD, Deborah Proctor, MD∗. Medicine/Gastroenterology, Yale
University School of Medicine, New Haven, CT.
Purpose: Inflammatory Bowel Disease (IBD) is a lifelong condition that
often requires multiple medications to treat flares of disease activity and to
maintain remission. The aim of this study was to investigate if a patient’s dis-
ease severity and duration influenced his or her choice of medical or surgical
treatment preferences, in order to better prescribe appropriate medication
for maximizing compliance.
Methods: A comprehensive questionnaire was administered to 50 consec-
utive patients with a known diagnosis of IBD, visiting the Yale IBD clinic
from July to November 2006. The questionnaire included demographics,
disease and medication history, questions on preferences of medication
types (5-aminosalicylic acid agents (5ASA), enemas, oral steroids, im-
munosuppressants, anti TNF agents and surgery) with reasons. The pa-
tients were divided into 2 groups based on their disease severity-mild
(1–4 bowel movements/day, no urgency, rare blood, mild pain) and mod-
erate/severe (>5 bowel movements/day with blood, urgency and inter-
ference with daily activities). The same set of patients were also di-
vided into 2 groups based on disease duration (DD)-≤10 years and >10
years.
Results: The questionnaire was completed by 50 patients (33 with CD and
17 with UC). The patients comprised 28 females and 22 males with a mean
age of 41.52(± 15) years and mean disease duration of 8.8(± 9.6) years.
Treatment preferences of the different groups are as follows:
Majority of the patients preferred 5ASA due to its efficacy and milder side
effect profile. Surgery was the least preferred treatment modality due to side
effects and cost, followed by steroids due to their side effects.
Conclusion: In our preliminary report, disease severity appeared to influence
the choice of preferred medication, with moderate to severe disease patients
preferring more aggressive treatment modality like anti TNF agents equally
to 5ASA. Patients with any disease severity unanimously chose surgery as
the least preferred treatment. Disease duration did not affect the preferred
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medication with 5ASA being the top choice of treatment, but patients with
shorter disease duration did not prefer oral steroids equally to surgery.
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Merkel Cell Carcinoma Arising after Therapy with Azathioprine for
Ulcerative Colitis
Monika Olchawa,∗, A. Albert, R. Chintam, M. Klamut, J. Cabrera.
Gastroenterology, LUMC, Maywood, IL.
Purpose: 1) To recognize an atypical skin lesion in the context of immuno-
suppression with azathioprine 2) To describe the clinical features, treatment
and recommendations for Merkel Cell Carcinoma 3) To illustrate the in-
creased risk of malignancy among patients with inflammatory bowel disease
treated with immunosuppression.
We report a case of a 78 year old male with Ulcerative Colitis (UC) main-
tained on azathioprine and asacol. His clinical course complicated by de-
velopment of Cutaneous Merkel Cell Carcinoma (MCC) of the right thigh.
After 18 months, his disease metastasized to the pelvic lymph nodes. Patient
underwent wide local excision with dissection of lymphatics, followed by
pelvic lymphadenectomy with chemotherapy and radiation. Pathophysiol-
ogy revealed clusters of neoplastic cells consistent with MCC. Azathioprine
was discontinued with subsequent exacerbation of UC. The patient presented
to our institution with severe colitis after completing radiation therapy for
Metastatic MCC with diagnoses of UC exacerbation and Cytomegalovirus
Colitis.
Physical Exam revealed well healed surgical scars in the right lower quadrant
and a right thigh, without any abdominal tenderness or masses. Rectal exam
was grossly positive for blood.
MCC is rare, aggressive, cutaneous malignant tumor with a high incidence
of local-regional recurrence, and distant metastases. The tumor arises from
Merkel cells in the basal layer of epidermis and hair follicles. It is firm, pain-
less, flesh colored or erythematous, noted on the head, neck, extremities and
trunk. Like other skin malignancies, it occurs in areas of greatest sun expo-
sure. Treatment involves; wide local excision, regional lymphadenectomy,
chemotherapy and radiation.
Review of literature proposed several mechanisms to explain the increase
risk of MCC, as well as other malignancies associated with azathioprine
use. Foremost, since azathioprine acts directly on disruption of cell-mediated
immunity by inhibiting purine synthesis (cell division), it can increase the
growth of neoplasm by compromising immune system surveillance. Sec-
ondly, azathioprine is a derivative of the purine analogue 6 mercapto-purine
and via its metabolite 6 thioguanine which is incorporated into DNA, can
lead to disruption of DNA synthesis. Lastly, azathioprine may potentiate
the effects of environmental carcinogens such as ultraviolet radiation by in-
creasing the number of DNA exchanges between sister chromatids leading
to gross chromatic aberrations and thus chromosome damage.
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The Impact of Ulcerative Colitis on Patients’ Lives Compared with
Other Chronic Diseases: A Patient Survey
David T. Rubin, MD∗, Marla C. Dubinsky, MD, Remo Panaccione, MD,
Corey A. Siegel, MD, David G. Binion, MD, Sunanda V. Kane, MD, Joseph
Hopper, PhD. Section of Gastroenterology, Department of Medicine,
University of Chicago Medical Center, Chicago, IL; Pediatric IBD Center,
Cedars–Sinai Medical Center, Los Angeles, CA; Division of
Gastroenterology, University of Calgary, Calgary, AL, Canada; Section of
Gastroenterology & Hepatology, Dartmouth–Hitchcock Medical Center,
Lebanon, NH; Division of Gastroenterology and Hepatology, Medical
College of Wisconsin, Milwaukee, WI; IBD Clinic, Mayo Clinic, Rochester,
MN and Richard Day Research, Evanston, IL.
Purpose: To understand patients’ perspectives of the impact that ulcerative
colitis (UC) has on their lives and to compare this impact with that of other
chronic conditions.
Methods: An internet survey covering a variety of disease-impact indices
was conducted in patients with UC, rheumatoid arthritis (RA), asthma or
migraine. Differences in responses between patient populations were con-
sidered significant if P < 0.05.
Results: Overall, 451 patients with UC (20% mild, 63% moderate, 13%
severe [as informed by their physician]), 309 with RA, 305 with asthma and
305 with migraine were included in the survey. Patients with UC reported a
mean of 8 flare-ups/year (normal disease and flare-ups were not pre-defined,
and thus open to patient interpretation). Significantly more patients with
UC (81%) believed the number of flare-ups they experienced was ‘normal’,
compared with patients with migraine (64%) or asthma (75%). Most patients
with UC considered not feeling well had become normal (73%) and it was
difficult to lead a normal life (62%). These numbers were significantly higher
than the corresponding values for patients with asthma (43% and 33%) or
migraine (64% and 59%, respectively). Significantly more patients with UC
thought their condition was controlling their lives (53%) compared with
patients with RA (44%), asthma (19%) or migraine (37%). Patients with
UC were also significantly more likely to: worry about the long-term effects
(84%); consider their condition was making life more stressful (82%); and
feel depressed (62%) and embarrassed (70%) than patients with the other
chronic conditions.
Conclusion: UC has a substantial detrimental effect on patients’ lives. Com-
pared with other chronic diseases, the impact is more severe, particularly with
regard to the psychological burden.
Abstracts S483
993
Inflammatory Bowel Disease in the Setting of Autoimmune Pancreatitis
Karthik Ravi, MD, Edward V. Loftus, MD∗, Suresh T. Chari, MD, Santhi S.
Vege, MD, William J. Sandborn, MD, Thomas C. Smyrk, MD. Internal
Medicine, Mayo Clinic, Rochester, MN; Gastroenterology and Hepatology,
Mayo Clinic, Rochester, MN and Pathology, Mayo Clinic, Rochester, MN.
Purpose: Though there have been scattered case reports of inflammatory
bowel disease (IBD) occurring in patients with autoimmune pancreatitis
(AIP), the prevalence of IBD in patients with AIP is unknown. We sought
to better characterize the putative association between the conditions.
Methods: Medical records of 71 patients with AIP meeting the HISORt
criteria (Clin Gastroenterol Hepatol 2006;4:1010–1016) were reviewed to
identify patients with endoscopic and biopsy evidence of IBD. Clinical fea-
tures and outcomes were described. Colon samples were immunostained to
identify IgG4 positive cells.
Results: 4 patients with AIP (5.6%) had a diagnosis of IBD; 3 had ulcerative
colitis (UC) and 1 had Crohns disease (CD). Diagnosis of IBD preceded
that of AIP in 3 patients, and was simultaneous in 1. Serum IgG4 was
elevated in 1 of 2 patients with AIP and IBD, compared to 31 of 44 in
those with AIP alone. Only 1 of 4 patients with AIP and IBD had a positive
p-ANCA. Primary sclerosing cholangitis-like intra-hepatic biliary strictures
were seen in 1 of 4 patients with AIP and IBD. 2 patients treated for AIP
with a standard prednisone taper had recurrence of AIP, with 1 requiring 6-
mercaptopurine for long-term steroid-sparing treatment. The other 2 patients
underwent Whipple procedures, with 1 recurrence of AIP. All 3 UC patients
presented with extensive colitis, with total colectomy for refractory colitis
necessary in 2 of 3 patients. Colon samples from 1 patient with UC and 1
patient with CD were available for review. 10 IgG4 positive cells/high power
field were noted on the colon sample from the patient with UC; none were
seen on the CD sample.
Conclusion: As recognition of AIP increases, several important clinical
associations become apparent, including the relationship between AIP and
IBD. Almost 6% of patients in our cohort of 71 patients with proven AIP had
a diagnosis of IBD, compared to a prevalence of approximately 0.4 – 0.5%
in the general population, potentially implying a 12-fold to 15-fold increase
in risk. Interestingly, all 3 UC-AIP patients presented with extensive colitis;
two with refractory colitis requiring total colectomy. The finding of IgG4
positive cells on colon biopsy suggests that IBD may represent an extra
pancreatic manifestation of AIP. Further studies are needed to determine if
IBD is an extra-pancreatic manifestation of AIP or an associated disease.
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Patient and Physician Perceptions on Living with Ulcerative Colitis:
Results from Two Internet Surveys
Incidence of Renal Insufficiency and Leukopenia with 5-ASA Medications
Number of Average daily mesalamine Average duration of exposure
patients (N) dose, gm/day (SEM) to mesalamine, months (SEM)
Ulcerative Colitis 95 3.11 (0.13) 43.08 (4.52)
Patients with Cr ≥ 1.2 mg/dl 6 2.53 (0.40) 52.83 (31.53)
Patients with WBC ≤ 4K 7 2.57 (0.39) 81.29 (20.40)
(4/7 were on 6MP)
Crohn’s Disease 110 3.17 (0.09) 35.77 (3.41)
Patients with Cr ≥ 1.2 mg/dl 6 2.89 (0.29) 24.33 (6.76)
Patients with WBC ≤ 4K 9 3.26 (0.22) 53.22 (10.67)
(8/9 were on 6MP)
Indeterminate Colitis 9 2.98 (0.28) 21.67 (7.49)
Patients with Cr ≥ 1.2 mg/dl 0 Number of patients with Number of patients with
WBC ≤ 4K Cr ≥ 1.2 mg/dl
Patients with WBC ≤ 4K 0 16 12
David T. Rubin, MD∗, Corey A. Siegel, MD, Sunanda V. Kane, MD, David
G. Binion, MD, Remo Panaccione, MD, Marla C. Dubinsky, MD, Joseph
Hopper, PhD. Section of Gastroenterology, Department of Medicine,
University of Chicago Medical Center, Chicago, IL; Gastroenterology &
Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH; IBD
Clinic, Mayo Clinic, Rochester, MN; Division of Gastroenterology and
Hepatology, Medical College of Wisconsin, Milwaukee, WI; Division of
Gastroenterology, University of Calgary, Calgary, AL, Canada; Pediatric
IBD Center, Cedars–Sinai Medical Center, Los Angeles, CA and Richard
Day Research, Evanston, IL.
Purpose: To understand how the perception of the impact of ulcerative colitis
(UC) on patients’ lives differs between patients and gastroenterologists.
Methods: Two national internet surveys were conducted: one in pa-
tients with UC and one in gastroenterologists. Here we present selected
results from these surveys. Patients with a history of colectomy were
excluded.
Results: 451 patients with UC (20% mild, 63% moderate, 13% severe [as
informed by their physician]) and 300 gastroenterologists (unassociated with
the patients) were included in the surveys. In total, 36% of patients reported
having ≥6 flares per year (subjective self-definition). This number exceeded
gastroenterologists’ expectations for a patient population with this distribu-
tion of disease severities. When patients were asked what being in remission
meant to them, 44% believed it meant living with UC symptoms, but man-
aging life without interruption. Although ∼55% of patients reported being
prescribed 5-aminosalicylic acid (5-ASA) therapy, the gastroenterologists
reported prescribing 5-ASA therapy to 87% of their patients. Both patients
and gastroenterologists reported that managing UC medication is a struggle
for patients (49 and 41%) and that it is difficult for patients to take medication
as prescribed every day (42 and 90%). Indeed, 46% of patients admitted to
not taking all of their medication in the past week, while gastroenterologists
believed that 41% of their patients were not adherent.
Conclusion: These surveys show important disparities between how patients
and gastroenterologists perceive the impact of living with UC. Results sug-
gest that many patients have adapted to live with their symptoms rather than
acting to optimize therapy and compliance. Improvements in management
strategies, education, and communication among patients and gastroenterol-
ogists are necessary.
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Long-Term Safety of 5 Aminosalicylates (Mesalamine) in the
Treatment of Inflammatory Bowel Disease
Chirag D. Trivedi, DO, Sima Mithani, MD, Eiswarya Chichili, MD, Danli
Xing, Kiron M. Das, MD, PhD∗. Department of Gastroenterology, Robert
Wood Johnson Medical School, New Brunswick, NJ.
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Purpose: The purpose of this study was to evaluated the safety of high
dose, chronic use of 5-ASAs and identify any adverse events focusing on
nephrotoxicity and hematologic side-effects.
Methods: We retrospectively reviewed 214 charts of patients with IBD.
For each patient we calculated the equivalent mesalamine dose using ap-
propriate conversion formulas, duration of exposure to the medication and
adverse events during the course of their follow up.
Results: Of the 214 patients, 134 patients were exposed to 5-ASAs for over
12 months. 198/214 patients (92%) were treated with an average mesalamine
dose greater than the FDA approved maintenance dosage.
Of the 12 patients with elevated serum creatinine concentrations, 4 were on
no other medications and had no concomitant illnesses accounting for renal
disease. Their glomerular filteration rates, as calculated by the Modifica-
tion of Diet in Renal Disease study equation, ranged from 69.24 to 85.06
ml/min/1.73 m2, implying a mild reduction or stage II kidney disease. Of the
16 patients with leukopenia, 4 were only on 5-ASA medications, 2 on sul-
fasalazine and the other 2 on mesalamine. These findings were independent
of the average daily 5-ASA dose or duration of exposure.
Conclusion: This is the first report regarding the long-term safety of 5-ASA
medications. Overall, these medications are safe at an average dose up to
3.17 gm/day over a period of up to 80 months. A small percentage of our
patients had evidence of Stage II kidney disease and leukopenia of unknown
etiology. Periodic monitoring of serum creatinine and CBC are warranted
during long-term treatment with 5-ASA medications.
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Observations on a Large Sample Set Using Serologic Markers To
Predict Inflammatory Bowel Disease, Ulcerative Colitis (UC), and
Crohn’s (CD)
Bruce Neri, PhD∗, Augusto Lois, PhD, Susan Carroll, PhD, Richard
Bogardt, PhD. R&D, Prometheus Laboratories, San Diego, CA.
Purpose: Over the past 10 years serological tests have been developed to
predict IBD and multiple serologic markers utilized in this process contribute
to the complexity of the analysis. Prometheus has developed an algorithmic
method to aid in resolving this complexity and to predict IBD. This obser-
vational study presents data on the use of this algorithm in a large cohort of
samples.
Methods: Over an extended period of time 47,017 samples were received
at Prometheus for IBD testing with unkown clinical diagnosis. All samples
were tested for several serological markers including ANCA, ASCA, Anti-
OmpC, and Anti CBir-1.
Results: The Prometheus smart diagnostic algorithm predicted CD in 34%
(16,058), UC in 11% (4,973), and non-IBD in 55% (25,986) of the samples
received. In order to investigate the contribution of individual markers to
the prediction, cut off analysis was performed for each of the 3 categories
of predictions. In the cut off analysis, a marker was positive if its value
was 2 standard deviations above a mean value calculated for non-disease
controls. For CD a cut-off analysis was done using the following 4 markers:
ASCA, Anti-CBir-1, Anti-OmpC and ANCA. Of the 16,058 CD predictions
86%, 28%, 14%, and 6% were positive for one, two, three, or 4 markers
respectively. In this analysis the predominant single marker was Anti-Cbir-1
followed by ASCA. In addition, 14% of the CD predicted samples had all
makers below cut-offs.
For UC a cut-off analysis was done using the same markers as were used for
the CD analysis. Of the 4,973 UC predictions 92%, 26%, 8%, and 1% were
positive for one, two, three, or 4 markers respectively. In this Analysis the
most predominant marker was ANCA followed by Anti-OmpC. In addition,
8% of the UC predicted samples had all makers below cut-offs.
For the non IBD category of prediction, 64% of all markers were below
cut off and 31% of the predictions have one marker above cut off and in
this analysis the predominant single marker was Anti-CBir-1 followed by
Anti-OmpC.
Conclusion: These data are consistent with published frequency of the four
previously identified serologic markers in IBD and indicate that IBD is a
very heterogeneous and complex disease. The number of markers required
to predict disease and the complexity of marker patterns is best served by a
sophisticated algorithmic approach. Results also indicate that a significant
number of patients predicted to have either CD or UC have serology markers
below the normal cut-offs.
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Compassionate Use of Certolizumab Pegol in Patients with Crohn’s
Disease for Whom Treatment with One or Two Anti-TNFs Failed
Severine Vermeire, MD∗, Benoıˆt Collin, Krassimir Mitchev, MD, Stefanie
Howaldt, MD, Daniel W. Hommes, MD, Paul J. Rutgeerts, MD.
Department of Gastroenterology, University Hospital Gasthuisberg,
Leuven, Belgium; Global Medical Care, UCB, Braine L’Alleud, Belgium;
Private Practice, Hamburg, Germany and Dept of Gastroenterology and
Hepatology, Leiden University Medical Centre, Leiden, Netherlands.
Purpose: The efficacy and safety of certolizumab pegol (CZP), the first Fc-
free PEGylated Fab’ anti TNF, in Crohn’s disease (CD) were shown in large
Phase III trials. A compassionate-use program (COMPAS) allows physicians
to use CZP in resistant cases. COMPAS provides the first data for CZP
effectiveness in CD in clinical practice.
Methods: COMPAS includes patients (pts) with CD for whom approved
conservative therapies had failed. The recommended dose regimen is that
on the submitted label (400 mg sc induction at Weeks (Wks) 0, 2, and 4,
then 400 mg sc maintenance every 4 wks). Treatment was deemed effective
if there was a clinical response (clinical improvement satisfactory to both pt
and investigator, with the pt remaining on treatment) and no adverse events
(AEs) leading to withdrawal.
Results: By May 2007, COMPAS involved 182 gastroenterologists in 18
countries, with requests received from 284 physicians. Drug-release crite-
ria were met by 216 pts and 160 (65% female; mean age 37 years) had
been treated. Most pts were receiving immunosuppressants and/or corticos-
teroids at baseline; 17 pts had fistulas; 114 pts (71.2%) are ongoing. At
the cut-off date, median exposure is 86 days (all pts) and 104 days (on-
going pts). At Wk 8, 79/160 pts (49.3%) responded. Of these, 59 (36.8%)
were still in response after 8 wks; 31 (52.5%) remained on treatment at
Wk 20, 11 (18.6%) at Wk 32, and 8 (13.6%) at Wk 40. No pts had re-
sponded to infliximab; 39 pts had not responded to either infliximab or adal-
imumab. Of the 39 pts, 21 (53.8%) responded to CZP induction and reached
the maintenance phase. AEs occurred in 22 pts, with 16 serious AEs that
included small intestine carcinoma (history of severe CD/successive im-
munosuppressives/5 months’ therapy), acute left cardiac insufficiency and
renal failure (obesity and family history of myocardial infarction/2 wks’
therapy), and acute urticaria (pt had similar reactions to previous anti-TNF
therapies).
Conclusion: COMPAS offers a first chance for pts with CD to receive CZP
in real-life conditions. Despite only pts with severe and resistant disease
being included, the clinical efficacy and safety profiles of CZP were similar
to those in controlled clinical trials.
This research was funded by UCB.
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Impact of Crohn’s Disease Severity on Healthcare Costs and Utilization
Patricia Grossman, PharmD∗, Edward Armstrong, PharmD, Lionel Van
Holle, MA, Andrea Beyer, MA, Vincent Bauchau, PhD. Global Outcomes
Research, UCB, Smyrna, GA; School of Pharmacy, University of Arizona,
Tucson, AZ; 4Clinics, All4IT, Waterloo, Belgium and Global Outcomes
Research, Modis International, London, United Kingdom.
Purpose: We quantified the impact of disease severity on healthcare uti-
lization and cost in patients (pts) with Crohn’s disease (CD) compared with
nonCD controls.
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Annualized Mean healthcare Utilization and Costs
Controls R M SDRS SDD SDRF CD (all)
Category N = 2972 N = 729 N = 711 N = 780 N = 514 N = 238 N = 2972
Mean healthcare claims/100 pt-years
Emergency room visits 26 47 59 94 74 84 70
Physician visits 500 1030 970 1270 1230 1270 1130
GI procedures 487 1432 1163 1744 1742 1989 1548
Hospitalizations 8 47 26 58 57 49 47
Mean healthcare costs (US $/pt-years)
Emergency room visits 76 157 264 319 223 343 251
Physician visits 306 702 680 908 934 900 807
GI procedures 350 1833 1513 2088 2113 10,491 2565
Hospitalizations 691 6107 3175 6172 6720 5196 5456
Methods: Patients from PharMetrics, a US claims database (Jan 2000–June
2005), were included with ≥3 distinct claims with a CD diagnosis or ≥2
claims including ≥1 diagnosis by a gastroenterologist. Cases were matched
(1:1) to controls by age, gender, region, enrollment year, length of enroll-
ment, and health plan. A treatment algorithm defined disease severity as:
remission (R); mild disease (M); severe disease drug-responsive (SDRS); se-
vere disease drug-dependent (SDD); severe disease drug-refractory (SDRF).
Differences in annualized utilization (mean number of outpatient care vis-
its, gastrointestinal [GI] procedures, and hospitalizations per 100 pt-years)
and payor-related costs (2005 US$/pt-year) were analyzed using Wilcoxon
signed-rank tests.
Results: The analysis included 2972 pts with CD (54% female). Main drivers
for outpatient care were GI procedures and physician visits. Most severe
disease required more outpatient care. Hospitalization and GI procedures
were the highest costs in the CD group; in the SDRF group, GI procedure
costs were substantially higher than for all other severity groups.
Conclusion: More severe disease was associated with greater healthcare
costs, with hospitalization as the main cost. Regardless of severity, all CD
pts had higher utilization and costs compared with controls. Costs were
comparatively high in the remission group, indicating a high demand for
healthcare services despite no/low medication use.
This research was funded by UCB.
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Changes in Utility Scores of Patients with Active Crohn’s Disease after
Certolizumab Pegol 400 mg Induction and Maintenance (PRECiSE 2)
Seng Tan, MSc∗, Brian G. Feagan, MD, Stefan Schreiber, MD, Martin C.J.
Brown, MSc, Laetitia C. Gerlier, MSc. Robarts Clinical Trials, Robarts
Research Institute, London, ON, Canada; Medicine, Christian-Albrechts
University, Kiel, Germany; Global Health Outcomes Research, UCB,
Slough, United Kingdom and Keyrus Biopharma, Levallois-Perret, France.
Purpose: PRECiSE 2 demonstrated the efficacy and safety of certolizumab
pegol (CZP), a PEGylated Fc-free Fab’ anti-TNFα, in Crohn’s disease (CD).1
Patient-reported health status was captured using the self-administered
EQ-5D questionnaire, which assesses mobility, self-care, usual activities,
pain/discomfort and anxiety/depression on a 3-point scale (no/some/extreme
problems).2 This analysis evaluated the effect of CZP on the utility scores
of CD patients in PRECiSE 2.
Methods: Patients with active CD who responded to induction therapy (CZP
400 mg, Weeks [Wks] 0, 2, and 4) at Wk 6 (64.1%) were randomized to
receive CZP 400 mg (N = 215) or placebo (PBO, N = 210) every 4 wks,
Wks 8–24. The EQ-5D was completed at Wks 0, 6, 16, and 26, and at
withdrawal. Responses were converted to utility scores,3 i.e. patients’ rating
of their current health states from -0.59 (worst state imaginable) to 1.00
(best).
Mean utility scores at Wks 0 and 6 were compared using a paired t-test;
scores were compared between treatment groups at each timepoint using the
Wilcoxon test.
Correlations between changes in baseline utility scores and in Inflammatory
Bowel Disease Questionnaire (IBDQ) scores at Wk 26 were evaluated using
Kendall’s tau coefficients.
Results: Mean utility scores increased by 34.3% (P < 0.001) during induc-
tion with CZP. During maintenance therapy, the mean utility score in the
CZP group was 8.6% (P = 0.007), 4.2% (P = 0.064), and 7.0% (P = 0.002)
higher than the mean utility score in the PBO group at Wks 16, 26 and at
the last/withdrawal visit, respectively. Gains in utility scores were associ-
ated with improvements in IBDQ scores (positive Kendall’s tau values, P <
0.001); correlations coefficients ranged from 0.34 (social function) to 0.42
(global score).
Conclusion: CZP maintained improvements in EQ-5D-derived utility scores
observed after CZP induction significantly better than PBO. These improve-
ments were associated with a better health-related quality of life for CD
patients.4
REFERENCES
1. Schreiber S, et al. Gut 2005;54>(Suppl. VII): A82 (Abstract).
2. EuroQol (EQ-5D) User Guide. 8th April 1996.
3. Kind P, et al. Centre for Health Economics. Discussion Paper 172.
4. Feagan B et al., Gut 2006;55 (Suppl. V): MON-G-219
This research was funded by UCB.
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Evaluation of Ten Cytokines in Response to Treatment of Active UC
Simon Travis∗, Piotr Krzeski, Kevin Wright, Simon Pack, Chris Bernhardt.
Department of Gastroenterology, John Radcliffe Hospital, Oxford,
Oxfordshire, United Kingdom and Procter and Gamble Pharmaceuticals,
Egham, Surrey, United Kingdom.
Purpose: There exists no reliable blood biomarker of the activity of UC. Al-
though CRP is widely used in clinical practice, it has limitations. Cytokines
that reflect Th1 and Th2 activity are other potential candidates. This pilot
study examines the relationship between clinical criteria of activity and the
cytokine levels in patients with active UC.
Methods: Samples from 21 patients with moderately active UC (Mayo score
7–11) were recruited after informed consent. Blood samples were taken
before and after treatment from each patient. Samples were analysed for
concentrations of IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IFN-
γ and TNF-α using a manufacturer defined protocol. Logistic regression
was used to model post-treatment Mayo scores as a function of baseline
cytokine concentration and the change in cytokine concentration after treat-
ment. Cytokine concentration was correlated with treatment outcome, symp-
toms (stool frequency and rectal bleeding), endoscopic appearance, extent
of UC and between biomarkers.
Results: The model identified a relationship between baseline [IL-5], [IL-8]
and [IL-10] and response to treatment, (βIL-5 = -1.1, P = 0.142, βIL-8 =
-0.07, P = 0.070, βIL-10 = -0.18, P = 0.034), but its predictive ability
was weak. Higher baseline [IL-5] and [IL-8] and lower [IL-10] predicted
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lower post-treatment Mayo scores. The relationship was strongly influenced
by data outliers. Modelling the change in cytokine concentration identified
only [IL-2] as potentially associated with treatment outcome (P = 0.0003).
Positive [IL-2] correlated with higher post treatment Mayo scores. The
relationship was not robust and had weak predictive ability. Concentrations
of IL-2, IL-4, IL-12, IFN-γ and TNF-α all correlated with each other (all
P < 0.0001), but neither individually nor in combination with treatment
outcome, clinical or endoscopic criteria of response.
Conclusion: Neither baseline nor changes in cytokine concentrations, ei-
ther singly or in combination, were sufficiently robust to predict treatment
response in this pilot study. Nevertheless, the combination of baseline [IL-5],
[IL-8] and [IL-10], or change in [IL-2] are worth exploring in larger studies.
Multiplex biomarker analysis has the potential for evaluating host response
to the disease activity. Clear correlations between IL-2, IL-4, IL12, IFN-
γ and TNF-α in patients with active UC support the concept of a balance
between Th1/Th2 responses in acute colitis.
1001
Evaluation of the Combination of Fecal Lactoferrin and Fecal
Anti-Saccharomyces Cerevesiae Antibodies To Detect Active Crohn’s
Disease
Edward V. Loftus, MD∗, Karen A. Hanson, RN, CNP, Darrell S. Pardi, MD,
Laurence J. Egan, MD, Jennifer L. Jones, MD, William A. Faubion, MD,
William J. Tremaine, MD, Kenneth W. Schroeder, MD, Darcy A. Whitlock,
MS, David M. Lyerly, PhD, James H. Boone, William J. Sandborn, MD.
Mayo Clinic, Rochester, MN and TECHLAB, Inc., Blacksburg, VA.
Purpose: Prior studies of a quantitative assay for fecal lactoferrin showed
high sensitivity and specificity in detecting intestinal inflammation in in-
flammatory bowel disease (IBD). Prior studies have indicated that an assay
to detect fecal antibodies to Saccharomyces cerevesiae (ASCA) may be able
to identify patients (pts) with Crohn’s disease (CD). We sought to determine
the diagnostic utility of a combined analysis to detect both fecal lactoferrin
and fecal ASCA in pts evaluated at an IBD clinic.
Methods: Between 3/04 and 10/06, pts with known or suspected CD who
were undergoing evaluation with colonoscopy +/− small bowel x-ray were
offered enrollment. Study subjects provided stool and serum samples within
72 hrs of colonoscopy and these were sent for analysis (quantitative enzyme-
linked immunoassay [EIA] for fecal lactoferrin, qualitative EIA for both fecal
and serum ASCA, and INOVA serum ASCA IgG). The reference standard
was physician global assessment based on colonoscopy, biopsy, and (if avail-
able) small bowel x-ray (CT enterography or small bowel follow-through).
Results: A total of 69 pts were enrolled (39 active CD, 12 inactive CD, 5
active ulcerative [UC] or indeterminate colitis[IC], and 13 non-IBD condi-
tions). In the active CD group, 6 did not submit stool samples and 3 did not
submit serum. Three non-IBD pts and 1 UC/IC pt did not submit serum.
See table for comparisons of fecal lactoferrin and fecal/serum ASCA. Fecal
lactoferrin was elevated in 33 of 38 pts with active IBD (87%) vs. 17% of
inactive CD and 38% non-IBD miscellaneous. Fecal ASCA was detected in
both active and inactive CD.
Conclusion: Fecal lactoferrin distinguishes active IBD from inactive IBD
and miscellaneous GI disorders. Fecal ASCA is present in the majority of
CD pts and may aid in distinguishing CD from non-IBD; however, additional
studies using a larger number of active UC pts are needed to evaluate the
role of fecal ASCA to differentiate UC from CD.
Active CD Inactive CD UC/IC Non-IBD
Elevated fecal lactoferrin, n (%) 29 (88%) 2 (17%) 4 (80%) 5 (38%)
Fecal ASCA, n (%) 21 (64%) 6 (50%) 4 (80%) 2 (15%)
Serum ASCA 23 (64%) 7 (58%) 0 0
INOVA ASCA 30 (83%) 6 (50%) 1 (25%) 1 (10%)
Mean (SD) lactoferrin ug/mL 1012 (1689) 6.5 (11.2) 6.5 (11.2) 14.5 (21.1)
1002
Willingness of Individuals with IBD To Use Complementary and
Alternative Medicine
Delia Daian, MD, Ashkan Farhadi, MD, MS∗, Majid Afsharzadeh, MD, Ali
Keshavarzian, MD. Division of Digestive Diseases, Rush University
Medical Center, Chicago, IL.
Purpose: Interventions that are not based on the standard therapeutic ap-
proaches of western medicine are categorized as techniques of Comple-
mentary and Alternative Medicine (CAM). However, almost half (3 billion
people) of the world’s population rely on their traditional CAM systems as
their primary form of health care. Even 30% of Americans use CAM for
their ailments. In this study we evaluated the willingness of IBD subjects to
use CAM and their experiences with these therapeutic modalities.
Methods: We had subjects with ulcerative colitis (UC) and Crohn’s disease
(CD) complete questionnaires that assessed disease severity, disease dura-
tion, and respondents’ opinions and experiences with various CAM tech-
niques including acupuncture, western herbs, Chinese medicine, Ayurvedic
medicine, probiotics, vitamins and minerals, aromatherapy, colon cleansing,
hypnosis, and nutritional supplementations. The subjects were also asked
about their views on the role of diet and type of food on the course of their
disease.
Results: We recruited 53 cases of IBD (16 UC and 37 CD). Most UC subjects
(69%) and about half of CD subjects (49%) thought CAM could be benefi-
cial for their IBD and 44% & 32%, respectively, were currently using CAM
remedies. Among IBD subjects only 2% thought that alternative medicine
is not effective, 28% believed that this approach is quite potent and effec-
tive, 56% were unsure, and 7% would never use it without their doctor’s
advice. Many subjects were willing to try different CAM techniques in-
cluding acupuncture (55%), western herbs (57%), Chinese medicine (57%),
Ayurvedic medicine (53%), probiotics (53%), vitamins and minerals (70%),
aromatherapy (47%), colon cleansing (28%), hypnosis (38%) and nutritional
supplementations (70%). Also, 70% of IBD subjects believed that diet af-
fects their disease activity. There were no significant differences between
type of IBD (UC vs. CD), disease severity and duration in their responses to
these questions.
Conclusion: Prior studies showed that IBD subjects use CAM more than
subjects with other GI ailments in the US (30% vs. 15%). Our study showed
that 32–44% of IBD subject are currently using CAM and one third to one
half are willing to try it. More than half of cases were open to the idea of
using CAM. Also, more than two thirds of IBD subjects thought diet affected
disease activity. Thus, we as physicians should address the issue of CAM
use very seriously when we approach our patients’ concerns in our clinical
encounters.
1003
Experience with Wireless Capsule Endoscopy in the Evaluation
of Patients with Crohn’s Disease
Adnan Muhammad, MD, Kiron M. Das, MD, PhD, C.S. Pitchumoni,
MACG∗. Gastroenterology, Hepatology and Clinical Nutrition, Saint
Peter’s University Hospital, New Brunswick, NJ and Gastroenterology,
Robert Wood Johnson University Hospital, New Brunswick, NJ.
Purpose: The diagnosis of Crohn’s disease (CD) is often difficult and many
patients remain in the category of “indeterminate colitis” or “inflammatory
bowel disease type unclassified” (IBDU). Traditionally, suspected CD has
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been evaluated with small bowel series and push enteroscopy where sedation
is required and only a part of small bowel is visualized (up to 120 cm beyond
the ligament of Trietz).
The introduction of WCE allows painless visualization of the entire
small bowel mucosa and also helps in the early detection of mucosal le-
sions/ulcerations in patients with suspected CD/IBDU. WCE has been shown
by meta-analysis to be a more sensitive method to investigate patients for
small bowel CD, with an incremental yield above 30% versus other imaging
modalities (Leighton et el. Inflammatory Bowel Dis. 2007;13:331–7).
Aim: The aim of this study is to present data based on our experience with
WCE in the evaluation of suspected CD and its utility in establishing a
diagnosis in patients with “indeterminate colitis”/IBDU.
Methods: In this retrospective study, data is from WCE performed during
the last 5-year period (2002–2007). Patients with complaints of unexplained
abdominal pain and/or chronic diarrhea underwent WCE for the evaluation
of suspected CD. The diagnosis of CD was made if WCE showed > 3
ulcerations (linear/aphthous). (Maunoury et al. Inflammatory Bowel Dis.
2007;13:152–5).
Results: Total no. of WCE: 652 (Males = 311, Females = 341) WCE
performed for suspected CD = 68/652 cases (10%) Diagnosis of CD was
made = 18/68 cases (26%) CD was diagnosed in patients with past history
Ulcerative colitis (UC) with total colectomy = 3 cases.
Retained capsule in small bowel due to a stricture secondary to CD = 1 case.
Conclusion: 1) WCE plays a major role in the diagnosis of CD especially
in cases of indeterminate colitis/IBDU. 2) In our observation, some patients
who have undergone total colectomy for the presumptive diagnosis of UC
showed small bowel lesions suggestive of CD. This raises a need of evaluating
small bowel mucosa by WCE prior to elective total colectomy for UC. It
may also be appropriate to evaluate the small bowel mucosa with WCE in all
patients with suspected UC. 3) Complications of WCE in patients with CD
although rare, include capsule retention at the stricture sites. The new AGILE
patency capsule (Given Imaging) can diminish this in high-risk patients.
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Hospitalization Rates for Crohn’s Disease Patients in Olmsted County,
Minnesota, in the Pre-Biologic Era
Steven B. Ingle, MD, Edward V. Loftus, MD∗, W. Scott Harmsen, MS, Alan
R. Zinsmeister, PhD, William J. Tremaine, MD, Brian G. Feagan, MD,
William J. Sandborn, MD. Mayo Clinic College of Medicine, Rochester,
MN and University of Western Ontario, London, ON, Canada.
Purpose: Inpatient hospitalization is a major component of health care re-
source consumption for patients (pts) with Crohn’s disease (CD). However,
there are limited data on annual hospitalization rates for CD pts not treated
with anti-tumor necrosis factor (TNF) therapy. We sought to estimate the
historical hospitalization rates for a population-based cohort of CD pts from
Olmsted County, Minnesota, in the pre-biologic era.
Methods: Previously identified county residents diagnosed with CD be-
tween January 1970 and June 1997 were included in the analysis and were
followed until June 1997. Medical records were abstracted for all CD-related
hospitalizations, which were classified as surgical or medical. For pts who
were hospitalized at the time of CD diagnosis (N = 73), the initial hospital-
ization was not included in estimates. Crude incidence rates over the entire
follow-up period and the first year after diagnosis of CD were calculated.
Results: A total of 211 patients with CD were included and were followed
for 2,247 pt-yrs. Median age at diagnosis was 29 years (range, 8.4–88.5),
and 51% were female. One hundred twenty pts (56.9%) had at least one
CD-related hospitalization (median per pt, 2 [range, 1–22]). Excluding the
73 initial hospitalizations at time of diagnosis, the patients experienced 437
hospitalizations (194 per 1000 pt-yrs), including 165 hospitalizations with
inpatient surgeries (73 per 1000 pt-yrs).
Conclusion: Before 1998, when biologics such as TNF antagonists were
not yet available, the crude rate of CD-related hospitalizations was relatively
high. The crude hospitalization rate in the first yr after CD diagnosis was
over twice as high as the overall rate. These data provide a baseline reference
for comparison to gauge the impact of anti-TNF therapy on hospitalization
rates in patients with CD. Therapies that reduce the hospitalization risk may
provide substantial benefits to patients with CD.
CD-Related Hospitalizations in Olmsted County, 1970–97
Medical Surgical Total
Pts With At Least 1 97 (46.0%) 89 (42.2%) 120 (56.9%)
Hospitalization, n (%)
Hospitalizations, n (Crude 272 (121) 165 (73) 437 (194)
Rate Per 1,000 Pt-Yrs)∗
Hospitalizations In First Yr 55 (277) 39 (197) 94 (474)
After Diagnosis, n (Crude
Rate Per 1,000 Pt-Yrs)∗
∗Excludes initial hospitalization if hospitalized at diagnosis.
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A Prospective, Controlled Longitudinal Study of the Effects of Oral
Steroids at 3 and 6 Months on Bone Mineral Density (BMD) in
Patients with IBD
Jae Geun Hyun, MD, Asher Kornbluth, MD∗, James George, MD, Peter
Legnani, MD, Simon Lichtiger, MD, Meredith Lewis, MS.
Gastroenterology, The Mount Sinai Medical Center, New York, NY.
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Purpose: Patients with IBD are at risk for steroid induced BMD loss. How-
ever, the duration of prednisone use required to produce bone loss, and the
natural history of BMD after cessation of prednisone is not well described
in IBD, The objective of this prospective study is to determine the rate and
course of bone loss at 3 and 6 months patients in treated with prednisone
(Pred), compared to a control group matched for disease activity, not treated
with prednisone (non-P).
Methods: Pred patients (N = 22) underwent baseline DEXA to determine
BMD at the lumbar sacral spine (LSS), and bilateral hips, and were com-
pared to non-P patients (N = 18) with active disease; all patients underwent
serial DEXA measurements at 3 and 6 months. All patients were treated
empirically with oral calcium 1500 mg/d and vitamin D 600 u/d. Baseline
disease activity was assessed using the modified Mayo score for UC, and the
Harvey Bradshaw Index for CD.
Results: 21 UC patients and 19 CD patients, 28 males and 12 females were
studied. There were no demographic differences or baseline risk factors
between groups. The proportion of patients with osteoporosis at baseline
were similar in the Pred and non-P groups (11.1% vs. 9.1%). The decline
in mean t scores at 3 months, compared to baseline, was greater in the Pred
group at the LSS, compared to non-P (-0.23 vs. -0.07), as well as at the hip
(−0.23 vs. 0). There was no further decline in mean t scores between 3 and
6 months at either the LSS or hip in either the Pred or non-P group. At 3
months, 7 of 22 (32%) patients in the Pred group had >5% decline in BMD
at the LSS; and 3 of 22 (14%) in the Pred group had a >5% decline in BMD
at the hip. At 6 months no additional patients in the Pred group developed
>5% BMD loss, and 3 of 22 reverted to <5% BMD loss at the LSS. No
additional Pred patients had > 5% BMD loss at the hip.
Conclusion: A 3 month course of prednisone led to a greater decline in
mean t scores at both the LSS and hip than in control patients by 3 months.
However, in this group of patients who had discontinuation of prednisone by
3 months, and maintained on calcium and Vitamin D supplementation, there
was no additional loss in BMD at the hip and a small number of patients
had improvement at the LSS. A short course of prednisone, therefore did not
lead to progressive bone loss beyond the duration of its use.
1007
Infliximab Therapy Is Associated with Unexpected Weight Gain in
Patients with Crohn’s Disease as Compared to Those with Rheumatoid
Arthritis
Cristal L. Brown, Kim L. Isaacs, MD∗. Division of Gastroenterology and
Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Purpose: Obesity has reached epidemic proportions in the United States
with approximately 31% of the population having a BMI > 30 and concern
stems from the multitude of health issues associated with this condition.
Crohn’s disease patients often battle weight loss and anorexia, but anecdotally
there appears to be significant weight gain associated with treatment of
refractory CD patients with infliximab therapy, beyond that expected by
improved nutritional status alone. Our purpose is to determine if infliximab
therapy in patients with refractory CD is associated with significant weight
gain that may change the long-term management of these patients.
Methods: The study is a single center retrospective chart review. IRB ap-
proval was obtained and a pharmacy list generated of patient receiving inflix-
imab infusions from January 2002 to August 2006 (N = 394). The charts of
92 Crohn’s patients and 51 rheumatoid arthritis patients that met the inclusion
criteria were reviewed. Statistical analysis was made using SAS8.2.
Results: The mean weight gain for the CD patients was 4.97 kg compared
to the mean weight gain for patients with RA of 1.1 kg (P < .0049). Patients
treated for “fistulous disease” (N = 34) had a weight gain of 6.2 kg compared
to those treated for “luminal disease” (N = 58), who experienced a 4.4
kg weight gain. (P = .2166) Chronic steroid use, smoking status, baseline
BMI and baseline Harvey Bradshaw Index were not found to significantly
influence weight gain in these patients.
Conclusion: Weight gain with infliximab therapy is more common in pa-
tients with Crohn’s disease than in patients with rheumatoid arthritis. There
was no significant difference in weight gain between patients treated for fistu-
lous or luminal disease. These findings together suggest that the weight gain
seen is not totally related to increase in nutrient absorption by improving lu-
minal disease activity. The findings of significant weight gain and increased
serum leptin levels in Crohn’s patients on infliximab therapy for 4 weeks in a
small prospective study conducted by Franchimont et al (2005) support this
conclusion. The consistent findings of significant weight gain underscore the
need for a larger prospective study to try to elucidate the cause of this weight
gain and the role of leptin. The absence of weight gain in patients with RA
may provide important clues to the mechanism of action of this effect.
1008
Prevalence of Cytomegalovirus and Epstein Barr Virus in Inflamed
Colon Tissue of Patients with Mild to Moderate Inflammatory Bowel
Disease – Preliminary Results
Paul A. Feldman, MD, MSc∗, Stephen Vernon, MD, Daniel L. Cohen, MD,
Jeffrey B. Raskin, MD, Nevis Fregien, PhD. Division of Gastroenterology,
University of Miami, School of Medicine, Miami, FL; Pathology,
University of Miami, School of Medicine, Miami, FL and Anatomy and
Cell Biology, University of Miami, School of Medicine, Miami, FL.
Purpose: Cytomegalovirus (CMV) infection and Epstein Barr virus (EBV)
DNA have been detected in colon tissue of patients with severe steroid
refractory inflammatory bowel disease (IBD). However, the prevalence of
CMV and EBV infection in colon tissue from patients with less severe IBD is
not known. We aimed to evaluate the prevalence of CMV and EBV infection
in colon tissue of patients with mild to moderate IBD as compared to their
prevalence in normal colon mucosa of non IBD patients, non inflamed colon
mucosa in same IBD patients and inflamed mucosa in patients with other
inflammatory diseases of the colon.
Methods: Consecutive colonic tissue biopsy specimens were taken through
colonoscopy from 41 patients with quiescent and mild to moderate IBD
(N = 30 with ulcerative colitis and N = 11 with Crohn’s colitis) and from 49
control patients; N = 6 with colitis from other inflammatory conditions of
the colon and N = 43 from patients without IBD undergoing colonoscopy
for purposes of colorectal cancer screening. Detection of CMV and EBV
infection from tissue biopsies was performed using quantitative PCR and
immunohistochemistry or in-situ hybridization.
Results: Prevalence of CMV and EBV in inflamed mucosa of quiescent and
mild-moderate IBD is 8.1% and 11.4%, respectively. CMV was significantly
more prevalent in inflamed mucosa of UC patients compared to healthy con-
trols (11.5% vs 0%; P < 0.05). EBV is significantly more prevalent in in-
flamed mucosa of IBD and ulcerative colitis patients as compared to healthy
controls (11.4% vs 0%; P < 0.04, 11.5% vs 0%; P < 0.05 respectively).
CMV and EBV were not detected in non inflamed mucosa of IBD patients
and EBV was detected in inflamed mucosa of one patient (16.7%) with
other inflammatory conditions of the colon. When compared with inflamed
mucosa of IBD patients, the differences were not statistical significant.
Conclusion: CMVand/or EBV have a predilection for inflamed mucosa in
IBD patients. Whether the presence of CMV and/or EBV in inflamed mucosa
predispose IBD patients to the development of severe steroid refractory
disease remains to be determined.
1009
Cost of Treating Crohn’s Disease
S. Clark∗, H. Tian, J. Marehbian, S. Hass, M. Arrighi, S. Panjabi. Health
Benchmarks, Woodland Hills, and Elan Pharmaceuticals, San Diego.
Purpose: To estimate differences in health care costs between Crohn’s dis-
ease (CD) patients (pts) and controls and to examine differences in CD costs
by prescription therapy.
Methods: Administrative claims data from geographically diverse private
US health plans with service dates between Jan 1, 2002 and Dec 31, 2005
were utilized. CD pts (ICD-9-CM code 555.x) were identified and matched
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to controls in a 1:5 ratio on age, gender, health plan, and duration of en-
rollment. Members with at least 1-year of continuous enrollment after a CD
diagnosis were included; total costs (2005 US$) were calculated by summing
the amount paid by the health plan for medical services and pharmaceuticals.
CD pts were grouped by drug regimen as follows: steroids, immunosuppres-
sants (IMMS), infliximab, any combination of the 3 drug classes, and no
CD-treatment or treatment not including studied regimens. Average medical
and pharmaceutical cost per pt per day was estimated in each group and
projected annually.
Results: 9,302 CD pts and 46,510 matched controls were identified. Total
annual cost per pt was nearly 4 times higher in the CD group ($11,454)
than the control group ($3,028, P < 0.01). Costs for medical services ac-
counted for greater than 80% of total costs in each group, $9,762 and $2,494,
respectively. CD pts not receiving any of the studied therapies had con-
siderably lower costs for medical services and pharmaceuticals compared
to the study groups (Table). Costs of medical services among CD pts re-
ceiving a steroid in combination with another therapy were substantially
higher compared to both monotherapy and combination therapies excluding
steroids.
Conclusion: CD pts incur significantly greater costs than a similar general
population. CD pts on no treatment or not receiving studied regimens incur
fewer costs suggesting that they may be experiencing remission or mild
symptoms. The use of steroids is associated with significantly higher medical
costs, which may be suggestive of uncontrolled symptoms or flares requiring
medical resources.
Mean Per Patient Per Day and Annual Costs by Drug Regimen
Medical Pharmacy Total
Cost (per Cost (per Cost
Groups pt per day) pt per day) (annual)
No Treatment or Treatment not 14.99 4.32 6,951
including Studied Regimens
Steroids 43.46 10.47 19,413
IMMS 19.96 8.95 10,407
IMMS + Steroids 50.25 13.97 23,122
Infliximab 32.74 53.01 30,871
Infliximab + Steroids 89.80 83.69 62,458
IMMS + infliximab 33.01 53.24 31,050
IMMS + infliximab + Steroids 78.17 61.34 50,224
1010
Immunization for Vaccine-Preventable Illnesses in Patients with
Inflammatory Bowel Disease
Shamita Shah, MD, John L. Gosserand, MD, Rahul Jasti, MD, Sandra
Kemmerly, MD, K. Shiva Kumar, MD, James W. Smith, MD∗. Division of
Gastroenterology & Hepatology, Ochsner Clinic Foundation, New
Orleans, LA.
Purpose: Vaccines are underutilized in immunocompromised patients in-
cluding those with Inflammatory bowel disease (IBD) on immunosuppres-
sive therapy, despite published guideline recommendations. IBD patients
on immunosuppressive therapy are at higher risk for infections. A recent
study suggests that immunization against vaccine-preventable illnesses is
uncommon in IBD patients and efforts are needed to improve vaccine ad-
ministration. Aim of our study was to determine the rate of immunization
among patients with Inflammatory bowel disease (IBD) on immunosuppres-
sive therapies, identify patients at risk for infection, and review reasons for
non-immunization. This study was undertaken to improve performance at
our institution.
Methods: Electronic medical records of all outpatients with IBD seen at
Ochsner Clinic Foundation between September 2005 and August 2006 were
retrieved based on ICD-9 codes between September 2005 to August 2006.
Patients on immunosuppressive therapy were administered a 25-point phone
survey questionnaire encompassing basic medical history, IBD related med-
ication exposure, vaccination history, previous infections with vaccine pre-
ventable diseases. Electronic medical records were assessed for hepatitis B
serology and varicella titers (IgG; ELISA). Information was collected on
exposure to known risk factors for acquiring selected vaccine preventable
diseases.
Results: 798 patients were coded as having IBD during the study period. A
phone survey questionnaire was administered to 189 patients on immuno-
suppressive therapies. Our final study population included 118 patients after
excluding 71. 95 (81%) patients recalled tetanus immunization within the
past 10 yrs, 53 (45%) reported annual flu shots, and 32 (27%) reported
pneumococcal vaccination. One of the more common reasons for nonim-
munization for influenza included lack of awareness (31%). 47 patients
(40%) were at risk for HBV but only 28 (24%) were vaccinated. 27 patients
could not recall a history of chicken pox; of these, 13 reported varicella
immunization.
Conclusion: Immunization against vaccine-preventable illnesses is under-
utilized in IBD patients on immunosuppressive therapies. Efforts are neces-
sary to improve immunization efforts in this at risk population.
1011
Risk Factors for Pouchitis after Ileal Pouch-Anal Anastomosis for
Ulcerative Colitis or Indeterminate Colitis: A Population-Based Study
Paul E. Evans, MD, Darrell S. Pardi, MD, William J. Sandborn, MD,
William J. Tremaine, MD, Eric J. Dozois, MD, Robert R. Cima, MD, David
W. Larson, MD, John H. Pemberton, MD, Bruce G. Wolff, MD, William S.
Harmsen, Alan R. Zinsmeister, PhD, Shamina Dhillon, MD, Patricia P.
Kammer, Edward V. Loftus, MD∗. Division of Gastroenterology and
Hepatology, Mayo Clinic, Rochester, MN; Division of Colon and Rectal
Surgery, Mayo Clinic, Rochester, MN and Divisions of Biostatistics and
Epidemiology, Mayo Clinic, Rochester, MN.
Purpose: Pouchitis is the most common form of pouch dysfunction follow-
ing ileal pouch-anal anastomosis (IPAA). We describe a population based
study of age at diagnosis, gender, PSC, and operative technique as risk factors
for the development of pouchitis after IPAA.
Methods: The Rochester Epidemiology Project, a medical records linkage
system providing data on all health care for the population of Olmsted County
was used to identify all county residents with a diagnosis of UC or IC from
1940–2005 who had an IPAA. Medical records were reviewed to characterize
clinical course following IPAA. The cumulative probability of developing
pouchitis was estimated using the Kaplan Meier method. Gender, age at
diagnosis < 30 years, PSC, and presence of a rectal cuff were assessed for
association with risk of pouchitis using Cox proportional hazards regression.
Results: Forty-five pts were identified, all of whom had a J-shape IPAA.
Six pts (13%) had their diagnosis changed to Crohn’s disease (CD). Of the
remaining 39 patients without CD, the median age at diagnosis of UC was
30 years. Twenty-five patients were male. Seven had PSC; 19 had a stapled
anastomosis with a rectal cuff. The cumulative probability of pouchitis at 1,
5 and 10 yrs was 27%, 58% and 68%, respectively. In a multiple variable
Cox model, male gender (hazard ratio [HR] 4.1, 95% CI 1.5–11.0), age
at diagnosis <30 yrs (HR 3.9, 95% CI 1.5–10.0) and PSC (HR 3.2, 95%
CI 1.2–8.6) were independently associated with the risk of pouchitis. The
presence of a rectal cuff was not a significant risk factor. No significant two
way interactions were detected.
Conclusion: A diagnosis of PSC, male gender and age at UC diagnosis less
than 30 years were independent risk factors for the development of pouchitis
after J-IPAA for UC in this population-based cohort. Previous studies have
found PSC to be a risk factor for pouchitis. Young age at UC diagnosis and
male gender are novel findings that could help to predict the clinical course
of a patient after J-IPAA for UC.
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Treatment of Inflammatory Bowel Disease with 6-Thioguanine (6-TG):
Retrospective Case Series from a Tertiary Care Center
Chhaya P. Hasyagar, MD, Erina N. Foster, MD, Mark Gerich, MD,
Thomas P. Prindiville, MD∗. Gastroenterology and Hepatology, UC Davis
Medical Center, Sacramento, CA.
Purpose: 6-TG has been suggested as an alternative treatment option for
patients with inflammatory bowel disease (IBD). However, hepatotoxicity,
especially nodular regenerative hyperplasia (NRH) has been described lead-
ing to recommendation not to consider the drug for long term treatment of
IBD. We would like to report our experience from a single tertiary referral
center with the use of 6-TG for treatment of IBD.
Methods: Retrospective case series study. We reviewed patient charts includ-
ing hospital and outpatient electronic record/chart of all patients followed in
our adult IBD clinic over past 5 years. We identified patients on 6-TG and
reviewed their charts for duration of treatment with 6-TG and adverse reac-
tions, specifically abnormal liver function tests (LFTS), NRH and lymphoma
during their follow-up.
Results: We reviewed the medical records of 289 patients followed in our
adult IBD clinic over the past 5 years. Of these, 24 patients were treated with
6-TG, 7 male (29%) and 17 (71%) female patients, mean age of 48 years
(range 17 to 86 years), 23 patients had crohn’s disease and one had ulcerative
colitis. The mean duration of treatment with 6-TG was 21 months (range from
2 months to 72 months). Only 2 patients, 1 male and 1 female, had significant
elevation in their LFTs on 6-TG. Both underwent liver biopsy with only one
(4%) reported to have NRH on liver biopsy. This patient discontinued 6-TG,
with complete normalization of his LFTs. No lymphoma was detected in
any patients receiving 6-TG.
Conclusion: 6-TG is rarely associated with NRH. This drug has been used at
our center for treatment of patients who cannot tolerate on other immunosup-
pressive agents. 6-TG is an alternative immunosupressive agent that can be
safely considered in the treatment of IBD. Prospective studies will be needed
to further evaluate for long term safety and efficacy of 6-TG in treatment of
IBD.
1013
Characteristics of an Inflammatory Bowel Disease Population with
Dysplasia and Adenocarcinoma
Bret A. Ancowitz, MD, Sally Stipho, MD, Samir Shah, MD, FACG∗.
Division of Gastroenterology and Hepatology, Brown University Medical
School, Providence, RI; University of Arizona, Phoenix, AZ and
Gastroenterology Associates, Providence, RI.
Purpose: Inflammatory bowel disease (IBD) is associated with an increased
risk of intestinal dysplasia and neoplasia. The purpose of our study was to
identify characteristics of IBD patients diagnosed with such findings.
Methods: Patients found to have both IBD and dysplasia or neoplasia on
histology between 1994 and 2004 were identified from a pathology database
of the largest healthcare system in Rhode Island and from community re-
cruitment. A retrospective chart review was then performed to identify the
demographic, historical, clinical, and histologic characteristics of qualifying
patients.
Results: 32 IBD patients were identified as having dysplasia and/or neoplasia
on histology. 25 (78%) were men, and 7 (22%) were women. Of the patients
for whom information was available, 24 (83%) had ulcerative colitis (UC)
and 5 (17%) had Crohn’s disease (CD). 21 of 32 patients (66%) had low or
moderate grade dysplasia, 5 of 32 (16%) had high grade dysplasia, and 13
of 32 (41%) had adenocarcinoma, with 8 of 32 patients (25%) having more
than one of the above findings concurrently. 5 of 20 IBD patients (25%) had
their dysplasia or neoplasia found during IBD surveillance while the other
15 (75%) were diagnosed either incidentally or due disease symptoms. The
average age of the 13 patients with neoplasia was 60 ± 17 years while it was
56 ± 17 years for the 13 patients without neoplasia. Of 13 patients with UC,
11 (85%) had pancolitis and 2 (15%) had solitary left-sided disease. Only
2 of 17 patients (12%) had a family history of colon cancer and no patients
had a history of primary sclerosing cholangitis.
Conclusion: A population of IBD patients from a large healthcare system in
Rhode Island found to have dysplasia or neoplasia was predominantly male
and without family history of colorectal cancer. Most had ulcerative colitis
with pancolitic involvement and none had primary sclerosing cholangitis.
The majority had their diagnoses made incidentally or because of disease
symptoms, not during IBD surveillance. The most common diagnoses were
low or moderate grade dysplasia or neoplasia. The average age of the sub-
group of patients with neoplasia was similar to those patients with dysplasia
without neoplasia.
1014
Safety and Efficacy of Adalimumab in Pediatric Crohn’s Disease
Patients
Alex Green, DO, Matthew Wyneski, MD, Robert Wyllie, MD, Marsha Kay,
MD, Lori Mahajan, MD∗. Pediatric Gastroenterology, Cleveland Clinic,
Cleveland, OH and Pediatrics, MetroHealth Medical Center, Cleveland,
OH.
Purpose: Attenuated response or anaphylaxis may develop to infliximab.
Adalimumab has recently emerged in the adult Crohn’s Disease (CD) pop-
ulation as an alternate TNF-alpha inhibitor. No studies of adalimumab use
in pediatric pts with CD have been reported. Our study aim was to examine
the safety and efficacy of adalimumab in pediatric CD pts.
Methods: Records of 15 pediatric pts with CD who received adalimumab
(Humira, Abbott Laboratories, Abbott Park, IL) were reviewed per an IRB
approved protocol. All pts had a prior attenuated response or anaphylaxis to
infliximab. Pts and/or caregivers were trained on SQ administration of adali-
mumab at home. They were to call the physician’s office if they experienced
any illness or adverse reaction between visits. Other medications remained
the same. Clinical response to adalimumab was classified as complete re-
sponse, partial response, or nonresponse.
Results: 15 pts with CD were prescribed adalimumab over a 33 month
period. One pt was lost to follow-up. 14 had adequate follow-up for review.
Average age at start of therapy was 16.6 (10.3–21.8) yrs. M:F ratio was 3:4.
The majority of pts received an 80 mg loading dose and 40 mg q2 wks.
Average duration of therapy was 10.8 months. A total of 272 injections were
given. Of the 14 pts, 7 (50%) had complete response, 2 (14%) had a partial
response, and 5 (36%) had no response to adalimumab. Complete response
was achieved on average after 5 injections. Of 5 pts with fistulizing disease, 3
maintained fistula closure; 1 had temporary closure and 1 pt required surgery.
26 adverse events occurred during 272 doses (9.6%). The most common
adverse events were abdominal pain and nausea. There were no serious
adverse events and no adverse events required adalimumab discontinuation.
Therapy was discontinued in 2 pts due to insurance denial.
Conclusion: Adalimumab was well tolerated in our pediatric pts with CD,
with 67% responding favorably. No serious adverse events occurred. Further
studies are needed to evaluate efficacy and determine optimal dosing of
adalimumab in this population.
1015
Family Medicine Practitioners Often Uncomfortable Providing
Preventive Care to Inflammatory Bowel Disease Patients
Lisbeth A. Selby, MD, John F. Wilson, PhD, Andrew Hoellein, MD, Freddy
Caldera, MD, Willem de Villiers, MD, PhD∗. Digestive Diseases and
Nutrition, University of Kentucky, Lexington, KY; Behavioral Medicine,
University of Kentucky, Lexington, KY and Internal Medicine, University of
Kentucky, Lexington, KY.
Purpose: Inflammatory bowel disease (IBD) patients may not receive pre-
ventive care at the same rate as the general population. Attitudes of primary
care providers may be a key factor.
Methods: We conducted an anonymous, cross-sectional survey of family
medicine practitioners. The survey consisted of 9 demographic items, 2
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items to assess comfort level with IBD patients and 6 vignettes of preventive
care issues.
Mulitple choice answers were designated to represent a range of attitudes
toward primary care in IBD patients: 1) active response to perform appro-
priate preventive health action; 2) minimal involvement; 3) generic lack of
involvement and 4) complete lack of involvement based on concept of severe
disease state.
Results: 42 of 97 surveys were returned. 7/924 responses were left blank
(0.75%).
Degrees of subjects were as follows: MD 83%, physician assistant 12%,
doctor of osteopathy 2% and international medical graduate 2%. Mean year
of graduation was 1986. Mean age of subjects was 48. Women comprised
31% of the group. 90% of subjects practice family medicine. 88% of sub-
jects practice mainly in outpatient settings. 16% indicated they were not
comfortable with primary care for any patients currently using medical ther-
apy for IBD. But 40% of subjects felt comfortable providing primary care
across a range of illness severity, which compares with 48% who reported
moderate/high exposure to IBD patients.
Vignettes 1 and 6 concerned reaction to mild hypertension. 90% of subjects’
answers represented an attitude of active involvement.
Vignette 2 elicited attitudes to lipid measurement in IBD patients. 63%
endorsed active response.
Vignette 3 assessed attitudes toward cardiovascular risk reduction. 87% en-
dorsed an active role.
Vignette 4 addressed need for vaccines in a young patient on maintenance in-
fliximab. Only 26% answered that they would take an active role to vaccinate
this person.
Vignette 5 also involved vaccines but the age of the patient was 65. 70% of
subjects chose the active role.
No subject endorsed complete lack of involvement based on a concept of
severe disease state.
Conclusion: Our study suggests family medicine doctors are uncomfortable
caring for IBD patients. Unfamiliarity with medications may be key and
explain low endorsement of vaccines for a case patient on infliximab.
1016
An Audit of Tolerability and Adverse Effects of Azathioprine and
6-Mercaptopurine in Patients with IBD
Mohammad A. Saeed, MBBS, Elmuhtady M. Said, MBBS, Jitendra N.
Singh, MRCP, Anand V. Reddy, MRCP, Athar A. Saeed, FRCP∗.
Gastroenterology, Queen Elizabeth Hospital, Gateshead, United Kingdom.
Purpose: To determine: 1) the percentage of patients who stopped azathio-
prine or 6-MP due to adverse reactions, 2) The side effect profile of these
treatments.
Methods: The case records of the patients with IBD, on immunosuppressive
treatment from 2001 to 2007 under gastroenterology follow up were exam-
ined, in a district hospital in the north of England, looking after a population
of 200,000.
Results: A total of 56 patients were identified who received treatment with
azathioprine. in 32 patients (57%), (average age 36.3) medication had to be
stopped due to side effects, after an average follow up of 233 days, (median
94 days). The medication was stopped due to abdominal or chest pain in 16,
(50%). The other side effects were as follows: Nausea or vomiting, 10 patients
(31%), hepatitis or abnormal liver function tests (LFTs), 7 (22%), dizziness
2 (6%), headache 2, (6%), pancreatitis 1 (3%), leucopenia or neutorpenia in
3 patients, (9%) (One was restarted after 2 weeks in a lower dose).
Out of these patients 9 patients were given 6 MP, 3 of them did not tolerate
this medication either, but 6 were able to tolerate it without significant side
effects. 6 patients were initiated on 6 MP, without previously having received
azathioprine and they were all able to continue it, (100%).
Conclusion: In our cohort of patients, a majority had to stop azathioprine
due to side effects, the commonest of which was abdominal pain, nausea or
vomiting and abnormal LFTs. 6-MP seems to be better tolerated, and should
be considered as a first line treatment.
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The Safety of Natalizumab in Patients with Relapsing Multiple
Sclerosis: An Update from TOUCH and TYGRIS
C. Bozic∗, G. Belcher, M. Kooijmans, R. Kim, F. Lynn, M. Panzara. Biogen
Idec, Cambridge.
Purpose: To report an update on the safety of natalizumab in relapsing
multiple sclerosis (MS) patients.
Methods: The TOUCH Prescribing Program is an ongoing, mandatory
safety registry in the US designed to ensure appropriate and informed use of
natalizumab; determine the incidence of and risk factors for serious oppor-
tunistic infections (OIs), including PML; and monitor patients for signs and
symptoms of PML. Physicians report on PML and serious OIs, deaths, and
natalizumab discontinuations. TYGRIS is a global observational study with
an expected enrollment of approximately 5000 patients. It was designed to
investigate the long-term safety of natalizumab in a clinical practice setting.
Patients in TYGRIS are evaluated at baseline and every 6 months thereafter
for 5 years, regardless of natalizumab treatment status. Data collected at each
evaluation include medical/MS history; prior natalizumab use; prior use of
immunomodulatory, antineoplastic, or immunosuppressive agents; and all
serious adverse events, including PML, serious OIs, and malignancies.
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Results: As of February 23, 2007, 5716 patients have been enrolled in
TOUCH and 114 patients have been enrolled in TYGRIS. The most current
exposure and safety data from patients receiving natalizumab worldwide will
be presented.
Conclusion: Updated safety results from TOUCH and TYGRIS will con-
tinue to expand our knowledge on the long-term safety of natalizumab in
relapsing MS.
1019
Item Content Validation for Two New Measures To Assess Crohn’s
Disease Patients’ Interest in Medication Change
M. Atkinson∗, R. Panaccione, S. Plevy, S. Kane, D. Wolf, S. Hass, S.
Panjabi. PRO-Spectrus, Encinitas; Univ of Calgary, Calgary, Canada;
Univ of Pittsburgh, Pittsburgh; Univ of Chicago, Chicago; Atlanta
Gastroenterology Assoc, Atlanta, and Elan Pharmaceuticals, San Diego.
Purpose: To develop content for two new clinical aids; a brief Screening Tool
that identifies Crohn’s disease (CD) patients’ with an interest in medication
change and a Monitoring Tool that provides a detailed assessment of patients’
treatment experiences.
Methods: Two internet focus group sessions were conducted with patients
(N = 34) from a US CD panel managed by MRxHealth. Participants in
each session were balanced by age, gender, self-rated symptom severity
(remission, mild, moderate and severe), and desire to switch medication (1/3
recent switch, 1/3 want to switch, 1/3 see no need to switch). A conceptual
model of CD’s impact on health-related quality of life provided the basis
for a qualitative inquiry of: (1) troublesome physical and psychological CD
symptoms, (2) optimal and troublesome medication attributes, and (3) CD’s
impact on patient’s life. Respondent transcripts were thematically coded
and the most frequently mentioned themes identified measurement domains
and allowed for the design of general and specific items for each domain.
Participants later responded to these items about the impact of CD and its
treatments over the last two weeks. Logistic regression analysis was used to
select the best predictors of participant interest in medication change.
Results: Six domains were identified and a general Screening Tool item
designed for each (GI symptom control, treatment side effects, emotional
distress, impact on significant relationships, social and community function,
and work/school/home productivity). Ratings of specific items in each of the
6 domains accounted for 14%-77% of the variance in participants’ interest
in medication change. Three items in each domain that most correlated with
interest in medication change were included in the Monitoring Tool.
Conclusion: Results from this initial study indicate that items predicting
patients’ interest in medication change involves symptomatic factors, as
well as the impact of uncontrolled symptoms and treatment side effects on
patients’ lives. The Screening and Monitoring tools will be subsequently
tested in a larger CD patient population to validate their use in clinical
settings.
1020
Gastroenterologists’ Tolerance for Crohn’s Disease Treatment Risks
B. Sands∗, C. Siegel, S. Ozdemir, S. Hass, D. Miller. Massachusetts
General Hospital, Boston; Dartmouth-Hitchcock Medical Center,
Lebanon; RTI International, Research Triangle Park, and Elan
Pharmaceuticals, San Diego.
Purpose: To quantify gastroenterologists’ maximum acceptable risk (MAR)
for treatment-related serious adverse events (SAEs) in Crohn’s disease (CD)
patients.
Methods: Gastroenterologists completed a series of choice-format conjoint
trade-off tasks, choosing 1 of 2 treatments for each of 3 patients (young,
middle-aged, and elderly with randomly assigned gender and number of prior
surgeries). Treatment attributes included daily symptom severity and activ-
ity limitations, potential for CD complications, time between flare-ups, oral
steroid use, and varying levels of three SAE mortality risks: serious infec-
tion, progressive multifocal leukoencephalopathy and lymphoma. Random-
parameters logit was used to obtain relative trade-off weights and calculate
the annual SAE-specific MAR for various benefit levels.
Results: A total of 315 gastroenterologists provided usable data for analy-
sis. Their mean (SD) age and years in practice were 48 (9) and 15 (3) years,
respectively. They treated a mean (SD) of 29 (31) CD patients in a typical
month. Improvement in daily symptom severity was the most important fac-
tor in treatment selection. Greater risk acceptance was seen for treatments
with higher levels of clinical benefit. In comparison to their preferences for
middle-aged patients, they were less tolerant of SAE risk for young patients
and more tolerant of risk for elderly patients. Risk tolerance was greatest
for the lymphoma SAE across all age groups, but particularly for elderly pa-
tients. For improvements from severe CD to mild CD or remission, patients’
preferences obtained from a parallel study are similar to that of gastroen-
terologists when they are prescribing for middle-aged patients. However,
patient respondents were generally twice as willing to accept SAE-related
risk for improvements from moderate CD symptoms.
Conclusion: Medical interventions carry risks of adverse outcomes that
must be evaluated relative to their clinical benefits. Gastroenterologists are
willing to accept defined mortality risks in exchange for clinical efficacy
and their acceptance is affected by the degree of benefit offered by the
treatment, the patient’s characteristics and the nature of the SAE. Compared
to prescribing physicians, patients are more willing to accept risk to avoid
moderate CD symptoms.
1021
Assessment of the Validity of Computed Tomographic Enterography
for Diagnosing Active Crohn’s Disease
Patricia Burgunder, ARNP∗, Ira Shafran, MD. Shafran Gastroenterology
Center, Winter Park, FL.
Purpose: Emerging research suggests that computed tomographic enterog-
raphy (CTE) provides a noninvasive method for diagnosing Crohn’s dis-
ease (CD). Many CTE studies have shown a correlation between CTE and
standard diagnostic techniques for assessing CD of the small bowel. This
retrospective review evaluated the validity of CTE for assessing CD in pa-
tients with anal, rectal, colonic, and small bowel involvement with or without
fistulous disease.
Methods: Medical records for consecutive adult patients with suspected
or confirmed CD who had undergone CTE for active disease assessment
or routine evaluation were reviewed. Results from CTE were compared
with those from other diagnostic and interventional assessments, including
colonoscopy, capsule endoscopy (CE), and direct surgical examination.
Results: The analysis included 25 patients (mean age, 41 y); 18 had previous
CD diagnosis, and 7 had no prior CD history. Of the patients with diagnosed
CD, 5 had CD involving the small bowel only, 3 had colonic, anal, and/or
rectal involvement only, and 10 had CD involving multiple locations; 7 had
prior bowel resection, and 6 had current fistulas. Additional assessments
were conducted within 14 months of CTE (median, 3 wk; range, 2 d–14
mo). Patients underwent colonoscopy only (N = 15), colonoscopy with CE
(N = 5), CE only (N = 1), or surgical intervention (N = 4). Results of
CTE were in concordance with 74% of colonoscopy and CE results. Con-
cordance was observed between CTE and colonoscopy for diagnosing ileal
or colonic/rectal disease activity (N = 5 and N = 6, respectively) and lack
of ileal or colonic/rectal disease activity (N = 3 and N = 4, respectively)
and between CTE and CE for ileal disease activity (N = 1) and lack of
small bowel disease activity (N = 1). Concordance between CTE and sur-
gical examination or colonoscopy for detecting fistulae was 50%, with CTE
detecting perianal (N = 1) and enteroenteric (N = 2) fistulae.
Conclusion: In this retrospective study, CTE demonstrated a high level of
agreement with standard diagnostic measures and direct surgical evalua-
tion on assessments of active ileal or colonic CD. These findings suggest
CTE may provide a valuable, noninvasive diagnostic tool with detection ca-
pabilities complementary to more invasive techniques. The fact that CTE
demonstrated a moderate capability for diagnosing active fistulous disease
suggests a potential need for more sensitive techniques for detecting fistulae.
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Natalizumab Induces Sustained Response and Remission in the
Absence of Concomitant Immunosuppressants in Patients with
Crohn’s Disease Who Failed Prior Anti-TNFα Therapy
B. Lashner, J.F. Colombel, R. Enns, B.G. Feagan, R.N. Fedorak, S.B.
Hanauer, I.C. Lawrance, R. Panaccione, D. Present, P. Rutgeerts, W.J.
Sandborn∗, M. Sanders, S. Schreiber, M.E. Spehlmann, Z. Tulassay, S. van
Deventer, M. Volfova, D.C. Wolf, S. Targan. Cleveland Clinic, Cleveland;
Hopital Claude Huriez, Lille, France; St Paul’s Hospital, University of
British Columbia, Vancouver, Canada; Robarts Research Institute,
University of Western Ontario, London, Canada; University of Alberta,
Edmonton, Canada; University of Chicago, Chicago, Belgium; University
of Western Australia, Western Australia, Australia; University of Calgary,
Calgary, Canada; Mount Sinai School of Medicine, New York; University
Hospital Gasthuisberg, Leuven, Belgium; Mayo Clinic, Rochester;
University of Virginia Health Systems, Charlottesville; Christian-Albrechts
University, Kiel, Germany; Asklepios Westklinikum, Hamburg, Germany;
Semmelweis Univ, Budapest, Hungary; University of Amsterdam Medical
School, Amsterdam, Netherlands; Hepato-Gastroenterology, Hradec
Kralove, Czech Republic; Atlanta Gastroenterology Assoc, Atlanta, and
Cedars Sinai, Los Angeles.
Purpose: This post-hoc analysis assessed the need for concomitant immuno-
suppressants (IMM) for induction and maintenance of response and remis-
sion with natalizumab (NAT) in patients (pts) who failed prior anti-tumor
necrosis factor α (TNFα) therapy.
Table 1
Month Response Remission
PBO NAT PBO NAT
1 33 43 10 13
2 22 50∗ 8 19
3 28 54∗ 10 22∗
2 & 3 14 41∗ 4 15∗
∗P < 0.05
Table 2
Month Response Remission
6 21 48 11 43∗
9 11 43∗ 11 43∗
12 11 43∗ 11 43∗
∗P < 0.05
Methods: In the ENCORE induction trial, 509 pts with CDAI scores ≥220
and ≤450 and CRP levels > 2.87 mg/L were randomized 1:1 to receive NAT
(N = 259) or placebo (PBO; N = 250) at Mths 0, 1 and 2. In the ENACT2
maintenance trial, NAT-treated pts who had responded in ENACT1 and had
Table. Hazard ratios for selected AEs by regimen groups
Steroids only anti-TNFα S/ anti-TNFα
541 pt-yrs only 434 pt-years combination 49 pt-years
AEs Hazard ratio vs referent group
Spesis (N = 2,113) 1.49∗ 1.55∗ 2.66∗†
Demyelination/multiple sclerosis/ 5.48∗ 1.33 25.21∗†
optic neuritis (N = 39)
Opportunistic infections (N = 379) 3.68∗ 1.57 4.41∗
Encephalopathy, encephalitis, 2.65∗ 1.10 4.82∗
meningitis (N = 593)
Any acute event (N = 3,365) 1.83∗ 1.40∗ 2.71∗††
Any adverse event (N = 7,352) 1.45∗ 1.21∗ 1.70∗
∗95% CI does not include 1.0; †P < 0.10 for combination therapy vs steroids alone; ††P < 0.10 for combination therapy vs TNFα alone
a CDAI score <220 were re-randomized 1:1 to receive monthly NAT (N =
168) or PBO (N = 171) for up to 12 mths.
Results: In ENCORE, 54 NAT- and 51 PBO-treated pts failed prior anti-
TNFα therapy and did not receive IMM at baseline. Within this subgroup a
significantly greater proportion of NAT-treated pts were in clinical response
at Mths 2 and 3 and at both timepoints combined, compared to PBO (Table
1). A significantly greater proportion of NAT-treated pts were in clinical re-
mission at Mth 3 and sustained remission through Mths 2 and 3 compared
to PBO (Table 1). In ENACT2 21 NAT- and 19 PBO-treated pts failed prior
anti-TNFα therapy and did not receive IMM at baseline. NAT treatment re-
sulted in more pts in clinical response and remission throughout the study
compared to PBO (Table 2). Significant differences in response and remis-
sion were observed, respectively, at Mths 9 through 12 and at Mths 6 through
12 (Table 2).
Conclusion: Analyses of these trials suggest that NAT was effective in in-
ducing response and maintaining remission in CD pts who failed prior anti-
TNFα therapy and did not receive concomitant IMM.
1023
Adverse Events Related to the Use of Corticosteroids,
Immunosuppressants, and Anti-TNFα Therapy in Crohn’s Disease
Patients
W. Sandborn∗, M. Arrighi, S. Hass, S. Clark, H. Tian, J. Marehbian. Mayo
Clinic, Rochester; Elan Pharmaceuticals, San Diego, and Health
Benchmarks, Woodland Hills.
Purpose: To assess adverse event (AE) rates associated with anti-tumor
necrosis factor α (TNFα) therapy, steroids, and steroid/TNFα combination
(S/TNFα) used in the treatment of Crohn’s disease (CD) patients (pts).
Methods: De-identified medical and pharmacy claims data with service
dates between Jan 1, 2002 and Dec 31, 2005 from geographically diverse
private US health plans were used for the analysis. CD pts were identified
using ICD-9-CM diagnosis code 555.x. At the time of an AE, pts were
grouped by therapy regimen: steroids, TNFα, S/TNFα, or referent group
(immunosuppressants, 5-aminosalicylates, and antibiotics). A Cox propor-
tional hazards model was used to estimate AE hazard ratios (HRs) in person
time units with Wald tests to assess statistical significance between groups.
Results: 8,581 CD cases were identified. Compared to the referent group,
steroids, TNFα, and S/TNFα were generally associated with increased risk of
sepsis, demyelinating conditions, opportunistic infections, and encephalopa-
thy or encephalitis (Table). For demyelination and sepsis, the risk for S/TNFα
therapy was elevated compared to steroids alone, while for all acute AEs, the
risk from S/TNFα therapy was elevated compared to TNFα alone. Analyses
with immunosuppressants as a separate regimen group did not influence the
outcome of examined events; they were combined into the referent treatment
group
Conclusion: Commonly used therapies for CD have been associated with
an increased risk of AEs. These results show excess risks for certain AEs in
pts using steroids or TNFα with increased risk for S/TNFα combination use.
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Further research should assess the benefit and risk of using these therapies
independently or in combination for the management of CD patients.
1024
Lactoferrin Assessment of Rectal Effluent as an Aid to Colonoscopy
for Determining Intestinal Inflammation
Darcy A. Whitlock, MS, James H. Boone, MS, David M. Lyerly, PhD,
Sunanda V. Kane, MD∗. Research & Development, TechLab, Inc.,
Blacksburg, VA and Dept. of Medicine, Gastroenterology, University of
Chicago, Chicago, IL.
Purpose: Accurate evaluation of intestinal inflammation is vital in the man-
agement of inflammatory bowel disease (IBD) patients. A limitation of con-
ventional colonoscopy is the inability to visualize the entire intestinal tract.
Fecal lactoferrin, a marker of intestinal inflammation, may function as an aid
to colonoscopy for assessing IBD patients. Our aim was to evaluate lacto-
ferrin levels in rectal effluent in conjunction with colonoscopy to assess the
presence of inflammation in IBD patients undergoing screening or diagnostic
colonoscopy.
Methods: Fifty-nine adult IBD patients from a single tertiary care center
were enrolled. Each subject provided a sample of the effluent passed towards
the end of the bowel preparation procedure prior to colonoscopy. The speci-
mens were screened for elevated lactoferrin using the IBD-CHEK, a com-
mercially available enzyme-linked immunosorbent assay (ELISA) (TechLab,
Blacksburg). There were 27 active patients and 32 inactive patients based on
colonoscopy and histology.
Results: Forty-four Crohn’s disease (CD) and 15 ulcerative colitis patients
were included in the study. The median age was 44 (22–72) and there were 42
females and 17 males. The lactoferrin ELISA had 74.1% sensitivity, 84.4%
specificity, and 79.7% correlation with colonoscopic findings. Five patients
characterized as inactive by colonoscopy had moderately high lactoferrin
levels. Four of these patients had Crohn’s disease, and the elevated lacto-
ferrin may represent inflammation unseen by conventional colonoscopy.
This suggests a role for lactoferrin testing to help target CD patients re-
quiring additional testing such as small bowel radiography. Seven samples
with endoscopically defined inflammation were negative on the lactoferrin
ELISA.
Conclusion: Rectal effluent samples are easily obtained with a relatively
high degree of patient compliance. Testing for lactoferrin provides an aid to
colonoscopy for determining intestinal inflammation. A positive lactoferrin
result in an endoscopically inactive patient may indicate unresolved inflam-
mation but further investigation is needed. A negative result in an effluent
sample is not clinically relevant due to the potential dilution of lactoferrin
during the bowel preparation procedure and should not be used to rule out
the presence of intestinal inflammation.
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Natalizumab Does Not Require the Concomitant Use of
Immunosuppressants or Corticosteriods for the Induction of Sustained
Response and Remission in Patients with Crohn’s Disease
D.C. Wolf, J.F. Colombel, R. Enns, B.G. Feagan, R.N. Fedorak, S.B.
Hanauer, B. Lashner, I.C. Lawrance, R. Panaccione, D. Present, P.
Rutgeerts, W.J. Sandborn, M. Sanders, S. Schreiber, M.E. Spehlmann, Z.
Tulassay, S. van Deventer, M. Volfova, S. Targan∗. Atlanta
Gastroenterology Associates, Atlanta; Hopital Claude Huriez, Lille,
France; St Paul’s Hospital, University of British Columbia, Vancouver,
Canada; Robarts Research Institute, University of Western Ontario,
London, Canada; University of Alberta, Edmonton, Canada; University of
Chicago, Chicago; Cleveland Clinic, Cleveland; University of Western
Australia, Western Australia, Australia; University of Calgary, Calgary,
Canada; Mount Sinai Medical School, New York; University Hospital
Gasthuisberg, Leuven, Belgium; Mayo Clinic, Rochester; University of
Virginia Health Systems, Charlottesville; Christian-Albrechts University,
Kiel, Germany; Asklepios Westklinikum, Hamburg, Germany; Semmelweis
University, Budapest, Hungary; University of Amsterdam Medical School,
Amsterdam, Netherlands; Hepato-Gastroenterology, Hradec Kra´love´,
Czech Republic and Cedars Sinai, Los Angeles.
Purpose: This post-hoc analysis assessed the need for concomitant immuno-
suppressants (IMM) or corticosteroids (CS) for induction of response and
remission with natalizumab (NAT) in the ENCORE and ENACT2 trials.
Methods: In the ENCORE induction trial, 509 patients (pts) with CDAI
scores ≥220 and ≤450 and CRP levels > 2.87 mg/L were randomized 1:1
to receive NAT 300 mg (N = 259) or placebo (PBO; N = 250) infusions at
Mths 0, 1, and 2. In the ENACT2 maintenance trial, NAT-treated pts who
responded in ENACT1 and had a CDAI score <220 were re-randomized 1:1
to receive monthly NAT (300 mg; N = 168) or placebo (N = 171) infusions
for up to 12 mths.
Results: In ENCORE, 188 pts were not receiving IMM or CS at baseline,
with 90 and 98 randomized to receive NAT and PBO, respectively. A sig-
nificantly greater proportion of NAT-treated pts were in clinical response at
both Months 2 and 3, and, individually, at Mths 1 through 3, compared to the
PBO group (Table 1). NAT treatment also resulted in a significantly greater
proportion of pts in clinical remission at both Mths 2 and 3 and, individually,
at Mths 1 and 3 compared to PBO (Table 1). In ENACT2, 138 pts were not
receiving IMM or CS at baseline, and following randomization, 70 and 68
pts received NAT and PBO, respectively. At Mths 6 through 12, a signifi-
cantly greater proportion of NAT-treated patients were in clinical response
and remission, compared to the PBO group (Table 2).
Conclusion: Analyses of these trials suggest that NAT was effective in in-
ducing response and sustaining remission in CD pts in the absence of con-
comitant IMM or CS therapy.
Table 1. ENCORE (Induction)
Month Response Remission
1 36 54∗ 8 22∗
2 40 56∗ 19 28
3 40 62∗ 22 39∗
2 and 3 31 51∗ 12 24∗
∗P < 0.05
Table 2. ENACT2 (Maintenance)
Month Response Remission
6 38 67∗ 34 56∗
9 35 64∗ 31 51∗
12 24 59∗ 22 54∗
∗P < 0.05
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Do Patients with Inflammatory Bowel Disease Worry about Their Risk
of Colon Cancer? A Study of Patients’ Perception of Their Own Colon
Cancer Risk
Sonia Friedman, MD∗, Adam Cheifitz, MD, Frank Farraye, MD. Medicine,
Brigham and Women’s Hospital, Boston, MA; Medicine, Beth Israel
Medical Center, Boston, MA and Medicine, Boston University Medical
Center, Boston, MA.
Purpose: Patients with chronic, extensive ulcerative or Crohn’s colitis have
an increased risk of colon cancer (about 0.5–1% per year after 8–10 years of
disease) and need colonoscopic surveillance every 2 years. The purpose of
this study is to assess patients’ perceptions of their own risk of colon cancer
and to see if this relates to adherence to surveillance colonoscopy.
Methods: 259 patients with UC or Crohn’s colitis for at least 7 yrs and at least
1/3 of the colon involved participated in this cross-sectional questionnaire
study. A chart review was also performed for each patient.
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Results: Median age was 48, and median disease duration 20 yrs. 44% of
patients had UC, and 51% were female. 49% of patients had waited more
than 2.5 yrs between exams and 40% of patients had waited longer than 3 yrs
between exams. The mean perceived risk of developing colon cancer during
each patient’s lifetime without having routine colonoscopies was 53%. In
comparison, the mean perceived risk of developing colon cancer with routine
colonoscopies was 36%. On a 0–10 scale, with 0 being no worries and 10
being extremely worried, the average worry of IBD patients for developing
colon cancer was 5.09. When asked to consider their level of worry of getting
colon cancer compared to the average person without IBD, IBD patients had
a mean of 3.39 times more worry. When asked how much risk (number of
times more likely for developing colon cancer compared to someone without
IBD) would cause them to never miss a colonoscopy, IBD patients responded
that they would have to be on average 11.97 times more likely to get colon
cancer in order to have a colonoscopy. Adherence was not related to worry
level or perceived risk.
Conclusion: IBD patients perceive that routine surveillance colonoscopies
reduce their risk of colon cancer development by about 17%. However, our
IBD patients would accept a mean of an almost 12-fold increased risk of
colon cancer, compared to an average person without IBD, before they would
adhere to surveillance colonoscopy. In addition, our IBD patients report a
more than three-fold increased worry level about developing colon cancer
compared to an average person without IBD. Worry level or perceived risk,
however, did not relate at all to adherence.
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Chronic Perceived Psychological Stress and the Regulation of
Pro-Inflammatory Cytokines in Ulcerative Colitis
Gary E. Wild, MD, PhD, FRCP c©∗. Gastroenterology, McGill University
Health Centre, Montreal, QC, Canada.
Purpose: While the etiology of IBD remains unclear, alterations in cytokine
profiles are key pathophysiological determinants. Psychological stress has
been associated with a diverse array of adverse health outcomes and there
is compelling evidence it can modulate the clinical course and severity of
IBD. Data from experimental models suggest that the effects of stress on in-
testinal inflammation are mediated through various neuroendocrine-immune
signaling pathways. The hypothalamic pituitary adrenal (HPA) axis is acti-
vated during the stress response and plays a central role in the regulation of
immune function during this period. Thus, the goal of the present study was
to determine the effects of the synthethic glucocorticosteroid receptor ago-
nist, dexamethasone (DEX) on LPS-stimulated pro-inflammatory cytokine
production by PBMC from ulcerative colitis (UC) patients in remission com-
pared to healthy control subjects.
Methods: 20 patients with established UC in clinical remission for at least 3
months were recruited from the IBD clinic. None of the patients were receiv-
ing oral or topical steroids as maintenance therapy. Age and gender matched
healthy subjectswere recruited as controls. Glucocorticosteroid sensitivity
of LPS induced TNF α, IL 6 and IL 1β production in whole blood samples
was measured using DEX at a final concentration of 0 nM (basal), 10 nM,
50 nM and 100 nM. Levels of chronic (1 month) perceived psychological
stress were measured using the 10 item Perceived Stress Scale (PSS).
Results: Patients with UC exhibited significantly less suppression of TNFα
production expressed as a proportion of the level measured in the absence
of DEX (.91 ± 0.05 vs. .53 ± 0.06 10 nM; .54 ± 0.06 vs. .28 ± 0.07 50 nM;
.37 ± 0.06 vs. .19 ± 0.05 100 nM. P < 0.01 in each instance). Significantly
less inhibition of IL 6 (.89 ± 0.04 vs. .65 ± 0.05 10 nM; .65 ± 0.06 vs
.29 ± 0.05 50 nM; .43 ± 0.05 vs. .20 ± 0.06 100 nM) and IL 1β (.84 ±
0.07 vs .56 ± 0.05 10 nM; .52 ± 0.07 vs. .23 ± 0.05 50 nM; .31 ± 0.05
vs. .12 ± 0.04 100 nM) production were also observed (P < 0.01 in each
instance). Finally, higher levels of chronic perceived stress were observed in
UC patients compared to healthy controls (21.6 ± 4.3 vs. 12.4 ± 3.2; P <
0.01).
Conclusion: These observations suggest that glucocorticoid resistance of
pro-inflammatoy cytokine synthesis may represent a novel pathway by which
chronic stress may alter the clinical course of ulcerative colitis. Potential
mechanisms may include the downregulation of glucocorticosteroid recep-
tors on immune cells.
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Serologic Markers Are Associated with Subsequent Crohn’s Disease
Diagnosis and Fistulous Complications in Ulcerative Colitis Patients
Who Undergo Ileal Pouch Anal Anastomosis
Kleanthis G. Dendrinos, MD, Arthur F. Stucchi, PhD, James Becker, MD,
Wayne LaMorte, MD, Francis A. Farraye, MD∗. Section of
Gastroenterology, Boston University School of Medicine, Boston, MA;
Department of Surgery, Boston University School of Medicine, Boston, MA
and Biostatistics, Boston University School of Public Health, Boston, MA.
Purpose: Approximately 5% of patients undergoing ileal pouch-anal anas-
tomosis (IPAA) for a diagnosis of ulcerative colitis (UC) are subsequently
diagnosed with Crohn’s disease (CD). In this case-control study, the associ-
ation of serologic markers with the development of CD after IPAA for UC
was evaluated.
Methods: 12 cases and 25 controls were enrolled during routine office vis-
its to Boston Medical Center. The cases were initially diagnosed with UC,
underwent IPAA, and subsequently diagnosed with CD. The diagnosis of
CD was made by the patients’ surgeon or gastroenterologist based on clin-
ical course and by standard criteria including inflammation of small bowel
mucosa proximal to the pouch, development of pouch fistula more than 3
months after ileostomy closure, etc. The controls were UC patients who un-
derwent IPAA and had a normal post-operative course defined as: no change
in diagnosis to CD, < 2 episodes of acute pouchitis/yr, and no pouchitis
within the last 6 months. Demographic and clinical factors were recorded.
Serum drawn at the time of last follow up was assayed by Prometheus Lab-
oratories for ASCA IgG and IgA, Omp C, anti-CBir1, and pANCA using
ELISA.
Results: The mean time to diagnosis of CD for the cases was 4.5 years.
Mean follow up time for the control group was 7.4 years. 7 patients devel-
oped fistulous complications. On average, the cases had higher titers of each
marker with the exception of Omp-C. There was a trend of sero-positivity
for ASCA-IgA in the cases that developed CD: 42% (5/12), compared to
controls 12% (3/25), P = 0.08. Those that developed fistulae were asso-
ciated with sero-positivity for both ASCA IgA and anti-CBir1: 43% (3/7)
compared to 6% (2/30) in those that did not develop fistulae, P = 0.04. Sub-
jects who were ASCA-IgA + were 5.24 times more likely to be diagnosed
with CD. Subjects that were both ASCA IgA + and anti-CBir1 + were 10.5
times more likely to develop fistulous complications.
Conclusion: UC patients that underwent IPAA and had their diagnosis
changed to CD were more likely to be seropositive for ASCA IgA, and
those seropositive for both ASCA IgA and anti-CBir1 were more likely to
have had fistulous complications. A larger study to validate these findings is
ongoing.
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Recurrent Colon Cancer or Dysplasia after Segmental Resection
in Crohn’s Colitis
Elana A. Maser, MD∗, David B. Sachar, MD, MACG, Ullman Thomas,
MD, Roth Esther, BA, Present H. Daniel, MD, MACG, Harpaz Noam, MD
PHD, Bauer Joel, MD. Medicine, Pathology, Surgery, Mount Sinai
Medical Center, New York, NY.
Purpose: In ulcerative colitis, total proctocolectomy is the treatment of
choice for patients with colonic dysplasia or cancer because of the high
risk for recurrent neoplasia. It is unknown whether patients with Crohn’s
colitis and cancer or dysplasia have a similar risk. The aim of this study was
to determine the risk of subsequent colon cancer or dysplasia after segmen-
tal resection or subtotal colectomy for dysplasia or cancer in patients with
Crohn’s colitis.
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Methods: Seventeen patients with Crohn’s disease and colon cancer or dys-
plasia that had been removed by segmental resection or subtotal colectomy
were identified in The Mount Sinai Medical Center’s pathology database.
Patient records and colonoscopy reports were reviewed to identify the pres-
ence or absence of subsequent colon cancer or dysplasia in these patients
during follow-up.
Results: Follow-up data were available for 12 patients. Nine of the 12 pa-
tients had colon cancer in their original resected specimens; 8 of the 9 had
a segmental resection and one had a subtotal colectomy with ileosigmoid
anastomosis. The remaining 3 of the 12 patients had dysplasia; two of them
underwent segmental resection and the third had a subtotal colectomy with
ileosigmoid anastomosis. At the time of surgery, the average duration of
disease was 23.1 years (range 5.7–43.9). The mean length of follow-up was
7.2 years (range 1.2–22.4 yrs). One patient developed colon cancer 5.9 years
after his original segmental resection for colon cancer. One patient developed
a metastatic lesion 2 years after her segmental resection for cancer. A third
patient developed low grade dysplasia 4.6 years after a segmental resection
for high grade dysplasia. There has been no evidence of metachronous dys-
plasia or cancer in the remaining 9 patients, in whom the mean follow-up
has been 7.5 years (range 1.2–22.4).
Conclusion: The heightened risk of recurrent colorectal neoplasia should be
reviewed with patients prior to surgery. Proceeding with segmental resection
or subtotal colectomy should be accompanied by insistence upon close post-
operative colonoscopic surveillance.
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Long-Term Results of Adalimumab Treatment in Subjects with
Moderately to Severely Active Fistulizing Crohn’s Disease Who Have
Failed Response or Showed Intolerance to Infliximab
F. Gomollon, MD, J. Hinojosa, MD, P. Nos, MD, M. Penate, MD, D.
Ceballos, MD, M.A. Gassull, MD∗. Hospital Clı´nico Lozano Blesa,
Zaragoza, Spain; Hospital Sagunto, Sagunto, Spain; Hospital La Fe,
Valencia, Spain; Hospital Insular Las Palmas, Las Palmas, Spain; Hospital
de Gran Canaria Dr. Negrin, Las Palmas, Spain and On Behalf of
GETECCU, Hospital Germans Trias I Pujol, Barcelona, Spain.
Purpose: We evaluated the long-term efficacy and safety of adali-
mumab, a fully human monoclonal antibody anti-TNF, in the induction
and maintenance of perianal fistula closure in subjects with fistulizing
Crohn’s disease (CD) who had lost response to or were intolerant of
infliximab.
Methods: In this observational, open-label, multi-centre, prospective study,
subjects were treated with subcutaneous adalimumab: 160 mg at week 0,
80 mg at week 2, then 40 mg eow for 52 weeks. Subjects were assessed for
complete or partial, (≥50%, decrease in number of draining fistulas) fistula
closure, PDAI score, and adverse events (AE).
Results: In 24 subjects with fistulizing CD (CDAI<220; N = 10) or luminal
and fistulizing CD (CDAI>220; N = 14), the mean duration of CD was 8.7 ±
6.4 years. At baseline, 79% of subjects were on AZA/6MP and 37% were
on corticosteroids, 29.2% showed loss of response and 70.8% intolerance to
infliximab, the PDAI score overall was 10.8 ± 2.8, and the mean number of
draining fistulas was 3.3 ± 3.7. Long-term overall results are presented in
the table.
PDAI and Fistula Closure Status Over Time in Subjects Treated With Adalimumab
Basal Week 4 Week 12 Week 20 Week 42 Week 52
Patients (n) 24 23 20 16 12 12
PDAI 10.8 5.8 5.6 3.8 3.4 4.4
Number of draining fistulae 3.3 0.86 1.21 0.47 0.27 1.0
Complete fistula closure (%) – 20.8 16.7 20.8 29.2 29.2
Partial fistula closure (%) – 41.7 37.5 37.5 41.7 41.7
ITT analysis
Conclusion: Adalimumab treatment maintains long-term reduction in PDAI
levels and complete or partial perianal fistulae closure in subjects with fis-
tulizing CD who had failed response or showed intolerance to infliximab.
No new safety concerns were found compared to other adalimumab-treated
populations.
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Adalimumab Safety in Crohn’s Disease Patients: Open-Label
Maintenance Following the Gain and CHARM Trials
J.F. Colombel, MD∗, P. Rutgeerts, MD, W.J. Sandborn, MD, R. Panaccione,
MD, W. Lau, PhD, K.G. Lomax, MD, P.F. Pollack, MD. CHU Lille, Lille,
France; University Hospital of Gasthuisberg, Leuven, Belgium; Mayo
Clinic, Rochester, MN; Health Science Centre, Calgary, AB, Canada and
Abbott, Parsippany, NJ.
Purpose: Adalimumab (ADA) is approved for the induction and mainte-
nance of remission in adults with moderate to severe Crohn’s disease (CD)
and has demonstrated efficacy and safety in patients with and without prior
anti-TNF experience.[1–3]
Methods: We assessed the safety of ADA maintenance therapy in patients
who completed either of two Phase III, double-blind, placebo-controlled,
adalimumab safety and efficacy trials, GAIN (4-week induction in infliximab
failures) and CHARM (1-year maintenance). Patients had active CD (CDAI
220–450) and included those naı¨ve to prior anti-TNF therapy (approximately
50% of 854 patients in CHARM) or who had lost response to/were intolerant
of prior infliximab therapy (GAIN). Safety was routinely assessed throughout
the Phase III trials and the open-label extension (OLE). Adverse events (AE)
were tabulated in events/100-patient-years (E/100 PY) through 1 year in the
OLE (combined data, representing 1 year since the start of GAIN and 2 years
since the start of CHARM).
Results: Of 1169 patients, all had received ADA in either GAIN (N =
315) or CHARM (N = 854) [including during the OLE]. Adverse events of
interest are listed (table). Non-systemic candidiasis comprised 27 of the 28
opportunistic infection AEs, with 1 case of coccidiodomycosis. Of the 21
malignant AEs, 11 were skin cancers and 1 was a lymphoma; the remainder
were widely scattered.
Events of Interest: GAIN/CHARM combined (N = 1,169; 1,299 PY)
Adverse Event (AE) E (E/100 PY)
Any AE 9,979 (768)
Any Serious AE 456 (35)
AE leading to discontinuation 284 (22)
Infectious AE 1,793 (138)
Serious infectious AE 82 (6)
Injection-site reactions 388 (30)
Opportunistic infection AE 28 (2.2)
Malignant neoplasms AE 21 (1.6)
Death 2 (0.2)
Conclusion: Adalimumab has proven to be well-tolerated in the treatment of
Crohn’s disease after the 1-year follow up of patients from GAIN, and the 2-
year follow up of patients from CHARM. This Crohn’s disease adalimumab
Abstracts S497
safety profile is consistent with the profiles in the original studies, as well
as with the safety profile from other adalimumab indications. 1. Sandborn
WJ, et al. Ann Intern Med. 2007;146(12):829–838. 2. Colombel JF, et al.
Gastroenterology. 2007;132:52–65. 3. Schiff MA, et al. Ann Rheum Dis.
2006;65:889–894.
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Participation in Colonoscopic Cancer Surveillance among Patients
with Ulcerative Colitis: Meeting Expectations?
Fernando S. Velayos, MD, MPH, Liyan Liu, PhD, Jonathan P. Terdiman,
MD, Bernie Collins, PhD, James A. Allison, MD, Lisa J. Herrinton, PhD∗.
Gastroenterology and Hepatology, Center for Crohns and Colitis,
University of California, San Francisco, San Francisco, CA and Division of
Research, Northern California Kaiser Permanente, Oakland, CA.
Purpose: To prevent colorectal cancer in ulcerative colitis (UC), major gas-
troenterology societies recommend an intensive program of colonoscopic
screening/surveillance every 1–2 years beginning 8 years after disease on-
set. In patients without UC, rates of participation in colonoscopic screening
programs have been well described. However in patients with UC, rates of
participation in colonoscopic surveillance programs have not.
Methods: We studied a previously described population-based cohort of 358
patients with left-sided (N = 151) or pancolonic (N = 207) ulcerative colitis
who received care for at least 2 years within an integrated health care system
and were eligible for screening colonoscopy based on duration of disease >
8 years. All procedures and pathology records were available electronically as
part of clinical care. We determined 1) What proportion of patients underwent
at least one screening/surveillance colonoscopy between 2001–2005; 2) what
proportion of patients who underwent surveillance colonoscopy underwent
a second surveillance within the recommended 1–2 years.
Results: Among 358 prevalent cases of UC eligible for screen-
ing/surveillance between 2001–2005, 123 (34%) underwent at least one
surveillance colonoscopy during this time period. Among 123 patients who
underwent one surveillance exam, 64 (52%) underwent an additional surveil-
lance colonoscopy within the recommended 1–2 years. Overall, 64 of the
358 patients (18%) who were eligible for surveillance adhered to the recom-
mended surveillance guidelines.
Conclusion: In an integrated health care system with access to colonoscopy,
few patients with UC adhered to the recommended colonoscopic surveillance
guidelines. If these guidelines represent the current standard of care, reasons
for such poor rates of adherence must be further investigated. Furthermore,
strategies to improve participation in colonoscopic surveillance must be
developed.
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Long-Term Efficacy of Adalimumab Treatment in Patients with
Moderately to Severely Active Luminal Crohn’s Disease Who Lost
Response or Showed Intolerance to Infliximab
J. Hinojosa, MD, F. Gomollon, MD, S. Garcia, MD, G. Bastida, MD, C.
Saro, MD, J. Cabriada, MD, M. Gassull, MD∗. Hospital de Sagunto,
Sagunto, Spain; Hospital Clı´nico Lozano Blesa, Zaragoza, Spain; Hospital
Miguel Servet, Zaragoza, Spain; Hospital La Fe, Valencia, Spain; Hospital
Adalimumab Efficacy Over Time in Patients With Luminal CD
Basal Week 2 (N = 37) Week 4 (N = 37) Week 12 (N = 33) Week 42 (N = 18) Week 52 (N = 17)
CDAI (mean) 310.7 175.9 167.4 145.4 115.6 91.5
Remission (%)∗(CDAI<150) – 34.2 42.1 63.2 60.5 60.5
CR100∗ (%) – 63.2 76.3 76.3 68.4 71.1
CR70∗ (%) – 73.7 84.2 89.5 84.2 84.2
∗ITT-LOCF analysis
de Cabuenes, Gijo´n, Spain; Hospital de Galdakao, Vizcaya, Spain and On
Behalf of GETECCU, Hospital Germans Trias I Pujol, Barcelona.
Purpose: We evaluated the long-term efficacy and safety of adalimumab, a
fully human monoclonal antibody against the tumor necrosis factor (TNF-α),
in the induction of clinical remission/response in patients with moderately
to severely active Crohn’s disease who lost response or showed intolerance
to infliximab.
Methods: In this observational open-label multi-centre, prospective study,
patients with moderate to severely active Crohn’s disease (CDAI > 220)
who had lost response or showed intolerance to infliximab were treated with
subcutaneous adalimumab: 160 mg at week 0, 80 mg at week 2, then 40 mg
eow for 52 weeks. Subjects were assessed for clinical remission (CDAI <
150), clinical response (CR) 70 and CR100 (CDAI decrease of more than
70 or 100 points comparing with baseline) and safety.
Results: 38 patients were recruited who had luminal Crohn’s disease (10
of them luminal fistulizing). Mean duration of CD was 8.8 ± 5.2 years.
At baseline, 55% were on AZA/6MP, 63% on corticosteroids, 42% had
previous loss of response to infliximab, and 58% had developed intolerance
to infliximab. The mean CDAI score at baseline was 310.7 ± 65.4. Long-term
results are shown in the table.
Conclusion: Adalimumab treatment was effective in inducing and main-
taining long-term clinical response and clinical remission in patients with
moderately to severely active luminal Crohn’s disease who had lost response
or showed intolerance to infliximab. No new safety concerns were found
compared with other adalimumab-treated populations.
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Sustainability of Adalimumab in Fistula Healing and Response: 2-Year
Data from CHARM and 12-Month Open-Label Extension Follow-Up
Study
J.F. Colombel, MD∗, M.A. Kamm, MD, D. Schwartz, MD, W.J. Sandborn,
MD, J. Li, PhD, K.G. Lomax, MD, P.F. Pollack, MD. CHU Lille, Lille,
France; St. Mark’s Hospital, Harrow, United Kingdom; Vanderbilt
University Medical Center, Nashville, TN; Mayo Clinic, Rochester, MA and
Abbott, Parsippany, NJ.
Purpose: Adalimumab (ADA), a fully human monoclonal antibody that tar-
gets tumor necrosis factor, has been shown to be efficacious in the induction
and maintenance of remission in patients (pts) with Crohn’s disease (CD).
Fistulizing disease complicates the course of CD in 20–30% of pts, in many
cases leading to surgical resection. The CHARM study has previously shown
efficacy of ADA in fistula closure and response. We assessed long-term ef-
ficacy of ADA in fistula healing and response in CD pts from the CHARM
trial in an open-label extension (OLE) follow-up study.
Methods: Pts in CHARM were randomized to placebo (PBO), 40 mg every
other week (EOW) or 40 mg weekly (EW). Pts with flare or non-response
could receive OL ADA at/after Week 12. At the end of CHARM (56 weeks),
pts were allowed to enroll into an open-label extension (OLE). In the OLE,
pts received EOW OL or remained on EW OL, and could change from EOW
to OL EW for flares or non-response. In this analysis, pts with fistulas at
baseline (BL) of CHARM were studied, pooling the 2 doses, using an ITT,
non-responder imputation analysis. Pts were analyzed for the percentage (%)
of healed fistulas and% with ≥50% fistula response at 6 and 12 months in
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Long-Term Efficacy of Fistula Healing and
Response with ADA Through 2 Years
Month since All ADA
Population Endpoint baseline∗ (EOW+EW combined)
% of pts with fistulas at BL of CHARM, (n/N) Fistula healing 6 30 (21/70)
12 33 (23/70)
18 54 (38/70)
24 51 (36/70)
% of pts with fistulas at BL of CHARM, (n/N) ≥50% Fistula response 6 46 (32/70)
12 49 (34/70)
18 70 (49/70)
24 61 (43/70)
∗18 and 24 months represent 6 and 12 months of OLE after 12 months of blinded therapy in the CHARM study.
the blinded study and at 6 and 12 months of the OLE follow-up study (for a
total of 24 months of therapy).
Results: Results are in the table below.
Conclusion: Sustainable efficacy of ADA in fistula healing and response
is evident after 2 years. ADA has shown sustained response in almost two-
thirds of the patients in the OLE who had fistulas at baseline of CHARM
and sustained closure in more than half of the ADA-treated patients.
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Adalimumab Therapy for Patients with Ulcerative Colitis Who Have
Lost Response or Are Intolerant of Infliximab
Eugene F. Yen, MD, Jonathan P. Terdiman, MD, Uma Mahadevan, MD∗.
Division of Gastroenterology, University of California San Francisco, San
Francisco, CA.
Purpose: Adalimumab (ADA), a human antibody to tumor necrosis fac-
tor (TNF), is an effective treatment for patients with Crohn’s disease who
have lost response or are intolerant of infliximab (INF). We assessed the
clinical response and adverse effects of adalimumab in patients with ulcer-
ative colitis (UC) who have failed INF due to intolerance or loss of clinical
response.
Methods: We queried the Inflammatory Bowel Disease Database at UCSF
to identify all patients with a history of UC who were treated with ADA. The
following data were retrospectively collected: patient demographics, clinical
history, adverse events on IFX and ADA, and clinical response to therapy.
Response to therapy was measured using the Simple Clinical Colitis Activity
Index, where response was defined as a score of <5.
Results: Five patients (3 M/2 F) were identified with UC and treatment with
ADA. The mean age was 29.6 [range 23–36] years, and 80% had pancolitis.
All patients had duration of colitis of at least 5 years, and all were previously
treated with INF. Three patients had an initial response to INF but eventu-
ally lost response despite 10 mg/kg every 4 week dosing, one patient never
achieved a durable response to INF, and one patient had a severe infusion
reaction in part due to episodic dosing of INF. One patient eventually re-
sponded to ADA after 11–12 weeks but required increased dosing to 40 mg
weekly. One patient stopped ADA due to significant myalgias and fatigue.
The remaining three patients failed to achieve a response to ADA and have
been referred for colectomy.
Table 1. Patient data
Patient Previous INF dose Reason for stopping INF ADA dose Clinical response Time to response ADA adverse effects
1 10 mg/kg q4 weeks Lost response 80 mg weekly No None
2 10 mg/kg q4 weeks Lost response 40 mg weekly Yes 11–12 weeks None
3 10 mg/kg q4 weeks Lost response 40 mg weekly No None
4 10 mg/kg q4 weeks Lost response 40 mg every other week No None
5 5 mg/kg (episodic) Severe infusion reaction 40 mg every other week No Myalgias, fatigue
Conclusion: ADA is well tolerated in patients with UC. Prospective studies
in INF-naive patients and past responders to INF are needed to determine
its efficacy in this group.
FUNCTIONAL BOWEL DISORDERS
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Predictors of Small Intestinal Bacterial Overgrowth in Patients with
Irritable Bowel Syndrome
Andrew W. DuPont, MD∗, Rajasekhara Mummadi, MD, Timothy Castro,
MD. Internal Medicine, Division of Gastroenterology, University of Texas
Medical Branch, Galveston, TX.
Purpose: Patients with irritable bowel syndrome (IBS) have been associated
with a higher prevalence of small intestinal bacterial overgrowth (SIBO)
when compared to healthy controls. The aim of this study was to identify
risk factors for SIBO in patients with IBS.
Methods: A total of 45 consecutive patients diagnosed with IBS who un-
derwent hydrogen and methane breath testing for SIBO were identified ret-
rospectively after excluding patients with other coexistent gastrointestinal
and systemic disorders. Based on the referring physician substrate prefer-
ence, 13 patients underwent glucose breath testing (GBT); 17 underwent
lactulose breath testing (LBT); and 15 were given a combined glucose and
lactulose solution. Among the 45 patients evaluated, 11 had positive breath
tests (cases) and 34 had negative tests (controls). The cases and controls
were compared with respect to age, duration of IBS symptoms, gender, pre-
dominant symptom, and Body Mass Index (BMI).
Results: Among the 45 patients with IBS who underwent breath testing, 11
(24.4%) had a positive test (5 with positive LBT, 5 with positive combined
lactulose and glucose solution, and 1 had a positive GBT). A significant
difference was seen in mean age and mean duration of symptoms in IBS
patients with positive breath tests when compared to IBS patients with nega-
tive breath tests. In the multivariate analysis using ANCOVA, only duration
of IBS symptoms remained statistically significant.
Conclusion: To our knowledge, this analysis is the first to evaluate age and
duration of symptoms as a risk factor for a positive breath test in an IBS
population. Our report suggests duration of IBS symptoms is independently
associated with a significant risk for SIBO. Our results suggest it may be
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more cost-effective to focus breath testing on those IBS patients with a longer
duration of symptoms; however this needs to be evaluated in a prospective
analysis.
Results
Positive Negative
Variable Breath test Breath test P value
Number 11/45 34/45 0.000000
Males 3/10 7/10
Females 8/35 27/35
BMI 28.6 ± 2.7 29.0 ± 1.2 0.655
Mean Age (years) 62.5 ± 3.3 51 ± 2.6 0.023
Median Age (years) 62 50
Mean Duration of Symptoms 25 ± 5.2 5.8 ± 1.4 <0.0001
(years)
Median Duration of 26 2
Symptoms (years)
Mean Age When Adjusted 58.07 51.57 0.254
for Duration
Mean Duration When 23.5 6.3 0.0000097
Adjusted for Age
1037
Quality of Life (QOL) but Not Symptom Reporting Is Significantly
Determined by Psychosocial Factors: Implications for Outcomes
Endpoints
Micahel P. Jones, MD∗, Jason Bratten, BS, Laurie Keefer, PhD, Michael D.
Crowell, PhD. Gastroenterology, Northwestern University, Chicago, IL
and Gastroenterology, Mayo Clinic, Scottsdale, AZ.
Purpose: Health-related QOL and subjective reports of symptoms (sxs) are
commonly assessed in both practice and research studies involving IBS pts.
Previous studies demonstrate that psychosocial distress is frequently present
in IBS and may influence both sxs and QOL. As the role of psychosocial
factors in mediating sx and QOL in IBS remains incompletely defined, we
sought to further clarify these relationships.
Methods: Rome II IBS pts were recruited through the NU GI Clinic and the
internet. Pts completed an IBS specific QOL assessment (IBS-QOL) along
with a GI sx measure (GISSI). Pts also completed measures of general-
ized anxiety and depression (HADS), measures of visceral-specific anxiety
(Visceral Sensitivity Index; VSI), vital exhaustion (VE) and recent stressful
life events (LE). Univariate analysis identified factors signif correlated with
IBS-QOL and GISSI and these factors were then entered into regression
analysis.
Results: 181 pts (mean (SD) age = 36(11); 88% F) were studied. With the
exception of LE, all candidate variables were signif correlated with sx and
QOL scores (Table). Stepwise regression of GISSI using signif correlated
psychosocial variables identified only VE as a signif predictor (r2 = 0.117;
P = 0.000). Stepwise regression of IBSQOL total scores identified a 3-step
model that included VSI (r2 = 0.4; P = 0.000), VSI+HADS-D (r2 = 0.53;
P = 0.000) and VSI+HADS-D+GISSI (r2 = 0.56; P = 0.001)
Conclusion: In IBS, sx scores are not signif influenced by psychosocial
factors with the exception of VE. QOL, however, is more signif influenced
HADS-A HADS-D VSI VE LEQ GISSI IBS-QOL
Score (SDEV) 9.21 ± 4.55 6.69 ± 4.17 45.1 ± 16.36 21.71 ± 10.78 160.08 ± 104.14 91.53 ± 19.52 93.76 ± 28.44
GISSI (r; p) 0.18 (0.01) 0.31 (0.00) 0.3 (0.00) 0.34 (0.000) 0.13 (0.07) 0.44 (0.00)
IBSQOL (r; p) 0.43 (0.00) 0.61 (0.00) 0.63 (0.00) 0.59 (0.00) 0.08 (0.18) 0.44 (0.00)
by visceral anxiety and depression than by sxs. These data demonstrate that
sx-based endpoints may be less confounded in clinical trials in IBS. These
data also demonstrate that digestive sx anxiety and depression are more
signif predictors of QOL in IBS than sxs. Optimizing clinical outcomes in
IBS requires attention to these factors.
1038
Nightly Tegaserod Prevents the Clinical Recurrence of Bacterial
Overgrowth Symptoms
Mark Pimentel, MD, FACG∗, Walter Morales, BS, Sheila Lezcano, BS,
Sun-Chuan Dai, MD, Kimberly Low, BA, Reza Khoshini, MD, Janet Yang,
MD. GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, CA.
Purpose: We have recently demonstrated that antibiotic therapy improves
IBS and is related to abnormalities on the lactulose breath test. We have
further demonstrated a deficiency of migrating motor complexes (MMC) in
IBS patients with an abnormal breath test. Based on a disturbed MMC, we
test whether low dose erythromycin or tegaserod can prevent the recurrence
of symptoms after successful antibiotic treatment.
Methods: In this study, a retrospective chart review was conducted on 203
consecutive patients seen in 2005 in the GI Motility Program. Patients were
excluded if they did not have IBS, did not have a positive breath test, had
an alternative diagnosis, or never had successful eradication of the abnor-
mal breath test with clinical resolution. Those with clinical and breath test
resolution were reviewed to determine the method of preventing symptom
recurrence (none, erythromycin or tegaserod) and the time to recurrence
with this method of prevention. Data was compared between groups as well
as within groups if multiple methods were used on the same patient.
Results: Out of 203 patients, 64 patients had IBS, abnormal breath test,
at least one successful treatment and follow up using a prevention strategy.
Based on only the first successful antibiotic treatment, no preventive strategy
(N = 6) meant a recurrence of symptoms in 59.7 ± 47.5 days compared to
138.5 ± 132.2 days for erythromycin (P = 0.16) and 241.6 ± 162.2 (P = 0.01
vs. none and P = 0.02 vs. erythromycin). Any use of prevention was 57.4 ±
44.0 for none, 144.7 ± 130.7 for erythromycin (P = 0.04 vs. erythromycin)
and 213.4 ± 152.7 days for tegaserod (P = 0.002 vs. none and P = 0.02 vs.
erythromycin). In 18 patients after recurrence with erythromycin, tegaserod
was used following antibiotic therapy. The number of days of prevention ex-
tended from 102.7 ± 67.8 with erythromycin to 224.3 ± 159.2 for tegaserod
(P = 0.002). 4 patients on no therapy were later given erythromycin or
tegaserod and extended prevention from 46.0 ± 50.1 to 222.8 ± 162.8 days
(P = 0.06). Also, 2 patients stopped taking tegaserod prevention after 209
and 365 days of normal bowel function. After stopping tegaserod, symptoms
recurred in 30 and 45 days respectively. 14 C-IBS patients used tegaserod
as prevention (189.3 ± 109.9 days) and 16 D-IBS (278.6 ± 197.4 days, P =
0.13).
Conclusion: Tegaserod is most effective in preventing relapse of clinical
symptoms in IBS patients with positive breath test after antibiotic eradica-
tion. This work was supported by Novartis Pharmaceuticals.
1039
Methane Production in IBS Subjects Is Associated with a
Constellation of Symptoms: Not Just Constipation
Mark Pimentel, MD, FRCP(C)∗, Lezcano Sheila, BS, Low Kimberly, BS.
GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, CA.
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Purpose: Recent data are supporting a significant association between the
presence of methane on lactulose breath test and constipation predominant
IBS (C-IBS). In this study we aim to determine if methane is but one of an
aggregate of GI symptoms that are typical of the methane producing IBS
patient.
Methods: Consecutive IBS patients, referred for a lactulose breath test were
prospectively enrolled in a database. Each patient was asked to complete a
GI symptom questionnaire. Specifically, the symptoms inquired about the
presence and degree of bloating, gas, abdominal pain, diarrhea, constipa-
tion, nausea, flatulence, urgency among others. The results of the lactulose
breath test were also documented. The presence or absence of symptom was
correlated between methane and non-methane producers. Since abdominal
pain is a prerequisite for IBS, it was not compared.
Results: In the dataset, there were 458 patients with IBS of whom 72 (15.7%)
were methane producers. In addition to constipation (P < 0.001), methane
producing subjects were more likely to have a greater degree of bloating
(P = 0.053), bloating with meals (P = 0.011) and small bm’s (P = 0.02).
In contrast, non-methane-producing IBS patients were more likely to have
diarrhea (P < 0.0001), fruit intolerance (P = 0.03), weight loss (P = 0.011),
urgency (P = 0.013) and dark stool (P = 0.043).
Conclusion: Discrete differences in symptom complex exist between
methane and hydrogen producing IBS subjects.
1040
The Utility of Probiotics in the Treatment of Irritable Bowel
Syndrome: A Systematic Review
Darren M. Brenner, MD, Matthew Moeller, MD, William D. Chey, MD,
Philip Schoenfeld, MD∗. Department of Gastroenterology, University of
Michigan Hospitals, Ann Arbor, MI and Department of Internal Medicine,
University of Michigan Hospitals, Ann Arbor, MI.
Purpose: To perform a systematic review of randomized controlled trials
(RCTs) evaluating the efficacy, safety and tolerability of probiotics in the
treatment of IBS.
Methods: Searches of MEDLINE, PUBMED, EMBASE and COCHRANE
databases were performed to identify appropriate studies. Study selection
criteria: (1) study design-randomized controlled trials (RCT),; (2) study
population-adults with IBS defined by Manning or Rome II criteria;, (3)
intervention-single or combination probiotic versus placebo; (4) outcome-
improvement in IBS symptoms and frequency of adverse events. Data about
quality of study design based upon Rome Committee recommendations was
also extracted. Data were extracted in duplicate. Due to extreme variability
in study design, study dosage, and outcome measures, quantitative pooling
of data was not feasible.
Results: 13 RCTs met selection criteria. 11/13 studies demonstrated sub-
optimal study design with inadequate blinding, inadequate trial length, inad-
equate sample size, and lack of ITT analysis. Only three studies provided any
quantifiable data about tolerability and adverse events. The only probiotic
to demonstrate significant improvement in IBS symptoms in appropriately
designed studies was Bifidobacterium infantis 35624 (Align , Proctor &
Gamble). In the first, Bifidobacterium infantis 35624 resulted in signifi-
cant improvement in the composite score abdominal pain/discomfort, bloat-
ing/distention and bowel movement difficulty compared to placebo for the
entire treatment period (P < 0.05). In a subsequent study, Bifidobacterium
infantis 35624 again demonstrated superior efficacy to placebo for the pri-
mary outcome measure abdominal pain/discomfort as well as the secondary
measures bloating/distention, incomplete evacuation, straining, passage of
gas and a composite score of abdominal pain/discomfort, bloating/distention,
and bowel movement satisfaction at the a priori time point four weeks.
Conclusion: Bifidobacterium infantis 35624 has demonstrated efficacy for
improvement in IBS symptoms. There is inadequate data to comment on
the efficacy of other probiotics. Most trials do not provide adequate data
about safety and tolerability. Future RCTs should follow Rome recommen-
dations for appropriate design of an RCT and should provide precise data
on tolerability and adverse events.
1041
Tegaserod (Zelnorm) Safety Profile in Pediatric Patients
Aileen F. Har, MD, Rita Steffen, MD, Barbara Kaplan, MD, Lori Mahajan,
MD∗. Pediatrics, Cleveland Clinic, Cleveland, OH.
Purpose: To evaluate for general as well as cardiovascular and neurologic is-
chemic side effects in pediatric pts prescribed tegaserod (Zelnorm). Zelnorm
a selective 5HT4 receptor agonist was used until recently as a prokinetic.
5HT4 receptors are found throughout the GI tract and help regulate peristal-
sis, intestinal secretion, smooth muscle tone, and visceral sensitivity. FDA
approval was in 2002 for the treatment of constipation predominant IBS
in women and then in 2004 for idiopathic chronic constipation in men and
women 18–65 yrs old. In March 2007, it was withdrawn from the market
due to a statistically significant number of cardiovascular ischemic events
in adult patients. The side effects of Zelnorm in the pediatric population
have not been previously studied although it is used in many pediatric GI
practices.
Methods: An IRB approved retrospective chart review was performed on
234 pts aged 21 and under prescribed Zelnorm. 133 charts had sufficient
information for analysis.
Results: Indications for therapy were IBS 59.4%, chronic constipation
21.1%, GERD 6%, pseudo obstruction 10.5%, gastroparesis 10.5%, SMA
syndrome 0.75%. 75.2% were female. Age range was 2–20 yrs (mean 14.4
yrs). Average duration of therapy was 146(range 2–1095) days. Most com-
mon complaints reported during therapy were abdominal pain (54%), con-
tinued constipation (31.6%), and nausea (23.3%). No pts had new onset
neurologic deficits. 4 pts had cardiac symptoms; 2 of which had postural
orthostatic tachycardia syndrome (POTS), 1 had panic attacks with anxiety
disorder, and 1 had sinus bradycardia. All pts with cardiac symptoms had
normal EKGs and no neurologic or cardiac side effects resulted in medi-
cation discontinuation. The most common reasons for discontinuation were
completion of course 24.2%, diarrhea 19.7%, and no effect 19.7%.
Conclusion: Zelnorm has been prescribed in pediatric pts for a variety of
indications. No cardiovascular or neurologic ischemic events were identified
in any of the 133 pediatrics pts. Based on our data, Zelnorm appears to be
safe for use in the pediatric population.
1042
Male Sex Hormone May Influence on Irritable Bowel Syndrome in
Young Men
Beom Jin Kim, Poong-Lyul Rhee∗, Hee Jung Son, Young-Ho Kim, Dong
Kyung Chang, Jae J. Kim, Jong Chul Rhee, Hyuk Lee. Medicine, Samsung
Medical Center, Sungkyunkwan University School of Medicine, Seoul,
Republic of Korea and Medicine, The Armed Forces Capital Hospital,
Seoul, Republic of Korea.
Purpose: The aim of the present study is to assess the sex hormone status of
young male subjects with IBS and investigate whether there is any difference
according to their predominant bowel symptoms.
Methods: Thirty eight young male patients with IBS were compared with 20
healthy young men. The symptom characteristics of patients were collected
by interviewing with a structured questionnaire. The questionnaire inquired
as to the duration, severity, and frequency of bowel symptom. Each subject
had blood test, stool examination, and colonoscopy were performed to rule
out the organic intestinal diseases.
Blood test included serum testosterone, free testosterone, sex hormone-
binding globulin (SHBG), follucle stimulating hormone (FSH), and luteniz-
ing hormone (LH). On the basis of the questionnaire, patients with IBS were
classified as two groups; diarrhea-predominant (IBS-D) and constipation-
predominant (IBS-C) groups.
Results: Among 38 patients with IBS, 24 patients were IBS-D and 14 patients
were IBS-C. Patients with IBS had lower levels of testosterone and SHBG
than control (P = 0.04 and P = 0.03, respectively). However, there was no
significant difference between IBS-D group and IBS-C group in Testosterone
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and SHBG. Levels (P > 0.05). In addition, there was no difference in duration
and severity of symptom between IBS-D group and IBS-C group (P > 0.05).
Conclusion: Sex hormonal status in young men may play a role in the
pathophysiology of IBS regardless of dorminant symptom type. Further ex-
ploration of the role of male sex hormones in IBS is needed.
1043
A Long-Term Follow-Up Study of Children with Chronic Constipation
Kirin Gorla, MD, Rita Steffen, MD∗, Gerard Banez, PhD. Pediatrics,
MetroHealth Medical Center, Cleveland, OH; Pediatric Gastroenterology,
Cleveland Clinic, Cleveland, OH and Behavioral Pediatrics, Cleveland
Clinic, Cleveland, OH.
Purpose: 1. Determine the outcome of CIC 10–15 years later. 2. Determine
the social, educational and occupational functioning in children with CIC.
3. To determine the factors influencing the outcome in childhood CIC.
Methods: Retrospective chart review followed by a telephone interview. A
total of 560 charts with CPT code for idiopathic constipation, seen between
1985–95, were randomly chosen and reviewed. 231 subjects met our inclu-
sion/exclusion criteria. Initial data was collected from these 231 subjects
and a follow-up questionnaire was sent to all of these subjects, 2 weeks prior
to telephone contact. A total of 73 (31.6%) subjects have responded when
contacted by telephone.
Results: Mean age at initial presentation and f/u data collection were 5.3 and
22.4 years, respectively. A slight male preponderance was noted both at the
initial presentation and f/u (54% vs. 46% and 60% vs. 40%). More than 70%
of subjects had problems with abdominal pain, stool impaction, large/hard
stools, painful defecation and stool withholding at initial presentation. How-
ever, at 10–15 years f/u, abdominal pain, painful defecation, rectal blood loss
and hard stools were rare (all P < 0.001). But 6% of the subjects reported
to have constipation and 18% of the subjects admitted to having at least
one symptom of constipation. About 6% of the subjects were still taking at
least one type of treatment and another 6% of the subjects reported to have
significant impairment in social, educational or occupational functioning.
Preliminary analysis shows that male sex was the only factor that influenced
the persistence of constipation at 10–15 years f/u.
Conclusion: CIC in childhood is a common condition that can persist even
10–15 years after initial presentation. About 6% of the subjects reported to
have constipation and 18% of the subjects continued to have at least one
symptom of constipation even 10–15 years after initial presentation. More
importantly, 6% of the subjects reported to have significant impairment in
social, educational or occupational functioning. Male sex may predispose
to the persistence of this condition into adulthood. Given the current preva-
lence of this condition in children, development of an effective long-term
intervention plan is recommended.
1044
Self-Perceived Stigma in IBS: Relationship to Quality of Life,
Self-Efficacy, Self-Esteem, and Psychiatric Distress
Michael P. Jones, MD∗, Jason Bratten, BS, Laurie Keefer, PhD, Greg
Sayuk, MD, Sarah Wessinger, MD, Michael D. Crowell, PhD, Rona L.
Levy, PhD, Olafur Palsson, PsyD. Northwestern University; Washington
University; Mayo Clinic College of Medicine; University of Washington,
and University of North Carolina.
Purpose: Half of IBS pts report feeling stigmatized with stigma severity
influenced by both degree of role limitations and the extent to which pts
feel their diagnosis is not regarded by themselves or others as a credible
explanation for role limitations (Gastroenterol 2007;132:A521). In other
disorders, stigma is assoc with poorer quality of life and psychiatric distress.
This has not been studied in IBS. We recently developed and validated a
measure of perceived stigma in IBS. This study examined the relationship
between relevant psychosocial constructs and stigma in IBS.
Methods: 67 pts with an established diagnosis of Rome II IBS were studied
(age = 51 ± 15 yrs; 57 F/10 M). Pts completed a measure of IBS-related
perceived stigma along with measures of QOL (SF-12) and psychiatric dis-
tress (BSI). The SF-12 reports QOL related to physical (PCS) and mental
function (MCS). The BSI includes scales for anxiety (BSI-A), depression
(BSI-D) and somatization (BSI-S) as well as a global symptom index (GSI).
Pts also completed HADS and measures of self-efficacy (EFF; Perceived
Self-Efficacy Scale) and self-esteem (EST; Rosenberg Self-Esteem Scale).
Results: Perceived stigma was not influenced by age or gender. Increasing
levels of perceived stigma were assoc with poorer QOL on MCS (r = −0.29;
P = 0.04) but not PCS scales (r = −0.07; P = 0.63). Increasing stigma was
assoc with increasing psychiatric distress on BSI-A (r = 0.40; P = 0.01) and
BSI-S (r = 0.31; P = 0.01) but not BSI-D (r = 0.2; P = 0.11). Increasing
stigma was assoc with higher HADS-Anx (r = 0.4; P = 0.001) and HADS-
Dep (r = 0.38; P = 0.002) scores. Perceived stigma was also assoc with
poorer EFF (−0.29; 0.02) and lower EST (−0.43; 0.00). Stepwise regression
identified only EST as a significant predictor of stigma (r2 = 0.19; P = 0.00).
Conclusion: Increasing levels of self-perceived stigma in IBS are assoc with
poorer QOL, psychiatric distress, poor self esteem and poor self-efficacy.
However, regression analysis identifies only low self-esteem as a significant
predictor of perceived stigma. These data are consistent with prior studies
identifying self-blaming, isolation and lack of diagnostic validity as im-
portant stigma determinants. Evaluation of IBS pts should include queries
regarding perceived stigmatization as well as psychiatric distress.
1045
A Randomized, Controlled, Double-Blind Trial of s-Pindolol in
Irritable Bowel Syndrome (IBS)
Eamonn M. Quigley, MD∗, John Devane, PhD, David Young, PhD, Jackie
Butler, PhD. Alimentary Pharmabiotic Centre, University College Cork,
Cork, Ireland; AGI Therapeutics Research Ltd, Athlone, Westmeath,
Ireland and AGI Therapeutics Inc, Columbia, MD.
Purpose: Pindolol is a synthetic beta-adrenergic receptor blocking agent
with intrinsic sympathomimetic activity which exists as a racemic mixture
of the R and S enantiomers. The R and S enantiomers of pindolol differ in
both their pharmacokinetics and pharmacodynamics. The beta-adrenoceptor
blocking effects of pindolol are largely confined to the S enantiomer, while
the intrinsic sympathomimetic activity is shared equally by the R and S
enantiomers. In addition, 5HT1a antagonism is a property of s-pindolol.
Given these properties and our current understanding of IBS, our aim was
to evaluate the efficacy of s-pindolol in IBS.
Methods: Following a 8–14 day run-in period, eligible patients were ran-
domly allocated to s-pindolol 2.5 mg t.i.d or placebo t.i.d. for four weeks.
Patients receiving s-pindolol then had dose adjusted to 5 mg t.i.d for a fur-
ther four weeks and to 7.5 mg t.i.d for the final four weeks, if tolerated.
Three primary endpoints: Difference in the percentage of responders be-
tween AGI-001 and placebo based on 1. patient’s global impression and 2.
relief of abdominal pain/discomfort; 3. use of rescue medication (paraceta-
mol). Numerous secondary endpoints were also assessed. The pre-defined
statistical analysis was a one-sided analysis based on the hypothesis that
s-pindolol is better than placebo.
Results: There was no difference between treatments in terms of the number
of patients who felt better on at least 50% of study days (one-sided P = 0.30).
Logistic regression analysis yielded an odds ratio for AGI-001 relative to
placebo: 0.73 (95% C.I. 0.24–2.20). The proportion of days of adequate
relief of abdominal discomfort/pain did not differ between treatments (one-
sided P = 0.34); odds ratio for AGI-001 relative to placebo: 0.77 (95% C.I.
0.25–2.42). Use of paracetamol was sparse and similar in both groups (one-
sided P = 0.11). There were significant s-pindolol related improvements
compared to baseline in the secondary endpoints of global severity of illness,
abdominal pain, bloating/distention and straining at the highest dose visit
(week 12). The incidence of adverse events was similar in s-pindolol- and
placebo-treated groups.
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Conclusion: In this IBS study we have failed to reveal a significant benefit
for s-pindolol at the doses administered in terms of global relief of IBS
symptoms, relief of abdominal pain, or use of rescue medication.
1046
A Randomised, Double-Blind, Placebo-Controlled Study of
r-Verapamil in Non-Constipated Irritable Bowel Syndrome
Eamonn M. Quigley, MD∗, John Devane, PhD, David Young, PhD, Jackie
Butler, PhD. Alimentary Pharmabiotic Centre, National University of
Ireland, Cork, Cork, Ireland; AGI Therapeutics Research Ltd, Athlone,
County Westmeath, Ireland and AGI Therapeutics Inc, Columbia, MD.
Purpose: IBS is a common and clinically challenging gastrointestinal dis-
order for which few therapies of proven value are available for clinical use.
Since the r-enantiomer of verapamil (r-verapamil) has been found to have a
unique combination of activity not involving 5HT3 or 5HT4 and has been
shown to have highly selective activity on the gastrointestinal tract compared
to the cardiovascular system, the aim of this study was to assess the efficacy
and safety of r-verapamil in the treatment of IBS.
Methods: 129 male or female patients who fulfilled Rome II criteria for
non-constipation predominant IBS were randomised to placebo (N = 64) or
to r-verapamil (N = 65). R-verapamil was administered in an ascending dose
schedule from 20, 40, to 80 mg t.i.d. across all r-verapamil treated patients.
Dose escalation occurred at 4-week intervals; the entire treatment period
was 12 weeks. The primary efficacy variables were the responder rates for
patient global impression and relief of abdominal pain/discomfort which in
turn were defined as feeling better on at least 50% of the entire 42 study
days. The pre-defined statistical analysis was a one-sided analysis based on
the hypothesis that r-verapamil is better than placebo.
Results: 14 patients discontinued prematurely, 6 in the r-verapamil and 8
in the placebo group. Analysis of the intention-to-treat (ITT) population for
the primary efficacy variables revealed significantly higher responder rates
for r-verapamil for both the patient global impression (56.9% vs 37.5%,
one-sided P = 0.0057) and abdominal pain/discomfort (56.9% vs 43.8%,
one-sided P = 0.05). Significant benefits for r-verapamil were also evident
for several secondary endpoints: composite GI symptom scale, bloating,
stool frequency, urgency, Bristol stool scale and quality of life, as measured
by the IBS-QOL. Adverse events were experienced by 17 patients in the
r-verapamil and 8 in the placebo group. No severe AEs were recorded with
the AE profile being very similar to the reported AE profile for racemic
verapamil. Only 4 patients reduced their dose because of an AE.
Conclusion: R-verapamil appears to be effective and well tolerated in the
management of patients with non-constipation predominant irritable bowel
syndrome given the significant response seen in the two primary and numer-
ous secondary endpoints.
1047
Predictors of Better Quality of Life Outcomes in Patients Suffering
from IBS
Pierre Pare, MD∗, Robert Balshaw, PhD, Olaf Heisel, MD, PhD, Rose Liu,
Martin Barbeau. Centre Hospitalier Affilie Universitaire de Quebec,
Hopital du Saint-Sacrement, Quebec City, QC, Canada; Vancouver
General Hospital, Vancouver, BC, Canada and Novartis Pharmaceuticals
Canada Inc., Montreal, QC, Canada.
Purpose: Abdominal pain/discomfort, bloating and constipation are gas-
trointestinal (GI) symptoms related with irritable bowel syndrome (IBS).
These symptoms are associated with impaired quality of life and work
productivity. LOGIC (Longitudinal Outcomes Study of GI Symptoms in
Canada) has been conducted as a prospective, observational study designed
to evaluate the treatment patterns and health outcomes of patients with IBS
symptoms in Canada.
Methods: The study was designed to characterize the clinical characteristics,
quality of life (IBS-QOL), healthcare resource utilization and productivity
of patients with symptoms associated with IBS over a 1-year period. A total
of 1556 subjects were enrolled at 147 centers across Canada. The present
analysis employed a multivariate logistic regression model to identify pre-
dictors associated with better IBS-QOL outcomes: subjects were declared
to have had a “better outcome” if they were in the top 25% of the baseline to
month 12 change scores, (i.e., a 13 point increase in IBS-QOL in this study).
Results: A total of 1035 subjects with complete data were included for this
logistic regression analysis. It showed that baseline IBS-QOL score (P <
0.001), usage of tegaserod∗ (i.e., subject reported taking >7 days or > 7
tablets of tegaserod in the first month; P = 0.006) and type of insurance
(public, private, both or none, P = 0.030) were significant predictors. The
effects of IBS subtype (IBS-C, IBS-D or IBS-A; P = 0.055) and employment
status (P = 0.082) were marginally significant, and age, gender, level of
education, number of prior specialist visits, use of prior pain medication
and disease severity were not significant. A more detailed analysis showed a
significantly increased probability for better outcomes (OR = 2.0292, P =
0.0023) among tegaserod treated subjects if they were untreated in the past
and lower baseline IBS-QOL scores increased the chance of a better outcome
(OR = 0.691 per 10-point increase in baseline IBS-QOL score).
Conclusion: Baseline IBS-QOL score, tegaserod use and insurance type play
major roles as predictors influencing the quality of life outcomes of patients
suffering from irritable bowel syndrome. ∗Please note that at Health Canada’s
request, as of March 30, 2007, Novartis Pharmaceuticals Canada Inc. has
suspended the marketing and sales of Zelnorm (tegaserod) in Canada.
1048
Expression of P2X Receptor in a Rat Model of Chronic Visceral
Hyperalgesia
Sahil Mittal, MD, Guang Yin Xu, PhD, John Winston, PhD, Mohan Shenoy,
PhD, Pankaj J. Pasricha, MD∗. Division of Gastroenterology &
Hepatology, Department of Internal Medicine, University of Texas Medical
Branch, Galveston, TX.
Purpose: Chronic visceral hypersensitivity (VH) is an established phe-
nomenon in patients with irritable bowel syndrome (IBS) suggesting sensi-
tization of nociceptive pathways. Recent studies suggest a role of purinergic
signaling mediated by the P2X receptor family in VH. P2XRs are non-
selective cation-permeable ion channels, gated by extracellular ATP and
predominantly expressed by nociceptive dorsal root ganglion (DRG) neu-
rons.
Our previous experiments on the rat model of IBS-like visceral hyperal-
gesia have shown that antagonism of P2XRs by TNP-ATP attenuates the
behavioral nociceptive responses to mechanical stimulation of the colon in
hypersensitive rats but not in controls. The aim of this study was to de-
termine if the expression of P2×3Rs in colonic sensory neurons was
increased in rats with colonic hyperalgesia.
Methods: Ten days old rat pups received a colorectal infusion of 0.5% acetic
acid (AA) in saline or saline alone (controls). At 8–12 weeks AA sensitized
rats displayed an increased sensitivity to colorectal distension & excitability
of colon-specific DRG neurons in the absence of structural or inflammatory
changes in the colon. Colon specific DRG neurons labeled by injecting lipid
soluble fluorescence dye (DiI) into rat colon. Sections from dissected out
T13-L2 & L6-S2 DRGs were stained with primary antibodies (anti-P2×3
receptors) and then fluorescent secondary antibody. Sections viewed under
BX60 Olympus microscope equipped with appropriate filter. Images were
analyzed with Metaview software. Neurons colabeled with DiI and P2×3
were counted for both groups (see Figure).
Results: Percentage of P2×3 positive colon specific DRG neurons
Thoraco-Lumbar: 18% for AA treated rats vs. 5% in controls, P < 0.05
Lumbo-Sacral: 56% in AA treated group vs. 28% in controls, P < 0.05
Conclusion: Colon specific sensory afferent neurons from AA sensitized
rats show an up regulation of P2X receptors. Thus we conclude that up
regulation of P2XRs is associated with chronic colorectal allodynia and
hyperalgesia in this model. This up-regulation may explain the efficacy of
the P2×3 antagonist in sensitized rats but not in controls.[figure1]
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Do Autonomic Function and α2 Adrenergic Genotypes Predict IBS
Phenotype?
Seth Sweetser, MD, Michael Camilleri, MD∗, Alan R. Zinsmeister, PhD,
Phillip A. Low, MD, Sanna McKinzie, MS. Clinical Enteric Neuroscience
Translational and Epidemiological Research, Mayo Clinic, Rochester, MN;
Department of Health Sciences Research, Division of Biostatistics, Mayo
Clinic, Rochester, MN and Department of Neurology, Mayo Clinic,
Rochester, MN.
Purpose: Autonomic nervous system (ANS) dysfunction may play a role
in irritable bowel syndrome (IBS). Most previous studies examined small
numbers of patients and came to disparate conclusions. Our aim was to clarify
whether autonomic function and candidate genes controlling α2 adrenergic
receptors predict the IBS phenotype.
Methods: Using Rome II criteria for IBS, 87 patients were subclassified as
constipation (C)- or diarrhea (D)- predominant, or mixed (M) IBS. There
were 36 controls. Autonomic function was determined by three sympathetic
adrenergic [change in systolic (S) and diastolic (D) blood pressure (BP),
plasma norepinephrine (NE) at 1 min standing, Valsalva ratio] and one va-
gal [heart rate (HR)] measurements. Associations between phenotype, ANS
and genotypes were tested using logistic regression models to predict pheno-
type adjusted for age, body mass index (BMI) anddepression/anxiety scores,
and using multiple linear regression models to predict ANS using genotype
adjusted for age and BMI.
Results: Clinically similar mean ANS test results were observed among IBS
subgroups and controls (table, mean ± SEM). There was no significant as-
sociation between autonomic function and IBS phenotype. The odds ratio
(95% CI) for C-IBS was modestly increased in subjects with α2A adrener-
gic GG/CG genotype [OR = 2.5 (0.9, 1.3), P = 0.09] while no significant
association was detected for α2C. However α2C adrenergic genotype mod-
estly influenced DBP response to standing while α2A did not appear to be
associated with ANS response.
Conclusion: Autonomic function andα2C adrenergic genotype do not appear
to predict IBS phenotype; the association of α2A adrenergic genotype and
IBS-C confirms the potential role of adrenoceptor control as a factor in IBS,
but this is not mediated through systemic adrenergic modulation.
n  SBP mmHg  DBP mmHg  NE pg/ml  HR/min
Controls 36 3.0 ± 1.2 −5.6 ± 1.1 154 ± 21 15.9 ± 1.7
IBS total 87 1.2 ± 0.9 −6.1 ± 0.9 174 ± 11 13.5 ± 1.4
IBS-C 33 3.1 ± 1.3 −5.9 ± 1.8 189 ± 20 15.2 ± 2.4
IBS-D 30 1.8 ± 1.5 −3.6 ± 1.4 152 ± 19 11.6 ± 2.3
IBS-M 24 −2.0 ± 1.8 −9.3 ± 1.3 183 ± 16 13.5 ± 2.5
α2C wildtype 107 1.7 ± 0.8 −5.6 ± 0.8 162 ± 11 13.5 ± 1.2
α2C non-wildtype 8 3.4 ± 2.6 −9.8 ± 2.8 202 ± 40 17.0 ± 4.7
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Colonic Diverticular Disease and Diarrhea-Predominant Irritable
Bowel Syndrome: An Etiological Link?
Hye-kyung Jung, MD, PhD, G. Richard Locke, III, MD, Cathy D. Schleck,
Alan R. Zinsmeister, PhD, Nicholas J. Talley, MD, PhD∗. Dyspepsia
Center, Division of Gastroenterology and Hepatology, Mayo Clinic College
of Medicine, Rochester, MN; School of Medicine, Ewha Womans
University, Seoul, Korea and Department of Health Sciences Research and
Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, MN.
Purpose: Colonic diverticular disease is common, and many of them report
unexplained lower GI symptoms. Some have attributed these symptoms to
irritable bowel syndrome (IBS), but whether IBS and diverticular disease
are causally linked is uncertain. We aimed to evaluate this association in a
representative population-based case-control study.
Methods: A population-based, cross-sectional survey was conducted by
mailing a valid symptom questionnaire to eligible residents of Olmsted
County, MN, aged 30–95 years. IBS was defined by Rome II. Colonic di-
verticular disease was ascertained through complete medical record abstrac-
tion of all responders. Subjects with at least one colon test (barium enema,
colonoscopy, or CT colonography) were included.
Results: Among 2298 subjects (55% response rate), there were 1784 re-
spondents with colon tests (78%): 959 women (54%); mean (± SD) age
65 (± 12). Colonic diverticular disease was identified in 43.1% (95% CI
40.7–45.4). Older age (≥60 years) was a significant predictor for diverticu-
lar disease (OR 2.21, 95% CI 2.00–2.44), but no association with gender was
detected. Overall, IBS was reported by 8.1% (95% CI 6.3–10.2) of men and
15.0% (95% CI 12.8–17.4) of women. After adjusting for age and gender,
the presence of IBS was significantly associated with an increased odds for
diverticular disease (OR 1.80, 95% CI 1.30–2.50,). Relative to the non-IBS
subgroup, diarrhea (D)- IBS and alternating (A)-IBS had significantly in-
creased odds for diverticular disease (OR 2.01, 95% CI 1.14–3.53 and OR
2.65, 95% CI 1.19–5.93, respectively); constipation (C)- IBS was not asso-
ciated. After adjusting for age and gender, higher somatic symptom score,
abdominal pain relieved by bowel movement, diarrhea, lower abdominal
pain and bloating were also each significantly associated with diverticular
disease, while smoking, alcohol, marital status, education, and body mass
index were not associated.
Conclusion: There is a significantly increased frequency of colonic diver-
ticular disease in subjects with D- and A-IBS in a US community, but not
C-IBS. The results suggest that D-IBS and colonic diverticular disease may
be etiologically connected, perhaps via localized inflammatory change.
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Risk Factors for Chronic Diarrhea Not Related to Irritable Bowel
Syndrome
Joseph Y. Chang, MD, MPH, Giles R. Locke, III, MD, Cathy D. Schleck,
BSc, Alan R. Zinsmeister, PhD, Nicholas J. Talley, MD, PhD∗. Mayo
Clinic College of Medicine, Mayo Clinic, Rochester, MN; Division of
Gastroenterology and Internal Medicine, Mayo Clinic, Rochester, MN and
Division of Biostatistics, Mayo Clinic, Rochester, MN.
Purpose: The prevalence of chronic unexplained diarrhea in the community
has not been well established, but many cases are presumably due to irritable
bowel syndrome (IBS). Risk factors for functional diarrhea in the absence
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of IBS are unknown. The objective of this study was to evaluate potential
risk factors for chronic unexplained diarrhea in the community excluding
IBS.
Methods: A valid self-report questionnaire that recorded gastrointestinal
symptoms required for a diagnosis of chronic diarrhea, self-reported mea-
sures of potential risk factors, and a somatic symptom checklist (SSC) was
mailed to an age- and gender- stratified random sample of Olmsted County,
Minnesota residents aged 30–64 yr. Chronic diarrhea was defined as having
one or more of the following symptoms: three or more bowel movements
a day, loose or watery stools, or fecal urgency. Subjects with symptoms of
IBS based on the Rome criteria were excluded. Univariate logistic regression
models and models that adjusted for age, gender, and SSC score were used
to identify factors associated with chronic diarrhea and compute Odds Ra-
tios (OR) [95% Confidence Intervals]. These models were examined using
all subjects not reporting IBS, and separately, the subset with no abdominal
pain.
Results: Of the 892 eligible subjects, 653 (73%) returned the survey. Among
the 523 respondents not reporting IBS, chronic diarrhea was reported by 148
(28%) subjects; 58 (39%) reported abdominal pain while 90 had chronic
painless diarrhea. Chronic diarrhea was significantly associated with food
allergy (OR = 2.05[1.31–3.20]) and stress (OR = 1.99[1.03–3.85]), but
the latter association was attenuated in the model adjusted for covariates.
Both remained significant in the adjusted variable models that excluded
subjects with any abdominal pain. Female gender (OR = 0.67[0.45–0.98])
and higher education level (OR = 0.60[0.39–0.92]) were factors with sig-
nificantly smaller odds for chronic diarrhea. No association was detected
for age, marital status, body mass index, cigarette or alcohol use, coffee,
analgesics, emotional support, pets, or water source.
Conclusion: Chronic diarrhea not related to IBS is common and most have
no abdominal pain; food allergy, male gender and a lower level of education
are risk factors. The etiologic role of these factors requires further investi-
gation.
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Work Productivity Is More Impaired in Functional Gastrointestinal
Disorders Compared to GERD: Six-Month Data from PROGRESS
Giles R. Locke, MD∗, Suzanne Clark, MS, Annamaria Cerulli, MPH, Josh
Marehbian, MPH, Kristijan H. Kahler, PhD, RPh, Michael A. Shetzline,
MD, PhD. Mayo Clinic College of Medicine, Rochster, MN; Health
Benchmarks, Inc., Woodland Hills, CA and Novartis Pharmaceuticals
Corporation, East Hanover, NJ.
Purpose: To assess work productivity and activity impairment over six
months in patients with functional GI disorders (FGIDs), including irrita-
ble bowel syndrome with constipation (IBS-C), chronic constipation (CC),
and functional dyspepsia (FD), compared to patients with gastroesophageal
reflux disease (GERD).
Methods: The Patient Registry for Observational Gastrointestinal Re-
search Epidemiology and Symptom Severity (PROGRESS) enrolled pa-
tients with one of the following GI conditions: IBS-C, CC, FD, or GERD,
Table 1. Mean WPAI Scores in GERD vs FGID Patients Over Six Months
Mean Scores (s.d.)/P-value∗
FGID
GERD
WPAI Categories TOTAL IBS-C CC FD
Work time missed 2.7 (1.2) 4.1 (2.6) P = .06 3.9 (3) P = .53 3.9 (2.9) P = 1 5.2 (4.2) P = .23
Impairment at work 14.1 (2.6) 23.8 (3) P < .001 24.4 (3.2) P < .001 21.9 (6.5) P = .03 25.3 (7.6) P = .26
Work productivity loss 15.8 (3.4) 25.8 (3.8) P < .001 25.9 (4.3) P = .003 23.8 (6.3) P = .14 28.6 (8.2) P = .05
Hours lost per week† 6.3 10.3 10.4 9.5 11.4
Daily activity impairment 16.8 (2.2) 24.5 (3) P < .001 25.7 (3) P = .01 26 (4) P = .05 20.5 (5.8) P = 1
∗Significant P-values indicate significant d ifferences between FGID cohort and GERD cohort † Assumes a 40-hour workweek
as confirmed by their primary care physician. The validated Work Pro-
ductivity and Activity Impairment questionnaire, adapted for GI diseases
(WPAI:GI), was administered biweekly between April 2005 and April 2006.
Scores were expressed as percent of impairment/productivity loss result-
ing from GI disorders (higher scores indicate greater impairment and less
productivity).
Results: 161 FGID (86 IBS-C, 39 CC, 36 FD) and 239 GERD patients
were enrolled. Surveys yielded mean response rates between 46% and 66%
for each of the WPAI categories. Mean age was 51 years, 69% of patients
were women, 82% were Caucasian, and 67% worked at least parttime at
baseline. FGID patients reported greater work and daily activity impairment
than patients with GERD (Table 1).
Conclusion: Patients diagnosed with a FGID, such as IBS-C, CC, or FD, re-
ported greater work productivity loss and daily activity impairment over
a six-month period compared to patients with GERD. This impairment
amounts to the loss of at least one day of work in a 40-hour workweek.
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Transition of Gastroesophageal Reflux Disease Symptoms into Other
Gastrointestinal Symptoms: Six Month Prospective Study
Giles R. Locke, MD∗, Suzanne Clark, MS, Annamaria Cerulli, MPH, Josh
Marehbian, MPH, Kristijan H. Kahler, PhD, RPh, Michael A. Shetzline,
MD, PhD. Mayo Clinic College of Medicine, Rochster, MN; Health
Benchmarks, Inc., Woodland Hills, CA and Novartis Pharmaceuticals
Corporation, East Hanover, NJ.
Purpose: To assess the transition of gastroesophageal reflux disease (GERD)
symptoms into chronic constipation (CC), diarrhea, and/or dysmotility
symptoms in patients with GERD.
Methods: 239 GERD patients were enrolled into the Patient Registry for Ob-
servational Gastrointestinal Research –Epidemiology and Symptom Sever-
ity (PROGRESS). Symptom frequency was assessed bi-weekly for 6 months
using a symptom assessment survey developed and validated for this study.
4 symptom scales were identified: CC, diarrhea, dysmotility, and reflux.
Scale scores range from 0 to 100 (higher scores: increasing severity). Trend
lines for all symptom scales were created for each patient using ordinary
least squares. A ‘transition’ was defined as an increase in the slope of the
trend line of a non-GERD symptom score combined with a decrease in the
slope of the trend line of the GERD symptom score. Means were calculated
for ‘transition’ patients in 3 scores: beginning, middle (average of 2 middle
scores used if even # of surveys completed), and end (score from last survey
completed), and were compared using ANOVA.
Results: GERD patients included in the analysis (N = 229) had a response
rate of 73%. Mean age was 52 yrs, 65% of patients were women, and 83%
were Caucasian. In this population, 28% (N = 63) of patients with a diagnosis
of GERD met the transition definition. Over the study period, 14% (N =
31) of GERD patients experienced a transition to CC, 16% (N = 36) to
diarrhea, and 15% (N = 34) to dysmotility. GERD scores decreased over time
(Table1).
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Table 1. Mean (sd) Symptom Scale Scores at Beginning, Middle, & End of Study
CC Diarrhea Dysmotility
Transition Symptom CC GERD Diarrhea GERD Dysmotility GERD
Beginning 15.7 (18.2) 25.5 (15) 16.2 (15.7) 31.4 (21.9) 20.4 (17.9) 28.8 (17.5)
Middle 18.4 (15) 17.6 (15.2) 21.2 (18.2) 17.9 (17.3) 24.1 (19.1) 18.1 (17.1)
End 18.5 (17.4) 11.3 (11.5) 25.2 (20.6) 14.4 (14.4) 28 (20.9) 15.6 (17.3)
P-value 0.46 0.001∗ 0.13 0.001∗ 0.23 0.004∗
∗Significant difference in mean scores for transition patients
Conclusion: Patients with GERD often will have symptom transition toward
a GI dysmotility and sensory disorder. Further research should be done to
establish a common gastrointestinal precursor to GERD and GI dysmotility.
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Development and Validation of the Bloating Symptom Impact Scale
(B-SIS)
Sarah B. Wessinger, MD, Michael P. Jones, MD, Lucinda A. Harris, MD,
John K. DiBaise, MD, Michael Crowell, PhD∗. Department of
Gastroenterology and Hepatology, Mayo Clinic Scottsdale, Scottsdale, AZ
and Department of Gastroenterology and Hepatology, Northwestern
University Medical School, Chicago, IL.
Purpose: Bloating is both common and bothersome in GI patients and has
been associated with increased healthcare utilization. Bloating can be present
in isolation, but is frequently a symptom associated with IBS and/or func-
tional dyspepsia. Several disease-specific QOL measures are available to
assess the impact of IBS and functional dyspepsia, but currently no bloating-
specific QOL instrument has been validated.
Aim: To develop and validate a new, multi-dimensional, bloating-specific
scale to assess the impact of bloating on HRQOL in patients with FGIDs.
Methods: Initially, 22 items were derived from focus groups, literature re-
view, professional experience and face validity. The survey was administered
to 122 GI out-patients with FGIDs. Principal Component Analysis (PCA)
with Varimax rotation and Kaiser Normalization (SPSS v14) was completed.
The number of components was determined by the total explained variance,
simple structure, and eigenvalues >1. The final subscales were comprised of
item loading exceeding 0.40 with a particular component, while minimizing
cross-loadings. Test-retest was assessed from 20 patients and controls who
completed the survey twice about 2 wks apart. Internal consistency was as-
sessed according to Cronbach’s alpha. Validity was assessed by comparing
domains of the B-SIS with SF-12 domains.
Results: The initial PCA suggested a five-component solution for the total
sample, but simple structure was best derived from 4 components: “Physical
Role” (58.5%), “Social Role”(10.1%), “Emotional” (6.8%), and “Ingestive
Behavior” (4.3%). Seven items demonstrated complex interactions with mul-
tiple components or failed to contribute significantly and were deleted. The
final questionnaire included 15 items and accounted for 80% of total vari-
ance. Cronbach’s alpha ranged from 0.87–0.93 for the subscales, supporting
good internal consistency. Test-retest reliability was adequate and ranged
from 0.55 – 0.95. Acceptable concurrent validity was demonstrated.
Conclusion: The B-SIS demonstrated excellent psychometric qualities and
provides a validated, multi-dimensional, bloating-specific scale to assess the
impact of bloating symptoms on HRQOL in patients with FGIDs.
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From Mouse Knockout to Investigational Drug: LX1031, a Novel
Potential Treatment for Irritable Bowel Syndrome
Phil Brown, MD∗, Jessica Jackson, Kenny Frazier, Alex Turner, PhD, Jim
Liu, PhD. Lexicon Pharmaceuticals, Inc., The Woodlands, TX.
Purpose: Peripheral serotonin (5-HT) plays a critical role in the modulation
of intestinal motility and nociception. 5-HT is also associated with functional
gastrointestinal disorders (FGID) such as irritable bowel syndrome (IBS).
Its synthesis in the gastrointestinal (GI) tract is initiated by the enzyme
tryptophan hydroxylase type I (TPH1) located in the enterochromaffin (EC)
cells. Pharmacological inhibition of TPH1 can reduce GI serotonin levels
and may provide treatment for IBS and other FGIDs.
Methods: Using gene knockout (KO) technology, the tph1 gene was func-
tionally deleted in the mouse. Mice lacking tph1 were viable and healthy.
Importantly, brain 5-HT, which is produced by a second isozyme of tph,
tph2, was maintained at normal levels. A small molecule inhibitor of TPH1,
LX1031, was discovered and developed. When administered orally to rodents
for up to five days, LX1031 reduced intestinal 5-HT levels dose dependently
without affecting brain 5-HT levels, effectively recapitulating the KO phe-
notype. LX1031 inhibits the TPH1 enzyme in the EC cells of the GI tract
without significant systemic exposure, thus reducing the potential for side
effects. Preclinical studies of LX1031 revealed an excellent safety profile
supporting the initiation of human clinical trials.
Results: In a randomized, double-blind, single ascending dose study,
LX1031 was well tolerated by healthy subjects at all doses given. The phar-
macokinetic behavior of the compound was consistent with preclinical ob-
servations with a low Cmax ranging from 75 ng/mL at 250 mg to 141 ng/mL
at 1500 mg in fasted subjects with exposure saturation suggested beginning
around 500 mg. In a cross-over study, after a 6-day washout, the 1000 mg
cohort showed 2-fold increased exposure when dosed following a high fat
meal. Tmax was achieved after approximately 4–5 hours for all fasted dose
groups and was slightly delayed with food, at 6 hours. Treatment emergent
adverse events were infrequent at all dose levels with no consistent findings
by dose or event type and none were considered related to LX1031.
Conclusion: Genetic analysis of tph1 KO mice and preclinical studies of
LX1031 indicate tph1 inhibition may provide a novel route to safely modulate
GI 5-HT levels. Initial clinical studies indicate that single doses of LX1031
are well tolerated up to 2000 mg with low systemic exposure. Multidose
studies are ongoing to assess the pharmacodynamic effects of LX1031 on
the whole blood 5-HT and urinary 5HIAA (a 5-HT metabolite) biomarkers.
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Functional Dyspepsia: The Economic Impact to Patients
Kirsten T. Weiser, MD∗, Abigail T. Kennedy, BA, Brian E. Lacy, PhD, MD,
Michael D. Crowell, PhD, Nicholas J. Talley, PhD, MD.
Dartmouth-Hitchock Medical Center, Lebanon, NH; Mayo Medical Center,
Scottsdale, AZ and Mayo Medical Center, Rochester, MN.
Purpose: Functional dyspepsia (FD) is a highly prevalent disorder that re-
sults in significant financial burden to the health care system. Little is known
about the economic impact of FD to patients. The aims of this study were to
use a validated questionnaire to quantify FD patients’ health care utilization
patterns and to estimate direct and indirect costs of FD to patients.
Methods: ICD-9 codes identified patients (≥18 years) with dyspepsia.
Charts were individually reviewed to confirm patients met Rome III criteria
for FD, and to document a normal upper endoscopy. A validated question-
naire was mailed to patients meeting these criteria. Responses were anony-
mous. Data was analyzed using SPSS statistical software.
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Results: 297 patients met inclusion criteria, and 178/297 (60%) responded.
The respondents’ mean age was 51 (±14) years; 75% were women, 87% were
Caucasian, and 16% earned more than $50,000 (US) per year. Respondents
had a mean of 8 (±8) years of FD symptoms, which were self-rated as
moderate (52%) or severe (20%). Patients reported a mean of 3 visits to
the primary care clinic over the last 12 months. To further evaluate their
FD symptoms, 95% reported having had blood work, 92% an EGD, 59%
an ultrasound, and 40% a CT scan. In this patient subset, the direct cost of
testing based upon the national Medicare reimbursement rate per patient is
$621. To improve their FD symptoms, 92% made dietary changes, 89% used
over-the-counter (OTC) medications, 88% used prescription medications,
25% tried alternative therapies, and 10% had seen a counselor. 18% of
respondents reported having been hospitalized at least once in their lifetime
for FD and 23% reported having had a surgery. Mean patient expenditure
over the last year was $246 for OTC medications (range $0–12,000), $290
for co-payments (range $0–9,000), $110 for alternative treatments (range
$0–3741), and $52 for counseling (range $0–3000). Total mean direct cost
per respondent per year was $698. In the 7 days prior to completing the
questionnaire, respondents reported a mean of 1.4 hours (of 36 hours) absent
from work due to FD symptoms.
Conclusion: This is the first study to estimate direct and indirect costs of
FD to patients. This study suggests that FD patients incur significant direct
costs related to evaluating, testing and treating FD as well as indirect cost
related to absenteeism and decreased productivity.
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Functional Dyspepsia: The Patient’s Perspective
Abigail T. Kennedy, BA∗, Kirsten T. Weiser, MD, Brian E. Lacy, PhD, MD,
Michael D. Crowell, PhD, Nicholas J. Talley, PhD, MD.
Dartmouth-Hitchcock Medical Center, Lebanon, NH; Mayo Medical
Center, Scottsdale, AZ and Mayo Medical Center, Rochester, MN.
Purpose: Functional dyspepsia (FD) is a highly prevalent disorder that sig-
nificantly affects patients’ quality of life. The aim of this study was to better
understand the perspective of FD patients, with an emphasis on knowledge,
fears and concerns.
Methods: ICD-9 codes identified adult patients (≥18 years) with dyspep-
sia. Charts were individually reviewed to confirm the absence of organic
disorders, to verify that patients met the Rome III criteria for FD, and to doc-
ument a normal upper endoscopy. A questionnaire was mailed to patients
meeting these criteria. Preliminary results obtained during the validation
process (N = 47) demonstrated that the questionnaire is consistent, reliable
and easy to use. (Kennedy et al, Gastroenterology 2007; 132: A68)
Results: 297 patients met all inclusion criteria and 60% (N = 179) re-
sponded. The mean age was 51+/−4 yrs, 75% were women, 90% were
Caucasian, 49% had completed college, and 26% earned > $50 k/yr. FD
symptoms were present for 8+/−8 yrs and were rated as moderate (63%) or
severe (22%). The most bothersome symptom was abdominal pain (35%),
followed by abdominal burning (15%). Patients’ most significant fears were
that their symptoms would never go away (45%) and that FD could turn
into cancer (20%). Only 33% of respondents recognized that FD is more
common in women. A minority of respondents (26%) recognized that FD
is more common than diabetes. 34% of patients believed that FD increased
their risk of cancer, and 50% believed that FD increased their risk of ul-
cer disease. Respondents noted that FD may be caused by genetic factors
(40%), dietary factors (70%), and anxiety or depression (68%). To diagnose
FD, 55% stated that blood tests were needed, while 70% and 43% stated
that EGD or ultrasound was required. Most felt that FD symptoms could be
relieved by diet (77%) or medications (73%). Only 13% believed that FD
symptoms could be improved by surgery.
Conclusion: This study confirms and extends our preliminary observations
regarding patients’ perspectives of FD. Patient misconceptions are common,
despite the educational level of respondents. These misconceptions may
contribute to the diminished quality of life seen in FD patients. Our results
highlight the need to educate FD patients about their condition.
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Impact of Combined Gastric and Sacral Stimulators on Upper/Lower
Gastrointestinal and Urinary Symptoms
Chris Abrasley, MD, Shaily Jain, MD, Paige White, MD, Thomas Abell,
MD∗. Dept. of Digestive Diseases, University of Mississippi Medical
Center, Jackson, MS.
Purpose: Gastric Electrical Stimulation (GES) is available as a Humani-
tarian Use Device for patients with the symptoms of gastroparesis and is
effective in reducing gastrointestinal symptoms. We have previously shown
that patients with gastric motor disorders often have co-existing abnormali-
ties of the genitourinary system (Gastroenterol 112: A737, 1997), which may
now be treated with sacral electrical stimulation (SES), resulting in similar
improvements in genitourinary symptoms. SES has been shown to be bene-
ficial in controlling fecal incontinence and resistant idiopathic constipation.
Methods: We compared the results of therapy with GES and SES in 21
patients (19 F, 2 M, mean age of 39.7 years) who were implanted with both
devices. Data for 16 patients is complete for upper and lower gastrointestinal
and urinary symptoms. Patients had documented gastroparesis as well as
bladder or other pelvic floor dysfunction. All 21 patients had received their
GES before the SES. Patients were evaluated at baseline and latest follow
up (median 4 years for GES and 2 years for SES). Scores of upper GI (GI:
0–4, TSS max 20), lower GI (GI: 0–3, TSS max9 and BM’s per day), and GU
(GU: 0–3, UTSS, max 18) function were recorded. Results were compared
by paired t-tests & reported as mean ± SE.
Results: All 16 patients improved both upper and lower GI and GU symp-
toms. Improvement in all parameters as nausea (2.81 vs. 71), vomiting (3.98
vs. 1.69), anorexia (3.4 vs. 1.48), bloating (3.7 vs. 12.07), abdominal pain
(3.8 vs. 1.48) and gastric total symptom score (TSS) (17.14 vs. 7.43), leakage
(1.48 vs. 29), urinary urgency (1.62 vs. 62), voiding difficulty (2.0 vs. 52),
straining (1.44 vs. 44), trouble starting stream (1.5 vs. 38), number of pads
used (.62 vs. .1) and urinary total symptom score (UTSS) (8.69 vs. 2.69),
fecal urgency (.89 vs. .58), constipation (2.15 vs .74), fecal total symptom
score (TSS) (3.63 vs. 1.63), and number of BM’s per day (.97 vs. 1.7) were
statistically significant. See table.
Conclusion: The combination of GES and SES appears to be both safe and
effective for patients with con-comitant gastroparesis and bladder dysfunc-
tion and SES improved coexistent fecal abnormalities as well.
Before GES/SES After GES/SES P values
Upper TSS 17.14 7.43 <0.01
Lower TSS 3.63 1.63 <0.01
Urinary TSS 8.69 2.69 <0.01
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Can Thrombosis Be Predicted in Patients with Gastroparesis?
Bradley Creel, MD, Thomas L. Abell, MD∗, William Rock, MD, William
Johnson, PhD. Department of Digestive Diseases, University of
Mississippi Medical Center, Jackson, MS; Department of Pathology,
University of Mississippi Medical Center, Jackson, MS and Department of
Preventive Medicine and Biostatistics, University of Mississippi Medical
Center, Jackson, MS.
Purpose: Recent reports have shown that nearly 90% of patients with gas-
troparesis have some sort of detectable hypercoagulable state. Also, a recent
series of gastroparesis patients has noted an unusually high incidence of
deep venous thrombosis, pulmonary embolism and/or line related throm-
bosis. The purpose of our study was to retrospectively examine a group of
patients with gastroparesis to identify risk factors for hypercoagulablility.
Methods: We retrospectively examined a series of 191 patients (30 were
male, 161 were female; 161 were white, 28 African American, and 2 were
Hispanic with the average age of 44 years) with gastroparesis. We deter-
mined if these patients had history of DVT, PE and/or line-related throm-
bosis (CLOT, N = 50) or no history of thrombosis (NOCLOT, N = 141).
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Thirteen factors were compiled on these patients: activated Protein C resis-
tance, fibrinogen levels, Protein C and S levels, antiphospholipid IgA, IgM
and IgG levels, anti-b2-glycoprotein IgA, IgM, and IgG levels, Factor VIII
levels, Antithrombin III levels, as well as the presence of the C677t methyl-
tetrahydrofolate reductase mutation. We used Fisher’s discriminant analysis
to determine a linear function of these 13 variables that classified the 191
patients into either the CLOT or NOCLOT group. Because true clotting his-
tory was known, we were able to assess the ability of the function to classify
each patient as if that patient’s clotting status was unknown.
Results: Of our 191 patients, 50 of whom had history of abnormal clotting
and 141 who did not, the derived function correctly classified 74% of the
patients into either the CLOT or NOCLOT group. The classification was
correct for 74% of the CLOT group (sensitivity) and 74% of the NOCLOT
group (specificity).
Conclusion: Our results suggest that clotting risk can be accurately predicted
with 74% certainty in these patients on the basis of his/her outcomes on the
13 factors listed above. Clinically, this could be used to risk stratify these
patients, the majority of whom have some hypercoagulable propensity, for
life-threatening thrombosis.
1060
Does Maternal Predominance Exist in the Cyclic Vomiting Pattern in
Gastroparesis?
Jane C. Williams, MD, Bradley Creel, MD, Thomas L. Abell, MD∗.
Department of Digestive Diseases, University of Mississippi Medical
Center, Jackson, MS.
Purpose: A cyclic pattern of Gastroparesis has recently been described and
shown to differ from non-cyclic patterns (NGM 18(8): A233, Aug 2006).
Likewise, cyclic patterns have been associated with migraine, which is felt
to be maternally inherited. We investigated the hypothesis that GP patients
with a cyclic pattern might have a more maternal pattern of inheritance for
migraine and related overlap syndromes.
Methods: From a data base of 345 consecutive patients seen, 48 patients
(8 m, 40 f, mean age 41.5 yrs) with Diagnosis: 18 Idiopathic, 27 Diabetes
Mellitus, 3 Post-Surgical disorders, presented with the symptoms (Sx) of GP.
Most patients were drug refractory and referred for possible GES. Patients
included 35 (3 m, 32 f) with Cyclic Symptoms (Cyc), and 13 (1 m, 12 f)
with No Cyclic Symptoms (NoCyc). 38 of the 48 patients (25 Cyc and 13
Nocyc) underwent implantation of permanent GES, mean of 33 months.
Family history of overlap syndromes and related disorders were determined
by interview. Both Maternal and Paternal family histories were compiled for
several overlap syndromes, as previously described (NGM, above).
Results: Maternal prevalence of migraine and related overlap syndromes
was nearly universally higher in patients with cyclic symptoms (see table
below) Vs those with non- cyclic symptoms.
Conclusion: GP patients with symptoms have a much higher female pre-
dominance of migraine and related overlap syndromes. These finding raise
the possibility of genetic, possibly mitochondrial DNA-linked biologic com-
ponent, in the cyclic nature of their symptoms.
MHA FMA Anx/Dep LDO ANS IBS BLAD
Mat-CYC 0.45 0.09 0.59 0.05 0.36 0.18 0.36
Pat-CYC 0.09 0.05 0.18 0.09 0.14 0.09 0.09
P-value 0.006 0.003 0.005 0.56 0.85 0.39 0.03
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Gastric Emptying Scintigraphy Results in the ROME III Subgroup
Classifications for Functional Gastroduodenal Disorders
Richard L. Walters, MD, Alan H. Maurer, MD, Henry P. Parkman, MD∗.
Medicine, Temple University School of Medicine, Philadelphia, PA.
Purpose: Delayed gastric emptying has been detected in 20 to 45% of pa-
tients with functional dyspepsia using gastric emptying scintigraphy (GES);
however, the association of symptoms to alterations in gastric emptying has
been difficult to delineate. ROME III criteria classify functional dyspepsia
by “meal-related” and “meal-unrelated” symptoms into postprandial distress
syndromes (PDS) and epigastric pain syndromes (EPS), respectively. Addi-
tionally, new categories of chronic idiopathic nausea (CIN) and functional
vomiting (FV) have been recognized. Although these new classifications were
devised to allow better pathophysiologic grouping for treatment purposes,
the prevalence of abnormal gastric emptying in the Rome III subgroups has
not been delineated.
Aim: The aim of this study was to compare GES results to Rome III symptom
subgroup classifications.
Methods: We designed a retrospective analysis of consecutive patients un-
dergoing GES at our tertiary care facility. GES was performed using 4 hour
imaging after ingestion of a radiolabeled Eggbeaters sandwich. The PAGI-
SYM questionnaire was completed at the time of imaging and used to classify
patients into subgroups of FD, EPS, PDS, CIN, and FV. Subgroup classifi-
cations were then correlated to scintigraphy data.
Results: Of 99 consecutive patients undergoing GES from February 2007 to
May 2007, 98 had analyzable GES data. GES revealed normal solid emptying
in 58 patients, delayed solid emptying in 37, rapid emptying in 3. Of the 37
patients with delayed gastric emptying, fullness/bloating was described as the
predominant symptom(s) in 15, vomiting in 9, abdominal pain/discomfort in
8, nausea in 7, reflux/heartburn in 7, regurgitation in 2, constipation in 2, and
early satiety in 1. Classification by ROME III criteria revealed 61 patients
with FD, 52 with PDS, 25 with EPS, 34 with CIN, and 27 with FV. Of these,
delayed gastric emptying was seen in 25 of the 61 (41%) FD patients, 21
of the 52 (40%) with PDS, 11 of the 25 (44%) with EPS, 13 of 34 (38%)
with CIN, and 14 of 27 (52%) with FV. Twenty-one patients were found to
have no definable ROME III disorder; of these, fourteen had normal GES
and seven with delayed.
Conclusion: In this tertiary care center experience, use of meal-related and
meal-unrelated symptoms did not identify a group with delayed gastric emp-
tying. There was a similar prevalence of delayed gastric emptying in the
ROME III classifications of the functional gastroduodenal disorders.
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Effects of Mesalazine Alone or Associated with Lactobacilus boulardii
on Diarrhea-Predominant Irritable Bowel Syndrome
Mauro Bafutto, Prof, Jose R. Almeida, Prof, Nayle V. Leite, MD, Maria C.F.
Passos, Prof, Joffre R. Filho, Prof∗. Instituto Goiano de Gastroenterologia,
Gastroenterology Division-Faculdade de Medicina UFGO, Goiania,
Goias, Brazil; Gastroenterology Division, Faculdade de Medicina-UFPE,
Recife, Pernambuco, Brazil and Gastroenterology Division, Faculdade de
Medicina, Belo Horizonte, Minas Gerais, Brazil.
Purpose: Recent studies have demonstrated that some irritable bowel syn-
drome (IBS) patients display persistent signs of minor mucosal inflammation
1,2. Mesalazine (M) has intestinal anti-inflammatory properties 3 and pro-
biotics may suppress the low-grade inflammation associated with IBS or
restore normal local immune function 4. The effects of M alone or com-
bined therapy of M and probiotics on diarrhea-predominant IBS (IBS-d) is
presently unknown.
Aims: Evaluate the effects of M and combined therapy of M with Lacto-
bacillus boulardii (Lb) on symptoms of IBS-d patients.
Methods: Based on Rome III criteria, 34 IBS-d patients (18 year or
more) were included. To exclude organic diseases all patients underwent
colonoscopy, stool culture, serum anti-endomisium antibody, lactose toler-
ance test and parasitologic stool examination. Patients were divided in two
groups: M Group (MG) -17 patients received M 800 mg t.i.d for 30 days
and M Lb Group (MLbG) – 17 patients received M 800 mg t.i.d and Lb 200
mg t.i.d. for 30 days. Drugs that might have any effect on intestinal motil-
ity or secretion were not allowed. Symptom evaluation at baseline and after
treatment were performed by means of a 4 point likert scale including: stool
frequency, stool consistency (Bristol scale), abdominal pain and distension.
Paired t test were used for statistical analyses.
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Results: MG presented a statistically significant reduction of the total symp-
tom (P < 0.0001). The stool frequency significantly reduced (P < 0.0001)
and the stool consistency improved (P < 0.0001). The abdominal pain (P <
0.0001) and abdominal distention significantly reduced (P = 0.0002). MLbG
presented a statistically significant reduction of the total symptom (P <
0.0001) Also, the stool frequency significantly reduced (P < 0.0001) and
the stool consistency improved (P < 0.0001). The abdominal pain (P =
0.0003) and abdominal distention significantly reduced (P = 0.0002)
Conclusion: Use of M and combined therapy of M and Lb reduced key
symptoms of IBS-d patients. These preliminary results warrant further
larger studies. 1. Talley NJ Lancet 2002; 360:555–5642. 2. Spiller RC Gut
2000;47:804–8113. 3. MacDermott RP Am J Gastroenterol 2000; 95: 3343–
3345. 4. Camilleri M Journal of Clinical Gastroenterology. 2006;40(3):264–
269.
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Familial Aggregation of Functional Dyspepsia: A Case-Control Study
Smita L.S. Halder, MRCP, Meredythe A. McNally, MD, Giles R. Locke,
MD, Judy A. Peterson, Prabin Thapa, MS, Scott Harmsen, MS, Alan R.
Zinsmeister, PhD, Nicholas J. Talley, MD∗. Department of
Gastroenterology, University of Manchester, Manchester, United Kingdom;
Dyspepsia Center, Mayo Clinic College of Medicine, Rochester, MN and
Department of Health Sciences Research, Mayo Clinic College of
Medicine, Rochester, MN.
Purpose: Functional dyspepsia (FD) is common, impacts on quality of life
and is very costly. The etiopathogenesis is uncertain. While in irritable bowel
syndrome there is evidence that genetic and intra-familial factors may be
involved, this has not been studied in FD. We hypothesized that if there
is familial aggregation, there would be an increased frequency of FD in
first-degree relatives of FD patients compared with relatives of controls (the
patient’s spouse).
Methods: The study design was a case-control study. Cases had undergone
a negative esophagogastroduodenoscopy at the Mayo Clinic for assessment
of dyspeptic symptoms; 455 were randomly selected from the endoscopy
database using the relevant diagnostic codes. A self report bowel disease
questionnaire (BDQ) that recorded symptoms, the somatic symptom check-
list, and a family information form (FIF) to collect the names and addresses
of all first-degree relatives were mailed to all cases and their spouses. A BDQ
was then mailed to all first-degree relatives of study subjects identified from
the FIF. FD diagnosis was based on the Rome II criteria.
Results: A total of 152 case-spouse pairs responded (33.4% of those mailed);
77 couples agreed to participate and gave family information. The BDQ
was sent to a total of 261 eligible relatives; 180 (69%) returned complete
questionnaires: 114 from case families, 66 from control families. A total of
37 cases reported FD and 21 of their 114 relatives reported FD (prevalence
rate 18% [95% CI: 12%, 27%]). A total of 17 of the spouses reported FD
and 4 of their 66 relatives had FD (prevalence rate 6% [95% CI: 2%, 15%].
(A chi-square test for the difference in proportions, 18% versus 6%, P =
0.03). Based on the 22 matched sets of family relatives with completed
questionnaires, 6 matched sets had a case family with one or more individuals
reporting FD, but none of the matched control families had any individual
report FD, while 3 matched sets had one or more of the control family
members report FD and none of the individuals in the matched case families
reported FD (P = 0.51, McNemar’s test).
Conclusion: This study suggests familial aggregation of FD occurs, sup-
porting a genetic or intra-familial environment component.
1064
Satiety Testing: Effects of Nutrient and Water Loading on Gastric
Volume and Emptying
Siva Doma, MD, Steve Kantor, Robert S. Fisher, MD, Linda C. Knight,
PhD, Alan H. Maurer, MD, Henry P. Parkman, MD∗. Medicine, Temple
University School of Medicine, Philadelphia, PA.
Purpose: Satiety tests to assess gastric accommodation in patients with
functional dyspepsia are performed with either nutrient or water loading. Si-
multaneous gastric volume and emptying can be measured scintigraphically
using gastric mucosal labeling with intravenous technetium-99m and gastric
emptying of a meal labeled with indium-111. The aim of this study was to
compare the results of satiety testing using nutrient and water loading on
gastric volume and emptying.
Methods: Six normal subjects underwent satiety testing and simultaneous
scintigraphic measurement of gastric volume and emptying: 3 with nutri-
ent drink and 3 with water loading. During fasting, Tc-99m pertechnetate
was injected IV to label the gastric mucosa followed by SPECT imaging to
determine gastric volume. Subjects ingested either water or Ensure, labeled
with indium-111 DTPA, until feeling completely full. SPECT imaging for
gastric volume and anterior/posterior In-111 imaging for gastric emptying
were performed over 4 hours.
Results: Subjects undergoing Ensure and water loading consumed similar
amounts to achieve the sensation of fullness (1500 ± 229 ml and 1500 ±
87 ml, respectively; mean ± SEM). Gastric volume tended to be larger
immediately after Ensure compared to water (1939 ± 324 and 1395 ± 294
mls; P = 0.28). At 60 min, postprandial gastric volume was significantly
higher after Ensure (1789 ± 203 mls) than water (667 ± 112 mls; P =
0.008). Higher gastric volume was persistent for the entire study period with
Ensure. Gastric emptying of Ensure was delayed compared to water (gastric
retention at 1 hour = 85 ± 3% vs 26 ± 7% for water; P = 0.0015). Gastric
volume in excess of estimated amount of liquid remaining (calculated by
multiplying volume ingested with percent gastric retention) was significantly
higher after Ensure ingestion than water (mean excess volume: 543 ± 16
and 175 ± 107 ml, P = 0.04). This excess gastric volume represents gastric
accommodation response and secretions.
Conclusion: Nutrient loading causes gastric accommodation which persists
for at least 4 hours whereas water loading does not produce gastric ac-
commodation. Although nutrient loading produces gastric accommodation
response, it does not result in higher ingested volume than with water load-
ing. This suggests maximum ingested volume during satiety testing is not
a measure of gastric accommodation. Satiety tests in general should not be
used as surrogate marker for gastric accommodation response.
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Use of Telemedicine To Follow Symptoms and Disease Course in
Patients with Gastroparesis: A Pilot Study
Siva Doma, MD, Edward Hoobler, William Santamore, PhD, Alfred Bove,
MD, PhD, Henry P. Parkman, MD∗. Medicine, Temple University School
of Medicine, Philadelphia, PA and Insight Telehealth Systems, Inc, Valley
Forge, PA.
Purpose: Chronic disease care, such as in gastroparesis, requires ongo-
ing communication between patient and physician. Telemedicine eliminates
geographic constraints and allows convenient access between patients and
physicians. Remote patient monitoring through telemedicine has improved
outcomes in disorders such as diabetes, heart failure and hypertension; but
has not been used to any great extent in GI disorders. Aims: 1) To set up
an operational Internet-based telemedicine system for convenient patient re-
porting of symptoms. 2) To evaluate the feasibility of monitoring symptoms
of patients with gastroparesis.
Methods: In this pilot longitudinal study of patients with gastroparesis, a
HIPAA compliant Internet-based telemedicine system was devised and used
to follow patients’ symptoms. Symptoms of gastroparesis were monitored
using 9 symptoms modified from the Gastroparesis Cardinal Symptom Index
(GCSI). Patients rated their symptoms – none, very mild, mild, moderate,
severe, very severe. In addition, diabetic patients could report blood glucose
levels. Selected patients were asked to participate and given a short instruc-
tional session on how to use the internet-based telemedicine system. They
were asked to enter their symptoms on a frequent basis, at least 3 times a
week.
Results: Ten patients with symptoms of gastroparesis were recruited to par-
ticipate (9 idiopathic gastroparesis, 1 diabetic gastroparesis). During the
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2-month monitoring period, 8 of the 10 patients reported their symptoms us-
ing this Internet-based telemedicine system. The number of days the patients
entered their symptoms averaged 18 ± 16 [mean ± SD] with a range of 2
to 48 sessions per patient. Interestingly, some patients had stable symptoms,
whereas other patients had periods of symptom exacerbations. Increases in
symptom scores were seen prior to patient visits to emergency rooms and
hospitalizations. In addition, decreases in symptom scores were seen with
instituting new treatments in some patients.
Conclusion: This pilot study shows that an Internet-based telemedicine sys-
tem can be used to follow patients’ symptoms. Use of telemedicine may be
useful to follow individual patient symptoms – both monitoring for symp-
tom exacerbations and symptom response to treatments. This discrete data
compiled on a regular basis over a long period provides a unique insight into
the disease course of patients with gastroparesis.
1066
Clinical Characteristics, Diagnostic Features, and Response to
Therapy in Patients with Rumination Syndrome
Christopher D. Miller, MD, Jiten D. Patel, MD, Farid Namin, MD, Richard
W. McCallum, MD∗. Division of Gastroenterology and Hepatology,
Universtiy of Tennessee Health Science Center, Memphis, TN and Center
for Gastrointestinal Nerve & Muscle Function, University of Kansas,
Kansas City, KS.
Purpose: The aim of this study was to retrospectively investigate the demo-
graphics, clinical features, and response to therapy in patients meeting the
Rome III criteria for rumination syndrome.
Methods: Retrospective chart review for the diagnosis of rumination syn-
drome in patients treated at the University of Kansas was performed. Patients
were then contacted via mailed questionnaire and/or telephone interview.
Data gathered included timing of episodes of emesis, additional symptoma-
tology, gastric emptying results (using a 4 hour study with a 2% egg beaters
meal; normal retentioN = <10% @ 4 hours), the use of behavioral therapy
and/or tricyclic antidepressants, and subjective and objective markers for
overall patient improvement.
Results: Thirty-six newly-diagnosed patients with rumination syndrome
(range = 14–67 y/o; meaN = 32.2 y/o) were identified from 2000–2007.
Each had failed prior therapy with traditional anti-emetic and prokinetic
agents initially prescribed for alternate diagnoses; none met criteria for an
underlying eating disorder (i.e. bulimia nervosa). Nausea was present in over
90% of patients but did not always precede their bouts of emesis. The timing
of the vomiting was directly related to eating, with most patients reporting
episodes of effortless vomiting within 15 minutes of the onset of meals, in-
cluding liquids. Both abdominal pain (epigastric pressure and fullness) and
weight loss were co-morbid factors (80–90%), with weight loss attributed
in part to avoidance of food in social settings. Of note, 19% of the patients
(7/36) had evidence of underlying delayed gastric emptying while the re-
mainder (29/36; 81%) were normal. Patients were treated with behavioral
therapy (relaxation tapes, breathing exercises, etc.) and/or tricyclic antide-
pressants for pain modification. The average symptom reduction achieved
was approximately 20–50% (range 0–100%), with the time to improvement
routinely reported as 2–8 weeks following the initiation of therapy.
Conclusion: Rumination syndrome: 1) is an under-recognized entity in gas-
troenterology practice, 2) can present with normal or slow gastric emptying,
and 3) characteristically presents with effortless vomiting immediately fol-
lowing ingestion of meals. Behavioral therapy is the primary treatment for
this disorder and often results in symptomatic and quality of life improve-
ments.
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Double Blinded Randomized Study of Temporary Gastric Electrical
Stimulation (GES): Preliminary Results of EndoSTIM Study and
Correlation with Mucosal EGG
Stephen Weeks, MD, Janell Thompson, MD, William D. Johnson, MD,
Thomas L. Abell, MD∗. Dept. of Digestive Diseases, University of
Mississippi Medical Center, Jackson, MS.
Purpose: We recently reported on temporary GES (TGES) in a double
blinded manner (DDW abstract 2007). We have also reported that the endo-
scopic mucosal EGG, done at the time of temporary electrode placement,
may predict response to TGES therapy (ACG abstract 2006).
Methods: We studied 58 patients (11 males, 47 females, mean age 46 years)
with the symptoms of gastroparesis (GP) and underlying diagnosis: (Idio-
pathic (ID), N = 38; Diabetes Mellitus (DM), N = 13; Post-surgical (PS),
N = 7) in a randomized placebo-controlled cross over study of TGES as two
consecutive four day sessions. We compared via linear regression the base-
line factors that correlated with the outcome of reduction in vomiting. We
examined all baseline characteristics, including symptoms and physiologic
measures versus outcome of vomiting, when the device was randomized to
ON or OFF.
Results: 28 patients had ON-OFF and 30 patients had OFF-ON; 45 of 58
patients finished all 8 days. When analyzed for all patients ON versus all
patients OFF both vomiting frequency and HRQOL improved significantly
(P < 0.05). By linear regression, a number of baseline parameters correlated
with outcome of TGES. Endoscopic mucosal EGG correlated greater with
outcome than did cutaneous EGG (See table 1).
Conclusion: TGES has now been shown effective by evidence based cri-
teria. A number of baseline characteristics correlate with the outcome of
TGES. The correlation of mucosal EGG may be particularly important, as
this measure can be done endoscopically at the time of temporary electrode
placement.
Table 1. Linear Regression Model Predictive Factors at Day 4
Vomiting Nausea TSS
Measure Correlation Correlation Correlation
Device ON or OFF P = 0.01
Baseline TSS P = 0.04 P = 0.06
Baseline GET 1 hour P = 0.02 P = 0.04 P = 0.03
Cyclic or non-cyclic sx pattern P = 0.02
Mucosal EGG at TGES placement P = 0.05
Baseline EGG average frequency P = 0.16 P = 0.09
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Rifaximin Therapy for Rome II–Positive Irritable Bowel Syndrome
(IBS)
Brian Muska, MD∗. Northwest Health Care Associates, Hoffman Estates,
IL.
Purpose: An emerging hypothesis suggests that small intestinal bacterial
overgrowth (SIBO) may contribute to IBS pathophysiology. Rifaximin is
a nonabsorbable antibiotic with broad-spectrum activity against intestinal
pathogens. Studies have demonstrated that reduction of SIBO with rifax-
imin may improve IBS symptoms. This retrospective chart review evaluated
rifaximin, administered alone or with other therapies, in improving func-
tional gastrointestinal (GI) symptoms in IBS patients.
Methods: Consecutive adult patients meeting Rome II criteria for IBS with
no history of IBD or bowel resection surgery were identified. Patients re-
ceived rifaximin 400 mg two or three times daily for 10 days. Most pa-
tients reporting partial relief of GI symptoms, or return of symptoms after
completing rifaximin treatment, received ≥1 additional rifaximin regimen.
Concomitant medications were permitted. Study endpoint was percentage
of patients reporting complete or partial relief of baseline functional GI
symptoms following rifaximin treatment.
Results: Analysis included 104 patients (mean age, 49.3 y) with mean
IBS duration of 3.8 y (range, 0–30 y). Forty patients (38%) had diarrhea-
predominant IBS (IBS-D), 23 (22%) had constipation-predominant IBS
(IBS-C), and 27 (26%) had alternating-form IBS (IBS-A). The most
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frequently reported baseline IBS symptoms were diarrhea (26%), constipa-
tion (15%), bloating (13%), abdominal pain (10%), and gas (7%). Initially,
80 patients (77%) received rifaximin 800 mg/d and 24 patients (23%) re-
ceived rifaximin 1200 mg/d for 10 days. Thirty-five patients (34%) received
>1 rifaximin regimen. Concomitant GI medications during rifaximin ther-
apy included tegaserod (11%), hyoscyamine (6%), rabeprazole (4%), lop-
eramide (3%), chlordiazepoxide/clidinium (3%), dycyclomine (2%), bel-
ladonna (<1%), oxybutynin (<1%), doxycycline (<1%), and fiber (<1%).
Thirty-four patients (33%) reported complete relief and 71 patients (68%)
reported partial or complete relief of baseline IBS symptoms following ≥1 ri-
faximin regimen. Symptom improvement was associated with IBS subtype,
with 40% of IBS-D patients, and only 13% of IBS-C patients, reporting
complete relief of baseline IBS symptoms following rifaximin treatment.
Adverse events associated with rifaximin were mild.
Conclusion: In this chart review, rifaximin 800 to 1200 mg/d for 10 days im-
proved functional GI symptoms in patients with Rome II IBS. These findings
provide additional evidence of the benefits of rifaximin, administered alone
or with other therapies, for IBS patients. Controlled trials are warranted to
further evaluate these findings.
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Functional Gastrointestinal Disorder Comorbidities: Comparisons of
Prevalence and Costs in the 6 Months before and after Diagnoses of
Constipation (C) and Irritable Bowel Syndrome and Constipation
(IBS+C)
R.A. Brook, MS∗, N.J. Talley, MD, N.L. Kleinman, PhD, R.W. Baran,
PharmD. JeSTARx Group, NJ; Dept Medicine, Mayo Clinic, MN; HCMS,
WY and Takeda Global R&D, IL.
Purpose: Patients with C and IBS can present with a wide range of functional
gastrointestinal disorder (FGID) comorbidities. However, it is unknown how
often these comorbidities occur or their temporal relationship to C and IBS.
Few studies have differentiated the occurrence of FGID comorbidities before
and after diagnoses of C and IBS.
Objective: To evaluate the prevalence and costs of FGID comorbidities in
a large sample of patients in the 6 months before and after diagnoses (DXs)
of C and IBS+C (co-occuring DXs of IBS and C).
Methods: A restrospective analysis was performed in an employer database
of greater than 500,000 employees. Patient cohorts with C (ICD9s 564.0,
564.00, 564.01, and 564.09), IBS+C (ICD9 564.1× and co-occurring C) and
a Control group (neither C nor IBS+C) were identified. For each IBS+C
patient identified, 5 C patients and 180 Control patients were matched using
logistic regression and propensity scores for age, job tenure, gender, marital
status, race, exempt- and full-time employment status, salary, region, Charl-
son Comorbidity Index Score, and the existence of medical claims. Preva-
lence and costs for FGID co-morbidities were calculated for the 6 months
before and after C and IBS+C DXs by FGID ICD9 code (see figure). Co-
morbidity comparisons were performed within (before vs after) and between
(C vs IBS-C vs control) groups. Prevalence comparisons used z-scores of
log odds ratios (Woolf method) and costs were compared by Sattherthwaite
t-tests.
Results: Data were available for 309 IBS-C patients, 1545 C patients, and
55,620 matched Controls. All cohorts averaged 41 years of age and 74%
were female. The prevalence and costs of FGID comorbidities within and
between C, IBS-C, and Control groups generally increased. Many findings
were significant (see figure).[figure1]
Conclusion: The prevalence and costs of FGID comorbidities increase after
diagnoses of C and IBS+C. Prevalence and costs of comorbidities were
similar between C and IBS+C cohorts.
1070
Type D Personality Is Associated with Impaired Health-Related
Quality of Life in Patients with Functional Bowel Disorders (FBDs)
Stephanie L. Hansel, MD, MS, Sarah B. Wessinger, MD, V. Ann Schettler,
RN, MHL, John K. DiBaise, MD, Michael P. Jones, MD, Michael D.
Crowell, PhD∗. Gastroenterology & Hepatology, Mayo Clinic Arizona,
Scottsdale, AZ and Gastroenterology, Northwestern University, Chicago,
IL.
Purpose: Few data are available on the impact of personality traits on HRQoL
in FBDs. Type D personality is characterized by a tendency to experience
negative emotions and to inhibit these emotions while avoiding social con-
tacts with others. We evaluated the hypothesis that Type D personality would
be associated with impaired HRQoL in FBDs.
Methods: Data were collected from consecutive patients undergoing hy-
drogen breath testing for functional GI symptoms at a tertiary clinic. They
completed the Type D Scale – 14 and the Short-Form Health Survey 12 (SF-
12v2) questionnaires. Standardized cut-offs≥10 identified Type-D caseness.
Discrete variables were compared with chi-square test. Continuous variables
were compared with Student’s t test. Differences between personality types
on HRQoL were analyzed using MANOVA. Multivariable logistic regression
analyses were used to examine if Type D was an independent determinant
of impaired HRQoL.
Results: Of 122 patients, 37% met criteria for Type D personality. Groups
did not differ in age (61 ± 15 vs 59 ± 18 yrs) or gender (72% F). Type
D patients had significantly lower scores on the Physical Component scale
(PCS) and the Mental Component scale (MCS) of the SF-12 and all SF-12
subscales compared with non-Type D patients. Type D personality remained
an independent predictor of impaired PCS and MCS after adjusting for
demographic and clinical characteristics.
Type D personality and impaired HRQoL
OR 95% CI P-Value
SF-12 component scores
PCS 4.13 1.78–9.80 0.001
MCS 11.03 3.25–37.49 0.000
SF-12 subscales
Physical Function 5.16 1.97–13.56 0.001
Role Physical 5.98 2.41–14.85 0.001
Bodily Pain 4.36 1.72–11.08 0.002
General Health 4.96 1.57–15.71 0.006
Vitality 7.21 2.54–20.44 0.000
Social Function 9.12 1.75–47.63 0.009
Role Emotional 19.05 4.61–52.06 0.000
Mental Health 15.49 4.61–52.06 0.000
Conclusion: Type D personality was associated with an increased risk of
impaired HRQoL in FBG patients. Type D personality construct may be an
important consideration when assessing HRQoL outcomes. Consideration
of personality type could improve risk stratification in research and clinical
practice in this patient group.
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Prevalence of Functional GI Disorders in Women with History of
Domestic Violence. Does the Type of Abuse Matter?
Jose M. Remes-Troche, MD∗, Silvia Cid-Juarez, MD, Antonio
Ramos-de-la-Medina, MD, Angelica Galmiche, MS, Max Schmulson, MD,
Federico Roesch, MD. Digestive Physiology and Motility Laboratory,
Medical-Biological Research Instituto, Universidad Veracruzana,
Veracruz, Mexico; Medical Education, Hospital Regional de Veracruz,
Veracruz, Mexico; La Casa de la Mujer, Veracruz, Mexico and Department
of Experimental Medicine, UNAM, Mexico City, Mexico.
Purpose: Previous studies have documented a high prevalence of abuse,
either physical or sexual, in patients with functional gastrointestinal disorders
(FGIDs). However, there is a lack of information regarding prevalence of
FGIDs in adults suffering domestic violence. Our aim was to evaluate the
prevalence of FGIDs in women with domestic violence and explore if the
type of abuse has any relationship with the presence of FGIDs.
Methods: 122 women at “Casa de la Mujer”, a Women’s Attention Center
that gives support to women who experience domestic violence, were in-
vited to participate. Prevalence of FGIDs was assessed using the Rome II
integrated questionnaire (Spanish validated version). Physical, psychologi-
cal and sexual abuse were assessed using a standard self reporting screening
instrument, and anxiety-depression levels using the Hospital Anxiety and
Depression scale (HAD) questionnaire.
Results: 87 (71%) women (mean age 39 ± 11 years) agreed to participate in
the study. 85(98%) reported psychological abuse, 66 (76%) physical, and 26
(30%) sexual abuse. Prevalence of FGIDs was 93% (N = 81) and 71 women
had more than 1 FGID (mean 3 ± 1). FGIDs reported were: functional dys-
pepsia 59%, IBS 39%, proctalgia fugax 38%, functional constipation 31%,
functional heartburn 22%, bloating 18%, fecal incontinence 13%, dyssyn-
ergia fecation 9%, abdominal pain 8%, chest pain 8%, rumination 5%, and
dysphagia 2%. 25 women had both dyspepsia and IBS. The mean global
score for HAD was 19 ± 7. Women with FGIDs had significantly higher
anxiety scores (11 ± 4 vs 6 ± 1, P = 0.005). Fecal incontinence (P = 0.05)
and proctalgia fugax (P = 0.04) were more common in women with sex-
ual abuse compared to other types of abuse. Women with sexual abuse had
higher global and anxiety scores (HAD) (P < 0.05).
Conclusion: Most women who suffer domestic violence experience FGIDs,
confirming that abuse plays an important role in FGIDs. Psychological dis-
tress, specifically anxiety, was more severe in women with FGIDs. Sexual
abuse is associated with functional anorectal disorders. We believe our study
has important clinical implications for comprehensive health care of women
in situations of abuse and women with FGIDs.
1072
Pilot Study on Patient Centered Educational Intervention in Irritable
Bowel Syndrome (IBS)
Albena Halpert, MD, Abha Verma, BA, Douglas Drossman, MD∗.
Medicine/Gastroenterology, Boston University Medical Center, Boston,
MA and UNC Center for Functional GI & Motility Disorders, University
of North Carolina, Chapel Hill, NC.
IBS-QOL and CG-FBD Scores
Group
Education (N = 25) Control (N = 25)
Baseline 1-Month 3-Month Baseline 1-Month 3-Month
Outcomes IBS-QOL 64.5 ± 27.7 65.3 ± 25.4 68.1 ± 26.4 82.0 ± 18.0 87.5 ± 21.4 81.2 ± 25.9
CG-FBD 4.8 ± 1.2 4.5 ± 1.2 4.4 ± 1.2 3.6 ± 1.1 3.6 ± 1.2 3.7 ± 1.4
Purpose: We tested the effectiveness of an individualized theory based ed-
ucational intervention on a) IBS quality of life (IBS-QOL) and b) health
cognition (CG-FBD).
Methods: Subjects with IBS were randomized into an education- (E) group,
who received a 30 min individualized educational intervention based on
Knowles’ theory of adult learning, or control group (C)- who read about
IBS for 30 min. Outcomes were measured at 1 and 3 months post interven-
tion. Analyses were done using a repeated measures ANOVA model. The
regression parameter of interest was group modification of the change in
outcome measures from baseline to follow-up.
Results: 50 subjects (1:1) were enrolled. Baseline differences in the E vs.
C group were noted for IBS-QOL (scale 0–100); P = 0.01, and for disease-
related cognition (CG-FBD) (scale 1–7, 7 = poorest cognition); P = 0.0002.
Accordingly, adjustments were made. In the adjusted analysis, there were no-
table observations about the E vs. C group (Table 1): 1) IBS-QOL improved
in the E group between baseline to 3 months (P = 0.003) and between 1–3
months (P = 0.03). Although these changes were statistically significant,
they did not reach clinical relevancy; 2) A trend towards improvement in
CG-FBD was noted in the E group from 0–1 month (P = 0.06) and 0–1–3
months (P = 0.10). At 0–3 and 1–3 months, changes were not statistically
significant (P = 0.24 and P = 0.79 correspondingly). A change of 0.5 on a 1–
7 scale is clinically significant; and 3) A trend of improvement of perceived
control over the illness was noted in the E group.
Conclusion: The study provides preliminary data that our educational model
has the potential to improve disease-related cognition, IBS-QOL, and per-
ceived control over the illness. The intervention is practical, inexpensive and
can be provided by a health care provider trained in the model.
1073
Rifaximin and IBS in the Adolescent Patients
Shivinder Narwal, MD∗, Graciela Wetzler, MD, Mary Molsky, CPNP.
Pediatric Gastroenterology, Maimonides Infant’s & Children’s Hospital,
Brooklyn, NY.
Purpose: To evaluate the efficacy of Rifaximin in the adolescent patients
with IBS. Irritable bowel syndrome (IBS) is a frequently encountered prob-
lem affecting the adolescent population. Medical help is only sought when
IBS starts to affects their school performance as well as social lifestyle. De-
lay in seeking medical help is most likely due to embarrassing symptoms.
Adolescent patients with IBS presents with bloating, abdominal cramps,
and extreme urgency to defecate, fear of soiling, uncontrollable flatulence,
diarrhea and sometimes constipation. Etiology of IBS is not clearly un-
derstood or established but inflammation, infectious gastroenteritis, small
bowel bacterial overgrowth, visceral hypersensitivity and altered gastroin-
testinal motility have been suggested as interrelated in pathophysiology of
IBS. Multiple therapeutic options including probiotics, fiber, laxatives, stool
softeners, antispasmodics and antidarrheals are available but not much suc-
cess has been documented with these treatments. Mostly these patients take
various combinations of prescription as well as over the counter medications
without much relief.
Methods: We evaluated 29 patients (age 15 to 19 years, 20 females and 9
males) who were diagnosed with IBS and were already on different treat-
ments without any success for a long period of time. After initial evaluation,
these patients were started on Rifaximin 400 mg twice a day for a period
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of 10 days to one month. Two patients required a second course after one
month of initial treatment due to recurrence of symptoms.
Results: After the treatment, 24 patients improved significantly with almost
complete resolution of their symptoms, two subjects required a second course
of treatment and three patients continued with IBS symptoms. Their quality
of life as well as school performance and attendance improved significantly.
They were not fearful of using the subway or school buses.
Conclusion: Among other treatment options available for IBS, Rifaximin
appears to be well tolerated and efficacious as the first line of therapy for the
adolescent population.
1074
Prevalence and Predictors of Non-Consulting for Chronic Constipation
Olafur S. Palsson, PsyD, Marsha J. Turner, MS, Rona L. Levy, PhD,
Andrew D. Feld, MD, Michael von Korff, ScD, William E. Whitehead,
PhD∗. University of North Carolina at Chapel Hill, NC; University of
Washington, Seattle, and Group Health Cooperative of Puget Sound,
Seattle.
Purpose: It is unknown what proportion of U.S. health maintenance orga-
nization (HMO) subscribers have chronic constipation but do not consult
health care providers about this problem. This work evaluated the preva-
lence and predictors of non-consulting constipation, and the quality of life
(QoL) and psychological symptoms in these individuals.
Methods: Adults enrolled in a large West Coast U.S. HMO with one or
more constipation visits on record in the past year, and a comparison sample
matched for age and gender with no constipation-related visits in the past
5 years, completed a mail survey including demographics, Rome III IBS
and constipation modules, PAC-QOL and SF-12 Qol questionnaires, and the
Brief Symptom Inventory-18.
Results: 671 constipation consulters (mean age 66.1 years, 68.5% female)
and 1022 comparison subjects (mean age 66.4 years, 68.0% female) com-
pleted the survey (60% overall response). 77.5% of the consulting sample
and 40.5% of the comparison sample met Rome III Chronic Constipation
(CC) criteria. CC non-consulters did not differ from CC consulters in age,
gender, race, psychological symptoms or SF-12 mental composite scores.
However, compared to CC-consulters, the CC-non-consulters had higher SF-
12 physical composite QoL scores (Mean ± S.D: 43.3 ± 13.2 vs. 39.6 ±
13.3; P < .0001), and less constipation-related QoL impairment on the PAC-
QOL (36.0 ± 19.0 vs. 46.6 ± 19.6; P < .0001), less frequent abdominal pain
and bloating (P < .0001 for both), and were less likely to meet Rome III
IBS criteria (43.2% vs. 58.7%; P < .0001). Compared to survey respondents
without bowel problems (no Rome III IBS or CC) in the comparison sam-
ple, CC non-consulters had lower SF-12 physical (43.3 ± 13.2 vs. 46.3 ±
11.6; P < .0001), and mental (50.1 ± 10.5 vs. 54.2 ± 8.3; P < .0001)
composite scores, as well as higher (P < .0001) BSI-18 anxiety, depression,
somatization and general distress scores.
Conclusion: Four out of 10 adult HMO patients have CC without consulting
health care providers about it. Our data indicate that whether patients consult
doctors about CC is unrelated to demographic or psychological characteris-
tics, but related to constipation frequency, amount of associated abdominal
pain and bloating, and impact on life functioning. CC non-consulters have
significantly poorer QoL and more psychological symptoms compared to in-
dividuals without bowel problems. [Supported by Novartis Pharmaceuticals
and R24 DK69674].
GET SBTT CTT WGTT # Markers Day 2 # Markers Day 5
Controls 3.6 ± 0.2 3.8 ± 0.1 29.8 ± 2.7 37.2 ± 2.7 8.8 ± 0.9 1.2 ± 0.4
Constipated 5.7 ± 1.2∗ 4.4 ± 0.2 59.3 ± 4.5∗ 68.3 ± 4.3∗ 16.1 ± 1.0 6.9 ± 1.0∗
1075
Investigation of Wireless Capsule (SmartPill) for Colonic Transit: A
Comparative Study with Radiopaque Markers in Health and
Constipation
S. Rao, MD, FACG∗, B. Kuo, MD, W. Chey, MD, FACG, J. DiBaise, MD,
FACG, L. Katz, MD, K. Koch, MD, FACG, J. Lackner, PsyD, R. McCallum,
MD, R. Saad, MD, K. Selover, J. Semler, PhD, M. Sitrin, MD, G. Wilding,
PhD, H. Parkman, MD, FACG. SmartPill Research Group.
Purpose: Traditionally, colonic transit time (CTT) has been assessed with ra-
diopaque marker (Sitzmarks (SZ)) technique. Although useful, it requires
radiation and is hindered by poor patient compliance and complex protocols.
This multicenter study aimed to simultaneously assess and compare CTT as
measured by SmartPill (SP)-wireless pH and pressure recording capsule
with that of Sitzmarks in constipated (Rome II) and healthy subjects.
Methods: After overnight fast, subjects ingested a nutrient bar (260 kcal)
followed by a Sitzmarks (24 markers) and a SmartPill capsule. Subjects
wore a data receiver for 5 days or until SmartPill was expelled and kept
stool diary. Abdominal x-rays were obtained on days 2 & 5. SmartPill
tracing was examined to assess gastric emptying time (GET) (time to rise in
pH>4), small bowel transit time (SBTT) (time to cecal entry with >1 pH
drop after GET), CTT (time from cecal entry to abrupt temperature drop),
and whole gut transit time (WGTT). To account for the known influence of
gender and age on CTT, analysis of covariance was used in the statistical
examination of SmartPill CTT.
Results: Table (mean ± SEM, ∗ = P< 0.05). 71 constipated (m/f = 8/63)
and 83 healthy (m/f = 42/41) subjects participated. CTT, WGTT, day 2
Sitzmarks transit, and day 5 Sitzmarks transit were different (P < 0.001)
between constipated patients and controls, even after accounting for gender
and age. CTT correlations between SmartPill and% of markers expelled
on day 5 were r = 0.59 (P < 0.0001) in patients and r = 0.46 (P < 0.001)
in controls. The diagnostic utility of CTT to predict historical diagnosis of
constipation was satisfactory with a computed ROC AUC of 0.74. Patients
had slower (P < 0.001) GET, slower (P < 0.01) CTT, and slower (P < 0.02)
WGTT compared to controls. There were no serious adverse events.
Conclusion: SmartPill is a novel, and more useful technique of assessing
CTT. Its transit highly correlates with Sitzmarks, and it provides compara-
ble data. Additionally, it provides regional information on GET and SBTT.
Thus, SmartPill provides comprehensive data under physiological condi-
tions, on whole gut and regional transit time in health and functional GI
disorders.
1076
Prevalence and Risk Factors for Abdominal Bloating and Visible
Distention: A Population-Based Cross Sectional Survey
Xuan Jiang, MD, Giles R. Locke, III, MD, FACG, Rok Seon Choung, MD,
Alan R. Zinsmeister, PhD, Cathy D. Schleck, BSc, Talley J. Nicholas, MD,
FACG∗. Division of Gastroenterology and Hepatology, Mayo Clinic
College of Medicine, Rochester, MN; Division of Gastroenterology and
Hepatology, People’s Hospital, Peking University, Beijing, China and
Department of Health Sciences Research and Division of Biostatistics,
Mayo Clinic College of Medicine, Rochester, MN.
Purpose: Abdominal bloating and visible distention are common yet poorly
understood symptoms. Whether the characteristics of those with visible dis-
tention differ from bloating without distention is unknown. We aimed to
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evaluate in a representative US population the prevalence of bloating and
distention, potential risk factors, and the distribution of functional GI disor-
ders (FGIDs).
Methods: A symptom questionnaire was mailed to a previously assembled
cohort that had been selected at random from the population of Olmsted
County, MN. The complete medical records were abstracted. This question-
naire measured abdominal bloating and separately visible distention.
Results: Among the 2259 subjects (53% female; mean age 62 yrs), 615
reported bloating (272 with and 343 without visible distension). The sex-
specific, age-adjusted (US White 2000) prevalence for bloating was 18.8%
(CI: 16.6, 20.9) and for visible distention 8.9% (CI: 7.2, 10.6). Female gender,
higher somatic symptom score, irritable bowel syndrome (IBS), functional
dyspepsia (FD) and gastroesophageal reflux disease (GERD) were risk fac-
tors for bloating as well as for visible distention (Table). Further, female gen-
der, higher somatic symptom score, IBS and specifically, IBS-constipation
(IBS-C) and IBS-mixed (IBS-M), FD but not GERD significantly increased
the odds for distension compared to bloating alone (Table).
Conclusion: Bloating and visible distention are common in the community,
and have similar risk factors. Female gender, somatic symptom score, IBS-C,
IBS-M, and FD increased the risk for distension versus bloating alone.
Table: Risk factors for bloating and distention
OR for OR for OR for distention
bloating distention vs bloating
Female vs male 1.9 (1.5, 2.4) 2.7 (2.1, 3.6) 1. 5 (1.0, 2.1)
SSC score per 1 unit 3.6 (2. 9, 4.6) 5.2 (4.1, 6.6) 1.4 (1.1, 1.8)
IBS vs no IBS 4.0 (2.8, 5.8) 7.4 (5.1, 10.7) 1.9 (1.3, 2.7)
IBS-C vs no IBS 4.5 (2.4, 8.5) 11.9 (6.6, 21.7) 2.7 (1.5, 4.8)
IBS-M vs no IBS 12.4 (3.9, 38.8) 26.8 (8.8, 82.2) 2.2 (1.1, 4.4)
FD vs no FD 2.9 (1.7, 5.0) 6.3 (3.8, 10.5) 2.2 (1.3, 3.7)
GERD vs no GERD 2.7 (2.0, 3.6) 3.2 (2.3, 4.4) 1.2 (0.9, 1.7)
1077
Studies of the Efficacy of Gastric Electrical Stimulation for
Gastroparesis-US/European Comparison—2007
J.M. Runnels, MD, S. Andersson, A. Al-Juburi, C. Lahr, H. Rashed, H.
Abrahamsson, P. Ducrotte, G. Fullarton, G. Lindberg, T. Abell, MD∗.
Dept. of Digestive Diseases, University of Mississippi Medical Center,
Jackson, MS.
Purpose: Gastric Electrical Stimulation (GES) is an accepted therapy for
drug refractory gastroparesis (GP). However, reports of efficacy have varied
between centers. We aimed to compare results from several centers for the
efficacy of GES by standardizing data between centers∗.
Methods: Consecutive patients with the symptoms of gastroparesis were
evaluated at each center located in Western Europe (4 centers) and Southern
US (4 centers). The patients were by demographics (sex; age), underlying
diagnosis (Idiopathic GP = I, Diabetic GP = D, Postsurgical GP = P),%
of centers where GET criteria were used, months (Mos) since implant, per-
centage change in symptoms (baseline to latest for Vomiting = Vom and GI
Total Symptom Score = TSS).
Results: See Table. The European centers show a higher percentage change
in vomiting than the US centers. However, the European centres had a larger
proportin of DGP patients compared to US centres (59% vs 22%) and a
smaller proportion of IGP patients (25% vs 72%).
Conclusion: This is the first non-formal trial comparison of the use of
GES for patients with the Symptoms of Gastroparesis confirming effec-
tiveness of GES. The specific localities studied (both US & Europe) reveal
similarities but also differences between centers, particularly with respect
to DGP/IGP proportions. Ongoing prospective comparisons of outcome
data are feasible and may be warranted with the continued clinical use of
GES.
Locat No F, M; yr DX:I, D, P GET Mos Vom TSS
EUR 61 38,23;41 15,36,10 100% 35 62.0 48.0
(one centre)
US 319 258,61;42 231,71,17 75% 49 45.0 38.0
ALL 380 296,84;42 246,107,27 88% 47 48.0 38.5
∗EXACTS (European Across American Comparative Trial of Stimulation) is formed
by ASSESS (Associated Southern Sites of Electrical Stimulation Studies) and EDGES
(European Data of Gastric Electrical Stimulation).
1078
Complete Spontaneous Bowel Movement Frequency as Primary
Outcome Measure in Patients with Chronic Constipation Treated with
Linaclotide
Jeffrey M. Johnston, MD∗, James Mac Dougall, PhD, Bernard J. Lavins,
MD, Caroline B. Kurtz, PhD. Microbia, Inc., Cambridge, MA.
Purpose: Complete spontaneous bowel movement (CSBM) is an attrac-
tive symptom-specific primary endpoint for trials of patients with chronic
constipation (CC), as it integrates the objective, quantitative sign of stool
frequency and the subjective, qualitative symptom of sensation of complete
defecation. Data from Phase 1 and 2 studies of linaclotide, a first-in-class ag-
onist of guanylate cyclase-C, were evaluated to compare attributes of CSBM
with SBM as the primary outcome measure.
Methods: Two studies of oral linaclotide, a Phase 1 study in healthy volun-
teers (HVs) and a multicenter Phase 2 study in patients with CC, evaluated
bowel habits of stool frequency, stool consistency, straining, and sensation
of complete evacuation. The CC study also evaluated global assessments
of abdominal discomfort, severity of constipation, and relief of symptoms.
Treatment effects of linaclotide doses were compared with placebo using
ANCOVA and Pearson’s correlation coefficients of outcome measures were
derived.
Results: Data from 48 HVs and 36 CC patients were analyzed. The mean
weekly baseline SBM and CSBM rates were 6.4 and 5.8 among HVs, and
1.9 and 0.23 among CCs. In HVs, the mean baseline CSBM:SBM ratio was
0.89 and was essentially unaffected by linaclotide treatment. In CC patients,
the mean CSBM:SBM ratio was 0.11 at baseline and progressively increased
with increasing dose of linaclotide (0.29 in placebo to 0.45 at high dose). In
CC patients, a comparison of CSBM and SBM responder analyses indicated
that CSBM is more specific (11% vs 44% placebo response and a treat-
ment effect of ∼4-fold vs ∼2-fold increase over placebo, respectively) but
less sensitive (43% vs 100% maximum response, respectively). In addition,
CSBMs were more strongly correlated than SBMs with other bowel habits
(}r} = 0.70–0.72 vs 0.42–0.47) and global assessments (|r| = 0.58–0.71 vs
0.42–0.49).
Conclusion: These data indicate that the normal rate of CSBMs in HVs
is approximately 1 per day, essentially the same as the rate of SBMs. CC
patients have both a lower frequency of CSBMs and SBMs, and a lower ratio
of CSBM:SBM compared with HVs. This ratio increased in CC patients in
parallel with response to treatment. CSBM compared to SBM demonstrated
a lower placebo response and a higher treatment effect relative to placebo
and correlated more strongly with other bowel habits and global assessments.
Based on these results, CSBM may be the preferred symptom-specific pri-
mary endpoint for clinical trials of new treatments for CC.
1079
Does Testing for Markers of Inflammation Assist in Differentiating
IBS from Other Organic Diseases?
Gaa O. Richardson, MD, Charlene Prather, MD∗. GI&Hepatology, Saint
Louis University, St. Louis, MO.
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Purpose: Many clinicians remain uncomfortable making an IBS diagnosis
based on symptom criteria and an absence of warning features. A biologic
marker would have potential value in excluding other organic diseases. Mark-
ers of inflammation such as c-reactive protein (CRP) and fecal lactoferrin
and calprotectin have been proposed as potentially useful in this regard.
This study aims to assess the clinical usefulness of CRP, lactoferrin and
calprotectin in differentiating IBS from other organic diseases.
Methods: This is an ongoing, prospective study. A consecutive sample of
patients with abdominal pain, diarrhea and/or constipation referred for con-
sultation in a tertiary care setting were offered enrollment. Patients were
excluded if they had a known diagnosis of inflammatory bowel disease, prior
GI resection, cancer or weight loss > 10 lbs within 6 months. All patients
were requested to complete a validated bowel disease questionnaire and have
CBC, albumin, TTG Ab, CRP, TSH, stool lactoferrin and calprotectin tests
performed. Colonsocopy and other testing was performed if deemed clin-
ically appropriate. The medical record was reviewed to determine clinical
diagnosis and fulfillment of Rome III criteria. Data were analyzed using Chi-
square analysis to assess associations between IBS diagnosis (clinical and
Rome III) or other functional bowel disorder versus other organic disease
and these markers.
Results: 26 patients have been enrolled to date (female = 20, male = 6; age
range 19 – 67 years [mean 36 yrs]). Diagnosis at last follow-up (N = 26):
IBS-D 14, IBS-C 4, IBS-A 1, chronic constipation 2, dyssynergic defeca-
tion 1, Crohn’s disease 1, small bowel bacterial overgrowth 2, no diagnosis
recorded 1. Abnormal test results at initial evaluation: hemoglobin < 12.0
in 3, albumin < 3.5 in 2, abnormal colonoscopy in 2, CRP positive in 2,
lactoferrin positive in 2, calprotectin positive in 7. No patient had positive
celiac antibodies. Chi square values were not significant for an association
between IBS vs. non-functional diagnosis and CRP, lactoferrin, calprotectin
or any positive single test.
Conclusion: Results from this interim analysis do not support routinely
checking CRP, fecal calprotectin and lactoferrin. Although they would have
identified the 1 patient with Crohn’s disease, this patient would have been
identified using traditional testing (i.e. hemoglobin and albumin). In addition,
there were many false positive calprotectin results. False positives have the
potential to confuse the diagnosis and lead to further, unnecessary testing.
1080
Multi-Specialty Functional Bowel Center Outcomes in Irritable Bowel
Syndrome
Yamini Subbiah, MD, Jorge Vazquez, MD, Kathy Sepesy, BSN, Paul J.
Lebovitz, MD∗. Department of Gastroenterology, Allegheny General
Hospital, Pittsburgh, PA.
Purpose: To describe population seen in a multi-disciplinary Functional
Bowel Center (FBC) and the impact of the center in the treatment of moderate
to severe irritable bowel syndrome (IBS) patients.
Methods: Retrospective chart review of 150 patients’ charts enrolled (2001
– 2006) at the FBC. The FBC is a multidisciplinary center involving Gas-
troenterolgy, Nutrition, Psychiatry, Spirituality and Alternative Medicine
specialists. Data extractor was used to collect demographic, medical, surgi-
cal and psychiatric histories, and the evaluations and treatments pre and post
FBC encounter. Institutional IRB approval was obtained.
Results: Population description as follows: 97% Caucasian, 2.6% AA, 123
females (average age 44.1), 27 males (average age 45.5). 73% of men and
43% women had > 5 years of complaints. IBS sub-typing was as follows:
Constipation predominant (57.8% of females and 38.4% of males), Diarrhea
predominant (29.6% of females and 30.7% of males), Alternating type (6%
of females, 3.8% of males), with uncategorized IBS (6% females and 19%
males). 7% of patients found alternate diagnosis (IBD, gastric sarcoid, ITP
with spleenomegaly, severe pan-motility disorders, bacterial over-growth,
sprue, and a neurological pain issue).
Psychiatric evaluation found 88% of women (56% pre-enrollment) and
88.4% of men (50% pre-enrollment) had a psychiatric issue (depression/
anxiety and adjustment disorders were predominant). 18% of patients were
found to have eating disorders (predominantly binge-eating) and obesity was
noted in 34.6% of males and 19% of females. 79% of women and 46% of
men had undergone related surgeries in the past. The most common surgery
was hysterectomy in females and gall bladder surgery in males.
Most common medication treatment was PPI (95%). The average number of
evaluation procedures & imaging was <1/patient after FBC enrollment. Per-
ceived improvement by both physician and patient on FBC follow-up found
only 38% felt improved, showing the difficulty in treating this population.
Conclusion: This is one of the first descriptive studies of this size, in the
setting of a multidisciplinary FBC population. Unique aspects of this pop-
ulation were the predominance of constipation predominant IBS, high psy-
chiatric comorbidities identified and the association of eating disorders and
obesity noted. We are currently in the process of collecting prospective data
and utilizing the SCL 90 and IBS QOL questionnaires and other indices to
determine the impact of the FBC on this population in more detail.
1081
Effectiveness of a Behavorial Medicine Program on Adolescent
Irritable Bowel Symptoms and Resource Utilization
Sripriya Balasubramanian, MD, Rhonda Gage, RN, Monica Randel, RD,
Andre Shaw, Robert Randel, Alisa Lene, Shawn Visger, Michael Lawson,
MD∗. Gastroenterology, Kaiser Permanente, Sacramento, CA.
Purpose: IBS is a common health syndrome affecting 10 – 15% of patients,
who are estimated to use 30% more of the medical budget than any other
disease category. No medical therapy is proven efficacious. Parental influence
appears key to the development of IBS in childhood. Contributing factors
include poor sleep patterns, lack of exercise and stress. Our hypothesis was
that a behavioral medicine program for adolescent patients with IBS and
their parents in a group setting will result in an improvement in symptoms
and reduced health care utilization.
Methods: Our intervention was a program for adolescents identified by pedi-
atric gastroenterologists with IBS, and their parents, consisting of 90 minute
consecutive sessions over 3 weeks incorporating exercise, relaxation skills
(using self guided imagery, yoga and Pilates), patient and parent education,
and a motivational movie of the life of a disabled athlete. Endpoints include
change in the visual Likert scale of the modified ROME criteria, (considered
the gold standard for IBS assessment) and change in medication use. Thera-
peutic response to the program was assessed at completion of the 3rd session
by a change in Likert score from baseline. To minimize placebo effect, scores
were also obtained at 3 and 6 months after completion of program.
Results: 61 subjects completed the program. At the time of writing the
abstract, completed scores were available for 57 subjects pre-intervention,
42 immediately post intervention, 21 at 3 months and 11 subjects at 6 months.
A paired t- test was performed on pre and post intervention scores that were
available on 40 subjects, and a statistically significant reduction in each
ROME Criterion was demonstrated (5.7 ± 1.98 vs. 4.0 ± 2.23 P = 0.003,
3.1 ± 2.84 vs 2.0 ± 2.24 P = 0.000, 3.6 ± 2.86 vs.2.4 ± 2.16 P = 0.002, 4.1 ±
2.68 vs 3.15 ± 2.32 P = 0.002). Mean total Likert scores were 14.6 ± 8.48
at baseline, 11.1 ± 6.85 post intervention, 8.9 ± 6.65 at 3 months and 11.1 ±
8.72 at 6 months. Reduction in Likert scores was found to be statistically
significant post intervention and at 3 months by repeated measures ANOVA
(P = 0.006). No significant difference was found between scores at 3 and 6
months.
Conclusion: A behavioral intervention program targeting adolescents with
IBS and their parents results in symptomatic improvement that is persis-
tent 6 months after completion of the program. Analysis of data regarding
utilization is in progress.
1082
Mucosal Cytokine Imbalance in Irritable Bowel Syndrome (IBS)
Eamonn M. Quigley, MD∗, John McSharry, PhD, Liam O’Mahony, PhD,
Aine Fanning, PhD, Emer Bairead, PhD, Paul Scully, PhD, Jay Tiesman,
PhD, Andy Fulmer, PhD, Timothy Dinan, MD, Graham Sherlock, PhD,
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Fergus Shanahan, MD. Alimentary Pharmabiotic Centre, University
College Cork, Cork, Ireland; Alimentary Health Ltd, Kinsale, Cork, Ireland
and Miami Valley Innovation Centre, Procter & Gamble, Cincinnati, OH.
Purpose: The diagnosis of IBS currently relies solely on patient history and
the exclusion of the many disorders which may share its symptomatology; no
reliable validated biomarker exists. Recently, however, evidence for immune
activation, including alterations in systemic levels of certain cytokines, has
been reported in IBS. However, the immune status of the intestinal mucosa,
in IBS, remains relatively unexplored. Our aim was to systematically exam-
ine mucosal biopsies for changes in cytokine gene expression and protein
secretion.
Methods: The study population consisted of 59 females with IBS and 39,
otherwise healthy, female volunteers attending for colonoscopy. Colonic
biopsies from subsets of these were studied by microarray analysis (IBS
N = 9; controls N = 8), quantitative RT-PCR (IBS N = 22; controls N =
21), and ex vivo biopsy culture (IBS N = 28, controls N = 10). Biopsies
from patients with active colitis were used as inflammatory disease controls
(IBD; Ulcerative colitis, UC N = 20; Crohn’s CD N = 8).
Results: While, as expected, gene array analysis revealed extensive overlap
between controls and IBS patients, a reduced expression of genes linked to
chemokine function was evident among the IBS patients alone. Differential
expression was confirmed by quantitative RT-PCR, or ex vivo biopsy culture
for 5 of 6 selected genes. Reduced secretion of chemokines (IL-8, CXCL-9
and MCP-1) but not pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β)
was established on the basis of results from the ex vivo biopsy cultures.
These findings, in the IBS patients, were in marked contrast to changes
in expression of the same cytokines in the patients with active IBD where
there was increased production of both chemokines and proinflammatory
cytokines.
Conclusion: Despite the expected heterogeneity of the disorder, differences
in mucosal chemokine signalling were evident in this cross-sectional study
of IBS patients, at the level of both gene expression and protein secretion,
with IBS patients demonstrating a consistent deficit in the expression and
secretion of chemokines known to play a critical role in mucosal defence.
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Test of Brain-Gut Axis in Humans Using Cortical Evoked Potentials
and Trans-Cranial, Trans-Lumbar, and Trans-Sacral Magnetic
Stimulation and Its Reproducibility
Jose Remes-Troche, MD, Ashok Attaluri, MD, Jessica Paulson, Satish Rao,
MD∗. Gastroenterology, Univ of Iowa, Iowa City, IA and Neurology, Univ
of Iowa, Iowa City, IA.
Purpose: Cortical Evoked Potentials (CEP) following anorectal electri-
cal stimulation, and Trans-cranial (TC-MEP), Trans-lumbar (TL-MEP) and
Trans-sacral (TS-MEP) motor evoked potentials (MEP) following magnetic
stimulation may assess cortical and brain gut interactions, but has not been
comprehensively evaluated.
Aim: To examine the feasibility and reproducibility of CEP, TC-MEP, TL-
MEP and TS-MEP tests.
Methods: Five healthy humans (3 females, mean age 38 years) underwent
a baseline assessment (Test 1) followed by a repeat assessment (Test 2)
after 3 months. Afferent pathway was assessed by CEP following electrical
stimulation of the anus and rectum with a probe containing 2 pairs of bipolar
ring electrodes. CEPs were recorded (Cz-Fz) at 2000 Hz with an epoch
duration of 500 ms. Efferent brain-gut function was assessed by recording
rectal and anal MEPs following magnetic stimulations with 70 mm coil
(Magstim) at 80–100% intensity, positioned over each side; 1–3 cm around
the vertex of the skull (TC-MEP), 5 cm lateral to the spinal cord at L4-L5
(TL-MEP), and 5 cm lateral to S1-S3 (TS-MEP). CEP responses (P1, N1,
P2, N2) were analyzed and the onset of N1 (ms) was used to determine CEP
latency. Amplitude was measured as peak-to-peak voltage (mV) of evoked
response.
Results: Mean data for tests 1 and 2 are shown in Table. Bland-Altman plots
showed good agreement between tests for the CEP latencies and for tran-
scranial, translumbar and transsacral MEPs, with a coefficient of variation
(CV) of <10% (standard deviation < 10% of mean). The amplitude of CEP
and MEP responses showed modest agreement (CV = 15–25%).
Conclusion: Combined CEP and MEP studies are feasible and reproducible,
both for mapping the entire brain-gut pathway as well as the regional brain-
gut segments. This test of brain-gut axis is a simple, inexpensive and valid
method of examining anorectal-cortical physiology and may facilitate de-
tection of segmental dysfunction in colorectal disorders.
Latencies (ms) Amplitude (µV)
Rectum Anus Rectum Anus
Test 1, Test 2 Test 1, Test 2 Test 1, Test 2 Test 1, Test 2
TC-MEP 21.5, 20.3 21.7, 22.4 16, 34 20, 31
TC-MEP 3, 3.2 3.2, 3.6 15, 24 20, 24
TS-MEP 2.5, 2.6 2.8, 2.9 18, 19 20, 26
CEP 104, 99 106, 101 4.8, 5.5 3.2, 4.0
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What Do Internal Medicine Residents Know about Irritable Bowel
Syndrome?
Baseer Qazi, MD, Naser Khan, MD, Amit Gupta, MD, Kenneth O’Riordan,
MD∗. Medicine, Division of Gastroenterology, Advocate Lutheran General
Hospital, Park Ridge, IL.
Purpose: To assess the ability of internal medicine residents to diagnose
and manage irritable bowel syndrome.
Methods: Eight multiple-choice question survey of forty three residents. 1.
Which of the following clinical criteria is most appropriate for diagnosing
irritable bowel syndrome? 2. What is the prevalence of irritable bowel syn-
drome in the general population? 3. Is irritable bowel sydrome a diagnosis of
exclusion? 4. For patients diagnosed with irritable bowel syndrome, which of
the following is the best recommended diet modification? 5. Of the patients
diagnosed with irritable bowel syndrome, what is the likelihood that these
patients have real organic disease? 6. Is a colonoscopy required to make a
diagnosis of irritable bowel syndrome? 7. Allosetron, a 5HT-3 antagonist,
is used as a treatment for diarrhea predominant irritable bowel syndrome.
However, its use is limited because of. . .? 8. What are the initial laboratory
tests recommended by irritable bowel syndrome experts?
Results: 13% (6 residents) knew the names of the diagnostic criteria. 46%
(20 residents) were aware of the prevalence of irritable bowel syndrome
(1). However, only 13% (6 residents) were aware that irritable bowel syn-
drome is not a diagnosis of exclusion(2). 44% (19 residents) were aware
of the recommended dietary modification in irritable bowel syndrome. 20%
(10 residents) were aware of the prevalence of organic disease in patients
with irritable bowel syndrome and when asked whether a colonoscopy was
required to make a diagnosis of irritable bowel syndrome, 16% (7 resi-
dents) answered yes; 67% (29 residents) answered no; while the remaining
16% answered variable (1). 11% (5 residents) knew ischemic colitis was
an adverse reaction to allosetron. No resident was able to correctly iden-
tify the initial laboratory tests recommended by irritable bowel syndrome
experts (2).
Conclusion: Internal medicine residents are suboptimal in all aspects of ir-
ritable bowel syndrome. With the proposed changes in ambulatory medicine
and block scheduling (3), we believe gastroenterologists should play a cen-
tral role in subspecialty ambulatory training. 1. Brandt, L et al, Systematic
Review on the Management of Irritable Bowel Sydrome in North America.
Am Jour of Gastro Vol. 97, no.11 Sup 2002. 2. Bates, B, IBS Diagnosis Con-
troversial, Despite Guidelines, Internal Medicine News, Jul 15th 06; 58. 3.
Fitzgibbons, J et al, Redesigning Residency Education in Internal Medicine:
A Position Paper from the APDIM. Ann Intern Med, Jun 06; 144: 920 – 926.
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Prevalence of Irritable Bowel Syndrome in an Older Bi-Racial
Population
Carline Quander, MD, MS∗, Martha Clare Morris, ScD, Julia L. Bienias,
ScD, Denis A. Evans, MD. Internal Medicine, Rush University Medical
Center, Chicago, IL and Rush Institute for Healthy Aging, Rush University
Medical Center.
Purpose: There is limited data on the prevalence of irritable bowel syndrome
in the elderly, particularly among older blacks. In a large community study
of elderly, we describe the prevalence of irritable bowel syndrome and its
association with age, gender, race and education.
Methods: Study subjects are participants in the Chicago Health and Aging
Project, a population based study of residents aged 65 years and older of a
geographically defined area. In the period 2002–2005, 5273 in-home inter-
views were administered. The interview included items on gastrointestinal
symptoms applying the ROME II criteria.
Results: Irritable Bowel syndrome was seen in 225 of 4058 participants
yielding an overall prevalence of 4.3%. In a logistic regression model in-
cluding terms for age, gender, race and education we found the prevalence
of irritable bowel syndrome was significantly higher with female gender
(OR = 1.4; 95% CI; 1.04,1.9), black race (OR = 2.0; 95% CI 1.4, 2.8),
increasing age (OR = 1.02; 95% CI 1.001,1.04) and lower education (OR =
0.78; 95% CI 0.63,0.96).
Conclusion: The prevalence of irritable bowel syndrome may be higher in
females, blacks, and individuals with lower educational attainment.
Multiple-Adjusted Odds ratios (95% confidence interval)
for Prevalence of IBS by age, sex, race and education.
Chicago Health and Aging Project 2002–2005.
Odds Ratio; (95% CI)
Age (years) 1.02; (1.001, 1.04) P = 0.04
Female Sex 1.4; (1.04, 1.9) P = 0.03
Black Race 2.0; (1.4, 2.8) P < 0.0001
Education 0.78; (0.63, 0.96) P = 0.02
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Pregabalin Ameliorates Abdominal Pain from Adhesions
Ann Silverman, MD∗, Helen Gikas, RN, Qiana Samuels, BA, Martin
Zonca, MD. Dept. of Internal Medicine, Div. of Gastroenterology, Henry
Ford Health System, Detroit, MI.
Purpose: Abdominal pain from adhesions is a common post-surgical prob-
lem. Re-operation for this condition does not afford long-term pain relief
in most patients. Many patients require life-long narcotic therapy that re-
duces their quality of life. Pregabalin is a drug that is structurally related to
gabapentin but has linear pharmacokinetics in the therapeutic range and is
FDA approved for the treatment of conditions with neuropathic pain such as
postherpetic neuralgia. We have successfully treated patients with abdom-
inal pain from adhesions with gabapentin for many years. The purpose of
this study was to determine if pregabalin ameliorates abdominal pain from
adhesions.
Methods: We designed a double blind placebo controlled 12-week crossover
study with pregabalin to treat patients with abdominal pain and documented
adhesions and a negative evaluation for chronic abdominal pain. The first 8
weeks is a randomized placebo controlled trial. During the final 4 weeks all
patients are offered open label pregabalin. The primary objective of the study
is to determine whether pregabalin demonstrates a statistically significant
reduction in abdominal pain as recorded on an 11 point Likert scale. The
secondary objective is to determine improvement in average daily sleep
scores (0–11).
Results: 13 patients have enrolled in the study and 8 patients have com-
pleted the open label portion. Because we have seen marked improvement in
patients on open label pregabalin, we report the open label findings to date.
The pre-treatment mean pain score was 6.09 SD 0.86 and the post-treatment
mean was 2.08 SD 1.97 (paired t test = 0.001). 7/8 patients had a mean drop
in daily pain score during the open label treatment by 2 points and 6/8 had
a mean drop of at least 3 points. The pre-treatment sleep interference score
was 5.08 SD 1.11 and the post-treatment mean was 1.48 SD 1.64 (paired
t-test < 0.001). 7/8 patients had a mean decline in daily sleep score of at
least 2 points.
Conclusion: The open label portion of the trial suggests that pregabalin
may be an effective treatment for abdominal pain from adhesions. Further
conclusions await the results of the randomized blinded portion of the study.
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Satisfaction with Laxatives in Chronic Constipation (CC) and Irritable
Bowel with Constipation (IBS-C)
Thao Nguyen, MD, Olafur S. Palsson, PsyD, Michael von Korff, ScD,
Andrew D. Feld, MD, Rona L. Levy, PhD, Marsha J. Turner, MS, William
E. Whitehead, PhD∗. University of North Carolina at Chapel Hill, NC;
Group Health Cooperative of Puget Sound, Seattle, WA and University of
Washington, Seattle, WA.
Purpose: Determine frequency of using laxative regimens, perceptions of
effectiveness, and satisfaction with laxative treatment in patients with CC
and IBS-C.
Methods: HMO patients were recruited into 2 groups: those with a clini-
cal diagnosis of constipation (564.0×) in the last year vs. those without a
diagnosis of constipation for the previous 5 years. Questionnaires identified
subjects in both groups meeting Rome III criteria for CC or IBS-C. Subjects
with CC or IBS-C but without a medical diagnosis of constipation were
designated non-consulters. This was a postal survey.
Results: There were 444 CC subjects and 318 IBS-C (consulters and non-
consulters pooled). Groups were similar in race, ethnicity, education, and
income. However, CC were older (mean age 70 vs. 61 years, P < 0.001) and
more likely to be male (34% vs. 21%, P < 0.001) and widowed (20% vs.
13%, P = 0.01).
CC were more likely than IBS-C to consult physicians (53 vs. 41%, P =
0.001) and less likely to use prescription laxatives (14% vs. 20%), P = 0.01),
over-the-counter laxatives (24% vs. 37%, P < 0.001), fiber supplement (28%
vs. 44%, P < 0.001), herbs (5% vs. 12%, P = 0.002), special diets (8% vs.
20%, P < 0.001), alternative therapy (0.5% vs. 4%, P = 0.001), exercise
(17% vs. 29%, P < 0.001) or lifestyle changes (3% vs. 6%, P = 0.02).
When they did use laxatives, CC reported greater satisfaction (55% vs. 36%
very or extremely satisfied; P = 0.004) and less severe side effects (SEs;
3% vs. 13% very or extremely severe; P < 0.01). There were no differences
in effectiveness (44% vs. 40% calling laxatives very or extremely effective;
P = 0.21).
When consulters were compared to non-consulters within the CC and IBS-C
groups, there were no differences in effectiveness, SE severity, or satisfaction
with laxatives.
Ordinal regression tested the combined effects on satisfaction with laxatives
of age, gender, race, consultation, diagnosis (CC vs. IBS-C), severity of SEs,
and perceived effectiveness. Significant predictors were perceived effective-
ness (P = 0.001), SE severity (P = 0.001), and diagnosis (P = 0.012). Total
variance explained was 57.7%.
Conclusion: Laxatives are equally effective in CC and IBS-C, but subjects
with CC have less severe Ses and are more satisfied with laxative treatment.
[Supported by Novartis Pharmaceuticals & R24 DK67674].
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High Dose Dexamethasone for Acute Idiopathic Gastroparesis
Eugene M. Cooper, MD, Jamie Barkin, MD∗. Division of
Gastroenterology, University of Miami/Jackson Memorial Hospital,
Miami, FL and Division of Gastroenetrology, Mount Sinai Medical Center,
Miami Beach, FL.
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Purpose: The management of acute idiopathic gastroparesis continues to
be a challenge for many practicing physicians. Antiemetics and prokinetic
agents (dopamine-2 antagonists, 5-HT4 agonists, macrolides) are commonly
considered first line therapy, but may provide only marginal benefit. In ad-
dition tolerance and untoward side effects limit their long-term use.
High dose dexamethasone alone or in combination with antiemetics is a
mainstay in the treatment of chemotherapy induced nausea and vomiting,
but to our knowledge has not been shown to be effective for idiopathic
gastroparesis.
We report 3 patients that presented with nausea, vomiting and gastroparesis
refractory to antiemetics and prokinetics. The duration of symptoms ranged
from 2 weeks to 2 months prior to the initiation of therapy. Patients 1 & 2
received an exhaustive work-up that included Computed Tomography (CT)
and Magnetic Resonance Imaging of the brain, as well as CT scans of the ab-
domen and pelvis. Patent 3 was 18 weeks gestation at the time of evaluation,
and declined radiographic imaging. Evaluation of all diagnostic information
failed to result in a diagnosis. Gastric emptying scintigraphy with 99MTc
colloid-labeled egg sandwich in patients 1 & 2 showed less than 23% and
19% gastric emptying at 2 hours. Both were started on parenteral nutrition
after no initial improvement.
Dexamethasone 4 mg intravenously twice daily was eventually started in
all three patients and resulted in prompt resolution of symptoms within 72
hours. All patients were eventually converted to the oral dexamethasone
and discharged with a tapering dose over several weeks. All three patients
remained asymptomatic at 8 week follow up.
We conclude that high dose dexamethasone may be a safe and effective
adjunct to standard first-line therapy in the treatment of refractory idiopathic
gastroparesis. Further investigation to determine its direct effects on gastric
emptying is warranted.
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Predictors of Response in Gastroparesis
Rajeswari Anaparthy, MD, Nonco Pehlivanov, MD, Price Sonia, RN,
Pasricha Jay Pankaj, MD∗. Department of Internal Medicine, University
of Texas Medical Branch, Galveston, TX and Department of
Gastroenterology, Internal Medicine, University of Texas Medical Branch,
Galveston, TX.
Purpose: Natural history and outcomes of gastroparesis are not well known
and the response to treatment is variable. We aim to determine which clinical
features could help identify patients with response to therapy.
Methods: 69 patients were included. Symptoms were scored using the Gas-
troparesis Cardinal Symptom Index, a validated scale of severity that utilizes
three clusters (nausea/vomiting, post-prandial fullness/satiety, and bloating).
Gastric emptying was measured using a standard 4-hour low fat solid meal.
Treatment included conservative measures like antiemetics, prokinetics, an-
tidepressants, analgesics. Interventions included enteral feeding and pacing
in selected patients. Response to treatment was defined as overall change in
GCSI score of 33% or more as compared with baseline.
Results: 29 out of 69 patients had diabetes. 40 had idiopathic gastroparesis.
49 were responders (71%). 20 were non responders (29%). Amongst re-
sponders 17 (34.69%) patients required enteral feeding and 10 (20.41%) pa-
tients underwent enterra placement as opposed to 8(42.11%) and 4(21.05%)
respectively in non responders. 52 patients had delayed gastric emptying
(75%). Proportion of responders was not different amongst patients with
delayed or normal emptying. Demographic characteristics or subtype of gas-
troparesis (diabetic/idiopathic) did not significantly differ among responders
and non-responders. Baseline scores for nausea, vomiting and retching were
similar. However, baseline scores for early satiety (P = 0.02), postprandial
fullness (P = 0.05), stomach distension (P = 0.0001) and bloating (P =
0.01) were significantly greater in non-responders.
Conclusion: Majority of patients with gastroparesis improve with therapy.
Specific symptoms seem to be of a predictive value, with severity of early
satiety, postprandial fullness, stomach distension and bloating being signifi-
cantly higher in non responders than responders. On the other hand, neither
the type of gastroparesis nor gastric emptying pattern appeared to predict
response. Future studies are needed to investigate whether the clinical phe-
notype of non-responders is associated with distinctive changes in gastric
pathophysiology.
ENDOSCOPY
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Colonoscopy Outcome Can Be Improved by Using Multiple
Assessment Criteria
Elmuhtady M. Said, MBBS, Rangarajan Kasturi, MRCP, Muhammad
Ayub, MRCP, Muthirulandi Kasimanickam, MBBS, Anand Reddy, MRCP,
Singh Jitendra, MRCP, Athar Saeed, FRCP∗. Gastroenterology, Queen
Elizabeth Hospital, Gateshead, Tyne and Wear, United Kingdom and
Gastroenterology, St. Luke’s Hospital, Middlesbrough, Cleveland, United
Kingdom.
Purpose: An audit of colonoscopy performance in out unit, using Endosoft
database.
Methods: A retrospective audit of colonoscopy practice, Jan- June 2006,
for these criteria: 1) Completion rate: Completion of colonoscopy to cecum,
terminal ileum or surgical anastomosis, regardless of bowel prep or stenosing
lesion. 2) Histology proven lesion rate: Composite standard, incorporating
lesion identification, excision or biopsy, retrieval and positive histology for
colorectal cancer or adenoma. 3) Use of sedation and analgesia: Mean dose
per procedure of midazolam and pethidine, for every endoscopist.
Results: 1) The unadjusted completion rate 82.5 percent, (significantly dif-
ferent among 10 endoscopists, range 64.71% to 90.43%), (Pearson Chi Sq
30.08, Degrees of Freedom 9 p0.000). 2) The histology proven lesion rate
10.36, (range 1.96 to 17.95). Difference among endoscopists was not sig-
nificant, (Pearson Chi Sq 5.41, DF 9 P = 0.79). total number 181 and it
is likely that it lacks power. 3) The mean dose of midazolam for all proce-
dures 3.26 mg, (range of mean 2.31 to 4.36). On analysis of variance:F 1.18
P = 0.299. The mean dose for pethidine 33.84 mg, (range of mean 25.8 to
43.3) On analysis of variance; F 1.67 P = 0.076. There was no significant
difference for either drug 4) The correlation of midazolam and pethidine
doses: Positive, the adjusted R sq 0.18 and Probability of F 0.000. (Linear
Regression). so when a higher dose of one drug associated with higher dose
of the second drug was used. 5) The completion rate was not correlated
with dose of pethidine and midazolam. (Binary Logistic Regression). The
odds ratio with CI: Pethidine 1.00 (0.9933306 to 1.022065), Midazolam
0.9469825, (0.7909089 to 0.133855) 6) The histology proven lesion rate
was positively related to completion rate. The weighted measures for total
procedures were highly correlated with R square of 0.72 and probability of
F 0.001.
Conclusion: There is a significant variation in colonoscopy performance.
Smaller doses of sedation and analgesia are used as compared to the past.
Use of larger dose of one drug is associated with a larger dose of the other.
Better performance in completion is not associated with use of higher dose of
medications. Lesion detection and performance in completion are positively
correlated. A cumulative rank table in these performance criteria may be
used to monitor and improve outcomes.
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Endoscopic Necrosectomy as a Primary Treatment Modality for
Pancreatic Abscess
Kevin P. Meitz, DO, Abraham Mathew, MD∗. Gastroenterology &
Hepatology, Hershey Medical Center/Penn State Unviersity, Hershey, PA.
Purpose: Previous case series have reported successful treatment of pan-
creatic abscess and necrosis with repeated necrosectomy in non-operative
candidates. We report our expierence with endoscopic necrosectomy in a
single session as a primary modality in treating six patients with pancreatic
abscess.
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Patient Characteristics and Outcomes
Post Complete Resolution/Asymptomatic/
Age/Etiology Abscess Size (cm) Total LOS Procedure LOS Unrestricted Diet (months)
54/biliary 8.5 × 2.7 10 8 TPN; intermittent nausea/abd discomfort; 2.4 × 6.6 cyst (1)
62/biliary 18 × 9 10 8 yes (5)
16/biliary 13.1 × 6.8 15 6 yes (3)
36/biliary 17 × 8 with extension into psoas 24 24 IDDM, pancreatic enzymes (3)
77/biliary 10 × 1.3 27 24 yes; 2.3 cm cyst (4)
43/idiopathic 13.5 × 6.9 18 4 yes; small ill-defined area (9)
LOS: length of stay
Methods: Six patients with pancreatic abscesses between April 2006 and
February 2007 were offered endoscopic necrosectomy as primary treatment.
All patients were informed of the limited experience with this approach and
informed that surgical intervention is considered standard of care. Utilizing
a linear array echoendoscope, a site was selected free of intervening vessels.
Transmural puncture was performed with a 19 gauge needle followed by
insertion of a 0.035 inch guidewire into the abscess. After sequential dilation
over the wire the echoendoscope was exchanged for a standard gastroscope,
which was used to enter the abscess. A single session necrosecotomy was
performed with a standard snare, retreival net and/or biopsy forceps. Upon
completion of the necrosectomy, two double-pigtailed stents were placed.
Results: See table 1. Surgery was avoided in all patients. The median size of
abscess was 13.3 cm. Three of the patients had undergone cystgastrostomy
stent placement prior to the necrosectomy. Nasocystic lavage was performed
in 4 of the 6 patients. There were no peri-procedural complications. Mean
follow-up was 3.5 months. Four of the 6 are tolerating an unrestricted diet
and all have noted an increase in weight. Three of the 6 have completely
resolved fluid collections on repeat CT scan. One patient developed insulin
dependent diabetes and requires pancreatic enzymes for steatorrhea. One
patient developed an ulcer at the cystgastostomy site, resulting in a minor
gastrointestinal bleed that was treated without complication.
Conclusion: Endoscopic necrosectomy appears safe and effective as a pri-
mary treatment in patients with pancreatic abscesses. Randomized studies
are warranted.
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Prophylactic Antibiotic Usage in Endoscopic Retrograde
Cholangiopancreatography (ERCP): A Meta-Analysis and Systematic
Overview
Faisal A. Bukeirat, MD∗, Rubayat Rahman, MD, MPH. Digestive
Diseases-Medicine, WVU School of Medicine, Morgantown, WV.
Purpose: Considerable controversy exists regarding the role of prophylactic
antibiotic administration prior to endoscopic retrograde cholangiopancre-
atography (ERCP). The aim of this meta-analysis is to analyze the data in
order to determine whether antibiotic prophylaxis reduces the rate of oc-
currence of bacteremia and/or the rate of sepsis/cholangitis among patients
undergoing ERCP.
Methods: Using PubMed, Medline, Embase, Current Contents, and the
Cochrane Database of Systematic Reviews databases (OVID), a literature
search was performed for papers published from January 1980 to Decem-
ber 2006. All retrieved papers comparing afromentioned outcomes with and
without prophylactic antibiotic before ERCP were rated according to the
strength of evidence and carefully analyzed.
Results: A total of 9 studies met the inclusion criteria for the meta-analysis.
All the studies were randomized and prospective. Total of 1547 subjects were
included in the analysis. 764 (49%) received prophylactic antibiotics and
783 (51%) received placebo. There was no statistical significant difference
between the two groups at base line. Relative risk (RR) for bacterimia was
2.65 times higher and for cholengitis/sepsis was 1.76 times higher in placebo
group than antibiotic group. RR for any of the above mentioned complication
was 2.02 times higher in placebo group than antibiotic group.
Conclusion: Antibiotic prophylaxis prior to ERCP reduces the incidence
of bacteremia, cholengitis and sepsis substantially. Our analysis concludes
that the routine use of antibiotic prophylaxis should be recommended for
all patients undergoing this procedure with a therapeutic intension, as no
one does diagnostic ERCPs any more. The Choice of antibiotics used is
based on published national guidelines, as well in keeping up with the local
microbiology results and trends in the specific medical institution, which is
revised on annual basis. In our own institution, we give one dose of IV
unasyn 3 grams IV prior to the procedure; alternatively IV gentamycin
(5 mg/Kg) and vancomycin (15 mg/Kg) are used if patient is allergic to
penicillins.
Key word: [Antibiotic prophylaxis, ERCP, cholengitis, sepsis, relative9 risk]
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A Simple Method for “Spontaneous” Colon Decompression during
Colonoscopy
Joseph C. Yarze, MD, FACP, FACG FASGE∗. GI Division,
Gastroenterology Associates of Northern New York, Glens Falls, NY.
Purpose: To describe a simple method for colon decompression during
colonoscopy. The anecdotal benefits of this maneuver are described.
Methods: During colonoscopy, if ambient air is utilized as the insufflating
agent, this may be associated with more prolonged post-procedure cramping
and belly distention. I have devised a method for simple, “spontaneous” colon
decompression, which I employ routinely as the colonoscopic procedure is
nearing completion (and at times, earlier during the procedure). I term this
“spontaneous,” as it does not involve use of endoscopic suction.
During colonoscope withdrawal, the rubber biopsy valve is removed from
the instrument channel port, which is located on the end of the endoscope
grip section (and a gauze pad is placed over the area), to allow spontaneous
passage of colon gas to the atmosphere. I sometimes place my right hand over
the abdomen (while the colonoscope is being held with the left hand), and
gentle transabdominal pressure usually facilitates more voluminous “spon-
taneous” transendoscopic gas egress. Sometimes, a couple of “taps” on the
suction valve are used to initiate gas egress (the suction channel sometimes
needs to be cleared of debris).
Results: By repeating this maneuver a few times during the withdrawal
phase of colonoscopy, the patient usually reaches the recovery area more
comfortably, and with minimal if any belly distention. The maneuver is also
employed after traversing a “difficult sigmoid”-when rapid proximal colon
decompression is desired to avoid the potential effects of barotrauma. I also
find the maneuver particularly helpful after a prolonged procedure, or one in
which a large polyp was removed in piecemeal fashion. Hearing the promi-
nent “spontaneous” passage of colon air through the instrument channel port
gives me certitude that perforation is very unlikely to have occurred. Under
the circumstances outlined, the colonoscope is simply acting as a “pressure
bridge” between the colon and the atmosphere (the anal sphincteric mecha-
nism is now not acting as a resistive factor to colon decompression). In this
situation, free egress of air through the colonoscope, in association with the
Abstracts S519
patient having a soft belly at the conclusion of colonoscopy, gives me- sat-
isfaction and certitude, my patient-more comfort, and the nurse overseeing
recovery-a less painstaking task.
Conclusion: The “spontaneous” colon decompression method described
above is a useful adjunct to the standard colonoscopic procedure. It is easy
to perform, safe to employ and provides the multiple potential advantages
noted.
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Prospective Colonoscopy Major Complication and Completion Rates
by a Community Practitioner
Joseph C. Yarze, MD, FACP, FACG FASGE∗. GI Division,
Gastroenterology Associates of Northern New York, Glens Falls, NY.
Purpose: To report prospective data relating to colonoscopy major compli-
cation and completion rates by a single community practitioner.
Methods: Study includes results relating to all colonoscopic procedures
performed by a board-certified community gastroenterologist (in practice
16 years). Exams were performed between 2/1/06 and 3/15/07. Informed
consent was obtained prior to each procedure. Olympus instruments used in-
cluded CFQ160L, CFQ180AL, PCF140L and on 4 occassions, GIFQ160L.
Instrument was chosen at the discretion of the endoscopist, who was able
to change endoscopes. Patients avoided ASA/NSAID’s for 7 days prior to
elective examinations. Warfarin anticoagulation was managed according to
guidelines. Polyps <1 cm were most often removed with cold-snare. Major
complications were prospectively captured utilizing mechanisms in place at
the community hospital and outpatient office endoscopy unit (OEU), where
> 99% of colonoscopic procedures were performed. At the hospital, the
QI department routinely screens all hospital admissions, as well as charts
of patients continuously hospitalized for major complications (including
post-procedure hemorrhage, perforation, cardiorespiratory events, events re-
quiring surgical management and post-polypectomy syndrome). Prospective
monitoring is also in place in the OEU [3-day post-procedure phone interview
and 30-day patient satisfaction mailing (includes questions which would trig-
ger further investigation if a complication was suspected)] to capture major
procedure-related complications. Patients were provided with phone con-
tact information and written instructions relating to signs and symptoms,
which would suggest a possible complication. Colonoscopy completion was
documented by the gastroenterologist performing the procedure. “Comple-
tion” required intubation of the cecum or passage of the colonoscope to the
ileocolonic anastomosis, and was documented by photographs (appendiceal
orifice, ileum, ileocecal valve, ileocolonic anastomosis or any combination).
Results: From 2/1/06 to 3/15/07, 1403 colonoscopic procedures were per-
formed. Colonoscopy was complete in 1391/1403 = 99.1%. Reasons for
an incomplete exam included: diverticular disease (4), poor preparation
(3), severe ischemic colitis (2), malignant obstruction (1), abdominal wall
hernia (1), obesity/colon redundancy (1). (1) major complication (post-
polypectomy hemorrhage) occurred.
Conclusion: Colonoscopy can be performed safely in the community set-
ting and with results comparable to those published by experts in academic
settings.
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ERCP-Associated Pancreatitis: Systematic Evaluation of 99,483 ERCP
Procedures with Qualitative Meta-Analysis
Nirmal S. Mann, MD, FACG∗, John D. Ward, MLS. Gastroenteroloy, UC
Davis, Sacramento, CA and Med Library, UC Davis, Sacramento, CA.
Purpose: ERCP-associated pancreatitis (EAP) is a serious complication of
ERCP. Contradictory data exist regarding prevention of ERCP. We did a
systematic eval of 99,483 ERCP procedures with qualitative meta- analysis
(Meta-ethnography).
Methods: PubMed Search for ERCP with no language barrier (1995–2006)
was done. Also PubMed Search for”PostERCPpancreatitis”was done. More
papers on EAP were added manually. Depending on the quality, trials were
classifiedLevel1–4. Meta-ethnography by Qualitative research methods was
performed (Eval Rev 9:627–643, 1985:The Lancet 358:483–488, 2001)
Results: From 1995 to 2006, there were 6140 citations for ERCP;5193(85%)
were in English. There were 203 citations for EAP;29 more papers on
EAP were added manually. Detailed eval of 232 papers was done:Summary
shheets were created. The total no. of ERCP procedures was 99,483; EAP oc-
curred in 4535 (4.5%, range 0.2–33%; Median 6.2%) cases. Gender info was
available in 34,951;20,062 (57%) were women. Mean age was 55.6 yrs. Phar-
macologic interventions to prevent EAP included somatostatin, Octreotide,
gabexate, ionic vs non-ionic contrast media, prednisone, allopurinol, hydro-
cortisone, glucagon, calcitonin, atropine, n-acetylcysteine, nifedipine, glyc-
eryl trinitrate, 5FU, Lidocaine or epinephrine spray, botulinum toxin, ulinas-
tatin, aprotinin, beta-carotene, S.Q. heparin, diclofenac, indocin (Rect Supp),
secretin, prophylactic antibiotics, interleukin-10 antag, monoleukast Na, H-
2 receptor antag, CCK antag, lexipanphate (PAF inhibitor) & oral tetra-
cycline. In general pharmacologic methods were ineffective:somatostatin,
gabexate, Ulinastatin showed promise. Osmolality of Contrast media had no
effect on EAP. Endoscopic methods included suprapapillary needle punc-
ture, transpapillary septotomy, biliary sphincterotomy, prophylactic pancre-
atic stent (PPS). The PPS seems effective in preventing EAP: however a
failure to put an attempted SSP more likely will result in SEVERE EAP. The
risk factors for EAP are:female gender, young age, precut sphinct, balloon
dilation of papilla, SOD, difficult cannulation, pancreatic injection, normal
bilirubin, previous h/o EAP.
Conclusion: The frequency of EAP is 4.5%; range 0.25 to 33%; median 6.5%
Pharmacologic methods to prevent EAP unsatisfactory. PPS is effective but
has important caveat. Risk factors for EAP should be recognized.
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Endoscopic Ultrasonographic Evaluation of Hemodynamics in
Esophageal Variceal Patients Related to Early Variceal Relapse
Takahiro Sato, MD∗, Katsu Yamazaki, MD, Jouji Toyota, MD, Yoshiyasu
Karino, MD, Takumi Ohmura, MD, Jun Akaike, MD. Gastroenterology,
Sapporo Kosei General Hospital, Sapporo, Japan.
Purpose: We evaluated retrospectively the hemodynamics of esophageal
varices before and after endoscopic injection sclerotherapy (EIS) and inves-
tigated the influence of hemodynamics on variceal recurrence as revealed
by endoscopic color Doppler ultrasonography (ECDUS).
Methods: Patients were divided according to those with early recurrence
(Group A, N = 16) and those without recurrence over the long-term (Group
B, N = 12), and those without recurrence between 1 and 3 years (Group
C, N = 281). All 309 cases were examined by ECDUS before EIS and 3–5
months after EIS. We monitored the color flow images of blood vessels of
paraesophageal veins (PEV), perforating veins (PFV), and cardiac intramural
veins (CV) with ECDUS. PEV were classified as either shallow PEV or deep
PEV, and PFV were classified as either the inflowing or the outflowing type
or mixed type.
Results: Before EIS, the detection rates of blood flow in Group A were 16/16
(100%) for PEV, 12/16 (75.0%) for CV, and 13/16 (81.3%) for PFV. PFV
were inflowing type in 10 of 13 cases. The detection rates of blood flow in
Group B were 12/12 (100%) for PEV, 9/12 (75.0%) for CV, and 6/12 (50.0%)
for PFV. PFV were inflowing type in 3 cases and outflowing type in one case,
and mixed type in 2 cases. The detection rates of blood flow in Group C were
281/281 (100%) for PEV, 219/281 (77.9%) for CV, and 131/281 (46.7%) for
PFV. PFV were inflowing type in 69 cases and outflowing type in 31 cases,
and mixed type in 31 cases. The detection rates by ECDUS of PFV and
inflowing PFV in Group A were significantly higher than those in Group B
and C before EIS.
After EIS, the detection rates of blood flow in Group A were 16/16 (100%)
for PEV, 9/16 (56.3%) for CV, and 5/16 (31.3%) for PFV. PFV were the
inflowing type in all 5 cases. The detection rates of blood flow in Group B
were 11/12 (91.7%) for PEV, zero/12 (0%) for CV, and 2/12 (16.7%) for PFV.
PFV were of the outflowing type in all 2 cases. The detection rates of blood
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flow in Group C were 251/281 (89.3%) for PEV, 33/281 (11.7%) for CV, and
6/281 (2.1%) for PFV. PFV were of the outflowing type in all 6 cases. The
detection rates by ECDUS of CV, PFV, and inflowing PFV in Group A were
significantly higher than those in Group B and C after EIS.
Conclusion: ECDUS enables prediction of early recurrence of esophageal
varices based on hemodynamic findings before and after EIS.
1097
Natural History of the Mallory Weiss Tear in African-American and
Hispanic Patients
Abbasi J. Akhtar, MD∗. Internal Medicine/Gastroenterology, Charles R.
Drew University of Medicine and Science, Los Angeles, CA.
Purpose: The Mallory Weiss Tear (MWT) is an important cause of acute up-
per gastrointestinal bleeding (AUGIB). However it is usually perceived to be
a trivial, uncommon and rather benign lesion and often does not claim urgent
attention like other lesions such as peptic ulcers and esophageal varices. The
literature is scant about the natural history of MWT in African-American
and Hispanic patients, which are our predominant clients. Aim of our study
was to determine the natural history of MWT in these two ethnic groups.
Methods: Medical records of all patients with AUGIB were reviewed retro-
spectively over a 10-year period (January 1996- December 2005). Patients
were excluded if endoscopy was not done. Endoscopic diagnosis of MWT
was made in 12% (N = 698) of all patients with AUGIB. The information
abstracted included, primary diagnosis, endoscopic findings, clinical and lab-
oratory parameters, associated comorbidity, therapeutic interventions, and
outcome over 30 days.
Results: Of 698 patients with MWT who presented with AUGIB, 398 (57%)
did not have a preceding history of retching or vomiting. Bleeding episode
was hemodynamically significant (orthostasis, a drop of hemoglobin < 10
g/dl, and/or >6 U of blood transfused) in 216 (31%) patients. Alcohol,
male gender, smoking, substance abuse, chronic kidney disease, coagulopa-
thy, and chronic lung disease were positively correlated with MWT (P <
0.0001). Most of the patients with MWT (80%) had an unremarkable and
short hospital stay (1–4 days). Recurrent bleeding occurred in 84 (12%) pa-
tients, within 30 days. Endoscopic hemostasis was unsuccessful in 77 (11%)
patients, 38 (50%) of these patients), required surgical intervention. Overall
mortality was 10% (70 patients), 7% (49 deceased patients) being in en-
doscopic hemostasis failure group. Most of the deaths (85%) occurred in
patients with associated comorbidities. There was no significant difference
in natural history or outcome of MWT amongst African- American and
Hispanic patients.
Conclusion: MWT is a significant cause of AUGIB in African-American
and Hispanic patients. More than half of our patients with MWT did not
have preceding history of retching or vomiting. It can may be associated
with rebleeding, significant morbidity and notable mortality.
1098
Predictors of Rebleed in Actively Bleeding Duodenal Ulcer after
Endoscopic Intervention in a Developing Asian Country
Shahid Majid, FCPS, Ashfaq Ahmed, FCPS, Wasim Jafri, FRCP, FACG∗,
Adeel Nasir, MBBS. Medicine, Aga Khan University Hospital, Karachi,
Pakistan.
Purpose: To determine the predictors of rebleeding in patients with ac-
tively bleeding duodenal ulcers after combined adrenaline injection and ar-
gon plasma coagulation (APC).
Methods: Consecutive patients who were admitted from December 2003 to
March 2007 with actively bleeding duodenal ulcers were included. Endo-
scopic intervention with injection adrenaline and APC was done to achieve
complete hemostasis. Actively bleeding duodenal ulcers were classified on
the basis of Forrest criteria. Primary out come measure was post intervention
rebleed and secondary outcome measure was 30 days mortality.
Results: Total of 74 patients were analyzed, who required the endoscopic
intervention with injection adrenaline and APC, all achieved initial hemosta-
sis. Mean age was 53 ± 16 years with 79.7% were male. Mean Rockall score
before endoscopy was 2.0 ± 1.3 and post endoscopy was 5.08 ± 1.3. Mean
packed cell transfusion was 2.2 ± 1.83. Out of 74 patients 16(21.6%) rebled.
History of NSAID use was in11 (68.8%). Out of 16 in 8 (50%) hemostasis
was achieved endoscopically, while 6 underwent surgery and two needed
angio-embolization. Predictors of rebleed on multiple logistic regression
analysis are shown in table 1. Overall 30- day mortality occurred in 2 (2.7%)
patients, one died of sepsis while other due to posts surgery myocardial
infarction.
Conclusion: Forrest score 1, large ulcers, high rockall score and ulcers at D1
and D2 junction were independent predictors of rebleed in duodenal ulcers
after successful endoscopic intervention.
Independent Predictors of Rebleed in bleeding
duodenal ulcers after intervention
Adjusted 95% CI for
Odd Ratio Adjusted Odd ratio P-value
Rockall score
<5 † 1
≥5 6.5 1.00–43.09 0.04
Site of Duodenal Ulcer
D1 † 1
Junction of D1 and D2 8.5 1.23–59.17 0.03
Size of Duodenal Ulcer
<1.5 † 1
≥1.5 15.9 3.22–79.15 0.001
Forrest Criteria
Forrest II † 1
Forrest I 7.1 1.32–38.05 0.02
1099
Incidental Findings on Peg Placement May Indicate Procedure
Deferment
Jonathan M. Rieber, MD∗, Eugene Wong, MD. Medicine, Allen Pavillion
Hospital, Columbia University Medical Center, New York, NY.
Purpose: Percutaneous endoscopic gastrostomy (Peg) placement is often
performed in cases of persistent refusal to take in adequate intake or with
patients with difficulty in swallowing. These patients often suffer from de-
mentia and may be nonverbal. They are unable to communicate pain or
discomfort. Swallow studies are performed in part to document the degree
of dysphagia and to recommend PEG placement when indicated. Calorie
counts are also performed to document poor intake. These studies do not
address the underlying etiology for the patients change in appetite. A pa-
tients refusal to take in nutrition may be multifactorial. A possible treatable
gastrointestinal source may be the cause for the decreased oral intake.
Methods: We conducted a retrospective analysis of a 135 consecutive pa-
tients. These patients were admitted between 8/03 and 3/05. All patients
who underwent endoscopy for the purpose of PEG placement were included
regardless if placement was successful. None of the patients had previous
peg placement. The study was performed at a university teaching hospital
Results: A total of 131 out of 135 procedures were completed with success-
ful PEG placement. Two of the four patients who had placement deferred had
endoscopies where adequate landmarks for placement could not be identi-
fied. Two previously unknown gastric cancers were discovered at the time of
endoscopy in the remaining two patients who had unsuccessful placement.
A total of 7 duodenal ulcers, 6 gastric ulcers were noted. Other findings
included esophagitis (14), gastritis (28) and duodenitis (13)
Conclusion: Serious endoscopic findings are often found while PEG place-
ment is being performed. These findings may often explain why a patient
who suffers from dementia may refuse oral intake. Therapy such as proton
pump inhibitors may be effective in treating acute gastrointestinal problems
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allowing the resumption of adequate oral nutrition. Further prospective stud-
ies may be necessary to assess if treating such findings may obviate the need
for peg placement.
1100
The Frequency of Intraabdominal Metastasis Identified during EUS
Staging for Lung Cancer in a Community Setting
John C. Deutsch, MD∗, Madeline S. Pokorney, BA, Kirk P. Bernadino, MD.
Gastroenterology, St. Marys Duluth Clinic, Duluth, MN.
Purpose: Lung cancer staging is performed to determine whether aggressive
local therapy (surgery, curative-intent radiotherapy) should be undertaken or
if metastasis precludes this approach. Endoscopic ultrasonography with fine
needle aspiration (EUS-FNA) of the mediastinum is frequently performed
as part of this staging, both to obtain cell type and to identify extent of
nodal involvement. The aim of this study was to determine the frequency of
pathologically identified intraabdominal metastasis found during EUS-FNA
staging of lung cancer in a community setting.
Methods: A retrospective review was undertaken of all patients referred
to gastroenterology at St. Mary’s/ Duluth Clinic, Duluth, MN for EUS lung
cancer evaluation/staging from 2003 to 2006. Categorical data were recorded
including age, sex, cell type, sites of FNA, and whether pre-EUS imaging
(CT/PET) suggested intraabdominal metastasis.
Results: 101 individual subjects (70 with non-small cell, 30 with small
cell and 1 with mixed non-small cell/small cell cancer) were identified for
inclusion. Intraabdominal metastases were confirmed by FNA in 22 subjects,
most commonly the left adrenal (10/22, 45%) and the liver (9/22, 41%). Other
sites included pancreas, spleen, and abdominal lymph nodes. More than one
abdominal site was confirmed in 3 subjects (liver/adrenal, pancreas/adrenal,
periduodenal nodes/adrenal). In 7/22 (32%), the intraabdominal disease was
not suggested by pre-EUS imaging. Small cell cancer tended to be found
in the abdomen more commonly (11/30, 37%) than non-small cell cancer
(11/70, 17%), (P = 0.08). In 2 cases, CT suggested an abnormal adrenal that
was found to be benign by FNA, and these subjects underwent thoracotomy
with curative intent resection.
Conclusion: Intraabdominal metastases of lung cancer are not infrequent,
occurring in 22% of our referral cohort. EUS-FNA identifies and cytolog-
ically confirms intraabdominal metastases suggested or missed by CT and
thus can dramatically alter patient management. EUS staging of lung cancer
should not be limited to the mediastinum and must include a careful exam-
ination of intraabdominal structures, with tissue confirmation of suspected
metastasis.
1101
Trimming of Migrated Metal Stent for Malignant Colonic Stricture
Using Argon Plasma Coagulation (APC)
Kiran V. Rao, MD, Gagan D. Beri, MD, Weizheng Wang, MD∗. Department
of Medicine, University of Medicine and Dentistry of NJ, Newark, NJ.
Purpose: Over the last decade colorectal stenting has been reported as an al-
ternative to emergency laparotomy to relieve malignant colonic obstruction.
Complications of colorectal stenting include tenesmus, transient anorectal
pain, rectal bleeding, colonic ulceration and perforation and even stent mi-
gration. APC has been used to trim metal biliary stents as well as metal
colonic stents. Trimming of metal colonic stents has been reported for the
indication of tenesmus. We report the first case of trimming of a migrated
metal colonic stent for stent induced severe anorectal pain.
Methods: We present a case of a 54-year-old female with history of
metastatic colorectal carcinoma who had stent placement secondary to ob-
struction. Subsequent distal migration of the stent caused ulcerations into the
rectal mucosa and excruciating anorectal pain. We used APC to successfully
trim the exposed distal portion of the metal stent and a rat tooth forceps to
retrieve the stent fragments.
Results: Upon follow up in one week, the patient reported complete relief
of stent induced anorectal pain.
Conclusion: The use of APC for trimming metallic stents is an effective
procedure that can be used to trim migrated rectal stents that result in sig-
nificant rectal pain. To date, a few studies have been published that use
APC to trim metallic stents placed in the gastrointestinal tract. Most cases
of stent trimming with APC have been reported in metallic biliary stents
that have migrated distally. Two cases have been reported where a colonic
stent was trimmed using APC for the treatment of tenesmus. To the best
of our knowledge, ours is the only known case in which the indication for
stent trimming was severe stent induced rectal pain. The procedure resulted
in complete relief of the patient’s symptom. Therefore, APC is a safe and
effective way to trim colo-rectal stents to definitively relieve the symptom
of stent induced rectal pain in patients who have experienced distal stent
migration and mucosal ulceration.
1102
Endoscopic Management of Postcholecystectomy Biliary Leaks
Virendra Singh, DM∗, Rahul Gupta, MD, Gurpreet Singh, MS, Ganga Ram
Verma, MS. Hepatology, Postgraduate Institute of Medical Education and
Research, Chandigarh, India and Surgery, Postgraduate Institute of
Medical Education and Research, Chandigarh, India.
Purpose: Biliary leak is a common complication following cholecystectomy.
Endotherapy is an established method of treatment. However, the optimal
intervention is not known.
Methods: Seventy three patients with postcholecystectomy biliary leaks
from July 2000 to April 2007 were retrospectively evaluated.
Results: There were 19 males and 54 females with a mean age of 43.06 years.
Patients presented 17.95 ± 17.09 days (range 1–90 days) following chole-
cystectomy (46 open and 27 laparoscopic) with pain abdomen (42), jaundice
(21), fever (21), and abdominal distension (37). Bilious abdominal drain was
present in 55 patients. Endoscopic retrograde cholangiopancreatography de-
tected leak at cystic duct stump in 35, stricture with mid common bile duct
(CBD) leak in 4, leak from right hepatic duct in 2 and ligated CBD in 32
patients. Nine patients also had bile duct stones. One patient had broken “T”
tube with stone. Endotherapy was possible in 41 patients and 32 patients
with ligated CBD underwent surgery. Two patients with stones, one patient
with broken “T” tube with stone and 4 patients with stricture common bile
duct with leak were managed with sphincterotomy and stent. Seven patients
with cystic duct stump leak with stone were managed with sphincterotomy
and stone extraction. Three outdoor patients with cystic duct stump leak
were managed with sphincterotomy and stent. Eleven patients with cystic
duct stump leak admitted in hospital were managed with sphincterotomy and
nasobiliary drain. Thirteen patients had coagulopathy hence sphincterotomy
could not be done and were managed with only nasobiliary drain (7) and
stent (6). Leak closure could be achieved in 100% patients. Mild pancreatitis
occurred in 4 patients who were managed conservatively.
Conclusion: Endoscopic intervention is a safe and effective method of treat-
ment of postcholecystectomy biliary leaks. However, management of postc-
holecystectomy biliary leaks should be individualized based on type of leak
and should include stent in outdoor patients and nasobiliary drain in indoor
patients with simple leak, sphincterotomy and stone extraction in patients
with stone, sphincterotomy and stent in patients with stricture with or without
leak and those with ligated duct should undergo surgery.
1103
Laparoscopic-Assisted Double Balloon Enteroscopy in Persistent
Obscure GI Bleeding
Erika M. Lee, MD, Vivek N. Prachand, MD, Carol E. Semrad, MD∗. Dept.
of Medicine, The University of Chicago, Chicago, IL; Section of
Gastroenterology, The University of Chicago, Chicago, IL and Dept. of
General Surgery, The University of Chicago, Chicago, IL.
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Purpose: Persistent obscure GI bleeding (OGIB) is a challenging clini-
cal problem. Open intraoperative enteroscopy (IOE), the gold standard in
management, has been associated with variable rates of morbidity (0–52%)
and mortality (0–11%)1. Double balloon enteroscopy (DBE) allows deep
intubation and therapeutics in the small bowel, but its success can be lim-
ited by bowel fixation from previous surgery. We evaluated the diagnostic
yield, complications, and outcome of laparoscopic-assisted double balloon
enteroscopy (LAP-DBE) for persistent OGIB when DBE fails to reach a
bleeding lesion.
Methods: Thirteen patients with planned LAP-DBE for persistent OGIB
were identified retrospectively from a prospective database from 8/04 to 3/07.
Patient demographics, laboratory studies, DBE and operative reports, and
length of stay were reviewed. LAP-DBE was performed under general anes-
thesia. DBE was performed using standard methods2. Laparoscopic instru-
mentation facilitated lysis of adhesions and advancement of the endoscope
around angulations in the small bowel. Lesions were treated with thermal
therapy (argon plasma coagulation or bipolar electrocautery), epinephrine
injection, endoscopic clips, or surgical resection.
Results: Of 13 patients with planned LAP-DBE, 9 patients underwent com-
plete LAP-DBE, 3 underwent laparoscopy only, and 1 underwent DBE only.
Bleeding lesions were identified in 11 (85%) of 13 patients, most commonly
Dieulafoy’s lesions, AVMs, and ulcers. Nine (82%) of 11 patients with iden-
tified lesions had partial small bowel resections; 2 (18%) were treated with
endoscopic therapy alone. Of two patients with negative LAP-DBE, one re-
bled. Four cases were converted from laparoscopic to open laparotomy for
further management of the bleeding site. One complication of devascular-
ized small bowel occurred (8%). Mortality rate was 0%. Average length of
stay following LAP-DBE was 5.2 ± 4.2 days. Over an average follow-up
period of >7 months (range 2–16 mo), 9 (69%) of 13 patients had no further
bleeding.
Conclusion: 1) LAP- DBE is effective in managing persistent OGIB when
standard endoscopy and unassisted DBE have failed to find a bleeding source.
2) Diagnostic and therapeutic yields in this series are comparable to those
previously reported for IOE1. 3) Average LOS after LAP-DBE was short.
1. Hartmann D et al. Gastrointest Endoscopy 2005;61: 826–832.
2. Yamamoto H et al. Gastrointest Endoscopy 2001;53: 216–220.
1104
Botulinum Injection for Satiety and Weight Loss
R. Andrew Packard, MD∗, Gina Packard, MS, James Helmreich, PhD.
Gastroenterology, Columbia Memorial Hospital, Hudson, NY.
Purpose: To show the efficacy of botulinum toxin injections for satiety and
weight loss.
Methods: Twelve patients were asked to take pre- and post-procedure gastric
emptying studies and to record satiety scores.
We injected 100 units of botulinum toxin into the pylorus.
Patients were followed for four months.
Results: Pre-procedure weights were 192.5–506 pounds. At 8 weeks all lost
weight. The two with the highest weights, 333.5 and 506, lost the most, 25.5
and 41 pounds.
With these outliers removed, the group’s mean weight loss of 1.1
pounds/week was significantly greater than zero (P < .001, 95% confidence
interval [0.6 1.6]). Individual weight loss averaged 0.13 to 2.31/week. Of the
eight patients with recorded weights at weeks 14–16, seven lost weight. Mean
weight loss for the group of 1.0 pounds/week was significantly different from
zero (P < .01, 95% confidence interval [0.4 1.7]).
Ten patients had pre-procedure emptying studies. Four had T 1/2 times less
than 20 minutes (N = 78 minutes ± 11). Four ranged from 26 to 54 minutes.
The last was 198 minutes.
With the outlier removed, at 8 weeks these times were weakly associated with
weight loss (P = .053, R-squared .36). With the outlier also removed at 14–
16 weeks, the remaining seven patients’ weight loss linearly associated with
their emptying times (P < .02, R-squared .65). Specifically, each increase
of 10 minutes of pre-procedure gastric emptying times was associated with
a .35 pound per week loss. No significant association was found between
post-procedure emptying times and weight loss, nor between pre- and post-
procedure difference in emptying times.
All patiens reported increased satiety. Nine reported gastroesophageal reflux
pre-procedure; all reported improvement after.
One patient had significant abdominal pain and a mildy elevated amylase
and lipase which resolved spontaneously in 3 days. Minor side effects varied
from belching, dry mouth, food intolerance to fat or fried foods, a variable
change in bowel habits, and mild nausea. All patients’ symptoms resolved
by week 5.
Conclusion: Studies have shown faster than normal gastric emptying in the
obese as did ours. We also showed that the closer to normal pre-procedure
emptying times, the greater the weight loss response to botulinum injections.
Our study and 3 others prove that botulinum toxin is safe when injected in the
stomach for weight loss. Further research is needed to confirm the correlation
between gastric emptying and response to and location of botulinum toxin
injection.
1105
Community-Based Helicobacter pylori Screening in Patients with
Endoscopic Evidence of Peptic Ulcer Disease
William J. Salyers, Jr., MD, Boutros El-Haddad, MD, Ali Mansour, MD, K.
James Kallail, PhD, Estephan N. Zayat, MD∗. Internal Medicine,
University of Kansas School of Medicine – Wichita, Wichita, KS.
Purpose: Identification of H. pylori (Hp) is important in the management
of peptic ulcer disease (PUD) as treatment greatly reduces the risk of ulcer
recurrence. Our study aimed to identify Hp screening rates in patients with
PUD as well as differences in screening and treatment rates between three
specialties performing endoscopies: Gastroenterology (GI), Surgery, and
Family Practice (FP).
Methods: Charts of 715 consecutive inpatients diagnosed with PUD on
upper endoscopy in Wichita, KS were reviewed for Hp screening with biopsy
or rapid urease testing, biopsy histology, culture, or PCR, fecal antigen,
serology, salivary assay, or urea breath testing. Charts of Hp positive patients
were reviewed for treatment with an approved regimen while hospitalized or
documented plans for outpatient therapy. Comparisons between endoscopist
specialties were made using chi-square analysis.
Results: 76.9% (550/715) of patients with PUD diagnosed on upper en-
doscopy were screened for Hp. Of those patients screened, 16.4% (90/550)
were Hp positive. While 63.3% (57/90) of Hp positive patients were treated
during hospitalization, only 9.1% (3/33) of the remaining untreated patients
had documented plans for outpatient treatment. Three endoscopies were per-
formed by Internal Medicine physicians and were excluded from specialty
analysis. GI performed 321 endoscopies and screened significantly more
frequently [83.5% (268/321)] than surgery [72.1% (261/362)] who screened
more frequently than FP [65.5% (19/29)] for Hp (x2 = 14.685; P = 0.001).
No significant differences by age group or gender and type of specialty were
identified. Comparison of treatment rates showed that GI treated Hp positive
patients significantly more frequently [80.4% (37/46)] than surgery [50%
(20/40)] with no FP patients (0/3) receiving treatment (x2 = 14.136; P =
0.001).
Conclusion: While GI screened and treated Hp positive patients more fre-
quently than other specialties, improvement is needed in both areas for all en-
doscopists. Patients not receiving inpatient treatment need well documented
plans for outpatient therapy to ensure adequate follow-up of pending results.
Rates of Hp were lower than expected indicating possible false negative test
results. As identification and eradication of Hp are important in the pre-
vention of recurrent PUD, potential sources for false negatives on initial
Hp testing should be identified so that repeat testing may be performed as
indicated.
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Lack of Education and Training in Video Capsule Endoscopy among
Pediatric Gastroenterology Fellows
Neville D. Bamji, MD, Brian P. Bosworth, MD, Robbyn E. Sockolow, MD,
Aliza Solomon, MD, Greifer K. Melanie, MD, Schnoll-Sussman H. Felice,
MD∗. Division of Gastroenterology and Hepatology, New York
Presbyterian Hospital – Weill/Cornell Medical Center, New York, NY.
Purpose: Since its approval in August 2001, Video Capsule Endoscopy
(VCE) has been performed in over 400,000 patients. The majority of these ex-
aminations have been conducted in the adult population, however, this tech-
nology has been approved in children greater than 10 years of age since 2003.
The primary method of teaching pediatric gastroenterologists-in-training to
use this revolutionary technology has been through gastrointestinal society
sponsored courses. Presently, however, there are no guidelines or strategies
for instructing pediatric gastroenterology fellows how to utilize and interpret
VCE studies. This has left individual training programs to develop their own
institution-specific ways of incorporating VCE into the existing curriculum.
We therefore conducted a survey of pediatric gastroenterology fellows to
investigate the prevailing practices of video capsule endoscopy education.
Methods: A 10 item questionnaire was both sent via email to pediatric gas-
troenterology fellows at 35 training programs as well as posted on the elec-
tronic pediatric gastroenterology fellows’ bulletin board about their use of
and instruction in video capsule endoscopy. All responses were kept anony-
mous and confidential in accordance with the practices of the hospital’s
Institutional Review Board.
Results: As of 2005, there were 175 pediatric gastroenterology fellows na-
tionwide, we received 51 responses (response rate of 29%). VCE is per-
formed in pediatric patients at 82.4% of training programs. Fellows, how-
ever, did not routinely participate in performing or interpreting VCE. Fellows
ordered a mean of 1.7 VCEs (range 0 to 10), and they reviewed a similar
number with an attending physician (mean 1.7, range 0 to 35). Only 17.6%
fellows reported receiving formal instruction in VCE, with 76.5% of fellows
stating that they would benefit from more teaching. Only 4 out of 51 (8%)
of respondents had attended a VCE seminar.
Conclusion: As video capsule endoscopy becomes a more widely utilized
modality of luminal evaluation in the pediatric population, it is critical that
pediatric gastroenterology fellows be trained in this skill. The current system
of haphazard education is ineffective and in need of formal guidelines.
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Application of Cyanoacrylate for Hemostasis in a Patient with
Refractory Post-Sphincterotomy Hemorrhage
Olivia C. Forys, MD, Dawn D. Ferguson, MD∗, Navtej Buttar, MD.
Internal Medicine, Mayo Clinic, Rochester, MN and Gastroenterology,
Mayo Clinic, Rochester, MN.
Purpose: To present cyanoacrylate as an alternative means of achieving
hemostasis in post-sphincterotomy bleeding.
Methods: Case Report
Results: A 58 year old male presented to our emergency department with
melena 72 hours post-ERCP with sphincterotomy and common bile duct
stone removal. In addition, he also had placement of a coronary artery bare
metal stent a month prior to the development of choledocholithiasis. Because
of the coronary stent, he required aspirin and clopidogrel therapy which was
not held for his sphincterotomy.
Upon admission an urgent EGD was performed revealing an actively bleed-
ing sphincterotomy site with adherent clot. Hemostasis was initially achieved
with epinephrine, placement of 6 hemoclips, and application of electro-
cautery. The patient’s cardiologist felt the risk of thrombosis of the coronary
stent was too high to discontinue the aspirin and clopidogrel.
The following day the patient developed hematochezia, hypotension and ane-
mia requiring a transfusion of 3 units of packed red blood cells to maintain
a hemoglobin over 10 g/dL. A second urgent EGD showed evidence of ac-
tive bleeding at the sphincterotomy site, and electrocautery and epinephrine
injection were applied for hemostasis.
Over the next 24 hours the patient continued to have multiple maroon stools
and a third EGD was performed. Prior to the procedure, the patient was
counseled on the risks of cyanoacrylate and its off label usage and agreed
to proceed. During the procedure, a large adherent clot was removed with a
snare to reveal a pulsating arterial bleed from the sphincterotomy site. Using
a Marcon-Haber needle, 1 cc of cyanoacrylate was injected inside the vessel.
There was immediate hemostasis. The patient tolerated the procedure well,
without clinical evidence of further gastrointestinal bleeding.
Conclusion: Post-sphincterotomy hemorrhage has an incidence of approx-
imately 2%. In this case, traditional endoscopic methods failed to achieve
lasting hemostasis, likely due to the concomitant use of aspirin and clopido-
grel.
Cyanoacrylates are a class of tissue adhesives that solidify upon contact with
weak bases such as water and blood. Cyanoacrylate application is increas-
ingly used as an alternative means of achieving hemostasis when traditional
endoscopic methods have failed, though it is not FDA approved for this indi-
cation. To the best of our knowledge, this is the first report of the successful
use of cyanoacrylate to achieve hemostasis in post-sphincterotomy bleeding.
1108
Combined Endoscopic Assisted Laparoscopic Resection of Upper and
Lower Gastrointestinal Adenomas, Carcinoids, and Stromal Tumors –
An Effective and More Targeted Resection of GI Tract Lesions
David M. Poppers, MD, Michael D. Lieberman, MD, Felice
Schnoll-Sussman, MD, Mark B. Pochapin, MD∗. Division of
Gastroenterology and Hepatology, New York Presbyterian Hospital – Weill
Cornell, New York, NY and Department of Surgery, New York Presbyterian
Hospital – Weill Cornell, New York, NY.
Purpose: Endoluminal screening and surveillance have led to the identifi-
cation of both symptomatic and clinically silent mucosal and nonmucosal
lesions throughout the gastrointestinal tract. A key challenge is to remove
these lesions while minimizing the extent and morbidity of resection. The
purpose of this study is to demonstrate the safety and utility of combined
endoscopic-laparoscopic resection of a variety of lesions from the gastroin-
testinal tract.
Methods: We present a series of nine patients with gastrointestinal polyps
and nodules in the stomach, duodenum, and colon. Laparoscopic ports were
inserted, the abdomen insufflated, and the stomach, duodenum, or colon
was mobilized. During simultaneous intraoperative endoscopy, lesions were
transilluminated and mobilized with biopsy forceps, and compressed laparo-
scopically from the serosa to confirm position. For some lesions, a suture was
passed from serosa to mucosa, and resection performed with an endo-stapler.
Results: Five lesions were located in the upper GI tract and four in the colon.
Upper GI tract lesions included a 3.5 cm flat mucosal duodenal adenoma, a
gastric antral neuroendocrine tumor, and a 2 cm antral gastrointestinal stro-
mal tumor (GIST). Colonic lesions included a 4 cm cecal villous adenoma,
transverse and right colonic tubular and tubulovillous adenomas, and a ser-
rated adenoma. Resection specimens demonstrated complete removal of all
lesions. Mean procedure time was 159.7 ± 56.9 min (range 60–268 min),
with upper GI tract shorter than colonic lesion resections (mean 133 ± 51.4
min vs 181 ± 56.8 min). Patients were discharged from hospital after a mean
4.88 ± 2.1 d (range 2–7 d), similar for upper (5 ± 1.41 d) and lower (4.8 ±
1.6 d) GI tract lesions.
Conclusion: Combined endoscopic-laparoscopic resection of gastrointesti-
nal polyps is straightforward, well-tolerated with a post-procedure length of
stay of 4.9 days, and without significant adverse events. This series high-
lights the safety and efficacy of this approach, which will aid in the targeted
management of a variety of mucosal and nonmucosal lesions throughout the
GI tract, with improved lesion identification, short procedural and recovery
times, excellent tolerability, and the avoidance of more extensive surgical
resection.
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ERCP Training: Too Little, Too Late and Too Lax
Stacy Tong, MD, Michael Brown, MD∗. Gastroenterology and Nutrition,
Rush University Medical Center, Chicago, IL.
Purpose: There has been much debate over ERCP training during a 3-year
gastroenterology (GI) fellowship. Our study is the first to survey gastroen-
terologists who have completed fellowship and assess their experiences train-
ing in ERCP.
Methods: Using an Internet survey tool, we developed a survey which was
emailed to gastroenterologists in the Midwest.
Results: 62 gastroenterologists completed the survey (N = 62). 37% (23/62)
described their practice as academic, 32% (20/62) as single-specialty, 18%
(11/62) as multi-specialty, and 13% (8/62) as solo or primary care. 94%
(58/62) did a 2–3 year fellowship and 6% (4/62) did fellowship in 4–5 years.
5% (3/62) did an additional 1-year fellowship in ERCP. The median num-
ber of ERCPs done during fellowship was 25–50. 14.5% (9/62) felt very
well trained, 6.5% (4/62) felt well trained, 40% (25/62) felt somewhat well
trained, and 39% (24/62) did not feel well trained at all in ERCP during
fellowship. After fellowship, 49% (28/57) were granted full privileges, 5%
(3/57) diagnostic but restricted therapeutic, 4% (2/57) diagnostic only, 7%
(4/57) granted with supervision, and 5% (3/57) were denied privileges in
ERCP. 30% (17/57) did not ask for privileges. 63% (39/62) are performing
ERCP after fellowship and 37% (23/62) are not. 29% (18/62) pursued ad-
ditional training after fellowship, while 71% (44/62) did not. Of those who
had more training, 61% (11/18) were trained by their partners, 22% (4/18)
by an ASGE course, and 17% (3/18) from another source.
Conclusion: Traditional 3-year GI fellowships do not provide adequate train-
ing for ERCP. The median number of ERCPs completed during fellowship
in this cohort was 25–50, which is well below the current consensus of
180–200 needed for ERCP competency. Despite this, 49% were granted full
privileges. The majority of those who pursued additional training in ERCP
after fellowship were trained by their partners, while some trained through
the ASGE or other sources. None of these methods provide formal evaluation
or ACGME oversight. Furthermore, training and privileging from partners is
biased. ERCP privileges should no longer be granted to fellows completing
a 3-year fellowship but rather reserved for those who complete a 4th year
formal pancreato-biliary training program.
1110
Is ERCP Necessary for Removal of Biliary Stent?
Yevgeniy Ostrinsky, MD, Swapna Gayam, MD, Uma Sundaram, MD∗.
Department of Medicine, Division of Digestive Diseases, West Virginia
University School of Medicine, Morgantown, WV.
Purpose: ERCPs are routinely done to remove biliary stents. From a tech-
nical, cost and patient safety and comfort perspective an EGD may suffice
Result on Initial ERCP
Choledocholithiasis/ Benign Obstruction/ Malignant Biliary Benign
Microlithiasis Stricture Obstruction Leak Pathology Total
(N = 25) (N = 20) (N = 16) (N = 8) (N = 53) (N = 69)
Demographics
Mean Age, y 57 65 66 40 58 60
Men, n (%) 10 (40) 7 (35) 9 (56) 4 (50) 21 (40) 30 (43)
Mean Days between ERCPs 59 69 74 75 65 67
Normal Result on Repeat ERCP, n (%) 9 (36) 5 (25) 0 7 (88) 21 (40) 21 (30)
Therapy on Repeat ERCP, n (%)
Dilation/Balloon Extraction/Lithotripsy 11 (44) 9 (45) 2 (13) 0 20 (38) 22 (32)
Sphincterotomy 6 (24) 2 (10) 4 (25) 0 8 (15) 12 (17)
Stent Placement∗ 4 (16) 6 (30) 16 (100) 1 (13) 11 (21) 27 (39)
Any Therapy∗ 13 (52) 11 (55) 16 (100) 1 (13) 25 (47) 41 (59)
∗P < 0.01
to remove biliary stents. However, therapeutic interventions requiring an
ERCP may preclude this option. Thus, the aim of this study was to deter-
mine the frequency of endoscopic therapy during ERCP for biliary stent
removal.
Methods: Procedure notes for ERCP for stent removal performed from Jan-
uary 2005 to December 2006 were retrieved. 109 cases were identified. Cases
with initial ERCP done at another institution, pancreatic stent exchange or
removal and duplicate procedures were discarded. Patient demographics and
ERCP therapies on initial and repeat ERCP were analyzed.
Results: A total of 69 patients were analyzed. On repeat ERCP 59% required
endoscopic therapy. 47% of patients with benign pathology during the initial
ERCP required therapy on repeat ERCP. Groups were further divided by
the results on initial ERCP into choledocholithiasis (52% therapy on repeat
ERCP), benign obstruction (55% repeat therapy), malignancy (100% repeat
therapy), and biliary leak (13% repeat therapy). Mean duration between
ERCPs in the biliary leak group with normal result on repeat ERCP was
80 days (range 35–168). One person with a biliary leak on repeat ERCP
underwent procedure 37 days after the initial ERCP.
Conclusion: A high incidence of abnormal findings requiring interventions
on repeat ERCP even in benign conditions precludes the use of EGD for
stent removal without ERCP. Patients who underwent ERCP for biliary leak
might be good candidates for EGD. However, a larger study in this cohort is
necessary to reach this conclusion.
1111
Critical Evaluation of the Efficacy of 4 Different Colon Preparations
Manish Arora, MD, Patrick I. Okolo, III, MD, Ethan Dubin, MD, Sudhir K.
Dutta, MD∗. Division of Gastroenterology, Department of Internal
Medicine, Sinai Hospital of Baltimore, Baltimore, MD; Division of
Gastroenterology, Johns Hopkins School of Medicine, Baltimore, MD and
Division of Gastroenterology, University of Maryland School of Medicine,
Baltimore, MD.
Purpose: The aim of this study is to evaluate the efficacy of various bowel
preparations in accomplishing colonic cleansing for optimal mucosal visu-
alization during colonoscopy.
Methods: The study included a cohort of 980 patients who underwent
colonoscopy at endoscopy center in last 3 years. Study patients were divided
into 4 groups of 245 each receiving a different type of bowel preparation as
shown in table 1.
A Colon Prep Score (CPS) was devised to compare the quality of the different
bowel preparations used.
The colonoscopy results from all patients were statistically analyzed using
one-way ANOVA and expressed as mean ± 1 SD.
Results: Group I patients had a mean CPS ± 1 SD of 3.11 ± 0.91. Group
II patients achieved a CPS of 3.37 ± 1.16. The patients in group III actually
showed the highest mean CPS of 3.44 ± 1.12. Group IV patients reached
a mean CPS of 3.23 ± 1.01. Group III patients demonstrated a statistically
Abstracts S525
higher CPS (P < 0.0006) in colon cleansing as compared to group I pa-
tients. Similarly, group II patients also showed improved colon cleansing
statistically (P < 0.006) as compared to group I patients.
Table 1. Study Groups
Number of
Group Patients Colon Preparation Used
I 245 Magnesium citrate and dulcolax
II 245 Oral Sodium phosphate (Fleets), Dulcolax
and Powder PEG-3350 in dosage of 136 g
III 245 Powder PEG-3350 in dosage of 204 g
IV 245 Oral Sodium phosphate (Fleets), Dulcolax
Table 2. Colon Prep Score (CPS)
Grades Score Description
A 4 A completely clean colon with no stool and little or no
liquid residue.
B 3 A moderately clean colon with small pools of liquid
residue but no solid stool.
C 2 A fair prep with large pools of liquid residue or solid
stool sticking to the colon wall but no solid stool in
the lumen.
D 1 A poor prep with large amounts of liquid residue and
some solid stool, but study completed.
F 0 A failed prep due to large amounts of solid, liquid stool
preveting the complete examintaion of the colon.
Conclusion: Overall, all four colon preparations achieved an average CPS
greater than 3.0 indicating clinically adequate colonic cleansing. However,
powder PEG-3350 alone and in combination with oral sodium phosphate
was observed to be statistically superior to magnesium citrate when used for
colon preparation for colonoscopy.
1112
Utility of Endoscopy in Evaluating Abnormal Findings of the
Gastrointestinal Tract on CT Scan
Muhammad S. Karim, MD, Uma Sundaram, MD∗. Section of Digestive
Diseases, West Virginia University School of Medicine, Morgantown, WV.
Purpose: Abdominal CT scans are frequently performed for a variety of
abdominal complaints. Not infrequently changes are noted of the gastroin-
testinal tract on these radiographic studies which prompts further endoscopic
evaluation. It is unclear whether the cost and risks of endoscopy are justified
given the subsequent yield on endoscopic examination of changes seen on
abdominal CT scans. Thus, the aim of this study was to correlate endoscopic
findings with abdominal CT scan findings that prompted the subsequent
endoscopic procedure.
Methods: This retrospective study was undertaken after appropriate IRB
exemption was obtained. Medical records of 169 patients referred for en-
doscopy following abnormal CT scan findings were reviewed from July 1,
Socioeconomic Strata and PEG Placement Results
Socio-Economic 200 Census Total # Total # Total # Total #
Stratum Median Income PEG (2003) Procedures (2003) % PEGs (2006) Procedures (2006) %
Low $29,526 456 7,312 6.2% 466 7,083 6.6%
Middle $51,802 223 10,049 2.2% 246 6,291 3.9%
High $77,538 394 25,552 1.5% 195 20,951 0.01%
2005 to June 30, 2006. Patient demographic information as well as findings
of the CT scan and endoscopic procedures was reviewed.
Results: The average age of patients ranged from 18 to 89 with a mean
of 55, 41% of these patients were male and 59% were female. The most
common pre-radiographic chief complaint was abdominal pain (66%). An
abnormal abdominal exam was noted in only 34% of patients on physical
exam. CT scan changes were noted less commonly of the upper GI tract
(45/169 patients) than in the lower GI tract (124/169 patients). Radiographic
changes of the upper GI tract was thickening of the esophagus, stomach, or
duodenum in 39/45 patients. Only 25 of these 39 patients on endoscopy had
pathology which consisted of ulceration or inflammation in the respective
organs. Thus, positive predictive value of thickening of the upper GI tract
seen on abdominal CT scan was 64% at the time of endoscopy. Of the 124
patients with pathology in the lower GI tract noted on CT scan, the most
common finding once again was wall thickening in 109/124 patients. Only
36 of the 109 patients were found to have pathology on endoscopic exam.
Inflammation was the most common result of the colonoscopy followed by
hyperplastic polyp. Thus, the positive predictive value for thickening seen
of the lower GI tract on abdominal CT scan was 33%.
Conclusion: Thickening of the gastrointestinal tract is not uncommonly
noted on abdominal CT scans. The resultant endoscopic evaluations of these
changes appear to yield more findings when changes are seen in the upper
GI tract as compared to the lower GI tract. Thus, while the gold standard
endoscopic examination is warranted to follow up abnormal CT scan findings
it is especially important when these changes pertain to the upper GI tract.
1113
Socioeconomic Status Directly Affects the Probability of Percutaneous
Endoscopic Gastrostomy Placement
Roberto Gamarra, MD, Rahil Shah, MD, Alan Cutler, MD∗.
Gastroenterology & Hepatology, Providence Hospital, Southfield, MI.
Purpose: The decision to place a percutaneous endoscopic gastrostomy
(PEG) tube is often a difficult one due to limited data on the survival benefit
in patients with multiple comorbidities. Many studies have aimed to identify
risk factors of poor outcome after PEG placement, but few have aimed to
identify factors affecting the likelihood of PEG placement. We hypothesized
that PEG tube insertion is inversely correlated to the patient’s socioeconomic
stratum (SES).
Methods: We compared the number of PEG tubes placed per total proce-
dures in endoscopy departments in three area hospitals throughout the 2003
and 2006 calendar years. These hospitals reside in distinctly different so-
cioeconomic areas. The average adjusted gross median income was verified
by the zip code of the hospital from the 2000 US Census.
Results: Distinct SES of the three area hospitals were varified by the 2000
US Census at $29,526, $51,802, and $77,538 for low, medium, and high
SES, respectively. In 2003, there were 6.2%, 2.2%, and 1.5% PEGs placed
in the low, medium, and high SES hospitals, respectively. In 2006, there
were 6.6%, 3.9%, and 0.01% PEGs placed in low, medium, and high SES
hospitals, respectively. These data reveal a trend of increasing number of
PEG tubes placed with decreasing SES which persists from 2003 to 2006.
Conclusion: There are several possible explanations for this inverse corre-
lation between PEG placement and SES. First of all, lower SES patients may
avoid routine health care and present with more advanced medical condi-
tions. Second, lower SES patients may have distant family members who will
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elect maximal treatment after long separations. Third, higher SES patients
may have more involved families who know their wishes, which often is to
withhold invasive procedures. Finally, there is a tendency towards increased
nursing home placements for patients in lower SES areas whose families
cannot hire specialized care. Nursing homes often require PEG placement
prior to admission for patients with poor oral intake. In conclusion, PEG
tube placement increases as SES decreases.
1114
Prokinetics Infusion Prior to Endoscopy for Acute Upper
Gastrointestinal Bleeding: A Randomized, Controlled, Double-Blind
& Placebo-Controlled Trial
Samir L. Habashi, MD, Louis R. Lambiase, MD, Ravi Kottoor, MD∗.
Gastroenterology, University of Florida Health Science
Center/Jacksonville, Jacksonville, FL.
Purpose: We investigated the relative benefit in the use of erythromycin/
metochlopramide to improve visualisation before endoscopyin in acute GI
bleeding, assisted by subjective & objective criteria.
Methods: Forty-five patients with hematemesis were randomly assigned
to receive placebo (intravenous saline), intravenous metochlopramide or
intravenous erythromycin before endoscopy in a double-blind study. All
the patients had gastric lavage done prior to the infusion of the study
medicine/placebo. The study had 15 patients in each arm and randomization
was done by the Department of Pharmacy.
Results: Characteristics of patients at admission were similar in the three
groups. Nineteen patients (42%) had peptic ulcer disease & nine patients
(20%) had esophageal varices. The gastric mucosa was entirely visualized
by the endoscopist in 86% of patients in the erythromycin group, versus
66% in the metochlopramide and placebo groups (P > 0.05). The quality
of examination of the upper gastrointestinal tract, assessed by using a four-
point scoring system (from zero to 3 with zero as the worst and three as the
best) was better in the erythromycin group (2.53/3) compared to metochlo-
pramide (2/3) and placebo (2.2/3) with (P > 0.05). Clots were found in
the stomach in 13% of the patients in the erythromycin group compared to
33% in the metochlopramide and the placebo group. Repeat endoscopy was
needed in one patient in the erythromycin group and three patients in the
placebo and metochlopramide group. The mean length of hospital stay was
not different among the three groups. The mean amount of blood transfusion
needed was 2.26 in the erythromycin group, 2.86 in the placebo group and
3.66 in the metochlopramide group. All patients tolerated erythromycin and
metochlopramide with no adverse effects.
Conclusion: The study did not detect a significant difference between
placebo and either study medication There is a possibility of a type II error
because of a relatively small sample size and high rate of success in the
placebo arm.
We estimated that, given the placebo response rate, about 100 patients needed
to be enrolled in each arm to have a 90 percent chance of detecting a statis-
tically significant (P value <0.05) difference in the medications.
The study also suggests that a thorough lavage with normal saline may
adequately cleanse the upper GI tract for good visualization in acute upper
GI bleeding.
1115
Presence of Lymph Node Vasculature: A New EUS Criterion for
Benign Nodes?
Joshua D. Hall, MD, Michel Kahaleh, MD, Grace White, RN, Patrick G.
Northup, MD, Vanessa M. Shami, MD∗. Internal Medicine, University of
Virginia, Charlottesville, VA.
Purpose: Since lymph nodes normally have prominent centrally located
blood vessels which may become obliterated with tumor infiltration, the
presence of vasculature traversing through a lymph node has been noted to
coincide with benign cytology. We sought to determine the test characteris-
tics of the presence of intranodal mediastinal vasculature during endoscopic
ultrasound (EUS) as well as to reexamine the classic indicators of malig-
nancy.
Methods: 67 mediastinal lymph nodes were evaluated by EUS in 66 patients
over a 1-year period. We evaluated for the four classic features of malignant
nodes as well as for the new characteristic in question. Vasculature was
considered benign when it traversed through the center of the lymph node
without disruption and had normal doppler flow.
Results: Of the 67 lymph nodes evaluated, 29 (43%) were found to be
malignant on cytopathologic review. Benign vascular markings were present
in 15 of the 67 (22.4%) lymph nodes evaluated. All 15 (100%) of these
nodes were found to have benign FNA results. Lack of benign vasculature
was found to have a positive predictive value of 55.8% while the presence of
benign vasculature had a negative predictive value of 100%. Adding a fifth
feature to the present diagnostic criteria for characterizing lymph nodes by
EUS increased the sensitivity of determining malignant nodes.
Conclusion: We found that when benign vasculature was seen, it was univer-
sally associated with a benign lymph node. The addition of this EUS finding
improves the ability to characterize lymph nodes and predict the likelihood
of malignant involvement.
1116
Colonic, Non-Rectal, Submucosal Lesions Referred for EUS
William E. Norris, MD, Bruce D. Greenwald, MD, Peter E. Darwin, MD,
Scott Oosterveen, MD∗. Gastroenterology and Hepatology, University of
Maryland School of Medicine, Baltimore, MD.
Purpose: EUS-FNA is commonly used to evaluate submucosal lesions of the
colon and rectum. Rectal lesions, being more common and accessible, have
been better characterized. The objective of our study is to retrospectively
review all submucosal, non-rectal, colonic lesions referred to a tertiary care
center for EUS examination.
Methods: All patients referred to the University of Maryland for EUS eval-
uation of a colonic, non-rectal, submucosal lesion between 9/02 and 5/07
were included. Patient demographics collected included age, sex, and date
of procedure. Procedure related data collected included location of the le-
sion, echoendoscope used, sonographic characteristics (i.e. intramucosal vs.
extraluminal, wall layer of origin, echotexture), biopsy techniques used, and
biopsy results.
Results: A total of 29 patients were referred for evaluation of 31 submucosal
lesions in the colon (non-rectum). The mean age was 59 (62.1% female).
Right-sided lesions (74.2%) out numbered left-sided lesions (25.8%). Three
lesions were diagnosed by endoscopic appearance alone and therefore EUS
was not performed (2 lipomas, 1 external compression). Twenty-eight lesions
were examined by EUS. A miniprobe was used in 92.9%. The 12 MHz
(UM-2R) miniprobe was used in 57.1%, the 20 MHz (UM-3R) miniprobe in
35.7%. A radial echoendoscope (GF-UM160) was used in 7.1% and a linear
echoendoscope (GF-UCT140, GF-UC140) in 10.7% of cases.
Twelve out of the 28 (42.9%) lesions were hyperechoic on EUS and diag-
nosed as lipomas. One isoechoic lesion was removed by endoscopic mucosal
resection and proved also to be a lipoma. Two anechoic lesions (7.1%) were
thought to represent simple cysts. Seven lesions (25%) were hypoechoic
on EUS. In this group, two adenocarcinomas (both diagnosed by FNA),
one lymphoma (diagnosed by bite on bite biopsies and FNA), and one en-
dometrioma (diagnosed by FNA) were found. Attempts to sample two of
the hypoechoic lesions using bite on bite biopsies revealed only normal mu-
cosa. Three “lesions” were found to be inverted appendices (10.7%). One
study revealed mild external compression in a normal cecum. One exam
of a “prominent fold” revealed mildly thickened mucosa on EUS. Mucosal
biopsy revealed adenoma.
Conclusion: Colonic, non-rectal, submucosal lesions are uncommon. Most
can be diagnosed with confidence by endoscopic appearance and miniprobe
endosonography. Lipomas represent the most common finding. Hypoechoic
lesions may represent malignancy and warrant tissue sampling.
Abstracts S527
1117
Endoscopic Full-Thickness Suturing in the Management of Gastric
Wall Defects
Daniel von Renteln, MD, Bettina Riecken, MD, Arthur Schmidt, MD, Karel
Caca, MD∗. Department of Gastroenterology, Klinikum Ludwigsburg,
Ludwigsburg, Baden-Wu¨rttemberg, Germany.
Purpose: The PlicatorTM (NDO Surgical, Inc.) is an endoscopic device de-
veloped for the treatment of GERD based on the principles of anti-reflux
surgery. The procedure places a transmural full-thickness suture under di-
rect endoscopic visualization. Endoscopic full-thickness plication permits
rapid and easy placement of transmural sutures and might be useful as an
endoscopic alternative to surgical intervention in patients with GI wall de-
fects.
Methods: By means of the Plicator device, a pre-tied suture can be deployed
to create a serosa-to-serosa full-thickness fold of GI-tissue. The average
procedure takes about 10–20 minutes to perform and provides placement of
a durable transmural suture comparable to a surgical suture. Therefore, we
investigated the possible use of the Plicator device for endoscopic restoration
of GI wall defects. Four subjects received endoscopic full-thickness suturing
for restoration of GI wall defects. Written informed consent was obtained
by all patients before intervention. Three received endoscopic full-thickness
suturing post or during endoscopic mucosal resection (EMR). One subject
received endoscopic full-thickness plication for treatment of a fistula.
Results: Mean procedure time for endoscopic full-thickness plication was
15 minutes. All Plicator interventions were performed under propofol and
midazolam sedation. In all cases, GI wall patency could be restored. All
post-procedure endoscopic and X-ray follow-up investigations confirmed
complete GI patency. No procedure-related complications occurred during
or after any of the full-thickness suturing interventions. Reestablishment of
enteral feeding was uncomplicated in all presented cases. No modification
of the standard Plicator instrument or sutures were necessary for endoscopic
full-thickness suturing in the presented cases.
Conclusion: The endoscopic full-thickness Plicator permits rapid and easy
placement of transmural sutures. Restoration of gastric wall defects was
easy to accomplish in all presented cases. If surgical intervention seems
necessary, a Plicator suture seems an appropriate endoscopic alternative
technique. Clipping should remain the first choice in small defects and the
Plicator intervention should be limited to cases with larger defects that might
otherwise require surgical intervention.
1118
Endoscopic Mucosal Ablation for the Treatment of Gastric Antral
Vascular Ectasia (GAVE) Using the HALO90 System: A Pilot Study
Seth A. Gross, MD, Mohammad Al-Haddad, MD, Kanwar R.S. Gill, MD,
Anthony N. Schore, MD, Michael B. Wallace, MD∗. Gastroenterology and
Hepatology, Mayo Clinic, Jacksonville, FL and Gastroenterology and
Hepatology, Indiana University, Indianapolis, IN.
Purpose: Gastric antral vascular ectasia (GAVE) often results in gastroin-
testinal bleeding and chronic anemia. Treatment options are limited and
include medical, endoscopic, and surgical therapies. The aim of our study
was to assess the utility of endoscopic mucosal ablative therapy using ra-
diofrequency, HALO90, system for patients with GAVE refractory to other
therapies.
Methods: A prospective pilot study analyzing our first 6 consecutive pa-
tients who received treatment with this ablative device for GAVE. Patients
had endoscopic confirmation of GAVE and correlation of the disorder with
chronic bleeding and transfusion dependency. All patients had failed prior
endoscopic therapy with other techniques. Halo90 ablation was repeated
circumferentially around the antrum until all areas of GAVE were treated
(Fig. 1). Clinical parameters evaluated included hemoglobin, blood transfu-
sion frequency and volume, GAVE extent, and number of ablation sessions
needed to reach a primary endpoint.
Results: Six patients, four males and two females (mean age 58, range
47–65)) underwent ten sessions of endoscopic mucosal ablation of antral
lesions (mean procedure time 29 min, mean number of sessions 1.7, range
1–3). Mean hemoglobin improved from 8.6 to 10.2 g/dl after treatment. Five
of 6 patients are no longer dependent on blood transfusion to maintain a
stable hemoglobin. There were no complications.
Conclusion: This pilot study suggests that endoscopic mucosal ablation us-
ing the HALO90 system should be considered as part of the armamentarium
for the treatment of refractory GAVE. To further validate the clinical benefit
of this technique, we recommend prospectively evaluating this intervention
in larger trials and in comparison to other established therapies, such as
APC.[figure1]
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Learning Curve for Double-Balloon Enteroscopy (DBE) at a U.S.
Center
Seth A. Gross, MD, Mark E. Stark, MD∗. Gastroenterology, Mayo Clinic,
Jacksonville, FL.
Purpose: Reports of DBE experience demonstrate the positive influence of
DBE on management of small intestine disorders, but also note long proce-
dure time, the use of special training, and a learning curve when endoscopists
first perform DBE. Our aim was to examine the learning curve for a single
endoscopist’s initial experience with DBE.
Methods: We analyzed the first 250 DBE performed at our center (9/05
– 4/07). DBE were performed by a single endoscopist using the Fuji-
non EN-450T5 and P5 enteroscopes. Complications, procedure duration,
length of small intestine examined, fluoroscopy time, rate of total en-
teroscopy, and proportion of DBE judged clinically “Helpful” were ana-
lyzed for sequential groups of 50 DBE, with comparison to the first 50
procedures.
Results: The only major complication was a self-contained perforation in
a patient in the last group of 50 DBE. Procedure parameters for sequential
groups of 50 DBE are shown in Tables 1 and 2; the statistic (p) compares
each group of 50 DBE to the first group.
Conclusion: There was no statistical decrease of DBE duration or fluo-
roscopy time with increasing experience. For oral DBE, the length of intes-
tine examined did not increase with experience for up to 250 procedures,
and increased for anal DBE after 100 DBE. The rate of total enteroscopy,
and proportion of “Helpful” procedures increased after 150 DBE. An endo-
scopist may be able to perform safe and useful DBE after limited training,
expertise may require more than 100 to 150 procedures.
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Table 1.
Position in DBE Duration (min) Length examined (cm) Fluoroscopy time (min)
DBE Series n Mean ± SD P mean ± SD P mean ± SD P
Oral
1–50 28 96 ± 24 – 220 ± 86 – 4.6 ± 2.3 –
51–100 23 108 ± 38 .42 229 ± 52 .62 4.5 ± 1.7 .98
101–150 31 100 ± 32 .78 226 ± 95 .92 5.0 ± 2.4 .49
151–200 33 98 ± 42 .78 207 ± 78 .33 4.0 ± 1.7 .46
201–250 30 107 ± 23 .04 236 ± 81 .43 5.0 ± 1.9 .29
Anal
1–50 22 97 ± 40 – 101 ± 53 – 5.1 ± 4.0 –
51–100 27 103 ± 31 .56 120 ± 43 .09 6.6 ± 3.7 .11
101–150 19 94 ± 38 .88 148 ± 68 .01 5.6 ± 2.9 .28
151–200 17 84 ± 18 .29 132 ± 77 .14 3.9 ± 2.0 .49
201–250 20 82 ± 37 .15 122 ± 81 .53 4.0 ± 2.3 .72
Table 2.
Position in Successful Total % Clinically
DBE Series Enteroscopy P “Helpful” P
1–50 8% (1 of 13) – 58% –
51–100 8% (1 of 12) 1 70% .45
101–150 17% (2 of 12) .59 73% .31
151–200 63% (5 of 8) .01 86% .017
201–250 67% (10 of 15) .002 89% .0006
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Do “No-Shows” Share Common Characteristics?
S.R.R. Muthavarapu, MD∗, Mohamad Erfani, MD, Pramod Joseph, MD,
Nejat Kiyici, MD, Hilary Hertan, MD, Edward P. Norkus, PhD. Division
of Gastroenterology, Our Lady of Mercy Medical Center, Bronx, NY.
Purpose: Failure to keep scheduled endoscopy appointments (No-shows)
is common. This may adversely affect the health of no-show patients. It
is also an inefficient use of staffing and considerable loses of health-care
revenue. Our aim was to examine whether no-show patients share similar
and identifiable characteristics
Methods: Data were collected, during 10 weeks in Spring ‘07, from patient
records and telephone interviews (for all procedures) of two staff gastroen-
terologists in our hospital.
Data on age, sex, race, type of procedure, indication, means of transport, time
of day, and day of week of appointment, history of past no-shows, education
and employment were collected
Results: A total of 623 endoscopies were scheduled [30% EGD, 60%
colonoscopy, 10% both]; mean age 57 ± 14(sd) yrs; 69% [females]; 40%
Hispanic, 40% African American, 20% Whites. No-shows were 17% (N =
105). No difference in age (P = .834), sex (P = .842), type of procedure (P =
253) or race (P = .126) between both groups. But several patterns distin-
guished patients who showed from no-shows. No-shows were twice as likely
on Mondays and Fridays (P = .002). In colonoscopies, 1.5 times more no-
shows were seen in males than females (P = .046). No-shows were 5.5 times
more likely in morning (P < .0005). No-shows also were 1.5 times more
likely among Hispanics vs. Whites and African Americans (P = .025). His-
panics were 1.4 times and 1.6 times more likely to provide incorrect contact
information than African Americans and Whites (P = .003), respectively.
The major reasons given for No-show was 1) Correctable causes [no one
to accompany /drive (17%), unable to take prep (15%), fear of procedure
(5%)] 2) Non-correctable causes [sickness (20%), no time off work (7%),
vacation/ travel (3%)].
Finally, 62% of Hispanics, 31% of African Americans and 7% of Whites
provided incorrect contact information halting the 48-hr pre-appointment
reminder phone calls
Conclusion: These findings suggest some general characteristics in Bronx,
NY residents; 1) No-shows are more common in Hispanics 2) Males are
more likely to be no-shows 3) No-shows are more prevalent on Mondays
and Fridays 4) No-shows cause significant waste of human resources and
healthcare funds 5) Majority of patients who did not show up fell in the cor-
rectable group We feel this information should be considered in scheduling
endoscopic procedures.
Other measures such as updating contact information, reminder calls and
clarifying patients concerns would help. We also feel free transportation
could be useful.
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The Study of Associated Cellular DNA Damage in Proliferous Cells by
Vital Dyes at Concentrations Used in Clinical Chromoendoscopy
Jihui Hao, PhD, Xiao Cang Cao, PhD∗, Qiang Liu, Wei Ting Du. Dept. of
Abdominal Surgery, Tianjin Medical University Cancer Institute and
Hospital, Tianjin, China; Dept. of Gastroenterology, Tianjin Med. Univ.
General Hosp., Tianjin, China; Contributed Equally; Institute of Radiation
Medicine, CAMS&PUMC, China and State Key Lab. of Experimental
Hematology, Institute of Haematology, CAMS&PUMC, Tianjin, China.
Purpose: Chromoendoscopy, aided by the use of vital dyes, has been shown
to improve the identification of mucosal abnormalities. Although it is widely
assumed that the vital dyes are safe at the concentration of clinical applica-
tion, their iatrogenic damage, especially on proliferous cells, has rarely been
investigated.
Methods: Here, we selected methylene blue (MB) and indigo carmine (IC),
two wide used vital dyes in chromoendoscopy, to study their effects on cell
damage and the mechanisms involved. To simulate chromoendoscopy in
vitro, methylene blue or indigo carmine dye was added to primary cells iso-
lated from patients biopsy and mesenchymal stem cells (MSC) before they
were exposed to cold white light for 3–30 min. The alkaline comet assay was
used to determine cell DNA damage. Two indexes were choiced, i.e. amount
of DNA in the comet tail and OliveTailMoment. Apoptosis of the cells was
determined by flow cytometry analysis using Annexin V-FITC/PI staining.
DCFH-DA (dichlorofluorescin diacetate) probe was used to determine en-
docellular Reactive Oxygen Species (ROS).
Results: The levels of DNA damage in primary cells isolated from patients
biopsy and MSC treated with methylene blue in the light were significantly
increased compared to that of control cells treated with white light alone or
indigo carmine either in the light or in the dark, or with methylene blue in the
dark. The DNA damage levels were related to the length of light exposure,
and the damage was recovered to a certain level after light withdraw. The
DNA impairment was associated with increase of apoptosis and endocellular
ROS. The similar results were observed in BGC823 and SGC7901 adeno-
carcinoma cells in our previous study although there was some difference.
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Conclusion: Our study demonstrated that MB, but not IC induced DNA
damage and apoptosis of the target cells through stimulating production of
ROS when used as a dye during chromoendoscopy. Because of the associa-
tion between oxidative DNA damage, mutagenesis and the development of
malignancy, especially for proliferous cells, it should be caution to use MB
in chromoendoscopy in high-risk groups. Vital dyes are not always safe, and
many other dyes should be evaluated carefully.
1122
Endoscopy after Myocardial Infarction: A Retrospective Evaluation of
Safety from a Tertiary-Care Center
Todd W. Kilgore, MD, Matthew L. Bechtold, MD, Kimberly S. Delcour, DO,
Michelle L. Matteson, APN, Srinivas R. Puli, MD, Jack D. Bragg, DO∗.
Division of Gastroenterology, University of Missouri, Columbia, MO.
Purpose: Myocardial infarction (MI) and gastrointestinal (GI) bleeding are
often related co-morbidities. Patients with anemia due to GI bleeding are
at increased risk of MI while patients with MI on potent anticoagulants
may exacerbate GI bleeding. Both conditions have many complications,
especially with procedures. The risk of endoscopy after myocardial infarction
has been postulated, but studies vary in definitions and methods and have
not used troponin I as selection criteria. This study examined the effect of
EGD after MI at a tertiary-care center.
Methods: A retrospective study (1/01–8/06) of 63 patients who underwent
EGD within 30 days of a MI at a single tertiary-care center. Patients were
identified by ICD-9 codes for MI (STEMI & NSTEMI) and CPT codes
for EGD. An extensive chart review was performed. MI was defined as
troponin I greater than laboratory reference “diagnostic of MI.” Data was
extracted for type of MI, peak troponin I, time from MI to EGD, Apache
II score at EGD, cardiac catheterization prior to EGD, and medical com-
plications within 24 hours of EGD. Medical complications were defined as
any documented changes in patients’ symptoms, vital signs (BP < 90/60
or > 180/100 mmHg, HR > 100 or < 60 bpm, RR > 24/minute, O2 satu-
ration < 90%, temperature < 35.0◦C), and telemetry (ventricular or atrial
arrhythmias). The data was analyzed by the chi-square test and Fisher’s
exact test.
Results: Sixty-three patients met the search criteria. Mean peak pre-
catheterization troponin I was 24.3 ± 67.2 ng/mL. Mean time from MI to
endoscopy was 5.8 ± 6.2 days. Mean Apache II score was 13.0 ± 5.4. Com-
plications were identified in 29.5%. Complications consisted of hypotension
(6), hypertension (2), tachypnea (2), sinus tachycardia (3), sinus bradycar-
dia (1), PVCs (1), hypothermia (1), and chest pain (2). Cardiac catheter-
ization was performed in 22.6% of patients prior to endoscopy. STEMI
patients underwent EGD sooner than NSTEMI patients (P = 0.0499). Oth-
erwise, no significant differences were noted between types of MI and
cardiac catheterization status for peak troponin I, Apache II score, or
complications.
Conclusion: EGD after acute MI appears to be relatively safe. Although
the occurrence of complications were 29.5%, these complications were only
minor and not associated with mortality. Complications after EGD may be
attributed to the EGD, overall health status of the patient, or combination of
both.
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New Suction-Aid Bite Block Enables Continuous, Hands-Free Suction
and Provides Greatly Improved Patient Comfort and Procedure
Efficiency
Wilson P. Pais, MD, MBA, FACP, FRCPC∗, Gregory J. Ward, MD, FRCPC,
Wayne J. Manishen, MD, FRCPC. Section of Gastroenterology, University
of Manitoba, Winnipeg, MB, Canada.
Purpose: Recent advancements in gastroenterology have led to increasingly
complex and lengthy diagnostic and therapeutic procedures involving the
upper gastrointestinal tract. Frequent suctioning of the mouth is needed to
remove oral secretions and prevent aspiration. The suctioning is usually
done by the endoscopy assistant who also performs other functions. The
suction catheter needs to be physically held in place by the assistant, caus-
ing delays in performing biopsies or procedures to control gastrointestinal
hemorrhage.
Methods: We developed Suction Aid bite block with several modifications
to the traditional bite block.
Results: Our bite block features multiple openings to allow stable positioning
of various sizes of suction catheters, which remain in a fixed position in the
mouth, thereby allowing continuous hands-free suction. This eliminates the
need for the endoscopy assistant to hold on to the suction catheter. With
continuous hands-free suction, patient monitoring and comfort are improved.
The endoscopist and endoscopy assistant can focus on timely completion of
the diagnostic or therapeutic procedure. This patent pending device has been
successfully utilized in various upper endoscopic procedures such as EGD,
EUS, ERCP, PEG placement, and small bowel enteroscopy.
Conclusion: Our new Suction Aid bite block designed for use in any upper
gastrointestinal endoscopy procedure and can accommodate various com-
monly used suction cannulae. It will improve patient comfort and help the
endoscopist and endoscopy assistant in managing efficiency of the proce-
dure.
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Management of the Poorly Prepared Colonoscopy Patient:
Colonoscopic Colon Enemas as a Preparation for Colonoscopy
Norman Sohn, MD∗, Michael A. Weinstein, MD. Surgery, Lenox Hill
Hospital, New York, NY.
Purpose: Colonoscopic colon enema (CCE) is an option for the management
of patients who are suboptimally prepared for colonoscopic examination due
to retained fecal material.
Methods: After colonoscopy is performed and the colonoscopist has reached
the right colon and the colon is deemed to be inadequately prepared, the
contents of two commercially available bisacodyl enemas are combined and
Patient Data
Gender
Male 13
Female 13
Age
Range 26–90
Mean 64.1
Median 65
Primary Prep
RVPB∗ 13
RVPB enhanced 2
PIE∗∗ 5
Other 4
None 2
CCE placed in
Cecum 18
Asc. colon 5
Trans. colon 2
Desc. colon 1
Diagnoses
Normal 13
Polyps 6
Diverticulosis 4
Fecal impaction 1
Rectal prolapse 1
Colovaginal fistula 1
Rectosigmoid CA 1
∗ Reduced volume PEG + bisacodyl, ∗∗Pulsed Irrigation Evacuation
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instilled into the right colon and another into the midsigmoid colon via the
colonoscope biopsy channel. Patients are allowed to recover from propofol
sedation, expel the lumenal contents, resedated, and examined.
Results: In this fashion, 26 patients over a 25 month period were suc-
cessfully cleansed of their retained fecal contents, permitting satisfactory
colonoscopic examinations. This avoided the need for postponement of the
procedure.
Conclusion: CCE is an innovative and simple option available to the colono-
scopist to manage the patient with an inadequately prepared colon. Since
it requires only minimal patient participation, it is also useful for pa-
tients who are unable or unwilling to undergo an ordinary colonoscopy
preparation.
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Accuracy of Endoscopic Ultrasound in Diagnosing Mediastinal Nodal
Staging of Esophageal Cancers: A Meta-Analysis and Systematic
Review
Srinivas R. Puli, MD, Jyotsna Batapati Krishna Reddy, MBBS, Matthew L.
Bechtold, MD, Ajitinder Grewal, MD, Christoper Bartalos, MD, Jack D.
Bragg, MD, Jamal A. Ibdah, MD, Mainor R. Antillon, MD∗. Department
of Gastroenterology and Hepatology, University of Missouri-Columbia,
Columbia, MO.
Purpose: Nodal staging of a patient with esophageal cancer predicts prog-
nosis and directs therapy. The published data on accuracy of endoscopic
ultrasound (EUS) for diagnosing nodal invasion in patients with esophageal
cancer has been inconsistent.
Aim: To evaluate the accuracy of EUS in diagnosing mediastinal nodal
metastasis of esophageal cancers.
Methods: Study Selection Criteria: Only EUS studies confirmed by
surgery or prolonged followup were selected.
Data collection & extraction: Articles were searched in Medline, Pubmed,
and Cochrane controlled trials registry. Two reviewers independently
searched and extracted data.
Statistical Method: Meta-analysis for the accuracy of EUS was analyzed
by calculating pooled estimates of sensitivity, specificity, likelihood ratios,
and diagnostic odds ratios. Pooling was conducted by both fixed and random
effects models. The heterogeneity of studies was tested using Cochran’s Q
test based upon inverse variance weights. Publication bias was estimated by
Harbord-Egger and Begg-Mazumdar bias indicator.
Results: Initial search identified 2610 articles, in which. 360 relevant ar-
ticles were selected and reviewed. Data was extracted from 44 studies
(N = 4398) that met the inclusion criteria. Pooled sensitivity of EUS in
diagnosing nodal involvement by esophageal cancers was 84.7% (95% CI:
82.9–86.4). EUS had a pooled specificity of 84.6% (95% CI: 83.2–85.9).
The positive likelihood ratio of EUS was 3.34 (95% CI: 2.62–4.25) and
negative likelihood ratio was 0.24 (95% CI: 0.91–0.30). The diagnostic
odds ratio, the odds of having nodal metastasis in positive as compared to
negative EUS studies, was 19.05 (95% CI: 12.72–28.52). All the pooled
estimates, calculated by fixed and random effect models, were similar.
SROC curves showed an area under the curve of 0.91. The P for chi-
squared heterogeneity for all the pooled accuracy estimates was > 0.10.
Harbord-Egger bias indicator was 1.08 (95% CI: −0.79–2.95, P = 0.29).
The Begg-Mazumdar indicator for bias gave a Kendall’s tau b value of 0.13
(P = 0.36).
Conclusion: EUS is an important and accurate diagnostic tool to evaluate
nodal metastasis of esophageal cancers. This meta-analysis shows that EUS
has a high specificity and sensitivity. EUS is an excellent diagnostic test to
diagnose nodal metastasis of esophageal cancers.
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Upper GI Cancer Assessment “Straight-to-Test” Service: A Safe,
Efficient, and Cost-Effective Approach
Ravi Madhotra, FRCP∗, Pam Steer, RGN, Ana Ignjatovic, MRCP, Chris
Akubuine, MD. Department of Gastroenterology, Milton Keynes General
Hospital, Milton Keynes, United Kingdom.
Purpose: Rapid access to diagnostics is key to early diagnosis of upper
gastro-intestinal (UGI) cancer. Due to rising healthcare costs, there is also
increasing pressure on gastroenterologists to cut the costs of treatment. In
the UK, Cancer Plan 2000 requires all suspected cancer patients to be seen
by specialists within 2 weeks of referral, and diagnostics must be completed
within 31 days. These targets put huge service delivery challenges for most
hospitals with limited resources. We started a “straight-to-test” (STT) service
to reduce time to diagnosis and staging of suspected UGI cancer. On recieving
referrals, patients were booked directly for upper endoscopy or ultrasound
as appropriate. Clinic appointment was booked after the test, if necessary.
There were no extra costs for setting.
Methods: A prospective study of new STT service over 12 months to study
safety, efficiency and cost-effectiveness. All consecutive patients referred by
GPs for UGI cancer assessment were studied. The patients were followed up
for 6 months after endoscopy by telephonic interview and/or review of hos-
pital medical records. Data included demographics, symptoms, endoscopy
findings, follow-up plans and clinical outcomes at 6 months. The cost savings
were calculated using Outpatient Mandatory Tarriff Coding System.
Results: 241 patients (116 m, 125 f) were referred, of which 95% had en-
doscopy and/or imaging within 2 weeks. The commonest symptom was dys-
pepsia (68%), follwoed by dysphagia (48%), and anorexia (41%). The en-
doscopy diagnoses were Gastritis (32%), Hiatus hernia (26.9%), Oesophagi-
tis (16.8%), duodenitis (12%), Cancer 27 (11.2%) and Gastric ulcers (2.4%).
Cancers included oesophageal 15, gastric 4, pancreas 3, liver 2, and colon 3.
107 (44.3%) were discharged back to GP and 134 (55.7%) were followed up.
Excluding cancer patients there was no significant difference between the 2
groups in clinical outcomes. There were no missed cancers. 31-day targets
were achieved in all cancer patients. STT service saved 107 new (@£188
each) and reduced 134 follow-up (@93 each). The net saving was £31373
over 12 months.
Conclusion: Our study shows that STT service for UGI cancer assessment
is safe, efficient and highly cost-effective. The study also showed that more
patients could be discharged back to GPs after cancer is excluded on gas-
troscopy and hence there is scope for more cost savings. STT model of
cancer assessment service has potential for widespread use in NHS and
other healthcare systems.
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Accuracy and Clinical Impact of EUS – FNA as the Definitive
Diagnostic or Staging Study in Patients with Suspected or Known
Lung Cancer
R. Srinivasan, MD, P. Gupta, MD, S. Jaganmohan, MD, J.B.
Zwischenberger, MD, M.S. Bhutani, MD∗. Division of Gastroenterology,
UTMB, Galveston, TX and Division of Gastroenterology, UT MD Anderson
Cancer Center, Houston, TX.
Purpose: Prognosis and management of non-small cell lung cancers
(NSCLC) are dependent on accurate staging for metastatic lymphadenopathy
(LAD). Endoscopic ultrasound guided fine needle aspiration (EUS-FNA) of
mediastinal nodes has emerged as a valuable minimally invasive alternative
for staging.
The objective of this study was to retrospectively determine the accuracy of
EUS-FNA of mediastinal LNs in patients with known or suspected NSCLC
and of mediastinal LAD of unknown etiology and review its clinical im-
pact. Also, determine the diagnostic yield of using EUS-FNA as a primary
modality for diagnosis and staging in patients with mediastinal LAD with
lung mass on imaging.
Methods: A retrospective chart review was performed on all 107 patients
that were identified. The EUS-FNA diagnosis was accepted as malignant
mediastinal LNs when cytology was positive by EUS. When cytology was
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non-malignant, the results were compared with the final surgical pathology
of the excised LNs.
Results: There were 79 patients who had mediastinal LAD with known
or suspected lung cancer by CT and 69 patients underwent FNA of sus-
picious nodes. 32 of 69 patients (46%) received a diagnosis of metastatic
disease with EUS-FNA and did not undergo further invasive workup. 37
patients had benign or non-diagnostic FNAs of which 26 patients under-
went surgical staging. Sensitivity, specificity and accuracy for EUS-FNA
of mediastinal LAD in patients with known or suspected lung cancer was
84%, 100% and 90% respectively. The negative predictive value was 79%,
the false negative rate was 15% and the positive predictive value was
100%.
There were 20 patients with suspicious mediastinal LAD of uncertain eti-
ology. The diagnostic yield of EGD/EUS-FNA in patients with mediastinal
LAD of unknown etiology was 95% (19 of 20 patients). 27 patients had
mediastinal LAD with lung mass on CT scan without a tissue diagnosis of
the primary tumor. Diagnosis and staging was made in 15 patients (56%)
thus avoiding further invasive workup.
Conclusion: EUS-FNA of mediastinal LNs has a high accuracy with a high
NPV and low false negative rate. Our data supports the use of EUS-FNA early
in the work-up of mediastinal LNs thus avoiding unnecessary imaging, more
invasive mediastinal sampling procedures and potentially futile surgery.
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Risk Factors for Hypoxemia during Elective Outpatient Endoscopy
Mohammed A. Qadeer, MD, John J. Vargo, MD∗, Rocio Lopez, MPH, John
A. Dumot, MD. Gastroenterology and Hepatology, Cleveland Clinic,
Cleveland, OH.
Purpose: Cardiopulmonary events account for 50% of all adverse events
during routine gastrointestinal endoscopy. Hypoxemia is the most common
precursor of such events. There is paucity of data about the risk factors of
hypoxemia during endoscopy. Thus, we conducted a post-hoc analysis from
a prospective observational study of procedural sedation to assess the risk
factors of hypoxemia.
Methods: The study enrolled patients with ASA class I-II for monitoring
sedation during outpatient endoscopy. All patients received sedation by a
combination of a narcotic and benzodiazepine. None of the patients received
oxygen at the start of the procedure. Hypoxemia was defined as oxygen sat-
uration ≤90% anytime during the procedure. Pre-procedure evaluation in-
cluded demographics while intra-procedural evaluation included timing and
dosages of medications and occurrence of hypoxemia. Univariable and mul-
tivariable analyses were performed for predetermined clinical variables and
interactions were assessed among all the significant variables. The relation-
ship of the velocity of meperidine and midazolam (mg/min) administration
to the development of hypoxemia was explored.
Results: A balanced procedural cohort of 80 patients (20 each for EGD,
colonoscopy, EUS, ERCP) were included in the study. The median age
was 62 years (interquartile range IQR 50–74) while the median body
mass index (BMI) was 25.7 (22.9–29.1). The proportion of obese (BMI
≥30) and non-obese (BMI <30) patients with hypoxemia were 71%
(10/14) and 46% (30/65), respectively (P = 0.08). On univariable anal-
yses, significant risk factors for hypoxemia were BMI (P = 0.04) and
age≥60 years (P = 0.03). On multivariable analysis, the odds ratios
(95% confidence intervals) for the development of hypoxemia were: age
≥60 years 4.5(1.4–14.3) P = 0.01; BMI [1 unit increment] 1.1(0.99–
1.2), [study range] 10.8(0.98–151) P = 0.07; and meperidine dose (25
mg) 2.6(1.02–6.6) P = 0.04. There were no significant interactions among
these variables. Even though hypoxemia was more common in procedures
with longer duration, the velocity of meperidine and midazolam admin-
istration did not differ significantly between the patients with or without
hypoxemia.
Conclusion: Age ≥60 years, BMI and meperidine dose appear to be signifi-
cant risk factors for hypoxemia during routine outpatient endoscopy although
BMI lost its significance marginally in multivariable analysis possibly due
to study sample size. A larger study is needed for the further exploration of
these variables as predictors of hypoxemia.
1129
A Single-Center Experience with 652 Cases of Wireless Capsule
Endoscopy over a Period of 5 Years
Adnan Muhammad, MD, Shivani Sharma, MD, Yougandhar Akula, MD,
Sandeep Bhargava, MD, C.S. Pitchumoni, MACG∗. Gastroenterology,
Hepatology and Clinical Nutrition, Saint Peter’s University Hospital, New
Brunswick, NJ.
Purpose: Wireless Capsule Endoscopy (WCE), a relatively new diagnostic
modality provides direct visualization of the entire small bowel mucosa. Its
impact on patient care and usefulness in clinical practice has steadily been
gaining ground. WCE is superior to barium radiography, push enteroscopy
and CT scan of abdomen for the detection of small bowel diseases (Triester
et al. A meta-analysis of the yield of WCE compared to other diagnostic
modalities in patients with OGIB. Am J Gastroenterol. 2005;100:2407–18).
Aim: To assess: 1) The data on the frequency of various indications and
small bowel mucosal abnormalities observed by WCE. 2) The diagnostic
yield of WCE for various indications.
Methods: In this retrospective study, data is collected from 652 cases of
WCE performed during the last 5-year period (2002–2007). Patients pre-
sented with various indications underwent WCE according to standard pro-
tocols.
Results: Total cases: 652 (Males = 311, Females = 341) A) Most common
indicatioN = Iron deficiency anemia (65%) B) Most common finding =
Small bowel erosion (29%) C) Diagnostic yield of WCE for: 1) Iron defi-
ciency anemia = 58% (244/424 cases) 2) OGIB = 62% (177/286 cases) D)
Active bleeding in small bowel = 10% (63/652 cases) which was successfully
thermo-coagulated by push enteroscopy.
Conclusion: 1) WCE played a major role in the detection of small bowel
mucosal diseases in patients presented with various indications. 2) With a
high diagnostic yield, WCE is the procedure of choice in patients with iron
deficiency anemia and OGIB. 3) In a small number of patients (10%) where
active bleeding was seen in small bowel, WCE resulted in the immediate
change of management.
Indications of WCE (Total cases = 652)
Indications No. of patients
Iron deficiency anemia 424 (65%)
OGIB 286 (44%)
Unexplained abdominal pain 100 (15%)
Suspected Crohn’s disease 68 (10%)
Chronic diarrhea 61 (9%)
Suspected Celiac disease 5 (0.8%)
Polyposis syndrome 5 (0.8%)
Multiple indications are present in few cases
Small bowel findings observed by WCE (Total cases = 652)
Findings No. of patients
Erosion (<5 mm in diameter) 192 (29%)
Ulceration (> 5 mm in diameter) 147 (23%)
Lymphangiectasia 144 (22%)
Angiodysplasia (AVM) 111 (17%)
Normal 91 (14%)
Active bleeding 63 (10%)
Polyp 50 (8%)
Nodular Lymphoid Hyperplasia 30 (5%)
Celiac disease 19 (3%)
Sub-mucosal bulge 22 (3%)
Tumor 7 (1%)
Multiple findings are present in few cases
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Problems, Complications and Failures of Wireless Capsule Endoscopy:
A Single-Center Experience with 652 Cases
Adnan Muhammad, MD, Sandeep Bhargava, MD, C.S. Pitchumoni,
MACG∗. Gastroenterology, Hepatology and Clinical Nutrition, Saint
Peter’s University Hospital, New Brunswick, NJ.
Purpose: Wireless Capsule Endoscopy (WCE), a relatively new diagnostic
modality has provided direct visualization of the entire small bowel mucosa.
Approximately over 400,000 patients worldwide have undergone WCE since
its availability in 2001 (Given Imaging data, 2007). The problems related
to WCE can be divided into technical limitations and failures secondary to
malfunctioning of equipment and patient related complications and failures.
A previous study from Europe based on data from 4 large referral centers has
been reported on complications and limitations of WCE (Rondonotti et al.
Gastrointest Endosc 2005;62:712–6).
Aim:The aim of this study is to identify the frequency and nature of com-
plications, limitations and failures of WCE.
Methods: In this retrospective study, data is collected from 652 consecutive
patients who underwent WCE during the last 5-year period (2002–2007).
Patients presented with various indications underwent WCE according to
standard protocols.
Results: Total cases: 652 (Males = 311, Females = 341) Total complica-
tions/failures = 96 out of 652 (15%) cases.
Most common complicatioN = Incomplete small bowel examination (11%).
Conclusion: WCE in this large single center series has shown excel-
lent utility with a limited number of technical failures and complications.
[figure1]
Technical failures of WCE
Type of No. of patients
failure (Total cases = 652)
Battery failure 22 (3%)
Download failure 2 (0.3%)
Clinical limitations and complications of WCE
No. of patients
Types of limitation (Total cases = 652)
Inability to swallow the capsule 3 (0.5%)
Incomplete small bowel examination secondary to: 69 (11%)
A) Capsule stayed in Esophagus 5 (0.8%)
B) Delayed gastric emptying 31 (5%)
C) Retained food particles/bile 30 (5%)
in small bowel obscuring the images
D) Retained capsule secondary to: 3 (0.5%)
1) Stricture secondary to Crohn’s disease 1
2) Intussusception secondary to Celiac disease 1
3) Small bowel tumor 1
Total Complications/failures 96 (15%)
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Novel Endoscopic Techniques for Stoma Size Reduction Following
Gastrojejunostomy
Richard I. Rothstein, MD, C. Alexander Mosse, PhD, C. Paul Swain, MD∗.
Gastroenterology and Hepatology, Dartmouth Medical School, Lebanon,
NH; University College London, London, United Kingdom and Surgical
Oncology and Technology, Imperial College of Science Technology and
Medicine, London, United Kingdom.
Purpose: Although significant weight loss can follow gastric bypass surgery,
over time some patients reach a plateau or begin to regain weight. One ex-
planation has been that the gastro-jejunal anastomosis may have enlarged
and reduction of stoma size might permit additional weight loss. The tech-
nique of directed hollow-needle t-tag suturing has been described for endo-
scopic procedures including oversew of ulcers, closure of lumenal defects,
and creation of enteric anastomosis. We describe the use of this technique
for simple sutured or patch closure of gastrojejunostomies in an animal
model.
Methods: 6 common farm pigs (30–35 kilos) underwent laparotomy and
creation of a gastrojejunostomy. Following recovery (8 to 14 days) the pigs
underwent upper endoscopy and the stoma size was measured using a cal-
ibrated rotatable catheter. (1) Suture closure: Bicap cautery was applied to
the gastric mucosa surrounding the anastomosis, and this area was brushed
to remove mucosa. Using a hollow-needle and backloaded t-tag suturing
system passed through the endoscope, multiple sets of stitches were placed
to effect closure of the gastro-enteric stoma. These were located within 1 cm
of the stoma edges and about 5 mm apart. The anastomosis was measured
at the conclusion of the procedure. (2) Patch Closure: In 3 pigs, an imper-
meable patch with a central hole of 5 mm diameter was sutured to the edges
of the GJ stoma using the t-tag system.
Results: Open surgical gastro-jejunostomies were successfully created in 6
pigs. Baseline anastomotic diameters ranged from 28 to 32 mm. Sewing: Clo-
sure of the stoma was successfully accomplished in all cases, requiring 4 sets
of stitches. Suture approximation was accomplished with a cinching/cutting
catheter placed through the endoscope channel. Final anastomotic size was
reduced to 4–5 mm. Patch: 3 pigs were treated with patches fixed with 6 to
8 pairs of threads and locks.
Conclusion: Large gastro-jejunostomy anastomotic openings can be eas-
ily, safely, accurately and effectively reduced in size using directed t-tag
sewing methods for simple sutured or patch closure. The precision in placing
stitches with this new technique offers an advantage over other endoscopic
sewing methods. This endoscopic sewing method may be useful for bariatric
patients with dilated gastro-enterostomies and further clinical study is
warranted.
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Does Pre-Procedural Counseling by Peers Improve Completion Rates?
Igal Khorshidi, MD, Eleazer Yousefzadeh, MD, Verenice Mackey, RN,
David Greenwald, MD∗. Gastroenterology, Montefiore Medical Center,
Albert Einstein College of Medicine, Bronx, NY.
Purpose: The aim of this study is to examine the relationship between im-
proved health literacy and patient compliance with gastrointestinal proce-
dures when pre-procedural counseling is provided by peers.
Methods: At an ambulatory clinic, the completion rate of 267 consecutive
patients scheduled for 297 gastrointestinal procedures (colonoscopy, EGD,
ERCP, EUS, or flexible sigmoidoscopy) who received pre-procedural coun-
seling was compared with the completion rate of 326 consecutive patients
scheduled for 331 procedures who did not receive this intensive counseling.
A second comparison was made between groups that compared adherence
to the originally scheduled appointment among those patients who followed
up for their procedure.
Results: Pre-procedural counseling increases the completion rate of EGD
(85.9% compared to 74.6) but does not increase overall colonoscopy
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completion rates (70.3% compared to 70.8%). However, patients who have
received pre-procedural counseling are more likely than those who have not
received counseling to attend their originally scheduled appointment, regard-
less of the type of procedure (75.3% compared to 56.2% for EGD; 64.6%
compared to 56.2% for colonoscopy).
Conclusion: Providing patients who may have limited health literacy with
pre-procedural counseling can help improve timely completion of neces-
sary gastrointestinal procedures. Counseling significantly improves patient
compliance with EGD and compliance with originally scheduled EGD and
colonoscopy appointments, while overall compliance with colonoscopy re-
mains poor.
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Diagnostic Yield of Wireless Capsule Endoscopy for the Evaluation of
Iron Deficiency Anemia in Different Age Groups
Adnan Muhammad, MD, Yugandhar Akula, MD, Shivani Sharma, MD,
C.S. Pitchumoni, MD∗. Gastroenterology, Hepatology and Clinical
Nutrition, Saint Peter’s University Hospital, New Brunswick, NJ.
Purpose: Obscure gastrointestinal bleeding (OGIB) could be the source of
iron deficiency anemia in patients with normal EGD and colonoscopy. WCE
helps in the detection of small bowel mucosal abnormalities such as erosions,
ulcerations, angiodysplasia and celiac disease resulting in OGIB and iron
deficiency anemia.
Aim: The aim of this study is to identify the source of bleeding (OGIB) in
the small bowel resulting in iron deficiency anemia with the help of WCE
and also to evaluate its diagnostic yield in different age groups.
Methods: In this retrospective study, data is collected from 652 consecutive
patients who underwent WCE during the last 5-years (2002–2007). Iron
deficiency anemia is defined on the basis of low serum ferritin levels (<15
mg/L) and low transferring saturation (<20%).
Results: Total cases: 652 (Males = 311, Females = 341).
Diagnostic yield of WCE for iron deficiency anemia in different age groups:
1) < 50 yrs = 41%
2) 50–64 yrs = 56%
3) 65–85 yrs = 61%
4) > 85 yrs = 70%
Conclusion:
1) Iron deficiency anemia is a frequent indication for WCE especially
in the older adults (age > 65).
2) The diagnostic yield of WCE in the evaluation of OGIB resulting
in iron deficiency anemia progressively increases as age advances.
3) Small bowel erosions, ulcerations and angiodysplasia are the most
frequent findings in patients with iron deficiency anemia.
4) Active bleeding in the small bowel was seen mostly in older adults,
resulting in an immediate change of management and outcome.[figure1]
Diagnostic yield of WCE for evaluation of
iron deficiency anemia in all age groups
Age < 50 yrs 50–64 yrs 65–85 yrs > 85 yrs
No. of patients 169 (26%) 166 (25%) 281 (43%) 36 (6%)
Patients with iron 58 (34%) 122 (74%) 217 (77%) 27 (75%)
deficiency anemia
SB Erosion (< 5 mm 10 (17%) 37 (30%) 73 (34%) 10 (37%)
in diameter)
SB ulceration (> 5 mm 11 (19%) 27 (22%) 44 (20%) 7 (26%)
in diameter)
Angiodysplasia (AVM) 3 (5%) 16 (13%) 44 (20%) 10 (37%)
Active bleeding in SB 4 (7%) 12 (10%) 30 (14%) 2 (7%)
Celiac disease 8 (14%) 4 (3%) 6 (3%) 1 (4%)
Diagnostic yield 41% 56% 61% 70%
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Retrospective Comparison of In-Hospital Rebleeding Rates in
Non-Variceal UGI Bleeding Demonstrates the Superiority of Clips
Therapy over Injection and/or Thermocoagulation
Kandarp K. Shah, MD∗, Muhammad Y. Sheikh, MD, Kalyani K. Shah, MD,
Mandeep Singh, MD, Jasjit Singh, MBBS. Gastroenterology,
UCSF-Fresno, Fresno, CA.
Purpose: Endoscopic intervention is recommended in patients with non-
variceal acute UGI bleeding (NVAUGIB) when active bleeding or stigmata of
higher risk of rebleeding are noted at the time of initial endoscopy. Opinions
regarding the best method of achieving hemostasis and reducing the risk of
rebleeding differ. We retrospectively studied the charts of such patients who
were admitted to our institution from 2005 to 2006 to determine which of
the modalities in NVAUGIB achieved lower rebleeding rates. In particular,
we wanted to compare the use of endoscopic clips with or without injection
therapy to the use of thermocaogulation and/or injection therapy.
Methods: Patients were included in the study only if active bleeding, ooz-
ing, visible vessel, or sentinel clot was seen on initial EGD and therapeutic
intervention occured. The patients were divided into two groups. Patients
with use of endoscopic clip with or without injection therapy were placed in
Group A and patients with thermocoagulation and/or injection therapy (but
not endoscopic clips) were placed in Group B. Only the in-hospital rebleed-
ing rate was assessed. Rebleeding was documented either by convincing
clinical picture or by endoscopic evidence.
Results: A total of 213 patients met the inclusion criteria. 78 patients were
placed in Group A. None of the patients in Group A had rebleeding (0/78).
135 patients fell into Group B. Eight patients in Group B (8/135, 5.9%)
rebled, with one requiring surgery. This agrees with previously published
data. The rebleeding rate of 0% in Group A was significantly lower than in
Group B (P value <0.03 using one-sided Fisher’s exact test). Both groups A
and B had comparable proportions of patients with visible vessel or active
bleeding (44.87% for Group A compared to 45.19% for Group B).
Conclusion: In non-variceal acute UGI bleeding, the use of endoscopic clips
alone or in combination with injection therapy is associated with a lower in-
hospital rebleeding rate than is thermocoagulation and/or injection therapy
without endoscopic clip therapy. Endoscopic clips should be regarded as the
therapy of choice in NVAUGIB. Injection therapy alone or combination ther-
apy with injection and thermocoagulation for NVAUGIB should be reserved
for those situations where the application of endoscopic clips is not feasible
or not successful and when the clips are not available.
S534 Abstracts
1135
EUS Findings of a Pancreatic Schwannoma Presenting as a Cystic
Lesion: A Case Report
Rajasekhara R. Mummadi, MD, William H. Nealon, MD, Manoop S.
Bhutani, MD∗. Division of Gastroenterology, The University of Texas
Medical Branch, Galveston, TX; Department of Surgery, The University of
Texas Medical Branch, Galveston, TX and Department of Gastrointestinal
Medicine and Nutrition, UT MD Anderson Cancer Center, Houston, TX.
Purpose: Pancreatic Schwannomas are extremely rare tumors. We here by
describe a pancreatic Schwannoma that presented as a cystic mass and had
unusual endosonographic features.
History: A 35 year old male presented with a 3 month history of epigastric
pain radiating to back. CT scan of the abdomen revealed a 6 cm × 6 cm
septated cystic lesion in the pancreatic body suggestive of a complex pseu-
docyst or less likely a cystic neoplasm. The patient underwent a linear EUS
demonstrating a 7 cm complex multiloculated cystic mass with thick septa-
tions and a solid component. The patient was not considered to have a typical
pseuodcyst based on EUS findings and a cystic tumor of the pancreas was
considered as the more likely diagnosis. Fine Needle Aspiration (FNA) of
the cyst was not done to avoid the risk of seeding in case the mass was a
malignant neoplasm as the patient was symptomatic and surgical resection
was considered appropriate regardless of the EUS FNA findings. Surgery
revealed a large, multiloculated mass with cystic and solid components and
histopathology revealed it to be a Schwannoma with cystic degeneration and
immunostaining for S100 was strongly positive, confirming the diagnosis.
The patient recovered uneventfully and is symptom free six months after
surgery.
Schwannomas arise from neural crest cells and are also known as neurilem-
momas. Pancreatic Schwannomas are very rare and the reported cases have
been around 40. More than half of them can undergo cystic degeneration
and mimic pancreatic pseudo cysts or cystic neoplasms. 83% of Schwanno-
mas are benign. EUS FNA is being increasingly used to diagnose pancreatic
cystic lesions. It is not clear if there are any distinctive EUS findings in
pancreatic Schwannoma. Schwannomas should be considered in the differ-
ential diagnosis of pancreatic cystic lesions or cystic lesions in patients with
Neurofibromatosis.[figure1]
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Visualizing the Ampulla of Vater Using a Forward Viewing Endoscope
Jermaine C. Ralph, MD∗, Matthew J. McKinley, MD, FACG, Lisa
Lih-Brody, MD, Paul S. Berg, MD, Robert Gal, MD, Gary S. Weissman,
MD. Medicine, North Shore University Hospital, Manhasset, NY and
Gastroenterology, ProHealthcare Associates, Lake Success, NY.
Purpose: The frequency of seeing the ampulla using a forward-viewing
endoscope is unknown. Many gastroenterologists note seeing the ampulla
on an inconsistent basis during routing upper endoscopy. Here, we attempt
to determine the frequency of ampullary visualization during routine upper
GI endoscopy with a forward-viewing endoscope.
Methods: February through April 2007, 224 patients underwent upper en-
doscopy using a forward viewing endoscope (Olympus GIFH180) for various
indications: anemia, GERD, dysphagia, malabsorption, neoplasia (Polypo-
sis syndromes, Barrett esophagus), etc. The endoscope was advance to 3rd
portion of the duodenum, and if the ampulla was visualized, photo docu-
mentation was obtained. Similarly, if the ampulla was not visualized, it was
reported as such. The upper endoscopies were performed by five gastroen-
terologists whom have advanced training/experience with upper endoscopy
and ERCP.
Results: A total of 224 patients underwent esophagogastroduodenscopy. Of
the 224 patients, seven patients have a history either of Whipple Procedure,
Billroth II or Gastric Bypass surgery. These patients were excluded from
final analysis of the data. The ampulla of Vater was identified in 154(70.9%)
of 217 patients, while in remaining 63(29%) of 217 patients, the ampulla was
not identified. When the ampulla was identified, the average insertion depth
of the instrument was 62.9 cm. In addition, three patients were found to have
benign villous adenoma at the ampulla. For the 224 esophagogastroduoden-
scopies that were completed in these patients, there were no complications
or prolongation of procedure time
Conclusion: The ampulla of Vater can be visualized in the majority of pa-
tients undergoing routine upper GI endoscopy on an outpatient basis. While
Kong et al, were able to detect the duodenal papilla via capsule endoscopy
in 43.6% of 112 cases in their retrospective review, we were able to iden-
tify and document seeing the ampulla of Vater 70.9% of the time using a
forward viewing endoscope. In this study, three ampullary adenomas were
coincidentally detected. A larger study is needed to determine if there is a
difference in ampullary identification based on the level of gastroenterologist
training and years of experience. Furthermore, if gastroenterologists start to
routinely identify the ampulla and biopsy as needed, the risks and benefits
related to the detection of ampullary neoplasms will have to be assessed.
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A Retrospective Study of Capsule Endoscopy at a Tertiary Care
Center: Inpatient Versus Outpatient Populations
Matthew A. Nikoloff, MD, Tri H. Le, MD∗. Department of Medicine,
Division of Gastroenterology and Hepatology, Penn State Milton S.
Hershey Medical Center, Hershey, PA.
Purpose: We intended to analyze the results of small bowel capsule studies
performed at one tertiary medical center. The primary aim was to evaluate the
inpatient and outpatient populations for completeness of study and adequate
small bowel visualization. The effect of diabetes on capsule studies was also
evaluated.
Methods: A chart review of 108 consecutive patients undergoing capsule
endoscopy from September 2003-September 2005 was carried out using
the electronic medical record. Statistical analysis was determined using chi-
square method.
Results: The most common indication for CE was obscure gastrointestinal
bleeding. The most common small bowel finding was AVMs. Capsule reten-
tion rate was 8.3%. Suboptimal visualization of the small intestine due to
poor bowel preparation was found in 15.7% of studies. The frequency of sub-
optimal studies was not different between inpatient and outpatient cases (P =
0.62). Seventy-seven studies (71.3%) were completed with capsule entering
the cecum. Accurate location of 5 studies (4.6%) could not be determined
at the end of the study. The proportion of incomplete inpatient studies was
not different from the outpatient population (P = 0.76). The presence of
diabetes did not effect study completion (P = 0.87).
Conclusion: A difference between the inpatient and outpatient populations
with regard to completion of a study or ability to visualize small bowel
mucosa was not found. Proposal for use of prokinetic agents and bowel
preparation could not be supported for the inpatient population. In addition,
diabetes did not appear to be a risk factor for completeness of a study.
Therefore, using prokinetic agents or placement of the capsule beyond the
pylorus with a gastroscope could not be justified.
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High-Definition White Light and High-Contrast Narrow-Band
Imaging at Standard Magnification To Predict Polyp Histology: An
In-Vivo Study
Daniel A. Ringold, MD, Sanjay K. Sikka, MD, Greg S. Sayuk, MD,
Jonnalagadda Sreenivasa, MD, Chandra Prakash, MD, Bhaskar Banerjee,
MD∗. Internal Medicine/Gastroenterology, Washington University in St.
Louis, St. Louis, MO.
Purpose: High-contrast imaging (HCI) can predict polyp histology using
high-magnification endoscopes. A prospective, in-vivo study was performed
to determine if high-definition white light (WL) and narrow-band HCI with-
out magnification can predict polyp histology during colonoscopy.
Methods: Subjects without risk factors for neoplastic polyps undergoing
routine screening colonoscopy were eligible. Four endoscopists performed
the procedures with Olympus CF-H180 AL/I colonoscopes and activated
narrow band imaging (NBI) with an endoscopic button. Polyp size (<10 mm
were included) and location were first recorded. Using WL, the presence or
absence of cerebriform pit pattern or prominent vascular markings (typical
of neoplastic polyps) were noted and histology predicted: neoplastic or non-
neoplastic. Confidence in the histological assignment and image quality were
rated on a 5-point Likert scale. The process was repeated using HCI.
Results: 55 subjects (58% female, mean age 58.6 years, range 45–85) with
93 polyps (56 neoplastic/37 non-neoplastic) were enrolled. The mean polyp
size was 4.7 mm ± 1.8, (range 2–10). The sensitivity, specificity, PPV, NPV
and accuracy of WL was 68%, 84%, 87%, 63% and 74% compared to 85%,
81%, 87%, 79%, and 84% for HCI. HCI improved the endoscopists’ ability
to determine histology in 9/56 (16%) neoplastic polyps. In 4 non-neoplastic
polyps, HCI incorrectly changed histology to neoplastic. In no cases was a
correct WL neoplastic designation changed to a non-neoplastic designation
by HCI. The mean histological confidence scores were 3.3 ± 1.1 for WL
and 4.1 ± 0.8 for NBI (P < 0.0001). The mean image quality scores were
3.9 ± 1.3 for WL and 4.4 ± 0.7 for HCI (P < 0.0001). Among correctly
assigned neoplastic polyps, HCI visualized prominent vascular or cerebri-
form patterns in 85% of polyps compared to 0% among incorrectly assigned
neoplastic polyps. Neither polyp size nor location influenced histological
designations.
Conclusion: To our knowledge, this is the first real-time evaluation of HCI
at standard magnification in determining polyp histology. HCI is a facile
technology that was 16% more sensitive in identifying neoplastic polyps
compared to WL. HCI also allowed for significantly more confidence in the
initial assessment of histology as well as better image quality. Although use-
ful, HCI without magnification is not accurate enough to replace histology.
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Does Scheduling Time Matter? 30 Minute Versus 60 Minute Intervals
for Colonoscopy
Yogesh J. Patel, DO, Akshay Trivedi, DO, Peter Sargon, MD, Dean Silas,
MD∗. Department of Medicine, Lutheran General Hospital, Park Ridge, IL.
Purpose: Colonoscopy is the gold standard screening tool for the detection of
colonic neoplasia. To accommodate the increasing demand of colonoscopy
many endoscopy centers have increased the number of procedures performed
Pooled polyp detection rates 8 busiest endoscopists∗
2003 2005 P value
% procedures with adenoma detection 22.91 ± 8.2 23.39 ± 7.2 0.678
# adenomas per procedure 0.37 ± 0.18 0.33 ± 0.15 0.113
# hyperplastic polyps per colonoscopy 0.26 ± 0.15 0.26 ± 0.10 0.934
# of advanced adenomas per colonoscopy 0.037 ± 0.013 0.041 ± 0.014 0.517
∗ Plus-minus values are means ± SD
per day by decreasing the allotted time intervals. In April of 2004, our institu-
tion allowed one-hour time intervals to be decreased to 30 minute intervals.
The objective of our study is to determine if adenoma detection rate is de-
creased by the change in allotted procedure time.
Methods: We performed a retrospective chart review of all screening colono-
scopies performed in 2003 (60 minute intervals) and 2005 (30 minute inter-
vals) to compare the adenoma detection rate. Patients were excluded if there
was family or personal history of colon polyps or colon cancer, personal
history of inflammatory bowel disease, or if the patient had rectal bleeding.
Physicians who had more than 100 screening colonoscopies during 2003 and
2005 were included in the study. Age, sex, endoscopist, total number and
size of polyps found was recorded. Pathology reports were reviewed for all
procedures where polyps were found. Histologic type of polyp was recorded
from the pathology reports.
Results: 22 physicians performed screening colonoscopies in 2003 and
2005. Only 8 physicians were identified as having more than 100 proce-
dures during each year of the study period. These 8 physicians performed
a total of 1531 screeing colonoscopies in 2003 and 1610 screening colono-
scopies in 2005. The mean patient age was 60.18 ± 8.86 in 2003 and 59.58 ±
8.8 in 2005 (P = 0.059). The% of patients that were male were 47.3 in 2003
and 46.7 in 2005 (P = 0.744). The% of colonoscopies where at least one
adenoma was found, mean number of adenomas per colonoscopy, mean num-
ber of hyperplastic polyps per colonoscopy, and mean number of advanced
adenomas per colonoscopy for these 8 physicians is reported below.
Conclusion: Reducing the scheduling interval for endoscopic procedures
from 60 minutes to 30 minutes does not affect adenoma detection rates.
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Capsule Endoscopy Performed for Small Bowel Obstruction: A
Tertiary-Referral Center Experience
Mark H. Flasar, MD, Douglas R. Morgan, MD, Kim L. Isaacs, MD∗.
Internal Medicine, Division of Gastroenterology and Hepatology,
University of Maryland School of Medicine, Baltimore, MD and Internal
Medicine, Division of Gastroenterology and Hepatology, University of
North Carolina School of Medicine, Chapel Hill, NC.
Purpose: It is suggested that the use of capsule endoscopy (CE) in patients
with known or suspected small bowel obstruction is contraindicated. We
describe the experience of a tertiary referral center’s use of CE for the specific
indication of small bowel obstruction.
Methods: From November 2003 to May 2007 at the University of North Car-
olina Hospitals, 54 CE studies were performed for the evaluation of small
bowel obstruction in patients whom were being evaluated for operative in-
tervention. We retrospectively reviewed the medical records and CE findings
of these patients.
Results: The majority of the population was female (57%) and Caucasian
(77.8%). The median age (Q1, Q3) was 48.9 years (38.7, 62.0). Most (87%)
of the studies were done on an outpatient basis. Approximately 1/3 of patients
had inflammatory bowel disease, 68% of which had Crohn’s disease. Recent
(within 7 days) or ongoing obstruction was the indication for CE in 24%
of patients; the remainder done for chronic or recurrent obstruction. The
median (Q1, Q3) duration of obstructive symptoms prior to CE was 210 days
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(60, 1460). Most (75.9%) patients had a history of prior abdominal surgery,
20% had been previously treated with pelvic external beam radiation, and
20% had NSAID use documented at the time of CE. Radiography revealed
obstruction in 32 patients (59%) prior to CE, with 24 patients (44%) having
obstruction on abdominal CT or small bowel barium study.
CE diagnosed potential obstructing lesions in 29 patients (54%), and 25
patients (46%) underwent surgery a median (Q1, Q3) of 20 days following
CE (10.5, 55.5). Surgery after CE was diagnostic of an obstructing lesion in
95% of these patients. The capsule reached the cecum in 35% of patients.
CE retention occurred in 10 patients (18.5%), with CE removal at surgery in
8 of these (14.8%). There were no perforations, emergent surgeries, or other
complications after CE. CE findings agreed with operative assessment of the
culprit obstructing lesion in 17 of the 25 patients whom underwent surgery
(68%). No preoperative, clinical factors were significantly associated with
odds of agreement between CE and surgical findings.
Conclusion: CE is safe and effective in selected patients with known or
suspected small bowel obstruction, based upon this review of a single tertiary
center’s experience.
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Disappointing Yield of Duodenal Biopsies for Celiac Disease in “At
Risk” Patients
Rajasekhara R. Mummadi, MD∗, Sahil Mittal, MD, Modar Shiban, MD,
Krishna S. Kasturi, MD. Division of Gastroenterology, The University of
Texas Medical Branch, Galveston, TX; and Tishreen University, Lattakia,
Syrian Arab Republic.
Purpose: Celiac Disease is a relatively common disease in people of Euro-
pean ancestry with a prevalence of around 0.5–1%. The prevalence of CD
in United States is estimated to be around 1 in 133 people. CD is thought to
be an under diagnosed disease with a ratio of 7:1 (undiagnosed:diagnosed).
Screening serological tests are avaible but duodenal biopsies are considered
to be the gold standard. Iron Deficiency Anemia (IDA), diarrhea, dyspepsia,
malabsorption are some of the common GI manifestations of CD. Many au-
thors recommend routine duodenal biopsies in the above”at risk” patients.
Most of the studies are from Europe where the prevalence of CD is higher
than in the United States (USA).
Aim: To study the diagnostic yield of duodenal biopsies for CD in a teaching
hospital in the US
Methods: Retrospective database review of all consecutive duodenal biop-
sies obtained to” rule out celiac disease” from June 2005 to June 2007.
Indications, endoscopic features and pathology reports were reviewed
Results: A total of 338 duodenal biopsies for CD were performed dur-
ing the two year time period in 138(41%) males and 200(59%) females.
Ethnicity wise 57% were caucasians followed by 25% African Ameri-
cans and 14% hispanics. Indications to suspect celiac disease were IDA
in 51.75%(175/338), diarrhea in 22%(75/338), dyspepsia in 20/338(5.9%),
weight loss in 18/338(5.3%). Reasons for suspecting CD were unknown in
10% patients. Among these patients only 4/338(1.1%) had serological testing
prior to endoscopy and 2/338(0.5%) had positive serology
Among the 338 biopsies only 2 (2/338 = 0.6%) revealed CD. 334/338
biopsies were intrepreted as normal and 1/338 was intrepreted as mild villous
atrophy and 1/338 was intrepeted as infectious duodenitis. In the two patients
diagnosed with CD one of them had anemia and positive celiac serology prior
to endoscopy and the second patient had severe diarrhea.
Limitations: All the inherent limitations of a retrospective study.
Conclusion: Since CD is thought to be an under diagnosed disease duodenal
biopsies are recommended in patients presenting with “high risk”symptoms
like diarrhea, IDA or weight loss or dyspepsia. Most of the data is based
on European population with high prevalence of CD. In our study the yield
of duodenal biopsies in patients with high risk symptoms is only 0.5%.
Prospective studies in USA to evaluate strategies like pre endoscopy sero-
logical screening are needed.
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Efficacy of Digital High Contrast Imaging Coupled with Standard
Colonoscopes in Predicting Colon Polyp Histology
Sanjay Sikka, MD, Daniel Ringold, MD, Abdul Aadam, MD, Rajesh Shah,
MD, Sreeni Jonnalagadda, MD, Bhaskar Banerjee, MD∗. Department of
Medicine, Division of Gastroenterology, Washington University School of
Medicine, St. Louis, MO.
Purpose: Recent data has shown digital high-contrast imaging (HCI) tech-
nologies to be useful in predicting colon polyp histology when using high-
magnification endoscopes. Little data exists on the ability of HCI to predict
polyp histology with standard endoscopes. As non-magnifying endoscopes
are widely available in standard practice settings, we performed a study to
compare the accuracy of (narrow band) HCI and high definition white light
(WL) images in predicting polyp histology without the use of high magnifi-
cation endoscopes.
Methods: We used HCI endoscopes and processors (Olympus CV180 with
Narrow Band ImagingTM) to visualize colonic polyps in patients undergo-
ing elective outpatient colonoscopy. Static digital images of polyps were
collected in both HCI and WL and polyp size and location were recorded.
Histology was later collected. Images were then assembled into power point
slide shows stratified by imaging modality. These were reviewed by 2 endo-
scopists blinded to all patient and polyp information, on a standard 19 inch
LCD monitor. Polyps were designated as either neoplastic or non-neoplastic,
based on pit patterns and presence of vascular markings. Predictions were
compared to histopathology as the gold standard. Image quality and reader
confidence were graded on a 5-point Likert scale with a score of 5 being
highest.
Results: Separate WL and HCI images of 80 (49 neoplastic, 31 non-
neoplastic) polyps from 63 patients were obtained. Mean polyp size was
5.13 ± 2.12 mm (5.35 ± 2.16 neoplastic; 4.42 ± 1.78 non-neoplastic (P =
0.02)). Pooling data from the 2 readers, HCI correctly predicted neoplastic
histology in 93 of 98 images (sensitivity 95%, PPV 94%) while WL did so
in 58 of 98 images (sensitivity 59%, PPV 80%). HCI correctly predicted
non-neoplastic histology in 56 of 62 images (specificity 90%, NPV 92%)
while WL did so in 47 of 62 image (specificity 76%, NPV 54%). Mean confi-
dence scores for HCI (3.97 ± 0.95) and WL (2.71 ± 0.95) were significantly
different (P < 0.0001). Mean image quality scores for HCI (3.79 ± 0.97)
was also higher than WL (3.14 ± 0.92) (P < 0.0001).
Conclusion: HCI with standard endoscopes was more accurate in predicting
colon polyp histology compared to WL. Confidence and image quality was
significantly higher in the HCI group. Based on our findings, HCI at low
magnification may be useful in predicting colon polyp histology.
1143
Does Tandem Colonoscopy Affect the Adenoma Detection Rate
Described with Narrow Band Imaging?
Sally Stipho, MD, Nooman Gilani, MD, FACG, Francisco C. Ramirez, MD,
FACG∗. Gastroenterology, Carl T. Hayden VA Medical Center, Phoenix,
AZ.
Purpose: Narrow band imaging (NBI) is a novel endoscopic optical tech-
nique that enhances tissue details by narrowing bandwidth of transmitted
light using optical filters. We previously demonstrated that using high def-
inition endoscopes, NBI with magnification allowed for a higher adenoma
detection rate compared to white light.
Aim: To determine whether the tandem nature of colonoscopy alone in our
prior study contributed to the improved detection rate seen with NBI.
Methods: Patients referred for average risk CRC screening from 09/2006 to
06/2007 were studied. Olympus H180 scope series were used. All procedures
were performed by 2 experienced gastroenterologists and a third year fellow.
Patients underwent tandem colonoscopy following cecal intubation. Initial
evaluation utilized the NBI mode and was then followed by re-evaluation
using white light, performed segmentally every 15 cm. Cecal and withdrawal
times were recorded. Detection of polyps by either WL or NBI as well as
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their histology, size and anatomical location were recorded and compared.
Students t test and Fishers exact test were used for statistical purposes.
Results: A total of 146 patients were evaluated, 100 patients in the NBI/HDM
group and 46 patients in the WL/tandem group. All were men with mean
ages of 62.2 and 60.4 respectively (P = NS). A total of 22/74 (29.7%) addi-
tional polyps were detected by WL/tandem compared with 31/214 (14%) in
the NBI/HDM group (P = 0.005). Of the polyps “gained”, 13/22 (59.1%)
were confirmed tubular adenomas in the WL/tandem group versus 11/31
(35%) in the NBI/HDM group (P = NS). The majority of TAs detected
in the WL/tandem group were 1–3 mm in size (8/13, 62%) and 4–6 mm
in size (4/13, 31%). 69% were located more proximally. The WL/tandem
group was associated with shorter withdrawal times (15.8 min vs 18.9 min,
P = 0.003), longer cecal intubation times (6.9 min vs 4.9 min, P < 0.005)
with similar total times (22.7 min vs 23.8 min, P = NS). These differences
may be explained by the addition of a fellow in the initial part of the pro-
cedures, with the tandem portions completed by the same 2 experienced
gastroenterologists.
Conclusion: 1) The WL/tandem group detected significantly more polyps
than the NBI/HDM group. 2) Athough the tubular adenoma detection rate
was also higher in the WL/tandem group, the difference was not statistically
different. 3) This suggests that the tandem nature of the procedure by itself,
may be a significant contributing factor for the increased polyp detection
rate (irrespective of using WL or NBI).
1144
CES E-Score for Esophageal Capsule Endoscopy Image Quality
Assessment
Disaya Chavalitdhamrong, MD∗, Oren Goltzer. Capsule Endoscopy
Services, Los Angeles, CA.
Purpose: The aim of this study was to develop and then validate a stan-
dardized grading scale to assess esophageal capsule endoscopy (ECE) video
image quality.
Methods: We devised the Capsule Endoscopy Services Esophageal score
(CES E-score) as a standardized grading scale to assess the quality of
esophageal images obtained during ECE examinations. The CES E-score
is comprised of an aggregate of 5 different parameters including visual-
ized anatomic landmarks, duration of esophageal imaging, image quality,
illumination, and artifacts (see Table 1).
A total of 318 de-identified ECE cases (GERD screening, N = 312;
esophageal varices surveillance, N = 6) were independently scored by 2
gastroenterologists in a randomized, blinded fashion. Each of the 5 parame-
ters were scored 0, 1, 2 based on the pre-defined criteria. The CES E-score
was calculated by the total sum of points, ranging from 0 (poorest quality) to
10 (highest quality). Concordance rates between the two GI’s were assessed
for each parameter as well as aggregate score.
Results: The concordance rate was ≥95% for all parameters, and >98% for
total score between the two GI’s. The mean CES E-score was 8.5 ± 1.1. The
median score was 9. The two major factors causing low scores were artifacts
and incomplete visualization of anatomical landmarks (bubbles/particulate
matter obscuring the distal esophagus). All scores were within 1 point for
all parameters for the two investigators.
Conclusion: The CES E-Score is a highly reproducible and valid scale to
assess the quality of ECE studies, and to identify areas for technological
CES E-Score Parameters Score = 0 Score = +1 Score = +2
1. Anatomical Landmarks(a) Non-visualized Adequate Good
2. Esophageal Transit Time(b) (seconds) < 1 1–5 > 5
3. Image Quality (resolution/focus) Poor Adequate Good
4. Illumination (Brightness/darkness) Poor Adequate Good
5. Artifacts (bubble, food particle, and liquid) All three Any 1 or 2 None
(a) = Visualization of the distal esophagus and squamocolumnar junction (Z line) in its entirety (antegrade and/or retrograde views) (b) = Time from first esophageal image to
first gastric image
improvement. This standardized scoring system can be a useful tool for
future ECE studies.
1145
Endosonographic Diagnosis of Gastric Variceal Bleeding
Sathya Jaganmohan, MD, Manoop Bhutani, MD, FACG, Gagan Sood,
MD∗. Gastroenterology, UTMB, Galveston, TX and Gastroenterology,
M.D. Anderson Cancer Center, Houston, TX.
Purpose: Gastric variceal bleeding remains a clinical challenge. Though the
risk of bleeding from gastric varices is significantly less than esophageal
varices, the transfusion requirements and mortality are significantly higher.
Identification of gastric varices is of paramount importance as the manage-
ment strategy is different from that of isolated esophageal varices.
Though identification of gastric varices is by endoscopic visualization, we
describe a challenging scenario in which suspected gastric variceal bleeding
was confirmed by endosonography.
Case: 56 y/o male with alcoholic cirrhosis was admitted for a recurrent
episode of hematochezia, hypotension and anemia. Two previous upper and
lower endoscopies for similar presentations had revealed esophagitis and no
explanation for blood loss. Patient presented with 3 episodes of hematochezia
1 day earlier without syncope. Admission labs were significant for a Hb of
6 gm/dl (baseline 12), INR 1.4, Platelet count 46,000, T. Bili 2.7 gm/dl.
Hemoglobin stabilized after admission with no further manifestations of
GI bleeding. Following transfusion and initiation of octreotide infusions,
EGD was performed which showed grade 1 esophageal varices with no
stigmata of recent bleeding and no fresh or old blood in the stomach. Three
linear mucosal folds traversed the lesser curvature from the GE junction. A
small 5 mm ulcer with an adherent clot was located on one of the folds near
the cardia. The remainder of the examination was normal. With suspicion
of underlying varices no endoscopic therapy was attempted to the ulcer.
The ulcer was examined with mini probe ultrasonography which showed
a large submucosal gastric varix and numerous portosystemic collaterals
near the GE junction. Radial EUS imaging further defined the ulcer and
the clot located directly overlying the vessel wall of a gastric varix. The
patient underwent urgent TIPS placement and has not had any recurrent
bleeding.
Conclusion: Endosonography can play an important role in identification of
suspected gastric varices that are not obvious on direct endoscopic visual-
ization.[figure1]
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Colonoscopy Procedure Times and Obesity: A Retrospective Review
Andrew B. Gentry, MD, Patrick E. Young, MD, Cecilia H. Kim, PMH,
Brooks D. Cash, MD∗. Gastroenterology, National Naval Medical Center,
Bethesda, MD.
Purpose: Obesity has now reached epidemic proportions in the United
States. Its relationship to diabetes, hypertension, and various neoplastic pro-
cesses are well documented, however its impact on endoscopic efficiency
is not well studied. Obesity has been cited as a potential barrier to colon
cancer screening, partly due to perceived procedural difficulty. Our goal is
to determine obesity’s effect on various endoscopic parameters.
Methods: Using the ProVation MD nursing and physician databases we
retrospectively reviewed data for all patients that underwent colonoscopy
in our center from 2005–06. From the 4500 colonoscopies performed we
excluded procedures with incomplete data, dual procedures, and procedures
involving trainees, leaving 724 procedures performed completely by staff
gastroenterologists. We calculated the exam time (defined as the time from
scope insertion to complete withdrawal), cecal intubation time, procedure
time (defined as start of sedation to complete withdrawal), and post procedure
recovery time (defined as the time from complete withdrawal to discharge
from center). The times were calculated for each patient, and the patients
were divided into categories according to BMI as follows: <20, 20–24, 25–
29, 30–34, >34. Significance was determined using analysis of variance.
Results: Obesity had no significant effect on exam time, cecal intubation
time, procedure time, or recovery time. The mean procedural times are shown
in the table.
Conclusion: Several studies demonstrate lower than average colon cancer
screening in obese patients despite a higher rate of adenomas. Perceived
technical difficulties and physician referral bias are possible causes for these
lower rates. We have shown no increase in exam time, cecal intubation time,
procedure time, and post procedure recovery time for the obese compared
to those with BMI’s ranging from 20–29. Perceived technical difficulties in
performing screening colonoscopy in the obese are unfounded.
1147
Role of Endoscopic Ultrasonography in the Evaluation of Gastric
Submucosal Lesions: A Single Center Experience
Shailender Singh, MD, Srinivas Puli, MD, Jyotsna Talapaneni, MD,
Melissa Oropeza-Vail, RN, Mojtaba Olyaee, MD∗. Medicine, Kansas
University Medical Center, Kansas City, KS.
Purpose: Gastric submucosal lesions are often seen on routine upper en-
doscopy. Endoscopic Ultrasound (EUS) is a valuable imaging modality for
gastrointestinal submucosal lesions. It is helpful in accurately assessing layer
of origin and can differentiate submucosal tumors from extragastric com-
pression as well.
Methods: EUS procedures performed at our center from April 2002 to
February 2006 were reviewed. Patients selected for this retrospective re-
view underwent an upper abdominal EUS for further evaluation of gastric
submucosal lesions or extragastric compression on endoscopy. Results were
compared with CT scan and surgical pathology whenever possible.
Results: 47 patients underwent EUS for gastric submucosal lesions. EUS
revealed stromal tumor arising from the muscularis propria in 42% (20/47).
Mean Procedural Times Grouped by BMI
Exam Time Cecal Int. TIme Procedure TIme Recovery Time
BMI < 20 N = 26 22.40 ± 7.05 11.65 ± 6.44 27.40 ± 7.43 39.77 ± 20.67
BMI 20–24 N = 200 20.68 ± 8.54 9.34 ± 5.30 25.45 ± 9.21 44.37 ± 22.77
BMI 25–29 N = 322 20.47 ± 9.37 8.73 ± 6.07 25.40 ± 10.61 44.87 ± 22.04
BMI 30–34 N = 132 20.64 ± 9.71 7.91 ± 5.40 25.70 ± 9.94 45.07 ± 28.16
BMI > 34 N = 44 21.70 ± 13.22 8.91 ± 6.89 27.38 ± 12.94 43.41 ± 20.01
The size varied from 8 mm to 7 cm. Two patients with tumor size more
than 3 cm presented with upper gastrointestinal bleeding. EUS guided fine
needle aspiration cytology revealed malignant stromal tumor in 3 patients,
which was confirmed later on surgery. Other findings included pancreatic
rest 3, lipoma 3, Dieulafoy 1, submucosal cyst 1, carcinoid 1 and non-specific
cellular aggregate in 12 patients. Extrinsic gastric compression was seen in 6
patients (splenic artery 4, left lobe liver 1 and anomalous spleen in 1 patient).
Conclusion: EUS is a useful tool in the evaluation of both benign and
malignant gastrointestinal submucosal tumors. External gastric compression
mimicking as submucosal lesion, as seen on upper endoscopy can also be
readily distinguished by EUS.
1148
Jejunostomy Tube Placement under Direct Visualization
Noel Martins, MD, Niraj Ajmere, MD, Kanishka Bhattacharya, MD, John
Levey, MD∗. Gastroenterology, University of Massachusetts Medical
School, Worcester, MA.
Purpose: To evaluate a novel technique for percutaneous endoscopic je-
junostomy tube (PEJ) placement under direct visualization.
Methods: A 35 kg pig was fasted for 48 hours prior to the surgery. This
pig was intubated and sedated with general anesthesia. A pediatric colono-
scope was passed to the proximal jejunum, and a location for the PEJ was
marked based on transillumination and digital pressure. An opening in the
jejunal wall was made using a gold probe. A Jagwire was then passed into
the peritoneal space. A small incision was made in the abdominal wall with
a scalpel, and a Kelly clamp was used to separate the fascia to facilitate
insertion of the pediatric gastroscope into the peritoneal cavity. The pe-
diatric colonoscope was used to visualize the transillumination from the
pediatric gastroscope and direct its advancement to the location of the Jag-
wire. The Jagwire was then grasped by the pediatric gastroscope (via snare),
and pulled out through the abdominal wall with the pediatric gastroscope.
The pediatric colonoscope was removed and a 20 Fr PEG tube was tied to
the Jagwire and pulled through the mouth and the upper gastrointestinal
tract and then into position with the bumper pulling the jejunal wall tight
against the abdominal wall. The pediatric colonoscope was then reintro-
duced and advanced to the PEJ site to confirm that the bumper was in good
position.
Results: PEJ placement using the method described above was successful in
a 35 kg pig. The jejunostomy tube was placed at 75 cm from the incisors, and
the position was confirmed endoscopically after placement. The bumper was
snug at 4 cm from the skin surface. There were no immediate complications.
The pig was euthanized after the procedure.
Conclusion: A number of endoscopic techniques for PEJ placement are cur-
rently being studied. Unfortunately, direct PEJ placement has moderate or
severe complications approximately 10% of the time. The use of T-fasteners
to aid in PEJ placement is promising, but it still does not allow for direct
visualization. We previously reported placement of PEJs in two 35 kg pigs
under transgastric endoscopic guidance. However, PEJ placement using the
novel technique described in this abstract allows for direct visualization
while avoiding the need to create and then close a gastrotomy. Further re-
search should focus on the refinement of the transabdominal instrument,
and survival animal studies will be needed to demonstrate weight gain and
monitor for leakage at the PEJ site.
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Identifying Barriers To Keeping Endoscopy Appointments
Raymond G. Duggan, DO, Dawn M. Sears, MD∗. Gastroenterology, Scott
& White Memorial Hospital, Temple, TX.
Purpose: Missed appointments and procedures account for a significant
burden to the healthcare system. Not only does it cause financial loss but
it places constraints on already limited schedules. Estimates reveal an ap-
proximate no-show rate of 10% for most clinical situations. No studies have
looked specifically at the experience in an endoscopy unit. The purpose of
our study was to look at patient characteristics and reasons for not showing
up for their endoscopic procedures.
Methods: Patient dates and times of missed procedures from our endoscopy
suite were recorded over a three month period. A questionnaire was devel-
oped to look at demographics, healthcare history, and reasons for failure to
make it to their appointment. Attempts were made to contact all of these
patients by telephone within a few weeks of their visit. A patient that had
their procedure from the same date and time of day was also contacted and
information utilized as a control.
Results: Of 1,160 patients scheduled, 110 patients failed to show. 29 were
reached and agreed to participate. The response rate equaled 26%. Our con-
trol group included 20 patients.
Patients more likely to miss their procedure were: female, on more than
one medication, missed other appointments, seen in the emergency room
more frequently, less likely to have had a Pap Smear, unemployed and dis-
abled in their own opinion. All of these findings met statistical significance.
Differences existed but were not significant for age greater than 66, num-
ber of medication allergies, distance traveled for procedure and presence of
chronic illnesses. No difference existed in marital status, children at home, or
having an annual mammogram. Missed procedures occurred most often on
Tuesdays and in the mornings. Reasons given for failure-to-show included
personal illness, death/illness of a family member and conflict in schedule.
Conclusion: Our study provides new insight on patients missing endoscopy
procedures. Unlike other studies forgetfulness was not a prevalent reason
for missing procedures. When asked how we could have helped them keep
their appointment most patients stated it was unavoidable although a few
indicated that better communication would have been beneficial. Studies
have shown that simply just asking “is this time okay for you?” can improve
attendance rates. Since personal and family illnesses cannot be predicted it
can be difficult to fill all procedure times completely. Our endoscopy unit
started scheduling one extra case per day to utilize any empty times due to
failure to keep appointments.
1150
Complications Requiring Hospitalization Following Primary
Screening Colonoscopy
Omar Sharif, MD, Essam R. Quraishi, MD, Kim Brown, MD∗. Department
of Internal Medicine, Henry Ford Hospital, Detroit, MI and Department of
Gastroenterology, Henry Ford Hospital, Detroit, MI.
Purpose: To compare complication rates in outpatient colonoscopies per-
formed for screening vs those performed for specific indications.
Background: Colonoscopy is the procedure of choice for Colon cancer
screening in all individuals over the age of 50. Complications of colonoscopy
have been described in the literature, but these studies have included colono-
scopies performed for a variety of indications. Our aim was to determine
if the complication rate for screening colonoscopy was similar to that of
colonoscopies performed for other indications.
Methods: We retrospectively reviewed all patients undergoing outpatient
colonoscopy at our institution from January 1, 1999 to April 1, 2006.
Indications and findings of colonoscopy were recorded using the endo-
scopic database maintained by the Gastroenterology Division. The corporate
database was used to verify if these patients were admitted to Henry Ford
Hospital within 30 days of the procedure. The admission records of these
patients were reviewed to verify if these admissions were related to compli-
cations of colonoscopy. Statistical analysis was performed using chi square
analysis.
Results: 18,193 outpatient colonoscopies were performed during this period,
of which 7344 were screening colonoscopies. There were 712 admissions
within 30 days of colonoscopy. Of these, 59 were related to colonoscopy
complications (3.7/1000), 19 of these were complications of screening
colonoscopy (2.6/1000) (P = NS). Most patients (88%) were admitted
within one week of the colonoscopy. Complications for all colonoscopies
included 36 bleeds, 11 perforations, 7 post-polypectomy syndrome and 5
miscellaneous. Bleeding was less common in patients undergoing screening
colonoscopy 0.11% vs 0.26% (P = 0.026). There was no statistically signif-
icant difference for other complications in screening colonoscopy patients.
There was one mortality in the non-screening group. There was no signifi-
cant association of complications with race, sex and type of bowel prep. Rate
of complication was 3.1/1000 when a fellow performed the test and 2.9/1000
if performed by senior staff (P = NS). Snare polypectomy was associated
with a RR of 3.6 for all complications P < 0.001.
Conclusion: We found that the rate of complications requiring hospi-
talization following screening colonoscopy is not significantly different
than colonoscopy performed for other indications at our institution. Snare
polypectomy was associated with a higher rate of complications.
1151
Endoscopic Ultrasonography Findings in Patients with Nonspecific
Changes of the Pancreas on Computed Tomography: A Single-Center
Experience
Sana Waheed, MD, Shailender Singh, MD, Savio Reddymasu, MD, Jyotsna
Talapaneni, MD, Benjamin Alsop, Melissa Oropeza-Vail, RN, Mojtaba
Olyaee, MD∗. Medicine, Kansas University Medical Center, Kansas City,
KS.
Purpose: To evaluate the efficacy of endoscopic ultrasound (EUS) in a co-
hort of patients with indeterminate pancreatic findings, such as “enlarged
pancreas” or “prominent pancreas” reported on computerized tomgraphy
(CT) scan of the abdomen.
Methods: Retrospective single center study of 107 patients (56 males), who
underwent EUS for further evaluation of inconclusive pancreatic findings on
abdominal CT scan performed for various indications. Clinical data reviewed
included: history of diabetes, alcoholism, weight loss; liver function tests;
CBD diameter on CT scan, EUS and fine needle aspiration (FNA) cytology
results.
Results: Mean age of the patients in the study was 61 years (range 26–
88 yrs). 20 (19%) patients had diabetes, 19 (18%) had jaundice, 35 (33%)
had significant weight loss, 20 (19%) had a history of alcoholism, and 34
(32%) had dilated CBD on the CT scan. After the upper abdominal EUS
exam (with FNA whenever indicated) in these patients- 22 patients (21%)
had adenocarcinoma of the pancreas, 14 (13%) had chronic pancreatitis, 28
(26%) had benign lesions, and 34 patients (32%) had a normal EUS exam.
Pancreatic cancer was more likely to be found in patients with significant
weight loss (OR-10.1; 95% CI: 3.3–30.60), jaundice (OR 9; 95% CI: 3–
26.0), and CBD dilatation (OR 3.2; 95% CI: 1.25–8.5) by EUS in this cohort
of patients with indeterminate CT scan findings.
Conclusion: EUS is an effective and safe modality for evaluating pancreatic
lesions in patients with subtle abnormalities of the pancreas found on CT
scan. Patients with jaundice, weight loss, and CBD dilatation are more likely
to have underlying pancreatic cancer and should be referred early for EUS.
1152
Upper Gastrointestinal Tract Lesion Identification by Small Bowel
Capsule Endoscopy
Somia Z. Mian, MD, Milan Dodig, MD∗, Janice M. Santisi, RN. Division
of Gastroenterology and Hepatology, Case Western Reserve at Metrohealth
Medical Center, Cleveland, OH and Department of Gastroenterology and
Hepatology, The Cleveland Clinic Foundation, Cleveland, OH.
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Purpose: Previous studies have demonstrated capsule endoscopy’s ability
to identify lesions within the reach of conventional endoscopy. However, the
significance of this has yet to be clarified, and at this time it is unclear in how
much detail upper gastrointestinal images need to be reviewed for routine
practice. The purpose of this retrospective review of capsule endoscopy
findings is to determine frequency and significance of lesions in the upper
gastrointestinal tract within the reach of conventional endoscopy.
Methods: A retrospective review was made of the Cleveland Clinic IRB
approved Capsule Endoscopy Database consisting of 296 patients who un-
derwent capsule endoscopy over a one year period at our institution. Sig-
nificant lesion was defined as a lesion which explained the patient’s clinical
presentation. Arbitrarily we defined upper gastrointestinal as proximal to the
ligament of treitz. Findings on capsule endoscopy were then compared to
findings on upper endoscopy or push enteroscopy.
Results: Out of 296 patients, 77 patients with positive capsule endoscopy
findings were identified (38 males, 39 females, mean age of 60.09 years). Of
these 23/ 77 (30%) patients had significant findings on capsule endoscopy of
upper gastrointestinal tract. The most common indications for capsule en-
doscopy were iron deficiency anemia (45%), gastrointestinal bleed (34%),
and FAP (8%). Upper endoscopy and push enteroscopy findings were re-
viewed and were available for all 23 patients with significant findings in the
upper gastrointestinal tract. 11/23 (47.8%) patients with positive capsule en-
doscopy had negative upper endoscopy or push enteroscopy. 12/23 (52.2%)
patients with positive capsule endoscopy had corresponding positive find-
ings identified on upper endoscopy or push enteroscopy. In 10/23 (43.5%)
patients positive findings identified by upper endoscopy or push enteroscopy
were not identified by capsule endoscopy.
Conclusion: Capsule endoscopy may be a useful diagnostic tool in identi-
fying upper gastrointestinal lesions. This study showed that 47.8% of upper
gastrointestinal lesions identified on capsule endoscopy was not seen on up-
per endoscopy or push enteroscopy. Although limitations of the study prevent
defining recommendations, it is our opinion that upper gastrointestinal im-
ages in capsule endoscopy need to be reviewed as carefully as small bowel
images.
1153
Automated Video Capture for Quality Control during Colonoscopy:
Real-Time Recognition of “Inside-the-Patient” Status
Piet C. de Groen, MD∗, Sean Stanek, Wallapak Tavanapong, PhD,
JungHwan Oh, PhD, Johnny Wong, PhD. Gastroenterology and
Hepatology, Mayo Clinic, Rochester, MN; Computer Science, Iowa State
University, Ames, IA and Computer Science, University of North Texas,
Denton, TX.
Purpose: Automated, objective quality control during colonoscopy requires
three key components: (1) automated digitial video file generation, (2) au-
tomated metric extraction, and (3) automated report generation. Here we
report on a novel, real-time image analysis technique that in completely
automated fashion creates multiple digital video files each representing a
single endoscopic procedure.
Methods: Two endoscopy rooms were equiped with video digitizers and
PC-compatible workstations. Endoscopy image streams were digitized and
forwarded to the workstations where during four days algorithms in real-
time (analysis rate: 30 frames per sec) determined whether an image
was “outside-the-patient” (OTP) or “inside-the-patient” (ITP; see fig-
ure). The algorithms are based on presence of specific color features and
movement. If an ITP signal was detected, a digitized video file was cre-
ated consisting of the first moment the endoscope was determined to be
ITP until a status was reached of several minutes OTP. This approach
allows for temporal removal of the endoscope for cleaning, polyp re-
trieval or combined procedures consisting of rectal stump and ileostomy
inspection.
Results: Sixty-nine procedures were performed during the four days (see
figure); all started with perianal or peristomal images and ended with sev-
eral minutes of OTP or no signal (equipment turned off). A few procedures
were short (flexible sigmoidoscopy, ileoscopy or an aborted colonoscopy).
A combined ileoscopy and rectal stump inspection was represented as
a single procedure. Three additional small files were recorded: two test
files in which the colon was simulated on purpose by introducting the
endoscope into an enclosed fist and one (1/70; 1%) false positive result
when the endoscope was left on in proximity of a material with skin
color.
Conclusion: We successfully developed automated, real-time recognition
of “inside-the-patient” endoscopy; our results form a first, important step
towards real-time quality control during colonoscopy.[figure1]
1154
Utility of EUS-Guided Trucut Biopsy To Distinguish Pancreatic Rests
from Gastrointestinal Stromal Tumors (A Case Series)
Junaid Siddiqui, MD, Andrew D. Vanderheyden, MD, Chris S. Jensen, MD,
Henning Gerke, MD∗. Internal Medicine/Gastroenterology and
Hepatology, University of Iowa Hospitals and Clinics, Iowa City, IA and
Department of Pathology, University of Iowa Hospitals and Clinics, Iowa
City, IA.
Purpose: Although gastric pancreatic heterotopia or pancreatic rest (PR) is
a harmless condition, it can be confused with other sub-epithelial tumors.
Distinction based on the endoscopic ultrasound (EUS) appearance may be
difficult if overlapping features are present. In these cases a histologic di-
agnosis is desirable. We describe our experience with EUS-guided trucut
biopsy in 3 cases.
Methods: We identified three patients with a final diagnosis of gas-
tric PR in whom EUS guided trucut biopsies were performed. The
endosonographic features and histology findings were retrospectively
reviewed.
Results: In all three patients EUS suggested involvement of the muscularis
propria as typical for a gastrointestinal stromal tumor (GIST). All lesions
were located in the gastric antrum, and the size of the lesions ranged from 14
mm × 10 mm to 15 mm × 11 mm. EUS-guided trucut biopsy was technically
difficult in one patient due to extreme angulation of the endoscope tip, and
no diagnostic specimen was obtained. Since a GIST was suspected, this
patient underwent laparoscopic resection, which revealed the diagnosis of a
PR. In the other two patients EUS-guided trucut biopsy enabled a histologic
diagnosis and no further surveillance or intervention was recommended. No
complications occurred.
Conclusion: Endoscopy and EUS appearances of a pancreatic rest can eas-
ily be confused with a GIST. EUS-guided trucut biopsy may enable a his-
tological diagnosis which can prevent frequent surveillance endoscopies or
surgery.
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Irrigation Pump as an Aid to Colonoscopy
Kavitha Kumbum, MD, Myrta Daniel, MD, Prospere Remy, MD∗.
Gastroenterology, Bronx Lebanon Hospital Center, Bronx, NY.
Purpose: Endoscopy irrigation pump is an aid to endoscopists which al-
lows cleansing or lavage of the bowel. The pump can be operated by the
endoscopist with a foot switch control without interrupting the procedure. It
allows rapid cleansing of a site especially in a poorly prepared patient. The
pump may also facilitate completion of a procedure that might otherwise be
discontinued due to poor preparation. It enables the nurse to concentrate on
other important functions like obtaining biopsies and assisting polypectomy.
Accidental splashes that could occur with the biopsy channel flush can also
be reduced. We wanted to investigate the effect of an irrigation pump on
quality of bowel preparation, completion of procedure, procedure time and
polyp detection.
Methods: We retrospectively reviewed colonoscopy data of patients over 15
day periods prior to and after introducing an irrigation pump at our endoscopy
center. All patients received same instructions for bowel preparation and the
same bowel preparation with Golytely and Dulcolax. Information collected
included indication for colonoscopy, quality of bowel preparation, time for
completion of procedure and findings on colonoscopy. Quality of bowel
preparation was graded by the individual endoscopist using the Aronchick
scale.
Results: Before introduction of irrigation pump (Group A) 103 patients un-
derwent colonoscopy over a 15 day period and 104 after the irrigation pump
(Group B). Both groups had similar number of patients for each indication
for colonoscopy as well as for constipation and change in bowel habits.
More patients in Group B had a good bowel preparation (40 vs 33) and more
patients in Group A had fair bowel preparation (50 vs 43). Both groups
had similar number of patients with poor (A/B: 16/17) and unsatisfactory
(A/B: 4/4) bowel preparation. The endoscopist documented a need for repeat
endoscopy for poor bowel preparation in 15 patients in Group A versus 8
patients in Group B. Both groups had same number of incomplete proce-
dures (4) and terminal ileum intubations (17). Mean time for completion of
procedure was significantly less in Group B (A/B: 27.95 ± 12.34 vs 23.36 ±
11.08, P value = 0.006). More patients in Group B had polyps though both
groups were identical in indication for colonoscopy. The absolute number
of polyps that were detected was greater in Group B (A/B: 167 vs 130).
Conclusion: Use of irrigation pump as an aid to endoscopy will improve a
fair bowel preparation to make it good, will decrease endoscopy time and
may improve polyp detection. This needs to be confirmed in a larger group
of patients.
1156
Safety Monitoring in a Phase 1 First-In-Human Study of the Anti-Viral
Agent CMX001: A Novel Application of Wireless Capsule Endoscopy
H.S. Vanderveldt, MD, W. Painter, MD, A. Robertson, PhD, J.S. Barkin,
MD∗. Div. of Gastroenterology, U. of Miami/Mt. Sinai Med. Ctr., Miami,
FL and Chimerix, Inc., Durham, NC.
Purpose: Wireless Capsule Endoscopy (WCE) is used to diagnose small
bowel disease however it has been utilized infrequently as a method of eval-
uating drug induced small bowel (SB) mucosal changes in healthy adults. In
preclinical studies the dose limiting toxicity of CMX001, a drug being devel-
oped to treat small pox, was enteropathy including small bowel involvement.
The aim of this study was to utilize WCE to monitor and evaluate the effects
of CMX001 on the SB mucosa for the purposes of determining the safety of
the medication.
Methods: Healthy volunteers were pre-selected and divided into 6 person
cohorts. Subjects with a history of significant GI disorders or recent NSAID
use were excluded. Two of five planned cohorts have been enrolled and
completed. In each cohort subjects were randomized to receive either a
single dose of 25µg/kg or 50µg/kg CMX001 or a placebo in a 4(CMX001)
to 2 (Placebo) ratio. The day prior to medication allocation each subject
underwent a baseline WCE. In preparation for the WCE, a clear liquid diet
was instituted following lunch on the day before each study and overnight
fasting was required. No bowel cleansing agents were administered. On
the third day following medication administration WCE was repeated. All
the WCE videos were evaluated twice by 2 separate readers; the readers
were blinded to both study drug versus placebo and pre- versus post- drug
exposure. Following WCE evaluation the results were paired by patient and
the Lewis Score was added as a quantitative method of scoring the results.
Results: There were no significant interval changes in the SB findings be-
tween the pre- and post-dose WCEs. Several patients had pre-dose Lewis
Scores that classified them as having existing mild inflammatory mucosal
changes (< 134). Findings were noted in all pre- and post- dose studies in
patients who received either study drug or placebo. None of these patients
experienced a post-dose worsening of their Lewis Score. Of the 24 sepa-
rate WCE performed findings included, 33.3% with erosions, 62.5% had
petechia, and 33.3% had erythematous/red spots. Other findings included
denudation and mucosal irregularities.
Conclusion: In this on-going clinical pharmaceutical trial, the WCE has
thus far successful demonstrated the lack of clinically significant change in
the SB mucosa of healthy volunteers ingesting a single dose of 25µg/kg or
50µg/kg CMX001.
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The Effect of Small Bowel Transit Time on the Yield of Video Capsule
Endoscopy
Anthony Aghenta, MD, Ayodele Osowo, MD, Vinodh Jeevanantham, MD,
Tarun Kothari, MD, FACG, FACP∗. Internal Medicine, Unity Health
System, Rochester, NY.
Purpose: Although the indications for capsule endoscopy (CE) continue
to expand, it is not fully understood how the small bowel transit time
(SBTT) affects the diagnostic yield of CE examination. Studies have shown
that colonoscopy withdrawal time significantly affects the detection rate of
colonic lesions: the faster the colonoscopy withdrawal time the lower the
yield. We applied the same concept to CE, looking at the small bowel transit
time (SBTT). Study aims: (1) To determine if increased duration of SBTT
increases yield; (2) To assess the optimal SBTT that maximizes yield.
Methods: Between May 2003 and March 2007 a total of 412 patients un-
derwent CE examination. All images were analyzed by an experienced team
of gastroenterologists. In cases of uncertainty about any image there was
a review by a second gastroenterologist before a consensus was reached.
We collected data retrospectively from patient charts and electronic medical
records. All 412 records were reviewed with 130 excluded based on defined
study criteria. We classified the lesions found into positive finding group
(PFG) and negative finding group (NPG). PFG represented any lesion types
detected, e.g. bleeding, tumor, stricture, while NFG represented the absence
of lesions.
Results: A total of 282 patients were included in the study. Mean age was
64.5 ± 15 yrs, and 59% were females. The mean gastric emptying time
(GET) and SBTT were 34.4 ± 35 mins and 239.9 ± 78.6 mins respectively.
The yield was 50.7% with positive findings in 143 patients. The mean age
was higher in the PFG compared to the NFG [66.5 ± 14.8 vs. 62.5 ± 15.1,
P 0.026]. The mean SBTT in the PFG was higher than NFG but was not
statistically significant (247.2 ± 74 vs. 232.3 ± 62.6, P 0.112). There was
a trend of increasing yield with increasing duration of SBTT. There were
more negative findings when the duration of SBTT was less than 200 minutes
(45/81, 55.6%), but there was more positive findings when the SBTT was >
200 mins (107/ 201, 53.2%) Yield by percentage in the PFG was lower than
the NFG until the SBTT became greater than 200 minutes.
Conclusion: Increasing small bowel transit time augments the yield of cap-
sule endoscopy. At SBTT greater than 200 minutes, more lesions are de-
tected. Knowledge and utilization of optimal SBTT can enhance the effec-
tiveness of CE examination of the small bowel. Newer agents need to be
developed to slow down capsule transit time to increase the diagnostic yield.
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Upper Gastrointestinal Findings in Hispanic Patients with Positive
Fecal Occult Blood Test
Javier A. Pou, MD, Maria I. Dueno, MD, Manuel Salcedo, MD, Jaime
Martinez-Souss, MD, Betty Chinea, MD, Doris Toro, MD∗.
Gastroenterology, Veterans Affairs Caribbean Healthcare System, San
Juan, Puerto Rico.
Purpose: Upper GI evaluation in patients with positive fecal occult blood
test (FOBT) and a negative colonoscopy has been justified in the presence of
anemia and upper gastrointestinal (UGI) symptoms. However, it is not clear
if asymptomatic or patients with colonic findings would benefit as well. The
purpose of this study is to determine the role of upper endoscopy (EGD) in
the evaluation of a positive FOBT.
Methods: From January 2000 to December 2005, we retrospectively re-
viewed the electronic medical records, endoscopic and pathology reports
of Hispanic patients consulted to the VA Caribbean Healthcare System GI
Service due to a positive FOBT. Those patients who had a colonoscopy and
an EGD performed for this indication, no more than 90 days apart, were in-
cluded in this study. Patients with history of gastrointestinal (GI) bleeding,
colon cancer and inflammatory bowel disease were excluded. The statistical
method use was Pearson Chi-Square and Odds Ratio.
Results: A total of 311 patients (97% men) with a mean age of 67 years
(range 28–88) met the inclusion criteria. Sixty eight percent (212/311)
of the patients had no reported upper GI symptoms. EGD was positive
in 67% (207/311) of the patients. Findings included: erosive gastritis in
122/207(59%), duodenitis 71/207(34%), peptic ulcer disease 47/207(23%),
erosive esophagitis 19/207(9%), angiodysplasias 13/207(6%), hyperten-
sive gastropathy 11/207(5%), Barrett’s 5/207(2.4%) and upper GI cancers
3/207(1.5%). NSAIDS and/or aspirin were used by 52% (163/311) of the
patients. NSAIDs (N = 89) but not low dose aspirin use, had a significant
association with UGI findings [OR 2; 95 CI (1.1–3.4); P < 0.02]. The pres-
ence or absence of upper GI symptoms did not predict upper GI lesions
(P < 0.21). Colonoscopy findings did not influence the presence or absence
of upper GI findings as well (P < 0.82). Synchronous upper and lower GI
lesions were present in 13% (40/311) of patients.
Conclusion: Upper endoscopy appears to play an important role in the eval-
uation of positive FOBT patients regardless of colonoscopy findings or the
presence or absence of upper GI symptoms. The use of NSAID’s is sig-
nificantly associated with the presence of UGI lesions, increasing the yield
of EGD. In this study, two thirds of our Hispanic patients had significant
UGI findings including 1.5% incidental UGI malignancies. Large prospec-
tive studies and analysis of the cost effectiveness of this approach needs to
be further evaluated.
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Direct Endoscopic Placement of the Wireless pH Monitoring Device
(The Bravo Capsule): A Novel Procedure
Isam Daboul, MD∗, Vikas Ghai, MD, Srini Hejeebu, DO, Adeel Husain.
Gastroenterology, University of Toledo, Toledo, OH and Medicine,
University of Toledo, Toledo, OH.
Purpose: The Bravo Capsule (pH sensor) is used for continuous wireless pH
monitoring in the diagnosis of Gastroesophageal Reflux Disease (GERD).
It is temporarily inserted into the esophagus and attached to the esophageal
wall with the assistance of the Bravo delivery system. Initially an endoscope
is used to determine the gastroesophageal junction distance. The endoscope
is then removed and the device is placed blindly using the Bravo delivery
system according to the measurements described by the endoscopy. After the
placement of the Bravo capsule, the endoscope is reinserted again to confirm
its attachment and location. This conventional method is a blind technique
of placement and requires a second intubation of the esophagus to confirm
attachment and correct positioning of the capsule.
The new technique used in the study of Bravo capsule placement provides
an accurate positioning and confirms attachment of the capsule under direct
endoscopic visualization. The Bravo delivery system is concurrently placed
without removing the endoscope and the device is released in the desired
location.
This sudy was designed to evaluate a new technique of Bravo wireless pH
device placement under direct endoscopic visualization.
Methods: After approval from the institutional review board (IRB), we con-
ducted a retrospective study of 58 patients (29 patients with indirect and
29 patients with direct visualization) who had Bravo capsule placement be-
tween 2005 and 2007. The physician endoscopy procedure notes, nurse’s
notes, post procedure notes, and recovery notes were all reviewed. The 48
hour pH monitoring computer generated analysis results were also reviewed.
Results: Out of the 58 patients who had direct and indirect bravo capsule
placement, there were no early detachments of the device and no immediate
complications related to the procedure reported. There were no failures due
to the technique in either the direct or indirect method.
Conclusion: There was no early detachment after the procedure from any
patient in either the direct or indirect endoscopic placement techniques. The
placement of the wireless pH monitoring device under direct endoscopic
visualization provides a sufficient and a safe technique that negates the need
for a second intubation. This also provides better confirmation of the attach-
ment and positioning of the device. A larger prospective study would provide
more information regarding complications and adverse effects.
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Seizure-like Activity and Other Adverse Events While Using Propofol:
A Retrospective Observational Study of 38,575 Sequential Endoscopies
in an Outpatient Gastrointestinal Endoscopy Center
Ketul Patel, MD, Ryan Fauble, MD, Su-Linn Zywiol, MS, Alan Cutler,
MD∗. Gastroenterology, Providence Hospital and Medical Center,
Southfield, MI and Michigan Endoscopy Center, Farmington Hills, MI.
Purpose: To examine the occurrence of seizure-like activity and other ad-
verse events during propofol-mediated gastrointestinal endoscopies.
Background: Propofol is a fast acting hypnotic, with action on GABA
receptors. In recent years propofol has increasingly been administered for
sedation during endoscopic procedures. Multiple studies have identified the
propofol-related cardiopulmonary complications. More recently there have
been case reports describing seizure like activity (SLA) in propofol-mediated
sedation. However, reports of SLA during gastrointestinal endoscopy are
scarce.
Methods: This is a retrospective observational study from a single outpa-
tient practice comprised of 18 U.S. gastrointestinal endoscopists. Data was
collected from January 2005 to May 2007. A total of 38,575 sequential en-
doscopic procedures were performed using propofol, administered by nurse
anesthetists. Procedures included both, esophagogastroduodenoscopies and
colonoscopies. ASA classes for patients undergoing endoscopy ranged from
I-III. Standard monitoring with pulse oximetry, automated sphygmomanom-
etry, and electrocardiographic telemetry was performed. All adverse events
related to propofol administration were recorded.
Results: The number of propofol administered endoscopic procedures per-
formed over a twenty-nine month period was 38,575, with a total of 107
(0.277%) anesthesia related complications. A total of 71 (0.18%) cardiopul-
monary complications: 5 (0.013%) apnea/hypoxia, 23 (0.06%) possible as-
pirations, 11 (0.029%) laryngospasms, 2 (0.005%) hypotension 10 (0.026%)
hypertension episodes, 17 (0.044%) arrhythmias, and 3 (0.0078% chest
pain). SLA was identified in 1 (0.0026%) patient. A sample of 190 patients
over a five-day consecutive period was evaluated to calculate the mean dose
of propofol given during procedures. The mean dose of propofol was 254 ±
78 mg (range of 60–600 mg). The one patient who had SLA received a total
of 150 mg. The SLA occurred during induction with propofol, the patient
remained conscious through the episode. Once resolved, the procedure was
completed without further incident.
Conclusion: Propofol can be safely administered for gastrointestinal en-
doscopy. Seizure like activity is an extremely rare occurrence when utilizing
propofol for sedation in patients undergoing gastrointestinal endoscopy, ir-
respective of dosage.
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A Retrospective Comparison of Percutaneous Endoscopic and
Radiologic Gastrostomy Tube Feeding
Saleh Alqahtani, FRCPC, Alaa Rostom, FRCPC, Eldon A. Shaffer,
FRCPC∗. Medicine, University of Calgary, Calgary, AB, Canada.
Purpose: To compare efficacy and safety of percutaneous endoscopic gas-
trostomy (PEG) versus percutaneous radiologic gastrostomy (PRG).
Methods: A retrospective review of 70 health records evaluated: the in-
dications for the procedure, technical success rate, complications during
hospitalization (wound infections, bleeding, perforation, and death), length
of hospital stay and death before discharge.
Results: 70 randomly selected patients with gastrostomies had a chart re-
view: N = 30 for PEG and N = 40 for PRG. PEG patients had a mean age of
71 ± 15 y; 56% were male. PRG patients had a mean age of 67 ± 18 y; 63%
were male. Major co-morbidities in the study population were: cardiac dis-
eases 37%, pulmonary diseases 30%, hypertension 53%, diabetes 23% and
neuromuscular diseases 77%. The mean length of hospitalization was 35 ±
27 days. The indications for gastrostomy feeding were: 74% for neurological
disorders, 18.6% for head and neck cancer; and 7.4% for dysphagia or other
reasons. Technical success was similar for PEG and PRG groups (93.3% vs.
92.5%, respectively). Early complications occurred in 10% of PEG group vs.
12.5% PRG and (P = 0.633). Two patients had GI bleed and required endo-
scopic intervention. 3 had bowel perforation and another 3 wound bleeding.
Wound infection was more frequent in PEG group than PRG group (10%
vs. 7.5% respectively; P = 0.711). Late complications were more common
in PRG group than PEG group (10% vs. 0%; P = 0.204) including GI bleed
in 2 patients, wound bleed in 1 and tube displacement in another. Inciden-
tal endoscopic abnormalities, an advantage of the endoscopic method, were
identified in 9 patients (30%) of the PEG group. Seven had PUD; 1 had
an esophageal ulcer, and another had a hiatus hernia. No procedure-related
mortality occurred either group. 10% of the study group died for reasons
other than the gastrostomy during the same hospital admission.
Conclusion: Percutaneous gastrostomy, whether placed endoscopically or
radiologically, is a quite safe and effective method for enteral feeding. The
radiologic method of insertion however had a modest increase in complica-
tions.
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Should Patients Be Screened for Celiac Disease Prior to Gastric
Bypass Surgery?
Nazif Chowdhury, MD, Zeba Anwar, MD, Ali Marhaba, MD∗. Internal
Medicine Residency Program, United Health Services, Johnson City, NY
and Gastroenterology, United Health Services, Johnson City, NY.
Purpose: Obesity is the second leading cause of preventable death in the
United States. It is estimated that there are 60 million obese people in the
US. With obesity reaching epidemic proportions gastric bypass surgery has
become an increasingly popular option for weight reduction. Therefore the
question of screening patients prior to surgery has arisen. At this time no
such screening criteria exists. Certain conditions such as the one presented in
this case, celiac disease, may be detrimental in a patient who has undergone
gastric bypass surgery.
Results: 57 year old obese Caucasian female who had gastric bypass surgery
6 months prior and presented with nausea, intermittent loose watery diar-
rhea, dull abdominal pain in the epigastric area for 2 weeks, iron deficiency
anemia and laboratory values with evidence of malabsorption. Patient’s post
operative period was uneventful and she lost a total of 140 lbs since the
operation. She underwent an upper endoscopy for evaluation which showed
gastritis and enteritis. A small bowel biopsy was taken which showed lympho-
cytic duodenitis and mild atrophy of the villi compatible with celiac disease.
Serologic studies were performed for endomysial IGA antibody and Gliadin
IGG and IGA antibodies all of which came back positive. The patient was
diagnosed with celiac disease and placed on a gluten free diet and proper
nutritional supplementation. Subsequently her symptoms resolved.
Conclusion: This case clearly illustrates a patient with malabsorption due
to celiac disease which was worsened by gastric bypass surgery. Therefore
the question arises: should patients be screened for celiac disease prior to
gastric bypass surgery. Further studies need to be performed to answer this
question.
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Biopsy Forceps-Guided Ileal Intubation (BIGII)
Tat-Kin Tsang, MD∗, Tiffany Graybill, MD. Department of Medicine,
Feinberg School of Medicine, Northwestern University, Evanston, IL.
Purpose: Majority of colonoscopies are done for screening for colon cancer
in this country. However, there are still quite a number of colonoscopies done
for diagnostic purposes, and in certain cases, ileal intubation is paramount
for diagnostic work-ups. However, in certain situations, when the ileocecal
valve is pointed southward and posteriorly, colonoscopic ileal intubation is
impossible. The purpose of this study is to describe a new technique for the
colonoscope to enter the terminal ileum in the cases of failed ileal intubation.
Methods: For the patients whom colonoscopic ileal intubation fails after 10
minutes of attempt, we would attempt to enter the terminal ileum with biopsy
forceps-guided ileal intubation (BIGII) in 4 steps: 1) Tort the scope so that
the ileocecal (IC) valve is at the lower quartrant; 2) Pass the biopsy forceps
so that it passes beyond the IC valve. Turn the scope down so that the biopsy
forceps is pressed against the IC valve; 3) withdraw the biopsy forceps slowly
until the IC valve opening appears. Then slide the biopsy forceps into the
terminal ileum (TI) as far as it meets resistance; 4) Gently push the scope
into the TI as the biopsy forceps was withdrawn simultaneously in an one to
one fashion.
Results: From December fifth to November 20, there were 1630 colono-
scopies performed. 326 required ileal intubation for diagnostic purposes
and 27 failed ileal intubation. The failure rate is 8.3%. The average age
was 61.1 ranging from 23 to 86. There were 12 males and 15 females. Diar-
rhea(8), abdominal pain(8), anemia/GI bleed(7) and IBD(5) are the common
indications for ileal intubation and only one has SBO. 24/27 (88.9%) were
successful in ileal intubtion by BIGII. And in most patients, the TI could be
intubated by BIGII in three minutes. One patient who failed ileal intubation
by BIGII was successful when the usual technique was attempted again.
Conclusion: BIGII is a very useful technique in intubating the terminal
ileum and helping the diagnosis when the usual technique fails to intubate
the terminal ileum.
1164
Radiation Exposure in Endoscopic Retrograde
Cholangiopancreatography
Vasu Appalaneni, Tammy Glenn, Donald G. Frey, Christopher Lawrence,
Brenda J. Hoffman∗. Digestive Disease Center, Medical University of
South Carolina, Charleston, SC.
Purpose: Present recommendations suggest limiting fetal irradiation to less
than 500 mrem (0.5 rad) during gestation. From prior studies, the estimated
fetal dose to pregnant patients undergoing endoscopic retrograde cholan-
giopancreatography (ERCP) who have been shielded with 0.5 mm lead
aprons has been within acceptable safety guidelines. The radiation expo-
sure to the pelvis from scattering of the x rays during ERCP is unknown. If
the patients were pregnant but not aware, they would need to be counseled
regarding the risk to the fetus following ERCP. To understand the level of
skin exposure and so the estimated level of exposure to the fetus for better
counseling, further studies are needed.
Aim: To determine the level of radiation exposure that occurs during ERCP
to see if shielding of the abdomen is necessary for female patients of child-
bearing age.
Methods: 5 prospective consecutive adult patients, (3 males and 2 non
pregnant females) who were scheduled to undergo ERCP with or without
pancreaticobiliary manometry were included in the study. Pre-procedure
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preparation was done in a standard local protocol. The study was approved
by local IRB, and all of the patients signed the informed consent. Prior
to the ERCP, a calibrated lithium fluoride thermo luminescent dosimeter
(TLD), (K&S Associates, Inc., Nashville, TN) were applied at four differ-
ent sites, one in the suprapubic region anteriorly, two on right and left mid
inguinal points respectively, and one over the sacrum. ERCP was performed
for various indications with patients in prone position. Dosimeters were then
removed and data was obtained on the level of radiation exposure. The results
were then compared.
Results: A total of 5 prospective consecutive patients were studied. The aver-
age time of radiation exposure was 11.44 minutes (range 5.6–15.4 minutes).
No adverse effects were reported secondary to the TLD. The average level
of exposure was 0.625 rads (range 0.1 to 2.2). The approximate amount
of radiation received at the center of pelvis is expected to be half of the
dose recorded on the surface TLD, which appears to be in a safe range in
pregnancy.
Conclusion: There is minimal radiation exposure to the unshielded abdomen
and the pelvis during ERCP, far below the acceptable safety guidelines.
Unshielded ERCP can be performed in a child bearing age female with or
without known pregnancy with limited radiation exposure to the fetus.
1165
Endoscopic Treatment of Malignant Colonic Obstruction Using
Expandable Metal Stents: Experience in 169 Patients
Aaron J. Small, BA, Todd H. Baron, MD∗. Dept of Medicine, Div of
Gastroenterology, Mayo Clinic College of Medicine, Rochester, MN.
Purpose: Self-expanding metal stent (SEMS) placement is a suitable ther-
apeutic option for relief of colonic obstruction for both palliation and as
“bridge to surgery.” This study aimed to investigate the efficacy of stent-
based treatment for malignant large bowel obstruction.
Methods: From April 1999 to August 2006, we monitored patients who
had undergone endoscopic placement of a SEMS for malignant colonic ob-
struction using a retrospective database. Enteral Wallstents and Ultraflex
Precision Colonic stents (Boston Scientific) were used. Patients were char-
acterized by age, malignant stricture location, stent-induced complications,
and need for reinterventions.
Results: In total, 134 patients were treated (mean age 63.5 years, range 17
to 94) with palliative intent and 35 were treated as “bridge to surgery.” For
160 of 169 patients (94.7%), stents were placed successfully and obstruc-
tion clinically resolved in all but one of patient. The remaining nine patients
experienced stent dislocation/dysfunction at the time of placement. The lo-
cation of obstruction was: rectosigmoid colon (N = 97, 57.4%), descending
colon (N = 24, 14.2%), splenic flexure (N = 11, 6.5%), transverse colon
(N = 15, 8.9%), hepatic flexure (N = 9, 5.3%), and ascending colon (N =
13, 7.7%). There was no peri-interventional morbidity or mortality. One pa-
tient experienced an intra-procedural perforation. The median in situ time
for the stents in the palliative group was 48.5 days (mean, 93 days) with 36
of 133 patients having complications (27.1%) including perforation (N =
12), occlusion (N = 12), migration (N = 8), erosion/ulcer (N = 3), and
stent collapse (N = 1). Twenty-eight patients were treated endoscopically,
and 36 underwent surgical intervention. Palliative patients had a median
survival time of 167 days (range, 43 to 291). In the preoperative group,
the median in situ time for the stents was 5.5 days (mean, 32 days). Three
of the 35 preoperative patients had complications (8.6%) prior to opera-
tion (one occlusion, one migration, and one perforation). Of these patients,
two required endoscopic reintervention. Overall, SEMS patients had an en-
doscopic reintervention rate of 17.8% and a surgical intervention rate of
21.3%. No further intervention was required for all remaining patients by
follow-up.
Conclusion: Endoscopic stenting can effectively relieve malignant colorec-
tal obstruction as both palliative and preoperative therapy. SEMS can be
applied to both left and right-sided colonic lesions with few complications.
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A Novel Use of Side-Viewing Endoscopy: Detection, Visualization, and
Removal of Technically Difficult Left Sided Polyps
Jerry Martel, MD, Amar Deshpande, MD, Robert I. Goldberg∗. Division
of Gastroenterology, Mount Sinai Medical Center, University of Miami
Miller School of Medicine, Miami Beach, FL.
Purpose: The traditional forward-viewing colonoscope provides a fairly
complete view of the colonic mucosa, yet polyps located in areas of acute
angulations and traversing folds have always been problematic to detect in
the forward view. Moreover, the suboptimal visualization of these areas can
make the excision of such polyps technically challenging. Here we describe
a novel use for the side-viewing duodenoscope in detecting, visualizing, and
removing technically difficult left-sided polyps around folds and turns in the
colon.
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Results: We report three patients who underwent colonoscopy for different
clinical conditions who were found to have left-sided polyps in technically
difficult positions with the traditional forward-viewing colonoscope. The
side-viewing endoscope was inserted and advanced to the area where the
polyp was located and proved to be better visualized (Fig. 1). The polyps
were removed en toto through different techniques through the side-viewing
endoscope providing unique angles of visualization and additional techni-
cal abilities to properly excise the polyp through the use of the elevator
(Fig. 2).[figure1][figure2]
Conclusion: The use of side-viewing endoscopy for technically difficult
polyps is a new application of an established instrument which should be
considered when encountering these lesions.
1167
Predicting Sedation Induced Respiratory Compromise during
Colonoscopy
Suzanne B. Karan, MD∗, William Voter, MA, Ashok Shah, MD, William
Sauer, BS, Denham S. Ward, MD, PhD. Anesthesiology, University of
Rochester, Rochester, NY and Gastroenterology, University of Rochester,
Rochester, NY.
Purpose: Predicting respiratory compromise during sedation for colono-
scopies is beneficial as more patients are presenting with obstructive sleep
apnea (OSA). Measurement of upper airway collapsibility (critical pressure
of the pharynx, Pcrit) offers potential in assessing the propensity for seda-
tives to produce airway obstruction 1;2. The specific aim for this study was to
compare Pcrit during sedation to the need for clinical intervention to maintain
adequate ventilation.
Methods: We recruited patients who were scheduled for outpatient
colonoscopy under intravenous sedation. Airway collapsibility was mea-
sured using a device to produce negative airway pressure and quantified in
terms of the amount of pressure required to produce no inspiratory flow in
spite of respiratory efforts. The comparison outcome measurement was a
“clinical intervention score (CIS)” – a graded intervention performed by the
nurse administering the sedation in order to restore adequate ventilation in
the subjects.
Results: 17 patients (6 F), mean age 54 yrs (29–68), mean BMI 29 (23–40)
completed the study. Sedation was managed by the gastroenterologist with
midazolam, fentanyl or meperidine. No patients had a history of OSA, though
three patients had an Epworth Sleepiness Scale score >10. Upper airway
collapse (UAC) was elicited in 9/17 subjects. In 7/9 subjects, the Pcrit was
less negative during sedation than while awake (indicating more collapsible
upper airways during sedation). Central apneas were elicited in 4 subjects
who did not experience frank UAC, and 1 patient had a combination of
central and obstructive apneas. 6/17 patients required a clinical intervention
during their colonoscopies, though these were not predicted by their Pcrit
during sedation.
Conclusion: Sedation induced Pcrit in our cohort did not predict the
clinical intervention needed to restore adequate ventilation during seda-
tion for colonoscopy. This contrasts with the correlation between Pcrit
under anesthesia with the patient’s sleep apnea hypopnea index. Seda-
tion may still maintain the pharyngeal tone that is abolished during
anesthesia. Negative airway pressure application did elicit central ap-
neas in our cohort, which may indicate instability of the central res-
piratory controller in the face of pharyngeal negative pressure reflex
instigation.
Support: FAER Research Starter Grant.
REFERENCES
1. Litman RS, et al. Anesthesiology 2002; 96: 342–5
2. Norton, JR, et al. Anesthesiolgy 2006; 104:1155–64.
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Recall of Informed Consent and Patient Satisfaction with the Addition
of an Educational Video Prior to Colonoscopy
Nirmala M. Sivaprakasapillai, MD, Aditi Nerurkar, MD, Gregory Seltzer,
MD, Adam B. Elfant, MD∗. Gastroenterology/Internal Medicine, Cooper
University Hospital, Camden, NJ.
Purpose: Obtaining informed consent prior to procedures is important for
medico-legal reasons as well as for patient satisfaction. Studies have shown
that patients often do not recall information about procedures. The purpose
of this study was to evaluate whether the addition of an educational video to
the standard informed consent process would improve recall and satisfaction
of patients undergoing colonoscopy.
Methods: 100 patients were randomized to either standard consent (NVG)
or standard consent plus an educational video (VG). Standard consent in-
volved obtaining written and verbal consent. The educational video taped
by an experienced endoscopist explaining the elements of informed consent
was shown the day of the colonoscopy. It included the various indications,
risks, benefits, and alternatives. Patients over 18, willing to participate were
enrolled. All received a follow up phone call within 72 hours, at which time
they were asked to recall the above elements of informed consent. We as-
sessed spontaneous recall (SR), no recall, and satisfaction in both groups.
10 patients were lost to follow up and 45 were enrolled in each arm. Re-
sults were analyzed utilizing binomial distribution. A P-value of <0.05 was
considered to be statistically significant.
Results: There was no significant difference in the demographic data be-
tween the groups. SR of the indications of gastrointestinal bleeding, anemia,
abdominal pain, and change in bowel habits was statistically significant in
favor of VG (P = 0.030,0.044,0.037, 0.0005 respectively). SR of infection
and perforation risks were significantly greater in the VG (P = 0.033, 0.010
respectively). The VG demonstrated statistically significant SR of the benefit
of removing colon polyps (P = 0.002). Patients in the VG had significantly
better SR of virtual colonoscopy (P = 0.0003) and barium enema (P =
0.001) as alternatives whereas the NVG had a significant lack of recall of the
same alternatives (P = 0.001, 0.019 respectively). The NVG had statistically
significant lack of recall for the indication of anemia (P = 0.021) and risk of
infection (P = 0.003). Level of satisfaction was significantly greater in the
VG (P = 0.016). A significant number of patients in the NVG compared to
the VG, felt that the information provided was not enough (P = 0.016).
Conclusion: The addition of an educational video prior to colonoscopy
significantly improves recall of the elements of informed consent and patient
satisfaction with their procedure.
1169
Comparison of Direct Endoscopic Guided Placement of the Bravo
Capsule with the Conventional Method
Isam Daboul, MD∗, Vikas Ghai, MD, Srini Hejeebu, DO, Adeel Husain.
Gastroenterology, University of Toledo, Toledo, OH and Medicine,
University of Toledo, Toledo, OH.
Purpose: The conventional method for Bravo placement used by the majority
of gastroenterologists is a blind technique of placement and requires a second
esophageal intubation to confirm attachment and correct positioning of the
capsule.
The new technique presented in this study uses the Bravo delivery system
without removing the endoscope and releases the capsule in the desired
location under direct endoscopic visualization.
This Bravo capsule placement study compares adverse effects between the
new direct endoscopic technique and the conventional indirect technique.
Methods: With institutional review board (IRB) approval, we conducted a
post-procedural questionnaire of 58 patients (29 patients with indirect and
29 patients with direct visualization) who had Bravo capsule placement be-
tween 2005 and 2007. Patients were assessed by post-procedural symptoms
including chest pain, sore throat, difficulty swallowing, and a satisfaction
grade (1–10).
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Results: Of the 58 patients who underwent Bravo capsule placement, 19 had
a sore throat after the procedure (7 patients with direct endoscopic capsule
placement compared to 12 with indirect capsule placement) (P = 0.26).
Thirteen patients had chest pain or chest discomfort following the procedure
(6 patients with direct placement compared to 7 with indirect placement)
(P = 1). An excellent satisfaction grade (8–10) was noted by 25 patients
from the direct endoscopy study and all 25 agreed to a repeat procedure if
necessary as compared to 23 from the indirect endoscopy study (P = 0.73).
Conclusion: The placement of the Bravo wireless pH monitoring device un-
der direct endoscopic visualization provides an effective and safe technique
that negates the need for a second esophageal intubation. This also provides
better confirmation of the attachment and positioning of the device. The inci-
dence of sore throat in the direct method proved to be less common than that
of the indirect method, however was not statistically significant. This can be
attributed to a single esophageal intubation in direct endoscopic visualiza-
tion versus reintubation in the indirect method, though a larger prospective
study is warranted.[figure1]
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Can Colonoscopy Performed for Reason Other Than Screening
Replace Screening Colonoscopy for Colorectal Carcinoma Screening
Hemal Patel, MD, Essam Quraishi, MD, Rana Sabbagh, MD, Osama
Alaradi, MD∗. Internal Medicine, and Gastroenterology, Henry Ford
Hospital, Detroit, MI.
Purpose: Colonoscopy is performed as a screening procedure for colorectal
cancer (CRC). During this procedure, polyps, which could be premalig-
nant lesions, are removed thereby reducing the risk of development of CRC.
Gastroenterologists also perform colonoscopy for other indications such as
bleeding and anemia. The aim of this study is to determine if there is a differ-
ence in the rate of polyp detection between screening and other indications
for colonoscopy.
Methods: All colonoscopies performed at Henry Ford Hospital for a period
of one year between 03/01/1999 to 04/01/2000 were reviewed. The indication
for colonoscopy and findings were noted in all cases. The primary end point
was the detection of any polyp based on size and the secondary end point
Table 1. Indication of colonoscopy and rate of polyp detection
Abnormal Postive Iron deficiency Change in
Indication Screening Surveillance radiology Bleeding FOBT anemia bowel habits
Rate of any polyp detection (%) 68 62 63 40 38 37 26
Rate of <10 mm polyp detection (%) 55 49 37 31 30 28 22
Rate of adenomatous polyp detection (%) 44 46 44 26 28 27 11
was the detection of an adenomatous polyp. The chi-square test was used to
calculate the percent differences in polyp detection between groups based
on the indication for colonoscopy.
Results: There were a total of 2096 colonoscopies performed on 1547 pa-
tients. Of these patients, 48% were male, 67% were African American and
30% were Caucasian. Of the 2096 colonoscopies performed, polyps were de-
tected in 980 (46.7%), and of these 675 (32%) were adenomatous polyps. Ma-
jor indications for colonoscopy were screening (12%), surveillance (18%),
abnormal radiology (4%), bleeding (30%), positive fecal occult blood test
(17%), iron deficiency anemia (11%) and bowel habit change (7%). Rate of
detection of any polyp, <10 mm polyp and adenomatous polyp are presented
in Table-1. Rate of polyp detection (for all three groups) in screening and
surveillance colonoscopy were higher in comparison with other indications
and were statistically significant (except abnormal radiology).
Conclusion: The rate of detection of all polyps, including polyps <10 mm
and adenomatous polyps, was significantly higher in screening and surveil-
lance colonoscopy than other indications for colonoscopy. Any program
using colonoscopy to screen for colo-rectal cancer that is based on bleeding
or anemia has rates of polyp detection inferior to general screening and is
inappropriate.
1171
The “Jist” of It: Transgastric EUS-Guided Diagnosis of Small Bowel
GIST Masquerading as a Peripancreatic Lymph Node
Amar R. Deshpande, MD, Afonso Ribeiro, MD∗. Division of
Gastroenterology, Department of Medicine, University of Miami Miller
School of Medicine, Miami, FL.
Purpose: A 76 y/o female with a history of coronary artery disease had an
episode of mild pancreatitis managed conservatively. There was no biliary,
toxic, or dyslipidemic etiology, and she denied jaundice, weight loss, dia-
betes, or steatorrhea. After a second episode 8 months later, a CT scan was
acquired, revealing a cystic lesion in the body of the pancreas.
She was therefore referred for EUS. This showed a 17×8 mm anechoic
lesion in the body of the pancreas with a thin wall and no septae. There
was no associated mass, internal debris, or chronic pancreatitis, and both the
common bile duct and pancreatic ducts were normal; FNA was performed.
Incidentally noted was a 24×11 mm peripancreatic solid lesion resembling
a lymph node (see image). A transgastric approach was then undertaken for
both FNA and Trucut core biopsy.
The FNA of the cystic lesion stained positive for mucin, fluid CEA was
1637 ng/mL, and the cytology was negative, all consistent with a mucinous
cystadenoma (MCA). The FNA of the peripancreatic mass was unrevealing,
but the core biopsy had foci of spindle cells that stained positive for c-kit,
strongly suggesting GIST.
The patient underwent an enucleation of the cystic lesion and a resection of a
submucosal lesion in the fourth portion of the duodenum. Surgical pathology
confirmed pancreatic MCA and small bowel GIST. In retrospect, the patient
denied any bleeding or obstructive symptoms; review of the prior CT also
failed to demonstrate any small bowel lesion.
This case highlights the discovery of a small bowel GIST found incidentally
on endosonography due to the serendipitous location of the distal duodenal
tumor immediately adjacent to the greater curvature of the stomach. GISTs
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are relatively uncommon, with a prevalence of about 15/million, only 20%
of which are found in the small bowel. The rate of malignancy is usually
low, but in small bowel GIST, about 50% of lesions are malignant. They
are classically subepithelial with central umbilication and positive immuno-
histochemistry for c-kit. The therapy for these tumors is resection if not
metastatic; otherwise, tyrosine kinase inhibitors can be used.[figure1]
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Successful Endoscopic Closure of Postoperative Colocutaneous Fistula
Rajasekhara R. Mummadi, MD, Guillermo Gomez, MD, Gottumukkala S.
Raju, MD, MRCP∗. Division of Gastroenterology, The University of Texas
Medical Branch, Galveston, TX and Department of Surgery, The University
of Texas Medical Branch, Galveston, TX.
Purpose: Colocutaneous fistula is a disabling complication of postopera-
tive anastomotic colonic leak. Endoluminal closure may be an option worth
pursuing in those who are not candidates for surgery.
Aim: We report endoscopic closure of a chronic colocutaneous fistula in a
morbidly obese patient who was not a candidate for surgical revision.
Case Report: A 56-year old woman with morbid obesity (390 lbs) and
sleep apnea underwent a right hemicolectomy for colon cancer. Her post
operative course was complicated by a pulmonary embolism. Anastomotic
leakage resulted in a large intra abdominal abscess that developed into a
colocutaneous fistula (daily output: 50–100 cc fecal matter and pus).
Due to morbid obesity and recent pulmonary embolism, surgery was de-
ferred; endoscopic therapy was recommended.
Endoscopic Therapy: Step 1:. Cap fitted colonoscopy allowed identification
of a 1 cm fistula at the anastomotic site. Step 2: The fistula was probed with
a forceps – small amount of pus came out. Step 3: Cautery of the fistula with
a BICAP probe to freshen up the wound Step 4: Clip closure of fistula: 4
Resolution clips were used to close the defect.
Follow-up: First 24 hours: The fistula out put decreased from 50 cc to 2
cc within 24 hours. 3 month followup: the fistula was found to be healed;
intermittently, the scab broke down with discharge of a few cc of pus that
required three courses of broad spectrum antibiotics. 6 months: complete
healing of fistula.
Summary & Conclusion: Our case demonstrates the feasibility of endo-
luminal closure of chronic colo-cutaneous fistula complicating anastomotic
leak following colon resection. Endoscopic therapy resulted in a dramatic
reduction of the fistula output from 50–100 cc to a few cc immediately after
closure, with eventual closure of fistula after a few weeks. In conclusion,
endoscopic closure of colocutaneous fistula complicating anastomotic leak
is an option worth pursuing.[figure1]
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Successful Ablation of Barrett Esophagus with Dysplasia Using the
HALO Ablation System in a Prospective Cohort
Virender K. Sharma, MD, Christopher Wells, MD, Hack J. Kim, MD,
Ananya Das, MD, Giovanni DePetris, MD, Roxane McLaughlin, RN∗,
David E. Fleischer, MD. Gastroenterology, Mayo Clinic Arizona,
Scottsdale, AZ.
Purpose: To assess the safety and efficacy of a step-wise regimen of circum-
ferential and focal ablation using the HALO ablation system (Barrx Medical
Inc., Sunnyvale, CA) for the treatment of Barrett esophagus (BE) containing
low-grade (LGD) or high-grade dysplasia (HGD).
Methods: HALO ablation system consists of a balloon based electrode array
for circumferential and an endoscope -mounted, paddle-based electrode ar-
ray for focal ablation of BE. Patients with BE and LGD or HGD, confirmed by
2 pathologists including 1 expert GI pathologists, were treated with circum-
ferential ablation. Repeat ablation (circumferential or focal) was performed
at 3 month intervals until BE was completely eradicated. Lugol’s chromoen-
doscopy with targeted biopsies from visible BE and random biopsies from
the original BE region were obtained at regular follow-up intervals to assess
for residual intestinal metaplasia (IM) and dysplasia. A complete response
(CR) is defined as all biopsies for a patient negative for any dysplasia, HGD,
LGD or IM (separate analyses) at last follow-up. All adverse events were
recorded.
Results: Sixty-four patients were treated, 62 had atleast one set of biopsies
post ablation and were included in the efficacy analyses (58 men; median age
71 years; median length of BE 5 cm; 39 LGD; 25 HGD, median follow-up
12 months). Results from the last biopsy follow-up of 38 LGD patients; 25
(68%) normal squamous mucosa, 8 (21%) focal islands of non-dysplastic
IM, 1 (3%) IM indefinite for dysplasia, 2 (5%) LGD, and 1 (3%) HGD in the
cardia. Results from the last available biopsy follow-up of 24 HGD patients;
13 (54%) normal squamous mucosa, 4 (17%) focal islands of non-dysplastic
IM, 3 (13%) IM indefinite for dysplasia, 1 (4%) LGD, and 3 (12%) HGD.
The CR for both LGD and HGD was 92% and 88%, respectively. A total
of 64 patients were included in the safety analyses. 1 (2%) patient each
had self-limited GI bleed and mild esophageal stricture. There have been no
instances of subsquamous intestinal metaplasia, “buried Barrett,” identified
on review of >3000 biopsies.
Conclusion: Ablation of BE containing dysplasia using the HALO ablation
system appears to be safe and effective, with CR for both LGD in the LGD
cohort and HGD in the HGD cohort was 92% and 88%, respectively. Patient
tolerance and safety with the procedure has been excellent. There has been
no evidence of subsquamous intestinal metaplasia, “Buried Barrett” post-
ablation.
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What Questions Do Patients Ask during Colonoscopy? A Prospective
Study in an Ambulatory Endoscopy Center
Lawrence M. Hurwitz, MD∗, Gregory A. Ardigo, MD, Shelley Lamkin, RN,
Huhn Kym, RN, Hutchens Jennifer, RN, Pena Jason. Endoscopy Center of
Inland Empire, Murrieta, CA.
Purpose: Patient education prior to colonoscopy is important in facilitating
compliance, reducing anxiety and establishing a better informed patient.
Patient understanding of the procedure and what events will happen during
the test are paramount in reducing stress driven reactions during the exam.
We conducted a prospective study cataloging patient questions prior to and
during conscious sedation to determine if current colonoscopy education
pamphlets meet patient needs.
Methods: Consecutive patients undergoing colonoscopy in an ambulatory
endoscopy center were enrolled. Age and sex demographics and indication
for the procedure were recorded. Questions asked by patients were recorded
during the procedure by nursing personnel.
Results: Study Duration: one week
Number of colonoscopies: 64
Age Range: 38–76
Median Age: 56
Modal Age: 46
Number of patients asking questions: 13
Indications for procedure: screening 12; change bowel movements: 1
Number of Questions Asked: 23
Categories of Questions and Percentage of Total Queries
Length of Procedure 17.4%
Interpretation of findings on Monitor 34.8%
Genitourinary query 4.3%
Medication questions 8.7%
Time to resumption of normal activities 4.3%
Administrative 4.3%
Queries regarding abdominal discomfort 8.7%
Queries regarding the colonoscope 4.3%
Limitations of examination 4.3%
Recovery time 8.7%
Conclusion: Patient questions during colonoscopy involved multiple topics
that are not often addressed in colonoscopy education pamphlets. Inclusion
of topics addressing explanation of images and artifacts on the endoscopy
monitor, medications utilized, recovery time and limitations of the examina-
tion would be helpful in aiding patient education.
1175
A Survey of the Practices of New York Area Endoscopists Regarding
Colonoscopic Surveillance Intervals in Patients with Incomplete Bowel
Preparation
Judy Oh, MD, Farooque Dastgir, MD, Toomas Sorra, MD, Adnan Khdair,
MD, Irwin M. Grosman, MD∗. Gastroenterology, Long Island College
Hospital, Brooklyn, NY.
Purpose: The purpose of the study was to conduct a survey of endoscopists
in New York City area regarding their opinions about surveillance intervals
for screening colonoscopy in patients with incomplete bowel preparation.
Methods: Approximately 300 surveys were mailed to NYC area gastroen-
terologists. Questions were asked regarding practice setting, involvement
with trainees, the number of colonoscopies performed annually and the bowel
prep used. Respondents were asked to define an “adequate prep.” Then they
were given different scenarios of reasons for surveillance in patients with
inadequate bowel prep, and asked when they would repeat the colonoscopy.
Results: Sixty five surveys were returned. Most respondents were in private
practice (80%) and the majority performed 600–1000 colonoscopies per
year. 73% of practitioners worked with fellows, of which 74% replied that
they performed >50% of the colonoscopies themselves. 70% preferred to
use a PEG solution while 30% used sodium phosphate based prep. 60%
of the endoscopists stated that they considered an adequate prep to be able
to visualize >90% of the mucosa, while 32% accepted liquid stool which
could be suctioned. The survey presented different scenarios of patients
with incomplete preparations and asked about surveillance intervals. For an
average risk patient with no polyp found, the majority would repeat before
3 years (26% in 1–3 years, 45% at or before one year). If the patient had an
increased risk (i.e. family history of colon cancer), 58% would repeat before
one year. If the patient had a prior tubular adenoma >1 cm, 30% would
repeat in one year, and 42% before one year. If the patient had 1–3 tubular
adenomas which were <5 mm found during the exam, 39% would repeat in
one year, and 33% before one year. When asked how they would prepare the
patient for the next exam, most preferred to use a “two-day” prep.
Conclusion: Colonoscopy remains the preferred method of colon cancer
screening. Several guidelines have been published recommending surveil-
lance intervals after initial screening colonoscopy. However, the guidelines
do not address the question of how to manage the inadequately prepped pa-
tient. This study illustrates the wide variety of practices among endoscopists
surveyed, and highlights the need for expert consensus opinion on how to
manage the important and common dilemma of the incompletely prepped
patient.
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Endoscopic Detection of Duodenogastric Reflux Using
Chromoendoscopy with Indigo Carmine
Serguei Mouzyka, MD∗. Endoscopic Department, Hospital LISSOD, Kiev,
Ukraine.
Purpose: Duodenogastric reflux (DGR) is risk factor for intestinal meta-
plasia (IM) of the stomach. IM is generally considered to be an early stage
in the multi-step process leading to the development of gastric cancer or to
be associated with an increased risk of gastric cancer. Detection of patients
with DGR may be significant for follow up patients, but endoscopist can not
always see reflux of bile during examination.
The aim of this prospective study was determination of the effectiveness
of dye spray (indigo carmine) on detection of DGR during routine upper
endoscopy.
Methods: In one institution, 55 patients (F20, M35; mean age 43) entered
into a prospective study. Duodenal stenoses, acute pancreatitis, ileus and
gastrointestinal bleeding were excluded. All endoscopic procedures were
performed with video endoscopes by a single endoscopist. All stainings
were performed during routine upper endoscopy after obtaining permission.
We used to spray 10 ml 0,2% solution indigo carmine onto the mucosa in the
second part of duodenum. Immediately after that, endoscope was removed
from duodenum to stomach. During one minute we determined grade of
dye’s reflux.
Results: There was not reflux of indigo carmine in 43 patients, reflux until
angle of stomach in 4, reflux to gastric body in 8 patients. In all patients,
who had reflux until gastric body, there was abundance of bile in stomach.
Pearson correlation coefficient between grade of dye’s reflux and presence
of bile in stomach was 0,94 (P < 0,001). There were no complications after
chromoendoscopy. Limitations: Small patient number and uni-centric study.
Conclusion: Here we present a new method of chromoendoscopy with in-
digo carmine. This new method is fast, easy and not expensive and can be
used for visual detection of DGR.
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Use of CO2 for Insufflation during Colonoscopy in Children
Eduardo Ibarguen-Secchia, MD∗. Pediatric Digestive Care, San Antonio,
TX.
Purpose: To determine safety, tolerability and comfort of use of carbon
dioxide for insufflation during colonoscopy in children.
Abstracts S549
Methods: After informed consent, a total of 84 consecutive patients under-
going colonoscopy were randomized to use either air or CO2 insufflation.
Ages ranged from 6 years to 16 years (mean 12). End tidal carbon dioxide
was recorded before the examination, at 2 minute intervals during the exam-
ination and 10 minutes after it. General anesthesia was used for sedation in
all cases. Pain at 5 and 15 minutes after the procedure was measured using
a ten-point analog scale.
Results: Pain scores at 5 minutes after the examination were 5.2 ± 0.3 for
the air group and 4.8 ± 0.2 for the CO2 group (no significant difference). At
15 minutes the score were 2.8 ± 0.3 for the air group and 0.7 ± 0.3 for the
CO2 group (significant at P < 0.05). End tidal CO2 in both groups was no
different.
Conclusion: Using CO2 for insufflation during colonoscopy is safe and
improves patient comfort. Patients who received CO2 insufflation during
their colonoscopy experienced less post-procedure discomfort. There was
no evidence of CO2 retention based on end tidal carbon dioxide monitoring.
1178
Proof That Some Kids Really Do Like Their Vegetables: A New Flavor
Option for PEG Solution
Pramodha Muniyappa, MD, Lori Mahajan, MD∗. Pediatric
Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland,
OH.
Purpose: Polyethylene glycol (PEG) bowel preparations are commonly used
prior to colonoscopy. Children often object to the taste of PEG due to the
salty flavor and oily consistency of the solution. The aim of our study was to
determine how mixing low sodium organic vegetable bouillon with Colyte
would compare to unflavored and fruit flavored options.
Methods: A prospective IRB approved study of children ages 8–18 yrs was
conducted in the Division of Pediatrics at the Cleveland Clinic. 100 children
were enrolled and asked to taste 3 solutions: standard unflavored Colyte,
cherry flavored Colyte and vegetable bouillon flavored Colyte. 1 oz servings
of each solution were placed in unlabeled covered cups. The order in which
they received each of the 3 cups was randomized. Each patient was asked to
rate the taste of each solution on a 4 point scale and then identify the best
and worst tasting flavor.
Results: For each flavor, the frequency and percentage of each ranking (best,
middle, and worst) were calculated. In addition, frequencies and percentages
of the rankings were calculated based upon the order in which the flavor was
received and the flavor that was administered just prior to the flavor. The
bouillon flavor was chosen as favorite by 55% of children (95% CI:44–
66%). Cherry was the favorite of 30%, while the plain flavor was favored by
15%. The plain flavor was chosen as the worst flavor by 49%, while 27% and
24% found the cherry and bouillon flavor to be worst, respectively. Ignoring
any potential effects of carryover and the ordering, there is a significant
difference in the rankings of the flavors overall (P < 0.001). Both the bouillon
(P < 0.001) and cherry (P = 0.004) flavors were significantly better ranked
than the plain flavor. However, a statistically significant difference between
bouillon and cherry flavors was not observed.
Conclusion: All prior studies of bowel preparation flavoring have compared
fruit flavors to each other or to unflavored solutions. This study is the first to
evaluate the addition of bouillon flavor to the already salty and oily tasting
PEG. Our study not only showed this to be a viable option but that children
actually preferred low sodium organic vegetable bouillon over standard fruit
flavoring. Bouillon flavoring of PEG has not previously been considered or
studied in trials of patients undergoing bowel preparation. A large prospective
trial studying the compliance and preparation outcome of this flavor option
should be performed.
1179
Impedance-pH Measuring in Preterm Infants with Apparently
Life-Threatening Events
Barbara Bizzarri, MD, Giulio Bevilacqua, Prof, Fabiola Fornaroli, MD,
Nicola de’Angelis, MD, Barbara Magiteri, MD, Gian Luigi de’Angelis,
Prof∗. Gynecological, Obstetrical and Neonatal Science, Pediatric
Gastroenterology Unit, Parma, Italy; Gynecological, Obstetrical and
Neonatal Science, Neonatal Intensive Care Unit, Parma, Italy and Surgery,
Genral Surgery, Parma, Italy.
Purpose: The aim of the study is to evaluate the diagnostic value of
impedance-pH measuring in preterm infants with suspected ALTE (appar-
ently life-threatening events).
Methods: Between December 2006 and April 2007, at the Paediatric Gas-
troenterology Unit of Parma, twenty-four-hour impedance-pH monitoring
was performed in 14 preterm infants (3 male- 4 female), hospitalized at
Neonatal Intensive Care Unit, University of Parma. The mean age of patients
was 28 days with a range between 16–40 days. The MII-pH technique records
changes in impedance to alternating current between electrodes caused by
the passage of a bolus inside the oesophageal lumen and the changes in pH.
A single-use combined MII/pH oesophageal probe, tested and calibrated
before each examination, was inserted transnasally. The catheter was com-
prised of six electrode pairs measuring intraluminal impedance 2–3, 5–5–6,
5–8–9, 5 cm above the LES, and an antimony pH sensor 2 cm above the LES
(Sandhill Scientific, Inc; Highlands Ranch, CO). An impedance amplifier
delivers current with resulting current flow variations in response to intralu-
minal impedance changes. The data were stored in an ambulatory recorder
and saved on a CompactFlash card.
Results: One study was excluded because of technical problems (total
recording time 6 hours); a total of 13 infants represents the final patients
included, all with a good tolerance of the study. The total recording time was
23.4 ± 1.5 hours. The medium time of the longest episode was 23 minutes
(range 4–52 minutes). The median number of reflux events in 24 hours was
73 (range 38–119), with median number of acid reflux 37 (range 20–60) and
of non-acid reflux 37 (range 11–62). The majority of reflux was only liquid
(90%).
The median time of acid exposure of the proximal esophagus (distal channel
of impedance probe) was 108 minutes (range 15–277 minutes).
Conclusion: Although more studies need to be executed, impedance-ph
measuring seems to be a useful diagnostic procedure also in preterm infants.
Our results showed that impedance-pH measuring is a useful and safe tech-
nique even in infants, althought a normal value for children and infants has
not been defined yet and more multicenter studies are necessary to better
evaluate and analyze the results, such as the correlation symptoms/reflux.
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Chromosomal 1p36 Deletion: Inflammatory Bowel Disease, Sclerosing
Cholangitis and Annular Pancreas
Samra S. Blanchard, MD, Rita Gnyawali, MD, Anjali Malkani, MD∗.
Pediatric Gastroenterology, University of Maryland, Baltimore, MD.
Purpose: Chromosome 1p36 deletion occurs in approximately 1 in 5,000–
10,000 live births. It is associated with psychomotor retardation, oropha-
ryngeal dysphagia, cardiac malformations, sensorineural hearing loss, de-
bilitating seizures and cranio-facial dysmorphism. There has been one case
report in the literature of annular pancreas with malrotation associated with
1p36 chromosomal deletion. There are no reports of sclerosing cholangitis
or inflammatory bowel disease (IBD). We report a 15 month old male with
chromosome 1p36 deletion who was referred for evaluation of persistent
leakage of gastric contents from the G-tube site. Inspite of acid suppression
and changing the length and diameter of the gastrostomy tube he contin-
ued to have leakage. He also developed bloody diarrhea of non-infectious
etiology and elevated liver functions. Esophagogastroduodenoscopy (EGD)
revealed a generous duodenal bulb but the endoscope was easily advanced
to the third portion of the duodenum. Upper gastrointestinal series (UGI)
was normal. Colonic biopsies revealed cryptitis with no granulomas. Liver
biopsy showed features of sclerosing cholangitis. He was started on steroids,
5-aminosalicylic acid and ursodiol with normalization of liver function tests
and resolution of diarrhea. However, he continued to have formula leaking
S550 Abstracts
from his G-tube site. UGI was repeated which showed nonobstructing nar-
rowing in the second part of duodenum with dilated first part of duodenum
consistent with an annular pancreas. During exploratory laparotomy for duo-
denoduodenoplasty, an intraoperative cholangiogram was obtained which
showed beading of the extra hepatic ducts confirming the diagnosis of scle-
rosing cholangitis. His liver function tests remained normal on azathioprine
and ursodiol. Inspite of the duodenoduodenoplasty, he had ongoing G-tube
drainage for which a feeding jejunostomy was placed.
Conclusion: To our knowledge, this is a first report of such association of
IBD, PSC and annular pancreas in such a young age with chromosome 1p36
deletion.
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Transient Neonatal Achalasia
Daniel Gelfond, MD, Samra S. Blanchard, MD, Anjali Malkani, MD∗.
Pediatric Gastroenterology, University of Maryland, Baltimore, MD.
Purpose: Neonatal achalasia is an uncommon entity in the newborn period
that can present with feeding intolerance, vomiting and excessive salivation.
We present two newborn infants diagnosed with achalasia after a subsequent
work up of feeding intolerance.
The first patient was the only viable child after twin – twin transfusion deliv-
ered at 30 weeks. She was noted to have dysmorphic features and diagnosed
with Cornelia De Lange syndrome. She was tolerating oral feedings until
acute onset of vomiting and feeding intolerance at 6 weeks of age. Upper
gastrointestinal series (UGI) showed narrowing of the distal esophagus with
an associated dilatation of the proximal esophagus consistent with achalasia.
Feedings were resumed through a nasogastric tube and an UGI was repeated
in 3 weeks. Repeated radiological study showed normal gastroesophageal
junction with no evidence of achalasia.
The second patient was a full term infant with unremarkable birth history.
She presented with gagging, stridor and central cyanosis after her first several
feedings. Upper GI study showed tapered lower esophagus with elongated
narrow gastroesophageal channel and dilated, dystonic proximal esophagus
compatible with diagnosis of achalasia. Nasogastric tube feedings were ini-
tiated and UGI was repeated in 1 week with significant improvement in
the distal esophageal narrowing. Esophagogastroduodenoscopy showed no
anatomic abnormalities with normal passage of the scope. She resumed oral
feedings and had no subsequent feeding intolerance.
Conclusion: Both cases represent radiological presentation of neonatal acha-
lasia that did not require further intervention which resolved over a short
period of time. Transient achalasia or transient spasm of lower esophageal
sphincter should be considered in infants with radiological findings sugges-
tive of achalasia. Nasogastric tube feedings with subsequent reimaging of the
esophagus should be attempted prior to conclusive diagnosis of achalasia.
1182
Pneumatosis Intestinalis: Rare Presentation of Crohn’s Disease
Exacerbation
Daniel Gelfond, MD, Samra S. Blanchard, MD, Anjali Malkani, MD∗.
Department of Pediatric Gastroenterology, University of Maryland,
Baltimore, MD.
Purpose: Pneumatosis Intestinalis (PI) is a well recognized manifestation of
necrotizing enterocolitis in neonates. Rarely seen beyond newborn period,
PI has been reported in adults with connective tissue disorders, pulmonary,
infectious and gastrointestinal diseases. We present a 15 year old girl with
diagnosis of gastric Crohn’s disease who developed sudden onset severe ab-
dominal pain. She was diagnosed with Crohn’s disease at 11 years of age
and treated with steroids and 6-Mercaptopurine (6-MP). She was weaned of
her medications after 2 years when she had normal histology on her endo-
scopic evaluation. Four years later, at the time of presentation, she was on
acid-blocker treatment. She had severe right lower and right upper quadrant
pain with no fever, diarrhea or vomiting. She had diffuse tenderness with
guarding and rebound. Her abdominal CAT scan showed multiple collections
of intramural air within the walls of distal ileum and right colon. Because
of persistent pain and rebound on exam, she underwent laparoscopic explo-
ration. Blebs on the serosal surface of the terminal ileum were recognized
as PI with no other abnormal finding requiring surgical intervention. She
was started on steroids and immunomodulator therapy with resolution of
her symptoms. There was no evidence of PI on repeated abdominal CAT
scan in 2 weeks. She underwent endoscopic evaluation which showed active
ileitis with normal colonic histology.
Conclusion: Although rare outside the neonatal period, PI can be a find-
ing in patients with acute exacerbation of inflammatory bowel disease. In
the absence of complications requiring surgical exploration, PI in a child
with inflammatory bowel disease should be treated with anti-inflammatory
therapy.
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Endomysial Antibody Testing Improves Sensitivity in Screening for
Celiac Disease in Young Children; a Five Year Single Center
Experience
Muralidhar Jatla, MD∗, Caroline Kieserman-Shmokler, Ritu Verma, MD.
Division of Gastroenterology and Nutrition, The Children’s Hospital of
Philadelphia, Philadelphia, PA.
Purpose: Screening for celiac disease (CD) is facilitated by sensitive (tissue
transglutaminase {TTG}) and specific (endomysial antibody {EMA}) test-
ing. At our institution, screening involves TTG and EMA testing. Our aim
was to analyze the use of serologic testing for CD at our children’s hospital
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over the past five years to characterize use patterns and to determine the
utility of EMA testing.
Methods: Retrospective review of celiac panels performed at CHOP be-
tween 1/02 and 3/07 was performed to identify all TTG and EMA IgA
testing. Electronic medical records were reviewed and clinical information
and results of statistical analyses are summarized in tables below.
Results: Overall, 9746 celiac panels were performed in 5890 patients, with
5.7% of patients displaying TTG positivity and 3.8% displaying EMA posi-
tivity. Data is analyzed by year and displayed in table below. The mean TTG
value in TTG+/EMA- discordant patients (30 ± 17) was significantly lower
than TTG+/EMA+ patients (214 ± 252) P < 0.001. TTG-/EMA+ patients
were significantly younger (8.8 ± 4.8 yrs) than TTG+/EMA+ (11.5 ± 4.0)
and TTG+/EMA- patients (11.4 ± 3.6) P < 0.01. Further analysis revealed a
higher rate of TTG-/EMA+ results in 0–4 year old children versus 5–20 year
old children.
Seropositivity by year
2002 2003 2004 2005 2006 2007 (3 mos)
Celiac panels 380 728 1141 1549 1635 451
TTG Positive % 6.58 5.91 4.38 4.91 6.61 5.54
EMA Positive % 3.42 3.02 3.24 4.26 3.97 4.00
TTG-/EMA+ Results by Age Group
0–4 Years Age 5–20 Years Age P value
TTG-/EMA+ in All Patients 3.10% 0.40% 0.013
TTG-/EMA+ in TTG- Patients 3.20% 1.00% 0.047
Conclusion: No major change in positivity rate was observed in the past
five years. Not surprisingly, EMA displayed a low sensitivity of 68%, with
greater sensitivity seen in higher TTG values. However, in 3.2% of patients,
EMA testing was positive in the face of negative TTG testing, particularly
in younger children. Despite the extra cost and subjectivity associated with
EMA testing, it may improve sensitivity when screening a young child.
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Prevalence of Gastroesophageal Reflux in Children Aged 2–15 Years
Old with Chronic Abdominal Pain: 9 Years Experience
Bashir Chomeili, MD∗, Pooya Chomeili, MD. Pediatrics, School of
Medicine, Jundishapour University of Medical Sciences, Ahwaz,
Khuzestan, Islamic Republic of Iran and Pediatrics Gastroenterology Ward,
Aboozar Children’s Hospital, Ahwaz, Khuzestan, Islamic Republic of Iran.
Purpose: Gastroesophageal reflux (GER) is one of the most frequent clini-
cal disorders affecting the gastrointestinal tract of infants and children and
chronic abdominal pain is one of the hallmarks of this disease. The purpose
of this study was to find the prevalence of GER in children with chronic
abdominal pain that needed esophagogastroduodenoscopy (EGD) for final
diagnosis.
Methods: All children aged 2–15 years old suffering from chronic abdom-
inal pain that underwent EGD by the author in the only pediatrics gastroen-
terology ward in south-western of Iran were reviewed and enrolled in this
study. The data obtained from the patients files which are kept in the hospital’s
archive.
Results: During 9 years(1998–2007) totally 1156 patients (599 boys, 557
girls) aged 1.5 months to 15 years with different upper GI tract problems
underwent EGD in the gastrointestinal ward of Aboozar Children’s Hospi-
tal, Jundishapour University of Medical Sciences. There were 804 (69.5%)
patients (416 boys, 388 girls) older than 2 years who enrolled in our study.
Among this age group, we found 449 cases (239 boys, 210 girls) with chronic
abdominal pain needed EGD. When the procedure was performed, the di-
agnosis of esophagitis due to GER was suspected in 86(19%) patients (49
boy-37 girl) by observing obliteration of the Z- line and was confirmed by
histopathological changes in esophageal biopsies. There were 8 cases with
Barrett’s esophagus all aged more than 6 years with history of suspicious
symptoms of GERin infancy and later on. Treatment with prokinetic drugs
and PPI or H2 receptor blockers was undertaken. Successful treatment was
observed in 96% of all patients 6 months after treatment was initiated and
on follow up. Surgical antireflux procedure was performed to patients with
no resolution of symptoms after 6 months of therapy.
Conclusion: In conclusion, GER in children with chronic abdominal pain
beyond infancy is not rare ant tends to be chronic and severe and such patients
are at high risk of developing serious complications without early diagnosis
and treatment.
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Use of Rifaximin in Pediatric Patients with Inflammatory Bowel
Disease
Pramodha Muniyappa, MD, Reema Gulati, MD, Hupertz Vera, MD∗.
Pediatric Gastroenterology, Cleveland Clinic, Cleveland, OH and
MetroHealth Medical Center, Cleveland, OH.
Purpose: Rifaximin is an antimicrobial approved by the U.S. FDA in 2004.
It has poor systemic absorption and in vitro activity against enteric Gram-
positive and Gram-negative bacteria making it a reasonable option for GI
infections. Adult studies that have been done show promising results evalu-
ating the efficacy of Rifaximin for use in inflammatory bowel disease (IBD).
Our aim was to determine if Rifaximin is an option for use in pediatric
patients with IBD.
Methods: A retrospective IRB approved study of 23 children ages 8–21 yrs
was conducted at the Cleveland Clinic in patients with known diagnosis
of IBD. We collected data including the time of diagnosis, extent of disease
involvement, previous treatments, more recent treatments and current symp-
toms. While on Rifaximin, symptom improvement and lag to improvement
were evaluated.
Results: Review of the data revealed that of the 23 patients, 12 had Crohn’s
and 11 had Ulcerative Colitis with a mean age of 15.08 yrs. The most com-
mon complaints were diarrhea (87%), abdominal pain (74%) and bloody
stools (65%). Of the 23 patients that were prescribed Rifaximin only 3 were
prescribed concurrent steroids. Patients were given Rifaximin at varying
doses from 400 mg to 1200 mg per day. Analysis revealed that of the 20 pa-
tients that presented with diarrhea 16 had relief of diarrhea within 4 weeks
of treatment, 5 within 1 week of starting Rifaximin. In 17 patients that pre-
sented with abdominal pain, 12 patients had relief within 4 weeks, 3 of these
patients had relief within 1 week. Visible bleeding resolved in 10 of 15 pa-
tients within 4 weeks of therapy, 3 of the 10 had improvement within 1 week.
Only one patient had a negative side effect of temporary increase in diarrhea
symptoms upon starting the Rifaximin.
Conclusion: Rifaximin was well tolerated in our pediatric patients with IBD
and showed favorable results. No serious adverse events occurred. Larger
prospective studies with standardized dosages are needed to evaluate efficacy
and determine optimal dosing of Rifaximin in this population.
1187
Utilization of Nitazoxanide for the Empiric Treatment of Pediatric
Diarrhea of Unknown Etiology
Youhanna Al-Tawil, MD∗, Alexandra Eidelwein, MD, Clarisa Cuevas, MD,
Anthony S. Jackson, PharmD. Childrens Hospital Pediatric
Gastroenterology, Knoxville, TN and Department of Medical Science,
Romark Laboratories, LC, Tampa, FL.
Purpose: Diarrhea of unknown etiology is a common reason a pediatric
patient seeks presents to the office. While there are many reasons pedi-
atric patients develop diarrhea, microbial insult has been targeted as a major
contributor to this disease. Parasites, bacteria, and viruses are part of the
spectrum of implicated organisms. Since testing for a specified organism
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is often inconclusive, untimely and costly, clinicians often prescribe a trial
of empiric antibiotics. Nitazoxanide (NTZ) is a first in class thiazolide an-
tibiotic, first indicated in pediatrics, with activity against anaerobic bacteria,
protozoans, helminthes, and gastrointestinal viruses. Furthermore, NTZ has
a placebo-like safety profile, high gastrointestinal (GI) concentration, and
has limited to no activity against probiotic species. The purpose of this review
is to evaluate the effectiveness of NTZ as empiric therapy for the treatment
of diarrhea of unknown etiology in pediatric patients.
Methods: A chart review was performed on all patients treated with NTZ
from February 2006 to May 2007 with complaints of generalized diarrhea
not attributed to any cause, including suspected small intestinal bacterial
overgrowth (SIBO) or Clostridium difficile associated diarrhea (CDAD).
Efficacy was measured as resolution of the patient’s diarrhea and resolution
of chief complaints by the end of therapy. Patients returned to the office 3–6
weeks post treatment for follow-up.
Results: Four patients were treated with NTZ for diarrhea of unknown eti-
ology in this time period. The range of NTZ doses used was 200 mg – 500
mg BID for 3–10 days, mean total dose and duration was 700 mg/d for 6
days. Overall 4/4 patients reported resolution of diarrhea and normalization
of stools as well as resolution of primary complaints (abdominal pain, nau-
sea, epigastric tenderness) that were present upon initial examination. No
clinically significant adverse reactions attributable to NTZ were identified
during the study.
Conclusion: Nitazoxanide appears to be a safe and effective therapy for
the empiric treatment of diarrhea of unknown etiology in pediatric patients.
Larger controlled clinical trials are warranted to support these findings.
1188
Pediatric Patients Have Shorter Lansoprazole Half-Life Than
Previously Reported
Jeffrey O. Phillips, PharmD∗, Jane E. Burnett, Shan H. Siddiqi, Marcella R.
Bothwell, MD. Surgery – Applied Research, University of Missouri School
of Medicine, Columbia, MO and Rady Children’s Hospital, San Diego, CA.
Purpose: Traditional pharmacokinetic teaching suggests that the elimination
rate (half-life) of drugs is related to patient age. However, the package insert
for lansoprazole, a common proton-pump inhibitor (PPI) drug, reports that
its “pharmacokinetics in pediatric patients aged 1 to 17 years [are] similar
to those observed in healthy adult subjects.” Numerous recent articles, in
contrast, suggest that higher dosages are needed for children, although these
articles establish no definite pharmacokinetic relationship between patient
age and drug half-life. Establishing the correct half-life is important for
appropriate dosage regimen development for PPI drugs.
Methods: Evaluation of previously published literature reveals an unusu-
ally large degree of variability in most studies. This variation can be caused
by: (1) rapid versus slow metabolizer status based on genetic variation in
Cytochrome P450, (2) immature hepatic function, (3) hepatic dysfunction,
Reflux Index (+) Respiratory Symptoms∗ (−) Respiratory Symptoms∗ Reference Normal RI values∗∗∗
PC Total Number of Reflux Episodes 12.9 ± 15.2 13.5 ± 18.2 24.32 ± 24.92
PC Fraction of Time pH<4 (%) 3.4 ± 4.1 3.4 ± 4.9 0.87 ± 1.01
PC Number of Long Reflux Episodes (>3 min) 1.4 ± 2.4 1.4 ± 2.5 0.31 ± 1.15
PC Duration of Longest Reflux (min) 7.9 ± 9.1 6.4 ± 13.0 2.72 ± 3.51
PC Esophageal Clearance Time (min/episode) 2.7 ± 1.4 ∗∗ 2.1 ± 2.2 0.44 ± 0.67
DC Total Number of Reflux Episodes 23.6 ± 21.1 26.4 ± 28.0 49.51 ± 34.88
DC Fraction of Time pH<4 (%) 6.2 ± 6.4 7.7 ± 10.4 2.19 ± 1.43
DC Number of Long Reflux Episodes (>3 min) 2.3 ± 2.9 3.2 ± 5.2 0.7 ± 0.89
DC Duration of Longest Reflux (min) 13.0 ± 18.9 13.5 ± 19.2 6.08 ± 5.58
DC Esophageal Clearance Time (min/episode) 2.7 ± 1.1 ∗∗ 3.2 ± 2.0 0.57 ± 0.37
∗There are no significant differences between any of the tested variables between children with or without RS manifestations of GER. ∗∗Esophageal clearance time in PC as
well as DC of children with GER and (+)RS was significantly different from normal reference RI values (P < 0.05). ∗∗∗Bogucka, J. Pediatric Gastroenterology and Nutrition 31:3, 2000
and (4) errors related to timing of blood draws with enteric-coated products.
Meanwhile, when the ages of the patients in the same studies are plotted
against the respective half-lives of lansoprazole, an increase in half-life with
age is observable. After removing data involving patients with immature
hepatic function and eliminating outlying points by using statistically ac-
ceptable methods, the relationship between age and half-life becomes even
more evident.
To further investigate this relationship between age and half-life, a single
dose of buffered lansoprazole suspension was administered to six children
and pharmacokinetics were evaluated by standard methods. The drug was
delivered in caracream, a flavored suspension that is buffered with sodium
bicarbonate (which causes immediate release of lansoprazole into the blood-
stream and, therefore, the elimination phase is discrete from the absorption
phase and timing of blood draws is much simpler).
Results: The half-life of the drug in each of the six patients was much lower
than in other studies involving adults; furthermore, almost no variability
was evident. When this data is compared with previously published data in
pediatrics, it becomes clear that lansoprazole half-life increases with age.
Conclusion: These results explain why many clinicians find a need for larger
daily doses of PPIs in children and the consideration of such factors is critical
in the effort to control Gastroesophageal Reflux Disease in children.
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pH Probe Indices in Infants with Gastroesophageal Reflux Presenting
with or without Respiratory Symptoms
N. Muckova, MD, S. Rajcevich, RN, A. Shah, M. Shah, MD∗. Pediatric
Gastroenterology, Loma Linda University, Loma Linda, CA.
Purpose: There is little data available about GER in proximal esophagus of
infants with and without respiratory symptoms (RS). We compared reflux
indices (RI) in proximal channel (PC) and distal channel (DC) of infants
suspected to have GER with or without RS to the previously published
normal values (Bogucka).
Methods: Retrospective review of RI in infants with suspected GER
who were admitted to Loma Linda Children’s Hospital and underwent
Medtronic(R) dual-channel EpHM (sensors spaced 5 cm apart) between
1/1/2005 and 12/31/2005. RI in PC and DC of these infants was then com-
pared to previously published normal RI values.
Results: There were 82 infants (age range 2 weeks to 12 months) who
underwent EpHM during the study period. Of these, 41 had RS such as cough,
wheezing and gagging (Group 1) while the other 41 had non-respiratory
manifestations of GER such as feeding disorder, failure to thrive, spitting or
vomiting (Group 2). Data was analyzed using a 2-tailed Pearsons Correlation.
Conclusion: 1. RI in PC and DC are correlated irrespective of presence
or absence of RS. 2. Esophageal clearance time is delayed in infants with
GER and (+)RS. 3. Abnormal esophageal motility may be the underlying
mechanism of GER with (+)RS.
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Pneumatic Dilation with a 35 mm Balloon, a Safe and Effective Initial
Therapy in Pediatric Achalasia
Inna Novak, MD, Tuvia Marciano, DO, Theresa Guerin, RN, Yolanda
Rivas, MD∗. Pediatric Gastroenterology and Nutrition, Children’s
Hospital at Montefiore, Bronx, NY.
Purpose: Achalasia is a progressive, incurable and rare disorder of
esophageal motility characterized by aperistalsis and incomplete relaxation
of the lower esophageal sphincter (LES) in response to swallow. Functional
obstruction created by the poorly functioning LES is thought to be the cause
of symptoms. Current therapies aim to reduce the distal esophageal obstruc-
tion. Pneumatic dilation (PD) use is well established in adults. However,
many patients require repeat dilations to achieve resolution of symptoms.
A number of factors, including young age, have been associated with poor
outcome. Only few studies describe successful PD in children. We report a
series of pediatric patients with achalasia initially treated with PD using a
35 mm Rigiflex II balloon dilator.
Methods: We report five consecutive patients, ages 13 to 18 years, di-
agnosed with achalasia at The Children’s Hospital at Montefiore between
July 2006 and October 2006, who underwent PD. Duration of symptoms
prior to presentation ranged from 2 months to 5 years. All patients met
the esophageal manometric criteria for achalasia. Follow–up period ranged
from 4 to 7 months post dilation. Patients underwent a single esophageal
PD using a 35 mm Rigiflex II achalasia balloon dilator. The dilator was
passed over a guidewire and positioned at the level of the gastroesophageal
junction under fluoroscopic guidance. The balloon was rapidly inflated
to achieve complete effacement of the waist. The inflation was main-
tained for 2 minutes. The balloon was then deflated and removed. An en-
doscopy was performed to evaluate the gastroesophageal junction. A wa-
ter soluble contrast study was obtained to evaluate for perforation. Pro-
cedures were performed under general anesthesia. Patients were observed
overnight.
Results: Patients reported complete resolution of achalasia related symp-
toms 1 to 2 weeks after the procedure. There were no complications during the
procedures or in the immediate post-dilation period. At 1 month follow-up
visit one patient reported symptoms of gastroesophageal reflux. All patients
were asymptomatic at the most recent visit, 4 to 7 month post-procedure.
Conclusion: In our patients, a single PD with a 35 mm balloon used as initial
therapy was safe and effective in the management of pediatric achalasia. We
speculate that using a large size balloon for the initial dilation in children
with achalasia minimized treatment failure related to greater esophageal wall
pliability noted in young patients.
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Demographic Profile of Children Diagnosed with Celiac Disease
Ajay Kaul, MD∗, Jose M. Garza, MD. Gastroenterology, Hepatology &
Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
Purpose: To study the demographic profile of children with Celiac Disease
(CD) diagnosed at a tertiary referral center in the Midwest.
Methods: Retrospective review of institutional database for all cases that
fulfilled the diagnostic criteria of CD during a 5 year period (2002–2007):
duodenal histology consistent with CD (Marsh criteria) and/or positive serol-
ogy (tissue transglutaminase, endomysial antibodies).
Results: A total of 120 children (13 months to 18 years; mean 7 years) were
diagnosed with CD. 22 (18%) were below 2 years. There were 50 males
and 70 females. Presenting symptoms were growth failure (35%), diarrhea
(29%), constipation (13%), anemia (6%), asymptomatic (17%). Comorbid
conditions included immunologic disorder (26%: IgA deficiency 12, IDDM
7, eosinophilic esophagitis 4, IgG2 deficiency 1, lupus 1, juvenile dermato-
myositis 1), genetic disorders (19%:Down Syndrome 17, Turner Syndrome
1, chromosomal deletion1), and developmental/behavioral disorders (6%:
Autism 1, Asperger syndrome 1, Tourette syndrome1, ADHD 2, Apraxia 1).
Family history was positive in 23% subjects (mother 8%, sibling 4%, father
3%). Endoscopic biopsies were performed in 99 of 120 subjects (82%) and
were positive in 85 (86%). All of the 14 subjects with normal biopsies had
positive serologies.
Conclusion: Younger age at diagnosis of CD at our center most likely re-
flects early recognition of risk factors (immunologic, genetic and develop-
mental/behavioral disorders) and screening. A higher prevalence of CD in
females and in mothers is a novel observation of this study.
1192
The Constipated Child: Is There a Correlation between Symptoms and
Manometric Findings?
Lisa A. Feinberg, MD, Lori Mahajan, MD, Rita M. Steffen, MD∗.
Department of Pedatric Gastroenterology, Cleveland Clinic Children’s
Hospital, Cleveland, OH.
Purpose: The aim of our study was to evaluate symptoms in chronically
constipated children undergoing anorectal manometry and determine if any
correlation exists with manometric variables.
Methods: 123 patients were prospectively enrolled and completed symptom
questionnaires. Anorectal manometry was performed per standard protocol.
Results: Of the 123 patients enrolled in the study 57.7% were male. Pa-
tient age ranged from 0.2 to 17.8 years, and the mean age was 7.5 years.
The average duration of constipation was 4.84 years. The average num-
ber of stools per week was 3.6. Average time spent in the defecation pro-
cess was 13.3 minutes. The incidence of hematochezia was 30%. Delayed
passage of meconium was reported in 45 of 99 patients (45.5%) Signifi-
cant correlation was found between frequency of soiling and threshold for
Recto-Anal Inhibitory Reflex (RAIR) (P = 0.029). The volume of first urge
was also positively correlated with frequency of soiling (P = 0.034). There
was significant correlation of withholding behavior and the maximum vol-
ume tolerated (P = 0.020). The presence of blood was inversely correlated
with the maximum volume tolerated (P = 0.004). No correlation was found
between severity of complaints and the presence of paradoxical puborec-
talis contraction, and 90.5% of patients did have paradoxical puborectalis
contraction.
Conclusion: Anorectal manometry continues to provide additional new in-
formation and assist in managing patients with this very common chronic
pediatric affliction. Based on our findings we recommend increased sitting
times for scheduled toileting, and additional attention should be paid to
patients with delayed passage of meconium.
1193
Spectrum of Hepatitis B Infection in Children: Report of 167 Cases
from a Developing Country
Ujjal Poddar, MD∗, Surinder K. Yachha, MD, S. Srinivas, MD, Srivastava
Anshu, MD. Pediatric Gastroenterology, Sanjay Gandhi Postgraduate
Institute of Medical Sciences, Lucknow, UP, India.
Purpose: Information regarding the various manifestations of hepatitis B
infection in children form developing countries is scanty. We have studied
the clinical, biochemical and serological aspects of hepatitis B infection in
children.
Methods: From January 1998 to May 2007, 167 children (up to 14 years of
age) presented with hepatitis B infection to our tertiary care hospital, were
studied. Their clinical, biochemical and serological details were recorded
in a proforma. Depending upon the serological pattern, the children were
classified into acute hepatitis B or AHB (HBsAg & IgM anti HBc positive),
chronic hepatitis B or CHB (HBsAg positivity for more than 6 months).
The latter group was further subdivided into three; inactive HBsAg carrier
(HBsAg, anti HBe positivity & HBeAg negative with ALT< 2 times upper
limit of normal [ULN]), replicating virus with activity (HBsAg and HBeAg
positive and anti HBe negative with ALT > 2 times ULN), and replicating
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virus without activity or immune tolerance phase (HBsAg, HBeAg positive
and anti HBe negative with ALT <2 times ULN).
Results: The mean age was 8.5 ± 3.8 years and 146 of them were male. The
proportion of AHB and CHB was 37% & 67% respectively. The source of
infection in the majority of AHB was intramuscular injection (53%) & 95%
became HBsAg negative after 6 months. Of the 105 CHB children, 76%
were incidentally detected and 24% were symptomatic (2% HCC and 22%
CLD). Of the 80 incidentally detected children, 37.5% had inactive hepatitis
B, 37.5% had replicating HBV without activity and just 25% had replicating
HBV with activity. The majority of mothers (61%) of children with immune
tolerance phase infection were positive for HBsAg. We managed to give
interferon therapy in 20 children and 10 of them (50%) had responded (e-
antigen seroconversion). Overall, 9 children died (7 of 10 FHF, and two
CLD).
Conclusion: In developing countries, almost one third of HBV infections are
acute and intramuscular injection is a common source. Like in adults, 95%
children too clear HBsAg after an attack of AHB. The majority of CHB in
children are incidentally detected and a major portion is perinatally acquired
and in immune tolerance phase.
COLORECTAL CANCER PREVENTION
1194
Outcomes and Complications in Average Risk Colon Cancer Screening
in a Community Hospital
Stephen J. Spellman, MD∗, Michael Bader, MD, Donald L. Zogg, MD,
Tessi Haverland, RHIT. Department of Gastroenterology, MeritCare
Health System, Fargo, ND and Qualtiy Assurance Department, MeritCare
Health System, Fargo, ND.
Purpose: To evaluate the outcomes and complications of average risk screen-
ing for colon cancer when done in a community hospital setting.
Methods: Between March 2002 and March 2007, all colonoscopies per-
formed by the study endoscopists were entered into a database. Complete-
ness of exam, adenoma detection rate, cancer detection rate, and signifi-
cant complications were recorded. Cancer staging was ascertained from the
pathological record.
Results: Of the 15,228 colonoscopies done during this period, 3968 (46%
M, 54% F) were done for average risk screening. The age range for those
screened was 40–49(.2%), 50–59(37%), 60–69(32%), 70–79(26%) and 80–
89(5%). Colonoscopy to the cecum was accomplished in 98%. Adenoma
detection rate was 513/1810 (28%) in males and 358/2158 (17%) in fe-
males. Colon cancer was found in 19 (11 M, 8 F). 8(42%) of cancers were
T1, 5 (26%) T2 and 6 (32%) T3. From 2004 to 2006, 229 colorectal can-
cers were reported to our tumor registry. The T stages were T1 (25%),
T2(24%), T3(27%) and T4(24%). Complications included perforation in
2 (0.05%). One perforation was instrumental and one was post polypec-
tomy. Post polypectomy bleeding occurred in 6 (0.15%). There was no
mortality.
Conclusion: Average risk screening colonoscopy is safe and finds signifi-
cant numbers of adenomas and early cancers when done in the community
hospital setting. Males are under represented in the total screened population
but over represented in both polyp and cancer detection. Efforts need to be
taken to encourage participation in colon cancer screening especially among
the male population.
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Body Mass Index, Waist-to-Hip Ratio, Family History and Risk of
Colorectal Cancer. A Prospective Study
Edson J. da Silva, MD∗, Alexandre D. Pelosi, MD, Glaucia R. de Freitas,
MD, Marcelo R. da Camara, MD, Eleodoro C. de Almeida, MD.
Proctology, Hospital dos Servidores do Estado, Rio de Janeiro, Brazil and
Digestive Endoscopy, Casa de Portugal, Rio de Janeiro, Brazil.
Purpose: To examine the association of body mass index BMI, waist-to-hip
ratio WHR and family history FH with the incidence of colon adenoma and
colorectal carcinoma CRC in brazilian adults.
Methods: From January 2006 to December 2006, consecutive patients >/=
50 years referred to colonoscopy were subject to measurement of BMI, WRH
and FH for CRC. Exclusion criteria: Inflammatory bowell disease, Lynch
syndrome, familial polyposis of the colon, chronic liver disease and chronic
renal failure. For anthropometric data, gender was analysed separatedly. Chi
square was used to compare proportional data whereas the student’s t test
was used to compare means. P < 0.05 was considered significant
Results: 489 patients were enrolled in this study, being 171 men and 318
women. Man with tumor (CRC and adenoma) n 80, age 64 ± 9.5, BMI 26 ±
4 and WHR 0.95 ± 0.05; woman with tumor (CRC and adenoma) n 137, age
65 ± 9.9, BMI 27 ± 4.8 and WHR 0.89 ± 0.08; man without tumor n 91,
age 64.6 ± 10, BMI 26 ± 3.7 and WHR 0.92 ± 0.21; woman without tumor
n 181, age 64 ± 9, BMI 26.3 ± 4.7 and WHR 0.89 ± 0.07 P > 0.05. FH
was positive for 76 (28%) patients without tumor and for 73 (36.6%) with
tumor P < 0.05 Adenoma was found in 50 (29%) of men and 73 (23%) of
women
Conclusion: Our data suggest a relationship of CRC with a FH, but not with
BMI and WHR ratio. This is an ongoing study. We have no disclosure to
make.
1196
Ethnic Differences in Findings on Screening Colonoscopy
Roy D. Yen, MD, Ognian Pomakov, MD, Michael Sitrin, MD, Shahid
Mehboob, MD∗. Internal Medicine/Gastroenterology, Univ at
Buffalo/Western NY VA, Buffalo, NY.
Purpose: There is increased incidence and mortality from colon cancer
(CCA) in African Americans, and CCA screening in this population is un-
derutilized. Some have suggested earlier screening in African Americans.
However, there is little data on the findings of screening colonoscopy in
this population. We performed a retrospective analysis to compare findings
of polyps/CCA in African Americans to Caucasians undergoing screening
colonoscopy at our institution.
Methods: We collected data for colonoscopies performed at our institu-
tion in 2004 and identified all screening/surveillance colonoscopies (N =
587). We assembled 2 cohorts: all patients (pts) who were self-identified as
African-American or Black (N = 78) and all pts who were self-identified
as Caucasian or White (N = 502). We collected data for age, colonoscopy
findings including number and location of polyps and presence of advanced
lesions (adenoma >1 cm, tubulovillous histology and CCA). Proportions
were compared by chi-square analysis; means were compared by t-test. All
significant P values reported for P < .05.
Results: There was no significant difference between the 2 groups for age,
previous endoscopy, h/o polyps, h/o CCA, and family history of CCA. We
Results
% of White pts % of Black pts P
Polyps 40.8 38.5 NS
Adv Polyps 12.4 19.2 .096
CCA 2.2 3.8 NS
Prox Polyps 18.3 26.9 .075
Prox Adv Polyps 5.4 14.1 <.01
Prox CCA 1.2 3.8 .078
Distal Polyps 30.5 17.9 <.05
Distal Adv Polyps 9.0 5.1 NS
Distal CCA 1.0 0.0 NS
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found there was no difference in% pts with any findings of polyps or CCA.
There were significantly fewer black pts with any distal polyps (17.9 vs
30.5%, P < .05) and significantly more black pts with proximal advanced
polyps (14.1 vs 5.4%, P < .01). There was a trend for more black pts with
findings of any advanced polyps (19.2 vs 12.4%, P = .096), proximal polyps
(26.9 vs 18.3%, P = .075), and proximal CCAs (3.8 vs 1.2%, P = .078).
There was no difference between the 2 groups for having distal advanced
polyps, distal CCAs, multiple polyps, or multiple advanced polyps.
Conclusion: In our analysis, we found that there were significantly more
black pts with proximal advanced polyps. There was also a trend for more
black pts with findings of advanced polyps, proximal polyps and proximal
CCAs. Flex sigmoidoscopy may be inadequate for CCA screening in this
population, and African Americans should undergo colonoscopy with par-
ticular attention for proximal lesions. However, further larger prospective
studies are needed.
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Reasons for Delay in the Diagnosis of Colon Cancer under
Colonoscopic Watch – Pilot Study
Amanpal Singh, MD∗, G.S. Raju, MD. Internal Medicine, UTMB,
Galveston, TX.
Purpose: Two questions are important to evaluate the quality of colonoscopic
screening of cancer. How often colon cancer is not detected at the first
examination? How often is it diagnosed on follow up? Our aim is to address
this issue by a retrospective data analysis.
Methods: Review of our pathology department’s database identified 300
consecutive cases of invasive colon cancer (2002–06). Then, the endoscopy
database was analyzed to check whether the colon cancer was diagnosed
at the first colonoscopy or diagnosed during follow up. Demographic data,
cancer characteristics, colonoscopy and histology findings and outcome on
follow up were collected. Analysis was done to identify factors for the delay
in diagnosis as shown in the table. Patients with poor preparation or patients
in whom cecum could not be reached were grouped as unsatisfactory exam.
Results: 264 colon cancers were diagnosed at the first colonoscopy and 36
cases not identified at the first colonoscopy were diagnosed during FU.
a. Delay in the diagnosis of cancer: The median interval between colono-
scopic diagnosis of cancer and previous colonoscopy unremarkable for can-
cer was 418.5 days (11–3137 days); 278 days (14–2854 days) in those with
an unsatisfactory colonoscopy and 632 days (11–3137 days) in those with a
satisfactory examination.
Colon cancer was diagnosed in 3 months in 12 patients, 3 to 60 months in
21 patients and after 60 months in 3 patients after a previous colonoscopy
unremarkable for cancer.
b. Reasons for the delay in diagnosis (see table):
c. Demographics and Characteristics: Mean age: 69 yrs (M:F:1:1); Indica-
tions for repeat colonoscopy: occult/overt GI bleeding:16; previous polyps:9;
abnormal imaging: 3; others; 8. Cancer location: Right colon:29 patients;
Left colon:7. Cancer staging (N = 31): I: 15; II: 7; III: 3 and IV: 6. All but
2 patients are surviving.
Conclusion: Although colon cancer is diagnosed at the first colonoscopic
examination in most patients, in 10% of patients the diagnosis was not ob-
vious at first examination. Reasons for the delay in diagnosis include failure
to repeat the exam after unsatisfactory exam, failure to identify the lesion as
cancer or rapidly growing tumor.
Satisfactory
Colonoscopy Unsatisfactory
Reasons for Cancer not Cancer not Cancer not Cancer seen: Cancer seen:
delay in seen: unsatisfactory seen: normal seen: incidental suspected to not suspected
diagnosis colonoscopy colonoscopy polyps be cancer to be cancer
No. 10 5 12 7 2
Diagnsosis delay∗ 278 1371 848 35 74
∗Median interval (days) between cancer diagnosis and previous colonoscopy
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Adherence to Polyp Surveillance Guidelines at an Academic VA
Medical Center
Adam C. Wachter, MD, Deborah A. Fisher, MD∗. Medicine, Duke
University Medical Center, Durham, NC and Medicine, Durham VA
Medical Center, Durham, NC.
Purpose: Recent surveys suggest that physicians recommend repeat
colonoscopy at shorter intervals than guidelines recommend. VA physician
adherence to colonoscopy guidelines is unknown. Our aim was to compare
recommendations for repeat colonoscopy made by gastroenterologists at a
single VA medical center to the 2006 published guidelines.
Methods: We collected data from 100 consecutive colonoscopies per-
formed in February 2007. Variables included patient demographics, prior
colonoscopy results, polyp characteristics, bowel prep quality, cecal in-
tubation, polypectomy completeness, and recommendations for repeat
colonoscopy.
Results: Seven patients with inflammatory bowel disease were excluded
from further analysis. The remaining sample was 95% men, 53% Caucasian,
43% African-American, 5% < 50 years, 41% 50–59 years, 28% 60–69 years,
17% 70–79 years, 9% ≥ 80 years. The colonoscopy was the first for 41%.
Findings were: cancer (2), multiple adenomas (35), 1–2 adenomas <10 mm
(15), hyperplastic polyps only (25), no polyps (16). For 74 of 93 (80%), the
physician recommendation followed the guidelines for a given endoscopic
and histologic finding and, where applicable, for prior history of neoplasia.
In addition, the following patients were recommended for earlier follow-up,
but had documented explanations: 2 patients with no polyps had poor prep; 1
patient with hyperplastic polyps had an incomplete colonoscopy; 4 patients
with multiple adenomas had >10 polyps each; and 4 other patients with
multiple adenomas had incomplete polypectomy. The remaining patients,
8/93, were recommended for earlier follow-up without documentation of
mitigating circumstances.
In summary, considering not only the guidelines for polyp characteristics and
prior neoplasia, but the guideline comments regarding poor bowel prepara-
tions, complete colonoscopy, greater than 10 adenomas, and incomplete
polyp removal, 85/93 or 91% of the recommendations followed guidelines.
Conclusion: Unlike other settings, there was no evidence of significant
overuse (or underuse) of colonoscopy at this VA facility. The 99% rate
of cecal intubation is on par with quality guidelines. The incidence of poor
bowel preparation (2%) and incomplete polypectomy (4%) were low, but
should be considered for further quality improvement. Examination of a na-
tional sample of VA facilities is warranted, but this study suggests that VA
gastroenterologists adhere to guidelines for repeat colonoscopy leading to
appropriate allocation of this resource.
1199
Open Access Colonoscopy: An Acceptable Strategy To Boost Colon
Cancer Screening Rates
Ian Logan, MD, Amar Al-Juburi, MD, Michele Limognes, Jacob Wegelin,
PhD, Juan Garcia, MD∗. Department of Internal Medicine, UC Davis
Medical Center, Sacramento, CA; Division of Gastroenterology, UC Davis
Medical Center, Sacramento, CA and Division of Biostatistics, UC Davis
Medical Center, Sacramento, CA.
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Purpose: Colorectal cancer is the second leading cause of cancer related
death in the United States. A conservative estimate of the demand for screen-
ing colonoscopies is at least 2.6 million per year. One attempt to improve
colon cancer screening rates is open access colonoscopy (OAC), where pri-
mary care physicians can directly refer patients for colonoscopy, providing
gastroenterologists with more time to perform endoscopies. Prior research on
OAC has addressed the appropriateness of referrals and diagnostic yield. Lit-
tle information is available regarding whether OAC is associated with shorter
time waited, improved patient satisfaction, or which type of patients would
benefit most from this modality. The goal of this study was to determine
whether OAC is associated with a similar time to colonoscopy and similar
patient satisfaction when compared to consultation-initiated colonoscopy.
Methods: Surveys were given to 217 patients prior to colonoscopy. In addi-
tion to demographic information, the following information was obtained:
reason for colonoscopy, time waited for colonoscopy, symptoms, and a series
of questions addressing patient satisfaction rated on a 1–10 scale. Patients
were classified into either OAC or consultation-initiated groups, and time
waited for colonoscopy and overall patient satisfaction were compared.
Results: Median time waited for colonoscopy for the OAC group was 8
weeks (mean 8.8, SD 10) versus 5 weeks (mean 9.4, SD 10) for the con-
sultation initiated group (chi-square = 0.03 on one degree of freedom, P =
0.86). Median overall satisfaction was 9 (mean 8.3, SD 2.1) in the OAC group
and 9.5 (mean 8.5, SD 2.3) in the consultation group (P = 0.37). Median
time waited for colonoscopy for patients with symptoms (open access and
consultation initiated combined) was 4 weeks (mean 8.3, SD 10.1) versus
8 weeks (mean 9.4, SD 10.5) for those undergoing screening colonoscopy
(P = 0.05).
Conclusion: Our data suggests that the time waited for colonoscopy and
patient satisfaction is similar between open access and consultation-initiated
colonoscopy. We conclude that OAC is a viable alternative to consultation-
initiated colonoscopy with respect to time to endoscopy and overall patient
satisfaction, a fact that is increasingly important when manpower in the field
is critically low.
1200
Screening Colonoscopy in Patients Older Than 80 Years
Roy D. Yen, MD, Ognian Pomakov, MD, Michael Sitrin, MD, Matthew
Baichi, MD∗. Gastroenterology, University at Buffalo/VA Western New
York, Buffalo, NY.
Purpose: Screening colonoscopy for age 80+ is controversial, given
age-associated comorbidities, surgical candidacy, and life expectancy.
We performed a retrospective review to determine the yield of screen-
ing/surveillance colonoscopies in this age group and compared findings on
colonoscopy to those in patients (pts) <80 yo.
Methods: We collected data for all screening/surveillance colonoscopies
performed at our institution in 2004 (N = 587). We assembled 2 cohorts:
pts who were ≥80 yo (N = 56) and pts who were <80 yo (N = 531) at time
of procedure. We collected data for colonoscopy findings including number
and location of adenomas, histology, presence of advanced adenomas (size
>1 cm, villous features, high grade dysplasia), and colon cancer (CCA).
Survival for >2.5 yrs from time of procedure for patients ≥80 yo was also
recorded. Proportions were compared by chi-square; all significant P values
reported for P < .05.
Results: Colonoscopies for pts ≥80 yo represented 9.5% of procedures.
There was no significant difference between the 2 groups for previous en-
doscopy or h/o CCA; however, more pts <80 yo had a (+) family h/o CCA
(18.6 vs 5.4%, P < .05). There was no difference in percentage of pts be-
tween the 2 groups for advanced adenomas or cancer. Significantly more pts
≥80 yo had adenomas (35.7 vs 20.4%, P < .01). There were significantly
more pts ≥80 yo with proximal adenomas (19.6 vs 9.8%, P < .05). There
was a trend for more proximal advanced adenomas (12.5 vs 6.0%, P = .06)
in pts ≥80 yo. There was no difference between the 2 groups for proximal
CCAs, distal advanced adenomas, or distal CCAs. 39 pts ≥80 yo (72.2%)
were alive >2.5 yrs after procedure. When compared to percentage of pts
70–79 yo who were alive >2.5 yrs after colonoscopy, there was no significant
difference between the 2 groups (72.2% vs 82.2%, P = NS).
Conclusion: Screening colonoscopy is controversial in pts ≥80 yo. In our
study more pts ≥80 yo had adenomas. There was a trend for more pts ≥80 yo
with proximal advanced adenomas. After 2.5 yr follow-up, 72.2% pts ≥80
yo were alive. This suggests that pts ≥80 yo may still benefit from screening
colonoscopy; however, additional studies are needed.
Results
% of Pts <80 yo % of Pts ≥80 P
Adenoma 20.4 35.7 <.01
Adv Adenoma 13.2 16.1 NS
CCA 2.1 5.4 NS
Prox Adv Adenoma 6.0 12.5 .06
Survival >2.5 yr 82.2 (70–79 yo) 72.2 NS
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Distribution of Colon Neoplasia in Chinese Patients: Implications for
Endoscopic Screening Strategies
Otto S. Lin, MD, MSc, Maw-Soan Soon, MD∗. Gastroenterology, Virginia
Mason Medical Center, Seattle, WA and Gastroenterology, ChangHua
Christian Medical Center, ChangHua, Taiwan.
Purpose: Our aim was to measure the prevalence and distribution of colonic
neoplasia in Chinese adults, and to estimate the sensitivity of sigmoidoscopic
screening strategies for detecting those with advanced neoplasia.
Methods: Asymptomatic, average-risk Chinese adults aged ≥50 years
underwent screening colonoscopy. The prevalence and distribution of
colonic neoplasia and advanced neoplasia (defined as an adenoma ≥10
mm or with villous, high-grade dysplastic or malignant features) were
recorded and the outcomes of various sigmoidoscopic screening strategies
estimated.
Results: Of 1382 subjects (833 men, 549 women; mean age 58.8 years)
included, 243 (18%) had colorectal neoplasia and 72 (5.2%) had advanced
neoplasia. Neoplasia prevalence was significantly higher in male and older
patients. There were no significant differences in neoplasia or advanced
neoplasia distribution between men and women. Overall, 24 patients had
advanced neoplasia in the proximal colon, of whom 4 had synchronous
distal neoplasia. The estimated sensitivity for detecting patients with ad-
vanced neoplasia was 72% if we assumed screening sigmoidoscopy was
performed, with follow-up colonoscopy for those with distal neoplasia; 165
patients would need to undergo colonoscopy. If instead we assumed follow-
up colonoscopy was done only for patients with distal advanced neoplasia,
the estimated sensitivity would decrease slightly to 71% but the number
of colonoscopies would decrease substantially to 51. The estimated sen-
sitivity of screening sigmoidoscopy (with follow-up colonoscopy for pa-
tients with distal neoplasia) was not statistically different in men and women
(75.5% versus 63.2%; P = 0.3). If we assumed that colonoscopy was per-
formed only for patients with distal advanced neoplasia, there was also
no significant difference between men and women (73.6% versus 63.2%;
P = 0.39).
Conclusion: In average-risk Chinese adults, screening sigmoidoscopy is
estimated to detect more than two-thirds of patients with advanced neoplasia.
In societies with limited health care resources, performing colonoscopy only
on Chinese patients with distal advanced neoplasia is a screening approach
that optimizes the return rate on colonoscopic capacity.
1202
Role of Resistant Starch in Colorectal Cancer Prevention: A
Prospective Randomised Controlled Trial
Shridhar S. Dronamraju, MD, Jonathan M. Coxhead, PhD, Seamus B.
Kelly, MD, John C. Mathers, PhD∗. Human Nutrition Research Centre,
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School of Clinical Medical Sciences, Newcastle University, Newcastle
upon Tyne, Tyne and Wear, United Kingdom and Department of General
Surgery, North Tyneside General Hospital, North Shields, Tyne and Wear,
United Kingdom.
Purpose: Colorectal cancer (CRC) is the second most common cause of
cancer related death in the western world. Resistant starch (RS), defined as
starch that resists digestion in the small intestine of a healthy individual, gets
converted to butyrate following bacterial fermentation in the colon. Butyrate
is shown to have potent anti-neoplastic effects on colon cancer cells in vitro.
This study investigated the anti-neoplastic effects of RS in patients with CRC
and its potential role of as a chemo-preventive agent.
Methods: A total of 65 (36 male) sporadic CRC patients were randomised
to treatment (40 gm/ day) with RS or ordinary starch (OS) for 2–4 weeks.
Pre-treatment and post-treatment biopsies were obtained from tumour and
normal mucosa and the effects of the intervention on cell proliferation and
expression of cell cycle regulatory genes CDK4 and GADD45A (using real
time RT-PCR) were investigated.
Results: The proportion of mitotic cells in the top half of the crypt (which is
a valid pre-malignant marker used to assess response to chemo-preventive
trials) was markedly reduced following RS treatment as compared with OS
treatment (P = 0.028) (Fig. 1). There was no effect of RS treatment on crypt
dimensions or tumour proliferation index.
The expression of key cell cycle regulatory gene CDK4 was upregulated
(P < 0.01) while that of GADD45A was down regulated (P < 0.001) in the
tumour tissue compared with normal flat mucosa. RS treatment for up to 4
weeks in CRC patients tended to increase CDK4 expression (P = 0.07) in
tumour tissue. Expression of GADD45A, which was suppressed in cancer,
was significantly upregulated (P = 0.048) following RS treatment (Fig. 2).
Conclusion: RS modulates the colonic crypt cell kinetics and has potential
as a chemo-preventive agent against CRC. The differential expression of
key cell cycle regulatory genes may play a role in these cellular effects of
RS.[figure1]
1203
Colorectal Cancer Screening in HIV-Infected Patients: Are They Still
Being Ignored?
Shahzad Iqbal, MD, Veron Browne-McDonald, MD, Mehjabin Zahir, MD,
Hashem Vahabzadeh-Monshie, MD, Bishnu Sapkota, MD, Rekha Khurana
Khurana, MD, Eric A. Jaffe, MD, Maurice A. Cerulli, FACG∗.
Gastroenterology & Hepatology, NY Methodist Hospital, Brooklyn, NY and
Internal Medicine, Interfaith Medical Center, Brooklyn, NY.
Purpose: Although many HIV-infected patients are living well beyond 50 yr
of age, there are no published data on colorectal cancer (CRC) screening in
this population. Studies published in last few years suggest that although the
incidence and proportion of polyps and clinically significant colonoscopic
lesions are similar in normal and HIV patients, HIV patients are less likely
to undergo screening colonoscopy. The aim of this study was to determine
and compare the incidence of colonoscopic screening in HIV and normal
patients.
Methods: This study is a retrospective review of all lower endoscopies per-
formed in the 12 month period from November 1, 2005 to October 31, 2006
at a large community hospital located in the Bedford Stuyvesant-Crown
Heights area of Brooklyn, NY. The neighborhood is primarily African-
American with a 1.86% prevalence of HIV in adults (the highest in NYC).
Results: The charts of all patients (573) who had colonoscopy during the 12
month period were reviewed. 21 of the patients were HIV-infected. Of the 316
patients who were screened for CRC, 12 (3.8%) were HIV-infected. Hence,
the percentage of HIV patients screened for CRC (3.8%) was even greater
than the 1.86% prevalence of HIV in the adult neighborhood population. The
proportion of screening to diagnostic testing in HIV patients was comparable
that in non-HIV patients (57% and 43% vs. 55% and 45% respectively). The
mean age at CRC screening was about 5 years younger in HIV vs. non-HIV
patients (56.5 vs. 60.8 years respectively). The bowel preparation and cecal
intubation rates were adequate in screened HIV patients (92% and 100%
respectively). All CRC screening was done by colonoscopy.
Conclusion: We found that HIV patients are being screened for CRC at a
rate comparable to non-HIV patients. This may be explained by the better
health care opportunities available to HIV patients in the US as well as proper
referral from primary care physicians who better understand the increased
life expectancy and implications for long term care including screening
colonoscopy in such patients.
1204
Access to Colonoscopy for Positive FOBT or Blood Per Rectum:
Gender Effect at a Veteran’s Hospital
Andrew D. Rhim, MD, Mary A. Rambus, Michael Lawson, MD, Martin
Tobi, MB∗. Gastroenterology Division, Univ of PA School of Medicine and
Philadelphia VAMC, Philadelphia, PA; Detroit VAMC Wayne State School
of Medicine, Detroit, MI and Kaiser Permanente, Sacramento, CA.
Purpose: Due to the relatively small percentage of women who seek medical
care in the US VA medical system, it has been purported that disparities in
health care delivered to women may exist in this network. While investigators
have analyzed the effect of gender on colorectal cancer (CRC) screening, no
study has been performed examining how accessible diagnostic colonoscopy
(c-s) is once a positive FOBT (the major mode of CRC screening in the VA
system) or other risk factors have been reported. Here, we present data to
suggest that a gender effect exists in access to c-s.
Methods: From 2000–2006, patients at the Detroit VAMC were enrolled
in a prospective longitudinal study examining c-s findings after stool test-
ing. Inclusion criteria for this secondary analysis were: patients under the
age of 65, having an indication other than screening for c-s (i.e., +FOBT,
history of polyps, blood per rectum, anemia, change in bowel habits, newly
identified family history of CRC) and inclusion of all data at analysis. Data
were prospectively collected to include the indication for c-s; length of time
from indication to performance of c-s; outcome of barium enema or flexible
sigmoidoscopy, if applicable; age; race; and pathological findings after c-s.
Students t-test, χ2 and Fisher’s exact tests were performed.
Results: 104 patients were included (14 females, 86 males). There were
no differences seen in age, race or resultant pathology. However, among
patients with any indication for colonoscopy, the time from identifica-
tion of indication to diagnostic c-s was 109.5 d in females v. 228.6 d in
males (P < 0.005). When time to c-s was examined among those with
new blood per rectum or +FOBT, the discrepancy was even greater (110.9
v. 236.2 d; P < 0.0005). Patients with +FOBT or complaints of BPR
tended to have pathology on c-s, though this difference did not reach
significance.
Conclusion: This is the first study addressing access to c-s after an indication
is identified. We show that females obtained c-s more expeditiously than
males once an indication is established. The reasons for such a gender effect
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are unclear, though recent changes in the VA system emphasizing gender-
specific healthcare in the form of women’s health clinics may play a role.
Further studies confirming these results as well as analyzing the etiologies
of this effect are warranted.
1205
Physician Workforce, Socioeconomic Factors, and Colorectal Cancer
Outcomes
Thad Wilkins, MD∗, Andria Thomas, PhD, Robert Schade, MD, D. Stephen
Goggans, MD, Peggy Wagner, PhD, Denise Hodo, MPH, D. Douglas
Miller, MD. Medical College of Georgia, Augusta, GA.
Purpose: To determine the relationship among the physician workforce,
socioeconomic factors, and colorectal cancer (CRC) in Georgia.
Methods: Data were obtained from publicly available sources: Georgia
Board for Physician Workforce, Health Resources Services Administra-
tion, U.S. Census Bureau, and Georgia Division of Public Health Online
Analytical Statiscial Information System (OASIS). All data were reduced
to the county level and are expressed as rates per 100,000. All data were
from 2004, except census data, which was from 2000. Statistical analyses
were performed using SAS 9.1. Since CRC mortality rate was skewed, a log
transformation was used. Pearson’s correlation coefficients were used to de-
termine associations between the predictor variables pertaining to socioeco-
nomic status, Medicare coverage, physician workforce, and CRC outcomes.
Linear regression analysis was used to model the relationship between CRC
outcomes and predictor variables.
Results: Only 150 (94%) counties were used due to missing values. Rates of
CRC hospital discharges and mortality were 43.0 ± 20.7 and 19.7 ± 12.8 per
100,000, respectively. The rate of primary care physicians defined as fam-
ily physicians, internists, and obstetricians and gynecologists was 72.8 per
100,000 while the rate of specialty physicians defined as gastroenterologists,
general surgeons, and colorectal surgeons was 7.1 per 100,000. Less than
high school education (r = 0.44 P < .01), MUA score (r = −0.19 P = .01),
median household income (r = −0.34 P < .01), Medicare coverage (r =
0.41 P < .01), rates of family physicians (r = 0.17 P = 0.03) and gastroen-
terologists (r = −0.20 P = 0.01) were significantly correlated with CRC
mortality rates. In a linear regression model, less than high school education
(adjusted R2 = 18%), median household income (adjusted R2 = 17%), and
Medicare coverage (adjusted R2 = 11%) contributed most to the variance.
Workforce variables contributed less to the variance in this model: MUA
score (adjusted R2 = 3%), gastroenterologist rate (adjusted R2 = 3%), and
family physician rate (adjusted R2 = 2%).
Conclusion: Socioeconomic factors are highly correlated with CRC
mortality, and any large-scale intervention to increase CRC screening
should take these into account. In addition, our data indicate that the
rate of gastroenterologists has a positive impact on CRC mortality,
the rate of family physicians has a negative impact on CRC mortal-
ity, and the rate of other specialties does not significantly affect CRC
mortality.
1206
Screening Colonoscopy in the Elderly, Is It Worthwhile?
Emily G. Singh, MD, Catherine T. Frenette, MD, Williamson B. Strum,
MD∗. GI, Scripps Clinic, La Jolla, CA.
Purpose: Colorectal cancer is the third most common cause of cancer in both
men and women. Mortality from CRC is related to stage at diagnosis. This
study was designed to determine if screening colonoscopy leads to earlier
stage of CRC diagnosis in elderly patients and, thus, improves survival. We
tested the null hypothesis that patient’s age ≥ than 75 years of age who
undergo screening colonoscopy do not have an earlier stage of disease at the
time of diagnosis.
Methods: Patient records were obtained from the Scripps Green Hospital
Cancer Registry. Our database of all patients diagnosed with pathology-
proven colorectal cancer between 1/2000 and 12/2005 were queried for 1)
verification of CRC, TNM stage, and location within the colon; (2) patient’s
age; (3) sex; and (3) presenting symptoms. Patients were excluded if they
had a history of inflammatory bowel disease or familial polyposis syndrome.
Patients were divided into two groups based on symptoms and by age and
stage of disease at diagnosis. The stages of disease were separated at a critical
point: between early (Stage 0-IIB) and late (Stage III-IV). We evaluated
survival from the time of diagnosis in all patients.
Results: We studied 356 patients; 243 symptomatic and 113 asymptomatic.
Seventeen were stage 0, 101 stage 1, 99 stage IIa, 6 stage IIb, 17 stage
IIIa, 55 stage IIIb, and 61 patients were stage IV. There was a sustained
difference in stage of disease favoring patients who were asymptomatic
versus symptomatic for the study group and for all ages between 50 and
84 years. These differences are highly significant (P < .00013). With 100% 2-
year minimum follow-up, we found asymptomatic patients had significantly
improved survival when compared to symptomatic patients (P < .001). These
data disprove the null hypothesis.
Conclusion: Our study demonstrates significantly favorable differences in
screening colonoscopies for asymptomatic vs. symptomatic patients by find-
ing early stage colon cancer through age 84 and by improving survival. We
conclude that there is a role for screening colonoscopy in asymptomatic in-
dividuals without significant comorbidities up to age 84. This is one of the
first studies demonstrating that screening colonoscopy improves survival in
elderly patients.
1207
Effect of Initial Polypectomy Versus Surveillance Polypectomy on
Colorectal Cancer Mortality Reduction: Micro-Simulation Modeling
of the National Polyp Study
Ann G. Zauber, PhD∗, Sidney J. Winawer, MD, Iris Lansdorp-Vogelaar,
MS, Marjolein van Ballegooijen, MD, PhD, Michael J. O’Brien, MD.
Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center,
New York, NY; Gastroenterology and Nutrition Service, Memorial
Sloan-Kettering Cancer Center, New York, NY; Erasmus MC, University
Medical Center Rotterdam, Rotterdam, Netherlands and Boston University,
Boston, MA.
Purpose: Colorectal polypectomy with surveillance reduced colorectal can-
cer (CRC) incidence by 76–90% (Winawer, 1993) and colorectal cancer mor-
tality by 69% to 92% (Zauber, DDW 2007) with 20 years of follow-up in the
National Polyp Study (NPS). The relative effect of the initial polypectomy
versus the surveillance colonoscopy on mortality reduction has implications
for follow-up intervals, screening colonoscopy studies, and understanding
the adenoma-carcinoma progression.
Methods: A Micro-Simulation Screening Analysis (MISCAN) model, de-
veloped at ErasmusMC Rotterdam in conjunction with the National Cancer
Institute, used the NPS data to predict CRC mortality: 1) with no initial
polypectomy or surveillance colonoscopy; 2) with initial polypectomy only;
and 3) with both initial polypectomy and surveillance colonoscopy. The
model predicted CRC mortality for up to thirty years after initial polypec-
tomy.
Results: The model demonstrated a dramatic reduction in expected CRC
mortality with initial polypectomy with or without surveillance and sug-
gests that the initial polypectomy accounts for the major component of the
mortality reduction (see Figure). The model predicts a modest benefit from
surveillance after 10 years.
Conclusion: The major effect on colorectal cancer mortality reduction pro-
duced by the initial polypectomy rather than surveillance colonoscopies
is consistent with the low incidence of advanced adenomas (≥ 1 cm, vil-
lous component, high grade dysplasia, or invasive CRC) observed dur-
ing NPS follow-up. This supports the recommendation for lengthening
the surveillance intervals to 6 or more years for most patients post-
polypectomy.[figure1]
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Mismatch Repair Gene Mutations in Iranian HNPCC Families
Katayoun Aghajani, MD, Babak Noorinayer, MD, Mohsen Chiani, MS,
Somayeh Ghiasi, MD, Mehrnoosh Tashakori, MD, Navaz Karimianpour,
MS, Nasim Rahnamaye Chitsaz, MD, Mahsa Molaee, MD, Faramarz
Derakhshan, MD, Maurizio Ponz de Leon, MD, Mohamamd Reza Zali,
MD, FACG∗. Research Center for Gastroenterology and Liver Diseases,
Shaheed Beheshti Medical University, Tehran, Islamic Republic of Iran and
Department of Internal Medicine, University of Modena and Reggio
Emilia, Modena, Italy.
Purpose: Determining the MMR gene mutation careers in HNPCC fami-
lies to prevent advanced disease by early diagnosis through recommended
screening tests, decreasing both mortality and morbidity rates.
Methods: 592 unselected colorectal cancer patients were screened for MMR
mutations by immunohistochemical analysis. For patients with defects in ex-
pression of at least one of the MMR proteins, full mutational analysis was
performed by PCR amplification of each exon of the respective gene, includ-
ing the flanking intronic regions, follwed by bidirectional sequencing. Any
variation in DNA sequence was confirmed on an independent PCR prod-
Clinical characteristics of 56 cases with colorectal
cancer who met the Amsterdam II Criteria
Characteristics Number (Frequency)
Age at diagnosis >50 y 35 (62.5%)
Age at diagnosis <50 y 21(37.5%)
Sex Male 33 (59%)
Sex Female 23 (41%)
Location of Tumor Left sided 37 (66%)
Location of Tumor Proximal 19 (34%)
Tumor Stage I 2 (3.5%)
Tumor Stage II 21 (37.5%)
Tumor Stage III 15 (27%)
Tumor Stage IV 11 (19.5%)
Tumor Stage Unknown 7 (12.5%)
uct. Paired tumoral and genomic DNA samples were used for microsatellite
instability testing.
Results: 56/592 families fulfilled the Amsterdam Criteria II. 47/592 patients
had lack of expression of MMR protein(s); 17(36%) MLH1, 25(53%) MSH2
and 5(11%) PMS2. Among them, we have found 20 mutations in 18/47
families so far. 7 mutations were novel mutations and were reported to the
GenBank (GenBank accession numbers: EF570785-EF570789, EF583852
and EF125076). Genetic tests were offered to at risk family members of
these patients.
Conclusion: Our results provide further insight into the mutational spectrum
of MMR genes in Iranian HNPCC families.
1209
Role of Tumor Necrosis Factor Gene Polymorphism (-308 and -238) in
Colorectal Cancer Susceptibility
Mehrnoosh Tashakori, MD, Babak Noorinayer, MD, Azadeh Safaee, MS,
Faramarz Derakhshan, MD, Mohammad Reza Zali, MD, FACG∗. Research
Center for Gastroenterology and Liver Diseases, Shaheed Beheshti
Medical University, Tehran, Islamic Republic of Iran.
Purpose: The purpose of this study is to investigate the potential association
of tumor necrosis factor-α (TNF-α) promoter polymorphisms (-308 G>A
and -238 G>A) with colorectal cancer susceptibility.
Methods: The study included 77 patients with colorectal cancer and 100
healthy controls. The polymorphisms were genotyped for these TNF-α poly-
morphisms by PCR-Pyrosequencing (Fig. 1). The distributions of TNF-
α promoter polymorphisms were compared between cancer patients and
healthy controls by the chi-square test. Odds ratios (OR) and 95% confi-
dence intervals (CI) were also calculated.
Results: The Genotype distributions and allele frequencies of the -308
(rs361525) and -238 (rs1800629) TNF-α polymorphism in cancer patients
and controls are shown in Table 1. Although the TNF-308A allele frequency
was lower in the cancer group compared with the control group (7.8% vs.
14.5%) and TNF-238A allele frequency was higher (7.8% in cancer group
vs. 6% in controls), the observed differences were not statistically significant
(P > 0.05). The odds ratio for cancer in subjects with the TNF-308A allele
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Table 1. Distributions of the two tumor necrosis factor (TNF) polymorphisms in colorectal cancer patients and healthy controls
Genotype Distribution Allele Frequency
Polymorphism Conrol/Case G/G∗ G/A∗ A/A∗ OR(95% CI) G∗ A∗
-308 Control (N = 100) 77 (77) 17 (17) 6 (6) 1.00 171 (85.5) 29 (14.5)
-308 CRC†(N = 77) 66 (13) 10 (13) 1 (1.3) 0.55 (0.24–1.25) 142 (92.2) 12 (7.8)
-238 Control (N = 100) 90 (90) 8 (8) 2 (2) 1.00 188 (94) 12 (6)
-238 CRC†(N = 77) 69 (89.6) 4 (5.2) 4 (5.2) 1.05 (0.37–3.00) 142 (92.2) 12 (7.8)
† CRC, Colorectal cancer; ∗ Figures in parentheses represent percentage values.
was 0.55(95% CI, 0.24–1.25) and with the TNF-238A allele was 1.05 (95%
CI, 0.37–3.0).
Conclusion: We found no association between the -308G>A polymorphism
and the -238G>A polymorphism in the promoter region of TNF-α and
susceptibility to colorectal cancer in an Iranian population.[figure1]
1210
Using Colon Cancer Screening To Aid in Identifying Obesity
Sindu Stephen, MD, Marie L. Borum, MD∗, Anita Mittal, MD. Department
of Gastroenterology, George Washington University, Washington, DC.
Purpose: While colon cancer screening aids in decreasing mortality and
morbidity, other health risks may be identified during these visits. This study
evaluated whether colon cancer consultations can be used to assess other
health risks in African American and Caucasian women such as obesity and
mammography adherence.
Methods: A retrospective chart review of 93 (61 African American and 33
Caucasian) female patients referred for colon cancer screening consultations
over a 2 month period were performed to assess the presence of screening
mammographies. Eighty-three (52 African American and 31 Caucasian)
charts recorded body mass indices, which were used to assess the presence
of obesity. A database was created using Microsoft Excel. Statistical analysis
was performed using Fisher’s exact test with significance set at P < 0.05.
Results: Fifty-four of 61 (88%) African American females and 28 of the 33
(85%) Caucasian females that had screening colonoscopies had undergone
screening mammographies. There was no statistical significance between the
two groups (P = 0.7477). Sixty-one of the 83 patients (73%) were overweight
or obese. Specifically, forty-one of 83 patients (49%) were obese and 20 of
the 83 patients were overweight. There was a significant (P = .0002) increase
of obese and overweight African-Americans (88%) than caucasians (48%).
Conclusion: Colonoscopy screening consultations provides another oppur-
tunity to identify and counsel patients with obesity.
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Feasibility and Results of a Colorectal Cancer Screening Program
Targeting Uninsured Patients
Gregory A. Cote, MD, Laura Michalski, BS, Christian S. Jackson, MD,
James Webster, MD, Babs Waldman, MD, Robert M. Craig, MD∗.
Gastroenterology, Northwestern University, Chicago, IL and Lederman
Family Health Center, Chicago, IL.
Purpose: Compliance with recommendations for colorectal cancer (CRC)
screening remains suboptimal. Primary prevention of CRC in uninsured
patients is especially problematic. We report our experience in the imple-
mentation of a CRC screening program within a free clinic and the results
of its first 13 months in practice.
Methods: Community health administrators and physicians recruited sup-
port from the affiliate academic medical center and local representatives
from medical industry (Fig. 1) to establish a CRC screening clinic. Records
of patients enrolled in the community health center 50 years of age or older
were screened for eligibility. Patients with a family history of CRC or symp-
toms of abdominal pain, weight loss, overt or occult gastrointestinal bleeding
were referred directly for colonoscopy. Otherwise average risk patients were
provided verbal and written instruction on FOBT and optical flexible sig-
moidoscopy (FS). FOBT negative patients underwent a FS at the community
health center. Per current guidelines, follow-up recommendations were pro-
vided based on FS results.
Results: 178 patients (mean age 59.2, 56.2% female, 70.3% Hispanic, and
median annual income US$8,280) underwent FS following negative FOBT.
5.2% of patients eligible for FS refused to participate. 22 patients (12.4%)
were found to have a tubular adenoma during FS and referred to colonoscopy.
Of these, 1 patient was found to have adenocarcinoma in-situ and 1 patient
with invasive adenocarcinoma. Patients found to have a tubular adenoma
were significantly older (62.4 years compared to 58.8 years, P = 0.04) com-
pared to normal subjects; sex, ethnicity and median annual income was not
associated.
Conclusion: The implementation of a colorectal cancer screening program
coordinating a free clinic, an academic medical center, physicians and the
medical industry is feasible and sustainable. The prevalence of adenomatous
polyps among a predominantly Hispanic population is significant. Future
studies should focus on the potential economic benefit of this type of primary
prevention on reducing health care costs.[figure1]
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Adherence to Screening Colonoscopy in a VA Setting
Samuel F. Castillo, MD, Felix W. Leung, MD, Francisco C. Ramirez, MD∗.
Gastroenterology, Carl T. Hayden VA Medical Center, Phoenix, AZ and
Medicine & Research, Sepulveda ACC, VAGLAHS, UCLA, North Hills, CA.
Purpose: Adherence (completion) rate for screening colonoscopy is reported
between 50% and 70%. Adherence is dependent on patient’s scheduling
and patient’s compliance. The main reason for non-adherence is the lack
of patient-driven scheduling. In the VA system, patient’s scheduling is GI-
service- rather than patient-driven with an unknown adherence rate. Aim:
Determine the adherence rate to screening colonoscopy in a VA Hospital.
Methods: Three scheduling strategies were tested: the PCP generated an
electronic (e-) consult to GI who contacted and scheduled the patient (Group
1); after a discussion with patient, the PCP generated an e-consult to GI
AND each patient was given written information detailing CRC and screen-
ing colonoscopy and prompting them to CALL that day to schedule the
procedure (Group 2); after a discussion with the patient, the PCP generated
an e-consult to GI AND gave them a card that prompted them to STOP BY
the GI section today and schedule the colonoscopy (Group 3). One week
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Adherence rates at 1 month
Scheduling Group 1 Group 2 Group 3 Overall
Patient-driven 0 24/72 (33.3%)a 19/34 (55.9%)a, b 43/135 (31.9%)
GI Service-driven 23/29 (79.3%) 37/72 (51.4%)a 12/34 (35.3%)a 72/135 (53.3%)
Overall 23/29 (79.3%) 61/72 (84.7%) 31/34 (91.2%) 115/135 (85.2%)
a vs Group 1; b vs. Group 2; P < 0.05; Chi square analysis
after receipt of the e-consult, GI phoned the patients who did not initiate
contact to schedule the procedure. The adherence rate was determined after
1 month.
Results: 184 consults were received (37, 101 and 46 in Groups 1, 2 and 3,
respectively). Excluded from the analysis were 10 patients who did not call
back after leaving messages 3 times, 12 who refused to undergo colonoscopy,
5 who had inappropriate referrals (surveillance, acute medical contraindi-
cations or other reasons), and 22 who were scheduled to have colonoscopy
beyond 1 month. The data of 135 patients were analyzed. Table 1 shows the
adherence rate for each of these 3 groups.
Conclusion: 1) Implementation of patient- and GI- driven scheduling strate-
gies at this VA Hospital resulted in an overall adherence rate at 1 month of
85%, a much higher rate than that reported in community practice (50 to
70%). 2) The strategy of instructing patients to go to GI immediately resulted
in the highest patient-driven (56%) and highest overall (91%) adherence rate.
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Disparities in Colon Cancer Screening – A Population Study
Carline Quander, MD, MS∗, Steve Whitman, PhD, Ami M. Shah, MPH.
Internal Medicine, Rush University Medical Center, Chicago, IL and
Urban Health Institute, Sinai Health System, Chicago, IL.
Purpose: The screening rates for colorectal cancer are lower in certain racial
and ethnic subgroups. We analyzed colorectal screening adherence across 6
geographically distinct multiracial communities in Chicago, Ill. We evalu-
ated various barriers to colorectal screening.
Methods: In 2002–2003, a comprehensive household health survey was
conducted in six community areas with 1,700 households in English and
Spanish. As a part of the survey, individuals over the age of 50 were asked
whether they had ever had colorectal cancer screening with either an endo-
scopic exam or blood stool test.
Results: The proportion of participants over the age of 50 who reported
ever having a blood stool test, or endoscopic test ranged from 42% to 70%,
and 36 to 54% across the 6 communities. The community with the highest
screening proportion for an endoscopic test (54%) was predominantly white
with the lowest poverty level. The communities with the lowest screening
proportion for an endoscopic test had the highest poverty levels and were
composed of predominantly, blacks and Hispanics. Within the 6 communi-
ties, Mexicans (33%) were less likely to report screening with a blood stool
test compared with whites (65%) (P < 0.0001). They were also less likely to
report ever having a sigmoidsocopy/colonoscopy. Participants whose home
was primarily Spanish speaking reported a lower adherence to occult blood
screening (31%), and endoscopic screening (38%) compared with homes
where English was the primary language (66%) (P < 0.0001). Having a
regular primary care physician, getting medical care other than when sick,
and having any doctor visits in the past 12 months were all associated with
adherence with colorectal cancer screening (P < 0.05).
Conclusion: Adherence to colorectal cancer screening varies widely be-
tween different communities. Community level analysis of screening adher-
ence would assist the shaping of culturally meaningful prevention efforts.
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Which Adenoma Characteristic Has the Strongest Effect on Predicting
Advanced Neoplasia or Numerous Adenomas on Follow up
Colonoscopy?
Carol A. Burke, MD∗, Leila Mott, John Baron, MD, Doug Roberston, MD,
The Polyp Prevention Study Group. Gastroenterology, Cleveland Clinic,
Cleveland, OH and Biostatistics and Epidemiology, Dartmouth, Lebanon,
NH.
Purpose: Adenoma size, number and pathology are independently associ-
ated with recurrence of advanced neoplasia (AN). The Multi-Society Task
Force (MSTF) recommends different surveillance intervals based on ade-
noma features: 5–10 yrs for individuals with low recurrence risk [LR] (<3,
< 10 mm, TA) and 3 yrs for those with high recurrence risk [HR] (>2, ≥
10 mm, or advanced neoplasia). Our aim was to determine the magnitude
of the effect of each factor in predicting recurrent AN or being classified as
HR at FU colonoscopy.
Methods: Data from subjects in the placebo arm of 3 postpolypectomy
chemoprevention trials were used. Subjects were divided into LR or HR
based on MSTF criteria. AN was defined as adenoma > 9 mm or with any
villous component/SD. Multivariate regression analysis was used to obtain
risk ratios for baseline adenoma factors, looking first at baseline risk status
(HR vs LR) and then size, histology and number of adenomas in a second
model. All models included age, sex, study, and follow-up time as covariates.
Results: 800 subjects with a baseline adenoma(s) and who underwent com-
plete polypectomy were included. The mean time to FU colonoscopy was
37 months. HR status at baseline was significantly associated with recurrent
AN, RR 1.9 (1.2–3.0, P = 0.01) and HR status on FU, RR 2.1 (1.5–3.1, P <
0.0001). When individual adenoma features were studied, adenoma multi-
plicity was associated with both outcomes, pathology was not associated
with either outcome and large size was only associated with AN (Table).
Conclusion: The number of adenomas (>2) is the strongest predictor of risk
of recurrent AN and being classified as HR at FU. Colonoscopists should be
diligent in efforts to detect synchronous neoplasia regardless of size in order
to recommend the proper postpolypectomy interval.
Effect of Adenoma features on Recurrence
Advanced Adenoma HR status
Baseline
Adenoma Factor ∗RR (95% CI) P value ∗RR (95% CI) P value
Size (mm)
6–9 vs >9 0.98 (0.51–1.89) 0.96 1.05 (0.64–1.72) 0.85
>9 vs <6 1.73 (1.03–2.90) 0.04 1.47 (0.96–2.26) 0.08
Pathology
VA vs TA 1.11 (0.67–1.85) 0.68 1.31 (0.87–1.98) 0.20
Number
>2 vs <3 1.69 (1.06–2.69) 0.03 2.25 (1.55–3.27) <0.001
∗Adjusted
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Adenomas Are Detected More Often on Morning Than Afternoon
Screening Colonoscopy
Madhusudhan R. Sanaka, MD∗, Fnu Deepinder, MD, Carol A. Burke, MD,
Rocio Lopez. Gastroenterology, Cleveland Clinic, Cleveland, OH.
Purpose: Effective colonoscopy (COL) depends on adenoma detection and
removal. We postulate that adenoma detection may be lower in afternoon
(PM) than morning (AM) COL due to factors other than inadequate bowel
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Demographic and Endoscopic Features of Subjects
Characteristic AM PM P value
Mean Age 58 59 0.22
Female 54% 50% 0.012
Indication (Average risk, Personal Hx, (53.2%, 31.7%, 10.7%, 4.5%) (59.9%, 26.6%, 8.9%, 4.5%) <0.001
Family Hx, Increased risk)
Fellow participation 4.7% 1% <0.001
Diverticulosis seen 32.1% 27.1% 0.001
Predictors of Adenoma Detection
Factor O.R. (95% CI) P value
Time of day AM vs PM 1.2 (1.04, 1.4) 0.008
Age Every 5 year increase 1.1 (1.08, 1.2) <0.0001
Gender Male vs Female 1.6 (1.4, 1.9) <0.0001
Indication Personal Hx vs Ave risk 2.0 (1.7, 2.4) <0.001
Diverticulosis No vs yes 1.2 (1.01, 1.4) 0.036
prep or incomplete COL. Our aim was to determine the effect of timing of
screening COL on adenoma detection.
Methods: The records of 9063 COL performed in 2006 at a tertiary care
gastroenterology department were reviewed. Data including patient demo-
graphics, indication for COL, time of COL (AM versus PM), COL findings,
presence of adenomas, and adenoma size, number, pathology were obtained.
Patients with incomplete COL, inadequate bowel prep, prior colonic resec-
tion, inpatient status, and COL done for indication other than screening were
excluded. AM COL was defined as COL that started before12 PM and PM
COL as an exam that started after 12 PM. Wilcoxon rank sum and Chi square
tests were used. Multivariable logistic regression analysis was used to study
factors affecting adenoma detection.
Results: 3621 COL included. 1749 (48.3%) were done in AM and 1872
(51.7%) in PM. Adenomas were detected in 29% of AM and 25% of PM
COL (P 0.008). More females, subjects with increased risk of neoplasia,
fellow participation in exam and diverticulosis were noted in the AM group
(Table 1). No difference in the size (P 0.4), number (P 0.8), location (P 0.4),
or pathology of adenomas (P 0.4) was observed between AM and PM COL.
In the multivariable analysis, AM COL were significantly associated with
higher adenoma detection as were male gender, increased risk status and
older age (Table 2).
Conclusion: AM colonoscopy is an independent predictor for increased
adenoma detection. The reason and implications of this finding should be
considered and studied further.
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Findings on Surveillance Colonoscopy in Patients with Low-Risk
Polyps on Initial Colonoscopy
Neil Mehta, MD, Jocelyne Miller, MD, Michael Feldman, MD, Emma
Furth, MD, Gregory Ginsberg, MD, James D. Lewis, MD∗. University of
Pennsylvania, Philadelphia, PA.
Purpose: Adenomatous polyps are commonly found on colonoscopy with
current guidelines recommending a detection rate of 25% in men and 15%
in women. Studies show that screening colonoscopy with post-polypectomy
surveillance reduces colon cancer risk, but the optimal timing of surveillance
exams in patients with low risk polyps is uncertain. This study describes the
prevalence of adenomatous polyps on follow-up after a colonoscopy finding
only 1–2 small tubular adenomas. We hypothesized that the prevalence of
adenomas and advanced adenomas identified on the 3rd colonoscopy would
be low and even lower if the 2nd colonoscopy had no adenomas identified.
Methods: We compiled a retrospective cohort of patients ≥ 49 yrs old
who had 1–2 small (<10 mm) tubular adenomas identified and removed
on colonoscopy and 2 subsequent colonoscopies, each ≥11 months apart.
Exclusion criteria included a history of polyps, cancer or surgery of the colon
or inflammatory bowel disease. Advanced adenoma was defined as ≥ 1 cm
or with tubulovillous or villous histology or high-grade dysplasia.
Results: We identified 1002 patients who had ≥3 colonoscopies performed
at an academic medical center from 1993 to 2006. 88 patients (52 men,
36 women, 66% white, 30% black, 4% other) met inclusion criteria. The
median age at 1st colonoscopy was 60 (range 49–85). The median time
between 1st and 2nd colonoscopy and between 2nd and 3rd colonoscopy
was 33 months (range 11–78) and 37 months (range 11–102), respectively.
At the 2nd and 3rd colonoscopy, 31/88 (35.2%) patients and 26/88 (29.6%)
patients had at least 1 adenoma, respectively. At colonoscopy #2, 4/88 (4.6%)
patients had an advanced adenoma or ≥3 adenomas. At colonoscopy #3, only
3/88 (3.4%) patients had advanced adenomas (95% CI 0.7–9.6%). One of
these 3 had an advanced adenoma on the 2nd colonoscopy, and the other 2
had no adenomas on the 2nd colonoscopy. Among the 56 patients without
adenomatous polyps at colonoscopy #2, the prevalence of any and advanced
adenomas on colonoscopy #3 was 25% (95% CI 14.4%-38.4%) and 3.6%
(95% CI 0.4%-12.3%), respectively. The presence of adenomas on the 3rd
procedure was not significantly associated with whether it was performed <
or > 3 years from the 2nd procedure.
Conclusion: In patients with 1–2 small tubular adenomas on initial
colonoscopy the prevalence of adenomas and advanced lesions on the third
colonoscopy is high enough to justify continued surveillance -within 5 years-
even if no adenomas are found on the 2nd colonoscopy.
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Low Frequency of Colon Polyps in Association with Diverticulosis
Amol S. Rangnekar, MD, Aaron Z. Tokayer, MD∗. Gastroenterology,
Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva
University, Bronx, NY.
Purpose: Prior research has suggested that there is a lower frequency of
colon cancer in areas of colon affected by diverticulosis. The aim of this
study was to determine the prevalence of adenomatous polyps in association
with adjacent diverticulosis.
Methods: 600 consecutive colonoscopy reports from a single endoscopist
at our institution were reviewed to determine the prevalence, location,
and co-association of diverticulosis and adenomatous polyps noted during
colonoscopy. Cases with incomplete evaluations were excluded, leaving 589
colonoscopies for inclusion in this study.
Results: Of 589 colonoscopies, 308 (mean age 63) exhibited diverticulosis,
while the remaining 281 (mean age 58) did not.142 (46%) of the 308 pa-
tients with diverticulosis were found to have polyps, and 128 (46%) of the
281 patients without diverticulosis were found to have polyps. To analyze
the co-association of polyps and diverticulosis in the same segment of colon
in affected patients, we subdivided the data by colonic segment. Of the 308
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patients with diverticulosis, 252 patients had diverticulosis in the rectosig-
moid colon, 188 patients in the descending colon, and 103 patients in the
proximal colon. In a subset analysis, concurrent polyps (in the same segment
of colon) were found in 17/252 (7%) of patients who had diverticulosis in the
rectosigmoid colon, 10/188 (5%) in the descending colon, and 18/103 (17%)
in the proximal colon. Among the patients who did not have diverticulosis
in those same segments of colon, polyps were found in 56/337 (17%) of
patients without diverticulosis in the rectosigmoid colon, 73/401 (18%) in
the descending colon, and 133/486 (27%) of patients in the proximal colon.
Thus, the prevalence of adenomatous polyps in colonic segments affected by
diverticulosis as opposed to the same segment unaffected by diverticulosis
was 7% v. 17% for the rectosigmoid colon (P = 0.008), 5% v. 18% for the
descending colon (P = 0.002), and 17% v. 27% for the proximal colon (P =
0.02).
Conclusion: The frequency of adenomatous polyps was significantly lower
in colonic segments with associated diverticulosis as compared to colonic
segments without associated diverticulosis. Despite a similar frequency of
polyps overall, patients were significantly less likely to have concurrent
polyps in the colonic segment affected by diverticulosis (rectosigmoid, de-
scending, and proximal colon). These data are consistent with the previous
finding of a lower prevalence of colon cancer in segments of colon affected
by diverticulosis.
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The Influence of Race and Gender on Colon Polyp Incidence after
Polypectomy
Eli Penn, MD, Donald Garrow, MD, Joseph Romagnuolo, MD∗. General
Internal Medicine, Medical University of South Carolina, Charleston, SC
and GI and Hepatology, Medical University of South Carolina, Charleston,
SC.
Purpose: To determine the effect of gender and race on incidence of new
polyp formation among individuals undergoing polypectomy at colonoscopy
for screening or minimal symptoms. There appear to be discrepancies be-
tween the effect of African-American (AA) race and gender on the risk
of colon cancer vs. the prevalence of colon polyps. One explanation is a
variable growth pattern and/or recurrence rate. Our recent polyp prevalence
study (DDW 2007) showed no effect by race, but males had an increased
polyp prevalence.
Methods: GI-Trac is an endoscopy database containing colonoscopy in-
formation prospectively collected over 10 years at the Medical University
of South Carolina (MUSC), including indications and symptoms, prior in-
tervention, disease risk factors, ASA comorbidity index, procedure times,
preparation quality, findings (including polyp size, location, and removal),
and completeness to the cecum. Patients who had a colonoscopy for screen-
ing or minimal symptoms and came back to MUSC for another colonoscopy
over the 10 years were included. A Cox proportional hazards model was built
to assess the effect of gender and race corrected for selected confounders on
polyp recurrence, determining adjusted hazard ratios (aHR) for “polyp-free
survival”. A random sample’s histology reports were manually reviewed to
assess for possible racial/gender differences in polyp histology.
Knowledge Score
Results (Mean ± SEM) N Maximum = 15) P (Unpaired t)
Did not know why having colonoscopy 21 6.4 ± 0.3 0.03
Knew why having colonoscopy 130 7.4 ± 0.2
Provider did not discuss colonoscopy 95 6.9 ± 0.2 0.003
Provider did discuss colonoscopy 55 7.9 ± 0.3
Would not recommend screening to family members 4 4.8 ± 1.4 0.004
Would recommend screening to family members 114 7.7 ± 0.2
Consider Unsedated Colonoscopy
(0 = no; 1 = yes)
Did not know about unsedated option 71 0.28 ± 0.05 0.024
Knew about unsedated option 45 0.49 ± 0.08
Results: 760 (20%) of 3732 subjects had polyps on a colonoscopy for
screening or minimal symptoms in our prevalence study, with roughly half
eligible for >5 year follow-up. Cecal intubation rate was 98.6%. A ran-
dom sample of pathology (N = 40) from this cohort showed there was no
significant racial difference in the proportion of polyps that were adeno-
matous (whites 68% vs. AA 60%, P = 0.60). 57 subjects had a follow-up
colonoscopy at MUSC a median of 3.58 years after their index procedure:
18 were male, 7 AA, 19 were over age 65 and 35 (61.4%) had a polyp re-
currence. Neither gender (aHR = 0.98; 95% CI (0.43 – 2.21)) nor race
(aHR 1.89; 95% CI (0.70 – 5.24)) significantly predicted recurrence of
polyps.
Conclusion: Gender and race do not appear to predict recurrence of colon
polyps after polypectomy; gender- and race- specific recommendations for
surveillance colonoscopy are not supported. Larger sample sizes may be
needed to further improve the precision of these estimates.
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Exploring Fund of Knowledge, Beliefs and Attitutes about Colo-Rectal
Cancer Screening. Results of a Patient Survey Undergoing Screening
Colonoscopy
Samuel Castillo, MD, Felix W. Leung, MD, Francisco C. Ramirez, MD∗.
Gastroenterology, Carl T. Hayden VA Medical Center, Phoenix, AZ and
Medicine and Research, Sepulveda ACC, VAGLAHS, UCLA, North Hills,
CA.
Purpose: Patient’s fund of knowledge, beliefs and attitutes towards CRC
screening are varied and is not known whether these affect compliance and
adherence to the different CRC screening strategies. We test the hypothesis
that certain patient attributes determine their knowledge of colorectal cancer
and screening.
Methods: Patients presenting for screening colonoscopy were asked to vol-
untarily and anonimously fill out a 21-question survey upon checking in to the
endoscopy unit. In addition to age, race and gender, questions explored their
understanding of why they had to undergo screening colonoscopy, whether
they perceived their providers had given them discussions of the colonoscopy,
and questions that determined their fund of knowledge about colon cancer
and colorectal cancer screening.
Results: 151 patients completed the survey. The mean age was 62.8 years
and the majority were men (5.3% were women). Significantly different
knowledge scores exist between subjects who indicated they knew or did
not know why they were having colonoscopy, whether their providers dis-
cussed details of colonoscopy, and if they would recommend colonoscopy
to family members. Subjects who knew about unsedated colonoscopy had
a significantly higher score in terms of willingness to consider use of
unsedated colonoscopy (Table 1). Knowledge score was not dependent on
first time screening colonoscopy, history of fecal occult blood testing, de-
layed screening, prior refusal of colonoscopy, and family history of colon
cancer.
Conclusion: There is significant room for improving patient’s overall and
specific colonoscopy screening fund of knowledge. The effects of such im-
proved education upon adherence and compliance need to be studied further.
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Obesity (BMI ≥30) Has Highest Attributable Risk for Colorectal
Neoplasia in Asymptomatic Women
Benjamin N. Stein, MD, Joseph C. Anderson, MD∗, Zvi Alpern, MD, Carol
M. Martin, ANP, Patricia Hubbard-Ells, ANP. Gastroenterology, Stony
Brook University, Stony Brook, NY.
Purpose: Screening for colorectal cancer is currently recommended to be-
gin at 50 for most patients. This recommendation does not include other
important factors such as BMI and smoking. Using these factors may al-
low for more effective screening, possibly by requiring less intense screen-
ing for some 50 year old women as suggested by one expert (Lieberman
AJG 2005). Our goal was to determine population attributable risk (PAR)
for age, smoking, BMI and family history in a screening population for
women.
Methods: We collected age, gender, height, weight, family history of col-
orectal cancer, smoking history, meds, alcohol use and dietary history from
asymptomatic patients >40 years presenting for screening colonoscopy. Pa-
tients were divided into those with BMI<30 kg/m2 and ≥30 kg/m2. For
smoking, patients were divided into three groups: 1) Heavy exposure- those
who had smoked > 10 pack years and who were currently smoking or had
quit in the past 10 years 2) Low exposure- those who had smoked <10
pack years or who had quit >10 years ago regardless of total pack years
3) No exposure- those who never smoked. Significant colorectal neoplasia
was defined as large (>10 mm) adenoma, villous adenoma, multiple (>2)
adenomas, high-grade dysplasia or cancer. All results were confirmed using
advanced neoplasia as an endpoint.
Significant Neoplasia in Asymptomatic Women
Risk Factor N % exposed Odds Ratio PAR P-value
Age <50 239 19.1 1.0 – –
Age 50–59 511 40.8 1.03 1.2 –
Age 60–69 328 26.2 1.45 10.6 –
Age >69 174 13.9 2.43 16.5 0.01
BMI<30 871 69.5 1.0 – –
BMI ≥30 381 30.4 1.84 20.4 .007
− FH CRC 1031 82.3 1.0 – –
+FH CRC 221 17.7 1.32 5.4 NS
No exposure smoking 743 59.3 1.0 – –
Low exposure smoking 326 22.6 0.90 N/A NS
Heavy exposure smoking 226 18.0 1.90 13.9 .014
PAR-population attributable risk
Results: 2695 patients were screened. Men had a greater risk of significant
neoplasia than for women (9.0% vs 6.9%; P = 0.037). The P values for
age refers to trend. Among women, BMI ≥30 had the highest PAR of all
significant risk factors (see Table).
Conclusion: Our data suggest that BMI≥30 is the most important risk factor
for colorectal neoplasia in our asymptomatic women, accounting for up
to 1 of 5 significant lesions detected on screening colonoscopy. Given the
increasing number of obese patients in the US, identifying them as high risk
may have important screening implications.
e-Consult Only Patient Called GI Patient Did not Call GI Patient Came to GI Patient Did not Come to GI
Intervals (days) N = 28 N = 25 N = 46 N = 21 N = 13
e-Consult to 1st GI Contact 9.9 + 3.5 ± 4.5 + 3.2 ± 12.6 + 5.6 ± 0.5 + 1.1∗ ± 10.9 + 4.8 ±
1st GI Contact to Colonoscopy 18.8 + 3.4 ± 19.2 + 3.2 ± 19.3 + 2.6 ± 14.2 + 2.9 ± 12.5 + 2.2 ±
e-Consult to Colonoscopy 28.6 + 3.5 ± 23.7 + 3.4 ± 31.9 + 2.8 ± 14.7 + 3.0∗ ± 23.5 + 3.1 ±
Number of Calls Made by GI 1.5 + 0.1 ± 1.3 + 0.1 ± 1.8 + 0.1 ± 0 + 0∗ ± 1.8 + 0.3 ±
∗ vs all other, P < 0.05, ANOVA with contrasts
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Strategies To Improve Scheduling and Completion of Screening
Colonoscopy in a VA Setting
Francisco C. Ramirez, MD∗, Samuel F. Castillo, MD, Felix W. Leung, MD.
Gastroenterology, Carl T. Hayden VA Medical Center, Phoenix, AZ and
Medicine & Research, Sepulveda ACC, VAGLAHS, UCLA, North Hills, CA.
Purpose: Veterans Health Administration (VHA) directive mandates that
screening colonoscopy must be completed < 60 days from referral. Aim:
To determine the best scheduling strategy for implementation.
Methods: Three strategies were tested: primary care provider (PCP) gener-
ated an electronic (e-) consult to GI to schedule the patient (Group 1); or
after discussion with patient, PCP generated an e-consult to GI AND each
patient was given written information about screening colonoscopy and in-
structed to CALL GI “today” (Group 2); or COME TO GI “today” (Group 3)
to schedule colonoscopy. One week after the e-consult, GI called the patients
who did not initiate contact to schedule colonoscopy. Study period: 4/4/07–
4/30/07. The following time intervals (days) were tabulated: e-consult to
1st GI contact, 1st GI contact to completed colonoscopy and e-consult to
completed colonoscopy. Number of calls made by GI was recorded.
Results: 184 patients (37, 101 and 46 in Groups 1, 2 and 3) were referred. We
excluded 10 who did not return phone calls after 3 messages; 12 who declined
colonoscopy; 5 who had inappropriate referrals and 22 who were scheduled
for colonoscopy after 6/4/07. The data of 135 patients were analyzed. Table
1 shows that when the scheduling was patient-driven (same day come to GI)
time intervals were significantly shorter.
Conclusion: The strategy of having patients come to GI personally on the
same day after PCP clinic visit resulted in significantly shorter time intervals
compared to e-consult only and patient-initiated phone scheduling. This
strategy also imposes the least amount of work load (initiating contact with
patients) on GI as seen by the significantly smaller number of calls needed
to schedule the patients. Patient-initiated same day personal scheduling with
GI appears to be the most efficient and effective to ensure timely completion
of screening colonoscopy.
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A Paid Day Off from Work Increased Willingness To Have Screening
Colonoscopy
Kavitha Kumbum, MD, David Widjaja, MD, Kalyan C. Kanneganti, MD,
Prospere Remy, MD, Sridhar S. Chilimuri, MD∗.
Gastroenterology/Medicine, Bronx Lebanon Hospital Center, Bronx, NY.
Purpose: Screening rate for colorectal cancer is still low. In an effort to
increase screening rates we conducted a survey among hospital employees
to assess if a paid day off from work will increase rates of colon cancer
screening.
Methods: All hospital employees of Bronx Lebanon Hospital Center, New
York were given an anonymous questionnaire which was distributed through
payroll. A pre-stamped envelope was provided so the questionnaire could be
returned by mail.
Results: A total of 4501 surveys were distributed and 916 (20.4%) employ-
ees responded. More women than men returned the surveys (658 versus
258). Among those who responded 789 (86.1%) were aware of colon can-
cer screening, 384 (41.9%) were more than 50 years old and 161 (17.6%)
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had family history of colon cancer or polyps. Among 161 respondents with
family history of colon cancer or polyps, 11 (6.8%) were not aware of colon
cancer screening tests, 78 (48.4%) were over the age of 50 and only 58
(36%) had a screening test for colon cancer. Of all the respondents, 297
(32.4%) had one or more of screening tests. Eighty nine of them had stool
test for occult blood, 16 had barium enema, 27 had sigmoidoscopy and 235
had colonoscopy. Of 603 respondents who never had a screening test, 407
(67.5%) were willing to have a screening test, 101 were not sure, 90 (14.9%)
were not willing to have a screening study and 5 did not respond to the
question. Six hundred and ninety one (75.4%) of respondents were willing
to have an initial or if needed a repeat screening colonoscopy if given a paid
day off from work. Of 63 respondents who were above 50 years and not
willing to have an initial or a repeat screening colonoscopy, 28 (44.4%) were
willing to have colonoscopy if given a paid day off. Among 228 respondents
who were unwilling to have an initial or a repeat screening colonoscopy,
there was statistically significant difference between male and female re-
spondents who finally would go for the screening colonoscopy if they were
given a paid day off [61% (27/44) male versus 38.6%(71/184) female,
P = 0.006].
Conclusion: Our survey suggests that among health care employees who
were initially unwilling to have screening colonoscopy, a paid day off from
work may increase willingness to have the procedure. This was significantly
higher in male respondents than female. A prospective study is needed to
assess the effectiveness of this strategy.
1223
CT Colonography (CTC) Reporting and Data System (CRADS): An
Effective Method To Manage Extracolonic (EC) Findings
Mazer R. Ally, MD, Ganesh R. Veerappan, MD, Jennifer S. Pak, Corinne L.
Maydonovitch, Jong-Ho R. Choi, MD, Roy K.H. Wong, MD∗.
Gastroenterology, Walter Reed Army Medical Center, Washington, DC and
Radiology, Walter Reed Army Medical Center, Washington, DC.
Purpose: CT colonography (CTC) is a new technology used to visualize
the colon and rectum. EC findings have raised concerns regarding additional
expense, patient anxiety and morbidity. CTC Reporting and Data System
(CRADS) is a classification system devised to help direct this work up. In
this schema, E3 and E4 represent clinically significant findings requiring ad-
ditional follow up. Most findings are E2 or clinically insignificant and require
no follow up. This classification system guides the physician to avoid un-
necessary work up of benign findings. Our study retrospectively investigates
the impact of CRADS on the work up of patients with E2 findings.
Methods: We retrospectively reviewed all CTC reports from July 2003
to June 2006. CRADS was fully implemented at our institution on Jan-
uary 1, 2006. Prior to this date, no specific classification system was
used for EC findings. For all CTC reports prior to January 1, 2006, a
CRADS score was assigned retrospectively by a board certified radiolo-
gist. We compared the number of patients with E2 findings that received
follow up pre and post CRADS implementation. Radiology studies gen-
erated from E2 findings pre and post CRADS implementation were also
calculated.
NaP lavage (N = 1000) PEG lavage (N = 1000)
Total adenomas per 1000 colonoscopies 514 426 P 0.03
Total adenomas > 9 mm 74 79 P 0.7
Total adenomas < 10 mm 440 347 P 0.01 OR 1.3
Total Patients with any adenomas 308 257 P 0.01 OR 1.28
Patients with adenoma >9 mm 62 61 NS
Patients with adenomas <10 mm 266 215 P 0.007 OR 1.3
Cancers < 10 mm 4 1 NS
Cancers >9 mm 8 3 NS
Results: 2277 patients had CTC from July 2003 to June 2006. 1038 patients
(45.6%) had a total of 2092 EC findings. E3 and E4 findings were found
in 252 (11%) patients. E2 findings were found in 791 patients (34.7%).
Within the E2 category, there were 555 patients with E2 findings prior to
Jan 1, 2006 and 236 patients over the next 6 months. Demographics were
similar. In patients with E2 findings, 9.2% (51/555) had follow up stud-
ies prior to implementation of CRADS and 4.7% (11/236) had follow up
studies after CRADS implementation (P = 0.03). There was also a sig-
nificant difference (P = 0.0004) in the total number of studies generated
before (72 studies) and after (11 studies) January 1, 2006. There were no
adverse outcomes from any of the E2 findings identified over this time
period.
Conclusion: CRADS is an effective method to stratify EC findings. In
this study, implementation of this system significantly decreased the num-
ber of follow up radiology studies ordered. CRADS reduces cost, patient
anxiety and morbidity. No E2 findings were found to be malignant. This
study validates CRADS as a tool to help primary care providers manage EC
findings.
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Comparing Adenoma Detection Rates among Colonoscopies Prepped
by Bowel Lavage with Sodium Phosphate Solution vs Pegylated
Electrolyte Lavage Solution
Michael J. Gilbert, MD, Arthur J. DeCross, MD∗. Division of
Gastroenterology and Hepatology, University of Rochester, Rochester, NY.
Purpose: To compare adenoma detection rates (ADRs) between patients un-
dergoing colonoscopy after colonic lavage with sodium phosphate solution
vs a pegylated electrolyte lavage solution, and subsequently characterize the
pathology based on degree of severity.
Methods: One thousand consecutive colonoscopies were studied for each
bowel lavage group, with retrospective analysis to determine ADR and fur-
ther characterize pathology. One group underwent pre-colonoscopy lavage
with sodium phosphate solution and the other with a pegylated electrolyte
lavage solution. All colonoscopies were performed by the same five endo-
scopists in one University practice group. Comparisons were made of colon
cancer detection rates, and ADR with characterization of adenomas greater
than or less than 1 cm. Statistical analysis included T test, Chi-square mul-
tivariant analysis and Odds ratios.
Results: Please see table below. Sodium phosphate lavage solution group =
NaP. Pegylated electrolyte lavage solution group = PEG.
Conclusion: Bowel lavage preparation with sodium phosphate solution re-
sulted in a significantly higher Adenoma Detection Rate and identified more
patients overall with adenomas, compared to bowel lavage with a pegylated
electrolyte lavage solution. However, there was no difference in the detec-
tion of significant pathology, as defined by adenomas >9 mm or neoplastic
lesions. We feel that it is important to recognize that pegylated electrolyte
lavage solutions perform as well as the sodium phosphate solutions in the de-
tection of significant pathology, given the concerns regarding nephrotoxicity
risks with sodium phosphate.
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Yield of Screening Colonoscopy Performed 6–7 Years after a Negative
Colonoscopy in a Veteran Population
Sulieman Abdal Raheem, MD, Ognian Pomakov, MD, Michael D. Sitrin,
MD∗. Internal Medicine, State University of New York at Buffalo, Buffalo,
NY.
Purpose: Colonoscopy is being increasingly used for colorectal cancer
screening. Current guidelines based on limited data recommend a 10 year
followup examination after a negative colonoscopy in average risk indi-
viduals. Concern has been raised, however, over reports of interval colon
cancers detected less than 10 years after a negative colonoscopy. Data indi-
cate that many individuals are being screened at a shorter interval. The goal
of the present study was to examine the results of screening colonoscopy
in patients with a prior negative colonoscopy at the VA Western New York
Medical Center.
Methods: We retrospectively reviewed the electronic database of screening
colonoscopies performed between 2003 and 2006. Patients who had a pre-
vious colonoscopy for screening or diagnostic purposes that did not show
adenomatous polyps were identified. Pathology reports from the screening
colonoscopy were reviewed. Advanced polyps were defined at those greater
than or equal to 1 cm, with villous histology, or high grade dysplasia or
cancer.
Results: A total of 1798 patients had screening colonoscopies during the
study period. 138 patients had a prior negative colonoscopy; 41 (30%) had
their initial colonoscopy done at the VA Western NY Medical Center. The
second colonoscopy reached the cecum in 98%. 97 (70%) were average risk
patients and 41 (30%) had a family history of colon cancer. In the average
risk group, 26 (27%) patients had polyps, 10 (10%) had adenomas, and none
had advanced adenomas; the second colonoscopy was done at an average of
7 years after the initial examination. Of those with positive family histories,
11 (27%) patients had polyps, 3 (7%) had adenomas, and one patient had
an advanced polyp (1 cm) in the proximal colon; the second colonoscopy
was done at an average of 6 years after the initial examination. There was
no difference in the incidence of adenomas between average risk patients
and those with a positive family history. No colorectal cancers were found
in either group.
Conclusion: In this patient population, a second colonoscopy performed
at an interval of 6–7 years, had a low yield of adenomas and advanced
adenomas. Therefore, a screening interval of 10 years after an initial negative
examination appears reasonable.
1226
Should Colonoscope Withdrawal Time Recommendations Be Adjusted
for Patient or Procedure Factors?
Audrey H. Calderwood, MD, Edwin J. Lai, MD, Gheorghe Doros, PhD,
Suraj Gupta, Brian C. Jacobson, MD∗. Gastroenterology, Boston
University Medical Center, Boston, MA and Biostatistics, Boston
University, Boston, MA.
Purpose: The ACG/ASGE Quality Taskforce recommended a mean colono-
scope withdrawal time ≥ 6 minutes for normal screening colonoscopies to
maximize polyp detection; however, this recommendation may need adjust-
ment for patient- or procedure-related factors.
Methods: To determine if there are patient- or procedure-related character-
istics associated with colonoscope withdrawal time, we prospectively col-
lected data from patients presenting for screening colonoscopy at an urban
academic medical center. Patient demographic information, colonoscope
withdrawal time and bowel preparation quality were collected. Withdrawal
time was the interval between initiation of withdrawal in the cecum and
removal of the colonoscope from the patient. We excluded patients with
polyps. We used the Wilcoxon rank-sum test and Pearson’s correlation co-
efficient to assess for associations between colonoscope withdrawal time
and potential predictor variables, including age, gender, race (Caucasian vs.
non-Caucasian), marital status (married vs. non-married), primary language
(English vs. non-English), history of prior colonoscopy, and quality of bowel
preparation (excellent/good/fair vs. poor/unsatisfactory).
Results: There were 362 screening colonoscopies with withdrawal times
documented. Exclusion of 139 cases with polyps left 223 procedures for
analysis. There were 85 men (38%) and the median age was 56 (interquar-
tile range [IQR] 51–62). Thirty-nine (17%) were Caucasian, 77 (35%)
were married, 141 (63%) were English-speakers, and 50 (22%) had a prior
colonoscopy. Bowel preparation was considered poor or unsatisfactory in 10
(4%) cases. The median colonoscope withdrawal time was 6 minutes (IQR
5–8 minutes). There were no significant associations detected between any
variables and withdrawal time, including age (P = 0.35), race (P = 0.64),
marital status (P = 0.63), language (P = 0.40), history of prior colonoscopy
(P = 0.91), or poor/unsatisfactory bowel preparation (P = 0.45). The median
colonscope withdrawal time for both men and women was 6 minutes, but the
IQR was larger for men (5–9 vs. 5–8 minutes), resulting in a trend toward
significance (P = 0.08).
Conclusion: The use of a single value to define an “appropriate” colonoscope
withdrawal time appears justified for a broad range of patients regardless of
factors such as age and race. Future studies should confirm that gender-
specific withdrawal time recommendations are not necessary.
1227
Measuring Compliance with Routine Screening Recommendations in
Health Care Workers
Zeba Anwar, MD∗, Nazif Chowdhury, MD, Leslie Bank, MD. Internal
Medicine, Wilson Memorial Regional Medical Center, Johnson City, NY;
and Gastroenterology, Wilson Memorial Regional Medical Center, Johnson
City, NY.
Purpose: Colorectal cancer is the third most commonly diagnosed cancer
in men and women in the United States. However, most Americans are
not screened for colorectal cancer. Information from the National Health
Interview Survey indicates that in 1992, only 17.3% of people 50 years of
age or older had undergone fecal occult blood testing in the previous year,
and 9.4% had undergone sigmoidoscopy in the previous 3 years.
As screening reduces mortality, the aim of this study was to determine com-
pliance with routine health screening recommendations among health care
workers.
Methods: A 1 page questionnaire distributed to health care workers within
the United Health Services, which were color coded to differentiate various
health care professions such as doctors, nurses, and other health care staff
were sent out anonymously from September 2006 to December 2006.
The main outcome measure was to determine the recent use of Colonoscopy,
but cancer preventive interventions like Papanicolau (Pap smear) and Pelvic
All Job Classifications
Screening Non-
eligible Compliant compliant %
Mammogram 45 41 4 91.1%
Colonoscopy 73 57 16 78.1%
PSA/DRE 68 46 22 67.6%
Pap smear and 70 62 8 88.6%
Pelvic Exam
Physicians
Screenig Non-
eligible Compliant compliant %
Mammogram 15 11 4 73.3%
Colonoscopy 52 43 9 82.7%
PSA/DRE 63 41 22 65.1%
Pap Smear and 4 4 0 100%
Pelvic Exam
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Exam, Mammography, PSA level testing or Digital Rectal Exam of the
prostate gland were also included.
Health care workers across the ages of 19 to 61 were assessed for compliance
with screening recommendations that were valid for their age and gender.
Results: A total of 169 surveys were found to be valid. The compliance
rate with colonoscopy for physicians was 82.7% compared with the other
job classifications of 78.1%. The results were interpreted according to the
guidelines approved by the American Cancer Society between Physicians
and All Job Classifications that included nurses, pharmacists, non clinical
and ancillary staff.
Conclusion: The results from the study reflect the need to continue efforts to
raise awareness regarding screening preventable cancers notably colorectal
cancer.
1228
Marked Racial/Ethnic Differences in Acceptance of and Barriers to
Colorectal Cancer Screening in a Primary Care Setting
Najm M. Soofi, MD, MPH, Aizenberg David, MD, Tenner T. Craig, MD,
Poles Michael, MD, PhD, Bini J. Edmund, MD, MPH∗. Gastroenterology,
New York University Medical Center, New York, NY and Internal Medicine,
New York University Medical Center, New York, NY.
Purpose: Racial/ethnic minorities have an increased incidence of colorectal
cancer (CRC) and tend to present with a more advanced stage of CRC rel-
ative to whites. In addition, studies have shown that racial/ethnic minorities
are also less likely to undergo CRC screening tests (including fecal occult
blood testing [FOBT], flexible sigmoidoscopy [FS], and colonoscopy) than
whites. The aim of this study was to identify the proportion of racial/ethnic
minorities that are offered and accept CRC screening and to identify barriers
to CRC screening among racial/ethnic minorities over the age of 50 years as
compared with whites.
Methods: Subjects ≥50 years old completed a detailed questionnaire at the
time of their scheduled outpatient primary care clinic visit. Data collected
included demographics, self-reported race/ethnicity, prior CRC screening
(FOBT, FS, and/or colonoscopy), as well as barriers to CRC screening.
Results: Of the 688 subjects enrolled, 376 were white (W), 188 were black
(B), 92 were Hispanic (H), and 32 identified their race/ethnicity as other (O).
W patients were slightly older than B, H, or O racial/ethnic groups (65.0 vs.
62.1 vs. 62.5 vs. 63.7 years; P = 0.002) but had a similar prevalence of
male subjects (93.1% vs. 92.0% vs 91.3% vs. 81.3%, P = 0.13). There were
no significant differences between W, B, H, and O racial/ethnic groups who
were offered FOBT (73.7% vs. 73.9% vs. 69.6% vs. 59.4%; P = 0.31), FS
(60.4% vs. 52.1% vs. 51.1% vs. 56.3%; P = 0.18), or screening colonoscopy
(73.7% vs. 67.0% vs. 67.4% vs. 68.8%; P = 0.34). However, whites were
significantly more likely than racial/ethnic minorities to ever have completed
FOBT (71.0% vs. 59.6% vs. 48.9% vs. 28.1%; P < 0.001), FS (60.4% vs.
49.5% vs. 34.8% vs. 28.1%; P < 0.001), and screening colonoscopy (73.1%
vs. 49.5% vs. 43.5% vs. 53.1%; P < 0.001). In addition, we found that
there were significant differences in the number and type of barriers to CRC
screening between whites and racial/ethnic minorities.
Conclusion: Racial/ethnic minorities are less likely to undergo CRC screen-
ing than whites. The lower rate of CRC screening among racial/ethnic mi-
norities is not due to provider discrimination and is explained by a lower
acceptance rate among racial/ethnic minorities as compared with whites.
Future studies to attempt to overcome barriers to CRC screening among
racial/ethnic minorities are needed.
1229
Gastroenterologists’ Patient Instructions for Oral Sodium Phosphate
Solution for Colonoscopy Preparation: A Survey among
Gastroenterologists in the State of Indiana
Veronika Gagovic, MD, Douglas K. Rex, MD∗. Department of Medicine,
Division of Gastroenterology, Indiana University, Indianapolis, IN.
Purpose: Oral sodium phosphate solution (OSPS) has been associated with
acute renal failure when used as a bowel preparation for colonoscopy. Our
aim was to determine whether gastroenterologists in Indiana follow recent
recommendations for safe and effective use of colonoscopy.
Methods: The study, conducted from May to September 2006, included prac-
ticing gastroenterologists in Indiana. Our office reviewed each physician’s
written instructions on the use of OSPS for bowel preparation with respect
to dosages, timing of dose, hydration instructions and type of hydration
solution recommended to patients receiving OSPS. These were compared
to safety recommendations developed by American Society of Colon and
Rectal Surgeons, The American Society of Endoscopy and The Society of
American Gastrointestinal and Endoscopic Surgeons which included use of
no more than two 45 ml bottles given at least 6–12 hours apart, approxi-
mately 960 ml of fluid given with each dose of OSPS and preference given
to carbohydrate-electrolyte solutions. Descriptive statistics was used for our
data analysis.
Results: 193 (97.5%) physicians participated in the study. 80.3% used OSPS
in their practice, with a mean total amount of solution given 87.3 ml. There
were no physicians that recommended more than 90 ml of OSPS. The mean
interval recommended between doses was 7.6 hours. 35.5% physicians pre-
scribed two 45 ml bottles of OSPS at an interval less than six hours apart.
9.7% of physicians using OSPS specified the amount and type of fluid prior
to first dose of OSPS, with a mean (range) of 660 ml (120–1440 ml). 93.7%
of physicians specified the fluid amount to be taken with or after the first
dose of OSPS with a mean (range) of 1002 ml (120–3000) ml. 89% of physi-
cians specified an amount of fluid to be taken with and after the second dose
of OSPS with a mean (range) of 660 ml (120–1560 ml). Carbohydrate rich
solution was preferred by 22% of physicians after the first and 16% of physi-
cians after the second dose. 33.5% physicians using OSPS recommended
more than 1920 ml of fluid to be taken with the OSPS prep.
Conclusion: Practicing Indiana gastroenterologists were universally con-
sistent with recent guidelines in their written instructions to patients with
regard to the total dose of OSPS for colonoscopy. They frequently recom-
mended OSPS at intervals shorter than current guidelines and often did not
give optimal instructions with regard to hydration during colonoscopy.
1230
Location of Adenoma, Not Removal Method, Is Associated with
Recurrent Neoplasia
Carol A. Burke, MD∗, Fnu Deepinder, MD, Madhu Sanaka, MD, Rocio
Lopez, MS. Department of Gastroenterology, Cleveland Clinic, Cleveland,
OH.
Purpose: Certain adenoma characteristics such as size≥10 mm, multiplicity
(>2) and advanced histology are associated with recurrent neoplasia. The
effect of method of polypectomy or location of polypectomy on recurrent
neoplasia has been less widely studied. We analyzed the effect of different
polypectomy methods (hot and cold biopsy [BX] vs hot and cold snare [SN])
and location of polyp removed, proximal vs distal, on polyp recurrence.
Methods: Colonoscopy and medical records of all individuals who had 1
polyp removed from a single colon segment and a FU colonoscopy ≥ 12 mos
after polypectomy were included. Polyp size, morphology, pathology and lo-
cation, method of polypectomy were included. Univariable and multivariable
Cox proportional hazards models were used to estimate the hazard rates for
polyp recurrence. Recurrence defined as a polyp detected on FU in the same
segment as initial polypectomy. “Proximal” defined as cecum, ascending and
transverse colon and “distal” as descending, sigmoid and rectum.
Results: 385 subjects (551 polyps) with a mean age of 62 yrs (62% male)
were included. Polyps recurred in 23%. Recurrence was associated with
polyp location: 28% in right vs 18% in left colon (P < 0.001) but not polypec-
tomy method 23% that had BX vs 21% that had SN (P = 0.6).[figure1]Even
after adjusting for age, polyp size and location, polypectomy type is not
associated with polyp recurrence. Contrarily, after adjusting for age, polyp
size and polypectomy type, the location of polypectomy was signficantly
associated with polyp recurrence.
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∗Recurrence after Polypectomy
Factor Level HR (95% CI) P value
Polypectomy BX vs SN 1.2 (0.74–1.9) 0.48
Polyp Location Proximal vs Distal 1.8 (1.3–2.7) 0.001
Polyp Size 1 level increase 1.3 (1.01–1.8) 0.042
(ie 6–9 vs 1–5, etc)
Age 5 yr increase 1.1 (1.03–1.2) 0.007
Cox proportional hazards multivariable analysis
Conclusion: The use of BX is not associated with an increased risk of polyp
recurrence. Most surprising was the significant association found between
polyps removed from the right sided of the colon and an 80% risk of polyp
recurrence in that segment on FU.
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Colon Cancer Screening at an HIV Outpatient Clinic: 2000–2006
Ryan M. Ford, MD, Matthew M. McMahon, MD, Jeffrey L. Lennox, MD,
Kamil Obideen, MD, Mohammad A. Wehbi, MD∗. Division of Digestive
Diseases, Emory University School of Medicine, Atlanta, GA; Division of
Infectious Diseases, Emory University School of Medicine, Atlanta, GA
and GA.
Purpose: It is currently unknown if patients with HIV have an increased risk
of colon cancer in the era of highly active anti-retroviral therapy (HAART).
Since patients with HIV are living longer, routine primary care and cancer
screening is recommended. It has previously been reported that colon cancer
screening is underutilized in the HIV population. We sought to determine,
over 6 years, the frequency and selected modality of colon cancer screening
in patients with HIV who were at least age 50 and were being followed at a
comprehensive HIV clinic in downtown Atlanta between 2000 and 2006.
Methods: We obtained a randomized sample of 81 out of 849 patients with
HIV who were age 50 or older and who were seen at the HIV clinic on Ponce
de Leon Avenue in downtown Atlanta, Georgia between 2000 and 2006.
From the medical charts, we obtained information on age, gender, pres-
ence of colon cancer screening, selected modality of colon cancer screen-
ing, CD4 count and viral load closest to the time of screening, and use of
HAART.
Results: Of the 81 patients sampled, 23 (28.4%) did not undergo any colon
cancer screening test during the specified time period. 31 patients (38.3%)
underwent fecal occult blood testing (FOBT), but not every year. 20 pa-
tients (25%) underwent a combination of FOBT and lower endoscopy (12
had a colonoscopy and 8 had a flexible sigmoidoscopy). 6 patients (7.4%)
underwent colonoscopy alone, and one patient (1.2%) underwent flexible
sigmoidoscopy alone. Six patients refused colonoscopy (two of them under-
went FOBT). The majority (69%) of patients were male. The majority of
patients were taking anti-retrovirals at the time of screening.
Conclusion: In the post-HAART era, the majority of patients who were
age 50 or older and seen in this comprehensive HIV clinic in Atlanta un-
derwent some form of colon cancer screening. FOBT testing was utilized
most often (63% of patients) but was not performed on a strict yearly ba-
sis. 22% of patients underwent colonoscopy and 11% of patients underwent
flexible sigmoidoscopy. When compared to data from the general population
regarding colon cancer screening, patients with HIV in this study were more
likely to undergo FOBT or flexible sigmoidoscopy and less likely to undergo
colonoscopy. More data is needed to investigate the risk of CRC with HIV
in the era of HAART.
1232
Endoscopists Recommend Shortened Surveillance Intervals
LeAnn C. Michaels, BS∗, Nora C. Mattek, MPH, Cynthia D. Morris, PhD,
David A. Lieberman, MD. Gastroenterology, OHSU, Portland, OR.
Purpose: In 2006 the American Cancer Society and US Multi-Society Task
Force on Colorectal Cancer published consensus guidelines for surveillance
colonoscopy after colorectal cancer and polyps. Dissemination and imple-
mentation of guidelines may lag in practice. We queried endoscopists who
use CORI on knowledge of guidelines and practice recommendations, and
will later compare to practice in the National Endoscopic Database (NED).
We analyzed endoscopist recommendations for common scenarios as com-
pared to guidelines, and for characteristics associated with variance.
Methods: All endoscopists who contribute data to NED were invited to
complete a survey via secure applet, mail, fax or telephone. Responses to
the survey were stored confidentially. Survey questions were directed at en-
doscopist demographics and practice description. We constructed seven pa-
tient scenarios to test knowledge of guidelines in cases of tubular adenomas,
tubulovillous adenomas, hyperplastic polyps, personal history of colorectal
cancer (CRC) and family history of CRC.
Results: Overall, 287 of 442 (65%) endoscopists participated, with 71%
among 356 practicing endoscopists and 38% in 86 fellows responding. Re-
spondents were primarily male (86%), Caucasian (74%, 21% Asian) gas-
troenterologists (90%) with a mean age of 45 years. Respondents complete
50–2,000 colonoscopies annually, with a mean of 676 procedures. The most
influential factor for colorectal cancer and polyp surveillance was cited as
clinical evidence in literature (89% rated very significant).
Each clinical scenario revealed endoscopists would recommend a surveil-
lance interval shorter than the guidelines. Those most likely to recommend
shorter intervals for 1–2 small adenomas are non-gastroenterologists (46%
v. 15%, P < 0.0001) and endoscopists not very influenced by clinical evi-
dence (45% v. 15%, P < 0.0001), nor by US Multi-Society Task Force (27%
v. 8%, P < 0.0001). Shortened intervals for hyperplastic polyps are seen in
non-gastroenterologists (54% v. 22%, P < 0.001).
Conclusion: A significant proportion of endoscopists suggest surveillance
colonoscopies for low-risk patients at more frequent intervals than recom-
mended. This could have a profound effect on endoscopy workforce demands
and limit availability for screening colonoscopy.
Proportion recommend shorter interval
Published Proportion surveillance
Scenario interval (years) shorter than guideline
Small tubular adenoma 5 18%
Multiple small adenomas 3 7%
Large adenoma 3 12%
Villous adenoma 3 17%
Hyperplastic polyps 10 25%
Personal history CRC 3 22%
Family history CRC 5 14%
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An Elevated Rate of Adenoma Detection in an Urban Latin American
Population Undergoing Colorectal Cancer Screening
K. Grover, MD, R.J. Bierwirth, MD, M.J. Sterling, MD, D.M. Rosenblum,
PhD, G. Ashrafzadeh, MD, S.H. Weiss, MD∗. The Division of
Gastroenterology and the Department of Preventative Medicine and
Community Health, UMDNJ – New Jersey Medical School, Newark, NJ.
Purpose: Colorectal cancer is the second leading cause of cancer death in
the United States. African Americans (AA) are known to have an elevated
rate of colonic neoplasms compared to the general population. There is
limited data on Latin Americans (LA) undergoing screening colonoscopies
with respect to the incidence and location of neoplasms. We retrospectively
reviewed screening colonoscopies performed at an inner city university hos-
pital that serves a predominately minority population to detail colon polyp
size, distribution, and pathology with respect to ethnicity.
Methods: There were a total of 2,698 colonoscopies performed at the Univer-
sity Hospital in Newark, NJ from 2005–2006. Of these, 756 were screening
colonoscopies performed on patients who were asymptomatic. These cases
were analyzed for presence, location, size, and pathology of polyps with
respect to patient ethnicity.
Results: Of the 756 screening colonoscopies, 287 (38%) were performed in
LA and 331 (44%) in AA. In LA, 112 patients (39%) were found to have
at least one polyp. This was not significantly different from AA (145 pa-
tients; 44%). Additionally, 56 (19%) LA were found to have a right-sided
lesion (proximal to the splenic flexure), which was comparable to AA (64
patients; 19%). Significant pathology was defined as adenomatous change
(AD), tubular adenoma (TA), tubulovillous adenoma (TVA), villous ade-
noma, or carcinoma (CA). Of the AA patients screened, 67 (46%) had
pathologically significant lesions (5 AD, 53 TA, 6 TVA, and 3 CA). LA
had a similar incidence (54 patients; 48%) and distribution of pathologi-
cally significant lesions (2 AD, 47 TA, 5 TVA, 0 CA). The percentage of
pathologically significant right-sided polyps were similar in AA (40 patients,
62%) and LA (32 patients, 57%). Of note, AA were significantly more likely
to have a large (> 1 cm) polyp than LA (8.5% vs. 3.1%, P < .01), and
were more likely to have a large right sided colonic polyp (4.6% vs. 1.7%,
P = .07).
Conclusion: This study provides evidence that LA undergoing screening
colonoscopy have a higher than expected incidence of colonic polyps, patho-
logically significant lesions, and pathologically significant right-sided le-
sions. These findings were similar to those of AA, a known high-risk group.
Our study suggests that screening guidelines for LA should reflect those for
AA and warrants further prospective trials.
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Mechanisms of Polyethylene Glycol (PEG) Anti-Proliferative Effects:
Implications for Colon Cancer Chemoprevention
Shabana Siddiqui, MD, Jennifer Koetsier, Mary Nyhuis, Ramesh Wali,
PhD, Dhananjay Kunte, PhD, Hemant K. Roy, MD∗. Research, Evanston
Northwestern Healthcare, Evanston, IL.
Purpose: The recent high profile failure in clinical trials of agents such as fo-
late (JAMA 2007) and celecoxib (NEJM 2006) have underscored the urgency
of developing safer and more effective chemopreventive agents against colon
cancer. One of the most promising agents in preclinical studies is PEG, a
widely used OTC agent for chronic constipation. However, progress devel-
oping this agent has been stymied by lack of mechanistic insights. We have
reported that PEG markedly suppressed epithelial hyperproliferation (Roy
et al., Mol Cancer Ther 2006). The present study explores the molecular
mechanisms of this effect.
Methods: The human colon cancer cell line HT-29 was used for these studies.
Cells were treated with 10% PEG 8000 or vehicle for 24 hours. Proliferation
was assessed by expression of proliferating cell nuclear antigen (PCNA).
Cell cycle distribution was assessed by flow cytometry using propridium
iodide. Immunoblot analysis with densitometry was performed with standard
techniques.
Results: 10% PEG 8000 treatment decreased PCNA expression (74.9% of
control, P < 0.01) indicating an anti-proliferative effect. PEG markedly
increased in proportion of non-replicating cells (G0-G1 phase 82.6 ± 1.1%
vs 51.6 ± 4.1% in vehicle controls, P < 0.005) with a concomitant profound
suppression of cells undergoing DNA replication (S phase 11.7 ± 6.3%
vs 44.9 ± 4.5% in controls, P < 0.005) indicating a G1-S phase arrest.
The effect on cell cycle with PEG 3350 was intermediate between control
and PEG 8000 (S phase∼36%) consistent with in vivo data (Roy et al.,
Cancer Lett 2004). To assess the mechanisms, we evaluated p21 cip/waf, a
potent inhibitor G1/S phase transition, which is frequently lost during colon
carcinogenesis. We observed that PEG dramatically augmented p21 cip/waf
expression (322% of control, P < 0.0001).
Conclusion: We demonstrate, for the first time, that the chemopreventive
properties of PEG may be related to induction of the tumor suppressor gene
p21 cip/waf with concomitant G1/S phase cell cycle arrest (see figure). This
provides biological rationale and an intermediate biomarker for the planned
clinical chemoprevention trials with PEG.[figure1]
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Gender and Subsite Locations Modulate the Chemopreventive
Efficacy of Celecoxib: A MIN Mouse Study
Mary Nyhuis, Jennifer Koetsier, Ramesh Wali, PhD, Dhananjay Kunte,
PhD, Russ Pelham, PhD, Mark Cleveland, PhD, Hemant K. Roy, MD∗.
Research, Evanston Northwestern Healthcare, Evanston, IL and Braintree
Labs, Braintree, MA.
Purpose: Elucidating determinants of chemopreventive responsiveness is
of major importance in designing cost-effective strategies against colorec-
tal cancer (CRC) given the profound biological differences in the proxi-
mal and distal colon. Our group and others have demonstrated that gender
impacts upon CRC location (Arch Int Med 2006). However, no previous
studies have addressed the effects of gender on efficacy of chemopreven-
tive agents against colonic neoplasia. We, therefore, conducted a study with
the well-validated murine model of FAP, the MIN mouse, using a potent,
well-established chemopreventive agent, celecoxib.
Methods: Male (N = 39) and female (N = 32) MIN mice, 5–6 weeks old,
were assigned to either AIN 76a diet alone or supplemented with celecoxib
1500 ppm. After ∼10 weeks on diet, animals were euthanized and tumors
scored by 3 independent observers blinded to treatment group. Separate
counts from proximal small bowel (PSB), distal small bowel (DSB) and
colon were recorded. A subset of tumors was histologically analyzed to
confirm adenomas.
Results: Females were noted to have dramatically more polyps than males
(52.3 ± 13.9 versus 35.4 ± 16.1, P < 0.0005). Celecoxib treatment resulted
in a significant reduction in total polyp number (43.9 ± 17.1 to 10.6 ± 6.3,
P < 0.00001), although the effect size was considerably greater in females
than males (87.8% versus 63.8%, P < 0.001). With regards to regional dis-
tribution, most adenomas were located in the DSB. Therefore, from a polyp
number point of view, the largest reduction occurred there (34.0 in females
and 16.2 in males, P = 0.01 for gender difference). However, the greatest rel-
ative decrease was found in the PSB where females experienced a remarkable
98.2% suppression in polyps whereas males had a 74.5% reduction. Intrigu-
ingly, in the colon, celecoxib did not afford males any protection (102.3% of
control, P = 0.93) and actually promoted tumorigenesis in females (216.1%
of control, P < 0.05).
Conclusion: We demonstrate, for the first time, that in the MIN mouse,
that the chemoreventive agent celecoxib was substantially more effective
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in females than males. Moreover, the adenoma suppression appeared to be
determined, at least in part, by region of the intestine. Aside from providing
important insights regarding the MIN mouse model, our study underscores
the need to consider both gender and subsite differences in designing and
analyzing chemoprevention trials.
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Positive Predictive Value of Fecal Occult Blood Testing in Patients
Taking Aspirin, Other NSAIDS, Warfarin or Clopidogrel
Heather E. McDougall, MD∗, Mandeep S. Sawhney, MBBS, Douglas B.
Nelson, MD, John H. Bond, MD. Internal Medicine, Minneapolis VA
Medical Center, Minneapolis, MN; Gastroenterology, Beth Israel
Deaconess Medical Center, Boston, MA and Gastroenterology,
Minneapolis VA Medical Center, Minneapolis, MN.
Purpose: To compare the positive predictive value (PPV) of FOBT to de-
tect advanced adenoma or advanced neoplasia in patients on anticoagu-
lant or antiplatelet medication with those not on these medications (control
group).
Methods: All patients that underwent a colonoscopy at our institution from
2/1/99 to 8/9/06 for positive FOBT (using Hemoccult II) were identified
using a computer database. Medical records were reviewed, and patients
were stratified into 5 groups a priori: aspirin users, other non-steroidal
anti-inflammatory (NSAIDS) users, warfarin users, clopidogrel users, and
controls. Primary outcome was the prevalence of advanced adenoma (AA–
defined by presence of adenoma ≥10 mm or tubulovillous adenoma) or
advanced neoplasia (AN–defined by presence of cancer, cancerous polyp, or
high grade dysplasia).
Results: During the study period, 1126 patients underwent colonoscopy for
a positive FOBT and met entry criteria. The average age of study partici-
pants was 69 years, and most were men. The PPV of FOBT for advanced
colon neoplasia was significantly higher in the control group [30.5%] when
compared with those on aspirin [20.5%; P = 0.003], other NSAIDs [19.7%;
P = 0.003], clopidogrel [7.3%; P = 0.002] or warfarin [20%; P = 0.05]. The
PPV of FOBT was significantly lower for those on clopidogrel than those
on aspirin [P = 0.04] or other NSAIDs [P = 0.05], but not warfarin [P =
0.08]. The PPV for FOBT was similar for those on aspirin, other NSAIDs
and warfarin. There was a linear trend between the number of positive FOBT
cards and prevalence of advanced colon neoplasia [P = 0.01].
Conclusion: Anticoagulants and antiplatelet medications lower the PPV
of FOBT for advanced colonic neoplasia. If feasible, these medications
should be stopped prior to stool collection. If these medications cannot be
safely stopped, other colon cancer screening modalities should be consid-
ered.[figure1]
